Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 2.3.2.27 - RING-type E3 ubiquitin transferase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
1,4-alpha-glucan branching enzyme deficiency
Proteomic characterisation of polyglucosan bodies in skeletal muscle in RBCK1 deficiency.
Abortion, Spontaneous
Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers.
The Slavic NBN Founder Mutation: A Role for Reproductive Fitness?
Acquired Immunodeficiency Syndrome
A 24-color metaphase-based radiation assay discriminates heterozygous BRCA2 mutation carriers from controls by chromosomal radiosensitivity.
A brief history of TRIM5alpha.
A patient decision aid for risk-reducing surgery in premenopausal BRCA1/2 mutation carriers: Development process and pilot testing.
Context dependent splicing functions of Bud31/Ycr063w define its role in budding and cell cycle progression.
Development of decision aids for female BRCA1 and BRCA2 mutation carriers in Germany to support preference-sensitive decision-making.
Effectiveness of decision aids for female BRCA1 and BRCA2 mutation carriers: a systematic review.
eIF3-f function in skeletal muscles: to stand at the crossroads of atrophy and hypertrophy.
Inhibition of HIV-1 replication by simian restriction factors, TRIM5alpha and APOBEC3G.
Restriction of the felid lentiviruses by a synthetic feline TRIM5-CypA fusion.
The initiation factor eIF3-f is a major target for atrogin1/MAFbx function in skeletal muscle atrophy.
TRIM5 modulates penile mucosal acquisition of simian immunodeficiency virus in rhesus monkeys.
TRIM5? and Species Tropism of HIV/SIV.
TRIM5alpha Modulates Immunodeficiency Virus Control in Rhesus Monkeys.
Acute Kidney Injury
WWP2 ameliorates acute kidney injury by mediating p53 ubiquitylation and degradation.
Acute Lung Injury
Parkin regulates lipopolysaccharide-induced proinflammatory responses in acute lung injury.
Adenocarcinoma
A metastasis of an adenocarcinoma in a BRCA1 mutation carrier, a diagnostic problem not solved by morphology alone.
A novel BRCA1 mutation in a Spanish patient with ovarian cancer.
A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination-deficient Pancreatic Cancer.
A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population.
AGER/RAGE-mediated autophagy promotes pancreatic tumorigenesis and bioenergetics through the IL6-pSTAT3 pathway.
An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions.
Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer.
Atm heterozygosity cooperates with loss of Brca1 to increase the severity of mammary gland cancer and reduce ductal branching.
BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma.
BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts.
BRCA1 germline mutation presenting as an adenocarcinoma of unknown primary.
BRCA1 mutation testing for Japanese patients with ovarian cancer in breast cancer screening.
Breast cancer in males, case presentation and literature review
Case report: Analysis of BRCA1 and BRCA2 gene mutations in a hereditary ovarian cancer family.
Chemosensitivity of BRCA1-Mutated Ovarian Cancer Cells and Established Cytotoxic Agents.
Clinicopathologic features and BRCA mutations in primary fallopian tube cancer in Japanese women.
Clinicopathological and Molecular Characteristics of Colorectal Signet Ring Cell Carcinoma: A Review.
Cofactor of BRCA1: a novel transcription factor regulator in upper gastrointestinal adenocarcinomas.
Comparison of Practice Guidelines, BRCAPRO, and Genetic Counselor Estimates to Identify Germline BRCA1 and BRCA2 Mutations in Pancreatic Cancer.
Dimeric switch of Hakai-truncated monomers during substrate recognition: insights from solution studies and NMR structure.
Distal chromosome 17q loss in Barrett's esophageal and gastric cardia adenocarcinomas: implications for tumorigenesis.
Diverse mechanisms of autophagy dysregulation and their therapeutic implications: does the shoe fit?
Down-regulation of BRCA1 in chronic pancreatitis and sporadic pancreatic adenocarcinoma.
Dramatic response of FOLFIRINOX regimen in a collision pancreatic adenocarcinoma patient with a germline BRCA2 mutation: a case report.
Excellent Response to Olaparib in a Patient with Metastatic Pancreatic Adenocarcinoma with Germline BRCA1 Mutation after Progression on FOLFIRINOX: Case Report and Literature Review.
Expression of IAP family proteins in colon cancers from patients with different age groups.
Gallbladder Adenocarcinoma as the First Manifestation of Germline BRCA1 Mutation.
Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers.
Genetic characteristics of gastric-type mucinous carcinoma of the uterine cervix.
Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.
Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma.
Germline BRCA1 Deletion as Driver Mutation for Metastatic Urachal Adenocarcinoma in Patient Who Achieved Complete Response to Rucaparib.
Germline BRCA1 mutations predispose to pancreatic adenocarcinoma.
Gross genomic alterations and gene expression profiles of high- grade serous carcinoma of the ovary with and without BRCA1 inactivation.
Haploinsufficiency of Casitas B-Lineage Lymphoma Augments the Progression of Colon Cancer in the Background of Adenomatous Polyposis Coli Inactivation.
Hereditary forms of ovarian cancer.
High prevalence of BRCA1 and BRCA2 germline mutations with loss of heterozygosity in a series of resected pancreatic adenocarcinoma and other neoplastic lesions.
Hormone therapy after prophylactic risk-reducing bilateral salpingo-oophorectomy in women who have BRCA gene mutation.
Impact of BRCA1/2 gene mutations on survival of patients with pancreatic cancer: A case-series analysis.
In vitro platination of human breast cancer suppressor gene1 (BRCA1) by the anticancer drug carboplatin.
Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma.
Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival.
Increased cell survival by inhibition of BRCA1 using an antisense approach in an estrogen responsive ovarian carcinoma cell line.
Increased Expression of BRCA2 and RAD51 in Lymph Node Metastases of Canine Mammary Adenocarcinomas.
Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations.
Molecular profiling of appendiceal serrated lesions, polyps and mucinous neoplasms: a single-centre experience.
mRNA Expression and Clinical Significance of ERCC1, BRCA1, RRM1, TYMS and TUBB3 in Postoperative Patients with Non-Small Cell Lung Cancer.
Mutational analysis of BRCA1 and BRCA2 and clinicopathologic analysis of ovarian cancer in 82 ovarian cancer families: two common founder mutations of BRCA1 in Japanese population.
Mutations in BRCA1, BRCA2, and PALB2, and a panel of 50 cancer-associated genes in pancreatic ductal adenocarcinoma.
Overexpression of cellular inhibitor of apoptosis protein 2 is an early event in the progression of pancreatic cancer.
Pancreatic adenocarcinoma: epidemiology and genetics.
Pancreatic intraductal tubulopapillary neoplasm is genetically distinct from intraductal papillary mucinous neoplasm and ductal adenocarcinoma.
Parkin protein expression and its impact on survival of patients with advanced colorectal cancer.
Pathology of ovarian cancers in BRCA1 and BRCA2 carriers.
Pattern of breast cancer susceptibility gene 1 expression is a potential prognostic biomarker in resectable pancreatic ductal adenocarcinoma.
Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation.
Post-transcriptional regulation of BRCA1 through its coding sequence by the miR-15/107 group of miRNAs.
Prevalence of pancreaticobiliary cancers in Irish families with pathogenic BRCA1 and BRCA2 variants.
Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation-related breast cancer.
PRP19 upregulation inhibits cell proliferation in lung adenocarcinomas by p21-mediated induction of cell cycle arrest.
Quantitative analysis of BRCA1, BRCA2 and Hmsh2 mRNA expression in colorectal Lieberkühnien adenocarcinomas and matched normal mucosa: relationship with cellular proliferation.
Reversal of P-glycoprotein-mediated multi-drug resistance by the E3 ubiquitin ligase Cbl-b in human gastric adenocarcinoma cells.
RNF43 is frequently mutated in colorectal and endometrial cancers.
Snail recruits Ring1B to mediate transcriptional repression and cell migration in pancreatic cancer cells.
SPOP regulates prostate epithelial cell proliferation and promotes ubiquitination and turnover of c-MYC oncoprotein.
TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients.
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
The epigenetic regulators Bmi1 and Ring1B are differentially regulated in pancreatitis and pancreatic ductal adenocarcinoma.
The Role of E3 Ubiquitin Ligase Cbl Proteins in ?-Elemene Reversing Multi-Drug Resistance of Human Gastric Adenocarcinoma Cells.
The ubiquitin ligase RNF43 downregulation increases membrane expression of frizzled receptor in pancreatic ductal adenocarcinoma.
TP53 p.R337H prevalence in a series of Brazilian hereditary breast cancer families.
TRIM25 blockade by RNA interference inhibited migration and invasion of gastric cancer cells through TGF-? signaling.
Urological cancer related to familial syndromes.
[Analysis of K-ras, BRCA1/2, CHEK2 mutations and microsatellite markers (loss of heterozygosity at 9p, 17p and 18q) in sporadic pancreas adenocarcinomas]
Adenocarcinoma of Lung
Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers.
ALCAP2 inhibits lung adenocarcinoma cell proliferation, migration and invasion via the ubiquitination of ?-catenin by upregulating the E3 ligase NEDD4L.
Alterations of the tumor suppressor gene Parkin in non-small cell lung cancer.
Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma.
ATR inhibitor M6620 (VX-970) enhances the effect of radiation in non-small cell lung cancer brain metastasis patient derived xenografts.
Cells redox environment modulates BRCA1 expression and DNA homologous recombination repair.
Clinical response to crizotinib and emergence of resistance in lung adenocarcinoma harboring a MET c-Cbl binding site mutation.
DNA damage response signaling in lung adenocarcinoma A549 cells following gamma and carbon beam irradiation.
E3 ubiquitin ligase PJA1 regulates lung adenocarcinoma apoptosis and invasion through promoting FOXR2 degradation.
Effect of etoposide-induced alteration of the Mdm2-Rb signaling pathway on cellular senescence in A549 lung adenocarcinoma cells.
Elevated TRIM23 expression predicts cisplatin resistance in lung adenocarcinoma.
Epigenetic inactivation of the chromosomal stability control genes BRCA1, BRCA2, and XRCC5 in non-small cell lung cancer.
Evaluation of gene expression levels in the diagnosis of lung adenocarcinoma and malignant pleural mesothelioma.
Expression pattern of parkin isoforms in lung adenocarcinomas.
Functional Link between BRCA1 and BAP1 through Histone H2A, Heterochromatin and DNA Damage Response.
Genetic and epigenetic alterations of the EGFR and mutually independent association with BRCA1, MGMT, and RASSF1A methylations in Vietnamese lung adenocarcinomas.
Identification of candidate genes and prognostic value analysis in patients with PDL1-positive and PDL1-negative lung adenocarcinoma.
Impact of siRNA targeting pirh2 on proliferation and cell cycle control of the lung adenocarcinoma cell line A549.
Integrative Genomic and Transcriptomic Analyses of Tumor Suppressor Genes and Their Role on Tumor Microenvironment and Immunity in Lung Squamous Cell Carcinoma.
Loss of the tumour-suppressor genes CHK2 and BRCA1 results in chromosomal instability.
Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27.
Parkin-Independent Mitophagy Controls Chemotherapeutic Response in Cancer Cells.
PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer.
Pellino-1 confers chemoresistance in lung cancer cells by upregulating cIAP2 through Lys63-mediated polyubiquitination.
PRP19 upregulation inhibits cell proliferation in lung adenocarcinomas by p21-mediated induction of cell cycle arrest.
RNF43 ubiquitinates and degrades phosphorylated E-cadherin by c-Src to facilitate epithelial-mesenchymal transition in lung adenocarcinoma.
Stratifin inhibits SCFFBW7 formation and blocks ubiquitination of oncoproteins during the course of lung adenocarcinogenesis.
The expression of four genes as a prognostic classifier for stage I lung adenocarcinoma in 12 independent cohorts.
Two-gene signature improves the discriminatory power of IASLC/ATS/ERS classification to predict the survival of patients with early-stage lung adenocarcinoma.
Upregulation of E3 Ubiquitin Ligase CBLC Enhances EGFR Dysregulation and Signaling in Lung Adenocarcinoma.
[Tripartite-motif protein 25 and pyruvate kinase M2 protein expression in non-small cell lung cancer].
Adenocarcinoma, Mucinous
Down-regulation of BRCA1 in human sporadic breast cancer; analysis of DNA methylation patterns of the putative promoter region.
Origins and molecular pathology of ovarian cancer.
RNF43 mutations are recurrent in Chinese patients with mucinous ovarian carcinoma but absent in other subtypes of ovarian cancer.
Adenocarcinoma, Papillary
Case Report: Double Germline Mutations in BRCA1 and MSH2 in a Patient With Mixed Serous-Endometrioid Endometrial Carcinoma.
Adenoma
Correlation of molecular and morphological features of appendiceal epithelial neoplasms.
Dysregulated Wnt?signalling and recurrent mutations?of?the tumour suppressor?RNF43?in early?gastric carcinogenesis.
Evaluation of the Expression of the Inhibitor of Apoptosis Protein Family and Human Telomerase Reverse Transcriptase in Patients With Advanced Colorectal Adenoma.
Frequent PTPRK-RSPO3 fusions and RNF43 mutations in colorectal traditional serrated adenoma.
Genetic analysis of a breast-ovarian cancer family, with 7 cases of colorectal cancer linked to BRCA1, fails to support a role for BRCA1 in colorectal tumorigenesis.
Haploinsufficiency of Casitas B-Lineage Lymphoma Augments the Progression of Colon Cancer in the Background of Adenomatous Polyposis Coli Inactivation.
Increased Expression of BRCA2 and RAD51 in Lymph Node Metastases of Canine Mammary Adenocarcinomas.
Mismatch repair deficiency commonly precedes adenoma formation in Lynch Syndrome-Associated colorectal tumorigenesis.
Mutated Rnf43 Aggravates Helicobacter Pylori-Induced Gastric Pathology.
RNF43 germline and somatic mutation in serrated neoplasia pathway and its association with BRAF mutation.
RNF43 Is an Early and Specific Mutated Gene in the Serrated Pathway, With Increased Frequency in Traditional Serrated Adenoma and Its Associated Malignancy.
RNF43 mutation analysis in serrated polyposis, sporadic serrated polyps and Lynch syndrome polyps.
Traditional serrated adenoma: an overview of pathology and emphasis on molecular pathogenesis.
[Changes in gene expression during the proliferative processes of parathyroid gland]
Adenomatous Polyposis Coli
BNIP3L-mediated mitophagy is required for mitochondrial remodeling during the differentiation of optic nerve oligodendrocytes.
Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.
Detection of heterozygous truncating mutations in the BRCA1 and APC genes by using a rapid screening assay in yeast.
Development of a universal gap repair vector for yeast-based screening of knockout rodents.
Dosage analysis of cancer predisposition genes by multiplex ligation-dependent probe amplification.
Expression of Parkin, APC, APE1, and Bcl-xL in Colorectal Polyps.
Familial pancreatic carcinoma in Jews.
FIP200 inhibits ?-catenin-mediated transcription by promoting APC-independent ?-catenin ubiquitination.
Genetic testing by cancer site: stomach.
Haploinsufficiency of Casitas B-Lineage Lymphoma Augments the Progression of Colon Cancer in the Background of Adenomatous Polyposis Coli Inactivation.
HectD1 E3 ligase modifies adenomatous polyposis coli (APC) with polyubiquitin to promote the APC-axin interaction.
Hereditary cancer syndromes.
Hereditary common cancers: molecular and clinical genetics.
Histological groups of human postpubertal testicular germ cell tumours harbour different genetic alterations.
Identification and management of inherited cancer susceptibility.
Inheritance of cancer.
Inherited predisposition to cancer: a historical overview.
Multiple gene methylation of nonsmall cell lung cancers evaluated with 3-dimensional microarray.
Not All Wnt Activation Is Equal: Ligand-Dependent versus Ligand-Independent Wnt Activation in Colorectal Cancer.
Novel LOVD databases for hereditary breast cancer and colorectal cancer genes in the Chinese population.
Preimplantation genetic diagnosis (PGD) for heritable neoplasia.
Preimplantation genetic diagnosis for cancer predisposition syndromes.
Adenoviridae Infections
Deletion of the E3 ubiquitin ligase, Parkin, exacerbates chronic alcohol intake-induced cardiomyopathy through an Ambra1-dependent mechanism.
Adenovirus Infections, Human
Human Adenovirus Infection Causes Cellular E3 Ubiquitin Ligase MKRN1 Degradation Involving the Viral Core Protein pVII.
Albinism
Generation of CRISPR/Cas9-mediated gene-targeted pigs via somatic cell nuclear transfer.
Albinism, Oculocutaneous
Genetic profiling of a rare condition: co-occurrence of albinism and multiple primary melanoma in a Caucasian family.
Alopecia
Effects of cinnarizine, a calcium antagonist that produces human parkinsonism, in parkin knock out mice.
Alzheimer Disease
Aberrant Accumulation of BRCA1 in Alzheimer Disease and Other Tauopathies.
Alternative splicing generates different parkin protein isoforms: evidences in human, rat, and mouse brain.
Alzheimer disease: BRCA1 involved in AD-related cognitive deficits.
BRCA1 and p53 Tumor Suppressor Molecules in Alzheimer's Disease.
BRCA1 may modulate neuronal cell cycle re-entry in Alzheimer disease.
Colocalization of BRCA1 with Tau Aggregates in Human Tauopathies.
Deficiency of TRIM32 Impairs Motor Function and Purkinje Cells in Mid-Aged Mice.
Diminished Parkin Solubility and Co-Localization with Intraneuronal Amyloid-? are Associated with Autophagic Defects in Alzheimer's Disease.
Diverse mechanisms of autophagy dysregulation and their therapeutic implications: does the shoe fit?
E3 Ligase STUB1/CHIP Regulates NAD(P)H:Quinone Oxidoreductase 1 (NQO1) Accumulation in Aged Brain, a Process Impaired in Certain Alzheimer Disease Patients.
Involvement and interplay of Parkin, PINK1, and DJ1 in neurodegenerative and neuroinflammatory disorders.
Isolated RING2 domain of parkin is sufficient for E2-dependent E3 ligase activity.
Mitochondrial nanomedicine: Subcellular organelle-specific delivery of molecular medicines.
Mitophagy in degenerative joint diseases.
Negative Selection on BRCA1 Susceptibility Alleles Sheds Light on the Population Genetics of Late-Onset Diseases and Aging Theory.
Neuron-specific methylome analysis reveals epigenetic regulation and tau-related dysfunction of BRCA1 in Alzheimer's disease.
NH2-truncated human tau induces deregulated mitophagy in neurons by aberrant recruitment of Parkin and UCHL-1: implications in Alzheimer's disease.
Organelle-specific autophagy in inflammatory diseases: a potential therapeutic target underlying the quality control of multiple organelles.
Overactive BRCA1 Affects Presenilin 1 in Induced Pluripotent Stem Cell-Derived Neurons in Alzheimer's Disease.
Parkin and synphilin-1 isoform expression changes in Lewy body diseases.
Parkin overexpression ameliorates hippocampal long-term potentiation and ss-amyloid load in an Alzheimer's disease mouse model.
Parkin Overexpression Ameliorates PrP106-126-Induced Neurotoxicity via Enhanced Autophagy in N2a Cells.
Parkin protects against mitochondrial toxins and beta-amyloid accumulation in skeletal muscle cells.
Parkin Regulation and Neurodegenerative Disorders.
Parkinson's disease-associated parkin colocalizes with Alzheimer's disease and multiple sclerosis brain lesions.
PINK1/PARKIN signalling in neurodegeneration and neuroinflammation.
PRKN-regulated mitophagy and cellular senescence during COPD pathogenesis.
Protein-Protein interactions uncover candidate 'core genes' within omnigenic disease networks.
Quantitative interaction proteomics of neurodegenerative disease proteins.
Role of BRCA1 in Neuronal Death in Alzheimer's Disease.
Ameloblastoma
Expression profile of polycomb group proteins in odontogenic keratocyst and ameloblastoma.
Amnesia
Performance on tests sensitive to frontal lobe lesions by patients with organic amnesia: Leng & Parkin revisited.
Amyloidosis
Parkin deletion causes cerebral and systemic amyloidosis in human mutated tau over-expressing mice.
The E3 ubiquitin ligase Idol controls brain LDL receptor expression, ApoE clearance, and A? amyloidosis.
Amyotrophic Lateral Sclerosis
Distinct multilevel misregulations of Parkin and PINK1 revealed in cell and animal models of TDP-43 proteinopathy.
Genetic activation of parkin rescues TAF15-induced neurotoxicity in a Drosophila model of amyotrophic lateral sclerosis.
Mice lacking the PSD-95-interacting E3 ligase, Dorfin/Rnf19a, display reduced adult neurogenesis, enhanced long-term potentiation, and impaired contextual fear conditioning.
Organelle-specific autophagy in inflammatory diseases: a potential therapeutic target underlying the quality control of multiple organelles.
Parkin expression reverses mitochondrial dysfunction in fused in sarcoma-induced amyotrophic lateral sclerosis.
Parkin Regulation and Neurodegenerative Disorders.
Anemia
An invariant surface patch on the TRIM5alpha PRYSPRY domain is required for retroviral restriction but dispensable for capsid binding.
BRCA1/FANCD2/BRG1-Driven DNA Repair Stabilizes the Differentiation State of Human Mammary Epithelial Cells.
Comparative requirements for the restriction of retrovirus infection by TRIM5alpha and TRIMCyp.
Crosstalk between BRCA-Fanconi anemia and mismatch repair pathways prevents MSH2-dependent aberrant DNA damage responses.
Effects of Sepantronium Bromide (YM-155) on the Whole Transcriptome of MDA-MB-231 Cells: Highlight on Impaired ATR/ATM Fanconi Anemia DNA Damage Response.
Ensemble-based virtual screening in discovering potent inhibitors targeting Von Hippel-Lindau (VHL) E3 ubiquitin ligase.
Erratum: BRCA1 homozygous unclassified variant in a patient with non-Fanconi anemia: A case report.
High throughput parallel analysis of hundreds of patient samples for more than 100 mutations in multiple disease genes.
Leukemic survival factor SALL4 contributes to defective DNA damage repair.
Preimplantation genetic diagnosis (PGD) for heritable neoplasia.
RAD6B is a major mediator of triple negative breast cancer cisplatin resistance: Regulation of translesion synthesis/Fanconi anemia crosstalk and BRCA1 independence.
Targeting the von Hippel-Lindau E3 Ubiquitin Ligase Using Small Molecules To Disrupt the VHL/HIF-1? Interaction.
Anemia, Refractory
A high occurrence of acquisition and/or expansion of C-CBL mutant clones in the progression of high-risk myelodysplastic syndrome to acute myeloid leukemia.
Anemia, Sickle Cell
High throughput parallel analysis of hundreds of patient samples for more than 100 mutations in multiple disease genes.
Metaplastic breast carcinoma: pathology and clinical outcome.
Aneurysm
Salvia miltiorrhiza-Derived Sal-miR-58 Induces Autophagy and Attenuates Inflammation in Vascular Smooth Muscle Cells.
Aneurysm, Dissecting
Disturbed P53-MDM2 feedback loop contributes to thoracic aortic dissection formation and may be a result of TRIM-25 overexpression.
Angelman Syndrome
A bipartite boundary element restricts UBE3A imprinting to mature neurons.
Adult Ube3a Gene Reinstatement Restores the Electrophysiological Deficits of Prefrontal Cortex Layer 5 Neurons in a Mouse Model of Angelman Syndrome.
An Angelman syndrome substitution in the HECT E3 ubiquitin ligase C-terminal Lobe of E6AP affects protein stability and activity.
Angelman Syndrome Protein Ube3a Regulates Synaptic Growth and Endocytosis by Inhibiting BMP Signaling in Drosophila.
Catalytically Important Residues of E6AP Ubiquitin Ligase Identified Using Acid-Cleavable Photo-Cross-Linkers.
Detailed Dissection of UBE3A-Mediated DDI1 Ubiquitination.
E3 Ubiquitin Ligases in Neurological Diseases: Focus on Gigaxonin and Autophagy.
E6AP goes viral: the role of E6AP in viral- and non-viral-related cancers.
Establishment of human induced pluripotent stem cell line from a patient with Angelman syndrome carrying the deletion of maternal chromosome 15q11.2-q13.
HAP1 is an in vivo UBE3A target that augments autophagy in a mouse model of Angelman syndrome.
Identification of Small-Molecule Activators of the Ubiquitin Ligase E6AP/UBE3A and Angelman Syndrome-Derived E6AP/UBE3A Variants.
Identification of UBE3A Protein in CSF and Extracellular Space of the Hippocampus Suggest a Potential Novel Function in Synaptic Plasticity.
Imbalanced mechanistic target of rapamycin C1 and C2 activity in the cerebellum of Angelman syndrome mice impairs motor function.
Imprinting effects of UBE3A loss on synaptic gene networks and Wnt signaling pathways.
JNK signaling activation in the Ube3a maternal deficient mouse model: Its specific inhibition prevents post-synaptic protein-enriched fraction alterations and cognitive deficits in Angelman Syndrome model.
Modulation of hippocampal synapse maturation by activity-regulated E3 ligase via non-canonical pathway.
Proteomic profiling in Drosophila reveals potential Dube3a regulation of the actin cytoskeleton and neuronal homeostasis.
Regulation of the polycomb protein Ring1B by self-ubiquitination or by E6-AP may have implications to the pathogenesis of Angelman syndrome.
The Angelman Syndrome protein Ube3A regulates synapse development by ubiquitinating arc.
The Angelman Syndrome Protein Ube3a/E6AP Is Required for Golgi Acidification and Surface Protein Sialylation.
The Autism and Angelman Syndrome Protein Ube3A/E6AP: The Gene, E3 Ligase Ubiquitination Targets and Neurobiological Functions.
The Drosophila homologue of the Angelman syndrome ubiquitin ligase regulates the formation of terminal dendritic branches.
The E3 ligase ube3a is required for learning in Drosophila melanogaster.
Ube3a is required for experience-dependent maturation of the neocortex.
UBE3A regulates MC1R expression: a link to hypopigmentation in Angelman syndrome.
UBE3A Regulates Synaptic Plasticity and Learning and Memory by Controlling SK2 Channel Endocytosis.
Ube3a, the E3 ubiquitin ligase causing Angelman syndrome and linked to autism, regulates protein homeostasis through the proteasomal shuttle Rpn10.
UBE3A-mediated PTPA ubiquitination and degradation regulate PP2A activity and dendritic spine morphology.
Angina Pectoris
Natural compound methyl protodioscin protects rat brain from ischemia/reperfusion injury through regulation of Mul1/SOD2 pathway.
Angiomyolipoma
Germline mutation in the NBR1 gene involved in autophagy detected in a family with renal tumors.
Anosmia
Nonmotor symptoms in Parkin gene-related parkinsonism.
Parkin is the most common causative gene in a cohort of mainland Chinese patients with sporadic early-onset Parkinson's disease.
Aortic Aneurysm
Ari-1 Regulates Myonuclear Organization Together with Parkin and Is Associated with Aortic Aneurysms.
Arteriovenous Malformations
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Arteritis
Nuclear localization signal in TRIM22 is essential for inhibition of type 2 porcine reproductive and respiratory syndrome virus replication in MARC-145 cells.
Arthritis
Critical roles of the E3 ubiquitin ligase FBW7 in B-cell response and the pathogenesis of experimental autoimmune arthritis.
Gene expression analysis approach to establish possible links between Parkinson's disease, cancer and cardiovascular diseases.
Loss of Parkin reduces inflammatory arthritis by inhibiting p53 degradation.
Paraneoplastic fasciitis and polyarthritis syndrome as a manifestation of breast cancer recurrence in a BRCA1 gene-positive patient.
Role of interleukin 17 in arthritis chronicity through survival of synoviocytes via regulation of synoviolin expression.
Arthritis, Experimental
Forkhead box o3a suppresses lipopolysaccharide-stimulated proliferation and inflammation in fibroblast-like synoviocytes through regulating tripartite motif-containing protein 3.
Arthritis, Rheumatoid
Activation of synoviolin promoter in rheumatoid synovial cells by a novel transcription complex of interleukin enhancer binding factor 3 and GA binding protein alpha.
CUL1, a component of E3 ubiquitin ligase, alters lymphocyte signal transduction with possible effect on rheumatoid arthritis.
Identification of the inhibitory activity of walnut extract on the E3 ligase Syvn1.
Loss of Parkin reduces inflammatory arthritis by inhibiting p53 degradation.
MicroRNA-17 Suppresses TNF-? Signaling by Interfering with TRAF2 and cIAP2 Association in Rheumatoid Arthritis Synovial Fibroblasts.
Overexpression of synoviolin in peripheral blood and synoviocytes from rheumatoid arthritis patients and continued elevation in nonresponders to infliximab treatment.
PRKN-regulated mitophagy and cellular senescence during COPD pathogenesis.
RING-finger type E3 ubiquitin ligase inhibitors as novel candidates for the treatment of rheumatoid arthritis.
Role of interleukin 17 in arthritis chronicity through survival of synoviocytes via regulation of synoviolin expression.
Synoviolin promotes IRE1 ubiquitination and degradation in synovial fibroblasts from mice with collagen-induced arthritis.
Targeting TRAF6 E3 ligase activity with a small-molecule inhibitor combats autoimmunity.
The NRF2?PGC?1? pathway activates kynurenine aminotransferase 4 via attenuation of an E3 ubiquitin ligase, synoviolin, in a cecal ligation/perforation?induced septic mouse model.
The triptolide-induced apoptosis of osteoclast precursor by degradation of cIAP2 and treatment of rheumatoid arthritis of TNF-transgenic mice.
TRIM32 promotes inflammatory responses in rheumatoid arthritis fibroblast-like synoviocytes.
Ubiquitin ligase substrate identification through quantitative proteomics at both the protein and peptide levels.
Upregulation of HRD1 promotes cell migration and invasion in colon cancer.
ZNRF3 Regulates Collagen-Induced Arthritis Through NF-kB and Wnt Pathways.
Asthma
A network approach predicts NFKBIA and BIRC3 as pathogenic genes in childhood asthma.
A protein interaction network associated with asthma.
BIRC3 single nucleotide polymorphism associate with asthma susceptibility and the abundance of eosinophils and neutrophils.
E3 ubiquitin ligase Cbl-b suppresses human ORMDL3 expression through STAT6 mediation.
March1 E3 Ubiquitin Ligase Modulates Features of Allergic Asthma in an Ovalbumin-Induced Mouse Model of Lung Inflammation.
Parkin, an E3 ubiquitin ligase, enhances airway mitochondrial DNA release and inflammation.
The E3 ubiquitin ligase midline 1 promotes allergen and rhinovirus-induced asthma by inhibiting protein phosphatase 2A activity.
Astrocytoma
Apoptosis and proliferation markers in diffusely infiltrating astrocytomas: profiling of 17 molecules.
E3 ubiquitin ligase siah?1 nuclear accumulation is critical for homocysteine?induced impairment of C6 astroglioma cells.
Expression profile of parkin isoforms in human gliomas.
Methylation profiles of thirty four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma.
Mislocalization of the E3 ligase, beta-transducin repeat containing protein 1 ({beta}-TrCP1) in glioblastoma uncouples negative feedback between the PH domain Leucine-rich repeat Protein Phosphatase 1 (PHLPP1) and Akt.
Parkinson's disease-associated parkin colocalizes with Alzheimer's disease and multiple sclerosis brain lesions.
Asymptomatic Infections
The presence of the Trim5alpha escape mutation H87Q in the capsid of late stage HIV-1 variants is preceded by a prolonged asymptomatic infection phase.
Ataxia
Ataxia telangiectasia-related protein is involved in the phosphorylation of BRCA1 following deoxyribonucleic acid damage.
Biallelic mutations in RNF220 cause laminopathies featuring leukodystrophy, ataxia and deafness.
Both DNA topoisomerase II-binding protein 1 and BRCA1 regulate the G2-M cell cycle checkpoint.
Indole-3-carbinol activates the ATM signaling pathway independent of DNA damage to stabilize p53 and induce G1 arrest of human mammary epithelial cells.
Phosphorylation of the BRCA1 C terminus (BRCT) repeat inhibitor of hTERT (BRIT1) protein coordinates TopBP1 protein recruitment and amplifies ataxia telangiectasia-mutated and Rad3-related (ATR) Signaling.
Regulation of BRCA1 phosphorylation by interaction with protein phosphatase 1alpha.
Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks.
RNF216 Regulates the Migration of Immortalized GnRH Neurons by Suppressing Beclin1-Mediated Autophagy.
Structural studies of parkin and sacsin: Mitochondrial dynamics in neurodegenerative diseases.
Ubiquitin Ligase RNF138 Promotes Episodic Ataxia Type 2-Associated Aberrant Degradation of Human Cav2.1 (P/Q-Type) Calcium Channels.
Ataxia Telangiectasia
A 20-year perspective on the International Fanconi Anemia Registry (IFAR).
Ataxia telangiectasia mutated (ATM) kinase and ATM and Rad3 related kinase mediate phosphorylation of Brca1 at distinct and overlapping sites. In vivo assessment using phospho-specific antibodies.
Ataxia telangiectasia mutated and checkpoint kinase 2 regulate BRCA1 to promote the fidelity of DNA end-joining.
Ataxia telangiectasia mutated interacts with Parkin and induces mitophagy independent of kinase activity. Evidence from mantle cell lymphoma.
Ataxia telangiectasia-related protein is involved in the phosphorylation of BRCA1 following deoxyribonucleic acid damage.
BRCA-related ATM-mediated DNA double-strand break repair and ovarian aging.
BRCA1 Deficiency Impairs Mitophagy and Promotes Inflammasome Activation and Mammary Tumor Metastasis.
BRCA1 phosphorylation regulates caspase-3 activation in UV-induced apoptosis.
CHK2 kinase promotes pre-mRNA splicing via phosphorylating CDK11(p110).
CtIP protein dimerization is critical for its recruitment to chromosomal DNA double-stranded breaks.
Current perspectives on radiation-induced breast cancer.
DDRI-9: a novel DNA damage response inhibitor that blocks mitotic progression.
DNA damage response is suppressed by the high cyclin-dependent kinase 1 activity in mitotic mammalian cells.
Effects of Sepantronium Bromide (YM-155) on the Whole Transcriptome of MDA-MB-231 Cells: Highlight on Impaired ATR/ATM Fanconi Anemia DNA Damage Response.
Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins.
Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53.
Familial pancreatic carcinoma in Jews.
Functional link of BRCA1 and ataxia telangiectasia gene product in DNA damage response.
Gallic acid induces DNA damage and inhibits DNA repair-associated protein expression in human oral cancer SCC-4 cells.
Gamma-irradiation-induced DNA damage checkpoint activation involves feedback regulation between extracellular signal-regulated kinase 1/2 and BRCA1.
Germline genetic variants in men with prostate cancer and one or more additional cancers.
Germline PALB2, ATM variants in a patient with breast and ovarian cancer at risk for familial cancer syndrome: Is there a role for risk-reducing salpingo-oophorectomy?
Inherited susceptibility to breast cancer.
Interactions Between Ataxia Telangiectasia Mutated Kinase Inhibition, Poly(ADP-ribose) Polymerase-1 Inhibition and BRCA1 Status in Breast Cancer Cells.
Loss of heterozygosity in human breast carcinomas in the ataxia telangiectasia, Cowden disease and BRCA1 gene regions.
Low concentrations of diindolylmethane, a metabolite of indole-3-carbinol, protect against oxidative stress in a BRCA1-dependent manner.
Management of women with a family history of breast cancer.
Melanoma cells express elevated levels of phosphorylated histone H2AX foci.
Mutagen sensitivity of human lymphoblastoid cells with a BRCA1 mutation in comparison to ataxia telangiectasia heterozygote cells.
Phosphorylation of ATR-interacting protein on Ser239 mediates an interaction with breast-ovarian cancer susceptibility 1 and checkpoint function.
Phosphorylation of SMURF2 by ATM exerts a negative feedback control of DNA damage response.
Protection from UV-induced skin carcinogenesis by genetic inhibition of the ataxia telangiectasia and Rad3-related (ATR) kinase.
PRP19 transforms into a sensor of RPA-ssDNA after DNA damage and drives ATR activation via a ubiquitin-mediated circuitry.
Recent advances in breast cancer biology.
Susceptibility to breast cancer: hereditary syndromes and low penetrance genes.
The Role of PALB2 in the DNA Damage Response and Cancer Predisposition.
Three-Dimensional Architecture of the Human BRCA1-A Histone Deubiquitinase Core Complex.
Ubiquitin-activating enzyme UBA1 is required for cellular response to DNA damage.
Atherosclerosis
Age-Associated Mitochondrial Dysfunction Accelerates Atherogenesis.
BRCA1 is a novel target to improve endothelial dysfunction and retard atherosclerosis.
E3 Ligase FBXW2 Is a New Therapeutic Target in Obesity and Atherosclerosis.
HRD1 prevents atherosclerosis-mediated endothelial cell apoptosis by promoting LOX-1 degradation.
Identification of differentially methylated BRCA1 and CRISP2 DNA regions as blood surrogate markers for cardiovascular disease.
ITCH modulates SIRT6 and SREBP2 to influence lipid metabolism and atherosclerosis in ApoE null mice.
Loss of Cellular Inhibitor of Apoptosis Protein 2 Reduces Atherosclerosis in Atherogenic apoE-/- C57BL/6 Mice on High-Fat Diet.
Nedd4 Deficiency in Vascular Smooth Muscle Promotes Vascular Calcification by Stabilizing pSmad1.
Polymicrobial Oral Infection with Four Periodontal Bacteria Orchestrates a Distinct Inflammatory Response and Atherosclerosis in ApoE null Mice.
Athetosis
Preliminary studies on parkin gene deletion at exons 1 to 6 in Chinese patients with praecox Parkinson's disease.
[Analysis of the parkin gene deletion mutations in Chinese patients with Parkinson's disease]
Autoimmune Diseases
c-Cbl targets PD-1 in immune cells for proteasomal degradation and modulates colorectal tumor growth.
CUL1, a component of E3 ubiquitin ligase, alters lymphocyte signal transduction with possible effect on rheumatoid arthritis.
Decreased expression of TRIM21 indicates unfavorable outcome and promotes cell growth in breast cancer.
E3 ligase FBXW7 aggravates TMPD-induced systemic lupus erythematosus by promoting cell apoptosis.
Human ITCH E3 ubiquitin ligase deficiency causes syndromic multisystem autoimmune disease.
In silico analysis of functional single nucleotide polymorphisms in the human TRIM22 gene.
Regulation of autoimmune disease by the E3 ubiquitin ligase Itch.
SS-A/Ro52 promotes apoptosis by regulating Bcl-2 production.
The E3 ubiquitin ligase Itch deficiency promotes antigen-driven B-cell responses in mice.
The E3 ubiquitin ligase Itch restricts antigen-driven B cell responses.
The ROQUIN family of proteins localizes to stress granules via the ROQ domain and binds target mRNAs.
TRIM21 Is Targeted for Chaperone-Mediated Autophagy during Salmonella Typhimurium Infection.
TRIM22: A Diverse and Dynamic Antiviral Protein.
Avian Leukosis
Avian leukosis virus subgroup J and reticuloendotheliosis virus coinfection induced TRIM62 regulation of the actin cytoskeleton.
Regulatory effects of chicken TRIM25 on the replication of ALV-A and the MDA5-mediated type I interferon response.
Bacterial Infections
A bacterial E3 ubiquitin ligase IpaH9.8 targets NEMO/IKKgamma to dampen the host NF-kappaB-mediated inflammatory response.
A zebrafish (Danio rerio) bloodthirsty member 20 with E3 ubiquitin ligase activity involved in immune response against bacterial infection.
AMPK activates Parkin independent autophagy and improves post sepsis immune defense against secondary bacterial lung infections.
Blocking of Birc3/TLR4/Myd88 signaling protects carbapenem-resistant klebsiella pneumoniae in a mouse model of infection.
M1-linked ubiquitination by LUBEL is required for inflammatory responses to oral infection in Drosophila.
Parkin-mediated responses against infection and wound involve TSPO-VDAC complex in Drosophila.
The ubiquitin ligase parkin mediates resistance to intracellular pathogens.
Bardet-Biedl Syndrome
Homozygosity mapping with SNP arrays identifies TRIM32, an E3 ubiquitin ligase, as a Bardet-Biedl syndrome gene (BBS11).
Basal Cell Nevus Syndrome
Coincident PTCH and BRCA1 germline mutations in a patient with nevoid basal cell carcinoma syndrome and familial breast cancer.
Basal Ganglia Diseases
Mutation analysis of the parkin gene in Russian families with autosomal recessive juvenile parkinsonism.
Bell Palsy
A family with Parkinson disease, essential tremor, bell palsy, and parkin mutations.
beta-Thalassemia
High throughput parallel analysis of hundreds of patient samples for more than 100 mutations in multiple disease genes.
Biliary Tract Neoplasms
Prevalence of pancreaticobiliary cancers in Irish families with pathogenic BRCA1 and BRCA2 variants.
Blast Crisis
c-Cbl tyrosine phosphorylation and subcellular localization in human primary leukemic cells.
Down-regulation of BRCA1 in BCR-ABL-expressing hematopoietic cells.
Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies.
Study of methylation levels of parkin gene promoter in Parkinson's disease patients.
Blister
Biallelic mutations in RNF220 cause laminopathies featuring leukodystrophy, ataxia and deafness.
c-Cbl-mediated selective virus-receptor translocations into lipid rafts regulate productive Kaposi's sarcoma-associated herpesvirus infection in endothelial cells.
Correction: Interaction of c-Cbl with Myosin IIA Regulates Bleb Associated Macropinocytosis of Kaposi's Sarcoma-Associated Herpesvirus.
ESCRT-I Protein Tsg101 Plays a Role in the Post-macropinocytic Trafficking and Infection of Endothelial Cells by Kaposi's Sarcoma-Associated Herpesvirus.
Interaction of c-Cbl with myosin IIA regulates Bleb associated macropinocytosis of Kaposi's sarcoma-associated herpesvirus.
Bloom Syndrome
Association of BLM and BRCA1 during Telomere Maintenance in ALT Cells.
Bloom syndrome cells undergo p53-dependent apoptosis and delayed assembly of BRCA1 and NBS1 repair complexes at stalled replication forks.
Coinheritance of BRCA1 and BRCA2 mutations with Fanconi anemia and Bloom syndrome mutations in Ashkenazi Jewish population: possible role in risk modification for cancer development.
Coregulation of FANCA and BRCA1 in human cells.
Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins.
Mendelian diseases among Roman Jews: implications for the origins of disease alleles.
System-wide analysis of SUMOylation dynamics in response to replication stress reveals novel SUMO target proteins and acceptor lysines relevant for genome stability.
Bone Diseases
Targeting the E3 ubiquitin casitas B-lineage lymphoma decreases osteosarcoma cell growth and survival and reduces tumorigenesis.
Bone Marrow Failure Disorders
Ablation of the Brca1-Palb2 Interaction Phenocopies Fanconi Anemia in Mice.
Biallelic germline BRCA1 mutations in a patient with early onset breast cancer, mild Fanconi anemia-like phenotype, and no chromosome fragility.
Biallelic variants in BRCA1 gene cause a recognisable phenotype within chromosomal instability syndromes reframed as BRCA1 deficiency.
Brca1 deficiency causes bone marrow failure and spontaneous hematologic malignancies in mice.
Fanconi Anemia Complementation Group FANCD2 Protein Serine 331 Phosphorylation Is Important for Fanconi Anemia Pathway Function and BRCA2 Interaction.
PALB2 (partner and localizer of BRCA2).
Bone Neoplasms
[Implication of the ubiquitin ligase c-Cbl in bone formation and tumorigenesis].
Bone Resorption
BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
c-Cbl and Cbl-b Act redundantly to protect osteoclasts from apoptosis and to displace HDAC6 from {beta}-tubulin, stabilizing microtubules and podosomes.
c-Cbl is downstream of c-Src in a signalling pathway necessary for bone resorption.
E3 ubiquitin ligase-mediated regulation of bone formation and tumorigenesis.
[Biology of osteoclasts; their role in bone metastases]
[Cell biology of osteoclasts and molecular mechanisms of bone resorption]
Brain Diseases
Abnormal regulation of TSG101 in mice with spongiform neurodegeneration.
Dysfunction of mitochondrial respiratory chain complex I in neurological disorders: genetics and pathogenetic mechanisms.
Levels of the Mahogunin Ring Finger 1 E3 ubiquitin ligase do not influence prion disease.
LRSAM1 E3 ubiquitin ligase: molecular neurobiological perspectives linked with brain diseases.
Oligodendroglial deletion of ESCRT-I component TSG101 causes spongiform encephalopathy.
Prion topology and toxicity.
TDP-43 upregulation mediated by the NLRP3 inflammasome induces cognitive impairment in 2 2',4,4'-tetrabromodiphenyl ether (BDE-47)-treated mice.
TRIM8 interacts with KIF11 and KIFC1 and controls bipolar spindle formation and chromosomal stability.
Brain Injuries
Mitochondrial E3 ubiquitin ligase 1 promotes brain injury by disturbing mitochondrial dynamics in a rat model of ischemic stroke.
Neuroprotective effects of targeting BET proteins for degradation with dBET1 in aged mice subjected to ischemic stroke.
RNF34 overexpression exacerbates neurological deficits and brain injury in a mouse model of intracerebral hemorrhage by potentiating mitochondrial dysfunction-mediated oxidative stress.
SCY1-like 1 binding protein 1 (SCYL1-bp1) interacts with p53-induced RING H2 protein (Pirh2) after traumatic brain injury in rats.
The E3 ubiquitin ligase TRIM31 is involved in cerebral ischemic injury by promoting degradation of TIGAR.
Brain Injuries, Traumatic
Changes in Pirh2 and p27(kip1) Expression Following Traumatic Brain Injury in Adult Rats.
SCY1-like 1 binding protein 1 (SCYL1-bp1) interacts with p53-induced RING H2 protein (Pirh2) after traumatic brain injury in rats.
Brain Ischemia
Down-regulation of parkin protein in transient focal cerebral ischemia: A link between stroke and degenerative disease?
PINK1 overexpression protects against cerebral ischemia through Parkin regulation.
Rehmapicroside ameliorates cerebral ischemia-reperfusion injury via attenuating peroxynitrite-mediated mitophagy activation.
The E3 ubiquitin ligase TRIM31 is involved in cerebral ischemic injury by promoting degradation of TIGAR.
TRIM62 knockout protects against cerebral ischemic injury in mice by suppressing NLRP3-regulated neuroinflammation.
Brain Neoplasms
A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity.
BRCA1 Mutations Associated With Increased Risk of Brain Metastases in Breast Cancer: A 1: 2 Matched-pair Analysis.
Correlation between BRCA1 expression and clinicopathological factors including brain metastases in patients with non-small-cell lung cancer.
Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO.
Glioma tumor grade correlates with parkin depletion in mutant p53-linked tumors and results from loss of function of p53 transcriptional activity.
High Expression of Pirh2 is Associated with Poor Prognosis in Glioma.
Human Brat ortholog TRIM3 is a tumor suppressor that regulates asymmetric cell division in glioblastoma.
Increased incidence of brain metastases in BRCA1-related ovarian cancers.
Loss of heterozygosity of TRIM3 in malignant gliomas.
Molecular and cellular response of the most extensively used rodent glioma models to radiation and/or cisplatin.
Next-Generation Sequencing Analysis of ctDNA for the Detection of Glioma and Metastatic Brain Tumors in Adults.
No evidence for germline PTEN mutations in families with breast and brain tumours.
Parkin pathway activation mitigates glioma cell proliferation and predicts patient survival.
Significance of BRCA1 expression in breast and ovarian cancer patients with brain metastasis - A multicentre study.
Spectrum of breast cancer metastasis in BRCA1 mutation carriers: highly increased incidence of brain metastases.
Successful treatment of a patient with brain metastases from endometrial cancer using Niraparib: a case report.
UBE4B promotes Hdm2-mediated degradation of the tumor suppressor p53.
Breast Carcinoma In Situ
Epidemiology, genetics, and risk evaluation of postmenopausal women at risk of breast cancer.
Molecular genetics of solid tumours: translating research into clinical practice. What we could do now: breast cancer.
Prevalence of BRCA1 and BRCA2 mutations in women with breast carcinoma In Situ and referred for genetic testing.
Screening and follow-up of the patient at high risk for breast cancer.
The role of MRI in breast cancer screening.
Use of bilateral prophylactic nipple-sparing mastectomy in patients with high risk of breast cancer.
Breast Diseases
BRCA1 gene exon 11 mutations in Uighur and Han women with early-onset sporadic breast cancer in the northwest region of China.
Clustering of variations and haplotype analysis in the highly variable region of exon 11 of BRCA1 in Chinese women with sporadic breast cancer.
Current methods to prevent the development of breast cancer.
Folate and breast cancer: what about high-risk women?
The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified.
[Analysis of the mutation of BRCA1 gene in 70 Uigur women breast cancer patients in Xinjiang]
Breast Neoplasms
"An addendum to breast cancer": the triple negative experience.
"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
"Decoding hereditary breast cancer" benefits and questions from multigene panel testing.
"Guys Don't Have Breasts": The Lived Experience of Men Who Have BRCA Gene Mutations and Are at Risk for Male Breast Cancer.
"Other" breast cancer susceptibility genes: searching for more holy grail.
"Social separation" among women under 40 years of age diagnosed with breast cancer and carrying a BRCA1 or BRCA2 mutation.
"The race" to clone BRCA1.
17 beta Hydroxysteroid dehydrogenase 1 "pseudogene" is differentially transcribed: still a candidate for the breast-ovarian cancer susceptibility gene (BRCA1).
18. Genetics of breast cancer.
19p13.1 is a triple negative-specific breast cancer susceptibility locus.
1H, 13C and 15N backbone resonance assignment of BRCA1 fragment 219-504.
3,3'-Diindolymethane ameliorates adriamycin-induced cardiac fibrosis via activation of a BRCA1-dependent anti-oxidant pathway.
53BP1, BRCA1, and the Choice between Recombination and End Joining at DNA Double-Strand Breaks.
655Val and 1170Pro ERBB2 SNPs in familial breast cancer risk and BRCA1 alterations.
?-hCG induced mutant BRCA1 ignites drug resistance in susceptible breast tissue.
?Np63? induces quiescence and downregulates the BRCA1 pathway in estrogen receptor-positive luminal breast cancer cell line MCF7 but not in other breast cancer cell lines.
A 12-year experience at a tertiary hospital on patients with multiple primary malignant neoplasms.
A 20-year perspective on the International Fanconi Anemia Registry (IFAR).
A 24-color metaphase-based radiation assay discriminates heterozygous BRCA2 mutation carriers from controls by chromosomal radiosensitivity.
A 45-year follow-up of kindred 107 and the search for BRCA2.
A biochemical analysis demonstrates that the BRCA1 intronic variant IVS10-2A--> C is a mutation.
A BRCA1 deficient, NF?B driven immune signal predicts good outcome in triple negative breast cancer.
A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity.
A BRCA1 promoter variant (rs11655505) and breast cancer risk.
A BRCA1-mutation associated DNA methylation signature in blood cells predicts sporadic breast cancer incidence and survival.
A breast cancer family from Spain with germline mutations in both the BRCA1 and BRCA2 genes.
A breast cancer patient from Italy with germline mutations in both the BRCA1 and BRCA2 genes.
A breast cancer patient of Scottish descent with germ-line mutations in BRCA1 and BRCA2.
A breast cancer prediction model incorporating familial and personal risk factors.
A case of familial breast cancer with double heterozygosity for BRCA1 and BRCA2 genes.
A Case Report of Germline Compound Heterozygous Mutations in the BRCA1 Gene of an Ovarian and Breast Cancer Patient.
A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.
A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer.
A chromatin-based signalling mechanism directs the switch from mutagenic to error-free repair of DNA double strand breaks.
A clinical case of diagnosis of breast cancer in patients with family history of BRCA mutations 1.
A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk.
A Clinically Validated Diagnostic Second-Generation Sequencing Assay for Detection of Hereditary BRCA1 and BRCA2 Mutations.
A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment.
A common Greenlandic Inuit BRCA1 RING domain founder mutation.
A Comparative Analysis of Breast and Ovarian Cancer-related Gene Mutations in Canadian and Saudi Arabian Patients with Breast Cancer.
A comparison of bilateral breast cancers in BRCA carriers.
A comparison of breast, testicular and prostate cancer in mass print media (1996-2001).
A comparison of male attendees and nonattendees at a familial cancer clinic.
A competing risks model with binary time varying covariates for estimation of breast cancer risks in BRCA1 families.
A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer.
A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes.
A comprehensive reference for BRCA1/2 genes pathogenic variants in Iran: published, unpublished and novel.
A computational approach to the study of interactions between proteins and miR10-b, miR-335, and miR-21 involved in breast cancer.
A CREB site in the BRCA1 proximal promoter acts as a constitutive transcriptional element.
A de novo complete BRCA1 gene deletion identified in a Spanish woman with early bilateral breast cancer.
A deleterious BRCA1 mutation in a young Pakistani woman with metaplastic breast carcinoma.
A deletion map of chromosome 17q in sporadic human mammary carcinomas.
A Devastatingly "Minor" Relationship Between Male Breast Cancer and Prostate Cancer.
A DGGE system for comprehensive mutation screening of BRCA1 and BRCA2: application in a Dutch cancer clinic setting.
A diagnostic genetic test for the physical mapping of germline rearrangements in the susceptibility breast cancer genes BRCA1 and BRCA2.
A distinct phenotype characterizes tumors from a putative genetic trait involving chondrosarcoma and breast cancer occurring in the same patient.
A DNA Repair BRCA1 Estrogen Receptor and Targeted Therapy in Breast Cancer.
A Dominantly Inherited 5' UTR Variant Causing Methylation-Associated Silencing of BRCA1 as a Cause of Breast and Ovarian Cancer.
A Frailty-Model-Based Approach to Estimating the Age-Dependent Penetrance Function of Candidate Genes Using Population-Based Case-Control Study Designs: An Application to Data on the BRCA1 Gene.
A Frailty-Model-Based Method for Estimating Age-Dependent Penetrance from Family Data.
A gene (DLG2) located at 17q12-q21 encodes a new homologue of the Drosophila tumor suppressor dIg-A.
A genome wide linkage search for breast cancer susceptibility genes.
A genome-wide strategy to identify causes and consequences of retrotransposon expression finds activation by BRCA1 in ovarian cancer.
A Genomewide Screen for Suppressors of Alu-Mediated Rearrangements Reveals a Role for PIF1.
A germline mosaic BRCA1 exon deletion in a woman with bilateral basal-like breast cancer.
A germline mutation in the BRCA1 3'UTR predicts Stage IV breast cancer.
A Germline Mutation in the BRCA1 3’UTR Variant Predicts Susceptibility to Breast Cancer in a Saudi Arabian Population
A guide for functional analysis of BRCA1 variants of uncertain significance.
A haplotype-based case-control study of BRCA1 and sporadic breast cancer risk.
A high frequency of BRCA mutations in young black women with breast cancer residing in Florida.
A high frequency of PALB2 mutations in Jamaican patients with breast cancer.
A high frequent BRCA1 founder mutation identified in the Greenlandic population.
A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families.
A high prevalence of BRCA1 mutations among breast cancer patients from the Bahamas.
A high proportion of founder BRCA1 mutations in Polish breast cancer families.
A high proportion of mutations in the BRCA1 gene in German breast/ovarian cancer families with clustering of mutations in the 3' third of the gene.
A High-Throughput Functional Complementation Assay for Classification of BRCA1 Missense Variants.
A high-throughput mutation detection method based on heteroduplex analysis using graft copolymer matrixes: application to Brca1 and Brca2 analysis.
A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors.
A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity.
A High-Throughput Screening Strategy for Development of RNF8-Ubc13 Protein-Protein Interaction Inhibitors.
A label-free genosensor for BRCA1 related sequence based on impedance spectroscopy.
A large deletion disrupts the exon 3 transcription activation domain of the BRCA2 gene in a breast/ovarian cancer family.
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population.
A low fouling electrochemical biosensor based on the zwitterionic polypeptide doped conducting polymer PEDOT for breast cancer marker BRCA1 detection.
A mammary-specific, long-range deletion on mouse chromosome 11 accelerates Brca1-associated mammary tumorigenesis.
A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance.
A metastasis of an adenocarcinoma in a BRCA1 mutation carrier, a diagnostic problem not solved by morphology alone.
A microchip platform for structural oncology applications.
A Microsimulation Model for Evaluating the Effectiveness of Cancer Risk Management for BRCA Pathogenic Variant Carriers: miBRovaCAre.
A miRNA-HERC4 pathway promotes breast tumorigenesis by inactivating tumor suppressor LATS1.
A modular PROTAC design for target destruction using a degradation signal based on a single amino acid.
A mouse model featuring tissue-specific deletion of p53 and Brca1 gives rise to mammary tumors with genomic and transcriptomic similarities to human basal-like breast cancer.
A Multi-Center Study of BRCA1 and BRCA2 Germline Mutations in Mexican-Mestizo Breast Cancer Families Reveals Mutations Unreported in Latin American Population.
A multi-gene panel study in hereditary breast and ovarian cancer in Colombia.
A multi-institutional study of the prevalence of BRCA1 and BRCA2 large genomic rearrangements in familial breast cancer patients.
A multigene test for the risk of sporadic breast carcinoma.
A multigenic study on breast cancer risk associated with genetic polymorphisms of ER Alpha, COMT and CYP19 gene in BRCA1/BRCA2 negative Shanghai women with early onset breast cancer or affected relatives.
A mutation analysis of the BRCA1 gene in 140 families from southeast France with a history of breast and/or ovarian cancer.
A mutation in the 5' untranslated region of the BRCA1 gene in sporadic breast cancer causes downregulation of translation efficiency.
A Nano-Biosensor for the Detection of 185delAG Mutation in BRCA1 Gene, Leading to Breast Cancer.
A network-based approach to identify disease-associated gene modules through integrating DNA methylation and gene expression.
A Network-Based Model of Oncogenic Collaboration for Prediction of Drug Sensitivity.
A new bioinformatics tool to help assess the significance of BRCA1 variants.
A new BRCA1 germline mutation (E879X) in a Malaysian breast cancer patient of Chinese descent.
A new BRCA1 mutation in a Filipino woman with a family history of breast and ovarian cancer.
A new case of "de novo" BRCA1 mutation in a patient with early-onset breast cancer.
A new class of coumate benzimidazole hybrids as BRCA-1 mimetics through unconventional binding mode; Synthesis and preliminary cytotoxicity screening.
A new germline mutation in BRCA1 gene in a sicilian family with ovarian cancer.
A new look at molecular biology of breast cancer.
A non-BRCA1/2 hereditary breast cancer sub-group defined by aCGH profiling of genetically related patients.
A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers.
A novel BRCA1 gene deletion detection in human breast carcinoma MCF-7 cells through FRET between quantum dots and silver nanoclusters.
A Novel BRCA1 Gene Mutation Detected With Breast Cancer in a Vietnamese Family by Targeted Next-Generation Sequencing: A Case Report.
A novel BRCA1 germline mutation promotes triple-negative breast cancer cells progression and enhances sensitivity to DNA damage agents.
A novel BRCA1 mutation in a patient with breast and ovarian cancer: A case report.
A novel BRCA1 mutation in an Indian family with hereditary breast/ovarian cancer.
A novel BRCA2 mutation in an Indonesian family found with a new, rapid, and sensitive mutation detection method based on pooled denaturing gradient gel electrophoresis and targeted sequencing.
A novel BRCA2 splice variant identified in a young woman.
A novel breast cancer-associated BRIP1 (FANCJ/BACH1) germ-line mutation impairs protein stability and function.
A novel crosstalk between BRCA1 and poly (ADP-ribose) polymerase 1 in breast cancer.
A novel de novo BRCA1 mutation in a Chinese woman with early onset breast cancer.
A novel de novo BRCA2 mutation of paternal origin identified in a Spanish woman with early onset bilateral breast cancer.
A novel deleterious c.2656G>T MSH2 germline mutation in a Pakistani family with a phenotypic overlap of hereditary breast and ovarian cancer and Lynch syndrome.
A novel deletion of BRCA1 gene that eliminates the ATG initiation codon without affecting the promoter region.
A novel domain of BRCA1 interacts with p53 in breast cancer cells.
A novel frequent BRCA1 allele in Chinese patients with breast cancer.
A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations.
A novel mechanism whereby BRCA1/1a/1b fine tunes the dynamic complex interplay between SUMO-dependent/independent activities of Ubc9 on E2-induced ERalpha activation/repression and degradation in breast cancer cells.
A novel method to detect the Mexican founder mutation BRCA1 ex9?12del associated with breast and ovarian cancer using quantitative polymerase chain reaction and TaqMan® probes.
A Novel Model to Characterize Structure and Function of BRCA1.
A novel mutation in the BRCA1 gene in a German early-onset breast cancer family.
A Novel Mutation-BRCA1 Associated Hereditary Haplotype of Intragenic Markers of BRCA1 Gene in a Family with History of Breast Cancer
A Novel Pathogenic BRCA1 Splicing Variant Produces Partial Intron Retention in the Mature Messenger RNA.
A novel RING-type ubiquitin ligase breast cancer-associated gene 2 correlates with outcome in invasive breast cancer.
A novel role for BRCA1 in regulating breast cancer cell spreading and motility.
A novel role for the SUMO E3 ligase PIAS1 in cancer metastasis.
A Novel Splice Site Mutation in the Noncoding Region of BRCA2: Implications for Fanconi Anemia and Familial Breast Cancer Diagnostics.
A novel tricomplex of BRCA1, Nmi, and c-Myc inhibits c-Myc-induced human telomerase reverse transcriptase gene (hTERT) promoter activity in breast cancer.
A novel ubiquitin ligase is deficient in Fanconi anemia.
A P1-based physical map of the region from D17S776 to D17S78 containing the breast cancer susceptibility gene BRCA1.
A Paternally Inherited BRCA1 Mutation Associated with an Unusual Aggressive Clinical Phenotype.
A Pharmacodynamic Study of the P-glycoprotein Antagonist CBT-1(R) in Combination With Paclitaxel in Solid Tumors.
A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.
A Phylogenetic Approach to Analyze the Conservativeness of BRCA1 and BRCA2 Mutations.
A physical map and candidate genes in the BRCA1 region on chromosome 17q12-21.
A Physical Mechanism and Global Quantification of Breast Cancer.
A pilot genome-wide association study of early-onset breast cancer.
A Pilot Study on Screening of BRCA1 Mutations (185delAG, 1294del40) in Nepalese Breast Cancer Patients.
A point mutation in the putative TATA box, detected in nondiseased individuals and patients with hereditary breast cancer, decreases promoter activity of the 17 beta-hydroxysteroid dehydrogenase type 1 gene 2 (EDH17B2) in vitro.
A polymorphism in Werner syndrome gene is associated with breast cancer susceptibility in Chinese women.
A population study of mutations and LOH at breast cancer gene loci in tumours from sister pairs: two recurrent mutations seem to account for all BRCA1/BRCA2 linked breast cancer in Iceland.
A Population-Based Analysis of BRCA1/2 Genes and Associated Breast and Ovarian Cancer Risk in Korean Patients: A Multicenter Cohort Study.
A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention.
A population-based assessment of the clustering of breast cancer in families eligible for testing of BRCA1 and BRCA2 mutations.
A Population-Based Study of Genes Previously Implicated in Breast Cancer.
A porcine model system of BRCA1 driven breast cancer.
A potent bivalent Smac mimetic (SM-1200) achieving rapid, complete, and durable tumor regression in mice.
A potential role for the XRCC2 R188H polymorphic site in DNA-damage repair and breast cancer.
A pre-emptive strike against breast cancer. Jessica Queller describes how she faced the BRCA1 gene.
A predictor based on the somatic genomic changes of the BRCA1/BRCA2 breast cancer tumors identifies the non-BRCA1/BRCA2 tumors with BRCA1 promoter hypermethylation.
A prior diagnosis of breast cancer is a risk factor for breast cancer in BRCA1 and BRCA2 carriers.
A prospective investigation of predictive and modifiable risk factors for breast cancer in unaffected BRCA1 and BRCA2 gene carriers.
A prospective study of peripheral blood DNA methylation at RPTOR, MGRN1 and RAPSN and risk of breast cancer.
A prospective study on predictive factors linked to the presence of BRCA1 and BRCA2 mutations in breast cancer patients.
A protective role for BRCA2 at stalled replication forks.
A protein truncating BRCA1 allele with a low penetrance of breast cancer.
A Provocative Molecular Link between Mammographic Density and BRCA1-loss associated TNBC.
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.
A radiation hybrid map of the BRCA1 region.
A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale.
A recurrent CHEK2 p.H371Y mutation is associated with breast cancer risk in Chinese women.
A recurrent mutation in PALB2 in Finnish cancer families.
A recurrent truncating germline mutation in the BRIP1/FANCJ gene and susceptibility to prostate cancer.
A region close to Tp53 shows LOH in familial breast cancer.
A reliable method for the detection of BRCA1 and BRCA2 mutations in fixed tumour tissue utilising multiplex PCR-based targeted next generation sequencing.
A review of hereditary breast cancer: from screening to risk factor modification.
A role for BRCA1 in sporadic breast cancer.
A role for paralog-specific sumoylation in histone deacetylase 1 stability.
A role of BRCA1 and BRCA2 germline mutations in breast cancer susceptibility within Sardinian population.
A Role of CREB in BRCA1 Constitutive Promoter Activity and Aromatase Basal Expression.
A role of estrogen/ERalpha signaling in BRCA1-associated tissue-specific tumor formation.
A salpingeal carcinoma revealed after prophylactic salpingoophorectomy in an asymptomatic BRCA1 carrier with breast malignancy.
A screening for BRCA1 mutations in breast and breast-ovarian cancer families from the Stockholm region.
A sensitive test for the detection of specific DSB repair defects in primary cells from breast cancer specimens.
A simple tool for identifying unaffected women at a moderately increased or potentially high risk of breast cancer based on their family history.
A single mutated BRCA1 allele leads to impaired fidelity of double strand break end-joining.
A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers.
A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers.
A somatic BRCA2 mutation in RER+ endometrial carcinomas that specifically deletes the amino-terminal transactivation domain.
A somatic mutation in the 5'UTR of BRCA1 gene in sporadic breast cancer causes down-modulation of translation efficiency.
A specific GFP expression assay, penetrance estimate, and histological assessment for a putative splice site mutation in BRCA1.
A sporadic breast tumor with a somatically acquired complex genomic rearrangement in BRCA1.
A strategy to apply quantitative epistasis analysis on developmental traits.
A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.
A structural bioinformatics approach to explore the interactions of P53 and BRCA1 gene products on ovarian and breast cancer.
A superfamily of conserved domains in DNA damage-responsive cell cycle checkpoint proteins.
A Survey of BRCA1, BRCA2, and PALB2 mutations in women with breast cancer in Trinidad and Tobago.
A survey of preventive measures among BRCA1 mutation carriers from Poland.
A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population.
A TGF?-miR-182-BRCA1 axis controls the mammary differentiation hierarchy.
A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers.
A yeast recombination assay to characterize human BRCA1 missense variants of unknown pathological significance.
A young woman with bilateral breast cancer: identifying a genetic cause and implications for management.
Aberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical features.
Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers.
Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells.
Aberrant promoter hypermethylation and genomic hypomethylation in tumor, adjacent normal tissues and blood from breast cancer patients.
Aberrant promoter methylation of cancer-related genes in human breast cancer.
Aberrant recombination and repair during immunoglobulin class switching in BRCA1-deficient human B cells.
Aberrant splicing induced by missense mutations in BRCA1: clues from a humanized mouse model.
Aberrant subcellular localization of BRCA1 in breast cancer.
Aberrations of breast cancer susceptibility genes occur early in sporadic breast tumors and in acquisition of breast epithelial immortalization.
Ablation of the Brca1-Palb2 Interaction Phenocopies Fanconi Anemia in Mice.
Abnormal expression of BRCA1 and BRCA1-interactive DNA-repair proteins in breast carcinomas.
Abnormal Mammary Adipose Tissue Environment of Brca1 Mutant Mice Show a Persistent Deposition of Highly Vascularized Multilocular Adipocytes.
Abnormalities of the inactive X chromosome are a common feature of BRCA1 mutant and sporadic basal-like breast cancer.
Abnormality of the DNA double-strand-break checkpoint/repair genes, ATM, BRCA1 and TP53, in breast cancer is related to tumour grade.
Abrupt involution induces inflammation, estrogenic signaling, and hyperplasia linking lack of breastfeeding with increased risk of breast cancer.
Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer.
Absence of Brca2 causes genome instability by chromosome breakage and loss associated with centrosome amplification.
Absence of CCND1 gene amplification in breast tumours of BRCA1 mutation carriers.
Absence of commonly recurring BRCA1 mutations in black South African women with breast cancer.
Absence of evidence for a familial breast cancer susceptibility gene at chromosome 8p12-p22.
Absence of germline BRCA1 mutations in familial pancreatic cancer patients.
Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes.
Absence of the common IGF1 19 CA-repeat allele is more common among BRCA1 mutation carriers than among non-carriers from BRCA1 families.
Absence of truncating BRIP1 mutations in chromosome 17q-linked hereditary prostate cancer families.
Accuracy of the BRCAPRO model among women with bilateral breast cancer.
Accurate prediction of BRCA1 and BRCA2 heterozygous genotype using expression profiling after induced DNA damage.
Acetyl-CoA carboxylase alpha gene and breast cancer susceptibility.
Activation of BRCA1/BRCA2-associated helicase BACH1 is required for timely progression through S phase.
Activation of estrogen signaling pathways collaborates with loss of Brca1 to promote development of ERalpha-negative and ERalpha-positive mammary preneoplasia and cancer.
Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation.
Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom.
Adaptive evolution of the tumour suppressor BRCA1 in humans and chimpanzees. Australian Breast Cancer Family Study.
Addressing health disparities in Hispanic breast cancer: accurate and inexpensive sequencing of BRCA1 and BRCA2.
Adenosine nucleotide modulates the physical interaction between hMSH2 and BRCA1.
Adjusting the estimated proportion of breast cancer cases associated with BRCA1 and BRCA2 mutations: public health implications.
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age.
Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer.
Advances in breast cancer: pathways to personalized medicine.
Advocate's Viewpoint on Hereditary Breast/Ovarian Cancer.
AeQTL: eQTL analysis using region-based aggregation of rare genomic variants.
After BRCA1 and BRCA2-what next? Multifactorial segregation analyses of three-generation, population-based Australian families affected by female breast cancer.
Age at diagnosis as an indicator of eligibility for BRCA1 DNA testing in familial breast cancer.
Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Age at first full-term birth and breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Age at menarche and menopause and breast cancer risk in the International BRCA1/2 Carrier Cohort Study.
Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Age at onset of bilateral breast cancer, the presence of hereditary BRCA1, BRCA2, CHEK2 gene mutations and positive family history of cancer.
Age-dependent penetrance of different germline mutations in the BRCA1 gene.
Age-specific incidence rates for breast cancer in carriers of BRCA1 mutations from Norway.
Age-specific risks of incident, contralateral and ipsilateral breast cancer among 1776 Polish BRCA1 mutation carriers.
AKT and p21 WAF1/CIP1 as potential genistein targets in BRCA1-mutant human breast cancer cell lines.
AKT1 inhibits homologous recombination by inducing cytoplasmic retention of BRCA1 and RAD51.
Akt1 inhibits homologous recombination in Brca1-deficient cells by blocking the Chk1-Rad51 pathway.
Alcohol consumption and the risk of breast cancer among BRCA1 and BRCA2 mutation carriers.
Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium.
Alcohol stimulates estrogen receptor signaling in human breast cancer cell lines.
All Paths Lead to TRIM25.
Allele age and a test for selection on rare alleles.
Allele imbalance, or loss of heterozygosity, in normal breast epithelium of sporadic breast cancer cases and BRCA1 gene mutation carriers is increased compared with reduction mammoplasty tissues.
Allelic imbalance and microsatellite instability in BRCA1 associated breast and ovarian tumors.
Allelic imbalance in BRCA1 and BRCA2 gene expression is associated with an increased breast cancer risk.
Allelic imbalance on chromosomes 13 and 17 and mutation analysis of BRCA1 and BRCA2 genes in monozygotic twins concordant for breast cancer.
Allelic loss at BRCA1, BRCA2, and adjacent loci in relation to TP53 abnormality in breast cancer.
Allelic loss at the BRCA1, BRCA2 and TP53 loci in human sporadic breast carcinoma.
Allelic loss of the BRCA1 and BRCA2 genes and other regions on 17q and 13q in breast cancer among women from Taiwan (area of low incidence but early onset).
Allelic phasing of a mouse chromosome 11 deficiency influences p53 tumorigenicity.
Allelic variants of breast cancer susceptibility genes PALB2 and RECQL in the Latvian population.
Alteration of BRCA1 expression affects alcohol-induced transcription of RNA Pol III-dependent genes.
Alteration of DNA methylation status in K562 and MCF-7 cancer cell lines by nucleoside analogues.
Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer.
Alterations in replication timing of cancer-related genes in malignant human breast cancer cells.
Altered DNA Binding and Amplification of Human Breast Cancer Suppressor Gene BRCA1 Induced by a Novel Antitumor Compound, [Ru(η6-p-phenylethacrynate)Cl2(pta)].
Altered Expression and Localization of Tumor Suppressive E3 Ubiquitin Ligase SMURF2 in Human Prostate and Breast Cancer.
Altered expression of anti-apoptotic proteins in non-involved tissue from cancer-containing breasts.
Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines.
Altered expression of proliferation-inducing and proliferation-inhibiting genes might contribute to acquired doxorubicin resistance in breast cancer cells.
Altered expression of telomere-associated genes in leukocytes among BRCA1 and BRCA2 carriers.
Altered proliferation and differentiation properties of primary mammary epithelial cells from BRCA1 mutation carriers.
Altered regulation of BRCA1 exon 11 splicing is associated with breast cancer risk in carriers of BRCA1 pathogenic variants.
Alternative splicing and molecular characterization of splice site variants: BRCA1 c.591C>T as a case study.
Alternative splicing of breast cancer associated gene BRCA1 from breast cancer cell line.
Alternative splicings on p53, BRCA1 and PTEN genes involved in breast cancer.
AMIGOS: a method for the inspection of genomic organisation or structure and its application to characterise conserved gene arrangements.
Amplification of TOP2A and HER-2 genes in breast cancers occurring in patients harbouring BRCA1 germline mutations.
Amplified label-free electrical detection of DNA hybridization.
An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients.
An analysis of age and family history on outcome after breast-conservation treatment: the University of Pennsylvania experience.
An efficient DNA-fueled molecular machine for the discrimination of single-base changes.
An epidemiology and molecular genetic study on breast cancer susceptibility.
An evaluation of BRCA1 and BRCA2 founder mutations penetrance estimates for breast cancer among Ashkenazi Jewish women.
An evaluation of common breast cancer gene mutations in a population of Ashkenazi Jews.
An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium.
An evaluation of the polymorphisms Ins16bp and Arg72Pro in p53 as breast cancer risk modifiers in BRCA1 and BRCA2 mutation carriers.
An hGCN5/TRRAP histone acetyltransferase complex co-activates BRCA1 transactivation function through histone modification.
An important role for BRCA1 in breast cancer progression is indicated by its loss in a large proportion of non-familial breast cancers.
An in vivo study of Cdh1/APC in breast cancer formation.
An Integrated Systems Biology Approach Identifies TRIM25 as a Key Determinant of Breast Cancer Metastasis.
An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA).
An investigation into 53BP1 complex formation.
An open letter to my daughter.
An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers.
An Overview of PARP Inhibitors for the Treatment of Breast Cancer.
An overview of triple negative breast cancer for surgical oncologists.
An ultrasensitive electrochemical impedance sensor for a special BRCA1 breast cancer gene sequence based on lambda exonuclease assisted target recycling amplification.
An update on genetic risk assessment and prevention: the role of genetic testing panels in breast cancer.
An updated review of epidemiology, risk factors, and management of male breast cancer.
Analysis and interpretation of RNA splicing alterations in genes involved in genetic disorders.
Analysis of 5382insC (BRCA1) and 6174delT (BRCA2) mutations in 382 healthy Chilean women with a family history of breast cancer.
Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects.
Analysis of BRCA1 and BRCA2 in breast and breast/ovarian cancer families shows population substructure in the Iberian peninsula.
Analysis of BRCA1 and BRCA2 mutations in Brazilian breast cancer patients with positive family history.
Analysis of BRCA1 and BRCA2 mutations in southern Iranian Breast cancer patients.
Analysis of BRCA1 and mtDNA haplotypes and mtDNA polymorphism in familial breast cancer.
Analysis of BRCA1 Gene Rearrangements in Breast Carcinomas by RT-PCR and ER, PR, HER2NEU Status by IHC and HPE Correlation.
Analysis of BRCA1 involvement in breast cancer in Indian women.
Analysis of BRCA1 variants in double-strand break repair by homologous recombination and single-strand annealing.
Analysis of BRCA1, TP53, and TSG101 germline mutations in German breast and/or ovarian cancer families.
Analysis of Brca1-deficient mouse mammary glands reveals reciprocal regulation of Brca1 and c-kit.
Analysis of BRCA1/2 mutation spectrum and prevalence in unselected Chinese breast cancer patients by next-generation sequencing.
Analysis of BRCA1/BRCA2 genes' contribution to breast cancer susceptibility in high risk Jewish Ashkenazi women.
Analysis of BRCA1and BRCA2 large genomic rearrangements in Sri Lankan familial breast cancer patients and at risk individuals.
Analysis of breast cancer susceptibility genes BRCA1 and BRCA2 in Thai familial and isolated early-onset breast and ovarian cancer.
Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource.
Analysis of chromosomal radiosensitivity of healthy BRCA2 mutation carriers and non-carriers in BRCA families with the G2 micronucleus assay.
Analysis of clinical characteristics of breast cancer patients with the Japanese founder mutation BRCA1 L63X.
Analysis of DNA Repair-Related Genes in Breast Cancer Reveals CUL4A Ubiquitin Ligase as a Novel Biomarker of Trabectedin Response.
Analysis of GADD45A sequence variations in French Canadian families with high risk of breast cancer.
Analysis of Heterozygous BRCA1 5382ins Founder Mutation in a Cohort of Egyptian Breast Cancer Female Patients Using Pyrosequencing Technique.
Analysis of Italian BRCA1/2 Pathogenic Variants Identifies a Private Spectrum in the Population from the Bergamo Province in Northern Italy.
Analysis of KLLN as a high-penetrance breast cancer predisposition gene.
Analysis of loss of heterozygosity and immunohistochemistry in BRCA1 gene in sporadic breast cancers.
Analysis of methylation-sensitive transcriptome identifies GADD45a as a frequently methylated gene in breast cancer.
Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD.
Analysis of novel mutations in BRCA1 in Iranian families with breast cancer.
Analysis of PALB2/FANCN-associated breast cancer families.
Analysis of PTEN in two BRCA1 and BRCA2 wild-type familial breast cancer patients.
Analysis of RAD51 polymorphism and BRCA1 mutations in Polish women with breast cancer.
Analysis of several BRCA1 and BRCA2 mutations in a hospital-based series of unselected breast cancer cases.
Analysis of SLX4/FANCP in non-BRCA1/2-mutated breast cancer families.
Analysis of the BRCA1 and BRCA2 genes in sporadic meningiomas.
Analysis of the DNA binding activity of BRCA1 and its modulation by the tumour suppressor p53.
Analysis of the G/C polymorphism in the 5'-untranslated region of the RAD51 gene in breast cancer.
Analysis of the pathogenic variants of BRCA1 and BRCA2 using next-generation sequencing in women with familial breast cancer: a case-control study.
Androgen pathway dysregulation in BRCA1-mutated breast tumors.
Androgen receptor CAG repeat length in Jewish Israeli women who are BRCA1/2 mutation carriers: association with breast/ovarian cancer phenotype.
Androgen receptor expression in breast cancer patients tested for BRCA1 and BRCA2 mutations.
Androgen receptor gene polymorphism and breast cancer susceptibility in The Philippines.
Androgens and estrogens in the etiology and prevention of breast cancer.
ANKLE1 N6 -Methyladenosine-related variant is associated with colorectal cancer risk by maintaining the genomic stability.
Anti-Warburg effect by targeting HRD1-PFKP pathway may inhibit breast cancer progression.
Antibody-drug conjugates in triple negative breast cancer.
Anticancer activity of RAPTA-EA1 in triple-negative BRCA1 proficient breast cancer cells: single and combined treatment with the PARP inhibitor olaparib.
Anticipation in hereditary breast cancer.
Antioxydation And Cell Migration Genes Are Identified as Potential Therapeutic Targets in Basal-Like and BRCA1 Mutated Breast Cancer Cell Lines.
Antisense RNA to the putative tumor suppressor gene BRCA1 transforms mouse fibroblasts.
APOE and Alzheimer disease: a major gene with semi-dominant inheritance.
Application of a miniature biochip using the molecular beacon probe in breast cancer gene BRCA1 detection.
Application of breast cancer risk prediction models in clinical practice.
Application of multiplex PCR with histopathologic features for detection of familial breast cancer in formalin-fixed, paraffin-embedded histologic specimens.
Applications for breast magnetic resonance imaging.
Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series.
Are ATM mutations 7271T-->G and IVS10-6T-->G really high-risk breast cancer-susceptibility alleles?
Are BRCA1- and BRCA2-associated breast cancers different? Prognosis of BRCA1-associated breast cancer.
Are BRCA1- and BRCA2-related breast cancers associated with increased mortality?
Are estrogen receptor-positive breast cancers in BRCA1 mutation carriers sporadic?
Are medullary breast cancers an indication for BRCA1 mutation screening? A mutation analysis of 42 cases of medullary breast cancer.
Are Trp53 rescue of Brca1 embryonic lethality and Trp53/Brca1 breast cancer association related?
Are VNTRs co-localizing with breast cancer-associated SNPs?
Aromatase, CYP1B1 and Fatty Acid Synthase Expression in Breast Tumors of BRCA1 Mutation Carriers.
Array-based mutation detection of BRCA1 using direct probe/target hybridization.
Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1.
Arsenic?induced BRCA1 CpG promoter methylation is associated with the downregulation of ER? and resistance to tamoxifen in MCF7 breast cancer cells and mouse mammary tumor xenografts.
Artificial neural network-based exploration of gene-nutrient interactions in folate and xenobiotic metabolic pathways that modulate susceptibility to breast cancer.
Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2.
Assays for Hypermethylation of the BRCA1 Gene Promoter in Tumor Cells to Predict Sensitivity to PARP-Inhibitor Therapy.
Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers.
Assessing breast cancer risk and BRCA1/2 carrier probability.
Assessing Risk of Breast Cancer: A Review of Risk Prediction Models.
Assessing the added value of breast tumor markers in genetic risk prediction model BRCAPRO.
Assessing the Knowledge and Attitudes Regarding Genetic Testing for Breast Cancer Risk in our Region of Southeastern Georgia.
Assessing the link between BACH1 and BRCA1 in the FA pathway.
Assessing the link between BACH1/FANCJ and MLH1 in DNA crosslink repair.
Assessing the RNA effect of 26 DNA variants in the BRCA1 and BRCA2 genes.
Assessing Women at High Risk of Breast Cancer: A Review of Risk Assessment Models.
Assessment and counseling for women with a family history of breast cancer. A guide for clinicians.
Assessment of DNA methylation profiling and copy number variation as indications of clonal relationship in ipsilateral and contralateral breast cancers to distinguish recurrent breast cancer from a second primary tumour.
Assessment of rare BRCA1 and BRCA2 variants of unknown significance using hierarchical modeling.
Assessment of the time-tradeoff values for prophylactic mastectomy of women with a suspected genetic predisposition to breast cancer.
Association analysis identifies 65 new breast cancer risk loci.
Association between a novel polymorphism (rs2046210) of the 6q25.1 locus and breast cancer risk.
Association between basal-like phenotype and BRCA1/2 germline mutations in Korean breast cancer patients.
Association Between BRCA Status and Triple-Negative Breast Cancer: A Meta-Analysis.
Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing.
Association between BRCA1 mutations and ratio of female to male births in offspring of families with breast cancer, ovarian cancer, or both.
Association between BRCA1 polymorphisms rs799917 and rs1799966 and breast cancer risk: a meta-analysis.
Association between BRCA1 rs799917 polymorphism and breast cancer risk: A meta-analysis of 19,878 subjects.
Association between BRIP1 (BACH1) polymorphisms and breast cancer risk: a meta-analysis.
Association between cytosolic expression of BRCA1 and metastatic risk in breast cancer.
Association between early-onset breast and laryngeal cancers.
Association between loss of heterozygosity of BRCA1 and BRCA2 and morphological attributes of sporadic breast cancer.
Association Between Loss-of-Function Mutations Within the FANCM Gene and Early-Onset Familial Breast Cancer.
Association between mitogen-activated protein kinase kinase kinase 1 rs889312 polymorphism and breast cancer risk: evidence from 59,977 subjects.
Association between RAD51 polymorphism and breast cancer susceptibility: a meta analysis.
Association between the BRCA2 N372H variant and male breast cancer risk: a population-based case-control study in Tuscany, Central Italy.
Association between the c.*229C>T polymorphism of the topoisomerase II? binding protein 1 (TopBP1) gene and breast cancer.
Association of 8q24 rs13281615A > G polymorphism with breast cancer risk: evidence from 40,762 cases and 50,380 controls.
Association of a LSP1 gene rs3817198T>C polymorphism with breast cancer risk: evidence from 33,920 cases and 35,671 controls.
Association of BRCA Mutation Types, Imaging Features, and Pathologic Findings in Patients With Breast Cancer With BRCA1 and BRCA2 Mutations.
Association of BRCA1 185 del AG with early age onset of breast cancer patients in selected cohort from Pakistani population.
Association of BRCA1 K1183R polymorphism with survival in BRCA1/2-negative chinese familial breast cancer.
Association of BRCA1 Promoter Methylation with Breast Cancer in Asia: A Meta- Analysis
Association of BRCA1 promoter methylation with rs11655505 (c.2265C>T) variants and decreased gene expression in sporadic breast cancer.
Association of BRCA1 promoter methylation with sporadic breast cancers: Evidence from 40 studies.
Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response.
Association of BRCA1, BRCA2, RAD51, and HER2 gene polymorphisms with the breast cancer risk in the Bangladeshi population.
Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
Association of Breast and Ovarian Cancers With Predisposition Genes Identified by Large-Scale Sequencing.
Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3.
Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21.
Association of Cytokeratin 5 and Claudin 3 expression with BRCA1 and BRCA2 germline mutations in women with early breast cancer.
Association of DEAR1 Tagging Single Nucleotide Polymorphisms With Breast Cancer in a Sample of Colombian Population: A Case Control Study.
Association of death receptor 4 variant (683A>C) with ovarian cancer risk in BRCA1 mutation carriers.
Association of E-selectin S128R Polymorphism with Hereditary Breast Carcinoma Susceptibility in Turkish Patients Without BRCA1/2 Germline Mutations.
Association of folate and other one-carbon related nutrients with hypermethylation status and expression of RARB, BRCA1, and RASSF1A genes in breast cancer patients.
Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer.
Association of hormone receptor status with grading, age of onset, and tumor size in BRCA1-associated breast cancer.
Association of loss of BRCA1 expression with centrosome aberration in human breast cancer.
Association of Rad51 polymorphism with DNA repair in BRCA1 mutation carriers and sporadic breast cancer risk.
Association of radiotherapy with preferential depletion of luminal epithelial cells in a BRCA1 mutation carrier.
Association of Risk-Reducing Salpingo-Oophorectomy With Breast Cancer Risk in Women With BRCA1 and BRCA2 Pathogenic Variants.
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
Association of the BRCA1 missense variant R1699W with a malignant phyllodes tumor of the breast.
Association of the BRCA1 promoter polymorphism rs11655505 with the risk of familial breast and/or ovarian cancer.
Association of the Variants CASP8 D302H and CASP10 V410I with Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.
Association of Vitamin D Receptor and Vitamin D-Binding Protein Polymorphisms with Familial Breast Cancer Prognosis in a Mono-Institutional Cohort.
Association of XPC polymorphisms with susceptibility and clinical outcome to chemotherapy in breast cancer patients.
Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.
Associations between single nucleotide polymorphisms in double-stranded DNA repair pathway genes and familial breast cancer.
Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers.
ATF-2 controls transcription of Maspin and GADD45 alpha genes independently from p53 to suppress mammary tumors.
ATM allelic variants associated to hereditary breast cancer in 94 Chilean women: susceptibility or ethnic influences?
ATM and genome maintenance: defining its role in breast cancer susceptibility.
ATM controls proper mitotic spindle structure.
Attitudes about genetic testing and genetic testing intentions in African American women at increased risk for hereditary breast cancer.
Attitudes and psychological impact of genetic testing, genetic counseling, and breast cancer risk assessment among women at increased risk.
Attitudes of obstetrician-gynecologists toward DNA testing for a genetic susceptibility to breast cancer.
Attitudes, knowledge, risk perceptions and decision-making among women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2 and their spouses.
AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study.
Autoantibodies directed to centromere protein F in a patient with BRCA1 gene mutation.
Autoantibodies in breast cancer: their use as an aid to early diagnosis.
Autoantibodies to tumor-associated antigens in breast carcinoma.
Automated detection of prevalent mutations in BRCA1 and BRCA2 genes, using a fluorogenic PCR allelic discrimination assay.
Autoubiquitination of BCA2 RING E3 ligase regulates its own stability and affects cell migration.
Autoubiquitination of feline E3 ubiquitin ligase BCA2.
Average age-specific cumulative risk of breast cancer according to type and site of germline mutations in BRCA1 and BRCA2 estimated from multiple-case breast cancer families attending Australian family cancer clinics.
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
Awareness and attitudes concerning BRCA gene testing.
BACH1 is a DNA repair protein supporting BRCA1 damage response.
BACH1 Ser919Pro variant and breast cancer risk.
BAP1 and breast cancer risk.
BAP1 promotes viability and migration of ECA109 cells through KLF5/CyclinD1/FGF-BP1.
Bar code screening on combed DNA for large rearrangements of the BRCA1 and BRCA2 genes in French breast cancer families.
BARD1 homozygous deletion, a possible alternative to BRCA1 mutation in basal breast cancer.
BARD1 induces BRCA1 intranuclear foci formation by increasing RING-dependent BRCA1 nuclear import and inhibiting BRCA1 nuclear export.
BARD1 regulates BRCA1 apoptotic function by a mechanism involving nuclear retention.
BARD1 variants are not associated with breast cancer risk in Australian familial breast cancer.
BARD1, a possible biomarker for breast and ovarian cancer.
Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families.
Basal Phenotype in Breast Carcinoma Occurring in Women Aged 35 or Younger.
Basal, oxidative and alkylative DNA damage, DNA repair efficacy and mutagen sensitivity in breast cancer.
Basal-like breast cancer and the BRCA1 phenotype.
Basal-like breast cancer: a critical review.
Base pair mismatch recognition using plasmon resonant particle labels.
Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Bcl-2 inhibits nuclear homologous recombination by localizing BRCA1 to the endomembranes.
BCoR-L1 variation and breast cancer.
Behavioral and psychosocial effects of rapid genetic counseling and testing in newly diagnosed breast cancer patients: design of a multicenter randomized clinical trial.
Beneficial Molecular Adaptations In BRCA-Mutation Carriers By Combined HIT/HIRT Intervention: Results From A Pilot Study.
BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy.
Beyond BRCA1 and BRCA2.
Bi-phasic expression of Heterochromatin Protein 1 (HP1) during breast cancer progression: Potential roles of HP1 and chromatin structure in tumorigenesis.
Biallelic germline BRCA1 mutations in a patient with early onset breast cancer, mild Fanconi anemia-like phenotype, and no chromosome fragility.
Biallelic Mutations in BRCA1 Cause a New Fanconi Anemia Subtype.
Bias Explains Most of the Parent-of-Origin Effect on Breast Cancer Risk in BRCA1/2 Mutation Carriers.
Bilateral breast cancers.
Bilateral breast reconstruction and the role of prophylactic mastectomy.
Bilateral Breast Reconstruction and the Role of Prophylactic Mastectomy.
Bilateral nipple-sparing mastectomy and breast reconstruction in BRCA1 mutation-positive simultaneous bilateral breast cancer: A case study.
Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
Bilateral Prophylactic Nipple-Sparing Mastectomy: Analysis of the Risk-Reducing Effect in BRCA1/2 Mutation Carriers.
Bilateral risk-reduction mastectomy in BRCA1 and BRCA2 mutation carriers: a meta-analysis.
Bilateral salpingo-oophorectomy and breast cancer risk for BRCA1 and BRCA2 mutation carriers: Assessing the evidence.
Bilateral Salpingo-Oophorectomy to Reduce Breast Cancer Risk in Women With Germline BRCA1 or BRCA2 Pathogenic Variants-Caution Needed-Reply.
Bilateral Salpingo-Oophorectomy to Reduce Breast Cancer Risk in Women With Germline BRCA1 or BRCA2 Pathogenic Variants-Caution Needed.
Bioactive food components prevent carcinogenic stress via Nrf2 activation in BRCA1 deficient breast epithelial cells.
Biobibliometrics (UGDH-TP53-BRCA1) Genes Connections in the Possible Relationship Between Breast Cancer and EEG.
Biochemical markers in breast cancer: which ones are clinically useful?
Bioinformatics Approaches to Explore the Phylogeny and Role of BRCA1 in Breast Cancer.
Biologic, demographic, and social factors affecting triple negative breast cancer outcomes.
Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer.
Biophenotypes and survival of BRCA1 and TP53 deleted breast cancer in young women.
Bispecific Estrogen Receptor ? Degraders Incorporating Novel Binders Identified Using DNA-Encoded Chemical Library Screening.
Blockade of miR-3614 maturation by IGF2BP3 increases TRIM25 expression and promotes breast cancer cell proliferation.
Blood Arsenic Levels as a Marker of Breast Cancer Risk among BRCA1 Carriers.
BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile.
BP1, an isoform of DLX4 homeoprotein, negatively regulates BRCA1 in sporadic breast cancer.
BRAP2 inhibits the Ras/Raf/MEK and PI3K/Akt pathways in leukemia cells, thereby inducing apoptosis and inhibiting cell growth.
BRCA 1 & 2 mutations in Sudanese secondary school girls with known breast cancer in their families.
BRCA 1 and 2--A Genetic Link to Familial Breast and Ovarian Cancer.
BRCA and Breast Cancer-Related High-Penetrance Genes.
BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations.
BRCA genes: lessons learned from experimental and clinical cancer.
BRCA Genes: The Role in Genome Stability, Cancer Stemness and Therapy Resistance.
BRCA Genetic Test and Risk-Reducing Salpingo-Oophorectomy for Hereditary Breast and Ovarian Cancer: State-of-the-Art.
BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers.
BRCA mutation characteristics in a series of index cases of breast cancer selected independent of family history.
BRCA mutation screening and patterns among high-risk Lebanese subjects.
BRCA mutation testing in determining breast cancer therapy.
BRCA Mutations and Breast Cancer Prevention.
BRCA mutations: is everything said?
BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers.
BRCA proteins and DNA damage checkpoints.
BRCA sequencing and large rearrangement testing in young Black women with breast cancer.
BRCA Testing by Single-Molecule Molecular Inversion Probes.
BRCA-associated breast cancer: absence of a characteristic immunophenotype.
BRCA-mutated Invasive Breast Carcinomas: Immunohistochemical Analysis of Insulin-like Growth Factor II mRNA-binding Protein (IMP3), Cytokeratin 8/18, and Cytokeratin 14.
BRCA1 - Conductor of the Breast Stem Cell Orchestra: The Role of BRCA1 in Mammary Gland Development and Identification of Cell of Origin of BRCA1 Mutant Breast Cancer.
BRCA1 2080insA mutation in familial breast cancer.
BRCA1 4153delA founder mutation in Russian ovarian cancer patients.
BRCA1 5083del19 mutant allele selectively up-regulates periostin expression in vitro and in vivo.
BRCA1 accumulates in the nucleus in response to hypoxia and TRAIL and enhances TRAIL-induced apoptosis in breast cancer cells.
BRCA1 activates a G2-M cell cycle checkpoint following 6-thioguanine-induced DNA mismatch damage.
BRCA1 activation of the GADD45 promoter.
BRCA1 affects global DNA methylation through regulation of DNMT1.
BRCA1 alterations with additional defects in DNA damage response genes may confer chemoresistance to BRCA-like breast cancers treated with neoadjuvant chemotherapy.
BRCA1 Alternative splicing landscape in breast tissue samples.
BRCA1 and acetyl-CoA carboxylase: the metabolic syndrome of breast cancer.
BRCA1 and BARD1 colocalize mainly in the cytoplasm of breast cancer tumors, and their isoforms show differential expression.
BRCA1 and BRCA1 Genes and Inherited Breast and/or Ovarian Cancer: Benefits of Genetic Testing.
BRCA1 and BRCA2 - update and implications on the genetics of breast cancer: a clinical perspective.
BRCA1 and BRCA2 5' noncoding region variants identified in breast cancer patients alter promoter activity and protein binding.
BRCA1 and BRCA2 and breast cancer incidence: a review.
BRCA1 and BRCA2 as molecular targets for phytochemicals indole-3-carbinol and genistein in breast and prostate cancer cells.
BRCA1 and BRCA2 associated breast cancer and the roles of current modelling systems in drug discovery.
BRCA1 and BRCA2 bind Stat5a and suppress its transcriptional activity.
BRCA1 and BRCA2 Common Mutations in Iranian Breast Cancer Patients: a Meta Analysis.
Brca1 and Brca2 expression patterns in mitotic and meiotic cells of mice.
BRCA1 and BRCA2 founder mutations in patients with bilateral breast cancer.
BRCA1 and BRCA2 Gene Expression: Diurnal Variability and Influence of Shift Work
BRCA1 and BRCA2 gene mutation analysis: visit to the Breast Cancer Information Core (BIC).
BRCA1 and BRCA2 gene mutations and risk of breast cancer. Public health perspectives.
BRCA1 and BRCA2 Gene Mutations Screening In Sporadic Breast Cancer Patients In Kazakhstan.
BRCA1 and BRCA2 genes mutations among high risk breast cancer patients in Jordan.
BRCA1 and BRCA2 genetic test in high risk patients and families: counselling and management.
BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models.
BRCA1 and BRCA2 germ-line mutations and oral contraceptives: to use or not to use.
BRCA1 and BRCA2 germline mutation analysis among Indian women from south India: identification of four novel mutations and high-frequency occurrence of 185delAG mutation.
BRCA1 and BRCA2 germline mutation analysis in the Indonesian population.
BRCA1 and BRCA2 Germline Mutation Screening in Western Algeria using High Resolution Melting Analysis (HRM).
BRCA1 and BRCA2 germline mutational spectrum and evidence for genetic anticipation in Portuguese breast/ovarian cancer families.
BRCA1 and BRCA2 germline mutations in 85 Iranian breast cancer patients.
BRCA1 and BRCA2 Germline Mutations in Japanese with Hereditary Breast Cancer Families.
BRCA1 and BRCA2 germline mutations in Korean breast cancer patients at high risk of carrying mutations.
BRCA1 and BRCA2 germline mutations in Korean patients with sporadic breast cancer.
BRCA1 and BRCA2 germline mutations in lymphoma patients.
BRCA1 and BRCA2 germline mutations in Malaysian women with early-onset breast cancer without a family history.
BRCA1 and BRCA2 germline mutations in Sardinian breast cancer families and their implications for genetic counseling.
BRCA1 and BRCA2 germline mutations screening in Algerian breast/ovarian cancer families.
BRCA1 and BRCA2 germline variants in breast cancer patients from the Republic of Macedonia.
BRCA1 and BRCA2 have a limited role in familial prostate cancer.
BRCA1 and BRCA2 heterozygosity and repair of X-ray-induced DNA damage.
BRCA1 and BRCA2 heterozygosity in embryonic stem cells reduces radiation-induced Rad51 focus formation but is not associated with radiosensitivity.
BRCA1 and BRCA2 in 2005.
BRCA1 and BRCA2 in breast cancer families from Wales: moderate mutation frequency and two recurrent mutations in BRCA1.
BRCA1 and BRCA2 in breast cancer predisposition and recombination control.
BRCA1 and BRCA2 in breast cancer.
BRCA1 and BRCA2 in hereditary breast cancer.
BRCA1 and BRCA2 in Indian breast cancer patients.
BRCA1 and BRCA2 missense variants of high and low clinical significance influence lymphoblastoid cell line post-irradiation gene expression.
BRCA1 and BRCA2 mRNA levels are coordinately elevated in human breast cancer cells in response to estrogen.
BRCA1 and BRCA2 mutation analysis in 86 early onset breast/ovarian cancer patients.
BRCA1 and BRCA2 mutation analysis of early-onset and familial breast cancer cases in Mexico.
BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research.
BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50.
BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic.
BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark.
BRCA1 and BRCA2 mutation status and cancer family history of Danish women affected with multifocal or bilateral breast cancer at a young age.
BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer.
BRCA1 and BRCA2 mutations among breast cancer patients from the Philippines.
BRCA1 and BRCA2 mutations among familial breast cancer patients from Costa Rica.
BRCA1 and BRCA2 mutations and breast cancer.
BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population.
BRCA1 and BRCA2 mutations and treatment strategies for breast cancer.
BRCA1 and BRCA2 mutations as prognostic factors in bilateral breast cancer patients.
BRCA1 and BRCA2 mutations in a population-based study of male breast cancer.
BRCA1 and BRCA2 mutations in a sample of breast and ovarian cancer families from the Colombian pacific.
BRCA1 and BRCA2 mutations in a study of African American breast cancer patients.
BRCA1 and BRCA2 Mutations in Breast and Ovarian Cancer Syndrome: Reflection on the Creighton University Historical Series of High Risk Families.
BRCA1 and BRCA2 mutations in breast cancer families with multiple primary cancers.
BRCA1 and BRCA2 mutations in breast cancer patients from Saudi Arabia.
BRCA1 and BRCA2 mutations in breast cancer patients from Venezuela.
BRCA1 and BRCA2 mutations in central and southern Italian patients.
BRCA1 and BRCA2 mutations in ethnic Lebanese Arab women with high hereditary risk breast cancer.
BRCA1 and BRCA2 mutations in Iranian breast cancer patients: A systematic review.
BRCA1 and BRCA2 mutations in Russian familial breast cancer.
BRCA1 and BRCA2 mutations in Scotland and Northern Ireland.
BRCA1 and BRCA2 mutations in Turkish breast/ovarian families and young breast cancer patients.
BRCA1 and BRCA2 mutations in women from Shanghai China.
BRCA1 and BRCA2 protein expressions in an ovotestis of a 46, XX true hermaphrodite.
BRCA1 and BRCA2 sequence variants in Chinese breast cancer families.
BRCA1 and BRCA2 status in a Central Sudanese series of breast cancer patients: interactions with genetic, ethnic and reproductive factors.
BRCA1 and BRCA2 Testing Among Young Breast Cancer Survivors.
BRCA1 and BRCA2 truncating mutations and variants of unknown significance in Egyptian female breast cancer patients.
BRCA1 and BRCA2--breast cancer susceptibility genes.
BRCA1 and BRCA2: 1994 and beyond.
BRCA1 and BRCA2: a common pathway of genome protection but different breast cancer subtypes.
BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double strand break repair.
BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis.
BRCA1 and BRCA2: different roles in a common pathway of genome protection.
BRCA1 and Breast Cancer: a Review of the Underlying Mechanisms Resulting in the Tissue-Specific Tumorigenesis in Mutation Carriers.
BRCA1 and cell signaling.
Brca1 and differentiation.
BRCA1 and estrogen signaling in breast cancer.
BRCA1 and estrogen/estrogen receptor in breast cancer: where they interact?
BRCA1 and FOXA1 proteins coregulate the expression of the cell cycle-dependent kinase inhibitor p27(Kip1).
BRCA1 and GATA3 corepress FOXC1 to inhibit the pathogenesis of basal-like breast cancers.
BRCA1 and Its Network of Interacting Partners.
BRCA1 and medullary breast cancer.
BRCA1 and p53: compensatory roles in DNA repair.
BRCA1 and pancreatic cancer: pedigree findings and their causal relationships.
BRCA1 and PARP1 mRNA expression during progression from normal breast to ductal carcinoma in situ and invasive breast cancer: a laser microdissection study.
BRCA1 and prostate cancer.
BRCA1 and TP53 Gene-Mutations: Family Predisposition and Radioecological Risk of Developing Breast Cancer.
BRCA1 and TP53 mutation spectrum of breast carcinoma in an ethnic population of Kashmir, an emerging high-risk area.
BRCA1 and VDR gene polymorphisms are associated with prostate cancer risk in Mexican men.
BRCA1 as target for breast cancer prevention and therapy.
BRCA1 at the crossroad of multiple cellular pathways: approaches for therapeutic interventions.
BRCA1 Attenuates Progesterone Effects on Proliferation and NF?B Activation in Normal Human Mammary Epithelial Cells.
BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells.
BRCA1 Breast Cancer Risk Is Modified by CYP19 Polymorphisms in Ashkenazi Jews.
Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics.
BRCA1 c.5470_5477del, a founder mutation in Chinese Han breast cancer patients.
BRCA1 c.68_69delAG (exon2), c.181T>G (exon5), c.798_799delTT and 943ins10 (exon11) mutations in Burkina Faso.
BRCA1 counteracts progesterone action by ubiquitination leading to progesterone receptor degradation and epigenetic silencing of target promoters.
BRCA1 deficiency sensitizes breast cancer cells to bromodomain and extra-terminal domain (BET) inhibition.
BRCA1 deficient Mouse Models to Study Pathogenesis and Therapy of Triple Negative Breast Cancer.
BRCA1 degradation in response to mitochondrial damage in breast cancer cells.
BRCA1 down-regulates cellular levels of reactive oxygen species.
BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance.
BRCA1 dysfunction in sporadic basal-like breast cancer.
BRCA1 E1644X: a deleterious mutation in an African American individual with early onset breast cancer.
BRCA1 effects on the cell cycle and the DNA damage response are linked to altered gene expression.
BRCA1 ensures genome integrity by eliminating estrogen-induced pathological topoisomerase II-DNA complexes.
BRCA1 establishes DNA damage signaling and pericentric heterochromatin of the X chromosome in male meiosis.
BRCA1 exon 11 alternative splicing, multiple functions and the association with cancer.
BRCA1 expression and molecular alterations in familial breast cancer.
BRCA1 expression during prenatal development of the human mammary gland.
BRCA1 expression in benign and malignant breast lesions.
BRCA1 expression in invasive breast carcinomas and clinicopathological correlations.
BRCA1 expression is not directly responsive to estrogen.
Brca1 expression is regulated by a bidirectional promoter that is shared by the Nbr1 gene in mouse.
BRCA1 expression levels predict distant metastasis of sporadic breast cancers.
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells.
BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair.
BRCA1 founder mutations compared to ovarian cancer in Belarus.
BRCA1 functions as a breast stem cell regulator.
BRCA1 gene exon 11 mutations in Uighur and Han women with early-onset sporadic breast cancer in the northwest region of China.
BRCA1 gene expression in breast cancer in Kuwait: correlation with prognostic parameters.
BRCA1 gene expression in breast cancer: a correlative study between real-time RT-PCR and immunohistochemistry.
BRCA1 gene in breast cancer.
BRCA1 gene Molecular Alterations in Omani Breast Cancer Patients.
BRCA1 Gene Mutation Screening for the Hereditary Breast and/or Ovarian Cancer Syndrome in Breast Cancer Cases: a First High Resolution DNA Melting Analysis in Indonesia.
BRCA1 Gene Mutations and Influence of Chemotherapy on Autophagy and Apoptotic Mechanisms in Egyptian Breast Cancer Patients.
BRCA1 Gene Mutations in Breast Cancer Patients from Kerman Province, Iran.
BRCA1 gene mutations in sporadic ovarian carcinomas: detection by PCR and reverse allele-specific oligonucleotide hybridization.
BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer - a population based study from the Western Sweden Health Care region.
BRCA1 gene sequence variation in centenarians.
BRCA1 gene testing for breast and ovarian cancer in one family.
BRCA1 gene variant p.P142H associated with male breast cancer: a two-generation genealogic study and literature review.
BRCA1 genetic testing in 106 breast and ovarian cancer families from southern Italy (Sicily): a mutation analyses.
BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients.
BRCA1 germ-line mutations and tumor characteristics in eastern Chinese women with familial breast cancer.
BRCA1 germline mutation in a woman with metaplastic squamous cell breast cancer.
BRCA1 germline mutational spectrum in Italian families from Tuscany: a high frequency of novel mutations.
BRCA1 germline mutations and tumor characteristics in Chinese women with familial or early-onset breast cancer.
BRCA1 germline mutations in Cypriot breast cancer patients from 26 families with family history.
BRCA1 germline mutations in Indian familial breast cancer.
BRCA1 haploinsufficiency, but not heterozygosity for a BRCA1-truncating mutation, deregulates homologous recombination.
BRCA1 haploinsufficiency: consequences for breast cancer.
Brca1 heterozygous mice have shortened life span and are prone to ovarian tumorigenesis with haploinsufficiency upon ionizing irradiation.
BRCA1 in cancer, cell cycle and genomic stability.
BRCA1 in clinical breast cancer.
BRCA1 in hormonal carcinogenesis: basic and clinical research.
BRCA1 in hormone-responsive cancers.
Brca1 in immunoglobulin gene conversion and somatic hypermutation.
BRCA1 in non-inherited breast carcinomas (Review).
BRCA1 in special populations.
BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair.
BRCA1 induces major energetic metabolism reprogramming in breast cancer cells.
BRCA1 inhibition of estrogen receptor signaling in transfected cells.
BRCA1 inhibition of telomerase activity in cultured cells.
BRCA1 inhibits AR-mediated proliferation of breast cancer cells through the activation of SIRT1.
BRCA1 inhibits membrane estrogen and growth factor receptor signaling to cell proliferation in breast cancer.
BRCA1 interaction of centrosomal protein Nlp is required for successful mitotic progression.
BRCA1 interacts with acetyl-CoA carboxylase through its tandem of BRCT domains.
BRCA1 interacts with and is required for paclitaxel-induced activation of mitogen-activated protein kinase kinase kinase 3.
BRCA1 interacts with Smad3 and regulates Smad3-mediated TGF-beta signaling during oxidative stress responses.
BRCA1 is a cell cycle-regulated nuclear phosphoprotein.
BRCA1 is a negative modulator of the PRC2 complex.
BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer.
BRCA1 is differentially expressed in human tumor cells.
Brca1 is required for embryonic development of the mouse cerebral cortex to normal size by preventing apoptosis of early neural progenitors.
BRCA1 IVS16+6T-->C is a deleterious mutation that creates an aberrant transcript by activating a cryptic splice donor site.
BRCA1 knock-down causes telomere dysfunction in mammary epithelial cells.
BRCA1 loss activates cathepsin L-mediated degradation of 53BP1 in breast cancer cells.
BRCA1 maps proximal to D17S579 on chromosome 17q21 by genetic analysis.
BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor.
BRCA1 mislocalization associated with breast carcinogenesis and poor prognosis in Taiwanese women.
BRCA1 modulates malignant cell behavior, the expression of survivin and chemosensitivity in human breast cancer cells.
BRCA1 modulates sensitivity to 5F-203 by regulating xenobiotic stress-inducible protein levels and EROD activity.
BRCA1 modulates xenobiotic stress-inducible gene expression by interacting with ARNT in human breast cancer cells.
BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer.
BRCA1 mRNA expression modifies the effect of T cell activation score on patient survival in breast cancer.
BRCA1 mRNA levels following a 4-6-week intervention with oral 3,3'-diindolylmethane.
BRCA1 mutation analysis in breast/ovarian cancer families from Greece.
BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.
BRCA1 mutation and young age predict fast breast cancer growth in the Dutch, United Kingdom, and Canadian magnetic resonance imaging screening trials.
BRCA1 mutation in breast cancer patients: Analysis of prognostic factors and survival.
BRCA1 mutation influences progesterone response in human benign mammary organoids.
BRCA1 Mutation Leads to Deregulated Ubc9 Levels which Triggers Proliferation and Migration of Patient-Derived High Grade Serous Ovarian Cancer and Triple Negative Breast Cancer Cells.
BRCA1 mutation spectrum, functions, and therapeutic strategies: The story so far.
BRCA1 mutation testing for Japanese patients with ovarian cancer in breast cancer screening.
BRCA1 mutation update and analysis.
BRCA1 mutation, leptin and estrogen levels in breast cancer patients.
BRCA1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with first-degree family history.
BRCA1 mutations and clinicopathological features in a sample of Italian women with early-onset breast cancer.
BRCA1 mutations and other sequence variants in a population-based sample of Australian women with breast cancer.
BRCA1 mutations and polymorphisms in a hospital-based consecutive series of breast cancer patients from Apulia, Italy.
BRCA1 Mutations Associated With Increased Risk of Brain Metastases in Breast Cancer: A 1: 2 Matched-pair Analysis.
BRCA1 mutations drive oxidative stress and glycolysis in the tumor microenvironment: implications for breast cancer prevention with antioxidant therapies.
BRCA1 mutations found in archived early onset breast tumours.
BRCA1 mutations in a population-based sample of young women with breast cancer.
BRCA1 mutations in a population-based study of breast cancer in Stockholm County.
BRCA1 mutations in a selected series of breast/ovarian cancer patients.
BRCA1 mutations in African Americans.
BRCA1 mutations in Algerian breast cancer patients: high frequency in young, sporadic cases.
BRCA1 mutations in familial ovarian cancer.
BRCA1 mutations in patients with familial risk of breast cancer.
BRCA1 mutations in primary breast and ovarian carcinomas.
BRCA1 mutations in southern England.
BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer.
BRCA1 mutations in women with familial or early-onset breast cancer and BRCA2 mutations in familial cancer in Estonia.
BRCA1 mutations in young women with breast cancer.
BRCA1 negatively regulates formation of autophagic vacuoles in MCF-7 breast cancer cells.
BRCA1 negatively regulates IGF-1 expression through an estrogen-responsive element-like site.
BRCA1 negatively regulates the cancer-associated aromatase promoters I.3 and II in breast adipose fibroblasts and malignant epithelial cells.
BRCA1 overexpression sensitizes cancer cells to lovastatin via regulation of cyclin D1-CDK4-p21WAF1/CIP1 pathway: analyses using a breast cancer cell line and tumoral xenograft model.
BRCA1 p.His1673del is a pathogenic mutation associated with a predominant ovarian cancer phenotype.
BRCA1 pathway function in basal-like breast cancer cells.
BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M transition.
BRCA1 phosphorylation regulates caspase-3 activation in UV-induced apoptosis.
BRCA1 phosphorylation: biological consequences.
BRCA1 plays a role in the hypoxic response by regulating HIF-1alpha stability and by modulating vascular endothelial growth factor expression.
BRCA1 point mutations in premenopausal breast cancer patients from Central Sudan.
BRCA1 polymorphism in breast cancer patients from Argentina.
BRCA1 polymorphisms and breast cancer epidemiology in the Western New York exposures and breast cancer (WEB) study.
BRCA1 positively regulates FOXO3 expression by restricting FOXO3 gene methylation and epigenetic silencing through targeting EZH2 in breast cancer.
BRCA1 promoter deletions in young women with breast cancer and a strong family history: a population-based study.
BRCA1 promoter hypermethylation in sporadic epithelial ovarian carcinoma: Association with low expression of BRCA1, improved survival and co-expression of DNA methyltransferases.
BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer.
BRCA1 promoter hypermethylation signature for early detection of breast cancer in the Vietnamese population.
BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer.
BRCA1 Promoter Methylation and Clinicopathological Characteristics in Sporadic Breast Cancer Patients in Indonesia
BRCA1 Promoter Methylation and Expression - Associations with ER+, PR+ and HER2+ Subtypes of Breast Carcinoma
BRCA1 promoter methylation associated with poor survival in Chinese patients with sporadic breast cancer.
BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy.
BRCA1 promoter methylation in peripheral blood cells and predisposition to breast cancer.
BRCA1 promoter methylation in peripheral blood cells is associated with increased risk of breast cancer with BRCA1 promoter methylation.
BRCA1 promoter methylation in peripheral blood DNA of mutation negative familial breast cancer patients with a BRCA1 tumour phenotype.
BRCA1 promoter methylation in peripheral blood DNA was identified in sporadic breast cancer and controls.
BRCA1 promoter methylation in peripheral blood is associated with the risk of triple-negative breast cancer.
BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy.
BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles.
BRCA1 promoter methylation is a marker of better response to anthracycline-based therapy in sporadic TNBC.
BRCA1 promoter methylation is associated with increased mortality among women with breast cancer.
BRCA1 promoter methylation of normal breast epithelial cells as a possible precursor for BRCA1-methylated breast cancer.
BRCA1 promoter methylation status does not predict response to tamoxifen in sporadic breast cancer patients.
BRCA1 Promoter Methylation Status in 1031 Primary Breast Cancers Predicts Favorable Outcomes Following Chemotherapy.
BRCA1 protein and nucleolin colocalize in breast carcinoma tissue and cancer cell lines.
BRCA1 protein expression and its correlation with ER/PR status in sporadic and familial breast cancer in Eastern Indian patients--a hospital based study.
BRCA1 protein expression and subcellular localization in primary breast cancer: Automated digital microscopy analysis of tissue microarrays.
BRCA1 Protein Expression Level and CD44(+)Phenotype in Breast Cancer Patients.
BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase A.
BRCA1 protein level is not affected by peptide growth factors in MCF10A cell line.
BRCA1 protein levels and PIK3CA mutations as predictive biomarkers for response to neoadjuvant chemotherapy in locally advanced breast cancer: An exploratory analysis.
BRCA1 proteins are transported to the nucleus in the absence of serum and splice variants BRCA1a, BRCA1b are tyrosine phosphoproteins that associate with E2F, cyclins and cyclin dependent kinases.
BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk.
BRCA1 Recruitment to Transcriptional Pause Sites Is Required for R-Loop-Driven DNA Damage Repair.
BRCA1 regulates acetylation and ubiquitination of estrogen receptor-alpha.
BRCA1 regulates gene expression for orderly mitotic progression.
BRCA1 regulates microtubule dynamics and taxane-induced apoptotic cell signaling.
BRCA1 regulates p53-dependent gene expression.
BRCA1 regulates PIG3-mediated apoptosis in a p53-dependent manner.
BRCA1 regulates the cancer stem cell fate of breast cancer cells in the context of hypoxia and histone deacetylase inhibitors.
BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage.
BRCA1 regulation of epidermal growth factor receptor (EGFR) expression in human breast cancer cells involves microRNA-146a and is critical for its tumor suppressor function.
BRCA1 regulation on ?-hCG: a mechanism for tumorigenicity in BRCA1 defective breast cancer.
BRCA1 represses amphiregulin gene expression.
BRCA1 requirement for the fidelity of plasmid DNA double-strand break repair in cultured breast epithelial cells.
BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance.
BRCA1 role in the mitigation of radiotoxicity and chromosomal instability through repair of clustered DNA lesions.
BRCA1 screening in a woman with breast cancer: a patient's perspective with commentary.
BRCA1 screening in patients with a family history of breast or ovarian cancer.
BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing.
BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Institut Curie Breast Cancer Group.
BRCA1 splice variants BRCA1a and BRCA1b associate with CBP co-activator.
BRCA1 status in Pakistani breast cancer patients with moderate family history.
BRCA1 suppresses osteopontin-mediated breast cancer.
BRCA1 suppresses the expression of survivin and promotes sensitivity to paclitaxel through the calcium sensing receptor (CaSR) in human breast cancer cells.
BRCA1 susceptibility markers and postmenopausal breast cancer: the Iowa Women's Health Study.
BRCA1 testing in breast and/or ovarian cancer families from northeastern France identifies two common mutations with a founder effect.
BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes.
BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years.
BRCA1 through Its E3 Ligase Activity Regulates the Transcription Factor Oct1 and Carbohydrate Metabolism.
BRCA1 transactivates the cyclin-dependent kinase inhibitor p27(Kip1).
BRCA1 transcriptionally regulates genes associated with the basal-like phenotype in breast cancer.
BRCA1 transcriptionally regulates genes involved in breast tumorigenesis.
BRCA1 tumours correlate with a HIF-1alpha phenotype and have a poor prognosis through modulation of hydroxylase enzyme profile expression.
BRCA1, a potential predictive biomarker in the treatment of breast cancer.
BRCA1, BRCA2 and breast cancer: a concise clinical review.
BRCA1, BRCA2 and CHEK2 (1100 del C) germline mutations in hereditary breast and ovarian cancer families in South India.
BRCA1, BRCA2 and CHEK2 c.1100 delC mutations in patients with double primaries of the breasts and/or ovaries.
BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer.
BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives.
BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway.
BRCA1, BRCA2, BRCA3 ... a myriad of breast cancer genes.
BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma.
BRCA1, C-erbB-2, and H-ras gene expressions in young women with breast cancer. An immunohistochemical study.
BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma.
BRCA1--a good predictive marker of drug sensitivity in breast cancer treatment?
BRCA1-associated breast and ovarian cancer risks in Poland: no association with commonly studied polymorphisms.
BRCA1-associated complexes: new targets to overcome breast cancer radiation resistance.
BRCA1-associated mammary tumorigenesis is dependent on estrogen rather than progesterone signaling.
BRCA1-associated R-loop affects transcription and differentiation in breast luminal epithelial cells.
BRCA1-BARD1 regulates axon regeneration in concert with the Gq?-DAG signaling network.
BRCA1-BRCT Mutations Alter the Subcellular Localization of BRCA1 In Vitro.
BRCA1-dependent and independent functions of BARD1.
BRCA1-induced apoptosis involves inactivation of ERK1/2 activities.
BRCA1-induced large-scale chromatin unfolding and allele-specific effects of cancer-predisposing mutations.
BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1? activation.
BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential.
BRCA1-mediated G2/M cell cycle arrest requires ERK1/2 kinase activation.
BRCA1-mediated inflammation and growth activated & inhibited transition mechanisms between no-tumor hepatitis/cirrhotic tissues and HCC.
BRCA1-mediated repression of mutagenic end-joining of DNA double-strand breaks requires complex formation with BACH1.
BRCA1-mediated repression of select X chromosome genes.
BRCA1-mediated signaling pathways in ovarian carcinogenesis.
BRCA1-methylated sporadic breast cancers are BRCA-like in showing a basal phenotype and absence of ER expression.
BRCA1-mutated estrogen receptor positive breast cancer shows BRCAness, suggesting sensitivity to drugs targeting homologous recombination deficiency.
BRCA1-No Matter How You Splice It.
BRCA1-related and sporadic ovarian cancer in the same family: implications for genetic testing.
BRCA1-related breast cancer in Austrian breast and ovarian cancer families: specific BRCA1 mutations and pathological characteristics.
BRCA1-related gene signature in breast cancer: the role of ER status and molecular type.
BRCA1/2 genes mutations, ovarian reserve and female reproductive outcomes: a systematic literature review.
BRCA1/2 in high-risk African American women with breast cancer: providing genetic testing through various recruitment strategies.
BRCA1/2 mutation analysis in male breast cancer families from North West England.
BRCA1/2 Mutations and Triple Negative Breast Cancers.
BRCA1/2 predictive testing and gender: uptake, motivation and psychological characteristics.
BRCA1/2 status and clinicopathologic characteristics of patients with double primary breast and ovarian cancer.
BRCA1/BARD1 E3 ubiquitin ligase can modify histones H2A and H2B in the nucleosome particle.
BRCA1/BRCA2 founder mutations and cancer risks: impact in the western Danish population.
BRCA1/BRCA2 gene mutations/SNPs and BRCA1 haplotypes in early-onset breast cancer patients of Indian ethnicity.
BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients.
BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: implications for breast-conserving management in patients with BRCA1/BRCA2 mutations.
BRCA1/BRCA2 mutation status and analysis of cancer family history in participants of the Royal Marsden Hospital tamoxifen chemoprevention trial.
BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
BRCA1/BRCA2 Mutations Shaped by Ancient Consanguinity Practice in Southern Mediterranean Populations
BRCA1/BRCA2 Pathogenic Variant Breast Cancer: Treatment and Prevention Strategies.
BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases.
BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1.
BRCA1: lessons learned from the breast cancer gene.
BRCA1: linking HOX to breast cancer suppression.
BRCA1: more than a hereditary breast cancer gene?
BRCA1a has antitumor activity in TN breast, ovarian and prostate cancers.
BRCA2 acts as a RAD51 loader to facilitate telomere replication and capping.
BRCA2 germline mutations in Japanese breast cancer families.
BRCA2 germline mutations in Swedish breast cancer families.
BRCA2 hypomorphic missense variants confer moderate risks of breast cancer.
BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2.
BRCA2 mutations and triple-negative breast cancer.
BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers.
BRCA2 T2722R is a deleterious allele that causes exon skipping.
BRCA2-Deficient CAPAN-1 Cells are Extremely Sensitive to the Inhibition of Poly (ADP-Ribose) Polymerase: An Issue of Potency.
BRCA2: a genetic risk factor for breast cancer.
Brcal Defective Breast Cancer Cells Induce in vitro Transformation of Cancer Associated Fibroblasts (CAFs) to Metastasis Associated Fibroblasts (MAF).
BRCAness is beneficial for indicating triple negative breast cancer patients resistant to taxane.
BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
BRCC36 is essential for ionizing radiation-induced BRCA1 phosphorylation and nuclear foci formation.
BRCT domain interactions in the heterodimeric DNA repair protein XRCC1-DNA ligase III.
Breast and ovarian cancer genetics and prevention.
Breast and ovarian cancer in relatives of cancer patients, with and without BRCA mutations.
Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
Breast and ovarian cancer penetrance of BRCA1/2 mutations among Hong Kong women.
Breast and ovarian cancer risk evaluation in families with a disease-causing mutation in BRCA1/2.
Breast and ovarian cancer risk perception after prophylactic salpingo-oophorectomy due to an inherited mutation in the BRCA1 or BRCA2 gene.
Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies.
Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores.
Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study.
Breast cancer 1 (BRCA1)-deficient embryos develop normally but are more susceptible to ethanol-initiated DNA damage and embryopathies.
Breast cancer 2004: Progress and promise on the clinical front.
Breast Cancer Adjuvant Radiotherapy in BRCA1/2, TP53, ATM Genes Mutations: Are There Solved Issues?
Breast cancer after mantle irradiation for Hodgkin's disease: correlation of clinical, pathologic, and molecular features including loss of heterozygosity at BRCA1 and BRCA2.
Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.
Breast cancer and BRCA1 mutations.
Breast cancer and family history: levels of lipid-associated sialic acid in plasma and absent family history of breast cancer in women who have breast tumors.
Breast cancer and genetic instability: the molecules behind the scenes.
Breast cancer and genetics.
Breast cancer and ovarian cancer genetics: an update.
Breast cancer and pregnancy.
Breast cancer associated pathogenic variants among women 61?years and older with triple negative breast cancer.
Breast cancer cell response to genistein is conditioned by BRCA1 mutations.
Breast cancer cells: Modulation by melatonin and the ubiquitin-proteasome system--a review.
Breast cancer detection among Irish BRCA1 & BRCA2 mutation carriers: a population-based study.
Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers.
Breast cancer epidemiology, prevention, and early detection.
Breast cancer gene 1 (BRCA1): role in cell cycle regulation and DNA repair--perhaps through transcription.
Breast cancer genes: beyond BRCA1 and BRCA2.
Breast cancer genes: therapeutic strategies.
Breast cancer genetics in African Americans.
Breast cancer genetics: family history, heterogeneity, molecular genetic diagnosis, and genetic counselling.
Breast cancer in a patient with Birt-Hogg-Dubé syndrome (BHDS) with dramatic response to neoadjuvant chemotherapy.
Breast cancer in a patient with Kindlers syndrome.
Breast cancer in adolescents and young women.
Breast cancer in BRCA mutation carriers: medical treatment.
Breast cancer in carriers of BRCA1 and BRCA2 mutations: tackling a molecular and clinical conundrum.
Breast cancer in males, case presentation and literature review
Breast cancer in patients with germline TP53 pathogenic variants have typical tumour characteristics: the Cohort study of TP53 carrier early onset breast cancer (COPE study).
Breast cancer in six families from Tolima and Huila: BRCA1 3450del4 mutation
Breast cancer in sub-Saharan Africa: how does it relate to breast cancer in African-American women?
Breast cancer in women at high risk: The role of rapid genetic testing for BRCA1 and -2 mutations and the consequences for treatment strategies.
Breast cancer in young women: do BRCA1 or BRCA2 mutations matter?
Breast Cancer Incidence After Risk-Reducing Salpingo-Oophorectomy in BRCA1 and BRCA2 Mutation Carriers.
Breast cancer incidence in BRCA mutation carriers with ovarian cancer: A longitudal observational study.
Breast cancer incidence, penetrance and survival in probable carriers of BRCA1 gene mutation in families linked to BRCA1 on chromosome 17q12-21.
Breast Cancer is Common in Women With Ovarian Malignant Mixed Mullerian Tumors.
Breast cancer metastasis suppressor 1 (BRMS1) is destabilized by the Cul3-SPOP E3 ubiquitin ligase complex.
Breast Cancer Mortality among Women with a BRCA1 or BRCA2 Mutation in a Magnetic Resonance Imaging Plus Mammography Screening Program.
Breast cancer patients suggestive of Li-Fraumeni syndrome: mutational spectrum, candidate genes, and unexplained heredity.
Breast cancer patients with hypermethylation in the promoter of BRCA1 gene exhibit favorable clinical status.
Breast cancer predisposing alleles in Poland.
Breast cancer predisposition syndromes.
Breast cancer prevention for BRCA1 and BRCA2 mutation carriers: is there a role for tamoxifen?
Breast cancer prevention in women with a BRCA1 or BRCA2 mutation.
Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study.
Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers.
Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers.
Breast cancer risk among male BRCA1 and BRCA2 mutation carriers.
Breast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2.
Breast cancer risk and germline genomic profiling of women with neurofibromatosis type 1 who developed breast cancer.
Breast cancer risk and the BRCA1 interacting protein CTIP.
Breast cancer risk and the DNA double-strand break end-joining capacity of nonhomologous end-joining genes are affected by BRCA1.
Breast Cancer Risk Assessment: Moving Beyond BRCA 1 and 2.
Breast cancer risk assessment: use of complete pedigree information and the effect of misspecified ages at diagnosis of affected relatives.
Breast cancer risk associated with AURKA 91T -->A polymorphism in relation to BRCA mutations.
Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations.
Breast cancer risk associated with BRCA1/2 variants in the Pakistani population.
Breast cancer risk associated with CHEK2 mutations.
Breast cancer risk associated with genotypic polymorphism of the nonhomologous end-joining genes: a multigenic study on cancer susceptibility.
Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations.
Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.
Breast cancer risk for Korean women with germline mutations in BRCA1 and BRCA2.
Breast cancer risk for noncarriers of family-specific BRCA1 and BRCA2 mutations: findings from the Breast Cancer Family Registry.
Breast Cancer Risk for Noncarriers of Family-Specific BRCA1 and BRCA2 Mutations: More Trouble With Phenocopies.
Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women.
Breast cancer risk in Ashkenazi BRCA1/2 mutation carriers: effects of reproductive history.
Breast cancer risk in BRCA1 and BRCA2 mutation carriers and polyglutamine repeat length in the AIB1 gene.
Breast cancer risk in BRCA1 mutation carriers: insight from mouse models.
Breast cancer risk in Chinese women with BRCA1 or BRCA2 mutations.
Breast Cancer Risk in Relation to Alcohol Consumption and BRCA Gene Mutations - A Case-Only Study of Gene-Environment Interaction.
Breast cancer risk is associated with the genes encoding the DNA double-strand break repair Mre11/Rad50/Nbs1 complex.
Breast cancer risk is not associated with polymorphic forms of xeroderma pigmentosum genes in a cohort of women from Washington County, Maryland.
Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applications.
Breast cancer risk perception among women who have undergone prophylactic bilateral mastectomy.
Breast Cancer Risk Prediction Using Clinical Models and 77 Independent Risk-Associated SNPs for Women Aged Under 50 Years: Australian Breast Cancer Family Registry.
Breast cancer risk reduction associated with the RAD51 polymorphism among carriers of the BRCA1 5382insC mutation in Poland.
Breast Cancer Risk Reduction Clinical Practice Guidelines in Oncology.
Breast Cancer Risk Reduction Decisions of the BRCA-Positive Patient: An Observational Study at a Single Institution.
Breast cancer risk-assessment models.
Breast cancer risks and risk prediction models.
Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2.
Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation.
Breast cancer screening in BRCA1 and BRCA2 mutation carriers after risk reducing salpingo-oophorectomy.
Breast cancer screening in BRCA1 mutation carriers: effectiveness of MR imaging--Markov Monte Carlo decision analysis.
Breast cancer sensitivity to neoadjuvant therapy in BRCA1 and CHEK2 mutation carriers and non-carriers.
Breast Cancer Surveillance Following Ovarian Cancer in BRCA Mutation Carriers.
Breast cancer surveillance in women with hereditary risk due to BRCA1 or BRCA2 mutations.
Breast cancer survival in BRCA1 carriers.
Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women.
Breast cancer susceptibility gene 1 (BRCAI) is a coactivator of the androgen receptor.
Breast cancer susceptibility genes.
Breast cancer susceptibility genes. BRCA1 and BRCA2.
Breast cancer susceptibility protein 1 (BRCA1) rescues neurons from cerebral ischemia/reperfusion injury through NRF2-mediated antioxidant pathway.
Breast cancer susceptibility testing: past, present and future.
Breast cancer susceptibility variants alter risk in familial ovarian cancer.
Breast cancer susceptibility variants alter risks in familial disease.
Breast cancer susceptibility-A new look at an old model.
Breast cancer susceptibility: current knowledge and implications for genetic counselling.
Breast cancer therapy for BRCA1 carriers: moving towards platinum standard?
Breast cancer treatment in mutation carriers: surgical treatment.
Breast cancer-associated abraxas mutation disrupts nuclear localization and DNA damage response functions.
Breast cancer.
Breast cancer: genetic predisposition and exposure to radiation.
Breast cancer: major risk factors and recent developments in treatment.
Breast cancer: oophorectomy for BRCA1 ER--negative disease-an open debate.
Breast cancers detected with imaging screening in the BRCA population: emphasis on MR imaging with histopathologic correlation.
Breast carcinoma in carriers of BRCA1 or BRCA2 mutations: implications of proposed distinct histologic phenotypes.
Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression.
Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: are they prognostically different?
Breast conservation in BRCA1 or BRCA2 mutation carriers with early stage breast cancer.
Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations.
Breast imaging findings in women with BRCA1- and BRCA2-associated breast carcinoma.
Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma.
Breast tumor characteristics of BRCA1 and BRCA2 gene mutation carriers on MRI.
Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis.
Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Breast-Specific Epigenetic Regulation of DeltaNp73 and Its Role in DNA-Damage-Response of BRCA1-Mutated Human Mammary Epithelial Cells.
Breast-Specific Molecular Clocks Comprised of ELF5 Expression and Promoter Methylation Identify Individuals Susceptible to Cancer Initiation.
Breastfeeding and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
Breed-related differences in altered BRCA1 expression, phenotype and subtype in malignant canine mammary tumors.
BRIP1 (BACH1) variants and familial breast cancer risk: a case-control study.
BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer.
BRIT1 regulates p53 stability and functions as a tumor suppressor in breast cancer.
Building capacity for human genetics and genomics research in Trinidad and Tobago.
C-Cbl reverses HER2-mediated tamoxifen resistance in human breast cancer cells.
c-Fos oncogene regulator Elk-1 interacts with BRCA1 splice variants BRCA1a/1b and enhances BRCA1a/1b-mediated growth suppression in breast cancer cells.
c-Kit is required for growth and survival of the cells of origin of Brca1-mutation-associated breast cancer.
c-Myc activates BRCA1 gene expression through distal promoter elements in breast cancer cells.
C-terminus of Hsc70-interacting protein regulates profilin1 and breast cancer cell migration.
CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer.
Cadmium malignantly transforms normal human breast epithelial cells into a basal-like phenotype.
CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers.
CAG repeat size in Huntingtin alleles is associated with cancer prognosis.
Can genetic testing guide treatment in breast cancer?
Can Soy Phytoestrogens Decrease DNA Methylation in BRCA1 and BRCA2 Oncosuppressor Genes in Breast Cancer?
Can we prevent BRCA1-associated breast cancer by RANKL inhibition?
Cancer genetics for the clinician: recommendations on screening for BRCA1 and BRCA2 mutations.
Cancer genetics in primary care.
Cancer genetics in the new era of molecular biology.
Cancer in Jews: introduction and overview.
Cancer incidence in a population of Jewish women at risk of ovarian cancer.
Cancer incidence in relatives of a population-based set of cases of early-onset breast cancer with a known BRCA1 and BRCA2 mutation status.
Cancer predisposing BARD1 mutations in breast-ovarian cancer families.
Cancer predisposing missense and protein truncating BARD1 mutations in non-BRCA1 or BRCA2 breast cancer families.
Cancer predisposition, radiosensitivity and the risk of radiation-induced cancers. IV. Prediction of risks in relatives of cancer-predisposed individuals.
Cancer Previvors in an Active Duty Service Women Population: An Opportunity for Prevention and Increased Force Readiness.
Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: Effects of oral contraceptive use and parental origin of mutation.
Cancer risks for Australian women with a BRCA1 or a BRCA2 mutation.
Cancer risks in first degree relatives of BRCA1 mutation carriers: effects of mutation and proband disease status.
Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13.
Cancer stem cell heterogeneity in hereditary breast cancer.
Cancer-specific methylation in the BRCA1 promoter in sporadic breast tumours.
Cancers in BRCA1 and BRCA2 carriers and in women at high risk for breast cancer: MR imaging and mammographic features.
Candidate tumor suppressor LUCA-15/RBM5/H37 modulates expression of apoptosis and cell cycle genes.
Canonical Wnt signaling regulates Slug activity and links epithelial-mesenchymal transition with epigenetic Breast Cancer 1, Early Onset (BRCA1) repression.
Cantharidin Induces DNA Damage and Inhibits DNA Repair-associated Protein Expressions in TSGH8301 Human Bladder Cancer Cell.
Carbon-nanotube-modified electrodes for amplified enzyme-based electrical detection of DNA hybridization.
Carboxyl terminus of Hsp70-interacting protein (CHIP) contributes to human glioma oncogenesis.
Carcinoma of the breast with medullary-like features: diagnostic challenges and relationship with BRCA1 and EZH2 functions.
CASP8 D302H polymorphism delays the age of onset of breast cancer in BRCA1 and BRCA2 carriers.
Caspase-3 mediated cleavage of BRCA1 during UV-induced apoptosis.
Catalytic inhibition of topoisomerase II by a novel rationally designed ATP-competitive purine analogue.
Caucasian family with two independent mutations: 2594delC in BRCA1 and 5392delAG in BRCA2 gene.
Caveolin-1 controls BRCA1 gene expression and cellular localization in human breast cancer cells.
Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer.
cbl-b inhibits EGF-receptor-induced apoptosis by enhancing ubiquitination and degradation of activated receptors.
CCND1 and ZNF217 gene amplification is equally frequent in BRCA1 and BRCA2 associated and non-BRCA breast cancer.
CDDO-Imidazolide Induces DNA Damage, G2/M Arrest and Apoptosis in BRCA1-Mutated Breast Cancer Cells.
Celebrity Health Announcements and Online Health Information Seeking: An Analysis of Angelina Jolie's Preventative Health Decision.
Cell cycle differences in DNA damage-induced BRCA1 phosphorylation affect its subcellular localization.
Cell cycle-dependent conjugation of endogenous BRCA1 protein with SUMO-2/3.
Cell density is a critical determinant of aromatase expression in adipose stromal cells.
Cell fate takes a slug in BRCA1-associated breast cancer.
Central catalytic domain of BRAP (RNF52) recognizes the types of ubiquitin chains and utilizes oligo-ubiquitin for ubiquitylation.
Centriole separation in DNA damage-induced centrosome amplification.
CGH analysis of familial non-BRCA1/BRCA2 breast tumors and mutation screening of a candidate locus on chromosome 17q11.2-12.
CGH-targeted linkage analysis reveals a possible BRCA1 modifier locus on chromosome 5q.
Challenges and Considerations on Risk-Reducing Surgery in BRCA1/2 Patients with Advanced Breast Cancer.
Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Changes in BRCA1 and BRCA2 expression produced by chemotherapeutic agents in human breast cancer cells.
Changes in BRCA2 expression during progression of the cell cycle.
Changes in classification of genetic variants in BRCA1 and BRCA2.
Changes in health-related behaviours following BRCA 1/2 genetic testing: the case of hormone replacement therapy.
Changes in the expression of plasma proteins associated with thrombosis in BRCA1 mutation carriers.
Characterisation of the BRCT domains of the breast cancer susceptibility gene product BRCA1.
Characteristics and spectrum of BRCA1 and BRCA2 mutations in 3,922 Korean patients with breast and ovarian cancer.
Characteristics of BRCA1 mutations in a population-based case series of breast and ovarian cancer.
Characteristics of BRCA1/2 mutations carriers including large genomic rearrangements in high risk breast cancer patients.
Characteristics of double heterozygosity for BRCA1 and BRCA2 germline mutations in Korean breast cancer patients.
Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2.
Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2.
Characteristics relating to ovarian cancer risk: implications for prevention and detection.
Characterization of 10 new polymorphic dinucleotide repeats and generation of a high-density microsatellite-based physical map of the BRCA1 region of chromosome 17q21.
Characterization of 2 novel and 2 recurring BRCA1 germline mutations in breast and/or ovarian carcinoma patients from the area of Naples.
Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier.
Characterization of a negative transcriptional element in the BRCA1 promoter.
Characterization of a novel breast carcinoma xenograft and cell line derived from a BRCA1 germ-line mutation carrier.
Characterization of a novel germline BRCA1 splice variant, c.5332+4delA.
Characterization of a novel large deletion and single point mutations in the BRCA1 gene in a Greek cohort of families with suspected hereditary breast cancer.
Characterization of a novel trans-activation domain of BRCA1 that functions in concert with the BRCA1 C-terminal (BRCT) domain.
Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study.
Characterization of BRCA1 and BRCA2 genetic variants in a cohort of Bahraini breast cancer patients using next-generation sequencing.
Characterization of BRCA1 and BRCA2 mutations in a large United States sample.
Characterization of BRCA1 and BRCA2 variants in multi-ethnic Asian cohort from a Malaysian case-control study.
Characterization of Brca1 deficient mice.
Characterization of BRCA1 Protein Targeting, Dynamics, and Function at the Centrosome: A ROLE FOR THE NUCLEAR EXPORT SIGNAL, CRM1, AND AURORA A KINASE.
Characterization of BRCA1/2 mutations in patients with family history of breast cancer in Armenia.
Characterization of cancer-linked BRCA1-BRCT missense variants and their interaction with phosphoprotein targets.
Characterization of COBRA1 in human breast cancer cell lines using a new polyclonal antibody against COBRA1.
Characterization of familial non-BRCA1/2 breast tumors by loss of heterozygosity and immunophenotyping.
Characterization of ten novel and 13 recurring BRCA1 and BRCA2 germline mutations in Italian breast and/or ovarian carcinoma patients. Mutations in brief no. 178. Online.
Characterization of the BRCA1-like immunoreactivity of human seminal plasma.
Characterization of therapy-related acute leukemia in hereditary breast-ovarian carcinoma patients: role of BRCA1 mutation and topoisomerase II-directed therapy.
Characterization of three alternative transcripts of the BRCA1 gene in patients with breast cancer and a family history of breast and/or ovarian cancer who tested negative for pathogenic mutations.
Checkpoint kinase 2-mediated phosphorylation of BRCA1 regulates the fidelity of nonhomologous end-joining.
CHEK2 1100delC and male breast cancer in the Netherlands.
CHEK2 1100delC is not a risk factor for male breast cancer population.
CHEK2 c.1100delC mutation is associated with an increased risk for male breast cancer in Finnish patient population.
CHEK2 contribution to hereditary breast cancer in non-BRCA families.
CHEK2 Germ Line Mutations are Lacking among Familial and Sporadic Breast Cancer Patients in Rwanda
CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.
Chemoprevention for high-risk women: tamoxifen and beyond.
Chemoprevention in BRCA1 mutation carriers (CIBRAC): protocol for an open allocation crossover feasibility trial assessing mechanisms of chemoprevention with goserelin and anastrozole versus tamoxifen and acceptability of treatment.
Chemoprevention of breast cancer.
Chemoprevention options for BRCA1 and BRCA2 mutation carriers.
Chemotherapy-Induced Amenorrhea in Patients With Breast Cancer With a BRCA1 or BRCA2 Mutation.
Childhood Cancer in Families with and without BRCA1 or BRCA2 Mutations Ascertained at a High-Risk Breast Cancer Clinic.
Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair.
Chromatin remodeling and activation of chromosomal DNA replication by an acidic transcriptional activation domain from BRCA1.
Chromogenic and fluorescent in situ hybridization in breast cancer.
Chromosomal aberrations involving telomeres in BRCA1 deficient human and mouse cell lines.
Chromosomal breakage syndromes and the BRCA1 genome surveillance complex.
Chromosomal instability in BRCA1- or BRCA2-defective human cancer cells detected by spontaneous micronucleus assay.
Chromosomal instability induced by mammography X-rays in primary human fibroblasts from BRCA1 and BRCA2 mutation carriers.
Chromosomal mutagen sensitivity associated with mutations in BRCA genes.
Chromosomal radiosensitivity in BRCA1 and BRCA2 mutation carriers.
Chromosome 12p Amplification in Triple-Negative/BRCA1-Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity.
Chromosome 17q linkage studies of 18 Utah breast cancer kindreds.
Chromosome 17q-linkage seems to be infrequent in Icelandic families at risk of breast cancer.
Chromosome 5 imbalance mapping in breast tumors from BRCA1 and BRCA2 mutation carriers and sporadic breast tumors.
Chronic Lymphocytic Leukemia in Neurofibromatosis Type 1 Patients: Case Report and Literature Review of a Rare Occurrence.
CIP2A is associated with human breast cancer aggressivity.
CircNR3C2 promotes HRD1-mediated tumor-suppressive effect via sponging miR-513a-3p in triple-negative breast cancer.
Circulatory miRNA-155, miRNA-21 target PTEN expression and activity as a factor in breast cancer development.
CK8/18 expression, the basal phenotype, and family history in identifying BRCA1-associated breast cancer in the Ontario site of the Breast Cancer Family Registry.
Class I histone deacetylase inhibition is synthetic lethal with BRCA1 deficiency in breast cancer cells.
Classifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profiling.
Clinical and Genetic Characteristics of BRCA1/2 Mutation in Korean Ovarian Cancer Patients: A Multicenter Study and Literature Review.
Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
Clinical and molecular characterization of the BRCA2 p.Asn3124Ile variant reveals substantial evidence for pathogenic significance.
Clinical and pathologic characteristics of breast cancer patients carrying the c.3481_3491del11 mutation.
Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.
Clinical and pathological characteristics of Chinese patients with BRCA related breast cancer.
Clinical and pathological features of BRCA1 associated carcinomas in a hospital-based sample of Dutch breast cancer patients.
Clinical and pathological features of BRCA1/2 tumors in a sample of high-risk Moroccan breast cancer patients.
Clinical and research issues in breast cancer genetics.
Clinical application of breast cancer risk assessment models.
Clinical Characteristics and Exploratory Genomic Analyses of Germline BRCA1 or BRCA2 Mutations in Breast Cancer.
Clinical Characteristics in Patients with Triple Negative Breast Cancer.
Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals.
Clinical Characteristics of Korean Breast Cancer Patients Who Carry Pathogenic Germline Mutations in Both BRCA1 and BRCA2: A Single-Center Experience.
Clinical characteristics of laryngeal cancer in BRCA-1 mutation carriers.
Clinical classification of BRCA1 and BRCA2 DNA sequence variants: the value of cytokeratin profiles and evolutionary analysis--a report from the kConFab Investigators.
Clinical experience of prophylactic mastectomy followed by immediate breast reconstruction in women at hereditary risk of breast cancer (HB(O)C) or a proven BRCA1 and BRCA2 germ-line mutation.
Clinical follow up of mexican women with early onset of breast cancer and mutations in the BRCA1 and BRCA2 genes.
Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer.
Clinical implications for BRCA gene mutation in breast cancer.
Clinical implications of genetic testing for BRCA1 and BRCA2 mutations in Austria.
Clinical implications of germline mutations in breast cancer genes: RECQL.
Clinical implications of low-penetrance breast cancer susceptibility alleles.
Clinical implications of the breast cancer susceptibility genes BRCA1 and BRCA2.
Clinical interpretation and recommendations for patients with a variant of uncertain significance in BRCA1 or BRCA2: a survey of genetic counseling practice.
Clinical management of BRCA1 and BRCA2 mutation carriers.
Clinical management of BRCA1- and BRCA2-associated breast cancer.
Clinical outcome and toxicity from taxanes in breast cancer patients with BRCA1 and BRCA2 pathogenic germline mutations.
Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes.
Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers.
Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations.
Clinical phenotypes combined with saturation genome editing identifying the pathogenicity of BRCA1 variants of uncertain significance in breast cancer.
Clinical practice guidelines for BRCA1 and BRCA2 genetic testing.
Clinical Significance of DNA Damage Response Factors and Chromosomal Instability in Primary Lung Adenocarcinoma.
Clinical significance of epigenetic inactivation of hMLH1 and BRCA1 in Tunisian patients with invasive breast carcinoma.
Clinical Significance of Receptor-Interacting Protein 3 and Parkin, Essential Molecules for Necroptosis, in Breast Cancer.
Clinical use and mechanisms of resistance for PARP inhibitors in homologous recombination-deficient cancers.
Clinically relevant biology of hereditary breast cancer.
Clinically Significant Unclassified Variants in BRCA1 and BRCA2 Genes Among Korean Breast Cancer Patients.
Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer.
Clinicopathologic features and genetic characteristics of the BRCA1/2 mutation in Turkish breast cancer patients.
Clinicopathological analysis of homologous recombination-deficient breast cancers with special reference to response to neoadjuvant paclitaxel followed by FEC.
Clinicopathological and molecular significance of Sumolyation marker (ubiquitin conjugating enzyme 9 (UBC9)) expression in breast cancer of black women.
Clinicopathological features and prognostic factors of young breast cancers in Eastern Guangdong of China.
Clinicopathological Features of BRCA1/2 Mutation-Positive Breast Cancer.
Clinicopathological Features of Hereditary Breast Cancer.
Clinicopathological Significance of BRCA1 Promoter Hypermethylation in Thai Breast Cancer Patients.
Clinicopathological significance of KU70/KU80, a key DNA damage repair protein in breast cancer.
Clinicopathological study of chromogranin A, B and BRCA1 expression in node-negative breast carcinoma.
Cloning and characterization of a new BRCA1 variant: A role for BRCT domains in apoptosis.
Cloning and functional identification of two novel BRCA1 splicing variants.
Cloning, genetic mapping and expression studies of the rat Brca1 gene.
Clues to the function of the tumour susceptibility gene BRCA2.
Clustering of variations and haplotype analysis in the highly variable region of exon 11 of BRCA1 in Chinese women with sporadic breast cancer.
Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers.
Co-existence of breast and ovarian cancers in BRCA germ-line mutation carriers.
Co-occurrence of germline BRCA1 and CDH1 pathogenic variants.
Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibition.
Cobaltous chloride and hypoxia inhibit aryl hydrocarbon receptor-mediated responses in breast cancer cells.
Coffee and caffeine intake and breast cancer risk: An updated dose-response meta-analysis of 37 published studies.
Coffee consumption and breast cancer risk among BRCA1 and BRCA2 mutation carriers.
Coffee consumption and breast cancer risk: a narrative review in the general population and in different subtypes of breast cancer.
Coincident PTCH and BRCA1 germline mutations in a patient with nevoid basal cell carcinoma syndrome and familial breast cancer.
Collaboration of Brca1 and Chk2 in tumorigenesis.
Collaboration of breast cancer clinic and genetic counseling division for BRCA1 and BRCA2 mutation family in Japan.
Collaboration of signal transducer and activator of transcription 1 (STAT1) and BRCA1 in differential regulation of IFN-gamma target genes.
Collective evidence supports neutrality of BRCA1 V1687I, a novel sequence variant in the conserved THV motif of the first BRCT repeat.
College Women's Responses to a Celebrity Health Disclosure.
Colorectal cancer in hereditary breast cancer kindreds.
Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer.
Combined microRNA and ER expression: a new classifier for familial and sporadic breast cancer patients.
Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers.
Common BRCA1 and BRCA2 mutations in breast cancer families: a meta-analysis from systematic review.
Common BRCA1 variants and susceptibility to breast and ovarian cancer in the general population.
Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers.
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction.
Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2.
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Common genetic variants and cancer risk in Mendelian cancer syndromes.
Common genetic variants contribute to incomplete penetrance: evidence from cancer-free BRCA1 mutation carriers.
Common genetic variation at BARD1 is not associated with Breast cancer risk in BRCA1 or BRCA2 mutation carriers.
Common mutations in BRCA1 and BRCA2 do not contribute to early prostate cancer in Jewish men.
Common non-synonymous polymorphisms in the BRCA1 Associated RING Domain (BARD1) gene are associated with breast cancer susceptibility: a case-control analysis.
Common nonsense mutations in RAD52.
Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families.
Common variants associated with breast cancer in genome wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers.
Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers.
Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk.
Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers.
Communicating genetic risk: pros, cons, and counsel.
Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.
Comparative analysis of BRCA1 and BRCA2 variants of uncertain significance in patients with breast cancer: a multifactorial probability-based model versus ACMG standards and guidelines for interpreting sequence variants.
Comparative genomic hybridization of microdissected familial ovarian carcinoma: two deleted regions on chromosome 15q not previously identified in sporadic ovarian carcinoma.
Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations.
Comparative microRNA profiling of sporadic and BRCA1 associated basal-like breast cancers.
Comparative pathology of mammary gland cancers in domestic and wild animals.
Comparing Coordinated Versus Sequential Salpingo-Oophorectomy for BRCA1 and BRCA2 Mutation Carriers With Breast Cancer.
Comparing the frequency of common genetic variants and haplotypes between carriers and non-carriers of BRCA1 and BRCA2 deleterious mutations in Australian women diagnosed with breast cancer before 40 years of age.
Comparison between genotype and phenotype identifies a high-risk population carrying BRCA1 mutations.
Comparison of BRCA1 Expression between Triple-Negative and Luminal Breast Tumors
Comparison of BRCT domains of BRCA1 and 53BP1: a biophysical analysis.
Comparison of conformation-sensitive gel electrophoresis and single-strand conformation polymorphism analysis for detection of mutations in the BRCA1 gene using optimized conformation analysis protocols.
Comparison of Patient Susceptibility Genes Across Breast Cancer: Implications for Prognosis and Therapeutic Outcomes.
Comparisons of gene coexpression network modules in breast cancer and ovarian cancer.
Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis.
Competing risks analysis of correlated failure time data.
Complete allelic analysis of BRCA1 and BRCA2 variants in young Nigerian breast cancer patients.
Complete mutation screening and haplotype characterization of BRCA1 gene in Tunisian patients with familial breast cancer.
Complete mutation screening and haplotype characterization of the BRCA1 gene in 61 familial breast cancer patients from Norway.
Complex Characterization of Germline Large Genomic Rearrangements of the BRCA1 and BRCA2 Genes in High-Risk Breast Cancer Patients-Novel Variants from a Large National Center.
Compliance With Tamoxifen in Women With Breast Cancer and a BRCA1 or BRCA2 Mutation.
Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population.
Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5931 Chinese women with breast cancer.
Comprehensive Analysis of BRCA1, BRCA2 and TP53 Germline Mutation and Tumor Characterization: A Portrait of Early-Onset Breast Cancer in Brazil.
Comprehensive analysis of germline mutations in northern Brazil: a panel of 16 genes for hereditary cancer-predisposing syndrome investigation.
Comprehensive BRCA1 and BRCA2 mutation analyses and review of French Canadian families with at least three cases of breast cancer.
Comprehensive BRCA1 and BRCA2 mutational profile in Lithuania.
Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.
Comprehensive genomic characterization of breast tumors with BRCA1 and BRCA2 mutations.
Comprehensive mutational analysis of BRCA1/BRCA2 for Korean breast cancer patients: evidence of a founder mutation.
Comprehensive prediction of mRNA splicing effects of BRCA1 and BRCA2 variants.
Comprehensive Proteomic Profiling-derived Immunohistochemistry-based Prediction Models for BRCA1 and BRCA2 Germline Mutation-related Breast Carcinomas.
Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries.
Comprehensive strategy for the design of precision drugs and identification of genetic signature behind proneness of the disease-a pharmacogenomic approach.
Comprehensive study for BRCA1 and BRCA2 entire coding regions in breast cancer.
Compromised BRCA1-PALB2 interaction is associated with breast cancer risk.
Computerized analysis of digitized mammograms of BRCA1 and BRCA2 gene mutation carriers.
Concerted action of two avirulent spore effectors activates Reaction to Puccinia graminis 1 (Rpg1)-mediated cereal stem rust resistance.
Concerted transcriptional regulation by BRCA1 and COBRA1 in breast cancer cells.
Concomitant loss of heterozygosity at the BRCA1 and FHIT genes as a prognostic factor in sporadic breast cancer.
Concurrent germline BRCA1, BRCA2, and CHEK2 pathogenic variants in hereditary breast cancer: a case series.
Conditions for single-strand conformation polymorphism (SSCP) analysis of BRCA1 gene using an automated electrophoresis unit.
Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families.
Confirmation of susceptibility locus on chromosome 13 in Australian breast cancer families.
Connection between Tumor Suppressor BRCA1 and PTEN in Damaged DNA Repair.
Consanguinity Protecting Effect Against Breast Cancer among Tunisian Women: Analysis of BRCA1 Haplotypes.
Conservative management of breast cancer in BRCA1/2 mutation carriers.
Conserved BRCT regions of TopBP1 and of the tumor suppressor BRCA1 bind strand breaks and termini of DNA.
Considerations in genetic counseling for inherited breast cancer predisposition.
Considerations when using breast cancer risk models for women with negative BRCA1/BRCA2 mutation results.
CONSTITUTIONAL METHYLATION OF THE BRCA1 PROMOTER IS SPECIFICALLY ASSOCIATED WITH BRCA1 MUTATION-ASSOCIATED PATHOLOGY IN EARLY-ONSET BREAST CANCER.
Constitutional Mosaic Epimutations - a hidden cause of cancer?
Constitutive BRCA1 Promoter Hypermethylation Can Be a Predisposing Event in Isolated Early-Onset Breast Cancer.
Constitutive expression of ?-H2AX has prognostic relevance in triple negative breast cancer.
Constitutive promoter methylation of BRCA1 and RAD51C in patients with familial ovarian cancer and early-onset sporadic breast cancer.
Consumption of reused vegetable oil intensifies BRCA1 mutations.
Contemplating chemosensitivity of basal-like breast cancer based on BRCA1 dysfunction.
Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: A WECARE Study Report.
Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers in a large cohort of unselected Chinese breast cancer patients.
Contralateral Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer.
Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis.
Contralateral recurrence and prognostic factors in familial non-BRCA1/2-associated breast cancer.
Contralateral risk reducing mastectomy in Non-BRCA-Mutated patients.
Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab).
Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia.
Contribution of BRCA1 and BRCA2 germ-line mutations to the incidence of breast cancer in young women: results from a prospective population-based study in France.
Contribution of BRCA1 and BRCA2 Germline Mutations to Early Algerian Breast Cancer.
Contribution of BRCA1 and BRCA2 germline mutations to early onset breast cancer: a series from north of Morocco.
Contribution of BRCA1 and BRCA2 germline mutations to the incidence of early-onset breast cancer in Cyprus.
Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in Pakistan.
Contribution of BRCA1 and BRCA2 to familial ovarian cancer: a gynecologic oncology group study.
Contribution of BRCA1 germ-line mutations to breast cancer in Greece: a hospital-based study of 987 unselected breast cancer cases.
Contribution of BRCA1 germline mutation in patients with sporadic breast cancer.
Contribution of epigenetic alteration of BRCA1 and BRCA2 genes in breast carcinomas in Tunisian patients.
Contribution of germline BRCA1 and BRCA2 sequence alterations to breast cancer in Northern India.
Contribution of Inherited Mutations in the BRCA2-Interacting Protein PALB2 to Familial Breast Cancer.
Contribution of large genomic BRCA1 alterations to early-onset breast cancer selected for family history and tumour morphology: a report from The Breast Cancer Family Registry.
Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis.
Contribution of the BRCA1 and BRCA2 mutations to breast cancer in Tunisia.
Contribution of the Defective BRCA1, BRCA2 and CHEK2 Genes to the Familial Aggregation of Breast Cancer: a Simulation Study Based on the Swedish Family-Cancer Database.
Controlled ovarian hyperstimulation for fertility preservation in women with breast cancer: Practical issues.
Controversial BRCA1 allelotypes in commonly used breast cancer cell lines.
Cooperation Between BRCA1 and p53 in Repair of Cyclobutane Pyrimidine Dimers.
Cooperation between BRCA1 and vitamin D is critical for histone acetylation of the p21waf1 promoter and growth inhibition of breast cancer cells and cancer stem-like cells.
Cooperativity of Rb, Brca1, and p53 in malignant breast cancer evolution.
COP1 and GSK3? Cooperate to Promote c-Jun Degradation and Inhibit Breast Cancer Cell Tumorigenesis.
Correcting errors in the BRCA1 warning system.
Correction to: Comprehensive study for BRCA1 and BRCA2 entire coding regions in breast cancer.
Correction to: KSR1 regulates BRCA1 degradation and inhibits breast cancer growth.
Correction to: Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers.
Correction: Methylation of BRCA1 promoter region is associated with unfavorable prognosis in women with early-stage breast cancer.
Correction: regulation of p53 level by UBE4B in breast cancer.
Correlation between BRCA1 expression and apoptosis-related biological parameters in sporadic breast carcinomas.
Correlation between Candidate Single Nucleotide Variants and Several Clinicopathological Risk Factors Related to Breast Cancer in Jordanian Women: A Genotype-Phenotype Study.
Correlation between morphology, immunohistochemistry and molecular pathology in hereditary and sporadic breast cancer cases.
Correspondence re: A. Rothfuss et al., Induced micronucleus frequencies in peripheral blood lymphocytes as a screening test for carriers of a BRCA1 mutation in breast cancer families. Cancer Res., 60: 390-394, 2000.
Corrigendum to "PARP inhibitor olaparib has a potential to increase the effectiveness of electrochemotherapy in BRCA1 mutated breast cancer in mice" [Bioelectrochemistry 2021 (140) 107832].
Cost of genetic counseling and testing for BRCA1 and BRCA2 breast cancer susceptibility mutations.
Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers.
Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer.
Cost-utility analysis of germline BRCA1/2 testing in women with high-grade epithelial ovarian cancer in Spain.
Counseling the at risk patient in the BRCA1 and BRCA2 Era.
Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility.
CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer.
CpG island methylation affects accessibility of the proximal BRCA1 promoter to transcription factors.
CpG island methylator phenotype of multigene in serum of sporadic breast carcinoma.
CpG methylation within the 5' regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB binding site.
CRISPR-Cas9/long-read sequencing approach to identify cryptic mutations in BRCA1 and other tumour suppressor genes.
CRISPR/Cas9-Mediated BRCA1 Knockdown Adipose Stem Cells Promote Breast Cancer Progression.
CRISPR/Cas9-mediated mutagenesis to validate the synergy between PARP1 inhibition and chemotherapy in BRCA1-mutated breast cancer cells.
Cross-issue synthesis: potential application to breast cancer, tamoxifen and genetic susceptibility.
Cross-talk between non-genomic and genomic signalling pathways - Distinct effect profiles of environmental estrogens.
Crystal structure of the BARD1 BRCT domains.
CUL4A contributes to the biology of basal-like breast tumors through modulation of cell growth and antitumor immune response.
Curcumin induces re?expression of BRCA1 and suppression of ? synuclein by modulating DNA promoter methylation in breast cancer cell lines.
Current knowledge of risk reducing mastectomy: Indications, techniques, results, benefits, harms.
Current knowledge on the pathophysiology of Fanconi anemia: from genes to phenotypes.
Current methods to prevent the development of breast cancer.
Current perspectives on BRCA1- and BRCA2-associated breast cancers.
Current perspectives on radiation-induced breast cancer.
Current policies for surveillance and management in women at risk of breast and ovarian cancer: a survey among 16 European family cancer clinics. European Familial Breast Cancer Collaborative Group.
Cyclin B1 stability is increased by interaction with BRCA1, and its overexpression suppresses the progression of BRCA1-associated mammary tumors.
Cyclin D1 antagonizes BRCA1 repression of estrogen receptor alpha activity.
Cyclin D1 expression analysis in familial breast cancers may discriminate BRCAX from BRCA2-linked cases.
Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment.
Cyclosporine A inhibition of prolactin-dependent up-regulation of BRCA1 protein expression in human breast cell lines.
CYP17 promoter polymorphism and breast cancer in Australian women under age forty years.
Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors.
Cytoplasmic mislocalization of BRCA1 caused by cancer-associated mutations in the BRCT domain.
Data mining of micrornas in breast carcinogenesis which may be a potential target for cancer prevention.
Data, Reagents, Assays and Merits of Proteomics for SARS-CoV-2 Research and Testing.
DCIS in BRCA1 and BRCA2 mutation carriers: prevalence, phenotype, and expression of oncodrivers C-MET and HER3.
DDRI-9: a novel DNA damage response inhibitor that blocks mitotic progression.
De novo BRCA1 mutation in a patient with breast cancer and an inherited BRCA2 mutation.
De novo recurrent germline mutation of the BRCA2 gene in a patient with early onset breast cancer.
Dealing with premature menopause in women at high-risk for hereditary genital and breast cancer.
DEAR1 Is a Chromosome 1p35 Tumor Suppressor and Master Regulator of TGF-?-Driven Epithelial-Mesenchymal Transition.
DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer.
DEAR1, a novel tumor suppressor that regulates cell polarity and epithelial plasticity.
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations.
Decision-making about genetic testing among women at familial risk for breast cancer.
Decisions and outcomes of genetic testing for inherited breast cancer risk.
Deconvolution of the Genomic and Epigenomic Interaction Landscape of Triple-Negative Breast Cancer.
Decreased BECN1 mRNA Expression in Human Breast Cancer is Associated with Estrogen Receptor-Negative Subtypes and Poor Prognosis.
Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions.
Decreased BRCA1 expression levels may arrest the cell cycle through activation of p53 checkpoint in human sporadic breast tumors.
Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression.
Decreased expression of BRCA1 in SK-BR-3 cells is the result of aberrant activation of the GABP Beta promoter by an NRF-1-containing complex.
Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase.
Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition.
Deletion mapping of chromosome segment 11q24-q25, exhibiting extensive allelic loss in early onset breast cancer.
Deletion of chromosomes 13q and 14q is a common feature of tumors with BRCA2 mutations.
Deletions on chromosome 4 in sporadic and BRCA mutated tumors and association with pathological variables.
Democratising access to genetic services.
Depletion of BRCA1 impairs differentiation but enhances proliferation of mammary epithelial cells.
Depletion of eIF2.GTP.Met-tRNAi translation initiation complex up-regulates BRCA1 expression in vitro and in vivo.
Deregulation of cofactor of BRCA1 expression in breast cancer cells.
Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.
Design and analysis issues in a population-based, case-control-family study of the genetic epidemiology of breast cancer and the Co-operative Family Registry for Breast Cancer Studies (CFRBCS).
Design and Characterization of SGK3-PROTAC1, an Isoform Specific SGK3 Kinase PROTAC Degrader.
Design and synthesis of some barbituric and 1,3-dimethylbarbituric acid derivatives: A non-classical scaffold for potential PARP1 inhibitors.
Design logic of a cannabinoid receptor signaling network that triggers neurite outgrowth.
Designed hybridization properties of DNA-gold nanoparticle conjugates for the ultraselective detection of a single-base mutation in the breast cancer gene BRCA1.
Detailed deletion mapping of chromosome segment 17q12-21 in sporadic breast tumours.
Detecting differential allelic expression using high-resolution melting curve analysis: application to the breast cancer susceptibility gene CHEK2.
Detection of a novel Alu-mediated BRCA1 exon 13 duplication in Chinese breast cancer patients and implications for genetic testing.
Detection of a novel mutation in exon 20 of the BRCA1 gene.
Detection of BRCA1 and BRCA2 gene mutation in Egyptian females with breast cancer and their relatives by PCR-SSCP method.
Detection of BRCA1 and BRCA2 mutations in breast cancer families by a comprehensive two-stage screening procedure.
Detection of BRCA1 gene mutations in families with breast cancer patients and their healthy relatives.
Detection of eight BRCA1 mutations in 10 breast/ovarian cancer families, including 1 family with male breast cancer.
Detection of germline BRCA1 mutations in breast cancer patients by quantitative messenger RNA in situ hybridization.
Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2.
Detection of heterozygous truncating mutations in the BRCA1 and APC genes by using a rapid screening assay in yeast.
Detection of inherited mutations for hereditary cancer using target enrichment and next generation sequencing.
Detection of large deletion in human BRCA1 gene in human breast carcinoma MCF-7 cells by using DNA-Silver Nanoclusters.
Detection of LOH and mitochondrial DNA alterations in ductal lavage and nipple aspirate fluids from hngh-risk patients.
Detection of loss of heterozygosity at RAD51, RAD52, RAD54 and BRCA1 and BRCA2 loci in breast cancer: pathological correlations.
Detection of New Point Mutations of BRCA1 and BRCA2 in Breast Cancer Patients.
Detection of novel germline mutations for breast cancer in non-BRCA1/2 families.
Detection of promoter methylation of tumor suppressor genes in serum DNA of breast cancer cases and benign breast disease controls.
Determinants of preferences for genetic counselling in Jewish women.
Deubiquitinase ubiquitin-specific protease 9X regulates the stability and function of E3 ubiquitin ligase ring finger protein 115 in breast cancer cells.
Developing functional assays for BRCA1 unclassified variants.
Developing strategies for intervention and prevention in hereditary breast cancer.
Development and applications of a real-time quantitative RT-PCR method (QRT-PCR) for BRCA1 mRNA.
Development and testing of a decision aid for breast cancer prevention for women with a BRCA1 or BRCA2 mutation.
Development and validation of a variant detection workflow for BRCA1 and BRCA2 genes and its clinical application based on the Ion Torrent technology.
Development of a communication aid to facilitate risk communication in consultations with unaffected women from high risk breast cancer families: a pilot study.
Development of a novel PTT assay for mutation detection in PALB2 large exons and PALB2 screening in medullary breast cancer.
Development of a universal gap repair vector for yeast-based screening of knockout rodents.
Development of an Interactive Decision Aid for Female BRCA1/BRCA2 Carriers.
Development of Breast Cancer in a 21-Year-Old Childhood Wilms' Tumor Survivor With a BRCA1 2634delC Mutation.
Development of the PARP inhibitor talazoparib for the treatment of advanced BRCA1 and BRCA2 mutated breast cancer.
Developmental expression of Brca2 colocalizes with Brca1 and is associated with proliferation and differentiation in multiple tissues.
Developmental studies of Brca1 and Brca2 knock-out mice.
Dexibuprofen amide derivatives as potential anticancer agents: synthesis, in silico docking, bioevaluation, and molecular dynamic simulation.
DHPLC/SURVEYOR Nuclease: A Sensitive, Rapid and Affordable Method to Analyze BRCA1 and BRCA2 Mutations in Breast Cancer Families.
Diabetes and breast cancer among women with BRCA1 and BRCA2 mutations.
Diagnostic algorithm for identification of individuals with hereditary predisposition to breast cancer.
Diagnostic and therapeutic ionizing radiation and the risk of a first and second primary breast cancer, with special attention for BRCA1 and BRCA2 mutation carriers: A critical review of the literature.
Diagnostic chest X-rays and breast cancer risk among women with a hereditary predisposition to breast cancer unexplained by a BRCA1 or BRCA2 mutation.
Diagnostic Chest X-Rays and Breast Cancer Risk before Age 50 Years for BRCA1 and BRCA2 Mutation Carriers.
Diagnostic yield of a custom-designed multi-gene cancer panel in Irish patients with breast cancer.
Diet quality and BRCA-associated breast cancer risk.
Diet, lifestyle and BRCA-related breast cancer risk among French-Canadians.
Diet, weight management, physical activity and Ovarian & Breast Cancer Risk in women with BRCA1/2 pathogenic Germline gene variants: systematic review.
Differences between women who pursued genetic testing for hereditary breast and ovarian cancer and their at-risk relatives who did not.
Differences in cysteine peptidases-like activity in sera of patients with breast cancer.
Differences in DNA methylation by extent of breast cancer family history in unaffected women.
Differences in the frequency and distribution of BRCA1 and BRCA2 mutations in breast/ovarian cancer cases from the Basque country with respect to the Spanish population: implications for genetic counselling.
Differences of Variable Number Tandem Repeats in XRCC5 Promoter Are Associated with Increased or Decreased Risk of Breast Cancer in BRCA Gene Mutation Carriers.
Different Array CGH profiles within hereditary breast cancer tumors associated to BRCA1 expression and overall survival.
Different cell cycle kinetic effects of N1,N11-diethylnorspermine-induced polyamine depletion in four human breast cancer cell lines.
Different CHEK2 germline mutations are associated with distinct immunophenotypic molecular subtypes of breast cancer.
Differential association of BRCA1 and BRCA2 genes with some breast cancer-associated genes in early and late onset breast tumors.
Differential Chemotherapeutic Sensitivity for Breast Tumors With "BRCAness": A Review.
Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer.
Differential Cytotoxicity, Cellular Uptake, Apoptosis and Inhibition of BRCA1 Expression of BRCA1-Defective and Sporadic Breast Cancer Cells Induced by an Anticancer Ruthenium(II)-Arene Compound, RAPTA-EA1.
Differential effects of n-3 and n-6 polyunsaturated fatty acids on BRCA1 and BRCA2 gene expression in breast cell lines.
Differential expressions of BRCA1 and BRCA2 in infantile gynecomastia.
Differential Gene Expression of BRCA1,ERBB2 and TP53 biomarkers between Human Breast Tissue and Peripheral Blood Samples of Breast Cancer.
Differential immunomodulatory effect of PARP inhibition in BRCA1 deficient and competent tumor cells.
Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents.
Differential transcriptional activation by the N-terminal region of BRCA1 splice variants BRCA1a and BRCA1b.
Differentially expressed genes and key molecules of BRCA1/2-mutant breast cancer: evidence from bioinformatics analyses.
Differentially expressed transcripts and dysregulated signaling pathways and networks in African American breast cancer.
Dinucleotide repeat polymorphisms of RAD51, BRCA1, BRCA2 gene regions in breast cancer.
Direct and nondestructive verification of PNA immobilization using click chemistry.
Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells.
Direct interaction of the Fanconi anaemia protein FANCG with BRCA2/FANCD1.
Direct visualization of the highly polymorphic RNU2 locus in proximity to the BRCA1 gene.
Direct-To-Consumer Genetic Testing: Is the Public Ready for Simple, At-Home DNA Tests to Detect Disease Risk?
Disclosure Pattern and Follow-Up After the Molecular Diagnosis of BRCA/CHEK2 Mutations.
Discordant pattern of BRCA1 gene epimutation in blood between mothers and daughters.
Discovering interactions among BRCA1 and other candidate genes associated with sporadic breast cancer.
Discovering moderate-risk breast cancer susceptibility genes.
Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent.
Discovery of isoquinolinone and naphthyridinone-based inhibitors of poly(ADP-ribose) polymerase-1 (PARP1) as anticancer agents: Structure activity relationship and preclinical characterization.
Discovery of the Anti-Tumor Mechanism of Calycosin Against Colorectal Cancer by Using System Pharmacology Approach.
Discussion: CRISPR/Cas9-Mediated BRCA1 Knockdown Adipose Stem Cells Promote Breast Cancer Progression.
Disease family history and modification of breast cancer risk in common BRCA2 variants.
Disparities in Genetic Testing and Care among Black women with Hereditary Breast Cancer.
Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinoma.
Dissecting systems-wide data using mixture models: application to identify affected cellular processes.
Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes.
Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study.
Distinct Ring1b complexes defined by DEAD-box helicases and EMT transcription factors synergistically enhance E-cadherin silencing in breast cancer.
Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations.
Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data.
Distribution of BRCA1 and BRCA2 Mutations in Asian Patients with Breast Cancer.
Distribution of family history of a disease as a function of mode of inheritance, genetic relative hazard, allele frequency and disease status of the proband, with application to female breast cancer.
Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer.
Diversifying selection of the tumor-growth promoter angiogenin in primate evolution.
DNA binding sites for putative methylation boundaries in the unmethylated region of the BRCA1 promoter.
DNA damage induces p53-dependent BRCA1 nuclear export.
DNA damage response and breast cancer development: Possible therapeutic applications of ATR, ATM, PARP, BRCA1 inhibition.
DNA damage response is suppressed by the high cyclin-dependent kinase 1 activity in mitotic mammalian cells.
DNA double strand break repair and its association with inherited predispositions to breast cancer.
DNA double strand break repair in mammalian cells.
DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
DNA hypermethylation in breast cancer and its association with clinicopathological features.
DNA ligase IV binds to XRCC4 via a motif located between rather than within its BRCT domains.
DNA methylation and breast tumor clinicopathological features: The Western New York Exposures and Breast Cancer (WEB) study.
DNA Methylation and microRNA patterns are in association with the expression of BRCA1 in ovarian cancer.
DNA methylation array analysis identifies breast cancer associated - RPTOR, MGRN1 and RAPSN hypomethylation in peripheral blood DNA.
DNA methylation of circulating DNA: a marker for monitoring efficacy of neoadjuvant chemotherapy in breast cancer patients.
DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response.
DNA methylation profiling to assess pathogenicity of BRCA1 unclassified variants in breast cancer.
DNA methylation variations in familial female and male breast cancer.
DNA Polymerase theta (POLQ) is important for repair of DNA double-strand breaks caused by fork collapse.
DNA repair capacity as a possible biomarker of breast cancer risk in female BRCA1 mutation carriers.
DNA repair genes implicated in triple negative familial non-BRCA1/2 breast cancer predisposition.
DNA repair genes PAXIP1 and TP53BP1 expression is associated with breast cancer prognosis.
Do BRCA1 and BRCA2 Mutation Carriers Have Earlier Natural Menopause Than Their Noncarrier Relatives? Results From the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer.
Do BRCA1 modifiers also affect the risk of breast cancer in non-carriers?
Does microenvironment contribute to the etiology of estrogen receptor-negative breast cancer?
Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women?
Does the age of breast cancer diagnosis in first-degree relatives impact on the risk of breast cancer in BRCA1 and BRCA2 mutation carriers?
Double heterozygosity for BRCA1 and hMLH1 gene mutations in a 46-year-old woman with five primary tumors.
Double heterozygosity for germline mutations in BRCA1 and p53 in a woman with early onset breast cancer.
Double heterozygosity for mutations in BRCA1 and BRCA2 in German breast cancer patients: implications on test strategies and clinical management.
Double heterozygosity for mutations in the BRCA1 and BRCA2 genes in a breast cancer patient.
Double heterozygosity in the BRCA1 and BRCA2 genes in Italian family.
Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1, and BLM germ-line mutations.
Double heterozygous mutation in the BRCA1 and ATM genes involved in development of primary metachronous tumours: a case report.
Double indemnity: p53, BRCA and cancer. p53 mutation partially rescues developmental arrest in Brca1 and Brca2 null mice, suggesting a role for familial breast cancer genes in DNA damage repair.
Double mutation of APC and BRCA1 in an Italian family.
Double PALB2 and BRCA1/BRCA2 mutation carriers are rare in breast cancer and breast-ovarian cancer syndrome families from the French Canadian founder population.
Double-strand break repair by homologous recombination in primary mouse somatic cells requires BRCA1 but not the ATM kinase.
Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers.
Down-regulation of BRCA1 in chronic pancreatitis and sporadic pancreatic adenocarcinoma.
Down-regulation of BRCA1 in human sporadic breast cancer; analysis of DNA methylation patterns of the putative promoter region.
Down-regulation of tripartite-motif containing 22 expression in breast cancer is associated with a lack of p53-mediated induction.
Downregulated PIRH2 Can Decrease the Proliferation of Breast Cancer Cells.
Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1.
Downregulation of stromal BRCA1 drives breast cancer tumor growth via upregulation of HIF-1?, autophagy and ketone body production.
Drug Targeting of Genomic Instability in Multiple Myeloma.
DSS1 is required for the stability of BRCA2.
Dual Modulators of p53 and Cyclin D in ER Alpha Signaling by Albumin Nanovectors Bearing Zinc Chaperones for ER-positive Breast Cancer Therapy.
Ductal carcinoma in situ in BRCA mutation carriers.
Ductal lavage of fluid-yielding and non-fluid-yielding ducts in BRCA1 and BRCA2 mutation carriers and other women at high inherited breast cancer risk.
Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
Dynamic interactions between the promoter and terminator regions of the mammalian BRCA1 gene.
E3 ligase activity and suppression of breast cancer.
E3 Ubiquitin Ligase Cbl-b Prevents Tumor Metastasis by Maintaining the Epithelial Phenotype in Multiple Drug-Resistant Gastric and Breast Cancer Cells.
E3 ubiquitin ligase RNF126 promotes cancer cell proliferation by targeting the tumor suppressor p21 for ubiquitin-mediated degradation.
Early Onset Breast Cancer in a Registry-based Sample of African-American Women: BRCA Mutation Prevalence, and Other Personal and System-level Clinical Characteristics.
Early onset breast cancer in Ashkenazi women carriers of founder BRCA1/2 mutations: beyond 10 years of follow-up.
Early radiation exposures and BRCA1-associated breast cancer in young women from Poland.
Early use of clinical BRCA1/2 testing: associations with race and breast cancer risk.
Early-Onset Breast Cancer in a Family with Neurofibromatosis Type 1 Associated with a Germline Mutation in BRCA1.
Early-onset malignant phyllodes breast tumor in a patient with germline pathogenic variants in NF1 and BRCA1 genes.
EDD inhibits ATM-mediated phosphorylation of P53.
Editorial: BRCA1 and BRCA2 gene mutations screening in sporadic breast cancer patients in Kazakhstan.
Effect of a computer-based decision aid on knowledge, perceptions, and intentions about genetic testing for breast cancer susceptibility: a randomized controlled trial.
Effect of adriamycin on BRCA1 and PARP-1 expression in MCF-7 breast cancer cells.
Effect of bilateral oophorectomy on mammary tumor formation in BRCA1 mutant mice.
Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis.
Effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history.
Effect of BRCA1 immunohistochemical localizations on prognosis of patients with sporadic breast carcinomas.
Effect of BRCA2 sequence variants predicted to disrupt exonic splice enhancers on BRCA2 transcripts.
Effect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutations.
Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group.
Effect of decision aid for breast cancer prevention on decisional conflict in women with a BRCA1 or BRCA2 mutation: a multisite, randomized, controlled trial.
Effect of mammography on breast cancer risk in women with mutations in BRCA1 or BRCA2.
Effect of omega-6 polyunsaturated fatty acid (linoleic acid) on BRCA1 gene expression in MCF-7 cell line.
Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers.
Effect of Prior Bilateral Oophorectomy on the Presentation of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes.
Effect of variation in miRNA-binding site (rs8176318) of the BRCA1 gene in breast cancer patients
Effectiveness of Neoadjuvant Therapy with Platinum-Based Agents for Patients with BRCA1 and BRCA2 Germline Mutations - A Retrospective Analysis of Breast Cancer Patients Treated at MMCI Brno.
Effects of 3300 del A-1061 Ter BRCA1 frameshift mutation and calcium propionate on oxidative stress and breast carcinogenesis.
Effects of aluminium chloride and aluminium chlorohydrate on DNA repair in MCF10A immortalised non-transformed human breast epithelial cells.
Effects of BRCA Germline Mutations on Triple-Negative Breast Cancer Prognosis.
Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.
Effects of individualized breast cancer risk counseling: a randomized trial.
Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations.
Effects of Radiation Therapy on Breast Epithelial Cells in BRCA1/2 Mutation Carriers.
Effects of resveratrol on the expression of a panel of genes interacting with the BRCA1 oncosuppressor in human breast cell lines.
Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers.
Efficacy of PARP inhibition combined with EZH2 inhibition depends on BRCA mutation status and microenvironment in breast cancer.
Efficacy versus effectiveness of clinical genetic testing criteria for BRCA1 and BRCA2 hereditary mutations in incident breast cancer.
EGFR expression predicts BRCA1 status in patients with breast cancer.
EGFR, BRCA1, BRCA2 and TP53 genetic profile in Moroccan triple negative breast cancer cases.
Egr-1 regulates the transcription of the BRCA1 gene by etoposide.
Electrochemical detection of a breast cancer susceptible gene using cDNA immobilized chitosan-co-polyaniline electrode.
Electrochemical DNA Sensor for Sensitive BRCA1 Detection Based on DNA Tetrahedral-Structured Probe and Poly-Adenine Mediated Gold Nanoparticles.
Electrochemical genosensors for biomedical applications based on gold nanoparticles.
Electrophoresis of BRCA1 oncosuppressor.
Electroretinographic changes in eyes of patients with BRCA1 gene mutation.
Elevated frequency and functional activity of a specific germ-line p53 intron mutation in familial breast cancer.
Elevated insulin-like growth factor-I receptor (IGF-IR) levels in primary breast tumors associated with BRCA1 mutations.
Elevated levels of somatic mutation in a manifesting BRCA1 mutation carrier.
Elevated radiation-induced ?H2AX foci in G2 phase heterozygous BRCA2 fibroblasts.
Eligibility for magnetic resonance imaging screening in the United Kingdom: effect of strict selection criteria and anonymous DNA testing on breast cancer incidence in the MARIBS Study.
Elucidating the novel BRCA1 function as a non-genomic metabolic restraint in ER-positive breast cancer cell lines.
Elucidation of the transmission of a novel mutation in BRCA1 (1125delCT) in a family with multiple cases of breast cancer.
Emerging roles of BRCA1 in transcriptional regulation and DNA repair.
Emerging therapeutic modalities of PARP inhibitors in breast cancer.
Endocrine metabolic disorders in patients with breast cancer, carriers of BRCA1 gene mutations.
Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update.
Endosomal sorting and c-Cbl targeting of paxillin to autophagosomes regulate cell-matrix adhesion turnover in human breast cancer cells.
Enforced expression of hsa-miR-125a-3p in breast cancer cells potentiates docetaxel sensitivity via modulation of BRCA1 signaling.
Enhanced charge transfer by gold nanoparticle at DNA modified electrode and its application to label-free DNA detection.
Enhanced sensitivity of peripheral blood lymphocytes from women carrying a BRCA1 mutation towards the mutagenic effects of various cytostatics.
Enhancement of BRCA1 gene expression by the peroxisome proliferator-activated receptor gamma in the MCF-7 breast cancer cell line.
Enhancement of Synthetic Lethality via Combinations of ABT-888, a PARP Inhibitor, and Carboplatin In Vitro and In Vivo Using BRCA1 and BRCA2 Isogenic Models.
Enhancing radiosensitivity: targeting the DNA repair pathways.
ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes.
Entertainment-education in a media-saturated environment: examining the impact of single and multiple exposures to breast cancer storylines on two popular medical dramas.
Enzyme-catalyzed signal amplification for electrochemical DNA detection with a PNA-modified electrode.
EP2 and EP4 receptors regulate aromatase expression in human adipocytes and breast cancer cells. Evidence of a BRCA1 and p300 exchange.
Epidemiology and prevention of breast cancer.
Epidemiology of breast cancer among BRCA mutation carriers: an overview.
Epidemiology of Breast Cancer in Women.
Epidemiology of pancreatic cancer: an overview.
Epidemiology of susceptibility to breast cancer.
Epidemiology, genetics, and risk evaluation of postmenopausal women at risk of breast cancer.
Epidemiology, prevention, and early detection of breast cancer.
Epigenetic Activation of BRCA1 by Genistein In Vivo and Triple Negative Breast Cancer Cells Linked to Antagonism toward Aryl Hydrocarbon Receptor.
Epigenetic and proteolytic inactivation of 14-3-3sigma in breast and prostate cancers.
Epigenetic changes in BRCA1-mutated familial breast cancer.
Epigenetic inactivation of BRCA1 is associated with aberrant expression of CTCF and DNA methyltransferase (DNMT3B) in some sporadic breast tumours.
Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer.
Epigenetic lesions causing genetic lesions in human cancer: promoter hypermethylation of DNA repair genes.
Epigenetic markers of early tumor development.
Epigenetic modulation of BRCA1 and BRCA2 gene expression by equol in breast cancer cell lines.
Epigenetic regulation of ID4 in the determination of the BRCAness phenotype in breast cancer.
Epigenetic repression of phosphatidylethanolamine, N-methyltransferase (PEMT) in BRCA1-mutated breast cancer.
Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer.
Epigenetic silencing of BRCA1 gene associated with demographic and pathologic factors in sporadic breast cancer: a study of an Indian population.
Epithelial ovarian cancer.
Epstein Barr virus: a prime candidate of breast cancer aetiology in Sudanese patients.
ERBB2, TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriers.
ERCC1 and CYP1B1 polymorphisms as predictors of response to neoadjuvant chemotherapy in estrogen positive breast tumors.
Erratum to "Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study" by Lieske H Schrijver et al.
Erratum to: Frequency of 5382insC mutation of BRCA1 gene among breast cancer patients: an experience from Eastern India.
Erratum to: recurrent mutation testing of BRCA1 and BRCA2 in Asian breast cancer patients identify carriers in those with presumed low risk by family history.
Erratum to: Seventeen years after BRCA1: what is the BRCA mutation status of the breast cancer patients in Africa? - a systematic review.
Establishment and Characterization of a Brca1-/-, p53-/- Mouse Mammary Tumor Cell Line.
Estimated risk of radiation-induced breast cancer from mammographic screening for young BRCA mutation carriers.
Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence.
Estimates of the likely prophylactic effect of tamoxifen in women with high risk BRCA1 and BRCA2 mutations.
Estimating risk of breast cancer in carriers of BRCA1 and BRCA2 mutations: a meta-analytic approach.
Estimating risks for variants of unknown significance according to their predicted pathogenicity classes with application to BRCA1.
Estrogen controls the survival of BRCA1-deficient cells via a PI3K-NRF2-regulated pathway.
Estrogen induces dynamic ER? and RING1B recruitment to control gene and enhancer activities in luminal breast cancer.
Estrogen Promotes Breast Cancer Cell Survival in an Inhibitor of Apoptosis (IAP)-Dependent Manner.
Estrogen promotes estrogen receptor negative BRCA1-deficient tumor initiation and progression.
Estrogen receptor alpha is a putative substrate for the BRCA1 ubiquitin ligase.
Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features.
Estrogen receptor status could modulate the genomic pattern in familial and sporadic breast cancer.
Estrogen Receptor Status Oppositely Modifies Breast Cancer Prognosis in BRCA1/BRCA2 Mutation Carriers Versus Non-Carriers.
Estrogen receptor-?, RBCK1, and protein kinase C ? 1 cooperate to regulate estrogen receptor-? gene expression.
Estrogens, BRCA1, and breast cancer.
Ethnic differences in cancer incidence: a marker for inherited susceptibility?
Ethnic differences in cancer risk resulting from genetic variation.
Etiology of familial breast cancer with undetected BRCA1 and BRCA2 mutations: clinical implications.
Ets-2 and components of mammalian SWI/SNF form a repressor complex that negatively regulates the BRCA1 promoter.
Evaluating breast cancer risk: available models to assess individual breast cancer risk and probability to be a BRCA mutation carrier.
Evaluating cancer epidemiologic risk factors using multiple primary malignancies.
Evaluating genetic variants associated with breast cancer risk in high and moderate-penetrance genes in Asians.
Evaluating the breast cancer predisposition role of rare variants in genes associated with low-penetrance breast cancer risk SNPs.
Evaluating the NCCN Clinical Criteria for Recommending BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer.
Evaluation and treatment of BRCA-positive patients.
Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA).
Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer.
Evaluation of BRCA1 and BRCA2 mutations and risk-prediction models in a typical Asian country (Malaysia) with a relatively low incidence of breast cancer.
Evaluation of BRCA1 Large Genomic Rearrangements in Group of Egyptian Female Breast Cancer Patients Using MLPA.
Evaluation of BRCA1/2 mutational status among German and Austrian women with triple-negative breast cancer.
Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer.
Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers.
Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis.
Evaluation of genetic variations in miRNA-binding sites of BRCA1 and BRCA2 genes as risk factors for the development of early-onset and/or familial breast cancer.
Evaluation of genotype data in clinical risk assessment: methods and application to BRCA1, BRCA2, and N-acetyl transferase-2 genotypes in breast cancer.
Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer.
Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium.
Evaluation of SNPs in miR-146a, miR196a2 and miR-499 as low-penetrance alleles in German and Italian familial breast cancer cases.
Evaluation of the BOADICEA risk assessment model in women with a family history of breast cancer.
Evaluation of the BRCA1 interacting genes RAP80 and CCDC98 in familial breast cancer susceptibility.
Evaluation of the diagnostic accuracy of the stop codon (SC) assay for identifying protein-truncating mutations in the BRCA1and BRCA2genes in familial breast cancer.
Evaluation of the need for routine clinical testing of PALB2 c.1592delT mutation in BRCA negative Northern Finnish breast cancer families.
Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2.
Evaluation of tumor-infiltrating lymphocytes and association with prognosis in BRCA-mutated breast cancer.
Evaluation of unclassified variants in the breast cancer susceptibility genes BRCA1 and BRCA2 using five methods: results from a population-based study of young breast cancer patients.
Evidence for a pathogenic role of BRCA1 L1705P and W1837X germ-line mutations.
Evidence for a transcriptional activation function of BRCA1 C-terminal region.
Evidence for an ancient BRCA1 mutation in breast cancer patients of Yoruban ancestry.
Evidence for an ancient BRCA1 pathogenic variant in inherited breast cancer patients from Senegal.
Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study.
Evidence for involvement of BRCA1 in sporadic breast carcinomas.
Evolutionary conservation analysis increases the colocalization of predicted exonic splicing enhancers in the BRCA1 gene with missense sequence changes and in-frame deletions, but not polymorphisms.
Evolutionary dynamics of BRCA1 alterations in breast tumorigenesis.
Evolutionary pathways in BRCA1-associated breast tumors.
Ex Vivo MRI Evaluation of Breast Tumors: A Novel Tool for Verifying Resection of Nonpalpable Only MRI Detected Lesions.
Examining Women's Health: 1996-1997.
Exceptionally high UBE2C expression is a unique phenomenon in basal-like type breast cancer and is regulated by BRCA1.
Excretion of estrogens, catecholestrogens and phytoestrogens in carriers of BRCA1 gene mutations: effects of metformin.
Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer.
Exome sequencing of germline DNA from non-BRCA1/2 familial breast cancer cases selected on the basis of aCGH tumor profiling.
Expanding the search for germline pathogenic variants for breast cancer. How far should we go and how high should we jump? The missed opportunity!
Experiences and decisions that motivate women at increased risk of breast cancer to participate in an experimental screening program.
Exploiting synthetic lethality to target BRCA1/2-deficient tumors: where we stand.
Exploring the role of BRCA1, BRCA2 and RAD51 as biomarkers for breast cancer.
Expression and function of BRCA1 and BRCA2 in familial and sporadic breast cancer.
Expression and mutations of BRCA in breast cancer and ovarian cancer: Evidence from bioinformatics analyses.
Expression and prognostic significance of Fanconi anemia group D2 protein and breast cancer type 1 susceptibility protein in familial and sporadic breast cancer.
Expression of Autophagy and Mitophagy Markers in Breast Cancer Tissues.
Expression of BRCA1 and BRCA2 in different tumor cell lines with various growth status.
Expression of BRCA1 and BRCA2 in male breast cancers and gynecomastias.
Expression of BRCA1 and BRCA2 in normal and neoplastic cells.
Expression of BRCA1 and BRCA2 proteins and their correlation with clinical staging in breast cancer.
Expression of Brca1 and splice variant Brca1delta11 RNA levels in mouse mammary gland during normal development and tumorigenesis.
Expression of Brca1 is associated with terminal differentiation of ectodermally and mesodermally derived tissues in mice.
Expression of BRCA1 protein in breast cancer and its prognostic significance.
Expression of BRCA1, HER-1 (EGFR) and HER-2 in sporadic breast cancer and relationships to other clinicopathological prognostic features.
Expression of BRCA1, NBR1 and NBR2 genes in human breast cancer cells.
Expression of breast cancer type 1 and its relation with expression of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2/neu in breast carcinoma on trucut biopsy specimens.
Expression of cancer testis antigens in human BRCA-associated breast cancers: potential targets for immunoprevention?
Expression of DNA Damage Response Molecules PARP1, ?H2AX, BRCA1, and BRCA2 Predicts Poor Survival of Breast Carcinoma Patients.
Expression of DNA Damage Response Proteins and Associations with Clinicopathologic Characteristics in Chinese Familial Breast Cancer Patients with BRCA1/2 Mutations.
Expression of epidermal growth factor receptor in relation to BRCA1 status, basal-like markers and prognosis in breast cancer.
Expression of estrogen receptor beta in the breast carcinoma of BRCA1 mutation carriers.
Expression of HER2 and BRCA1 Correlates with Prognosis in Patients with Breast Cancer After Radiotherapy: A Case-Control Study.
Expression of human BRCA1 variants in mouse ES cells allows functional analysis of BRCA1 mutations.
Expression of human BRCA1?17-19 alternative splicing variant with a truncated BRCT domain in MCF-7 cells results in impaired assembly of DNA repair complexes and aberrant DNA damage response.
Expression of miR-146a-5p in breast cancer and its role in proliferation of breast cancer cells.
Expression of Nestin associates with BRCA1 mutations, a basal-like phenotype and aggressive breast cancer.
Expression of PCNA-binding domain of CtIP, a motif required for CtIP localization at DNA replication foci, causes DNA damage and activation of DNA damage checkpoint.
Expression of the BRCA1 complex member BRE predicts disease free survival in breast cancer.
Expression of the circadian clock genes Per1 and Per2 in sporadic and familial breast tumors.
Expression of the forkhead box transcription factor FOXP1 is associated with oestrogen receptor alpha, oestrogen receptor beta and improved survival in familial breast cancers.
Expression of the stem cell marker ALDH1 in BRCA1 related breast cancer.
Expression of the three components of linear ubiquitin assembly complex in breast cancer.
Expression patterns of the BRCA1 splicing variants in canine normal tissues and mammary gland tumors.
Expression profile of BRCA1 and BRCA2 genes in premenopausal Mexican women with breast cancer: clinical and immunohistochemical correlates.
Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors.
External quality assessment for mutation detection in the BRCA1 and BRCA2 genes: EMQN's experience of 3 years.
Extracellular matrix enhances heregulin-dependent BRCA1 phosphorylation and suppresses BRCA1 expression through its C terminus.
EZH2 Is Overexpressed in BRCA1-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy.
EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors.
FAAP100 is essential for activation of the Fanconi anemia-associated DNA damage response pathway.
Factors forming the BRCA1-A complex orchestrate BRCA1 recruitment to the sites of DNA damage.
Factors increasing local recurrence in breast-conserving surgery.
FAM35A/SHLD2/RINN2: A novel determinant of double strand break repair pathway choice and genome stability in cancer.
Familial breast cancer and the hCHK2 1100delC mutation: assessing cancer risk.
Familial breast cancer in Costa Rica: an initial approach.
Familial breast cancer in southern Taiwan.
Familial breast cancer risk assessment.
Familial breast cancer, underlying genes, and clinical implications: a review.
Familial breast cancer.
Familial breast cancer. Approaching the isolation of a susceptibility gene.
Familial breast cancer. BRCA1 down, BRCA2 to go.
Familial breast cancer: an investigation into the outcome of treatment for early stage disease.
Familial breast cancer: double heterozygosity for BRCA1 and BRCA2 mutations with differing phenotypes.
Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers.
Familial Breast/Ovarian Cancer and BRCA1/2 Genetic Screening: The Role of Immunohistochemistry as an Additional Method in the Selection of Patients.
Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population.
Familial concordance of breast cancer pathology as an indicator of genotype in multiple-case families.
Familial invasive breast cancers: worse outcome related to BRCA1 mutations.
Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q.
Familial non-BRCA1/BRCA2-associated breast cancer.
Familial relative risks for breast cancer by pathological subtype: a population-based cohort study.
Familial risk and genetic susceptibility for breast cancer.
Familial risk, abortion and their interactive effect on the risk of breast cancer--a combined analysis of six case-control studies.
Familial risks, early-onset breast cancer, and BRCA1 and BRCA2 germline mutations.
Familial sarcoma: challenging pedigrees.
Familial site-specific ovarian cancer is linked to BRCA1 on 17q12-21.
Family history of breast and ovarian cancer and the risk of breast carcinoma in situ.
Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer.
Family history of breast cancer and all-cause mortality after breast cancer diagnosis in the Breast Cancer Family Registry.
Family history of breast cancer in men with non-BRCA male breast cancer: implications for cancer risk counseling.
Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations.
Family history predictors of BRCA1/BRCA2 mutation status among Tunisian breast/ovarian cancer families.
Family specific genetic predisposition to breast cancer: results from Tunisian whole exome sequenced breast cancer cases.
FANCD2 associated with sporadic breast cancer risk.
FANCJ (BACH1) helicase forms DNA damage inducible foci with replication protein A and interacts physically and functionally with the single-stranded DNA-binding protein.
FANCJ helicase operates in the Fanconi Anemia DNA repair pathway and the response to replicational stress.
FANCL replaces BRCA1 as the likely ubiquitin ligase responsible for FANCD2 monoubiquitination.
Fanconi anemia FANCG protein in mitigating radiation- and enzyme-induced DNA double-strand breaks by homologous recombination in vertebrate cells.
Fanconi Anemia Pathway: Mechanisms of Breast Cancer Predisposition Development and Potential Therapeutic Targets.
Faulty BRCA1, BRCA2 genes: how poor is the prognosis?
Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy.
Favourable ten-year overall survival in a Caucasian population with high probability of hereditary breast cancer.
Fertility treatments and breast cancer risk in Jewish Israeli BRCA mutation carriers.
Field cancerization in mammary carcinogenesis - Implications for prevention and treatment of breast cancer.
Filamin A inhibits tumor progression through regulating BRCA1 expression in human breast cancer.
Fine needle aspiration cytology of a myxoid adrenocortical adenoma. A case report.
First case of invasive breast cancer following prophylactic bilateral skin sparing mastectomy in a BRCA1 mutation carrier.
First description of a double heterozygosity for BRCA1 and BRCA2 pathogenic variants in a French metastatic breast cancer patient: A case report.
First description of a sporadic breast cancer in a woman with BRCA1 germline mutation.
First description of an acinic cell carcinoma of the breast in a BRCA1 mutation carrier: a case report.
FISH detection of HER-2/neu oncogene amplification in early onset breast cancer.
Five screening-detected breast cancer cases in initially disease-free BRCA1 or BRCA2 mutation carriers.
Folate and breast cancer: what about high-risk women?
Folic acid supplement use and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a case-control study.
Founder BRCA1 and BRCA2 mutations in early-onset French Canadian breast cancer cases unselected for family history.
Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families.
Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history.
Founder mutation in the BRCA1 gene in Malay breast cancer patients from Singapore.
Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer.
Founder mutations of BRCA1 and BRCA2 in North American families of Polish origin that are affected with breast cancer.
Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden.
Four novel BRCA variants found in Chinese hereditary breast cancer patients by next-generation sequencing.
Four regions of allelic imbalance on 17q12-qter associated with high-grade breast tumors.
FOXA1 repression is associated with loss of BRCA1 and increased promoter methylation and chromatin silencing in breast cancer.
FOXC1 identifies basal-like breast cancer in a hereditary breast cancer cohort.
FOXP3 Regulates Sensitivity of Cancer Cells to Irradiation by Transcriptional Repression of BRCA1.
Frailty Models for Familial Risk with Application to Breast Cancer.
Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients.
Frequency and spectrum of founder and non-founder BRCA1 and BRCA2 mutations in a large series of Russian breast cancer and ovarian cancer patients.
Frequency of 5382insC mutation of BRCA1 gene among breast cancer patients: an experience from Eastern India.
Frequency of BRCA1 and BRCA2 germline mutations in Japanese breast cancer families.
Frequency of BRCA1 and BRCA2 Mutations in Individuals with Breast and Ovarian Cancer in a Chinese Hakka Population Using Next-Generation Sequencing.
Frequency of BRCA1 mutation 5382insC in German breast cancer patients.
Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases.
Frequency of breast cancer attributable to BRCA1 in a population-based series of American women.
Frequency of Contralateral Prophylactic Mastectomy in Breast Cancer Patients with a Negative BRCA1 and BRCA2 Rapid Genetic Test Result.
Frequency of germ-line BRCA1 mutations among Spanish families from a Mediterranean area.
Frequency of heterozygous germline pathogenic variants in genes for Fanconi anemia in patients with non-BRCA1/BRCA2 breast cancer: a meta-analysis.
Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic.
Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel.
Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations.
Frequency of Pathogenic Germline Variants in CDH1, BRCA2, CHEK2, PALB2, BRCA1, and TP53 in Sporadic Lobular Breast Cancer.
Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families.
Frequency of the ATM IVS10-6T-->G variant in Australian multiple-case breast cancer families.
Frequent allelic loss at the TOC locus on 17q25.1 in primary breast cancers.
Frequent alterations of homologous recombination repair pathway in primary and chemotolerant breast carcinomas: clinical importance.
Frequent loss of BRCA1 nuclear expression in young women with breast cancer: an immunohistochemical study from an area of low incidence but early onset.
Frequent met oncogene amplification in a Brca1/Trp53 mouse model of mammary tumorigenesis.
Frequent somatic loss of BRCA1 in breast tumours from BRCA2 germ-line mutation carriers and vice versa.
Fresh and ozonized black carbon promoted DNA damage and repair responses in A549 cells.
From BRCA1 to RAP1: a widespread BRCT module closely associated with DNA repair.
From the small screen to breast cancer screening: examining the effects of a television storyline on awareness of genetic risk factors.
Functional analysis of BARD1 missense variants in homology-directed repair and damage sensitivity.
Functional analysis of BRCA1 missense variants of uncertain significance in Japanese breast cancer families.
Functional and physical interactions between BRCA1 and p53 in transcriptional regulation of the IGF-IR gene.
Functional characterization of BRCA1 gene variants by mini-gene splicing assay.
Functional classification of DNA variants by hybrid minigenes: Identification of 30 spliceogenic variants of BRCA2 exons 17 and 18.
Functional domains of the BRCA1 and BRCA2 proteins.
Functional evaluation of BRCA2 variants mapping to the PALB2-binding and C-terminal DNA-binding domains using a mouse ES cell-based assay.
Functional Ex Vivo Assay to Select Homologous Recombination-Deficient Breast Tumors for PARP Inhibitor Treatment.
Functional Impact of Sequence Alterations Found in BRCA1 Promoter/5'UTR Region in Breast/Ovarian Cancer Families from Upper Silesia, Poland.
Functional Impacts of the BRCA1-mTORC2 Interaction in Breast Cancer.
Functional implications of BRCA1 for early detection, prevention, and treatment of breast cancer.
Functional interaction between the Fanconi Anemia D2 protein and proliferating cell nuclear antigen (PCNA) via a conserved putative PCNA interaction motif.
Functional investigation of the BRCA1 Val1714Gly and Asp1733Gly variants by computational tools and yeast transcription activation assay.
Functional link of BRCA1 and ataxia telangiectasia gene product in DNA damage response.
Functional nsSNPs from carcinogenesis-related genes expressed in breast tissue: Potential breast cancer risk alleles and their distribution across human populations.
Functional polymorphisms in the BRCA1 promoter influence transcription and are associated with decreased risk for breast cancer in Chinese women.
Functional profiling of nucleotide Excision repair in breast cancer.
Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin.
Functions of the BRCA1 and BRCA2 genes.
Future possibilities in the prevention of breast cancer: intervention strategies in BRCA1 and BRCA2 mutation carriers.
GA-binding protein alpha/beta is a critical regulator of the BRCA1 promoter.
Gadd45a Suppresses Ras-Driven Mammary Tumorigenesis by Activation of c-Jun NH2-Terminal Kinase and p38 Stress Signaling Resulting in Apoptosis and Senescence.
Gallic acid induces DNA damage and inhibits DNA repair-associated protein expression in human oral cancer SCC-4 cells.
Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.
GATA3 functions downstream of BRCA1 to suppress EMT in breast cancer.
Gene analysis techniques and susceptibility gene discovery in non-BRCA1/BRCA2 familial breast cancer.
Gene expression in inherited breast cancer.
Gene Expression Profiling in Hereditary, BRCA1-linked Breast Cancer: Preliminary Report.
Gene expression profiling integrated into network modelling reveals heterogeneity in the mechanisms of BRCA1 tumorigenesis.
Gene expression profiling of formalin-fixed, paraffin-embedded familial breast tumours using the whole genome-DASL assay.
Gene knockout experiments to quantify a G2/M genetic network simulation for mammary cancer susceptibility.
Gene methylation in breast ductal fluid from BRCA1 and BRCA2 mutation carriers.
Gene panel testing for hereditary breast cancer.
Gene selection: a Bayesian variable selection approach.
Gene Sequencing for Pathogenic Variants Among Adults With Breast and Ovarian Cancer in the Caribbean.
Gene x Gene interaction between MnSOD and GPX-1 and breast cancer risk: a nested case-control study.
Gene-based association analysis of survival traits via functional regression-based mixed effect cox models for related samples.
Gene-body hypermethylation of ATM in peripheral blood DNA of bilateral breast cancer patients.
Gene-environment interactions in breast cancer.
Gene-expression profiles in hereditary breast cancer.
Gene-gene interactions in breast cancer susceptibility.
Gene-Specific Genetic Complementation between Brca1 and Cobra1 During Mouse Mammary Gland Development.
Generation and analysis of Brca1 conditional knockout mice.
Generation of induced pluripotent stem cell (iPSC) line from a patient with triple negative breast cancer with hereditary exon 17 deletion of BRCA1 gene.
Genes implicated in hereditary breast cancer syndromes.
Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility.
GENESIS: a French national resource to study the missing heritability of breast cancer.
Genetic alterations in breast cancer.
Genetic analyses of male breast cancer in Israel.
Genetic analysis of a breast-ovarian cancer family, with 7 cases of colorectal cancer linked to BRCA1, fails to support a role for BRCA1 in colorectal tumorigenesis.
Genetic analysis of BRCA1 function in a defined tumor cell line.
Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility.
Genetic analysis of eight breast-ovarian cancer families with suspected BRCA1 mutations.
Genetic analysis of the BRCA1 region in a large breast/ovarian family: refinement of the minimal region containing BRCA1.
Genetic and clinical landscape of breast cancers with germline BRCA1/2 variants.
Genetic and epigenetic characterization of the BRCA1 gene in Brazilian women at-risk for hereditary breast cancer.
Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts.
Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance.
Genetic anticipation is associated with telomere shortening in hereditary breast cancer.
Genetic contribution of GADD45A to susceptibility to sporadic and non-BRCA1/2 familial breast cancers: a systematic evaluation in Chinese populations.
Genetic counseling for families with inherited susceptibility to breast and ovarian cancer.
Genetic counseling for patients and families with hereditary breast and ovarian cancer in a developing Asian country: an observational descriptive study.
Genetic counselling and testing for susceptibility to breast, ovarian and colon cancer: where are we today?
Genetic developments in breast cancer.
Genetic epidemiology of early onset breast cancer.
Genetic epidemiology of female breast cancer.
Genetic evaluation based on family history and Her2 status correctly identifies TP53 mutations in very early onset breast cancer cases.
Genetic evaluation of BRCA1 associated a complex genes with triple-negative breast cancer susceptibility in chinese women.
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.
Genetic heterogeneity in breast cancer susceptibility.
Genetic heterogeneity in hereditary breast cancer: role of BRCA1 and BRCA2.
Genetic instability in the RAD51 and BRCA1 regions in breast cancer.
Genetic interactions among Brca1, Brca2, Palb2, and Trp53 in mammary tumor development.
Genetic interactions between INPP4B and RAD50 is prognostic of breast cancer survival.
Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis.
Genetic Landscape of Male Breast Cancer.
Genetic mapping of the breast-ovarian cancer syndrome to a small interval on chromosome 17q12-21: exclusion of candidate genes EDH17B2 and RARA.
Genetic modifiers of cancer risk for BRCA1 and BRCA2 mutation carriers.
Genetic polymorphims of estrogen receptor alpha -397 PvuII (T>C) and -351 XbaI (A>G) in a portuguese population: prevalence and relation with breast cancer susceptibility.
Genetic polymorphisms and protein expression of P53 and BRCA1 in preneoplastic and neoplastic rat mammary glands.
Genetic polymorphisms and susceptibility to cancer development.
Genetic polymorphisms in AURKA and BRCA1 are associated with breast cancer susceptibility in a Chinese Han population.
Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221).
Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate.
Genetic predisposition syndromes and their management.
Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.
Genetic predisposition to breast cancer: past, present, and future.
Genetic predisposition to male breast cancer in Poland.
Genetic predisposition to radiation induced sarcoma: possible role for BRCA and p53 mutations.
Genetic risk assessment and prevention: the role of genetic testing panels in breast cancer.
Genetic risk of breast cancer.
Genetic risk transmission in a family affected by familial breast cancer.
Genetic sequence variations of BRCA1-interacting genes AURKA, BAP1, BARD1 and DHX9 in French Canadian Families with high risk of breast cancer.
Genetic steps of mammalian homologous repair with distinct mutagenic consequences.
Genetic suppression reveals DNA repair-independent antagonism between BRCA1 and COBRA1 in mammary gland development.
Genetic susceptibility for breast cancer--risk assessment and counseling.
Genetic susceptibility for breast cancer: how many more genes to be found?
Genetic susceptibility for breast cancer: testing and primary prevention options.
Genetic susceptibility testing for breast and ovarian cancer: a progress report.
Genetic susceptibility to breast and ovarian cancer.
Genetic susceptibility to breast cancer in French-Canadians: role of carcinogen-metabolizing enzymes and gene-environment interactions.
Genetic susceptibility to breast cancer.
Genetic Susceptibility to Triple-Negative Breast Cancer.
Genetic testing and interpretive complexity: a BRCA1 gene mutation example.
Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients.
Genetic testing for BRCA1 and BRCA2: recommendations of the Stanford Program in Genomics, Ethics, and Society. Breast Cancer Working Group.
Genetic testing for BRCA1: effects of a randomised study of knowledge provision on interest in testing and long term test uptake; implications for the NICE guidelines.
Genetic testing for breast cancer risk, from BRCA1/2 to a seven gene panel: an ethical analysis.
Genetic testing for breast cancer susceptibility: frequency of BRCA1 and BRCA2 mutations.
Genetic testing for susceptibility to breast cancer: findings from women's focus groups.
Genetic testing in a cohort of young patients with HER2-amplified breast cancer.
Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry.
Genetic testing in women with breast cancer: implications for treatment.
Genetic testing in young women with breast cancer: results from a Web-based survey.
Genetic variants and haplotype analyses of the ZBRK1/ZNF350 gene in high-risk non BRCA1/2 French Canadian breast and ovarian cancer families.
Genetic Variants Associated with Clinicopathological Profiles in Sporadic Breast Cancer in Sri Lankan Women.
Genetic variants of BLM interact with RAD51 to increase breast cancer susceptibility.
Genetic Variation in IGF2 and HTRA1 and Breast Cancer Risk among BRCA1 and BRCA2 Carriers.
Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers.
Genetic variation of the brca1 and brca2 genes in macedonian patients.
Genetic Variations, Exposure to Persistent Organic Pollutants and Breast Cancer Risk: A Greenlandic Case-Control Study.
Genetically engineered ER? positive breast cancer mouse models.
Genetics and the young woman with breast cancer.
Genetics of androgen metabolism in women with infertility and hypoandrogenism.
Genetics of breast and ovarian cancer.
Genetics of breast cancer.
Genistein inhibits Brca1 mutant tumor growth through activation of DNA damage checkpoints, cell cycle arrest, and mitotic catastrophe.
Genistein Inhibits Proliferation of BRCA1 Mutated Breast Cancer Cells: The GPR30-Akt Axis as a Potential Target.
Genistein Prevents BRCA1 CpG Methylation and Proliferation in Human Breast Cancer Cells with Activated Aromatic Hydrocarbon Receptor.
Genome instability in blood cells of a BRCA1+ breast cancer family.
Genome-wide analysis reveals a role for BRCA1 and PALB2 in transcriptional co-activation.
Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses.
Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk.
Genome-wide DNA methylation assessment of 'BRCA1-like' early-onset breast cancer: Data from the Australian Breast Cancer Family Registry.
Genome-Wide Gene Expression Analyses of BRCA1- and BRCA2-Associated Breast and Ovarian Tumours.
Genome-wide linkage scan for breast cancer susceptibility loci in Swedish hereditary non-BRCA1/2 families: suggestive linkage to 10q23.32-q25.3.
Genome-wide linkage scan in Dutch hereditary non-BRCA1/2 breast cancer families identifies 9q21-22 as a putative breast cancer susceptibility locus.
Genome-wide linkage scan reveals three putative breast-cancer-susceptibility loci.
Genome-wide scanning for linkage in Finnish breast cancer families.
Genome-wide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma: an implication for mutator phenotype and breast cancer pathogenesis.
Genomewide high-density SNP linkage analysis of non-BRCA1/2 breast cancer families identifies various candidate regions and has greater power than microsatellite studies.
Genomic alterations in histopathologically normal breast tissue from BRCA1 mutation carriers may be caused by BRCA1 haploinsufficiency.
Genomic analyses as a guide to target identification and preclinical testing of mouse models of breast cancer.
Genomic analysis of the 8p11-12 amplicon in familial breast cancer.
Genomic approaches to identifying breast cancer susceptibility factors.
Genomic Biomarkers for Breast Cancer Risk.
Genomic deletions in the BRCA1, BRCA2 and TP53 regions associate with low expression of the estrogen receptor in sporadic breast carcinoma.
Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes.
Genomic profiling of CHEK2*1100delC-mutated breast carcinomas.
Genomic rearrangement screening of the BRCA1 from seventy Iranian high-risk breast cancer families.
Genomic rearrangements in BRCA1 and BRCA2: A literature review.
Genomic rearrangements of the BRCA1 gene in Chilean breast cancer families: an MLPA analysis.
Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors.
Genomic signatures of BRCA1 but not BRCA2 associated high-grade serous carcinoma resemble basal-like breast cancer.
Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics.
Genomics and pharmacogenomics of breast cancer: current knowledge and trends.
Genotype in BRCA-associated breast cancers.
Genotype-Phenotype Correlations by Ethnicity and Mutation Location in BRCA Mutation Carriers.
Genotype/Phenotype correlations in patients with hereditary breast cancer.
Genotyping of BRCA1, BRCA2, p53, CDKN2A, MLH1 and MSH2 genes in a male patient with secondary breast cancer.
Germ line BRCA1 and BRCA2 gene mutations in Turkish breast cancer patients.
Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer.
Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer.
Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer.
Germ-line BRCA1 mutations in women with sporadic breast cancer: clinical correlations.
Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
German family study on hereditary breast and/or ovarian cancer: germline mutation analysis of the BRCA1 gene.
Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study.
Germline BRCA1 185delAG mutations in Jewish women with breast cancer.
Germline BRCA1 alterations in a population-based series of ovarian cancer cases.
Germline BRCA1 and BRCA2 testing for breast cancer survivors.
Germline BRCA1 and HMLH1 mutations in a family with male and female breast carcinoma.
Germline BRCA1 mutation analysis in Indian breast/ovarian cancer families.
Germline BRCA1 mutation and survival analysis in familial breast cancer patients in Kerala; South India.
Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.
Germline BRCA1 mutations and G/C polymorphism in the 5'-untranslated region of the RAD51 gene in Polish women with breast cancer.
Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer.
Germline BRCA1 mutations in Iranian women with breast cancer.
Germline BRCA1 mutations increase prostate cancer risk.
Germline BRCA1 promoter deletions in UK and Australian familial breast cancer patients: Identification of a novel deletion consistent with BRCA1:psiBRCA1 recombination.
Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer.
Germline copy number variants are not associated with globally acquired copy number changes in familial breast tumours.
Germline deleterious mutations in genes other than BRCA2 are infrequent in male breast cancer.
Germline E-cadherin mutations in familial lobular breast cancer.
Germline gene polymorphisms predisposing domestic mammals to carcinogenesis.
Germline Genetic Testing: What the Breast Surgeon Needs to Know.
Germline large genomic alterations on 7q in patients with multiple primary cancers.
Germline Mutation in 1338 BRCA-Negative Chinese Hereditary Breast and/or Ovarian Cancer Patients: Clinical Testing with a Multigene Test Panel.
Germline mutation of Brca1 alters the fate of mammary luminal cells and causes luminal-to-basal mammary tumor transformation.
Germline mutation of BRCA1 in Japanese breast cancer families.
Germline mutational analysis of the C19orf62 gene in African-American women with breast cancer.
Germline mutations 657del5 of the NBS1 gene contribute significantly to the incidence of breast cancer in Central Poland.
Germline Mutations in BRCA1 and BRCA2 in Breast Cancer Patients with High Genetic Risk in Turkish Population.
Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic.
Germline mutations in BRIP1 and PALB2 in Jewish high cancer risk families.
Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients.
Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers.
Germline mutations in NF1 and BRCA1 in a family with neurofibromatosis type 1 and early-onset breast cancer.
Germline mutations in RAD51C in Jewish high cancer risk families.
Germline mutations in the breast cancer susceptibility gene PTEN are rare in high-risk non-BRCA1/2 French Canadian breast cancer families.
Germline mutations in the PTEN gene in Israeli patients with Bannayan-Riley-Ruvalcaba syndrome and women with familial breast cancer.
Germline mutations of BRCA1 and BRCA2 in Korean sporadic ovarian carcinoma.
Germline mutations of the BRCA1 and BRCA2 genes in a breast and ovarian cancer patient.
Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation.
Germline mutations of TP53 and BRCA2 genes in breast cancer/sarcoma families.
Germline PALB2, ATM variants in a patient with breast and ovarian cancer at risk for familial cancer syndrome: Is there a role for risk-reducing salpingo-oophorectomy?
Germline pathogenic variants in BRCA1, BRCA2, PALB2 and RAD51C in breast cancer women from Argentina.
Germline promoter hypermethylation in BRCA1 and BRCA2 genes is not present in hereditary breast cancer patients.
Germline RAP80 mutations and susceptibility to breast cancer.
Germline RBBP8 variants associated with early-onset breast cancer compromise replication fork stability.
Germline RECQL mutations in high risk Chinese breast cancer patients.
Germline TP53 mutational spectrum in French Canadians with breast cancer.
Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families.
Germline truncating-mutations in BRCA1 and MSH6 in a patient with early onset endometrial cancer.
Germline variants in cancer genes in high-risk non-BRCA patients from Puerto Rico.
Giant Intrathoracic Meningocele and Breast Cancer in a Neurofibromatosis Type I Patient.
Giant prolactinoma, germline BRCA1 mutation, and depression: a case report.
Glomeruloid microvascular proliferation is associated with p53 expression, germline BRCA1 mutations and an adverse outcome following breast cancer.
Glucose Concentration in Cell Culture Medium Influences the BRCA1-Mediated Regulation of the Lipogenic Action of IGF-I in Breast Cancer Cells.
Gold nanoparticle-based label-free detection of BRCA1 mutations utilizing DNA ligation on DNA microarray.
Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Growth factor signaling pathways modulate BRCA1 repression of estrogen receptor-alpha activity.
Growth retardation and tumour inhibition by BRCA1.
GUARDIN is a p53-responsive long non-coding RNA that is essential for genomic stability.
GWAS identifies a common breast cancer risk allele among BRCA1 carriers.
Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy.
Gynecological-endocrinological aspects in women carriers of BRCA1/2 gene mutations.
H19 non coding RNA-derived miR-675 enhances tumorigenesis and metastasis of breast cancer cells by downregulating c-Cbl and Cbl-b.
H4K20me0 recognition by BRCA1-BARD1 directs homologous recombination to sister chromatids.
Haplo-insufficiency of BRCA1 in sporadic breast cancer.
Haploinsufficiency for BRCA1 is associated with normal levels of DNA nucleotide excision repair in breast tissue and blood lymphocytes.
Haploinsufficiency for BRCA1 leads to cell-type-specific genomic instability and premature senescence.
Haplotype Analysis of BRCA1 Gene D17S855 and D17S1322 Markers in Iranian Familial Breast Cancer Patients.
Haplotype analysis of BRCA1 intragenic markers in Iranian patients with familial breast and ovarian cancer.
Haplotype analysis of common variants in the BRCA1 gene and risk of sporadic breast cancer.
Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent.
Haplotype analysis of two recurrent genomic rearrangements in the BRCA1 gene suggests they are founder mutations for the Greek population.
Haplotype-based analysis of common variation in the acetyl-coA carboxylase alpha gene and breast cancer risk: a case-control study nested within the European Prospective Investigation into Cancer and Nutrition.
Health insurance and discrimination concerns and BRCA1/2 testing in a clinic population.
Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study.
Hematologic toxicity in BRCA1 and BRCA2 mutation carriers during chemotherapy: A retrospective matched cohort study.
HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry.
HER2-positive breast cancer in a germline BRCA1 gene large deletion carrier.
HERC2 interacts with Claspin and regulates DNA origin firing and replication fork progression.
HERC2 is an E3 ligase that targets BRCA1 for degradation.
Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis.
Hereditary breast and ovarian cancer and reproduction: an observational study on the suitability of preimplantation genetic diagnosis for both asymptomatic carriers and breast cancer survivors.
Hereditary breast and ovarian cancer in Andalusian families: a genetic population study.
Hereditary breast and ovarian cancer in Asia: genetic epidemiology of BRCA1 and BRCA2.
Hereditary breast and ovarian cancer in Cyprus: identification of a founder BRCA2 mutation.
Hereditary breast cancer and family cancer syndromes.
Hereditary breast cancer and handling of patients at risk.
Hereditary breast cancer and linkage analysis to BRCA1.
Hereditary breast cancer considering Cowden syndrome: a case study.
Hereditary breast cancer in Middle Eastern and North African (MENA) populations: identification of novel, recurrent and founder BRCA1 mutations in the Tunisian population.
Hereditary breast cancer.
Hereditary breast cancer. Identifying and managing BRCA1 and BRCA2 carriers.
Hereditary breast cancer: a brief overview.
Hereditary breast cancer: clinical, pathological and molecular characteristics.
Hereditary breast cancer: from molecular pathology to tailored therapies.
Hereditary breast cancer: high risk genes, genetic testing and clinical implications.
Hereditary breast cancer: part II. Management of hereditary breast cancer: implications of molecular genetics and pathology.
Hereditary breast cancer: pathobiology, clinical translation, and potential for targeted cancer therapeutics.
Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage.
Hereditary breast cancer: the era of new susceptibility genes.
Hereditary breast cancer: translation into clinical practice of recent American Society of Clinical Oncology, American Society of Radiation Oncology, and Society of Surgical Oncology recommendations.
Hereditary breast cancer; Genetic penetrance and current status with BRCA.
Hereditary breast-ovarian cancer: clinical findings and medical management.
Hereditary cancer: family history, diagnosis, molecular genetics, ecogenetics, and management strategies.
Hereditary ovarian cancer: molecular genetics and clinical implications.
Hereditary predisposition to breast cancer.
Hereditary predisposition to cancers of the digestive tract, breast, gynecological and gonadal: Focus on the Peutz-Jeghers.
Hereditary Risk of Breast and Ovarian Carcinoma: The Role of the Oncologist.
Hereditary risk of breast cancer: not only BRCA.
Hereditary susceptibility to breast cancer: significance of age of onset in family history and contribution of BRCA1 and BRCA2.
Heregulin induces phosphorylation of BRCA1 through phosphatidylinositol 3-Kinase/AKT in breast cancer cells.
Heregulin-dependent delay in mitotic progression requires HER4 and BRCA1.
Heterochromatin instability in cancer: From the Barr body to satellites and the nuclear periphery.
Heterochromatin-Encoded Satellite RNAs Induce Breast Cancer.
Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis.
Heterogenous point mutations in the BRCA1 breast cancer susceptibility gene occur in high frequency at the site of homonucleotide tracts, short repeats and methylatable CpG/CpNpG motifs.
Heterozygosity for a mutation in Brca1 or Atm does not increase susceptibility to ENU-induced mammary tumors in Apc(Min)/+ mice.
Heterozygote BRCA1 status and skewed chromosome X inactivation.
High chromosome instability identified by low-pass whole-genome sequencing assay is associated with TP53 copy loss and worse prognosis in BRCA1 germline mutation breast cancer.
High efficacy of cisplatin neoadjuvant therapy in a prospective series of patients carrying BRCA1 germ-line mutation.
High efficiency of BRCA1 knockout using rAAV-mediated gene targeting: developing a pig model for breast cancer.
High Expression of Stem Cell Marker ALDH1 is Associated with Reduced BRCA1 in Invasive Breast Carcinomas.
High expression of the breast cancer susceptibility gene BRCA1 in long-lived termite kings.
High follicular phase luteinizing hormone levels in young healthy BRCA1 mutation carriers: implications for breast and ovarian cancer risk.
High frequency and allele-specific differences of BRCA1 founder mutations in breast cancer and ovarian cancer patients from Belarus.
High frequency of allelic imbalance at the BRCA1 region on chromosome 17q in both familial and sporadic ductal breast carcinomas.
High frequency of BRCA1 5382insC mutation in Russian breast cancer patients.
High frequency of BRCA1 founder mutations in Polish women with nonfamilial breast cancer.
High frequency of HIF-1alpha overexpression in BRCA1 related breast cancer.
High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors.
High incidence of loss of heterozygosity at chromosome 17p13 in breast tumours from BRCA2 mutation carriers.
High likelihood of actionable pathogenic variant detection in breast cancer genes in women with very early onset breast cancer.
High prevalence of BRCA1 and BRCA2 mutations in unselected Nigerian breast cancer patients.
High prevalence of preinvasive lesions adjacent to BRCA1/2-associated breast cancers.
High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer.
High prevalence of two BRCA1 mutations, 4154delA and 5382insC, in Latvia.
High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia.
High proportion of missense mutations of the BRCA1 and BRCA2 genes in Japanese breast cancer families.
High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area.
High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer.
High throughput fluorescence-based conformation-sensitive gel electrophoresis (F-CSGE) identifies six unique BRCA2 mutations and an overall low incidence of BRCA2 mutations in high-risk BRCA1-negative breast cancer families.
High XIST and Low 53BP1 Expression Predict Poor Outcome after High-Dose Alkylating Chemotherapy in Patients with a BRCA1-like Breast Cancer.
High-Grade Serous Tumor Arising from Fallopian Tube in a BRCA Mutation Carrier after Prophylactic Oophorectomy.
High-Resolution Bisulfite-Sequencing of Peripheral Blood DNA Methylation in Early-Onset and Familial Risk Breast Cancer Patients.
High-resolution oligonucleotide array-CGH applied to the detection and characterization of large rearrangements in the hereditary breast cancer gene BRCA1.
High-throughput mutation detection method to scan BRCA1 and BRCA2 based on heteroduplex analysis by capillary array electrophoresis.
Higher antitumor activity of trabectedin in germline BRCA2 carriers with advanced breast cancer as compared to BRCA1 carriers: A subset analysis of a dedicated phase II trial.
Highlight: BRCA1 and BRCA2 proteins in breast cancer.
Histological groups of human postpubertal testicular germ cell tumours harbour different genetic alterations.
Histone Methyltransferase EZH2 Induces Akt-Dependent Genomic Instability and BRCA1 Inhibition in Breast Cancer.
Histopathological criteria and selection algorithms for BRCA1 genetic testing.
Histopathological features of 'BRCAX' familial breast cancers in the kConFab resource.
Histopathological features of breast cancer in carriers of ATM gene variants.
Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families.
Histopathology of BRCA1- and BRCA2-associated breast cancer.
HMGA1 protein expression in familial breast carcinoma patients.
HMGA1 protein expression sensitizes cells to cisplatin-induced cell death.
Homocysteine aggravates DNA damage by impairing the FA/Brca1 Pathway in NE4C murine neural stem cells.
Homologous recombinational repair of DNA ensures mammalian chromosome stability.
Homology-directed dna repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation.
Hormonal and Surgical Treatment in Trans-Women with BRCA1 Mutations: A Controversial Topic.
Hormonal prevention of hereditary breast cancer.
Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study.
Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers.
Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis.
Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden.
Hormone replacement therapy is more prevalent among Jewish BRCA1/2 mutation carriers.
Hormone responsive breast cancer and BRCA1 mutation: mechanism, regulation and iron-mediated effects.
Hormone therapy after prophylactic risk-reducing bilateral salpingo-oophorectomy in women who have BRCA gene mutation.
Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers.
Hormone-dependent regulation of BRCA1 in human breast cancer cells.
How can Australia integrate routine genetic sequencing in oncology: a qualitative study through an implementation science lens.
How do mutations affecting the breast cancer genes BRCA1 and BRCA2 cause cancer susceptibility?
How do women at increased, but unexplained, familial risk of breast cancer perceive and manage their risk? A qualitative interview study.
How latent viruses cause breast cancer: An explanation based on the microcompetition model.
How should we discuss genetic testing with women newly diagnosed with breast cancer? Design and implementation of a randomized controlled trial of two models of delivering education about treatment-focused genetic testing to younger women newly diagnosed with breast cancer.
HOXA9 regulates BRCA1 expression to modulate human breast tumor phenotype.
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.
Human BRCA1-associated breast cancer: no increase in numerical chromosomal instability compared to sporadic tumors.
Human familial and sporadic breast cancer: analysis of the coding regions of the 17 beta-hydroxysteroid dehydrogenase 2 gene (EDH17B2) using a single-strand conformation polymorphism assay.
Human FBXL8 Is a Novel E3 Ligase Which Promotes BRCA Metastasis by Stimulating Pro-Tumorigenic Cytokines and Inhibiting Tumor Suppressors.
Human gene patents: the possible impacts on genetic services healthcare.
Human immunodeficiency virus type 1 Vpr induces G2 checkpoint activation by interacting with the splicing factor SAP145.
Human immunodeficiency virus type 1 Vpr-mediated G2 arrest requires Rad17 and Hus1 and induces nuclear BRCA1 and gamma-H2AX focus formation.
Human papilloma virus and breast cancer: the role of inflammation and viral expressed proteins.
Human relevance of rodent prolactin-induced non-genotoxic mammary carcinogenesis: prolactin involvement in human breast cancer and significance for toxicology risk assessments.
Human transcription elongation factor NELF: identification of novel subunits and reconstitution of the functionally active complex.
Human, canine and murine BRCA1 genes: sequence comparison among species.
HUWE1 interacts with BRCA1 and promotes its degradation in the ubiquitin-proteasome pathway.
Hyaluronan-mediated motility receptor gene single nucleotide polymorphisms and risk of breast cancer.
Hydrocortisone down-regulates the tumor suppressor gene BRCA1 in mammary cells: a possible molecular link between stress and breast cancer.
Hypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer.
Hypermethylation of the breast cancer-associated gene 1 promoter does not predict cytologic atypia or correlate with surrogate end points of breast cancer risk.
Hypermethylation of tumor suppressor genes BRCA1, p16 and 14-3-3sigma in serum of sporadic breast cancer patients.
Hypoxia-induced protein CAIX is associated with somatic loss of BRCA1 protein and pathway activity in triple negative breast cancer.
ID4 controls luminal lineage commitment in normal mammary epithelium and inhibits BRCA1 function in basal-like breast cancer.
Id4 protein is highly expressed in triple-negative breast carcinomas: possible implications for BRCA1 downregulation.
Identification and evaluation of 55 genetic variations in the BRCA1 and the BRCA2 genes of patients from 50 Japanese breast cancer families.
Identification and frequency of the rs12516 and rs8176318 BRCA1 gene polymorphisms among different populations.
Identification and functional analysis of novel BRCA1 transcripts, including mouse Brca1-Iris and human pseudo-BRCA1.
Identification and in silico analysis of functional SNPs of the BRCA1 gene.
Identification and Management of Women With BRCA Mutations or Hereditary Predisposition for Breast and Ovarian Cancer.
Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer.
Identification of a 14 kb deletion involving the promoter region of BRCA1 in a breast cancer family.
Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk.
Identification of a C/G polymorphism in the promoter region of the BRCA1 gene and its use as a marker for rapid detection of promoter deletions.
Identification of a Danish breast/ovarian cancer family double heterozygote for BRCA1 and BRCA2 mutations.
Identification of a de novo BRCA1 mutation in a woman with early onset bilateral breast cancer.
Identification of a founder BRCA1 mutation in the Moroccan population.
Identification of a founder BRCA2 mutation in Sardinian breast cancer families.
Identification of a Novel BRCA2 and CHEK2 A-C-G-C Haplotype in Turkish Patients Affected with Breast Cancer.
Identification of a novel breast cancer-causing mutation in the BRCA1 gene by targeted next generation sequencing: A case report.
Identification of a novel CHEK2 variant and assessment of its contribution to the risk of breast cancer in French Canadian women.
Identification of a novel putative non-selenocysteine containing phospholipid hydroperoxide glutathione peroxidase (NPGPx) essential for alleviating oxidative stress generated from polyunsaturated fatty acids in breast cancer cells.
Identification of a novel splice-site mutation of the BRCA1 gene in two breast cancer families: screening reveals low frequency in Icelandic breast cancer patients.
Identification of a novel transcriptional repressor element located in the first intron of the human BRCA1 gene.
Identification of a possible somatic BRCA1 mutation affecting translation efficiency in an early-onset sporadic breast cancer patient.
Identification of a recurrent BRCA1 exon 21-22 genomic rearrangement in Malay breast cancer patients.
Identification of a RING protein that can interact in vivo with the BRCA1 gene product.
Identification of a Src tyrosine kinase/SIAH2 E3 ubiquitin ligase pathway that regulates C/EBP? expression and contributes to transformation of breast tumor cells.
Identification of an apoptotic cleavage product of BARD1 as an autoantigen: a potential factor in the antitumoral response mediated by apoptotic bodies.
Identification of BAF57 mutations in human breast cancer cell lines.
Identification of BRCA1 and BRCA2 mutations from Korean breast cancer patients using denaturing HPLC.
Identification of BRCA1 As a Potential Biomarker for Insulin-Like Growth Factor-1 Receptor Targeted Therapy in Breast Cancer.
Identification of BRCA1 Deficiency Using Multi-Analyte Estimation of BRCA1 and Its Repressors in FFPE Tumor Samples from Patients with Triple Negative Breast Cancer.
Identification of BRCA1 missense substitutions that confer partial functional activity: potential moderate risk variants?
Identification of BRCA1/2 Founder Mutations in Southern Chinese Breast Cancer Patients Using Gene Sequencing and High Resolution DNA Melting Analysis.
Identification of BRCA1/2 p.Ser1613Gly, p.Pro871Leu, p.Lys1183Arg, p.Glu1038Gly, p.Ser1140Gly, p.Ala2466Val, p.His2440Arg variants in women under 45 years old with breast nodules suspected of having breast cancer in Burkina Faso.
Identification of BRCA2 Cis Double Heterozygous Breast Cancer Cases Using Whole Exome Sequencing: Phenotypic Expression and Impact on Personalized Oncology.
Identification of Breast Cancer Subtype Specific MicroRNAs Using Survival Analysis to Find Their Role in Transcriptomic Regulation.
Identification of breast tumor mutations in BRCA1 that abolish its function in homologous DNA recombination.
Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families.
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors.
Identification of differentially expressed genes associated with colorectal cancer liver metastasis.
Identification of direct target genes of miR-7, miR-9, miR-96, and miR-182 in the human breast cancer cell lines MCF-7 and MDA-MB-231.
Identification of Domains of BRCA1 Critical for the Ubiquitin-Dependent Inhibition of Centrosome Function.
Identification of Eleven Novel BRCA Mutations in Tunisia: Impact on the Clinical Management of BRCA Related Cancers.
Identification of fifteen novel germline variants in the BRCA1 3'UTR reveals a variant in a breast cancer case that introduces a functional miR-103 target site.
Identification of four novel human genes amplified and overexpressed in breast carcinoma and localized to the q11-q21.3 region of chromosome 17.
Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer.
Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines.
Identification of genes induced by BRCA1 in breast cancer cells.
Identification of germline alterations in breast cancer predisposition genes among Malaysian breast cancer patients using panel testing.
Identification of germline BRCA1 and BRCA2 genetic alterations in Greek breast cancer moderate-risk and low-risk individuals--correlation with clinicopathological data.
Identification of Germline BRCA1 Mutations among Breast Cancer Families in Northeastern Iran.
Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients.
Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus.
Identification of Mutation in Exon11 of BRCA1 Gene in Bangladeshi Patients with Breast Cancer.
Identification of novel alternatively spliced BRCA1-associated RING domain (BARD1) messenger RNAs in human peripheral blood lymphocytes and in sporadic breast cancer tissues.
Identification of novel biomarkers in chronic immune thrombocytopenia (ITP) by microarray-based serum protein profiling.
Identification of novel BRCA founder mutations in Middle Eastern breast cancer patients using capture and Sanger sequencing analysis.
Identification of Novel BRCA1 and RAD50 Mutations Associated With Breast Cancer Predisposition in Tunisian Patients.
Identification of Novel Breast Cancer Subtype-Specific Biomarkers by Integrating Genomics Analysis of DNA Copy Number Aberrations and miRNA-mRNA Dual Expression Profiling.
Identification of novel intronic BRCA1 variants of uncertain significance in a Thai hereditary breast cancer family.
Identification of novel large genomic rearrangements at the BRCA1 locus in Malaysian women with breast cancer.
Identification of potential binding sites for the FHA domain of human Chk2 by in vitro binding studies.
Identification of proteins that interact with BRCA1 by Far-Western library screening.
Identification of recurrent BRCA1 mutation and its clinical relevance in Chinese Triple-negative breast cancer cohort.
Identification of Recurrent Variants in BRCA1 and BRCA2 across Multiple Cancers in the Chinese Population.
Identification of sequences that target BRCA1 to nuclear foci following alkylative DNA damage.
Identification of the BRCA1 breast cancer gene and its clinical implications.
Identification of the deleterious 2080insA BRCA1 mutation in a male renal cell carcinoma patient from a family with multiple cancer diagnoses from Pakistan.
Identification of the first case of germline duplication of BRCA1 exon 13 in an Italian family.
Identification of the SUMO E3 ligase PIAS1 as a potential survival biomarker in breast cancer.
Identification of two evolutionarily conserved and functional regulatory elements in intron 2 of the human BRCA1 gene.
Identification of Variants (rs11571707, rs144848, and rs11571769) in the BRCA2 Gene Associated with Hereditary Breast Cancer in Indigenous Populations of the Brazilian Amazon.
Identification of women with an increased risk of developing radiation-induced breast cancer.
Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study.
Identifying and exploiting defects in the Fanconi anemia/BRCA pathway in oncology.
Identifying breast cancer susceptibility genes - a review of the genetic background in familial breast cancer.
Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance.
IGF1 htSNPs in relation to IGF-1 levels in young women from high-risk breast cancer families: implications for early-onset breast cancer.
IL-1? induces up-regulation of BIRC3, a gene involved in chemoresistance to doxorubicin in breast cancer cells.
Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers.
Immunohistochemical detection of a germline BRCA1 mutation in a breast and ovarian cancer family.
Immunohistochemical expression of BRCA1 protein in invasive ductal carcinoma of the breast.
Immunohistochemical Expression of BRCA1 Protein, ER, PR and Her2/neu in Breast Cancer: A Clinicopathological Study.
Immunohistochemical Loss of BRCA1 Protein in Uterine Serous Carcinoma.
Immunohistochemistry for the detection of BRCA1 and BRCA2 proteins in patients with ovarian cancer: a systematic review.
Immunolocalization of BRCA1 protein in normal breast tissue and sporadic invasive ductal carcinomas: a correlation with other biological parameters.
Immunolocalization of BRCA1 protein in tumor breast tissue: prescreening of BRCA1 mutation in Tunisian patients with hereditary breast cancer?
Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers.
Impact of a paternal origin of germline BRCA1/2 mutations on the age at breast and ovarian cancer diagnosis in a Southern Swedish cohort.
Impact of BRCA1 and BRCA2 mutations on ovarian reserve and fertility preservation outcomes in young women with breast cancer.
Impact of BRCA1 BRCT domain missense substitutions on phospho-peptide recognition.
Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients.
Impact of cancer predisposition and radiosensitivity on the population risk of radiation-induced cancers.
Impact of clinical targeted sequencing on endocrine responsiveness in estrogen receptor-positive, HER2-negative metastatic breast cancer.
Impact of Etoposide on BRCA1 Expression in Various Breast Cancer Cell Lines.
Impact of genetic counseling on the uptake of contralateral prophylactic mastectomy among younger women with breast cancer.
Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data.
Impact of Hyperhomocysteinemia on Breast Cancer Initiation and Progression: Epigenetic Perspective.
Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors.
Impact that Timing of Genetic Mutation Diagnosis has on Surgical Decision Making and Outcome for BRCA1/BRCA2 Mutation Carriers with Breast Cancer.
Impaired tamoxifen metabolism reduces survival in familial breast cancer patients.
Impaired turnover of prolactin receptor contributes to transformation of human breast cells.
Impairment of homologous recombination control in a Fanconi anemia-like Chinese hamster cell mutant.
Implication of BRCA1 gene in breast cancer.
Implications of using whole genome sequencing to test unselected populations for high risk breast cancer genes: a modelling study.
Improved efficacy of mitochondrial disrupting agents upon inhibition of autophagy in a mouse model of BRCA1-deficient breast cancer.
In brief: BRCA1 and BRCA2.
In search of breast cancer culprits: suspecting the suspected and the unsuspected.
In Situ Protein Expression of RRM1, ERCC1, and BRCA1 in Metastatic Breast Cancer Patients Treated with Gemcitabine-Based Chemotherapy.
In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy.
In Their Own Words: A Qualitative Study of Kenyan Breast Cancer Survivors' Knowledge, Experiences, and Attitudes Regarding Breast Cancer Genetics.
In vitro assessment of the role of DpC in the treatment of head and neck squamous cell carcinoma.
In vitro diagnosis of DNA methylation biomarkers with digital PCR in breast tumors.
In Vitro Enhanced Sensitivity to Cisplatin in D67Y BRCA1 RING Domain Protein.
In vitro repression of Brca1-associated RING domain gene, Bard1, induces phenotypic changes in mammary epithelial cells.
In-situ breast cancer and BRCA1.
Inactivation of the prolyl isomerase Pin1 sensitizes BRCA1-proficient breast cancer to PARP inhibition.
Inadequate DNA Damage Repair Promotes Mammary Transdifferentiation, Leading to BRCA1 Breast Cancer.
Incidence of BRCA1 and BRCA2 mutations in young Korean breast cancer patients.
Incidence of contralateral and ipsilateral breast cancers and prognosis in BRCA1/2 pathogenic variant carriers based on the Japanese HBOC Consortium registration.
Incidental Carcinomas in Prophylactic Specimens in BRCA1 and BRCA2 Germ-line Mutation Carriers, With Emphasis on Fallopian Tube Lesions: Report of 6 Cases and Review of the Literature.
Incorporating tumour pathology information into breast cancer risk prediction algorithms.
Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells.
Increased cancer risks for relatives of very early-onset breast cancer cases with and without BRCA1 and BRCA2 mutations.
Increased chromosomal radiosensitivity in asymptomatic carriers of a heterozygous BRCA1 mutation.
Increased chromosomal radiosensitivity in women carrying BRCA1/BRCA2 mutations assessed with the G2 assay.
Increased expression of BRCA1 mRNA predicts favorable response to anthracycline-containing chemotherapy in breast cancers.
Increased expression of the E3 ubiquitin ligase RNF5 is associated with decreased survival in breast cancer.
Increased frequency of ATM mutations in breast carcinoma patients with early onset disease and positive family history.
Increased Identification of Candidates for High-Risk Breast Cancer Screening Through Expanded Genetic Testing.
Increased progesterone receptor expression in benign epithelium of BRCA1-related breast cancers.
Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in breast cancer tissue.
Increased risk for familial ovarian cancer among Jewish women: a population-based case-control study.
Increased sensitivity of BRCA defective triple negative breast tumors to plumbagin through induction of DNA Double Strand Breaks (DSB).
Increasing incidence of breast cancer in family with BRCA1 mutation.
Independent origin of 185delAG BRCA1 mutation in an Indian family.
Individual and family characteristics associated with protein truncating BRCA1 and BRCA2 mutations in an Ontario population based series from the Cooperative Family Registry for Breast Cancer Studies.
Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome.
Induced Cre-mediated knockdown of Brca1 in skeletal muscle reduces mitochondrial respiration and prevents glucose intolerance in adult mice on a high-fat diet.
Induced in vivo knockdown of the Brca1 gene in skeletal muscle results in skeletal muscle weakness.
Induced micronucleus frequencies in peripheral lymphocytes as a screening test for carriers of a BRCA1 mutation in breast cancer families.
Induction and processing of complex DNA damage in human breast cancer cells MCF-7 and nonmalignant MCF-10A cells.
Induction of apoptosis by the tumor suppressor protein BRCA1.
Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1.
Induction of hemeoxygenase-1 expression after inhibition of hemeoxygenase activity promotes inflammation and worsens ischemic brain damage in mice.
Induction of phosphorylation on BRCA1 during the cell cycle and after DNA damage.
Induction of the long noncoding RNA NBR2 from the bidirectional BRCA1 promoter under hypoxic conditions.
Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study.
Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women.
Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland.
Informed consent and BRCA1 mutation detection in archived breast tumor specimens.
Inheritance of cancer.
Inherited BRCA2 mutation associated with high grade breast cancer.
Inherited breast and ovarian cancer.
Inherited Breast Cancer in Nigerian Women.
Inherited breast cancer.
Inherited genetic susceptibility to breast cancer.
Inherited mutations in breast cancer genes-risk and response.
Inherited predisposition to breast cancer among African American women.
Inherited predisposition to breast cancer in the Carolina Breast Cancer Study.
Inherited susceptibility to breast cancer.
Inhibiting neddylation modification alters mitochondrial morphology and reprograms energy metabolism in cancer cells.
Inhibition of BACH1 (FANCJ) helicase by backbone discontinuity is overcome by increased motor ATPase or length of loading strand.
Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway.
Inhibition of constitutively activated phosphoinositide 3-kinase/AKT pathway enhances antitumor activity of chemotherapeutic agents in breast cancer susceptibility gene 1-defective breast cancer cells.
Inhibition of E2-induced expression of BRCA1 by persistent organochlorines.
Inhibition of Karyopherin-?2 Augments Radiation-Induced Cell Death by Perturbing BRCA1-Mediated DNA Repair.
Inhibition of redox/Fyn/c-Cbl pathway function by Cdc42 controls tumour initiation capacity and tamoxifen sensitivity in basal-like breast cancer cells.
Inhibitory targeting of checkpoint kinase signaling overrides radiation-induced cell cycle gene regulation: a therapeutic strategy in tumor cell radiosensitization?
Initiation, evolution, phenotype and outcome of BRCA1 and BRCA2 mutation-associated breast cancer.
INPP4B and RAD50 have an interactive effect on survival after breast cancer.
Insights into the Molecular Basis of Human Hereditary Breast Cancer from Studies of the BRCA1 BRCT Domain.
Insulin-like growth factor I polymorphism and breast cancer risk in Jewish women.
Insulin-like growth factor-1 genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating insulin-like growth factor-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families.
Insulin-like growth factor-I controls BRCA1 gene expression through activation of transcription factor Sp1.
Integrating DNA methylation measures to improve clinical risk assessment: are we there yet? The case of BRCA1 methylation marks to improve clinical risk assessment of breast cancer.
Integrating Germline and Somatic Mutation Information for the Discovery of Biomarkers in Triple-Negative Breast Cancer.
Integrating poly(ADP-ribose) polymerase (PARP) inhibitors in the treatment of early breast cancer.
Integration of BRCA1-mediated miRNA and mRNA profiles reveals microRNA regulation of TRAF2 and NF?B pathway.
Integrative Bioinformatics and Functional Analyses of GEO, ENCODE, and TCGA Reveal FADD as a Direct Target of the Tumor Suppressor BRCA1.
Integrative data fusion for comprehensive assessment of a novel CHEK2 variant using combined genomics, imaging, and functional-structural assessments via protein informatics.
Integrative tumor board: a case report and discussion from Dana-Farber Cancer Institute.
Integrin beta3 Leu33Pro polymorphism increases BRCA1-associated ovarian cancer risk.
Intensive radiologic surveillance: a focus on the psychological issues.
Intensive surveillance with bi-annual dynamic contrast-enhanced magnetic resonance imaging downstages breast cancer in BRCA1 mutation carriers.
Interaction between BRCA1 and human papilloma virus E7: an ontology study.
Interaction between BRCA2 and replication protein A is compromised by a cancer-predisposing mutation in BRCA2.
Interaction between Hormonal Receptor Status, Age and Survival in Patients with BRCA1/2 Germline Mutations: A Systematic Review and Meta-Regression.
Interaction fallacy.
Interaction of p14(ARF) with Brca1 in cancer cell lines and primary breast cancer.
Interaction of the EWS NH2 terminus with BARD1 links the Ewing's sarcoma gene to a common tumor suppressor pathway.
Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway.
Interactions Between Ataxia Telangiectasia Mutated Kinase Inhibition, Poly(ADP-ribose) Polymerase-1 Inhibition and BRCA1 Status in Breast Cancer Cells.
Interactions of BRCA1-mutated Breast Cancer Cell Lines with Adipose-derived Stromal Cells (ADSCs).
Interest in BRCA1/2 testing in a primary care population.
Interferon-? signaling is associated with BRCA1 loss-of-function mutations in high grade serous ovarian cancer.
International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation.
International Rates of Breast Reconstruction After Prophylactic Mastectomy in BRCA1 and BRCA2 Mutation Carriers.
International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers.
Interplay between BRCA1 and GADD45A and Its Potential for Nucleotide Excision Repair in Breast Cancer Pathogenesis.
Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer.
Intratumoral IGF-I protein expression is selectively upregulated in breast cancer patients with BRCA1/2 mutations.
Intronic alterations in BRCA1 and BRCA2: effect on mRNA splicing fidelity and expression.
Investigating of variations in BRCA1 gene in Iranian families with breast cancer.
Investigating the effects of additional truncating variants in DNA-repair genes on breast cancer risk in BRCA1-positive women.
Investigation of The Relationship of TNFRSF11A Gene Polymorphisms with Breast Cancer Development and Metastasis Risk in Patients with BRCA1 Or BRCA2 Pathogenic Variants Living in The Trakya Region of Turkey.
Involvement of BRCA1 and BRCA2 in breast cancer in a western Finnish sub-population.
Involvement of IGF-1R regulation by miR-515-5p modifies breast cancer risk among BRCA1 carriers.
Involvement of MyoD and c-myb in regulation of basal and estrogen-induced transcription activity of the BRCA1 gene.
Ionizing radiation or mitomycin-induced micronuclei in lymphocytes of BRCA1 or BRCA2 mutation carriers.
Is BRCA1 associated with familial breast cancer in India?
Is BRCA1/BRCA2-related breast carcinogenesis estrogen dependent?
Is early onset breast cancer with no family history a good criterion for testing BRCA1 and BRCA2 genes? A small population-based study.
Is multiple SNP testing in BRCA2 and BRCA1 female carriers ready for use in clinical practice? Results from a large Genetic Centre in the UK.
Is RNASEL:p.Glu265* a modifier of early-onset breast cancer risk for carriers of high-risk mutations?
Is there more to BARD1 than BRCA1?
Isolation of a diverged homeobox gene, MOX1, from the BRCA1 region on 17q21 by solution hybrid capture.
Isolation of a functional copy of the human BRCA1 gene by transformation-associated recombination in yeast.
Isolation, purification and quantification of BRCA1 protein from tumour cells by affinity perfusion chromatography.
Issues of concern in risk assessment, genetic counseling, and genetic testing of younger breast cancer patients in Japan.
Japanese Late-Onset Breast Cancer Families: Their Clincopathological Characteristics and Absence of BRCA1 and BRCA2 Germline Mutations.
Joint effects of single nucleotide polymorphisms in P53BP1 and p53 on breast cancer risk in a Chinese population.
Kaiso depletion attenuates the growth and survival of triple negative breast cancer cells.
KIAA0101 Interacts with BRCA1 and Regulates Centrosome Number.
Kin-cohort designs for gene characterization.
Kin-cohort estimates for familial breast cancer risk in relation to variants in DNA base excision repair, BRCA1 interacting and growth factor genes.
Kinetic analysis of interaction of BRCA1 tandem breast cancer c-terminal domains with phosphorylated peptides reveals two binding conformations.
Knowledge Level and Educational Needs of Turkish Oncology Nurses Regarding the Genetics of Hereditary Breast and Ovarian Cancer.
Knowledge of Breast Cancer Genetics Among Breast Cancer Patients and First-Degree Relatives of Affected Individuals.
Knowledge Regarding and Patterns of Genetic Testing in Patients Newly Diagnosed With Breast Cancer Participating in the iCanDecide Trial.
KOHBRA BRCA risk calculator (KOHCal): a model for predicting BRCA1 and BRCA2 mutations in Korean breast cancer patients.
KSR1 regulates BRCA1 degradation and inhibits breast cancer growth.
Laboratory determination of hereditary susceptibility to breast and ovarian cancer.
Lack of association between androgen receptor CAG polymorphism and familial breast/ovarian cancer.
Lack of association of BRCA1 and BRCA2 variants with breast cancer in an ethnic population of Saudi Arabia, an emerging high-risk area.
Lack of germ-line promoter methylation in BRCA1-negative families with familial breast cancer.
Lack of HIN-1 methylation in BRCA1-linked and "BRCA1-like" breast tumors.
Landscape of Germline Mutations in DNA Repair Genes for Breast Cancer in Latin America: Opportunities for PARP-Like Inhibitors and Immunotherapy.
Large BRCA1 gene deletions are found in 3% of German high-risk breast cancer families.
Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method.
Large genomic rearrangement in BRCA1 and BRCA2 and clinical characteristics of men with breast cancer in the United States.
Large genomic rearrangement of BRCA1 and BRCA2 genes in familial breast cancer patients in Korea.
Large genomic rearrangements in the familial breast and ovarian cancer gene BRCA1 are associated with an increased frequency of high risk features.
Large genomic rearrangements of both BRCA2 and BRCA1 are a feature of the inherited breast/ovarian cancer phenotype in selected families.
Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families.
Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification.
Large-scale meta-analysis of mutations identified in panels of breast/ovarian cancer-related genes - Providing evidence of cancer predisposition genes.
Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom.
Lessons learned from BRCA1 and BRCA2.
Leucocytes telomere length and breast cancer risk/ susceptibility: A case-control study.
Li-Fraumeni-like syndrome associated with a large BRCA1 intragenic deletion.
Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations.
Ligand binding prediction for BRCA1, a key molecule in the pathogenesis of breast cancer.
Liganded ER? Stimulates the E3 Ubiquitin Ligase Activity of UBE3C to Facilitate Cell Proliferation.
Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers.
Limited relevance of the CHEK2 gene in hereditary breast cancer.
Limited significance of family history for presence of BRCA1 gene mutation in Polish breast and ovarian cancer cases.
LIMK2 is a crucial regulator and effector of Aurora-A-kinase-mediated malignancy.
Linc01638 promotes tumorigenesis in HER2+ breast cancer.
Linkage analysis of BRCA1 in Japanese breast cancer families.
Linkage analysis of DRD2, a marker linked to the ataxia-telangiectasia gene, in 64 families with premenopausal bilateral breast cancer.
Lipid and Metabolite Deregulation in the Breast Tissue of Women Carrying BRCA1 and BRCA2 Genetic Mutations.
Liquiritigenin decreases tumorigenesis by inhibiting DNMT activity and increasing BRCA1 transcriptional activity in triple-negative breast cancer.
Living with the BRCA genetic mutation: An uncertain conclusion to an unending process.
LncRNA AY343892 inhibits breast cancer development by positively regulating BRCA1-mediated transcription of PTEN.
LncRNA HCP5 promotes triple negative breast cancer progression as a ceRNA to regulate BIRC3 by sponging miR-219a-5p.
Lobular breast cancer: incidence and genetic and non-genetic risk factors.
Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy.
Localisation of the breast-ovarian cancer susceptibility gene (BRCA1) on 17q12-21 to an interval of < or = 1 cM.
Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13.
Localization of a growth suppressor activity in MCF7 breast cancer cells to chromosome 17q24-q25.
Localization of BRCA1 protein in breast cancer tissue and cell lines with mutations.
Localization of BRCA1 protein in human breast cancer cells.
Localization of breast cancer susceptibility loci by genome-wide SNP linkage disequilibrium mapping.
Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas.
Localization of the human homolog of the yeast cell division control 27 gene (CDC27) proximal to ITGB3 on human chromosome 17q21.3.
Long-Range PCR and Next-Generation Sequencing of BRCA1 and BRCA2 in Breast Cancer.
Long-Term Follow-Up of a Female Patient Treated with Olaparib-Hope for a Long Life without Relapse?
Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status.
Long-term prognosis of early-onset breast cancer in a population-based cohort with a known BRCA1/2 mutation status.
Long-term prospective clinical follow-up after BRCA1/2 presymptomatic testing: BRCA2 risks higher than in adjusted retrospective studies.
Long-term treatment with the PARP inhibitor niraparib does not increase the mutation load in cell line models and tumour xenografts.
Longitudinal Changes in Patient Distress following Interactive Decision Aid Use among BRCA1/2 Carriers: A Randomized Trial.
Loss of BRCA1 expression and morphological features associated with BRCA1 promoter methylation status in triple-negative breast cancer.
Loss of BRCA1 expression in sporadic male breast carcinoma.
Loss of BRCA1 expression may predict shorter time-to-progression in metastatic breast cancer patients treated with taxanes.
Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo.
Loss of BRCA2 correlates with reduced long-term survival of sporadic breast cancer patients.
Loss of chromosome 17 loci in prostate cancer detected by polymerase chain reaction quantitation of allelic markers.
Loss of expression of FANCD2 protein in sporadic and hereditary breast cancer.
Loss of glucocorticoid receptor activation is a hallmark of BRCA1-mutated breast tissue.
Loss of heterozygosity analysis at the BRCA loci in tumor samples from patients with familial breast cancer.
Loss of Heterozygosity at BRCA1 Locus Is Significantly Associated with Aggressiveness and Poor Prognosis in Breast Cancer.
Loss of heterozygosity at BRCA1, TP53, nm-23 and other loci on chromosome 17q in human breast carcinoma.
Loss of heterozygosity at the BRCA1 locus in Tunisian women with sporadic breast cancer.
Loss of heterozygosity in BRCA1 and BRCA2 markers and high-grade malignancy in breast cancer.
Loss of heterozygosity in familial breast carcinomas.
Loss of heterozygosity in familial tumors from three BRCA1-linked kindreds.
Loss of heterozygosity in human breast carcinomas in the ataxia telangiectasia, Cowden disease and BRCA1 gene regions.
Loss of heterozygosity in normal breast epithelial tissue and benign breast lesions in BRCA1/2 carriers with breast cancer.
Loss of heterozygosity in the region including the BRCA1 gene on 17q in colon cancer.
Loss of heterozygosity of BRCA1, BRCA2 and ATM genes in sporadic invasive ductal breast carcinoma.
Loss of heterozygosity of p53, BRCA1, VHL, and estrogen receptor genes in breast carcinoma: correlation with related protein products and morphologic features.
Loss of heterozygosity of the BRCA1 and FHIT genes in patients with sporadic breast cancer from Southern Brazil.
Loss of heterozygosity studies in tumors from families with breast-ovarian cancer syndrome.
Loss of nuclear BRCA1 expression in breast cancers is associated with a highly proliferative tumor phenotype.
Loss of nuclear BRCA1 localization in breast carcinoma is age dependent.
Loss of nuclear BRCA1 protein staining in normal tissue cells derived from BRCA1 and BRCA2 mutation carriers.
Loss of oncogenic miR-155 in tumor cells promotes tumor growth by enhancing C/EBP-?-mediated MDSC infiltration.
Loss of SIRT4 promotes the self-renewal of Breast Cancer Stem Cells.
Loss of the BRCA1-Interacting Helicase BRIP1 Results in Abnormal Mammary Acinar Morphogenesis.
Loss of the E3 ubiquitin ligase HACE1 results in enhanced Rac1 signaling contributing to breast cancer progression.
Loss of the novel tumour suppressor and polarity gene Trim62 (Dear1) synergizes with oncogenic Ras in invasive lung cancer.
Low expression of bcl-2 in Brca1-associated breast cancers.
Low fouling label-free DNA sensor based on polyethylene glycols decorated with gold nanoparticles for the detection of breast cancer biomarkers.
Low Frequency Loss of Heterozygosity in the BRCA1 Region in Japanese Sporadic Breast Cancer.
Low frequency of CHEK2 1100delC allele in Australian multiple-case breast cancer families: functional analysis in heterozygous individuals.
Low frequency of microsatellite instability in BRCA1 mutated breast tumours.
Low frequency of recurrent BRCA1 and BRCA2 mutations in Spain.
Low incidence of BRCA2 mutations in breast carcinoma and other cancers.
Low incidence of methylation of the promoter region of the FANCF gene in Japanese primary breast cancer.
Low penetrance genes associated with increased risk for breast cancer.
Low prevalence of BRCA1 and BRCA2 mutations in the sporadic breast cancer of Spanish population.
Low prevalence of BRCA1 exon rearrangements in familial and young sporadic breast cancer patients.
Low prevalence of germline BRCA1 mutations in early onset breast cancer without a family history.
Low prevalence of germline PALB2 mutations in Australian triple-negative breast cancer.
Low prevalence of HER2 positivity amongst BRCA1 and BRCA2 mutation carriers and in primary BRCA screens.
Low Prevalence of the Four Common Colombian Founder Mutations in BRCA1 and BRCA2 in Early-Onset and Familial Afro-Colombian Patients with Breast Cancer.
Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes.
Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.
LSD1 Overexpression Is Associated with Poor Prognosis in Basal-Like Breast Cancer, and Sensitivity to PARP Inhibition.
Lympho-vascular invasion in BRCA related breast cancer compared to sporadic controls.
Lymphoblasts of women with BRCA1 mutations are deficient in cellular repair of 8,5'-Cyclopurine-2'-deoxynucleosides and 8-hydroxy-2'-deoxyguanosine.
Lymphocyte radiosensitivity in BRCA1 and BRCA2 mutation carriers and implications for breast cancer susceptibility.
Lymphocytes of BRCA1 and BRCA2 germ-line mutation carriers, with or without breast cancer, are not abnormally sensitive to the chromosome damaging effect of moderate folate deficiency.
Mainstream genetic testing for breast cancer patients: early experiences from the Parkville Familial Cancer Centre.
Mainstreaming genetic counseling for BRCA testing into oncology clinics - Indian perspective.
Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer.
MALAT1 Promotes Tumorigenesis and Increases Cellular Sensitivity to Herceptin in HER2-positive Breast Cancer.
MALDI-TOF based mutation detection using tagged in vitro synthesized peptides.
Male breast cancer--an andrological disease: risk factors and diagnosis.
Mammalian DNA double-strand break repair protein XRCC4 interacts with DNA ligase IV.
Mammalian protein homologous to VAT-1 of Torpedo californica: isolation from Ehrlich ascites tumor cells, biochemical characterization, and organization of its gene.
Mammary gland development, reproductive history, and breast cancer risk.
Mammary tumor development in dogs is associated with BRCA1 and BRCA2.
Mammary tumor formation in p53- and BRCA1-deficient mice.
Mammary tumor induction and premature ovarian failure in ApcMin mice are not enhanced by Brca2 deficiency.
Mammary tumorigenesis following transgenic expression of a dominant negative CHK2 mutant.
Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer.
Mammary tumors initiated by constitutive Cdk2 activation contain an invasive basal-like component.
Mammographic density and breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Mammographic screening in BRCA1 mutation carriers postponed until age 40: Evaluation of benefits, costs and radiation risks using models.
Mammography behavior after receiving a negative BRCA1 mutation test result in the Ashkenazim: a community-based study.
Mammography of breast carcinoma in women who have mutations of the breast cancer gene BRCA1: initial experience.
Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study.
Management of breast cancer risk in BRCA1/2 mutation carriers who are unaffected with cancer.
Management of Breast Cancer Risk in Women with Ovarian Cancer and Deleterious BRCA1 or BRCA2 Mutations.
Management of early-onset breast cancer and BRCA1 or BRCA2 status.
Management of women with a family history of breast cancer.
Management of women with BRCA mutations: a 41-year-old woman with a BRCA mutation and a recent history of breast cancer.
Management of Women With Breast Cancer and Pathogenic Variants in Genes Other Than BRCA1 or BRCA2.
Management updates for women with a BRCA1 or BRCA2 mutation.
Manumycin polyketides act as molecular glues between UBR7 and P53.
Mapping and conformational characterization of the DNA-binding region of the breast cancer susceptibility protein BRCA1.
Marsupial BRCA1: conserved regions in mammals and the potential effect of missense changes.
Massive parallel amplicon sequencing of the breast cancer genes BRCA1 and BRCA2: opportunities, challenges, and limitations.
Maternal and paternal lineage double heterozygosity alteration in familial breast cancer: a first case report.
MCPIP1 Selectively Destabilizes Transcripts Associated with an Antiapoptotic Gene Expression Program in Breast Cancer Cells That Can Elicit Complete Tumor Regression.
MDC1 and RNF8 function in a pathway that directs BRCA1-dependent localization of PALB2 required for homologous recombination.
MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling.
Mechanisms of the Synergistic Interaction between the Bisphosphonate Zoledronic Acid and the Chemotherapy Agent Paclitaxel in Breast Cancer Cells in vitro.
Medical hypothesis: bifunctional genetic-hormonal pathways to breast cancer.
Medical radiation exposure and breast cancer risk: findings from the Breast Cancer Family Registry.
Medical students' attitudes toward genetic testing of minors.
Medullary carcinoma of breast with a novel germline mutation 1123t >g in exon 11 of brca1.
Meeting the challenges of interpreting variants of unknown clinical significance in BRCA testing.
MERIT40 controls BRCA1-Rap80 complex integrity and recruitment to DNA double-strand breaks.
MERIT40 facilitates BRCA1 localization and DNA damage repair.
Meta-analysis of BRCA1 and BRCA2 penetrance.
Meta-Analysis of BRCA1 Polymorphisms and Breast Cancer Susceptibility.
Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.
Metabolomics reveals novel blood plasma biomarkers associated to the BRCA1-mutated phenotype of human breast cancer.
Metachronous Contralateral Male Breast Cancer: Case Report and Literature Review.
Metaplastic carcinoma of the breast and BRCA1 germline mutation: a case report and review.
Metastatic Triple-negative Breast Cancer.
Metformin inhibits RANKL and sensitizes cancer stem cells to denosumab.
Methionine-Dependence Phenotype in the de novo Pathway in BRCA1 and BRCA2 Mutation Carriers with and without Breast Cancer.
Methyl group metabolism gene polymorphisms as modifier of breast cancer risk in Italian BRCA1/2 carriers.
Methylated genes in breast cancer: Associations with clinical and histopathological features in a familial breast cancer cohort.
Methylation Analysis of BRCA1 and APC in Breast Cancer and It's Relationship to Clinicopathological Features.
Methylation is less abundant in BRCA1-associated compared with sporadic breast cancer.
Methylation not a frequent "second hit" in tumors with germline BRCA mutations.
Methylation of BRCA1 and MGMT genes in white blood cells are transmitted from mothers to daughters.
Methylation of BRCA1 promoter region is associated with unfavorable prognosis in women with early-stage breast cancer.
Methylation of Breast Cancer Predisposition Genes in Early-Onset Breast Cancer: Australian Breast Cancer Family Registry.
Methylation of cancer related genes in tumor and peripheral blood DNA from the same breast cancer patient as two independent events.
Methylation of the BRCA1 gene in sporadic breast cancer.
Methylation of the BRCA1 promoter in peripheral blood DNA is associated with triple-negative and medullary breast cancer.
Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens.
Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics.
Methylation of the tumor suppressor protein, BRCA1, influences its transcriptional cofactor function.
Methylation Profiles of BRCA1, RASSF1A and GSTP1 in Vietnamese Women with Breast Cancer
Methylation profiles of the BRCA1 promoter in hereditary and sporadic breast cancer among Han Chinese.
Methylation target array for rapid analysis of CpG island hypermethylation in multiple tissue genomes.
Methylation-related mutations in the BRCA1 promoter in peripheral blood cells from cancer-free women.
Methylation-sensitive, single-strand conformation analysis (MS-SSCA): A rapid method to screen for and analyze methylation.
Mexican BRCA1 founder mutation: Shortening the gap in genetic assessment for hereditary breast and ovarian cancer patients.
Mice heterozygous for a Brca1 or Brca2 mutation display distinct mammary gland and ovarian phenotypes in response to diethylstilbestrol.
Microarray-based detection of Korean-specific BRCA1 mutations.
Microcephalin is a new novel prognostic indicator in breast cancer associated with BRCA1 inactivation.
Microelectronic DNA assay for the detection of BRCA1 gene mutations.
MicroRNA deregulation in triple negative breast cancer reveals a role of miR-498 in regulating BRCA1 expression.
MicroRNA expression signatures for the prediction of BRCA1/2 mutation-associated hereditary breast cancer in paraffin-embedded formalin-fixed breast tumors.
MicroRNA miR-335 is crucial for the BRCA1 regulatory cascade in breast cancer development.
MicroRNA signatures in hereditary breast cancer.
MicroRNA-155, induced by FOXP3 through transcriptional repression of BRCA1, is associated with tumor initiation in human breast cancer.
MicroRNA-based molecular classification of non-BRCA1/2 hereditary breast tumours.
Microsatellite instability of D17S513 on chromosome 17 is associated with progression of breast cancer.
Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies.
Minor role of BRCA2 mutation (Exon2 and Exon11) in patients with early-onset breast cancer amongst Iranian Azeri-Turkish women.
miR-10b, miR-26a, miR-146a And miR-153 Expression in Triple Negative Vs Non Triple Negative Breast Cancer: Potential Biomarkers.
miR-142-3p attenuates breast cancer stem cell characteristics and decreases radioresistance in vitro.
miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors.
MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1.
MiR-29b-1-5p is altered in BRCA1 mutant tumours and is a biomarker in basal-like breast cancer.
miR-342 regulates BRCA1 expression through modulation of ID4 in breast cancer.
miR-4513 promotes breast cancer progression through targeting TRIM3.
miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers.
miRNA expression profiling of formalin-fixed paraffin-embedded (FFPE) hereditary breast tumors.
miRNA expression profiling of hereditary breast tumors from BRCA1- and BRCA2-germline mutation carriers in Brazil.
MiRNAs prognostic for basal and BRCA1 breast cancer.
Misbehaviour of XIST RNA in Breast Cancer Cells.
Mismatch Repair Polymorphisms as Markers of Breast Cancer Prevalence in the Breast Cancer Family Registry.
Missense alterations of BRCA1 gene detected in diverse cancer patients.
Missense mutations in the transactivation region of the BRCA1 gene in breast cancer.
Missense variants of uncertain significance (VUS) altering the phosphorylation patterns of BRCA1 and BRCA2.
Mitochondrial localization, ELK-1 transcriptional regulation and growth inhibitory functions of BRCA1, BRCA1a, and BRCA1b proteins.
Mixed epithelial/mesenchymal metaplastic carcinoma (carcinosarcoma) of the breast in BRCA1 carrier.
MLPA screening in the BRCA1 gene from 1,506 German hereditary breast cancer cases: novel deletions, frequent involvement of exon 17, and occurrence in single early-onset cases.
MMTV-trBrca1 mice display strain-dependent abnormalities in vaginal development.
Modeling breast cancer-associated c-Src and EGFR overexpression in human MECs: c-Src and EGFR cooperatively promote aberrant three-dimensional acinar structure and invasive behavior.
Modeling familial clustered breast cancer using published data.
Modeling the study of DNA damage responses in mice.
Models of genetic susceptibility to breast cancer.
Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer.
Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history.
Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1 Interacting Genes.
Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat.
Modifying effect of reproductive risk factors on the age at onset of breast cancer for German BRCA1 mutation carriers.
Modulating Effect of Hypnea musciformis (Red Seaweed) on Lipid Peroxidation, Antioxidants and Biotransforming Enzymes in 7,12-Dimethylbenz (a) Anthracene Induced Mammary Carcinogenesis in Experimental Animals.
Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells.
Modulation of interaction of mutant TP53 and wild type BRCA1 by alkaloids: a computational approach towards targeting protein-protein interaction as a futuristic therapeutic intervention strategy for breast cancer impediment.
Modulation of the BRCA1 protein and induction of apoptosis in triple negative breast cancer cell lines by the polyphenolic compound curcumin.
Molecular analysis of BRCA1 and BRCA2 genes by next generation sequencing and ultrastructural aspects of breast tumor tissue.
Molecular Analysis of BRCA1 in Human Breast Cancer Cells Under Oxidative Stress.
Molecular analysis of PALB2-associated breast cancers.
Molecular analysis of the BRCA1 and BRCA2 genes in 32 breast and/or ovarian cancer Spanish families.
Molecular analysis of the breast cancer genes BRCA1 and BRCA2 using amplicon-based massive parallel pyrosequencing.
Molecular analysis of the eighteen most frequent mutations in the BRCA1 gene in 63 Chilean breast cancer families.
Molecular analysis of the six most recurrent mutations in the BRCA1 gene in 87 Spanish breast/ovarian cancer families.
Molecular and cellular functions of the FANCJ DNA helicase defective in cancer and in Fanconi anemia.
Molecular and in silico analysis of BRCA1 and BRCA2 variants.
Molecular and pathological characterization of inherited breast cancer.
Molecular aspects of breast cancer resistance to drugs (Review).
Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer.
Molecular biology in radiation oncology. Radiation oncology perspective of BRCA1 and BRCA2.
Molecular biology of breast cancer.
Molecular characteristics of breast cancer according to clinicopathological factors.
Molecular characterization and cancer risk associated with BRCA1 and BRCA2 splice site variants identified in multiple-case breast cancer families.
Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
Molecular characterization of breast cancer in young Brazilian women.
Molecular characterization of germline mutations in the BRCA1 and BRCA2 genes from breast cancer families in Taiwan.
Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors.
Molecular classification of familial non-BRCA1/BRCA2 breast cancer.
Molecular cloning and characterization of a human homologue of TBPIP, a BRCA1 locus-related gene.
Molecular cloning of BRCA1: a gene for early onset familial breast and ovarian cancer.
Molecular contribution of BRCA1 and BRCA2 to genome instability in breast cancer patients: review of radiosensitivity assays.
Molecular dissection of a cosmid from a gene-rich region in 17q21 and characterization of a candidate gene for alpha-N-acetylglucosaminidase with two cDNA isoforms.
Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations.
Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status.
Molecular genetics of breast cancer progression.
Molecular genetics of breast cancer.
Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer.
Molecular insights into the association of obesity with breast cancer risk: relevance to xenobiotic metabolism and CpG island methylation of tumor suppressor genes.
Molecular morphological approach to the pathological study of development and advancement of human breast cancer.
Molecular pathways: understanding the role of Rad52 in homologous recombination for therapeutic advancement.
Molecular Portrait of the Normal Human Breast Tissue and Its Influence on Breast Carcinogenesis.
Molecular profile and clinical variables in BRCA1-positive breast cancers. A population-based study.
Molecular profiles of BRCA1-mutated and matched sporadic breast tumours: relation with clinico-pathological features.
Molecular structure of BRCA1-estrogen receptor alpha-estrogen complex: relevance to breast cancer?
Molecular trail for the anticancer behavior of a novel copper carbohydrazone complex in BRCA1 mutated breast cancer.
Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers.
More breast cancer genes?
More Modifiers Move on DNA Damage.
Morphological features of TMPRSS2-ERG gene fusion prostate cancer.
Morphological predictors of BRCA1 germline mutations in young women with breast cancer.
Morphology of breast cancer as a means of triage of patients for BRCA1 genetic testing.
Motivations and concerns of women considering genetic testing for breast cancer: a comparison between affected and at-risk probands.
Mouse embryonic stem cell-based functional assay to evaluate mutations in BRCA2.
Mouse mammary tumor virus (MMTV) - like exogenous sequences are associated with sporadic but not hereditary human breast carcinoma.
Mouse models for breast cancer susceptibility.
Mouse Models for Deciphering the Impact of Homologous Recombination on Tumorigenesis.
Mouse models of BRCA1 and their application to breast cancer research.
Moving into the mainstream: healthcare professionals' views of implementing treatment focussed genetic testing in breast cancer care.
MRE11 and EXO1 nucleases degrade reversed forks and elicit MUS81-dependent fork rescue in BRCA2-deficient cells.
MRI and breast cancer: role in detection, diagnosis, and staging.
MRI in the early detection of breast cancer in women with high genetic risk.
MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial.
MRN Complex and Cancer Risk: Old Bottles, New Wine.
MUC1 promotes glycolysis through inhibiting BRCA1 expression in pancreatic cancer.
Multi-Omics Characterization of the 4T1 Murine Mammary Gland Tumor Model.
Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim results.
Multicolor FISH mapping with Alu-PCR-amplified YAC clone DNA determines the order of markers in the BRCA1 region on chromosome 17q12-q21.
Multifocal Breast Cancer in Young Women with Prolonged Contact between Their Breasts and Their Cellular Phones.
Multigene methylation in serum of sporadic Chinese female breast cancer patients as a prognostic biomarker.
Multigene panel testing results in patients with multiple breast cancer primaries.
Multimodel assessment of BRCA1 mutations in Taiwanese (ethnic Chinese) women with early-onset, bilateral or familial breast cancer.
Multiple copies of mutant BRCA1 and BRCA2 alleles in breast tumors from germ-line mutation carriers.
Multiple fibroadenomas harbouring carcinoma in situ in a woman with a family history of breast/ovarian cancer.
Multiple gene methylation of nonsmall cell lung cancers evaluated with 3-dimensional microarray.
Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice.
Multiple roles of BRIT1/MCPH1 in DNA damage response, DNA repair, and cancer suppression.
Multiple Susceptibility Loci for Radiation-Induced Mammary Tumorigenesis in F2[Dahl S x R]-Intercross Rats.
Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer.
Multiplex mutation screening of the BRCA1 gene in 1000 Japanese breast cancers.
Multiplex single-nucleotide primer extension analysis to simultaneously detect eleven BRCA1 mutations in breast cancer families.
Multiplex SNaPshot for detection of BRCA1/2 common mutations in Spanish and Spanish related breast/ovarian cancer families.
Multiplying functions for BRCA1 and BRCA2?. Meeting report, The Breakthrough Breast Cancer Second International Workshop on the function of BRCA1 and BRCA2, Cambridge, UK, 9-10 September 1999.
Multistep level sections to detect occult fallopian tube carcinoma in risk-reducing salpingo-oophorectomies from women with BRCA mutations: implications for defining an optimal specimen dissection protocol.
Mutagen sensitivity of peripheral blood from women carrying a BRCA1 or BRCA2 mutation.
Mutant BRCA1 genes antagonize phenotype of wild-type BRCA1.
Mutants TP53 p.R273H and p.R273C but not p.R273G Enhance Cancer Cell Malignancy.
Mutation analysis of BRCA1 and BRCA2 cancer predisposition genes in radiation hypersensitive cancer patients.
Mutation analysis of BRCA1 and BRCA2 from 793 Korean patients with sporadic breast cancer.
Mutation analysis of BRCA1 and BRCA2 genes in Iranian high risk breast cancer families.
Mutation analysis of BRCA1 gene in African-American patients with breast cancer.
Mutation analysis of BRCA1, TP53, and KRAS2 in ovarian and related pelvic tumors.
Mutation analysis of BRCA1/2 mutations with special reference to polymorphic SNPs in Indian breast cancer patients.
Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives.
Mutation analysis of PALB2 gene in French breast cancer families.
Mutation analysis of RAD51L1 (RAD51B/REC2) in multiple-case, non-BRCA1/2 breast cancer families.
Mutation analysis of the ATR gene in breast and ovarian cancer families.
Mutation analysis of the BCCIP gene for breast cancer susceptibility in breast/ovarian cancer families.
Mutation analysis of the BRCA1 gene in 23 families with cases of cancer of the breast, ovary, and multiple other sites.
Mutation analysis of the BRCA1 gene in Malaysian breast cancer patients.
Mutation analysis of the breast cancer gene BRCA1 among breast cancer Jordanian females.
Mutation analysis of the CHK2 gene in families with hereditary breast cancer.
Mutation analysis of the SHFM1 gene in breast/ovarian cancer families.
Mutation analysis of the THRA1 gene in breast cancer: deletion/fusion of the gene to a novel sequence on 17q in the BT474 cell line.
Mutation and association analysis of GEN1 in breast cancer susceptibility.
Mutation detection in the breast cancer gene BRCA1 using the protein truncation test.
Mutation in Exon2 of BRCA1 Gene in Adult Bengali Bangladeshi Female Patients with Breast Cancer: An Experience from Two Tertiary-Care Hospitals.
Mutation of the PTCH1 gene predicts recurrence of breast cancer.
Mutation scanning by meltMADGE: validations using BRCA1 and LDLR, and demonstration of the potential to identify severe, moderate, silent, rare, and paucimorphic mutations in the general population.
Mutation screening of BRCA1 using PTT and LOH analysis at 17q21 in breast carcinomas from familial and non-familial cases.
Mutation screening of MIR146A/B and BRCA1/2 3'-UTRs in the GENESIS study.
Mutation screening of PALB2 in clinically ascertained families from the Breast Cancer Family Registry.
Mutation screening of the BRCA1 gene in early onset and familial breast/ovarian cancer in Moroccan population.
Mutation screening of the BRCA1 gene in Slovak patients.
Mutation screening of the BRCA1 gene in sporadic breast cancer in southern Chinese populations.
Mutation screening of the MERIT40 gene encoding a novel BRCA1 and RAP80 interacting protein in breast cancer families.
Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations.
Mutation testing of early-onset breast cancer genes BRCA1 and BRCA2.
Mutational analysis of BARD1 in familial breast cancer patients in Japan.
Mutational analysis of BRCA1 and BRCA2 genes in Mexican breast cancer patients.
Mutational analysis of BRCA1 and BRCA2 genes in Peruvian families with hereditary breast and ovarian cancer.
Mutational analysis of BRCA1 and BRCA2 genes in women with familial breast cancer from different regions of Colombia.
Mutational analysis of BRCA1 and BRCA2 in Mediterranean Spanish women with early-onset breast cancer: identification of three novel pathogenic mutations.
Mutational analysis of BRCA1/2 gene and pathologic characteristics from Kazakh population with sporadic breast cancer in northwestern China.
Mutational analysis of BRCA2 in Spanish breast cancer patients from Castilla-Leon: identification of four novel truncating mutations.
Mutational analysis of FANCL, FANCM and the recently identified FANCI suggests that among the 13 known Fanconi Anemia genes, only FANCD1/BRCA2 plays a major role in high-risk breast cancer predisposition.
Mutational analysis of telomere genes in BRCA1/2-negative breast cancer families with very short telomeres.
Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families.
Mutational Landscape of the Essential Autophagy Gene BECN1 in Human Cancers.
Mutational screening of breast cancer susceptibility gene 1 from early onset, bi-lateral, and familial breast cancer patients in Taiwan.
Mutational Screening of the BRCA1 Gene in Sporadic Breast Cancer in Kazakhstan Population.
Mutations analysis of BRCA1 gene in patients with breast cancer in South Khorasan province, East Iran.
Mutations and alternative splicing of the BRCA1 gene in UK breast/ovarian cancer families.
Mutations and polymorphic BRCA variants transmission in breast cancer familial members.
Mutations at BRCA1: the medullary breast carcinoma revisited.
Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer-susceptibility genes?
Mutations in BRCA1, BRCA2, and PALB2, and a panel of 50 cancer-associated genes in pancreatic ductal adenocarcinoma.
Mutations in the BRCA1 gene in Japanese breast cancer patients.
Mutations in the BRCT binding site of BRCA1 result in hyper-recombination.
Mutations of a novel human RAD54 homologue, RAD54B, in primary cancer.
Mutations of the BRCA1 and BRCA2 genes and the possibilities for predictive testing.
Mutations of the BRCA1 and BRCA2 genes in patients with bilateral breast cancer.
Mutations of the BRCA1 gene in human cancer.
Mutations predisposing to breast cancer in 12 candidate genes in breast cancer patients from Poland.
Mutator pathways unleashed by epigenetic silencing in human cancer.
MYB oncogene amplification in hereditary BRCA1 breast cancer.
MYC amplification in breast cancer: a chromogenic in situ hybridisation study.
MYC and Breast Cancer.
MYC overexpression and poor prognosis in sporadic breast cancer with BRCA1 deficiency.
Myricetin Apoptotic Effects on T47D Breast Cancer Cells is a P53-Independent Approach.
Myricetin Exerts its Apoptotic Effects on MCF-7 Breast Cancer Cells through Evoking the BRCA1-GADD45 Pathway.
N-(4-Hydroxyphenyl)retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells.
Nano-delivery of RAD6/Translesion Synthesis Inhibitor SMI#9 for Triple-negative Breast Cancer Therapy.
Nano-LC based proteomic approach identifies that E6AP interacts with ENO1 and targets it for degradation in breast cancer cells.
Nanostructured SERS-electrochemical biosensors for testing of anticancer drug interactions with DNA.
Natural selection and mammalian BRCA1 sequences: elucidating functionally important sites relevant to breast cancer susceptibility in humans.
Navigating the body of literature assessing BRCA1/2 mutations and markers of ovarian function: a systematic review and meta-analysis.
Negative correlation of ITCH E3 ubiquitin ligase and miRNA-106b dictates metastatic progression in pancreatic cancer.
Negative feedback loop of BRCA1-BARD1 ubiquitin ligase on estrogen receptor alpha stability and activity antagonized by cancer-associated isoform of BARD1.
Negative regulation of BRCA1 by transforming acidic coiled-coil protein 3 (TACC3).
Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma.
Negotiating jurisdictional boundaries in response to new genetic possibilities in breast cancer care: The creation of an 'oncogenetic taskscape'.
Neo-tanshinlactone selectively inhibits the proliferation of estrogen receptor positive breast cancer cells through transcriptional down-regulation of estrogen receptor alpha.
Nerve growth factor scales endocannabinoid signaling by regulating monoacylglycerol lipase turnover in developing cholinergic neurons.
Nestin is expressed in the basal/myoepithelial layer of the mammary gland and is a selective marker of basal epithelial breast tumors.
Network Meta-Analysis on the Effects of DNA Damage Response-Related Gene Mutations on Overall Survival of Breast Cancer Based on TCGA Database.
New advances in the DNA damage response network of Fanconi anemia and BRCA proteins. FAAP95 replaces BRCA2 as the true FANCB protein.
New complexities for BRCA1 and BRCA2.
New concepts on BARD1: Regulator of BRCA pathways and beyond.
New germline mutations in BRCA1, ATM, MUTYH, and RAD51D genes in Tuvans early-onset breast cancer patients.
New insights into breast cancer genetics and impact on patient management.
New insights into the performance of multigene panel testing: Two novel nonsense variants in BRIP1 and TP53 in a young woman with breast cancer.
New insights into the prevention and treatment of familial breast cancer.
New role for nuclear hormone receptors and coactivators in regulation of BRCA1-mediated DNA repair in breast cancer cell lines.
New single nucleotide polymorphisms (SNPs) in homologous recombination repair genes detected by microarray analysis in Polish breast cancer patients.
New variants in the BRCA1 gene in Buryat Mongol breast cancer patients: Report from two families.
Next generation sequencing analysis of BRCA1 and BRCA2 identifies novel variations in breast cancer.
Next Generation Sequencing Reveals High Prevalence of BRCA1 and BRCA2 Variants of Unknown Significance in Early-Onset Breast Cancer in African American Women.
Next-Generation Sequencing Identifies BRCA1 and/or BRCA2 Mutations in Women at High Hereditary Risk for Breast Cancer with Shorter Telomere Length.
Next-generation sequencing of BRCA1 and BRCA2 in breast cancer patients and control subjects.
NHERF1 together with PARP1 and BRCA1 expression as a new potential biomarker to stratify breast cancer patients.
Nicotinamide sensitizes human breast cancer cells to the cytotoxic effects of radiation and cisplatin.
Nine novel conserved motifs in BRCA1 identified by the chicken orthologue.
Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study.
Nitric Oxide: Genomic Instability And Synthetic Lethality.
No Association of Early-Onset Breast or Ovarian Cancer with Early-Onset Cancer in Relatives in BRCA1 or BRCA2 Mutation Families.
No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study.
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.
No difference in the frequency of locus-specific methylation in the peripheral blood DNA of women diagnosed with breast cancer and age-matched controls.
No evidence for breast cancer susceptibility associated with variants of BRD7, a component of p53 and BRCA1 pathways.
No evidence for germline PTEN mutations in families with breast and brain tumours.
No evidence of increased breast cancer risk for proven noncarriers from BRCA1 and BRCA2 families.
No evidence that CDKN1B (p27) polymorphisms modify breast cancer risk in BRCA1 and BRCA2 mutation carriers.
No evidence that GATA3 rs570613 SNP modifies breast cancer risk.
No germline mutations in the histone acetyltransferase gene EP300 in BRCA1 and BRCA2 negative families with breast cancer and gastric, pancreatic, or colorectal cancer.
No increased risk of breast cancer associated with alcohol consumption among carriers of BRCA1 and BRCA2 mutations ages <50 years.
No MSH6 germline mutations in breast cancer families with colorectal and/or endometrial cancer.
Non-BRCA1/2 Breast Cancer Susceptibility Genes: A New Frontier with Clinical Consequences for Plastic Surgeons.
Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy.
Non-Coding Variants in BRCA1 and BRCA2 Genes: Potential Impact on Breast and Ovarian Cancer Predisposition.
Non-founder BRCA1 mutations in Russian breast cancer patients.
Non-Surgical Cancer Risk Reduction in BRCA1 Mutation Carriers: Disabling the Remote Control.
Noncoding RNA Ginir functions as an oncogene by associating with centrosomal proteins.
Nonhomologous end-joining of ionizing radiation-induced DNA double-stranded breaks in human tumor cells deficient in BRCA1 or BRCA2.
Nonsense mutation at codon 63 of the BRCA1 gene in Japanese breast cancer patients.
Normal breast: myths, realities, and prospects.
Novel and recurrent BRCA2 mutations in Italian breast/ovarian cancer families widen the ovarian cancer cluster region boundaries to exons 13 and 14.
Novel and reported pathogenic variants in exon 11 of BRCA2 gene in a cohort of Sri Lankan young breast cancer patients.
Novel BRCA1 deleterious mutation (c.1949_1950delTA) in a woman of Senegalese descent with triple-negative early-onset breast cancer.
Novel BRCA1 Large Genomic Rearrangements in Italian Breast/Ovarian Cancer Patients.
Novel BRCA1 mutations and more frequent intron-20 alteration found among 236 women from Western Poland.
Novel BRCA1/2 mutations in Serbian breast and breast-ovarian cancer patients with hereditary predisposition.
Novel BRCA2 pathogenic genotype and breast cancer phenotype discordance in monozygotic triplets.
Novel BRCA2 pathogenic variant c.5219 T > G; p.(Leu1740Ter) in a consanguineous Senegalese family with hereditary breast cancer.
Novel consensus DNA-binding sequence for BRCA1 protein complexes.
Novel deletion at codon 1254 of the BRCA1 gene in an Italian breast cancer kindred.
Novel Genetic Markers for Early Detection of Elevated Breast Cancer Risk in Women.
Novel germline BRCA1 and BRCA2 mutations in breast and breast/ovarian cancer families from the Czech Republic.
Novel germline BRCA1 mutation (155del4) in an African American with early-onset breast cancer.
Novel germline BRCA1 mutations detected in women in singapore who developed breast carcinoma before the age of 36 years.
Novel Germline Mutation of BRCA1 Gene in a 56-Year-Old Woman with Breast Cancer, Ovarian Cancer, and Diffuse Large B-Cell Lymphoma.
Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
Novel Germline Mutations of BRCA1 and BRCA2 in Korean Familial Breast Cancer Patients.
Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families.
Novel LOVD databases for hereditary breast cancer and colorectal cancer genes in the Chinese population.
Novel mutations in the BRCA1 and BRCA2 genes in Iranian women with early-onset breast cancer.
Novel mutations in the RING-finger domain of BRCA1 gene in clinically diagnosed breast cancer patients.
Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions.
Novel RING E3 ubiquitin ligases in breast cancer.
Novel role of BRCA1 interacting C-terminal helicase 1 (BRIP1) in breast tumour cell invasion.
Novel sequence variants and a high frequency of recurrent polymorphisms in BRCA1 gene in Sri Lankan breast cancer patients and at risk individuals.
Novel sequence variants and common recurrent polymorphisms of BRCA2 in Sri Lankan breast cancer patients and a family with BRCA1 mutations.
Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Novel somatic mutations in the BRCA1 gene in sporadic breast tumors.
Novel splice-switching oligonucleotide promotes BRCA1 aberrant splicing and susceptibility to PARP inhibitor action.
NPR3 protects cardiomyocytes from apoptosis through inhibition of cytosolic BRCA1 and TNF-?.
Nrdp1 expression to predict clinical outcome and efficacy of adjuvant anthracyclines-based chemotherapy in breast cancer: \newline A retrospective study.
Nrf2 is associated with the regulation of basal transcription activity of the BRCA1 gene.
Nuclear and cytoplasmic expressions of ERbeta1 and ERbeta2 are predictive of response to therapy and alters prognosis in familial breast cancers.
Nuclear export of BRCA1 occurs during early S phase and is calcium-dependent.
Nuclear location and cell cycle regulation of the BRCA2 protein.
Nucleolar localization of BRCA1 protein in human breast cancer.
Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer.
Numerous high-risk epithelial lesions in familial breast cancer.
Obesity alters the ovarian DNA damage response and apoptotic proteins.
Occult fallopian tube cancer in a patient with BRCA1 breast cancer.
Occult Tubal Carcinoma After Risk-Reducing Salpingo-oophorectomy: A Systematic Review.
Oestrogen causes degradation of KLF5 by inducing the E3 ubiquitin ligase EFP in ER-positive breast cancer cells.
Olaparib for the treatment of breast cancer.
Olaparib: A Novel Therapy for Metastatic Breast Cancer in Patients With a BRCA1/2 Mutation.
Old and new concepts in histopathological characterization of familial breast cancer.
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.
On the dynamics of breast tumor development in women carrying germline BRCA1 and BRCA2 mutations.
On the use of familial aggregation in population-based case probands for calculating penetrance.
Oncogene-mediated inhibition of glycogen synthase kinase 3 beta impairs degradation of prolactin receptor.
Oncogenic pathways in hereditary and sporadic breast cancer.
One step direct detection of recurrent mutations in the breast cancer susceptibility gene, BRCA1.
Oophorectomy after menopause and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers.
Oophorectomy benefits in breast cancer patients with BRCA1 mutation.
Oophorectomy for breast cancer prevention in women with BRCA1 or BRCA2 mutations.
Opportunities and hurdles in the treatment of BRCA1-related breast cancer.
Opposing roles for mammary epithelial-specific PPAR? signaling and activation during breast tumour progression.
Optimal age to start preventive measures in women with BRCA1/2 mutations or high familial breast cancer risk.
Optimization of Porous Silicon Conditions for DNA-based Biosensing via Reflectometric Interference Spectroscopy.
Optimization of prediction methods for risk assessment of pathogenic germline variants in the Japanese population.
Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study.
Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations.
Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group.
Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study.
Oral contraceptives and risk of familial breast cancer.
Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis.
Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
Orchestration of the DNA-damage response by the RNF8 ubiquitin ligase.
Osteopontin can act as an effector for a germline mutation of BRCA1 in malignant transformation of breast cancer-related cells.
Osteoprotegerin: Relationship to Breast Cancer Risk and Prognosis.
Out-RANKing BRCA1 in Mutation Carriers.
Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status.
Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers.
Outcome of triple negative breast cancer: comparison of sporadic and BRCA1-associated cancers.
Outcomes of Incidental Fallopian Tube High-Grade Serous Carcinoma and Serous Tubal Intraepithelial Carcinoma in Women at Low Risk of Hereditary Breast and Ovarian Cancer.
Outcomes of women at high familial risk for breast cancer: An 8-year single-center experience.
Ovarian and breast cancer risks to women in families with two or more cases of ovarian cancer.
Ovarian cancer among 8005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative for BRCA1 and BRCA2.
Ovarian Cancer Gene Therapy with BRCA1-An Overview.
Ovarian cancer molecular pathology.
Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus.
Ovarian cancer risk in Polish BRCA1 mutation carriers is not associated with the prohibitin 3' untranslated region polymorphism.
Ovarian Pathology in Risk-reducing Salpingo-oophorectomies From Women With BRCA Mutations, Emphasizing the Differential Diagnosis of Occult Primary and Metastatic Carcinoma.
Ovarian remnant syndrome in an aromatase inhibitor-treated patient with BRCA2 mutation following bilateral oophorectomy.
Ovary removal is linked to lower breast cancer mortality in BRCA1 carriers.
Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer.
Overcoming Chemoresistance in Cancer via Combined MicroRNA Therapeutics with Anticancer Drugs Using Multifunctional Magnetic Core-Shell Nanoparticles.
Overexpression of BRCA1 in Neural Stem Cells Enhances Cell Survival and Functional Recovery after Transplantation into Experimental Ischemic Stroke.
Overexpression of WWP1 is associated with the estrogen receptor and insulin-like growth factor receptor 1 in breast carcinoma.
Oxidative stress induced carbonylation in human plasma.
P-Cadherin is Co-Expressed with Cd44 and Cd49f and Mediates Stem Cell Properties in Basal-Like Breast Cancer.
p300 Modulates the BRCA1 inhibition of estrogen receptor activity.
p53 inactivation is a rare event in familial breast tumors negative for BRCA1 and BRCA2 mutations.
p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours.
p53, BRCA1 and breast Cancer chemoresistance.
p53-Dependent BRCA1 Nuclear Export Controls Cellular Susceptibility to DNA Damage.
p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer.
Paired tumor sequencing and germline testing in breast cancer management: An experience of a single academic center.
PALB2 and breast cancer: ready for clinical translation!
PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2.
PALB2 interacts with KEAP1 to promote NRF2 nuclear accumulation and function.
PALB2 mutations 1592delT and 229delT are not present in Korean breast cancer patients negative for BRCA1 and BRCA2 mutations.
PALB2/FANCN: recombining cancer and Fanconi anemia.
Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor.
Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care.
Paraneoplastic fasciitis and polyarthritis syndrome as a manifestation of breast cancer recurrence in a BRCA1 gene-positive patient.
Parental origin of mutation and the risk of breast cancer in a prospective study of women with a BRCA1 or BRCA2 mutation.
Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriers.
Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers.
Parkin enhances the expression of cyclin-dependent kinase 6 and negatively regulates the proliferation of breast cancer cells.
Parkin gene mutations are not common, but its epigenetic inactivation is a frequent event and predicts poor survival in advanced breast cancer patients.
Parkin regulates paclitaxel sensitivity in breast cancer via a microtubule-dependent mechanism.
Parkin targets HIF-1? for ubiquitination and degradation to inhibit breast tumor progression.
Parkin ubiquitinates phosphoglycerate dehydrogenase to suppress serine synthesis and tumor progression.
PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer.
PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells.
PARP inhibitor development for systemic cancer targeting.
PARP inhibitor olaparib has a potential to increase the effectiveness of electrochemotherapy in BRCA1 mutated breast cancer in mice.
PARP Inhibitor Olaparib Use in a BRCA1-Positive Patient With Metastatic Triple-Negative Breast Cancer, Without the Initial Use of Platinum-Based Chemotherapy, Showing Significant Rapid Near Resolution of Large Liver Metastasis While Patient Experienced Gout-Like Symptoms.
PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?
PARP Inhibitors Display Differential Efficacy in Models of BRCA Mutant High-Grade Serous Ovarian Cancer.
PARP Inhibitors in Triple-Negative Breast Cancer Including Those With BRCA Mutations.
PARP-1 inhibitors: a novel genetically specific agents for cancer therapy.
PARP1-driven poly-ADP-ribosylation regulates BRCA1 function in homologous recombination-mediated DNA repair.
Partnering in Oncogenetic Research - The INHERIT BRCAs Experience: Opportunities and Challenges.
Pathobiologic characteristics of hereditary breast cancer.
Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.
Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy.
Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients.
Pathologic findings in prophylactic oophorectomy specimens in high-risk women.
Pathological complete response after primary chemotherapy in a mother and daughter with hereditary breast carcinoma: two case reports.
Pathological features and BRCA1 mutation screening in premenopausal breast cancer patients.
Pathological splice mutations outside the invariant AG/GT splice sites of BRCA1 exon 5 increase alternative transcript levels in the 5' end of the BRCA1 gene.
Pathological tumor response to neoadjuvant chemotherapy using anthracycline and taxanes in patients with triple-negative breast cancer.
Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations.
Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).
Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.
Pathology of hereditary breast cancer.
Pathology of sporadic breast tumors with LOH at the BRCA1 locus: correlation with histopathological features specific to familial BRCA1 tumors and absence of microsatellite instability.
Patients with pathogenic variants for breast cancer other than BRCA1 and BRCA2: qualitative interviews about health care experiences.
Patterns and Prevalence of BRCA1 and BRCA2 Germline Mutations Among Patients with Triple-Negative Breast Cancer: Regional Perspectives.
Patterns and Prevalence of Germline BRCA1 and BRCA2 Mutations among High-Risk Breast Cancer Patients in Jordan: A Study of 500 Patients.
Patterns of allelic loss at the BRCA1 locus in Arabic women with breast cancer.
Patterns of reduced nipple aspirate fluid production and ductal lavage cellularity in women at high risk for breast cancer.
Pedigree and BRCA gene analysis in breast cancer patients to identify hereditary breast and ovarian cancer syndrome to prevent morbidity and mortality of disease in Indian population.
Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family.
Penetrance of Breast and Ovarian Cancer in Women Who Carry a BRCA1/2 Mutation and Do Not Use Risk-Reducing Salpingo-Oophorectomy: An Updated Meta-Analysis.
Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
Penetrances of BRCA1 1675delA and 1135insA with respect to breast cancer and ovarian cancer.
Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations.
Perceptions of Ashkenazi Jewish breast cancer patients on genetic testing for mutations in BRCA1 and BRCA2.
Performance of multiplicom's BRCA MASTR Dx kit on the detection of BRCA1 and BRCA2 mutations in fresh frozen ovarian and breast tumor samples.
Performance of prediction models for BRCA mutation carriage in three racial/ethnic groups: findings from the Northern California Breast Cancer Family Registry.
Peritoneal cancer arising after total abdominal hysterectomy and bilateral salpingo-oophorectomy for cervical cancer in a patient with right breast cancer and germline mutation of BRCA1 gene: a case report and literature review.
Peroxisome proliferator-activated receptor gamma and BRCA1.
Personalized prevention in high risk individuals: Managing hormones and beyond.
Perspectives in the clinical management of BRCA mutations carriers.
Perturbed myoepithelial cell differentiation in BRCA mutation carriers and in ductal carcinoma in situ.
PFKP is transcriptionally repressed by BRCA1/ZBRK1 and predicts prognosis in breast cancer.
Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening.
Phenocopy breast cancer rates in Israeli BRCA1 BRCA2 mutation carrier families: is the risk increased in non-carriers?
Phenol sulfotransferases: hormonal regulation, polymorphism, and age of onset of breast cancer.
Phenotypic analysis of familial breast cancer: Comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer.
Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers.
PHF20L1 as a H3K27me2 reader coordinates with transcriptional repressors to promote breast tumorigenesis.
Phosphatidylinositol 3-kinase/Akt signaling enhances nuclear localization and transcriptional activity of BRCA1.
Physical activity during adolescence and young adulthood and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
PIAS? expression in relation to clinicopathological, tumour factors and survival in indigenous black breast cancer women.
PIBF (progesterone induced blocking factor) is overexpressed in highly proliferating cells and associated with the centrosome.
PIK3CA Mutations and BRCA1 Expression in Breast Cancer: Potential Biomarkers for Chemoresistance.
Pit-1 inhibits BRCA1 and sensitizes human breast tumors to cisplatin and vitamin D treatment.
Pitaya Extracts Induce Growth Inhibition and Proapoptotic Effects on Human Cell Lines of Breast Cancer via Downregulation of Estrogen Receptor Gene Expression.
PKC? Attenuates Jagged-1-Mediated Notch Signaling in ErbB-2-Positive Breast Cancer to Reverse Trastuzumab Resistance.
Plasma Metabolome Signature Indicative of BRCA1 Germline Status Independent of Cancer Incidence.
Plasma micronutrients, trace elements, and breast cancer in BRCA1 mutation carriers: an exploratory study.
Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Plasma RANKL levels are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Plasmonics nanoprobes: detection of single-nucleotide polymorphisms in the breast cancer BRCA1 gene.
Platinum Sensitivity in a BRCA1 Mutation Carrier with Advanced Breast Cancer.
PLGA-PEG nano-delivery system for epigenetic therapy.
Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation.
PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation.
PML protein expression in hereditary and sporadic breast cancer.
Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer.
Polycomb complexes associate with enhancers and promote oncogenic transcriptional programs in cancer through multiple mechanisms.
Polyglutamine repeat length in the AIB1 gene modifies breast cancer susceptibility in BRCA1 carriers.
Polymer microfluidic chips with integrated waveguides for reading microarrays.
Polymorphic Repeat Length in the AIB1 Gene and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: A Meta-Analysis of Observational Studies.
Polymorphic variations in the FANCA gene in high-risk non-BRCA1/2 breast cancer individuals from the French Canadian population.
Polymorphisms in BRCA1, BRCA1-interacting genes and susceptibility of breast cancer in Chinese women.
Polymorphisms in BRCA2 resulting in aberrant codon-usage and their analysis on familial breast cancer risk.
Polymorphisms in DNA repair genes, ionizing radiation exposure and risk of breast cancer in U.S. Radiologic technologists.
Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women.
Pooled analysis indicates that the GSTT1 deletion, GSTM1 deletion, and GSTP1 Ile105Val polymorphisms do not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Population and breast cancer patients' analysis reveals the diversity of genomic variation of the BRCA genes in the Mexican population.
Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
Population frequencies of pathogenic alleles of BRCA1 and BRCA2: analysis of 173 Danish breast cancer pedigrees using the BOADICEA model.
Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study.
Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2.
Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients.
Population-based study of BRCA1/2 mutations: Family history based criteria identify minority of mutation carriers.
Population-based study of risk of breast cancer in carriers of BRCA2 mutation.
Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2.
Population-Calibrated Gene Characterization: Estimating Age at Onset Distributions Associated With Cancer Genes.
Positional analyses of BRCA1-dependent expression in Saccharomyces cerevisiae.
Positive cross-talk between estrogen receptor and NF-kappaB in breast cancer.
Positive regulation of the BRCA1 promoter.
Positive selection in the evolution of cancer.
Possible causes of chromosome instability: comparison of chromosomal abnormalities in cancer cell lines with mutations in BRCA1, BRCA2, CHK2 and BUB1.
Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics.
Post-mastectomy surveillance of BRCA1/BRCA2 mutation carriers: Outcomes from a specialized clinic for high-risk breast cancer patients.
Posttranscriptional regulation of the breast cancer susceptibility gene BRCA1 by the RNA binding protein HuR.
PP2C? inhibits p300-mediated p53 acetylation via ATM/BRCA1 pathway to impede DNA damage response in breast cancer.
Practical consensus recommendation on when to do BRCA testing.
Practical implementation of frailty models in Mendelian risk prediction.
Preclinical mouse models for BRCA1-associated breast cancer.
Prediagnosis aspirin use, DNA methylation, and mortality after breast cancer: A population-based study.
Predicted anti-oestrogen resistance in BRCA-associated familial breast cancers.
Predicted Chemotherapy Benefit for Breast Cancer Patients With Germline Pathogenic Variants in Cancer Susceptibility Genes.
Prediction of BRCA1 germ-line mutation status in patients with breast cancer using histoprognosis grade, MS110, Lys27H3, vimentin, and KI67.
Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype.
Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH.
Prediction of pathogenic mutations in patients with early-onset breast cancer by family history.
Predictive Factors for BRCA1 and BRCA2 Genetic Testing in an Asian Clinic-Based Population.
Predictive value of BRCA1/2 mRNA expression for response to neoadjuvant chemotherapy in BRCA-negative breast cancers.
Predictive value of MGMT, hMLH1, hMSH2 and BRCA1 protein expression for pathological complete response to neoadjuvant chemotherapy in basal-like breast cancer patients.
Predictors and outcomes of contralateral prophylactic mastectomy among breast cancer survivors.
Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.
Predictors of mammographic density among women with a strong family history of breast cancer.
Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.
Predictors of survival for breast cancer patients with a BRCA1 mutation.
Preferences for breast cancer prevention among women with a BRCA1 or BRCA2 mutation.
Preferences for breast cancer risk reduction among BRCA1/BRCA2 mutation carriers: a discrete-choice experiment.
Preferences for multigene panel testing for hereditary breast cancer risk among ethnically diverse BRCA-uninformative families.
Preferential allelic expression can lead to reduced expression of BRCA1 in sporadic breast cancers.
Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS).
Pregnancy and breast cancer risk in women with BRCA1 or BRCA2 mutations.
Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2.
Pregnancy-associated breast cancer in BRCA1 and BRCA2 germline mutation carriers.
Pregnancy-associated breast cancer.
Preimplantation genetic diagnosis for BRCA1 exon 13 duplication mutation using linked polymorphic markers resulting in a live birth.
Preimplantation genetic diagnosis for inherited breast cancer: first clinical application and live birth in Spain.
Preliminary results of targeted sequencing of BRCA1 and BRCA2 in a cohort of breast cancer families: New insight into pathogenic variants in patients and at?risk relatives.
Premature menopause in patients with BRCA1 gene mutation.
Premature senescence is a major response to DNA cross-linking agents in BRCA1-defective cells: implication for tailored treatments of BRCA1 mutation carriers.
Preoperative Systemic Treatment in BRCA-Positive Breast Cancer Patients: Case Report and Review of the Literature.
Prepubertal estradiol and genistein exposures up-regulate BRCA1 mRNA and reduce mammary tumorigenesis.
Prepubertal octylphenol exposure up-regulate BRCA1 expression, down-regulate ERalpha expression and reduce rat mammary tumorigenesis.
Prepubertal physical activity up-regulates estrogen receptor beta, BRCA1 and p53 mRNA expression in the rat mammary gland.
Preserving the Self: The Process of Decision Making About Hereditary Breast Cancer and Ovarian Cancer Risk Reduction.
Presymptomatic breast cancer in Egypt: role of BRCA1 and BRCA2 tumor suppressor genes mutations detection.
Prevalance of BRCA1 and BRCA2 mutations in familial breast cancer patients in Lebanon.
Prevalence and characterization of BRCA1 and BRCA2 germline mutations in Chinese women with familial breast cancer.
Prevalence and clinical outcomes of germline mutations in BRCA1/2 and PALB2 genes in 2769 unselected breast cancer patients in China.
Prevalence and clinical significance of pathogenic germline BRCA1/2 mutations in Chinese non-small cell lung cancer patients.
Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer.
Prevalence and impact of founder mutations in hereditary breast cancer in Latin America.
Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer.
Prevalence and Penetrance of BRCA1 and BRCA2 Germline Mutations in Colombian Breast Cancer Patients.
Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group.
Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.
Prevalence and Predictors of BRCA1 and BRCA2 Mutations in a Population-Based Study of Breast Cancer in White and Black American Women Ages 35 to 64 Years.
Prevalence and predictors of germline BRCA1 and BRCA2 mutations among young patients with breast cancer in Jordan.
Prevalence and Prognostic Role of BRCA1/2 Variants in Unselected Chinese Breast Cancer Patients.
Prevalence and reclassification of BRCA1 and BRCA2 variants in a large, unselected Chinese Han breast cancer cohort.
Prevalence and spectrum of BRCA germline variants in mainland Chinese familial breast and ovarian cancer patients.
Prevalence and Spectrum of BRCA1/2 Germline Mutations in Women with Breast Cancer in China Based on Next-Generation Sequencing.
Prevalence and spectrum of germline rare variants in BRCA1/2 and PALB2 among breast cancer cases in Sarawak, Malaysia.
Prevalence of 185delAG and 5382insC mutations in BRCA1, and 6174delT in BRCA2 in women of Ashkenazi Jewish origin in southern Brazil.
Prevalence of BRCA1 and BRCA2 gene mutations in Chinese patients with high-risk breast cancer.
Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer.
Prevalence of BRCA1 and BRCA2 genes promoter hypermethylation in breast cancer tissue.
Prevalence of BRCA1 and BRCA2 genomic rearrangements in a cohort of consecutive Italian breast and/or ovarian cancer families.
Prevalence of BRCA1 and BRCA2 Germline Mutations in Breast Cancer Women of Multiple Ethnic Region in Northwest China.
Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer.
Prevalence of BRCA1 and BRCA2 germline mutations in young breast cancer patients: a population-based study.
Prevalence of BRCA1 and BRCA2 Jewish mutations in Spanish breast cancer patients.
Prevalence of BRCA1 and BRCA2 mutations among clinic-based African American families with breast cancer.
Prevalence of BRCA1 and BRCA2 Mutations Among High-Risk Saudi Patients With Breast Cancer.
Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil.
Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Cuba.
Prevalence of BRCA1 and BRCA2 mutations in Korean breast cancer patients.
Prevalence of BRCA1 and BRCA2 mutations in non-familial breast cancer patients with high risks in Korea: The Korean Hereditary Breast Cancer (KOHBRA) Study.
Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patients.
Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer.
Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Greece.
Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from medellín, Colombia.
Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Peru.
Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ.
Prevalence of BRCA1 and BRCA2 mutations in women with breast carcinoma In Situ and referred for genetic testing.
Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort.
Prevalence of BRCA1 gene mutation in breast cancer patients in Guangxi, China.
Prevalence of BRCA1 in a hospital-based population of Dutch breast cancer patients.
Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study.
Prevalence of BRCA1 Mutations in Familial and Sporadic Greek Ovarian Cancer Cases.
Prevalence of BRCA1/2 germline mutations in 21?401 families with breast and ovarian cancer.
Prevalence of BRCA1/2 large genomic rearrangements in Chinese women with sporadic triple-negative or familial breast cancer.
Prevalence of BRCA1/BRCA2 pathogenic variation in Chinese Han population.
Prevalence of breast cancer predisposition gene mutations in Chinese women and guidelines for genetic testing.
Prevalence of deleterious mutations among patients with breast cancer referred for multigene panel testing in a Romanian population.
Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in Hungary.
Prevalence of founder BRCA1 and BRCA2 mutations in unselected French Canadian women with breast cancer.
Prevalence of founder mutations in the BRCA1 and BRCA2 genes among unaffected women from the Bahamas.
Prevalence of germline variants in inflammatory breast cancer.
Prevalence of Inherited Mutations in Breast Cancer Predisposition Genes among Women in Uganda and Cameroon.
Prevalence of mutations in the BRCA1 gene among Chinese patients with breast cancer.
Prevalence of PALB2 mutations in Australasian multiple-case breast cancer families.
Prevalence of PALB2 mutations in Australian familial breast cancer cases and controls.
Prevalence of PALB2 mutations in the Creighton University Breast Cancer Family Registry.
Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups.
Prevalence of pre-malignant and malignant lesions in prophylactic mastectomy specimens of BRCA1 mutation carriers: comparison with a control group.
Prevalence of RECQL germline variants in Pakistani early-onset and familial breast cancer patients.
Prevalence of Recurrent Mutations Predisposing to Breast Cancer in Early-Onset Breast Cancer Patients from Poland.
Prevalence of recurring BRCA mutations among Ashkenazi Jewish women with breast cancer.
Prevalence of the BRCA1 c.68_69delAG (BIC: 185delAG) mutation in women with breast cancer from north-central Poland and a review of the literature on other regions of the country.
Prevalence of the most frequent BRCA1 mutations in Polish population.
Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families.
Prevalence of TP53 germ line mutations in young Pakistani breast cancer patients.
Preventing BRCA1/ ZBRK1 repressor complex binding to the GOT2 promoter results in accelerated aspartate biosynthesis and promotion of cell proliferation.
Preventing Ovarian Cancer in High-risk Women: One Surgery at a Time.
Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist.
Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature.
Prevention of breast cancer.
Preventive mastectomy in patients at breast cancer risk due to genetic alterations in the BRCA1 and BRCA2 gene.
Primary fibroblasts from BRCA1 heterozygotes display an abnormal G1/S cell cycle checkpoint following UVA irradiation but show normal levels of micronuclei following oxidative stress or mitomycin C treatment.
Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome.
Primary resistance to docetaxel-based chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations.
Prioritizing candidate genetic modifiers of BRCA1 and BRCA2 using a combinatorial analysis of global expression and polymorphism association studies of breast cancer.
Prioritizing disease biomarkers using functional module based network analysis: A multilayer consensus driven scheme.
PRMT1-dependent methylation of BRCA1 contributes to the epigenetic defense of breast cancer cells against ionizing radiation.
Probability estimation models for prediction of BRCA1 and BRCA2 mutation carriers: COS compares favourably with other models.
Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history.
Profiling of Cross-Functional Peptidases Regulated Circulating Peptides in BRCA1 Mutant Breast Cancer.
Profiling of the germline mutation BRCA1: p.Ile1845fs in a large cohort of Han Chinese breast cancer.
Progesterone induces BRCA1 mRNA decrease, cell cycle alterations and apoptosis in the MCF7 breast cancer cell line.
Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives.
Progestin and breast cancer. The missing pieces of a puzzle.
Prognosis of BRCA1 hereditary breast cancer.
Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations.
Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and review.
Prognostic effects of abnormal DNA damage response protein expression in breast cancer.
Prognostic impact of a single-nucleotide polymorphism near the CTSO gene in hormone receptor-positive breast cancer patients.
Prognostic Impact of BRCA1 and BRCA2 Mutations on Long-Term Survival Outcomes in Egyptian Female Breast Cancer Patients.
Prognostic Impact of Breast-Conserving Therapy Versus Mastectomy of BRCA1/2 Mutation Carriers Compared With Noncarriers in a Consecutive Series of Young Breast Cancer Patients.
Prognostic role of methylated GSTP1, p16, ESR1 and PITX2 in patients with breast cancer: A systematic meta-analysis under the guideline of PRISMA.
Prognostic Significance of Basal-Like Phenotype and Fascin Expression in Node-Negative Invasive Breast Carcinomas.
Prognostic significance of BRCA1 expression in Japanese sporadic breast carcinomas.
Prognostic significance of BRCA1 expression in sporadic breast carcinomas.
Prognostic value of BRCA1 mutations in familial breast cancer patients affected by a second primary cancer.
Progress toward isolation of a breast cancer susceptibility gene, BRCA1.
Prolactin and androgen R1881 induce pro-survival carboxypeptidase-D and EDD E3 ligase in triple-negative and HER2+ breast cancer.
Prolactin blocks nuclear translocation of VDR by regulating its interaction with BRCA1 in osteosarcoma cells.
Prolactin levels, breast-feeding and milk production in a cohort of young healthy women from high-risk breast cancer families: implications for breast cancer risk.
Prolactin-dependent up-regulation of BRCA1 expression in human breast cancer cell lines.
Prolactin-inducible EDD E3 ubiquitin ligase promotes TORC1 signalling, anti-apoptotic protein expression, and drug resistance in breast cancer cells.
Proliferation and ovarian hormone signaling are impaired in normal breast tissues from women with BRCA1 mutations: benefit of a progesterone receptor modulator treatment as a breast cancer preventive strategy in women with inherited BRCA1 mutations.
Prolonged response to treatment based on cell-free DNA analysis and molecular profiling in three patients with metastatic cancer: a case series.
Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors.
Promoter Hypermethylation and Expression Changes of BRCA1 Gene in a Cohort of Sporadic Breast Cancer Cases among Pakistani Population.
Promoter hypermethylation and post-transcriptional mechanisms for reduced BRCA1 immunoreactivity in sporadic human breast cancers.
Promoter Hypermethylation in White Blood Cell DNA and Breast Cancer Risk.
Promoter hypermethylation of BRCA1 correlates with absence of expression in hereditary breast cancer tumors.
Promoter hypermethylation of p16, BRCA1 and RASSF1A genes in triple-negative breast cancer patients from Serbia.
Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer.
Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients.
Promoter methylation and expression changes of BRCA1 in cancerous tissues of patients with sporadic breast cancer.
Promoter methylation of BRCA1 in the prognosis of breast cancer: a meta-analysis.
Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy.
Promoter methylation of BRCA1 is associated with estrogen, progesterone and human epidermal growth factor receptor-negative tumors and the prognosis of breast cancer: A meta-analysis.
Promoter Methylation of BRCA1, DAPK1 and RASSF1A is Associated with Increased Mortality among Indian Women with Breast Cancer
Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and P53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation carriers.
Promoter Methylation Status of Breast Cancer Susceptibility Gene 1 and 17 Beta Hydroxysteroid Dehydrogenase Type 1 Gene in Sporadic Breast Cancer Patients.
Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation-related breast cancer.
Prophylactic bilateral mastectomy: patterns of practice.
Prophylactic mastectomy and genetic testing: an update.
Prophylactic mastectomy and inherited predisposition to breast carcinoma.
Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer.
Prophylactic mastectomy: indications, options, and reconstructive alternatives.
Prophylactic mastectomy: why and when?
Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers.
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers.
Prophylactic salpingo-oophorectomy in BRCA1 mutation carriers and postoperative incidence of peritoneal and breast cancers.
Prophylactic window therapy with the clinical poly(ADP-ribose) polymerase inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice.
Proposed roadmap to stepwise integration of genetics in family medicine and clinical research.
Prospective blinded surveillance screening of Swedish women with increased hereditary risk of breast cancer.
Prospective evaluation of alcohol consumption and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Prospective evaluation of body size and breast cancer risk among BRCA1 and BRCA2 mutation carriers.
Prospective screening study of 0.5 Tesla dedicated magnetic resonance imaging for the detection of breast cancer in young, high-risk women.
Prospective Study of Breast Cancer Incidence in Women With a BRCA1 or BRCA2 Mutation Under Surveillance With and Without Magnetic Resonance Imaging.
Prospective study of breast cancer risk for mutation negative women from BRCA1 or BRCA2 mutation positive families.
Prospective study of high-risk, BRCA1/2-mutation negative women: the 'negative study'.
Prospective study of Outcomes in Sporadic versus Hereditary breast cancer (POSH): study protocol.
Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover.
Prostate screening uptake in Australian BRCA1 and BRCA2 carriers.
Proteasome-mediated degradation of BRCA1 protein in MCF-7 human breast cancer cells.
Protective effect of cigarette smoking on breast cancer risk in women with BRCA1 or BRCA2 mutations???
Protein expression and methylation of DNA repair genes hMLH1, hMSH2, MGMT and BRCA1 and their correlation with clinicopathological parameters and prognosis in basal-like breast cancer.
Protein stability versus function: effects of destabilizing missense mutations on BRCA1 DNA repair activity.
Protein truncating BRCA1 and BRCA2 mutations in African women with pre-menopausal breast cancer.
Protein-Protein interactions uncover candidate 'core genes' within omnigenic disease networks.
Proteome changes in ovarian epithelial cells derived from women with BRCA1 mutations and family histories of cancer.
Proteomic analysis of BRCA1-depleted cell line reveals a putative role for replication protein A2 up-regulation in BRCA1 breast tumor development.
Proteomic Analysis of Medicinal Plant Calotropis Gigantea by insilico Peptide Mass Fingerprinting.
Proteomic Profiling of ?-hCG-Induced Spheres in BRCA1 Defective Triple Negative Breast Cancer Cells.
Proteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with diagnostic and prognostic value in human breast cancer.
Proven non-carriers in BRCA families have an earlier age of onset of breast cancer.
PRRG4 promotes breast cancer metastasis through the recruitment of NEDD4 and downregulation of Robo1.
PS2 expression in BRCA1-associated breast cancers.
Pseudo-likelihood estimates of the cumulative risk of an autosomal dominant disease from a kin-cohort study.
Psychological impact of genetic counselling and testing in women previously diagnosed with breast cancer.
Psychological issues in genetic testing for breast cancer.
Psychosocial and ethical issues relating to genetic testing for BRCA1 and BRCA2 breast cancer susceptibility genes.
Psychosocial functioning in women who have undergone bilateral prophylactic mastectomy.
Psychosocial impact of BRCA testing in young Black breast cancer survivors.
Psychosocial Impact of Lynch Syndrome on Affected Individuals and Families.
Psychosocial issues following a positive result of genetic testing for BRCA1 and BRCA2 mutations: findings from a focus group and a needs-assessment survey.
Psychotherapy with a woman at high risk for developing breast cancer.
PTEN breast cancer susceptibility: a matter of dose.
Publisher Correction: Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes.
Purification and characterisation of a soluble N-terminal fragment of the breast cancer susceptibility protein BRCA1.
Pyrosequencing analysis of BRCA1 methylation level in breast cancer cells.
Pyrosequencing quantified methylation level of BRCA1 promoter as prognostic factor for survival in breast cancer patient.
Q356R and S1512I are BRCA1 variants that may be associated with breast cancer in a Cypriot family.
Quantification of BRCA1 protein in sporadic breast carcinoma with or without loss of heterozygosity of the BRCA1 gene.
Quantitative analysis of BRCA1 and BRCA2 mRNA expression in sporadic breast carcinomas and its relationship with clinicopathological characteristics.
Quantitative detection of methylation of FHIT and BRCA1 promoters in the serum of ductal breast cancer patients.
Quantitative imaging of single mRNA splice variants in living cells.
Racial differences in genetic factors associated with breast cancer.
Racial differences in the incidence of BRCA1 and BRCA2 mutations in a cohort of early onset breast cancer patients: African American compared to white women.
RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies.
RAD51 135G>C does not modify breast cancer risk in non-BRCA1/2 mutation carriers: evidence from a meta-analysis of 12 studies.
RAD51 135G>C polymorphism and risk of familial breast cancer in a South American population.
RAD51 and breast cancer susceptibility: no evidence for rare variant association in the Breast Cancer Family Registry study.
RAD51 up-regulation bypasses BRCA1 function and is a common feature of BRCA1-deficient breast tumors.
RAD51, XRCC3, and XRCC2 mutation screening in Finnish breast cancer families.
RAD51C germline mutations in breast and ovarian cancer cases from high-risk families.
RAD52 aptamer regulates DNA damage repair and STAT3 in BRCA1/BRCA2?deficient human acute myeloid leukemia.
Rad52 gene mutations in breast/ovarian cancer families and sporadic ovarian carcinoma patients.
RAD6B is a major mediator of triple negative breast cancer cisplatin resistance: Regulation of translesion synthesis/Fanconi anemia crosstalk and BRCA1 independence.
Radiation-induced micronucleus induction in lymphocytes identifies a high frequency of radiosensitive cases among breast cancer patients: a test for predisposition?
Radiation-Related Deregulation of TUBB3 and BRCA1/2 and Risk of Secondary Lung Cancer in Women With Breast Cancer.
Radiosensitivity of lymphoblastoid cell lines with a heterozygous BRCA1 mutation is not detected by the comet assay and pulsed field gel electrophoresis.
Radiotherapy for breast cancer in BRCA1/BRCA2 carriers: clinical issues and management dilemmas.
Radiotherapy in the treatment of hereditary breast cancer.
RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.
RANKL and RANK: From Mammalian Physiology to Cancer Treatment.
RANKL/RANK control Brca1 mutation-driven mammary tumors.
RANKL/RANK: from bone loss to the prevention of breast cancer.
RAP80 responds to DNA damage induced by both ionizing radiation and UV irradiation and is phosphorylated at Ser 205.
Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib.
Rapid and cost-effective high-throughput sequencing for identification of germline mutations of BRCA1 and BRCA2.
Rapid and deep-scale ubiquitylation profiling for biology and translational research.
Rapid Genetic Testing for BRCA1 and BRCA2 Mutations at the Time of Breast Cancer Diagnosis: An Observational Study.
Rapid mutation detection in complex genes by heteroduplex analysis with capillary array electrophoresis.
Rare BRCA1 haplotypes including 3'UTR SNPs associated with breast cancer risk.
Rare BRIP1 Missense Alleles Confer Risk for Ovarian and Breast Cancer.
Rare copy number variants observed in hereditary breast cancer cases disrupt genes in estrogen signaling and TP53 tumor suppression network.
Rare germline large rearrangements in the BRCA1/2 genes and eight candidate genes in 472 patients with breast cancer predisposition.
RASSF1A polymorphism A133S is associated with early onset breast cancer in BRCA1/2 mutation carriers.
RASSF1A polymorphism in familial breast cancer.
Rates of BRCA1/2 mutation testing among young survivors of breast cancer.
RBCK1 drives breast cancer cell proliferation by promoting transcription of estrogen receptor alpha and cyclin B1.
RBR-type E3 ubiquitin ligase RNF144A targets PARP1 for ubiquitin-dependent degradation and regulates PARP inhibitor sensitivity in breast cancer cells.
RE: Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
Re: Effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history.
Re: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.
Re: Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers.
Re: Increased Cancer Risks for Relatives of Very Early-Onset Breast Cancer Cases With and Without BRCA1 and BRCA2 Mutations.
Re: Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Re: Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients.
Real-time PCR quantification of full-length and exon 11 spliced BRCA1 transcripts in human breast cancer cell lines.
Reappearance from Obscurity: Mammalian Rad52 in Homologous Recombination.
Recent advances in breast cancer biology.
Recent advances in molecular genetics of breast cancer.
Recent advances in understanding of genetic susceptibility to breast cancer.
Recent developments in critical genes in the molecular biology of breast cancer.
Recent patents on genes and gene sequences useful for developing breast cancer detection systems.
Reclassification of BRCA1 and BRCA2 variants of uncertain significance: a multifactorial analysis of multicentre prospective cohort.
Recognition and management of hereditary breast cancer syndromes.
Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium.
Recommendations for Preventive Care for Women with Rare Genetic Cause of Breast and Ovarian Cancer.
Recreational Physical Activity Is Associated with Reduced Breast Cancer Risk in Adult Women at High Risk for Breast Cancer: A Cohort Study of Women Selected for Familial and Genetic Risk.
Recruitment of black women for a study of inherited breast cancer using a cancer registry-based approach.
Recruitment of phosphorylated NPM1 to sites of DNA damage through RNF8-dependent ubiquitin conjugates.
Recurrent BRCA1 and BRCA2 mutations in breast cancer patients of African ancestry.
Recurrent BRCA1 and BRCA2 Mutations in Mexican Women with Breast Cancer.
Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer.
Recurrent germ-line BRCA1 mutations in extended African American families with early-onset breast cancer.
Recurrent Germline BRCA2 Gene Mutation in Lithuanian Family.
Recurrent mutation testing of BRCA1 and BRCA2 in Asian breast cancer patients identify carriers in those with presumed low risk by family history.
Recurrent mutations of BRCA1 and BRCA2 in Poland: an update.
Reduced association of anti-apoptotic protein Mcl-1 with E3 ligase Mule increases the stability of Mcl-1 in breast cancer cells.
Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia.
Reduced cell death, invasive and angiogenic features conferred by BRCA1-deficiency in mammary epithelial cells transformed with H-Ras.
Reduced ligation during DNA base excision repair supported by BRCA2 mutant cells.
Reducing the risk of breast cancer with tamoxifen in women at increased risk.
Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases.
Reevaluation of RINT1 as a breast cancer predisposition gene.
Referencing BRCA in hereditary cancer risk discussions: In search of an anchor in a sea of uncertainty.
Referral and experience with genetic testing among women with early onset breast cancer.
Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia.
Refining clinical practice: transforming science research into the art of medicine.
Refining the role of BRCA1 in combating oxidative stress.
Regional methylation of the 5' end CpG island of BRCA1 is associated with reduced gene expression in human somatic cells.
Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: a cohort study.
Regulating BRCA1 protein stability by cathepsin S-mediated ubiquitin degradation.
Regulation of BRCA1 and BRCA2 expression in human breast cancer cells by DNA-damaging agents.
Regulation of BRCA1 expression and its relationship to sporadic breast cancer.
Regulation of BRCA1 expression by the Rb-E2F pathway.
Regulation of BRCA1 messenger RNA stability in human epithelial cell lines and during cell cycle progression.
Regulation of BRCA1 transcription by specific single-stranded DNA binding factors.
Regulation of clustered gene expression by cofactor of BRCA1 (COBRA1) in breast cancer cells.
Regulation of CNKSR2 protein stability by the HECT E3 ubiquitin ligase Smurf2, and its role in breast cancer progression.
Regulation of epithelial to mesenchymal transition by BRCA1 in breast cancer.
Regulation of p53 level by UBE4B in breast cancer.
Regulation of progesterone receptor signaling by BRCA1 in mammary cancer.
Regulation of the estrogen-inducible gene expression profile by the breast cancer susceptibility gene BRCA1.
Regulatory aspects of genetic research with residual human tissue: Effective and efficient data coding.
Relationship between Caffeine and Levels of DNA Repair and Oxidative Stress in Women with and without a BRCA1 Mutation.
Relationship Between Hereditary Cancer Syndromes and Oncotype DX Recurrence Score.
Relationship between three novel SNPs of BRCA1 and canine mammary tumors.
Relationship of BRCA1 and BRCA2 mutations with cancer burden in the family and tumor incidence.
Relationship of p215BRCA1 to tyrosine kinase signaling pathways and the cell cycle in normal and transformed cells.
Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families.
Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women.
Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: A national cohort study.
Repetitive demand for radical cancer risk reduction surgery in a young BRCA1 mutation carrier with strong family history of BRCA linked malignancies.
Replication Gaps Underlie BRCA Deficiency and Therapy Response.
Report of Endometrial Cancer in Australian BRCA1 and BRCA2 Mutation-Positive Families.
Repression of mRNA for the PLK cell cycle gene after DNA damage requires BRCA1.
Reproductive factors and breast cancer risk among BRCA1 or BRCA2 mutation carriers: results from ten studies.
Reproductive factors and risk of contralateral breast cancer by BRCA1 and BRCA2 mutation status: results from the WECARE study.
Reproductive factors in hereditary breast cancer.
Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks.
Requirement of heterogeneous nuclear ribonucleoprotein C for BRCA gene expression and homologous recombination.
Response of Estrogen-Receptor-Positive Metastatic Breast Cancer to Olaparib in Late-Line Therapy.
Response to "Male Patients With Breast Cancer: Addressing Needs Using an Educational Task Force".
Response to neo-adjuvant chemotherapy in BRCA1 and BRCA2 related stage III breast cancer.
Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers.
Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience.
Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations.
Response to: The GPRC5A frameshift variant c.183del is not associated with increased breast cancer risk in BRCA1 mutation carriers.
Restriction endonuclease fingerprinting enhanced conformation sensitive gel electrophoresis (REF-CSGE) in the analysis of BRCA1 exon 11 mutations in a high-risk breast cancer cohort.
Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer.
Resveratrol Ameliorates Cardiac Hypertrophy by Down-regulation of miR-155 Through Activation of Breast Cancer Type 1 Susceptibility Protein.
Resveratrol increases BRCA1 and BRCA2 mRNA expression in breast tumour cell lines.
Resveratrol modulates epigenetic regulators of promoter histone methylation and acetylation that restores BRCA1, p53, p21CIP1 in human breast cancer cell lines.
Retinoblastoma susceptibility protein, Rb, possesses multiple BRCT-Ws, BRCA1 carboxyl-terminus-related W regions with DNA break-binding activity.
Retinoic acid protects human breast cancer cells against etoposide-induced apoptosis by NF-kappaB-dependent but cIAP2-independent mechanisms.
Revisiting breast cancer patients who previously tested negative for BRCA mutations using a 12-gene panel.
RING finger nuclear factor RNF168 is important for defects in homologous recombination caused by loss of the breast cancer susceptibility factor BRCA1.
RING finger protein 31 promotes p53 degradation in breast cancer cells.
Risk assessment for hereditary breast cancer: BRCA1 and BRCA2.
Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Risk estimation as a decision-making tool for genetic analysis of the breast cancer susceptibility genes. EC Demonstration Project on Familial Breast Cancer.
Risk factors and risk reduction of breast and ovarian cancer.
Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation.
Risk factors for detecting germline BRCA1 and BRCA2 founder mutations in Ashkenazi Jewish women with breast or ovarian cancer.
Risk factors for ovarian cancer and early-onset breast cancer in Mongolia.
Risk for breast cancer and management of unaffected individuals with non-BRCA hereditary breast cancer.
Risk models for familial ovarian and breast cancer.
Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women's Environmental Cancer and Radiation Epidemiology Study.
Risk of Breast Cancer in Women With a CHEK2 Mutation With and Without a Family History of Breast Cancer.
Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.
Risk of cancer in BRCA1 and BRCA2 mutation-positive and -negative breast cancer families (Finland).
Risk of colorectal cancer associated with BRCA1 and/or BRCA2 mutation carriers: systematic review and meta-analysis.
Risk of contralateral breast cancer associated with common variants in BRCA1 and BRCA2: potential modifying effect of BRCA1/BRCA2 mutation carrier status.
Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis.
Risk of Contralateral Breast Cancer in Women with and without Pathogenic Variants in BRCA1, BRCA2, and TP53 Genes in Women with Very Early-Onset (<36 Years) Breast Cancer.
Risk of Having BRCA1 Mutation in High-Risk Women with Triple-Negative Breast Cancer: A Meta-Analysis.
Risk of Ipsilateral and Contralateral Cancer in BRCA Mutation Carriers with Breast Cancer.
Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers.
Risk of ipsilateral breast tumor recurrence in primary invasive breast cancer following breast-conserving surgery with BRCA1 and BRCA2 mutation in China.
Risk of Late-Onset Breast Cancer in Genetically Predisposed Women.
Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families.
Risk of ovarian cancer in breast-cancer patients with a family history of breast or ovarian cancer: a population-based cohort study.
Risk prediction models for familial breast cancer.
Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers.
Risk-reducing appendectomy and the elimination of BRCA1-associated intraperitoneal cancer.
Risk-Reducing Bilateral Salpingo-Oophorectomy for BRCA Mutation Carriers and Hormonal Replacement Therapy: If It Should Rain, Better a Drizzle than a Storm.
Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
Risk-reducing mastectomy.
Risk-Reducing Oophorectomy and Breast Cancer Risk Across the Spectrum of Familial Risk.
Risk-reducing salpingo-oophorectomy and breast cancer incidence among Jewish BRCA1/BRCA2-mutation carriers-an Israeli matched-pair study.
Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199).
Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers.
Risk-reducing surgery increases survival in BRCA1/2 mutation carriers unaffected at time of family referral.
Risks and Function of Breast Cancer Susceptibility Alleles.
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
RNA analysis of eight BRCA1 and BRCA2 unclassified variants identified in breast/ovarian cancer families from Spain.
RNA structure analysis assisted by capillary electrophoresis.
RNF115/BCA2 E3 Ubiquitin Ligase Promotes Breast Cancer Cell Proliferation through Targeting p21(Waf1/Cip1) for Ubiquitin-Mediated Degradation.
RNF144A functions as a tumor suppressor in breast cancer through ubiquitin ligase activity-dependent regulation of stability and oncogenic functions of HSPA2.
RNF20 and histone H2B ubiquitylation exert opposing effects in Basal-Like versus luminal breast cancer.
RNF20 Is Critical for Snail-Mediated E-Cadherin Repression in Human Breast Cancer.
RNF4-dependent hybrid SUMO-ubiquitin chains are signals for RAP80 and thereby mediate the recruitment of BRCA1 to sites of DNA damage.
RNF8 Promotes Epithelial-Mesenchymal Transition in Lung Cancer Cells via Stabilization of Slug.
RNF8-dependent histone ubiquitination during DNA damage response and spermatogenesis.
Role for ATM in DNA damage-induced phosphorylation of BRCA1.
Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1.
Role of BRCA1 in Neuronal Death in Alzheimer's Disease.
Role of BRCA1, HSD17B1 and HSD17B2 methylation in breast cancer tissue.
Role of BRCA2 mutation status on overall survival among breast cancer patients from Sardinia.
Role of Breast Surgery in BRCA Mutation Carriers.
Role of calcium sensing receptor (CaSR) in tumorigenesis.
Role of direct interaction in BRCA1 inhibition of estrogen receptor activity.
Role of IFI16 in DNA damage and checkpoint.
Role of single nucleotide polymorphisms and haplotypes in BRCA1 in breast cancer: Czech case-control study.
Role of steroid hormones and growth factors in breast cancer.
Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation.
Roscovitine and Trichostatin A promote DNA damage repair during porcine oocyte maturation.
rs15869 at miRNA binding site in BRCA2 is associated with breast cancer susceptibility.
Rtt107/Esc4 binds silent chromatin and DNA repair proteins using different BRCT motifs.
S100A2 is a BRCA1/p63 coregulated tumour suppressor gene with roles in the regulation of mutant p53 stability.
Salivary Gland Function, Antioxidant Defence and Oxidative Damage in the Saliva of Patients with Breast Cancer: Does the BRCA1 Mutation Disturb the Salivary Redox Profile?
Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma.
Scanning for clues to better use selective estrogen receptor modulators.
SCF(JFK) is a bona fide E3 ligase for ING4 and a potent promoter of the angiogenesis and metastasis of breast cancer.
Score tests for familial correlation in genotyped-proband designs.
Screening and clinical implications for BRCA1 and BRCA2 mutation carriers.
Screening and follow-up of the patient at high risk for breast cancer.
Screening behaviors among African American women at high risk for breast cancer: do beliefs about god matter?
Screening BRCA1 and BRCA2 Mutation Carriers for Breast Cancer.
Screening for ATM sequence alterations in African-American women diagnosed with breast cancer.
Screening for BRCA1 and BRCA2 mutations among French-Canadian breast cancer cases attending an outpatient clinic in Montreal.
Screening for BRCA1 and BRCA2 mutations in breast cancer patients from Mexico: the public health perspective.
Screening for BRCA1 and BRCA2 mutations in Eastern Finnish breast/ovarian cancer families.
Screening for BRCA1 large genomic rearrangements in female Egyptian hereditary breast cancer patients.
Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Screening for BRCA2 mutations in 81 Dutch breast-ovarian cancer families.
Screening for breast cancer by molecular testing for three founder mutations in the BRCA1 and BRCA2 genes among women of Ashkenazi Jewish heritage.
Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement.
Screening for colorectal cancer using the faecal occult blood test, hemoccult.
Screening for Del 185 AG and 4627C>A BRCA1 Mutations in Breast Cancer Patients from Lahore, Pakistan.
Screening for genetic risk of breast cancer.
Screening for genomic rearrangements at BRCA1 locus in Iranian women with breast cancer using multiplex ligation-dependent probe amplification.
Screening for germ-line rearrangements and regulatory mutations in BRCA1 led to the identification of four new deletions.
Screening for germline BRCA1, BRCA2, TP53 and CHEK2 mutations in families at-risk for hereditary breast cancer identified in a population-based study from Southern Brazil.
Screening for large genomic rearrangements of the BRIP1 and CHK1 genes in Finnish breast cancer families.
Screening for mutations in exon 11 of the BRCA1 gene in 70 Italian breast and ovarian cancer patients by protein truncation test.
Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study.
Screening of 185DelAG, 1014DelGT and 3889DelAG BRCA1 mutations in breast cancer patients from North-East India.
Screening of BRCA1 variants c.190T>C, 1307delT, g.5331G>A and c.2612C>T in breast cancer patients from North India.
Screening of exon 11 of BRCA1 gene using the high resolution melting approach for diagnosis in Moroccan breast cancer patients.
Screening of over 1000 Indian patients with breast and/or ovarian cancer with a multi-gene panel: prevalence of BRCA1/2 and non-BRCA mutations.
Screening of women at high risk for breast cancer.
Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS).
Screening, diagnosis and genetic study of breast cancer patients in Pakistan.
Search for large genomic alterations of the BRCA1 gene in a Finnish population.
Searching for genetic determinants of human aging and longevity: opportunities and challenges.
Searching for large genomic rearrangements of the BRCA1 gene in a Nigerian population.
Second primary breast cancer in BRCA1 and BRCA2 mutation carriers: 10-year cumulative incidence in the Breast Cancer Family Registry.
Secondary Angiosarcoma With C-MYC Amplification Following Prophylactic Bilateral Mastectomy and Autologous Breast Reconstruction: Report of a Case and Review of the Literature.
Secretome proteomics reveals candidate non-invasive biomarkers of BRCA1 deficiency in breast cancer.
Segregation analysis of 231 Ashkenazi Jewish families for evidence of additional breast cancer susceptibility genes.
Selected Aspects of Molecular Diagnostics of Constitutional Alterations in BRCA1 and BRCA2 Genes Associated with Increased Risk of Breast Cancer in the Polish Population.
Selected medical interventions in women with a deleterious BRCA mutation: a population-based study in British Columbia.
Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention.
Selective immobilization of DNA and antibody probes on electrode arrays: simultaneous electrochemical detection of DNA and protein on a single platform.
Selective loss of heterozygosity in multiple breast cancers from a carrier of mutations in both BRCA1 and BRCA2.
Selective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells.
Selective nanopore sequencing of human BRCA1 by Cas9-assisted targeting of chromosome segments (CATCH).
Selective progesterone receptor blockade prevents BRCA1-associated mouse mammary tumors through modulation of epithelial and stromal genes.
Selenium and GPx-1 overexpression protect mammalian cells against UV-induced DNA damage.
Selenium Supplementation Reduced Oxidative DNA Damage in Adnexectomized BRCA1 Mutations Carriers.
Selenomethionine protects hematopoietic stem/progenitor cells against cobalt nanoparticles by stimulating antioxidant actions and DNA repair functions.
Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor activity of olaparib in triple negative breast cancer regardless of BRCA1 mutation status.
Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.
Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk.
Sequencing-based breast cancer diagnostics as an alternative to routine biomarkers.
Seventeen years after BRCA1: what is the BRCA mutation status of the breast cancer patients in Africa? - a systematic review.
Sex hormone-binding globulin polymorphisms in familial and sporadic breast cancer.
Shorter telomere length is associated with increased ovarian cancer risk in both familial and sporadic cases.
Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy?
Should the use of contralateral prophylactic mastectomy be increasing as it is?
Should Tumor Infiltrating Lymphocytes, Androgen Receptor, and FOXA1 Expression Predict the Clinical Outcome in Triple Negative Breast Cancer Patients?
Should we screen BRCA1 mutation carriers only with MRI? A multicenter study.
Significance of BRCA1 expression in breast and ovarian cancer patients with brain metastasis - A multicentre study.
Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico.
Significant contribution of germline BRCA2 rearrangements in male breast cancer families.
Significantly lower rates of BRCA1/BRCA2 founder mutations in Ashkenazi women with sporadic compared with familial early onset breast cancer.
Similar contributions of BRCA1 and BRCA2 germline mutations to early-onset breast cancer in Germany.
Similar prevalence of founder BRCA1 and BRCA2 mutations among Ashkenazi and non-Ashkenazi men with breast cancer: Evidence from 261 cases in Israel, 1976-1999.
Simultaneous ATM/BRCA1/RAD51 expression variations associated with prognostic factors in Iranian sporadic breast cancer patients.
Single nucleotide polymorphisms in miRNA binding sites and miRNA genes as breast/ovarian cancer risk modifiers in Jewish high-risk women.
Single-Cell RNA Sequencing Reveals the Cellular Origin and Evolution of Breast Cancer in BRCA1 Mutation Carriers.
Single-nucleotide polymorphism genotyping by nanoparticle-enhanced surface plasmon resonance imaging measurements of surface ligation reactions.
Single-port versus conventional multiport access prophylactic laparoscopic bilateral salpingo-oophorectomy in high-risk patients for ovarian cancer: a comparison of surgical outcomes.
Single-strand conformation polymorphism analysis by capillary and microchip electrophoresis: a fast, simple method for detection of common mutations in BRCA1 and BRCA2.
SIRT5 as a biomarker for response to anthracycline-taxane-based neoadjuvant chemotherapy in triple-negative breast cancer.
Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Skp2 is a promising therapeutic target in breast cancer.
Smad ubiquitination regulatory factor 2 promotes metastasis of breast cancer cells by enhancing migration and invasiveness.
Small GTPase Rho regulates R-cadherin through Dia1/profilin-1.
Smoking and physical inactivity increase cancer prevalence in BRCA-1 and BRCA-2 mutation carriers: results from a retrospective observational analysis.
Smoking and risk of breast cancer in carriers of mutations in BRCA1 or BRCA2 aged less than 50 years.
Smoking and the risk of breast cancer among carriers of BRCA mutations.
Smoking and the risk of breast cancer in BRCA1 and BRCA2 carriers: an update.
Smurf2 E3 ubiquitin ligase modulates proliferation and invasiveness of breast cancer cells in a CNKSR2 dependent manner.
SNP Set Association Testing for Survival Outcomes in the Presence of Intrafamilial Correlation.
SNP-SNP interactions in breast cancer susceptibility.
SNPs near the cysteine proteinase cathepsin O gene (CTSO) determine tamoxifen sensitivity in ER?-positive breast cancer through regulation of BRCA1.
Society of gynecologic oncologists education committee statement on risk assessment for inherited gynecologic cancer predispositions.
Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions.
Sociocultural predictors of breast cancer risk perceptions in African American breast cancer survivors.
Somatic BRCA1 mutations in clinically sporadic breast cancer with medullary histological features.
Somatic BRCA1-associated protein 1 (BAP1) loss is an early and rare event in esophageal adenocarcinoma.
Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus.
Somatic genetic alterations in BRCA2-associated and sporadic male breast cancer.
Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer.
Somatic mutations in the BRCA1 gene in Chinese sporadic breast and ovarian cancer.
Somatic mutations in the BRCA1 gene in Chinese women with sporadic breast cancer.
Some public health issues in the current state of genetic testing for breast cancer in Australia.
Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer.
Soya phytonutrients act on a panel of genes implicated with BRCA1 and BRCA2 oncosuppressors in human breast cell lines.
Specific binding of the methyl binding domain protein 2 at the BRCA1-NBR2 locus.
Specific BRCA1 gene variations amongst young Moroccan breast cancer patients.
Specific changes in the proteomic pattern produced by the BRCA1-Ser1841Asn missense mutation.
Specific H-Ras minisatellite alleles in breast cancer susceptibility.
Spectra of BRCA1 and BRCA2 mutations in Korean patients with breast cancer: the importance of whole-gene sequencing.
Spectrum and frequencies of BRCA1/2 mutations in Bulgarian high risk breast cancer patients.
Spectrum and prevalence of BRCA1 and BRCA2 germline mutations in Sardinian patients with breast carcinoma through hospital-based screening.
Spectrum of breast cancer metastasis in BRCA1 mutation carriers: highly increased incidence of brain metastases.
Spectrum of Germline BRCA1 and BRCA2 Variants Identified in 2351 Ovarian and Breast Cancer Patients Referring to a Reference Cancer Hospital of Rome.
Spectrum of mutations in BRCA1 gene in hereditary forms of breast and ovarian cancer in Russian families.
Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
Spiritual faith and genetic testing decisions among high-risk breast cancer probands.
Splicing and multifactorial analysis of intronic BRCA1 and BRCA2 sequence variants identifies clinically significant splicing aberrations up to 12 nucleotides from the intron/exon boundary.
Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers.
Sporadic and Hereditary Breast Cancer Genetics.
Sporadic breast cancer in young women: prevalence of loss of heterozygosity at p53, BRCA1 and BRCA2.
Sporadic breast carcinomas with somatic BRCA1 gene deletions share genotype/phenotype features with familial breast carcinomas.
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.
Stage of breast cancers found during the surveillance of women with a familial or hereditary risk.
Standardization of a sample preparation and analytical workflow for proteomics of archival endometrial cancer tissue.
Standardization of the methylation?specific PCR method for analyzing BRCA1 and ER methylation.
State Institution "National Research Center for Radiation Medicine of the National Academy of Medical Sciences of Ukraine" - research activities and scientific advance in 2013.
Staurosporine-sensitive protein phosphorylation is required for postreplication DNA repair in human cells.
Stem cell therapy for hereditary breast cancer.
Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes.
Strategies for recruitment of relatives of BRCA mutation carriers to a genetic testing program in the Bahamas.
Strong feature sets from small samples.
Strong founder effects in BRCA1 mutation carrier breast cancer patients from Latvia. Mutation in brief no. 258. Online.
Structural analysis of BRCA1 reveals modification hotspot.
Structural basis for regulation of human acetyl-CoA carboxylase.
Structure meets function--centrosomes, genome maintenance and the DNA damage response.
Structure of an XRCC1 BRCT domain: a new protein-protein interaction module.
Structure-based assessment of BRCA1 and BRCA2 mutations in a small Spanish population.
Studies on the methylation status of CpG sequences located in promoters of selected tumour suppressor genes in breast cancer cells.
Study design: evaluating gene-environment interactions in the etiology of breast cancer - the WECARE study.
Study of BRCA1 gene in hereditary breast and ovarian cancer.
Study protocol: a cluster randomized controlled trial of web-based decision support tools for increasing BRCA1/2 genetic counseling referral in primary care.
Studying Therapy Response and Resistance in Mouse Models for BRCA1-Deficient Breast Cancer.
Subcellular localization and analysis of apparent 180-kDa and 220-kDa proteins of the breast cancer susceptibility gene, BRCA1.
Subcellular localization of BRCA1 protein in sporadic breast carcinoma with or without allelic loss of BRCA1 gene.
Subcellular localization of the BRCA1 gene product in mitotic cells.
Sublocalization of smallest common regions of deletion on chromosome 17q12-q23 in sporadic primary breast-tumors.
Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis.
Substitution of aspartic acid with glutamic acid at position 67 of the BRCA1 RING domain retains ubiquitin ligase activity and zinc(II) binding with a reduced transition temperature.
Subtypes of familial breast tumours revealed by expression and copy number profiling.
SUMO E3 ligase CBX4 regulates hTERT-mediated transcription of CDH1 and promotes breast cancer cell migration and invasion.
SUMOylation proteins in breast cancer.
Suppression and recovery of BRCA1-mediated transcription by HP1? via modulation of promoter occupancy.
Suppression of BRCA1 sensitizes cells to proteasome inhibitors.
Suppression of breast cancer invasion and migration by indole-3-carbinol: associated with up-regulation of BRCA1 and E-cadherin/catenin complexes.
Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors.
Suppression of malignant phenotype in a human prostate cancer cell line by fragments of normal chromosomal region 17q.
Suppression of tumorigenicity of breast cancer cells by transfer of human chromosome 17 does not require transferred BRCA1 and p53 genes.
Surface plasmon resonance biosensor for label-free and highly sensitive detection of point mutation using polymerization extension reaction.
Surgical and Systemic Treatment of Hereditary Breast Cancer: A Mini-Review With a Focus on BRCA1 and BRCA2 Mutations.
Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.
Surveillance of women at increased risk of breast cancer using mammography and clinical breast examination: Further evidence of benefit.
Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers.
Survival and tumor characteristics of German hereditary breast cancer patients.
Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1.
Survival benefit in women with BRCA1 mutation or familial risk in the MRI screening study (MRISC).
Survival in early-onset BRCA1 breast-cancer patients. Institut Curie Breast Cancer Group.
Survival in hereditary breast cancer associated with germline mutations of BRCA2.
Survival in Norwegian BRCA1 mutation carriers with breast cancer.
Survival in prospectively ascertained familial breast cancer: analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy.
Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden.
Survival of breast cancer patients in BRCA1, BRCA2, and non-BRCA1/2 breast cancer families: a relative survival analysis from Finland.
Survival of patients with BRCA1-associated breast cancer diagnosed in an MRI-based surveillance program.
Survival of patients with breast cancer and BRCA1 mutations.
Susceptibility to breast cancer: hereditary syndromes and low penetrance genes.
SYK expression level distinguishes control from BRCA1-mutated lymphocytes.
Synaptonemal Complex Protein 3 Transcript Analysis in Breast Cancer.
Synchronous ovarian dysgerminoma and breast carcinoma in a patient with positive immunostain of BRCA1.
Synergistic anticancer action of quercetin and curcumin against triple-negative breast cancer cell lines.
Synergistic Effect of Trabectedin and Olaparib Combination Regimen in Breast Cancer Cell Lines.
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors.
Synthetically Lethal BMN 673 (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 Mutant Triple Negative Breast Cancer.
Systematic review of the empirical investigation of resources to support decision-making regarding BRCA1 and BRCA2 genetic testing in women with breast cancer.
Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer.
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
Talazoparib Loaded Solid Lipid Nanoparticles: Preparation, Characterization and Evaluation the Therapeutic Efficacy In Vitro.
Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.
Tamoxifen and breast cancer risk in women harboring a BRCA1 germline mutation: computed efficacy, effectiveness and impact.
Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update.
Tamoxifen and risk of contralateral breast cancer among women with inherited mutations in BRCA1 and BRCA2: a meta-analysis.
Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group.
Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers.
Tamoxifen as chemoprevention in BRCA1 and BRCA2 mutation carriers with breast cancer: a pilot survey of physicians.
Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1.
Targeted deep sequencing revealed variants in cell-free DNA of hormone receptor-positive metastatic breast cancer patients.
Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos.
Targeted Next-generation Sequencing for Reliable Detection of Genetic Status in Breast Cancer.
Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic.
Targeted sequencing of crucial cancer causing genes of breast cancer in Saudi patients.
Targeted sequencing to discover germline variants in the BRCA1 and BRCA2 genes in a Russian population and their association with breast cancer risk.
Targeted Vaccination against Human ?-Lactalbumin for Immunotherapy and Primary Immunoprevention of Triple Negative Breast Cancer.
Targeting beta-transducin repeat-containing protein E3 ubiquitin ligase augments the effects of antitumor drugs on breast cancer cells.
Targeting BRCA1 localization to augment breast tumor sensitivity to poly(ADP-ribose) polymerase inhibition.
Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitors.
Targeting DNA damage and repair by curcumin.
Targeting DNA repair in breast cancer: A clinical and translational update.
Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer.
Targeting of DNA Damage Signaling Pathway Induced Senescence and Reduced Migration of Cancer cells.
Targeting the Akt/mTOR pathway in Brca1-deficient cancers.
Targeting the BRCA1/2 tumor suppressors.
Targeting the epigenetics of the DNA damage response in breast cancer.
Targeting the FANCJ-BRCA1 interaction promotes a switch from recombination to poleta-dependent bypass.
Targeting the oncogenic E3 ligase Skp2 in prostate and breast cancer cells with a novel energy restriction-mimetic agent.
Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON.
TAT-ODD-p53 enhances the radiosensitivity of hypoxic breast cancer cells by inhibiting Parkin-mediated mitophagy.
Tbx2 is overexpressed and plays an important role in maintaining proliferation and suppression of senescence in melanomas.
TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumors.
Teaching efficacy of a medical education module on genetic testing for cancer.
Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer.
Ten genes for inherited breast cancer.
Ten-Year Survival in Patients With BRCA1-Negative and BRCA1-Positive Breast Cancer.
Testing Ashkenazi Jewish Women for Mutations Predisposing to Breast Cancer in Genes Other Than BRCA1 and BRCA2-Reply.
Testing Ashkenazi Jewish Women for Mutations Predisposing to Breast Cancer in Genes Other Than BRCA1 and BRCA2.
Testing for BRCA1 in hereditary breast cancer.
Testing for BRCA1 mutations: a cost-effectiveness analysis.
Testing for hereditary breast and ovarian cancer in the southeastern United States.
Testing for inherited susceptibility to breast cancer: a survey of informed consent forms for BRCA1 and BRCA2 mutation testing.
Testing for the breast cancer predisposition gene, BRCA1.
TGF? induces "BRCAness" and sensitivity to PARP inhibition in breast cancer by regulating DNA-repair genes.
TGFBR1 Signaling and Breast Cancer.
Thai patients who fulfilled NCCN criteria for breast/ovarian cancer genetic assessment demonstrated high prevalence of germline mutations in cancer susceptibility genes: implication to Asian population testing.
The 12 base pair duplication/insertion alteration could be a regulatory mutation.
The 3' untranslated region C > T polymorphism of prohibitin is a breast cancer risk modifier in Polish women carrying a BRCA1 mutation.
The accumulation of specific amplifications characterizes two different genomic pathways of evolution of familial breast tumors.
The AIB1 glutamine repeat polymorphism is not associated with risk of breast cancer before age 40 years in Australian women.
The AIB1 polyglutamine repeat does not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers.
The analysis of BRCA1 mutations in eastern Chinese patients with early onset breast cancer and affected relatives.
The androgen receptor CAG repeat polymorphism and modification of breast cancer risk in BRCA1 and BRCA2 mutation carriers.
The androgen receptor CAG repeat: a modifier of carcinogenesis?
The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services.
The anti-proliferative effects of 1alpha,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression.
The antiestrogenic effects of black cohosh on BRCA1 and steroid receptors in breast cancer cells.
The antitumorigenic roles of BRCA1-BARD1 in DNA repair and replication.
The association between the methylation frequency of BRCA1/2 gene promoter and occurrence and prognosis of breast carcinoma: A meta-analysis.
The ATM gene and breast cancer: is it really a risk factor?
The atypical ubiquitin ligase RNF31 stabilizes estrogen receptor ? and modulates estrogen-stimulated breast cancer cell proliferation.
The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
The BARD1 Cys557Ser variant and risk of familial breast cancer in a South-American population.
The basal phenotype of BRCA1-related breast cancer: past, present and future.
The basal-like mammary carcinomas induced by Brca1 or Bard1 inactivation implicate the BRCA1/BARD1 heterodimer in tumor suppression.
The BOADICEA model of genetic susceptibility to breast and ovarian cancer.
The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions.
The BRCA1 and BRCA2 breast cancer genes.
The BRCA1 and BRCA2 Genes in Early-Onset Breast Cancer Patients.
The Brca1 and Brca2 proteins and tumor pathogenesis.
The BRCA1 Breast Cancer Suppressor: Regulation of Transport, Dynamics, and Function at Multiple Subcellular Locations.
The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium.
The BRCA1 E3 Ubiquitin Ligase Controls Centrosome Dynamics.
The BRCA1 Pseudogene Negatively Regulates Antitumor Responses through Inhibition of Innate Immune Defense Mechanisms.
The BRCA1 RING and BRCT domains cooperate in targeting BRCA1 to ionizing radiation-induced nuclear foci.
The BRCA1 Variant p.Ser36Tyr Abrogates BRCA1 Protein Function and Potentially Confers a Moderate Risk of Breast Cancer.
The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations.
The BRCA1-dependent ubiquitin ligase, gamma-tubulin, and centrosomes.
The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia.
The BRCA1/BARD1-interacting protein OLA1 functions in centrosome regulation.
The BRCA1/BRCA2/Rad51 complex is a prognostic and predictive factor in early breast cancer.
The BRCA2 372 HH genotype is associated with risk of breast cancer in Australian women under age 60 years.
The BRCA2 c.9004G>A (E2003K) variant is likely pathogenic and recurs in breast and/or ovarian cancer families of French Canadian descent.
The breast cancer low-penetrance allele 1100delC in the CHEK2 gene is not present in Spanish familial breast cancer population.
The breast cancer susceptibility allele CHEK2*1100delC promotes genomic instability in a knock-in mouse model.
The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin.
The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells.
The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers.
The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype.
The breast surgeon's role in BRCA1 and BRCA2 testing.
The cancer genetics and pathology of male breast cancer.
The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals.
The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%.
The CASP8 rs3834129 polymorphism and breast cancer risk in BRCA1 mutation carriers.
The CD44+/CD24- phenotype is enriched in basal-like breast tumors.
The Cell of Origin of BRCA1 Mutation-associated Breast Cancer: A Cautionary Tale of Gene Expression Profiling.
The CHEK2 1100delC mutation is not present in Korean patients with breast cancer cases tested for BRCA1 and BRCA2 mutation.
The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families.
The Chinese hamster FANCG/XRCC9 mutant NM3 fails to express the monoubiquitinated form of the FANCD2 protein, is hypersensitive to a range of DNA damaging agents and exhibits a normal level of spontaneous sister chromatid exchange.
The Clinical and Pathological Profile of BRCA1 Gene Methylated Breast Cancer Women: A Meta-Analysis.
The Clinical Value and Interpretation of Anti-Müllerian Hormone in Women With Cancer.
The complex genetic landscape of familial breast cancer.
The complex relationship between BRCA1 and ERalpha in hereditary breast cancer.
The contribution of breast cancer pathology to statistical models to predict mutation risk in BRCA carriers.
The contribution of founder mutations in BRCA1 to breast cancer in Belarus.
The contribution of founder mutations to early-onset breast cancer in French-Canadian women.
The contribution of germline predisposition gene mutations to clinical subtypes of invasive breast cancer from a clinical genetic testing cohort.
The contribution of inherited factors to the clinicopathological features and behavior of breast cancer.
The contribution of large genomic rearrangements in BRCA1 and BRCA2 to South African familial breast cancer.
The correlations between BRCA1 defect and environmental factors in the risk of breast cancer.
The cost-utility of magnetic resonance imaging for breast cancer in BRCA1 mutation carriers aged 30-49.
The CYP17A1 -34T > C polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers.
The CYP1A2 genotype modifies the association between coffee consumption and breast cancer risk among BRCA1 mutation carriers.
The DeltaNp63 proteins are key allies of BRCA1 in the prevention of basal-like breast cancer.
The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer.
The DNA double-strand break response pathway: becoming more BRCAish than ever.
The DNA resection protein CtIP promotes mammary tumorigenesis.
The downregulation of BAP1 expression by BCR-ABL reduces the stability of BRCA1 in chronic myeloid leukemia.
The E3 ubiquitin ligase Cbl-b improves the prognosis of RANK positive breast cancer patients by inhibiting RANKL-induced cell migration and metastasis.
The E3 ubiquitin ligase Cbl-b inhibits tumor growth in multidrug-resistant gastric and breast cancer cells.
The E3 Ubiquitin Ligase Cbl-b Predicts Favorable Prognosis in Breast Cancer.
The ectopic expression of BRCA1 is associated with genesis, progression, and prognosis of breast cancer in young patients.
The effect of oral 3,3'-diindolylmethane supplementation on the 2:16?-OHE ratio in BRCA1 mutation carriers.
The effectiveness of cucurbitacin B in BRCA1 defective breast cancer cells.
The effects of BRCA1 expression on the chemosensitivity of gastric cancer cells to platinum agents.
The effects of BRCA1 missense variants V1804D and M1628T on transcriptional activity.
The effects of lycopene on the proliferation of human breast cells and BRCA1 and BRCA2 gene expression.
The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.
The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation.
The endonuclease EEPD1 mediates synthetic lethality in RAD52-depleted BRCA1 mutant breast cancer cells.
The EphB6 receptor cooperates with c-Cbl to regulate the behavior of breast cancer cells.
The Evolution, Functions and Applications of the Breast Cancer Genes BRCA1 and BRCA2.
The expected benefit of preventive mastectomy on breast cancer incidence and mortality in BRCA mutation carriers, by age at mastectomy.
The Expression of ERCC1, RRM1, and BRCA1 in Breast Cancer According to the Immunohistochemical Phenotypes.
The F-box protein FBXO44 mediates BRCA1 ubiquitination and degradation.
The FANCJ/MutLalpha interaction is required for correction of the cross-link response in FA-J cells.
The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer.
The Fanconi anaemia/BRCA pathway and cancer susceptibility. Searching for new therapeutic targets.
The Fanconi anemia family of genes and its correlation with breast cancer susceptibility and breast cancer features.
The FBXW2-MSX2-SOX2 axis regulates stem cell property and drug resistance of cancer cells.
The first case report of a large deletion of the BRCA1 gene in Croatia: A case report.
The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women.
The founder mutations in the BRCA1, BRCA2, and ATM genes in Moroccan Jewish women with breast cancer.
The fragile histidine triad/common chromosome fragile site 3B locus and repair-deficient cancers.
The frequency and outcome of breast cancer risk-reducing surgery in finnish BRCA1 and BRCA2 mutation carriers.
The frequency of BRCA1 founder mutation c.5266dupC (5382insC) in breast cancer patients from Ukraine.
The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators.
The Function of BARD1 in Centrosome Regulation in Cooperation with BRCA1/OLA1/RACK1.
The functions of breast cancer susceptibility gene 1 (BRCA1) product and its associated proteins.
The future of breast cancer systemic therapy: the next 10 years.
The Genetic Analyses of French Canadians of Quebec Facilitate the Characterization of New Cancer Predisposing Genes Implicated in Hereditary Breast and/or Ovarian Cancer Syndrome Families.
The genetic basis of breast cancer and its clinical implications.
The genetic components of susceptibility to breast cancer in the rat.
The genetic epidemiology of BRCA1. Breast Cancer Linkage Consortium.
The genetics of breast and ovarian cancer.
The genetics of breast cancer susceptibility.
The genetics of breast cancer: risk factors for disease.
THe genetics of familial breast cancer.
The genetics of inherited breast cancer.
The GPRC5A frameshift variant c.183del is not associated with increased breast cancer risk in BRCA1 mutation carriers.
The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study.
The HLA class III subregion is responsible for an increased breast cancer risk.
The impact of a prevention effort on the community.
The impact of contralateral mastectomy on mortality in BRCA1 and BRCA2 mutation carriers with breast cancer.
The impact of oophorectomy on survival after breast cancer in BRCA1-positive breast cancer patients.
The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation.
The importance of analysis of long-range rearrangement of BRCA1 and BRCA2 in genetic diagnosis of familial breast cancer.
The importance of BRCA1 and BRCA2 genes mutations in breast cancer development.
The incidence of cardiomyopathy in BRCA1 and BRCA2 mutation carriers after anthracycline-based adjuvant chemotherapy.
The influence of familial and hereditary factors on the prognosis of breast cancer.
The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations.
The influence of psychological distress on use of genetic testing for cancer risk.
The influence of reproductive factors on breast cancer risk in women with pathogenic mutations.
The Inhibition and Treatment of Breast Cancer with Poly (ADP-ribose) Polymerase (PARP-1) Inhibitors.
The Interaction of CtIP and Nbs1 Connects CDK and ATM to Regulate HR-Mediated Double-Strand Break Repair.
The interaction of PP1 with BRCA1 and analysis of their expression in breast tumors.
The intronic G13964C variant in p53 is not a high-risk mutation in familial breast cancer in Australia.
The joint effect of smoking and AIB1 on breast cancer risk in BRCA1 mutation carriers.
The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers.
The Leu33Pro polymorphism in the ITGB3 gene does not modify BRCA1/2-associated breast or ovarian cancer risks: results from a multicenter study among 15,542 BRCA1 and BRCA2 mutation carriers.
The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
The LIM domain protein LMO4 interacts with the cofactor CtIP and the tumor suppressor BRCA1 and inhibits BRCA1 activity.
The majority of 22 Dutch high-risk breast cancer families are due to either BRCA1 or BRCA2.
The mammary gland carcinogens: the role of metal compounds and organic solvents.
The management of familial breast cancer.
The Mcs7 quantitative trait locus is associated with an increased susceptibility to mammary cancer in congenic rats and an allele-specific imbalance.
The methyltransferase EZH2 is not required for mammary cancer development, although high EZH2 and low H3K27me3 correlate with poor prognosis of ER-positive breast cancers.
The miR-106b-25 cluster mediates breast tumor initiation through activation of NOTCH1 via direct repression of NEDD4L.
The molecular basis of radiosensitivity and chemosensitivity in the treatment of breast cancer.
The molecular genetics of breast cancer and targeted therapy.
The molecular pathology of hereditary breast cancer.
The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications.
The molecular significance of methylated BRCA1 promoter in white blood cells of cancer-free females.
The Novel Ribonucleotide Reductase Inhibitor COH29 Inhibits DNA Repair In Vitro.
The nuclear localization sequences of the BRCA1 protein interact with the importin-alpha subunit of the nuclear transport signal receptor.
The ordering of expression among a few genes can provide simple cancer biomarkers and signal BRCA1 mutations.
The other side of the coin: dissecting molecular mechanisms behind hereditary breast cancer in search of therapeutic opportunities.
The p21-dependent radiosensitization of human breast cancer cells by MLN4924, an investigational inhibitor of NEDD8 activating enzyme.
The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells.
The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation.
The pathology of familial breast cancer: Clinical and genetic counselling implications of breast cancer pathology.
The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2.
The pathology of familial breast cancer: How do the functions of BRCA1 and BRCA2 relate to breast tumour pathology?
The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.
The pathology of familial breast cancer: The pre-BRCA1/BRCA2 era: historical perspectives.
The pathology of hereditary breast cancer.
The pathology of inherited breast cancer.
The PIAS3-Smurf2 sumoylation pathway suppresses breast cancer organoid invasiveness.
The Pink Underside: The Commercialization of Medical Risk Assessment and Decision-Making Tools for Hereditary Breast Cancer Risk.
The Polycomb group protein RING1B is overexpressed in ductal breast carcinoma and is required to sustain FAK steady state levels in breast cancer epithelial cells.
The Potential Contribution of BRCA Mutations to Early Onset and Familial Breast Cancer in Uzbekistan.
The potential for aromatase inhibition in breast cancer prevention.
The PPAR? agonist efatutazone increases the spectrum of well-differentiated mammary cancer subtypes initiated by loss of full-length BRCA1 in association with TP53 haploinsufficiency.
The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant.
The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations.
The presence of hereditary BRCA1 gene mutations in women with familial breast or ovarian cancer and the frequency of occurrence of these tumours in their relatives.
The prevalence and spectrum of BRCA1 and BRCA2 mutations in Korean population: recent update of the Korean Hereditary Breast Cancer (KOHBRA) study.
The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified.
The prevalence of BRCA1 and BRCA2 mutations in eastern Chinese women with breast cancer.
The prevalence of BRCA1 mutations among young women with triple-negative breast cancer.
The prevalence of BRCA1 mutations in Chinese patients with early onset breast cancer and affected relatives.
The prevalence of BRCA1/2 mutations of triple-negative breast cancer patients in Xinjiang multiple ethnic region of China.
The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30.
The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy.
The prevention of hereditary breast cancer.
The problems with risk selection; scientific and psychosocial aspects.
The prodigious network of chromosome 17 miRNAs regulating cancer genes that influence the hallmarks of cancer.
The progestin ORG2058 but not retinoic acid stimulates BRCA1 mRNA expression in MCF-7 human breast cancer cells.
The prognostic impact of hormone receptors and c-erbB-2 in pregnancy-associated breast cancer and their correlation with BRCA1 and cell cycle modulators.
The prognostic value of BRCA1 mRNA expression levels following neoadjuvant chemotherapy in breast cancer.
The prognostic value of BRCA1 promoter methylation in early stage triple negative breast cancer.
The pros and cons of genetic testing for breast and ovarian cancer risk.
The R71G BRCA1 is a founder Spanish mutation and leads to aberrant splicing of the transcript.
The RAD51 135 G>C polymorphism modifies breast cancer and ovarian cancer risk in Polish BRCA1 mutation carriers.
The RAD52-S346X variant reduces risk of developing breast cancer in carriers of pathogenic germline BRCA2 mutations.
The rate of recurrent BRCA1, BRCA2, and TP53 mutations in the general population, and unselected ovarian cancer cases, in Belo Horizonte, Brazil.
The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families.
The Retinoblastoma Gene Undergoes Rearrangements in BRCA1-Deficient Basal-like Breast Cancer.
The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by the platinum-based anticancer drugs.
The RING-H2 protein RNF11 is overexpressed in breast cancer and is a target of Smurf2 E3 ligase.
The risk of breast cancer in BRCA1 and BRCA2 mutation carriers without a first-degree relative with breast cancer.
The risk of breast cancer in women with a BRCA1 mutation from north america and poland.
The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.
The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study.
The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers.
The RNF146 and ECHDC1 genes as candidates for inherited breast and ovarian cancer in Jewish Ashkenazi women.
The Role of BCA2 in the Endocytic Trafficking of EGFR and Significance as a Prognostic Biomarker in Cancer.
The role of BRCA status on prognosis in patients with triple-negative breast cancer.
The role of BRCA1 and BRCA2 in prostate cancer.
The role of BRCA1 gene mutations and apoptosis phenomenon in sporadic breast cancer.
The role of BRCA1 in DNA double-strand repair: past and present.
The role of BRCA1 in non-homologous end-joining.
The role of endogenous hormones in the etiology and prevention of breast cancer: the epidemiological evidence.
The role of epigenetic transcriptional regulation in BRCA1-mediated tumor suppression.
The Role of Genetic Testing in Patients With Breast Cancer: A Review.
The role of magnetic resonance imaging in screening women at high risk of breast cancer.
The role of pathologists in recognition of morphologic and biologic features of genetically mutated breast cancer.
The role of Rak in the regulation of stability and function of BRCA1.
The rs2910164:G>C SNP in the MIR146A gene is not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.
The spectrum of BRCA1 and BRCA2 mutations and clinicopathological characteristics in Chinese women with early-onset breast cancer.
The Spectrum of BRCA1 and BRCA2 mutations in Breast Cancer Patients in the Bahamas.
The spectrum of mutations predisposing to familial breast cancer in Poland.
The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.
The tumor suppressor activity induced by adenovirus-mediated BRCA1 overexpression is not restricted to breast cancers.
The tumor suppressor BRCA1-BARD1 complex localizes to the synaptonemal complex and regulates recombination under meiotic dysfunction in Caenorhabditis elegans.
The unliganded glucocorticoid receptor positively regulates the tumour suppressor gene BRCA1 through GABP beta.
The UPS: a promising target for breast cancer treatment.
The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation.
The usefulness of antibodies to the BRCA1 protein in detecting the mutated BRCA1 gene. An immunohistochemical study.
The validation and clinical implementation of BRCAplus: a comprehensive high-risk breast cancer diagnostic assay.
The validation of a simulation model incorporating radiation risk for mammography breast cancer screening in women with a hereditary-increased breast cancer risk.
The value of clinical breast examination in a breast cancer surveillance program for women with germline BRCA1 or BRCA2 mutations.
The VEGF_936_C>T 3'UTR polymorphism reduces BRCA1-associated breast cancer risk in Polish women.
The yield of targeted genotyping for the recurring mutations in BRCA1/2 in Israel.
Therapeutic Approaches for Women Predisposed to Breast Cancer.
Therapeutic exploitation of tumor cell defects in homologous recombination.
Therapeutic opportunities for PLK1 inhibitors: Spotlight on BRCA1-deficiency and triple negative breast cancers.
Therapeutic potential of stem cells expressing suicide genes that selectively target human breast cancer cells: evidence that they exert tumoricidal effects via tumor tropism (review).
Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation.
Therapy response testing of breast cancer in a 3D high-throughput perfused microfluidic platform.
Thyroid Hormone Receptors Predict Prognosis in BRCA1 Associated Breast Cancer in Opposing Ways.
Thyroid Hormones and Vitamin D in Patients with Breast Cancer with Mutations in BRCA1 or BRCA2 Genes.
Time to reconsider subcutaneous mastectomy for breast-cancer prevention?
Time-resolved single-cell analysis of Brca1 associated mammary tumourigenesis reveals aberrant differentiation of luminal progenitors.
Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers.
Tissue-based predictors of germ-line BRCA1 mutations: implications for triaging of genetic testing.
TNRC9 downregulates BRCA1 expression and promotes breast cancer aggressiveness.
Too much, too soon? Patients and health professionals' views concerning the impact of genetic testing at the time of breast cancer diagnosis in women under the age of 40.
Tools for translational epigenetic studies involving formalin-fixed paraffin-embedded human tissue: applying the Infinium HumanMethyation450 Beadchip assay to large population-based studies.
Towards a dietary prevention of hereditary breast cancer.
Towards classification of BRCA1 missense variants using a biophysical approach.
Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer.
TP53 Binding to BRCA1 and RAD51 in MCF7 and MDA-MB-468 Breast Cancer Cell Lines In vivo and In vitro.
TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution.
TP53 mutations in familial breast cancer: functional aspects.
TP53, BRCA1, and BRCA2 tumor suppressor genes are not commonly mutated in survivors of Hodgkin's disease with second primary neoplasms.
Transactivation of repair genes by BRCA1.
Transcript identification in the BRCA1 candidate region.
Transcriptional autoregulation by BRCA1.
Transcriptional down-regulation of Brca1 and E-cadherin by CtBP1 in breast cancer.
Transcriptional Pathways Altered in Response to Vibration in a Model of Hand-Arm Vibration Syndrome.
Transcriptional profiling of breast cancer cells exposed to soy phytoestrogens after BRCA1 knockdown with a whole human genome microarray approach.
Transcriptional regulation of BRCA1 expression by a metabolic switch.
Transcriptional regulation of the base excision repair pathway by BRCA1.
Transcriptional repression of BRCA1 by aberrant cytosine methylation, histone hypoacetylation and chromatin condensation of the BRCA1 promoter.
Transcriptome mining of non-BRCA1/A2 and BRCA1/A2 familial breast cancer.
Treatment of hereditary breast cancer.
Treatment-focused DNA testing for newly diagnosed breast cancer patients: some implications for clinical practice.
Tree-based analysis of microarray data for classifying breast cancer.
Trends in contralateral prophylactic mastectomy rate according to clinicopathologic and socioeconomic status.
Trends in diagnosis and control of bovine mastitis: a review.
TRIM25 promotes Capicua degradation independently of ERK in the absence of ATXN1L.
TRIM25: A central factor in breast cancer.
TRIM27 Functions as a Novel Oncogene in Non-Triple-Negative Breast Cancer by Blocking Cellular Senescence through p21 Ubiquitination.
TRIM3 inhibits P53 signaling in breast cancer cells.
TRIM59 deficiency curtails breast cancer metastasis through SQSTM1-selective autophagic degradation of PDCD10.
Tripartite motif-containing 3 (TRIM3) enhances ER signaling and confers tamoxifen resistance in breast cancer.
Triple Negative Breast Cancer in BRCA1 Mutation Carriers With a Complete Radiologic Response to Neoadjuvant Paclitaxel: A Case Report.
Triple negative breast cancer: microRNA expression profile and novel discriminators according to BRCA1 status.
Triple negative breast cancers: clinical and prognostic implications.
Triple negative tumours: a critical review.
Triple-negative breast cancer and Poly(ADP-ribose) polymerase inhibitors.
Triple-negative breast cancer and PTEN (phosphatase and tensin homologue)loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer.
Triple-negative breast cancer frequency and type of BRCA mutation: Clues from Sardinia.
Triple-negative breast cancer in African-American women: disparities versus biology.
Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing.
Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies.
Triple-Negative Breast Cancer: Clinical and Histological Correlations.
Triple-negative breast cancer: epidemiological considerations and recommendations.
TrkC-Targeted Kinase Inhibitors And PROTACs.
Tuberin and p27 expression in breast cancer patients with or without BRCA germline mutations.
Tumor classification using phylogenetic methods on expression data.
Tumor markers in breast cancer--evaluation of their clinical usefulness.
Tumor sequencing is useful to refine the analysis of germline variants in unexplained high-risk breast cancer families.
Tumor suppressor BRCA1 inhibits a breast cancer-associated promoter of the aromatase gene (CYP19) in human adipose stromal cells.
Tumor suppressor genes and breast cancer.
Tumor suppressor loss in pituitary tumors.
Tumor-associated inflammation as a potential prognostic tool in BRCA1/2-associated breast cancer.
Tumoral Expression of BRCA1, Estrogen Receptor Alpha and ID4 Protein in Patients with Sporadic Breast Cancer.
Tumors overexpressing RNF168 show altered DNA repair and responses to genotoxic treatments, genomic instability and resistance to proteotoxic stress.
Tumour biological features of BRCA1-induced breast and ovarian cancer.
Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant.
Tumour morphology of early-onset breast cancers predicts breast cancer risk for first-degree relatives: the Australian Breast Cancer Family Registry.
Tumour spectrum in non-BRCA hereditary breast cancer families in Sweden.
TUSC4 functions as a tumor suppressor by regulating BRCA1 stability.
Twenty Years of BRCA1 and BRCA2 Molecular Analysis at MMCI - Current Developments for the Classification of Variants.
Two approaches to mutation detection based on functional data.
Two contiguously located germline BRCA1 mutations in a Spanish early-onset breast cancer family.
Two decades after BRCA: setting paradigms in personalized cancer care and prevention.
Two identical triplet sisters carrying a germline BRCA1 gene mutation acquire very similar breast cancer somatic mutations at multiple other sites throughout the genome.
Two Missense Variants Detected in Breast Cancer Probands Preventing BRCA2-PALB2 Protein Interaction.
Two PALB2 germline mutations found in both BRCA1+ and BRCAx familial breast cancer.
Two truncating variants in FANCC and breast cancer risk.
Ubc9 mediates nuclear localization and growth suppression of BRCA1 and BRCA1a proteins.
Ubiquitination and downregulation of BRCA1 by ubiquitin-conjugating enzyme E2T overexpression in human breast cancer cells.
Ubiquitination of NF-?B p65 by FBXW2 suppresses breast cancer stemness, tumorigenesis, and paclitaxel resistance.
UHRF1 is associated with epigenetic silencing of BRCA1 in sporadic breast cancer.
ULK2 is essential for degradation of ubiquitinated protein aggregates and homeostasis in skeletal muscle.
Ultraselective electrochemiluminescence biosensor based on locked nucleic acid modified toehold-mediated strand displacement reaction and junction-probe.
Ultrasonographic characteristics and BI-RADS-US classification of BRCA1 mutation-associated breast cancer in Guangxi, China.
Uncovering the Translational Regulatory Activity of the Tumor Suppressor BRCA1.
Under-ascertainment of breast cancer susceptibility gene carriers in a cohort of New Zealand female breast cancer patients.
Underestimated survival predictions of the prognostic tools Adjuvant! Online and PREDICT in BRCA1-associated breast cancer patients.
Understanding BRCA Mutation Carriers' Preferences for Communication of Genetic Modifiers of Breast Cancer Risk.
Understanding missense mutations in the BRCA1 gene: an evolutionary approach.
Uninterrupted Sedentary Behavior Downregulates BRCA1 Gene Expression.
Unravelling modifiers of breast and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: update on genetic modifiers.
Update on breast cancer susceptibility genes.
Update on genetic predisposition to breast cancer.
Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial.
Uptake of offer to receive genetic information about BRCA1 and BRCA2 mutations in an Australian population-based study.
Uptake of risk-reducing salpingo-oophorectomy in women carrying a BRCA1 or BRCA2 mutation: evidence for lower uptake in women affected by breast cancer and older women.
Use of association studies to define genetic modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Use of bilateral prophylactic nipple-sparing mastectomy in patients with high risk of breast cancer.
Use of DNA-damaging agents and RNA pooling to assess expression profiles associated with BRCA1 and BRCA2 mutation status in familial breast cancer patients.
Use of fertility treatments in BRCA1/2 mutation carriers and risk for ovarian and breast cancer: a systematic review.
Use of Gene Expression Profiles of Peripheral Blood Lymphocytes to Distinguish BRCA1 Mutation Carriers in High Risk Breast Cancer Families.
Usefulness of breast MRI in a patient with genetic risk.
Using gene carrier probability to select high risk families for identifying germline mutations in breast cancer susceptibility genes.
Using MLPA for large genomic rearrangements detection in breast cancer predisposition genes.
Using whole-genome sequencing data to derive the homologous recombination deficiency scores.
Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies.
Utilization of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patients.
Utilization of breast cancer risk prediction models by cancer genetic counselors in clinical practice predominantly in the United States.
Utilization of breast cancer screening in a clinically based sample of women after BRCA1/2 testing.
Utilizing fluorescent life time imaging microscopy technology for identify carriers of BRCA2 mutation.
Validation of family history of breast cancer and identification of the BRCA1 and other syndromes using a population-based cancer registry.
Validation of transgenic models of breast cancer: ductal carcinoma in situ (DCIS) and Brca1-mutation-related breast cancer.
Variation in breast cancer risk associated with factors related to pregnancies according to truncating mutation location, in the French National BRCA1 and BRCA2 mutations carrier cohort (GENEPSO).
Variation in breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Variation in mutation spectrum partly explains regional differences in the breast cancer risk of female BRCA mutation carriers in the Netherlands.
Variation in the BRCA2 gene in a child with medulloblastoma and a family history of breast cancer.
Variation in the RAD51 gene and familial breast cancer.
Variation of breast cancer risk among BRCA1/2 carriers.
Vascular endothelial growth factor (VEGF) levels and mutation of the BRCA1 gene in breast cancer patients.
VCP, a weak ATPase involved in multiple cellular events, interacts physically with BRCA1 in the nucleus of living cells.
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Vitamin D receptor, Retinoid X receptor and peroxisome proliferator-activated receptor ? are overexpressed in BRCA1 mutated breast cancer and predict prognosis.
Vitamin D3 analogs and their 24-oxo metabolites equally inhibit clonal proliferation of a variety of cancer cells but have differing molecular effects.
What?s Happening to Your DNA Data?: Genetic Testing Services Abound, but Consumers Opting to Use Them Should Be Aware of the Pitfalls.
When to Consider Risk-Reducing Mastectomy in BRCA1/BRCA2 Mutation Carriers with Advanced Stage Ovarian Cancer: a Case Study Illustrating the Genetic Counseling Challenges.
Whole exome sequencing of breast cancer (TNBC) cases from India: association of MSH6 and BRIP1 variants with TNBC risk and oxidative DNA damage.
Whole exome sequencing suggests much of non-BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles.
Why are the majority of hereditary cases of early-onset breast cancer sporadic? A simulation study.
Widespread bimodal intrachromosomal genomic instability in sporadic breast cancers associated with 13q allelic imbalance.
Wild-type BRCA1, but not mutated BRCA1, regulates the expression of the nuclear form of beta-catenin.
Wild-type genotypes of BRCA1 gene SNPs combined with micro-RNA over-expression in mammary tissue leading to familial breast cancer with an increased risk of distant metastases' occurrence.
WIP1 Promotes Homologous Recombination and Modulates Sensitivity to PARP Inhibitors.
Withaferin a induces proteasome-dependent degradation of breast cancer susceptibility gene 1 and heat shock factor 1 proteins in breast cancer cells.
Withdrawal: EP2 and EP4 receptors regulate aromatase expression in human adipocytes and breast cancer cells: Evidence of a BRCA1 and p300 exchange.
WITHDRAWN: BRCA1 protein expression and TOP2A gene aberration and protein expression in four molecular subtypes of breast cancer.
Women at high risk of breast cancer: Molecular characteristics, clinical presentation and management.
Women with hereditary breast cancer predispositions should avoid using their smartphones, tablets, and laptops at night.
Women's Decision Making about Risk-Reducing Strategies in the Context of Hereditary Breast and Ovarian Cancer: A Systematic Review.
Women's health 2019: Osteoporosis, breast cancer, contraception, and hormone therapy.
Women's preferences for contralateral prophylactic mastectomy: An investigation using protection motivation theory.
WSB-1 regulates the metastatic potential of hormone receptor negative breast cancer.
WWP1 E3 ligase targets LATS1 for ubiquitin-mediated degradation in breast cancer cells.
X inactive-specific transcript RNA coating and genetic instability of the X chromosome in BRCA1 breast tumors.
X-chromosome inactivation: X marks the spot for BRCA1.
X-linked inhibitor of apoptosis protein and its E3 ligase activity promote transforming growth factor-{beta}-mediated nuclear factor-{kappa}B activation during breast cancer progression.
X-rays increase breast cancer risk in women with gene mutation.
Y179C, F486L and N550H are BRCA1 variants that may be associated with breast cancer in a Sicilian family: results of a 5-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study.
YC-1 inhibits proliferation of breast cancer cells by downregulating EZH2 expression via activation of c-Cbl and ERK.
Yeast Screens Identify the RNA Polymerase II CTD and SPT5 as Relevant Targets of BRCA1 Interaction.
Yin Yang 1 positively regulates BRCA1 and inhibits mammary cancer formation.
Young age at first pregnancy does protect against early onset breast cancer in BRCA1 and BRCA2 mutation carriers.
Younger birth cohort correlates with higher breast and ovarian cancer risk in European BRCA1 mutation carriers.
ZNF365 promotes stalled replication forks recovery to maintain genome stability.
Zwitterionic peptide anchored to conducting polymer PEDOT for the development of antifouling and ultrasensitive electrochemical DNA sensor.
[(18)F]FluorThanatrace uptake as a marker of PARP1 expression and activity in breast cancer.
[5589del8: the recurrent mutation of BRCA1 gene in Chinese breast cancer patients]
[Advance in researches on BRCA1.]
[An immunohistochemical study of aromatase, estrogen 4-hydroxylase and fatty acid synthetase in breast cancer tissues from BRCA1 mutation carriers]
[An integrated early detection concept in women with a genetic predisposition for breast cancer]
[Analysis of BRCA1 gene mutations in patients with early-onset breast cancer and their affected relatives in Guangdong province]
[Analysis of BRCA1 mutations in Chinese patients with early onset breast cancer and affected relatives.]
[Analysis of loss of heterozygosity and microsatellite instability RAD52, RAD54 and RAD54B gene and BRCA1 gene mutation in breast cancer]
[Analysis of mutation sites of BRCA1 gene in Chinese patients with breast cancer]
[Analysis of mutations in genes BRCA1 and BRCA2 among patients with breast and ovarian cancer in northern Portugal and Galicia]
[Analysis of mutations in the BRCA1 gene in patients with cancer of the breast and/or the ovary in Portugal]
[Analysis of polymorphisms in genes of insulin receptor substrate-1 and enzymes involved in estrogen biosynthesis and metabolism among breast cancer patients with BRCA1 mutations]
[Analysis of the mutation of BRCA1 gene in 70 Uigur women breast cancer patients in Xinjiang]
[Analysis of the mutations of BRCA1 in 9 familiar breast cancer patients]
[Are the hereditary forms of BRCA1 and BRCA2 breast cancer sensitive to estrogens?]
[Attitudes towards screening and prevention of breast and ovarian cancers with hereditary predisposition. Survey by female gynecologists in the north of France]
[BRCA mutations: from Angelina Jolie to specific therapies].
[BRCA1 1100delAT is a recurrent mutation in Chinese women with familial breast cancer]
[BRCA1 and BRCA2 gene mutations of familial breast cancer from Shanghai in China]
[BRCA1 and BRCA2 have reached the clinical medicine. The 10-year old finding of the genetic mutation makes it now possible to prevent breast cancer]
[BRCA1 and BRCA2 mutations in families studied in the Program of Genetic Counselling in Cancer of the Valencian Community (Spain).]
[BRCA1 and BRCA2 mutations in patients with familial breast cancer]
[BRCA1 and BRCA2: mutations and other genetic changes--practical relevance]
[BRCA1 and Estrogen Receptor ? Expression Regulation in Breast Cancer Cells].
[BRCA1 gene mutations in early-onset breast cancer]
[BRCA1 germ line mutations in Chinese early-onset breast cancer patients.]
[BRCA1 inhibits progesterone-induced proliferation and migration of breast cancer cells].
[BRCA1 protein expression in sporadic breast and its clinical significance]
[BRCA1 regulates progesterone receptors A and B protein expressions in breast cancer cells in vitro]
[BRCA1 selectively regulates the expression of progesterone receptor A in sporadic invasive ductal breast carcinoma]
[BRCA1/2 gene mutation in Chinese familial breast cancer patients: a multi-center report of 115 cases]
[Breast cancer after preventive subcutaneous mastectomy]
[Breast cancer genetics. BRCA1 and BRCA2: the main genes for disease predisposition]
[Breast cancer in BRCA1/2 mutation carriers].
[Breast Cancer in Young Women - Correlation of Clinical Histomorphological, and Molecular-genetic Features of Breast Carcinoma in Women Younger than 35 Years of Age].
[Breast cancer screening different from that used for the general population: who is concerned and with which approach?]
[Breast cancer susceptibility gene BRCA1 of hereditary breast cancer/ ovarian cancer syndrome]
[Characteristics of selected clinical features in BRCA1 mutation carriers affected with breast cancer undergoing preventive female genital tract surgeries].
[Characterization of the BRCA1 gene and its significance in hereditary breast cancer]
[CHEK2 and breast cancer risk]
[CHEK2-mutation in Dutch breast cancer families: expanding genetic testing for breast cancer].
[Choices for women at risk of hereditary breast cancer].
[Clinical and pathological characteristics and clinical course of patients with breast cancer and BRCA1/BRCA2 mutations]
[Clinical value of gene diagnosis in breast cancer]
[Cloning of BRCA1 cDNA and detection of BRCA1 mRNA expression in breast cancer cells]
[Comparative study on functional characters of MCF7 and HCC1937 cell lines in response to DNA damage].
[Correlation anslysis of sporadic breast cancer and BRCA1 gene plymorphisms in the Han Nationality and the Mongol Nationality of Inner Mongolia Region].
[Correlation of BRCA1 and APC aberrant methylation with the response to anthracycline-based neoadjuvant chemotherapy in primary breast cancer]
[Cytogenetic abnormalities, genetic alterations, and applications for genetic diagnosis in breast cancer]
[Detection of 5382insC mutation in human BRCA1 gene using fluorescent labeled oligonucleotides]
[Detection of a BRCA1 c.2013_2014ins GT variant an ethnic Han Chinese pedigree affected with breast cancer].
[Determination of a BRCA1 gene mutation in a family with hereditary breast cancer]
[Diagnostic molecular biology in breast cancer]
[Diagnostic value of BRCA1 and p16 gene methylation in sporadic breast cancer.]
[Effects of lovastatin on cell cycle distribution in MCF-7 cells transfected with BRCA1]
[Effects of Olaparib, a PARP-1 Inhibitor, on Triple Negative Breast Cancer Cells with a BRCA1 Mutation].
[Estimation of individual breast cancer risk: relevance and limits of risk estimation models]
[Ethnic aspects of hereditary breast cancer in the region of Siberia].
[Evaluation of stomatognathic system in BRCA1 gene mutation carriers before and after prophylactic adnexectomy--part II: evaluation of stomatognathic system in BRCA1 gene mutation carriers after prophylactic adnexectomy]
[Explosive growth of uterine leiomyomas and carcinologic ovarian risk in a non-menopausal patient with BRCA1-BRCA2 mutation treated by tamoxifen]
[Expression of BRCA1 and WWOX and their clinicopathologic implication in breast carcinomas occurring in young women].
[Expression of E3 ligase HERC4 in breast cancer and its clinical implications].
[Familial breast cancer]
[Familial cancer and oncogenic factors]
[Frequency of the 185delAG mutation in the BRCA1 gene in Chilean healthy women with family history of breast cancer]
[From gene to disease; from BRCA1 or BRCA2 to breast cancer]
[From gene to disease; from BRCA1 OR BRCA2 to breast cancer]
[From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
[Function of BRCA1 and BRCA2 genes associated with hereditary predisposition to breast cancer]
[Genes beyond BRCA1 and BRCA2 for hereditary breast cancer.]
[Genetic alterations and DNA-based diagnosis in breast cancer]
[Genetic predisposition for breast cancer: BRCA1 and BRCA2 genes].
[Genetic predisposition to cancer: familial forms of medullary thyroid cancer and breast cancer]
[Genetic research with stored human tissue: a coding procedure with optimal use of information and protection of privacy]
[Genetic test and prophylactic treatment in breast cancer families]
[Genetics and cancer: application to the breast]
[Genotyping of BRCA1, BRCA2 and CHEK2 germline mutations in Russian breast cancer patients using diagnostic biochips].
[Germline mutation of BRCA1 gene in Polish families with strong aggregation of breast and/or ovarian cancer based on coding sequence analysis using the SSCP method]
[Germline mutations in the BRCA1 and BRCA2 genes from breast cancer families in China Han people]
[Hereditary breast and ovarian cancer].
[Hereditary breast cancer in Norway]
[Hereditary breast cancers]
[Hereditary breast cancer]
[Hereditary breast carcinomas pathologist's perspective].
[Hereditary ovarian cancer. The role of BRCA1 gene dysfunction in response to chemotherapy].
[Hereditary predispositions to gynaecological cancers]
[Human genes patents: yes or no? Reflections on the ruling of the Supreme Court of the United States].
[Impact of recent oncogenetic progress on the management of high risk breast cancer patients: the example of BRCA1 and BRCA2 genes]
[Implications of genetic risk factors in breast cancer: culprit genes and associated malignancies]
[Inherited predisposition to breast cancer: after the BRCA1 and BRCA2 genes, what next?]
[Inhibition of cellular proliferation by knockdown of MARCH6 gene expression in breast cancer cells].
[Initial Dutch results with a presymptomatic DNA tests in familial breast/ovarian carcinoma. Rotterdamse Werkgroep voor Erfelijke Tumoren]
[Investigation of mutations of BRCA1 and BRCA2 genes in 52 breast cancer patients]
[Is hereditary predisposition to breast cancer linked to BRCA1 a disease of response to genotoxic lesions?]
[Loss of heterozygosity and microsatellite instability in the region including BRCA1 of breast cancer in Chinese]
[Medical management of women with inherited predisposition to breast cancer: indications and procedures for mammographic screening]
[Molecular alterations in breast cancer: clinical implications and new analytical tools]
[Molecular basis of breast cancer related to BRCA 1 and BRCA2 genes: characteristics and targeting therapy]
[Molecular Diagnosis and Treatment of HBOC Syndrome].
[Molecular genetics and clinics of hereditary breast cancer]
[Molecular genetics of hereditary breast carcinoma]
[Molecular study of the BRCA1 and BRCA2 genes in 153 breast cancer families from Castilla and León (Spain): new nine unclassified variants identified]
[Multiple primary malignancies in BRCA1 mutation carriers--two clinical cases].
[Mutation BRCA1 gene in 186 breast cancer patients]
[Mutation of breast cancer susceptibility gene in ovarian cancer and its clinical significance]
[Mutational analysis of BRCA1 and BRCA2 genes in early-onset breast cancer patients in Shanghai]
[Mutational analysis of breast/ovarian cancer hereditary predisposition gene BRCA1 in Tunisian women]
[Mutations in the BRCA1 gene (185delAG and 5382insC) are not present in any of the 30 breast cancer patients analyzed from eastern Colombia]
[Mutations in the BRCA1 gene in young Spanish women with breast cancer]
[Novel BRCA1 gene mutations in breast cancer patients from St. Petersburg]
[Opposition to Myriad Genetics patents and their total or partial revocation in Europe: early conclusions]
[Pathogenesis of Fanconi anemia: FA-BRCA network -- review]
[Penetrance of BRCA1 gene mutation and DNA mitochondrial in Tunisian breast cancer occurrence]
[Perception accuracy of BRCA1/2 mutation predisposition in breast cancer women and associated factors].
[Population genetic analysis of the association between the BRCA1 and P53 gene polymorphisms and the risk of sporadic breast cancer]
[Pregnancy and risk of early breast cancer in patients sith BRCA1 and BRCA2 mutations]
[Prevalence of mutations BRCA1 5382insC, and CHEK2 1100delC in the population of Siberian region].
[Prevalence of the 185Ag deletion of the BRCA1 gene in Chilean women with breast neoplasm]
[Prevalence of widespread BRCA1 gene mutations in patients with familial breast cancer from St. Petersburg]
[Preventive surgical prcedures for inherited risk of breast cancer]
[Primary ovarian malignant mixed mesodermal tumor (MMMT) as a second primary tumor in a patient with invasive breast carcinoma--case report].
[Relationship between BRCA1 mRNA expression in tumor cells from malignant effusions and chemosensitivity to cisplatin in patients with metastatic malignant effusions].
[Relationship between mutation of BRCA1 and susceptibility to early onset of breast cancer]
[Relationship of clinicopathological features and chemotherapeutic outcomes in women with BRCA1 and BRCA2 mutation-negative familial breast cancer].
[Report of the National Oncology Research and Developement Consortium, 2003]
[Report on the first year of the activity of the National Oncological RD Consortium]
[Roles of Aurora-A in tumorigenesis and prognosis of breast cancer.]
[Search for frequently encountered mutations in genes predisposing to breast cancer]
[Sequence analysis of BRCA1 gene in young breast cancer patients and/or positive family history]
[Should knowledge of BRCA1 status impact the choice of chemotherapy in metastatic breast cancer: A review].
[Significance and expressions of BRCA1 and BRCA2 protein in sporadic breast cancer].
[Study of BRCA1 and BRCA2 gene mutations in human sporadic breast cancers]
[Surgical prevention of breast carcinoma in patients with hereditary risk].
[Surgical procedure in primary and metastatic breast carcinoma]
[Systematic breast self-examination is not a useful screening procedure, except in hereditary or familial increased risk of breast cancer]
[The clinical importance of a genetic analysis of moderate-risk cancer susceptibility genes in breast and other cancer patients from the Czech Republic].
[The human genome--chromosome 17]
[The importance of genetic factors for development of breast cancer]
[The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada]
[The risk-reducing mastectomy: unnecessary hysteria or life-saving prophylaxis?].
[The role of BRCA1 and BRCA2 genes in hereditary breast cancer]
[Triple Negative Breast Cancer].
[Triple-negative breast cancer: molecular characteristics and potential therapeutic approaches].
[What attitude to women at high risk of breast cancer?]
[What do we know about ATM protein expression in breast tissue?]
Breast Neoplasms, Male
A high incidence of BRCA1 mutations in 20 breast-ovarian cancer families.
An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium.
BRCA1 and BRCA2 germline mutational spectrum and evidence for genetic anticipation in Portuguese breast/ovarian cancer families.
BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic.
BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.
BRCA1 and BRCA2 mutations in a population-based study of male breast cancer.
BRCA1 gene variant p.P142H associated with male breast cancer: a two-generation genealogic study and literature review.
BRCA1/2 mutation analysis in male breast cancer families from North West England.
Breast cancer risk among male BRCA1 and BRCA2 mutation carriers.
CHEK2 1100delC and male breast cancer in the Netherlands.
CHEK2 c.1100delC mutation is associated with an increased risk for male breast cancer in Finnish patient population.
Colorado family physicians' knowledge of hereditary breast cancer and related practice.
Contribution of MUTYH Variants to Male Breast Cancer Risk: Results From a Multicenter Study in Italy.
Contribution of the BRCA1 and BRCA2 mutations to breast cancer in Tunisia.
Detection of eight BRCA1 mutations in 10 breast/ovarian cancer families, including 1 family with male breast cancer.
Evaluation of CYP17A1 and CYP1B1 polymorphisms in male breast cancer risk.
Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q.
Family history predictors of BRCA1/BRCA2 mutation status among Tunisian breast/ovarian cancer families.
Genetic predisposition to male breast cancer in Poland.
Genetic testing results in Slovenian male breast cancer cohort indicate the BRCA2 7806-2A?>?G founder variant could be associated with higher male breast cancer risk.
Genomic Large Rearrangement Screening of BRCA1 and BRCA2 Genes in High-Risk Turkish Breast/Ovarian Cancer Patients by Using Multiplex Ligation-Dependent Probe Amplification Assay.
Germline deleterious mutations in genes other than BRCA2 are infrequent in male breast cancer.
Hereditary predisposition to breast cancer.
High frequency of germ-line BRCA2 mutations among Hungarian male breast cancer patients without family history.
Identification of germline BRCA1 and BRCA2 genetic alterations in Greek breast cancer moderate-risk and low-risk individuals--correlation with clinicopathological data.
Increased risk of male cancer and identification of a potential prostate cancer cluster region in BRCA2.
Inherited breast and ovarian cancer.
Italian family with two independent mutations: 3358T/A in BRCA1 and 8756delA in BRCA2 genes.
Large genomic BRCA2 rearrangements and male breast cancer.
Large genomic rearrangement in BRCA1 and BRCA2 and clinical characteristics of men with breast cancer in the United States.
Large genomic rearrangements of both BRCA2 and BRCA1 are a feature of the inherited breast/ovarian cancer phenotype in selected families.
Localization of breast cancer susceptibility loci by genome-wide SNP linkage disequilibrium mapping.
Loss of BRCA1 expression in sporadic male breast carcinoma.
Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.
Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2.
MLPA screening in the BRCA1 gene from 1,506 German hereditary breast cancer cases: novel deletions, frequent involvement of exon 17, and occurrence in single early-onset cases.
Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer.
Molecular analysis of the BRCA1 and BRCA2 genes in 32 breast and/or ovarian cancer Spanish families.
Molecular and pathological characterization of inherited breast cancer.
Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim results.
Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population.
Mutation analysis of BRCA1 and BRCA2 in Turkish cancer families: a novel mutation BRCA2 3414del4 found in male breast cancer.
Mutation Screening of BRCA Genes in 10 Iranian Males with Breast Cancer.
Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer-susceptibility genes?
Mutations of the BRCA1 and BRCA2 genes and the possibilities for predictive testing.
Novel nonsense mutation of BRCA2 gene in a Moroccan man with familial breast cancer.
Performance of BRCA1/2 mutation prediction models in male breast cancer patients.
Prevalence of BRCA1 and BRCA2 mutations in male breast cancer patients in Canada.
Prevention and Screening in Hereditary Breast and Ovarian Cancer.
Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history.
Significant contribution of germline BRCA2 rearrangements in male breast cancer families.
Similar prevalence of founder BRCA1 and BRCA2 mutations among Ashkenazi and non-Ashkenazi men with breast cancer: Evidence from 261 cases in Israel, 1976-1999.
The cancer genetics and pathology of male breast cancer.
Brucellosis
Brucella infection inhibits macrophages apoptosis via Nedd4-dependent degradation of calpain2.
Bulbo-Spinal Atrophy, X-Linked
CHIP deletion reveals functional redundancy of E3 ligases in promoting degradation of both signaling proteins and expanded glutamine proteins.
Burkitt Lymphoma
Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas.
Canavan Disease
High throughput parallel analysis of hundreds of patient samples for more than 100 mutations in multiple disease genes.
Mendelian diseases among Roman Jews: implications for the origins of disease alleles.
Screening semen donors for hereditary diseases. The Fairfax cryobank experience.
Carcinogenesis
53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks.
?-transducin repeat-containing E3 ubiquitin protein ligase inhibits migration, invasion and proliferation of glioma cells.
A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1/2.
A dual role of BRCA1 in two distinct homologous recombination mediated repair in response to replication arrest.
A Hypoxia-Induced SCFFBXL1 E3 Ligase Ubiquitinates and Degrades the MEN1 Tumor Suppressor to Promote Colorectal Cancer Tumorigenesis.
A hypoxia-responsive TRAF6-ATM-H2AX signalling axis promotes HIF1? activation, tumorigenesis and metastasis.
A mammary-specific, long-range deletion on mouse chromosome 11 accelerates Brca1-associated mammary tumorigenesis.
A mouse model for the molecular characterization of brca1-associated ovarian carcinoma.
A novel oncoprotein Pirh2: rising from the shadow of MDM2.
A novel oncoprotein RNF43 functions in an autocrine manner in colorectal cancer.
A novel tricomplex of BRCA1, Nmi, and c-Myc inhibits c-Myc-induced human telomerase reverse transcriptase gene (hTERT) promoter activity in breast cancer.
A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol.
A phospho-switch controls RNF43-mediated degradation of Wnt receptors to suppress tumorigenesis.
A possible role of cIAP2 in Helicobacter pylori-associated gastric cancer.
A role for Brca1 in chromosome end maintenance.
A role of estrogen/ERalpha signaling in BRCA1-associated tissue-specific tumor formation.
A targeted disruption of the murine Brca1 gene causes gamma-irradiation hypersensitivity and genetic instability.
A TGF?-miR-182-BRCA1 axis controls the mammary differentiation hierarchy.
Aberrant expression of miR-638 contributes to benzo(a)pyrene-induced human cell transformation.
Abnormal Mammary Adipose Tissue Environment of Brca1 Mutant Mice Show a Persistent Deposition of Highly Vascularized Multilocular Adipocytes.
Absence of CCND1 gene amplification in breast tumours of BRCA1 mutation carriers.
Absence of DICER1, CTCF, RPL22, DNMT3A, TRRAP, IDH1 and IDH2 hotspot mutations in patients with various subtypes of ovarian carcinomas.
Absence of full-length Brca1 sensitizes mice to oxidative stress and carcinogen-induced tumorigenesis in the esophagus and forestomach.
Absence of mature microRNAs inactivates the response of gene expression to carcinogenesis induced by N-ethyl-N-nitrosourea in mouse liver.
Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes.
Absence of the full-length breast cancer-associated gene-1 leads to increased expression of insulin-like growth factor signaling axis members.
Acceleration of gastric tumorigenesis through MKRN1-mediated posttranslational regulation of p14ARF.
Acetaldehyde stimulates FANCD2 monoubiquitination, H2AX phosphorylation, and BRCA1 phosphorylation in human cells in vitro: Implications for alcohol-related carcinogenesis.
Acetylation Stabilizes Phosphoglycerate Dehydrogenase by Disrupting the Interaction of E3 Ligase RNF5 to Promote Breast Tumorigenesis.
Activated Wnt/?-Catenin signaling contributes to E3 ubiquitin ligase EDD-conferred docetaxel resistance in prostate cancer.
Activation of FGFR2 Signaling Suppresses BRCA1 and Drives Triple-Negative Mammary Tumorigenesis That is Sensitive to Immunotherapy.
Akt1 inhibits homologous recombination in Brca1-deficient cells by blocking the Chk1-Rad51 pathway.
Allelic loss and microsatellite instability in prostate cancers in Japan.
Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer.
Alterations of the tumor suppressor gene Parkin in non-small cell lung cancer.
Altered BRCA1 and BRCA2 responses and mutation of BRCA1 gene in mice exposed chronically and transgenerationally to aqueous extract of betel nut (AEBN).
Altered Expression and Localization of Tumor Suppressive E3 Ubiquitin Ligase SMURF2 in Human Prostate and Breast Cancer.
Altering the Microbiome Inhibits Tumorigenesis in a Mouse Model of Oviductal High-Grade Serous Carcinoma.
Alternative splicing of breast cancer associated gene BRCA1 from breast cancer cell line.
Analysis of Brca1-deficient mouse mammary glands reveals reciprocal regulation of Brca1 and c-kit.
Analysis of GADD45A sequence variations in French Canadian families with high risk of breast cancer.
Antisense inhibition of BRCA1 expression and molecular analysis of hereditary tumors indicate that functional inactivation of the p53 DNA damage response pathway is required for BRCA-associated tumorigenesis.
Aromatase expression is increased in BRCA1 mutation carriers.
Aryl hydrocarbon receptor suppresses intestinal carcinogenesis in ApcMin/+ mice with natural ligands.
Association between cytosolic expression of BRCA1 and metastatic risk in breast cancer.
Association between prognostic survival of human colorectal carcinoma and ZNRF3 expression.
Association between single-nucleotide polymorphisms in miRNA and breast cancer risk: an updated review.
ATM-Chk2-p53 activation prevents tumorigenesis at an expense of organ homeostasis upon Brca1 deficiency.
ATR/ATM-Mediated Phosphorylation of BRCA1 T1394 Promotes Homologous Recombinational Repair and G2-M Checkpoint Maintenance.
Attenuation of proteolysis-mediated cyclin E regulation by alternatively spliced Parkin in human colorectal cancers.
BCoR-L1 variation and breast cancer.
Beta-catenin signaling: linking renal cell carcinoma and polycystic kidney disease.
beta-TrCP inhibition reduces prostate cancer cell growth via upregulation of the aryl hydrocarbon receptor.
Bioactive food components prevent carcinogenic stress via Nrf2 activation in BRCA1 deficient breast epithelial cells.
Blood Cell DNA Methylation of Aging-Related Ubiquitination Gene DZIP3 Can Predict the Onset of Early Stage Colorectal Cancer.
BP1, an isoform of DLX4 homeoprotein, negatively regulates BRCA1 in sporadic breast cancer.
BRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer - an observational cohort study.
BRCA1 185delAG truncation protein, BRAt, amplifies caspase-mediated apoptosis in ovarian cells.
BRCA1 Alternative splicing landscape in breast tissue samples.
BRCA1 and Breast Cancer: a Review of the Underlying Mechanisms Resulting in the Tissue-Specific Tumorigenesis in Mutation Carriers.
Brca1 and differentiation.
BRCA1 and estrogen signaling in breast cancer.
BRCA1 and estrogen/estrogen receptor in breast cancer: where they interact?
BRCA1 and homologous recombination: implications from mouse embryonic development.
BRCA1 and Oxidative Stress.
BRCA1 and p53 protein expression in cultured ovarian surface epithelial cells derived from women with and without a BRCA1 germline mutation.
BRCA1 and p53: compensatory roles in DNA repair.
BRCA1 Attenuates Progesterone Effects on Proliferation and NF?B Activation in Normal Human Mammary Epithelial Cells.
BRCA1 binds c-Myc and inhibits its transcriptional and transforming activity in cells.
BRCA1 carries tumor suppressor activity distinct from that of p53 and p21.
BRCA1 deficiency induces protective autophagy to mitigate stress and provides a mechanism for BRCA1 haploinsufficiency in tumorigenesis.
BRCA1 ensures genome integrity by eliminating estrogen-induced pathological topoisomerase II-DNA complexes.
BRCA1 gene in breast cancer.
BRCA1 gene mutations in sporadic ovarian carcinomas: detection by PCR and reverse allele-specific oligonucleotide hybridization.
Brca1 heterozygous mice have shortened life span and are prone to ovarian tumorigenesis with haploinsufficiency upon ionizing irradiation.
BRCA1 in cancer, cell cycle and genomic stability.
BRCA1 in hormonal carcinogenesis: basic and clinical research.
BRCA1 inhibition of estrogen receptor signaling in transfected cells.
BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival.
BRCA1 involvement in toxicological responses and human cancer etiology.
BRCA1 is associated with the centrosome during mitosis.
BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor.
BRCA1 methylation: a significant role in tumour development?
BRCA1 mislocalization associated with breast carcinogenesis and poor prognosis in Taiwanese women.
BRCA1 mRNA expression modifies the effect of T cell activation score on patient survival in breast cancer.
BRCA1 mutations attenuate super-enhancer function and chromatin looping in haploinsufficient human breast epithelial cells.
BRCA1 Mutations in Cancer: Coordinating Deficiencies in Homologous Recombination with Tumorigenesis.
BRCA1 promoter hypermethylation and protein expression in ovarian carcinoma-an Indian study.
BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy.
BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles.
BRCA1 regulates human mammary stem/progenitor cell fate.
BRCA1 regulates RAD51 function in response to DNA damage and suppresses spontaneous sister chromatid replication slippage: implications for sister chromatid cohesion, genome stability, and carcinogenesis.
BRCA1 regulates transforming growth factor-? (TGF-?1) signaling through Gadd45a by enhancing the protein stability of Smad4.
BRCA1 regulation on ?-hCG: a mechanism for tumorigenicity in BRCA1 defective breast cancer.
BRCA1 requirement for the fidelity of plasmid DNA double-strand break repair in cultured breast epithelial cells.
BRCA1 splice variants exhibit overlapping and distinct transcriptional transactivation activities.
BRCA1 suppresses epithelial-to-mesenchymal transition and stem cell dedifferentiation during mammary and tumor development.
BRCA1 transcriptionally regulates genes involved in breast tumorigenesis.
BRCA1-associated mammary tumorigenesis is dependent on estrogen rather than progesterone signaling.
BRCA1-associated tumorigenesis: what have we learned from knockout mice?
BRCA1-mediated signaling pathways in ovarian carcinogenesis.
BRCA1-mediated ubiquitylation.
BRCA1-mutated estrogen receptor positive breast cancer shows BRCAness, suggesting sensitivity to drugs targeting homologous recombination deficiency.
BRCA1/2 mutations perturb telomere biology: characterization of structural and functional abnormalities in vitro and in vivo.
BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1.
BRCA1: a movement toward cancer prevention.
BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution.
Breast Cancer Predisposition Genes and Synthetic Lethality.
Breast cancer risk associated with genotypic polymorphism of the nonhomologous end-joining genes: a multigenic study on cancer susceptibility.
c-Cbl is involved in Met signaling in B cells and mediates hepatocyte growth factor-induced receptor ubiquitination.
C-Cbl protein in human cancer tissues is frequently tyrosine phosphorylated in a tumor-specific manner.
c-Cbl: An Important Regulator and a Target in Angiogenesis and Tumorigenesis.
Can we prevent BRCA1-associated breast cancer by RANKL inhibition?
Case Report: Double Germline Mutations in BRCA1 and MSH2 in a Patient With Mixed Serous-Endometrioid Endometrial Carcinoma.
CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases.
CBLL1 is highly expressed in non-small cell lung cancer and promotes cell proliferation and invasion.
Cbx4 governs HIF-1? to potentiate angiogenesis of hepatocellular carcinoma by its SUMO E3 ligase activity.
Cdh1 inhibits WWP2-mediated ubiquitination of PTEN to suppress tumorigenesis in an APC-independent manner.
Cell cycle-dependent conjugation of endogenous BRCA1 protein with SUMO-2/3.
Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells.
Characterisation of the BRCT domains of the breast cancer susceptibility gene product BRCA1.
Characterization of a novel trans-activation domain of BRCA1 that functions in concert with the BRCA1 C-terminal (BRCT) domain.
Characterization of FANCL variants observed in patient cancer cells.
Characterization of the gene structure, functional significance, and clinical application of RNF180, a novel gene in gastric cancer.
Chemopreventive efficacy of stampidine in a murine breast cancer model.
Chromosomal instability in BRCA1- or BRCA2-defective human cancer cells detected by spontaneous micronucleus assay.
cIAP2 Is an Independent Signaling and Survival Factor during Mammary Lactational Involution and Tumorigenesis.
Classification of IVS1-10T-->C as a polymorphism of BRCA1.
Collaboration of Brca1 and Chk2 in tumorigenesis.
Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss-Driven Tumorigenesis.
Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers.
Comparison of prophylactic oophorectomy specimens from carriers and noncarriers of a BRCA1 or BRCA2 gene mutation. United Kingdom Coordinating Committee on Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group.
Conditional knockout of brca1/2 and p53 in mouse ovarian surface epithelium: do they play a role in ovarian carcinogenesis?
Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation.
Construction and characterization of recombinant adenoviruses expressing human BRCA1 or murine Brca1 genes.
Context Matters: RNF168 Connects with PALB2 to Rewire Homologous Recombination in BRCA1 Haploinsufficiency.
Cop1 constitutively regulates c-Jun protein stability and functions as a tumor suppressor in mice.
Correlation between BRCA1 expression and apoptosis-related biological parameters in sporadic breast carcinomas.
CPNE1 silencing inhibits the proliferation, invasion and migration of human osteosarcoma cells.
CRL4B promotes tumorigenesis by coordinating with SUV39H1/HP1/DNMT3A in DNA methylation-based epigenetic silencing.
CUL4B promotes proliferation and inhibits apoptosis of human osteosarcoma cells.
Cullin 3 and Its Role in Tumorigenesis.
Cullin 4-DCAF Proteins in Tumorigenesis.
Cullin-RING ligases in regulation of autophagy.
Cytoplasmic CUL9/PARC ubiquitin ligase is a tumor suppressor and promotes p53-dependent apoptosis.
Cytoplasmic HuR expression correlates with cIAP2 expression and clinicopathologic factors in oral squamous cell carcinoma cells.
DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer.
Decreased CUL4B expression inhibits malignant proliferation of glioma in vitro and in vivo.
Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase.
Depletion of BRCA1 impairs differentiation but enhances proliferation of mammary epithelial cells.
Depletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis.
Deregulated estrogen receptor signaling and DNA damage response in breast tumorigenesis.
Deregulated intracellular signaling by mutated c-CBL in myeloid neoplasms.
Differential effects of n-3 and n-6 polyunsaturated fatty acids on BRCA1 and BRCA2 gene expression in breast cell lines.
Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-delta11b.
Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells.
Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study.
DNA binding sites for putative methylation boundaries in the unmethylated region of the BRCA1 promoter.
DNA double-strand breaks: signaling, repair and the cancer connection.
DNA methylation profile in diffuse type gastric cancer: evidence for hypermethylation of the BRCA1 promoter region in early-onset gastric carcinogenesis.
DNA methylation-mediated downregulation of PTPN3 attenuates to boost TGF-? signaling in osteosarcoma cells.
Dominant-negative activity of a Brca1 truncation mutant: effects on proliferation, tumorigenicity in vivo, and chemosensitivity in a mouse ovarian cancer cell line.
Down-regulation of BRCA1 in chronic pancreatitis and sporadic pancreatic adenocarcinoma.
Down-regulation of BRCA1 in human sporadic breast cancer; analysis of DNA methylation patterns of the putative promoter region.
Down-regulation of RFWD3 inhibits cancer cells proliferation and migration in gastric carcinoma.
Downregulation of decidual SKP2 is associated with human recurrent miscarriage.
Drosophila Brat and human ortholog TRIM3 maintain stem cell equilibrium and suppress brain tumorigenesis by attenuating Notch nuclear transport.
Dysregulated expression of repetitive DNA in ER+/HER2- breast cancer.
Dysregulation of the centrosome induced by BRCA1 deficiency contributes to tissue-specific carcinogenesis.
E2F3b over-expression in ovarian carcinomas and in BRCA1 Haploinsufficient fallopian tube epithelium.
E3 Ubiquitin Ligase HRD1 Promotes Lung Tumorigenesis by Promoting Sirtuin 2 Ubiquitination and Degradation.
E3 ubiquitin ligase isolated by differential display regulates cervical cancer growth in vitro and in vivo via microRNA-143.
E3 ubiquitin ligase RNF126 affects bladder cancer progression through regulation of PTEN stability.
E3 ubiquitin ligase TRIM32 negatively regulates tumor suppressor p53 to promote tumorigenesis.
E3 ubiquitin ligase-mediated regulation of bone formation and tumorigenesis.
Early Loss of Histone H2B Monoubiquitylation Alters Chromatin Accessibility and Activates Key Immune Pathways That Facilitate Progression of Ovarian Cancer.
Effect of BRCA1 missense variants on gene reversion in DNA double-strand break repair mutants and cell cycle-arrested cells of Saccharomyces cerevisiae.
Effects of 3300 del A-1061 Ter BRCA1 frameshift mutation and calcium propionate on oxidative stress and breast carcinogenesis.
EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis.
Elevated expression of WWP2 in human lung adenocarcinoma and its effect on migration and invasion.
Elevated levels of somatic mutation in a manifesting BRCA1 mutation carrier.
Emerging roles of F-box proteins in cancer drug resistance.
Endocrinology of the wild and mutant BRCA1 gene and types of hormonal carcinogenesis.
Endothelial reprograming stimulated by oncostatin M promotes inflammation and tumorigenesis in VHL-deficient kidney tissue.
Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer.
Epigenetic markers of early tumor development.
Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer.
Epstein Barr virus: a prime candidate of breast cancer aetiology in Sudanese patients.
Erbin interacts with c-Cbl and promotes tumourigenesis and tumour growth in colorectal cancer by preventing c-Cbl-mediated ubiquitination and down-regulation of EGFR.
Erbin is a novel substrate of the Sag-?TrCP E3 ligase that regulates KrasG12D-induced skin tumorigenesis.
Establishment and histopathological study of patient-derived xenograft models and primary cell lines of epithelioid malignant peritoneal mesothelioma.
ETS2 and Twist1 promote invasiveness of Helicobacter pylori-infected gastric cancer cells by inducing Siah2.
Eukaryotic translation elongation factor 1 delta inhibits the ubiquitin ligase activity of SIAH-1.
Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma.
Evolutionary dynamics of BRCA1 alterations in breast tumorigenesis.
Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma.
Expression and mutations of BRCA in breast cancer and ovarian cancer: Evidence from bioinformatics analyses.
Expression and purification of human WWP2 HECT domain in Escherichia coli.
Expression of BRCA1 and BRCA2 in normal and neoplastic cells.
Expression of BRCA1 and BRCA2 proteins and their correlation with clinical staging in breast cancer.
Expression of Brca1 and splice variant Brca1delta11 RNA levels in mouse mammary gland during normal development and tumorigenesis.
Expression of estrogen receptor-alpha and Ki67 in relation to pathological and molecular features in early-onset infiltrating ductal carcinoma.
Expression of Pirh2, a newly identified ubiquitin protein ligase, in lung cancer.
Expression of TRF1, TRF2, TIN2, TERT, KU70, and BRCA1 proteins is associated with telomere shortening and may contribute to multistage carcinogenesis of gastric cancer.
Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors.
EZH2 and ALDH-1 mark breast epithelium at risk for breast cancer development.
FBXO31 Suppresses Gastric Cancer EMT by Targeting Snail1 for Proteasomal Degradation.
Four and a half LIM domains 2 contributes to the development of human tongue squamous cell carcinoma.
Four new cases of double heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and family characteristics.
Foxo3a transcription factor is a negative regulator of Skp2 and Skp2 SCF complex.
Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50?years.
Frequent frameshift mutations in 2 mononucleotide repeats of RNF43 gene and its regional heterogeneity in gastric and colorectal cancers.
Functional analysis of Cullin 3 E3 ligases in tumorigenesis.
Functional Analysis of Familial Asp67Glu and Thr1051Ser BRCA1 Mutations in Breast/Ovarian Carcinogenesis.
Functional assay for BRCA1: mutagenesis of the COOH-terminal region reveals critical residues for transcription activation.
Functional characterization of SAG/RBX2/ROC2/RNF7, an antioxidant protein and an E3 ubiquitin ligase.
Functional Impacts of the BRCA1-mTORC2 Interaction in Breast Cancer.
G:C > A:T mutations and potential epigenetic regulation of p53 in breast cancer.
Gadd45a Suppresses Ras-Driven Mammary Tumorigenesis by Activation of c-Jun NH2-Terminal Kinase and p38 Stress Signaling Resulting in Apoptosis and Senescence.
Gain-of-function c-CBL mutations associated with uniparental disomy of 11q in myeloid neoplasms.
GATA3 functions downstream of BRCA1 to suppress EMT in breast cancer.
Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers.
Gene expression profiling integrated into network modelling reveals heterogeneity in the mechanisms of BRCA1 tumorigenesis.
Gene expression profiling of taxol-resistant nasopharyngeal carcinoma cells with siRNA-mediated FOLR1 downregulation.
Generation and analysis of Brca1 conditional knockout mice.
Generation and Validation of Intracellular Ubiquitin Variant Inhibitors for USP7 and USP10.
Generation of focal mutations and large genomic deletions in the pancreas using inducible in vivo genome editing.
Genetic analysis of a breast-ovarian cancer family, with 7 cases of colorectal cancer linked to BRCA1, fails to support a role for BRCA1 in colorectal tumorigenesis.
Genetic interactions among Brca1, Brca2, Palb2, and Trp53 in mammary tumor development.
Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis.
Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy.
Genetic predisposition and chromosome instability in neuroblastoma.
Genetic Tracing of Clonal Expansion and Progression of Pancreatic Ductal Adenocarcinoma: A Case Report and Multi-Region Sequencing Analysis.
Genetic variants of BLM interact with RAD51 to increase breast cancer susceptibility.
Genomic alterations in histopathologically normal breast tissue from BRCA1 mutation carriers may be caused by BRCA1 haploinsufficiency.
Germline BRCA1 mutation reprograms breast epithelial cell metabolism towards mitochondrial-dependent biosynthesis: Evidence for metformin-based "starvation" strategies in BRCA1 carriers.
Germline BRCA1 mutations predispose to pancreatic adenocarcinoma.
Germline mutations of BRCA1 and BRCA2 in Korean sporadic ovarian carcinoma.
H19 non coding RNA-derived miR-675 enhances tumorigenesis and metastasis of breast cancer cells by downregulating c-Cbl and Cbl-b.
H2AK119Ub1 and H3K27Me3 in molecular staging for survival prediction of patients with pancreatic ductal adenocarcinoma.
Haploinsufficiency of Casitas B-Lineage Lymphoma Augments the Progression of Colon Cancer in the Background of Adenomatous Polyposis Coli Inactivation.
Helicobacter pylori Eradication Downregulates Cellular Inhibitor of Apoptosis Protein 2 in Gastric Carcinogenesis.
Hepatitis B virus upregulates cellular inhibitor of apoptosis protein 2 expression via the PI3K/AKT/NF-?B signaling pathway in liver cancer.
Heterozygosity for a mutation in Brca1 or Atm does not increase susceptibility to ENU-induced mammary tumors in Apc(Min)/+ mice.
HIF-1? overexpression in ductal carcinoma in situ of the breast in BRCA1 and BRCA2 mutation carriers.
High frequency of BRCA1 185delAG mutation in ovarian cancer in Israel. National Israel Study of Ovarian Cancer.
High proportion of missense mutations of the BRCA1 and BRCA2 genes in Japanese breast cancer families.
HMGA2 and high-grade serous ovarian carcinoma.
Homologous repair of DNA damage and tumorigenesis: the BRCA connection.
How do mutations affecting the breast cancer genes BRCA1 and BRCA2 cause cancer susceptibility?
HP1 promotes tumor suppressor BRCA1 functions during the DNA damage response.
Human Kruppel-like factor 5 is a target of the E3 ubiquitin ligase WWP1 for proteolysis in epithelial cells.
HUWE1 controls the development of non-small cell lung cancer through down-regulation of p53.
Hydrocortisone down-regulates the tumor suppressor gene BRCA1 in mammary cells: a possible molecular link between stress and breast cancer.
Identification of a comprehensive spectrum of genetic factors for hereditary breast cancer in a Chinese population by next-generation sequencing.
Identification of a gamma-tubulin-binding domain in BRCA1.
Identification of abrogated pathways in fallopian tube epithelium from BRCA1 mutation carriers.
Identification of DBC1 as a transcriptional repressor for BRCA1.
Immunohistochemical Loss of BRCA1 Protein in Uterine Serous Carcinoma.
Impaired skin and mammary gland development and increased gamma-irradiation-induced tumorigenesis in mice carrying a mutation of S1152-ATM phosphorylation site in Brca1.
Implication of BRCA1 gene in breast cancer.
In vitro analysis of genomic instability triggered by BRCA1 missense mutations.
Inactivation of parkin by promoter methylation correlated with lymph node metastasis and genomic instability in nasopharyngeal carcinoma.
Inactivation of SAG/RBX2 E3 ubiquitin ligase suppresses KrasG12D-driven lung tumorigenesis.
Inactivation of sag/rbx2/roc2 e3 ubiquitin ligase triggers senescence and inhibits kras-induced immortalization.
Inactivation of the Cullin (CUL)-RING E3 ligase by the NEDD8-activating enzyme inhibitor MLN4924 triggers protective autophagy in cancer cells.
Inactivation of the polycomb group protein Ring1B unveils an antiproliferative role in hematopoietic cell expansion and cooperation with tumorigenesis associated with Ink4a deletion.
Incorporating immunohistochemical markers into screening methods for BRCA1-mutated breast cancer.
Increased progesterone receptor expression in benign epithelium of BRCA1-related breast cancers.
Induction of ovarian leiomyosarcomas in mice by conditional inactivation of Brca1 and p53.
Infantile Epithelioid Sarcoma with Genomic Segmental Amplification of BIRC3/YAP1 as Double Minutes Plus Trisomy 2: A Case Report.
Inflammation and DNA Methylation-Dependent Down-Regulation of miR-34b-5p Mediates c-MYC Expression and CRL4DCAF4 E3 Ligase Activity in Colitis-Associated Cancer.
Influence of BRCA1 Germline Mutations in the Somatic Mutational Burden of Triple-Negative Breast Cancer.
Inherited breast cancer: an emerging picture.
Inhibition of RAS-mediated transformation and tumorigenesis by targeting the downstream E3 ubiquitin ligase seven in absentia homologue.
Integration of BRCA1-mediated miRNA and mRNA profiles reveals microRNA regulation of TRAF2 and NF?B pathway.
Integrative analysis of genomic alterations in triple-negative breast cancer in association with homologous recombination deficiency.
Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis.
Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer.
Intraductal Papillary Mucinous Neoplasms Arise From Multiple Independent Clones, Each With Distinct Mutations.
Introduction: BRCA1 and BRCA2 in mammary gland development and tumorigenesis.
Is there a link between ovarian cancer and tooth agenesis?
Knockdown of RNF6 inhibits gastric cancer cell growth by suppressing STAT3 signaling.
Knockout mouse models and mammary tumorigenesis.
Lack of Correlation between Aberrant p16, RAR-?2, TIMP3, ERCC1, and BRCA1 Protein Expression and Promoter Methylation in Squamous Cell Carcinoma Accompanying Candida albicans-Induced Inflammation.
Lack of RING Finger Domain (RFD) Mutations of the c-Cbl Gene in Oral Squamous Cell Carcinomas in Chennai, India.
Linc01638 promotes tumorigenesis in HER2+ breast cancer.
Liquiritigenin decreases tumorigenesis by inhibiting DNMT activity and increasing BRCA1 transcriptional activity in triple-negative breast cancer.
Loss of 53BP1 is a gain for BRCA1 mutant cells.
Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention.
Loss of BRCA1 Spontaneously Induces the Tumorigenesis in Lacrimal Gland.
Loss of COP1 expression determines poor prognosisin patients with gastric cancer.
Loss of expression of FANCD2 protein in sporadic and hereditary breast cancer.
Loss of heterozygosity at 8p, 9p and 17q in laryngeal cytological specimens.
Loss of heterozygosity at BRCA1, TP53, nm-23 and other loci on chromosome 17q in human breast carcinoma.
Loss of heterozygosity at the BRCA1 locus in Tunisian women with sporadic breast cancer.
Loss of RNF43 Function Contributes to Gastric Carcinogenesis by Impairing DNA Damage Response.
Loss of the inactive X chromosome and replication of the active X in BRCA1-defective and wild-type breast cancer cells.
Loss of the novel tumour suppressor and polarity gene Trim62 (Dear1) synergizes with oncogenic Ras in invasive lung cancer.
Low expression of bcl-2 in Brca1-associated breast cancers.
Mammalian Rad51 protein: a RecA homologue with pleiotropic functions.
Mammary tumorigenesis following transgenic expression of a dominant negative CHK2 mutant.
MARCH6 promotes hepatocellular carcinoma development through up-regulation of ATF2.
MARCH6 promotes Papillary Thyroid Cancer development by destabilizing DHX9.
MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent.
Mechanisms of alcohol-associated cancers: introduction and summary of the symposium.
Mechanisms of increased risk of tumorigenesis in Atm and Brca1 double heterozygosity.
Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.
Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus.
Methylation is less abundant in BRCA1-associated compared with sporadic breast cancer.
Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens.
Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics.
MEX3C regulates lipid metabolism to promote bladder tumorigenesis through JNK pathway.
miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers.
Missense mutations of BRCA1 gene affect the binding with p53 both in vitro and in vivo.
Mitotic accumulation of dimethylated lysine 79 of histone h3 is important for maintaining genome integrity during mitosis in human cells.
Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis.
Molecular analysis of DNA repair gene methylation and protein expression during chemical-induced rat lung carcinogenesis.
Molecular evidence for putative tumour suppressor genes on chromosome 13q specific to BRCA1 related ovarian and fallopian tube cancer.
Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers.
Molecular Role of RNF43 in Canonical and Noncanonical Wnt Signaling.
Mouse models for BRCA1 associated tumorigenesis: from fundamental insights to preclinical utility.
Mouse models of BRCA1 and their application to breast cancer research.
MSH2 role in BRCA1-driven tumorigenesis: A preliminary study in yeast and in human tumors from BRCA1-VUS carriers.
Mule Regulates the Intestinal Stem Cell Niche via the Wnt Pathway and Targets EphB3 for Proteasomal and Lysosomal Degradation.
Multi-step process of human breast carcinogenesis: a role for BRCA1, BECN1, CCND1, PTEN and UVRAG.
Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice.
Multiplex ddPCR assay for screening copy number variations in BRCA1 gene.
Mutant BRCA1 genes antagonize phenotype of wild-type BRCA1.
Mutation analysis of BRCA1, TP53, and KRAS2 in ovarian and related pelvic tumors.
Mutation analysis of the BRCA1 gene in 76 Japanese ovarian cancer patients: four germline mutations, but no evidence of somatic mutation.
Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells.
Mutation screening of BRCA1 using PTT and LOH analysis at 17q21 in breast carcinomas from familial and non-familial cases.
Mutational analysis of BARD1 in familial breast cancer patients in Japan.
Mutational analysis of BRCA1 gene in ovarian and breast-ovarian cancer families in Japan.
Mutations in the BRCA1 gene in Japanese breast cancer patients.
Mutations of the BRCA1 gene in human cancer.
Negative feedback loop of BRCA1-BARD1 ubiquitin ligase on estrogen receptor alpha stability and activity antagonized by cancer-associated isoform of BARD1.
Negative Regulation of AKT Activation by BRCA1.
New boys in town: prognostic role of SF3B1, NOTCH1 and other cryptic alterations in chronic lymphocytic leukemia and how it works.
Noncanonical Role of FBXO6 in Regulating Antiviral Immunity.
Normal lymphocyte development and thymic lymphoma formation in Brca1 exon-11-deficient mice.
Novel somatic mutations in the BRCA1 gene in sporadic breast tumors.
NUSAP1 influences the DNA damage response by controlling BRCA1 protein levels.
Oestrogen causes ATBF1 protein degradation through the oestrogen-responsive E3 ubiquitin ligase EFP.
Oncogenic activity of BIRC2 and BIRC3 mutants independent of nuclear factor-?B-activating potential.
Oncogenic Wnt/?-catenin signalling pathways in the cancer-resistant epididymis have implications for cancer research.
Opposing roles for mammary epithelial-specific PPAR? signaling and activation during breast tumour progression.
OTUD5 cooperates with TRIM25 in transcriptional regulation and tumor progression via deubiquitination activity.
Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus.
Ovarian cancer stroma: pathophysiology and the roles in cancer development.
Ovarian carcinoma in situ with germline BRCA1 mutation and loss of heterozygosity at BRCA1 and TP53.
Ovarian surface epithelium: family history and early events in ovarian cancer.
Overexpression of HACE1 in gastric cancer inhibits tumor aggressiveness by impeding cell proliferation and migration.
Overexpression of Ran GTPase Components Regulating Nuclear Export, but not Mitotic Spindle Assembly, Marks Chromosome Instability and Poor Prognosis in Breast Cancer.
p16INK4a suppresses BRCA1-deficient mammary tumorigenesis.
PALB2 is an integral component of the BRCA complex required for homologous recombination repair.
Parkin as a tumor suppressor gene for hepatocellular carcinoma.
Parkin deficiency contributes to pancreatic tumorigenesis by inducing spindle multipolarity and misorientation.
Parkin enhances the expression of cyclin-dependent kinase 6 and negatively regulates the proliferation of breast cancer cells.
Parkin facilitates proteasome inhibitor-induced apoptosis via suppression of NF-?B activity in hepatocellular carcinoma.
Parkin in cancer: Mitophagy-related/unrelated tasks.
Parkin Regulates Mitosis and Genomic Stability through Cdc20/Cdh1.
Parkin ubiquitinates phosphoglycerate dehydrogenase to suppress serine synthesis and tumor progression.
Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect.
Parkinson's disease-associated protein Parkin: an unusual player in cancer.
Pathology of sporadic breast tumors with LOH at the BRCA1 locus: correlation with histopathological features specific to familial BRCA1 tumors and absence of microsatellite instability.
Pellino-1 confers chemoresistance in lung cancer cells by upregulating cIAP2 through Lys63-mediated polyubiquitination.
Phosphorylation-dependent ubiquitination of cyclin D1 by the SCF(FBX4-alphaB crystallin) complex.
Phytoestrogens regulate the expression of genes involved in different biological processes in BRCA2 knocked down MCF-7, MDA-MB-231 and MCF-10a cell lines.
PINK1/Parkin Influences Cell Cycle by Sequestering TBK1 at Damaged Mitochondria, Inhibiting Mitosis.
Pirh2 RING-finger E3 ubiquitin ligase: its role in tumorigenesis and cancer therapy.
Poly(ADP-Ribose) Polymerase Inhibitors in Prostate Cancer: Molecular Mechanisms, and Preclinical and Clinical Data.
Polymorphisms in HPV E6/E7 protein interacted genes and risk of cervical cancer in Chinese women: a case-control analysis.
Post-translational modification of Parkin and its research progress in cancer.
Predicting high risk disease using serum and DNA biomarkers.
Preferential allelic expression can lead to reduced expression of BRCA1 in sporadic breast cancers.
Premature menopause in patients with BRCA1 gene mutation.
Prepubertal estradiol and genistein exposures up-regulate BRCA1 mRNA and reduce mammary tumorigenesis.
Prepubertal octylphenol exposure up-regulate BRCA1 expression, down-regulate ERalpha expression and reduce rat mammary tumorigenesis.
Primary Squamous Cell Carcinoma of the Endometrium Unrelated to Human Papilloma Virus: A Molecular Study.
Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells.
Promoter Hypermethylation and Expression Changes of BRCA1 Gene in a Cohort of Sporadic Breast Cancer Cases among Pakistani Population.
Promoter hypermethylation of BRCA1 correlates with absence of expression in hereditary breast cancer tumors.
Promoter methylation of BRCA1 in the prognosis of breast cancer: a meta-analysis.
Prophylactic window therapy with the clinical poly(ADP-ribose) polymerase inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice.
Protective effects of prepubertal genistein exposure on mammary tumorigenesis are dependent on BRCA1 expression.
PTEN breast cancer susceptibility: a matter of dose.
Quantitative analysis of BRCA1, BRCA2 and Hmsh2 mRNA expression in colorectal Lieberkühnien adenocarcinomas and matched normal mucosa: relationship with cellular proliferation.
RAD51 up-regulation bypasses BRCA1 function and is a common feature of BRCA1-deficient breast tumors.
RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis.
Rb inactivation accelerates neoplastic growth and substitutes for recurrent amplification of cIAP1, cIAP2 and Yap1 in sporadic mammary carcinoma associated with p53 deficiency.
Reduced BRCA1 transcript levels in freshly isolated blood leukocytes from BRCA1 mutation carriers is mutation specific.
Reduced cell death, invasive and angiogenic features conferred by BRCA1-deficiency in mammary epithelial cells transformed with H-Ras.
Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases.
Regulation of BRCA1 expression and its relationship to sporadic breast cancer.
Regulation of p53 level by UBE4B in breast cancer.
Regulation of progesterone receptor signaling by BRCA1 in mammary cancer.
Retroviral transduction of splice variant Brca1-Delta11 or mutant Brca1-W1777Stop causes mouse epithelial mammary atypical duct hyperplasia.
Reversing effect of ring finger protein 43 inhibition on malignant phenotypes of human hepatocellular carcinoma.
RING1B recruits EWSR1-FLI1 and cooperates in the remodeling of chromatin necessary for Ewing sarcoma tumorigenesis.
Risk of Serous Endometrial Carcinoma in Women With Pathogenic BRCA1/2 Variant After Risk-Reducing Salpingo-Oophorectomy.
RN181 suppressed tumor growth of hepatocellular carcinoma by inhibition of the ERK/MAPK pathway.
RNF128 Promotes Malignant Behaviors via EGFR/MEK/ERK Pathway in Hepatocellular Carcinoma.
RNF13: a novel RING-type ubiquitin ligase over-expressed in pancreatic cancer.
RNF168 regulates R-loop resolution and genomic stability in BRCA1/2-deficient tumors.
RNF183 Is a Prognostic Biomarker and Correlates With Tumor Purity, Immune Infiltrates in Uterine Corpus Endometrial Carcinoma.
RNF20 Suppresses Tumorigenesis by Inhibiting SREBP1c-PTTG1 Axis in Kidney Cancer.
RNF43 and ZNRF3 are commonly altered in serrated pathway colorectal tumorigenesis.
RNF43 frameshift mutations contribute to tumourigenesis in right-sided colon cancer.
RNF43 interacts with NEDL1 and regulates p53-mediated transcription.
RNF43 mutations are recurrent in Chinese patients with mucinous ovarian carcinoma but absent in other subtypes of ovarian cancer.
RNF43 Pathogenic Germline Variant in a Family with Colorectal Cancer.
Role of E3 ubiquitin ligases in lung cancer.
Role of Pirh2 in mediating the regulation of p53 and c-Myc.
Role of RNF20 in cancer development and progression - a comprehensive review.
Role of the tumor suppressor gene Brca1 in genetic stability and mammary gland tumor formation.
Roles of BRCA1 in DNA damage repair: a link between development and cancer.
Roles of E3 ubiquitin ligases in gastric cancer carcinogenesis and their effects on cisplatin resistance.
SAG expression associates with COPB2-related signaling and a poorer prognosis in breast cancer.
SAG/ROC/Rbx/Hrt, a zinc RING finger gene family: molecular cloning, biochemical properties, and biological functions.
SAG/ROC2 E3 ligase regulates skin carcinogenesis by stage-dependent targeting of c-Jun/AP1 and IkappaB-alpha/NF-kappaB.
Screening and verification of proteins that interact with HSPC238.
SCYL1 binding protein 1 promotes the ubiquitin-dependent degradation of Pirh2 and has tumor-suppressive function in the development of hepatocellular carcinoma.
Selective loss of heterozygosity in multiple breast cancers from a carrier of mutations in both BRCA1 and BRCA2.
Senescence, aging, and malignant transformation mediated by p53 in mice lacking the Brca1 full-length isoform.
Skp-cullin-F box E3 ligase component FBXL2 ubiquitinates Aurora B to inhibit tumorigenesis.
Skp2 overexpression is associated with loss of BRCA2 protein in human prostate cancer.
Skp2-mediated ubiquitination and mitochondrial localization of Akt drive tumor growth and chemoresistance to cisplatin.
Small molecule TSC01682 inhibits osteosarcoma cell growth by specifically disrupting the CUL4B-DDB1 interaction and decreasing the ubiquitination of CRL4B E3 ligase substrates.
Small RING finger proteins RBX1 and RBX2 of SCF E3 ubiquitin ligases: the role in cancer and as cancer targets.
SMURF2 prevents detrimental changes to chromatin, protecting human dermal fibroblasts from chromosomal instability and tumorigenesis.
Smurf2 regulates the senescence response and suppresses tumorigenesis in mice.
Somatic mutations in the BRCA1 gene in sporadic ovarian tumours.
Specific changes in the proteomic pattern produced by the BRCA1-Ser1841Asn missense mutation.
Spinophilin loss contributes to tumorigenesis in vivo.
SPOP inhibits mice pancreatic stellate cell activation by promoting FADD degradation in cerulein-induced chronic pancreatitis.
SPOP promotes tumor progression via activation of ?-catenin/TCF4 complex in clear cell renal cell carcinoma.
SPOP-mediated ubiquitination and degradation of PDK1 suppresses AKT kinase activity and oncogenic functions.
SPOP-PTEN-SUFU axis promotes progression of clear cell renal cell carcinoma via activating SHH and WNT pathway.
Sporadic breast carcinomas with somatic BRCA1 gene deletions share genotype/phenotype features with familial breast carcinomas.
Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway.
Src promotes destruction of c-Cbl: implications for oncogenic synergy between Src and growth factor receptors.
Stromal adipocyte PPAR? protects against breast tumorigenesis.
Structural Basis for the BRCA1 BRCT Interaction with the Proteins ATRIP and BAAT1.
Structural basis of DDB1-and-Cullin 4-associated Factor 1 (DCAF1) recognition by merlin/NF2 and its implication in tumorigenesis by CD44-mediated inhibition of merlin suppression of DCAF1 function.
Structure and function of the papillomavirus E6 protein and its interacting proteins.
Structure of a Bmi-1-Ring1B polycomb group ubiquitin ligase complex.
Studying Therapy Response and Resistance in Mouse Models for BRCA1-Deficient Breast Cancer.
Suppression of tumorigenicity of breast cancer cells by transfer of human chromosome 17 does not require transferred BRCA1 and p53 genes.
Synthetic lethal targeting of RNF20 through PARP1 silencing and inhibition.
Synthetic lethality: the road to novel therapies for breast cancer.
Targeted Inhibition of the E3 Ligase SCFSkp2/Cks1 Has Antitumor Activity in RB1-Deficient Human and Mouse Small-Cell Lung Cancer.
Targeting Hedgehog Signalling through the Ubiquitylation Process: The Multiple Roles of the HECT-E3 Ligase Itch.
Targeting the Akt/mTOR pathway in Brca1-deficient cancers.
TGF-beta1 inhibits BRCA1 expression through a pathway that requires pRb.
The 5' end of the BRCA1 gene lies within a duplicated region of human chromosome 17q21.
The AMPK-Parkin axis negatively regulates necroptosis and tumorigenesis by inhibiting the necrosome.
The basal phenotype of BRCA1-related breast cancer: past, present and future.
The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells.
The cancer connection: BRCA1 and BRCA2 tumor suppression in mice and humans.
The characteristics and roles of ?-TrCP1/2 in carcinogenesis.
The correlations between BRCA1 defect and environmental factors in the risk of breast cancer.
The E3 ubiquitin ligase CHIP/miR-92b/PTEN regulatory network contributes to tumorigenesis of glioblastoma.
The E3 ubiquitin ligase RNF135 regulates the tumorigenesis activity of tongue cancer SCC25 cells.
The emerging role for Cullin 4 family of E3 ligases in tumorigenesis.
The emerging role of SPOP protein in tumorigenesis and cancer therapy.
The Environmental Sensor AHR Protects from Inflammatory Damage by Maintaining Intestinal Stem Cell Homeostasis and Barrier Integrity.
The expanding role of yeast in cancer research and diagnosis: insights into the function of the oncosuppressors p53 and BRCA1/2.
The Function of BARD1 in Centrosome Regulation in Cooperation with BRCA1/OLA1/RACK1.
The functional BRCA1 rs799917 genetic polymorphism is associated with gastric cancer risk in a Chinese Han population.
The future of breast cancer systemic therapy: the next 10 years.
The histone H2B-specific ubiquitin ligase RNF20/hBRE1 acts as a putative tumor suppressor through selective regulation of gene expression.
The important molecular markers on chromosome 17 and their clinical impact in breast cancer.
The incidence of occult ovarian neoplasia and cancer in BRCA1/2 mutation carriers after the bilateral prophylactic salpingo-oophorectomy (PBSO): A single-center prospective study.
The interaction of PP1 with BRCA1 and analysis of their expression in breast tumors.
The Isolated C-Terminal Domain of Ring1B Is a Dimer Made of Stable, Well-Structured Monomers.
The joint effect of smoking and AIB1 on breast cancer risk in BRCA1 mutation carriers.
The mammary gland carcinogens: the role of metal compounds and organic solvents.
The most common RNF43 mutant G659Vfs*41 is fully functional in inhibiting Wnt signaling and unlikely to play a role in tumorigenesis.
The RNA-binding protein HuR is a novel target of Pirh2 E3 ubiquitin ligase.
The role and mechanism of action of RNF186 in colorectal cancer through negative regulation of NF-?B.
The role of BRCA1 and BRCA2 in prostate cancer.
The role of BRCA1 in homologous recombination repair in response to replication stress: significance in tumorigenesis and cancer therapy.
The role of cullin4B in human cancers.
The Role of E3, E4 Ubiquitin Ligase (UBE4B) in Human Pathologies.
The role of the breast cancer susceptibility gene 1 (BRCA1) in sporadic epithelial ovarian cancer.
The Role of Tripartite Motif Family Proteins in TGF-? Signaling Pathway and Cancer.
The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis.
The Skp2-SCF E3 Ligase Regulates Akt Ubiquitination, Glycolysis, Herceptin Sensitivity, and Tumorigenesis.
The transcription factor GATA3 is required for homologous recombination repair by regulating CtIP expression.
The two human homologues of yeast UFD2 ubiquitination factor, UBE4A and UBE4B, are located in common neuroblastoma deletion regions and are subject to mutations in tumours.
The ubiquitin ligase RNF220 enhances canonical Wnt signaling through USP7-mediated deubiquitination of ?-catenin.
The unliganded glucocorticoid receptor positively regulates the tumour suppressor gene BRCA1 through GABP beta.
Time-resolved single-cell analysis of Brca1 associated mammary tumourigenesis reveals aberrant differentiation of luminal progenitors.
TP53, BRCA1, and BRCA2 tumor suppressor genes are not commonly mutated in survivors of Hodgkin's disease with second primary neoplasms.
Tracking evolution of BRCA1-associated breast cancer.
TRAIP promotes malignant behaviors and correlates with poor prognosis in liver cancer.
Transcription alterations of members of the ubiquitin-proteasome network in prostate carcinoma.
Transcriptional autoregulation by BRCA1.
Transcriptional characteristics of familial non-BRCA1/BRCA2 breast tumors.
Transcriptional profiling of breast cancer cells exposed to soy phytoestrogens after BRCA1 knockdown with a whole human genome microarray approach.
TRIM Family Proteins: Roles in Autophagy, Immunity, and Carcinogenesis.
TRIM22 inhibits the proliferation of gastric cancer cells through the Smad2 protein.
TRIM23 overexpression is a poor prognostic factor and contributes to carcinogenesis in colorectal cancer.
TRIM32 Protein Sensitizes Cells to Tumor Necrosis Factor (TNF{alpha})-induced Apoptosis via Its RING Domain-dependent E3 Ligase Activity against X-linked Inhibitor of Apoptosis (XIAP).
TRIM59 as a novel molecular biomarker to predict the prognosis of patients with NSCLC.
TRIM65 in White Matter Lesions, Innate Immunity and Tumor.
TRIMming Type I Interferon-Mediated Innate Immune Response in Antiviral and Antitumor Defense.
Tripartite motif-containing 3 (TRIM3) enhances ER signaling and confers tamoxifen resistance in breast cancer.
Tripartite motif-containing protein 37 is overexpressed in human glioma and its downregulation inhibits human glioma cell growth in vitro.
Tumor formation in mice with conditional inactivation of Brca1 in epithelial tissues.
Tumor suppressor genes and breast cancer.
Tumorigenesis as a consequence of genetic instability in Brca1 mutant mice.
Tumorigenesis in mice carrying a truncating Brca1 mutation.
Tumour biological features of BRCA1-induced breast and ovarian cancer.
Tumour induction by activated abl involves tyrosine phosphorylation of the product of the cbl oncogene.
Ubiquitination of NF-?B p65 by FBXW2 suppresses breast cancer stemness, tumorigenesis, and paclitaxel resistance.
Unique BIR domain sets determine inhibitor of apoptosis protein-driven cell death and NOD2 complex signal specificity.
Using mouse models to investigate the biological and physiological consequences of defects in the Fanconi anaemia/breast cancer DNA repair signalling pathway.
Uterus hyperplasia and increased carcinogen-induced tumorigenesis in mice carrying a targeted mutation of the Chk2 phosphorylation site in Brca1.
Whence High-Grade Serous Ovarian Cancer.
Widespread bimodal intrachromosomal genomic instability in sporadic breast cancers associated with 13q allelic imbalance.
Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy.
[A paradox and three egnimas about the role of BRCA1 in breast and ovarian cancers]
[Analysis of loss of heterozygosity of the tumor suppressor genes p53 and BRCA1 in ovarial carcinomas]
[CRL4B complex promotes the development of pancreatic cancer by inhibiting secreted frizzled related protein 1].
[Effect of STIL on the Gene Expression Profile of Gastric Cancer Cells].
[Implication of the ubiquitin ligase c-Cbl in bone formation and tumorigenesis].
[Roles of Aurora-A in tumorigenesis and prognosis of breast cancer.]
[The function of Aurora A and its role in the development of liver cancer].
[Ubiquitination-mediated degradation of epidermal growth factor receptor]
Carcinoma
53BP1 expression in sporadic and inherited ovarian carcinoma: Relationship to genetic status and clinical outcomes.
A BAP1 Mutation-specific MicroRNA Signature Predicts Clinical Outcomes in Clear Cell Renal Cell Carcinoma Patients with Wild-type BAP1.
A candidate precursor to serous carcinoma that originates in the distal fallopian tube.
A descriptive study of BRCA1 testing and reactions to disclosure of test results.
A diagnostic dilemma following risk-reducing surgery for BRCA1 mutation - a case report of primary papillary serous carcinoma presenting as sigmoid cancer.
A functional BRCA1 coding sequence genetic variant contributes to risk of esophageal squamous cell carcinoma.
A genetic epidemiological study of carcinoma of the fallopian tube.
A Human Head and Neck Squamous Cell Carcinoma Cell Line with Acquired cis-Diamminedichloroplatinum-Resistance Shows Remarkable Upregulation of BRCA1 and Hypersensitivity to Taxane.
A low-grade ovarian carcinoma case with coincident LOH of PTCH1 and BRCA1, and a mutation in BRCA1.
A Mouse Model That Reproduces the Developmental Pathways and Site Specificity of the Cancers Associated With the Human BRCA1 Mutation Carrier State.
A novel gene encoding a B-box protein within the BRCA1 region at 17q21.1.
A Novel Pathway that Links Caveolin-1 Down-Regulation to BRCA1 Dysfunction in Serous Epithelial Ovarian Cancer Cells.
A population-based analysis of germline BAP1 mutations in melanoma.
A rectovaginal septum mass in a BRCA1 positive patient years after risk reducing surgery: A case report.
A salpingeal carcinoma revealed after prophylactic salpingoophorectomy in an asymptomatic BRCA1 carrier with breast malignancy.
A systematic review on the frequency of BRCA promoter methylation in breast and ovarian carcinomas of BRCA germline mutation carriers: Mutually exclusive, or not?
Aberrant methylation of the HACE1 gene is frequently detected in advanced colorectal cancer.
Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma.
Absence of DICER1, CTCF, RPL22, DNMT3A, TRRAP, IDH1 and IDH2 hotspot mutations in patients with various subtypes of ovarian carcinomas.
Absence of loss of heterozygosity of BRCA1 in a renal tumor from a BRCA1 germline mutation carrier.
Additional molecular and clinical evidence open the way to definitive IARC classification of the BRCA1 c.5332G?>?A (p.Asp1778Asn) variant.
AGO Austria recommendations for genetic testing of patients with ovarian cancer.
Allelic deletion on chromosome 17p13.3 in early ovarian cancer.
Allelic imbalance and microsatellite instability in BRCA1 associated breast and ovarian tumors.
Allelic loss of 6q25-27, the PARKIN tumor suppressor gene locus, in cervical carcinoma.
Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinoma.
Alterations of the tumor suppressor gene Parkin in non-small cell lung cancer.
Altering the Microbiome Inhibits Tumorigenesis in a Mouse Model of Oviductal High-Grade Serous Carcinoma.
Alternatives to risk-reducing surgery for ovarian cancer.
An Alternate Diagnostic Algorithm for the Diagnosis of Intraepithelial Fallopian Tube Lesions.
An update on DNA-based BRCA1/BRCA2 genetic counseling in hereditary breast cancer.
Analysis of BRCA1 and RAD51C Promoter Methylation in Italian Families at High-Risk of Breast and Ovarian Cancer.
Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
Analysis of ZNF350/ZBRK1 promoter variants and breast cancer susceptibility in non-BRCA1/2 French Canadian breast cancer families.
Anti-Apoptotic Signature in Thymic Squamous Cell Carcinomas - Functional Relevance of Anti-Apoptotic BIRC3 Expression in the Thymic Carcinoma Cell Line 1889c.
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
Association between clinical pathology and multiple genes mRNA expression in Chinese patients with NSCLC.
Association of HMGB1, BRCA1 and P62 expression in ovarian cancer and chemotherapy sensitivity.
Association of the von Hippel-Lindau protein with AUF1 and posttranscriptional regulation of VEGFA mRNA.
Atm heterozygosity cooperates with loss of Brca1 to increase the severity of mammary gland cancer and reduce ductal branching.
Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers.
Author Correction: CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity.
BAP1 promotes viability and migration of ECA109 cells through KLF5/CyclinD1/FGF-BP1.
BAP1 tumor predisposition syndrome case report: pathological and clinical aspects of BAP1-inactivated melanocytic tumors (BIMTs), including dermoscopy and confocal microscopy.
Basal-like Breast Cancer: Comparison of Imaging Characteristics.
Biallelic Deleterious BRCA1 Mutations in a Woman with Early-Onset Ovarian Cancer.
Biomarkers of Targeted Therapy and Immuno-Oncology in Cancers Metastatic to the Breast.
BRCA germline mutations in women with uterine serous carcinoma--still a debate.
BRCA, the oviduct, and the space and time continuum of pelvic serous carcinogenesis.
BRCA1 5382insC mutation in sporadic and familial breast and ovarian carcinoma in Scotland.
BRCA1 and ?H2AX as independent prognostic markers in oral squamous cell carcinoma.
BRCA1 and BRCA2 families and the risk of skin cancer.
BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
BRCA1 and BRCA2 mutations among 233 unselected Finnish ovarian carcinoma patients.
BRCA1 and BRCA2 mutations among Finnish ovarian carcinoma families.
BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma.
BRCA1 and BRCA2 mutations in ovarian cancer: Covariation with specific cytogenetic features.
BRCA1 and MAD2 Are Coexpressed and Are Prognostic Indicators in Tubo-ovarian High-Grade Serous Carcinoma.
BRCA1 and p53 protein expression in cultured ovarian surface epithelial cells derived from women with and without a BRCA1 germline mutation.
BRCA1 Associated Protein Increases Invasiveness of Esophageal Squamous-Cell Carcinoma.
BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study.
BRCA1 expression in benign and malignant breast lesions.
BRCA1 expression in leukoplakia and carcinoma of the tongue.
BRCA1 Expression is an Important Biomarker for Chemosensitivity: Suppression of BRCA1 Increases the Apoptosis via Up-regulation of p53 and p21 During Cisplatin Treatment in Ovarian Cancer Cells.
BRCA1 gene mutations in sporadic ovarian carcinomas: detection by PCR and reverse allele-specific oligonucleotide hybridization.
BRCA1 gene mutations in women with papillary serous carcinoma of the peritoneum.
BRCA1 germline mutation presenting as an adenocarcinoma of unknown primary.
BRCA1 immunohistochemical staining as a prognostic indicator in uterine serous carcinoma.
BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas.
BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance.
BRCA1 is expressed in uterine serous carcinoma (USC) and controls insulin-like growth factor I receptor (IGF-IR) gene expression in USC cell lines.
BRCA1 Loss Induces GADD153-Mediated Doxorubicin Resistance in Prostate Cancer.
BRCA1 mRNA expression as a predictive and prognostic marker in advanced esophageal squamous cell carcinoma treated with cisplatin- or docetaxel-based chemotherapy/chemoradiotherapy.
BRCA1 mutation site may be linked with nuclear DNA ploidy in BRCA1-mutated ovarian carcinomas.
BRCA1 mutations in familial ovarian cancer.
BRCA1 mutations in primary breast and ovarian carcinomas.
BRCA1 mutations in Taiwanese with epithelial ovarian carcinoma and sporadic primary serous peritoneal carcinoma.
BRCA1 p.His1673del is a pathogenic mutation associated with a predominant ovarian cancer phenotype.
BRCA1 promoter hypermethylation and protein expression in ovarian carcinoma-an Indian study.
BRCA1 promoter hypermethylation in sporadic epithelial ovarian carcinoma: Association with low expression of BRCA1, improved survival and co-expression of DNA methyltransferases.
BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study.
BRCA1 regulates follistatin function in ovarian cancer and human ovarian surface epithelial cells.
BRCA1 regulation on ?-hCG: a mechanism for tumorigenicity in BRCA1 defective breast cancer.
BRCA1 supports XIST RNA concentration on the inactive X chromosome.
BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II).
BRCA1, Ki67, and ?-Catenin Immunoexpression Is Not Related to Differentiation, Platinum Response, or Prognosis in Women With Low- and High-Grade Serous Ovarian Carcinoma.
BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma.
BRCA1-associated epigenetic regulation of p73 mediates an effector pathway for chemosensitivity in ovarian carcinoma.
BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1? activation.
BRCA1-related malignancies in a family presenting with von Recklinghausen's disease.
BRCA1/2 Germline Mutations in Jewish Patients With Uterine Serous Carcinoma.
BRCA1: the enigma of tissue-specific tumor development.
BRCA2 mutations in primary breast and ovarian cancers.
BRCA2, but not BRCA1, mutations account for familial ovarian cancer in Iceland: a population-based study.
Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study.
Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA.
Breast imaging findings in women with BRCA1- and BRCA2-associated breast carcinoma.
Can personality traits affect the quality of life of women with the BRCA1/BRCA2 mutations before and after prophylactic adnexectomy?
Cancer in Jews: introduction and overview.
Carcinoma of the breast with medullary-like features: diagnostic challenges and relationship with BRCA1 and EZH2 functions.
Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer.
Cells redox environment modulates BRCA1 expression and DNA homologous recombination repair.
Changes in the mouse estrus cycle in response to BRCA1 inactivation suggest a potential link between risk factors for familial and sporadic ovarian cancer.
Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers.
Characteristics of women with ovarian carcinoma who have BRCA1 and BRCA2 mutations not identified by clinical testing.
Characterization of 2 novel and 2 recurring BRCA1 germline mutations in breast and/or ovarian carcinoma patients from the area of Naples.
Characterization of ten novel and 13 recurring BRCA1 and BRCA2 germline mutations in Italian breast and/or ovarian carcinoma patients. Mutations in brief no. 178. Online.
Characterization of therapy-related acute leukemia in hereditary breast-ovarian carcinoma patients: role of BRCA1 mutation and topoisomerase II-directed therapy.
Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations.
CHIP/Stub1 regulates the Warburg effect by promoting degradation of PKM2 in ovarian carcinoma.
Clear cell carcinoma of the fimbria of the fallopian tube in a BRCA1 carrier undergoing prophylactic surgery.
Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers.
Clinical and pathological features of BRCA1 associated carcinomas in a hospital-based sample of Dutch breast cancer patients.
Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma.
Clinical Impact of Somatic Variants in Homologous Recombination Repair-Related Genes in Ovarian High-Grade Serous Carcinoma.
Clinical importance of FANCD2, BRIP1, BRCA1, BRCA2 and FANCF expression in ovarian carcinomas.
Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up.
Cloning, genetic mapping and expression studies of the rat Brca1 gene.
Coexistence of the BRCA1 and KRAS mutations in a patient with salivary gland carcinoma arising in mediastinal mature teratoma.
Coincident PTCH and BRCA1 germline mutations in a patient with nevoid basal cell carcinoma syndrome and familial breast cancer.
Combined Treatment Modalities for High-Energy Proton Irradiation: Exploiting Specific DNA Repair Dependencies.
Contribution of epigenetic alteration of BRCA1 and BRCA2 genes in breast carcinomas in Tunisian patients.
Correction to: Rb inactivation accelerates neoplastic growth and substitutes for recurrent amplification of cIAP1, cIAP2 and Yap1 in sporadic mammary carcinoma associated with p53 deficiency.
Corrigendum: The Polycomb proteins RING1B and EZH2 repress the tumoral pro-inflammatory function in metastasizing primary cutaneous squamous cell carcinoma.
CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity.
CUL4 E3 ligase regulates the proliferation and apoptosis of lung squamous cell carcinoma and small cell lung carcinoma.
Cultures of ovarian surface epithelium from women with and without a hereditary predisposition to develop female adnexal carcinoma.
Cytogenetic instability in ovarian epithelial cells from women at risk of ovarian cancer.
Cytoplasmic HuR expression correlates with cIAP2 expression and clinicopathologic factors in oral squamous cell carcinoma cells.
Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression.
Deletions of BRCA1/2 and p53 R248W gain-of-function mutation suggest impaired homologous recombination repair in fragile histidine triad-negative sebaceous gland carcinomas.
Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer.
DNA copy number profiling reveals extensive genomic loss in hereditary BRCA1 and BRCA2 ovarian carcinomas.
DNA methylation profile in diffuse type gastric cancer: evidence for hypermethylation of the BRCA1 promoter region in early-onset gastric carcinogenesis.
Double heterozygosity for mutations in the BRCA1 and BRCA2 genes in a breast cancer patient.
Downregulation of Fanconi anemia genes in sporadic head and neck squamous cell carcinoma.
DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells.
Dysregulated Wnt?signalling and recurrent mutations?of?the tumour suppressor?RNF43?in early?gastric carcinogenesis.
E2F3b over-expression in ovarian carcinomas and in BRCA1 Haploinsufficient fallopian tube epithelium.
E3 ligase STUB1 attenuates stemness and tumorigenicity of oral carcinoma cells via transglutaminase 2 regulation.
E3 ubiquitin ligase Pirh2 enhances tumorigenic properties of human non-small cell lung carcinoma cells.
Effect of BRCA1 on the Concurrent Chemoradiotherapy Resistance of Cervical Squamous Cell Carcinoma Based on Transcriptome Sequencing Analysis.
Effects of JWA, XRCC1 and BRCA1 mRNA expression on molecular staging for personalized therapy in patients with advanced esophageal squamous cell carcinoma.
Electrophoresis of BRCA1 oncosuppressor.
Endometrium is not the primary site of origin of pelvic high-grade serous carcinoma in BRCA1 or BRCA2 mutation carriers.
Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations.
Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer.
Epigenetic inactivation of the chromosomal stability control genes BRCA1, BRCA2, and XRCC5 in non-small cell lung cancer.
Establishment and characterization of human ovarian carcinoma cell lines.
Establishment of primary mixed cell cultures from spontaneous canine mammary tumors: Characterization of classic and new cancer-associated molecules.
Evidence for clinical efficacy of mitomycin C in heavily pretreated ovarian cancer patients carrying germ-line BRCA1 mutation.
Ex Vivo MRI Evaluation of Breast Tumors: A Novel Tool for Verifying Resection of Nonpalpable Only MRI Detected Lesions.
Exploring the Ubiquitin-Proteasome System (UPS) through PROTAC Technology.
Expression analysis of MIR182 and its associated target genes in advanced ovarian carcinoma.
Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma.
Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene.
Expression of BRCA1 protein in breast cancer and its prognostic significance.
Expression of BRCA1, a factor closely associated with relapse-free survival, in patients who underwent neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil for squamous cell carcinoma of the esophagus.
Expression of breast cancer type 1 and its relation with expression of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2/neu in breast carcinoma on trucut biopsy specimens.
Expression of DNA repair genes in ovarian cancer samples: Biological and clinical considerations.
Expression of E6AP and PML predicts for prostate cancer progression and cancer-specific death.
Expression of ERCC1 and BRCA1 predict the clinical outcome of non-small cell lung cancer in patients receiving platinum-based chemotherapy.
Expression of inhibitors of apoptosis proteins in salivary gland adenoid cystic carcinoma: XIAP is an independent marker of impaired cause-specific survival.
Expression parameters of the inhibitors of apoptosis cIAP1 and cIAP2 in renal cell carcinomas and their prognostic relevance.
Fallopian tube intraluminal tumor spread from noninvasive precursor lesions: a novel metastatic route in early pelvic carcinogenesis.
First description of an acinic cell carcinoma of the breast in a BRCA1 mutation carrier: a case report.
Four new cases of double heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and family characteristics.
Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases.
Frequent loss of heterozygosity in the region including BRCA1 on chromosome 17q in squamous cell carcinomas of the esophagus.
Frequent RNF43 mutation contributes to moderate activation of Wnt signaling in colorectal signet-ring cell carcinoma.
Functional Link between BRCA1 and BAP1 through Histone H2A, Heterochromatin and DNA Damage Response.
Functional single-nucleotide polymorphisms in the BRCA1 gene and risk of salivary gland carcinoma.
Genetic analysis of a breast-ovarian cancer family, with 7 cases of colorectal cancer linked to BRCA1, fails to support a role for BRCA1 in colorectal tumorigenesis.
Genetic changes in inherited and sporadic ovarian carcinomas by comparative genomic hybridization: extensive similarity except for a difference at chromosome 2q24-q32.
Genetic characterization of early onset ovarian carcinoma.
Genetic factors in ovarian carcinoma.
Genetic predisposition to radiation induced sarcoma: possible role for BRCA and p53 mutations.
Genetic variants of BRCA1 and BRCA2 genes in cats with mammary gland carcinoma.
Genomic Aberrations of BRCA1-Mutated Fallopian Tube Carcinomas.
Genomic characterization of malignant progression in neoplastic pancreatic cysts.
Genomic profiling of the genes on chromosome 3p in sporadic clear cell renal cell carcinoma.
Genomic signatures of BRCA1 but not BRCA2 associated high-grade serous carcinoma resemble basal-like breast cancer.
Genomic structure of chromosome 17 deletions in BRCA1-associated ovarian cancers.
Germline BRCA1 and BRCA2 Mutations in Ovarian Cancer: Utility of a Histology-Based Referral Strategy.
Germline BRCA1 mutated esophageal squamous cell carcinoma.
Germline mutations of BRCA1 and BRCA2 in Korean sporadic ovarian carcinoma.
Germline mutations of the BRCA1 and BRCA2 genes in a breast and ovarian cancer patient.
Gross genomic alterations and gene expression profiles of high- grade serous carcinoma of the ovary with and without BRCA1 inactivation.
Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study.
Hereditary Carcinomas of the Ovary, Fallopian Tube, and Peritoneum.
Hereditary ovarian cancer: beyond the usual suspects.
Heterozygote BRCA1 status and skewed chromosome X inactivation.
HIF-1? overexpression in ductal carcinoma in situ of the breast in BRCA1 and BRCA2 mutation carriers.
High frequency of allelic loss at the BRCA1 locus in ovarian cancers: clinicopathologic and molecular associations.
High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors.
High-grade serous carcinomas arise in the mouse oviduct via defects linked to the human disease.
Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
Histopathologic features of genetically determined ovarian cancer.
Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study.
HMGA1 protein expression in familial breast carcinoma patients.
HMGA1 protein expression sensitizes cells to cisplatin-induced cell death.
Human Homolog of Drosophila Ariadne (HHARI) is a marker of cellular proliferation associated with nuclear bodies.
HUWE1 ubiquitylates and degrades the RAC activator TIAM1 promoting cell-cell adhesion disassembly, migration, and invasion.
Hypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer.
Hypoxia-induced SUMOylation of E3 ligase HAF determines specific activation of HIF2 in clear-cell renal cell carcinoma.
Hysterectomy at the time of risk-reducing surgery in BRCA carriers.
Identification of a BRCA1-associated kinase with potential biological relevance.
Identification of a preneoplastic gene expression profile in tubal epithelium of BRCA1 mutation carriers.
Identification of a Small Molecule Inhibitor of RAD52 by Structure-Based Selection.
Identification of abrogated pathways in fallopian tube epithelium from BRCA1 mutation carriers.
Identification of germline 185delAG BRCA1 mutations in non-Jewish Americans of Spanish ancestry from the San Luis Valley, Colorado.
Identification of immune-enhanced molecular subtype associated with BRCA1 mutations, immune checkpoints and clinical outcome in ovarian carcinoma.
Identification of Pirh2E and Pirh2F, two additional novel isoforms of Pirh2 ubiquitin ligase from human hepatocellular liver carcinoma cell line.
Identification of the deleterious 2080insA BRCA1 mutation in a male renal cell carcinoma patient from a family with multiple cancer diagnoses from Pakistan.
Identification of TRIM25 as a Negative Regulator of Caspase-2 Expression Reveals a Novel Target for Sensitizing Colon Carcinoma Cells to Intrinsic Apoptosis.
Immunogenomics of Metastatic Clear-Cell Renal Cell Carcinoma: Remarkable Response to Nivolumab in a Patient With a Pathogenic Germ Line BRCA1 Mutation.
Immunohistochemical analysis of BRCA1 and acetyl-histone H3 in squamous cell carcinoma of the mobile tongue.
Immunohistochemical and molecular profiling of histologically defined apocrine carcinomas of the breast.
Immunohistochemical Expression of BRCA1 Protein, ER, PR and Her2/neu in Breast Cancer: A Clinicopathological Study.
Immunohistochemical Loss of BRCA1 Protein in Uterine Serous Carcinoma.
Improved survival in women with BRCA-associated ovarian carcinoma.
Inactivation of BRCA1 and BRCA2 in ovarian cancer.
Inactivation of SAG or ROC1 E3 Ligase Inhibits Growth and Survival of Renal Cell Carcinoma Cells: Effect of BIM.
Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival.
Incidence of germline BRCA1/2 mutations in women with tubo-ovarian high-grade serous carcinomas with and without serous tubal intra-epithelial carcinomas.
Incidence of loss of heterozygosity at p53 and BRCA1 loci in serous surface carcinoma.
Incidental Carcinomas in Prophylactic Specimens in BRCA1 and BRCA2 Germ-line Mutation Carriers, With Emphasis on Fallopian Tube Lesions: Report of 6 Cases and Review of the Literature.
Incidental serous tubal intraepithelial carcinoma and early invasive serous carcinoma in the nonprophylactic setting: analysis of a case series.
Increased cell survival by inhibition of BRCA1 using an antisense approach in an estrogen responsive ovarian carcinoma cell line.
Inherited Mutations in Women With Ovarian Carcinoma.
Integrative Genomic and Transcriptomic Analyses of Tumor Suppressor Genes and Their Role on Tumor Microenvironment and Immunity in Lung Squamous Cell Carcinoma.
Intercepting early pelvic serous carcinoma by routine pathological examination of the fimbria.
Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss.
Intrahepatic cholangiocarcinoma development in a patient with a novel BAP1 germline mutation and low exposure to asbestos.
Invasion patterns of metastatic high-grade serous carcinoma of ovary or fallopian tube associated with BRCA deficiency.
Inverse correlation between Naa10p and Pirh2 expression and the combined prognostic value in oral squamous cell carcinoma patients.
Involvement of general control nonderepressible kinase 2 in cancer cell apoptosis by posttranslational mechanisms.
Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome?
Knockdown of COUP-TFII inhibits cell proliferation and induces apoptosis through upregulating BRCA1 in renal cell carcinoma cells.
Lack of Correlation between Aberrant p16, RAR-?2, TIMP3, ERCC1, and BRCA1 Protein Expression and Promoter Methylation in Squamous Cell Carcinoma Accompanying Candida albicans-Induced Inflammation.
Lack of evidence for CDK12 as an ovarian cancer predisposing gene.
Lack of RING Finger Domain (RFD) Mutations of the c-Cbl Gene in Oral Squamous Cell Carcinomas in Chennai, India.
Lack of the predominant BRCA1 and BRCA2 mutations in Jewish ovarian carcinoma patients who previously underwent ovulation induction.
Laparoscopic surgery for isolated inguinal node relapse of high grade serous ovarian cancer using a bipolar combination instrument.
LEF1 is preferentially expressed in the tubal-peritoneal junctions and is a reliable marker of tubal intraepithelial lesions.
Lessons learned from understanding chemotherapy resistance in epithelial tubo-ovarian carcinoma from BRCA1and BRCA2mutation carriers.
Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy.
Loss of BRCA1 expression in sporadic male breast carcinoma.
Loss of BRCA1 expression leads to worse survival in patients with gastric carcinoma.
Loss of c-Cbl expression correlates with de-differentiation status and lymphatic metastasis in gastric cancer.
Loss of heterozygosity at 8p, 9p and 17q in laryngeal cytological specimens.
Loss of heterozygosity of nucleotide excision repair factors in sporadic oral squamous cell carcinoma using microdissected tissue.
Loss of heterozygosity of the PTH/PTHrP type 1 receptor in oral squamous cell carcinoma.
Low concentrations of diindolylmethane, a metabolite of indole-3-carbinol, protect against oxidative stress in a BRCA1-dependent manner.
Low expression of bcl-2 in Brca1-associated breast cancers.
Low grade serious carcinoma of the peritoneum in a BRCA1 carrier previously diagnosed with a "low-grade serous tubal intra-epithelial carcinoma" (STIC) on risk reducing surgery.
Low neighbor of Brca1 gene expression predicts poor clinical outcome and resistance of sunitinib in clear cell renal cell carcinoma.
Low-grade adenosquamous carcinoma of the breast-A case report with a BRCA1 germline mutation.
Maternal BCAS2 protects genomic integrity in mouse early embryonic development.
Measles virus: evidence for association with lung cancer.
Mechanism of cytokinesis failure in ovarian cystadenomas with defective BRCA1 and P53 pathways.
Mechanisms of BRCA1 Tumor Suppression.
Metaplastic breast carcinoma: pathology and clinical outcome.
Metaplastic carcinoma of the breast and BRCA1 germline mutation: a case report and review.
Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas.
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.
Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics.
Methylation of the HACE1 Gene is Frequently Detected in Hepatocellular Carcinoma.
Microenvironmental Regulation of BRCA1 Gene Expression by c-Jun and Fra2 in Premalignant Human Ovarian Surface Epithelial Cells.
Mitophagy in Carcinogenesis and Tumor progression- A New paradigm with Emerging Importance.
Mixed epithelial/mesenchymal metaplastic carcinoma (carcinosarcoma) of the breast in BRCA1 carrier.
Molecular analysis of DNA repair gene methylation and protein expression during chemical-induced rat lung carcinogenesis.
Molecular cloning of BRCA1: a gene for early onset familial breast and ovarian cancer.
Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations.
Molecular evidence for putative tumour suppressor genes on chromosome 13q specific to BRCA1 related ovarian and fallopian tube cancer.
Molecular Mechanism Linking BRCA1 Dysfunction to High Grade Serous Epithelial Ovarian Cancers with Peritoneal Permeability and Ascites.
Molecular pathology of epithelial ovarian cancer.
Molecular profiles of BRCA1-associated ovarian cancer treated by platinum-based therapy: Analysis of primary, residual and relapsed tumors.
Morphologic correlates of molecular alterations in extrauterine Müllerian carcinomas.
Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma.
Mutated Rnf43 Aggravates Helicobacter Pylori-Induced Gastric Pathology.
Mutation analysis of BRCA1, TP53, and KRAS2 in ovarian and related pelvic tumors.
Mutation analysis of the BRCA1 gene in ovarian cancers.
Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors.
Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing.
MYC amplification in breast cancer: a chromogenic in situ hybridisation study.
Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma.
No BRCA1 germline mutation in a family with uterine papillary serous carcinoma: a case report.
Non-Surgical Cancer Risk Reduction in BRCA1 Mutation Carriers: Disabling the Remote Control.
Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas.
Novel BRCA1 Large Genomic Rearrangements in Italian Breast/Ovarian Cancer Patients.
Novel germline BRCA1 mutations detected in women in singapore who developed breast carcinoma before the age of 36 years.
Nucleolar localization of BRCA1 protein in human breast cancer.
Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status.
Occult tubal carcinoma found at risk reducing salpingectomy in a BRCA1 carrier.
Oncogenic Role of the E3 Ubiquitin Ligase NEDD4-1, a PTEN Negative Regulator, in Non-Small-Cell Lung Carcinomas.
One Case of a BRCA1 Germ Line Mutation Ovarian Carcinoma Patient Based on Abnormal Immunohistochemistry Finding.
One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden.
Origins and molecular pathology of ovarian cancer.
Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations.
Ovarian carcinoma in situ with germline BRCA1 mutation and loss of heterozygosity at BRCA1 and TP53.
Ovarian carcinoma screening in women at intermediate risk: impact on quality of life and need for invasive follow-up.
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities.
Ovarian surface epithelium: family history and early events in ovarian cancer.
Overexpression of cIAP2 contributes to 5-FU resistance and a poor prognosis in oral squamous cell carcinoma.
Pancancer survival analysis of cancer hallmark genes.
Papers to appear in forthcoming issues
Parkin Gene Alterations in Ovarian Carcinoma from Northern Indian Population.
Pathologic findings in prophylactic oophorectomy specimens in high-risk women.
Peritoneal cancer arising after total abdominal hysterectomy and bilateral salpingo-oophorectomy for cervical cancer in a patient with right breast cancer and germline mutation of BRCA1 gene: a case report and literature review.
Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.
Peritoneal washing cytology in patients with BRCA1 or BRCA2 mutations undergoing risk-reducing salpingo-oophorectomies: a 10-year experience and reappraisal of its clinical utility.
Phenotypic characterization of hereditary epithelial ovarian cancer based on a tissue microarray study.
Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry.
Phosphatase and tensin homolog deleted on chromosome 10 degradation induced by NEDD4 promotes acquired erlotinib resistance in non-small-cell lung cancer.
Phosphatase and tensin homolog regulates stability and activity of EphB1 receptor.
Poly r(C) Binding Protein 1 Regulates Posttranscriptional Expression of the Ubiquitin Ligase TRIM56 in Ovarian Cancer.
Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival.
Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2.
Precursors to pelvic serous carcinoma and their clinical implications.
Prevalence of BRCA1 and BRCA2 germ line mutations among women with carcinoma of the fallopian tube.
Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil.
Prevalence of the BRCA1 founder mutation c.5266dup in Brazilian individuals at-risk for the Hereditary Breast and Ovarian Cancer Syndrome.
Prognosis of patients with BRCA1-associated ovarian carcinomas depends on TP53 accumulation status in tumor cells.
Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma.
Prognostic significance of BRCA1 expression in Japanese sporadic breast carcinomas.
Prolonged response of relapsed high grade serous ovarian carcinoma to the oral angiokinase inhibitor nintedanib in a patient with a germline BRCA1 mutation.
Prolonged response to treatment based on cell-free DNA analysis and molecular profiling in three patients with metastatic cancer: a case series.
Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors.
Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
PRP19 upregulation inhibits cell proliferation in lung adenocarcinomas by p21-mediated induction of cell cycle arrest.
PTEN and NEDD4 in Human Breast Carcinoma.
PTEN mutation, expression and LOH at its locus in ovarian carcinomas. Relation to TP53, K-RAS and BRCA1 mutations.
Rare BRIP1 Missense Alleles Confer Risk for Ovarian and Breast Cancer.
Rb inactivation accelerates neoplastic growth and substitutes for recurrent amplification of cIAP1, cIAP2 and Yap1 in sporadic mammary carcinoma associated with p53 deficiency.
RBCK1 promotes p53 degradation via ubiquitination in renal cell carcinoma.
Re: "A low-grade ovarian carcinoma case with coincident LOH of PTCH1 and BRCA1, and a mutation in BRCA1," Int J Gyn Pathol 2012 May;31: 264-271.
Re: "Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations".
Recurrent BRCA1 Mutation, but no BRCA2 Mutation, in Vietnamese Patients with Ovarian Carcinoma Detected with Next Generation Sequencing.
Redox-dependent Brca1 transcriptional regulation by an NADH-sensor CtBP1.
Reduced Brca1 protein expression in 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced rat mammary carcinomas.
Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases.
Regulation of p27 by ubiquitin ligases and its pathological significance in human lung carcinomas.
Regulation of the BRCA1 promoter in ovarian surface epithelial cells and ovarian carcinoma cells.
Repeat chemosensitivity of epithelial ovarian carcinoma in a BRCA1 mutation carrier to paclitaxel/platinum combination chemotherapy.
Retrospective study of a 16?year cohort of BRCA1 and BRCA2 carriers presenting for RRSO: Prevalence of invasive and in-situ carcinoma, with follow-up.
RN181 is a tumour suppressor in gastric cancer by regulation of the ERK/MAPK-cyclin D1/CDK4 pathway.
RN181 regulates the biological behaviors of oral squamous cell carcinoma cells via mediating ERK/MAPK signaling pathway.
RNF43 Inhibits Cancer Cell Proliferation and Could be a Potential Prognostic Factor for Human Gastric Carcinoma.
RNF43 is a Novel Tumor Suppressor and Prognostic Indicator in Clear Cell Renal Cell Carcinoma.
RNF43 is a tumour suppressor gene mutated in mucinous tumours of the ovary.
RNF43 mutations are recurrent in Chinese patients with mucinous ovarian carcinoma but absent in other subtypes of ovarian cancer.
Role of RNF20 in cancer development and progression - a comprehensive review.
Routine germline BRCA1 and BRCA2 testing in ovarian carcinoma patients: analysis of the Scottish real life experience.
Screening for mutations in exon 11 of the BRCA1 gene in 70 Italian breast and ovarian cancer patients by protein truncation test.
Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance.
Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube.
Selective toxicity of rose bengal to ovarian cancer cells in vitro.
Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk.
Serous tubal intraepithelial carcinoma: diagnostic reproducibility and its implications.
Simultaneous osteosarcoma and renal cell carcinoma with BRCA1 mutation in a young male adult with prior oligodendroglioma.
Single nucleotide polymorphisms in breast cancer susceptibility gene 1 are associated with susceptibility to lung cancer.
SMURF1, a promoter of tumor cell progression?
SNU cell lines and their application for cancer research.
Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer.
Somatic mRNA Analysis of BRCA1 Splice Variants Provides a Direct Theranostic Impact on PARP Inhibitors.
SPOP Promotes Tumorigenesis by Acting as a Key Regulatory Hub in Kidney Cancer.
SPOP-PTEN-SUFU axis promotes progression of clear cell renal cell carcinoma via activating SHH and WNT pathway.
Sporadic breast carcinomas with somatic BRCA1 gene deletions share genotype/phenotype features with familial breast carcinomas.
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.
Study of Selected BRCA1, BRCA2, and PIK3CA Mutations in Benign and Malignant Lesions of Anogenital Mammary-Like Glands.
Subsequent breast and high grade serous carcinomas after risk-reducing salpingo-oophorectomy in BRCA mutation carriers and patients with history of breast cancer.
Successful treatment of a patient with brain metastases from endometrial cancer using Niraparib: a case report.
Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status.
Survivin nuclear labeling index: a superior biomarker in superficial urothelial carcinoma of human urinary bladder.
Synchronous Bilateral Tubal Serous Carcinomas in a Patient With Exon 13 Duplication and Loss of Function of BRCA1.
TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients.
Targeting TRIM3 deletion-induced tumor-associated lymphangiogenesis prohibits lymphatic metastasis in esophageal squamous cell carcinoma.
The basal-like mammary carcinomas induced by Brca1 or Bard1 inactivation implicate the BRCA1/BARD1 heterodimer in tumor suppression.
The BRCA1 syndrome and other inherited breast or breast-ovarian cancers in a Norwegian prospective series.
The cancer connection: BRCA1 and BRCA2 tumor suppression in mice and humans.
The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer.
The E3 ligase HECTD3 promotes esophageal squamous cell carcinoma (ESCC) growth and cell survival through targeting and inhibiting caspase-9 activation.
The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro.
The E3 ubiquitin ligase EDD regulates S-phase and G(2)/M DNA damage checkpoints.
The E3 ubiquitin ligase NEDD4 induces endocytosis and lysosomal sorting of connexin 43 to promote loss of gap junctions.
The E3 ubiquitin ligase SIAH2 is a prosurvival factor overexpressed in oral cancer.
The EMSY threonine 207 phospho-site is required for EMSYdriven suppression of DNA damage repair.
The expression of DBC1/CCAR2 is associated with poor prognosis of ovarian carcinoma.
The expression of FHIT, PCNA and EGFR in benign and malignant breast lesions.
The GADD45, ZBRK1 and BRCA1 pathway: quantitative analysis of mRNA expression in colon carcinomas.
The genesis and evolution of high-grade serous ovarian cancer.
The impact of tissue block sampling on the detection of p53 signatures in fallopian tubes from women with BRCA 1 or 2 mutations (BRCA+) and controls.
The miR-205-5p/BRCA1/RAD17 Axis Promotes Genomic Instability in Head and Neck Squamous Cell Carcinomas.
The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations.
The molecular pathology of hereditary breast cancer.
The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications.
The pathology of hereditary breast cancer.
The Polycomb proteins RING1B and EZH2 repress the tumoral pro-inflammatory function in metastasizing primary cutaneous squamous cell carcinoma.
The prevalence of occult ovarian cancer in the series of 155 consequently operated high risk asymptomatic patients - Slovenian population based study.
The Prognostic Value of BRCA1 and PARP Expression in Epithelial Ovarian Carcinoma: Immunohistochemical Detection.
The role of the breast cancer susceptibility gene 1 (BRCA1) in sporadic epithelial ovarian cancer.
The Roles of Ubiquitination Factor E4B (UBE4B) in the Postoperative Prognosis of Patients with Renal Cell Carcinoma and in Renal Tumor Cells Growth and Metastasis.
The Roles of VHL-Dependent Ubiquitination in Signaling and Cancer.
The shifting landscape of genetic alterations separating endometriosis and ovarian endometrioid carcinoma.
Therapy susceptible germline-related BRCA 1-mutation in a case of metastasized mixed adeno-neuroendocrine carcinoma (MANEC) of the small bowel.
Three primary malignancies related to BRCA mutation successively occurring in a BRCA1 185delAG mutation carrier.
TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival.
TP53 p.R337H prevalence in a series of Brazilian hereditary breast cancer families.
Transitional cell metaplasia of fallopian tube fimbriae: a potential mimic of early tubal carcinoma in risk reduction salpingo-oophorectomies from women With BRCA mutations.
Transitional cell ovarian carcinoma in a BRCA1 mutation carrier.
TRIM25 is associated with cisplatin resistance in non-small-cell lung carcinoma A549 cell line via downregulation of 14-3-3?.
Tumor BRCA Testing in High Grade Serous Carcinoma: Mutation Rates and Optimal Tissue Requirements.
Understanding the pathogenesis of primary peritoneal carcinoma: involvement of the BRCA1 and p53 genes.
Use of adenoviral E1A protein to analyze K18 promoter deregulation in colon carcinoma cells discloses a role for CtBP1 and BRCA1.
VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma.
Whole-exome sequencing of pancreatic neoplasms with acinar differentiation.
[Analysis of loss of heterozygosity of the tumor suppressor genes p53 and BRCA1 in ovarial carcinomas]
[Analysis of the mutation of BRCA1 gene in 70 Uigur women breast cancer patients in Xinjiang]
[BRCA1 and BRCA2 - pathologists starting kit].
[Clinicopathological and biological features of breast cancer in young females and their relationship with prognosis]
[Does ovarian cancer start in the fallopian tubes? Possible implications for preventive adnexal removal].
[Expression and clinical significance of BRCA1 in human esophageal squamous cell carcinoma].
[Expression of c-Cbl, Cbl-b, and epidermal growth factor receptor in gastric carcinoma and their clinical significance]
[Genetic diagnosis and therapy of hereditary breast carcinoma]
[Hereditary breast and ovarian cancer].
[Hereditary breast cancers]
[Hereditary breast carcinomas pathologist's perspective].
[Identification of basal-like carcinomas in clinical practice: "triple zero/BRCA1-like" carcinomas]
[Molecular-genetic disruption in area near the BRCA1 gene, associated with ovarian carcinoma]
[Pirh2 shRNA mediated by psiRNA-hH1 vector plasmid effectively inhibits the proliferation of lung carcinoma cells: in vitro and in vivo experiments]
[Systematic breast self-examination is not a useful screening procedure, except in hereditary or familial increased risk of breast cancer]
[Tripartite-motif protein 25 and pyruvate kinase M2 protein expression in non-small cell lung cancer].
Carcinoma in Situ
A candidate precursor to serous carcinoma that originates in the distal fallopian tube.
Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression.
Evaluation of the Expression of the Inhibitor of Apoptosis Protein Family and Human Telomerase Reverse Transcriptase in Patients With Advanced Colorectal Adenoma.
Identification of a preneoplastic gene expression profile in tubal epithelium of BRCA1 mutation carriers.
Incidental serous tubal intraepithelial carcinoma and early invasive serous carcinoma in the nonprophylactic setting: analysis of a case series.
Ovarian cancer.
Ovarian carcinoma in situ with germline BRCA1 mutation and loss of heterozygosity at BRCA1 and TP53.
Precursors to pelvic serous carcinoma and their clinical implications.
Serous Tubal Intraepithelial Carcinoma in a Japanese Woman with a Deleterious BRCA1 Mutation.
Serous Tubal Intraepithelial Carcinoma: A Concise Review for the Practicing Pathologist and Clinician.
Serous tubal intraepithelial carcinoma: diagnostic reproducibility and its implications.
Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status.
The BRCA1 syndrome and other inherited breast or breast-ovarian cancers in a Norwegian prospective series.
Carcinoma, Acinar Cell
First description of an acinic cell carcinoma of the breast in a BRCA1 mutation carrier: a case report.
Carcinoma, Adenoid Cystic
Basal-like Breast Cancer: Comparison of Imaging Characteristics.
Expression of inhibitors of apoptosis proteins in salivary gland adenoid cystic carcinoma: XIAP is an independent marker of impaired cause-specific survival.
Prolonged response to treatment based on cell-free DNA analysis and molecular profiling in three patients with metastatic cancer: a case series.
Carcinoma, Adenosquamous
Low-grade adenosquamous carcinoma of the breast-A case report with a BRCA1 germline mutation.
Carcinoma, Basal Cell
A population-based analysis of germline BAP1 mutations in melanoma.
BRCA1 and BRCA2 families and the risk of skin cancer.
BRCA1 regulation on ?-hCG: a mechanism for tumorigenicity in BRCA1 defective breast cancer.
Coincident PTCH and BRCA1 germline mutations in a patient with nevoid basal cell carcinoma syndrome and familial breast cancer.
Carcinoma, Ductal
Aberrant promoter hypermethylation and genomic hypomethylation in tumor, adjacent normal tissues and blood from breast cancer patients.
Abnormality of the DNA double-strand-break checkpoint/repair genes, ATM, BRCA1 and TP53, in breast cancer is related to tumour grade.
Allelic imbalance in the region of the BRCA1 gene in ductal carcinoma in situ of the breast.
Analysis of BRCA1 Gene Rearrangements in Breast Carcinomas by RT-PCR and ER, PR, HER2NEU Status by IHC and HPE Correlation.
Autoantibodies in breast cancer: their use as an aid to early diagnosis.
Basal phenotype breast cancer: implications for treatment and prognosis.
BRCA1 and BRCA2 mutations in ethnic Lebanese Arab women with high hereditary risk breast cancer.
BRCA1 and PARP1 mRNA expression during progression from normal breast to ductal carcinoma in situ and invasive breast cancer: a laser microdissection study.
Breast cancer screening in BRCA1 mutation carriers: effectiveness of MR imaging--Markov Monte Carlo decision analysis.
Breast imaging findings in women with BRCA1- and BRCA2-associated breast carcinoma.
Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma.
Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer.
Clinicopathological study of chromogranin A, B and BRCA1 expression in node-negative breast carcinoma.
Correlation between BRCA1 expression and apoptosis-related biological parameters in sporadic breast carcinomas.
DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer.
Development of Breast Cancer in a 21-Year-Old Childhood Wilms' Tumor Survivor With a BRCA1 2634delC Mutation.
DNA methylation of multiple tumor-related genes in association with overexpression of DNA methyltransferase 1 (DNMT1) during multistage carcinogenesis of the pancreas.
Down-regulation of BRCA1 in human sporadic breast cancer; analysis of DNA methylation patterns of the putative promoter region.
Estrogen Promotes Breast Cancer Cell Survival in an Inhibitor of Apoptosis (IAP)-Dependent Manner.
Expression of BRCA1 protein in breast cancer and its prognostic significance.
Familial breast cancer in southern Taiwan.
Founder BRCA1 and BRCA2 mutations in early-onset French Canadian breast cancer cases unselected for family history.
Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50?years.
Genetic analysis of a breast-ovarian cancer family, with 7 cases of colorectal cancer linked to BRCA1, fails to support a role for BRCA1 in colorectal tumorigenesis.
Germline BRCA1 and HMLH1 mutations in a family with male and female breast carcinoma.
HIF-1? overexpression in ductal carcinoma in situ of the breast in BRCA1 and BRCA2 mutation carriers.
Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers.
Immunohistochemical expression of BRCA1 protein in invasive ductal carcinoma of the breast.
Immunolocalization of BRCA1 protein in normal breast tissue and sporadic invasive ductal carcinomas: a correlation with other biological parameters.
Is mammographic breast density a breast cancer risk factor in women with BRCA mutations?
Lobular breast cancer: incidence and genetic and non-genetic risk factors.
Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas.
Loss of heterozygosity at BRCA1, TP53, nm-23 and other loci on chromosome 17q in human breast carcinoma.
Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers.
p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer.
Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.
Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ.
Prognostic significance of BRCA1 expression in sporadic breast carcinomas.
Promoter hypermethylation and post-transcriptional mechanisms for reduced BRCA1 immunoreactivity in sporadic human breast cancers.
Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients.
Prospective screening study of 0.5 Tesla dedicated magnetic resonance imaging for the detection of breast cancer in young, high-risk women.
Quantitative detection of methylation of FHIT and BRCA1 promoters in the serum of ductal breast cancer patients.
Should we screen BRCA1 mutation carriers only with MRI? A multicenter study.
The Cell of Origin of BRCA1 Mutation-associated Breast Cancer: A Cautionary Tale of Gene Expression Profiling.
The clinical impact of MRI screening for BRCA mutation carriers: the first report in Japan.
The pathology of hereditary breast cancer.
The penetrance of ductal carcinoma in situ among BRCA1 and BRCA2 mutation carriers.
[Clinical and pathological characteristics and clinical course of patients with breast cancer and BRCA1/BRCA2 mutations]
Carcinoma, Embryonal
Abnormal level of CUL4B-mediated histone H2A ubiquitination causes disruptive HOX gene expression.
TRIM32 promotes retinoic acid receptor ?-mediated differentiation in human promyelogenous leukemic cell line HL60.
Carcinoma, Endometrioid
Case Report: Double Germline Mutations in BRCA1 and MSH2 in a Patient With Mixed Serous-Endometrioid Endometrial Carcinoma.
Origins and molecular pathology of ovarian cancer.
Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry.
Recurrent BRCA1 Mutation, but no BRCA2 Mutation, in Vietnamese Patients with Ovarian Carcinoma Detected with Next Generation Sequencing.
Unilateral Optic Disc Papilloedema following Administration of Carboplatin Chemotherapy for Ovarian Carcinoma.
Carcinoma, Hepatocellular
A 2-Benzylmalonate Derivative as STAT3 Inhibitor Suppresses Tumor Growth in Hepatocellular Carcinoma by Upregulating ?-TrCP E3 Ubiquitin Ligase.
A novel SMAC mimetic APG-1387 exhibits dual antitumor effect on HBV-positive hepatocellular carcinoma with high expression of cIAP2 by inducing apoptosis and enhancing innate anti-tumor immunity.
A20 targets PFKL and glycolysis to inhibit the progression of hepatocellular carcinoma.
Activating transcription factor 6 limits intracellular accumulation of mutant ?(1)-antitrypsin Z and mitochondrial damage in hepatoma cells.
Ajuba inhibits hepatocellular carcinoma cell growth via targeting of ?-catenin and YAP signaling and is regulated by E3 ligase Hakai through neddylation.
BRCA1 and BRCA2 expression patterns and prognostic significance in digestive system cancers.
BRCA1 Is a Novel Prognostic Indicator and Associates with Immune Cell Infiltration in Hepatocellular Carcinoma.
BRCA1-mediated inflammation and growth activated & inhibited transition mechanisms between no-tumor hepatitis/cirrhotic tissues and HCC.
Cbx4 governs HIF-1? to potentiate angiogenesis of hepatocellular carcinoma by its SUMO E3 ligase activity.
Characterization of six tumor suppressor genes and microsatellite instability in hepatocellular carcinoma in southern African blacks.
cIAP2 via NF-?B signalling affects cell proliferation and invasion in hepatocellular carcinoma.
Cullin3-TNFAIP1 E3 Ligase Controls Inflammatory Response in Hepatocellular Carcinoma Cells via Ubiquitination of RhoB.
Decreased expression of TRIM3 is associated with poor prognosis in patients with primary hepatocellular carcinoma.
Deubiquitinase USP39 and E3 ligase TRIM26 balance the level of ZEB1 ubiquitination and thereby determine the progression of hepatocellular carcinoma.
DNA damage induces down-regulation of Prp19 via impairing Prp19 stability in hepatocellular carcinoma cells.
Dual roles of ULK1 (unc-51 like autophagy activating kinase 1) in cytoprotection against lipotoxicity.
E3 ligase ZFP91 inhibits Hepatocellular Carcinoma Metabolism Reprogramming by regulating PKM splicing.
E3 Ubiquitin Ligase Siah-1 is Down-regulated and Fails to Target Natural HBx Truncates for Degradation in Hepatocellular Carcinoma.
Expression and prognostic role of ubiquitination factor E4B in primary hepatocellular carcinoma.
Expression of Pirh2, a p27(Kip1) ubiquitin ligase, in hepatocellular carcinoma: correlation with p27(Kip1) and cell proliferation.
HBx regulates transcription factor PAX8 stabilization to promote the progression of hepatocellular carcinoma.
Heat shock protein gp96 decreases p53 stability by regulating Mdm2 E3 ligase activity in liver cancer.
Hepatitis C Virus Non-Structural Protein 5A (NS5A) Disrupts Mitochondrial Dynamics and Induces Mitophagy.
High expression of Parkin predicts easier recurrence of patients with adjuvant transarterial chemoembolization.
Hint1 Up-Regulates I?B? by Targeting the ?-TrCP Subunit of SCF E3 Ligase in Human Hepatocellular Carcinoma Cells.
Identification of microRNA-124 in regulation of Hepatocellular carcinoma through BIRC3 and the NF-?B pathway.
Identification of Recurrent Variants in BRCA1 and BRCA2 across Multiple Cancers in the Chinese Population.
Integrative proteomics reveals the role of E3 ubiquitin ligase SYVN1 in hepatocellular carcinoma metastasis.
LncRNA XIST upregulates TRIM25 via negatively regulating miR-192 in hepatitis B virus-related hepatocellular carcinoma.
MARCH6 promotes hepatocellular carcinoma development through up-regulation of ATF2.
MiR-486-5p Suppresses Proliferation and Migration of Hepatocellular Carcinoma Cells through Downregulation of the E3 Ubiquitin Ligase CBL.
Multiplexed Proteomic Approach for Identification of Serum Biomarkers in Hepatocellular Carcinoma Patients with Normal AFP.
Nuclear expression of the ubiquitin ligase seven in absentia homologue (SIAH)-1 induces proliferation and migration of liver cancer cells.
Parkin as a tumor suppressor gene for hepatocellular carcinoma.
Parkin facilitates proteasome inhibitor-induced apoptosis via suppression of NF-?B activity in hepatocellular carcinoma.
Parkin gene alterations in hepatocellular carcinoma.
Prp19 Arrests Cell Cycle via Cdc5L in Hepatocellular Carcinoma Cells.
Prp19 facilitates invasion of hepatocellular carcinoma via p38 mitogen-activated protein kinase/twist1 pathway.
RLIM suppresses hepatocellular carcinogenesis by up-regulating p15 and p21.
RN181 suppressed tumor growth of hepatocellular carcinoma by inhibition of the ERK/MAPK pathway.
Role of fanconi anemia/BRCA pathway genes in hepatocellular carcinoma chemoresistance.
Role of the E3 Ubiquitin Ligase TRIM4 in Predicting the Prognosis of Hepatocellular Carcinoma.
Screening and verification of proteins that interact with HSPC238.
SCYL1 binding protein 1 promotes the ubiquitin-dependent degradation of Pirh2 and has tumor-suppressive function in the development of hepatocellular carcinoma.
Structure of the FP domain of Fbxo7 reveals a novel mode of protein-protein interaction.
The E3 ligase for metastasis associated 1 protein, TRIM25, is targeted by microRNA-873 in hepatocellular carcinoma.
The E3 ubiquitin ligase TRIM7 suppressed hepatocellular carcinoma progression by directly targeting Src protein.
The ubiquitin ligase TRIM25 inhibits hepatocellular carcinoma progression by targeting metastasis associated 1 protein.
TRIM25 promotes Capicua degradation independently of ERK in the absence of ATXN1L.
TRIM25 promotes the cell survival and growth of hepatocellular carcinoma through targeting Keap1-Nrf2 pathway.
TRIM26 Induces Ferroptosis to Inhibit Hepatic Stellate Cell Activation and Mitigate Liver Fibrosis Through Mediating SLC7A11 Ubiquitination.
TRIM65 triggers ?-catenin signaling via ubiquitylation of Axin1 to promote hepatocellular carcinoma.
Tripartite motif protein 25 is associated with epirubicin resistance in hepatocellular carcinoma cells via regulating PTEN/AKT pathway.
Tripartite motif-containing 22 inhibits the activity of hepatitis B virus core promoter, which is dependent on nuclear-located RING domain.
Tripartite motif-containing 3 (TRIM3) inhibits tumor growth and metastasis of liver cancer.
Ubiquitin C-terminal Hydrolase 37, a novel predictor for hepatocellular carcinoma recurrence, promotes cell migration and invasion via interacting and deubiquitinating PRP19.
Carcinoma, Intraductal, Noninfiltrating
Allelic imbalance in the region of the BRCA1 gene in ductal carcinoma in situ of the breast.
Association between loss of heterozygosity of BRCA1 and BRCA2 and morphological attributes of sporadic breast cancer.
Autoantibodies in breast cancer: their use as an aid to early diagnosis.
Basal phenotype breast cancer: implications for treatment and prognosis.
BRCA1 and PARP1 mRNA expression during progression from normal breast to ductal carcinoma in situ and invasive breast cancer: a laser microdissection study.
BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
Breast cancer screening in BRCA1 mutation carriers: effectiveness of MR imaging--Markov Monte Carlo decision analysis.
Breast imaging findings in women with BRCA1- and BRCA2-associated breast carcinoma.
Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma.
Characterization of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis.
Comparative analysis of loss of heterozygosity and expression profile in normal tissue, DCIS and invasive breast cancer.
DCIS in BRCA1 and BRCA2 mutation carriers: prevalence, phenotype, and expression of oncodrivers C-MET and HER3.
DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer.
Development of Breast Cancer in a 21-Year-Old Childhood Wilms' Tumor Survivor With a BRCA1 2634delC Mutation.
Ductal carcinoma in situ in BRCA mutation carriers.
Estrogen Promotes Breast Cancer Cell Survival in an Inhibitor of Apoptosis (IAP)-Dependent Manner.
Family history of breast and ovarian cancer and the risk of breast carcinoma in situ.
Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50?years.
Genetic analysis of a breast-ovarian cancer family, with 7 cases of colorectal cancer linked to BRCA1, fails to support a role for BRCA1 in colorectal tumorigenesis.
HIF-1? overexpression in ductal carcinoma in situ of the breast in BRCA1 and BRCA2 mutation carriers.
Is mammographic breast density a breast cancer risk factor in women with BRCA mutations?
Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status.
Molecular characterization of intraductal breast carcinomas.
Molecular genetics of solid tumours: translating research into clinical practice. What we could do now: breast cancer.
Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers.
Numerous high-risk epithelial lesions in familial breast cancer.
Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.
Perturbed myoepithelial cell differentiation in BRCA mutation carriers and in ductal carcinoma in situ.
Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ.
Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ.
Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer.
Screening and follow-up of the patient at high risk for breast cancer.
Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series.
The expression of FHIT, PCNA and EGFR in benign and malignant breast lesions.
The penetrance of ductal carcinoma in situ among BRCA1 and BRCA2 mutation carriers.
Tumour morphology of early-onset breast cancers predicts breast cancer risk for first-degree relatives: the Australian Breast Cancer Family Registry.
[Analyses of LOH and expression in healthy gland, DCIS and invasive breast cancer gland]
Carcinoma, Lobular
Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer.
Down-regulation of BRCA1 in human sporadic breast cancer; analysis of DNA methylation patterns of the putative promoter region.
Epidemiology, genetics, and risk evaluation of postmenopausal women at risk of breast cancer.
Low risk of invasive lobular carcinoma of the breast in carriers of BRCA1 (hereditary breast and ovarian cancer) and TP53 (Li-Fraumeni syndrome) germline mutations.
Molecular genetics of solid tumours: translating research into clinical practice. What we could do now: breast cancer.
Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.
Promoter hypermethylation and post-transcriptional mechanisms for reduced BRCA1 immunoreactivity in sporadic human breast cancers.
Screening and follow-up of the patient at high risk for breast cancer.
The role of MRI in breast cancer screening.
Use of bilateral prophylactic nipple-sparing mastectomy in patients with high risk of breast cancer.
Carcinoma, Medullary
Atypical medullary carcinoma of the breast with cartilaginous metaplasia in a patient with a BRCA1 germline mutation.
Basal-like Breast Cancer: Comparison of Imaging Characteristics.
Carcinoma of the breast with medullary-like features: diagnostic challenges and relationship with BRCA1 and EZH2 functions.
Comparison of age distribution patterns for different histopathologic types of breast carcinoma.
Down-regulation of BRCA1 in human sporadic breast cancer; analysis of DNA methylation patterns of the putative promoter region.
First description of an acinic cell carcinoma of the breast in a BRCA1 mutation carrier: a case report.
Medullary carcinoma of breast with a novel germline mutation 1123t >g in exon 11 of brca1.
Medullary carcinoma of the breast and BRCA1 mutation.
Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.
The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study.
The pathology of familial breast cancer: Morphological aspects.
[Basal-like carcinoma of the breast--the actual review and clinico-pathological corelations]
Carcinoma, Neuroendocrine
Metastatic Castration-Resistant Prostate Cancer with Neuroendocrine Transformation and BRCA 1 Germ-Line Mutation: A Case Report and Literature Review.
Carcinoma, Non-Small-Cell Lung
A critical re-assessment of DNA repair gene promoter methylation in non-small cell lung carcinoma.
A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts.
Alterations of the tumor suppressor gene Parkin in non-small cell lung cancer.
An E3 ubiquitin ligase: c-Cbl: A New Therapeutic Target of Lung Cancer.
Analysis of ERCC1, BRCA1, RRM1 and TUBB3 as predictors of prognosis in patients with non-small cell lung cancer who received cisplatin-based adjuvant chemotherapy: A prospective study.
Association between clinical pathology and multiple genes mRNA expression in Chinese patients with NSCLC.
Association between EGFR mutation and expression of BRCA1 and RAP80 in non-small cell lung cancer.
Association between epidermal growth factor receptor gene copy number and ERCC1, BRCA1 protein expression in Chinese patients with non-small cell lung cancer.
Association of BRCA1, ERCC1, RAP80, PKM2, RRM1, RRM2, TS, TSP1, and TXR1 mRNA expression levels between primary tumors and infiltrated regional lymph nodes in patients with resectable non-small cell lung cancer.
Association of EGFR mutations with low BRCA1 gene expression in non-small cell lung cancer.
BAP1 promotes viability and migration of ECA109 cells through KLF5/CyclinD1/FGF-BP1.
BRCA1 regulates microtubule dynamics and taxane-induced apoptotic cell signaling.
CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases.
Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy.
Correlation between BRCA1 and TopBP1 protein expression and clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.
DNA Repair Genes ERCC1 and BRCA1 Expression in Non-Small Cell Lung Cancer Chemotherapy Drug Resistance.
DREAMing: a simple and ultrasensitive method for assessing intratumor epigenetic heterogeneity directly from liquid biopsies.
E3 ligase MKRN3 is a tumor suppressor regulating PABPC1 ubiquitination in non-small cell lung cancer.
E3 ubiquitin ligase HECW1 promotes the metastasis of non-small cell lung cancer cells through mediating the ubiquitination of Smad4.
E3 ubiquitin ligase Pirh2 enhances tumorigenic properties of human non-small cell lung carcinoma cells.
E3 ubiquitin ligase tripartite motif-containing 71 promotes the proliferation of non-small cell lung cancer through the inhibitor of kappaB-?/nuclear factor kappaB pathway.
E3 ubiquitin ligases Cbl-b and c-Cbl downregulate PD-L1 in EGFR wild-type non-small cell lung cancer.
Epigenetic inactivation of the chromosomal stability control genes BRCA1, BRCA2, and XRCC5 in non-small cell lung cancer.
ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancer.
ERCC1 and BRCA1 mRNA expression predicts the clinical outcome of non-small cell lung cancer receiving platinum-based chemotherapy.
ERCC1 and BRCA1 mRNA expressions are associated with clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.
ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer.
Expression of ERCC1 and BRCA1 predict the clinical outcome of non-small cell lung cancer in patients receiving platinum-based chemotherapy.
Expression of RRM1 and RRM2 as a novel prognostic marker in advanced non-small cell lung cancer receiving chemotherapy.
FBW7 loss promotes epithelial-to-mesenchymal transition in non-small cell lung cancer through the stabilization of Snail protein.
Genetic variants of BIRC3 and NRG1 in the NLRP3 inflammasome pathway are associated with non-small cell lung cancer survival.
High expression of lncRNA MEG3 participates in non-small cell lung cancer by regulating microRNA-7-5p.
High UDG and BRCA1 expression is associated with adverse outcome in patients with pemetrexed treated non-small cell lung Cancer.
Individualized Chemotherapy in Advanced NSCLC Patients Based on mRNA Levels of BRCA1 and RRM1.
Induction of c-Cbl contributes to anti-cancer effects of HDAC inhibitor in lung cancer.
LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC.
Loss of the novel tumour suppressor and polarity gene Trim62 (Dear1) synergizes with oncogenic Ras in invasive lung cancer.
mRNA Expression and Clinical Significance of ERCC1, BRCA1, RRM1, TYMS and TUBB3 in Postoperative Patients with Non-Small Cell Lung Cancer.
MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 Trial.
Non-small cell lung cancer cells with deficiencies in homologous recombination genes are sensitive to PARP inhibitors.
Oncogenic Role of the E3 Ubiquitin Ligase NEDD4-1, a PTEN Negative Regulator, in Non-Small-Cell Lung Carcinomas.
Phytochemical library screening reveals betulinic acid as a novel Skp2-SCF E3 ligase inhibitor in non-small cell lung cancer.
PIAS1-FAK Interaction Promotes the Survival and Progression of Non-Small Cell Lung Cancer.
Poor response to platinum-based chemotherapy is associated with KRAS mutation and concomitant low expression of BRAC1 and TYMS in NSCLC.
Predictive role of RRM1 and BRCA1 mRNA expression on the clinical outcome of advanced non-small cell lung cancer.
Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
Prognostic significance of BRCA1, ERCC1, RRM1, and RRM2 in patients with advanced non-small cell lung cancer receiving chemotherapy.
Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer.
Prognostic value of ERCC1, RRM1, BRCA1 and SETDB1 in early stage of non-small cell lung cancer.
Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib.
Reduced abundance of the E3 ubiquitin ligase E6AP contributes to decreased expression of the INK4/ARF locus in non-small cell lung cancer.
Regulation of autophagy flux by E3 ubiquitin ligase Pirh2 in lung cancer.
RNF111/Arkadia is regulated by DNA methylation and affects TGF-?/Smad signaling associated invasion in NSCLC cells.
SIRT2 inhibits non-small cell lung cancer cell growth through impairing Skp2-mediated p27 degradation.
Skp2 regulates non-small cell lung cancer cell growth by Meg3 and miR-3163.
Targeting MALAT1 induces DNA damage and sensitize non-small cell lung cancer cells to cisplatin by repressing BRCA1.
The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection.
The role of BRCA1 in non-small cell lung cancer.
TRIM22 confers poor prognosis and promotes epithelial-mesenchymal transition through regulation of AKT/GSK3?/?-catenin signaling in non-small cell lung cancer.
TRIM25 activates AKT/mTOR by inhibiting PTEN via K63-linked polyubiquitination in non-small cell lung cancer.
TRIM25 is associated with cisplatin resistance in non-small-cell lung carcinoma A549 cell line via downregulation of 14-3-3?.
TRIM59 Promotes the Proliferation and Migration of Non-Small Cell Lung Cancer Cells by Upregulating Cell Cycle Related Proteins.
Tumor-treating fields elicit a conditional vulnerability to ionizing radiation via the downregulation of BRCA1 signaling and reduced DNA double-strand break repair capacity in non-small cell lung cancer cell lines.
[Chinese multicenter randomized trial of customized chemotherapy based on BRCA1 (breast cancer susceptibility gene 1)-RAP80 (receptor-associated protein 80) mRNA expression in advanced non-small cell lung cancer (NSCLC) patients].
[Detection of RRM1, ERCC1 and BRCA1 gene expression in non-small cell lung cancer tissues and peripheral blood by SYBR real-time fluorescent quantitative PCR].
[Expressions of c-Cbl, Cbl-b and EGFR and its role of prognosis in NSCLC].
[Relationship between the protein expression of ERCC1, BRCA, ?-tubulin and K-ras and the efficacy and prognosis in advanced non-small cell lung cancer].
Carcinoma, Ovarian Epithelial
"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
A 400 kb novel deletion unit centromeric to the BRCA1 gene in sporadic epithelial ovarian cancer.
A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.
A Novel Pathway that Links Caveolin-1 Down-Regulation to BRCA1 Dysfunction in Serous Epithelial Ovarian Cancer Cells.
A population-based study of BRCA1 and BRCA2 mutations in Jewish women with epithelial ovarian cancer.
AGO Austria recommendations for genetic testing of patients with ovarian cancer.
Allelic loss on chromosome arm 8p: analysis of sporadic epithelial ovarian tumors.
An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.
Association of expression of p53, livin, ERCC1, BRCA1 and PARP1 in epithelial ovarian cancer tissue with drug resistance and prognosis.
Association of HMGB1, BRCA1 and P62 expression in ovarian cancer and chemotherapy sensitivity.
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
BRCA and Early Events in the Development of Serous Ovarian Cancer.
BRCA immunohistochemistry for screening of BRCA mutation in epithelial ovarian cancer patients.
BRCA1 affects the resistance and stemness of SKOV3-derived ovarian cancer stem cells by regulating autophagy.
BRCA1 and MAD2 Are Coexpressed and Are Prognostic Indicators in Tubo-ovarian High-Grade Serous Carcinoma.
BRCA1 as a Therapeutic Target in Sporadic Epithelial Ovarian Cancer.
BRCA1 Expression by Immunohistochemistry and Prognosis in Ovarian Cancer: A Systematic Review and Meta-Analysis.
BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study.
BRCA1 expression, proliferative and apoptotic activities in ovarian epithelial inclusions.
BRCA1 germline mutations and polymorphisms in a clinic-based series of ovarian cancer cases: a Gynecologic Oncology Group study.
BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer.
BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy.
BRCA1 Mutation Status and Follicular Fluid Exposure Alters NF?B Signaling and ISGylation in Human Fallopian Tube Epithelial Cells.
BRCA1 mutation testing for Japanese patients with ovarian cancer in breast cancer screening.
BRCA1 mutations in Taiwanese with epithelial ovarian carcinoma and sporadic primary serous peritoneal carcinoma.
BRCA1 promoter hypermethylation and protein expression in ovarian carcinoma-an Indian study.
BRCA1 promoter hypermethylation in sporadic epithelial ovarian carcinoma: Association with low expression of BRCA1, improved survival and co-expression of DNA methyltransferases.
BRCA1 promoter methylation is a marker of better response to platinum-taxane-based therapy in sporadic epithelial ovarian cancer.
BRCA1/2 mutation status influences somatic genetic progression in inherited and sporadic epithelial ovarian cancer cases.
Breast Cancer Surveillance Following Ovarian Cancer in BRCA Mutation Carriers.
Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation.
CDK9 inhibitor CDKI-73 is synergetic lethal with PARP inhibitor olaparib in BRCA1 wide-type ovarian cancer.
Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21).
Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1.
Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status.
Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis.
Concomitant BRCA1 and BRCA2 gene mutations in an Ashkenazi Jewish woman with primary breast and ovarian cancer.
Contribution of BRCA1 and BRCA2 mutations to inherited ovarian cancer.
Distinct Clinical Courses of Epithelial Ovarian Cancer with Mutations in BRCA1 5' and 3' Exons.
Dominant-negative activity of a Brca1 truncation mutant: effects on proliferation, tumorigenicity in vivo, and chemosensitivity in a mouse ovarian cancer cell line.
Epidemiologic analysis of breast and gynecologic cancers.
Epithelial ovarian cancer.
Epithelial ovarian cancer: prevention, diagnosis, and treatment.
Establishment and characterization of xenografts and cancer cell cultures derived from BRCA1 -/- epithelial ovarian cancers.
Evaluation of germline BRCA1 and BRCA2 mutations in a multi-ethnic Asian cohort of ovarian cancer patients.
Expression analysis of the MCPH1/BRIT1 and BRCA1 tumor suppressor genes and telomerase splice variants in epithelial ovarian cancer.
Expression and clinical implication of Beclin1, HMGB1, p62, survivin, BRCA1 and ERCC1 in epithelial ovarian tumor tissues.
EZH2 participates in malignant biological behavior of epithelial ovarian cancer through regulating the expression of BRCA1.
Familial site-specific ovarian cancer is linked to BRCA1 on 17q12-21.
Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers.
Frequency of BRCA1 dysfunction in ovarian cancer.
Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers.
Generation of induced pluripotent stem cell (iPSC) line from a patient with triple negative breast cancer with hereditary exon 17 deletion of BRCA1 gene.
Genetic alterations detected by comparative genomic hybridization and recurrence rate in epithelial ovarian carcinoma.
Genetic predisposition in gynecologic cancers.
Genetic Versus Epigenetic BRCA1 Silencing Pathways: Clinical Effects in Primary Ovarian Cancer Patients: A Study of the Tumor Bank Ovarian Cancer Consortium.
Germline BRCA1 and BRCA2 Mutations in Ovarian Cancer: Utility of a Histology-Based Referral Strategy.
Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer.
Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil.
Germline mutations of BRCA1 gene exon 11 are not associated with platinum response neither with survival advantage in patients with primary ovarian cancer: understanding the clinical importance of one of the biggest human exons. A study of the Tumor Bank Ovarian Cancer (TOC) Consortium.
Germline whole exome sequencing and large-scale replication identifies FANCM as a likely high grade serous ovarian cancer susceptibility gene.
Glucocorticoids inhibit cell death in ovarian cancer and up-regulate caspase inhibitor cIAP2.
Hereditary Ovarian Cancer and Risk Reduction.
High Expression of RING Finger Protein 126 Predicts Unfavorable Prognosis of Epithelial Ovarian Cancer.
Immunohistochemistry for the detection of BRCA1 and BRCA2 proteins in patients with ovarian cancer: a systematic review.
Improved survival in BRCA2 carriers with ovarian cancer.
Lack of the predominant BRCA1 and BRCA2 mutations in Jewish ovarian carcinoma patients who previously underwent ovulation induction.
Long-Term Follow-Up of a Female Patient Treated with Olaparib-Hope for a Long Life without Relapse?
Loss of BRCA1 protein expression as indicator of the BRCAness phenotype is associated with favorable overall survival after complete resection of sporadic ovarian cancer.
Loss of markers linked to BRCA1 precedes loss at important cell cycle regulatory genes in epithelial ovarian cancer.
Methylation profile of BRCA1, RASSF1A and ER in Vietnamese women with ovarian cancer.
Methylation status and immunohistochemistry of BRCA1 in epithelial ovarian cancer.
Molecular Mechanism Linking BRCA1 Dysfunction to High Grade Serous Epithelial Ovarian Cancers with Peritoneal Permeability and Ascites.
Molecular profiles of BRCA1-mutated and matched sporadic breast tumours: relation with clinico-pathological features.
Mutation analysis of BRCA1, TP53, and KRAS2 in ovarian and related pelvic tumors.
Mutation analysis of the BRCA1 gene in ovarian cancers.
No association between BRCA1 immunohistochemical expression and tumor grade, stage or overall survival in platinum-treated epithelial ovarian cancer patients.
Olaparib for the treatment of relapsed ovarian cancer with a BRCA1/2 mutation.
One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden.
Ovarian cancer BRCA1 mutation detection: Protein truncation test (PTT) outperforms single strand conformation polymorphism analysis (SSCP).
Ovarian surface epithelium: family history and early events in ovarian cancer.
Pathway-specific engineered mouse allograft models functionally recapitulate human serous epithelial ovarian cancer.
Perturbation of Rb, p53, and Brca1 or Brca2 Cooperate in Inducing Metastatic Serous Epithelial Ovarian Cancer.
Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants.
Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer.
Predictive value of ATP7b, BRCA1, BRCA2, PARP1, UIMC1 (RAP80), HOXA9, DAXX, TXN (TRX1), THBS1 (TSP1) and PRR13 (TXR1) genes in patients with epithelial ovarian cancer who received platinum-taxane first-line therapy.
Prevalence of BRCA1 expression in epithelial ovarian cancer: immunohistochemical study.
Prevalence, spectrum, and founder effect of BRCA1 and BRCA2 mutations in epithelial ovarian cancer from the Middle East.
Protein expression analysis using quantitative fluorescence image analysis on tissue microarray slides.
Rates of Jewish ancestral mutations in BRCA1 and BRCA2 in borderline ovarian tumors.
Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
Reliability of Tumor Testing Compared to Germline Testing for Detecting BRCA1 and BRCA2 Mutations in Patients with Epithelial Ovarian Cancer.
Repeat chemosensitivity of epithelial ovarian carcinoma in a BRCA1 mutation carrier to paclitaxel/platinum combination chemotherapy.
Role of BRCA1 and BRCA2 gene mutations in epithelial ovarian cancer in Indian population: a pilot study.
Role of genetic polymorphisms and ovarian cancer susceptibility.
Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway.
Survival Benefit of Germline BRCA Mutation is Associated with Residual Disease in Ovarian Cancer.
Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group.
Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations.
The BRCA1 syndrome and other inherited breast or breast-ovarian cancers in a Norwegian prospective series.
The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer.
The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population.
The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes.
The Different Impact of BRCA Mutations on the Survival of Epithelial Ovarian Cancer Patients: A Retrospective Single-Center Experience.
The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro.
The genetic epidemiology of early-onset epithelial ovarian cancer: a population-based study.
The Prognostic Value of BRCA1 and PARP Expression in Epithelial Ovarian Carcinoma: Immunohistochemical Detection.
The role of the breast cancer susceptibility gene 1 (BRCA1) in sporadic epithelial ovarian cancer.
The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 2: extending the scope beyond olaparib and BRCA1/2 mutations.
Therapy-related myeloid neoplasms in epithelial ovarian cancer patients carrying BRCA1 mutation: Report of two cases.
TP53 p.R337H prevalence in a series of Brazilian hereditary breast cancer families.
Transitional cell ovarian carcinoma in a BRCA1 mutation carrier.
When to Consider Risk-Reducing Mastectomy in BRCA1/BRCA2 Mutation Carriers with Advanced Stage Ovarian Cancer: a Case Study Illustrating the Genetic Counseling Challenges.
[Association between single nucleotide polymorphism of BARD1 gene and BRCA1 gene mutation in epithelial ovarian cancer].
[Clinical Management of HBOC in Our Hospital].
[Inactivation of BRCA1, BRCA2 and p53 genes in sporadic ovarian cancer]
[Preventive surgical prcedures for inherited risk of breast cancer]
[Recommendations for biomarker testing in epithelial ovarian cancer. A national consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology].
Carcinoma, Papillary
BRCA germline mutations in Jewish women with uterine serous papillary carcinoma.
BRCA1 germline mutations in women with uterine serous papillary carcinoma.
BRCA2 germline mutation in a woman with uterine serous papillary carcinoma--case report.
Is uterine serous papillary carcinoma a BRCA1-related disease? Case report and review of the literature.
Pancancer survival analysis of cancer hallmark genes.
Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening.
Primary peritoneal serous papillary carcinoma: a new epidemiologic trend? A matched-case comparison with ovarian serous papillary cancer.
Carcinoma, Renal Cell
A BAP1 Mutation-specific MicroRNA Signature Predicts Clinical Outcomes in Clear Cell Renal Cell Carcinoma Patients with Wild-type BAP1.
A population-based analysis of germline BAP1 mutations in melanoma.
Absence of loss of heterozygosity of BRCA1 in a renal tumor from a BRCA1 germline mutation carrier.
Association of the von Hippel-Lindau protein with AUF1 and posttranscriptional regulation of VEGFA mRNA.
BAP1 promotes viability and migration of ECA109 cells through KLF5/CyclinD1/FGF-BP1.
BAP1 tumor predisposition syndrome case report: pathological and clinical aspects of BAP1-inactivated melanocytic tumors (BIMTs), including dermoscopy and confocal microscopy.
Exploring the Ubiquitin-Proteasome System (UPS) through PROTAC Technology.
Expression parameters of the inhibitors of apoptosis cIAP1 and cIAP2 in renal cell carcinomas and their prognostic relevance.
Functional Link between BRCA1 and BAP1 through Histone H2A, Heterochromatin and DNA Damage Response.
Genomic profiling of the genes on chromosome 3p in sporadic clear cell renal cell carcinoma.
Hypoxia-induced SUMOylation of E3 ligase HAF determines specific activation of HIF2 in clear-cell renal cell carcinoma.
Identification of the deleterious 2080insA BRCA1 mutation in a male renal cell carcinoma patient from a family with multiple cancer diagnoses from Pakistan.
Immunogenomics of Metastatic Clear-Cell Renal Cell Carcinoma: Remarkable Response to Nivolumab in a Patient With a Pathogenic Germ Line BRCA1 Mutation.
Inactivation of SAG or ROC1 E3 Ligase Inhibits Growth and Survival of Renal Cell Carcinoma Cells: Effect of BIM.
Insulin-induced gene 1 (INSIG1) inhibits HIV-1 production by degrading Gag via activity of the ubiquitin ligase TRC8.
Intrahepatic cholangiocarcinoma development in a patient with a novel BAP1 germline mutation and low exposure to asbestos.
Knockdown of COUP-TFII inhibits cell proliferation and induces apoptosis through upregulating BRCA1 in renal cell carcinoma cells.
Low neighbor of Brca1 gene expression predicts poor clinical outcome and resistance of sunitinib in clear cell renal cell carcinoma.
pVHL Acts as an Adaptor to Promote the Inhibitory Phosphorylation of the NF-kappaB Agonist Card9 by CK2.
RBCK1 promotes p53 degradation via ubiquitination in renal cell carcinoma.
RNF43 is a Novel Tumor Suppressor and Prognostic Indicator in Clear Cell Renal Cell Carcinoma.
Role of RNF20 in cancer development and progression - a comprehensive review.
Simultaneous osteosarcoma and renal cell carcinoma with BRCA1 mutation in a young male adult with prior oligodendroglioma.
SMURF1, a promoter of tumor cell progression?
SPOP Promotes Tumorigenesis by Acting as a Key Regulatory Hub in Kidney Cancer.
SPOP-PTEN-SUFU axis promotes progression of clear cell renal cell carcinoma via activating SHH and WNT pathway.
The Roles of Ubiquitination Factor E4B (UBE4B) in the Postoperative Prognosis of Patients with Renal Cell Carcinoma and in Renal Tumor Cells Growth and Metastasis.
The Roles of VHL-Dependent Ubiquitination in Signaling and Cancer.
The TRC8 E3 ligase ubiquitinates MHC class I molecules before dislocation from the ER.
VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma.
Carcinoma, Squamous Cell
A Human Head and Neck Squamous Cell Carcinoma Cell Line with Acquired cis-Diamminedichloroplatinum-Resistance Shows Remarkable Upregulation of BRCA1 and Hypersensitivity to Taxane.
Anti-Apoptotic Signature in Thymic Squamous Cell Carcinomas - Functional Relevance of Anti-Apoptotic BIRC3 Expression in the Thymic Carcinoma Cell Line 1889c.
BRCA1 expression in leukoplakia and carcinoma of the tongue.
CircDOCK1 suppresses cell apoptosis via inhibition of miR?196a?5p by targeting BIRC3 in OSCC.
Corrigendum: The Polycomb proteins RING1B and EZH2 repress the tumoral pro-inflammatory function in metastasizing primary cutaneous squamous cell carcinoma.
CUL4 E3 ligase regulates the proliferation and apoptosis of lung squamous cell carcinoma and small cell lung carcinoma.
Effect of BRCA1 on the Concurrent Chemoradiotherapy Resistance of Cervical Squamous Cell Carcinoma Based on Transcriptome Sequencing Analysis.
Epigenetic inactivation of the chromosomal stability control genes BRCA1, BRCA2, and XRCC5 in non-small cell lung cancer.
Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma.
Expression of BRCA1, a factor closely associated with relapse-free survival, in patients who underwent neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil for squamous cell carcinoma of the esophagus.
Frequent loss of heterozygosity in the region including BRCA1 on chromosome 17q in squamous cell carcinomas of the esophagus.
Human Homolog of Drosophila Ariadne (HHARI) is a marker of cellular proliferation associated with nuclear bodies.
Immunohistochemical analysis of BRCA1 and acetyl-histone H3 in squamous cell carcinoma of the mobile tongue.
Integrative Genomic and Transcriptomic Analyses of Tumor Suppressor Genes and Their Role on Tumor Microenvironment and Immunity in Lung Squamous Cell Carcinoma.
Intrahepatic cholangiocarcinoma development in a patient with a novel BAP1 germline mutation and low exposure to asbestos.
Lack of Correlation between Aberrant p16, RAR-?2, TIMP3, ERCC1, and BRCA1 Protein Expression and Promoter Methylation in Squamous Cell Carcinoma Accompanying Candida albicans-Induced Inflammation.
Loss of heterozygosity at 8p, 9p and 17q in laryngeal cytological specimens.
Papers to appear in forthcoming issues
Redox-dependent Brca1 transcriptional regulation by an NADH-sensor CtBP1.
Regulation of Hippo/YAP signaling and Esophageal Squamous Carcinoma progression by an E3 ubiquitin ligase PARK2.
Single nucleotide polymorphisms in breast cancer susceptibility gene 1 are associated with susceptibility to lung cancer.
TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients.
The miR-205-5p/BRCA1/RAD17 Axis Promotes Genomic Instability in Head and Neck Squamous Cell Carcinomas.
The Polycomb proteins RING1B and EZH2 repress the tumoral pro-inflammatory function in metastasizing primary cutaneous squamous cell carcinoma.
[Tripartite-motif protein 25 and pyruvate kinase M2 protein expression in non-small cell lung cancer].
Carcinosarcoma
Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden.
High-grade serous carcinomas arise in the mouse oviduct via defects linked to the human disease.
Cardiomegaly
Endogenous muscle atrophy F-box is involved in the development of cardiac rupture after myocardial infarction.
Into the heart: The emerging role of the ubiquitin-proteasome system.
MuRF1 Negatively Regulates Pathological Cardiac Hypertrophy Through Downregulation of Calcineurin A.
Parkin does not prevent accelerated cardiac aging in mitochondrial DNA mutator mice.
RBCK1, a protein kinase CbetaI (PKCbetaI)-interacting protein, regulates PKCbeta-dependent function.
Resveratrol Ameliorates Cardiac Hypertrophy by Down-regulation of miR-155 Through Activation of Breast Cancer Type 1 Susceptibility Protein.
Selective translation of mRNAs in the left ventricular myocardium of the mouse in response to acute pressure overload.
Stability of F-box protein atrogin-1 is regulated by p38 mitogen-activated protein kinase pathway in cardiac H9c2 cells.
Targeting E3 Ubiquitin Ligase WWP1 Prevents Cardiac Hypertrophy Through Destabilizing DVL2 via Inhibition of K27-Linked Ubiquitination.
The E3 ubiquitin ligase HectD3 attenuates cardiac hypertrophy and inflammation in mice.
Zonisamide alleviates cardiac hypertrophy in rats by increasing Hrd1 expression and inhibiting endoplasmic reticulum stress.
Cardiomyopathies
Biallelic mutations in RNF220 cause laminopathies featuring leukodystrophy, ataxia and deafness.
BRCA1 Reflects Myocardial Adverse Remodeling in Idiopathic Dilated Cardiomyopathy.
Cullin-RING ligases in regulation of autophagy.
Deletion of the E3 ubiquitin ligase, Parkin, exacerbates chronic alcohol intake-induced cardiomyopathy through an Ambra1-dependent mechanism.
Identification of critical regions and candidate genes for cardiovascular malformations and cardiomyopathy associated with deletions of chromosome 1p36.
Interdependence of Parkin-Mediated Mitophagy and Mitochondrial Fission in Adult Mouse Hearts.
Polyglucosan body myopathy 1 may cause cognitive impairment: a case report from China.
Polyglucosan body myopathy caused by defective ubiquitin ligase RBCK1.
The incidence of cardiomyopathy in BRCA1 and BRCA2 mutation carriers after anthracycline-based adjuvant chemotherapy.
Cardiomyopathy, Alcoholic
Deletion of the E3 ubiquitin ligase, Parkin, exacerbates chronic alcohol intake-induced cardiomyopathy through an Ambra1-dependent mechanism.
Cardiomyopathy, Dilated
BRCA1 Reflects Myocardial Adverse Remodeling in Idiopathic Dilated Cardiomyopathy.
Parkin regulation of CHOP modulates susceptibility to cardiac endoplasmic reticulum stress.
The E3 ubiquitin ligase c-Cbl mediates integrin ?1 ubiquitination during dilated cardiomyopathy.
Ufm1-Specific Ligase Ufl1 Regulates Endoplasmic Reticulum Homeostasis and Protects Against Heart Failure.
Cardiomyopathy, Hypertrophic
The E3 ubiquitin ligase Asb2? is downregulated in a mouse model of hypertrophic cardiomyopathy and targets desmin for proteasomal degradation.
Cardiotoxicity
Activation of the ubiquitin-proteasome system against arsenic trioxide cardiotoxicity involves ubiquitin ligase Parkin for mitochondrial homeostasis.
An Exploratory Study to Determine Whether BRCA1 and BRCA2 Mutation Carriers Have Higher Risk of Cardiac Toxicity.
Deletion of the E3 ubiquitin ligase, Parkin, exacerbates chronic alcohol intake-induced cardiomyopathy through an Ambra1-dependent mechanism.
Enhanced mitophagy mediated by the YAP/Parkin pathway protects against DOX-induced cardiotoxicity.
The incidence of cardiomyopathy in BRCA1 and BRCA2 mutation carriers after anthracycline-based adjuvant chemotherapy.
TRIM25 Rescues Against Doxorubicin-Induced Pyroptosis Through Promoting NLRP1 Ubiquitination.
Cardiovascular Diseases
Discovery of Therapeutic Deubiquitylase Effector Molecules: Current Perspectives.
E3 Ubiquitin ligase NEDD4 family?regulatory network in cardiovascular disease.
Identification of differentially methylated BRCA1 and CRISP2 DNA regions as blood surrogate markers for cardiovascular disease.
Risk of cardiovascular disease in women with BRCA1 and BRCA2 mutations.
Cataract
TRIM69 inhibits cataractogenesis by negatively regulating p53.
Central Nervous System Diseases
Cytokines, signaling and diseases - a pharmacologist's view.
Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers.
Transcriptome sequencing of neurologic diseases associated genes in HHV-6A infected human astrocyte.
Cerebellar Ataxia
Parkin mutations are frequent in patients with isolated early-onset parkinsonism.
Charcot-Marie-Tooth Disease
SIMPLE mutations in Charcot-Marie-Tooth disease and the potential role of its protein product in protein degradation.
Cholangiocarcinoma
BAP1 promotes viability and migration of ECA109 cells through KLF5/CyclinD1/FGF-BP1.
BEX2 suppresses mitochondrial activity and is required for dormant cancer stem cell maintenance in intrahepatic cholangiocarcinoma.
E3 ubiquitin ligase FBW7? inhibits cholangiocarcinoma cell proliferation by downregulating c-Myc and cyclin E.
Hybrid Capture-Based Tumor Sequencing and Copy Number Analysis to Confirm Origin of Metachronous Metastases in BRCA1-Mutant Cholangiocarcinoma Harboring a Novel YWHAZ-BRAF Fusion.
Ring finger protein 43 expression is associated with genetic alteration status and poor prognosis among patients with intrahepatic cholangiocarcinoma.
Cholestasis
Canalicular membrane MRP2/ABCC2 internalization is determined by Ezrin Thr567 phosphorylation in human obstructive cholestasis.
Chondroma
A distinct phenotype characterizes tumors from a putative genetic trait involving chondrosarcoma and breast cancer occurring in the same patient.
Chondrosarcoma
A distinct phenotype characterizes tumors from a putative genetic trait involving chondrosarcoma and breast cancer occurring in the same patient.
Chordoma
C-Cbl and Cbl-b expression in skull base chordomas is associated with tumor progression and poor prognosis.
Choroidal Neovascularization
Role of c-Cbl Dependent Regulation of Phospholipase C gamma 1 Activation in Experimental Choroidal Neovascularization.
Classical Swine Fever
Porcine RING finger protein 114 inhibits classical swine fever virus replication via the K27-linked polyubiquitination of viral NS4B.
Viral strategies for triggering and manipulating mitophagy.
Cleft Palate
Alteration of DNA Damage Response Causes Cleft Palate.
Mutations in the HECT domain of NEDD4L lead to AKT-mTOR pathway deregulation and cause periventricular nodular heterotopia.
Cockayne Syndrome
BRCA1 contributes to transcription-coupled repair of DNA damage through polyubiquitination and degradation of Cockayne syndrome B protein.
Damage-induced ubiquitylation of human RNA polymerase II by the ubiquitin ligase Nedd4, but not Cockayne syndrome proteins or BRCA1.
Overexpression of parkin rescues the defective mitochondrial phenotype and the increased apoptosis of Cockayne Syndrome A cells.
ROS-induced R loops trigger a transcription-coupled but BRCA1/2-independent homologous recombination pathway through CSB.
Structural basis of human transcription-DNA repair coupling.
Valosin-containing Protein (VCP)/p97 Segregase Mediates Proteolytic Processing of Cockayne Syndrome Group B (CSB) in Damaged Chromatin.
Coinfection
Avian leukosis virus subgroup J and reticuloendotheliosis virus coinfection induced TRIM62 regulation of the actin cytoskeleton.
Increased expression and dysregulated association of restriction factors and type I interferon in HIV, HCV mono- and co-infected patients.
Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson's disease.
Parkin gene therapy for alpha-synucleinopathy: A rat model of Parkinson's disease.
Restriction of feline immunodeficiency virus by Ref1, Lv1, and primate TRIM5alpha proteins.
Colitis
3, 3'-Diindolylmethane decreases VCAM-1 expression and alleviates experimental colitis via BRCA1-dependent antioxidant pathway.
A critical role for cellular inhibitor of protein 2 (cIAP2) in colitis-associated colorectal cancer and intestinal homeostasis mediated by the inflammasome and survival pathways.
Dietary flaxseed intake exacerbates acute colonic mucosal injury and inflammation induced by dextran sodium sulfate.
E3 ligase c-Cbl regulates intestinal inflammation through suppressing fungi-induced noncanonical NF-?B activation.
Ginsenoside Rb1 alleviates colitis in mice via activation of endoplasmic reticulum-resident E3 ubiquitin ligase Hrd1 signaling pathway.
Gut Microbiota Contributes to Spontaneous Colitis in E3 Ligase Itch-Deficient Mice.
RNF186 regulates EFNB1 (ephrin B1)-EPHB2-induced autophagy in the colonic epithelial cells for the maintenance of intestinal homeostasis.
Colitis, Ulcerative
A critical role for cellular inhibitor of protein 2 (cIAP2) in colitis-associated colorectal cancer and intestinal homeostasis mediated by the inflammasome and survival pathways.
A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis.
Deep Resequencing of GWAS Loci Identifies Rare Variants in CARD9, IL23R and RNF186 That Are Associated with Ulcerative Colitis.
Emerging views of mitophagy in immunity and autoimmune diseases.
Erratum: A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis.
Regulation of antiapoptotic and cytoprotective pathways in colonic epithelial cells in ulcerative colitis.
RNF186 regulates EFNB1 (ephrin B1)-EPHB2-induced autophagy in the colonic epithelial cells for the maintenance of intestinal homeostasis.
Upregulation of cIAP2 in regenerating colonocytes in ulcerative colitis.
Colitis-Associated Neoplasms
A critical role for cellular inhibitor of protein 2 (cIAP2) in colitis-associated colorectal cancer and intestinal homeostasis mediated by the inflammasome and survival pathways.
Inflammation and DNA Methylation-Dependent Down-Regulation of miR-34b-5p Mediates c-MYC Expression and CRL4DCAF4 E3 Ligase Activity in Colitis-Associated Cancer.
Inflammation-dependent overexpression of c-Myc enhances CRL4DCAF4 E3 ligase activity and promotes ubiquitination of ST7 in colitis-associated cancer.
Colonic Neoplasms
A cancer-associated RING finger protein, RNF43, is a ubiquitin ligase that interacts with a nuclear protein, HAP95.
A novel sensitive method to detect frameshift mutations in exonic repeat sequences of cancer-related genes.
A phospho-switch controls RNF43-mediated degradation of Wnt receptors to suppress tumorigenesis.
An apoptosis-independent role of SMAC in tumor suppression.
Analysis of the molecular nature associated with microsatellite status in colon cancer identifies clinical implications for immunotherapy.
Assessment of tumor suppressor promoter methylation in healthy individuals.
Attenuation of proteolysis-mediated cyclin E regulation by alternatively spliced Parkin in human colorectal cancers.
Berberine binds RXR? to suppress ?-catenin signaling in colon cancer cells.
Bias in intervention studies that enroll patients from high-risk clinics.
BRCA1 expression serves a role in vincristine resistance in colon cancer cells.
Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program.
Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations.
Cancer risks in women with 2 breast or ovarian cancers: clues to genetic cancer susceptibility.
CDX2 inducible microRNAs sustain colon cancer by targeting multiple DNA damage response pathway factors.
Clinical significance of epigenetic inactivation of hMLH1 and BRCA1 in Tunisian patients with invasive breast carcinoma.
DNA damage-induced cytotoxicity is dissociated from BRCA1's DNA repair function but is dependent on its cytosolic accumulation.
Down-regulation of cIAP2 enhances 5-FU sensitivity through the apoptotic pathway in human colon cancer cells.
Evaluation of psychosocial effects of pre-symptomatic testing for breast/ovarian and colon cancer pre-disposing genes: a 12-month follow-up.
Expression of an Oncogenic BARD1 Splice Variant Impairs Homologous Recombination and Predicts Response to PARP-1 Inhibitor Therapy in Colon Cancer.
Germline variants of the promyelocytic leukemia tumor suppressor gene in patients with familial cancer.
Inheritance of cancer.
KDM5c Promotes Colon Cancer Cell Proliferation Through the FBXW7-c-Jun Regulatory Axis.
Long Noncoding RNA LINC01207 Promotes Colon Cancer Cell Proliferation and Invasion by Regulating miR-3125/TRIM22 Axis.
Long-term treatment with the PARP inhibitor niraparib does not increase the mutation load in cell line models and tumour xenografts.
Loss of heterozygosity in the region including the BRCA1 gene on 17q in colon cancer.
Loss of heterozygosity studies in tumors from families with breast-ovarian cancer syndrome.
Low levels of BRCA1 protein expression predict a worse prognosis in stage I-II colon cancer.
Microelectronic DNA assay for the detection of BRCA1 gene mutations.
Modeling the study of DNA damage responses in mice.
Morphological features of TMPRSS2-ERG gene fusion prostate cancer.
Mutual regulation between OGT and XIAP to control colon cancer cell growth and invasion.
MYC-nick promotes cell migration by inducing fascin expression and Cdc42 activation.
Parallel states of pathological Wnt signaling in neonatal brain injury and colon cancer.
Potential role of TRIM3 as a novel tumour suppressor in colorectal cancer (CRC) development.
Reversible regulation of SATB1 ubiquitination by USP47 and SMURF2 mediates colon cancer cell proliferation and tumor progression.
Ring finger protein 43 as a new target for cancer immunotherapy.
RNF43 frameshift mutations contribute to tumourigenesis in right-sided colon cancer.
SMURF1, a promoter of tumor cell progression?
The contribution of founder mutations in BRCA1 to breast and ovarian cancer in Lithuania.
The E3 ligase RNF43 inhibits Wnt signaling downstream of mutated ?-catenin by sequestering TCF4 to the nuclear membrane.
The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.
The role of genetic testing for cancer susceptibility in gynecologic practice.
The ubiquitin ligase RNF220 enhances canonical Wnt signaling through USP7-mediated deubiquitination of ?-catenin.
Ubiquitin Ligase, Fbw7, Targets CDX2 for Degradation via Two Phosphodegron Motifs in a GSK3beta-dependent Manner.
Variable NF-?B pathway responses in colon cancer cells treated with chemotherapeutic drugs.
[Genetic instability on chromosome 17q21 in gastric cancer of Chinese patients]
[Hereditary predispositions to gynaecological cancers]
Colorectal Neoplasms
A critical role for cellular inhibitor of protein 2 (cIAP2) in colitis-associated colorectal cancer and intestinal homeostasis mediated by the inflammasome and survival pathways.
A Hypoxia-Induced SCFFBXL1 E3 Ligase Ubiquitinates and Degrades the MEN1 Tumor Suppressor to Promote Colorectal Cancer Tumorigenesis.
A microsatellite within the MUC1 locus at 1q21 is altered in the neoplastic cells of breast cancer patients.
A novel oncoprotein RNF43 functions in an autocrine manner in colorectal cancer.
A review of the clinical relevance of mismatch-repair deficiency in ovarian cancer.
Adenosine nucleotide modulates the physical interaction between hMSH2 and BRCA1.
An Integrative Omics Approach Reveals Involvement of BRCA1 in Hepatic Metastatic Progression of Colorectal Cancer.
Analysis and interpretation of RNA splicing alterations in genes involved in genetic disorders.
Analysis of microsatellite instability and BRCA1 mutations in patients from hereditary nonpolyposis colorectal cancer (HNPCC) family.
Aneuploidy is associated with TP53 expression but not with BRCA1 or TERT expression in sporadic colorectal cancer.
Aspirin and alterations in DNA repair proteins in the SW480 colorectal cancer cell line.
Associations among beta-TrCP, an E3 ubiquitin ligase receptor, beta-catenin, and NF-kappaB in colorectal cancer.
Attenuation of proteolysis-mediated cyclin E regulation by alternatively spliced Parkin in human colorectal cancers.
BAP1 promotes viability and migration of ECA109 cells through KLF5/CyclinD1/FGF-BP1.
BRCA1 and BRCA2 expression patterns and prognostic significance in digestive system cancers.
BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer.
BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-analysis.
BRCA1 and BRCA2 mutations and the risk for colorectal cancer.
BRCA1 and ERCC1 mRNA levels are associated with lymph node metastasis in Chinese patients with colorectal cancer.
BRCA1 in special populations.
BRCA1 mutations and colorectal cancer in Poland.
BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing.
c-Cbl Expression Correlates with Human Colorectal Cancer Survival and Its Wnt/?-Catenin Suppressor Function Is Regulated by Tyr371 Phosphorylation.
c-Cbl mediates the degradation of tumorigenic nuclear ?-catenin contributing to the heterogeneity in Wnt activity in colorectal tumors.
c-Cbl targets PD-1 in immune cells for proteasomal degradation and modulates colorectal tumor growth.
Case Report: Coinheritance of Germline Mutations in APC and BRCA1 in Colorectal Cancer.
CDC25A, VAV1, TP73, BRCA1 and ZAP70 gene overexpression correlates with radiation response in colorectal cancer.
cIAP2 as a therapeutic target in colorectal cancer and other malignancies.
Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal Cancer.
Colorectal cancer in hereditary breast cancer kindreds.
Colorectal carcinomas show frequent allelic loss on the long arm of chromosome 17 with evidence for a specific target region.
Common genetic variants and cancer risk in Mendelian cancer syndromes.
Commonly observed RNF43 mutations retain functionality in attenuating Wnt/?-catenin signaling and unlikely confer Wnt-dependency onto colorectal cancers.
Constitutional Mosaic Epimutations - a hidden cause of cancer?
Copy number variation of E3 ubiquitin ligase genes in peripheral blood leukocyte and colorectal cancer.
Curcumin Regulates the Progression of Colorectal Cancer via LncRNA NBR2/AMPK Pathway.
Defining UHRF1 Domains that Support Maintenance of Human Colon Cancer DNA Methylation and Oncogenic Properties.
Detection of Pathogenic Germline Variants Among Patients With Advanced Colorectal Cancer Undergoing Tumor Genomic Profiling for Precision Medicine.
DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis.
Dosage analysis of cancer predisposition genes by multiplex ligation-dependent probe amplification.
Down-regulation of cIAP2 enhances 5-FU sensitivity through the apoptotic pathway in human colon cancer cells.
Downregulation of HERC5 E3 ligase attenuates the ubiquitination of CtBP1 to inhibit apoptosis in colorectal cancer cells.
Downregulation of ring-finger protein 43 in glioma associates with poor prognosis.
E3 ubiquitin ligase SMURF2 prevents colorectal cancer by reducing the stability of the YY1 protein and inhibiting the SENP1/c-myc axis.
E3 ubiquitin ligase Smurf2: a prognostic factor in microsatellite stable colorectal cancer.
Effect of NS398 on metastasis-associated gene expression in a human colon cancer cell line.
Enhancement of TGF-? signaling responses by the E3 ubiquitin ligase Arkadia provides tumor suppression in colorectal cancer.
Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer.
Erbin interacts with c-Cbl and promotes tumourigenesis and tumour growth in colorectal cancer by preventing c-Cbl-mediated ubiquitination and down-regulation of EGFR.
Expression of DNA Double-Strand Break Repair Proteins ATM and BRCA1 Predicts Survival in Colorectal Cancer.
Familial sarcoma: challenging pedigrees.
FBW7-Dependent Mcl-1 Degradation Mediates the Anticancer Effect of Hsp90 Inhibitors.
Frameshift mutations of ubiquitination-related genes HERC2, HERC3, TRIP12, UBE2Q1 and UBE4B in gastric and colorectal carcinomas with microsatellite instability.
Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer.
Frequent frameshift mutations in 2 mononucleotide repeats of RNF43 gene and its regional heterogeneity in gastric and colorectal cancers.
Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer.
Genetic analysis of a breast-ovarian cancer family, with 7 cases of colorectal cancer linked to BRCA1, fails to support a role for BRCA1 in colorectal tumorigenesis.
Genetic testing by cancer site: ovary.
Genetics and the management of women at high risk for breast cancer.
Genital Cancers in Women: Ovarian Cancer.
Genome-wide CRISPR screens reveal a Wnt-FZD5 signaling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumors.
Germline genetic variation, cancer outcome, and pharmacogenetics.
Hereditary cancer syndromes.
Hereditary common cancers: molecular and clinical genetics.
Hereditary Factors in Gynecologic Cancer.
Hereditary risk of women's cancers.
Heterogeneous nuclear ribonucleoprotein L facilitates recruitment of 53BP1 and BRCA1 at the DNA break sites induced by oxaliplatin in colorectal cancer.
Identification of colorectal cancers with defective DNA damage repair by immunohistochemical profiling of mismatch repair proteins, CDX2 and BRCA1.
Identification of differentially expressed genes associated with colorectal cancer liver metastasis.
Impact of gene patents and licensing practices on access to genetic testing for inherited susceptibility to cancer: comparing breast and ovarian cancers with colon cancers.
Impact of loss-of-function mutations at the RNF43 locus on colorectal cancer development and progression.
Implication of alterations in Parkin gene among North Indian patients with colorectal cancer.
Incidence of BRCA1 and BRCA2 mutations in Ashkenazi colorectal cancer patients: preliminary study.
Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study.
Inhibition of Karyopherin-?2 Augments Radiation-Induced Cell Death by Perturbing BRCA1-Mediated DNA Repair.
Inhibitor of apoptosis protein family as diagnostic markers and therapeutic targets of colorectal cancer.
Intratumoral heterogeneity in microsatellite alterations in BRCA1 and PTEN regions in sporadic colorectal cancer.
Is there really an increased risk of early colorectal cancer in women with BRCA1 pathogenic mutations?
Kras mutation subtypes distinctly affect colorectal cancer cell sensitivity to FL118, a novel inhibitor of survivin, Mcl-1, XIAP, cIAP2 and MdmX.
Localization of human BRCA1 and BRCA2 in non-inherited colorectal carcinomas and matched normal mucosas.
Loss of endogenous RNF43 function enhances proliferation and tumour growth of intestinal and gastric cells.
Missense alterations of BRCA1 gene detected in diverse cancer patients.
Mule Regulates the Intestinal Stem Cell Niche via the Wnt Pathway and Targets EphB3 for Proteasomal and Lysosomal Degradation.
MYC-nick promotes cell migration by inducing fascin expression and Cdc42 activation.
Next-generation sequencing reveals lymph node metastasis associated genetic markers in colorectal cancer.
No germline mutations in the histone acetyltransferase gene EP300 in BRCA1 and BRCA2 negative families with breast cancer and gastric, pancreatic, or colorectal cancer.
Not All Wnt Activation Is Equal: Ligand-Dependent versus Ligand-Independent Wnt Activation in Colorectal Cancer.
Ovarian cancer at young age: the contribution of mismatch-repair defects in a population-based series of epithelial ovarian cancer before age 40.
Ovarian cancer screening.
PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice.
Parkin protein expression and its impact on survival of patients with advanced colorectal cancer.
Phase I clinical trial of a novel peptide vaccine in combination with UFT/LV for metastatic colorectal cancer.
Phase I clinical trial of a peptide vaccine combined with tegafur-uracil plus leucovorin for treatment of advanced or recurrent colorectal cancer.
Potential role of TRIM3 as a novel tumour suppressor in colorectal cancer (CRC) development.
Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.
Prognostic significance of the allelic loss of the BRCA1 gene in colorectal cancer.
Proteomic identification of a PSF/p54nrb heterodimer as RNF43 oncoprotein-interacting proteins.
Quantitative analysis of BRCA1, BRCA2 and Hmsh2 mRNA expression in colorectal Lieberkühnien adenocarcinomas and matched normal mucosa: relationship with cellular proliferation.
RBBP6, a RING finger-domain E3 ubiquitin ligase, induces epithelial-mesenchymal transition and promotes metastasis of colorectal cancer.
RBCK1 contributes to chemoresistance and stemness in colorectal cancer (CRC).
Re: BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer.
RE: BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-analysis.
Reduced Frequency and Prognostic Significance of Ring Finger Protein 43 Nucleotide Polymorphisms in a Chinese Colorectal Cancer Cohort.
Ribosomal protein RPS15A augments proliferation of colorectal cancer RKO cells via regulation of BIRC3, p38 MAPK and Chk1.
Risk of colorectal cancer associated with BRCA1 and/or BRCA2 mutation carriers: systematic review and meta-analysis.
Risk-benefit assessment of the combined oral contraceptive pill in women with a family history of female cancer.
RNF180 Inhibits Proliferation and Promotes Apoptosis of Colorectal Cancer Through Ubiquitination of WISP1.
RNF43 interacts with NEDL1 and regulates p53-mediated transcription.
RNF43 Is an Early and Specific Mutated Gene in the Serrated Pathway, With Increased Frequency in Traditional Serrated Adenoma and Its Associated Malignancy.
RNF43 is mutated less frequently in Lynch Syndrome compared with sporadic microsatellite unstable colorectal cancers.
RNF43 mutation analysis in serrated polyposis, sporadic serrated polyps and Lynch syndrome polyps.
RNF43 mutation is associated with aggressive tumor biology along with BRAF V600E mutation in right-sided colorectal cancer.
RNF43 Pathogenic Germline Variant in a Family with Colorectal Cancer.
RT-qPCR analysis of the tumor antigens TOMM34 and RNF43 in samples extracted from paraffin-embedded specimens of colorectal cancer.
Segregation analysis of epithelial ovarian cancer in Finland.
Study uncovers mutation involved in two cancers.
The apoptosis-inducing effect of gastrin on colorectal cancer cells relates to an increased IEX-1 expression mediating NF-kappa B inhibition.
The c-MYC/NAMPT/SIRT1 feedback loop is activated in early classical and serrated route colorectal cancer and represents a therapeutic target.
The CARM1-p300-c-Myc-Max (CPCM) transcriptional complex regulates the expression of CUL4A/4B and affects the stability of CRL4 E3 ligases in colorectal cancer.
The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer.
The E3 Ubiquitin Ligase Asb2? in T Helper 2 Cells Negatively Regulates Antitumor Immunity in Colorectal Cancer.
The E3 ubiquitin ligase RNF146 promotes colorectal cancer by activating the Wnt/?-catenin pathway via ubiquitination of Axin1.
The E3 ubiquitin ligase RNF40 suppresses apoptosis in colorectal cancer cells.
The frequency of the predominant Jewish mutations in BRCA1 and BRCA2 in unselected Ashkenazi colorectal cancer patients.
The genetics of uterine leiomyomata: what clinicians need to know.
The putative oncogene CEP72 inhibits the mitotic function of BRCA1 and induces chromosomal instability.
The role and mechanism of action of RNF186 in colorectal cancer through negative regulation of NF-?B.
The SMAC mimetic BV6 sensitizes colorectal cancer cells to ionizing radiation by interfering with DNA repair processes and enhancing apoptosis.
Traditional serrated adenoma: an overview of pathology and emphasis on molecular pathogenesis.
Transcriptome analysis of paired primary colorectal carcinoma and liver metastases reveals fusion transcripts and similar gene expression profiles in primary carcinoma and liver metastases.
Translating genomics in cancer care.
TRIM23 overexpression is a poor prognostic factor and contributes to carcinogenesis in colorectal cancer.
TRIM25 regulates oxaliplatin resistance in colorectal cancer by promoting EZH2 stability.
Tripartite motif containing 25 promotes proliferation and invasion of colorectal cancer cells through TGF-? signaling.
Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors.
Uncovering and deciphering the pro-invasive role of HACE1 in melanoma cells.
Up-regulation of c-Cbl suggests its potential role as oncogene in primary colorectal cancer.
[Predictive genetic testing for hereditary breast cancer and hereditary nonpolyposis colorectal cancer]
[Preliminary study of Peptide vaccine with UFT/LV as adjuvant setting for stage III colorectal cancer].
[Prophylactic surgery of mammary and ovarian carcinoma.]
[Treatment outcome of peptide vaccination for advanced colorectal cancer].
Colorectal Neoplasms, Hereditary Nonpolyposis
A novel deleterious c.2656G>T MSH2 germline mutation in a Pakistani family with a phenotypic overlap of hereditary breast and ovarian cancer and Lynch syndrome.
A review of the clinical relevance of mismatch-repair deficiency in ovarian cancer.
AGA Clinical Practice Update on Pancreas Cancer Screening in High-Risk Individuals: Expert Review.
Analysis and interpretation of RNA splicing alterations in genes involved in genetic disorders.
Analysis of microsatellite instability and BRCA1 mutations in patients from hereditary nonpolyposis colorectal cancer (HNPCC) family.
BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing.
Common genetic variants and cancer risk in Mendelian cancer syndromes.
Contribution of Massive Parallel Sequencing to Diagnosis of Hereditary Ovarian Cancer in the Czech Republic.
Defective DNA repair in hereditary ovarian cancers: Implications for therapy.
Dosage analysis of cancer predisposition genes by multiplex ligation-dependent probe amplification.
Double heterozygosity for BRCA1 and hMLH1 gene mutations in a 46-year-old woman with five primary tumors.
Evaluating the role of public health in implementation of genomics-related recommendations: a case study of hereditary cancers using the CDC Science Impact Framework.
Genetic testing by cancer site: ovary.
Genetic testing by cancer site: stomach.
Genetics and the management of women at high risk for breast cancer.
Genital Cancers in Women: Ovarian Cancer.
Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer.
Germline genetic variation, cancer outcome, and pharmacogenetics.
Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohort.
Germline pathogenic variants identified in women with ovarian tumors.
Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome.
Hereditary Factors in Gynecologic Cancer.
Hereditary forms of ovarian cancer.
Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management.
Hereditary ovarian carcinomas: clinico-biological features and treatment.
HPV nonrelated endocervical adenocarcinoma in hereditary cancer syndromes.
Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome.
Identification of germline genetic mutations in patients with pancreatic cancer.
Identifying Lynch syndrome in patients with ovarian carcinoma: the significance of tumor subtype.
Improving attendance to genetic counselling services for gynaecological oncology patients.
Inherited predisposition to cancer: a historical overview.
Initial Findings from a High Genetic Risk Prostate Cancer Clinic.
Lifestyle Risk Factors Among People Who Have Had Cancer Genetic Testing.
Novel LOVD databases for hereditary breast cancer and colorectal cancer genes in the Chinese population.
Ovarian cancer at young age: the contribution of mismatch-repair defects in a population-based series of epithelial ovarian cancer before age 40.
Ovarian cancer screening.
Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry.
Predicted Chemotherapy Benefit for Breast Cancer Patients With Germline Pathogenic Variants in Cancer Susceptibility Genes.
Preventing Ovarian Cancer in High-risk Women: One Surgery at a Time.
Radiologic-Histopathologic Correlation of Transvaginal US and Risk-reducing Salpingo-oophorectomy for Women at High Risk for Tubo-ovarian Carcinoma.
Recent progress in the diagnosis and treatment of ovarian cancer.
Risk-benefit assessment of the combined oral contraceptive pill in women with a family history of female cancer.
RNF43 is mutated less frequently in Lynch Syndrome compared with sporadic microsatellite unstable colorectal cancers.
RNF43 mutation analysis in serrated polyposis, sporadic serrated polyps and Lynch syndrome polyps.
The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer.
The genetics of uterine leiomyomata: what clinicians need to know.
The role of genetic testing for cancer susceptibility in gynecologic practice.
Two Cases of Carcinosarcomas of the Ovary Involved in Hereditary Cancer Syndromes.
Universal screening for Lynch syndrome in uterine cancer patients: A quality improvement initiative.
[Chemoprevention and prophylactic surgery in ovarian carcinoma]
[Genetic consultation: hereditary cancer risk?].
[Predictive genetic testing for hereditary breast cancer and hereditary nonpolyposis colorectal cancer]
[Prophylactic surgery of mammary and ovarian carcinoma.]
Communicable Diseases
Autophagy in infection.
Confusion
MdmX protein is essential for Mdm2 protein-mediated p53 polyubiquitination.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Arsenite Binds to the RING Finger Domain of FANCL E3 Ubiquitin Ligase and Inhibits DNA Interstrand Crosslink Repair.
Coronary Artery Disease
How to keep on going: Editorial comment on The long-term effects of a randomized trial comparing aerobic interval versus continuous training in coronary artery disease patients: one-year data from the SAINTEX-CAD study.
Negative Selection on BRCA1 Susceptibility Alleles Sheds Light on the Population Genetics of Late-Onset Diseases and Aging Theory.
Coronavirus Infections
The Severe Acute Respiratory Syndrome Coronavirus Nucleocapsid Inhibits Type I Interferon Production by Interfering with TRIM25-Mediated RIG-I Ubiquitination.
Corticobasal Degeneration
Aberrant Accumulation of BRCA1 in Alzheimer Disease and Other Tauopathies.
COVID-19
Coronavirus 2019 Silver Linings.
Lung expression of genes putatively involved in SARS-CoV-2 infection is modulated in cis by germline variants.
Protease cleavage of RNF20 facilitates coronavirus replication via stabilization of SREBP1.
Utility of a mainstreamed genetic testing pathway in breast and ovarian cancer patients during the COVID-19 pandemic.
Craniofacial Abnormalities
The polycomb group protein ring1b/rnf2 is specifically required for craniofacial development.
Craniosynostoses
A recurrent PJA1 variant in trigonocephaly and neurodevelopmental disorders.
Creutzfeldt-Jakob Syndrome
Absence of Association between Two HECTD2 Polymorphisms and Sporadic Creutzfeldt-Jakob Disease.
Crohn Disease
Emerging views of mitophagy in immunity and autoimmune diseases.
Inhibitor of apoptosis proteins are required for effective fusion of autophagosomes with lysosomes.
RNF186 regulates EFNB1 (ephrin B1)-EPHB2-induced autophagy in the colonic epithelial cells for the maintenance of intestinal homeostasis.
Variants in TRIM22 That Affect NOD2 Signaling Are Associated With Very-Early-Onset Inflammatory Bowel Disease.
Cystadenocarcinoma
Cells redox environment modulates BRCA1 expression and DNA homologous recombination repair.
Cystadenocarcinoma, Mucinous
Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report.
Cystadenocarcinoma, Serous
[Differential expression of USP2, USP14 and UBE4A between ovarian serous cystadenocarcinoma and adjacent normal tissues]
Cystadenoma
Mechanism of cytokinesis failure in ovarian cystadenomas with defective BRCA1 and P53 pathways.
Ovarian cystadenoma as a characteristic feature of families with hereditary ovarian cancers unassociated with BRCA1 and BRCA2 mutations.
Reduction of BRCA1 expression in sporadic ovarian cancer.
Role of BRCA1 in controlling mitotic arrest in ovarian cystadenoma cells.
Cystadenoma, Serous
Cell-nonautonomous induction of ovarian and uterine serous cystadenomas in mice lacking a functional Brca1 in ovarian granulosa cells.
Granulosa Cell-Specific Brca1 Loss Alone or Combined with Trp53 Haploinsufficiency and Transgenic FSH Expression Fails to Induce Ovarian Tumors.
Serous cystic neoplasms of the pancreas: clinicopathologic and molecular characteristics.
Cystic Fibrosis
Application of DNA Machineries for the Barcode Patterned Detection of Genes or Proteins.
c-Cbl facilitates endocytosis and lysosomal degradation of cystic fibrosis transmembrane conductance regulator in human airway epithelial cells.
c-Cbl reduces stability of rescued ?F508-CFTR in human airway epithelial cells: Implications for cystic fibrosis treatment.
High throughput parallel analysis of hundreds of patient samples for more than 100 mutations in multiple disease genes.
Medical students' attitudes toward genetic testing of minors.
RNF185 is a novel E3 ligase of Endoplasmic Reticulum Associated Degradation (ERAD) that targets Cystic Fibrosis Transmembrane conductance Regulator (CFTR).
Screening semen donors for hereditary diseases. The Fairfax cryobank experience.
Cysts
A combination of molecular markers and clinical features improve the classification of pancreatic cysts.
Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes.
Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes.
Loss of Drosophila E3 Ubiquitin Ligase Hyd Promotes Extra Mitosis in Germline Cysts and Massive Cell Death During Oogenesis.
RNF43 is a tumour suppressor gene mutated in mucinous tumours of the ovary.
The Drosophila parkin homologue is required for normal mitochondrial dynamics during spermiogenesis.
The potato cyst nematode effector RHA1B is a ubiquitin ligase and uses two distinct mechanisms to suppress plant immune signaling.
Cytochrome-c Oxidase Deficiency
Mitochondrial pathology in muscle of a patient with a novel parkin mutation.
Cytomegalovirus Infections
Degradation of SAMHD1 Restriction Factor Through Cullin-Ring E3 Ligase Complexes During Human Cytomegalovirus Infection.
Deafness
Biallelic mutations in RNF220 cause laminopathies featuring leukodystrophy, ataxia and deafness.
Dehydration
Arabidopsis BRCA1 represses RRTF1-mediated ROS production and ROS-responsive gene expression under dehydration stress.
Functional roles of the pepper RING finger protein gene, CaRING1, in abscisic acid signaling and dehydration tolerance.
The Arabidopsis RING E3 ubiquitin ligase AtAIRP2 plays combinatory roles with AtAIRP1 in abscisic acid-mediated drought stress responses.
The E3 Ligase AtRDUF1 Positively Regulates Salt Stress Responses in Arabidopsis thaliana.
Dementia
Altered ?-synuclein, parkin, and synphilin isoform levels in multiple system atrophy brains.
Clinical, neuropathological and genotypic variability in SNCA A53T familial Parkinson's disease. Variability in familial Parkinson's disease.
Differential expression of alpha-synuclein, parkin, and synphilin-1 isoforms in Lewy body disease.
Morphological substrates of mental dysfunction in Lewy body disease: an update.
Parkin and PINK1 parkinsonism may represent nigral mitochondrial cytopathies distinct from Lewy body Parkinson's disease.
Parkin and synphilin-1 isoform expression changes in Lewy body diseases.
Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies.
Parkin Null Cortical Neuronal/Glial Cultures are Resistant to Amyloid-?1-42 Toxicity: A Role for Autophagy?
Repair of oxidative DNA damage, cell-cycle regulation and neuronal death may influence the clinical manifestation of Alzheimer's disease.
RNF216 Regulates the Migration of Immortalized GnRH Neurons by Suppressing Beclin1-Mediated Autophagy.
Special bioactive compounds and functional foods may exhibit neuroprotective effects in patients with dementia (Review).
TRIM9, a novel brain-specific E3 ubiquitin ligase, is repressed in the brain of Parkinson's disease and dementia with Lewy bodies.
[Revisit to Kii ALS--the innovated concept of ALS-Parkinsonism-dementia complex, clinicopathological features, epidemiology and etiology]
Dengue
Dengue subgenomic RNA binds TRIM25 to inhibit interferon expression for epidemiological fitness.
Interferon-stimulated TRIM69 interrupts dengue virus replication by ubiquitinating viral nonstructural protein 3.
The C-terminal Tail of TRIM56 Dictates Antiviral Restriction of Influenza A and B Viruses by Impeding Viral RNA Synthesis.
The E3 Ubiquitin Ligase SIAH1 Targets MyD88 for Proteasomal Degradation During Dengue Virus Infection.
TRIM69 inhibits Vesicular Stomatitis Indiana Virus (VSIV).
Viral strategies for triggering and manipulating mitophagy.
Diabetes Mellitus
Association between single nucleotide polymorphism of DNA repair genes and endometrial cancer: a case-control study.
Gene expression analysis approach to establish possible links between Parkinson's disease, cancer and cardiovascular diseases.
Glucose-Sensitive Myokine/Cardiokine MG53 Regulates Systemic Insulin Response and Metabolic Homeostasis.
Parkin Coordinates Platelet Stress Response in Diabetes Mellitus: A Big Role in a Small Cell.
The GID ubiquitin ligase complex is a regulator of AMPK activity and organismal lifespan.
Diabetes Mellitus, Type 1
Clarifying the function of genes at the chromosome 16p13 locus in type 1 diabetes: CLEC16A and DEXI.
Diabetes Susceptibility Genes Pdx1 and Clec16a Function in a Pathway Regulating Mitophagy in ?-Cells.
Proteomic characterization of pancreatic islet {beta}-cells stimulated with pancreatic carcinoma cell conditioned medium.
Visualizing the role of Cbl-b in control of islet-reactive CD4 T cells and susceptibility to type 1 diabetes.
Diabetes Mellitus, Type 2
Casitas B-Lineage Lymphoma RING Domain Inhibitors Protect Mice against High-Fat Diet-Induced Obesity and Insulin Resistance.
Casitas b-Lineage Lymphoma-Deficient Mice Are Protected Against High-Fat Diet-Induced Obesity and Insulin Resistance.
Common variants in or near ZNRF1, COLEC12, SCYL1BP1 and API5 are associated with diabetic retinopathy in Chinese patients with type 2 diabetes.
Glucose-Sensitive Myokine/Cardiokine MG53 Regulates Systemic Insulin Response and Metabolic Homeostasis.
MG53: Biological Function and Potential as a Therapeutic Target.
Post-translational modification of Parkin and its research progress in cancer.
Protein-Protein interactions uncover candidate 'core genes' within omnigenic disease networks.
The E3 ubiquitin ligase parkin is dispensable for metabolic homeostasis in murine pancreatic ? cells and adipocytes.
The GID ubiquitin ligase complex is a regulator of AMPK activity and organismal lifespan.
Diabetic Cardiomyopathies
Diabetic Cardiomyopathy: Role of the E3 Ubiquitin Ligase.
Hydrogen Sulfide Regulates Muscle RING Finger-1 Protein S-Sulfhydration at Cys44 to Prevent Cardiac Structural Damage in Diabetic Cardiomyopathy.
Melatonin activates Parkin translocation and rescues the impaired mitophagy activity of diabetic cardiomyopathy through Mst1 inhibition.
Diabetic Nephropathies
Bone morphogenetic protein (BMP) 7 expression is regulated by the E3 ligase UBE4A in diabetic nephropathy.
Parkin ubiquitinates GATA4 and attenuates the GATA4/GAS1 signaling and detrimental effects on diabetic nephropathy.
Diabetic Retinopathy
Common variants in or near ZNRF1, COLEC12, SCYL1BP1 and API5 are associated with diabetic retinopathy in Chinese patients with type 2 diabetes.
Digestive System Neoplasms
BRCA1 and BRCA2 expression patterns and prognostic significance in digestive system cancers.
Disorders of Excessive Somnolence
Genome-wide gene expression array identifies novel genes related to disease severity and excessive daytime sleepiness in patients with obstructive sleep apnea.
Quality of Life in Newly Diagnosed Patients With Parkin-Related Parkinson's Disease.
Restless legs syndrome, rapid eye movement sleep behavior disorder, and hypersomnia in patients with two parkin mutations.
DNA Repair-Deficiency Disorders
Biallelic variants in BRCA1 gene cause a recognisable phenotype within chromosomal instability syndromes reframed as BRCA1 deficiency.
BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
BRCAness as an Important Prognostic Marker in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy: A Multicenter Retrospective Study.
Links between genome integrity and BRCA1 tumor suppression.
Radiosensitivity of lymphoblastoid cell lines with a heterozygous BRCA1 mutation is not detected by the comet assay and pulsed field gel electrophoresis.
Solving the RIDDLE of 53BP1 recruitment to sites of damage.
DNA Virus Infections
Tripartite Motif 22 (TRIM22) protein restricts herpes simplex virus 1 by epigenetic silencing of viral immediate-early genes.
Down Syndrome
Modelling human regulatory variation in mouse: finding the function in genome-wide association studies and whole-genome sequencing.
Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification.
Using a Historical Lens to Envision the Next Generation of Genomic Translation Research.
Dwarfism
SIZ1 controls cell growth and plant development in Arabidopsis through salicylic acid.
The Ubiquitin Ligase TRAIP: Double-Edged Sword at the Replisome.
Dysgerminoma
Mixed ovarian germ cell tumor in a BRCA2 mutation carrier.
Primary ovarian dysgerminoma in a patient with a germline BRCA1 mutation.
Synchronous ovarian dysgerminoma and breast carcinoma in a patient with positive immunostain of BRCA1.
Dyskinesias
A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia.
Early Dyskinesias in Parkinson's Disease Patients With Parkin Mutation: A Primary Corticostriatal Synaptopathy?
Effects of cinnarizine, a calcium antagonist that produces human parkinsonism, in parkin knock out mice.
L-DOPA impairs proteasome activity in parkinsonism through D1 dopamine receptor.
Parkin deletions in a family with adult-onset, tremor-dominant parkinsonism: expanding the phenotype.
Parkin disease in a Brazilian kindred: Manifesting heterozygotes and clinical follow-up over 10 years.
Parkin disease: a phenotypic study of a large case series.
Parkin mutation and deep brain stimulation outcome.
Parkinson's disease in Ireland: clinical presentation and genetic heterogeneity in patients with parkin mutations.
Dysplastic Nevus Syndrome
Inherited predisposition to cancer: a historical overview.
Dystonia
A novel family with an unusual early-onset generalized dystonia.
Camptocormia, axial dystonia, and parkinsonism: phenotypic heterogeneity of a parkin mutation.
Clinical findings in a large family with a parkin ex3delta40 mutation.
Diagnostic considerations in juvenile parkinsonism.
Early Dyskinesias in Parkinson's Disease Patients With Parkin Mutation: A Primary Corticostriatal Synaptopathy?
Early-onset Parkinson's disease associated with a new parkin mutation in a Spanish family.
Foot Drop Dystonia Resulting from parkin (PARK2) Mutation.
How much phenotypic variation can be attributed to parkin genotype?
Isolated limb dystonia as presenting feature of Parkin disease.
Levodopa-responsive dystonia. GTP cyclohydrolase I or parkin mutations?
Molecular analyses of GCH-1, TH and parkin genes in Chinese dopa-responsive dystonia families.
Mutational analysis of the PINK1 gene in early-onset parkinsonism in Europe and North Africa.
Parkin deletions in a family with adult-onset, tremor-dominant parkinsonism: expanding the phenotype.
Parkin disease in a Brazilian kindred: Manifesting heterozygotes and clinical follow-up over 10 years.
Parkin Disease: A Clinicopathologic Entity?
Parkin mutations in a patient with hemiparkinsonism-hemiatrophy: a clinical-genetic and PET study.
Parkinson's disease in Ireland: clinical presentation and genetic heterogeneity in patients with parkin mutations.
Quantitative gait analysis in parkin disease: Possible role of dystonia.
Relative high frequency of the c.255delA parkin gene mutation in Spanish patients with autosomal recessive parkinsonism.
Significance of the parkin gene and protein in understanding Parkinson's disease.
Dystonic Disorders
Parkin disease: a phenotypic study of a large case series.
Ectodermal Dysplasia
Recognition of p63 by the E3 ligase ITCH: Effect of an ectodermal dysplasia mutant.
Ectromelia
The poxvirus p28 virulence factor is an E3 ubiquitin ligase.
Encephalitis
Characterization of simian immunodeficiency virus (SIV) that induces SIV encephalitis in rhesus macaques with high frequency: role of TRIM5 and major histocompatibility complex genotypes and early entry to the brain.
GDNF-expressing macrophages restore motor functions at a severe late-stage, and produce long-term neuroprotective effects at an early-stage of Parkinson's disease in transgenic Parkin Q311X(A) mice.
Neuroinflammation in Parkinson's disease: role in neurodegeneration and tissue repair.
Peli1 signaling blockade attenuates congenital zika syndrome.
The E3 Ubiquitin Ligase c-Cbl Inhibits Microglia-Mediated CNS Inflammation by Regulating PI3K/Akt/NF-?B Pathway.
The role of microglia in viral encephalitis: a review.
Encephalitis, Japanese
E3 Ubiquitin Ligase Nedd4 Promotes Japanese Encephalitis Virus Replication by Suppressing Autophagy in Human Neuroblastoma Cells.
Pathogenicity and virulence of Japanese encephalitis virus: Neuroinflammation and neuronal cell damage.
Encephalomyelitis
Hectd3 promotes pathogenic Th17 lineage through Stat3 activation and Malt1 signaling in neuroinflammation.
PARKIN modifies peripheral immune response and increases neuroinflammation in active experimental autoimmune encephalomyelitis (EAE).
Peli1 facilitates virus replication and promotes neuroinflammation during West Nile virus infection.
Encephalomyelitis, Autoimmune, Experimental
Hectd3 promotes pathogenic Th17 lineage through Stat3 activation and Malt1 signaling in neuroinflammation.
PARKIN modifies peripheral immune response and increases neuroinflammation in active experimental autoimmune encephalomyelitis (EAE).
Endometrial Neoplasms
A novel sensitive method to detect frameshift mutations in exonic repeat sequences of cancer-related genes.
Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families.
Association of genetic polymorphisms in AURKA, BRCA1, CCNE1 and CDK2 with the risk of endometrial carcinoma and clinicopathological parameters among Chinese Han women.
BARD1 variants Cys557Ser and Val507Met in breast cancer predisposition.
BRCA1 and BRCA2 pathogenic variant carriers and endometrial cancer risk: A cohort study.
Case Report: Double Germline Mutations in BRCA1 and MSH2 in a Patient With Mixed Serous-Endometrioid Endometrial Carcinoma.
Case-case analysis addressing ascertainment bias for multigene panel testing implicates BRCA1 and PALB2 in endometrial cancer.
CRL3-SPOP ubiquitin ligase complex suppresses the growth of diffuse large B-cell lymphoma by negatively regulating the MyD88/NF-?B signaling.
Cullin-5, a ubiquitin ligase scaffold protein, is significantly underexpressed in endometrial adenocarcinomas and is a target of miR-182.
Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data.
Effect of Ursolic Acid on MAPK in Cyclin D1 Signaling and RING-Type E3 Ligase (SCF E3s) in Two Endometrial Cancer Cell Lines.
Endometrial Cancer in Germline BRCA Mutation Carriers: A Systematic Review and Meta-analysis.
Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study.
Endometrial Cancer, BRCA1, and BRCA2 in the UK Biobank Cohort.
Endometrial cancer-associated mutants of SPOP are defective in regulating estrogen receptor-? protein turnover.
Endometrial Cancers in BRCA1 or BRCA2 Germline Mutation Carriers: Assessment of Homologous Recombination DNA Repair Defects.
Endometrium is not the primary site of origin of pelvic high-grade serous carcinoma in BRCA1 or BRCA2 mutation carriers.
eVIP2: Expression-based variant impact phenotyping to predict the function of gene variants.
Expression of DNA repair proteins in endometrial cancer predicts disease outcome.
Frequent frameshift mutations in 2 mononucleotide repeats of RNF43 gene and its regional heterogeneity in gastric and colorectal cancers.
Genetics of endometrial cancer.
Germline truncating-mutations in BRCA1 and MSH6 in a patient with early onset endometrial cancer.
Hereditary gynaecological malignancies: advances in screening and treatment.
Hereditary non-BRCA gynaecological tumors.
Identification of TRIM22 as a progesterone-responsive gene in Ishikawa endometrial cancer cells.
Inhibitors of SCF-Skp2/Cks1 E3ligase block estrogen-induced growth stimulation and degradation of nuclear p27kip1: therapeutic potential for endometrial cancer.
Is uterine serous papillary carcinoma a BRCA1-related disease? Case report and review of the literature.
Loss of heterozygosity of BRCA1, TP53 and TCRD markers analysed in sporadic endometrial cancer.
miR-182-5p and miR-96-5p Target PIAS1 and Mediate the Negative Feedback Regulatory Loop between PIAS1 and STAT3 in Endometrial Cancer.
Molecular basis of gynecological cancer.
Mutational analysis of the BRCA1 tumor suppressor gene in endometrial carcinoma.
PP2A and E3 ubiquitin ligase deficiencies: Seminal biological drivers in endometrial cancer.
Preventing Ovarian Cancer in High-risk Women: One Surgery at a Time.
Progesterone Receptor-B Induction of BIRC3 Protects Endometrial Cancer Cells from AP1-59-Mediated Apoptosis.
Progestin and breast cancer. The missing pieces of a puzzle.
Prolonged survival among women with BRCA germline mutations and advanced endometrial cancer: a case series.
RE: Endometrial Cancer Risk in Women with Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study.
Report of Endometrial Cancer in Australian BRCA1 and BRCA2 Mutation-Positive Families.
Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study.
RNF183 Is a Prognostic Biomarker and Correlates With Tumor Purity, Immune Infiltrates in Uterine Corpus Endometrial Carcinoma.
RNF43 is frequently mutated in colorectal and endometrial cancers.
SPOP suppresses osteosarcoma invasion via PI3K/AKT/NF-?B signaling pathway.
Standardization of a sample preparation and analytical workflow for proteomics of archival endometrial cancer tissue.
TGF-? activates APC through Cdh1 binding for Cks1 and Skp2 proteasomal destruction stabilizing p27kip1 for normal endometrial growth.
The emerging role of speckle-type POZ protein (SPOP) in cancer development.
The genetics of uterine leiomyomata: what clinicians need to know.
The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study.
The rate of the predominant Jewish mutations in the BRCA1, BRCA2, MSH2 and MSH6 genes in unselected Jewish endometrial cancer patients.
The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study.
TRIM22 inhibits endometrial cancer progression through the NOD2/NF??B signaling pathway and confers a favorable prognosis.
[Genetic consultation: hereditary cancer risk?].
[Hereditary predispositions to gynaecological cancers]
[Prophylactic surgery of mammary and ovarian carcinoma.]
Endometriosis
Association Between Impairment of DNA Double Strand Break Repair and Decreased Ovarian Reserve in Patients With Endometriosis.
BRCA1 alterations are associated with endometriosis, but BRCA2 alterations show no detectable endometriosis risk: a study in Indian population.
Case report: Analysis of BRCA1 and BRCA2 gene mutations in a hereditary ovarian cancer family.
E3 ubiquitin ligase TRIM24 deficiency promotes NLRP3/caspase-1/IL-1?-mediated pyroptosis in endometriosis.
Mutation analysis of BrCA1, BrCA2, and p53 versus soluble HLA class I and class II in a case of familial endometriosis.
Origins and molecular pathology of ovarian cancer.
Ovarian endometriosis, a precursor of ovarian cancer: Histological aspects, gene expression and microRNA alterations (Review).
Surgically treated ovarian endometriosis association with BRCA1 and BRCA2 mutations.
Endotoxemia
Effect of Deletion of cIAP2 on Intestinal Microcirculation in Mouse Endotoxemia and Poly-bacterial Sepsis.
Sequential ubiquitination of NLRP3 by RNF125 and Cbl-b limits inflammasome activation and endotoxemia.
Enterovirus Infections
Regulation of mitochondrial antiviral signaling (MAVS) expression and signaling by the mitochondria-associated endoplasmic reticulum membrane (MAM) protein Gp78.
Ephemeral Fever
RACK1 degrades MAVS to promote bovine ephemeral fever virus replication via upregulating E3 ubiquitin ligase STUB1.
Epilepsies, Myoclonic
Unstable TTTTA/TTTCA expansions in MARCH6 are associated with Familial Adult Myoclonic Epilepsy type 3.
Epilepsies, Partial
A recurrent PJA1 variant in trigonocephaly and neurodevelopmental disorders.
Epilepsy
De novo TRIM8 variants impair its protein localization to nuclear bodies and cause developmental delay, epilepsy, and focal segmental glomerulosclerosis.
Genetic determinants of common epilepsies: a meta-analysis of genome-wide association studies.
Glial overexpression of Dube3a causes seizures and synaptic impairments in Drosophila concomitant with down regulation of the Na(+)/K(+) pump ATP?.
Uncovering the Pharmacological Mechanism of Chaibei Zhixian Decoction on Epilepsy by Network Pharmacology Analysis.
Epstein-Barr Virus Infections
BRCA1 Regulates IFI16 Mediated Nuclear Innate Sensing of Herpes Viral DNA and Subsequent Induction of the Innate Inflammasome and Interferon-? Responses.
DNA methylation profile in diffuse type gastric cancer: evidence for hypermethylation of the BRCA1 promoter region in early-onset gastric carcinogenesis.
[Hierarchical clustering analysis to detect associations between clinical and pathological features of gastric tumors and hypermethylation of suppressor genes.]
Equine Infectious Anemia
An invariant surface patch on the TRIM5alpha PRYSPRY domain is required for retroviral restriction but dispensable for capsid binding.
Comparative requirements for the restriction of retrovirus infection by TRIM5alpha and TRIMCyp.
Esophageal Neoplasms
BRCA1 mRNA expression as a predictive and prognostic marker in advanced esophageal squamous cell carcinoma treated with cisplatin- or docetaxel-based chemotherapy/chemoradiotherapy.
Combination of histoculture drug response assay and qPCR as an effective method to screen biomarkers for personalized chemotherapy in esophageal cancer.
Frequent allelic loss at the TOC locus on 17q25.1 in primary breast cancers.
Ubiquitination of NOTCH2 by DTX3 suppresses the proliferation and migration of human esophageal carcinoma.
[High throughput-targeted sequencing panel for exploring radiosensitivity associated genes in esophageal squamous cell carcinoma].
Esophageal Squamous Cell Carcinoma
A functional BRCA1 coding sequence genetic variant contributes to risk of esophageal squamous cell carcinoma.
BRCA1 mRNA expression as a predictive and prognostic marker in advanced esophageal squamous cell carcinoma treated with cisplatin- or docetaxel-based chemotherapy/chemoradiotherapy.
Effects of JWA, XRCC1 and BRCA1 mRNA expression on molecular staging for personalized therapy in patients with advanced esophageal squamous cell carcinoma.
Germline BRCA1 mutated esophageal squamous cell carcinoma.
Targeting TRIM3 deletion-induced tumor-associated lymphangiogenesis prohibits lymphatic metastasis in esophageal squamous cell carcinoma.
The E3 ligase HECTD3 promotes esophageal squamous cell carcinoma (ESCC) growth and cell survival through targeting and inhibiting caspase-9 activation.
[Expression and clinical significance of BRCA1 in human esophageal squamous cell carcinoma].
Essential Tremor
A family with Parkinson disease, essential tremor, bell palsy, and parkin mutations.
Mutational analysis of parkin gene by denaturing high-performance liquid chromatography (DHPLC) in essential tremor.
Exanthema
DNA methylation patterns in naïve CD4+ T cells identify epigenetic susceptibility loci for malar rash and discoid rash in systemic lupus erythematosus.
Fallopian Tube Neoplasms
BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations.
Factors associated with use of hormone therapy after preventive oophorectomy in BRCA mutation carriers.
Fallopian tube cancer in a BRCA1 mutation carrier: rapid development and failure of screening.
Laparoscopic total fallopian tube removal at the time of bilateral salpingo-oophorectomy in BRCA2 positive women.
Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.
Molecular evidence for putative tumour suppressor genes on chromosome 13q specific to BRCA1 related ovarian and fallopian tube cancer.
Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations.
Molecular Mechanism Linking BRCA1 Dysfunction to High Grade Serous Epithelial Ovarian Cancers with Peritoneal Permeability and Ascites.
Neoadjuvant chemoteraphy in unresectable ovarian cancer with olaparib and weekly carboplatin plus paclitaxel: a phase II, open label multicenter study (NUVOLA trial).
Occult fallopian tube cancer in a patient with BRCA1 breast cancer.
Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry.
Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancer.
Prevalence of BRCA1 and BRCA2 germ line mutations among women with carcinoma of the fallopian tube.
Prevalence of BRCA1 and BRCA2 Mutations Among Patients With Ovarian, Primary Peritoneal, and Fallopian Tube Cancer in India: A Multicenter Cross-Sectional Study.
Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation.
Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.
Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making.
The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation.
Familial Mediterranean Fever
Structural and functional insights into the B30.2/SPRY domain.
Structural basis for PRYSPRY-mediated tripartite motif (TRIM) protein function.
Fanconi Anemia
A Case Report of Germline Compound Heterozygous Mutations in the BRCA1 Gene of an Ovarian and Breast Cancer Patient.
A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1/2.
A founder variant in the South Asian population leads to a high prevalence of FANCL Fanconi anemia cases in India.
A game of substrates: replication fork remodeling and its roles in genome stability and chemo-resistance.
A human ortholog of archaeal DNA repair protein Hef is defective in Fanconi anemia complementation group M.
A novel ubiquitin ligase is deficient in Fanconi anemia.
A phthalimidoalkanamide derived novel DNMT inhibitor enhanced radiosensitivity of A549 cells by inhibition of homologous recombination of DNA damage.
A tough row to hoe: when replication forks encounter DNA damage.
Ablation of the Brca1-Palb2 Interaction Phenocopies Fanconi Anemia in Mice.
Absence of truncating BRIP1 mutations in chromosome 17q-linked hereditary prostate cancer families.
Accelerated Evolution in Distinctive Species Reveals Candidate Elements for Clinically Relevant Traits, Including Mutation and Cancer Resistance.
Arsenite Binds to the RING Finger Domain of FANCL E3 Ubiquitin Ligase and Inhibits DNA Interstrand Crosslink Repair.
ATR-ATRIP Kinase Complex Triggers Activation of the Fanconi Anemia DNA Repair Pathway.
Attenuation of the formation of DNA-repair foci containing RAD51 in Fanconi anaemia.
Biallelic Deleterious BRCA1 Mutations in a Woman with Early-Onset Ovarian Cancer.
Biallelic germline BRCA1 mutations in a patient with early onset breast cancer, mild Fanconi anemia-like phenotype, and no chromosome fragility.
Biallelic Germline Mutations in RFWD3 May Induce Fanconi Anemia.
Biallelic Mutations in BRCA1 Cause a New Fanconi Anemia Subtype.
Biallelic variants in BRCA1 gene cause a recognisable phenotype within chromosomal instability syndromes reframed as BRCA1 deficiency.
Biomarkers and mechanisms of FANCD2 function.
Brca1 deficiency causes bone marrow failure and spontaneous hematologic malignancies in mice.
BRCA1 interacts directly with the Fanconi anemia protein FANCA.
BRIP1 (BACH1) variants and familial breast cancer risk: a case-control study.
Chromosomal instability induced by mammography X-rays in primary human fibroblasts from BRCA1 and BRCA2 mutation carriers.
Chromosome breakage syndromes and cancer.
Coinheritance of BRCA1 and BRCA2 mutations with Fanconi anemia and Bloom syndrome mutations in Ashkenazi Jewish population: possible role in risk modification for cancer development.
Compromised Fanconi anemia response due to BRCA1 deficiency in cisplatin-sensitive head and neck cancer cell lines.
Connecting Fanconi anemia to BRCA1.
Conserved overlapping gene arrangement, restricted expression, and biochemical activities of DNA polymerase ? (POLN).
Corrigendum to "The conserved Fanconi anemia nuclease Fan1 and the SUMO E3 ligase Pli1 act in two novel Pso2-independent pathways of DNA interstrand crosslink repair in yeast" [DNA Repair 12 (December (12)) (2013) 1011-1023].
CTDP1 regulates breast cancer survival and DNA repair through BRCT-specific interactions with FANCI.
Decreased FANCJ caused by 5FU contributes to the increased sensitivity to oxaliplatin in gastric cancer cells.
Dedicated to the core: Understanding the Fanconi anemia complex.
Deep learning enables the atomic structure determination of the Fanconi Anemia core complex from cryoEM.
Defective DNA repair in hereditary ovarian cancers: Implications for therapy.
Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors.
DNA helicases FANCM and DDX11 are determinants of PARP inhibitor sensitivity.
Evaluation of Fanconi anaemia genes FANCA, FANCC and FANCL in cervical cancer susceptibility.
Exome sequencing of oral leukoplakia and oral squamous cell carcinoma implicates DNA damage repair gene defects in malignant transformation.
Expression and prognostic significance of Fanconi anemia group D2 protein and breast cancer type 1 susceptibility protein in familial and sporadic breast cancer.
FAAP100 is essential for activation of the Fanconi anemia-associated DNA damage response pathway.
FANCJ (BACH1) helicase forms DNA damage inducible foci with replication protein A and interacts physically and functionally with the single-stranded DNA-binding protein.
FANCL replaces BRCA1 as the likely ubiquitin ligase responsible for FANCD2 monoubiquitination.
FANCL ubiquitinates ?-catenin and enhances its nuclear function.
Fanconi Anemia Complementation Group FANCD2 Protein Serine 331 Phosphorylation Is Important for Fanconi Anemia Pathway Function and BRCA2 Interaction.
Fanconi Anemia Proteins Function in Mitophagy and Immunity.
Genetic basis of Fanconi anemia.
Genome-scale CRISPR knockout screen identifies TIGAR as a modifier of PARP inhibitor sensitivity.
Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.
Genome-wide profiling of oral squamous cell carcinoma by array-based comparative genomic hybridization.
Hallmarks of 'BRCAness' in sporadic cancers.
Hereditary breast cancer: from molecular pathology to tailored therapies.
High expression of UBE2T predicts poor prognosis and survival in multiple myeloma.
High throughput parallel analysis of hundreds of patient samples for more than 100 mutations in multiple disease genes.
Homocysteine aggravates DNA damage by impairing the FA/Brca1 Pathway in NE4C murine neural stem cells.
HP1 regulates the localization of FANCJ at sites of DNA double-strand breaks.
Human disorders of ubiquitination and proteasomal degradation.
Identification and characterization of mutations in FANCL gene: A second case of Fanconi anemia belonging to FA-L complementation group.
Identification of a comprehensive spectrum of genetic factors for hereditary breast cancer in a Chinese population by next-generation sequencing.
Identification of FAAP24, a Fanconi anemia core complex protein that interacts with FANCM.
Identification of novel biomarkers in chronic immune thrombocytopenia (ITP) by microarray-based serum protein profiling.
Identifying and exploiting defects in the Fanconi anemia/BRCA pathway in oncology.
Impairment of homologous recombination control in a Fanconi anemia-like Chinese hamster cell mutant.
Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway.
Interstrand crosslink-induced radials form between non-homologous chromosomes, but are absent in sex chromosomes.
Isomerization of BRCA1-BARD1 promotes replication fork protection.
Loss of GGN Leads to Pre-Implantation Embryonic Lethality and Compromised Male Meiotic DNA Double Strand Break Repair in the Mouse.
Loss-of-function FANCL Mutations Associate with Severe Fanconi Anemia Overlapping the VACTERL Association.
Low incidence of methylation of the promoter region of the FANCF gene in Japanese primary breast cancer.
Mechanism for survival of homozygous nonsense mutations in the tumor suppressor gene BRCA1.
Mendelian diseases among Roman Jews: implications for the origins of disease alleles.
Methodology for the identification of small molecule inhibitors of the Fanconi Anaemia ubiquitin E3 ligase complex.
Modularized functions of the Fanconi anemia core complex.
Molecular Trajectory of BRCA1 and BRCA2 Mutations.
Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer.
Mutational analysis of FANCL, FANCM and the recently identified FANCI suggests that among the 13 known Fanconi Anemia genes, only FANCD1/BRCA2 plays a major role in high-risk breast cancer predisposition.
Natural human knockouts and Mendelian disorders: deep phenotyping in Italian isolates.
New advances in the DNA damage response network of Fanconi anemia and BRCA proteins. FAAP95 replaces BRCA2 as the true FANCB protein.
No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing.
Novel homozygous FANCL mutation and somatic heterozygous SETBP1 mutation in a Chinese girl with Fanconi Anemia.
PALB2 (partner and localizer of BRCA2).
PALB2 links BRCA1 and BRCA2 in the DNA-damage response.
Rad18 confers hematopoietic progenitor cell DNA damage tolerance independently of the Fanconi Anemia pathway in vivo.
Rad18 E3 ubiquitin ligase activity mediates fanconi anemia pathway activation and cell survival following DNA Topoisomerase 1 Inhibition.
Revisiting the morbid genome of Mendelian disorders.
RFWD3-Mediated Ubiquitination Promotes Timely Removal of Both RPA and RAD51 from DNA Damage Sites to Facilitate Homologous Recombination.
RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis.
Role of fanconi anemia/BRCA pathway genes in hepatocellular carcinoma chemoresistance.
S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51.
Screening for large genomic rearrangements of the BRIP1 and CHK1 genes in Finnish breast cancer families.
siRNA depletion of BRCA1, but not BRCA2, causes increased genome instability in Fanconi anemia cells.
Structural analysis of human FANCL, the E3 ligase in the fanconi anemia pathway.
Structure of the human FANCL RING-Ube2T complex reveals determinants of cognate E3-E2 selection.
The BRIP1 helicase functions independently of BRCA1 in the Fanconi anemia pathway for DNA crosslink repair.
The Carboxy Terminus of FANCE Recruits FANCD2 to the FA E3 Ligase Complex to Promote the Fanconi Anemia DNA Repair Pathway.
The conserved Fanconi anemia nuclease Fan1 and the SUMO E3 ligase Pli1 act in two novel Pso2-independent pathways of DNA interstrand crosslink repair in yeast.
The FA Core Complex Contains a Homo-dimeric Catalytic Module for the Symmetric Mono-ubiquitination of FANCI-FANCD2.
The Fanconi Anemia DNA Repair Pathway Is Regulated by an Interaction between Ubiquitin and the E2-like Fold Domain of FANCL.
The Fanconi anemia ubiquitin E3 ligase complex as an anti-cancer target.
The PI3K/Akt1 pathway enhances steady-state levels of FANCL.
The Role of Replication-Associated Repair Factors on R-Loops.
The structure of the catalytic subunit FANCL of the Fanconi anemia core complex.
The WD40 repeats of FANCL are required for Fanconi anemia core complex assembly.
Transcriptional Silencing of ALDH2 Confers a Dependency on Fanconi Anemia Proteins in Acute Myeloid Leukemia.
UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative autoregulation.
UBE2W interacts with FANCL and regulates the monoubiquitination of Fanconi anemia protein FANCD2.
WNT inhibition creates a BRCA-like state in Wnt-addicted cancer.
Zalypsis displays preclinical activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response.
[Functions of FANCL in primordial germ cell formation and Fanconi anemia]
Fasciitis
Paraneoplastic fasciitis and polyarthritis syndrome as a manifestation of breast cancer recurrence in a BRCA1 gene-positive patient.
Fatty Liver
DDB1 E3 ligase controls dietary fructose-induced ChREBP? stabilization and liver steatosis via CRY1.
Increase of E3 ubiquitin ligase NEDD4 expression leads to degradation of its target proteins PTEN/IGF1R during the formation of goose fatty liver.
Parkin deficiency prevents chronic ethanol-induced hepatic lipid accumulation through ?-catenin accumulation.
Sirtuin 7-dependent deacetylation of DDB1 regulates the expression of nuclear receptor TR4.
Smurf1 aggravates non-alcoholic fatty liver disease by stabilizing SREBP-1c in an E3 activity-independent manner.
The E3 ligase tripartite motif 8 targets TAK1 to promote insulin resistance and steatohepatitis.
Triggering of Parkin Mitochondrial Translocation in Mitophagy: Implications for Liver Diseases.
Febrile Neutropenia
BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients.
Fetal Diseases
Cereblon-Based Small-Molecule Compounds to Control Neural Stem Cell Proliferation in Regenerative Medicine.
Fibroadenoma
Quantitative detection of methylation of FHIT and BRCA1 promoters in the serum of ductal breast cancer patients.
Fibrocystic Breast Disease
Microglandular adenosis of the breast in a BRCA1 mutation carrier: radiological features.
[BRCA1 selectively regulates the expression of progesterone receptor A in sporadic invasive ductal breast carcinoma]
Fibrosarcoma
The prostate cancer-associated human retrovirus XMRV lacks direct transforming activity but can induce low rates of transformation in cultured cells.
Flavivirus Infections
The E3 ligase TRIM56 is a host restriction factor of Zika virus and depends on its RNA-binding activity but not miRNA regulation, for antiviral function.
Friedreich Ataxia
E3 Ligase RNF126 Directly Ubiquitinates Frataxin, Promoting Its Degradation: Identification of a Potential Therapeutic Target for Friedreich Ataxia.
Frontotemporal Dementia
Aberrant Accumulation of BRCA1 in Alzheimer Disease and Other Tauopathies.
Organelle-specific autophagy in inflammatory diseases: a potential therapeutic target underlying the quality control of multiple organelles.
Frontotemporal Lobar Degeneration
Parkin Levels Decrease in Fibroblasts With Progranulin (PGRN) Pathogenic Variants and in a Cellular Model of PGRN Deficiency.
Gallbladder Neoplasms
cIAP2 promotes gallbladder cancer invasion and lymphangiogenesis by activating the NF-?B pathway.
Olaparib Treatment in a Patient with Advanced Gallbladder Cancer Harboring BRCA1 Mutation.
Ganglioglioma
Parkin, PINK1 and DJ1 as possible modulators of mTOR pathway in ganglioglioma.
Gastritis
Promoter methylation of RNF180 is associated with H.pylori infection and serves as a marker for gastric cancer and atrophic gastritis.
Gastritis, Atrophic
Promoter methylation of RNF180 is associated with H.pylori infection and serves as a marker for gastric cancer and atrophic gastritis.
Gastroenteritis
Putative E3 ubiquitin ligase of human rotavirus inhibits NF-?B activation by using molecular mimicry to target ?-TrCP.
Viral strategies for triggering and manipulating mitophagy.
Gastrointestinal Neoplasms
Loss of endogenous RNF43 function enhances proliferation and tumour growth of intestinal and gastric cells.
Phenotypic characteristics of colorectal cancer in BRCA1/2 mutation carriers.
Gaucher Disease
Decreased glucocerebrosidase activity in Gaucher disease parallels quantitative enzyme loss due to abnormal interaction with TCP1 and c-Cbl.
Interaction between parkin and mutant glucocerebrosidase variants: a possible link between Parkinson disease and Gaucher disease.
Mitochondrial dysfunction and mitophagy defect triggered by heterozygous GBA mutations.
Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature.
Parkinsonisms and Glucocerebrosidase Deficiency: A Comprehensive Review for Molecular and Cellular Mechanism of Glucocerebrosidase Deficiency.
Screening semen donors for hereditary diseases. The Fairfax cryobank experience.
Genetic Diseases, Inborn
Ablation of the Brca1-Palb2 Interaction Phenocopies Fanconi Anemia in Mice.
Bi-phasic expression of Heterochromatin Protein 1 (HP1) during breast cancer progression: Potential roles of HP1 and chromatin structure in tumorigenesis.
Candidate gene analysis of BRCA1/2 mutation-negative high-risk Russian breast cancer patients.
Comparative genomic hybridization of microdissected familial ovarian carcinoma: two deleted regions on chromosome 15q not previously identified in sporadic ovarian carcinoma.
CpG methylation within the 5' regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB binding site.
Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data.
FANCJ (BACH1) helicase forms DNA damage inducible foci with replication protein A and interacts physically and functionally with the single-stranded DNA-binding protein.
Impairment of homologous recombination control in a Fanconi anemia-like Chinese hamster cell mutant.
OLA1 gene sequencing in patients with BRCA1/2 mutation-negative suspected hereditary breast and ovarian cancer.
Ovarian cancer genome.
Ubiquitination, Biotech Startups, and the Future of TRIM Family Proteins: A TRIM-Endous Opportunity.
Genital Diseases, Female
GWAS of five gynecologic diseases and cross-trait analysis in Japanese.
Giant Axonal Neuropathy
Abnormal intermediate filament organization alters mitochondrial motility in giant axonal neuropathy fibroblasts.
Explaining intermediate filament accumulation in giant axonal neuropathy.
Giant axonal neuropathy-associated gigaxonin mutations impair intermediate filament protein degradation.
Glaucoma
Overexpression of Optic Atrophy Type 1 Protects Retinal Ganglion Cells and Upregulates Parkin Expression in Experimental Glaucoma.
Overexpression of parkin protects retinal ganglion cells in experimental glaucoma.
Glioblastoma
A PRMT5-RNF168-SMURF2 Axis Controls H2AX Proteostasis.
A20 ubiquitin ligase-mediated polyubiquitination of RIP1 inhibits caspase-8 cleavage and TRAIL-induced apoptosis in glioblastoma.
BIRC3 is a biomarker of mesenchymal habitat of glioblastoma, and a mediator of survival adaptation in hypoxia-driven glioblastoma habitats.
BIRC3 is a novel driver of therapeutic resistance in Glioblastoma.
BRCA1 germline mutation and glioblastoma development: report of cases.
BRCA1 Protein Expression Predicts Survival in Glioblastoma Patients from an NRG Oncology RTOG Cohort.
BRCA1-regulated RRM2 expression protects glioblastoma cells from endogenous replication stress and promotes tumorigenicity.
c-Cbl regulates ?Pix-mediated cell migration and invasion.
Cannabidiol inhibits human glioma by induction of lethal mitophagy through activating TRPV4.
Cool-1 mediated inhibition of c-Cbl modulates multiple critical properties of glioblastomas, including the ability to generate tumors in vivo.
Deleterious c-Cbl Exon Skipping Contributes to Human Glioma.
Dissociation of mitochondrial HK-II elicits mitophagy and confers cardioprotection against ischemia.
Drosophila Brat and human ortholog TRIM3 maintain stem cell equilibrium and suppress brain tumorigenesis by attenuating Notch nuclear transport.
Glioma tumor grade correlates with parkin depletion in mutant p53-linked tumors and results from loss of function of p53 transcriptional activity.
Histone H2AX sensitizes glioma cells to genotoxic stimuli by recruiting DNA double-strand break repair proteins.
Human Brat ortholog TRIM3 is a tumor suppressor that regulates asymmetric cell division in glioblastoma.
Identification of a cullin5-RING E3 ligase transcriptome signature in glioblastoma multiforme.
Identification of key genes in glioblastoma-associated stromal cells using bioinformatics analysis.
Integrating cullin2-RING E3 ligase as a potential biomarker for glioblastoma multiforme prognosis and radiosensitivity profiling.
Mislocalization of the E3 ligase, beta-transducin repeat containing protein 1 ({beta}-TrCP1) in glioblastoma uncouples negative feedback between the PH domain Leucine-rich repeat Protein Phosphatase 1 (PHLPP1) and Akt.
Modulation of angiogenic and inflammatory response in glioblastoma by hypoxia.
Next generation sequencing of BRCA genes in glioblastoma multiform Egyptian patients: a pilot study.
Parkin Regulates the Activity of Pyruvate Kinase M2.
Polyubiquitination of apurinic/apyrimidinic endonuclease 1 by Parkin.
PRAJA is overexpressed in glioblastoma and contributes to neural precursor development.
Redox biology in normal cells and cancer: Restoring function of the redox/Fyn/c-Cbl pathway in cancer cells offers new approaches to cancer treatment.
RNF135, RING finger protein, promotes the proliferation of human glioblastoma cells in vivo and in vitro via the ERK pathway.
SMURF1, a promoter of tumor cell progression?
The E3 ubiquitin ligase CHIP/miR-92b/PTEN regulatory network contributes to tumorigenesis of glioblastoma.
TRIM22 activates NF-?B signaling in glioblastoma by accelerating the degradation of I?B?.
TRIM3, a tumor suppressor linked to regulation of p21(Waf1/Cip1).
TRIM8-driven transcriptomic profile of neural stem cells identified glioma-related nodal genes and pathways.
Ubiquitin Specific Peptidase 15 (USP15) suppresses glioblastoma cell growth via stabilization of HECTD1 E3 ligase attenuating WNT pathway activity.
Widely metastatic glioblastoma with BRCA1 and ARID1A mutations: a case report.
Glioma
An E3 Ubiquitin Ligase RNF139 Serves as a Tumor-Suppressor in Glioma.
An NF-?B p65-cIAP2 link is necessary for mediating resistance to TNF-? induced cell death in gliomas.
Analysis of the inhibitors of apoptosis identifies BIRC3 as a facilitator of malignant progression in glioma.
Bcl-2 family member Mcl-1 expression is reduced under hypoxia by the E3 ligase FBW7 contributing to BNIP3 induced cell death in glioma cells.
BIRC3 and BIRC5: multi-faceted inhibitors in cancer.
BRCA1 identified as a modulator of temozolomide resistance in P53 wild-type GBM using a high-throughput shRNA-based synthetic lethality screening.
BRCA1-regulated RRM2 expression protects glioblastoma cells from endogenous replication stress and promotes tumorigenicity.
C-Cbl and Cbl-b expression in skull base chordomas is associated with tumor progression and poor prognosis.
c-Cbl regulates ?Pix-mediated cell migration and invasion.
c-Cbl regulates glioma invasion through matrix metalloproteinase 2.
CacyBP/SIP protein reduces p53 stability by enhancing Mdm2 activity in p53 mutant glioma cells.
Cannabidiol inhibits human glioma by induction of lethal mitophagy through activating TRPV4.
Carboxyl terminus of Hsp70-interacting protein (CHIP) contributes to human glioma oncogenesis.
Deleterious c-Cbl Exon Skipping Contributes to Human Glioma.
Development of a prognostic model of glioma based on immune-related genes.
Downregulation of RNF138 inhibits cellular proliferation, migration, invasion and EMT in glioma cells via suppression of the Erk signaling pathway.
Expression profile of parkin isoforms in human gliomas.
Genomic and Functional Analysis of the E3 Ligase PARK2 in Glioma.
Glioma tumor grade correlates with parkin depletion in mutant p53-linked tumors and results from loss of function of p53 transcriptional activity.
Hemoglobins, Hemorphins, and 11p15.5 Chromosomal Region in Cancer Biology and ?mmunity with Special Emphasis for Brain Tumors.
High c-Cbl expression in gliomas is associated with tumor progression and poor prognosis.
High Expression of Pirh2 is Associated with Poor Prognosis in Glioma.
hsa-miR-212 modulates the radiosensitivity of glioma cells by targeting BRCA1.
Human Brat ortholog TRIM3 is a tumor suppressor that regulates asymmetric cell division in glioblastoma.
Identification and validation of RNA-binding protein-related gene signature revealed potential associations with immunosuppression and drug sensitivity in glioma.
Knocking down of Polo-like kinase 2 inhibits cell proliferation and induced cell apoptosis in human glioma cells.
Lipolytic inhibitor G0S2 modulates glioma stem-like cell radiation response.
Loss of heterozygosity of TRIM3 in malignant gliomas.
Molecular and cellular response of the most extensively used rodent glioma models to radiation and/or cisplatin.
Nutlin-3a Nanodisks Induce p53 Stabilization and Apoptosis in a Subset of Cultured Glioblastoma Cells.
Pancancer survival analysis of cancer hallmark genes.
Parkin pathway activation mitigates glioma cell proliferation and predicts patient survival.
Resveratrol induces cellular senescence with attenuated mono-ubiquitination of histone H2B in glioma cells.
Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent.
The E3 ligase PARC mediates the degradation of cytosolic cytochrome c to promote survival in neurons and cancer cells.
The ubiquitin ligase CHIP regulates c-Myc stability and transcriptional activity.
TRIM11, a direct target of miR-24-3p, promotes cell proliferation and inhibits apoptosis in colon cancer.
TRIM22 activates NF-?B signaling in glioblastoma by accelerating the degradation of I?B?.
TRIM3, a tumor suppressor linked to regulation of p21(Waf1/Cip1).
Tripartite motif-containing protein 37 is overexpressed in human glioma and its downregulation inhibits human glioma cell growth in vitro.
Ubiquitination of p21 by E3 Ligase TRIM21 Promotes the Proliferation of Human Neuroblastoma Cells.
[Increased TRIM5 is associated with a poor prognosis and immune infiltration in glioma patients].
Glucose Intolerance
Induced Cre-mediated knockdown of Brca1 in skeletal muscle reduces mitochondrial respiration and prevents glucose intolerance in adult mice on a high-fat diet.
Glycogen Storage Disease
Polyglucosan body myopathy 1 may cause cognitive impairment: a case report from China.
Update on new muscle glycogenosis.
What have we learned about glycogenosis in recent years?
glycogenin glucosyltransferase deficiency
Proteomic characterisation of polyglucosan bodies in skeletal muscle in RBCK1 deficiency.
Gynecomastia
An updated review of epidemiology, risk factors, and management of male breast cancer.
Differential expressions of BRCA1 and BRCA2 in infantile gynecomastia.
High frequency of germ-line BRCA2 mutations among Hungarian male breast cancer patients without family history.
Hamartoma
Apparent preferential loss of heterozygosity at TSC2 over TSC1 chromosomal region in tuberous sclerosis hamartomas.
Hamartoma Syndrome, Multiple
Breast cancer predisposition syndromes.
Can genetic testing guide treatment in breast cancer?
Genetics of breast cancer.
Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome.
Hereditary breast cancer.
Loss of heterozygosity in human breast carcinomas in the ataxia telangiectasia, Cowden disease and BRCA1 gene regions.
Management of women with a family history of breast cancer.
PTEN breast cancer susceptibility: a matter of dose.
Recent advances in understanding of genetic susceptibility to breast cancer.
Susceptibility to breast cancer: hereditary syndromes and low penetrance genes.
Head and Neck Neoplasms
BRCA1 and MDM2 as independent blood-based biomarkers of head and neck cancer.
Cancer stem-like cell related protein CD166 degrades through E3 ubiquitin ligase CHIP in head and neck cancer.
Compromised Fanconi anemia response due to BRCA1 deficiency in cisplatin-sensitive head and neck cancer cell lines.
Downregulation of ATM and BRCA1 Predicts Poor Outcome in Head and Neck Cancer: Implications for ATM-Targeted Therapy.
High expression of Pirh2, an E3 ligase for p27, is associated with low expression of p27 and poor prognosis in head and neck cancers.
Non-thermal plasma induces AKT degradation through turn-on the MUL1 E3 ligase in head and neck cancer.
Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin.
[Genetic predeterminations of head and neck cancer]
[Report on the first year of the activity of the National Oncological RD Consortium]
Heart Defects, Congenital
Human melanocortin 1 receptor-mediated ubiquitination of nonvisual arrestins. Role of Mahogunin Ring Finger 1 E3 ligase.
Mahogunin Ring Finger 1 Is Required for Genomic Stability and Modulates the Malignant Phenotype of Melanoma Cells.
Mahogunin Ring Finger-1 (MGRN1), a Multifaceted Ubiquitin Ligase: Recent Unraveling of Neurobiological Mechanisms.
Mice with mutations in Mahogunin ring finger-1 (Mgrn1) exhibit abnormal patterning of the left-right axis.
The MGRN1 E3 ubiquitin-ligase inhibits signaling from melanocortin receptors by competition with Galphas.
Ubiquitin-mediated regulation of the E3 ligase GP78 by MGRN1 in trans affects mitochondrial homeostasis.
Heart Failure
BRCA1 is an essential regulator of heart function and survival following myocardial infarction.
Mitochondrial contagion induced by Parkin deficiency in Drosophila hearts and its containment by suppressing mitofusin.
Overexpression of Nrdp1 in the heart exacerbates doxorubicin-induced cardiac dysfunction in mice.
Xin Fu Kang oral liquid inhibits excessive myocardial mitophagy in a rat model of advanced heart failure.
hect-type e3 ubiquitin transferase deficiency
Smurf2 regulates the senescence response and suppresses tumorigenesis in mice.
Hemangioma
Spindle Cell Hemangioma and Atypically Localized Juxtaglomerular Cell Tumor in a Patient with Hereditary BRIP1 Mutation: A Case Report.
Hemangiosarcoma
Genetic predisposition to radiation induced sarcoma: possible role for BRCA and p53 mutations.
Secondary Angiosarcoma With C-MYC Amplification Following Prophylactic Bilateral Mastectomy and Autologous Breast Reconstruction: Report of a Case and Review of the Literature.
Hematologic Neoplasms
A Cereblon Modulator CC-885 Induces CRBN- and p97-Dependent PLK1 Degradation and Synergizes with Volasertib to Suppress Lung Cancer.
Brca1 deficiency causes bone marrow failure and spontaneous hematologic malignancies in mice.
c-Cbl: An Important Regulator and a Target in Angiogenesis and Tumorigenesis.
Cbl proteins in platelet activation.
Cereblon modulator CC-885 induces CRBN-dependent ubiquitination and degradation of CDK4 in multiple myeloma.
Hemochromatosis
Structure and phylogenetic analysis of an endogenous retrovirus inserted into the human growth factor gene pleiotrophin.
Hemoglobinopathies
Screening semen donors for hereditary diseases. The Fairfax cryobank experience.
Hemophilia A
The sampling distribution of disease-associated alleles.
Hepatitis B
A bioinformatics investigation into molecular mechanism of Yinzhihuang granules for treating hepatitis B by network pharmacology and molecular docking verification.
E3 ubiquitin ligase Siah-1 facilitates poly-ubiquitylation and proteasomal degradation of the hepatitis B viral X protein.
E3 ubiquitin ligase TRIM21 restricts hepatitis B virus replication by targeting HBx for proteasomal degradation.
HDM2 Promotes NEDDylation of Hepatitis B Virus HBx To Enhance Its Stability and Function.
Hepatitis B Virus HBx Protein Mediates the Degradation of Host Restriction Factors through the Cullin 4 DDB1 E3 Ubiquitin Ligase Complex.
Hepatitis B virus induces sorafenib resistance in liver cancer via upregulation of cIAP2 expression.
Hepatitis B virus X protein activates E3 ubiquitin ligase Siah-1 to control virus propagation via a negative feedback loop.
Hepatitis B Virus X Protein Sensitizes TRAIL-Induced Hepatocyte Apoptosis by Inhibiting the E3 Ubiquitin Ligase A20.
In silico analysis of functional single nucleotide polymorphisms in the human TRIM22 gene.
Inhibition of hepatitis B virus replication by cIAP2 involves accelerating the ubiquitin-proteasome-mediated destruction of polymerase.
LncRNA XIST upregulates TRIM25 via negatively regulating miR-192 in hepatitis B virus-related hepatocellular carcinoma.
Notch Signaling and Liver Cancer.
Promoter occupancy of MLL1 histone methyltransferase seems to specify the proliferative and apoptotic functions of E2F1 in a tumour microenvironment.
Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfected patients.
SNU cell lines and their application for cancer research.
TRIM22 Inhibits Influenza A Virus Infection by Targeting the Viral Nucleoprotein for Degradation.
TRIM22: A Diverse and Dynamic Antiviral Protein.
Tripartite motif-containing 22 inhibits the activity of hepatitis B virus core promoter, which is dependent on nuclear-located RING domain.
Hepatitis C
ENCODE tiling array analysis identifies differentially expressed annotated and novel 5' capped RNAs in hepatitis C infected liver.
Hepatitis C virus core protein suppresses mitophagy by interacting with parkin in the context of mitochondrial depolarization.
Hepatitis C virus induces the mitochondrial translocation of Parkin and subsequent mitophagy.
HERC5 and the ISGylation Pathway: Critical Modulators of the Antiviral Immune Response.
Inhibition of Hepatitis C Virus RNA Replication by ISG15 does not Require Its Conjugation to Protein Substrates by the HERC5 E3 Ligase.
Innate Immune Responses against Viral Infection and Its Suppression by Viral Proteins.
Interferon alpha (IFN?)-induced TRIM22 interrupts HCV replication by ubiquitinating NS5A.
Multi?layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/??catenin signaling activation (Review).
The mitochondrial targeting chaperone 14-3-3? regulates a RIG-I translocon that mediates membrane association and innate antiviral immunity.
Hepatitis C, Chronic
Associations between human TRIM22 gene expression and the response to combination therapy with Peg-IFN?-2a and ribavirin in Iranian patients with chronic hepatitis C.
Evaluation of TRIM5 and TRIM22 polymorphisms on treatment responses in Iranian patients with chronic hepatitis C virus infection.
Expression of TRIM22 mRNA in chronic hepatitis C patients treated with direct-acting antiviral drugs.
Hepatitis, Alcoholic
Aberrant modulation of the BRCA1 and G1/S cell cycle pathways in alcoholic hepatitis patients with Mallory Denk Bodies revealed by RNA sequencing.
Hepatoblastoma
Cellular cIAP2 gene expression associated with anti-HBV activity of TNF-alpha in hepatoblastoma cells.
Hereditary Breast and Ovarian Cancer Syndrome
A case series of three Sri Lankan families with hereditary breast and ovarian cancer syndrome due to pathogenic germline mutations in the BRCA1 gene
A highly accurate, low cost test for BRCA1 mutations.
A novel deleterious c.2656G>T MSH2 germline mutation in a Pakistani family with a phenotypic overlap of hereditary breast and ovarian cancer and Lynch syndrome.
A novel germline BRCA1 mutation identified in a family with hereditary breast and ovarian cancer syndrome.
A Novel Splice Site Mutation in the Noncoding Region of BRCA2: Implications for Fanconi Anemia and Familial Breast Cancer Diagnostics.
A tandem duplication of BRCA1 exons 1-19 through DHX8 exon 2 in four families with hereditary breast and ovarian cancer syndrome.
Analysis of BRCA1 and BRCA2 mutations in an Iranian family with hereditary breast and ovarian cancer syndrome.
Analysis of BRCA1 mutations in a Pakistani family with hereditary breast and ovarian cancer syndrome.
Analysis of clinical characteristics of breast cancer patients with the Japanese founder mutation BRCA1 L63X.
BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
BRCA1 and BRCA2 rearrangements in Brazilian individuals with Hereditary Breast and Ovarian Cancer Syndrome.
Can chimerism explain breast/ovarian cancers in BRCA non-carriers from BRCA-positive families?
Characterization of a new BRCA1 rearrangement in an Italian woman with hereditary breast and ovarian cancer syndrome.
Constitutional mosaicism for a BRCA2 mutation as a cause of early-onset breast cancer.
Correlation between BRCA1 expression and apoptosis-related biological parameters in sporadic breast carcinomas.
Current condition of genetic medicine for hereditary breast cancer.
Design and validation of a next generation sequencing assay for hereditary BRCA1 and BRCA2 mutation testing.
Experience of Risk-reducing Salpingo-oophorectomy for a BRCA1 Mutation Carrier and Establishment of a System Performing a Preventive Surgery for Hereditary Breast and Ovarian Cancer Syndrome in Japan: Our Challenges for the Future.
Final report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology, on a fact-finding questionnaire on the status of treatment of hereditary breast and ovarian cancer syndrome in Japan.
First description of a double heterozygosity for BRCA1 and BRCA2 pathogenic variants in a French metastatic breast cancer patient: A case report.
Functional and structural analysis of C-terminal BRCA1 missense variants.
Genetic testing by cancer site: ovary.
Genetic testing by cancer site: stomach.
Georgia Primary Care Providers' Knowledge of Hereditary Breast and Ovarian Cancer Syndrome.
Hereditary breast and ovarian cancer susceptibility genes (Review).
Hereditary Breast and Ovarian Cancer Syndrome: Moving Beyond BRCA1 and BRCA2.
Hereditary breast cancer and family cancer syndromes.
Hereditary Ovarian Cancer and Risk Reduction.
High occurrence of BRCA1 intragenic rearrangements in hereditary breast and ovarian cancer syndrome in the Czech Republic.
Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
Identification and comprehensive characterization of large genomic rearrangements in the BRCA1 and BRCA2 genes.
Identification of twenty-nine novel germline unclassified variants of BRCA1 and BRCA2 genes in 1400 Italian individuals.
Identifying Women at Risk for Hereditary Breast and Ovarian Cancer Syndrome Utilizing Breast Care Nurse Navigation at Mammography and Imaging Centers.
Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Investigating the effect of 28 BRCA1 and BRCA2 mutations on their related transcribed mRNA.
Knowledge and opinions regarding BRCA1 and BRCA2 genetic testing among primary care physicians.
Metabolomics reveals novel blood plasma biomarkers associated to the BRCA1-mutated phenotype of human breast cancer.
Molecular Trajectory of BRCA1 and BRCA2 Mutations.
Next-generation sequencing meets genetic diagnostics: development of a comprehensive workflow for the analysis of BRCA1 and BRCA2 genes.
Novel BRCA1 Large Genomic Rearrangements in Italian Breast/Ovarian Cancer Patients.
Pathogenicity assessment of variants for breast cancer susceptibility genes based on BRCAness of tumor sample.
Pathogenicity reclassification of two BRCA1/BRCA2 exonic duplications after identification of genomic breakpoints and tandem orientation.
Pedigree and BRCA gene analysis in breast cancer patients to identify hereditary breast and ovarian cancer syndrome to prevent morbidity and mortality of disease in Indian population.
Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.
Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry.
Population-based study of BRCA1/2 mutations: Family history based criteria identify minority of mutation carriers.
Practice Bulletin No 182: Hereditary Breast and Ovarian Cancer Syndrome.
Practice Bulletin No. 182 Summary: Hereditary Breast and Ovarian Cancer Syndrome.
Prevalence of the BRCA1 founder mutation c.5266dup in Brazilian individuals at-risk for the Hereditary Breast and Ovarian Cancer Syndrome.
Progesterone induces BRCA1 mRNA decrease, cell cycle alterations and apoptosis in the MCF7 breast cancer cell line.
Recent advances in molecular genetics of breast cancer.
Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases.
Serous Tubal Intraepithelial Carcinoma in a Japanese Woman with a Deleterious BRCA1 Mutation.
The Combination of Single-Cell and Next-Generation Sequencing Can Reveal Mosaicism for BRCA2 Mutations and the Fine Molecular Details of Tumorigenesis.
The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer.
The impact of a cascade testing video on recipients' knowledge, cognitive message processing, and affective reactions: A formative evaluation.
Trans-activation-based risk assessment of BRCA1 BRCT variants with unknown clinical significance.
Tumor BRCA Testing in High Grade Serous Carcinoma: Mutation Rates and Optimal Tissue Requirements.
Tumour spectrum in non-BRCA hereditary breast cancer families in Sweden.
Validation of a next generation sequencing assay for BRCA1, BRCA2, CHEK2 and PALB2 genetic testing.
[A Case Report on the Effectiveness of Olaparib in a Patient with Recurrent Breast Cancer with Human Immunodeficiency Virus Infection].
[Genetic counselling in male carriers of BRCA1 and BRCA2 gene mutations].
[Prophylactic surgery of mammary and ovarian carcinoma.]
Hernias, Diaphragmatic, Congenital
Decreased pulmonary c-Cbl expression and tyrosine phosphorylation in the nitrofen-induced rat model of congenital diaphragmatic hernia.
Herpes Simplex
A flow cytometric assay for the study of E3 ubiquitin ligase activity.
A quantitative assay to monitor HSV-1 ICP0 ubiquitin ligase activity in vitro.
A Tale of Two PMLs: Elements Regulating a Differential Substrate Recognition by the ICP0 E3 Ubiquitin Ligase of Herpes Simplex Virus 1.
A viral E3 ligase targets RNF8 and RNF168 to control histone ubiquitination and DNA damage responses.
Cbl E3 Ligase Mediates the Removal of Nectin-1 from the Surface of Herpes Simplex Virus 1-Infected Cells.
Centromere architecture breakdown induced by the viral E3 ubiquitin ligase ICP0 protein of herpes simplex virus type 1.
Centromeric protein CENP-B proteasomal degradation induced by the viral protein ICP0.
Characterization of Elements Regulating the Nuclear-to-Cytoplasmic Translocation of ICP0 in Late Herpes Simplex Virus 1 Infection.
Characterization of the novel E3 ubiquitin ligase encoded in exon 3 of herpes simplex virus-1-infected cell protein 0.
Comparative proteomics identifies Schlafen 5 (SLFN5) as a herpes simplex virus restriction factor that suppresses viral transcription.
Comparison of the biological and biochemical activities of several members of the alphaherpesvirus ICP0 family of proteins.
Discovery of Small-Molecule Inhibitors Targeting the E3 Ubiquitin Ligase Activity of the Herpes Simplex Virus 1 ICP0 Protein Using an In Vitro High-Throughput Screening Assay.
Effect of SUMO-SIM Interaction on the ICP0-Mediated Degradation of PML Isoform II and Its Associated Proteins in Herpes Simplex Virus 1 Infection.
Functional characterization of residues required for the herpes simplex virus 1 E3 ubiquitin ligase ICP0 to interact with the cellular E2 ubiquitin-conjugating enzyme UBE2D1 (UbcH5a).
Herpes Simplex Virus 1 E3 Ubiquitin Ligase ICP0 Protein Inhibits TNF-?-induced NF-?B Activation by Interacting with p65/RelA and p50/NF-?B1.
Herpes simplex virus 1 ICP0 phosphorylation site mutants are attenuated for viral replication and impaired for explant-induced reactivation.
Herpes simplex virus 1 mutant in which the ICP0 HUL-1 E3 ubiquitin ligase site is disrupted stabilizes cdc34 but degrades D-type cyclins and exhibits diminished neurotoxicity.
Herpes simplex virus 1-infected cell protein 0 contains two E3 ubiquitin ligase sites specific for different E2 ubiquitin-conjugating enzymes.
Herpes simplex virus immediate-early protein ICP0 is targeted by SIAH-1 for proteasomal degradation.
Herpes simplex virus tegument ICP0 is capsid associated, and its E3 ubiquitin ligase domain is important for incorporation into virions.
Herpes simplex virus type 1 ICP0 phosphorylation mutants impair the E3 ubiquitin ligase activity of ICP0 in a cell type-dependent manner.
HSV-1 ICP0: An E3 Ubiquitin Ligase That Counteracts Host Intrinsic and Innate Immunity.
ICP0 antagonizes Stat 1-dependent repression of herpes simplex virus: implications for the regulation of viral latency.
ICP0 dismantles microtubule networks in herpes simplex virus-infected cells.
Identification of a novel higher molecular weight isoform of USP7/HAUSP that interacts with the Herpes simplex virus type-1 immediate early protein ICP0.
Interaction between the cellular E3 ubiquitin ligase SIAH-1 and the viral immediate-early protein ICP0 enables efficient replication of Herpes Simplex Virus type 2 in vivo.
Interaction With 14-3-3 Correlates With Inactivation of the RIG-I Signalosome by Herpesvirus Ubiquitin Deconjugases.
Relative Contributions of Herpes Simplex Virus 1 ICP0 and vhs to Loss of Cellular IFI16 Vary in Different Human Cell Types.
Roles of TRIM32 in Corneal Epithelial Cells After Infection with Herpes Simplex Virus.
Sequences related to SUMO interaction motifs in herpes simplex virus 1 protein ICP0 act cooperatively to stimulate virus infection.
Simian TRIM5alpha proteins reduce replication of herpes simplex virus.
Temporal Analysis of the Nuclear-to-cytoplasmic Translocation of a Herpes Simplex Virus 1 Protein by Immunofluorescent Confocal Microscopy.
The infected cell protein 0 of herpes simplex virus 1 dynamically interacts with proteasomes, binds and activates the cdc34 E2 ubiquitin-conjugating enzyme, and possesses in vitro E3 ubiquitin ligase activity.
Therapeutic efficacy of a herpes simplex virus with radiation or temozolomide for intracranial glioblastoma after convection-enhanced delivery.
TRIM23 mediates virus-induced autophagy via activation of TBK1.
TRIM30? Is a Negative-Feedback Regulator of the Intracellular DNA and DNA Virus-Triggered Response by Targeting STING.
Ubiquitin-specific protease 9X in host cells interacts with herpes simplex virus 1 ICP0.
Viral E3 Ubiquitin Ligase-Mediated Degradation of a Cellular E3: Viral Mimicry of a Cellular Phosphorylation Mark Targets the RNF8 FHA Domain.
Viral strategies for triggering and manipulating mitophagy.
ZNRF1 Mediates Epidermal Growth Factor Receptor Ubiquitination to Control Receptor Lysosomal Trafficking and Degradation.
Herpes Zoster
The E3 Ubiquitin Ligase Mahogunin Ubiquitinates the Melanocortin 2 Receptor.
Herpesviridae Infections
A genome-wide screen of Epstein-Barr virus proteins that modulate host SUMOylation identifies a SUMO E3 ligase conserved in herpesviruses.
Hirschsprung Disease
Aberrant UBR4 expressions in Hirschsprung disease patients.
Histiocytic Sarcoma
Germline gene polymorphisms predisposing domestic mammals to carcinogenesis.
histone acetyltransferase deficiency
Functional Interaction of BRCA1 and CREBBP in Murine Hematopoiesis.
HIV Infections
Association of TRIM22 with Type 1 Interferon Response and Viral Control during Primary HIV-1 Infection.
BRCA1 functions as a novel transcriptional cofactor in HIV-1 infection.
Evolution of TRIM5alpha B30.2 (SPRY) domain in New World primates.
Generation of macrophages with altered viral sensitivity from genome-edited rhesus macaque iPSCs to model human disease.
Genome-wide scan in two groups of HIV-infected patients treated with dendritic cell-based immunotherapy.
Interpreting missense mutations in Human TRIM5alpha by computational methods.
The interferon-stimulated gene TRIM22: A double-edged sword in HIV-1 infection.
Hodgkin Disease
Breast cancer after mantle irradiation for Hodgkin's disease: correlation of clinical, pathologic, and molecular features including loss of heterozygosity at BRCA1 and BRCA2.
Breast cancer in adolescents and young women.
Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas.
TP53, BRCA1, and BRCA2 tumor suppressor genes are not commonly mutated in survivors of Hodgkin's disease with second primary neoplasms.
Huntington Disease
Behavioral science in translational research and cancer control.
Construction of human embryonic cDNA libraries: HD, PKD1 and BRCA1 are transcribed widely during embryogenesis.
Deregulation of BRCA1 leads to impaired spatiotemporal dynamics of ?-H2AX and DNA damage responses in Huntington's disease.
Juvenile Huntington's Disease Skin Fibroblasts Respond with Elevated Parkin Level and Increased Proteasome Activity as a Potential Mechanism to Counterbalance the Pathological Consequences of Mutant Huntingtin Protein.
Medical students' attitudes toward genetic testing of minors.
Modelling human regulatory variation in mouse: finding the function in genome-wide association studies and whole-genome sequencing.
Quantitative interaction proteomics of neurodegenerative disease proteins.
Hydrocephalus
Deletion of the Parkin co-regulated gene causes defects in ependymal ciliary motility and hydrocephalus in the quakingviable mutant mouse.
Hyperaldosteronism
CUL4-DDB1-CRBN E3 Ubiquitin Ligase Regulates Proteostasis of ClC-2 Chloride Channels: Implication for Aldosteronism and Leukodystrophy.
Hyperalgesia
MYCBP2 Is a Guanosine Exchange Factor for Ran Protein and Determines Its Localization in Neurons of Dorsal Root Ganglia.
Spinal RNF20-mediated histone H2B monoubiquitylation regulates mGluR5 transcription for neuropathic allodynia.
Hypercholesterolemia
Genetic variation of RNF145 gene and blood lipid levels in Xinjiang population, China.
Hyperglycemia
Hyperglycemia induces skeletal muscle atrophy via a WWP1/KLF15 axis.
Mex3c mutation reduces adiposity partially through increasing physical activity.
Hyperhomocysteinemia
Impact of Hyperhomocysteinemia on Breast Cancer Initiation and Progression: Epigenetic Perspective.
Hyperinsulinism
Perspective of future drugs targeting sterile 20/SPS1-related proline/alanine-rich kinase for blood pressure control.
Rnf20 deficiency in adipocyte impairs adipose tissue development and thermogenesis.
Hyperkalemia
Angiotensin II signaling via protein kinase C phosphorylates Kelch-like 3, preventing WNK4 degradation.
Hyperlipidemias
Age-Associated Mitochondrial Dysfunction Accelerates Atherogenesis.
Mex3c mutation reduces adiposity partially through increasing physical activity.
Hyperpigmentation
Human melanocortin 1 receptor-mediated ubiquitination of nonvisual arrestins. Role of Mahogunin Ring Finger 1 E3 ligase.
Mahogunin Ring Finger 1 Is Required for Genomic Stability and Modulates the Malignant Phenotype of Melanoma Cells.
Hyperprolactinemia
Giant prolactinoma, germline BRCA1 mutation, and depression: a case report.
Human relevance of rodent prolactin-induced non-genotoxic mammary carcinogenesis: prolactin involvement in human breast cancer and significance for toxicology risk assessments.
Hypersensitivity
53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks.
A Human Head and Neck Squamous Cell Carcinoma Cell Line with Acquired cis-Diamminedichloroplatinum-Resistance Shows Remarkable Upregulation of BRCA1 and Hypersensitivity to Taxane.
A targeted disruption of the murine Brca1 gene causes gamma-irradiation hypersensitivity and genetic instability.
Ablation of the Brca1-Palb2 Interaction Phenocopies Fanconi Anemia in Mice.
APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency.
Biallelic Mutations in BRCA1 Cause a New Fanconi Anemia Subtype.
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells.
BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair.
Brca1 heterozygous mice have shortened life span and are prone to ovarian tumorigenesis with haploinsufficiency upon ionizing irradiation.
BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer.
Breast cancer cell response to genistein is conditioned by BRCA1 mutations.
Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity.
CDK9 inhibitor CDKI-73 is synergetic lethal with PARP inhibitor olaparib in BRCA1 wide-type ovarian cancer.
Cytogenetic instability in ovarian epithelial cells from women at risk of ovarian cancer.
Drosophila homologs of FANCD2 and FANCL function in DNA repair.
Dysregulation of p53 and Parkin Induce Mitochondrial Dysfunction and Leads to the Diabetic Neuropathic Pain.
Epithelial cell transforming factor ECT2 is an important regulator of DNA double-strand break repair and genome stability.
Evidence of haplotype insufficiency in human cells containing a germline mutation in BRCA1 or BRCA2.
Expression of human BRCA1 variants in mouse ES cells allows functional analysis of BRCA1 mutations.
Gene-specific chromatin damage in human spermatozoa can be blocked by antioxidants that target mitochondria.
Hypersensitivity of Brca1-deficient MEF to the DNA interstrand crosslinking agent mitomycin C is associated with defect in homologous recombination repair and aberrant S-phase arrest.
Impairment of homologous recombination control in a Fanconi anemia-like Chinese hamster cell mutant.
Incidence of Hypersensitivity Reactions to Carboplatin or Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer With or Without BRCA1 or BRCA2 Mutations.
Interaction between DNA Polymerase ? and BRCA1.
Lessons learned from BRCA1 and BRCA2.
Links between genome integrity and BRCA1 tumor suppression.
Mutagen sensitivity of human lymphoblastoid cells with a BRCA1 mutation in comparison to ataxia telangiectasia heterozygote cells.
Mutation analysis of BRCA1 and BRCA2 cancer predisposition genes in radiation hypersensitive cancer patients.
Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells.
New roads to FA/BRCA pathway: H2AX.
Parkin-mediated responses against infection and wound involve TSPO-VDAC complex in Drosophila.
Poly(ADP-ribose) binding to Chk1 at stalled replication forks is required for S-phase checkpoint activation.
Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks.
SDIR1 is a RING finger E3 ligase that positively regulates stress-responsive abscisic acid signaling in Arabidopsis.
The Arabidopsis RING Finger E3 Ligase RHA2b Acts Additively with RHA2a in Regulating ABA Signaling and Drought Response.
The endonuclease EEPD1 mediates synthetic lethality in RAD52-depleted BRCA1 mutant breast cancer cells.
The PARP-1 inhibitor Olaparib suppresses BRCA1 protein levels, increases apoptosis and causes radiation hypersensitivity in BRCA1
The role of BRCA1 in homologous recombination repair in response to replication stress: significance in tumorigenesis and cancer therapy.
Tumorigenesis as a consequence of genetic instability in Brca1 mutant mice.
Hypertension
Angiotensin II signaling via protein kinase C phosphorylates Kelch-like 3, preventing WNK4 degradation.
Association between single nucleotide polymorphism of DNA repair genes and endometrial cancer: a case-control study.
Cullin-Ring ubiquitin ligases in kidney health and disease.
Genome-wide gene expression array identifies novel genes related to disease severity and excessive daytime sleepiness in patients with obstructive sleep apnea.
Inhibition of Siah2 ubiquitin ligase ameliorates monocrotaline-induced pulmonary arterial remodeling through inactivation of YAP.
Perspective of future drugs targeting sterile 20/SPS1-related proline/alanine-rich kinase for blood pressure control.
Spindle Cell Hemangioma and Atypically Localized Juxtaglomerular Cell Tumor in a Patient with Hereditary BRIP1 Mutation: A Case Report.
The CUL3-KLHL3 E3 ligase complex mutated in Gordon's hypertension syndrome interacts with and ubiquitylates WNK isoforms: disease-causing mutations in KLHL3 and WNK4 disrupt interaction.
The CUL3/KLHL3-WNK-SPAK/OSR1 pathway as a target for antihypertensive therapy.
Hyperthyroidism
Prevalence and clinical correlations of BRCA1/BRCA2 unclassified variant carriers among unselected primary ovarian cancer cases - preliminary report.
Hypoglycemia
Severe hypoglycemia and finger clubbing in a patient with a BRCA1 mutation in a solitary fibrous tumor: a case report.
Hypogonadism
RNF216 Regulates the Migration of Immortalized GnRH Neurons by Suppressing Beclin1-Mediated Autophagy.
Hypokalemia
Deletion of renal Nedd4-2 abolishes the effect of high sodium intake (HS) on Kir4.1, ENaC, and NCC and causes hypokalemia during high HS.
Hypokinesia
parkin-induced defects in neurophysiology and locomotion are generated by metabolic dysfunction and not oxidative stress.
Preliminary studies on parkin gene deletion at exons 1 to 6 in Chinese patients with praecox Parkinson's disease.
[Analysis of the parkin gene deletion mutations in Chinese patients with Parkinson's disease]
Hypoventilation
The E3 ubiquitin ligase TRIM11 mediates the degradation of congenital central hypoventilation syndrome-associated polyalanine-expanded PHOX2B.
Immune System Diseases
Itch: a HECT-type E3 ligase regulating immunity, skin and cancer.
The E3 ligase Itch knock-out mice show hyper-proliferation and wound healing alteration.
The E3 ubiquitin ligase Itch in T cell activation, differentiation, and tolerance.
TRIMming Type I Interferon-Mediated Innate Immune Response in Antiviral and Antitumor Defense.
Incontinentia Pigmenti
Human disorders of ubiquitination and proteasomal degradation.
Infarction, Middle Cerebral Artery
BNIP3L/NIX degradation leads to mitophagy deficiency in ischemic brains.
Infections
A brief history of TRIM5alpha.
A human TRIM5alpha B30.2/SPRY domain mutant gains the ability to restrict and prematurely uncoat B-tropic murine leukemia virus.
A non-canonical role for the autophagy machinery in anti-retroviral signaling mediated by TRIM5?.
A novel HIV-1 restriction factor that is biologically distinct from APOBEC3 cytidine deaminases in a human T cell line CEM.NKR.
A possible role of cIAP2 in Helicobacter pylori-associated gastric cancer.
A protein complex required for polar growth of rhizobial infection threads.
A quantitative assay to monitor HSV-1 ICP0 ubiquitin ligase activity in vitro.
A retrovirus restriction factor TRIM5alpha is transcriptionally regulated by interferons.
A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction.
A specific region of 37 amino acid residues in the SPRY (B30.2) domain of African green monkey TRIM5alpha determines species-specific restriction of simian immunodeficiency virus SIVmac infection.
A TRIM5alpha exon 2 polymorphism is associated with protection from HIV-1 infection in the Pumwani sex worker cohort.
A ubiquitin ligase of symbiosis receptor kinase involved in nodule organogenesis.
A viral E3 ligase targets RNF8 and RNF168 to control histone ubiquitination and DNA damage responses.
Accumulation of substrates of the anaphase-promoting complex (APC) during human cytomegalovirus infection is associated with the phosphorylation of Cdh1 and the dissociation and relocalization of APC subunits.
Activation of non-canonical NF-{kappa}B signaling by the oncoprotein TIO.
Active Depletion of Host Cell Inhibitor-of-Apoptosis Proteins Triggers Apoptosis upon Baculovirus DNA Replication.
Adaptive evolution of primate TRIM5alpha, a gene restricting HIV-1 infection.
AMPK activates Parkin independent autophagy and improves post sepsis immune defense against secondary bacterial lung infections.
An active TRIM5 protein in rabbits indicates a common antiviral ancestor for mammalian TRIM5 proteins.
An E3 ubiquitin ligase TRIM9 is involved in WSSV infection via interaction with ?-TrCP.
An invariant surface patch on the TRIM5alpha PRYSPRY domain is required for retroviral restriction but dispensable for capsid binding.
Analysis of the adenovirus E1B-55K-anchored proteome reveals its link to ubiquitination machinery.
Anaplasma phagocytophilum Up-regulates some Anti-apoptotic Genes in Neutrophils and Pro-inflammatory Genes in Mononuclear Cells of Sheep.
Anti-retroviral activity of TRIM5 alpha.
Antiretroviral potential of human tripartite motif-5 and related proteins.
Antiviral molecules correlate with vitamin D pathway genes and are associated with natural resistance to HIV-1 infection.
APOBEC3G/3F mediates intrinsic resistance of monocyte-derived dendritic cells to HIV-1 infection.
Association of TRIM22 with Type 1 Interferon Response and Viral Control during Primary HIV-1 Infection.
Autophagy in infection.
BRCA1 functions as a novel transcriptional cofactor in HIV-1 infection.
BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M transition.
BRCA1 Regulates IFI16 Mediated Nuclear Innate Sensing of Herpes Viral DNA and Subsequent Induction of the Innate Inflammasome and Interferon-? Responses.
Brca1-deficient murine mammary epithelial cells have increased sensitivity to CDDP and MMS.
c-Cbl shRNA-expressing adenovirus sensitizes TRAIL-induced apoptosis in prostate cancer DU-145 through increases of DR4/5.
c-Cbl-mediated selective virus-receptor translocations into lipid rafts regulate productive Kaposi's sarcoma-associated herpesvirus infection in endothelial cells.
Cellular inhibitor of apoptosis proteins prevent clearance of hepatitis B virus.
Cellular inhibitors of apoptosis proteins cIAP1 and cIAP2 are increased after labour in foetal membranes and myometrium and are essential for TNF-?-induced expression of pro-labour mediators.
Centromere architecture breakdown induced by the viral E3 ubiquitin ligase ICP0 protein of herpes simplex virus type 1.
Characterisation and function of TRIM23 in grass carp (Ctenopharyngodon idella).
CIB1 synergizes with EphrinA2 to regulate Kaposi's sarcoma-associated herpesvirus macropinocytic entry in human microvascular dermal endothelial cells.
Classification of barley U-box E3 ligases and their expression patterns in response to drought and pathogen stresses.
Close Relationship between cIAP2 and Human ARDS Induced by Severe H7N9 Infection.
Comparative Proteomic Analysis of Wild Type and Mutant Lacking an SCF E3 Ligase F-Box Protein in Magnaporthe oryzae.
Comparative proteomics identifies Schlafen 5 (SLFN5) as a herpes simplex virus restriction factor that suppresses viral transcription.
Comparative requirements for the restriction of retrovirus infection by TRIM5alpha and TRIMCyp.
Comparison of the biological and biochemical activities of several members of the alphaherpesvirus ICP0 family of proteins.
Control of Viral Infectivity by Tripartite Motif Proteins.
Control of viral infectivity by tripartite motif proteins.
CSFV induced mitochondrial fission and mitophagy to inhibit apoptosis.
Cyclophilin A is required for TRIM5{alpha}-mediated resistance to HIV-1 in Old World monkey cells.
Cyclophilin A, TRIM5, and resistance to human immunodeficiency virus type 1 infection.
Cyclophilin A: an auxiliary but not necessary cofactor for TRIM5alpha restriction of HIV-1.
Cyclophilin interactions with incoming human immunodeficiency virus type 1 capsids with opposing effects on infectivity in human cells.
DEAR1, a transcriptional repressor of DREB protein that mediates plant defense and freezing stress responses in Arabidopsis.
Determinants for the rhesus monkey TRIM5alpha-mediated block of the late phase of HIV-1 replication.
Differential restriction of human immunodeficiency virus type 2 and simian immunodeficiency virus SIVmac by TRIM5alpha alleles.
Discordant evolution of the adjacent antiretroviral genes TRIM22 and TRIM5 in mammals.
Discovery of Small-Molecule Inhibitors Targeting the E3 Ubiquitin Ligase Activity of the Herpes Simplex Virus 1 ICP0 Protein Using an In Vitro High-Throughput Screening Assay.
Disruption of human TRIM5alpha antiviral activity by nonhuman primate orthologues.
DNA Geminivirus Infection Induces an Imprinted E3 Ligase Gene to Epigenetically Activate Viral Gene Transcription.
E3 Ubiquitin Ligase RNF114 Inhibits Innate Immune Response to Red-Spotted Grouper Nervous Necrosis Virus Infection in Sea Perch by Targeting MAVS and TRAF3 to Mediate Their Degradation.
E6AP goes viral: the role of E6AP in viral- and non-viral-related cancers.
Ectopic Expression of TRIM25 Restores RIG-I Expression and IFN Production Reduced by Multiple Enteroviruses 3Cpro.
Effects of human TRIM5alpha polymorphisms on antiretroviral function and susceptibility to human immunodeficiency virus infection.
Ehrlichia chaffeensis TRP120 Moonlights as a HECT E3 Ligase Involved in Self- and Host Ubiquitination To Influence Protein Interactions and Stability for Intracellular Survival.
EphrinA2 regulates clathrin mediated KSHV endocytosis in fibroblast cells by coordinating integrin-associated signaling and c-Cbl directed polyubiquitination.
Evolution of the rodent Trim5 cluster is marked by divergent paralogous expansions and independent acquisitions of TrimCyp fusions.
Exploring the associations of host genes for viral infection revealed by genome-wide RNAi and virus-host protein interactions.
Expression profiles and interaction suggest TBK1 can be regulated by Nrdp1 in response to immune stimulation in large yellow croaker Larimichthys crocea.
Fates of Retroviral Core Components during Unrestricted and TRIM5-Restricted Infection.
Functional interplay between the B-box 2 and the B30.2(SPRY) domains of TRIM5alpha.
Functional replacement of the RING, B-box 2, and coiled-coil domains of tripartite motif 5alpha (TRIM5alpha) by heterologous TRIM domains.
Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer.
Gain-of-sensitivity mutations in a Trim5-resistant primary isolate of pathogenic SIV identify two independent conserved determinants of Trim5? specificity.
GBP5 Is an Interferon-Induced Inhibitor of Respiratory Syncytial Virus.
Generation and characterization of a stable full-length ecotropic murine leukemia virus molecular clone that produces novel phenotypes to Fv1 restriction.
Generation of an HIV-1 resistant immune system with CD34+ HSCs transduced with a triple combination anti-HIV lentiviral vector.
Generation of human TRIM5alpha mutants with high HIV-1 restriction activity.
Genetic association of the antiviral restriction factor TRIM5alpha with human immunodeficiency virus type 1 infection.
Genotyping of TRIM5 locus in northern pig-tailed macaques (Macaca leonina), a primate species susceptible to Human Immunodeficiency Virus type 1 infection.
GhCyP3 improves the resistance of cotton to Verticillium dahliae by inhibiting the E3 ubiquitin ligase activity of GhPUB17.
H. pylori infection confers resistance to apoptosis via Brd4-dependent BIRC3 eRNA synthesis.
HACE1, an E3 ubiquitin-protein ligase, Mitigates Kaposi's Sarcoma-Associated Herpesvirus (KSHV) Infection Induced Oxidative Stress by Promoting Nrf2 Activity.
Heat shock perturbs TRIM5alpha restriction of human immunodeficiency virus type 1.
HECTD3 mediates TRAF3 polyubiquitination and type I interferon induction during bacterial infection.
Helicobacter pylori Eradication Downregulates Cellular Inhibitor of Apoptosis Protein 2 in Gastric Carcinogenesis.
Hepatitis B virus upregulates cellular inhibitor of apoptosis protein 2 expression via the PI3K/AKT/NF-?B signaling pathway in liver cancer.
Hepatitis C virus core protein suppresses mitophagy by interacting with parkin in the context of mitochondrial depolarization.
Hepatitis C virus induces the mitochondrial translocation of Parkin and subsequent mitophagy.
Heroin use is associated with lower levels of restriction factors and type I interferon expression and facilitates HIV-1 replication.
Herpes simplex virus type 1 ICP0 phosphorylation mutants impair the E3 ubiquitin ligase activity of ICP0 in a cell type-dependent manner.
High-frequency persistence of an impaired allele of the retroviral defense gene TRIM5alpha in humans.
HIV-1 Nef promotes ubiquitination and proteasomal degradation of p53 tumor suppressor protein by using E6AP.
HIV-1 Vpr Reprograms CLR4DCAF1 E3 Ubiquitin Ligase to Antagonize Exonuclease 1-Mediated Restriction of HIV-1 Infection.
Host Intrinsic and Innate Intracellular Immunity During Herpes Simplex Virus Type 1 (HSV-1) Infection.
Hsp70 interacts with the retroviral restriction factor TRIM5alpha and assists the folding of TRIM5alpha.
HSV-1 ICP0: An E3 Ubiquitin Ligase That Counteracts Host Intrinsic and Innate Immunity.
Human cytomegalovirus evades ZAP detection by suppressing CpG dinucleotides in the major immediate early 1 gene.
Human Immunodeficiency Virus Type 1 Restriction by Human-Rhesus Chimeric Tripartite Motif 5alpha (TRIM 5alpha) in CD34(+) Cell-Derived Macrophages In Vitro and in T Cells In Vivo in Severe Combined Immunodeficient (SCID-hu) Mice Transplanted with Human Fetal Tissue.
Human Pirh2 is a novel inhibitor of prototype foamy virus replication.
Human TRIM5alpha Expression Levels and Reduced Susceptibility to HIV-1 Infection.
Human TRIM5alpha mediated restriction of different HIV-1 subtypes and Lv2 sensitive and insensitive HIV-2 variants.
Human tripartite motif 5alpha domains responsible for retrovirus restriction activity and specificity.
Hypothesis: Is there a link between the immune response to Human Herpes Virus type 6? (HHV-6?) infection and the interaction network (interactome) of the genes encoding the CTSS, PTX3, CHI3L1, Mx1, CXCL16, BIRC3 and BST2 proteins?
ICP0 enables and monitors the function of D cyclins in herpes simplex virus 1 infected cells.
ICP0 prevents RNase L-independent rRNA cleavage in herpes simplex virus type 1-infected cells.
Identification of postentry restrictions to Mason-Pfizer monkey virus infection in New World monkey cells.
Identification of residues within the L2 region of rhesus TRIM5alpha that are required for retroviral restriction and cytoplasmic body localization.
Identification of TRAF6 as a ubiquitin ligase engaged in the ubiquitination of SopB, a virulence effector protein secreted by Salmonella typhimurium.
Identification of TRIM27 as a novel degradation target of herpes simplex virus 1 ICP0.
Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys.
Immune-Related Gene Expression Patterns in GPV- or H9N2-Infected Goose Spleens.
Impact of a single amino acid in the variable region 2 of the Old World monkey TRIM5alpha SPRY (B30.2) domain on anti-human immunodeficiency virus type 2 activity.
Impact of novel TRIM5alpha variants, Gly110Arg and G176del, on the anti-HIV-1 activity and the susceptibility to HIV-1 infection.
Impact of TRIM5? in vivo.
Implication of TRIM alpha and TRIMCyp in interferon-induced anti-retroviral restriction activities.
Increased expression and dysregulated association of restriction factors and type I interferon in HIV, HCV mono- and co-infected patients.
Independent evolution of an antiviral TRIMCyp in rhesus macaques.
Independent genesis of chimeric TRIM5-cyclophilin proteins in two primate species.
Induction of cyclophilin A by influenza A virus infection facilitates group A Streptococcus coinfection.
Induction of HOX Genes by Hepatitis C Virus Infection via Impairment of Histone H2A Monoubiquitination.
InFLUencing host survival: cIAP2 tips the scales.
Influenza A virus protein PB1-F2 impairs innate immunity by inducing mitophagy.
Inhibitory effect of human TRIM5alpha on HIV-1 production.
Interaction of c-Cbl with myosin IIA regulates Bleb associated macropinocytosis of Kaposi's sarcoma-associated herpesvirus.
Interactions of the antiviral factor IFI16 mediate immune signaling and herpes simplex virus-1 immunosuppression.
Interfering residues narrow the spectrum of MLV restriction by human TRIM5alpha.
Interferon antagonist NSs of La Crosse virus triggers a DNA damage response-like degradation of transcribing RNA polymerase II.
Interferon-stimulated TRIM69 interrupts dengue virus replication by ubiquitinating viral nonstructural protein 3.
Intrinsic immunity: a front-line defense against viral attack.
IPS-1 differentially induces TRAIL, BCL2, BIRC3 and PRKCE in type I interferons-dependent and -independent anticancer activity.
ISGylation of Hepatitis C Virus NS5A Protein Promotes Viral RNA Replication via Recruitment of Cyclophilin A.
Kaposi's sarcoma-associated herpesvirus interacts with EphrinA2 receptor to amplify signaling essential for productive infection.
KDM2B Overexpression Facilitates Lytic De Novo KSHV Infection by Inducing AP-1 Activity Through Interaction with the SCF E3 Ubiquitin Ligase Complex.
KSHV Entry and Trafficking in Target Cells-Hijacking of Cell Signal Pathways, Actin and Membrane Dynamics.
Latency-Associated Nuclear Antigen E3 Ubiquitin Ligase Activity Impacts Gammaherpesvirus-Driven Germinal Center B Cell Proliferation.
Leishmania differentiation requires ubiquitin conjugation mediated by a UBC2-UEV1 E2 complex.
Lentiviral Vpx accessory factor targets VprBP/DCAF1 substrate adaptor for cullin 4 E3 ubiquitin ligase to enable macrophage infection.
Life History of the Oldest Lentivirus: Characterization of ELVgv Integrations in the Dermopteran Genome.
Limited HIV-2 reservoirs in central-memory CD4 T-cells associated to CXCR6 co-receptor expression in attenuated HIV-2 infection.
Long-term balancing selection maintains trans-specific polymorphisms in the human TRIM5 gene.
Long-Term BRCA1 Down-Regulation by Small Hairpin RNAs Targeting the 3' Untranslated Region.
Loss of RNF43 Function Contributes to Gastric Carcinogenesis by Impairing DNA Damage Response.
Lotus japonicus E3 ligase SEVEN IN ABSENTIA4 destabilizes the symbiosis receptor-like kinase SYMRK and negatively regulates rhizobial infection.
Macrophage migration inhibitory factor enhances influenza-associated mortality in mice.
MicroRNA-325-3p Facilitates Immune Escape of Mycobacterium tuberculosis through Targeting LNX1 via NEK6 Accumulation to Promote Anti-Apoptotic STAT3 Signaling.
MiR-202-5p Inhibits RIG-I-Dependent Innate Immune Responses to RGNNV Infection by Targeting TRIM25 to Mediate RIG-I Ubiquitination.
miR-215 Enhances HCV Replication by Targeting TRIM22 and Inactivating NF-?B Signaling.
Mitochondria-Derived Vesicles Deliver Antimicrobial Reactive Oxygen Species to Control Phagosome-Localized Staphylococcus aureus.
Mitofusin 2-Deficiency Suppresses Mycobacterium tuberculosis Survival in Macrophages.
Mode of transmission affects the sensitivity of human immunodeficiency virus type 1 to restriction by rhesus TRIM5alpha.
Molecular characterization, tissue distribution and expression analysis of TRIM25 in Gallus gallus domesticus.
Multi?layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/??catenin signaling activation (Review).
Murine double minute 2 as a modulator of retroviral restrictions mediated by TRIM5alpha.
Murine gammaherpesvirus 68 evades host cytokine production via replication transactivator-induced RelA degradation.
NEURL3 is an inducible antiviral effector to inhibit HCV assembly by targeting viral E1 glycoprotein.
Nonproteolytic K29-Linked Ubiquitination of the PB2 Replication Protein of Influenza A Viruses by Proviral Cullin 4-Based E3 Ligases.
Not so unique to Primates: The independent adaptive evolution of TRIM5 in Lagomorpha lineage.
Novel TRIM5 Isoforms Expressed by Macaca nemestrina.
NtRNF217, Encoding a Putative RBR E3 Ligase Protein of Nicotiana tabacum, Plays an Important Role in the Regulation of Resistance to Ralstonia solanacearum Infection.
Nuclear localization signal in TRIM22 is essential for inhibition of type 2 porcine reproductive and respiratory syndrome virus replication in MARC-145 cells.
Nuclear Medicine in Prostate Cancer: A New Era for Radiotracers.
Nuclear redistribution of BRCA1 during viral infection.
Overexpression of feline tripartite motif-containing 25 interferes with the late stage of feline leukemia virus replication.
p47 licenses activation of the immune deficiency pathway in the tick Ixodes scapularis.
p62/Sequestosome1 associates with and sustains the expression of the retroviral restriction factor TRIM5{alpha}
Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson's disease.
Parkin gene therapy for alpha-synucleinopathy: A rat model of Parkinson's disease.
Parkin-mediated responses against infection and wound involve TSPO-VDAC complex in Drosophila.
Pathogen-induced ubiquitin-editing enzyme A20 bifunctionally shuts off NF-?B and caspase-8-dependent apoptotic cell death.
Perception of the plant immune signal salicylic acid.
Phosphorylation drives an apoptotic protein to activate antiapoptotic genes: paradigm of influenza A matrix 1 protein function.
Phytophthora infestans effector AVR3a is essential for virulence and manipulates plant immunity by stabilizing host E3 ligase CMPG1.
Phytophthora sojae effector Avr1d functions as an E2 competitor and inhibits ubiquitination activity of GmPUB13 to facilitate infection.
Pioneer surgeon drove ultra clean technology.
Polymicrobial Oral Infection with Four Periodontal Bacteria Orchestrates a Distinct Inflammatory Response and Atherosclerosis in ApoE null Mice.
Porcine Circovirus 2 Induction of ROS Is Responsible for Mitophagy in PK-15 Cells via Activation of Drp1 Phosphorylation.
Porcine reproductive and respiratory syndrome virus triggers mitochondrial fission and mitophagy to attenuate apoptosis.
Potent inhibition of HIV-1 by TRIM5-cyclophilin fusion proteins engineered from human components.
Potent inhibition of simian immunodeficiency virus (SIV) replication by an SIV-based lentiviral vector expressing antisense Env.
Preparation and Application of a Monoclonal Antibody Against Chicken TRIM62.
Primate TRIM5 proteins form hexagonal nets on HIV-1 capsids.
Promoter methylation of RNF180 is associated with H.pylori infection and serves as a marker for gastric cancer and atrophic gastritis.
Proteasomal degradation of TRIM5alpha during retrovirus restriction.
Proteasome inhibition reveals that a functional preintegration complex intermediate can be generated during restriction by diverse TRIM5 proteins.
Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse transcription and infection.
Protein Kinase R Degradation Is Essential for Rift Valley Fever Virus Infection and Is Regulated by SKP1-CUL1-F-box (SCF)FBXW11-NSs E3 Ligase.
PUB1 interacts with the receptor kinase DMI2 and negatively regulates rhizobial and arbuscular mycorrhizal symbioses through its ubiquitination activity in Medicago truncatula.
Pulmonary Pseudomonas aeruginosa infection induces autophagy and proteasome proteolytic pathways in skeletal muscles: effects of a pressurized whey protein-based diet in mice.
Quantitative Proteomics Reveals a Novel Role of the E3 Ubiquitin-Protein Ligase FANCL in the Activation of the Innate Immune Response through Regulation of TBK1 Phosphorylation during Peste des Petits Ruminants Virus Infection.
Regulation of Anti-Apoptotic SOD2 and BIRC3 in Periodontal Cells and Tissues.
Removal of arginine 332 allows human TRIM5alpha to bind human immunodeficiency virus capsids and to restrict infection.
Restriction of an extinct retrovirus by the human TRIM5alpha antiviral protein.
Restriction of the felid lentiviruses by a synthetic feline TRIM5-CypA fusion.
Retroviral restriction factors Fv1 and TRIM5alpha act independently and can compete for incoming virus before reverse transcription.
Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha.
Retrovirus restriction by TRIM5alpha variants from Old World and New World primates.
Rickettsia rickettsii Infection Protects Human Microvascular Endothelial Cells against Staurosporine-Induced Apoptosis by a cIAP(2)-Independent Mechanism.
RING domain is essential for the antiviral activity of TRIM25 from orange spotted grouper.
RIPLET, and not TRIM25, is required for endogenous RIG-I-dependent antiviral responses.
RKP, a RING finger E3 ligase induced by BSCTV C4 protein, affects geminivirus infection by regulation of the plant cell cycle.
RNA helicase DEAD box protein 5 regulates Polycomb repressive complex 2/Hox transcript antisense intergenic RNA function in hepatitis B virus infection and hepatocarcinogenesis.
RNF111-facilitated neddylation potentiates cGAS-mediated antiviral innate immune response.
RNF220 mediates K63-linked polyubiquitination of STAT1 and promotes host defense.
Role of a novel pathogen-induced pepper C3-H-C4 type RING-finger protein gene, CaRFPI, in disease susceptibility and osmotic stress tolerance.
Role of common human TRIM5alpha variants in HIV-1 disease progression.
Role of potential COVID-19 immune system associated genes and the potential pathways linkage with type-2 diabetes.
Roles of TRIM32 in Corneal Epithelial Cells After Infection with Herpes Simplex Virus.
ROQUIN signalling pathways in innate and adaptive immunity.
Rubella vaccine-induced cellular immunity: evidence of associations with polymorphisms in the Toll-like, vitamin A and D receptors, and innate immune response genes.
Saturation of TRIM5 alpha-mediated restriction of HIV-1 infection depends on the stability of the incoming viral capsid.
Selective autophagy limits cauliflower mosaic virus infection by NBR1-mediated targeting of viral capsid protein and particles.
Sequences related to SUMO interaction motifs in herpes simplex virus 1 protein ICP0 act cooperatively to stimulate virus infection.
Simian TRIM5alpha proteins reduce replication of herpes simplex virus.
Species-specific variation in the B30.2(SPRY) domain of TRIM5alpha determines the potency of human immunodeficiency virus restriction.
Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor.
Stabilized Human TRIM5 Alpha Protects Human T cells from HIV-1 Infection.
Strong, but Age-Dependent, Protection Elicited by a Deoxyribonucleic Acid/Modified Vaccinia Ankara Simian Immunodeficiency Virus Vaccine.
Structural insights for HIV-1 therapeutic strategies targeting Vif.
Structure and function of Parkin E3 ubiquitin ligase reveals aspects of RING and HECT ligases.
Susceptibility to Repeated, Low-Dose, Rectal SHIVSF162P3 Challenge Is Independent of TRIM5 Genotype in Rhesus Macaques.
Targeting the E3 ubiquitin casitas B-lineage lymphoma decreases osteosarcoma cell growth and survival and reduces tumorigenesis.
The Arabidopsis MIEL1 E3 ligase negatively regulates ABA signalling by promoting protein turnover of MYB96.
The Arabidopsis transcriptional repressor ERF9 participates in resistance against necrotrophic fungi.
The chicken adenovirus Gam1 protein, an inhibitor of the sumoylation pathway, partially complements ICP0 null mutant HSV-1.
The Chlamydia pneumoniae invasin protein Pmp21 recruits the EGF receptor for host cell entry.
The contribution of RING and B-box 2 domains to retroviral restriction mediated by monkey TRIM5alpha.
The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys.
The E3 ubiquitin ligase HectD3 attenuates cardiac hypertrophy and inflammation in mice.
The E3 ubiquitin ligase midline 1 promotes allergen and rhinovirus-induced asthma by inhibiting protein phosphatase 2A activity.
The E3 Ubiquitin Ligase Siah-1 Suppresses Avian Reovirus Infection by Targeting p10 for Degradation.
The E3 Ubiquitin Ligase SIAH1 Targets MyD88 for Proteasomal Degradation During Dengue Virus Infection.
The E3 Ubiquitin Ligase Mind Bomb 1 Controls Adenovirus Genome Release at the Nuclear Pore Complex.
The Effect of Trim5 Polymorphisms on the Clinical Course of HIV-1 Infection.
The EHEC type III effector NleL is an E3 ubiquitin ligase that modulates pedestal formation.
The Human Adenovirus Type 5 E4orf6/E1B55K E3 Ubiquitin Ligase Complex Can Mimic E1A Effects on E2F.
The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities.
The Human IL-22 Receptor Is Regulated through the Action of the Novel E3 Ligase Subunit FBXW12, Which Functions as an Epithelial Growth Suppressor.
The interferon-stimulated gene TRIM22: A double-edged sword in HIV-1 infection.
The Medicago truncatula E3 Ubiquitin Ligase PUB1 Interacts with the LYK3 Symbiotic Receptor and Negatively Regulates Infection and Nodulation.
The Pathogenic Effects of Fusobacterium nucleatum on the Proliferation, Osteogenic Differentiation, and Transcriptome of Osteoblasts.
The Pepper E3 Ubiquitin Ligase RING1 Gene, CaRING1, Is Required for Cell Death and the Salicylic Acid-Dependent Defense Response.
The poxvirus p28 virulence factor is an E3 ubiquitin ligase.
The presence of the Trim5alpha escape mutation H87Q in the capsid of late stage HIV-1 variants is preceded by a prolonged asymptomatic infection phase.
The TRIM5alpha B-box 2 domain promotes cooperative binding to the retroviral capsid by mediating higher-order self-association.
The TRIM5{alpha} Genotype of Rhesus Macaques Affects Acquisition of Simian Immunodeficiency Virus SIVsmE660 Infection after Repeated Limiting-Dose Intrarectal Challenge.
The ubiquitin ligase Cbl-b limits Pseudomonas aeruginosa exotoxin T-mediated virulence.
Transcriptome analysis of liver elucidates key immune-related pathways in Nile tilapia Oreochromis niloticus following infection with tilapia lake virus.
TRIM22 Inhibits Influenza A Virus Infection by Targeting the Viral Nucleoprotein for Degradation.
TRIM22 inhibits respiratory syncytial virus replication by targeting JAK-STAT1/2 signaling.
TRIM22 regulates macrophage autophagy and enhances Mycobacterium tuberculosis clearance by targeting the nuclear factor-multiplicity ?B/beclin 1 pathway.
TRIM25 and its emerging RNA-binding roles in antiviral defense.
TRIM25 upregulation by Mycobacterium tuberculosis infection promotes intracellular survival of M.tb in RAW264.7 cells.
TRIM30? Is a Negative-Feedback Regulator of the Intracellular DNA and DNA Virus-Triggered Response by Targeting STING.
TRIM41-Mediated Ubiquitination of Nucleoprotein Limits Influenza A Virus Infection.
TRIM41-Mediated Ubiquitination of Nucleoprotein Limits Vesicular Stomatitis Virus Infection.
TRIM5 allelic polymorphism in macaque species/populations of different geographic origins: its impact on SIV vaccine studies.
TRIM5 gene polymorphisms in HIV-1-infected patients and healthy controls from Northeastern Brazil.
TRIM5 is an innate immune sensor for the retrovirus capsid lattice.
TRIM5 modulates penile mucosal acquisition of simian immunodeficiency virus in rhesus monkeys.
TRIM5 suppresses cross-species transmission of a primate immunodeficiency virus and selects for emergence of resistant variants in the new species.
TRIM5? and TRIM22 Are Differentially Regulated According to HIV-1 Infection Phase and Compartment.
Trim5alpha accelerates degradation of cytosolic capsid associated with productive HIV-1 entry.
TRIM5alpha and TRIMCyp form apparent hexamers and their multimeric state is not affected by exposure to restriction-sensitive viruses or by treatment with pharmacological inhibitors.
TRIM5alpha association with cytoplasmic bodies is not required for antiretroviral activity.
TRIM5alpha mediates the postentry block to N-tropic murine leukemia viruses in human cells.
TRIM5alpha Modulates Immunodeficiency Virus Control in Rhesus Monkeys.
TRIM5alpha-independent anti-human immunodeficiency virus type 1 activity mediated by cyclophilin A in Old World monkey cells.
TRIM5alpha.
TRIM5alpharh expression restricts HIV-1 infection in lentiviral vector-transduced CD34+-cell-derived macrophages.
TRIM5{alpha} Disrupts the Structure of Assembled HIV-1 Capsid Complexes in vitro.
TRIM62 From Chicken as a Negative Regulator of Reticuloendotheliosis Virus Replication.
TRIM62-mediated restriction of avian leukosis virus subgroup J replication is dependent on the SPRY domain.
TRIM69 inhibits Vesicular Stomatitis Indiana Virus (VSIV).
Tripartite Motif 22 (TRIM22) protein restricts herpes simplex virus 1 by epigenetic silencing of viral immediate-early genes.
Tripartite motif-containing 3 (TRIM3) inhibits tumor growth and metastasis of liver cancer.
Type I IFN augments IL-27-dependent TRIM25 expression to inhibit HBV replication.
Ubiquitin E3 Ligase c-Cbl Is a Host Negative Regulator of Nef Protein of HIV-1.
Ubiquitination and degradation of NF90 by Tim-3 inhibits antiviral innate immunity.
Unique features of TRIM5alpha among closely related human TRIM family members.
Vif substitution enables persistent infection of pig-tailed macaques by human immunodeficiency virus type 1.
Viral E3 Ubiquitin Ligase-Mediated Degradation of a Cellular E3: Viral Mimicry of a Cellular Phosphorylation Mark Targets the RNF8 FHA Domain.
Virion-Associated Vpr Alleviates a Postintegration Block to HIV-1 Infection of Dendritic Cells.
Virus-specific effects of TRIM5?(rh) RING domain functions on restriction of retroviruses.
Visualization of a proteasome-independent intermediate during restriction of HIV-1 by rhesus TRIM5alpha.
Zebrafish TRIM25 Promotes Innate Immune Response to RGNNV Infection by Targeting 2CARD and RD Regions of RIG-I for K63-Linked Ubiquitination.
ZNRF1 Mediates Epidermal Growth Factor Receptor Ubiquitination to Control Receptor Lysosomal Trafficking and Degradation.
[Identification of the TRIM5/TRIMCyp heterozygous genotype in Macaca assamensis].
[TRIM5alpha]
Infertility
A RING-type E3 ligase controls anther dehiscence by activating the jasmonate biosynthetic pathway gene DEFECTIVE IN ANTHER DEHISCENCE1 in Arabidopsis.
Assessment of ovarian reserve and reproductive outcomes in BRCA1 or BRCA2 mutation carriers.
Association of BRCA1 Mutations with Impaired Ovarian Reserve: Connection Between Infertility and Breast/Ovarian Cancer Risk.
Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks.
BARD1 expression during spermatogenesis is associated with apoptosis and hormonally regulated.
BRCA-related ATM-mediated DNA double-strand break repair and ovarian aging.
Chronology of meiosis & synaptonemal complex abnormalities in normal & abnormal spermatogenesis.
Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study.
Lack of the predominant BRCA1 and BRCA2 mutations in Jewish ovarian carcinoma patients who previously underwent ovulation induction.
Pregnancy after in vitro fertilization-intracytoplasmic sperm injection obtained with a modified natural cycle in a BRCA1 mutation carrier.
Preimplantation genetic diagnosis for inherited breast cancer: first clinical application and live birth in Spain.
Prevalence and clinical correlations of BRCA1/BRCA2 unclassified variant carriers among unselected primary ovarian cancer cases - preliminary report.
Silencing of unsynapsed meiotic chromosomes in the mouse.
The effects of parity, breastfeeding, and infertility treatment on the risk of hereditary breast and ovarian cancer: a review.
Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation.
Infertility, Female
Diminution of eIF4E activity suppresses parkin mutant phenotypes.
[Functions of FANCL in primordial germ cell formation and Fanconi anemia]
Infertility, Male
A homozygous RNF220 mutation leads to male infertility with small-headed sperm.
Deletion of the Parkin coregulated gene causes male sterility in the quaking(viable) mouse mutant.
DJ-1 is critical for mitochondrial function and rescues PINK1 loss of function.
Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin.
H2B ubiquitination regulates meiotic recombination by promoting chromatin relaxation.
Investigating the relationship between BRCA1 and BRCA2 genes methylation profile and sperm DNA fragmentation in infertile men.
Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants.
Molecular analysis of the PArkin co-regulated gene and association with male infertility.
Parkin blushed by PINK1.
Parkin is protective against proteotoxic stress in a transgenic zebrafish model.
Parkin mutant in the fly is largely rescued by metal-responsive transcription factor (MTF-1).
The Arabidopsis U-box/ARM repeat E3 ligase AtPUB4 influences growth and degeneration of tapetal cells, and its mutation leads to conditional male sterility.
Inflammatory Bowel Diseases
E3 Ubiquitin ligase RNF183 Is a Novel Regulator in Inflammatory Bowel Disease.
Emerging views of mitophagy in immunity and autoimmune diseases.
Ginsenoside Rb1 alleviates colitis in mice via activation of endoplasmic reticulum-resident E3 ubiquitin ligase Hrd1 signaling pathway.
RNF186 regulates EFNB1 (ephrin B1)-EPHB2-induced autophagy in the colonic epithelial cells for the maintenance of intestinal homeostasis.
RNF20 and RNF40 regulate vitamin D receptor-dependent signaling in inflammatory bowel disease.
The E3 ubiquitin ligase RNF186 and RNF186 risk variants regulate innate receptor-induced outcomes.
The E3 ubiquitin ligase UBR5 interacts with TTC7A and may be associated with very early onset inflammatory bowel disease.
Unique BIR domain sets determine inhibitor of apoptosis protein-driven cell death and NOD2 complex signal specificity.
Variants in TRIM22 That Affect NOD2 Signaling Are Associated With Very-Early-Onset Inflammatory Bowel Disease.
[Protein ubiquitination on the regulation of inflammatory bowel disease].
Influenza in Birds
Duck PIAS2 Promotes H5N1 Avian Influenza Virus Replication Through Its SUMO E3 Ligase Activity.
Influenza, Human
A SPOPL/Cullin-3 ubiquitin ligase complex regulates endocytic trafficking by targeting EPS15 at endosomes.
Cellular inhibitor of apoptosis protein cIAP2 protects against pulmonary tissue necrosis during influenza virus infection to promote host survival.
E3 Ubiquitin Ligase NEDD4 Promotes Influenza Virus Infection by Decreasing Levels of the Antiviral Protein IFITM3.
In silico analysis of functional single nucleotide polymorphisms in the human TRIM22 gene.
InFLUencing host survival: cIAP2 tips the scales.
Influenza A Virus Infection Induces Muscle Wasting via IL-6 Regulation of the E3 Ubiquitin Ligase Atrogin-1.
Influenza A virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I.
Influenza A virus protein PB1-F2 impairs innate immunity by inducing mitophagy.
Influenza A virus TRIMs the type I interferon response.
Interactome Analysis of the NS1 Protein Encoded by Influenza A H1N1 Virus Reveals a Positive Regulatory Role of Host Protein PRP19 in Viral Replication.
Interferon-? Stimulation Elicited by the Influenza Virus Is Regulated by the Histone Methylase Dot1L through the RIG-I-TRIM25 Signaling Axis.
Molecular mechanism of influenza A NS1-mediated TRIM25 recognition and inhibition.
Mutations Conferring Increased Sensitivity to Tripartite Motif 22 Restriction Accumulated Progressively in the Nucleoprotein of Seasonal Influenza A (H1N1) Viruses between 1918 and 2009.
Nuclear TRIM25 Specifically Targets Influenza Virus Ribonucleoproteins to Block the Onset of RNA Chain Elongation.
Phosphatidylinositol-3-kinase (PI3K) is activated by influenza virus vRNA via the pathogen pattern receptor Rig-I to promote efficient type I interferon production.
Phosphorylation drives an apoptotic protein to activate antiapoptotic genes: paradigm of influenza A matrix 1 protein function.
RIPLET, and not TRIM25, is required for endogenous RIG-I-dependent antiviral responses.
Robust Lys63-Linked Ubiquitination of RIG-I Promotes Cytokine Eruption in Early Influenza B Virus Infection.
Species-specific inhibition of RIG-I ubiquitination and IFN induction by the influenza A virus NS1 protein.
Subcellular Localizations of RIG-I, TRIM25, and MAVS Complexes.
The nucleoprotein of influenza A virus induces p53 signaling and apoptosis via attenuation of host ubiquitin ligase RNF43.
TRIM proteins: another class of viral victims.
TRIM22 Inhibits Influenza A Virus Infection by Targeting the Viral Nucleoprotein for Degradation.
TRIM22. A Multitasking Antiviral Factor.
TRIM23 mediates virus-induced autophagy via activation of TBK1.
TRIM69 inhibits Vesicular Stomatitis Indiana Virus (VSIV).
Viral strategies for triggering and manipulating mitophagy.
Insulin Resistance
beta-arrestin-1 competitively inhibits insulin-induced ubiquitination and degradation of insulin receptor substrate 1.
Breast cancer 1 (BrCa1) may be behind decreased lipogenesis in adipose tissue from obese subjects.
Central role of E3 ubiquitin ligase MG53 in insulin resistance and metabolic disorders.
Evaluation of common variants in MG53 and the risk of type 2 diabetes and insulin resistance in Han Chinese.
Genetic ablation of the c-Cbl ubiquitin ligase domain results in increased energy expenditure and improved insulin action.
Glucose-Sensitive Myokine/Cardiokine MG53 Regulates Systemic Insulin Response and Metabolic Homeostasis.
HSP72 is a Mitochondrial Stress Sensor Critical for Parkin Action, Oxidative Metabolism, and Insulin Sensitivity in Skeletal Muscle.
Infusion of adipose?derived mesenchymal stem cells inhibits skeletal muscle mitsugumin 53 elevation and thereby alleviates insulin resistance in type 2 diabetic rats.
Lack of the E3 Ubiquitin Ligase March1 Affects CD8 T Cell Fate and Exacerbates Insulin Resistance in Obese Mice.
Liver-specific Prkn knockout mice are more susceptible to diet-induced hepatic steatosis and insulin resistance.
Methylglyoxal attenuates insulin signaling and downregulates the enzymes involved in cholesterol biosynthesis.
Mex3c mutation reduces adiposity partially through increasing physical activity.
MG53 is a double-edged sword for human diseases.
MG53-IRS-1 (Mitsugumin 53-Insulin Receptor Substrate-1) Interaction Disruptor Sensitizes Insulin Signaling in Skeletal Muscle.
MG53: Biological Function and Potential as a Therapeutic Target.
Myostatin Induces Insulin Resistance via Casitas B-Lineage Lymphoma b (Cblb)-mediated Degradation of Insulin Receptor Substrate 1 (IRS1) Protein in Response to High Calorie Diet Intake.
Parkin deficiency accentuates chronic alcohol intake-induced tissue injury and autophagy defects in brain, liver and skeletal muscle.
RNF186 impairs insulin sensitivity by inducing ER stress in mouse primary hepatocytes.
Stat3 activation induces insulin resistance via a muscle-specific E3 ubiquitin ligase Fbxo40.
Targeting Trim69 alleviates high fat diet (HFD)-induced hippocampal injury in mice by inhibiting apoptosis and inflammation through ASK1 inactivation.
The E3 ligase tripartite motif 8 targets TAK1 to promote insulin resistance and steatohepatitis.
The E3 ubiquitin ligase parkin is dispensable for metabolic homeostasis in murine pancreatic ? cells and adipocytes.
The E3 ubiquitin ligase Pellino3 protects against obesity-induced inflammation and insulin resistance.
The Pivotal Role of Mitsugumin 53 in Cardiovascular Diseases.
Ubiquitin ligase Cbl-b and obesity-induced insulin resistance [Review].
Upregulation of MG53 Induces Diabetic Cardiomyopathy Through Transcriptional Activation of Peroxisome Proliferation-Activated Receptor ?.
Insulinoma
Analysis of selected genes in neuroendocrine tumours: insulinomas and phaeochromocytomas.
Intellectual Disability
Biallelic UBE4A loss-of-function variants cause intellectual disability and global developmental delay.
Cereblon in health and disease.
Functional Diversification of SRSF Protein Kinase to Control Ubiquitin-Dependent Neurodevelopmental Signaling.
Functional modulation of AMP-activated protein kinase by cereblon.
Genetics of androgen metabolism in women with infertility and hypoandrogenism.
HERC1 Ubiquitin Ligase Is Required for Hippocampal Learning and Memory.
Impaired oxidative stress response characterizes HUWE1-promoted X-linked intellectual disability.
Pathogenic variants in E3 ubiquitin ligase RLIM/RNF12 lead to a syndromic X-linked intellectual disability and behavior disorder.
RNF12 X-Linked Intellectual Disability Mutations Disrupt E3 Ligase Activity and Neural Differentiation.
RNF220/ZC4H2-mediated monoubiquitination of Phox2 is required for noradrenergic neuron development.
Submicroscopic duplications of the hydroxysteroid dehydrogenase HSD17B10 and the E3 ubiquitin ligase HUWE1 are associated with mental retardation.
The RING Domain of RING Finger 12 Efficiently Builds Degradative Ubiquitin Chains.
The X-linked intellectual disability gene product and E3 ubiquitin ligase KLHL15 degrades doublecortin proteins to constrain neuronal dendritogenesis.
Truncation of the E3 ubiquitin ligase component FBXO31 causes non-syndromic autosomal recessive intellectual disability in a Pakistani family.
Ubiquitin ligase HUWE1 regulates axon branching through the Wnt/?-catenin pathway in a Drosophila model for intellectual disability.
Intervertebral Disc Degeneration
CRISPR/dCas9-Mediated Parkin Inhibition Impairs Mitophagy and Aggravates Apoptosis of Rat Nucleus Pulposus Cells Under Oxidative Stress.
Mitophagy in degenerative joint diseases.
Intracranial Aneurysm
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Intracranial Hemorrhages
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Iron Deficiencies
Iron-binding E3 ligase mediates iron response in plants by targeting basic helix-loop-helix transcription factors.
The bHLH transcription factor POPEYE regulates response to iron deficiency in Arabidopsis roots.
Irritable Bowel Syndrome
Upregulation of cIAP2 in regenerating colonocytes in ulcerative colitis.
Ischemic Attack, Transient
Down-regulation of parkin protein in transient focal cerebral ischemia: A link between stroke and degenerative disease?
Ischemic Stroke
Danhong injection facilitates recovery of post-stroke motion deficit via Parkin-enhanced mitochondrial function.
Mitochondrial E3 ubiquitin ligase 1 promotes brain injury by disturbing mitochondrial dynamics in a rat model of ischemic stroke.
Neuroprotective effects of targeting BET proteins for degradation with dBET1 in aged mice subjected to ischemic stroke.
NPD1-mediated stereoselective regulation of BIRC3 expression through cREL is decisive for neural cell survival.
Overexpression of BRCA1 in Neural Stem Cells Enhances Cell Survival and Functional Recovery after Transplantation into Experimental Ischemic Stroke.
The E3 ubiquitin ligase TRIM31 is involved in cerebral ischemic injury by promoting degradation of TIGAR.
TRIM62 knockout protects against cerebral ischemic injury in mice by suppressing NLRP3-regulated neuroinflammation.
Joint Diseases
Synoviolin/Hrd1, an E3 ubiquitin ligase, as a novel pathogenic factor for arthropathy.
[Signal transduction of inflammatory synoviocytes in rheumatoid arthritis]
Keloid
A Role for the E3 Ubiquitin Ligase NEDD4 in Keloid Pathogenesis.
Inactivating the ubiquitin ligase Parkin suppresses cell proliferation and induces apoptosis in human keloids.
The Ubiquitin Proteasome System and Skin Fibrosis.
Kidney Neoplasms
A BAP1 Mutation-specific MicroRNA Signature Predicts Clinical Outcomes in Clear Cell Renal Cell Carcinoma Patients with Wild-type BAP1.
Folliculin deficient renal cancer cells exhibit BRCA1 A complex expression impairment and sensitivity to PARP1 inhibitor olaparib.
Frequent genomic rearrangements of BRCA1 associated protein-1 (BAP1) gene in Japanese malignant mesothelioma-characterization of deletions at exon level.
Identification and management of inherited cancer susceptibility.
Low neighbor of Brca1 gene expression predicts poor clinical outcome and resistance of sunitinib in clear cell renal cell carcinoma.
New Insights into Protein Hydroxylation and Its Important Role in Human Diseases.
RBCK1 promotes p53 degradation via ubiquitination in renal cell carcinoma.
RNF20 Suppresses Tumorigenesis by Inhibiting SREBP1c-PTTG1 Axis in Kidney Cancer.
Small-Molecule Targeting of E3 Ligase Adaptor SPOP in Kidney Cancer.
The sterol-sensing endoplasmic reticulum (ER) membrane protein TRC8 hampers ER to Golgi transport of sterol regulatory element-binding protein-2 (SREBP-2)/SREBP cleavage-activated protein and reduces SREBP-2 cleavage.
The TRC8 E3 ligase ubiquitinates MHC class I molecules before dislocation from the ER.
TRC8 suppresses tumorigenesis through targeting heme oxygenase-1 for ubiquitination and degradation.
Ufmylation Is Activated in Renal Cancer and Is Not Associated with von Hippel-Lindau Mutation.
Klatskin Tumor
Cullin 4A is associated with epithelial to mesenchymal transition and poor prognosis in perihilar cholangiocarcinoma.
Klinefelter Syndrome
An updated review of epidemiology, risk factors, and management of male breast cancer.
Lobular carcinoma of the breast in an 85-year-old man.
Male breast cancer.
Vitamin D receptor gene polymorphisms and male breast cancer risk in Turkish population.
Kyphosis
Induced in vivo knockdown of the Brca1 gene in skeletal muscle results in skeletal muscle weakness.
Lafora Disease
Genetic depletion of the malin E3 ubiquitin ligase in mice leads to lafora bodies and the accumulation of insoluble laforin.
Genetics of Lafora progressive myoclonic epilepsy: current perspectives.
Glycogen hyperphosphorylation underlies lafora body formation.
Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin.
Lafora disease E3 ubiquitin ligase malin is recruited to the processing bodies and regulates the microRNA-mediated gene silencing process via the decapping enzyme Dcp1a.
Laforin is required for the functional activation of malin in endoplasmic reticulum stress resistance in neuronal cells.
Laforin-Malin Complex Degrades Polyglucosan Bodies in Concert with Glycogen Debranching Enzyme and Brain Isoform Glycogen Phosphorylase.
Loss of GABAergic cortical neurons underlies the neuropathology of Lafora disease.
Protein Degradation and Quality Control in Cells from Laforin and Malin Knockout Mice.
Proteomic characterisation of polyglucosan bodies in skeletal muscle in RBCK1 deficiency.
Laminopathies
Biallelic mutations in RNF220 cause laminopathies featuring leukodystrophy, ataxia and deafness.
Lamin A ?exon9 mutation leads to telomere and chromatin defects but not genomic instability.
Language Development Disorders
PIAS4 is associated with macro/microcephaly in the novel interstitial 19p13.3 microdeletion/microduplication syndrome.
Laryngeal Neoplasms
Association between early-onset breast and laryngeal cancers.
Clinical characteristics of laryngeal cancer in BRCA-1 mutation carriers.
Latent Infection
Latency-Associated Nuclear Antigen E3 Ubiquitin Ligase Activity Impacts Gammaherpesvirus-Driven Germinal Center B Cell Proliferation.
Leiomyosarcoma
A role for BRCA1 in uterine leiomyosarcoma.
Conditional inactivation of Brca1, p53 and Rb in mouse ovaries results in the development of leiomyosarcomas.
Induction of ovarian leiomyosarcomas in mice by conditional inactivation of Brca1 and p53.
Lentivirus Infections
SAMHD1: a novel antiviral factor in intrinsic immunity.
Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein.
Leprosy
Genetics of host response in leprosy.
Pleiotropic effects for Parkin and LRRK2 in leprosy type-1 reactions and Parkinson's disease.
Post-translational modification of Parkin and its research progress in cancer.
Leukemia
"Trim"ming PolyQ proteins with engineered PML.
6-Formylindolo(3,2-b)Carbazole (FICZ) Modulates the Signalsome Responsible for RA-Induced Differentiation of HL-60 Myeloblastic Leukemia Cells.
A flow cytometric assay for the study of E3 ubiquitin ligase activity.
A human TRIM5alpha B30.2/SPRY domain mutant gains the ability to restrict and prematurely uncoat B-tropic murine leukemia virus.
A label-free quantitative proteomic strategy to identify E3 ubiquitin ligase substrates targeted to proteasome degradation.
A point mutation of zebrafish c-cbl gene in the ring finger domain produces a phenotype mimicking human myeloproliferative disease.
A Potent Postentry Restriction to Primate Lentiviruses in a Yinpterochiropteran Bat.
A subset of mixed lineage leukemia proteins has plant homeodomain (PHD)-mediated E3 ligase activity.
Adenovirus E1B 55-Kilodalton Protein Is a p53-SUMO1 E3 Ligase That Represses p53 and Stimulates Its Nuclear Export through Interactions with Promyelocytic Leukemia Nuclear Bodies.
Alpha interferon enhances TRIM5alpha-mediated antiviral activities in human and rhesus monkey cells.
An aberrantly sustained emergency granulopoiesis response accelerates postchemotherapy relapse in MLL1-rearranged acute myeloid leukemia in mice.
An invariant surface patch on the TRIM5alpha PRYSPRY domain is required for retroviral restriction but dispensable for capsid binding.
Analysis of alternative lengthening of telomere markers in BRCA1 defective cells.
Arsenic trioxide induces apoptosis in NB-4, an acute promyelocytic leukemia cell line, through up-regulation of p73 via suppression of nuclear factor kappa B-mediated inhibition of p73 transcription and prevention of NF-kappaB-mediated induction of XIAP, cIAP2, BCL-X(L) and survivin.
BRCA1 deficiency and synthetic lethality in leukemias; not only gene mutation matters.
c-Cbl interacts with CD38 and promotes retinoic acid-induced differentiation and G0 arrest of human myeloblastic leukemia cells.
c-CBL is not required for leukemia induction by Bcr-Abl in mice.
c-Cbl tyrosine phosphorylation and subcellular localization in human primary leukemic cells.
c-Cbl-mediated neddylation antagonizes ubiquitination and degradation of the TGF-? type II receptor.
CBL mutations drive PI3K/AKT signaling via increased interaction with LYN and PIK3R1.
CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells.
Characterization of therapy-related acute leukemia in hereditary breast-ovarian carcinoma patients: role of BRCA1 mutation and topoisomerase II-directed therapy.
Clinical significance of high c-MYC and low MYCBP2 expression and their association with Ikaros dysfunction in adult acute lymphoblastic leukemia.
Colostrum of Healthy Mothers Contains Broad Spectrum of Secretory IgA Autoantibodies.
Dasatinib Targets B-Lineage Cells but Does Not Provide an Effective Therapy for Myeloproliferative Disease in c-Cbl RING Finger Mutant Mice.
Deficiency of the dual ubiquitin/SUMO ligase Topors results in genetic instability and an increased rate of malignancy in mice.
Disruption of human TRIM5alpha antiviral activity by nonhuman primate orthologues.
Down-regulation of BRCA1 in BCR-ABL-expressing hematopoietic cells.
Downregulation of BRCA1 protein in BCR-ABL1 leukemia cells depends on stress-triggered TIAR-mediated suppression of translation.
E6AP ubiquitin ligase regulates PML-induced senescence in Myc-driven lymphomagenesis.
Effects of human TRIM5alpha polymorphisms on antiretroviral function and susceptibility to human immunodeficiency virus infection.
Expression of BRCA1 and BRCA2 in male breast cancers and gynecomastias.
Expression of the inhibitor of apoptosis (IAP) family members in human neutrophils: up-regulation of cIAP2 by granulocyte colony-stimulating factor and overexpression of cIAP2 in chronic neutrophilic leukemia.
Expression profiles of BRCA1 splice variants in asynchronous and in G1/S synchronized tumor cell lines.
Gain of Additional BIRC3 Protein Functions through 3'-UTR-Mediated Protein Complex Formation.
GNL3L stabilizes the TRF1 complex and promotes mitotic transition.
Herpes simplex virus immediate-early protein ICP0 is targeted by SIAH-1 for proteasomal degradation.
Herpes simplex virus type 1 ICP0 phosphorylation mutants impair the E3 ubiquitin ligase activity of ICP0 in a cell type-dependent manner.
Histone H2B ubiquitin ligase RNF20 is required for MLL-rearranged leukemia.
Hsa-miR-520d-5p promotes survival in human dermal fibroblasts exposed to a lethal dose of UV irradiation.
Human tripartite motif 5alpha domains responsible for retrovirus restriction activity and specificity.
Inactivation of SAG E3 ubiquitin ligase blocks embryonic stem cell differentiation and sensitizes leukemia cells to retinoid acid.
Interfering residues narrow the spectrum of MLV restriction by human TRIM5alpha.
Interferon regulatory factor-1 binds c-Cbl, enhances mitogen activated protein kinase signaling and promotes retinoic acid-induced differentiation of HL-60 human myelo-monoblastic leukemia cells.
Isolation of an active Lv1 gene from cattle indicates that tripartite motif protein-mediated innate immunity to retroviral infection is widespread among mammals.
Leukemia inhibitory factor arrests oligodendrocyte death and demyelination in spinal cord injury.
Loss of c-Cbl E3 ubiquitin ligase activity enhances the development of myeloid leukemia in FLT3-ITD mutant mice.
Loss of TRIM62 expression is an independent adverse prognostic factor in acute myeloid leukemia.
Mechanisms of apoptosis by the tyrphostin AG957 in hematopoietic cells.
MEN1 is a melanoma tumor suppressor that preserves genomic integrity by stimulating transcription of genes that promote homologous recombination-directed DNA repair.
Murine double minute 2 as a modulator of retroviral restrictions mediated by TRIM5alpha.
Mutations in the BRCT binding site of BRCA1 result in hyper-recombination.
Mutations in TOPORS Cause Autosomal Dominant Retinitis Pigmentosa with Perivascular Retinal Pigment Epithelium Atrophy.
Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia.
Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies.
Nuclear-cytoplasmic shuttling of a RING-IBR protein RBCK1 and its functional interaction with nuclear body proteins.
PALB2 (partner and localizer of BRCA2).
Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile.
PHOSPHORYLATION-DEPENDENT INTERACTION OF SATB1 AND PIAS1 DIRECTS SUMO-REGULATED CASPASE CLEAVAGE OF SATB1.
PML requirement for interferon-induced global cellular SUMOylation.
Proteasomal degradation of TRIM5alpha during retrovirus restriction.
Proteasome inhibition reveals that a functional preintegration complex intermediate can be generated during restriction by diverse TRIM5 proteins.
Proteomic Analysis of Medicinal Plant Calotropis Gigantea by insilico Peptide Mass Fingerprinting.
Proteosomal degradation of NSD2 by BRCA1 promotes leukemia cell differentiation.
Reciprocal activities between herpes simplex virus type 1 regulatory protein ICP0, a ubiquitin E3 ligase, and ubiquitin-specific protease USP7.
Regulation by survivin of cancer cell death induced by F14512, a polyamine-containing inhibitor of DNA topoisomerase II.
Restoration of tumor suppression in prostate cancer by targeting the E3 ligase E6AP.
Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha.
Retrovirus restriction by TRIM5 proteins requires recognition of only a small fraction of viral capsid subunits.
Retrovirus restriction by TRIM5alpha variants from Old World and New World primates.
Role of RNF20 in cancer development and progression - a comprehensive review.
Role of SUMO in RNF4-mediated PML degradation: PML sumoylation and phospho-switch control of its SUMO binding domain dissected in living cells"
SLAP2 Adaptor Binding Disrupts c-CBL Autoinhibition to Activate Ubiquitin Ligase Function.
Structural basis for PRYSPRY-mediated tripartite motif (TRIM) protein function.
The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers.
The double life of MULE in preeclamptic and IUGR placentae.
The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities.
The human TRIM5alpha restriction factor mediates accelerated uncoating of the N-tropic murine leukemia virus capsid.
The ND10 Component Promyelocytic Leukemia Protein Acts as an E3 Ligase for SUMOylation of the Major Immediate Early Protein IE1 of Human Cytomegalovirus.
The novel Chk1 inhibitor MK-8776 sensitizes human leukemia cells to HDAC inhibitors by targeting the intra-S checkpoint and DNA replication and repair.
The sequences of the human and mouse c-cbl proto-oncogenes show v-cbl was generated by a large truncation encompassing a proline-rich domain and a leucine zipper-like motif.
The spectrum of genetic defects in chronic lymphocytic leukemia.
TRF1 averts chromatin remodelling, recombination and replication dependent-break induced replication at mouse telomeres.
Triggering Fbw7-mediated proteasomal degradation of c-Myc by oridonin induces cell growth inhibition and apoptosis.
TRIM5alpha mediates the postentry block to N-tropic murine leukemia viruses in human cells.
Trim5alpha protein restricts both HIV-1 and murine leukemia virus.
Tripartite Motif-Containing Protein 22 Interacts with Class II Transactivator and Orchestrates Its Recruitment in Nuclear Bodies Containing TRIM19/PML and Cyclin T1.
Two surface-exposed elements of the B30.2/SPRY domain as potency determinants of N-tropic murine leukemia virus restriction by human TRIM5alpha.
[TRIM5alpha]
Leukemia, Erythroblastic, Acute
alpha4 phosphoprotein interacts with EDD E3 ubiquitin ligase and poly(A)-binding protein.
Expression of c-cbl proto-oncogene is modulated during differentiation but not during induction of proliferation.
Leukemia, Feline
Overexpression of feline tripartite motif-containing 25 interferes with the late stage of feline leukemia virus replication.
Leukemia, Lymphocytic, Chronic, B-Cell
A reduced panel of eight genes (ATM, SF3B1, NOTCH1, BIRC3, XPO1, MYD88, TNFAIP3, and TP53) as an estimator of the tumor mutational burden in chronic lymphocytic leukemia.
ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial.
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia.
Biological significance of monoallelic and biallelic BIRC3 loss in del(11q) chronic lymphocytic leukemia progression.
BIRC3 and BIRC5: multi-faceted inhibitors in cancer.
BIRC3 mutations in chronic lymphocytic leukemia - uncommon and unfavorable.
Chronic Lymphocytic Leukemia in Neurofibromatosis Type 1 Patients: Case Report and Literature Review of a Rare Occurrence.
Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1 and ATM mutations in chronic lymphocytic leukemia.
Clinical impact of small subclones harboring NOTCH1, SF3B1 or BIRC3 mutations in chronic lymphocytic leukemia.
Design and MinION testing of a nanopore targeted gene sequencing panel for chronic lymphocytic leukemia.
Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild type chronic lymphocytic leukemia.
Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2.
Expression and regulation of COP1 in chronic lymphocytic leukemia cells for promotion of cell proliferation and tumorigenicity.
Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas.
Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans.
IgM peak independently predicts treatment-free survival in chronic lymphocytic leukemia and correlates with accumulation of adverse oncogenetic events.
Inhibitors of apoptosis proteins (IAPs) as potential molecular targets for therapy of hematological malignancies.
Negative correlation of ITCH E3 ubiquitin ligase and miRNA-106b dictates metastatic progression in pancreatic cancer.
NOTCH1, SF3B1, BIRC3 AND TP53 mutations in chronic lymphocytic leukemia patients undergoing first-line treatment: correlation with biological parameters and response to treatment.
Perspectives on Precision Medicine in Chronic Lymphocytic Leukemia: Targeting Recurrent Mutations-NOTCH1, SF3B1, MYD88, BIRC3.
Recurrent mutations refine prognosis in chronic lymphocytic leukemia.
State Institution "National Research Center for Radiation Medicine of the National Academy of Medical Sciences of Ukraine" - research activities and scientific advance in 2013.
Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia.
c-Cbl tyrosine phosphorylation and subcellular localization in human primary leukemic cells.
Diverse mechanisms of autophagy dysregulation and their therapeutic implications: does the shoe fit?
Expression of Oncogenic Kinase Bcr-Abl Impairs Mitotic Checkpoint and Promotes Aberrant Divisions and Resistance to Microtubule-Targeting Agents.
Expression of the inhibitor of apoptosis (IAP) family members in human neutrophils: up-regulation of cIAP2 by granulocyte colony-stimulating factor and overexpression of cIAP2 in chronic neutrophilic leukemia.
Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells.
Study of methylation levels of parkin gene promoter in Parkinson's disease patients.
The downregulation of BAP1 expression by BCR-ABL reduces the stability of BRCA1 in chronic myeloid leukemia.
TRIM22 knockdown suppresses chronic myeloid leukemia via inhibiting PI3K/Akt/mTOR signaling pathway.
Leukemia, Myeloid
A common environmental carcinogen unduly affects carriers of cancer mutations: Carriers of genetic mutations in a specific protective response are more susceptible to an environmental carcinogen.
A label-free quantitative proteomic strategy to identify E3 ubiquitin ligase substrates targeted to proteasome degradation.
Chronic Deletion and Acute Knockdown of Parkin have Differential Responses to Acetaminophen-Induced Mitophagy and Liver Injury in Mice.
DNA damage induces down-regulation of Prp19 via impairing Prp19 stability in hepatocellular carcinoma cells.
E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and a myeloproliferative disease.
Loss of c-Cbl E3 ubiquitin ligase activity enhances the development of myeloid leukemia in FLT3-ITD mutant mice.
Myeloid leukemia development in c-Cbl RING finger mutant mice is dependent on FLT3 signaling.
Shuttling imbalance of MLF1 results in p53 instability and increases susceptibility to oncogenic transformation.
The Cbl protooncogene product: from an enigmatic oncogene to center stage of signal transduction.
Tumor necrosis factor?related apoptosis?inducing ligand as a therapeutic option in urothelial cancer cells with acquired resistance against first?line chemotherapy.
Leukemia, Myeloid, Acute
A high occurrence of acquisition and/or expansion of C-CBL mutant clones in the progression of high-risk myelodysplastic syndrome to acute myeloid leukemia.
BRCA1, PARP1 and ?H2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib.
BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1? activation.
c-Cbl tyrosine phosphorylation and subcellular localization in human primary leukemic cells.
CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells.
CC-90009: A Cereblon E3 Ligase Modulating Drug That Promotes Selective Degradation of GSPT1 for the Treatment of Acute Myeloid Leukemia.
E3 ligase SCFSKP2 ubiquitinates and degrades tumor suppressor C/EBP? in acute myeloid leukemia.
E3 ubiquitin ligase Cbl-b activates the p53 pathway by targeting Siva1, a negative regulator of ARF, in FLT3 inhibitor-resistant acute myeloid leukemia.
Gene expression analysis approach to establish possible links between Parkinson's disease, cancer and cardiovascular diseases.
Histone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells.
Loss of FBXO9 Enhances Proteasome Activity and Promotes Aggressiveness in Acute Myeloid Leukemia.
Loss of TRIM62 expression is an independent adverse prognostic factor in acute myeloid leukemia.
Myeloid leukemia factor 1 stabilizes tumor suppressor C/EBP? to prevent Trib1-driven acute myeloid leukemia.
Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia.
Rapid Screening of ASXL1, IDH1, IDH2, and c-CBL Mutations in de Novo Acute Myeloid Leukemia by High-Resolution Melting.
Stabilization of fatty acid synthesis enzyme acetyl-CoA carboxylase 1 suppresses acute myeloid leukemia development.
The E3 ubiquitin ligase Triad1 influences development of Mll-Ell-induced acute myeloid leukemia.
TRIM25 contributes to the malignancy of acute myeloid leukemia and is negatively regulated by microRNA-137.
Leukemia, Myelomonocytic, Chronic
CBL mutations drive PI3K/AKT signaling via increased interaction with LYN and PIK3R1.
Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia.
Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies.
Leukemia, Myelomonocytic, Juvenile
Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia.
Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies.
Leukemia, Neutrophilic, Chronic
Expression of the inhibitor of apoptosis (IAP) family members in human neutrophils: up-regulation of cIAP2 by granulocyte colony-stimulating factor and overexpression of cIAP2 in chronic neutrophilic leukemia.
Leukemia, Promyelocytic, Acute
A label-free quantitative proteomic strategy to identify E3 ubiquitin ligase substrates targeted to proteasome degradation.
Arsenic trioxide induces apoptosis in NB-4, an acute promyelocytic leukemia cell line, through up-regulation of p73 via suppression of nuclear factor kappa B-mediated inhibition of p73 transcription and prevention of NF-kappaB-mediated induction of XIAP, cIAP2, BCL-X(L) and survivin.
Role of SUMO in RNF4-mediated PML degradation: PML sumoylation and phospho-switch control of its SUMO binding domain dissected in living cells"
Leukemia, T-Cell
Differential subcellular localization regulates c-Cbl E3 ligase activity upon Notch3 protein in T-cell leukemia.
The sequences of the human and mouse c-cbl proto-oncogenes show v-cbl was generated by a large truncation encompassing a proline-rich domain and a leucine zipper-like motif.
Leukemia-Lymphoma, Adult T-Cell
The E3/E4 ubiquitin conjugation factor UBE4B interacts with and ubiquitinates the HTLV-1 Tax oncoprotein to promote NF-?B activation.
Leukoplakia
BRCA1 expression in leukoplakia and carcinoma of the tongue.
Lewy Body Disease
Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death.
Differential expression of alpha-synuclein, parkin, and synphilin-1 isoforms in Lewy body disease.
Identification of far upstream element-binding protein-1 as an authentic Parkin substrate.
S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function.
{alpha}-Synuclein Aggregates Interfere with Parkin Solubility and Distribution: ROLE IN THE PATHOGENESIS OF PARKINSON DISEASE.
Li-Fraumeni Syndrome
Breast cancer patients suggestive of Li-Fraumeni syndrome: mutational spectrum, candidate genes, and unexplained heredity.
Breast cancer predisposition syndromes.
Familial cancer risks to offspring from mothers with 2 primary breast cancers: leads to cancer syndromes.
Familial sarcoma: challenging pedigrees.
Genetic testing and prevention of hereditary cancer at the MMCI--over 10 years of experience.
Genetic testing by cancer site: stomach.
Germ-line TP53 mutations in Finnish cancer families exhibiting features of the Li-Fraumeni syndrome and negative for BRCA1 and BRCA2.
Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families.
Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome.
Hereditary breast cancer: practical pursuit for clinical translation.
Hereditary common cancers: molecular and clinical genetics.
Identification and management of inherited cancer susceptibility.
Inheritance of cancer.
Li-Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis.
Management of women with a family history of breast cancer.
Preimplantation genetic diagnosis (PGD) for heritable neoplasia.
Susceptibility to breast cancer: hereditary syndromes and low penetrance genes.
Tumor suppressor loss in pituitary tumors.
Liddle Syndrome
ENaC and its regulatory proteins as drug targets for blood pressure control.
Lipoma
Germline mutations in MEN1 and BRCA1 genes in a woman with familial multiple endocrine neoplasia type 1 and inherited breast-ovarian cancer syndromes: a case report.
Liposarcoma
Ebp1 sumoylation, regulated by TLS/FUS E3 ligase, is required for its anti-proliferative activity.
Liver Cirrhosis
E3 ubiquitin ligase synoviolin is involved in liver fibrogenesis.
Hrd1 suppresses Nrf2-mediated cellular protection during liver cirrhosis.
Identification of the inhibitory activity of walnut extract on the E3 ligase Syvn1.
Multiplexed Proteomic Approach for Identification of Serum Biomarkers in Hepatocellular Carcinoma Patients with Normal AFP.
Overexpression of ring finger protein 20 inhibits the progression of liver fibrosis via mediation of histone H2B lysine 120 ubiquitination.
Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfected patients.
Smurf2, an E3 ubiquitin ligase, interacts with PDE4B and attenuates liver fibrosis through miR-132 mediated CTGF inhibition.
The NRF2?PGC?1? pathway activates kynurenine aminotransferase 4 via attenuation of an E3 ubiquitin ligase, synoviolin, in a cecal ligation/perforation?induced septic mouse model.
TIM-4 interference in Kupffer cells against CCL4-induced liver fibrosis by mediating Akt1/Mitophagy signalling pathway.
TRIM26 Induces Ferroptosis to Inhibit Hepatic Stellate Cell Activation and Mitigate Liver Fibrosis Through Mediating SLC7A11 Ubiquitination.
Liver Cirrhosis, Biliary
Emerging views of mitophagy in immunity and autoimmune diseases.
Liver Diseases
Overexpression of ring finger protein 20 inhibits the progression of liver fibrosis via mediation of histone H2B lysine 120 ubiquitination.
Parkin deficiency prevents chronic ethanol-induced hepatic lipid accumulation through ?-catenin accumulation.
Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfected patients.
Triggering of Parkin Mitochondrial Translocation in Mitophagy: Implications for Liver Diseases.
Why Hepatic CYP2E1-Elevation by Itself Is Insufficient for Inciting NAFLD/NASH: Inferences from Two Genetic Knockout Mouse Models.
Liver Neoplasms
cIAP2 via NF-?B signalling affects cell proliferation and invasion in hepatocellular carcinoma.
Dysregulated PJA1-TGF-? signaling in cancer stem cell-associated liver cancers.
Gp78, an E3 ubiquitin ligase acts as a gatekeeper suppressing nonalcoholic steatohepatitis (NASH) and liver cancer.
Heat shock protein gp96 decreases p53 stability by regulating Mdm2 E3 ligase activity in liver cancer.
Hepatitis B virus induces sorafenib resistance in liver cancer via upregulation of cIAP2 expression.
Hepatitis B virus upregulates cellular inhibitor of apoptosis protein 2 expression via the PI3K/AKT/NF-?B signaling pathway in liver cancer.
Induction of autophagy and senescence by knockdown of ROC1 E3 ubiquitin ligase to suppress the growth of liver cancer cells.
New insight into BIRC3: A novel prognostic indicator and a potential therapeutic target for liver cancer.
Parkin facilitates proteasome inhibitor-induced apoptosis via suppression of NF-?B activity in hepatocellular carcinoma.
Proliferation defects and genome instability in cells lacking Cul4A.
RNA helicase DEAD box protein 5 regulates Polycomb repressive complex 2/Hox transcript antisense intergenic RNA function in hepatitis B virus infection and hepatocarcinogenesis.
Silencing of WWP2 inhibits adhesion, invasion, and migration in liver cancer cells.
The Neddylation-Cullin 2-RBX1 E3 Ligase Axis Targets Tumor Suppressor RhoB for Degradation in Liver Cancer.
Tripartite motif-containing 3 (TRIM3) inhibits tumor growth and metastasis of liver cancer.
Lung Diseases
MID1-PP2A complex functions as new insights in human lung adenocarcinoma.
Tumor necrosis factor-alpha-induced lung cell expression of antiapoptotic genes TRAF1 and cIAP2.
Lung Injury
E3 ubiquitin ligase Cblb regulates the acute inflammatory response underlying lung injury.
Lipoxin A4 reduces hyperoxia-induced lung injury in neonatal rats through PINK1 signaling pathway.
Polydatin mediates Parkin-dependent mitophagy and protects against mitochondria-dependent apoptosis in acute respiratory distress syndrome.
Lung Neoplasms
A comprehensive search for DNA amplification in lung cancer identifies inhibitors of apoptosis cIAP1 and cIAP2 as candidate oncogenes.
A critical re-assessment of DNA repair gene promoter methylation in non-small cell lung carcinoma.
A new efficient method to detect genetic interactions for lung cancer GWAS.
A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts.
A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: role of BRCA1.
Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation.
Alterations of the tumor suppressor gene Parkin in non-small cell lung cancer.
Altered expression of FANCL confers mitomycin C sensitivity in Calu-6 lung cancer cells.
Altered expression of microRNA-365 is related to the occurrence and development of non-small-cell lung cancer by inhibiting TRIM25 expression.
An E3 ubiquitin ligase: c-Cbl: A New Therapeutic Target of Lung Cancer.
An integrated inspection of the somatic mutations in a lung squamous cell carcinoma using next-generation sequencing.
Analysis of ERCC1, BRCA1, RRM1 and TUBB3 as predictors of prognosis in patients with non-small cell lung cancer who received cisplatin-based adjuvant chemotherapy: A prospective study.
Application of Multilayer Evidence for Annotation of C-Terminal BRCA2 Variants.
Association between EGFR mutation and expression of BRCA1 and RAP80 in non-small cell lung cancer.
Association between epidermal growth factor receptor gene copy number and ERCC1, BRCA1 protein expression in Chinese patients with non-small cell lung cancer.
Association of BRCA1, ERCC1, RAP80, PKM2, RRM1, RRM2, TS, TSP1, and TXR1 mRNA expression levels between primary tumors and infiltrated regional lymph nodes in patients with resectable non-small cell lung cancer.
Association of EGFR mutations with low BRCA1 gene expression in non-small cell lung cancer.
BAP1 promotes viability and migration of ECA109 cells through KLF5/CyclinD1/FGF-BP1.
BRCA1 and BRCA2 Gene Mutations and Lung Cancer Sisk: A Meta-Analysis.
BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer.
BRCA1 regulates microtubule dynamics and taxane-induced apoptotic cell signaling.
BRCA1, LMO4, and CtIP mRNA expression in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations.
BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1? activation.
BRCA1: a new genomic marker for non-small-cell lung cancer.
BRCA1: A Novel Prognostic Factor in Resected Non-Small-Cell Lung Cancer.
BRMS1 suppresses lung cancer metastases through an E3 ligase function on histone acetyltransferase p300.
CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases.
Chromosomal microarray provides enhanced targetable gene aberration detection when paired with next generation sequencing panel in profiling lung and colorectal tumors.
cIAP2 Upregulated by E6 Oncoprotein via Epidermal Growth Factor Receptor/Phosphatidylinositol 3-Kinase/AKT Pathway Confers Resistance to Cisplatin in Human Papillomavirus 16/18-Infected Lung Cancer.
Clinical response to crizotinib and emergence of resistance in lung adenocarcinoma harboring a MET c-Cbl binding site mutation.
Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer.
Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy.
Correlation between BRCA1 and TopBP1 protein expression and clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.
Correlation between BRCA1 expression and clinicopathological factors including brain metastases in patients with non-small-cell lung cancer.
Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer.
Covalent ISG15 conjugation to CHIP promotes its ubiquitin E3 ligase activity and inhibits lung cancer cell growth in response to type I interferon.
Customized chemotherapy in metastatic non-small cell lung cancer (NSCLC).
Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression.
DCUN1D1 facilitates tumor metastasis by activating FAK signaling and up-regulates PD-L1 in non-small-cell lung cancer.
Differential response between the p53 ubiquitin-protein ligases Pirh2 and MdM2 following DNA damage in human cancer cells.
Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL.
DNA Repair Genes ERCC1 and BRCA1 Expression in Non-Small Cell Lung Cancer Chemotherapy Drug Resistance.
DREAMing: a simple and ultrasensitive method for assessing intratumor epigenetic heterogeneity directly from liquid biopsies.
Drug Targeting of Genomic Instability in Multiple Myeloma.
E3 ligase MKRN3 is a tumor suppressor regulating PABPC1 ubiquitination in non-small cell lung cancer.
E3 ubiquitin ligase Hakai regulates cell growth and invasion, and increases the chemosensitivity to cisplatin in non?small?cell lung cancer cells.
E3 ubiquitin ligase HECW1 promotes the metastasis of non-small cell lung cancer cells through mediating the ubiquitination of Smad4.
E3 ubiquitin ligase TRIM7 negatively regulates NF-kappa B signaling pathway by degrading p65 in lung cancer.
E3 ubiquitin ligase tripartite motif-containing 71 promotes the proliferation of non-small cell lung cancer through the inhibitor of kappaB-?/nuclear factor kappaB pathway.
E3 ubiquitin ligases Cbl-b and c-Cbl downregulate PD-L1 in EGFR wild-type non-small cell lung cancer.
Effect of BRCA1 haplotype on survival of non-small-cell lung cancer patients treated with platinum-based chemotherapy.
Epigenetic inactivation of the chromosomal stability control genes BRCA1, BRCA2, and XRCC5 in non-small cell lung cancer.
ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancer.
ERCC1 and BRCA1 mRNA expression predicts the clinical outcome of non-small cell lung cancer receiving platinum-based chemotherapy.
ERCC1 and BRCA1 mRNA expressions are associated with clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.
ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer.
ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy.
ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer.
Exosomes Derived From Macrophages Enhance Aerobic Glycolysis and Chemoresistance in Lung Cancer by Stabilizing c-Myc via the Inhibition of NEDD4L.
Expression of ERCC1 and BRCA1 predict the clinical outcome of non-small cell lung cancer in patients receiving platinum-based chemotherapy.
Expression of Pirh2, a newly identified ubiquitin protein ligase, in lung cancer.
Expression of RRM1 and RRM2 as a novel prognostic marker in advanced non-small cell lung cancer receiving chemotherapy.
Expression pattern of parkin isoforms in lung adenocarcinomas.
FBW7 loss promotes epithelial-to-mesenchymal transition in non-small cell lung cancer through the stabilization of Snail protein.
Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden.
Functional Impact of Sequence Alterations Found in BRCA1 Promoter/5'UTR Region in Breast/Ovarian Cancer Families from Upper Silesia, Poland.
Genetic Disruption of KEAP1/CUL3 E3 Ubiquitin Ligase Complex Components is a Key Mechanism of NF-KappaB Pathway Activation in Lung Cancer.
Genetic polymorphisms and haplotypes of BRCA1 gene associated with quality of life and survival among patients with non-small-cell lung cancer.
Genetic variants of BIRC3 and NRG1 in the NLRP3 inflammasome pathway are associated with non-small cell lung cancer survival.
Germline mutations in young non-smoking women with lung adenocarcinoma.
Growth retardation and tumour inhibition by BRCA1.
High expression of lncRNA MEG3 participates in non-small cell lung cancer by regulating microRNA-7-5p.
High UDG and BRCA1 expression is associated with adverse outcome in patients with pemetrexed treated non-small cell lung Cancer.
Histone demethylase LSD2 acts as an E3 ubiquitin ligase and inhibits cancer cell growth through promoting proteasomal degradation of OGT.
HUWE1 controls the development of non-small cell lung cancer through down-regulation of p53.
Impact of siRNA targeting pirh2 on proliferation and cell cycle control of the lung adenocarcinoma cell line A549.
In Silico and In Vitro Analysis of lncRNA XIST Reveals a Panel of Possible Lung Cancer Regulators and a Five-Gene Diagnostic Signature.
Individualized Chemotherapy in Advanced NSCLC Patients Based on mRNA Levels of BRCA1 and RRM1.
Induction of c-Cbl contributes to anti-cancer effects of HDAC inhibitor in lung cancer.
LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC.
Lipid metabolic pathways as lung cancer therapeutic targets: a computational study.
Loss of H2B monoubiquitination is associated with poor-differentiation and enhanced malignancy of lung adenocarcinoma.
Loss of the novel tumour suppressor and polarity gene Trim62 (Dear1) synergizes with oncogenic Ras in invasive lung cancer.
MLN4924 suppresses the BRCA1 complex and synergizes with PARP inhibition in NSCLC cells.
mRNA Expression and Clinical Significance of ERCC1, BRCA1, RRM1, TYMS and TUBB3 in Postoperative Patients with Non-Small Cell Lung Cancer.
MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 Trial.
Multiple-level validation identifies PARK2 in the development of lung cancer and chronic obstructive pulmonary disease.
Mutual regulation between OGT and XIAP to control colon cancer cell growth and invasion.
Non-small cell lung cancer cells with deficiencies in homologous recombination genes are sensitive to PARP inhibitors.
Noncanonical Role of FBXO6 in Regulating Antiviral Immunity.
Optimization of genetics to create therapies for metastatic (stage IV) non-small-cell lung cancer.
Overexpression of TRIM25 in Lung Cancer Regulates Tumor Cell Progression.
Parkin ubiquitinates phosphoglycerate dehydrogenase to suppress serine synthesis and tumor progression.
PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer.
Pellino-1 confers chemoresistance in lung cancer cells by upregulating cIAP2 through Lys63-mediated polyubiquitination.
Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors.
Phytochemical library screening reveals betulinic acid as a novel Skp2-SCF E3 ligase inhibitor in non-small cell lung cancer.
PIAS1-FAK Interaction Promotes the Survival and Progression of Non-Small Cell Lung Cancer.
Poor response to platinum-based chemotherapy is associated with KRAS mutation and concomitant low expression of BRAC1 and TYMS in NSCLC.
Predictive role of RRM1 and BRCA1 mRNA expression on the clinical outcome of advanced non-small cell lung cancer.
Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
Predictive Value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOP?-IIA, TOPOIIB and C-MYC Genes in Patients with Small Cell Lung Cancer (SCLC) Who Received First Line Therapy with Cisplatin and Etoposide.
Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non-Small-Cell Lung Cancer Patients with EGFR Mutations.
Prognostic significance of BRCA1, ERCC1, RRM1, and RRM2 in patients with advanced non-small cell lung cancer receiving chemotherapy.
Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer.
Prognostic significance of ERCC1, RRM1, TOP1, TOP2A, TYMS, TUBB3, GSTP1 AND BRCA1 mRNA expressions in patients with non-small-cell lung cancer receiving a platinum-based chemotherapy.
Prognostic value of ERCC1, RRM1, BRCA1 and SETDB1 in early stage of non-small cell lung cancer.
Radiation-Related Deregulation of TUBB3 and BRCA1/2 and Risk of Secondary Lung Cancer in Women With Breast Cancer.
Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib.
Reduced abundance of the E3 ubiquitin ligase E6AP contributes to decreased expression of the INK4/ARF locus in non-small cell lung cancer.
Regulation of autophagy flux by E3 ubiquitin ligase Pirh2 in lung cancer.
RNA interferences targeting the Fanconi anemia/BRCA pathway upstream genes reverse cisplatin resistance in drug-resistant lung cancer cells.
RNF111/Arkadia is regulated by DNA methylation and affects TGF-?/Smad signaling associated invasion in NSCLC cells.
Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial.
Screening for colorectal cancer using the faecal occult blood test, hemoccult.
Single nucleotide polymorphisms in breast cancer susceptibility gene 1 are associated with susceptibility to lung cancer.
Single Nucleotide Polymorphisms in CBLB, a Regulator of T-Cell Response, Predict Radiation Pneumonitis and Outcomes After Definitive Radiotherapy for Non-Small-Cell Lung Cancer.
SIRT2 inhibits non-small cell lung cancer cell growth through impairing Skp2-mediated p27 degradation.
Skp2 regulates non-small cell lung cancer cell growth by Meg3 and miR-3163.
Smurf1 regulates lung cancer cell growth and migration through interaction with and ubiquitination of PIPKI?.
Somatic and germline mutations in the tumor suppressor gene PARK2 impair PINK1/Parkin-mediated mitophagy in lung cancer cells.
Targeted Inhibition of the E3 Ligase SCFSkp2/Cks1 Has Antitumor Activity in RB1-Deficient Human and Mouse Small-Cell Lung Cancer.
Targeting MALAT1 induces DNA damage and sensitize non-small cell lung cancer cells to cisplatin by repressing BRCA1.
The E3 ligase C-CBL inhibits cancer cell migration by neddylating the proto-oncogene c-Src.
The E3 Ligase CHIP Mediates p21 Degradation to Maintain Radioresistance.
The E3 ubiquitin ligase NEDD4 mediates cell migration signaling of EGFR in lung cancer cells.
The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy.
The predictive value of BRCA1 and RAP80 mRNA expression in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy.
The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection.
The role of BRCA1 in non-small cell lung cancer.
Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum.
TRIM11, a direct target of miR-24-3p, promotes cell proliferation and inhibits apoptosis in colon cancer.
TRIM22 confers poor prognosis and promotes epithelial-mesenchymal transition through regulation of AKT/GSK3?/?-catenin signaling in non-small cell lung cancer.
TRIM25 activates AKT/mTOR by inhibiting PTEN via K63-linked polyubiquitination in non-small cell lung cancer.
TRIM59 Promotes the Proliferation and Migration of Non-Small Cell Lung Cancer Cells by Upregulating Cell Cycle Related Proteins.
Tubuline, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy.
Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients.
Tumor-treating fields elicit a conditional vulnerability to ionizing radiation via the downregulation of BRCA1 signaling and reduced DNA double-strand break repair capacity in non-small cell lung cancer cell lines.
Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies.
Two-gene signature improves the discriminatory power of IASLC/ATS/ERS classification to predict the survival of patients with early-stage lung adenocarcinoma.
UBR-box containing protein, UBR5, is over-expressed in human lung adenocarcinoma and is a potential therapeutic target.
Upregulation of Neural Precursor Cell Expressed Developmentally Downregulated 4-1 is Associated with Poor Prognosis and Chemoresistance in Lung Adenocarcinoma.
XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression.
[Chinese multicenter randomized trial of customized chemotherapy based on BRCA1 (breast cancer susceptibility gene 1)-RAP80 (receptor-associated protein 80) mRNA expression in advanced non-small cell lung cancer (NSCLC) patients].
[Detection of RRM1, ERCC1 and BRCA1 gene expression in non-small cell lung cancer tissues and peripheral blood by SYBR real-time fluorescent quantitative PCR].
[EGFR gene copy number, ERCC1 and BRCA1 protein expression and their relationship in non-small cell lung cancer].
[Expressions of c-Cbl, Cbl-b and EGFR and its role of prognosis in NSCLC].
[Pirh2 shRNA mediated by psiRNA-hH1 vector plasmid effectively inhibits the proliferation of lung carcinoma cells: in vitro and in vivo experiments]
[Relationship between the protein expression of ERCC1, BRCA, ?-tubulin and K-ras and the efficacy and prognosis in advanced non-small cell lung cancer].
Lupus Erythematosus, Systemic
Autoantibodies to the functionally active RING-domain of Ro52/SSA are associated with disease activity in patients with lupus.
E3 ligase FBXW7 aggravates TMPD-induced systemic lupus erythematosus by promoting cell apoptosis.
Emerging views of mitophagy in immunity and autoimmune diseases.
Lys63-Polyubiquitination by the E3 Ligase Casitas B-Lineage Lymphoma-b (Cbl-b) Modulates Peripheral Regulatory T Cell Tolerance in Patients with Systemic Lupus Erythematosus.
SS-A/Ro52 promotes apoptosis by regulating Bcl-2 production.
Transcription factor RFX1 is ubiquitinated by E3 ligase STUB1 in systemic lupus erythematosus.
Lymphadenopathy
MRI and breast cancer: role in detection, diagnosis, and staging.
Lymphatic Metastasis
Association of BRCA1 promoter methylation with sporadic breast cancers: Evidence from 40 studies.
BRCA1 and ERCC1 mRNA levels are associated with lymph node metastasis in Chinese patients with colorectal cancer.
CDC25A, VAV1, TP73, BRCA1 and ZAP70 gene overexpression correlates with radiation response in colorectal cancer.
Characterization of a novel breast carcinoma xenograft and cell line derived from a BRCA1 germ-line mutation carrier.
cIAP2 promotes gallbladder cancer invasion and lymphangiogenesis by activating the NF-?B pathway.
Clinical and experimental role of ring finger protein 180 on lymph node metastasis and survival in gastric cancer.
Clinical implications for BRCA gene mutation in breast cancer.
Coexistent Loss of the Expressions of BRCA1 and p53 Predicts Poor Prognosis in Triple-Negative Breast Cancer.
Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis.
Correlation between BRCA1 expression and apoptosis-related biological parameters in sporadic breast carcinomas.
Detection of aberrant promoter methylation of RNF180, DAPK1 and SFRP2 in plasma DNA of patients with gastric cancer.
Detection of novel germline mutations in six breast cancer predisposition genes by targeted next-generation sequencing.
Effect of BRCA1 immunohistochemical localizations on prognosis of patients with sporadic breast carcinomas.
Elevated TRIM23 expression predicts poor prognosis in Chinese gastric cancer.
Hypoxia-induced factor-1 alpha, vascular endothelial growth factor expression in BRCA1-related breast cancer: A prospective study in tertiary care hospital.
Inactivation of parkin by promoter methylation correlated with lymph node metastasis and genomic instability in nasopharyngeal carcinoma.
Increased Expression of BRCA2 and RAD51 in Lymph Node Metastases of Canine Mammary Adenocarcinomas.
Loss of c-Cbl expression correlates with de-differentiation status and lymphatic metastasis in gastric cancer.
Loss of heterozygosity in BRCA1 and BRCA2 markers and high-grade malignancy in breast cancer.
Methylation Analysis of BRCA1 and APC in Breast Cancer and It's Relationship to Clinicopathological Features.
Methylation of BRCA1 promoter region is associated with unfavorable prognosis in women with early-stage breast cancer.
Multigene methylation in serum of sporadic Chinese female breast cancer patients as a prognostic biomarker.
MYC overexpression and poor prognosis in sporadic breast cancer with BRCA1 deficiency.
Next-generation sequencing reveals lymph node metastasis associated genetic markers in colorectal cancer.
Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers.
Recurring Amplification at 11q22.1-q22.2 Locus Plays an Important Role in Lymph Node Metastasis and Radioresistance in OSCC.
Risk factors for lymph node metastasis of ovarian, fallopian tube and primary peritoneal cancer in hereditary breast and ovarian cancer syndrome.
Targeting TRIM3 deletion-induced tumor-associated lymphangiogenesis prohibits lymphatic metastasis in esophageal squamous cell carcinoma.
The BRCA1 Methylation and PD-L1 Expression in Sporadic Ovarian Cancer.
TRIM23 overexpression is a poor prognostic factor and contributes to carcinogenesis in colorectal cancer.
[Diagnostic value of BRCA1 and p16 gene methylation in sporadic breast cancer.]
[Tripartite-motif protein 25 and pyruvate kinase M2 protein expression in non-small cell lung cancer].
Lymphocytic Choriomeningitis
Control of virus-specific CD8+ T-cell exhaustion and immune-mediated pathology by E3 ubiquitin ligase Cbl-b during chronic viral infection.
Lymphocytosis
Normal serum protein electrophoresis and mutated IGHV genes detect very slowly evolving chronic lymphocytic leukemia patients.
Lymphoma
53BP1 loss rescues embryonic lethality but not genomic instability of BRCA1 total knockout mice.
?-Catenin Increases the Stability of EGFR by Decreasing c-Cbl Interaction and Enhances EGFR/Erk1/2 Signaling in Prostate Cancer.
A critical role for the E3-ligase activity of c-Cbl in VEGFR-2-mediated PLCgamma1 activation and angiogenesis.
A novel host cell reactivation assay to assess homologous recombination capacity in human cancer cell lines.
Absence of Grail promotes CD8(+) T cell anti-tumour activity.
Activation of atypical protein kinase Czeta toward TC10 is regulated by high-fat diet and aerobic exercise in skeletal muscle.
Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma.
Alteration of BIRC3 and multiple other NF-?B pathway genes in splenic marginal zone lymphoma.
An E3 ubiquitin ligase: c-Cbl: A New Therapeutic Target of Lung Cancer.
Ataxia telangiectasia mutated interacts with Parkin and induces mitophagy independent of kinase activity. Evidence from mantle cell lymphoma.
BAL1 and its partner E3 ligase, BBAP, link Poly(ADP-ribose) activation, ubiquitylation, and double-strand DNA repair independent of ATM, MDC1, and RNF8.
BBAP monoubiquitylates histone H4 at lysine 91 and selectively modulates the DNA damage response.
Bcl-2 inhibits nuclear homologous recombination by localizing BRCA1 to the endomembranes.
BRCA1 and BRCA2 germline mutations in lymphoma patients.
Brca1 heterozygous mice have shortened life span and are prone to ovarian tumorigenesis with haploinsufficiency upon ionizing irradiation.
c-CBL E3 Ubiquitin Ligase Expression Increases Across the Spectrum of Benign and Malignant T-Cell Skin Diseases.
c-Cbl Inhibition Improves Cardiac function and Survival in Response to Myocardial Ischemia.
c-CBL regulates melanoma proliferation, migration, invasion and the FAK-SRC-GRB2 nexus.
c-Cbl targets PD-1 in immune cells for proteasomal degradation and modulates colorectal tumor growth.
c-Cbl Ubiquitin Ligase Regulates Focal Adhesion Protein Turnover and Myofibril Degeneration Induced by Neutrophil Protease Cathepsin G.
c-Cbl, a ubiquitin E3 ligase that targets active ?-catenin: a novel layer of Wnt signaling regulation.
c-Cbl-deficient mice have reduced adiposity, higher energy expenditure, and improved peripheral insulin action.
c-Cbl-mediated ubiquitination of IRF3 negatively regulates IFN-? production and cellular antiviral response.
Casitas B-Lineage Lymphoma RING Domain Inhibitors Protect Mice against High-Fat Diet-Induced Obesity and Insulin Resistance.
CBL mutations drive PI3K/AKT signaling via increased interaction with LYN and PIK3R1.
CD30-induced up-regulation of the inhibitor of apoptosis genes cIAP1 and cIAP2 in anaplastic large cell lymphoma cells.
Characterization of ARF-BP1/HUWE1 Interactions with CTCF, MYC, ARF and p53 in MYC-Driven B Cell Neoplasms.
CIAP2 inhibits anigen receptor signaling by targeting Bcl10 for degredation.
cIAP2 is a ubiquitin protein ligase for BCL10 and is dysregulated in mucosa-associated lymphoid tissue lymphomas.
cIAP2 is highly expressed in Hodgkin-Reed-Sternberg cells and inhibits apoptosis by interfering with constitutively active caspase-3.
Complex Effects of Putative DRP-1 Inhibitors on Stress Responses in Mouse Heart and Rat Cardiomyoblasts.
Correction for Pedersen et al., Regulation of CARD11 Signaling and Lymphoma Cell Survival by the E3 Ubiquitin Ligase RNF181.
Decreased protein levels of the c-Cbl protooncogene in murine AIDS.
Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL.
DNA-PKcs: a T-cell tumour suppressor encoded at the mouse scid locus.
Drug Resistance to Inhibitors of the Human Double Minute-2 E3 Ligase is Mediated by Point Mutations of p53, but can be Overcome with the p53 Targeting Agent RITA.
Dynamic trafficking and turnover of JAM-C is essential for endothelial cell migration.
E3 Ubiquitin Ligase c-cbl Inhibits Microglia Activation After Chronic Constriction Injury.
E3 ubiquitin ligase Cbl-b negatively regulates C-type lectin receptor-mediated antifungal innate immunity.
E3 ubiquitin ligase Cbl-b suppresses human ORMDL3 expression through STAT6 mediation.
Exosomes from Dendritic Cells Loaded with Chaperone-Rich Cell Lysates Elicit a Potent T Cell Immune Response Against Intracranial Glioma in Mice.
Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas.
Identification of a synergistic combination of Smac mimetic and Bortezomib to trigger cell death in B-cell non-Hodgkin lymphoma cells.
Increased expression of the Cbl family of E3 ubiquitin ligases decreases Interleukin-2 production in a rat model of peripheral neuropathy.
Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC).
Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage--independent p53 phosphorylation in mantle cell lymphoma.
Multipoint methylation analysis indicates a distinctive epigenetic phenotype among testicular germ cell tumors and testicular malignant lymphomas.
NADPH Oxidase 1 Activity and ROS Generation Are Regulated by Grb2/Cbl-Mediated Proteasomal Degradation of NoxO1 in Colon Cancer Cells.
Negative Regulation of CARD11 Signaling and Lymphoma Cell Survival by the E3 Ubiquitin Ligase RNF181.
Negative regulation of CD40-mediated B cell responses by E3 ubiquitin ligase Casitas-B-lineage lymphoma protein-B.
Normal lymphocyte development and thymic lymphoma formation in Brca1 exon-11-deficient mice.
Novel Germline Mutation of BRCA1 Gene in a 56-Year-Old Woman with Breast Cancer, Ovarian Cancer, and Diffuse Large B-Cell Lymphoma.
PKC-theta modulates the strength of T cell responses by targeting Cbl-b for ubiquitination and degradation.
Pomalidomide restores immune recognition of primary effusion lymphoma through upregulation of ICAM-1 and B7-2.
Proteosomal degradation of NSD2 by BRCA1 promotes leukemia cell differentiation.
Regulation of peripheral T cell tolerance by the E3 ubiquitin ligase Cbl-b.
Regulator of epidermal growth factor signaling: Sprouty.
Rsf?1 regulates malignant melanoma cell viability and chemoresistance via NF??B/Bcl?2 signaling.
Silencing Autocrine Death: A Ubiquitin Ligase that Blocks Activation-Induced Cell Death in Cutaneous T-Cell Lymphoma.
Single Nucleotide Polymorphisms in CBLB, a Regulator of T-Cell Response, Predict Radiation Pneumonitis and Outcomes After Definitive Radiotherapy for Non-Small-Cell Lung Cancer.
Sp-CBL inhibits white spot syndrome virus replication by enhancing apoptosis in mud crab (Scylla paramamosain).
Suppressed Expression of Cbl-b by NF-?B Mediates Icotinib Resistance in EGFR-mutant Non-Small-Cell Lung Cancer.
T cell activation threshold regulated by E3 ubiquitin ligase Cbl-b determines fate of inducible regulatory T cells.
Targeting protein neddylation with an NEDD8-activating enzyme inhibitor MLN4924 induced apoptosis or senescence in human lymphoma cells.
Targeting the E3 ubiquitin casitas B-lineage lymphoma decreases osteosarcoma cell growth and survival and reduces tumorigenesis.
Temozolomide sensitizes stem-like cells of glioma spheres to TRAIL-induced apoptosis via upregulation of casitas B-lineage lymphoma (c-Cbl) protein.
The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers.
The Casitas B lineage lymphoma (Cbl) mutant G306E enhances osteogenic differentiation in human mesenchymal stromal cells in part by decreased Cbl-mediated platelet-derived growth factor receptor alpha and fibroblast growth factor receptor 2 ubiquitination.
The Cbl protooncogene product: from an enigmatic oncogene to center stage of signal transduction.
The Clinical Value and Interpretation of Anti-Müllerian Hormone in Women With Cancer.
The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma.
The Novel Anticancer Agent JNJ-26854165 Induces Cell Death through Inhibition of Cholesterol Transport and Degradation of ABCA1.
The role of aberrant proteolysis in lymphomagenesis.
TRIB3 promotes MYC-associated lymphoma development through suppression of UBE3B-mediated MYC degradation.
Triggering Fbw7-mediated proteasomal degradation of c-Myc by oridonin induces cell growth inhibition and apoptosis.
Ubiquitin ligase Cbl-b and obesity-induced insulin resistance [Review].
ZNRF1 Mediates Epidermal Growth Factor Receptor Ubiquitination to Control Receptor Lysosomal Trafficking and Degradation.
[Expression of c-Cbl, Cbl-b, and epidermal growth factor receptor in gastric carcinoma and their clinical significance]
Lymphoma, B-Cell
Ataxia telangiectasia mutated interacts with Parkin and induces mitophagy independent of kinase activity. Evidence from mantle cell lymphoma.
Decreased protein levels of the c-Cbl protooncogene in murine AIDS.
E3 Ubiquitin Ligase c-cbl Inhibits Microglia Activation After Chronic Constriction Injury.
Essential role of E3 ubiquitin ligase activity in Cbl-b-regulated T cell functions.
Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas.
From Inhibition to Degradation: Targeting the Antiapoptotic Protein Myeloid Cell Leukemia 1 (MCL1).
KLHL6 is a tumor suppressor gene in diffuse large B-cell lymphoma.
Marginal zone lymphoma-derived interfollicular diffuse large B-cell lymphoma harboring 20q12 chromosomal deletion and missense mutation of BIRC3 gene: a case report.
Novel Germline Mutation of BRCA1 Gene in a 56-Year-Old Woman with Breast Cancer, Ovarian Cancer, and Diffuse Large B-Cell Lymphoma.
Pathogenicity and virulence of Japanese encephalitis virus: Neuroinflammation and neuronal cell damage.
Proteasome inhibitors and Smac mimetics cooperate to induce cell death in Diffuse Large B-cell Lymphoma by stabilizing NOXA and triggering mitochondrial apoptosis.
Smurf2 suppresses B-cell proliferation and lymphomagenesis by mediating ubiquitination and degradation of YY1.
Lymphoma, B-Cell, Marginal Zone
Auto-ubiquitination-induced degradation of MALT1-API2 prevents BCL10 destabilization in t(11;18)(q21;q21)-positive MALT lymphoma.
CIAP2 inhibits anigen receptor signaling by targeting Bcl10 for degredation.
cIAP2 is a ubiquitin protein ligase for BCL10 and is dysregulated in mucosa-associated lymphoid tissue lymphomas.
Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas.
Lymphoma, Follicular
Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas.
Lymphoma, Large B-Cell, Diffuse
Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas.
Marginal zone lymphoma-derived interfollicular diffuse large B-cell lymphoma harboring 20q12 chromosomal deletion and missense mutation of BIRC3 gene: a case report.
Novel Germline Mutation of BRCA1 Gene in a 56-Year-Old Woman with Breast Cancer, Ovarian Cancer, and Diffuse Large B-Cell Lymphoma.
Proteasome inhibitors and Smac mimetics cooperate to induce cell death in Diffuse Large B-cell Lymphoma by stabilizing NOXA and triggering mitochondrial apoptosis.
Lymphoma, Large-Cell, Anaplastic
CD30-induced up-regulation of the inhibitor of apoptosis genes cIAP1 and cIAP2 in anaplastic large cell lymphoma cells.
cIAP2 is highly expressed in Hodgkin-Reed-Sternberg cells and inhibits apoptosis by interfering with constitutively active caspase-3.
Lymphoma, Mantle-Cell
Ataxia telangiectasia mutated interacts with Parkin and induces mitophagy independent of kinase activity. Evidence from mantle cell lymphoma.
Drug Resistance to Inhibitors of the Human Double Minute-2 E3 Ligase is Mediated by Point Mutations of p53, but can be Overcome with the p53 Targeting Agent RITA.
Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage--independent p53 phosphorylation in mantle cell lymphoma.
The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma.
The Novel Anticancer Agent JNJ-26854165 Induces Cell Death through Inhibition of Cholesterol Transport and Degradation of ABCA1.
Lymphoma, Non-Hodgkin
Cancer Incidence in First- and Second-Degree Relatives of BRCA1 and BRCA2 Mutation Carriers.
Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas.
Pharmacologic inhibition of the ubiquitin-activating enzyme induces ER stress and apoptosis in chronic lymphocytic leukemia and ibrutinib-resistant mantle cell lymphoma cells.
Lymphoma, Primary Effusion
Pomalidomide restores immune recognition of primary effusion lymphoma through upregulation of ICAM-1 and B7-2.
Lymphoma, T-Cell, Cutaneous
A rearrangement of the c-cbl proto-oncogene in HUT78 T-lymphoma cells results in a truncated protein.
c-CBL E3 Ubiquitin Ligase Expression Increases Across the Spectrum of Benign and Malignant T-Cell Skin Diseases.
c-CBL E3 ubiquitin ligase is overexpressed in cutaneous T-cell lymphoma: its inhibition promotes activation-induced cell death.
Lymphoproliferative Disorders
Unique BIR domain sets determine inhibitor of apoptosis protein-driven cell death and NOD2 complex signal specificity.
Lynch Syndrome II
Hereditary Factors in Gynecologic Cancer.
Machado-Joseph Disease
Ataxin-3 deubiquitination is coupled to Parkin ubiquitination via E2 ubiquitin-conjugating enzyme.
Diverse mechanisms of autophagy dysregulation and their therapeutic implications: does the shoe fit?
Malaria
Inhibitors of ubiquitin E3 ligase as potential new antimalarial drug leads.
Overexpression of the HECT ubiquitin ligase PfUT prolongs the intraerythrocytic cycle and reduces invasion efficiency of Plasmodium falciparum.
Malocclusion
[Evaluation of stomatognathic system in BRCA1 gene mutation carriers before and after prophylactic adnexectomy--part I: evaluation of stomatognathic system in youth BRCA1 gene mutation carriers]
Mastitis
BRCA1: a new candidate gene for bovine mastitis and its association analysis between single nucleotide polymorphisms and milk somatic cell score.
Identification of Gene Modules and Hub Genes Involved in Mastitis Development Using a Systems Biology Approach.
Investigation on BRCA1 SNPs and its effects on mastitis in Chinese commercial cattle.
Polymorphism in DNA repair gene BRCA1 associated with clinical mastitis and production traits in indigenous dairy cattle.
Mastocytosis
E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and a myeloproliferative disease.
Measles
Inhibition of ubiquitination and stabilization of human ubiquitin E3 ligase PIRH2 by measles virus phosphoprotein.
Measles virus: evidence for association with lung cancer.
Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfected patients.
Showing your ID: intrinsic disorder as an ID for recognition, regulation and cell signaling.
Viral strategies for triggering and manipulating mitophagy.
Medulloblastoma
Histone deacetylase and Cullin3-REN(KCTD11) ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation.
RNF220 is required for cerebellum development and regulates medulloblastoma progression through epigenetic modulation of Shh signaling.
Silencing of E3 ubiquitin ligase RNF8 enhances ionizing radiation sensitivity of 5 medulloblastoma cells by promoting the deubiquitination of PCNA.
Variation in the BRCA2 gene in a child with medulloblastoma and a family history of breast cancer.
Melanoma
"I Am Uncertain About What My Uncertainty Even Is": Men's Uncertainty and Information Management of Their BRCA-Related Cancer Risks.
A cryptic BAP1 splice mutation in a family with uveal and cutaneous melanoma, and paraganglioma.
A novel germline BRCA1 mutation identified in a family with hereditary breast and ovarian cancer syndrome.
A novel sensitive method to detect frameshift mutations in exonic repeat sequences of cancer-related genes.
A population-based analysis of germline BAP1 mutations in melanoma.
Absence of founder BRCA1 and BRCA2 mutations in coetaneous malignant melanoma patients of Ashkenazi origin.
ANXA10 promotes melanoma metastasis by suppressing E3 ligase TRIM41-directed PKD1 degradation.
BAP1 promotes viability and migration of ECA109 cells through KLF5/CyclinD1/FGF-BP1.
BAP1 tumor predisposition syndrome case report: pathological and clinical aspects of BAP1-inactivated melanocytic tumors (BIMTs), including dermoscopy and confocal microscopy.
Bovine Delta Papillomavirus E5 Oncoprotein Interacts With TRIM25 and Hampers Antiviral Innate Immune Response Mediated by RIG-I-Like Receptors.
BRCA1 gene mutation in thymic malignant melanoma.
BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma.
c-CBL regulates melanoma proliferation, migration, invasion and the FAK-SRC-GRB2 nexus.
Cancer risks in women with 2 breast or ovarian cancers: clues to genetic cancer susceptibility.
Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian.
Caspases and inhibitor of apoptosis proteins in cutaneous and mucosal melanoma: expression profile and clinicopathologic significance.
Comprehensive molecular profiling of UV-induced metastatic melanoma in Nme1/Nme2-deficient mice reveals novel markers of survival in human patients.
CSN6 promotes melanoma proliferation and metastasis by controlling the UBR5-mediated ubiquitination and degradation of CDK9.
CtBP1 Is Expressed in Melanoma and Represses the Transcription of p16INK4a and Brca1.
Cystatin B inhibition of TRAIL-induced apoptosis is associated with the protection of FLIP(L) from degradation by the E3 ligase itch in human melanoma cells.
DEAF1 Is a Pellino1-interacting Protein Required for Interferon Production by Sendai Virus and Double-stranded RNA.
Deficiency of parkin suppresses melanoma tumor development and metastasis through inhibition of MFN2 ubiquitination.
Differential expression of lncRNAs and predicted target genes in normal mouse melanocytes and B16 cells.
Digital Image Analysis of BAP-1 Accurately Predicts Uveal Melanoma Metastasis.
Downregulation of BRCA1 in A375 melanoma cell line increases radio-sensitivity and modifies metastatic and angiogenic gene expression.
E2F1-dependent oncogenic addiction of melanoma cells to MDM2.
E3 ubiquitin ligase HECTD2 mediates melanoma progression and immune evasion.
E3 ubiquitin ligase PARK2, an inhibitor of melanoma cell growth, is repressed by the oncogenic ERK1/2-ELK1 transcriptional axis.
Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma.
Emerging views of mitophagy in immunity and autoimmune diseases.
Engaging Men With BRCA-Related Cancer Risks: Practical Advice for BRCA Risk Management From Male Stakeholders.
Epigallocatechin-3-gallate(EGCG) suppresses melanoma cell growth and metastasis by targeting TRAF6 activity.
Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma.
Expression levels of FBXW7 and MDM2 E3 ubiquitin ligases and their c-Myc and p53 substrates in patients with dysplastic nevi or melanoma.
Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden.
Frequent genomic rearrangements of BRCA1 associated protein-1 (BAP1) gene in Japanese malignant mesothelioma-characterization of deletions at exon level.
Functional Link between BRCA1 and BAP1 through Histone H2A, Heterochromatin and DNA Damage Response.
Genetic profiling of a rare condition: co-occurrence of albinism and multiple primary melanoma in a Caucasian family.
Genetic testing and prevention of hereditary cancer at the MMCI--over 10 years of experience.
Genome-wide screening identifies novel genes and biological processes implicated in cisplatin resistance.
Genomic characterisation of acral melanoma cell lines.
Genomic profiling of the genes on chromosome 3p in sporadic clear cell renal cell carcinoma.
Germline gene polymorphisms predisposing domestic mammals to carcinogenesis.
Germline mutations predisposing to melanoma.
Hereditary common cancers: molecular and clinical genetics.
Hormone therapy after prophylactic risk-reducing bilateral salpingo-oophorectomy in women who have BRCA gene mutation.
Identification of a Novel BRCA1 Alteration in Recurrent Melanocytoma Resulting in Increased Proliferation.
Inherited predisposition to cancer: a historical overview.
Intrahepatic cholangiocarcinoma development in a patient with a novel BAP1 germline mutation and low exposure to asbestos.
MAGE-D1 regulates expression of depression-like behavior through serotonin transporter ubiquitylation.
Mahogunin Ring Finger 1 Is Required for Genomic Stability and Modulates the Malignant Phenotype of Melanoma Cells.
Management of breast cancer risk in BRCA1/2 mutation carriers who are unaffected with cancer.
Mapping of a novel ocular and cutaneous malignant melanoma susceptibility locus to chromosome 9q21.32.
Melanoma cells express elevated levels of phosphorylated histone H2AX foci.
Melanoma predisposition-A limited role for germline BRCA1 and BRCA2 variants.
NEDD4 Negatively Regulates GITR via Ubiquitination in Immune Microenvironment of Melanoma.
PARKIN Inactivation Links Parkinson's Disease to Melanoma.
Parkin Somatic Mutations Link Melanoma and Parkinson's Disease.
Prevalence and Preliminary Validation of Screening Criteria to Identify Carriers of Germline BAP1 Mutations.
Refinement of the endogenous epitope tagging technology allows the identification of a novel NRAS binding partner in melanoma.
Regulation by survivin of cancer cell death induced by F14512, a polyamine-containing inhibitor of DNA topoisomerase II.
Regulation of BRCA1 by protein degradation.
Regulation of MDA5-MAVS Antiviral Signaling Axis by TRIM25 through TRAF6-mediated NF-?B Activation.
Regulation of SOX10 stability via ubiquitination-mediated degradation by Fbxw7? modulates melanoma cell migration.
Regulators of global genome repair do not respond to DNA damaging therapy but correlate with survival in melanoma.
Riok3 inhibits the antiviral immune response by facilitating TRIM40-mediated RIG-I and MDA5 degradation.
Skin Cancer Risk in BRCA1/2 Mutation Carriers.
The association between Parkinson's disease and melanoma.
The E3 ligase APC/C(Cdh1) promotes ubiquitylation-mediated proteolysis of PAX3 to suppress melanocyte proliferation and melanoma growth.
The FBXO4 tumor suppressor functions as a barrier to BrafV600E-dependent metastatic melanoma.
The MGRN1 E3 ubiquitin-ligase inhibits signaling from melanocortin receptors by competition with Galphas.
The Novel SMAC Mimetic Birinapant Exhibits Potent Activity against Human Melanoma Cells.
The Roles of Cullin-2 E3 Ubiquitin Ligase Complex in Cancer.
The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer.
The Zinc-finger AN1-type Domain 2a Gene Acts as a Regulator of Cell Survival in Human Melanoma: Role of E3-Ligase cIAP2.
TRIM25 in the Regulation of the Antiviral Innate Immunity.
Ubiquitination of P53 by E3 ligase MKRN2 promotes melanoma cell proliferation.
Memory Disorders
Behavioral phenotyping of Parkin-deficient mice: looking for early preclinical features of Parkinson's disease.
DNA repair factor BRCA1 depletion occurs in Alzheimer brains and impairs cognitive function in mice.
Meningioma
A cryptic BAP1 splice mutation in a family with uveal and cutaneous melanoma, and paraganglioma.
A population-based analysis of germline BAP1 mutations in melanoma.
Analysis of the BRCA1 and BRCA2 genes in sporadic meningiomas.
Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO.
Hypermethylation of BRCA1 Gene in Meningioma in Elderly Males.
Lack of genetic and epigenetic changes in meningiomas without NF2 loss.
Loss-of-Function Mutations in TRAF7 and KLF4 Cooperatively Activate RAS-Like GTPase Signaling and Promote Meningioma Development.
No evidence for germline PTEN mutations in families with breast and brain tumours.
Meningomyelocele
The Impact of BRCA1 on Spina Bifida Meningomyelocele Lesions.
Menopause, Premature
Age of natural menopause onset in BRCA1/2 carriers - systematic review and meta-analysis.
Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation.
Premature menopause in patients with BRCA1 gene mutation.
Mental Retardation, X-Linked
Rescue of the genetically engineered Cul4b mutant mouse as a potential model for human X-linked mental retardation.
Targeted deep resequencing identifies MID2 mutation for X-linked intellectual disability with varied disease severity in a large kindred from India.
MERRF Syndrome
Parkin-mediated mitophagy and autophagy flux disruption in cellular models of MERRF syndrome.
Mesothelioma
A cryptic BAP1 splice mutation in a family with uveal and cutaneous melanoma, and paraganglioma.
A population-based analysis of germline BAP1 mutations in melanoma.
BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas.
BRCA1 is an essential mediator of vinorelbine induced apoptosis in mesothelioma.
Evaluation of gene expression levels in the diagnosis of lung adenocarcinoma and malignant pleural mesothelioma.
Germline BAP1 mutations predispose to malignant mesothelioma.
Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53.
Intrahepatic cholangiocarcinoma development in a patient with a novel BAP1 germline mutation and low exposure to asbestos.
Malignant Mesothelioma: Time to Translate?
Prevalence and Preliminary Validation of Screening Criteria to Identify Carriers of Germline BAP1 Mutations.
Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis.
Retrospective response analysis of BAP1 expression to predict the clinical activity of systemic cytotoxic chemotherapy in mesothelioma.
Mesothelioma, Malignant
BAP1 tumor predisposition syndrome case report: pathological and clinical aspects of BAP1-inactivated melanocytic tumors (BIMTs), including dermoscopy and confocal microscopy.
Evaluation of gene expression levels in the diagnosis of lung adenocarcinoma and malignant pleural mesothelioma.
Functional Link between BRCA1 and BAP1 through Histone H2A, Heterochromatin and DNA Damage Response.
Genomic profiling of the genes on chromosome 3p in sporadic clear cell renal cell carcinoma.
High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma.
Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53.
Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis.
Metabolic Diseases
MG53 is a double-edged sword for human diseases.
MG53: Biological Function and Potential as a Therapeutic Target.
RNF186 impairs insulin sensitivity by inducing ER stress in mouse primary hepatocytes.
The E3 ubiquitin ligase TRIM25 regulates adipocyte differentiation via proteasome-mediated degradation of PPAR?.
Metabolic Syndrome
BRCA1 and acetyl-CoA carboxylase: the metabolic syndrome of breast cancer.
Glucose-Sensitive Myokine/Cardiokine MG53 Regulates Systemic Insulin Response and Metabolic Homeostasis.
Loss of the E3 ubiquitin ligase MKRN1 represses diet-induced metabolic syndrome through AMPK activation.
SCFJFK is functionally linked to obesity and metabolic syndrome.
Metrorrhagia
Creating highly dense and uniform protein and DNA microarrays through photolithography and plasma modification of glass substrates.
Microcephaly
Coregulation of FANCA and BRCA1 in human cells.
Homozygous loss of function BRCA1 variant causing a Fanconi-anemia-like phenotype, a clinical report and review of previous patients.
Identification of microcephalin, a protein implicated in determining the size of the human brain.
Microcephalin regulates BRCA2 and Rad51-associated DNA double-strand break repair.
Systematic detection of brain protein-coding genes under positive selection during primate evolution and their roles in cognition.
Mitochondrial Diseases
AMPK activation of muscle autophagy prevents fasting-induced hypoglycemia and myopathy during aging.
Parkin overexpression selects against a deleterious mtDNA mutation in heteroplasmic cybrid cells.
Peripheral neuropathy in Parkinson's disease.
Motor Neuron Disease
[Revisit to Kii ALS--the innovated concept of ALS-Parkinsonism-dementia complex, clinicopathological features, epidemiology and etiology]
Mouth Neoplasms
Cytoplasmic HuR expression correlates with cIAP2 expression and clinicopathologic factors in oral squamous cell carcinoma cells.
E3 ubiquitin ligase, RNF139, inhibits the progression of tongue cancer.
E3 Ubiquitin Ligases as Molecular Targets in Human Oral Cancers.
Secretory clusterin promotes oral cancer cell survival via inhibiting apoptosis by activation of autophagy in AMPK/mTOR/ULK1 dependent pathway.
The E3 ubiquitin ligase SIAH2 is a prosurvival factor overexpressed in oral cancer.
Movement Disorders
Analysis of PARK genes in a Korean cohort of early-onset Parkinson disease.
Distribution and immunohistochemical characterization of torsinA immunoreactivity in rat brain.
Genetic Variations and Neuropathologic Features of Patients with PRKN Mutations.
Genotype-Phenotype Relations for the Atypical Parkinsonism Genes: MDSGene Systematic Review.
Molecular analysis of the parkin gene in South African patients diagnosed with Parkinson's disease.
Nigrostriatal dysfunction in homozygous and heterozygous parkin gene carriers: An (18)F-dopa PET progression study.
Novel monoclonal antibodies demonstrate biochemical variation of brain parkin with age.
parkin mutation analysis in clinic patients with early-onset Parkinson's disease.
Parkin mutation dosage and the phenomenon of anticipation: a molecular genetic study of familial parkinsonism.
Restless legs syndrome, rapid eye movement sleep behavior disorder, and hypersomnia in patients with two parkin mutations.
Structural studies of parkin and sacsin: Mitochondrial dynamics in neurodegenerative diseases.
Moyamoya Disease
Moyamoya disease factor RNF213 is a giant E3 ligase with a dynein-like core and a distinct ubiquitin-transfer mechanism.
PTP1B controls non-mitochondrial oxygen consumption by regulating RNF213 to promote tumour survival during hypoxia.
Mucocele
Risk-reducing appendectomy and the elimination of BRCA1-associated intraperitoneal cancer.
Mucositis
Genetic polymorphisms associated with outcome in multiple myeloma patients receiving high-dose melphalan.
Mulibrey Nanism
TRIM37 defective in mulibrey nanism is a novel RING finger ubiquitin E3 ligase.
TRIM37 prevents formation of centriolar protein assemblies by regulating Centrobin.
Multiple Endocrine Neoplasia
Germline BRCA1 Mutation Detected in a Multiple Endocrine Neoplasia Type 2 Case With RET Codon 634 Mutation.
Germline mutations in MEN1 and BRCA1 genes in a woman with familial multiple endocrine neoplasia type 1 and inherited breast-ovarian cancer syndromes: a case report.
Multiple Endocrine Neoplasia Type 1
Germline mutations in MEN1 and BRCA1 genes in a woman with familial multiple endocrine neoplasia type 1 and inherited breast-ovarian cancer syndromes: a case report.
Multiple Endocrine Neoplasia Type 2a
Germline BRCA1 Mutation Detected in a Multiple Endocrine Neoplasia Type 2 Case With RET Codon 634 Mutation.
Multiple Myeloma
1,4-Naphthoquinones as inhibitors of Itch, a HECT domain-E3 ligase, and tumor growth suppressors in multiple myeloma.
Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker.
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs.
Differential effect of MMSET mRNA levels on survival to first-line FOLFOX and second-line docetaxel in gastric cancer.
Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma.
Down-regulation of RFWD3 inhibits cancer cells proliferation and migration in gastric carcinoma.
Drug Resistance to Inhibitors of the Human Double Minute-2 E3 Ligase is Mediated by Point Mutations of p53, but can be Overcome with the p53 Targeting Agent RITA.
Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survival.
Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of CrbnI391V.
Homo-PROTACs for the Chemical Knockdown of Cereblon.
IAP antagonists induce anti-tumor immunity in multiple myeloma.
Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN.
IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM).
IKZF1/3 and CRL4-CRBN E3 ubiquitin ligase mutations and IMiD resistance in multiple myeloma.
Increased resistance to proteasome inhibitors in multiple myeloma mediated by cIAP2 - implications for a combinatorial treatment.
Inhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737.
Novel immunomodulatory drugs and neo-substrates.
Pharmacologic inhibition of the ubiquitin-activating enzyme induces ER stress and apoptosis in chronic lymphocytic leukemia and ibrutinib-resistant mantle cell lymphoma cells.
Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs.
Targeted degradation of the enhancer lysine acetyltransferases CBP and p300.
Targeting oncoproteins with a positive selection assay for protein degraders.
The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma.
The NEDD4-1 E3 ubiquitin ligase: A potential molecular target for bortezomib sensitivity in multiple myeloma.
The Novel Anticancer Agent JNJ-26854165 Induces Cell Death through Inhibition of Cholesterol Transport and Degradation of ABCA1.
[Expression down-regulation of c-Cbl and Cbl-b genes in peripheral blood mononuclear cells from multiple myeloma patients].
Multiple Sclerosis
A gene expression study denies the ability of 25 candidate biomarkers to predict the interferon-beta treatment response in multiple sclerosis patients.
Ancient and recent adaptive evolution in the antiviral TRIM22 gene: identification of a single-nucleotide polymorphism that impacts TRIM22 function.
Co-occurrence of multiple sclerosis and cancer in a BRCA1 positive family.
Evaluation of the Diagnostic and Predictive Value of Serum Levels of ANT1, ATG5, and Parkin in Multiple Sclerosis.
Hectd3 promotes pathogenic Th17 lineage through Stat3 activation and Malt1 signaling in neuroinflammation.
In silico analysis of functional single nucleotide polymorphisms in the human TRIM22 gene.
Involvement and interplay of Parkin, PINK1, and DJ1 in neurodegenerative and neuroinflammatory disorders.
Parkinson's disease-associated parkin colocalizes with Alzheimer's disease and multiple sclerosis brain lesions.
Potential of PINK1 and PARKIN Proteins as Biomarkers for Active Multiple Sclerosis: A Japanese Cohort Study.
The etiology of multiple sclerosis: genetic evidence for the involvement of the human endogenous retrovirus HERV-Fc1.
Multiple System Atrophy
Altered ?-synuclein, parkin, and synphilin isoform levels in multiple system atrophy brains.
LRRK2 and parkin immunoreactivity in multiple system atrophy inclusions.
Mutational analysis of parkin and PINK1 in multiple system atrophy.
Pael-R is accumulated in Lewy bodies of Parkinson's disease.
Quantitative analysis of nasal transcripts reveals potential biomarkers for Parkinson's disease.
Murine Acquired Immunodeficiency Syndrome
Decreased protein levels of the c-Cbl protooncogene in murine AIDS.
Muscle Hypotonia
De novo variants in SIAH1, encoding an E3 ubiquitin ligase, are associated with developmental delay, hypotonia and dysmorphic features.
Muscle Rigidity
Detection of compound heterozygous deletions in the parkin gene of fibroblasts in patients with autosomal recessive hereditary parkinsonism (PARK2).
Muscle Spasticity
Structural studies of parkin and sacsin: Mitochondrial dynamics in neurodegenerative diseases.
Muscle Weakness
Induced in vivo knockdown of the Brca1 gene in skeletal muscle results in skeletal muscle weakness.
Polyglucosan body myopathy caused by defective ubiquitin ligase RBCK1.
Muscular Atrophy
A Discovery of a Genetic Mutation Causing Reduction of Atrogin-1 Expression in Broiler Chicken Muscle.
A subset of microRNAs in the Dlk1-Dio3 cluster regulates age-associated muscle atrophy by targeting Atrogin-1.
Angiotensin II Induces Skeletal Muscle Atrophy by Activating TFEB-Mediated MuRF1 Expression.
Aspirin alleviates denervation-induced muscle atrophy via regulating the Sirt1/PGC-1? axis and STAT3 signaling.
Characterisation and differential regulation of MAFbx/Atrogin-1 alpha and beta transcripts in skeletal muscle of Atlantic salmon (Salmo salar).
CHIP deletion reveals functional redundancy of E3 ligases in promoting degradation of both signaling proteins and expanded glutamine proteins.
Continuous administration of poloxamer 188 reduces overload-induced muscular atrophy in dysferlin-deficient SJL mice.
Dexamethasone exacerbates cisplatin-induced muscle atrophy.
Dkk3 dependent transcriptional regulation controls age related skeletal muscle atrophy.
Effect of dexamethasone on the expression of atrogin-1/MAFbx in chick skeletal muscle.
Effects of Insulin-Like Growth Factor-I on the Expression of Atrogin-1/MAFbx in Chick Myotube Cultures.
Endogenous muscle atrophy F-box is involved in the development of cardiac rupture after myocardial infarction.
Endogenous muscle atrophy F-box mediates pressure overload-induced cardiac hypertrophy through regulation of nuclear factor-kappaB.
Exercise training has beneficial anti-atrophy effects by inhibiting oxidative stress-induced MuRF1 upregulation in rats with diabetes.
FBXO32 Targets c-Myc for Proteasomal Degradation and Inhibits c-Myc Activity.
HDAC4 Knockdown Alleviates Denervation-Induced Muscle Atrophy by Inhibiting Myogenin-Dependent Atrogene Activation.
Histone deacetylase inhibition suppresses myogenin-dependent atrogene activation in spinal muscular atrophy mice.
IKKbeta/NF-kappaB activation causes severe muscle wasting in mice.
Inhibition of Atrogin-1/MAFbx Expression by Adenovirus-Delivered Small Hairpin RNAs Attenuates Muscle Atrophy in Fasting Mice.
Insulin and amino acid availability regulate atrogin-1 in avian QT6 cells.
Intermittent reloading attenuates muscle atrophy through modulating Akt/mTOR pathway.
Iron-induced skeletal muscle atrophy involves an Akt-forkhead box O3-E3 ubiquitin ligase-dependent pathway.
Leucine attenuates skeletal muscle wasting via inhibition of ubiquitin ligases.
Loss of Parkin Impairs Mitochondrial Function and Leads to Muscle Atrophy.
Maintenance of muscle mass and load-induced growth in Muscle RING Finger 1 null mice with age.
MFB-1, an F-box-type ubiquitin ligase, regulates TGF-beta signalling.
MicroRNA351 targeting TRAF6 alleviates dexamethasone-induced myotube atrophy.
Molecular characterization of atrogin-1/F-box protein-32 (FBXO32) and F-box protein-25 (FBXO25) in rainbow trout (Oncorhynchus mykiss): Expression across tissues in response to feed deprivation.
MURF contributes to skeletal muscle atrophy through suppressing autophagy.
MuRF1/TRIM63, Master Regulator of Muscle Mass.
Opposite roles of myocardin and atrogin-1 in L6 myoblast differentiation.
P38?-MAPK Signaling Inhibition Attenuates Soleus Atrophy during Early Stages of Muscle Unloading.
Parkin Overexpression Attenuates Sepsis-Induced Muscle Wasting.
Ret finger protein mediates Pax7-induced ubiquitination of MyoD in skeletal muscle atrophy.
Role of altered proteostasis network in chronic hypobaric hypoxia induced skeletal muscle atrophy.
Sirtuin 3 deficiency accelerates Angiotensin II-induced skeletal muscle atrophy.
Skeletal muscle in MuRF1 null mice is not spared in low-gravity conditions, indicating atrophy proceeds by unique mechanisms in space.
Targeting the Ubiquitin E3 Ligase MuRF1 to Inhibit Muscle Atrophy.
The E3 Ubiquitin Ligase TRAF6 Intercedes in Starvation-Induced Skeletal Muscle Atrophy through Multiple Mechanisms.
The E3 ubiquitin ligase TRIM62 and inflammation-induced skeletal muscle atrophy.
The initiation factor eIF3-f is a major target for atrogin1/MAFbx function in skeletal muscle atrophy.
The regulation of Akt and FoxO transcription factors during dehydration in the African clawed frog (Xenopus laevis).
UBR5 is a novel E3 ubiquitin ligase involved in skeletal muscle hypertrophy and recovery from atrophy.
Unexpected regulation pattern of the IKK?/NF-?B/MuRF1 pathway with remarkable muscle plasticity in the Daurian ground squirrel (Spermophilus dauricus).
Muscular Atrophy, Spinal
Genetic zebrafish models of neurodegenerative diseases.
Muscular Diseases
AMPK activation of muscle autophagy prevents fasting-induced hypoglycemia and myopathy during aging.
Deficiency of the E3 ubiquitin ligase TRIM32 in mice leads to a myopathy with a neurogenic component.
Impaired muscle morphology in a Drosophila model of myosin storage myopathy was supressed by overexpression of an E3 ubiquitin ligase.
Induced in vivo knockdown of the Brca1 gene in skeletal muscle results in skeletal muscle weakness.
Mitochondrial pathology in muscle of a patient with a novel parkin mutation.
Mutations outside the N-terminal part of RBCK1 may cause polyglucosan body myopathy with immunological dysfunction: expanding the genotype-phenotype spectrum.
Nonimmune mechanisms of muscle damage in myositis: role of the endoplasmic reticulum stress response and autophagy in the disease pathogenesis.
Polyglucosan body myopathy 1 may cause cognitive impairment: a case report from China.
Polyglucosan body myopathy caused by defective ubiquitin ligase RBCK1.
Proteomic characterisation of polyglucosan bodies in skeletal muscle in RBCK1 deficiency.
Update Review about Metabolic Myopathies.
Muscular Dystrophies
Analysis of the Zn-Binding Domains of TRIM32, the E3 Ubiquitin Ligase Mutated in Limb Girdle Muscular Dystrophy 2H.
Generation of the short TRIM32 isoform is regulated by Lys 247 acetylation and a PEST sequence.
Interaction with the Bardet-Biedl Gene Product TRIM32/BBS11 Modifies the Half-life and Localization of Glis2/NPHP7.
The E3 ubiquitin ligase TRIM32 regulates myoblast proliferation by controlling turnover of NDRG2.
TRIM32 Protein Sensitizes Cells to Tumor Necrosis Factor (TNF{alpha})-induced Apoptosis via Its RING Domain-dependent E3 Ligase Activity against X-linked Inhibitor of Apoptosis (XIAP).
Muscular Dystrophies, Limb-Girdle
Analysis of the Zn-Binding Domains of TRIM32, the E3 Ubiquitin Ligase Mutated in Limb Girdle Muscular Dystrophy 2H.
Satellite cell senescence underlies myopathy in a mouse model of limb-girdle muscular dystrophy 2H.
The E3 ubiquitin ligase TRIM32 regulates myoblast proliferation by controlling turnover of NDRG2.
Muscular Dystrophy, Duchenne
Detection of exon skipping events in BRCA1 RNA using MLPA kit P002.
Mycoses
CERBERUS and NSP1 of Lotus japonicus are Common Symbiosis Genes that Modulate Arbuscular Mycorrhiza Development.
Classification of barley U-box E3 ligases and their expression patterns in response to drought and pathogen stresses.
The KEEP ON GOING protein of Arabidopsis regulates intracellular protein trafficking and is degraded during fungal infection.
Myelodysplastic Syndromes
A high occurrence of acquisition and/or expansion of C-CBL mutant clones in the progression of high-risk myelodysplastic syndrome to acute myeloid leukemia.
Acquired uniparental disomy and c-CBL mutation in myelodysplastic syndromes.
Can synthetic lethality approach be used with DNA repair genes for primary and secondary MDS?
DNA repair gene expressions are related to bone marrow cellularity in myelodysplastic syndrome.
Myeloproliferative Disorders
Role of Ubiquitylation in Controlling Suppressor of Cytokine Signalling 3 (SOCS3) Function and Expression.
Myocardial Infarction
Apigenin attenuates myocardial infarction-induced cardiomyocyte injury by modulating Parkin-mediated mitochondrial autophagy.
BRCA1 is an essential regulator of heart function and survival following myocardial infarction.
Parkin protein deficiency exacerbates cardiac injury and reduces survival following myocardial infarction.
Parkin Regulates Mitochondrial Autophagy After Myocardial Infarction in Rats.
PINK1 Is Dispensable for Mitochondrial Recruitment of Parkin and Activation of Mitophagy in Cardiac Myocytes.
The role of Parkin protein in cardiac function and ventricular remodeling in myocardial infarction rats.
[Overexpression of PPENK reduces myocardial ischemia reperfusion injury by promoting mitophagy in rats].
Myocardial Ischemia
c-Cbl Inhibition Improves Cardiac function and Survival in Response to Myocardial Ischemia.
c-Cbl inhibition: A novel therapeutic approach for attenuating myocardial ischemia and reperfusion injury.
Natural compound methyl protodioscin protects rat brain from ischemia/reperfusion injury through regulation of Mul1/SOD2 pathway.
Myoclonic Epilepsies, Progressive
Diverse mechanisms of autophagy dysregulation and their therapeutic implications: does the shoe fit?
Genetic depletion of the malin E3 ubiquitin ligase in mice leads to lafora bodies and the accumulation of insoluble laforin.
Genetics of the epilepsies.
Protein Degradation and Quality Control in Cells from Laforin and Malin Knockout Mice.
Myoclonus
Clinical, neuropathological and genotypic variability in SNCA A53T familial Parkinson's disease. Variability in familial Parkinson's disease.
Myoma
[Explosive growth of uterine leiomyomas and carcinologic ovarian risk in a non-menopausal patient with BRCA1-BRCA2 mutation treated by tamoxifen]
Myositis
Parkin and its association with alpha-synuclein and AbetaPP in inclusion-body myositis and AbetaPP-overexpressing cultured human muscle fibers.
Parkin protects against mitochondrial toxins and beta-amyloid accumulation in skeletal muscle cells.
The ER-Bound RING Finger Protein 5 (RNF5/RMA1) Causes Degenerative Myopathy in Transgenic Mice and Is Deregulated in Inclusion Body Myositis.
Myositis, Inclusion Body
Parkin protects against mitochondrial toxins and beta-amyloid accumulation in skeletal muscle cells.
Myxoma
The poxviral scrapin MV-LAP requires a myxoma viral infection context to efficiently downregulate MHC-I molecules.
nad+ adp-ribosyltransferase deficiency
Poly(ADP-ribose) polymerase-1 plays a role in suppressing mammary tumourigenesis in mice.
Narcolepsy
Restless legs syndrome, rapid eye movement sleep behavior disorder, and hypersomnia in patients with two parkin mutations.
Nasal Polyps
Expression and distributional patterns of the inhibitor of apoptosis protein family and caspase 3 in nasal polyps.
Nasopharyngeal Carcinoma
EBV-encoded miRNAs can sensitize nasopharyngeal carcinoma to chemotherapeutic drugs by targeting BRCA1.
Expression of BRCA1 and ERCC1 as predictive clinical outcome after radiochemotherapy in patients with locoregionally moderate-advanced nasopharyngeal carcinoma.
Expression of DNA-PKcs and BRCA1 as prognostic indicators in nasopharyngeal carcinoma following intensity-modulated radiation therapy.
Inactivation of parkin by promoter methylation correlated with lymph node metastasis and genomic instability in nasopharyngeal carcinoma.
Prevalent somatic BRCA1 mutations shape clinically relevant genomic patterns of nasopharyngeal carcinoma in Southeast Europe.
Silencing UBE4B induces nasopharyngeal carcinoma apoptosis through the activation of caspase3 and p53.
Skp2-mediated ubiquitination and mitochondrial localization of Akt drive tumor growth and chemoresistance to cisplatin.
Nasopharyngeal Neoplasms
Parkin enhances sensitivity of paclitaxel to NPC by arresting cell cycle.
Neoplasm Metastasis
A Germline Mutation in the BRCA1 3’UTR Variant Predicts Susceptibility to Breast Cancer in a Saudi Arabian Population
A metastasis of an adenocarcinoma in a BRCA1 mutation carrier, a diagnostic problem not solved by morphology alone.
A novel role for the SUMO E3 ligase PIAS1 in cancer metastasis.
A Novel Signature of CCNF-Associated E3 Ligases Collaborate and Counter Each Other in Breast Cancer.
A novel Ubc9 -dependent pathway regulates SIRT1- ER-? Axis and BRCA1-associated TNBC lung metastasis.
A Provocative Molecular Link between Mammographic Density and BRCA1-loss associated TNBC.
An E3 ubiquitin ligase: c-Cbl: A New Therapeutic Target of Lung Cancer.
An Integrated Systems Biology Approach Identifies TRIM25 as a Key Determinant of Breast Cancer Metastasis.
An Integrative Omics Approach Reveals Involvement of BRCA1 in Hepatic Metastatic Progression of Colorectal Cancer.
An oncogenic viral interferon regulatory factor upregulates CUB domain-containing protein 1 to promote angiogenesis by hijacking transcription factor lymphoid enhancer-binding factor 1 and metastasis suppressor CD82.
Androgens regulate SMAD ubiquitination regulatory factor-1 expression and prostate cancer cell invasion.
ANXA10 promotes melanoma metastasis by suppressing E3 ligase TRIM41-directed PKD1 degradation.
Association between cytosolic expression of BRCA1 and metastatic risk in breast cancer.
Association of BRCA1 promoter methylation with sporadic breast cancers: Evidence from 40 studies.
Basal phenotype breast cancer: implications for treatment and prognosis.
BRCA1 and ERCC1 mRNA levels are associated with lymph node metastasis in Chinese patients with colorectal cancer.
BRCA1 and pancreatic cancer: pedigree findings and their causal relationships.
BRCA1 Deficiency Impairs Mitophagy and Promotes Inflammasome Activation and Mammary Tumor Metastasis.
BRCA1 expression levels predict distant metastasis of sporadic breast cancers.
BRCA1 mislocalization associated with breast carcinogenesis and poor prognosis in Taiwanese women.
BRCA1 suppresses epithelial-to-mesenchymal transition and stem cell dedifferentiation during mammary and tumor development.
Brcal Defective Breast Cancer Cells Induce in vitro Transformation of Cancer Associated Fibroblasts (CAFs) to Metastasis Associated Fibroblasts (MAF).
Breast cancer metastasis suppressor 1 (BRMS1) is destabilized by the Cul3-SPOP E3 ubiquitin ligase complex.
BRMS1 suppresses lung cancer metastases through an E3 ligase function on histone acetyltransferase p300.
C-terminus of Hsc70-interacting protein regulates profilin1 and breast cancer cell migration.
Case Report: Frontoparietal Metastasis From a Primary Fallopian Tube Carcinoma.
CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases.
CDC25A, VAV1, TP73, BRCA1 and ZAP70 gene overexpression correlates with radiation response in colorectal cancer.
Characterization of a novel breast carcinoma xenograft and cell line derived from a BRCA1 germ-line mutation carrier.
CHIP functions as a novel suppressor of tumour angiogenesis with prognostic significance in human gastric cancer.
CHIP regulates osteoclast formation through promoting TRAF6 protein degradation.
cIAP2 promotes gallbladder cancer invasion and lymphangiogenesis by activating the NF-?B pathway.
circNDUFB2 inhibits non-small cell lung cancer progression via destabilizing IGF2BPs and activating anti-tumor immunity.
Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein.
Clinical and experimental role of ring finger protein 180 on lymph node metastasis and survival in gastric cancer.
Clinical implications for BRCA gene mutation in breast cancer.
Clinical significance of epigenetic inactivation of hMLH1 and BRCA1 in Tunisian patients with invasive breast carcinoma.
Clonal lineage of high grade serous ovarian cancer in a patient with neurofibromatosis type 1.
Coexistent Loss of the Expressions of BRCA1 and p53 Predicts Poor Prognosis in Triple-Negative Breast Cancer.
Coexpression of the mutated BRCA1 mRNA and p53 mRNA and its association in Chinese prostate cancer.
Comparative genomic hybridization in inherited and sporadic ovarian tumors in Israel.
Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis.
Computational exploration of the activated pathways associated with DNA damage response in breast cancer.
Correlation between BRCA1 expression and apoptosis-related biological parameters in sporadic breast carcinomas.
Corrigendum: E3 Ubiquitin Ligase UBR5 Promotes the Metastasis of Pancreatic Cancer via Destabilizing F-Actin Capping Protein CAPZA1.
Crystal structure of HECT domain of UBE3C E3 ligase and its ubiquitination activity.
Cullin5 deficiency promotes small-cell lung cancer metastasis by stabilizing integrin ?1.
DCUN1D1 facilitates tumor metastasis by activating FAK signaling and up-regulates PD-L1 in non-small-cell lung cancer.
Deficiency of parkin suppresses melanoma tumor development and metastasis through inhibition of MFN2 ubiquitination.
Detection of aberrant promoter methylation of RNF180, DAPK1 and SFRP2 in plasma DNA of patients with gastric cancer.
Detection of novel germline mutations in six breast cancer predisposition genes by targeted next-generation sequencing.
Digital Image Analysis of BAP-1 Accurately Predicts Uveal Melanoma Metastasis.
Distinct Ring1b complexes defined by DEAD-box helicases and EMT transcription factors synergistically enhance E-cadherin silencing in breast cancer.
DNA damage response genes and the development of cancer metastasis.
Downregulation of BRCA1 in A375 melanoma cell line increases radio-sensitivity and modifies metastatic and angiogenic gene expression.
E3 ligase ZFP91 inhibits Hepatocellular Carcinoma Metabolism Reprogramming by regulating PKM splicing.
E3 Ubiquitin Ligase Cbl-b Prevents Tumor Metastasis by Maintaining the Epithelial Phenotype in Multiple Drug-Resistant Gastric and Breast Cancer Cells.
E3 ubiquitin ligase HECW1 promotes the metastasis of non-small cell lung cancer cells through mediating the ubiquitination of Smad4.
E3 Ubiquitin Ligase UBR5 Drives the Growth and Metastasis of Triple-Negative Breast Cancer.
E3 Ubiquitin Ligase UBR5 Promotes the Metastasis of Pancreatic Cancer via Destabilizing F-Actin Capping Protein CAPZA1.
ECD promotes gastric cancer metastasis by blocking E3 ligase ZFP91-mediated hnRNP F ubiquitination and degradation.
Effect of BRCA1 immunohistochemical localizations on prognosis of patients with sporadic breast carcinomas.
Elevated TRIM23 expression predicts poor prognosis in Chinese gastric cancer.
Epigenetic modification and a role for the E3 ligase RNF40 in cancer development and metastasis.
ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel.
Estrogen promotes estrogen receptor negative BRCA1-deficient tumor initiation and progression.
Exome profiling of primary, metastatic and recurrent ovarian carcinomas in a BRCA1-positive patient.
Exosomal TRIM3 is a novel marker and therapy target for gastric cancer.
Expression of BRCA1, HER-1 (EGFR) and HER-2 in sporadic breast cancer and relationships to other clinicopathological prognostic features.
Expression profile of BRCA1 and BRCA2 genes in premenopausal Mexican women with breast cancer: clinical and immunohistochemical correlates.
Extent of breast cancer type 1 promoter methylation correlates with clinicopathological features in breast cancers.
F-box protein 11 promotes the growth and metastasis of gastric cancer via PI3K/AKT pathway-mediated EMT.
FBXL5 attenuates RhoGDI2-induced cisplatin resistance in gastric cancer cells.
Formal modeling and analysis of ER-? associated Biological Regulatory Network in breast cancer.
GATA3 functions downstream of BRCA1 to suppress EMT in breast cancer.
GP78 Cooperates with Dual-Specificity Phosphatase 1 To Stimulate Epidermal Growth Factor Receptor-Mediated Extracellular Signal-Regulated Kinase Signaling.
H19 non coding RNA-derived miR-675 enhances tumorigenesis and metastasis of breast cancer cells by downregulating c-Cbl and Cbl-b.
Human FBXL8 Is a Novel E3 Ligase Which Promotes BRCA Metastasis by Stimulating Pro-Tumorigenic Cytokines and Inhibiting Tumor Suppressors.
Hybrid Capture-Based Tumor Sequencing and Copy Number Analysis to Confirm Origin of Metachronous Metastases in BRCA1-Mutant Cholangiocarcinoma Harboring a Novel YWHAZ-BRAF Fusion.
Hypermethylation of SHISA3 Promotes Nasopharyngeal Carcinoma Metastasis by Reducing SGSM1 Stability.
Hypoxia induces TWIST-activated epithelial-mesenchymal transition and proliferation of pancreatic cancer cells in vitro and in nude mice.
Hypoxia-induced factor-1 alpha, vascular endothelial growth factor expression in BRCA1-related breast cancer: A prospective study in tertiary care hospital.
Hypoxia-Induced WSB1 Promotes the Metastatic Potential of Osteosarcoma Cells.
Identification of a novel glycolysis-related gene signature for predicting metastasis and survival in patients with lung adenocarcinoma.
Identification of a preneoplastic gene expression profile in tubal epithelium of BRCA1 mutation carriers.
Identification of the SUMO E3 ligase PIAS1 as a potential survival biomarker in breast cancer.
Impact of Hyperhomocysteinemia on Breast Cancer Initiation and Progression: Epigenetic Perspective.
Implication of alterations in Parkin gene among North Indian patients with colorectal cancer.
Inactivation of parkin by promoter methylation correlated with lymph node metastasis and genomic instability in nasopharyngeal carcinoma.
Incidental Carcinomas in Prophylactic Specimens in BRCA1 and BRCA2 Germ-line Mutation Carriers, With Emphasis on Fallopian Tube Lesions: Report of 6 Cases and Review of the Literature.
Increased Expression of BRCA2 and RAD51 in Lymph Node Metastases of Canine Mammary Adenocarcinomas.
Increased incidence of brain metastases in BRCA1-related ovarian cancers.
Individual and Combined Expression of DNA Damage Response Molecules PARP1, ?H2AX, BRCA1, and BRCA2 Predict Shorter Survival of Soft Tissue Sarcoma Patients.
Integrative proteomics reveals the role of E3 ubiquitin ligase SYVN1 in hepatocellular carcinoma metastasis.
Invasion patterns of metastatic high-grade serous carcinoma of ovary or fallopian tube associated with BRCA deficiency.
Investigation of The Relationship of TNFRSF11A Gene Polymorphisms with Breast Cancer Development and Metastasis Risk in Patients with BRCA1 Or BRCA2 Pathogenic Variants Living in The Trakya Region of Turkey.
LncRNA DUXAP9-206 directly binds with Cbl-b to augment EGFR signaling and promotes non-small cell lung cancer progression.
Loss of c-Cbl expression correlates with de-differentiation status and lymphatic metastasis in gastric cancer.
Loss of endogenous RNF43 function enhances proliferation and tumour growth of intestinal and gastric cells.
Loss of heterozygosity in BRCA1 and BRCA2 markers and high-grade malignancy in breast cancer.
Loss of heterozygosity in P53, BRCA1, and estrogen receptor genes and correlation to expression of p53 protein in ovarian epithelial tumors of different cell types and biological behavior.
Loss of the novel tumour suppressor and polarity gene Trim62 (Dear1) synergizes with oncogenic Ras in invasive lung cancer.
Loss of ZBRK1 Contributes to the Increase of KAP1 and Promotes KAP1-Mediated Metastasis and Invasion in Cervical Cancer.
Mechanism of TRIM25 mediated ubiquitination of metastasis associated protein (MTA) 1 in normal liver cells.
Metastatic patterns of breast cancer subtypes: what radiologists should know in the era of personalized cancer medicine.
Methylation Analysis of BRCA1 and APC in Breast Cancer and It's Relationship to Clinicopathological Features.
Methylation of BRCA1 promoter region is associated with unfavorable prognosis in women with early-stage breast cancer.
MEX3C promotes osteosarcoma malignant progression through negatively regulating FGF14.
MicroRNA-324-5p suppresses the migration and invasion of MM cells by inhibiting the SCF?-TrCP E3 ligase.
Mind Bomb 1 Promotes Pancreatic Cancer Proliferation by Activating ?-Catenin Signaling.
Multigene methylation in serum of sporadic Chinese female breast cancer patients as a prognostic biomarker.
Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer -Association With Patient and Disease Characteristics and Effect on Prognosis.
MYC overexpression and poor prognosis in sporadic breast cancer with BRCA1 deficiency.
New insight into BIRC3: A novel prognostic indicator and a potential therapeutic target for liver cancer.
New prognostic markers revealed by evaluation of genes correlated with clinical parameters in Wilms tumors.
Next-generation sequencing reveals lymph node metastasis associated genetic markers in colorectal cancer.
Noncanonical Role of FBXO6 in Regulating Antiviral Immunity.
Novel roles of Skp2 E3 ligase in cellular senescence, cancer progression, and metastasis.
Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients.
Orthotopic implantation mouse model and cDNA microarray analysis indicates several genes potentially involved in lymph node metastasis of colorectal cancer.
Osteopontin can act as an effector for a germline mutation of BRCA1 in malignant transformation of breast cancer-related cells.
Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations.
p27kip1 Expression in non-small cell lung cancer is not an independent prognostic factor.
Pancancer survival analysis of cancer hallmark genes.
Parkin targets HIF-1? for ubiquitination and degradation to inhibit breast tumor progression.
Parkinson's disease-associated protein Parkin: an unusual player in cancer.
Pathology of Breast Cancer Metastasis and A View of Metastasis to The Brain.
Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers.
Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.
Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression.
PHF20L1 as a H3K27me2 reader coordinates with transcriptional repressors to promote breast tumorigenesis.
Phytochemical library screening reveals betulinic acid as a novel Skp2-SCF E3 ligase inhibitor in non-small cell lung cancer.
Polycomb chromobox 4 enhances migration and pulmonary metastasis of hepatocellular carcinoma cell line MHCC97L.
Polycomb complexes associate with enhancers and promote oncogenic transcriptional programs in cancer through multiple mechanisms.
Potential role of targeted therapies in the treatment of triple-negative breast cancer.
Prognostic values of F-box members in breast cancer: an online database analysis and literature review.
Prp19 Is an Independent Prognostic Marker and Promotes Neuroblastoma Metastasis by Regulating the Hippo-YAP Signaling Pathway.
Punicalagin suppresses osteosarcoma growth and metastasis by regulating NF-?B signaling.
RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis.
RBBP6, a RING finger-domain E3 ubiquitin ligase, induces epithelial-mesenchymal transition and promotes metastasis of colorectal cancer.
Recent advances in SCF ubiquitin ligase complex: Clinical implications.
Recurring Amplification at 11q22.1-q22.2 Locus Plays an Important Role in Lymph Node Metastasis and Radioresistance in OSCC.
Regulation of epithelial to mesenchymal transition by BRCA1 in breast cancer.
Regulation of p27 by ubiquitin ligases and its pathological significance in human lung carcinomas.
Ring finger protein 43 associates with gastric cancer progression and attenuates the stemness of gastric cancer stem-like cells via the Wnt-?/catenin signaling pathway.
RING-finger protein 6 enhances c-Myc-mediated Warburg effect by promoting MAD1 degradation to facilitate pancreatic cancer metastasis.
Risk factors for lymph node metastasis of ovarian, fallopian tube and primary peritoneal cancer in hereditary breast and ovarian cancer syndrome.
RNF111/Arkadia is regulated by DNA methylation and affects TGF-?/Smad signaling associated invasion in NSCLC cells.
RNF144A functions as a tumor suppressor in breast cancer through ubiquitin ligase activity-dependent regulation of stability and oncogenic functions of HSPA2.
RNF208, an estrogen-inducible E3 ligase, targets soluble Vimentin to suppress metastasis in triple-negative breast cancers.
RNF43 frameshift mutations contribute to tumourigenesis in right-sided colon cancer.
RNF43 Inhibits Cancer Cell Proliferation and Could be a Potential Prognostic Factor for Human Gastric Carcinoma.
RNF43 ubiquitinates and degrades phosphorylated E-cadherin by c-Src to facilitate epithelial-mesenchymal transition in lung adenocarcinoma.
RNF8 Promotes Epithelial-Mesenchymal Transition in Lung Cancer Cells via Stabilization of Slug.
RT-qPCR analysis of the tumor antigens TOMM34 and RNF43 in samples extracted from paraffin-embedded specimens of colorectal cancer.
SCF(JFK) is a bona fide E3 ligase for ING4 and a potent promoter of the angiogenesis and metastasis of breast cancer.
Significance of BRCA1 expression in breast and ovarian cancer patients with brain metastasis - A multicentre study.
Somatic aberrations of BRCA1 gene are associated with ALDH1, EGFR, and tumor progression in prostate cancer.
Spectrum of breast cancer metastasis in BRCA1 mutation carriers: highly increased incidence of brain metastases.
Studies on selected molecular factors in endometrial cancers.
Survival benefit in women with BRCA1 mutation or familial risk in the MRI screening study (MRISC).
Synergistic Therapeutic Effect of Cisplatin and Phosphatidylinositol 3-Kinase (PI3K) Inhibitors in Cancer Growth and Metastasis of Brca1 Mutant Tumors.
Targeted deep sequencing revealed variants in cell-free DNA of hormone receptor-positive metastatic breast cancer patients.
Targeting the E3 ubiquitin casitas B-lineage lymphoma decreases osteosarcoma cell growth and survival and reduces tumorigenesis.
The basal phenotype of BRCA1-related breast cancer: past, present and future.
The BRCA1 Methylation and PD-L1 Expression in Sporadic Ovarian Cancer.
The Drosophila F-box protein Slimb controls dSmurf protein turnover to regulate the Hippo pathway.
The E3 ligase C-CBL inhibits cancer cell migration by neddylating the proto-oncogene c-Src.
The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells.
The E3 ligase for metastasis associated 1 protein, TRIM25, is targeted by microRNA-873 in hepatocellular carcinoma.
The E3 ubiquitin ligase Cbl-b improves the prognosis of RANK positive breast cancer patients by inhibiting RANKL-induced cell migration and metastasis.
The E3 ubiquitin ligase NEDD4 mediates cell migration signaling of EGFR in lung cancer cells.
The expression of DBC1/CCAR2 is associated with poor prognosis of ovarian carcinoma.
The microRNA maturation regulator Drosha is an independent predictor of outcome in breast cancer patients.
The Roles of Ubiquitination Factor E4B (UBE4B) in the Postoperative Prognosis of Patients with Renal Cell Carcinoma and in Renal Tumor Cells Growth and Metastasis.
The shifting landscape of genetic alterations separating endometriosis and ovarian endometrioid carcinoma.
The ubiquitin ligase TRIM25 inhibits hepatocellular carcinoma progression by targeting metastasis associated 1 protein.
TRAF6 inhibits colorectal cancer metastasis through regulating selective autophagic CTNNB1/?-catenin degradation and is targeted for GSK3B/GSK3?-mediated phosphorylation and degradation.
TRIM22 confers poor prognosis and promotes epithelial-mesenchymal transition through regulation of AKT/GSK3?/?-catenin signaling in non-small cell lung cancer.
TRIM23 overexpression is a poor prognostic factor and contributes to carcinogenesis in colorectal cancer.
TRIM59 deficiency curtails breast cancer metastasis through SQSTM1-selective autophagic degradation of PDCD10.
Tripartite motif containing 62 is a novel prognostic marker and suppresses tumor metastasis via c-Jun/Slug signaling-mediated epithelial-mesenchymal transition in cervical cancer.
Tripartite motif-containing 3 (TRIM3) inhibits tumor growth and metastasis of liver cancer.
Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes.
Tumor protein expression of the DNA repair gene BRCA1 and lethal prostate cancer.
Ubiquitination-mediated degradation of cell cycle-related proteins by F-box proteins.
Wild-type genotypes of BRCA1 gene SNPs combined with micro-RNA over-expression in mammary tissue leading to familial breast cancer with an increased risk of distant metastases' occurrence.
[Diagnostic value of BRCA1 and p16 gene methylation in sporadic breast cancer.]
[Genetic instability on chromosome 17q21 in gastric cancer of Chinese patients]
[Nasosinusal adenocarcinoma: molecular and genetic analysis by MLPA]
[Tripartite-motif protein 25 and pyruvate kinase M2 protein expression in non-small cell lung cancer].
Neoplasm, Residual
Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study.
High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation.
Molecular profiles of BRCA1-associated ovarian cancer treated by platinum-based therapy: Analysis of primary, residual and relapsed tumors.
Neoplasms
"I Am Uncertain About What My Uncertainty Even Is": Men's Uncertainty and Information Management of Their BRCA-Related Cancer Risks.
"It wasn't just for me": Motivations and implications of genetic testing for women at a low risk of hereditary breast and ovarian cancer syndrome.
"Ring-fencing" BRCA1 tumor suppressor activity.
"Smurf"-ing tumors on the chromatin through RNF20.
14-3-3-protein regulates Nedd4-2 by modulating interactions between HECT and WW domains.
17 beta Hydroxysteroid dehydrogenase 1 "pseudogene" is differentially transcribed: still a candidate for the breast-ovarian cancer susceptibility gene (BRCA1).
19F NMR tagging and PRE-based conformational analysis of intrinsically disordered protein complexes.
2-oxoglutarate downregulates expression of vascular endothelial growth factor and erythropoietin through decreasing hypoxia-inducible factor-1alpha and inhibits angiogenesis.
250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies.
53BP1 ablation rescues genomic instability in mice expressing 'RING-less' BRCA1.
53BP1 fosters fidelity of homology-directed DNA repair.
53BP1 is a positive regulator of the BRCA1 promoter.
53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers.
53BP1 loss rescues embryonic lethality but not genomic instability of BRCA1 total knockout mice.
53BP1 promotes ATM activity through direct interactions with the MRN complex.
53BP1, BRCA1, and the Choice between Recombination and End Joining at DNA Double-Strand Breaks.
655Val and 1170Pro ERBB2 SNPs in familial breast cancer risk and BRCA1 alterations.
69-Year-Old Man With Castration-Resistant Prostate Cancer Progressing After Docetaxel and Androgen Receptor-Targeting Agent.
?-hCG induced mutant BRCA1 ignites drug resistance in susceptible breast tissue.
?Np63? induces quiescence and downregulates the BRCA1 pathway in estrogen receptor-positive luminal breast cancer cell line MCF7 but not in other breast cancer cell lines.
A 1-kb Alu-mediated germ-line deletion removing BRCA1 exon 17.
A 2-Benzylmalonate Derivative as STAT3 Inhibitor Suppresses Tumor Growth in Hepatocellular Carcinoma by Upregulating ?-TrCP E3 Ubiquitin Ligase.
A 400 kb novel deletion unit centromeric to the BRCA1 gene in sporadic epithelial ovarian cancer.
A 45-year follow-up of kindred 107 and the search for BRCA2.
A bicyclic monoterpene diol and UVB stimulate BRCA1 phosphorylation in human keratinocytes.
A biomarker profile for predicting efficacy of cisplatin-vinorelbine therapy in malignant pleural mesothelioma.
A BRCA1 deficient, NF?B driven immune signal predicts good outcome in triple negative breast cancer.
A BRCA1 founder mutation, identified with haplotype analysis, allowing genotype/phenotype determination and predictive testing.
A BRCA2 mutation incorrectly mapped in the original BRCA2 reference sequence, is a common West Danish founder mutation disrupting mRNA splicing.
A breast/ovarian cancer patient with germline mutations in both BRCA1 and BRCA2.
A cancer ubiquitome landscape identifies metabolic reprogramming as target of Parkin tumor suppression.
A case of familial breast cancer with double heterozygosity for BRCA1 and BRCA2 genes.
A case of loss of heterozygosity in the BRCA2 gene of a borderline ovarian tumor: case report and review of literature.
A case of neurofibromatosis and breast cancer: loss of heterozygosity of NF1 in breast cancer.
A CD146 FACS Protocol Enriches for Luminal Keratin 14/19 Double Positive Human Breast Progenitors.
A cluster of genes located in 1p36 are down-regulated in neuroblastomas with poor prognosis, but not due to CpG island methylation.
A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening.
A combination of molecular markers and clinical features improve the classification of pancreatic cysts.
A common deletion at chromosomal region 17q21 in sporadic prostate tumors distal to BRCA1.
A common Greenlandic Inuit BRCA1 RING domain founder mutation.
A common region of deletion on chromosome 17q in both sporadic and familial epithelial ovarian tumors distal to BRCA1.
A common SNP in the uracil-DNA glycosylase gene UNG decreases ovarian cancer risk in BRCA2 mutation carriers.
A comparison of 100 human genes using an alu element-based instability model.
A comparison of bilateral breast cancers in BRCA carriers.
A comparison of male attendees and nonattendees at a familial cancer clinic.
A comparison of the detection of BRCA mutation carriers through the provision of Jewish population-based genetic testing compared with clinic-based genetic testing.
A computer model to simulate family history of breast/ovarian cancer in BRCA1 mutation carriers.
A conditional mouse model for measuring the frequency of homologous recombination events in vivo in the absence of essential genes.
A conserved pathway to activate BRCA1-dependent ubiquitylation at DNA damage sites.
A critical re-appraisal of BRCA1 methylation studies in ovarian cancer.
A critical re-assessment of DNA repair gene promoter methylation in non-small cell lung carcinoma.
A critical role for cellular inhibitor of protein 2 (cIAP2) in colitis-associated colorectal cancer and intestinal homeostasis mediated by the inflammasome and survival pathways.
A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage.
A critical role for noncoding 5S rRNA in regulating Mdmx stability.
A death-associated protein kinase (DAPK)-interacting protein, DIP-1, is an E3 ubiquitin ligase that promotes tumor necrosis factor-induced apoptosis and regulates the cellular levels of DAPK.
A deleterious RNF43 germline mutation in a severely affected serrated polyposis kindred.
A deletion map of chromosome 17q in sporadic human mammary carcinomas.
A Devastatingly "Minor" Relationship Between Male Breast Cancer and Prostate Cancer.
A DGGE system for comprehensive mutation screening of BRCA1 and BRCA2: application in a Dutch cancer clinic setting.
A diagnostic dilemma following risk-reducing surgery for BRCA1 mutation - a case report of primary papillary serous carcinoma presenting as sigmoid cancer.
A discrete choice experiment of preferences for genetic counselling among Jewish women seeking cancer genetics services.
A Drosophila Model of HPV E6-Induced Malignancy Reveals Essential Roles for Magi and the Insulin Receptor.
A family pedigree of malignancies associated with BRCA1 pathogenic variants: a reflection of the state of art in China.
A family with three germline mutations in BRCA1 and BRCA2.
A game of substrates: replication fork remodeling and its roles in genome stability and chemo-resistance.
A gene hypermethylation profile of human cancer.
A genetic epidemiological study of carcinoma of the fallopian tube.
A genome-wide strategy to identify causes and consequences of retrotransposon expression finds activation by BRCA1 in ovarian cancer.
A Genomewide Screen for Suppressors of Alu-Mediated Rearrangements Reveals a Role for PIF1.
A guide for functional analysis of BRCA1 variants of uncertain significance.
A haplotype containing the p53 polymorphisms Ins16bp and Arg72Pro modifies cancer risk in BRCA2 mutation carriers.
A high expression ratio of RhoA/RhoB is associated with the migratory and invasive properties of basal-like Breast Tumors.
A high frequency of germline BRCA1/2 mutations in western Sweden detected with complementary screening techniques.
A high incidence of BRCA1 mutations in 20 breast-ovarian cancer families.
A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families.
A high prevalence of BRCA1 mutations among breast cancer patients from the Bahamas.
A high proportion of DNA variants of BRCA1 and BRCA2 is associated with aberrant splicing in breast/ovarian cancer patients.
A high proportion of founder BRCA1 mutations in Polish breast cancer families.
A high proportion of mutations in the BRCA1 gene in German breast/ovarian cancer families with clustering of mutations in the 3' third of the gene.
A Hypoxia-Induced SCFFBXL1 E3 Ligase Ubiquitinates and Degrades the MEN1 Tumor Suppressor to Promote Colorectal Cancer Tumorigenesis.
A knowledge-based framework for the discovery of cancer-predisposing variants using large-scale sequencing breast cancer data.
A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.
A large kindred with 17q-linked breast and ovarian cancer: genetic, phenotypic, and genealogical analysis.
A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families.
A low-grade ovarian carcinoma case with coincident LOH of PTCH1 and BRCA1, and a mutation in BRCA1.
A macrohistone variant links dynamic chromatin compaction to BRCA1-dependent genome maintenance.
A mammary-specific, long-range deletion on mouse chromosome 11 accelerates Brca1-associated mammary tumorigenesis.
A mechanism for transcriptional repression dependent on the BRCA1 E3 ubiquitin ligase.
A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance.
A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family history.
A microchip platform for structural oncology applications.
A MicroRNA/Ubiquitin Ligase Feedback Loop Regulates Slug-Mediated Invasion in Breast Cancer.
A miRNA-HERC4 pathway promotes breast tumorigenesis by inactivating tumor suppressor LATS1.
A modular PROTAC design for target destruction using a degradation signal based on a single amino acid.
A Molecular Toolkit to Visualize Native Protein Assemblies in the Context of Human Disease.
A mouse model featuring tissue-specific deletion of p53 and Brca1 gives rise to mammary tumors with genomic and transcriptomic similarities to human basal-like breast cancer.
A mouse model for the molecular characterization of brca1-associated ovarian carcinoma.
A mouse model of basal-like breast carcinoma with metaplastic elements.
A Mouse Model That Reproduces the Developmental Pathways and Site Specificity of the Cancers Associated With the Human BRCA1 Mutation Carrier State.
A multi-gene panel study in hereditary breast and ovarian cancer in Colombia.
A multi-lock inhibitory mechanism for fine-tuning enzyme activities of the HECT family E3 ligases.
A multicenter phase II study of TAS-114 in combination with S-1 in patients with pretreated advanced gastric cancer (EPOC1604).
A Multiplex Homology-Directed DNA Repair Assay Reveals the Impact of More Than 1,000 BRCA1 Missense Substitution Variants on Protein Function.
A mutation analysis of the BRCA1 gene in 140 families from southeast France with a history of breast and/or ovarian cancer.
A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer.
A naturally occurring mutation in an ATP-binding domain of the recombination repair gene XRCC3 ablates its function without causing cancer susceptibility.
A Naturally-Occurring Dominant-Negative Inhibitor of Keap1 Competitively against Its Negative Regulation of Nrf2.
A new alternative splice variant of BRCA1 containing an additional in-frame exon.
A new bioinformatics tool to help assess the significance of BRCA1 variants.
A new class of coumate benzimidazole hybrids as BRCA-1 mimetics through unconventional binding mode; Synthesis and preliminary cytotoxicity screening.
A new founder BRCA1 haplotype identified in the Puglia region is associated with a specific age-related cancer onset in three unrelated families.
A new hybrid record linkage process to make epidemiological databases interoperable: application to the GEMO and GENEPSO studies involving BRCA1 and BRCA2 mutation carriers.
A new paradigm of genetic testing for hereditary breast/ovarian cancers.
A New Rapid Methodological Strategy to Assess BRCA Mutational Status.
A new scoring system in cancer genetics: application to criteria for BRCA1 and BRCA2 mutation screening.
A New Strategy to Control and Eradicate "Undruggable" Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology.
A non-BRCA1/2 hereditary breast cancer sub-group defined by aCGH profiling of genetically related patients.
A novel BRCA1 gene deletion detection in human breast carcinoma MCF-7 cells through FRET between quantum dots and silver nanoclusters.
A novel BRCA1 mutation in an identical twin pair with similar clinical histories.
A novel BRCA1 mutation in an Indian family with hereditary breast/ovarian cancer.
A Novel BRCA1-Associated Protein-1 Isoform Affects Response of Mesothelioma Cells to Drugs Impairing BRCA1-Mediated DNA Repair.
A novel de novo BRCA1 mutation in a Chinese woman with early onset breast cancer.
A novel de novo BRCA2 mutation of paternal origin identified in a Spanish woman with early onset bilateral breast cancer.
A novel deleterious c.2656G>T MSH2 germline mutation in a Pakistani family with a phenotypic overlap of hereditary breast and ovarian cancer and Lynch syndrome.
A novel deletion of BRCA1 gene that eliminates the ATG initiation codon without affecting the promoter region.
A novel frequent BRCA1 recurrent variant c.5117G > A (p.Gly1206Glu) identified after 20?years of BRCA1/2 research in the Baltic region: cohort study and literature review.
A novel germline BRCA1 mutation identified in a family with hereditary breast and ovarian cancer syndrome.
A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations.
A novel host cell reactivation assay to assess homologous recombination capacity in human cancer cell lines.
A novel mechanism of irinotecan targeting MDM2 and Bcl-xL.
A Novel Mechanism to Induce BRCAness in Cancer Cells.
A novel mechanism whereby BRCA1/1a/1b fine tunes the dynamic complex interplay between SUMO-dependent/independent activities of Ubc9 on E2-induced ERalpha activation/repression and degradation in breast cancer cells.
A novel method to detect the Mexican founder mutation BRCA1 ex9?12del associated with breast and ovarian cancer using quantitative polymerase chain reaction and TaqMan® probes.
A Novel Mutation-BRCA1 Associated Hereditary Haplotype of Intragenic Markers of BRCA1 Gene in a Family with History of Breast Cancer
A novel oncoprotein Pirh2: rising from the shadow of MDM2.
A Novel Pathogenic BRCA1 Splicing Variant Produces Partial Intron Retention in the Mature Messenger RNA.
A novel role for BRCA1 in regulating breast cancer cell spreading and motility.
A novel role for the SUMO E3 ligase PIAS1 in cancer metastasis.
A novel sensitive method to detect frameshift mutations in exonic repeat sequences of cancer-related genes.
A novel site of AKT-mediated phosphorylation in the human MDM2 onco-protein.
A novel somatic BRCA2 point mutation in a metastatic pancreatic cancer patient: a case report.
A novel TP53 germline mutation in a family with a history of multiple malignancies: case report and review of the literature.
A novel tricomplex of BRCA1, Nmi, and c-Myc inhibits c-Myc-induced human telomerase reverse transcriptase gene (hTERT) promoter activity in breast cancer.
A nuclear function for the tumor suppressor BRCA1.
A paradigm for class prediction using gene expression profiles.
A Pharmacodynamic Study of the P-glycoprotein Antagonist CBT-1(R) in Combination With Paclitaxel in Solid Tumors.
A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.
A Phase 2, Single Arm Study of Iniparib in Patients With BRCA1 or BRCA2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
A phase I clinical trial of RNF43 peptide-related immune cell therapy combined with low-dose cyclophosphamide in patients with advanced solid tumors.
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.
A phenotypic mouse model of basaloid breast tumors.
A phospho-switch controls RNF43-mediated degradation of Wnt receptors to suppress tumorigenesis.
A Physical Mechanism and Global Quantification of Breast Cancer.
A plasma telomeric cell-free DNA level in unaffected women with BRCA1 or/and BRCA2 mutations: a pilot study.
A point mutation of zebrafish c-cbl gene in the ring finger domain produces a phenotype mimicking human myeloproliferative disease.
A population study of mutations and LOH at breast cancer gene loci in tumours from sister pairs: two recurrent mutations seem to account for all BRCA1/BRCA2 linked breast cancer in Iceland.
A Population-Based Analysis of BRCA1/2 Genes and Associated Breast and Ovarian Cancer Risk in Korean Patients: A Multicenter Cohort Study.
A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention.
A porcine model system of BRCA1 driven breast cancer.
A portable BRCA1-HAC (human artificial chromosome) module for analysis of BRCA1 tumor suppressor function.
A portrayal of E3 ubiquitin ligases and deubiquitylases in cancer.
A PP1-binding motif present in BRCA1 plays a role in its DNA repair function.
A predictor based on the somatic genomic changes of the BRCA1/BRCA2 breast cancer tumors identifies the non-BRCA1/BRCA2 tumors with BRCA1 promoter hypermethylation.
A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families.
A profile on the FoundationFocus CDxBRCA tests.
A Provocative Molecular Link between Mammographic Density and BRCA1-loss associated TNBC.
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.
A radiation hybrid map of the BRCA1 region.
A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale.
A rapid fluorescent multiplexed-PCR analysis (FMPA) for founder mutations in the BRCA1 and BRCA2 genes.
A reduced panel of eight genes (ATM, SF3B1, NOTCH1, BIRC3, XPO1, MYD88, TNFAIP3, and TP53) as an estimator of the tumor mutational burden in chronic lymphocytic leukemia.
A Regulatory Axis of circ_0008193/miR-1180-3p/TRIM62 Suppresses Proliferation, Migration, Invasion, and Warburg Effect in Lung Adenocarcinoma Cells Under Hypoxia.
A reliable method for the detection of BRCA1 and BRCA2 mutations in fixed tumour tissue utilising multiplex PCR-based targeted next generation sequencing.
A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS).
A Review of Cancer Genetics and Genomics Studies in Africa.
A review of histopathological subtypes of ovarian cancer in BRCA-related French Canadian cancer families.
A role for Brca1 in chromosome end maintenance.
A role for BRCA1 in sporadic breast cancer.
A role for BRCA1 in uterine leiomyosarcoma.
A role for KAI1 in promotion of cell proliferation and mammary gland hyperplasia by the gp78 ubiquitin ligase.
A role for the p53 tumour suppressor in regulating the balance between homologous recombination and non-homologous end joining.
A role of estrogen/ERalpha signaling in BRCA1-associated tissue-specific tumor formation.
A salpingeal carcinoma revealed after prophylactic salpingoophorectomy in an asymptomatic BRCA1 carrier with breast malignancy.
A screening for BRCA1 mutations in breast and breast-ovarian cancer families from the Stockholm region.
A selective requirement for 53BP1 in the biological response to genomic instability induced by Brca1 deficiency.
A sensitive test for the detection of specific DSB repair defects in primary cells from breast cancer specimens.
A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers.
A Single Conserved Amino Acid Residue as a Critical Context-Specific Determinant of the Differential Ability of Mdm2 and MdmX RING Domains to Dimerize.
A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers.
A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers.
A small ubiquitin binding domain inhibits ubiquitin-dependent protein recruitment to DNA repair foci.
A somatic BRCA1 mutation in an ovarian tumour.
A somatic BRCA2 mutation in RER+ endometrial carcinomas that specifically deletes the amino-terminal transactivation domain.
A specific GFP expression assay, penetrance estimate, and histological assessment for a putative splice site mutation in BRCA1.
A splice variant of stress response gene ATF3 counteracts NF-kappaB-dependent anti-apoptosis through inhibiting recruitment of CREB-binding protein/p300 coactivator.
A sporadic breast tumor with a somatically acquired complex genomic rearrangement in BRCA1.
A survey of preventive measures among BRCA1 mutation carriers from Poland.
A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor.
A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair.
A synthetic oxygen sensor for plants based on animal hypoxia signalling.
A systematic review and meta-analysis of telephone vs in-person genetic counseling in BRCA1/BRCA2 genetic testing.
A Systems Biology Comparison of Ovarian Cancers Implicates Putative Somatic Driver Mutations through Protein-Protein Interaction Models.
A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population.
A targeted disruption of the murine Brca1 gene causes gamma-irradiation hypersensitivity and genetic instability.
A transcription-based mechanism for oncogenic ?-catenin-induced lethality in BRCA1/2-deficient cells.
A truncated splice variant of human BARD1 that lacks the RING finger and ankyrin repeats.
A tumor suppressor function of Smurf2 associated with controlling chromatin landscape and genome stability through RNF20.
A twist of cell fate.
A Two-Phase Approach to Developing SNAP: an iPhone Application to Support Appointment Scheduling and Management for Women with a BRCA Mutation.
A UbcH5/ubiquitin noncovalent complex is required for processive BRCA1-directed ubiquitination.
A ubiquitin variant-based affinity approach selectively identifies substrates of the ubiquitin ligase E6AP in complex with HPV-11 E6 or HPV-16 E6.
A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment.
A Variant Smurf2 Protects Mice Against Colitis-Associated Colon Cancer by Inducing Transforming Growth Factor ? Signaling.
A Very Long-Acting PARP Inhibitor Suppresses Cancer Cell Growth in DNA Repair-Deficient Tumor Models.
A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers.
A yeast recombination assay to characterize human BRCA1 missense variants of unknown pathological significance.
A ZNRF3-dependent Wnt/?-catenin signaling gradient is required for adrenal homeostasis.
A20 targets PFKL and glycolysis to inhibit the progression of hepatocellular carcinoma.
A20 ubiquitin ligase-mediated polyubiquitination of RIP1 inhibits caspase-8 cleavage and TRAIL-induced apoptosis in glioblastoma.
Aberrant DNA methylation as a cancer-inducing mechanism.
Aberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical features.
Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers.
Aberrant methylation of the HACE1 gene is frequently detected in advanced colorectal cancer.
Aberrant promoter hypermethylation and genomic hypomethylation in tumor, adjacent normal tissues and blood from breast cancer patients.
Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma.
Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential.
Aberrant recombination and repair during immunoglobulin class switching in BRCA1-deficient human B cells.
Aberrant subcellular localization of BRCA1 in breast cancer.
Aberrations of breast cancer susceptibility genes occur early in sporadic breast tumors and in acquisition of breast epithelial immortalization.
Ablation of the Brca1-Palb2 Interaction Phenocopies Fanconi Anemia in Mice.
Abnormality of the DNA double-strand-break checkpoint/repair genes, ATM, BRCA1 and TP53, in breast cancer is related to tumour grade.
Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response.
Abrogation of FBW7?-dependent p53 degradation enhances p53's function as a tumor suppressor.
Absence of 185delAG and 6174delT Mutations among Breast Cancer Patients of Eastern India.
Absence of CCND1 gene amplification in breast tumours of BRCA1 mutation carriers.
Absence of full-length Brca1 sensitizes mice to oxidative stress and carcinogen-induced tumorigenesis in the esophagus and forestomach.
Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families.
Absence of germline BRCA1 mutations in familial pancreatic cancer patients.
Absence of Grail promotes CD8(+) T cell anti-tumour activity.
Absence of loss of heterozygosity of BRCA1 in a renal tumor from a BRCA1 germline mutation carrier.
Absence of the BRCA1 del (exons 9-12) mutation in breast/ovarian cancer families outside of Mexican Hispanics.
Absence of the full-length breast cancer-associated gene-1 leads to increased expression of insulin-like growth factor signaling axis members.
Abundance of BRCA1 transcripts in human cancer and lymphoblastoid cell lines carrying BRCA1 germ-line alterations.
ACAA1 Is a Predictive Factor of Survival and Is Correlated With T Cell Infiltration in Non-Small Cell Lung Cancer.
ACCA phosphopeptide recognition by the BRCT repeats of BRCA1.
Accelerated regeneration of the skeletal muscle in RNF13-knockout mice is mediated by macrophage-secreted IL-4/IL-6.
Acceleration of chromosomal instability by loss of BRCA1 expression and p53 abnormality in sporadic breast cancers.
Acceleration of chromosomal instability of BRCA1-associated hereditary breast cancers by p53 abnormality.
Acceptance of genetic testing for hereditary breast ovarian cancer among study enrollees from an African American kindred.
Accumulated promoter methylation as a potential biomarker for esophageal cancer.
Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death.
Accuracy of cancer family histories: comparison of two breast cancer syndromes.
Accuracy of self-reported family history of cancer, mutation status and tumor characteristics in patients with early onset breast cancer.
Accurate classification of BRCA1 variants with saturation genome editing.
Accurate clinical detection of exon copy number variants in a targeted NGS panel using DECoN.
Accurate detection and quantification of epigenetic and genetic second hits in BRCA1 and BRCA2-associated hereditary breast and ovarian cancer reveals multiple co-acting second hits.
Acetyl-CoA carboxylase alpha gene and breast cancer susceptibility.
Acetylation-dependent regulation of MDM2 E3 ligase activity dictates its oncogenic function.
Acquired resistance to immunotherapy in MMR-D pancreatic cancer.
Activating Mutations of ESR1, BRCA1 and CYP19 Aromatase Genes Confer Tumor Response in Breast Cancers Treated with Antiestrogens.
Activation of estrogen signaling pathways collaborates with loss of Brca1 to promote development of ERalpha-negative and ERalpha-positive mammary preneoplasia and cancer.
Activation of FGFR2 Signaling Suppresses BRCA1 and Drives Triple-Negative Mammary Tumorigenesis That is Sensitive to Immunotherapy.
Activation of the E3 ligase function of the BRCA1/BARD1 complex by polyubiquitin chains.
Activation of TNF-?/NF-?B axis enhances CRL4B
Activation of transcription in vitro by the BRCA1 carboxyl-terminal domain.
Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation.
Adaptive evolution of the tumour suppressor BRCA1 in humans and chimpanzees. Australian Breast Cancer Family Study.
Adding In Silico Assessment of Potential Splice Aberration to the Integrated Evaluation of BRCA Gene Unclassified Variants.
Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing.
Addressing health disparities in Hispanic breast cancer: accurate and inexpensive sequencing of BRCA1 and BRCA2.
Adenomatoid tumors of the male and female genital tract are defined by TRAF7 mutations that drive aberrant NF-kB pathway activation.
Adequacy of risk-reducing gynaecologic surgery in BRCA1 or BRCA2 mutation carriers and other women at high risk of pelvic serous cancer.
Adjusting the estimated proportion of breast cancer cases associated with BRCA1 and BRCA2 mutations: public health implications.
Advances in the use of PARP inhibitor therapy for breast cancer.
Adverse prognostic and predictive significance of low DNA-dependent protein kinase catalytic subunit (DNA-PKcs) expression in early-stage breast cancers.
Age at diagnosis as an indicator of eligibility for BRCA1 DNA testing in familial breast cancer.
Age at diagnosis of cancer in 185delAG BRCA1 mutation carriers of diverse ethnicities: tentative evidence for modifier factors.
Age at onset of bilateral breast cancer, the presence of hereditary BRCA1, BRCA2, CHEK2 gene mutations and positive family history of cancer.
Age of natural menopause onset in BRCA1/2 carriers - systematic review and meta-analysis.
AGER/RAGE-mediated autophagy promotes pancreatic tumorigenesis and bioenergetics through the IL6-pSTAT3 pathway.
Aggressiveness of non-EMT breast cancer cells relies on FBXO11 activity.
AGO Austria recommendations for genetic testing of patients with ovarian cancer.
AKT and p21 WAF1/CIP1 as potential genistein targets in BRCA1-mutant human breast cancer cell lines.
AKT1 inhibits homologous recombination by inducing cytoplasmic retention of BRCA1 and RAD51.
AKT1/BRCA1 in the control of homologous recombination and genetic stability: the missing link between hereditary and sporadic breast cancers.
Alcoholic hepatitis versus non-alcoholic steatohepatitis: Levels of expression of some proteins involved in tumorigenesis.
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.
Allele loss and mutation screen at the Peutz-Jeghers (LKB1) locus (19p13.3) in sporadic ovarian tumours.
Allele loss of tumour suppressor genes on chromosome 17 in human testicular germ cell tumours.
Allelic imbalance and microsatellite instability in BRCA1 associated breast and ovarian tumors.
Allelic imbalance on chromosomes 13 and 17 and mutation analysis of BRCA1 and BRCA2 genes in monozygotic twins concordant for breast cancer.
Allelic loss at BRCA1, BRCA2, and adjacent loci in relation to TP53 abnormality in breast cancer.
Allelic loss of 6q25-27, the PARKIN tumor suppressor gene locus, in cervical carcinoma.
Allelic loss of the BRCA1 and BRCA2 genes and other regions on 17q and 13q in breast cancer among women from Taiwan (area of low incidence but early onset).
Allelic loss on chromosome arm 8p: analysis of sporadic epithelial ovarian tumors.
Allelic phasing of a mouse chromosome 11 deficiency influences p53 tumorigenicity.
Allelic Transcripts Dosage Effect in Morphologically Normal Ovarian Cells from Heterozygous Carriers of a BRCA1/2 French Canadian Founder Mutation.
Allelotyping defines minimal imbalance at chromosomal region 17q25 in non-serous epithelial ovarian cancers.
Allosteric effects in the marginally stable von Hippel-Lindau tumor suppressor protein and allostery-based rescue mutant design.
Alteration of BRCA1 expression affects alcohol-induced transcription of RNA Pol III-dependent genes.
Alteration of DNA methylation status in K562 and MCF-7 cancer cell lines by nucleoside analogues.
Alterations in Brca1 expression in mouse ovarian granulosa cells have short-term and long-term consequences on estrogen-responsive organs.
Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinoma.
Alterations in replication timing of cancer-related genes in malignant human breast cancer cells.
Alterations in the common fragile site gene Parkin in ovarian and other cancers.
Alterations of pre-mRNA splicing in cancer.
Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study.
Alterations of the tumor suppressor gene Parkin in non-small cell lung cancer.
Altered BRCA1 and BRCA2 responses and mutation of BRCA1 gene in mice exposed chronically and transgenerationally to aqueous extract of betel nut (AEBN).
Altered Expression and Localization of Tumor Suppressive E3 Ubiquitin Ligase SMURF2 in Human Prostate and Breast Cancer.
Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines.
Altered mitochondrial quality control signaling in muscle of old gastric cancer patients with cachexia.
Altering the Microbiome Inhibits Tumorigenesis in a Mouse Model of Oviductal High-Grade Serous Carcinoma.
Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance.
Alternative splicing and molecular characterization of splice site variants: BRCA1 c.591C>T as a case study.
Alternative splicing generates different parkin protein isoforms: evidences in human, rat, and mouse brain.
Alternative splicing of breast cancer associated gene BRCA1 from breast cancer cell line.
Alternative splicings on p53, BRCA1 and PTEN genes involved in breast cancer.
Alternative strategies for targeting mouse double minute 2 activity with small molecules: novel patents on the horizon?
Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer.
Amplification of TOP2A and HER-2 genes in breast cancers occurring in patients harbouring BRCA1 germline mutations.
An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients.
An adenoviral vector containing an arg-gly-asp (RGD) motif in the fiber knob enhances protein product levels from transgenes refractory to expression.
An Algorithm Combining Patient Performance Status, Second Hit Analysis, PROVEAN and Dann Prediction Tools Could Foretell Sensitization to PARP Inhibitors in Digestive, Skin, Ovarian and Breast Cancers.
An Alternate Diagnostic Algorithm for the Diagnosis of Intraepithelial Fallopian Tube Lesions.
An amino-terminal motif functions as a second nuclear export sequence in BRCA1.
An antibody assay predictive of BRCA1 mutations in ovarian tumors and normal tissue.
An apoptosis-independent role of SMAC in tumor suppression.
An E3 Ubiquitin Ligase RNF139 Serves as a Tumor-Suppressor in Glioma.
An E3 ubiquitin ligase: c-Cbl: A New Therapeutic Target of Lung Cancer.
An entire exon 3 germ-line rearrangement in the BRCA2 gene: pathogenic relevance of exon 3 deletion in breast cancer predisposition.
An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium.
An evaluation of the challenges to developing tumor BRCA1 and BRCA2 testing methodologies for clinical practice.
An evaluation of the polymorphisms Ins16bp and Arg72Pro in p53 as breast cancer risk modifiers in BRCA1 and BRCA2 mutation carriers.
An evolving role for DEPTOR in tumor development and progression.
An important role for BRCA1 in breast cancer progression is indicated by its loss in a large proportion of non-familial breast cancers.
An inevitable dilemma: prenatal testing for mutations in the BRCA1 breast-ovarian cancer susceptibility gene.
An integrated genomics analysis of epigenetic subtypes in human breast tumors links DNA methylation patterns to chromatin states in normal mammary cells.
An Integrated Systems Biology Approach Identifies TRIM25 as a Key Determinant of Breast Cancer Metastasis.
An integrative hypothesis about the origin and development of sporadic and familial breast cancer subtypes.
An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA).
An RNF168 fragment defective for focal accumulation at DNA damage is proficient for inhibition of homologous recombination in BRCA1 deficient cells.
An unaffected individual from a breast/ovarian cancer family with germline mutations in both BRCA1 and BRCA2.
An unorthodox partnership in DNA repair pathway choice.
An unusual BRCA mutation distribution in a high risk cancer genetics clinic.
An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
An update on DNA-based BRCA1/BRCA2 genetic counseling in hereditary breast cancer.
An update on PARP inhibitors--moving to the adjuvant setting.
Analysis and interpretation of RNA splicing alterations in genes involved in genetic disorders.
Analysis of a set of missense, frameshift, and in-frame deletion variants of BRCA1.
Analysis of Adaptive Olaparib Resistance Effects on Cisplatin Sensitivity in Triple Negative Breast Cancer Cells.
Analysis of alternative lengthening of telomere markers in BRCA1 defective cells.
Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects.
Analysis of BRCA1 and BRCA2 in breast and breast/ovarian cancer families shows population substructure in the Iberian peninsula.
Analysis of BRCA1 and BRCA2 mutations in Hungarian families with breast or breast-ovarian cancer.
Analysis of BRCA1 and BRCA2 mutations in southern Iranian Breast cancer patients.
Analysis of BRCA1 and RAD51C Promoter Methylation in Italian Families at High-Risk of Breast and Ovarian Cancer.
Analysis of BRCA1 involvement in breast cancer in Indian women.
Analysis of Brca1-deficient mouse mammary glands reveals reciprocal regulation of Brca1 and c-kit.
Analysis of BRCA1/2 mutation spectrum and prevalence in unselected Chinese breast cancer patients by next-generation sequencing.
Analysis of BRCA1/BRCA2 genes' contribution to breast cancer susceptibility in high risk Jewish Ashkenazi women.
Analysis of breast cancer susceptibility genes BRCA1 and BRCA2 in Thai familial and isolated early-onset breast and ovarian cancer.
Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource.
Analysis of clinical characteristics of breast cancer patients with the Japanese founder mutation BRCA1 L63X.
Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
Analysis of ERCC1, BRCA1, RRM1 and TUBB3 as predictors of prognosis in patients with non-small cell lung cancer who received cisplatin-based adjuvant chemotherapy: A prospective study.
Analysis of estrogen-responsive finger protein expression in benign and malignant human breast.
Analysis of Founder Mutations in Rare Tumors Associated With Hereditary Breast/Ovarian Cancer Reveals a Novel Association of BRCA2 Mutations with Ampulla of Vater Carcinomas.
Analysis of GADD45A sequence variations in French Canadian families with high risk of breast cancer.
Analysis of Induced Pluripotent Stem Cells from a BRCA1 Mutant Family.
Analysis of large mutations in BARD1 in patients with breast and/or ovarian cancer: the Polish population as an example.
Analysis of loss of heterozygosity and immunohistochemistry in BRCA1 gene in sporadic breast cancers.
Analysis of microsatellite instability and BRCA1 mutations in patients from hereditary nonpolyposis colorectal cancer (HNPCC) family.
Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation.
Analysis of Mutation and Loss of Heterozygosity by Whole-Exome Sequencing Yields Insights into Pseudomyxoma Peritonei.
Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD.
Analysis of several BRCA1 and BRCA2 mutations in a hospital-based series of unselected breast cancer cases.
Analysis of somatic microsatellite indels identifies driver events in human tumors.
Analysis of the DNA binding activity of BRCA1 and its modulation by the tumour suppressor p53.
Analysis of the inhibitors of apoptosis identifies BIRC3 as a facilitator of malignant progression in glioma.
Ancestry dependent DNA methylation and influence of maternal nutrition.
Ancient and recent adaptive evolution in the antiviral TRIM22 gene: identification of a single-nucleotide polymorphism that impacts TRIM22 function.
Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer.
Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer.
Androgens regulate SMAD ubiquitination regulatory factor-1 expression and prostate cancer cell invasion.
Aneuploidy is associated with TP53 expression but not with BRCA1 or TERT expression in sporadic colorectal cancer.
Angiomotin binding-induced activation of Merlin/NF2 in the Hippo pathway.
Annotation of Sequence Variants in Cancer Samples: Processes and Pitfalls for Routine Assays in the Clinical Laboratory.
Anti-Apoptotic Signature in Thymic Squamous Cell Carcinomas - Functional Relevance of Anti-Apoptotic BIRC3 Expression in the Thymic Carcinoma Cell Line 1889c.
Anti-tumoral effect of desmethylclomipramine in lung cancer stem cells.
Anti-Warburg effect by targeting HRD1-PFKP pathway may inhibit breast cancer progression.
Antibody-drug conjugates in triple negative breast cancer.
Anticipated uptake and impact of genetic testing in hereditary breast and ovarian cancer families.
Anticipated versus actual emotional reactions to disclosure of results of genetic tests for cancer susceptibility: findings from p53 and BRCA1 testing programs.
Antimony exposure promotes bladder tumor cell growth by inhibiting PINK1-Parkin-mediated mitophagy.
Antioxydation And Cell Migration Genes Are Identified as Potential Therapeutic Targets in Basal-Like and BRCA1 Mutated Breast Cancer Cell Lines.
Antiproliferative effect of D-glucuronyl C5-epimerase in human breast cancer cells.
Antisense inhibition of BRCA1 expression and molecular analysis of hereditary tumors indicate that functional inactivation of the p53 DNA damage response pathway is required for BRCA-associated tumorigenesis.
Antisense RNA to the putative tumor suppressor gene BRCA1 transforms mouse fibroblasts.
Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety.
Antitumor effects of recombinant human adenovirus-p53 against human cutaneous squamous cell carcinoma in mice.
APC shuttling to the membrane, nucleus and beyond.
Apparent preferential loss of heterozygosity at TSC2 over TSC1 chromosomal region in tuberous sclerosis hamartomas.
Appendectomy and cancer risk in Jewish BRCA1 and BRCA2 mutation carriers.
Application of embryonic lethal or other obvious phenotypes to characterize the clinical significance of genetic variants found in trans with known deleterious mutations.
Are BRCA1- and BRCA2-associated breast cancers different? Prognosis of BRCA1-associated breast cancer.
Are BRCA1- and BRCA2-related breast cancers associated with increased mortality?
Are estrogen receptor-positive breast cancers in BRCA1 mutation carriers sporadic?
Are medullary breast cancers an indication for BRCA1 mutation screening? A mutation analysis of 42 cases of medullary breast cancer.
Are Parkinson disease patients protected from some but not all cancers?
Are pathogenic BRCA1 mutations associated with parotid mucoepidermoid carcinoma? A case report.
Are Trp53 rescue of Brca1 embryonic lethality and Trp53/Brca1 breast cancer association related?
ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation.
Aromatase expression is increased in BRCA1 mutation carriers.
Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1.
Arsenic trioxide reactivates proteasome-dependent degradation of mutant p53 protein in cancer cells in part via enhanced expression of Pirh2 E3 ligase.
Arsenic?induced BRCA1 CpG promoter methylation is associated with the downregulation of ER? and resistance to tamoxifen in MCF7 breast cancer cells and mouse mammary tumor xenografts.
Artemisitene suppresses tumorigenesis by inducing DNA damage through deregulating c-Myc-topoisomerase pathway.
Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2.
ASPM promotes homologous recombination-mediated DNA repair by safeguarding BRCA1 stability.
Assays for Hypermethylation of the BRCA1 Gene Promoter in Tumor Cells to Predict Sensitivity to PARP-Inhibitor Therapy.
Assembly of an Evolutionarily Conserved Alternative Proteasome Isoform in Human Cells.
Assessing breast cancer risk and BRCA1/2 carrier probability.
Assessment of DNA methylation profiling and copy number variation as indications of clonal relationship in ipsilateral and contralateral breast cancers to distinguish recurrent breast cancer from a second primary tumour.
Assessment of DNA Repair Gene Expressions in Vitrified Mouse Preantral Follicles.
Assessment of human Nter and Cter BRCA1 mutations using growth and localization assays in yeast.
Assessment of the functional impact of germline BRCA1/2 variants located in non-coding regions in families with breast and/or ovarian cancer predisposition.
ASSESSMENT OF THE VALUE OF METHYLATION FEATURES IN DIFFERENT TISSUES FOR PREOPERATIVE IDENTIFICATION OF HIGH-RISK BREAST TUMORS.
Assessment of tumor suppressor promoter methylation in healthy individuals.
Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing.
Association between BRCA1 mutations and ratio of female to male births in offspring of families with breast cancer, ovarian cancer, or both.
Association between BRCA1 P871L polymorphism and cancer risk: evidence from a meta-analysis.
Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Association between cytosolic expression of BRCA1 and metastatic risk in breast cancer.
Association between epidermal growth factor receptor gene copy number and ERCC1, BRCA1 protein expression in Chinese patients with non-small cell lung cancer.
Association between hereditary predisposition to common cancers and congenital multimalformations.
Association between loss of heterozygosity of BRCA1 and BRCA2 and morphological attributes of sporadic breast cancer.
Association between Presenilin-1 and TRAF6 modulates regulated intramembrane proteolysis of the p75NTR neurotrophin receptor.
Association between single nucleotide polymorphism of DNA repair genes and endometrial cancer: a case-control study.
Association between vitamin D and ovarian cancer development in BRCA1 mutation carriers.
Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes.
Association of BLM and BRCA1 during Telomere Maintenance in ALT Cells.
Association of BRCA Mutantations and BRCAness Status With Anticancer Drug Sensitivities in Triple-Negative Breast Cancer Cell Lines.
Association of BRCA Mutation Types, Imaging Features, and Pathologic Findings in Patients With Breast Cancer With BRCA1 and BRCA2 Mutations.
Association of BRCA1 185 del AG with early age onset of breast cancer patients in selected cohort from Pakistani population.
Association of BRCA1 Mutations with Impaired Ovarian Reserve: Connection Between Infertility and Breast/Ovarian Cancer Risk.
Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks.
Association of BRCA1 Promoter Methylation with Breast Cancer in Asia: A Meta- Analysis
Association of BRCA1 promoter methylation with rs11655505 (c.2265C>T) variants and decreased gene expression in sporadic breast cancer.
Association of BRCA1 promoter methylation with sporadic breast cancers: Evidence from 40 studies.
Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response.
Association of BRCA1 with the inactive X chromosome and XIST RNA.
Association of BRCA1, ERCC1, RAP80, PKM2, RRM1, RRM2, TS, TSP1, and TXR1 mRNA expression levels between primary tumors and infiltrated regional lymph nodes in patients with resectable non-small cell lung cancer.
Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer.
Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
Association of Breast and Ovarian Cancers With Predisposition Genes Identified by Large-Scale Sequencing.
Association of Cytokeratin 5 and Claudin 3 expression with BRCA1 and BRCA2 germline mutations in women with early breast cancer.
Association of DEAR1 Tagging Single Nucleotide Polymorphisms With Breast Cancer in a Sample of Colombian Population: A Case Control Study.
Association of E6AP (UBE3A) with human papillomavirus type 11 E6 protein.
Association of HMGB1, BRCA1 and P62 expression in ovarian cancer and chemotherapy sensitivity.
Association of HO-1 and BRCA1 Is Critical for the Maintenance of Cellular Homeostasis in Prostate Cancer.
Association of hormone receptor status with grading, age of onset, and tumor size in BRCA1-associated breast cancer.
Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non-Small Cell Lung Cancer.
Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction.
Association of radiotherapy with preferential depletion of luminal epithelial cells in a BRCA1 mutation carrier.
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
Association of the BRCA1 promoter polymorphism rs11655505 with the risk of familial breast and/or ovarian cancer.
Association of the von Hippel-Lindau protein with AUF1 and posttranscriptional regulation of VEGFA mRNA.
Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.
Association of XPC polymorphisms with susceptibility and clinical outcome to chemotherapy in breast cancer patients.
Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers.
Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations.
Asymmetric recruitment of cIAPs by TRAF2.
Ataxia telangiectasia-related protein is involved in the phosphorylation of BRCA1 following deoxyribonucleic acid damage.
ATF-2 controls transcription of Maspin and GADD45 alpha genes independently from p53 to suppress mammary tumors.
ATM and genome maintenance: defining its role in breast cancer susceptibility.
ATM engages autodegradation of the E3 ubiquitin ligase COP1 after DNA damage.
Atm heterozygosity cooperates with loss of Brca1 to increase the severity of mammary gland cancer and reduce ductal branching.
ATM Regulated PTEN Degradation Is XIAP E3 Ubiquitin Ligase Mediated in p85? Deficient Cancer Cells and Influence Platinum Sensitivity.
ATM-Deficient Cancers Provide New Opportunities for Precision Oncology.
ATP stimulates MDM2-mediated inhibition of the DNA-binding function of E2F1.
ATR/ATM-Mediated Phosphorylation of BRCA1 T1394 Promotes Homologous Recombinational Repair and G2-M Checkpoint Maintenance.
ATR/Chk1/Smurf1 pathway determines cell fate after DNA damage by controlling RhoB abundance.
Attenuation of proteolysis-mediated cyclin E regulation by alternatively spliced Parkin in human colorectal cancers.
Attitudes about genetic testing for breast-ovarian cancer susceptibility.
Attitudes toward the genetic testing of children among adults in a Utah-based kindred tested for a BRCA1 mutation.
Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2.
Attitudes, knowledge, risk perceptions and decision-making among women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2 and their spouses.
AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study.
Aurora B Kinase Promotes CHIP-Dependent Degradation of HIF1? in Prostate Cancer Cells.
Auto-ubiquitination of Mdm2 enhances its substrate ubiquitin ligase activity.
Autoimmune response to PARP and BRCA1/BRCA2 in cancer.
Autonomy of the epithelial phenotype in human ovarian surface epithelium: changes with neoplastic progression and with a family history of ovarian cancer.
Autophagic Degradation of NBR1 Restricts Metastatic Outgrowth during Mammary Tumor Progression.
Autophagy defects and related genetic variations in renal cell carcinoma with eosinophilic cytoplasmic inclusions.
Autophagy opposes p53-mediated tumor barrier to facilitate tumorigenesis in a model of PALB2-associated hereditary breast cancer.
Autophagy orchestrates the regulatory program of tumor-associated myeloid-derived suppressor cells.
Autoubiquitination of the BRCA1*BARD1 RING ubiquitin ligase.
Average age-specific cumulative risk of breast cancer according to type and site of germline mutations in BRCA1 and BRCA2 estimated from multiple-case breast cancer families attending Australian family cancer clinics.
Axin determines cell fate by controlling the p53 activation threshold after DNA damage.
Axl/Gas6/NF?B signalling in schwannoma pathological proliferation, adhesion and survival.
BACH1 is a DNA repair protein supporting BRCA1 damage response.
BAP1 inhibits the ER stress gene regulatory network and modulates metabolic stress response.
BAP1 promotes viability and migration of ECA109 cells through KLF5/CyclinD1/FGF-BP1.
BAP1 tumor predisposition syndrome case report: pathological and clinical aspects of BAP1-inactivated melanocytic tumors (BIMTs), including dermoscopy and confocal microscopy.
BAP1, a candidate tumor suppressor protein that interacts with BRCA1.
BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression.
BARD1 and breast cancer in Poland.
BARD1 and Breast Cancer: The Possibility of Creating Screening Tests and New Preventive and Therapeutic Pathways for Predisposed Women.
BARD1 Gene Polymorphisms Confer Nephroblastoma Susceptibility.
BARD1 homozygous deletion, a possible alternative to BRCA1 mutation in basal breast cancer.
BARD1 induces BRCA1 intranuclear foci formation by increasing RING-dependent BRCA1 nuclear import and inhibiting BRCA1 nuclear export.
BARD1 may be renamed ROW1 because it functions mainly as a REPRESSOR OF WUSCHEL1.
BARD1 participates with BRCA1 in homology-directed repair of chromosome breaks.
BARD1 Pathogenic Variants are Associated with Triple-Negative Breast Cancer in a Spanish Hereditary Breast and Ovarian Cancer Cohort.
BARD1 regulates BRCA1 apoptotic function by a mechanism involving nuclear retention.
BARD1 regulates BRCA1-mediated transactivation of the p21(WAF1/CIP1) and Gadd45 promoters.
BARD1 variants Cys557Ser and Val507Met in breast cancer predisposition.
Basal Cytokeratin and Epidermal Growth Factor Receptor Expression Are Not Predictive of BRCA1 Mutation Status in Women With Triple-negative Breast Cancers.
Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families.
Basal repression of BRCA1 by multiple E2Fs and pocket proteins at adjacent E2F sites.
Basal-like breast cancer and the BRCA1 phenotype.
Basal-like breast cancer displays distinct patterns of promoter methylation.
Basal-like breast cancer: a critical review.
Basal-like Breast Cancer: Comparison of Imaging Characteristics.
Basal-like breast cancers: the phenotypic disparity between the cancer-initiating cells and tumor histology.
Basal-like breast carcinoma: from expression profiling to routine practice.
Basal-like subtype and BRCA1 dysfunction in breast cancers.
Bayes analysis provides evidence of pathogenicity for the BRCA1 c.135-1G>T (IVS3-1) and BRCA2 c.7977-1G>C (IVS17-1) variants displaying in vitro splicing results of equivocal clinical significance.
BCA2 is differentially expressed in renal oncocytoma: an analysis of 158 renal neoplasms.
Bcl-2 inhibits nuclear homologous recombination by localizing BRCA1 to the endomembranes.
BECN1 and BRCA1 Deficiency Sensitizes Ovarian Cancer to Platinum Therapy and Confers Better Prognosis.
Behavioral science in translational research and cancer control.
Being 'at-risk' for developing cancer: cognitive representations and psychological outcomes.
Beyond BRCA1 and BRCA2: Deleterious Variants in DNA Repair Pathway Genes in Italian Families with Breast/Ovarian and Pancreatic Cancers.
Beyond triple-negative breast cancer: the need to define new subtypes.
Bi-phasic expression of Heterochromatin Protein 1 (HP1) during breast cancer progression: Potential roles of HP1 and chromatin structure in tumorigenesis.
Biallelic Deleterious BRCA1 Mutations in a Woman with Early-Onset Ovarian Cancer.
Biallelic germline BRCA1 mutations in a patient with early onset breast cancer, mild Fanconi anemia-like phenotype, and no chromosome fragility.
Biallelic inactivation of BRCA2 in Fanconi anemia.
Biallelic variants in BRCA1 gene cause a recognisable phenotype within chromosomal instability syndromes reframed as BRCA1 deficiency.
Bid Promotes K63-Linked Polyubiquitination of Tumor Necrosis Factor Receptor Associated Factor 6 (TRAF6) and Sensitizes to Mutant SOD1-Induced Proinflammatory Signaling in Microglia.
Bilateral breast cancers.
Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers.
Bilateral risk-reducing oophorectomy in BRCA1 and BRCA2 mutation carriers.
Bilateral salpingo-oophorectomy and breast cancer risk for BRCA1 and BRCA2 mutation carriers: Assessing the evidence.
Bilateral Triple-Negative Invasive Breast Cancer with a BRCA2 Mutation, and Glioblastoma: A Case Report and Literature Review.
Bile acids upregulate BRCA1 and downregulate estrogen receptor 1 gene expression in ovarian cancer cells.
Binding and recognition in the assembly of an active BRCA1/BARD1 ubiquitin-ligase complex.
Binding of CtIP to the BRCT repeats of BRCA1 involved in the transcription regulation of p21 is disrupted upon DNA damage.
Biobibliometrics (UGDH-TP53-BRCA1) Genes Connections in the Possible Relationship Between Breast Cancer and EEG.
Biochemical aspects of the neuroprotective mechanism of PTEN-induced kinase-1 (PINK1).
Bioinformatics Approaches to Explore the Phylogeny and Role of BRCA1 in Breast Cancer.
Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting.
Biological processes, properties and molecular wiring diagrams of candidate low-penetrance breast cancer susceptibility genes.
Biomarker-Guided Development of DNA Repair Inhibitors.
Biomarkers and mechanisms of FANCD2 function.
Biomarkers in the ovary.
Biomarkers in triple negative breast cancer: A review.
Biomarkers of Targeted Therapy and Immuno-Oncology in Cancers Metastatic to the Breast.
Biophenotypes and survival of BRCA1 and TP53 deleted breast cancer in young women.
BIRC3 alterations in chronic and B-cell acute lymphocytic leukemia patients.
BIRC3 and BIRC5: multi-faceted inhibitors in cancer.
BIRC3 is a biomarker of mesenchymal habitat of glioblastoma, and a mediator of survival adaptation in hypoxia-driven glioblastoma habitats.
Birinapant (TL32711), a Bivalent SMAC Mimetic, Targets TRAF2-Associated cIAPs, Abrogates TNF-Induced NF-?B Activation, and Is Active in Patient-Derived Xenograft Models.
Bispecific Estrogen Receptor ? Degraders Incorporating Novel Binders Identified Using DNA-Encoded Chemical Library Screening.
Bivalent smac mimetics with a diazabicyclic core as highly potent antagonists of XIAP and cIAP1/2 and novel anticancer agents.
Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
Blood Arsenic Levels as a Marker of Breast Cancer Risk among BRCA1 Carriers.
Both sides of the same coin: Rac1 alternative splicing by EGF signaling.
Box BRCA1 tumour inhibition.
BP1, an isoform of DLX4 homeoprotein, negatively regulates BRCA1 in sporadic breast cancer.
BRACking news on triple-negative/basal-like breast cancers: how BRCA1 deficiency may result in the development of a selective tumor subtype.
Brain Metastases from Ovarian Cancer: Current Evidence in Diagnosis, Treatment, and Prognosis.
BRCA 1 and 2--A Genetic Link to Familial Breast and Ovarian Cancer.
BRCA and Beyond: Comprehensive Image-rich Review of Hereditary Breast and Gynecologic Cancer Syndromes.
BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations.
BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2.
BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer.
BRCA Genes: The Role in Genome Stability, Cancer Stemness and Therapy Resistance.
BRCA germline mutations in Jewish women with uterine serous papillary carcinoma.
BRCA immunohistochemistry for screening of BRCA mutation in epithelial ovarian cancer patients.
BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers.
BRCA mutation-negative women from hereditary breast and ovarian cancer families: a qualitative study of the BRCA-negative experience.
BRCA Mutations in the Young, High-Risk Female Population: Genetic Testing, Management of Prophylactic Therapies, and Implications for Plastic Surgeons.
BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing.
BRCA, the oviduct, and the space and time continuum of pelvic serous carcinogenesis.
BRCA-associated breast cancer: absence of a characteristic immunophenotype.
BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance.
BRCA1 - Conductor of the Breast Stem Cell Orchestra: The Role of BRCA1 in Mammary Gland Development and Identification of Cell of Origin of BRCA1 Mutant Breast Cancer.
BRCA1 16 years later: risk-associated BRCA1 mutations and their functional implications.
BRCA1 1675delA and 1135insA account for one third of Norwegian familial breast-ovarian cancer and are associated with later disease onset than less frequent mutations.
BRCA1 4153delA founder mutation in Russian ovarian cancer patients.
BRCA1 5083del19 mutant allele selectively up-regulates periostin expression in vitro and in vivo.
BRCA1 5272-1G>A and BRCA2 5374delTATG are founder mutations of high relevance for genetic counselling in breast/ovarian cancer families of Spanish origin.
BRCA1 5382insC founder mutation has not a significative recurrent presence in Northeastern Romanian cancer patients.
BRCA1 affects global DNA methylation through regulation of DNMT1.
BRCA1 affects lipid synthesis through its interaction with acetyl-CoA carboxylase.
BRCA1 affects protein phosphatase 6 signalling through its interaction with ANKRD28.
BRCA1 allele-specific expression in genetic predisposed breast/ovarian cancer.
BRCA1 alterations with additional defects in DNA damage response genes may confer chemoresistance to BRCA-like breast cancers treated with neoadjuvant chemotherapy.
BRCA1 and ?H2AX as independent prognostic markers in oral squamous cell carcinoma.
BRCA1 and acetyl-CoA carboxylase: the metabolic syndrome of breast cancer.
BRCA1 and BARD1 colocalize mainly in the cytoplasm of breast cancer tumors, and their isoforms show differential expression.
BRCA1 And BRCA2 analysis of Argentinean breast/ovarian cancer patients selected for age and family history highlights a role for novel mutations of putative south-American origin.
BRCA1 and BRCA2 and the genetics of breast and ovarian cancer.
BRCA1 and BRCA2 are necessary for the transcription-coupled repair of the oxidative 8-oxoguanine lesion in human cells.
BRCA1 and BRCA2 as ovarian cancer susceptibility genes.
BRCA1 and BRCA2 associated breast cancer and the roles of current modelling systems in drug discovery.
BRCA1 and BRCA2 cancer risks.
BRCA1 and BRCA2 expression patterns and prognostic significance in digestive system cancers.
BRCA1 and BRCA2 gene mutation analysis: visit to the Breast Cancer Information Core (BIC).
BRCA1 and BRCA2 gene mutations and risk of breast cancer. Public health perspectives.
BRCA1 and BRCA2 genes: role in hereditary breast and ovarian cancer in Italy.
BRCA1 and BRCA2 genetic testing for ovarian cancer: is it all good news?
BRCA1 and BRCA2 germline mutation analysis among Indian women from south India: identification of four novel mutations and high-frequency occurrence of 185delAG mutation.
BRCA1 and BRCA2 Germline Mutation Analysis in Hereditary Breast/Ovarian Cancer Families from the Aures Region (Eastern Algeria): First Report.
BRCA1 and BRCA2 germline mutation analysis in the Indonesian population.
BRCA1 and BRCA2 germline mutation spectrum and frequencies in Belgian breast/ovarian cancer families.
BRCA1 and BRCA2 germline mutation spectrum in hereditary breast/ovarian cancer families from Maghrebian countries.
BRCA1 and BRCA2 germline mutational spectrum and evidence for genetic anticipation in Portuguese breast/ovarian cancer families.
BRCA1 and BRCA2 germline mutations in 85 Iranian breast cancer patients.
BRCA1 and BRCA2 Germline Mutations in Japanese with Hereditary Breast Cancer Families.
BRCA1 and BRCA2 germline mutations in lymphoma patients.
BRCA1 and BRCA2 germline mutations in Moroccan breast/ovarian cancer families: novel mutations and unclassified variants.
BRCA1 and BRCA2 germline mutations in Uruguayan breast and breast-ovarian cancer families. Identification of novel mutations and unclassified variants.
BRCA1 and BRCA2 germline mutations screening in Algerian breast/ovarian cancer families.
BRCA1 and BRCA2 heterozygosity in embryonic stem cells reduces radiation-induced Rad51 focus formation but is not associated with radiosensitivity.
BRCA1 and BRCA2 in 2005.
BRCA1 and BRCA2 in breast cancer.
BRCA1 and BRCA2 mutation analysis in 86 early onset breast/ovarian cancer patients.
BRCA1 and BRCA2 mutation analysis in breast-ovarian cancer families from northeastern Poland.
BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer.
BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark.
BRCA1 and BRCA2 mutation status and cancer family history of Danish women affected with multifocal or bilateral breast cancer at a young age.
BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.
BRCA1 and BRCA2 mutation type associated with cancer risk.
BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
BRCA1 and BRCA2 mutations among 233 unselected Finnish ovarian carcinoma patients.
BRCA1 and BRCA2 mutations among familial breast cancer patients from Costa Rica.
BRCA1 and BRCA2 mutations among Finnish ovarian carcinoma families.
BRCA1 and BRCA2 mutations and the risk for colorectal cancer.
BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma.
BRCA1 and BRCA2 mutations in a South American population.
BRCA1 and BRCA2 Mutations in Breast and Ovarian Cancer Syndrome: Reflection on the Creighton University Historical Series of High Risk Families.
BRCA1 and BRCA2 mutations in breast cancer families with multiple primary cancers.
BRCA1 and BRCA2 mutations in breast/ovarian cancer patients from central Italy.
BRCA1 and BRCA2 mutations in central and southern Italian patients.
BRCA1 and BRCA2 mutations in Japanese patients with ovarian, fallopian tube, and primary peritoneal cancer.
BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.
BRCA1 and BRCA2 mutations in Russian familial breast cancer.
BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer.
BRCA1 and BRCA2 mutations in women with familial or early-onset breast/ovarian cancer in the Czech Republic.
BRCA1 and BRCA2 pathogenic sequence variants in women of African origin or ancestry.
BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian.
BRCA1 and BRCA2 risk perceptions among African American women at increased risk for hereditary breast-ovarian cancer.
BRCA1 and BRCA2 Testing through Next Generation Sequencing in a Small Cohort of Italian Breast/Ovarian Cancer Patients: Novel Pathogenic and Unknown Clinical Significance Variants.
BRCA1 and BRCA2 Tumor Suppressor Function in Meiosis.
BRCA1 and BRCA2 tumor suppressors in neural crest cells are essential for craniofacial bone development.
BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity.
BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.
BRCA1 and BRCA2 Variation in Taiwanese General Population and the Cancer Cohort.
BRCA1 and BRCA2 whole cDNA analysis in unsolved hereditary breast/ovarian cancer patients.
BRCA1 and BRCA2--breast cancer susceptibility genes.
BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double strand break repair.
BRCA1 and Breast Cancer: a Review of the Underlying Mechanisms Resulting in the Tissue-Specific Tumorigenesis in Mutation Carriers.
BRCA1 and cell signaling.
BRCA1 and CtIP promote alternative non-homologous end-joining at uncapped telomeres.
Brca1 and differentiation.
BRCA1 and estrogen/estrogen receptor in breast cancer: where they interact?
BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotype.
BRCA1 and FancJ cooperatively promote interstrand crosslinker induced centrosome amplification through the activation of polo-like kinase 1.
BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents.
BRCA1 and GATA3 corepress FOXC1 to inhibit the pathogenesis of basal-like breast cancers.
BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation.
BRCA1 and implications for response to chemotherapy in ovarian cancer.
BRCA1 and Its Network of Interacting Partners.
BRCA1 and its toolbox for the maintenance of genome integrity.
BRCA1 and MDM2 as independent blood-based biomarkers of head and neck cancer.
BRCA1 and MicroRNAs: Emerging networks and potential therapeutic targets.
BRCA1 and p53 protein expression in cultured ovarian surface epithelial cells derived from women with and without a BRCA1 germline mutation.
BRCA1 and p53 regulate critical prostate cancer pathways.
BRCA1 and p53 Tumor Suppressor Molecules in Alzheimer's Disease.
BRCA1 and p53: compensatory roles in DNA repair.
BRCA1 and PALB2 in a Messy Breakup.
BRCA1 and prostate cancer.
BRCA1 and RNAi factors promote repair mediated by small RNAs and PALB2-RAD52.
BRCA1 and S phase DNA repair pathways restrict LINE-1 retrotransposition in human cells.
BRCA1 and stem cells: tumour typecasting.
BRCA1 and transcription.
BRCA1 as a potential human prostate tumor suppressor: modulation of proliferation, damage responses and expression of cell regulatory proteins.
BRCA1 as a Therapeutic Target in Sporadic Epithelial Ovarian Cancer.
BRCA1 as a tumor suppressor linked to the regulation of epigenetic states: keeping oncomiRs under control.
BRCA1 as target for breast cancer prevention and therapy.
BRCA1 as tumor suppressor: lord without its RING?
BRCA1 associates with human papillomavirus type 18 E2 and stimulates E2-dependent transcription.
BRCA1 associates with processive RNA polymerase II.
BRCA1 associates with the inactive X chromosome in late S-phase, coupled with transient H2AX phosphorylation.
BRCA1 at the crossroad of multiple cellular pathways: approaches for therapeutic interventions.
BRCA1 Attenuates Progesterone Effects on Proliferation and NF?B Activation in Normal Human Mammary Epithelial Cells.
BRCA1 augments transcription by the NF-kappaB transcription factor by binding to the Rel domain of the p65/RelA subunit.
BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells.
BRCA1 binds c-Myc and inhibits its transcriptional and transforming activity in cells.
Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics.
BRCA1 c.2845insA is a founder mutation in Singaporean Malay women with early onset breast/ovarian cancer.
BRCA1 c.2845insA is a recurring mutation with a founder effect in Singapore Malay women with early onset breast/ovarian cancer.
BRCA1 carries tumor suppressor activity distinct from that of p53 and p21.
BRCA1 Circos: a visualisation resource for functional analysis of missense variants.
BRCA1 contributes to cell cycle arrest and chemoresistance in response to the anticancer agent irofulven.
BRCA1 control of steroid receptor ubiquitination.
BRCA1 controls homologous recombination at Tus/Ter-stalled mammalian replication forks.
Brca1 controls homology-directed DNA repair.
BRCA1 controls the cell division axis and governs ploidy and phenotype in human mammary cells.
BRCA1 cooperates with NUFIP and P-TEFb to activate transcription by RNA polymerase II.
BRCA1 deficiency and synthetic lethality in leukemias; not only gene mutation matters.
BRCA1 DEFICIENCY EXACERBATES ESTROGEN INDUCED DNA DAMAGE AND GENOMIC INSTABILITY.
BRCA1 Deficiency Impairs Mitophagy and Promotes Inflammasome Activation and Mammary Tumor Metastasis.
BRCA1 deficiency in ovarian cancer is associated with alteration in expression of several key regulators of cell motility - A proteomics study.
BRCA1 deficiency induces protective autophagy to mitigate stress and provides a mechanism for BRCA1 haploinsufficiency in tumorigenesis.
BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation.
Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities.
BRCA1 deficiency sensitizes breast cancer cells to bromodomain and extra-terminal domain (BET) inhibition.
BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents.
BRCA1 deficient embryonic stem cells display a decreased homologous recombination frequency and an increased frequency of non-homologous recombination that is corrected by expression of a brca1 transgene.
BRCA1 deficient Mouse Models to Study Pathogenesis and Therapy of Triple Negative Breast Cancer.
BRCA1 degradation in response to mitochondrial damage in breast cancer cells.
BRCA1 disease-associated haplotypes in Singapore Malay women with early-onset breast/ovarian cancer.
BRCA1 DNA-binding activity is stimulated by BARD1.
BRCA1 does not paint the inactive X to localize XIST RNA but may contribute to broad changes in cancer that impact XIST and Xi heterochromatin.
BRCA1 dysfunction in sporadic basal-like breast cancer.
BRCA1 E1644X: a deleterious mutation in an African American individual with early onset breast cancer.
BRCA1 effects on the cell cycle and the DNA damage response are linked to altered gene expression.
BRCA1 ensures genome integrity by eliminating estrogen-induced pathological topoisomerase II-DNA complexes.
BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer.
BRCA1 exon 11 alternative splicing, multiple functions and the association with cancer.
BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study.
BRCA1 expression and molecular alterations in familial breast cancer.
BRCA1 Expression by Immunohistochemistry and Prognosis in Ovarian Cancer: A Systematic Review and Meta-Analysis.
BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study.
BRCA1 expression in benign and malignant breast lesions.
BRCA1 expression in canine mammary dysplasias and tumours: relationship with prognostic variables.
BRCA1 expression in leukoplakia and carcinoma of the tongue.
BRCA1 expression in triple negative sporadic breast cancers.
BRCA1 Expression is an Important Biomarker for Chemosensitivity: Suppression of BRCA1 Increases the Apoptosis via Up-regulation of p53 and p21 During Cisplatin Treatment in Ovarian Cancer Cells.
BRCA1 expression is induced before DNA synthesis in both normal and tumor-derived breast cells.
Brca1 expression is regulated by a bidirectional promoter that is shared by the Nbr1 gene in mouse.
BRCA1 expression levels predict distant metastasis of sporadic breast cancers.
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells.
BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair.
BRCA1 expression status in relation to DNA methylation of the BRCA1 promoter region in sporadic breast cancers.
BRCA1 expression, proliferative and apoptotic activities in ovarian epithelial inclusions.
BRCA1 facilitates stress-induced apoptosis in breast and ovarian cancer cell lines.
BRCA1 foci in normal S-phase nuclei are linked to interphase centromeres and replication of pericentric heterochromatin.
BRCA1 forks over new roles in DNA-damage response- before and beyond the breaks.
BRCA1 Forms a Functional Complex with ?-H2AX as a Late Response to Genotoxic Stress.
BRCA1 founder mutations do not contribute to increased risk of gastric cancer in the Polish population.
BRCA1 function in T lymphocytes: a cellular specificity of a different kind.
BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis.
BRCA1 gene expression in breast cancer in Kuwait: correlation with prognostic parameters.
BRCA1 gene in breast cancer.
BRCA1 gene mutation and loss of heterozygosity on chromosome 17q21 in primary prostate cancer.
BRCA1 gene mutation in thymic malignant melanoma.
BRCA1 Gene Mutations and Influence of Chemotherapy on Autophagy and Apoptotic Mechanisms in Egyptian Breast Cancer Patients.
BRCA1 gene mutations in sporadic ovarian carcinomas: detection by PCR and reverse allele-specific oligonucleotide hybridization.
BRCA1 gene mutations in women with papillary serous carcinoma of the peritoneum.
BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer - a population based study from the Western Sweden Health Care region.
BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD).
BRCA1 gene variant p.P142H associated with male breast cancer: a two-generation genealogic study and literature review.
BRCA1 genetic testing in 106 breast and ovarian cancer families from southern Italy (Sicily): a mutation analyses.
BRCA1 genetic testing in a Pakistani breast-ovarian cancer family with multiple consanguineous marriages.
BRCA1 germ-line mutations and tumor characteristics in eastern Chinese women with familial breast cancer.
BRCA1 germline mutation and glioblastoma development: report of cases.
BRCA1 germline mutation in a woman with metaplastic squamous cell breast cancer.
BRCA1 germline mutational spectrum in Italian families from Tuscany: a high frequency of novel mutations.
BRCA1 germline mutations and polymorphisms in a clinic-based series of ovarian cancer cases: a Gynecologic Oncology Group study.
BRCA1 germline mutations and tumor characteristics in Chinese women with familial or early-onset breast cancer.
BRCA1 germline mutations in Cypriot breast cancer patients from 26 families with family history.
BRCA1 germline mutations in women with uterine serous papillary carcinoma.
BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells.
BRCA1 Haploinsufficiency Is Masked by RNF168-Mediated Chromatin Ubiquitylation.
BRCA1 haploinsufficiency leads to altered expression of genes involved in cellular proliferation and development.
BRCA1 haploinsufficiency, but not heterozygosity for a BRCA1-truncating mutation, deregulates homologous recombination.
BRCA1 haploinsufficiency: consequences for breast cancer.
Brca1 heterozygous mice have shortened life span and are prone to ovarian tumorigenesis with haploinsufficiency upon ionizing irradiation.
BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas.
BRCA1 in breast and ovarian cancer predisposition.
BRCA1 in cancer, cell cycle and genomic stability.
BRCA1 in hormonal carcinogenesis: basic and clinical research.
BRCA1 in hormone-responsive cancers.
BRCA1 in non-inherited breast carcinomas (Review).
BRCA1 in the DNA damage response and at telomeres.
Brca1 inactivation induces p27(Kip1)-dependent cell cycle arrest and delayed development in the mouse mammary gland.
BRCA1 induces major energetic metabolism reprogramming in breast cancer cells.
BRCA1 inhibition of estrogen receptor signaling in transfected cells.
BRCA1 inhibition of telomerase activity in cultured cells.
BRCA1 inhibits membrane estrogen and growth factor receptor signaling to cell proliferation in breast cancer.
BRCA1 interacts with dominant negative SWI/SNF enzymes without affecting homologous recombination or radiation-induced gene activation of p21 or Mdm2.
BRCA1 interacts with FHL2 and enhances FHL2 transactivation function.
BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival.
BRCA1 interacts with poly(A)-binding protein: implication of BRCA1 in translation regulation.
BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance.
BRCA1 involvement in toxicological responses and human cancer etiology.
BRCA1 is a component of the RNA polymerase II holoenzyme.
BRCA1 is a key regulator of breast differentiation through activation of Notch signalling with implications for anti-endocrine treatment of breast cancers.
BRCA1 Is a Novel Prognostic Indicator and Associates with Immune Cell Infiltration in Hepatocellular Carcinoma.
BRCA1 is a novel target to improve endothelial dysfunction and retard atherosclerosis.
BRCA1 is a selective co-activator of 14-3-3 sigma gene transcription in mouse embryonic stem cells.
BRCA1 is an essential regulator of heart function and survival following myocardial infarction.
BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer.
BRCA1 is differentially expressed in human tumor cells.
Brca1 is expressed independently of hormonal stimulation in the mouse ovary.
BRCA1 is regulated by Chk2 in response to spindle damage.
BRCA1 is required for common-fragile-site stability via its G2/M checkpoint function.
BRCA1 Is Required for Maintenance of Phospho-Chk1 and G2/M Arrest during DNA Cross-Link Repair in DT40 Cells.
BRCA1 is required for meiotic spindle assembly and spindle assembly checkpoint activation in mouse oocytes.
BRCA1 is secreted and exhibits properties of a granin.
BRCA1 localization to the telomere and its loss from the telomere in response to DNA damage.
BRCA1 loss activates cathepsin L-mediated degradation of 53BP1 in breast cancer cells.
BRCA1 Loss Induces GADD153-Mediated Doxorubicin Resistance in Prostate Cancer.
BRCA1 loss preexisting in small subpopulations of prostate cancer is associated with advanced disease and metastatic spread to lymph nodes and peripheral blood.
BRCA1 methylation: a significant role in tumour development?
BRCA1 mislocalization associated with breast carcinogenesis and poor prognosis in Taiwanese women.
BRCA1 modulates sensitivity to 5F-203 by regulating xenobiotic stress-inducible protein levels and EROD activity.
BRCA1 modulates the expression of hnRNPA2B1 and KHSRP.
BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer.
BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer.
BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy.
BRCA1 mRNA expression modifies the effect of T cell activation score on patient survival in breast cancer.
BRCA1 mutation analysis in 83 Spanish breast and breast/ovarian cancer families.
BRCA1 mutation analysis in breast/ovarian cancer families from Greece.
BRCA1 mutation and young age predict fast breast cancer growth in the Dutch, United Kingdom, and Canadian magnetic resonance imaging screening trials.
BRCA1 mutation influences progesterone response in human benign mammary organoids.
BRCA1 Mutation Leads to Deregulated Ubc9 Levels which Triggers Proliferation and Migration of Patient-Derived High Grade Serous Ovarian Cancer and Triple Negative Breast Cancer Cells.
BRCA1 mutation site may be linked with nuclear DNA ploidy in BRCA1-mutated ovarian carcinomas.
BRCA1 mutation testing for Japanese patients with ovarian cancer in breast cancer screening.
BRCA1 mutation- oncological treatment- reconstructive surgery of the breast- pregnancy: diagnostic and therapeutic procedures in a 28 year old patient diagnosed with a tumor in the left breast with a BRCA1 mutation.
BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance.
BRCA1 Mutation: A Predictive Marker for Radiation Therapy?
BRCA1 mutations and clinicopathological features in a sample of Italian women with early-onset breast cancer.
BRCA1 mutations and colorectal cancer in Poland.
BRCA1 mutations and luminal-basal transformation.
BRCA1 mutations drive oxidative stress and glycolysis in the tumor microenvironment: implications for breast cancer prevention with antioxidant therapies.
BRCA1 mutations found in archived early onset breast tumours.
BRCA1 mutations in a selected series of breast/ovarian cancer patients.
BRCA1 mutations in Algerian breast cancer patients: high frequency in young, sporadic cases.
BRCA1 Mutations in Cancer: Coordinating Deficiencies in Homologous Recombination with Tumorigenesis.
BRCA1 mutations in familial ovarian cancer.
BRCA1 mutations in German breast-cancer families.
BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study.
BRCA1 mutations in primary breast and ovarian carcinomas.
BRCA1 mutations in South African breast and/or ovarian cancer families: evidence of a novel founder mutation in Afrikaner families.
BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer.
BRCA1 mutations in women with familial or early-onset breast cancer and BRCA2 mutations in familial cancer in Estonia.
BRCA1 negatively regulates formation of autophagic vacuoles in MCF-7 breast cancer cells.
BRCA1 or CDK12 loss sensitizes cells to CHK1 inhibitors.
BRCA1 overexpression sensitizes cancer cells to lovastatin via regulation of cyclin D1-CDK4-p21WAF1/CIP1 pathway: analyses using a breast cancer cell line and tumoral xenograft model.
BRCA1 partially reverses the transforming activity of the ras oncogene.
BRCA1 participates in DNA decatenation.
BRCA1 pathway function in basal-like breast cancer cells.
BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M transition.
BRCA1 phosphorylation regulates caspase-3 activation in UV-induced apoptosis.
BRCA1 phosphorylation: biological consequences.
BRCA1 physically and functionally interacts with ATF1.
BRCA1 physically associates with p53 and stimulates its transcriptional activity.
BRCA1 plays a role in the hypoxic response by regulating HIF-1alpha stability and by modulating vascular endothelial growth factor expression.
BRCA1 point mutations in premenopausal breast cancer patients from Central Sudan.
BRCA1 positively regulates FOXO3 expression by restricting FOXO3 gene methylation and epigenetic silencing through targeting EZH2 in breast cancer.
BRCA1 promoter deletions in young women with breast cancer and a strong family history: a population-based study.
BRCA1 promoter hypermethylation and protein expression in ovarian carcinoma-an Indian study.
BRCA1 promoter hypermethylation in human placenta: A hidden link with ?-hCG expression.
BRCA1 promoter hypermethylation in sporadic epithelial ovarian carcinoma: Association with low expression of BRCA1, improved survival and co-expression of DNA methyltransferases.
BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer.
BRCA1 promoter hypermethylation signature for early detection of breast cancer in the Vietnamese population.
BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer.
BRCA1 Promoter Methylation and Expression - Associations with ER+, PR+ and HER2+ Subtypes of Breast Carcinoma
BRCA1 promoter methylation associated with poor survival in Chinese patients with sporadic breast cancer.
BRCA1 promoter methylation in peripheral blood DNA of mutation negative familial breast cancer patients with a BRCA1 tumour phenotype.
BRCA1 promoter methylation in peripheral blood is associated with the risk of triple-negative breast cancer.
BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy.
BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles.
BRCA1 promoter methylation is associated with increased mortality among women with breast cancer.
BRCA1 Promoter Methylation Is Linked to Defective Homologous Recombination Repair and Elevated miR-155 to Disrupt Myeloid Differentiation in Myeloid Malignancies.
BRCA1 promoter methylation of normal breast epithelial cells as a possible precursor for BRCA1-methylated breast cancer.
BRCA1 promoter methylation predicts adverse ovarian cancer prognosis.
BRCA1 Promoter Methylation Status in 1031 Primary Breast Cancers Predicts Favorable Outcomes Following Chemotherapy.
BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study.
BRCA1 promotes induction of ssDNA by ionizing radiation.
BRCA1 promotes unloading of the CMG helicase from a stalled DNA replication fork.
BRCA1 protein and nucleolin colocalize in breast carcinoma tissue and cancer cell lines.
BRCA1 protein expression and its correlation with ER/PR status in sporadic and familial breast cancer in Eastern Indian patients--a hospital based study.
BRCA1 protein expression and subcellular localization in primary breast cancer: Automated digital microscopy analysis of tissue microarrays.
BRCA1 Protein Expression Predicts Survival in Glioblastoma Patients from an NRG Oncology RTOG Cohort.
BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase A.
BRCA1 protein levels and PIK3CA mutations as predictive biomarkers for response to neoadjuvant chemotherapy in locally advanced breast cancer: An exploratory analysis.
BRCA1 proteins are transported to the nucleus in the absence of serum and splice variants BRCA1a, BRCA1b are tyrosine phosphoproteins that associate with E2F, cyclins and cyclin dependent kinases.
BRCA1 proteins regulate growth of ovarian cancer cells by tethering Ubc9.
BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk.
BRCA1 R71K missense mutation contributes to cancer predisposition by increasing alternative transcript levels.
BRCA1 R841W: a strong candidate for a common mutation with moderate phenotype.
BRCA1 regulates caveolin-1 expression and inhibits cell invasiveness.
BRCA1 Regulates g-Tubulin Binding to Centrosomes.
BRCA1 regulates gene expression for orderly mitotic progression.
BRCA1 regulates IFN-gamma signaling through a mechanism involving the type I IFNs.
Brca1 regulates in vitro differentiation of mammary epithelial cells.
BRCA1 regulates microRNA biogenesis via the DROSHA microprocessor complex.
BRCA1 regulates microtubule dynamics and taxane-induced apoptotic cell signaling.
BRCA1 regulates RAD51 function in response to DNA damage and suppresses spontaneous sister chromatid replication slippage: implications for sister chromatid cohesion, genome stability, and carcinogenesis.
BRCA1 regulates the cancer stem cell fate of breast cancer cells in the context of hypoxia and histone deacetylase inhibitors.
BRCA1 regulates the interferon gamma-mediated apoptotic response.
BRCA1 regulates transforming growth factor-? (TGF-?1) signaling through Gadd45a by enhancing the protein stability of Smad4.
BRCA1 regulation of epidermal growth factor receptor (EGFR) expression in human breast cancer cells involves microRNA-146a and is critical for its tumor suppressor function.
BRCA1 regulation of transcription.
BRCA1 regulation on ?-hCG: a mechanism for tumorigenicity in BRCA1 defective breast cancer.
BRCA1 represses amphiregulin gene expression.
BRCA1 requirement for the fidelity of plasmid DNA double-strand break repair in cultured breast epithelial cells.
BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance.
BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing.
BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Institut Curie Breast Cancer Group.
BRCA1 shifts p53-mediated cellular outcomes towards irreversible growth arrest.
BRCA1 signals ARF-dependent stabilization and coactivation of p53.
BRCA1 splice variants BRCA1a and BRCA1b associate with CBP co-activator.
BRCA1 supports XIST RNA concentration on the inactive X chromosome.
BRCA1 suppresses epithelial-to-mesenchymal transition and stem cell dedifferentiation during mammary and tumor development.
BRCA1 suppresses insulin-like growth factor-I receptor promoter activity: potential interaction between BRCA1 and Sp1.
BRCA1 suppresses osteopontin-mediated breast cancer.
BRCA1 targets G2/M cell cycle proteins for ubiquitination and proteasomal degradation.
BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes.
BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years.
BRCA1 testing with definitive results: a prospective study of psychological distress in a large clinic-based sample.
BRCA1 through Its E3 Ligase Activity Regulates the Transcription Factor Oct1 and Carbohydrate Metabolism.
BRCA1 transcriptionally regulates damaged DNA binding protein (DDB2) in the DNA repair response following UV-irradiation.
BRCA1 transcriptionally regulates genes associated with the basal-like phenotype in breast cancer.
BRCA1 transcriptionally regulates genes involved in breast tumorigenesis.
BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity.
BRCA1 tumor suppressor gene product shares immunoreactive epitopes with a protein present in seminal plasma.
BRCA1 tumor suppressor network: focusing on its tail.
BRCA1 tumour suppression occurs via heterochromatin-mediated silencing.
BRCA1 tumours correlate with a HIF-1alpha phenotype and have a poor prognosis through modulation of hydroxylase enzyme profile expression.
BRCA1 ubiquitinates its phosphorylation-dependent binding partner CtIP.
BRCA1 ubiquitinates RPB8 in response to DNA damage.
BRCA1 ubiquitylation of CtIP: Just the tIP of the iceberg?
BRCA1 wild-type allele modifies risk of ovarian cancer in carriers of BRCA1 germ-line mutations.
BRCA1, a 'complex' protein involved in the maintenance of genomic stability.
BRCA1, BRCA2 and breast cancer: a concise clinical review.
BRCA1, BRCA2 and CHEK2 (1100 del C) germline mutations in hereditary breast and ovarian cancer families in South India.
BRCA1, BRCA2 and CHEK2 c.1100 delC mutations in patients with double primaries of the breasts and/or ovaries.
BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing.
BRCA1, C-erbB-2, and H-ras gene expressions in young women with breast cancer. An immunohistochemical study.
BRCA1, histone H2AX phosphorylation, and male meiotic sex chromosome inactivation.
BRCA1, hormone, and tissue-specific tumor suppression.
BRCA1, microRNAs and cancer predisposition: challenging the dogma.
BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability.
BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma.
BRCA1--a good predictive marker of drug sensitivity in breast cancer treatment?
BRCA1-associated complexes: new targets to overcome breast cancer radiation resistance.
BRCA1-associated epigenetic regulation of p73 mediates an effector pathway for chemosensitivity in ovarian carcinoma.
BRCA1-associated mammary tumorigenesis is dependent on estrogen rather than progesterone signaling.
BRCA1-associated protein 1 interferes with BRCA1/BARD1 RING heterodimer activity.
BRCA1-associated structural variations are a consequence of polymerase theta-mediated end-joining.
BRCA1-associated tumorigenesis: what have we learned from knockout mice?
BRCA1-BARD1 regulates axon regeneration in concert with the Gq?-DAG signaling network.
BRCA1-BARD1 regulates transcription through BRD4 in Xenopus nucleoplasmic extract.
BRCA1-deficient breast cancer cell lines are resistant to MEK inhibitors and show distinct sensitivities to 6-thioguanine.
BRCA1-dependent Chk1 phosphorylation triggers partial chromatin disassociation of phosphorylated Chk1 and facilitates S-phase cell cycle arrest.
BRCA1-Dependent Translational Regulation in Breast Cancer Cells.
BRCA1-directed, enhanced and aberrant homologous recombination: Mechanism and potential treatment strategies.
BRCA1-hapoinsufficiency: Unraveling the molecular and cellular basis for tissue-specific cancer.
BRCA1-Interacting Protein OLA1 Requires Interaction with BARD1 to Regulate Centrosome Number.
BRCA1-IRIS overexpression promotes and maintains the tumor initiating phenotype: implications for triple negative breast cancer early lesions.
BRCA1-IRIS overexpression promotes formation of aggressive breast cancers.
BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1? activation.
BRCA1-Ku80 Protein Interaction Enhances End-joining Fidelity of Chromosomal Double-strand Breaks in the G1 Phase of the Cell Cycle.
BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial.
BRCA1-like profile predicts benefit of tandem high dose epirubicin-cyclophospamide-thiotepa in high risk breast cancer patients randomized in the WSG-AM01 trial.
BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential.
BRCA1-mediated chromatin silencing is limited to oocytes with a small number of asynapsed chromosomes.
BRCA1-mediated repression of mutagenic end-joining of DNA double-strand breaks requires complex formation with BACH1.
BRCA1-mediated signaling pathways in ovarian carcinogenesis.
BRCA1-mediated ubiquitylation.
BRCA1-methylated sporadic breast cancers are BRCA-like in showing a basal phenotype and absence of ER expression.
BRCA1-mutated estrogen receptor positive breast cancer shows BRCAness, suggesting sensitivity to drugs targeting homologous recombination deficiency.
BRCA1-No Matter How You Splice It.
BRCA1-p53 relationship in hereditary breast cancer.
BRCA1-regulated RRM2 expression protects glioblastoma cells from endogenous replication stress and promotes tumorigenicity.
BRCA1-related and sporadic ovarian cancer in the same family: implications for genetic testing.
BRCA1-related malignancies in a family presenting with von Recklinghausen's disease.
BRCA1-Sp1 interactions in transcriptional regulation of the IGF-IR gene.
BRCA1/2 genetic background-based therapeutic tailoring of human ovarian cancer : hope or reality?
BRCA1/2 mutations and risk-reducing bilateral salpingo-oophorectomy among Latinas: The UPTAKE study.
BRCA1/2 Mutations and Triple Negative Breast Cancers.
BRCA1/2 mutations in Swiss patients with familial or early-onset breast and ovarian cancer.
BRCA1/2 status and clinicopathologic characteristics of patients with double primary breast and ovarian cancer.
BRCA1/BARD1 complex interacts with steroidogenic factor 1--A potential mechanism for regulation of aromatase expression by BRCA1.
BRCA1/BARD1 inhibition of mRNA 3' processing involves targeted degradation of RNA polymerase II.
BRCA1/BARD1 orthologs required for DNA repair in Caenorhabditis elegans.
BRCA1/BARD1 ubiquitinate phosphorylated RNA polymerase II.
BRCA1/BRCA2 founder mutations and cancer risks: impact in the western Danish population.
BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma.
BRCA1/BRCA2 mutation status and analysis of cancer family history in participants of the Royal Marsden Hospital tamoxifen chemoprevention trial.
BRCA1/P53: Two strengths in cancer chemoprevention.
BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1.
BRCA1: a movement toward cancer prevention.
BRCA1: Beyond double-strand break repair.
BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution.
BRCA1: exploring the links to transcription.
BRCA1: linking HOX to breast cancer suppression.
BRCA1: mechanisms of inactivation and implications for management of patients.
BRCA1: the enigma of tissue-specific tumor development.
BRCA1a has antitumor activity in TN breast, ovarian and prostate cancers.
BRCA2 acts as a RAD51 loader to facilitate telomere replication and capping.
BRCA2 and Other DDR Genes in Prostate Cancer.
BRCA2 carriers with male breast cancer show elevated tumour methylation.
BRCA2 founder mutation in Slovenian breast cancer families.
BRCA2 germline mutation in a woman with uterine serous papillary carcinoma--case report.
BRCA2 germline mutations in Japanese breast cancer families.
BRCA2 germline mutations in male breast cancer cases and breast cancer families.
BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2.
BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo.
BRCA2 mutation analysis of 87 Spanish breast/ovarian cancer families.
BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays.
BRCA2 mutations and triple-negative breast cancer.
BRCA2-Deficient CAPAN-1 Cells are Extremely Sensitive to the Inhibition of Poly (ADP-Ribose) Polymerase: An Issue of Potency.
BRCA2-dependent homologous recombination is required for repair of Arsenite-induced replication lesions in mammalian cells.
BRCA2: a genetic risk factor for breast cancer.
Brcal Defective Breast Cancer Cells Induce in vitro Transformation of Cancer Associated Fibroblasts (CAFs) to Metastasis Associated Fibroblasts (MAF).
BRCAness is beneficial for indicating triple negative breast cancer patients resistant to taxane.
BRCAness revisited.
BRCC36A is epistatic to BRCA1 in DNA crosslink repair and homologous recombination in Arabidopsis thaliana.
BRCT domains: phosphopeptide binding and signaling modules.
BRD7: a novel tumor suppressor gene in different cancers.
Breast and Axillary Lymph Node Metastasis from Ovarian Cancer: A Case Report.
Breast and ovarian cancer in relatives of cancer patients, with and without BRCA mutations.
Breast and Ovarian Cancer Risk due to Prevalence of BRCA1 and BRCA2 Variants in Pakistani Population: A Pakistani Database Report.
Breast and ovarian cancer risk perception after prophylactic salpingo-oophorectomy due to an inherited mutation in the BRCA1 or BRCA2 gene.
Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
Breast and ovarian cancer: the forgotten paternal contribution.
Breast Cancer Adjuvant Radiotherapy in BRCA1/2, TP53, ATM Genes Mutations: Are There Solved Issues?
Breast cancer after mantle irradiation for Hodgkin's disease: correlation of clinical, pathologic, and molecular features including loss of heterozygosity at BRCA1 and BRCA2.
Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.
Breast cancer and genetic instability: the molecules behind the scenes.
Breast cancer cell response to genistein is conditioned by BRCA1 mutations.
Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers.
Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis.
Breast cancer gene 1 (BRCA1): role in cell cycle regulation and DNA repair--perhaps through transcription.
Breast cancer genes: therapeutic strategies.
Breast cancer genetics and managed care. The Kaiser Permanente experience.
Breast cancer genetics: family history, heterogeneity, molecular genetic diagnosis, and genetic counselling.
Breast cancer genetics: unsolved questions and open perspectives in an expanding clinical practice.
Breast cancer in a patient with Birt-Hogg-Dubé syndrome (BHDS) with dramatic response to neoadjuvant chemotherapy.
Breast cancer in BRCA mutation carriers: medical treatment.
Breast cancer in patients with germline TP53 pathogenic variants have typical tumour characteristics: the Cohort study of TP53 carrier early onset breast cancer (COPE study).
Breast cancer in six families from Tolima and Huila: BRCA1 3450del4 mutation
Breast Cancer Incidence After Risk-Reducing Salpingo-Oophorectomy in BRCA1 and BRCA2 Mutation Carriers.
Breast Cancer is Common in Women With Ovarian Malignant Mixed Mullerian Tumors.
Breast cancer markers.
Breast cancer patients suggestive of Li-Fraumeni syndrome: mutational spectrum, candidate genes, and unexplained heredity.
Breast cancer patients with hypermethylation in the promoter of BRCA1 gene exhibit favorable clinical status.
Breast Cancer Predisposition Genes and Synthetic Lethality.
Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers.
Breast cancer risk among male BRCA1 and BRCA2 mutation carriers.
Breast cancer risk and the DNA double-strand break end-joining capacity of nonhomologous end-joining genes are affected by BRCA1.
Breast cancer risk associated with BRCA1/2 variants in the Pakistani population.
Breast cancer risk for Korean women with germline mutations in BRCA1 and BRCA2.
Breast cancer risk perception among women who have undergone prophylactic bilateral mastectomy.
Breast cancer risks and risk prediction models.
Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation.
Breast cancer screening in BRCA1 and BRCA2 mutation carriers after risk reducing salpingo-oophorectomy.
Breast cancer stem cell markers - the rocky road to clinical applications.
Breast Cancer Surveillance Following Ovarian Cancer in BRCA Mutation Carriers.
Breast cancer susceptibility genes. BRCA1 and BRCA2.
Breast cancer susceptibility protein 1 (BRCA1) rescues neurons from cerebral ischemia/reperfusion injury through NRF2-mediated antioxidant pathway.
Breast cancer susceptibility testing: past, present and future.
Breast cancer-associated abraxas mutation disrupts nuclear localization and DNA damage response functions.
Breast Cancers with a BRCA1-like DNA Copy Number Profile Recur Less Often Than Expected after High-Dose Alkylating Chemotherapy.
Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomol.
Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: are they prognostically different?
Breast conservation in BRCA1 or BRCA2 mutation carriers with early stage breast cancer.
Breast ductal lavage for biomarker assessment in high risk women: rationale, design and methodology of a randomized phase II clinical trial with nimesulide, simvastatin and placebo.
Breast MRI as a screening tool: the appropriate role.
Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis.
Breed-related differences in altered BRCA1 expression, phenotype and subtype in malignant canine mammary tumors.
Bringing prostate cancer germline genetics into clinical practice.
BRIP1, a potential candidate gene in development of non-BRCA1/2 breast cancer.
BRIT-1 expression and its relationship with PARP-1 and CAF-1/p60 in cutaneous melanoma.
BRIT1 regulates p53 stability and functions as a tumor suppressor in breast cancer.
BRIT1/MCPH1 is essential for mitotic and meiotic recombination DNA repair and maintaining genomic stability in mice.
C-Cbl and Cbl-b expression in skull base chordomas is associated with tumor progression and poor prognosis.
c-Cbl Expression Correlates with Human Colorectal Cancer Survival and Its Wnt/?-Catenin Suppressor Function Is Regulated by Tyr371 Phosphorylation.
c-Cbl inhibits angiogenesis and tumor growth by suppressing activation of PLC?1.
c-Cbl is a suppressor of the neu oncogene.
c-Cbl mediates the degradation of tumorigenic nuclear ?-catenin contributing to the heterogeneity in Wnt activity in colorectal tumors.
C-Cbl protein in human cancer tissues is frequently tyrosine phosphorylated in a tumor-specific manner.
c-Cbl regulates ?Pix-mediated cell migration and invasion.
C-Cbl reverses HER2-mediated tamoxifen resistance in human breast cancer cells.
c-Cbl shRNA-expressing adenovirus sensitizes TRAIL-induced apoptosis in prostate cancer DU-145 through increases of DR4/5.
c-Cbl targets PD-1 in immune cells for proteasomal degradation and modulates colorectal tumor growth.
c-Cbl: An Important Regulator and a Target in Angiogenesis and Tumorigenesis.
c-Kit is required for growth and survival of the cells of origin of Brca1-mutation-associated breast cancer.
c9t11-Conjugated linoleic acid-rich oil fails to attenuate wasting in colon-26 tumor-induced late-stage cancer cachexia in male CD2F1 mice.
CA 125: fundamental and clinical aspects.
Cadmium malignantly transforms normal human breast epithelial cells into a basal-like phenotype.
Caenorhabditis elegans RBX1 is essential for meiosis, mitotic chromosomal condensation and segregation, and cytokinesis.
CAF-like state in primary skin fibroblasts with constitutional BRCA1 epimutation sheds new light on tumor suppressor deficiency-related changes in healthy tissue.
CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers.
CAG repeat length in exon 1 of the androgen receptor gene is related to age of diagnosis but not germ line BRCA1 mutation status in ovarian cancer.
CAG repeat size in Huntingtin alleles is associated with cancer prognosis.
Can bilateral prophylactic salpingo-oophorectomy reduce cancer mortality in carriers of a BRCA1 or BRCA2 mutation?
Can personality traits affect the quality of life of women with the BRCA1/BRCA2 mutations before and after prophylactic adnexectomy?
Can the status of the breast and ovarian cancer susceptibility gene 1 product (BRCA1) predict response to taxane-based cancer therapy?
Can we prevent BRCA1-associated breast cancer by RANKL inhibition?
Cancer and heterogeneity of obesity: a potential contribution of brown fat.
Cancer associated missense mutations in BAP1 catalytic domain induce amyloidogenic aggregation: A new insight in enzymatic inactivation.
Cancer control in susceptible groups: opportunities and challenges.
Cancer gene therapy and immunotherapy (review).
Cancer genetics and reproduction.
Cancer genetics for the clinician: recommendations on screening for BRCA1 and BRCA2 mutations.
Cancer genetics in primary care.
Cancer genetics in the new era of molecular biology.
Cancer incidence in a population of Jewish women at risk of ovarian cancer.
Cancer Incidence in BRCA1 mutation carriers.
Cancer Incidence in First- and Second-Degree Relatives of BRCA1 and BRCA2 Mutation Carriers.
Cancer incidence in relatives of a population-based set of cases of early-onset breast cancer with a known BRCA1 and BRCA2 mutation status.
Cancer predisposing mutations in BRCT domains.
Cancer predisposition, radiosensitivity and the risk of radiation-induced cancers. II. A Mendelian single-locus model of cancer predisposition and radiosensitivity for predicting cancer risks in populations.
Cancer predisposition, radiosensitivity and the risk of radiation-induced cancers. IV. Prediction of risks in relatives of cancer-predisposed individuals.
Cancer prevalence in 129 breast-ovarian cancer families tested for BRCA1 and BRCA2 mutations.
Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy.
Cancer research. Transatlantic war over BRCA1 patent.
Cancer risk assessment at the atomic level.
Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program.
Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: Effects of oral contraceptive use and parental origin of mutation.
Cancer Risk Management Decisions of Women with BRCA1 or BRCA2 Variants of Uncertain Significance.
Cancer risk management in Tasmanian women with BRCA1 and BRCA2 mutations.
Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers.
Cancer risks among BRCA1 and BRCA2 mutation carriers.
Cancer risks for Australian women with a BRCA1 or a BRCA2 mutation.
Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.
Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature.
Cancer risks in BRCA1 carriers: time for the next generation of studies.
Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations.
Cancer risks in first degree relatives of BRCA1 mutation carriers: effects of mutation and proband disease status.
Cancer risks in Jewish male BRCA1 and BRCA2 mutation carriers.
Cancer risks in women with 2 breast or ovarian cancers: clues to genetic cancer susceptibility.
Cancer Selective Target Degradation by Folate-Caged PROTACs.
Cancer stem cell heterogeneity in hereditary breast cancer.
Cancer stem-like cell related protein CD166 degrades through E3 ubiquitin ligase CHIP in head and neck cancer.
Cancer suppression by the chromosome custodians, BRCA1 and BRCA2.
Cancer susceptibility and the functions of BRCA1 and BRCA2.
Cancer treatment according to BRCA1 and BRCA2 mutations.
Cancer-causing mutations in a novel transcription-dependent nuclear export motif of VHL abrogate oxygen-dependent degradation of hypoxia-inducible factor.
Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity.
Cancer-related mutations in BRCA1-BRCT cause long-range structural changes in protein-protein binding sites: a molecular dynamics study.
Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian.
Cancers in BRCA1 and BRCA2 carriers and in women at high risk for breast cancer: MR imaging and mammographic features.
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.
Candidate gene association studies: successes and failures.
Cannabidiol inhibits human glioma by induction of lethal mitophagy through activating TRPV4.
Canonical Wnt signaling regulates Slug activity and links epithelial-mesenchymal transition with epigenetic Breast Cancer 1, Early Onset (BRCA1) repression.
Capillary electrophoresis as alternative method to detect tumor genetic mutations: the model built on the founder BRCA1 c.4964_4982del19 variant.
Carboplatin and gemcitabine combination in metastatic triple-negative anthracycline- and taxane-pretreated breast cancer patients: a phase II study.
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.
Carcinoid tumor of lung and BRCA mutation: a case report.
Carcinoma of the breast with medullary-like features: diagnostic challenges and relationship with BRCA1 and EZH2 functions.
CARP-1/CCAR1: a biphasic regulator of cancer cell growth and apoptosis.
Case Report: Frontoparietal Metastasis From a Primary Fallopian Tube Carcinoma.
Caspase-1 and caspase-8 cleave and inactivate cellular parkin.
Caspase-dependent BRCA1 cleavage facilitates chemotherapy-induced apoptosis.
Catalytically Important Residues of E6AP Ubiquitin Ligase Identified Using Acid-Cleavable Photo-Cross-Linkers.
Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer.
CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases.
CBL mutations drive PI3K/AKT signaling via increased interaction with LYN and PIK3R1.
CBP/p300 interact with and function as transcriptional coactivators of BRCA1.
Cbx2 stably associates with mitotic chromosomes via a PRC2- or PRC1-independent mechanism and is needed for recruiting PRC1 complex to mitotic chromosomes.
CCND1 and ZNF217 gene amplification is equally frequent in BRCA1 and BRCA2 associated and non-BRCA breast cancer.
CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer.
Cdc42: an effector and regulator of ErbB1 as a strategic target in breast cancer therapy.
CDDO-Imidazolide Induces DNA Damage, G2/M Arrest and Apoptosis in BRCA1-Mutated Breast Cancer Cells.
CDDO-methyl ester delays breast cancer development in BRCA1-mutated mice.
Cdh1 inhibits WWP2-mediated ubiquitination of PTEN to suppress tumorigenesis in an APC-independent manner.
Cdk1 participates in BRCA1-dependent S phase checkpoint control in response to DNA damage.
CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.
CDK9 inhibitor CDKI-73 is synergetic lethal with PARP inhibitor olaparib in BRCA1 wide-type ovarian cancer.
CDKN2A is the main susceptibility gene in Italian pancreatic cancer families.
CDKN2A mutation in a non-FAMMM kindred with cancers at multiple sites results in a functionally abnormal protein.
cDNA analysis demonstrates that the BRCA2 intronic variant IVS4-12del5 is a deleterious mutation.
cDNA sequence and chromosomal localization of mouse Dlgh3 gene adjacent to the BRCA1 tumor suppressor locus.
Celastrol-Induced Nur77 Interaction with TRAF2 Alleviates Inflammation by Promoting Mitochondrial Ubiquitination and Autophagy.
Celebrity Health Announcements and Online Health Information Seeking: An Analysis of Angelina Jolie's Preventative Health Decision.
Cell biology of cancer: BRCA1 and sister chromatid pairing reactions?
Cell cycle differences in DNA damage-induced BRCA1 phosphorylation affect its subcellular localization.
Cell cycle regulation of BRCA1 messenger RNA in human breast epithelial cells.
Cell cycle-dependent colocalization of BARD1 and BRCA1 proteins in discrete nuclear domains.
Cell cycle-dependent expression of cIAP2 at G2/M phase contributes to survival during mitotic cell cycle arrest.
Cell cycle-dependent ubiquitylation and destruction of NDE1 by CDK5-FBW7 regulates ciliary length.
Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING.
Cell-nonautonomous induction of ovarian and uterine serous cystadenomas in mice lacking a functional Brca1 in ovarian granulosa cells.
Cell-surface and mitotic-spindle RHAMM: moonlighting or dual oncogenic functions?
Cells redox environment modulates BRCA1 expression and DNA homologous recombination repair.
Cellular inhibitors of apoptosis (cIAP) 1 and 2 are increased in placenta from obese pregnant women.
Cellular responses of BRCA1-defective and triple-negative breast cancer cells and in vitro BRCA1 interactions induced by metallo-intercalator ruthenium(II) complexes containing chloro-substituted phenylazopyridine.
Central European BRCA2 mutation carriers: birth cohort status correlates with onset of breast cancer.
Centriole separation in DNA damage-induced centrosome amplification.
Centrosomal microtubule nucleation activity is inhibited by BRCA1-dependent ubiquitination.
Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells.
Centrosome amplification, chromosome instability and cancer development.
Cereblon attenuates DNA damage-induced apoptosis by regulating the transcription-independent function of p53.
CGH-targeted linkage analysis reveals a possible BRCA1 modifier locus on chromosome 5q.
Challenges and Considerations on Risk-Reducing Surgery in BRCA1/2 Patients with Advanced Breast Cancer.
Changes in health-related behaviours following BRCA 1/2 genetic testing: the case of hormone replacement therapy.
Changes in the mouse estrus cycle in response to BRCA1 inactivation suggest a potential link between risk factors for familial and sporadic ovarian cancer.
Characterisation of a 161 kb deletion extending from the NBR1 to the BRCA1 genes in a French breast-ovarian cancer family.
Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
Characterisation of PALB2 tumours through whole-exome and whole-transcriptomic analyses.
Characterisation of the BRCT domains of the breast cancer susceptibility gene product BRCA1.
Characteristics of BRCA1 mutations in a population-based case series of breast and ovarian cancer.
Characteristics of BRCA1/2 Mutation-Positive Breast Cancers in Korea: A Comparison Study Based on Multicenter Data and the Korean Breast Cancer Registry.
Characteristics of ovarian tumors of low malignant potential in BRCA mutation carriers: A case series.
Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2.
Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women.
Characteristics, treatment, and outcome of breast cancers diagnosed in BRCA1 and BRCA2 gene mutation carriers in intensive screening programs including magnetic resonance imaging.
Characterization of 2 novel and 2 recurring BRCA1 germline mutations in breast and/or ovarian carcinoma patients from the area of Naples.
Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier.
Characterization of a carboxy-terminal BRCA1 interacting protein.
Characterization of a novel breast carcinoma xenograft and cell line derived from a BRCA1 germ-line mutation carrier.
Characterization of a novel germline BRCA1 splice variant, c.5332+4delA.
Characterization of an Italian founder mutation in the RING-finger domain of BRCA1.
Characterization of BRCA1 and BRCA2 variants in multi-ethnic Asian cohort from a Malaysian case-control study.
Characterization of Brca1 deficient mice.
Characterization of BRCA1/2 mutations in patients with family history of breast cancer in Armenia.
Characterization of cancer-linked BRCA1-BRCT missense variants and their interaction with phosphoprotein targets.
Characterization of COBRA1 in human breast cancer cell lines using a new polyclonal antibody against COBRA1.
Characterization of dual PTEN and p53-targeting microRNAs identifies microRNA-638/Dnm2 as a two-hit oncogenic locus.
Characterization of FANCL variants observed in patient cancer cells.
Characterization of functional messenger RNA splice variants of BRCA1 expressed in nonmalignant and tumor-derived breast cells.
Characterization of Potent SMAC Mimetics that Sensitize Cancer Cells to TNF Family-Induced Apoptosis.
Characterization of segments from the central region of BRCA1: an intrinsically disordered scaffold for multiple protein-protein and protein-DNA interactions?
Characterization of six tumor suppressor genes and microsatellite instability in hepatocellular carcinoma in southern African blacks.
Characterization of ten novel and 13 recurring BRCA1 and BRCA2 germline mutations in Italian breast and/or ovarian carcinoma patients. Mutations in brief no. 178. Online.
Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).
Characterization of the gene structure, functional significance, and clinical application of RNF180, a novel gene in gastric cancer.
Characterization of the pathogenic mechanism of a novel BRCA2 variant in a Chinese family.
Characterization of tumor-associated Chk2 mutations.
Characterization of two novel BRCA1 germ-line mutations involving splice donor sites.
Characterization, Detection, and Treatment Approaches for Homologous Recombination Deficiency in Cancer.
Characterizing the novel protein p33MONOX.
Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations.
Checkpoint kinase 2-mediated phosphorylation of BRCA1 regulates the fidelity of nonhomologous end-joining.
CHEK2 1100delC is not a risk factor for male breast cancer population.
Chemical probes of Skp2-mediated p27 ubiquitylation and degradation.
Chemoprevention options for BRCA1 and BRCA2 mutation carriers.
Chemopreventive Effects of ROS Targeting in a Murine Model of BRCA1-Deficient Breast Cancer.
Chemopreventive efficacy of stampidine in a murine breast cancer model.
Chemosensitivity of BRCA1-Mutated Ovarian Cancer Cells and Established Cytotoxic Agents.
Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness.
Chicoric acid (CA) induces autophagy in gastric cancer through promoting endoplasmic reticulum (ER) stress regulated by AMPK.
Childhood Cancer in Families with and without BRCA1 or BRCA2 Mutations Ascertained at a High-Risk Breast Cancer Clinic.
CHIP functions as a novel suppressor of tumour angiogenesis with prognostic significance in human gastric cancer.
CHIP functions as an oncogene by promoting colorectal cancer metastasis via activation of MAPK and AKT signaling and suppression of E-cadherin.
CHIP involves in non-small cell lung cancer prognosis through VEGF pathway.
CHIP is a novel tumor suppressor in pancreatic cancer through targeting EGFR.
CHIP regulates osteoclast formation through promoting TRAF6 protein degradation.
CHIP/Stub1 regulates the Warburg effect by promoting degradation of PKM2 in ovarian carcinoma.
Chk1 phosphorylated at serine(345) is a predictor of early local recurrence and radio-resistance in breast cancer.
Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair.
CHK2-BRCA1 tumor-suppressor axis restrains oncogenic Aurora-A kinase to ensure proper mitotic microtubule assembly.
Chl1p, a DNA helicase-like protein in budding yeast, functions in sister-chromatid cohesion.
Chromatin remodeling and histone modification in the conversion of oligodendrocyte precursors to neural stem cells.
Chromogenic and fluorescent in situ hybridization in breast cancer.
Chromosomal breakage syndromes and the BRCA1 genome surveillance complex.
Chromosomal instability induced by mammography X-rays in primary human fibroblasts from BRCA1 and BRCA2 mutation carriers.
Chromosome 17q linkage studies of 18 Utah breast cancer kindreds.
Chromosome 17q-linkage seems to be infrequent in Icelandic families at risk of breast cancer.
Chromosome 5 imbalance mapping in breast tumors from BRCA1 and BRCA2 mutation carriers and sporadic breast tumors.
Chromosome breakage syndromes and cancer.
Chromothripsis in human breast cancer.
cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination.
cIAP2 as a therapeutic target in colorectal cancer and other malignancies.
cIAP2 expression and clinical significance in pigmented villonodular synovitis.
cIAP2 Is an Independent Signaling and Survival Factor during Mammary Lactational Involution and Tumorigenesis.
cIAP2 is highly expressed in Hodgkin-Reed-Sternberg cells and inhibits apoptosis by interfering with constitutively active caspase-3.
cIAP2 promotes gallbladder cancer invasion and lymphangiogenesis by activating the NF-?B pathway.
cIAP2 represses IKK?/?-mediated activation of MDM2 to prevent p53 degradation.
cIAP2 Upregulated by E6 Oncoprotein via Epidermal Growth Factor Receptor/Phosphatidylinositol 3-Kinase/AKT Pathway Confers Resistance to Cisplatin in Human Papillomavirus 16/18-Infected Lung Cancer.
circNDUFB2 inhibits non-small cell lung cancer progression via destabilizing IGF2BPs and activating anti-tumor immunity.
CircNR3C2 promotes HRD1-mediated tumor-suppressive effect via sponging miR-513a-3p in triple-negative breast cancer.
Circulating tumor cells and breast cancer-specific mutations in primary breast cancer.
ciRs-6 upregulates March1 to suppress bladder cancer growth by sponging miR-653.
Cisplatin affects the conformation of apo form, not holo form, of BRCA1 RING finger domain and confers thermal stability.
Cisplatin-damaged BRCA1 exhibits altered thermostability and transcriptional transactivation.
CK8/18 expression, the basal phenotype, and family history in identifying BRCA1-associated breast cancer in the Ontario site of the Breast Cancer Family Registry.
Classification of BRCA1 missense variants of unknown clinical significance.
Classification of IVS1-10T-->C as a polymorphism of BRCA1.
Classification of missense variants of unknown significance in BRCA1 based on clinical and tumor information.
Classification of ovarian cancer associated with BRCA1 mutations, immune checkpoints, and tumor microenvironment based on immunogenomic profiling.
Classification of the spliceogenic BRCA1 c.4096+3A>G variant as likely benign based on cosegregation data and identification of a healthy homozygous carrier.
Classification of variants of uncertain significance in BRCA1 and BRCA2 using personal and family history of cancer from individuals in a large hereditary cancer multigene panel testing cohort.
Classification of VUS and unclassified variants in BRCA1 BRCT repeats by molecular dynamics simulation.
Classifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profiling.
Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein.
Clinical and ethical issues in the diagnosis of hereditary breast cancer (review).
Clinical and experimental role of ring finger protein 180 on lymph node metastasis and survival in gastric cancer.
Clinical and genetic characterization of hereditary breast cancer in a Chinese population.
Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
Clinical and molecular prognostic predictors of malignant peripheral nerve sheath tumor.
Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.
Clinical and pathologic differences between BRCA1-, BRCA2-, and non-BRCA-associated breast cancers in a multiracial developing country.
Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers.
Clinical and pathological characteristics of Chinese patients with BRCA related breast cancer.
Clinical and Pathological Characteristics of Patients with High-Risk Breast Cancer Based on BRCA Mutation Profiles: A Retrospective Study.
Clinical and pathological features of BRCA1 associated carcinomas in a hospital-based sample of Dutch breast cancer patients.
Clinical and pathological features of BRCA1/2 tumors in a sample of high-risk Moroccan breast cancer patients.
Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1.
Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals.
Clinical Characteristics of Korean Breast Cancer Patients Who Carry Pathogenic Germline Mutations in Both BRCA1 and BRCA2: A Single-Center Experience.
Clinical characteristics of laryngeal cancer in BRCA-1 mutation carriers.
Clinical classification of BRCA1 and BRCA2 DNA sequence variants: the value of cytokeratin profiles and evolutionary analysis--a report from the kConFab Investigators.
Clinical correlates of 'BRCAness' in triple-negative breast cancer of patients receiving adjuvant chemotherapy.
Clinical features of familial ovarian cancer lacking mutations in BRCA1 or BRCA2.
Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1.
Clinical genetic testing outcome with multi-gene panel in Asian patients with multiple primary cancers.
Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer.
Clinical implications for BRCA gene mutation in breast cancer.
Clinical implications of genetic testing for BRCA1 and BRCA2 mutations in Austria.
Clinical management of BRCA1 and BRCA2 mutation carriers.
Clinical management of BRCA1- and BRCA2-associated breast cancer.
Clinical management of hereditary breast cancer syndromes.
Clinical management of women with genomic BRCA1 and BRCA2 mutations.
Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation.
Clinical outcome of hereditary breast cancer in the lithuanian population.
Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up.
Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers.
Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations.
Clinical practice guidelines for BRCA1 and BRCA2 genetic testing.
Clinical significance of BRCA1 and BRCA2 mRNA and protein expression in patients with sporadic gastric cancer.
Clinical significance of epigenetic inactivation of hMLH1 and BRCA1 in Tunisian patients with invasive breast carcinoma.
Clinical significance of large rearrangements in BRCA1 and BRCA2.
Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients.
Clinical significance of promoter hypermethylation of RASSF1A, RARbeta2, BRCA1 and HOXA5 in breast cancers of Indian patients.
Clinical use and mechanisms of resistance for PARP inhibitors in homologous recombination-deficient cancers.
Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms.
Clinical, pathological and genetic features of women at high familial risk of breast cancer undergoing prophylactic mastectomy.
Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance.
Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer.
Clinicopathologic Characteristics and Survival in BRCA1- and BRCA2-Related Adnexal Cancer: Are They Different?
Clinicopathologic features and genetic characteristics of the BRCA1/2 mutation in Turkish breast cancer patients.
Clinicopathological and molecular characteristics of Ku 70/80 expression in Nigerian breast cancer and its potential therapeutic implications.
Clinicopathological and molecular significance of Sumolyation marker (ubiquitin conjugating enzyme 9 (UBC9)) expression in breast cancer of black women.
Clinicopathological and Molecular Study of Triple-Negative Breast Cancer in Algerian Patients.
Clinicopathological Correlates of ?? T Cell Infiltration in Triple-Negative Breast Cancer.
Clinicopathological features of tumor mutation burden, Epstein-Barr virus infection, microsatellite instability and PD-L1 status in Chinese patients with gastric cancer.
Clinicopathological Significance of BRCA1 Promoter Hypermethylation in Thai Breast Cancer Patients.
Clinicopathological significance of KU70/KU80, a key DNA damage repair protein in breast cancer.
Clinicopathological significance of somatic RNF43 mutation and aberrant expression of ring finger protein 43 in intraductal papillary mucinous neoplasms of the pancreas.
Clinicopathological study of chromogranin A, B and BRCA1 expression in node-negative breast carcinoma.
Clonal lineage of high grade serous ovarian cancer in a patient with neurofibromatosis type 1.
Cloning and characterization of a new BRCA1 variant: A role for BRCT domains in apoptosis.
Cloning and functional identification of two novel BRCA1 splicing variants.
Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers.
Co-occurrence of multiple sclerosis and cancer in a BRCA1 positive family.
Codon-substitution models for detecting molecular adaptation at individual sites along specific lineages.
Coexistent Loss of the Expressions of BRCA1 and p53 Predicts Poor Prognosis in Triple-Negative Breast Cancer.
Coexpression of the mutated BRCA1 mRNA and p53 mRNA and its association in Chinese prostate cancer.
Coinheritance of BRCA1 and BRCA2 mutations with Fanconi anemia and Bloom syndrome mutations in Ashkenazi Jewish population: possible role in risk modification for cancer development.
Collaboration of signal transducer and activator of transcription 1 (STAT1) and BRCA1 in differential regulation of IFN-gamma target genes.
Colorado family physicians' knowledge of hereditary breast cancer and related practice.
Combination of histoculture drug response assay and qPCR as an effective method to screen biomarkers for personalized chemotherapy in esophageal cancer.
Combination of photoactive hypericin and Manumycin A exerts multiple anticancer effects on oxaliplatin-resistant colorectal cells.
Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.
Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer.
Combinatorial cancer immunotherapy strategies with proapoptotic small-molecule IAP antagonists.
Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer.
Combined genetic and splicing analysis of BRCA1 c.[594-2A>C; 641A>G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithms.
Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss-Driven Tumorigenesis.
Combined microRNA and ER expression: a new classifier for familial and sporadic breast cancer patients.
Combined Treatment Modalities for High-Energy Proton Irradiation: Exploiting Specific DNA Repair Dependencies.
Combined tumor genomic profiling and exome sequencing in a breast cancer family implicates ATM in tumorigenesis: A proof of principle study.
Combining Homologous Recombination and Phosphopeptide-binding Data to Predict the Impact of BRCA1 BRCT Variants on Cancer Risk.
Combining intracellular antibodies to restore function of mutated p53 in cancer.
Commentary on "the E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity." Qi J, Tripathi M, Mishra R, Sahgal N, Fazli L, Ettinger S, Placzek WJ, Claps G, Chung LW, Bowtell D, Gleave M, Bhowmick N, Ronai ZA, Signal Transduction Program, Cancer Center, Sanford-Burnham Medical Research Institute, La Jolla, CA, USA.: Cancer Cell 2013;23(6):332-46.
Commentary: The unliganded glucocorticoid receptor positively regulates the tumor suppressor gene BRCA1 through GABP beta.
Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers.
Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers.
Common breast cancer risk variants in the post-COGS era: a comprehensive review.
Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2.
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Common clonal origin of chronic myelomonocytic leukemia and B-cell acute lymphoblastic leukemia in a patient with a germline CHEK2 variant.
Common genetic variants and cancer risk in Mendelian cancer syndromes.
Common genetic variation at BARD1 is not associated with Breast cancer risk in BRCA1 or BRCA2 mutation carriers.
Common non-synonymous polymorphisms in the BRCA1 Associated RING Domain (BARD1) gene are associated with breast cancer susceptibility: a case-control analysis.
Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk.
Common variation in BRCA1 may have a role in progression to lethal prostate cancer after radiation treatment.
Common, germline genetic variations in the novel tumor suppressor
Commonly observed RNF43 mutations retain functionality in attenuating Wnt/?-catenin signaling and unlikely confer Wnt-dependency onto colorectal cancers.
Communication and decision-making about seeking inherited cancer risk information: findings from female survivor-relative focus groups.
Communication of BRCA1 and BRCA2 results to at-risk relatives: a cancer risk assessment program's experience.
Comparative genomic hybridization in inherited and sporadic ovarian tumors in Israel.
Comparative genomic hybridization of microdissected familial ovarian carcinoma: two deleted regions on chromosome 15q not previously identified in sporadic ovarian carcinoma.
Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations.
Comparative genomics and protein domain graph analyses link ubiquitination and RNA metabolism.
Comparative inhibitory profile and distribution of bacterial PARPs, using Clostridioides difficile CD160 PARP as a model.
Comparative microRNA profiling of sporadic and BRCA1 associated basal-like breast cancers.
Comparing the frequency of common genetic variants and haplotypes between carriers and non-carriers of BRCA1 and BRCA2 deleterious mutations in Australian women diagnosed with breast cancer before 40 years of age.
Comparison between genotype and phenotype identifies a high-risk population carrying BRCA1 mutations.
Comparison of age distribution patterns for different histopathologic types of breast carcinoma.
Comparison of BRCA1 Expression between Triple-Negative and Luminal Breast Tumors
Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations.
Comparison of Practice Guidelines, BRCAPRO, and Genetic Counselor Estimates to Identify Germline BRCA1 and BRCA2 Mutations in Pancreatic Cancer.
Comparison of prophylactic oophorectomy specimens from carriers and noncarriers of a BRCA1 or BRCA2 gene mutation. United Kingdom Coordinating Committee on Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group.
Comparisons of gene coexpression network modules in breast cancer and ovarian cancer.
Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis.
Complete BRCA mutation screening in breast and ovarian cancer predisposition families from a North-Eastern Romanian population.
Complete genomic sequence and analysis of 117 kb of human DNA containing the gene BRCA1.
Complete pathological response to olaparib and bevacizumab in advanced cervical cancer following chemoradiation in a BRCA1 mutation carrier: a case report.
Complete response to orally administered melphalan in malignant pleural effusion from an occult female genital organ primary neoplasm with BRCA1/2 mutations: a case report.
Complex Breakpoints and Template Switching Associated with Non-canonical Termination of Homologous Recombination in Mammalian Cells.
Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population.
Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5931 Chinese women with breast cancer.
Comprehensive Analysis of BRCA1, BRCA2 and TP53 Germline Mutation and Tumor Characterization: A Portrait of Early-Onset Breast Cancer in Brazil.
Comprehensive analysis of germline mutations in northern Brazil: a panel of 16 genes for hereditary cancer-predisposing syndrome investigation.
Comprehensive analysis of lncRNA expression profiles reveals a novel lncRNA signature to discriminate nonequivalent outcomes in patients with ovarian cancer.
Comprehensive annotation of BRCA1 and BRCA2 missense variants by functionally validated sequence-based computational prediction models.
Comprehensive BRCA mutation analysis in the Greek population. Experience from a single clinical diagnostic center.
Comprehensive BRCA1 and BRCA2 mutation analyses and review of French Canadian families with at least three cases of breast cancer.
Comprehensive genomic characterization of breast tumors with BRCA1 and BRCA2 mutations.
Comprehensive Genomic Profiling of Androgen-Receptor-Negative Canine Prostate Cancer.
Comprehensive molecular biomarker identification in breast cancer brain metastases.
Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers.
Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries.
Comprehensive study for BRCA1 and BRCA2 entire coding regions in breast cancer.
Compromised BRCA1-PALB2 interaction is associated with breast cancer risk.
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.
Computational and Experimental Characterization of NF023, A Candidate Anticancer Compound Inhibiting cIAP2/TRAF2 Assembly.
Computational Tools for Splicing Defect Prediction in Breast/Ovarian Cancer Genes: How Efficient Are They at Predicting RNA Alterations?
Conclusions and recommendations from the Helene Harris Memorial Trust Fourth Biennial International Forum on Ovarian Cancer 11-14 May 1993, Toronto, Canada.
Concurrent alterations in TERT, KDM6A, and the BRCA pathway in bladder cancer.
Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes.
Conditional inactivation of Brca1, p53 and Rb in mouse ovaries results in the development of leiomyosarcomas.
Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation.
Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families.
Connection between Tumor Suppressor BRCA1 and PTEN in Damaged DNA Repair.
Conservation of function and primary structure in the BRCA1-associated RING domain (BARD1) protein.
Conserved BRCT regions of TopBP1 and of the tumor suppressor BRCA1 bind strand breaks and termini of DNA.
Considerations in genetic counseling for inherited breast cancer predisposition.
Considering the Role of Murine Double Minute 2 in the Cardiovascular System?
Consistency of BRCA1 and BRCA2 Variant Classifications Among Clinical Diagnostic Laboratories.
Constitutional CHEK2 mutations are infrequent in early-onset and familial breast/ovarian cancer patients from Pakistan.
CONSTITUTIONAL METHYLATION OF THE BRCA1 PROMOTER IS SPECIFICALLY ASSOCIATED WITH BRCA1 MUTATION-ASSOCIATED PATHOLOGY IN EARLY-ONSET BREAST CANCER.
Constitutive BRCA1 Promoter Hypermethylation Can Be a Predisposing Event in Isolated Early-Onset Breast Cancer.
Construction and characterization of recombinant adenoviruses expressing human BRCA1 or murine Brca1 genes.
Consulting prostate cancer cohort data uncovers transcriptional control: Regulation of the MARCH6 gene.
Contemplating chemosensitivity of basal-like breast cancer based on BRCA1 dysfunction.
Context Matters: RNF168 Connects with PALB2 to Rewire Homologous Recombination in BRCA1 Haploinsufficiency.
Context-dependent AMPK activation distinctly regulates TAp73 stability and transcriptional activity.
Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells.
Contralateral Breast Cancer and Ipsilateral Breast Tumor Recurrence in BRCA1/2 Carriers and Non-Carriers at High-Risk of Hereditary Breast Cancer.
Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
Contrasting effects of an Mdm2 functional polymorphism on tumor phenotypes.
Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia.
Contribution of BRCA1 large genomic rearrangements to early-onset and familial breast/ovarian cancer in Pakistan.
Contribution of epigenetic alteration of BRCA1 and BRCA2 genes in breast carcinomas in Tunisian patients.
Contribution of germline mutations in the BRCA and PALB2 genes to pancreatic cancer in Italy.
Contribution of large genomic BRCA1 alterations to early-onset breast cancer selected for family history and tumour morphology: a report from The Breast Cancer Family Registry.
Contribution of the BRCA1 and BRCA2 mutations to breast cancer in Tunisia.
Contribution of the Defective BRCA1, BRCA2 and CHEK2 Genes to the Familial Aggregation of Breast Cancer: a Simulation Study Based on the Swedish Family-Cancer Database.
Contribution of two independent MDM2-binding domains in p14(ARF) to p53 stabilization.
Control of biochemical reactions through supramolecular RING domain self-assembly.
Controlled trial of pretest education approaches to enhance informed decision-making for BRCA1 gene testing.
Cool-1 mediated inhibition of c-Cbl modulates multiple critical properties of glioblastomas, including the ability to generate tumors in vivo.
Cooperation between BRCA1 and vitamin D is critical for histone acetylation of the p21waf1 promoter and growth inhibition of breast cancer cells and cancer stem-like cells.
Cop1 constitutively regulates c-Jun protein stability and functions as a tumor suppressor in mice.
COP1, the negative regulator of ETV1, influences prognosis in triple-negative breast cancer.
Copy neutral loss of heterozygosity: a novel chromosomal lesion in myeloid malignancies.
Copy number variations are not modifiers of phenotypic expression in a pair of identical twins carrying a BRCA1 mutation.
Correcting errors in the BRCA1 warning system.
Correction for Ho et al., Itch E3 ubiquitin ligase regulates large tumor suppressor 1 stability.
Correction to: BRCA1 and BRCA2 Germline Mutation Analysis in Hereditary Breast/Ovarian Cancer Families from the Aures Region (Eastern Algeria): First Report.
Correction: Møller, P.; et al. Causes for Frequent Pathogenic BRCA1 Variants Include Low Penetrance in Fertile Ages, Recurrent De-Novo Mutations and Genetic Drift. Cancers 2019, 11, 132.
Correlation between BRCA1 and TopBP1 protein expression and clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.
Correlation between BRCA1 expression and apoptosis-related biological parameters in sporadic breast carcinomas.
Correlation between BRCA1 expression and clinicopathological factors including brain metastases in patients with non-small-cell lung cancer.
Correlation between morphology, immunohistochemistry and molecular pathology in hereditary and sporadic breast cancer cases.
Correlation between MR imaging - prognosis factors and molecular classification of breast cancers.
Correlation of molecular and morphological features of appendiceal epithelial neoplasms.
Correspondence re: A. Rothfuss et al., Induced micronucleus frequencies in peripheral blood lymphocytes as a screening test for carriers of a BRCA1 mutation in breast cancer families. Cancer Res., 60: 390-394, 2000.
Cost effectiveness of in vitro fertilisation and preimplantation genetic testing to prevent transmission of BRCA1/2 mutations.
Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.
Counseling the at risk patient in the BRCA1 and BRCA2 Era.
Counselling framework for moderate-penetrance cancer-susceptibility mutations.
Covalent ISG15 conjugation to CHIP promotes its ubiquitin E3 ligase activity and inhibits lung cancer cell growth in response to type I interferon.
CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer.
CpG island methylation affects accessibility of the proximal BRCA1 promoter to transcription factors.
CpG methylation within the 5' regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB binding site.
CRISPR-Cas9/long-read sequencing approach to identify cryptic mutations in BRCA1 and other tumour suppressor genes.
CRISPR-dCas9 mediated TET1 targeting for selective DNA demethylation at BRCA1 promoter.
CRISPR/Cas9-mediated mutagenesis to validate the synergy between PARP1 inhibition and chemotherapy in BRCA1-mutated breast cancer cells.
Critical role for BRCA1 expression as a marker of chemosensitivity response and prognosis.
CRL4BRBBP7 targets HUWE1 for ubiquitination and proteasomal degradation.
CRL4Cdt2: master coordinator of cell cycle progression and genome stability.
Cross-sectional analysis of germline BRCA1 and BRCA2 mutations in Japanese patients suspected to have hereditary breast/ovarian cancer.
Crosstalk between ubiquitin and other post-translational modifications on chromatin during double-strand break repair.
Crucial Role for Early Growth Response-1 in the Transcriptional Regulation of miR-20b in Breast Cancer.
CRY2 and FBXL3 Cooperatively Degrade c-MYC.
Crystal Structure and Interaction Studies of the Human FBxo3 ApaG Domain.
Crystal structure of HECT domain of UBE3C E3 ligase and its ubiquitination activity.
Crystal structure of the BARD1 ankyrin repeat domain and its functional consequences.
Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1.
CSE1L/CAS: its role in proliferation and apoptosis.
CSN6 controls the proliferation and metastasis of glioblastoma by CHIP-mediated degradation of EGFR.
CSN6-TRIM21 axis instigates cancer stemness during tumorigenesis.
CtIP, a candidate tumor susceptibility gene is a team player with luminaries.
CUL4 E3 ligase regulates the proliferation and apoptosis of lung squamous cell carcinoma and small cell lung carcinoma.
Cul4a as a New Interaction Protein of PARP1 Inhibits Oxidative Stress-Induced H9c2 Cell Apoptosis.
CUL4A is overexpressed in human pituitary adenomas and regulates pituitary tumor cell proliferation.
Cullin 3 and Its Role in Tumorigenesis.
Cullin-4A·DNA damage-binding protein 1 E3 ligase complex targets tumor suppressor RASSF1A for degradation during mitosis.
Curcumin exerts its tumor suppressive function via inhibition of NEDD4 oncoprotein in glioma cancer cells.
Curcumin homing to the nucleolus: mechanism for initiation of an apoptotic program.
Current and emerging breast cancer biomarkers.
Current condition of genetic medicine for hereditary breast cancer.
Current perspectives on BRCA1- and BRCA2-associated breast cancers.
Current policies for surveillance and management in women at risk of breast and ovarian cancer: a survey among 16 European family cancer clinics. European Familial Breast Cancer Collaborative Group.
Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
Current Treatment Options in Triple Negative Breast Cancer.
Cutaneous Melanoma: Mutational Status and Potential Links to Tertiary Lymphoid Structure Formation.
CVID-Associated Tumors: Czech Nationwide Study Focused on Epidemiology, Immunology, and Genetic Background in a Cohort of Patients With CVID.
Cyclin B1 stability is increased by interaction with BRCA1, and its overexpression suppresses the progression of BRCA1-associated mammary tumors.
Cyclin D1 expression analysis in familial breast cancers may discriminate BRCAX from BRCA2-linked cases.
Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment.
Cyclin F: A component of an E3 ubiquitin ligase complex with roles in neurodegeneration and cancer.
Cyclin-Dependent Kinase 2 Functions in Normal DNA Repair and Is a Therapeutic Target in BRCA1-Deficient Cancers.
Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors.
Cytokines, signaling and diseases - a pharmacologist's view.
Cytology material is equivalent to tumor tissue in determining mutations of BRCA 1/2 genes in patients with tubo-ovarian high grade serous carcinoma.
Cytoplasmic CUL9/PARC ubiquitin ligase is a tumor suppressor and promotes p53-dependent apoptosis.
Cytoplasmic HuR expression correlates with cIAP2 expression and clinicopathologic factors in oral squamous cell carcinoma cells.
Cytoplasmic mislocalization of BRCA1 caused by cancer-associated mutations in the BRCT domain.
Damage-induced BRCA1 phosphorylation by Chk2 contributes to the timing of end resection.
Daxx Represses Expression of a Subset of Antiapoptotic Genes Regulated by Nuclear Factor-{kappa}B.
DcR3 binds to ovarian cancer via heparan sulfate proteoglycans and modulates tumor cells response to platinum with corresponding alteration in the expression of BRCA1.
DCUN1D1 facilitates tumor metastasis by activating FAK signaling and up-regulates PD-L1 in non-small-cell lung cancer.
De novo Alu element insertions targeted to a sequence common to the BRCA1 and BRCA2 genes.
De novo pathogenic germline variant in PALB2 in a patient with pancreatic cancer.
De novo recurrent germline mutation of the BRCA2 gene in a patient with early onset breast cancer.
DEAR1 Is a Chromosome 1p35 Tumor Suppressor and Master Regulator of TGF-?-Driven Epithelial-Mesenchymal Transition.
DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer.
DEAR1, a novel tumor suppressor that regulates cell polarity and epithelial plasticity.
Decapping protein EDC4 regulates DNA repair and phenocopies BRCA1.
Deciphering the BRCA1 Tumor Suppressor Network.
Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients.
Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations.
Decision-making about genetic testing among women at familial risk for breast cancer.
Deconvolution of the Genomic and Epigenomic Interaction Landscape of Triple-Negative Breast Cancer.
Decreased BECN1 mRNA Expression in Human Breast Cancer is Associated with Estrogen Receptor-Negative Subtypes and Poor Prognosis.
Decreased BRCA1 expression levels may arrest the cell cycle through activation of p53 checkpoint in human sporadic breast tumors.
Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression.
Decreased expression of BRCA1 in SK-BR-3 cells is the result of aberrant activation of the GABP Beta promoter by an NRF-1-containing complex.
Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer.
Decreased expression of CHIP leads to increased angiogenesis via VEGF-VEGFR2 pathway and poor prognosis in human renal cell carcinoma.
Decreased expression of TRIM3 gene predicts a poor prognosis in gastric cancer.
Decreased expression of TRIM3 is associated with poor prognosis in patients with primary hepatocellular carcinoma.
Decreased FANCJ caused by 5FU contributes to the increased sensitivity to oxaliplatin in gastric cancer cells.
Deep Targeted Sequencing and Its Potential Implication for Cancer Therapy in Chinese Patients with Gastric Adenocarcinoma.
Defect of tumour necrosis factor-alpha (TNF-alpha) production and TNF-alpha-induced ICAM-1-expression in BRCA1 mutations carriers.
Defective DNA repair in hereditary ovarian cancers: Implications for therapy.
Defective homologous recombination in human cancers.
Deficiency of human BRCA2 leads to impaired homologous recombination but maintains normal nonhomologous end joining.
Deficiency of parkin suppresses melanoma tumor development and metastasis through inhibition of MFN2 ubiquitination.
Defining biochemical functions for the BRCA1 tumor suppressor protein: analysis of the BRCA1 binding protein BAP1.
Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex.
Deleterious c-Cbl Exon Skipping Contributes to Human Glioma.
Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883).
Deletion of Exons 1a-2 of BRCA1: A Rather Frequent Pathogenic Abnormality.
Deletion of tumor suppressor genes in Chinese non-small cell lung cancer.
Deletions on chromosome 4 in sporadic and BRCA mutated tumors and association with pathological variables.
Delineating the molecular mechanisms of tamoxifen's oncolytic actions in estrogen receptor-negative cancers.
Demographic and genetic characteristics of patients with borderline ovarian tumors as compared to early stage invasive ovarian cancer.
Dependence of Human Colorectal Cells Lacking the FBW7 Tumor Suppressor on the Spindle Assembly Checkpoint.
Depletion of NBR1 in urothelial carcinoma cells enhances rapamycin-induced apoptosis through impaired autophagy and mitochondrial dysfunction.
Depletion of the 26S Proteasome Adaptor Ecm29 Increases Toll-Like Receptor 3 Signaling.
Deregulated estrogen receptor signaling and DNA damage response in breast tumorigenesis.
Deregulated intracellular signaling by mutated c-CBL in myeloid neoplasms.
Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.
Description of Genetic Variants in BRCA Genes in Mexican Patients with Ovarian Cancer: A First Step towards Implementing Personalized Medicine.
Design and Activity of Specific Hypoxia-Inducible Factor 2? (HIF-2?) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: Discovery of Clinical Candidate ( S)-3-((2,2-difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385).
Design and validation of a next generation sequencing assay for hereditary BRCA1 and BRCA2 mutation testing.
Design, synthesis and biological activity of novel molecules designed to target PARP and DNA.
Designing Smac-mimetics as antagonists of XIAP, cIAP1, and cIAP2.
Detecting cancer outlier genes with potential rearrangement using gene expression data and biological networks.
Detection of aberrant promoter methylation of RNF180, DAPK1 and SFRP2 in plasma DNA of patients with gastric cancer.
Detection of BRCA1 and BRCA2 germline mutations in Japanese population using next-generation sequencing.
Detection of breast cancer in nipple aspirate fluid by CpG island hypermethylation.
Detection of clustered DNA lesions: Biological and clinical applications.
Detection of eight BRCA1 mutations in 10 breast/ovarian cancer families, including 1 family with male breast cancer.
Detection of exon skipping events in BRCA1 RNA using MLPA kit P002.
Detection of genomic variations in BRCA1 and BRCA2 genes by long-range PCR and next-generation sequencing.
Detection of germline BRCA1 mutations in breast cancer patients by quantitative messenger RNA in situ hybridization.
Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing.
Detection of LOH and mitochondrial DNA alterations in ductal lavage and nipple aspirate fluids from hngh-risk patients.
Detection of loss of heterozygosity at RAD51, RAD52, RAD54 and BRCA1 and BRCA2 loci in breast cancer: pathological correlations.
Detection of polymorphisms in the estradiol 17 beta-hydroxysteroid dehydrogenase II gene at the EDH17B2 locus on 17q11-q21.
Detection of protein folding defects caused by BRCA1-BRCT truncation and missense mutations.
Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis.
Determination of molecular markers for BRCA1 and BRCA2 heterozygosity using gene expression profiling.
Determining joint carrier probabilities of cancer-causing genes using Markov chain Monte Carlo methods.
Detoxification: A Novel Function of BRCA1 in Tumor Suppression?
Deubiquitination of Chfr, a checkpoint protein, by USP7/HAUSP regulates its stability and activity.
Developing culturally sensitive cancer genetics communication aids for African Americans.
Development and analytical validation of a 25-gene next generation sequencing panel that includes the BRCA1 and BRCA2 genes to assess hereditary cancer risk.
Development and pilot evaluation of novel genetic educational materials designed for an underserved patient population.
Development and testing of a decision aid for breast cancer prevention for women with a BRCA1 or BRCA2 mutation.
Development and Validation of a 34-Gene Inherited Cancer Predisposition Panel Using Next-Generation Sequencing.
Development of a high risk pancreatic screening clinic using 3.0 T MRI.
Development of a homogeneous AlphaLISA ubiquitination assay using ubiquitin binding matrices as universal components for the detection of ubiquitinated proteins.
Development of breast tumors in CHEK2, NBN/NBS1 and BLM mutation carriers does not commonly involve somatic inactivation of the wild-type allele.
Development of PARP inhibitors in oncology.
Development of Serous Ovarian Cancer is Associated with the Expression of Homologous Recombination Pathway Proteins.
Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome.
Development of the PARP inhibitor talazoparib for the treatment of advanced BRCA1 and BRCA2 mutated breast cancer.
Developmental expression of Brca2 colocalizes with Brca1 and is associated with proliferation and differentiation in multiple tissues.
Developmental studies of Brca1 and Brca2 knock-out mice.
Developments in Clinical Practice: Follow up Clinic for BRCA Mutation Carriers: a Case Study Highlighting the "Virtual Clinic".
Dhh1 regulates the G1/S-checkpoint following DNA damage or BRCA1 expression in yeast.
DHPLC/SURVEYOR Nuclease: A Sensitive, Rapid and Affordable Method to Analyze BRCA1 and BRCA2 Mutations in Breast Cancer Families.
Diagnostic criteria for testing for BRCA1 and BRCA2: the experience of the Department of Defense Familial Breast/Ovarian Cancer Research Project.
Dideoxy fingerprinting assay for BRCA1 mutation analysis.
Difference in Risk of Breast and Ovarian Cancer According to Putative Functional Domain Regions in Korean BRCA1/2 Mutation Carriers.
Differences in cysteine peptidases-like activity in sera of patients with breast cancer.
Differences in Natural History between Breast Cancers in BRCA1 and BRCA2 Mutation Carriers and Effects of MRI Screening-MRISC, MARIBS, and Canadian Studies Combined.
Differences in Ovarian and Other Cancers Risks by Population and BRCA Mutation Location.
Differences in the frequency and distribution of BRCA1 and BRCA2 mutations in breast/ovarian cancer cases from the Basque country with respect to the Spanish population: implications for genetic counselling.
Different Array CGH profiles within hereditary breast cancer tumors associated to BRCA1 expression and overall survival.
Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo.
Different expressivity of BRCA1 and BRCA2: analysis of 179 Italian pedigrees with identified mutation.
Differential Chemotherapeutic Sensitivity for Breast Tumors With "BRCAness": A Review.
Differential Claudin 3 and EGFR Expression Predicts BRCA1 Mutation in Triple-Negative Breast Cancer.
Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer.
Differential diagnosis of serous papillary carcinoma of the gynaecological tract and basal breast carcinoma: an immunohistochemical approach.
Differential Display Analysis of 2,3,7,8-Tetrachlorodibenzo-p-dioxin Identified Induction of Ras-related Nuclear Protein Binding Protein2 (RanBP2) Gene.
Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data.
Differential efatutazone's impact on mammary neoplasia dependent upon Brca1 dose.
Differential effects of n-3 and n-6 polyunsaturated fatty acids on BRCA1 and BRCA2 gene expression in breast cell lines.
Differential expressions of BRCA1 and BRCA2 in infantile gynecomastia.
Differential Gene Expression of BRCA1,ERBB2 and TP53 biomarkers between Human Breast Tissue and Peripheral Blood Samples of Breast Cancer.
Differential immunomodulatory effect of PARP inhibition in BRCA1 deficient and competent tumor cells.
Differential Profile of BRCA1 vs. BRCA2 Mutated Families: A Characterization of the Main Differences and Similarities in Patients.
Differential regulation of cardiomyocyte survival and hypertrophy by MDM2, an E3 ubiquitin ligase.
Differential response between the p53 ubiquitin-protein ligases Pirh2 and MdM2 following DNA damage in human cancer cells.
Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents.
Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-delta11b.
Differential transcriptional activation by the N-terminal region of BRCA1 splice variants BRCA1a and BRCA1b.
Differentiating pathogenic mutations from polymorphic alterations in the splice sites of BRCA1 and BRCA2.
Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors.
Differing effects of breast cancer 1, early onset (BRCA1) and ataxia-telangiectasia mutated (ATM) mutations on cellular responses to ionizing radiation.
DiNeR: a Differential graphical model for analysis of co-regulation Network Rewiring.
Diosgenin inhibits the expression of NEDD4 in prostate cancer cells.
Direct detection of mutations in the breast and ovarian cancer susceptibility gene BRCA1 by PCR-mediated site-directed mutagenesis.
Direct DNA binding by Brca1.
Direct effects of Bmi1 on p53 protein stability inactivates oncoprotein stress responses in embryonal cancer precursor cells at tumor initiation.
Direct genomic multiplex PCR for BRCA1 and application to mutation detection by single-strand conformation and heteroduplex analysis.
Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells.
Direct stimulation of transcription initiation by BRCA1 requires both its amino and carboxyl termini.
Discovering interactions among BRCA1 and other candidate genes associated with sporadic breast cancer.
Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent.
Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation.
Discovery of cell-permeable inhibitors that target the BRCT domain of BRCA1 protein by using a small-molecule microarray.
Discovery of Mdm2-MdmX E3 ligase inhibitors using a cell-based ubiquitination assay.
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity.
Discovery of small molecule WWP2 ubiquitin ligase inhibitors.
Discovery of Therapeutic Deubiquitylase Effector Molecules: Current Perspectives.
Discussion on the use of taxanes for treatment of breast cancers in BRCA1 mutations carriers.
Dishevelled promotes Wnt receptor degradation through recruitment of ZNRF3/RNF43 E3 ubiquitin ligases.
Disruption of BRCA1 function results in telomere lengthening and increased anaphase bridge formation in immortalized cell lines.
Disruption of BRCA1 LXCXE motif alters BRCA1 functional activity and regulation of RB family but not RB protein binding.
Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinoma.
Dissecting PARP inhibitor resistance with functional genomics.
Distinct Brca1 Mutations Differentially Reduce Hematopoietic Stem Cell Function.
Distinct claudin expression characterizes BRCA1-related breast cancer.
Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes.
Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization.
Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study.
Distinct Ring1b complexes defined by DEAD-box helicases and EMT transcription factors synergistically enhance E-cadherin silencing in breast cancer.
Distinct roles of RAD52 and POLQ in chromosomal break repair and replication stress response.
Distinct roles of TRAF6 and TAK1 in the regulation of adipocyte survival, thermogenesis program, and high-fat diet-induced obesity.
Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations.
Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data.
DLG1 is an anchor for the E3 ligase MARCH2 at sites of cell-cell contact.
DNA array-based method for detection of large rearrangements in the BRCA1 gene.
DNA damage induces p53-dependent BRCA1 nuclear export.
DNA damage repair functions and targeted treatment in breast cancer.
DNA damage response as an anti-cancer barrier: damage threshold and the concept of 'conditional haploinsufficiency'.
DNA damage response genes and the development of cancer metastasis.
DNA damage response markers are differentially expressed in BRCA-mutated breast cancers.
DNA damage-induced activation of CUL4B targets HUWE1 for proteasomal degradation.
DNA damage-induced cell cycle checkpoints and DNA strand break repair in development and tumorigenesis.
DNA damage-induced cytotoxicity is dissociated from BRCA1's DNA repair function but is dependent on its cytosolic accumulation.
DNA double strand break repair and its association with inherited predispositions to breast cancer.
DNA double-strand break repair pathway choice and cancer.
DNA double-strand breaks: signaling, repair and the cancer connection.
DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
DNA methylation and breast tumor clinicopathological features: The Western New York Exposures and Breast Cancer (WEB) study.
DNA Methylation profiles as predictors of recurrence in non muscle invasive bladder cancer: an MS-MLPA approach.
DNA methylation profiling to assess pathogenicity of BRCA1 unclassified variants in breast cancer.
DNA methylome profiling identifies novel methylated genes in epithelial ovarian cancer patients with platinum resistance.
DNA polymerase stalling, sister chromatid recombination and the BRCA genes.
DNA Polymerase theta (POLQ) is important for repair of DNA double-strand breaks caused by fork collapse.
DNA repair and cell cycle checkpoint defects in a mouse model of 'BRCAness' are partially rescued by 53BP1 deletion.
DNA Repair and Ovarian Carcinogenesis: Impact on Risk, Prognosis and Therapy Outcome.
DNA repair and synthetic lethality.
DNA repair deficiency as a therapeutic target in cancer.
DNA repair genes implicated in triple negative familial non-BRCA1/2 breast cancer predisposition.
DNA repair genes PAXIP1 and TP53BP1 expression is associated with breast cancer prognosis.
DNA-PKcs: a T-cell tumour suppressor encoded at the mouse scid locus.
Do BRCA1 modifiers also affect the risk of breast cancer in non-carriers?
Do Ovarian Cancer Patients with a Family History of Cancer (Suspected BRCA1 or BRCA2 Mutation) Suffer Greater Chemotherapy Toxicity?
Does familial breast cancer and thymoma suggest a cancer syndrome? A family perspective.
Does family history predict the age at onset of new breast cancers in BRCA1 and BRCA2 mutation-positive families?
Does the occurrence of certain rare cancers indicate an inherited cancer susceptibility?
Dosage analysis of cancer predisposition genes by multiplex ligation-dependent probe amplification.
Double heterozygosity for BRCA1 and hMLH1 gene mutations in a 46-year-old woman with five primary tumors.
Double heterozygosity for mutations in BRCA1 and BRCA2 in German breast cancer patients: implications on test strategies and clinical management.
Double heterozygosity for mutations in the BRCA1 and BRCA2 genes in a breast cancer patient.
Double heterozygosity for TP53 and BRCA1 mutations: clinical implications in populations with founder mutations.
Double Heterozygosity of BRCA2 and STK11 in Familial Breast Cancer Detected by Exome Sequencing.
Double heterozygous mutation in the BRCA1 and ATM genes involved in development of primary metachronous tumours: a case report.
Double PALB2 and BRCA1/BRCA2 mutation carriers are rare in breast cancer and breast-ovarian cancer syndrome families from the French Canadian founder population.
Down-regulation of BRCA1 and BRCA2 in human ovarian cancer cells exposed to adriamycin and ultraviolet radiation.
Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers.
Down-regulation of BRCA1 in chronic pancreatitis and sporadic pancreatic adenocarcinoma.
Down-regulation of BRCA1 in human sporadic breast cancer; analysis of DNA methylation patterns of the putative promoter region.
Down-regulation of BRCA1-BARD1 ubiquitin ligase by CDK2.
Down-regulation of cIAP2 enhances 5-FU sensitivity through the apoptotic pathway in human colon cancer cells.
Down-regulation of RFWD3 inhibits cancer cells proliferation and migration in gastric carcinoma.
Down-regulation of UHRF1, associated with re-expression of tumor suppressor genes, is a common feature of natural compounds exhibiting anti-cancer properties.
Downregulated PIRH2 Can Decrease the Proliferation of Breast Cancer Cells.
Downregulation of ATM and BRCA1 Predicts Poor Outcome in Head and Neck Cancer: Implications for ATM-Targeted Therapy.
Downregulation of BRCA1 in A375 melanoma cell line increases radio-sensitivity and modifies metastatic and angiogenic gene expression.
Downregulation of BRCA1 protein in BCR-ABL1 leukemia cells depends on stress-triggered TIAR-mediated suppression of translation.
Downregulation of p53 by phosphatase of regenerating liver 3 is mediated by MDM2 and PIRH2.
Downregulation of ring-finger protein 43 in glioma associates with poor prognosis.
Downregulation of stromal BRCA1 drives breast cancer tumor growth via upregulation of HIF-1?, autophagy and ketone body production.
Downregulation of TGF-?1 suppressed proliferation and increased chemosensitivity of ovarian cancer cells by promoting BRCA1/Smad3 signaling.
DREAMing: a simple and ultrasensitive method for assessing intratumor epigenetic heterogeneity directly from liquid biopsies.
Drosophila von Hippel-Lindau tumor suppressor complex possesses E3 ubiquitin ligase activity.
Drug-targeted inhibition of peroxisome proliferator-activated receptor-gamma enhances the chemopreventive effect of anti-estrogen therapy.
Drugging the Cancers Addicted to DNA Repair.
Dual immunofluorescence labeling with cell-specific markers localizes BRCA1 in both basal and luminal epithelial cells in primary outgrowth from noncancerous mammary ductal and alveolar preparations.
Dual Modulators of p53 and Cyclin D in ER Alpha Signaling by Albumin Nanovectors Bearing Zinc Chaperones for ER-positive Breast Cancer Therapy.
Dual-fluorophore quantitative high-throughput screen for inhibitors of BRCT-phosphoprotein interaction.
Dualistic Role of BARD1 in Cancer.
Dynamic interactions between the promoter and terminator regions of the mammalian BRCA1 gene.
Dynamics in the p53-Mdm2 ubiquitination pathway.
Dynamics of DNA repair suggested by the subcellular localization of Brca1 and Brca2 proteins.
Dysfunction of the MDM2/p53 axis is linked to premature aging.
Dysfunctional BRCA1 is only indirectly linked to multiple centrosomes.
Dysregulated Wnt?signalling and recurrent mutations?of?the tumour suppressor?RNF43?in early?gastric carcinogenesis.
Dysregulation of Parkin-mediated mitophagy in thyroid Hürthle cell tumors.
Dysregulation of the centrosome induced by BRCA1 deficiency contributes to tissue-specific carcinogenesis.
Dysregulation of x chromosome inactivation in high grade ovarian serous adenocarcinoma.
E2-EPF UCP targets pVHL for degradation and associates with tumor growth and metastasis.
E2F1 interactive with BRCA1 pathway induces HCC two different small molecule metabolism or cell cycle regulation via mitochondrion or CD4+T to cytosol.
E2F3b over-expression in ovarian carcinomas and in BRCA1 Haploinsufficient fallopian tube epithelium.
E2F6 negatively regulates BRCA1 in human cancer cells without methylation of histone H3 on lysine 9.
E3 ligase activity of BRCA1 is not essential for mammalian cell viability or homology-directed repair of double-strand DNA breaks.
E3 ligase activity of XIAP RING domain is required for XIAP-mediated cancer cell migration, but not for its RhoGDI binding activity.
E3 ligase EDD1/UBR5 is utilized by the HPV E6 oncogene to destabilize tumor suppressor TIP60.
E3 ligase FBXW7 aggravates TMPD-induced systemic lupus erythematosus by promoting cell apoptosis.
E3 ligase FBXW7 restricts M2-like tumor-associated macrophage polarization by targeting c-Myc.
E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.
E3 ligase MKRN3 is a tumor suppressor regulating PABPC1 ubiquitination in non-small cell lung cancer.
E3 ligase RCHY1 negatively regulates HDAC2.
E3 ligase SCFSKP2 ubiquitinates and degrades tumor suppressor C/EBP? in acute myeloid leukemia.
E3 Ubiquitin Ligase c-cbl Inhibits Microglia Activation After Chronic Constriction Injury.
E3 Ubiquitin Ligase Cbl-b Prevents Tumor Metastasis by Maintaining the Epithelial Phenotype in Multiple Drug-Resistant Gastric and Breast Cancer Cells.
E3 ubiquitin ligase Cullin-5 modulates multiple molecular and cellular responses to heat shock protein 90 inhibition in human cancer cells.
E3 ubiquitin ligase HECTD2 mediates melanoma progression and immune evasion.
E3 ubiquitin ligase isolated by differential display regulates cervical cancer growth in vitro and in vivo via microRNA-143.
E3 Ubiquitin Ligase RLIM Negatively Regulates c-Myc Transcriptional Activity and Restrains Cell Proliferation.
E3 ubiquitin ligase RNF126 affects bladder cancer progression through regulation of PTEN stability.
E3 ubiquitin ligase RNF126 promotes cancer cell proliferation by targeting the tumor suppressor p21 for ubiquitin-mediated degradation.
E3 ubiquitin ligase Skp2 as an attractive target in cancer therapy.
E3 ubiquitin ligase TRIM32 negatively regulates tumor suppressor p53 to promote tumorigenesis.
E3 Ubiquitin Ligase UBR5 Promotes the Metastasis of Pancreatic Cancer via Destabilizing F-Actin Capping Protein CAPZA1.
E3 ubiquitin ligase-mediated regulation of bone formation and tumorigenesis.
E6AP promotes prostate cancer by reducing p27 expression.
Early cancer detection programmes for women at high risk for breast and ovarian cancer: a proposal of practical guidelines.
Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials.
Early Loss of Histone H2B Monoubiquitylation Alters Chromatin Accessibility and Activates Key Immune Pathways That Facilitate Progression of Ovarian Cancer.
Early onset breast cancer in Ashkenazi women carriers of founder BRCA1/2 mutations: beyond 10 years of follow-up.
Early-Onset Breast Cancer in a Family with Neurofibromatosis Type 1 Associated with a Germline Mutation in BRCA1.
Early-onset malignant phyllodes breast tumor in a patient with germline pathogenic variants in NF1 and BRCA1 genes.
ECD promotes gastric cancer metastasis by blocking E3 ligase ZFP91-mediated hnRNP F ubiquitination and degradation.
Economic modeling of risk-adapted screen-and-treat strategies in women at high risk for breast or ovarian cancer.
Ectopic expression of RNF168 and 53BP1 increases mutagenic but not physiological non-homologous end joining.
Ectopic RNF168 expression promotes break-induced replication-like DNA synthesis at stalled replication forks.
EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer.
Editorial: Childhood Cancer in sub-Saharan Africa.
Educational review: role of the surgeon in hereditary breast cancer.
Effect of 7-hydroxystaurosporine on glioblastoma cell invasion and migration.
Effect of bilateral oophorectomy on mammary tumor formation in BRCA1 mutant mice.
Effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history.
Effect of BRCA1 immunohistochemical localizations on prognosis of patients with sporadic breast carcinomas.
Effect of omega-6 polyunsaturated fatty acid (linoleic acid) on BRCA1 gene expression in MCF-7 cell line.
Effect of pentoxifylline on tumor suppressor and proto-oncogene apoptosis in sperm.
Effect of Prior Bilateral Oophorectomy on the Presentation of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
Effect of S-phase kinase-associated protein 2 expression on distant metastasis and survival in nasopharyngeal carcinoma patients.
Effect of TPA and HTLV-1 Tax on BRCA1 and ERE controlled genes expression.
Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer.
Effectiveness of risk-reducing salpingo-oophorectomy in preventing ovarian cancer in a high-risk French Canadian population.
Effects of bisphenol A exposure on the proliferation and senescence of normal human mammary epithelial cells.
Effects of BRCA1 transgene expression on murine mammary gland development and mutagen-induced mammary neoplasia.
Effects of germline and somatic events in candidate BRCA-like genes on breast-tumor signatures.
Effects of Radiation Therapy on Breast Epithelial Cells in BRCA1/2 Mutation Carriers.
Effects on human transcriptome of mutated BRCA1 BRCT domain: a microarray study.
Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS).
Efficacy of Neoadjuvant Therapy With Cisplatin Plus Mitomycin C in BRCA1-Mutated Ovarian Cancer.
Efficient deletion of normal Brca2-deficient intestinal epithelium by poly(ADP-ribose) polymerase inhibition models potential prophylactic therapy.
Egr-1 regulates the transcription of the BRCA1 gene by etoposide.
Ehrlichia chaffeensis TRP120-mediated ubiquitination and proteasomal degradation of tumor suppressor FBW7 increases oncoprotein stability and promotes infection.
eIF3-f function in skeletal muscles: to stand at the crossroads of atrophy and hypertrophy.
Electrophoresis of BRCA1 oncosuppressor.
Elevated estrogen receptor-? in VHL-deficient condition induces microtubule organizing center amplification via disruption of BRCA1/Rad51 interaction.
Elevated expression of Ki-67 identifies aggressive prostate cancers but does not distinguish BRCA1 or BRCA2 mutation carriers.
Elevated insulin-like growth factor-I receptor (IGF-IR) levels in primary breast tumors associated with BRCA1 mutations.
Elevated levels of somatic mutation in a manifesting BRCA1 mutation carrier.
Elevated TRIM23 expression predicts poor prognosis in Chinese gastric cancer.
ELL targets c-Myc for proteasomal degradation and suppresses tumour growth.
Embryonic mammary signature subsets are activated in Brca1-/- and basal-like breast cancers.
Emerging PARP inhibitors for treating breast cancer.
Emerging roles of BRCA1 alternative splicing.
Emerging roles of BRCA1 in transcriptional regulation and DNA repair.
Emerging roles of F-box proteins in cancer drug resistance.
Emerging views of mitophagy in immunity and autoimmune diseases.
Emotional impact on the results of BRCA1 and BRCA2 genetic test: an observational retrospective study.
EMSY copy number variation in male breast cancers characterized for BRCA1 and BRCA2 mutations.
Endocrinology of the wild and mutant BRCA1 gene and types of hormonal carcinogenesis.
Endogenous DNA 3' Blocks Are Vulnerabilities for BRCA1 and BRCA2 Deficiency and Are Reversed by the APE2 Nuclease.
Endometrial Cancers in BRCA1 or BRCA2 Germline Mutation Carriers: Assessment of Homologous Recombination DNA Repair Defects.
Endorepellin remodels the endothelial transcriptome toward a pro-autophagic and pro-mitophagic gene signature.
Endothelial deletion of Sag/Rbx2/Roc2 E3 ubiquitin ligase causes embryonic lethality and blocks tumor angiogenesis.
Enforced expression of hsa-miR-125a-3p in breast cancer cells potentiates docetaxel sensitivity via modulation of BRCA1 signaling.
Engaging Men With BRCA-Related Cancer Risks: Practical Advice for BRCA Risk Management From Male Stakeholders.
Enhanced charge transfer by gold nanoparticle at DNA modified electrode and its application to label-free DNA detection.
Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53.
Enhanced metastasis in RNF13 knockout mice is mediated by a reduction in GM-CSF levels.
Enhanced RAD21 cohesin expression confers poor prognosis in BRCA2 and BRCAX, but not BRCA1 familial breast cancers.
Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations.
Enhanced sensitivity of peripheral blood lymphocytes from women carrying a BRCA1 mutation towards the mutagenic effects of various cytostatics.
Enhancement of BRCA1 E3 ubiquitin ligase activity through direct interaction with the BARD1 protein.
Enhancement of BRCA1 gene expression by the peroxisome proliferator-activated receptor gamma in the MCF-7 breast cancer cell line.
Enhancement of TGF-? signaling responses by the E3 ubiquitin ligase Arkadia provides tumor suppression in colorectal cancer.
Enigma negatively regulates p53 through MDM2 and promotes tumor cell survival in mice.
Ensemble-based virtual screening in discovering potent inhibitors targeting Von Hippel-Lindau (VHL) E3 ubiquitin ligase.
Epigenetic alterations in patients with type 2 diabetes mellitus.
Epigenetic alterations of BRG1 leads to cancer development through its nuclear-cytoplasmic shuttling abnormalities.
Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer.
Epigenetic inactivation of BRCA1 is associated with aberrant expression of CTCF and DNA methyltransferase (DNMT3B) in some sporadic breast tumours.
Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer.
Epigenetic modification and a role for the E3 ligase RNF40 in cancer development and metastasis.
Epigenetic modification and cancer: mark or stamp?
Epigenetic modulation of FBW7/Mcl-1 pathway for lung cancer therapy.
Epigenetic pathogenesis of human papillomavirus in upper aerodigestive tract cancers.
Epigenetic regulation of ID4 in the determination of the BRCAness phenotype in breast cancer.
Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer.
Epigenetic silencing of BRCA1 gene associated with demographic and pathologic factors in sporadic breast cancer: a study of an Indian population.
Epigenetic tumor suppression by BRCA1.
Epimutation and cancer: a new carcinogenic mechanism of Lynch syndrome (Review).
Epistasis in genomic and survival data of cancer patients.
Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations.
Epstein Barr virus: a prime candidate of breast cancer aetiology in Sudanese patients.
ER functions of oncogenes and tumor suppressors: Modulators of intracellular Ca(2+) signaling.
ER-stress-associated functional link between Parkin and DJ-1 via a transcriptional cascade involving the tumor suppressor p53 and the spliced X-box binding protein XBP-1.
Erbin interacts with c-Cbl and promotes tumourigenesis and tumour growth in colorectal cancer by preventing c-Cbl-mediated ubiquitination and down-regulation of EGFR.
ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel.
ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy.
ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer.
ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin.
ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma.
Escape, or Vanish: Control the Fate of p53 through MDM2-Mediated Ubiquitination.
Essential role of E3 ubiquitin ligase activity in Cbl-b-regulated T cell functions.
Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: the role of massively parallel sequencing.
Establishment and characterization of a breast cell strain containing a BRCA1 185delAG mutation.
Establishment and characterization of xenografts and cancer cell cultures derived from BRCA1 -/- epithelial ovarian cancers.
Estimate of the penetrance of BRCA mutation and the COS software for the assessment of BRCA mutation probability.
Estimates of the likely prophylactic effect of tamoxifen in women with high risk BRCA1 and BRCA2 mutations.
Estimating genetic influence on disease from population-based case-control data: application to cancers of the breast and ovary.
Estimating risks for variants of unknown significance according to their predicted pathogenicity classes with application to BRCA1.
Estrogen controls the survival of BRCA1-deficient cells via a PI3K-NRF2-regulated pathway.
Estrogen promotes estrogen receptor negative BRCA1-deficient tumor initiation and progression.
Estrogen receptor ? is a novel target of the Von Hippel-Lindau protein and is responsible for the proliferation of VHL-deficient cells under hypoxic conditions.
Estrogen receptor alpha is a putative substrate for the BRCA1 ubiquitin ligase.
Estrogen receptor alpha, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers.
Estrogen receptor beta decreases survival of p53-defective cancer cells after DNA damage by impairing G(2)/M checkpoint signaling.
Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features.
Estrogen receptor status could modulate the genomic pattern in familial and sporadic breast cancer.
Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type.
Estrogen receptor-beta mediates the protective effects of aromatase induction in the MMTV-Her-2/neu x aromatase double transgenic mice.
Estrogen upregulation of BRCA1 expression with no effect on localization.
Estrogens, BRCA1, and breast cancer.
Ethical issues in cancer genetics: I 1) whose information is it?
Ethical issues related to BRCA gene testing in orthodox Jewish women.
Ethics of predictive DNA-testing for hereditary breast and ovarian cancer.
Ethnic differences in cancer incidence: a marker for inherited susceptibility?
Ethnic differences in knowledge and attitudes about BRCA1 testing in women at increased risk.
ETS2 and Twist1 promote invasiveness of Helicobacter pylori-infected gastric cancer cells by inducing Siah2.
Evaluating the clinical feasibility: The direct bisulfite genomic sequencing for examination of methylated status of E3 ubiquitin ligase RNF180 DNA promoter to predict the survival of gastric cancer.
Evaluation of a Clinical Decision Support System for the Prescription of Genetic Tests in the Gynecological Cancer Risk.
Evaluation of a Next-Generation Sequencing Assay for BRCA1 and BRCA2 Mutation Detection.
Evaluation of BRCA1 mutations in an unselected patient population with triple-negative breast cancer.
Evaluation of BRCA1-related molecular features and microRNAs as prognostic factors for triple negative breast cancers.
Evaluation of BRCA1/2 mutational status among German and Austrian women with triple-negative breast cancer.
Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer.
Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers.
Evaluation of data quality at the Gambia national cancer registry.
Evaluation of expression profiles of microRNAs and two target genes, FOXO3a and RUNX2, effectively supports diagnostics and therapy predictions in breast cancer.
Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer.
Evaluation of observed and the expected incidence of common cancers: An experience from Southwestern of Iran, 2010-2014.
Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers.
Evaluation of the BRCA1 interacting genes RAP80 and CCDC98 in familial breast cancer susceptibility.
Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma.
Evaluation of the Dutch BRCA1/2 clinical genetic center referral criteria in an unselected early breast cancer population.
Evaluation of the protective effect of Nigella sativa extract and its primary active component thymoquinone against DMBA-induced breast cancer in female rats.
Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2.
Evaluation of tumor-infiltrating lymphocytes and association with prognosis in BRCA-mutated breast cancer.
Evidence for a pathogenic role of BRCA1 L1705P and W1837X germ-line mutations.
Evidence for a tumor suppressor gene distal to BRCA1 in prostate cancer.
Evidence for an ancient BRCA1 pathogenic variant in inherited breast cancer patients from Senegal.
Evidence for predictive role of BRCA1 and bTUBIII in gastric cancer.
Evidence of a founder mutation of BRCA1 in a highly homogeneous population from southern Italy with breast/ovarian cancer.
Evidence of haplotype insufficiency in human cells containing a germline mutation in BRCA1 or BRCA2.
Evidence of independent origin of multiple tumors from patients with prostate cancer.
Evironmental pollutant perfluorodecanoic acid upregulates cIAP2 to suppress gastric cell senescence.
Evolution and cancer: a mathematical biology approach.
Evolution of the tumor suppressor BRCA1 locus in primates: implications for cancer predisposition.
Evolutionary analysis of DNA-protein-coding regions based on a genetic code cube metric.
Evolutionary constraint helps unmask a splicing regulatory region in BRCA1 exon 11.
Evolutionary dynamics of BRCA1 alterations in breast tumorigenesis.
Ex Vivo MRI Evaluation of Breast Tumors: A Novel Tool for Verifying Resection of Nonpalpable Only MRI Detected Lesions.
Examining the Relationship between Pre-Malignant Breast Lesions, Carcinogenesis and Tumor Evolution in the Mammary Epithelium Using an Agent-Based Model.
Excellent Response to Olaparib in a Patient with Metastatic Pancreatic Adenocarcinoma with Germline BRCA1 Mutation after Progression on FOLFIRINOX: Case Report and Literature Review.
Excretion of estrogens, catecholestrogens and phytoestrogens in carriers of BRCA1 gene mutations: effects of metformin.
Exome profiling of primary, metastatic and recurrent ovarian carcinomas in a BRCA1-positive patient.
Exome sequencing and characterization of 49,960 individuals in the UK Biobank.
Exome sequencing reveals a high prevalence of BRCA1 and BRCA2 founder variants in a diverse population-based biobank.
Exome sequencing reveals a potential mutational trajectory and treatments for a specific pancreatic cancer patient.
Exome Sequencing-Based Screening for BRCA1/2 Expected Pathogenic Variants Among Adult Biobank Participants.
Exome-level comparison of primary well-differentiated neuroendocrine tumors and their cell lines.
Exosomal TRIM3 is a novel marker and therapy target for gastric cancer.
Exosome-mediated Delivery of the Intrinsic C-terminus Domain of PTEN Protects It From Proteasomal Degradation and Ablates Tumorigenesis.
Exosomes Secreted from Human Cancer Cell Lines Contain Inhibitors of Apoptosis (IAP).
Expanding perspectives on the significance of mitophagy in cancer.
Experience of Norwegian Female BRCA1 and BRCA2 Mutation-Carrying Participants in Educational Support Groups: a Qualitative Study.
Exploiting DNA Damage Repair in Precision Cancer Therapy: BRCA1 as a Prime Therapeutic Target.
Exploiting DNA repair defects in colorectal cancer.
Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer.
Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer.
Exploring the Role of Mutations in Fanconi Anemia Genes in Hereditary Cancer Patients.
Expression analyses of nuclear receptor genes in breast cancer cell lines exposed to soy phytoestrogens after BRCA2 knockdown by TaqMan Low-Density Array (TLDA).
Expression analysis of MIR182 and its associated target genes in advanced ovarian carcinoma.
Expression analysis of the gene encoding for the U-box-type ubiquitin ligase UBE4A in human tissues.
Expression analysis of the MCPH1/BRIT1 and BRCA1 tumor suppressor genes and telomerase splice variants in epithelial ovarian cancer.
Expression and clinical implication of Beclin1, HMGB1, p62, survivin, BRCA1 and ERCC1 in epithelial ovarian tumor tissues.
Expression and localization of inhibitor of apoptosis proteins in normal human tissues.
Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma.
Expression and mutations of BRCA in breast cancer and ovarian cancer: Evidence from bioinformatics analyses.
Expression and prognostic significance of Fanconi anemia group D2 protein and breast cancer type 1 susceptibility protein in familial and sporadic breast cancer.
Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias.
Expression levels of FBXW7 and MDM2 E3 ubiquitin ligases and their c-Myc and p53 substrates in patients with dysplastic nevi or melanoma.
Expression microarray identifies the unliganded glucocorticoid receptor as a regulator of gene expression in mammary epithelial cells.
Expression of a truncated Brca1 protein delays lactational mammary development in transgenic mice.
Expression of an amino-terminal BRCA1 deletion mutant causes a dominant growth inhibition in MCF10A cells.
Expression of an Oncogenic BARD1 Splice Variant Impairs Homologous Recombination and Predicts Response to PARP-1 Inhibitor Therapy in Colon Cancer.
Expression of androgen receptor coregulators in prostate cancer.
Expression of Autophagy and Mitophagy Markers in Breast Cancer Tissues.
Expression of BRCA1 and BRCA2 in different tumor cell lines with various growth status.
Expression of BRCA1 and BRCA2 in male breast cancers and gynecomastias.
Expression of BRCA1 and BRCA2 in normal and neoplastic cells.
Expression of BRCA1 and BRCA2 proteins and their correlation with clinical staging in breast cancer.
Expression of Brca1 and splice variant Brca1delta11 RNA levels in mouse mammary gland during normal development and tumorigenesis.
Expression of Brca1 is associated with terminal differentiation of ectodermally and mesodermally derived tissues in mice.
Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene.
Expression of BRCA1 protein in breast cancer and its prognostic significance.
Expression of BRCA1, a factor closely associated with relapse-free survival, in patients who underwent neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil for squamous cell carcinoma of the esophagus.
Expression of BRCA1, HER-1 (EGFR) and HER-2 in sporadic breast cancer and relationships to other clinicopathological prognostic features.
Expression of BRCA1, NBR1 and NBR2 genes in human breast cancer cells.
Expression of cancer related BRCA1 missense variants decreases MMS-induced recombination in Saccharomyces cerevisiae without altering its nuclear localization.
Expression of DNA Damage Response Molecules PARP1, ?H2AX, BRCA1, and BRCA2 Predicts Poor Survival of Breast Carcinoma Patients.
Expression of DNA Damage Response Proteins and Associations with Clinicopathologic Characteristics in Chinese Familial Breast Cancer Patients with BRCA1/2 Mutations.
Expression of DNA repair genes in ovarian cancer samples: Biological and clinical considerations.
Expression of DNA-PKcs and BRCA1 as prognostic indicators in nasopharyngeal carcinoma following intensity-modulated radiation therapy.
Expression of estrogen receptor beta in the breast carcinoma of BRCA1 mutation carriers.
Expression of estrogen receptor-alpha and Ki67 in relation to pathological and molecular features in early-onset infiltrating ductal carcinoma.
Expression of IAP family proteins in esophageal cancer.
Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas.
Expression of MDR1 in epithelial ovarian cancer and its association with disease progression.
Expression of Nestin associates with BRCA1 mutations, a basal-like phenotype and aggressive breast cancer.
Expression of oncogenic BARD1 isoforms affects colon cancer progression and correlates with clinical outcome.
Expression of p53 protein product in triple negative breast cancers and relation with clinical and histopathological parameters.
Expression of Parkin, APC, APE1, and Bcl-xL in Colorectal Polyps.
Expression of Pirh2, a newly identified ubiquitin protein ligase, in lung cancer.
Expression of Pirh2, a p27(Kip1) ubiquitin ligase, in hepatocellular carcinoma: correlation with p27(Kip1) and cell proliferation.
Expression of potential biomarkers associated with homologous recombination repair in patients with ovarian or triple-negative breast cancer.
Expression of Ribonucleotide Reductase Subunit-2 and Thymidylate Synthase Correlates with Poor Prognosis in Patients with Resected Stages I-III Non-Small Cell Lung Cancer.
Expression of steroid hormone receptors in BRCA1-associated ovarian carcinomas.
Expression of the circadian clock genes Per1 and Per2 in sporadic and familial breast tumors.
Expression of the forkhead box transcription factor FOXP1 is associated with oestrogen receptor alpha, oestrogen receptor beta and improved survival in familial breast cancers.
Expression of the three components of linear ubiquitin assembly complex in breast cancer.
Expression parameters of the inhibitors of apoptosis cIAP1 and cIAP2 in renal cell carcinomas and their prognostic relevance.
Expression pattern of parkin isoforms in lung adenocarcinomas.
Expression patterns of the BRCA1 splicing variants in canine normal tissues and mammary gland tumors.
Expression profile of BRCA1 and BRCA2 genes in premenopausal Mexican women with breast cancer: clinical and immunohistochemical correlates.
Expression profile of parkin isoforms in human gliomas.
Expression profiles of BRCA1 splice variants in asynchronous and in G1/S synchronized tumor cell lines.
Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors.
Extensive post-translational modification of active and inactivated forms of endogenous p53.
Extent of breast cancer type 1 promoter methylation correlates with clinicopathological features in breast cancers.
Extracellular matrix enhances heregulin-dependent BRCA1 phosphorylation and suppresses BRCA1 expression through its C terminus.
EZH2 Is Overexpressed in BRCA1-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy.
EZH2 participates in malignant biological behavior of epithelial ovarian cancer through regulating the expression of BRCA1.
EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation.
F-box only protein 31 (FBXO31) negatively regulates p38 mitogen-activated protein kinase (MAPK) signaling by mediating lysine 48-linked ubiquitination and degradation of mitogen-activated protein kinase kinase 6 (MKK6).
F-box protein 11 promotes the growth and metastasis of gastric cancer via PI3K/AKT pathway-mediated EMT.
Factors associated with the mammalian RNA polymerase II holoenzyme.
Factors associated with use of hormone therapy after preventive oophorectomy in BRCA mutation carriers.
Factors Influencing Clinical Follow-Up for Individuals with a Personal History of Breast and/or Ovarian Cancer and Previous Uninformative BRCA1 and BRCA2 Testing.
Factors Influencing Men's Interest in Gene Testing for Prostate Cancer Susceptibility.
Failure of BRCA1 dysfunction to alter ovarian cancer survival.
Falcarindiol Enhances Cisplatin Chemosensitivity of Hepatocellular Carcinoma via Down-Regulating the STAT3-Modulated PTTG1 Pathway.
Fallopian tube cancer in a BRCA1 mutation carrier: rapid development and failure of screening.
Fallopian tube intraluminal tumor spread from noninvasive precursor lesions: a novel metastatic route in early pelvic carcinogenesis.
Fallopian tube lesions in women at high risk for ovarian cancer: A multicenter study.
FAM35A/SHLD2/RINN2: A novel determinant of double strand break repair pathway choice and genome stability in cancer.
Familial aggregation of breast/ovarian cancer: age of onset along subsequent generations in Brazil.
Familial and Racial Determinants of Tumor Suppressor Genes Promoter Hypermethylation in Breast Tissues from Healthy Women.
Familial breast cancer and the hCHK2 1100delC mutation: assessing cancer risk.
Familial breast cancer screening reveals an alteration in the RAP80 UIM domain that impairs DNA damage response function.
Familial breast cancer. Approaching the isolation of a susceptibility gene.
Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers.
Familial breast-ovarian cancer syndromes: BRCA1 and BRCA2.
Familial Breast/Ovarian Cancer and BRCA1/2 Genetic Screening: The Role of Immunohistochemistry as an Additional Method in the Selection of Patients.
Familial cancer risks to offspring from mothers with 2 primary breast cancers: leads to cancer syndromes.
Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population.
Familial concordance of breast cancer pathology as an indicator of genotype in multiple-case families.
Familial context of genetic testing for cancer susceptibility: moderating effect of siblings' test results on psychological distress one to two weeks after BRCA1 mutation testing.
Familial invasive breast cancers: worse outcome related to BRCA1 mutations.
Familial non-BRCA1/BRCA2-associated breast cancer.
Familial pancreatic carcinoma in Jews.
Familial site-specific ovarian cancer is linked to BRCA1 on 17q12-21.
Familial vs sporadic ovarian tumors: characteristic genomic alterations analyzed by CGH.
Family communication about positive BRCA1 and BRCA2 genetic test results.
Family history and BRCA1/BRCA2 status among Japanese ovarian cancer patients and occult cancer in a BRCA1 mutant case.
Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation.
Family history of breast and ovarian cancer and the risk of breast carcinoma in situ.
Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer.
Family history of breast cancer in first-degree relatives and triple-negative breast cancer risk.
Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations.
Family planning in carriers of BRCA1 and BRCA2 pathogenic variants.
FANCJ compensates for RAP80 deficiency and suppresses genomic instability induced by interstrand cross-links.
FANCJ helicase controls the balance between short- and long-tract gene conversions between sister chromatids.
Fanconi Anemia Complementation Group FANCD2 Protein Serine 331 Phosphorylation Is Important for Fanconi Anemia Pathway Function and BRCA2 Interaction.
Fanconi anemia genes are highly expressed in primitive CD34+ hematopoietic cells.
Fanconi Anemia Pathway: Mechanisms of Breast Cancer Predisposition Development and Potential Therapeutic Targets.
Faulty BRCA1, BRCA2 genes: how poor is the prognosis?
FBW7 loss promotes epithelial-to-mesenchymal transition in non-small cell lung cancer through the stabilization of Snail protein.
FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation.
Fbw7 regulates the activity of endoreduplication mediators and the p53 pathway to prevent drug-induced polyploidy.
FBW7 suppresses cell proliferation and G2/M cell cycle transition via promoting ?-catenin K63-linked ubiquitylation.
FBW7-Dependent Mcl-1 Degradation Mediates the Anticancer Effect of Hsp90 Inhibitors.
FBW7-mediated ubiquitination and degradation of KLF5.
FBXL5 attenuates RhoGDI2-induced cisplatin resistance in gastric cancer cells.
FBXO16-mediated hnRNPL ubiquitination and degradation plays a tumor suppressor role in ovarian cancer.
FBXO22 Suppresses Metastasis in Human Renal Cell Carcinoma via Inhibiting MMP-9-Mediated Migration and Invasion and VEGF-Mediated Angiogenesis.
FBXO22, an epigenetic multiplayer coordinating senescence, hormone signaling, and metastasis.
FBXO25 Promotes Cutaneous Squamous Cell Carcinoma Growth and Metastasis through Cyclin D1.
FBXO38 Drives PD-1 to Destruction.
Fbxo4-mediated degradation of Fxr1 suppresses tumorigenesis in head and neck squamous cell carcinoma.
Fbxo45-mediated degradation of the tumor-suppressor Par-4 regulates cancer cell survival.
FBXW7 influences murine intestinal homeostasis and cancer, targeting Notch, Jun, and DEK for degradation.
Fbxw7 is an independent prognostic marker and induces apoptosis and growth arrest by regulating YAP abundance in hepatocellular carcinoma.
Fbxw7 regulates hepatocellular carcinoma migration and invasion via Notch1 signaling pathway.
Fbxw7 regulates tumor apoptosis, growth arrest and the epithelial-to-mesenchymal transition in part through the RhoA signaling pathway in gastric cancer.
FBXW7 Triggers Degradation of KMT2D to Favor Growth of Diffuse Large B-cell Lymphoma Cells.
FDA Approval Summary: Rucaparib for the treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer.
Features of the Copy Number Variation of Certain Genes in Tumor Cells in Patients with Serous Ovarian Adenocarcinoma.
Feed-forward regulatory loop driven by IRF4 and NF-?B in adult T-cell leukemia/lymphoma.
FEN1 endonuclease as a therapeutic target for human cancers with defects in homologous recombination.
Fertility preservation in BRCA mutation carriers.
Fibrosis and hypoxia-inducible factor-1?-dependent tumors of the soft tissue on loss of von Hippel-Lindau in mesenchymal progenitors.
Fidelity of DNA double-strand break repair in heterozygous cell lines harbouring BRCA1 missense mutations.
Filamin A inhibits tumor progression through regulating BRCA1 expression in human breast cancer.
Final report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology, on a fact-finding questionnaire on the status of treatment of hereditary breast and ovarian cancer syndrome in Japan.
Fine tuning chemotherapy to match BRCA1 status.
First application of next-generation sequencing in Moroccan breast/ovarian cancer families and report of a novel frameshift mutation of the BRCA1 gene.
First BRCA1 and BRCA2 gene testing implemented in the health care system of Stockholm.
First description of a sporadic breast cancer in a woman with BRCA1 germline mutation.
First description of an acinic cell carcinoma of the breast in a BRCA1 mutation carrier: a case report.
FISH analysis of BRCA1 copy number in paraffin-embedded ovarian cancer tissue samples.
Fish TRIM8 exerts antiviral roles through regulation of the proinflammatory factors and interferon signaling.
Five families living with hereditary breast and ovarian cancer risk.
Five Italian Families with Two Mutations in BRCA Genes.
Five screening-detected breast cancer cases in initially disease-free BRCA1 or BRCA2 mutation carriers.
Fixed and modifiable risk factors for breast cancer.
FKBP25, a novel regulator of the p53 pathway, induces the degradation of MDM2 and activation of p53.
FL118, a novel camptothecin analogue, overcomes irinotecan and topotecan resistance in human tumor xenograft models.
Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trials.
Folic acid supplementation in vitro induces cell type-specific changes in BRCA1 and BRCA 2 mRNA expression, but does not alter DNA methylation of their promoters or DNA repair.
Follicle stimulating hormone-induced growth promotion and gene expression profiles on ovarian surface epithelial cells.
Forkhead box o3a suppresses lipopolysaccharide-stimulated proliferation and inflammation in fibroblast-like synoviocytes through regulating tripartite motif-containing protein 3.
Forkhead Transcription Factor 3a (FOXO3a) Modulates Hypoxia Signaling via Up-regulation of the von Hippel-Lindau Gene (VHL).
Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance.
Formal modeling and analysis of ER-? associated Biological Regulatory Network in breast cancer.
Formation of the retinotectal projection requires Esrom, an ortholog of PAM (protein associated with Myc).
Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families.
Founder BRCA1 and BRCA2 mutations in early-onset French Canadian breast cancer cases unselected for family history.
Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families.
Founder BRCA1 mutations and two novel germline BRCA2 mutations in breast and/or ovarian cancer families from North-Eastern Poland.
Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control.
Founder mutation in the BRCA1 gene in Malay breast cancer patients from Singapore.
Founder mutations account for the majority of BRCA1-attributable hereditary breast/ovarian cancer cases in a population from Tuscany, Central Italy.
Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer.
Founder mutations in the BRCA1 gene in west Belarusian breast-ovarian cancer families.
Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden.
Four regions of allelic imbalance on 17q12-qter associated with high-grade breast tumors.
FOXC1 identifies basal-like breast cancer in a hereditary breast cancer cohort.
FOXO3a-dependent Parkin regulates the development of gastric cancer by targeting ATP-binding cassette transporter E1.
FOXP3 Regulates Sensitivity of Cancer Cells to Irradiation by Transcriptional Repression of BRCA1.
Frameshift mutations at coding mononucleotide repeats of the hRAD50 gene in gastrointestinal carcinomas with microsatellite instability.
Frequency of BRCA mutations in primary peritoneal carcinoma in Israeli Jewish women.
Frequency of BRCA1 and BRCA2 germline mutations in Japanese breast cancer families.
Frequency of BRCA1 dysfunction in ovarian cancer.
Frequency of BRCA1 mutation 5382insC in German breast cancer patients.
Frequency of germline and somatic BRCA1 mutations in ovarian cancer.
Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel.
Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations.
Frequency of the ATM IVS10-6T-->G variant in Australian multiple-case breast cancer families.
Frequency of three BRCA1 gene founder mutations in breast/ovarian cancer families from the Pomerania-Kujawy region of Poland.
Frequent allelic loss at the TOC locus on 17q25.1 in primary breast cancers.
Frequent disease progression and early recurrence in patients with familial ovarian cancer primarily treated with paclitaxel and cis- or carboplatin (preliminary report).
Frequent engagement of RelB activation is critical for cell survival in multiple myeloma.
Frequent frameshift mutations in 2 mononucleotide repeats of RNF43 gene and its regional heterogeneity in gastric and colorectal cancers.
Frequent loss of BRCA1 mRNA and protein expression in sporadic ovarian cancers.
Frequent loss of BRCA1 nuclear expression in young women with breast cancer: an immunohistochemical study from an area of low incidence but early onset.
Frequent loss of heterozygosity at the interferon regulatory factor-1 gene locus in breast cancer.
Frequent met oncogene amplification in a Brca1/Trp53 mouse model of mammary tumorigenesis.
Frequent microsatellite instability and loss of heterozygosity in the region including BRCA1 (17q21) in young patients with gastric cancer.
Frequent somatic loss of BRCA1 in breast tumours from BRCA2 germ-line mutation carriers and vice versa.
Frequent somatic mutations of GATA3 in non-BRCA1/BRCA2 familial breast tumors, but not in BRCA1-, BRCA2- or sporadic breast tumors.
Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers.
Full in-frame exon 3 skipping of BRCA2 confers high risk of breast and/or ovarian cancer.
Full-exon pyrosequencing screening of BRCA germline mutations in Mexican women with inherited breast and ovarian cancer.
Fully integrated monolithic optoelectronic transducer for real-time protein and DNA detection: The NEMOSLAB approach.
Functional analysis and consequences of Mdm2 E3 ligase inhibition in human tumor cells.
Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families.
Functional analysis of BRCA1 missense variants of uncertain significance in Japanese breast cancer families.
Functional analysis of BRCA1 RING domain variants: computationally derived structural data can improve upon experimental features for training predictive models.
Functional analysis of CpG methylation in the BRCA1 promoter region.
Functional Analysis of Familial Asp67Glu and Thr1051Ser BRCA1 Mutations in Breast/Ovarian Carcinogenesis.
Functional analysis of the transcription repressor PLU-1/JARID1B.
Functional and mutational landscapes of BRCA1 for homology-directed repair and therapy resistance.
Functional and physical interactions between BRCA1 and p53 in transcriptional regulation of the IGF-IR gene.
Functional assay for BRCA1: mutagenesis of the COOH-terminal region reveals critical residues for transcription activation.
Functional assays for BRCA1 and BRCA2.
Functional Assessment of Genetic Variants with Outcomes Adapted to Clinical Decision-Making.
Functional assessment of intrinsic disorder central domains of BRCA1.
Functional Categorization of BRCA1 Variants of Uncertain Clinical Significance in Homologous Recombination Repair Complementation Assays.
Functional characterization of BRCA1 and BRCA2: clues from their interacting proteins.
Functional characterization of BRCA1 sequence variants using a yeast small colony phenotype assay.
Functional characterization of SAG/RBX2/ROC2/RNF7, an antioxidant protein and an E3 ubiquitin ligase.
Functional classification of proteins and protein variants.
Functional consequences of cyclin D1/BRCA1 interaction in breast cancer cells.
Functional dissection of transcription factor ZBRK1 reveals zinc fingers with dual roles in DNA-binding and BRCA1-dependent transcriptional repression.
Functional domains of the BRCA1 and BRCA2 proteins.
Functional impact of missense variants in BRCA1 predicted by supervised learning.
Functional Impact of Sequence Alterations Found in BRCA1 Promoter/5'UTR Region in Breast/Ovarian Cancer Families from Upper Silesia, Poland.
Functional implications of BRCA1 for early detection, prevention, and treatment of breast cancer.
Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells.
Functional Interaction Between BRCA1 and DNA Repair in Yeast May Uncover a Role of RAD50, RAD51, MRE11A, and MSH6 Somatic Variants in Cancer Development.
Functional Interaction of BRCA1 and CREBBP in Murine Hematopoiesis.
Functional interactions between BRCA1 and the checkpoint kinase ATR during genotoxic stress.
Functional investigation of the BRCA1 Val1714Gly and Asp1733Gly variants by computational tools and yeast transcription activation assay.
Functional isogenic modeling of BRCA1 alleles reveals distinct carrier phenotypes.
Functional Link between BRCA1 and BAP1 through Histone H2A, Heterochromatin and DNA Damage Response.
Functional Polymorphisms in BARD1 Association with Neuroblastoma in a regional Han Chinese Population.
Functional Radiogenetic Profiling Implicates ERCC6L2 in Non-homologous End Joining.
Functional Roles of the E3 Ubiquitin Ligase UBR5 in Cancer.
Functional significance and therapeutic implication of ring-type E3 ligases in colorectal cancer.
Functional single-nucleotide polymorphisms in the BRCA1 gene and risk of salivary gland carcinoma.
Functional Variant Analyses (FVAs) Predict Pathogenicity in the BRCA1 DNA Double-Strand Break Repair Pathway.
Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin.
Functions and characteristics of PINK1 and Parkin in cancer.
Functions of BRCA1 and BRCA2 in the biological response to DNA damage.
Further evidence for the contribution of the BRCA1-interacting protein-terminal helicase 1 (BRIP1) gene in breast cancer susceptibility.
Fusion kinases identified by genomic analyses of sporadic microsatellite instability-high colorectal cancers.
Future possibilities in the prevention of breast cancer: intervention strategies in BRCA1 and BRCA2 mutation carriers.
G1738R is a BRCA1 founder mutation in Greek breast/ovarian cancer patients: evaluation of its pathogenicity and inferences on its genealogical history.
G:C > A:T mutations and potential epigenetic regulation of p53 in breast cancer.
Gadd45a functions as a promoter or suppressor of breast cancer dependent on the oncogenic stress.
Gadd45a Interacts with Aurora-A and Inhibits Its Kinase Activity.
Gadd45a Suppresses Ras-Driven Mammary Tumorigenesis by Activation of c-Jun NH2-Terminal Kinase and p38 Stress Signaling Resulting in Apoptosis and Senescence.
Gain of function mutant p53 proteins cooperate with E2F4 to transcriptionally downregulate RAD17 and BRCA1 gene expression.
Gain-of-function c-CBL mutations associated with uniparental disomy of 11q in myeloid neoplasms.
Gain-of-function mutation of c-CBL tumor suppressor gene in myeloid neoplasms.
Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms.
Gastric Cancer in BRCA1 Germline Mutation Carriers: Results of Endoscopic Screening and Molecular Analysis of Tumor Tissues.
GATA3 functions downstream of BRCA1 to suppress EMT in breast cancer.
Gene expression in inherited breast cancer.
Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers.
Gene expression profiling after radiation-induced DNA damage is strongly predictive of BRCA1 mutation carrier status.
Gene expression profiling in breast cancer research.
Gene expression profiling integrated into network modelling reveals heterogeneity in the mechanisms of BRCA1 tumorigenesis.
Gene expression profiling predicts clinical outcome of breast cancer.
Gene expression profiling reveals two separate mechanisms regulating apoptosis in rectal carcinomas in vivo.
Gene panel sequencing in familial Breast/Ovarian Cancer patients identifies multiple novel mutations also in genes others than BRCA1/2.
Gene Panel Testing in Hereditary Breast Cancer.
Gene Panel Tumor Testing in Ovarian Cancer Patients Significantly Increases the Yield of Clinically Actionable Germline Variants beyond BRCA1/BRCA2.
Gene promoter methylation is associated with increased mortality among women with breast cancer.
Gene selection: a Bayesian variable selection approach.
Gene therapy for carcinoma of the breast: Therapeutic genetic correction strategies.
Gene-expression profiles in hereditary breast cancer.
Gene-Specific Genetic Complementation between Brca1 and Cobra1 During Mouse Mammary Gland Development.
Generation and characterization of induced pluripotent stem cells from a family carrying the BRCA1 mutation c.3612delA.
Generation of induced pluripotent stem cell (iPSC) line from a patient with triple negative breast cancer with hereditary exon 17 deletion of BRCA1 gene.
Generation of the short TRIM32 isoform is regulated by Lys 247 acetylation and a PEST sequence.
Genes, chromatin, and breast cancer: an epigenetic tale.
Genetic alterations detected by comparative genomic hybridization and recurrence rate in epithelial ovarian carcinoma.
Genetic alterations in hereditary breast cancer.
Genetic analyses of male breast cancer in Israel.
Genetic analysis in the clinical management of biliary tract cancer.
Genetic analysis of a breast-ovarian cancer family, with 7 cases of colorectal cancer linked to BRCA1, fails to support a role for BRCA1 in colorectal tumorigenesis.
Genetic analysis of BRCA1 and BRCA2 in breast/ovarian cancer families from Aragon (Spain): two novel truncating mutations and a large genomic deletion in BRCA1.
Genetic analysis of BRCA1 function in a defined tumor cell line.
Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility.
Genetic analysis of eight breast-ovarian cancer families with suspected BRCA1 mutations.
Genetic analysis of postoperative recurrence of pancreatic cancer potentially owing to needle tract seeding during EUS-FNB.
Genetic analysis of the BRCA1 region in a large breast/ovarian family: refinement of the minimal region containing BRCA1.
Genetic and clinical characterization of BRCA-associated hereditary breast and ovarian cancer in Navarra (Spain).
Genetic and epigenetic alterations of the EGFR and mutually independent association with BRCA1, MGMT, and RASSF1A methylations in Vietnamese lung adenocarcinomas.
Genetic and epigenetic characterization of the BRCA1 gene in Brazilian women at-risk for hereditary breast cancer.
Genetic and epigenetic silencing of the beclin 1 gene in sporadic breast tumors.
Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance.
Genetic Counseling, Cancer Screening, Breast Cancer Characteristics, and General Health among a Diverse Population of BRCA Genetic Testers.
Genetic determinants at the interface of cancer and neurodegenerative disease.
Genetic diagnosis of familial breast cancer using clonal sequencing.
Genetic epidemiology of BRCA1.
Genetic evaluation of BRCA1 associated a complex genes with triple-negative breast cancer susceptibility in chinese women.
Genetic evidence supporting the taxonomic separation of the Arabian and Northwest African subspecies of the desert hedgehog (Paraechinus aethiopicus).
Genetic factors in ovarian carcinoma.
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.
Genetic heterogeneity by comparative genomic hybridization in BRCAx breast cancers.
Genetic heterogeneity in breast cancer susceptibility.
Genetic heterogeneity in hereditary breast cancer: role of BRCA1 and BRCA2.
Genetic interactions among Brca1, Brca2, Palb2, and Trp53 in mammary tumor development.
Genetic interactions between INPP4B and RAD50 is prognostic of breast cancer survival.
Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis.
Genetic landscape of a case of extraovarian peritoneal serous papillary carcinoma.
Genetic mapping of the breast-ovarian cancer syndrome to a small interval on chromosome 17q12-21: exclusion of candidate genes EDH17B2 and RARA.
Genetic modifiers of cancer risk for BRCA1 and BRCA2 mutation carriers.
Genetic pathways of colorectal carcinogenesis rarely involve the PTEN and LKB1 genes outside the inherited hamartoma syndromes.
Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy.
Genetic polymorphisms and protein expression of P53 and BRCA1 in preneoplastic and neoplastic rat mammary glands.
Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate.
Genetic predisposition to breast cancer: a surgical perspective.
Genetic profiles distinguish different types of hereditary ovarian cancer.
Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.
Genetic susceptibility to breast cancer.
Genetic testing and prevention of hereditary cancer at the MMCI--over 10 years of experience.
Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients.
Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing.
Genetic testing for BRCA1 and BRCA2: recommendations of the Stanford Program in Genomics, Ethics, and Society. Breast Cancer Working Group.
Genetic testing for breast cancer susceptibility: frequency of BRCA1 and BRCA2 mutations.
Genetic testing for women previously diagnosed with breast/ovarian cancer: examining the impact of BRCA1 and BRCA2 mutation searching.
Genetic testing in women with breast cancer: implications for treatment.
Genetic Tracing of Clonal Expansion and Progression of Pancreatic Ductal Adenocarcinoma: A Case Report and Multi-Region Sequencing Analysis.
Genetic variants of BRCA1 and BRCA2 genes in cats with mammary gland carcinoma.
Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers.
Genetic variations of BRCA1 and BRCA2 genes in dogs with mammary tumours.
Genetic Versus Epigenetic BRCA1 Silencing Pathways: Clinical Effects in Primary Ovarian Cancer Patients: A Study of the Tumor Bank Ovarian Cancer Consortium.
Genetic, functional, and histopathological evaluation of two C-terminal BRCA1 missense variants.
Genetically Defined Syngeneic Mouse Models of Ovarian Cancer as Tools for the Discovery of Combination Immunotherapy.
Genetics and ovarian carcinoma.
Genetics and the management of women at high risk for breast cancer.
Genetics of breast and ovarian cancer.
Genetics of breast cancer.
Genetics of host response in leprosy.
Genetics of triple-negative breast cancer: Implications for patient care.
Genistein induces apoptosis in ovarian cancer cells via different molecular pathways depending on Breast Cancer Susceptibility gene-1 (BRCA1) status.
Genistein inhibits Brca1 mutant tumor growth through activation of DNA damage checkpoints, cell cycle arrest, and mitotic catastrophe.
Genistein Inhibits Proliferation of BRCA1 Mutated Breast Cancer Cells: The GPR30-Akt Axis as a Potential Target.
Genistein Prevents BRCA1 CpG Methylation and Proliferation in Human Breast Cancer Cells with Activated Aromatic Hydrocarbon Receptor.
Genome-scale CRISPR knockout screen identifies TIGAR as a modifier of PARP inhibitor sensitivity.
Genome-wide analysis reveals a role for BRCA1 and PALB2 in transcriptional co-activation.
Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses.
Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk.
Genome-wide CRISPR screens reveal a Wnt-FZD5 signaling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumors.
Genome-wide CRISPR screens reveal cyclin C as synthetic survival target of BRCA2.
Genome-wide DNA methylation assessment of 'BRCA1-like' early-onset breast cancer: Data from the Australian Breast Cancer Family Registry.
Genome-Wide Gene Expression Analyses of BRCA1- and BRCA2-Associated Breast and Ovarian Tumours.
Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.
Genome-wide screening identifies novel genes and biological processes implicated in cisplatin resistance.
Genome-wide transcriptome profiling of homologous recombination DNA repair.
Genomic analysis of follicular dendritic cell sarcoma by molecular inversion probe array reveals tumor suppressor-driven biology.
Genomic analysis of inherited breast cancer among Palestinian women: Genetic heterogeneity and a founder mutation in TP53.
Genomic and Functional Analysis of the E3 Ligase PARK2 in Glioma.
Genomic and non-genomic effects of glucocorticoids: implications for breast cancer.
Genomic characterisation of acral melanoma cell lines.
Genomic Characterization of de novo Metastatic Breast Cancer.
Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma.
Genomic characterization reveals potential biomarkers in nasopharyngeal carcinoma patients with relapse.
Genomic differences between estrogen receptor (ER)-positive and ER-negative human breast carcinoma identified by single nucleotide polymorphism array comparative genome hybridization analysis.
Genomic hallmarks of homologous recombination deficiency in invasive breast carcinomas.
Genomic instability and cancer: Networks involved in response to DNA damage.
Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers.
Genomic instability in breast cancer: Pathogenesis and clinical implications.
Genomic Large Rearrangement Screening of BRCA1 and BRCA2 Genes in High-Risk Turkish Breast/Ovarian Cancer Patients by Using Multiplex Ligation-Dependent Probe Amplification Assay.
Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes.
Genomic profiling of CHEK2*1100delC-mutated breast carcinomas.
Genomic profiling of the genes on chromosome 3p in sporadic clear cell renal cell carcinoma.
Genomic rearrangements account for more than one-third of the BRCA1 mutations in northern Italian breast/ovarian cancer families.
Genomic rearrangements at the BRCA1 locus in Spanish families with breast/ovarian cancer.
Genomic rearrangements in BRCA1 and BRCA2: A literature review.
Genomic rearrangements of the BRCA1 gene in Chilean breast cancer families: an MLPA analysis.
Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers.
Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors.
Genomic structure of chromosome 17 deletions in BRCA1-associated ovarian cancers.
Genotype in BRCA-associated breast cancers.
Genotype/Phenotype correlations in patients with hereditary breast cancer.
Germ line BRCA1 & BRCA2 mutations in Greek breast/ovarian cancer families: 5382insC is the most frequent mutation observed.
Germ line BRCA1 and BRCA2 gene mutations in Turkish breast cancer patients.
Germ line mutations associated with breast cancer susceptibility.
Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer.
Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer.
Germ-line BRCA1 mutations in women with sporadic breast cancer: clinical correlations.
Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
Germ-line TP53 mutations in Finnish cancer families exhibiting features of the Li-Fraumeni syndrome and negative for BRCA1 and BRCA2.
Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in normal tissues and human primary tumors.
German family study on hereditary breast and/or ovarian cancer: germline mutation analysis of the BRCA1 gene.
Germline alterations in patients with biliary tract cancers: A spectrum of significant and previously underappreciated findings.
Germline alterations in the CLSPN gene in breast cancer families.
Germline Analysis from Tumor-Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings.
Germline and somatic mutation profile in Cancer patients revealed by a medium-sized pan-Cancer panel.
Germline and somatic mutations of multi-gene panel in Chinese patients with epithelial ovarian cancer: a prospective cohort study.
Germline and Somatic NF1 Alterations Are Linked to Increased HER2 Expression in Breast Cancer.
Germline BRCA mutation in male carriers-ripe for precision oncology?
Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.
Germline BRCA1 185delAG mutations in Jewish women with breast cancer.
Germline BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance associated with breast/ovarian cancer: a report from North India.
Germline BRCA1 and HMLH1 mutations in a family with male and female breast carcinoma.
Germline BRCA1 mutation analysis in Indian breast/ovarian cancer families.
Germline BRCA1 mutation and survival analysis in familial breast cancer patients in Kerala; South India.
Germline BRCA1 Mutation Detected in a Multiple Endocrine Neoplasia Type 2 Case With RET Codon 634 Mutation.
Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.
Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer.
Germline BRCA1 mutations in Iranian women with breast cancer.
Germline BRCA1 mutations predispose to pancreatic adenocarcinoma.
Germline deleterious mutations in genes other than BRCA2 are infrequent in male breast cancer.
Germline E-cadherin mutations in familial lobular breast cancer.
Germline genetic variation, cancer outcome, and pharmacogenetics.
Germline large genomic alterations on 7q in patients with multiple primary cancers.
Germline Missense Variants in BRCA1: New Trends and Challenges for Clinical Annotation.
Germline mutation analysis of BRCA1 and BRCA2 genes in Yugoslav breast/ovarian cancer families.
Germline Mutation in 1338 BRCA-Negative Chinese Hereditary Breast and/or Ovarian Cancer Patients: Clinical Testing with a Multigene Test Panel.
Germline mutation in the NBR1 gene involved in autophagy detected in a family with renal tumors.
Germline mutation landscape of Chinese patients with familial breast/ovarian cancer in a panel of 22 susceptibility genes.
Germline mutation of Brca1 alters the fate of mammary luminal cells and causes luminal-to-basal mammary tumor transformation.
Germline mutation of BRCA1 in Japanese breast cancer families.
Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.
Germline mutational spectrum in Armenian breast cancer patients suspected of hereditary breast and ovarian cancer.
Germline mutations in 40 cancer susceptibility genes among Chinese patients with high hereditary risk breast cancer.
Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic.
Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients.
Germline mutations in MEN1 and BRCA1 genes in a woman with familial multiple endocrine neoplasia type 1 and inherited breast-ovarian cancer syndromes: a case report.
Germline mutations in the BRCA1 and BRCA2 genes in Turkish breast/ovarian cancer patients.
Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms.
Germline mutations in young non-smoking women with lung adenocarcinoma.
Germline mutations of BRCA1 gene exon 11 are not associated with platinum response neither with survival advantage in patients with primary ovarian cancer: understanding the clinical importance of one of the biggest human exons. A study of the Tumor Bank Ovarian Cancer (TOC) Consortium.
Germline mutations of BRCA1 in two Korean hereditary breast/ovarian cancer families.
Germline mutations of the BRCA1 and BRCA2 genes in a breast and ovarian cancer patient.
Germline mutations of the BRCA1-associated ring domain (BARD1) gene in breast and breast/ovarian families negative for BRCA1 and BRCA2 alterations.
Germline mutations predisposing to melanoma.
Germline PTEN mutations in Cowden syndrome-like families.
Germline TP53 mutational spectrum in French Canadians with breast cancer.
Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families.
Germline variants in DNA repair genes, including BRCA1/2, may cause familial myeloproliferative neoplasms.
Germline Variation in Cancer-Susceptibility Genes in a Healthy, Ancestrally Diverse Cohort: Implications for Individual Genome Sequencing.
GFP-centrin as a marker for centriole dynamics in the human breast cancer cell line MCF-7.
Glioma tumor grade correlates with parkin depletion in mutant p53-linked tumors and results from loss of function of p53 transcriptional activity.
Global Disparities in Breast Cancer Genetics Testing, Counselling and Management.
Glucose Concentration in Cell Culture Medium Influences the BRCA1-Mediated Regulation of the Lipogenic Action of IGF-I in Breast Cancer Cells.
Glucose-regulated protein 78 as a novel effector of BRCA1 for inhibiting stress-induced apoptosis.
Good COP1 or bad COP1? In vivo veritas.
Good timing in the cell cycle for precise DNA repair by BRCA1.
GP78 Cooperates with Dual-Specificity Phosphatase 1 To Stimulate Epidermal Growth Factor Receptor-Mediated Extracellular Signal-Regulated Kinase Signaling.
Granulosa Cell-Specific Brca1 Loss Alone or Combined with Trp53 Haploinsufficiency and Transgenic FSH Expression Fails to Induce Ovarian Tumors.
Graphical methods for class prediction using dimension reduction techniques on DNA microarray data.
Greek BRCA1 and BRCA2 mutation spectrum: two BRCA1 mutations account for half the carriers found among high-risk breast/ovarian cancer patients.
Gross genomic alterations and gene expression profiles of high- grade serous carcinoma of the ovary with and without BRCA1 inactivation.
Group-Based Optimization of Potent and Cell-Active Inhibitors of the von Hippel-Lindau (VHL) E3 Ubiquitin Ligase: Structure-Activity Relationships Leading to the Chemical Probe (2S,4R)-1-((S)-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (VH298).
Grouper TRIM13 exerts negative regulation of antiviral immune response against nodavirus.
Growth factor receptors and apoptosis regulators: signaling pathways, prognosis, chemosensitivity and treatment outcomes of breast cancer.
Growth factor signaling pathways modulate BRCA1 repression of estrogen receptor-alpha activity.
Growth retardation and tumour inhibition by BRCA1.
Gynecological-endocrinological aspects in women carriers of BRCA1/2 gene mutations.
H2AK119Ub1 and H3K27Me3 in molecular staging for survival prediction of patients with pancreatic ductal adenocarcinoma.
Hace1 controls ROS generation of vertebrate Rac1-dependent NADPH oxidase complexes.
HACE1 is a potential tumor suppressor in osteosarcoma.
HACE1 is a putative tumor suppressor gene in B-cell lymphomagenesis and is down-regulated by both deletion and epigenetic alterations.
HACE1 is a tumor suppressor gene candidate in natural killer cell neoplasms.
HACE1 Prevents Lung Carcinogenesis via Inhibition of RAC-Family GTPases.
HACE1-dependent protein degradation provides cardiac protection in response to haemodynamic stress.
Hacking RNA: Hakai promotes tumorigenesis by enhancing the RNA-binding function of PSF.
HAF : the new player in oxygen-independent HIF-1alpha degradation.
Hallmarks of 'BRCAness' in sporadic cancers.
Haplo-insufficiency of BRCA1 in sporadic breast cancer.
Haploinsufficiency for BRCA1 is associated with normal levels of DNA nucleotide excision repair in breast tissue and blood lymphocytes.
Haploinsufficiency for BRCA1 leads to cell-type-specific genomic instability and premature senescence.
Haplotype analysis of a BRCA1: 185delAG mutation in a Chilean family supports its Ashkenazi origins.
Haplotype analysis of BRCA1 gene reveals a new gene rearrangement: characterization of a 19.9 KBP deletion.
Haplotype analysis of BRCA1 intragenic markers in Iranian patients with familial breast and ovarian cancer.
Haplotype analysis reveals that the recurrent BRCA1 deletion of exons 23 and 24 is a Greek founder mutation.
Haplotype and cancer risk analysis of two common mutations, BRCA1 4184del4 and BRCA2 2157delG, in high risk northwest England breast/ovarian families.
Haplotype and linkage disequilibrium architecture for human cancer-associated genes.
Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study.
Haplotype and quantitative transcript analyses of Portuguese breast/ovarian cancer families with the BRCA1 R71G founder mutation of Galician origin.
Haplotype-based analysis of common variation in the acetyl-coA carboxylase alpha gene and breast cancer risk: a case-control study nested within the European Prospective Investigation into Cancer and Nutrition.
Haplotypic characterization of BRCA1 c.5266dupC, the prevailing mutation in Brazilian hereditary breast/ovarian cancer.
Harnessing DNA Double-Strand Break Repair for Cancer Treatment.
HDAC inhibitors repress BARD1 isoform expression in acute myeloid leukemia cells via activation of miR-19a and/or b.
HDM2 Promotes NEDDylation of Hepatitis B Virus HBx To Enhance Its Stability and Function.
Health care provider recommendations for reducing cancer risks among women with a BRCA1 or BRCA2 mutation.
Health professional and at-risk BRCA young adult perspectives about information needs: What does Gen Y need to know?
Hemoglobins, Hemorphins, and 11p15.5 Chromosomal Region in Cancer Biology and ?mmunity with Special Emphasis for Brain Tumors.
Hepatitis B virus induces sorafenib resistance in liver cancer via upregulation of cIAP2 expression.
HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry.
HER2 Amplification Has no Prognostic Value in Sporadic and Hereditary Ovarian Tumours.
Hereditary and familial ovarian cancer in southern Ontario.
Hereditary and sporadic ovarian cancer: genetic testing and clinical implications (review).
Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome.
Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2.
Hereditary breast and ovarian cancer susceptibility genes (Review).
Hereditary breast cancer.
Hereditary breast cancer: a brief overview.
Hereditary breast cancer: from molecular pathology to tailored therapies.
Hereditary breast cancer: new genetic developments, new therapeutic avenues.
Hereditary breast cancer: part I. Diagnosing hereditary breast cancer syndromes.
Hereditary breast cancer: part II. Management of hereditary breast cancer: implications of molecular genetics and pathology.
Hereditary breast cancer: pathobiology, clinical translation, and potential for targeted cancer therapeutics.
Hereditary breast cancer: practical pursuit for clinical translation.
Hereditary breast cancer: translation into clinical practice of recent American Society of Clinical Oncology, American Society of Radiation Oncology, and Society of Surgical Oncology recommendations.
Hereditary breast cancer; Genetic penetrance and current status with BRCA.
Hereditary cancer screening: Case reports and review of literature on ten Ashkenazi Jewish founder mutations.
Hereditary cancer syndromes.
Hereditary Cancer-Associated Mutations in Women Diagnosed with Two Primary Cancers: An Opportunity to Identify Hereditary Cancer Syndromes after the First Cancer Diagnosis.
Hereditary cancers in obstetrics and gynecology.
Hereditary Carcinomas of the Ovary, Fallopian Tube, and Peritoneum.
Hereditary Factors in Gynecologic Cancer.
Hereditary forms of ovarian cancer.
Hereditary ovarian cancer and two-compartment tumor metabolism: epithelial loss of BRCA1 induces hydrogen peroxide production, driving oxidative stress and NF?B activation in the tumor stroma.
Hereditary ovarian cancer.
Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management.
Hereditary ovarian carcinomas: clinico-biological features and treatment.
Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2.
Hereditary premenopausal breast cancer.
Hereditary Risk of Breast and Ovarian Carcinoma: The Role of the Oncologist.
Hereditary risk of women's cancers.
Heregulin induces phosphorylation of BRCA1 through phosphatidylinositol 3-Kinase/AKT in breast cancer cells.
Heterochromatin instability in cancer: From the Barr body to satellites and the nuclear periphery.
Heterochromatin-Encoded Satellite RNAs Induce Breast Cancer.
Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis.
Heterogenous point mutations in the BRCA1 breast cancer susceptibility gene occur in high frequency at the site of homonucleotide tracts, short repeats and methylatable CpG/CpNpG motifs.
Heterozygosity for a mutation in Brca1 or Atm does not increase susceptibility to ENU-induced mammary tumors in Apc(Min)/+ mice.
Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype.
Hexabromocyclododecane-induced Genotoxicity in Cultured Human Breast Cells through DNA Damage.
HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia.
HIF-1? overexpression in ductal carcinoma in situ of the breast in BRCA1 and BRCA2 mutation carriers.
HIF-1? promotes autophagic proteolysis of Dicer and enhances tumor metastasis.
HIF-1alpha and EPAS ubiquitination mediated by the VHL tumour suppressor involves flexibility in the ubiquitination mechanism, similar to other RING E3 ligases.
HIF2?-Targeted RNAi Therapeutic Inhibits Clear Cell Renal Cell Carcinoma.
HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing.
High c-Cbl expression in gliomas is associated with tumor progression and poor prognosis.
High efficacy of cisplatin neoadjuvant therapy in a prospective series of patients carrying BRCA1 germ-line mutation.
High epithelial and stromal genetic instability of chromosome 17 in ulcerative colitis-associated carcinogenesis.
High Expression of Pirh2 is Associated with Poor Prognosis in Glioma.
High expression of Pirh2, an E3 ligase for p27, is associated with low expression of p27 and poor prognosis in head and neck cancers.
High Expression of Stem Cell Marker ALDH1 is Associated with Reduced BRCA1 in Invasive Breast Carcinomas.
High follicular phase luteinizing hormone levels in young healthy BRCA1 mutation carriers: implications for breast and ovarian cancer risk.
High frequency and allele-specific differences of BRCA1 founder mutations in breast cancer and ovarian cancer patients from Belarus.
High frequency of allelic loss at the BRCA1 locus in ovarian cancers: clinicopathologic and molecular associations.
High frequency of BRCA1 185delAG mutation in ovarian cancer in Israel. National Israel Study of Ovarian Cancer.
High frequency of BRCA1 5382insC mutation in Russian breast cancer patients.
High frequency of HIF-1alpha overexpression in BRCA1 related breast cancer.
High frequency of pathogenic germline variants within homologous recombination repair in patients with advanced cancer.
High frequency of pathogenic non-founder germline mutations in BRCA1 and BRCA2 in families with breast and ovarian cancer in a founder population.
High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors.
High Incidence of 4153delA BRCA1 Gene Mutations in Lithuanian Breast- and Breast-ovarian Cancer Families.
High incidence of loss of heterozygosity at chromosome 17p13 in breast tumours from BRCA2 mutation carriers.
High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
High occurrence of BRCA1 intragenic rearrangements in hereditary breast and ovarian cancer syndrome in the Czech Republic.
High penetrances of BRCA1 and BRCA2 mutations confirmed in a prospective series.
High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients.
High prevalence of BRCA1 and BRCA2 mutations in unselected Nigerian breast cancer patients.
High prevalence of BRCA1 deletions in BRCAPRO-positive patients with high carrier probability.
High prevalence of BRCA1 founder mutations in Greek breast/ovarian families.
High prevalence of cancer-associated TP53 variants in the gnomAD database: a word of caution concerning the use of variant filtering.
High prevalence of GPRC5A germline mutations in BRCA1-mutant breast cancer patients.
High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia.
High proportion of novel mutations of BRCA1 and BRCA2 in breast/ovarian cancer patients from Castilla-León (central Spain).
High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation.
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
High SINE RNA Expression Correlates with Post-Transcriptional Downregulation of BRCA1.
High Skp2 expression is associated with a mesenchymal phenotype and increased tumorigenic potential of prostate cancer cells.
High Skp2/Low p57(Kip2) Expression is Associated with Poor Prognosis in Human Breast Carcinoma.
High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma.
High-density genetic map of the BRCA1 region of chromosome 17q12-q21.
High-dose folic acid supplementation alters the human sperm methylome and is influenced by the MTHFR C677T polymorphism.
High-grade serous carcinomas arise in the mouse oviduct via defects linked to the human disease.
High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors.
High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer.
High-Throughput Amplicon-Based Copy Number Detection of 11 Genes in Formalin-Fixed Paraffin-Embedded Ovarian Tumour Samples by MLPA-Seq.
High-throughput fluorescence polarization assay to identify inhibitors of Cbl(TKB)-protein tyrosine kinase interactions.
Higher occurrence of childhood cancer in families with germline mutations in BRCA2, MMR and CDKN2A genes.
Histological groups of human postpubertal testicular germ cell tumours harbour different genetic alterations.
Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells.
Histone demethylase LSD2 acts as an E3 ubiquitin ligase and inhibits cancer cell growth through promoting proteasomal degradation of OGT.
Histone Methyltransferase EZH2 Induces Akt-Dependent Genomic Instability and BRCA1 Inhibition in Breast Cancer.
Histopathologic features of genetically determined ovarian cancer.
Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study.
Histopathological criteria and selection algorithms for BRCA1 genetic testing.
Histopathological features of 'BRCAX' familial breast cancers in the kConFab resource.
Histopathological features of breast cancer in carriers of ATM gene variants.
Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families.
Histopathology of familial ovarian tumors in women from families with and without germline BRCA1 mutations.
Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry.
HIV-1 TAT-mediated microglial activation: role of mitochondrial dysfunction and defective mitophagy.
HMGA1 protein expression sensitizes cells to cisplatin-induced cell death.
HMGA2 is regulated by LIN28 and BRCA1 in human placental cells.
Homeostatic MyD88-dependent signals cause lethal inflamMation in the absence of A20.
Homo-PROTAC mediated suicide of MDM2 to treat non-small cell lung cancer.
Homologous recombination and cell cycle checkpoints: Rad51 in tumour progression and therapy resistance.
Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins.
Homologous Recombination Deficiency: Cancer Predispositions and Treatment Implications.
Homologous recombination in cancer development, treatment and development of drug resistance.
Homologous repair deficiency score for identifying breast cancers with defective DNA damage response.
Homology-Directed Repair and the Role of BRCA1, BRCA2, and Related Proteins in Genome Integrity and Cancer.
Homotypic association between tumour-associated VHL proteins leads to the restoration of HIF pathway.
Homozygous deficiency of ubiquitin-ligase ring-finger protein RNF168 mimics the radiosensitivity syndrome of ataxia-telangiectasia.
Homozygous deletion of p16(INK4a) and tobacco carcinogen exposure in nonsmall cell lung cancer.
Homozygous loss of function BRCA1 variant causing a Fanconi-anemia-like phenotype, a clinical report and review of previous patients.
Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study.
Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers.
Hormone status of in-situ cancer in BRCA1 and BRCA2 mutation carriers.
How do mutations affecting the breast cancer genes BRCA1 and BRCA2 cause cancer susceptibility?
How do real tumors become resistant to cisplatin?
How does a hydrocarbon staple affect peptide hydrophobicity?
How does intestinal-type intraductal papillary mucinous neoplasm emerge? CDX2 plays a critical role in the process of intestinal differentiation and progression.
How Far Do We Go With Genetic Evaluation? Gene, Panel, and Tumor Testing.
How latent viruses cause breast cancer: An explanation based on the microcompetition model.
How Protective are Nipple-Sparing Prophylactic Mastectomies in BRCA1 and BRCA2 Mutation Carriers?
How to manage BRCA mutation carriers?
HOXA9 regulates BRCA1 expression to modulate human breast tumor phenotype.
HP1 promotes tumor suppressor BRCA1 functions during the DNA damage response.
HPV nonrelated endocervical adenocarcinoma in hereditary cancer syndromes.
HPV16 E6 confers p53-dependent and p53-independent phenotypes in the epidermis of mice deficient for E6AP.
HRD1 sensitizes breast cancer cells to Tamoxifen by promoting S100A8 degradation.
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.
Hsa-miR-520d-5p promotes survival in human dermal fibroblasts exposed to a lethal dose of UV irradiation.
HTLV-1 Tax oncoprotein inhibits the estrogen-induced-ER ?-Mediated BRCA1 expression by interaction with CBP/p300 cofactors.
Human Brat ortholog TRIM3 is a tumor suppressor that regulates asymmetric cell division in glioblastoma.
Human BRCA1 gene rescues the embryonic lethality of Brca1 mutant mice.
Human BRCA1 inhibits growth in yeast: potential use in diagnostic testing.
Human BRCA1-associated breast cancer: no increase in numerical chromosomal instability compared to sporadic tumors.
Human BRE1 is an E3 ubiquitin ligase for Ebp1 tumor suppressor.
Human Claspin works with BRCA1 to both positively and negatively regulate cell proliferation.
Human CtIP: A 'double agent' in DNA repair and tumorigenesis.
Human FBXL8 Is a Novel E3 Ligase Which Promotes BRCA Metastasis by Stimulating Pro-Tumorigenic Cytokines and Inhibiting Tumor Suppressors.
Human ovarian cancer of the surface epithelium.
Human papillomavirus 16 E6 contributes HIF-1? induced Warburg effect by attenuating the VHL-HIF-1? interaction.
Human papillomavirus E7 oncoprotein targets RNF168 to hijack the host DNA damage response.
Human papillomavirus-16 (HPV-16) infection association with CIAP-2 expression in head and neck cancer.
HUWE1 interacts with BRCA1 and promotes its degradation in the ubiquitin-proteasome pathway.
HUWE1 ubiquitylates and degrades the RAC activator TIAM1 promoting cell-cell adhesion disassembly, migration, and invasion.
Hybrid Capture-Based Tumor Sequencing and Copy Number Analysis to Confirm Origin of Metachronous Metastases in BRCA1-Mutant Cholangiocarcinoma Harboring a Novel YWHAZ-BRAF Fusion.
Hydrocortisone down-regulates the tumor suppressor gene BRCA1 in mammary cells: a possible molecular link between stress and breast cancer.
Hydrogen alleviated organ injury and dysfunction in sepsis: The role of cross-talk between autophagy and endoplasmic reticulum stress: Experimental research.
Hypermethylation in histologically distinct classes of breast cancer.
Hypermethylation of BRCA1 Gene in Meningioma in Elderly Males.
Hypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer.
Hypermethylation of tumor suppressor genes BRCA1, p16 and 14-3-3sigma in serum of sporadic breast cancer patients.
Hyperphosphorylation of the BARD1 tumor suppressor in mitotic cells.
Hyperplasia and spontaneous tumor development in the gynecologic system in mice lacking the BRCA1-Delta11 isoform.
Hypoxia inactivates the VHL tumor suppressor through PIASy-mediated SUMO modification.
Hypoxia induces TWIST-activated epithelial-mesenchymal transition and proliferation of pancreatic cancer cells in vitro and in nude mice.
Hypoxia-induced down-regulation of BRCA1 expression by E2Fs.
Hypoxia-Induced Epigenetic Regulation and Silencing of the BRCA1 Promoter.
Hypoxia-induced factor-1 alpha, vascular endothelial growth factor expression in BRCA1-related breast cancer: A prospective study in tertiary care hospital.
Hypoxia-induced protein CAIX is associated with somatic loss of BRCA1 protein and pathway activity in triple negative breast cancer.
Hypoxia-Induced WSB1 Promotes the Metastatic Potential of Osteosarcoma Cells.
ID4 controls luminal lineage commitment in normal mammary epithelium and inhibits BRCA1 function in basal-like breast cancer.
Id4 protein is highly expressed in triple-negative breast carcinomas: possible implications for BRCA1 downregulation.
Identification and characterization of cancer initiating cells from BRCA1 related mammary tumors using markers for normal mammary stem cells.
Identification and characterization of two novel isoforms of Pirh2 ubiquitin ligase that negatively regulate p53 independent of RING finger domains.
Identification and frequency of the rs12516 and rs8176318 BRCA1 gene polymorphisms among different populations.
Identification and functional analysis of novel BRCA1 transcripts, including mouse Brca1-Iris and human pseudo-BRCA1.
Identification and functional characterization of a PP1-binding site in BRCA1.
Identification and management of inherited cancer susceptibility.
Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer.
Identification of a 14 kb deletion involving the promoter region of BRCA1 in a breast cancer family.
Identification of a 3 kb Alu-mediated BRCA1 gene rearrangement in two breast/ovarian cancer families.
Identification of a Danish breast/ovarian cancer family double heterozygote for BRCA1 and BRCA2 mutations.
Identification of a functional nuclear export sequence in BRCA1.
Identification of a large rearrangement of the BRCA1 gene using colour bar code on combed DNA in an American breast/ovarian cancer family previously studied by direct sequencing.
Identification of a new TRAF6 inhibitor for the treatment of hepatocellular carcinoma.
Identification of a novel BRCA1 large genomic rearrangement in a Spanish breast/ovarian cancer family.
Identification of a novel BRCA1 nucleotide 4803delCC/c.4684delCC mutation and a nucleotide 249T>A/c.130T>A (p.Cys44Ser) mutation in two Greenlandic Inuit families: implications for genetic screening of Greenlandic Inuit families with high risk for breast and/or ovarian cancer.
Identification of a Novel BRCA2 and CHEK2 A-C-G-C Haplotype in Turkish Patients Affected with Breast Cancer.
Identification of a novel CHEK2 variant and assessment of its contribution to the risk of breast cancer in French Canadian women.
Identification of a novel in-frame deletion in BRCA2 and analysis of variants of BRCA1/2 in Italian patients affected with hereditary breast and ovarian cancer.
Identification of a potential tumor suppressor gene, UBL3, in non-small cell lung cancer.
Identification of a preneoplastic gene expression profile in tubal epithelium of BRCA1 mutation carriers.
Identification of a RING protein that can interact in vivo with the BRCA1 gene product.
Identification of a Small Molecule Inhibitor of RAD52 by Structure-Based Selection.
Identification of a TLR2-regulated gene signature associated with tumor cell growth in gastric cancer.
Identification of aberrantly expressed F-box proteins in squamous-cell lung carcinoma.
Identification of abrogated pathways in fallopian tube epithelium from BRCA1 mutation carriers.
Identification of an integrated SV40 T/t-antigen cancer signature in aggressive human breast, prostate, and lung carcinomas with poor prognosis.
Identification of BAF57 mutations in human breast cancer cell lines.
Identification of BARD1 splice-isoforms involved in human trophoblast invasion.
Identification of BRCA1 As a Potential Biomarker for Insulin-Like Growth Factor-1 Receptor Targeted Therapy in Breast Cancer.
Identification of BRCA1 Deficiency Using Multi-Analyte Estimation of BRCA1 and Its Repressors in FFPE Tumor Samples from Patients with Triple Negative Breast Cancer.
Identification of BRCA1 germline mutation, 797delAA, in a Japanese breast-ovarian cancer patient.
Identification of BRCA1-deficient ovarian cancers.
Identification of breast tumor mutations in BRCA1 that abolish its function in homologous DNA recombination.
Identification of c-Cbl as a new ligase for insulin-like growth factor-I receptor with distinct roles from Mdm2 in receptor ubiquitination and endocytosis.
Identification of cancer predisposition variants in apparently healthy individuals using a next-generation sequencing-based family genomics approach.
Identification of cancer-associated missense mutations in hace1 that impair cell growth control and Rac1 ubiquitylation.
Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families.
Identification of colorectal cancers with defective DNA damage repair by immunohistochemical profiling of mismatch repair proteins, CDX2 and BRCA1.
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors.
Identification of differentially expressed genes associated with colorectal cancer liver metastasis.
Identification of direct target genes of miR-7, miR-9, miR-96, and miR-182 in the human breast cancer cell lines MCF-7 and MDA-MB-231.
Identification of DNA Repair Pathways that Affect the Survival of Ovarian Cancer Cells Treated with a PARP Inhibitor in a Novel Drug Combination.
Identification of Domains of BRCA1 Critical for the Ubiquitin-Dependent Inhibition of Centrosome Function.
Identification of FDA-approved Drugs that Computationally Bind to MDM2.
Identification of fifteen novel germline variants in the BRCA1 3'UTR reveals a variant in a breast cancer case that introduces a functional miR-103 target site.
Identification of genes induced by BRCA1 in breast cancer cells.
Identification of Germline BRCA1 Mutations among Breast Cancer Families in Northeastern Iran.
Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach.
Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing.
Identification of miR-10b, miR-26a, miR-146a and miR-153 as potential triple-negative breast cancer biomarkers.
Identification of missense and truncating mutations in the BRCA1 gene in sporadic and familial breast and ovarian cancer.
Identification of Multiple Proteins Coupling Transcriptional Gene Silencing to Genome Stability in Arabidopsis thaliana.
Identification of Mutation in Exon11 of BRCA1 Gene in Bangladeshi Patients with Breast Cancer.
Identification of novel BRCA large genomic rearrangements in Singapore Asian breast and ovarian patients with cancer.
Identification of nuclear export signal in KLLN suggests potential role in proteasomal degradation in cancer cells.
Identification of Patients at High Risk of Psychological Distress after BRCA1 Genetic Testing.
Identification of peptidomimetic telomere dysfunction inhibitor (TELODIN) through telomere dysfunction-induced foci (TIF) assay.
Identification of Pirh2D, an Additional Novel Isoform of Pirh2 Ubiquitin Ligase.
Identification of Pirh2E and Pirh2F, two additional novel isoforms of Pirh2 ubiquitin ligase from human hepatocellular liver carcinoma cell line.
Identification of point mutations and large rearrangements in the BRCA1 gene in 667 Turkish unselected ovarian cancer patients.
Identification of prognostic genes in uveal melanoma microenvironment.
Identification of proteins that interact with BRCA1 by Far-Western library screening.
Identification of putative phenotype-modifying genetic factors associated with phenotypic diversity in Brooke-Spiegler syndrome.
Identification of RBCK1 as a novel regulator of FKBPL: implications for tumor growth and response to tamoxifen.
Identification of Recurrent Variants in BRCA1 and BRCA2 across Multiple Cancers in the Chinese Population.
Identification of residues critical for regulation of protein stability and the transactivation function of the hypoxia-inducible factor-1alpha by the von Hippel-Lindau tumor suppressor gene product.
Identification of sequences that target BRCA1 to nuclear foci following alkylative DNA damage.
Identification of seven new BRCA1 germline mutations in Italian breast and breast/ovarian cancer families.
Identification of Somatically Acquired BRCA1/2 Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer.
Identification of the deleterious 2080insA BRCA1 mutation in a male renal cell carcinoma patient from a family with multiple cancer diagnoses from Pakistan.
Identification of the first case of germline duplication of BRCA1 exon 13 in an Italian family.
Identification of the tumor metastasis suppressor Nm23-H1/Nm23-R1 as a constituent of the centrosome.
Identification of three regions on chromosome 17q in primary human breast carcinomas which are frequently deleted.
Identification of twenty-nine novel germline unclassified variants of BRCA1 and BRCA2 genes in 1400 Italian individuals.
Identifying and exploiting defects in the Fanconi anemia/BRCA pathway in oncology.
Identifying and managing hereditary risk of breast and ovarian cancer.
Identifying Ashkenazi Jewish BRCA1/2 founder variants in individuals who do not self-report Jewish ancestry.
Identifying germline APOBEC3B deletion and immune phenotype in Korean patients with operable breast cancer.
Identifying Women at Risk for Hereditary Breast and Ovarian Cancer Syndrome Utilizing Breast Care Nurse Navigation at Mammography and Imaging Centers.
IGF-1 and BRCA1 signalling pathways in familial cancer.
IL-6 secreted by cancer-associated fibroblasts induces tamoxifen resistance in luminal breast cancer.
Immune microenvironment composition in high-grade serous ovarian cancers based on BRCA mutational status.
Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome.
Immunohistochemical analyses of sporadic and familial (185delAG carriers) ovarian cancer in Israel.
Immunohistochemical analysis of BRCA1 expression in normal human buccal cells.
Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers.
Immunohistochemical detection of a germline BRCA1 mutation in a breast and ovarian cancer family.
Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy.
Immunohistochemical expression of BRCA1 and lethal prostate cancer.
Immunohistochemical Expression of BRCA1 Protein, ER, PR and Her2/neu in Breast Cancer: A Clinicopathological Study.
Immunohistochemical expression of DNA repair proteins in familial breast cancer differentiate BRCA2-associated tumors.
Immunohistochemical Loss of BRCA1 Protein in Uterine Serous Carcinoma.
Immunohistochemistry for the detection of BRCA1 and BRCA2 proteins in patients with ovarian cancer: a systematic review.
Immunolocalization of BRCA1 protein in normal breast tissue and sporadic invasive ductal carcinomas: a correlation with other biological parameters.
Immunolocalization of BRCA1 protein in tumor breast tissue: prescreening of BRCA1 mutation in Tunisian patients with hereditary breast cancer?
Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers.
Immunoprofile from tissue microarrays to stratify familial breast cancer patients.
Impact of amino acid substitutions at secondary structures in the BRCT domains of the tumor suppressor BRCA1: Implications for clinical annotation.
Impact of BRCA1 BRCT domain missense substitutions on phospho-peptide recognition.
Impact of BRCA1 testing on women with cancer: a pilot study.
Impact of cancer predisposition and radiosensitivity on the population risk of radiation-induced cancers.
Impact of Etoposide on BRCA1 Expression in Various Breast Cancer Cell Lines.
Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data.
Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313).
Impact of Hyperhomocysteinemia on Breast Cancer Initiation and Progression: Epigenetic Perspective.
Impact of loss-of-function mutations at the RNF43 locus on colorectal cancer development and progression.
Impact of mitochondrial transcription factor A expression on the outcomes of ovarian, endometrial and cervical cancers.
Impact of Oophorectomy on Cancer Incidence and Mortality in Women With a BRCA1 or BRCA2 Mutation.
Impact of RING and BRCT domain mutations on BRCA1 protein stability, localization and recruitment to DNA damage.
Impact of siRNA targeting pirh2 on proliferation and cell cycle control of the lung adenocarcinoma cell line A549.
Impact of SNPs on CpG Islands in the MYC and HRAS oncogenes and in a wide variety of tumor suppressor genes: A multi-cancer approach.
Impaired DNA damage response - An Achilles' heel sensitizing cancer to chemotherapy and radiotherapy.
Impaired skin and mammary gland development and increased gamma-irradiation-induced tumorigenesis in mice carrying a mutation of S1152-ATM phosphorylation site in Brca1.
Implication of alterations in Parkin gene among North Indian patients with colorectal cancer.
Implication of BRCA1 gene in breast cancer.
Implications of a novel cryptic splice site in the BRCA1 gene.
Implications of the age range in a population-based BRCA1 testing program with eligibility based on family history of breast and ovarian cancer.
Importance of DNA damage checkpoints in the pathogenesis of human cancers.
Importin-? and CRM1 control a RANBP2 spatiotemporal switch essential for mitotic kinetochore function.
Improved efficacy of mitochondrial disrupting agents upon inhibition of autophagy in a mouse model of BRCA1-deficient breast cancer.
Improved Therapeutic Window in BRCA-mutant Tumors with Antibody-linked Pyrrolobenzodiazepine Dimers with and without PARP Inhibition.
Improving attendance to genetic counselling services for gynaecological oncology patients.
Improving Gemcitabine Sensitivity in Pancreatic Cancer Cells by Restoring miRNA-217 Levels.
In brief: BRCA1 and BRCA2.
In silico analysis of functional single nucleotide polymorphisms in the human TRIM22 gene.
In their own words: treating very young BRCA1/2 mutation-positive women with care and caution.
In vitro analysis of genomic instability triggered by BRCA1 missense mutations.
In vitro and in vivo correlates of physiological and neoplastic human Fallopian tube stem cells.
In Vitro Enhanced Sensitivity to Cisplatin in D67Y BRCA1 RING Domain Protein.
In vitro repression of Brca1-associated RING domain gene, Bard1, induces phenotypic changes in mammary epithelial cells.
Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma.
Inactivation of BRCA1 and BRCA2 in ovarian cancer.
Inactivation of CtIP leads to early embryonic lethality mediated by G1 restraint and to tumorigenesis by haploid insufficiency.
Inactivation of parkin by promoter methylation correlated with lymph node metastasis and genomic instability in nasopharyngeal carcinoma.
Inactivation of sag/rbx2/roc2 e3 ubiquitin ligase triggers senescence and inhibits kras-induced immortalization.
Inactivation of the Cullin (CUL)-RING E3 ligase by the NEDD8-activating enzyme inhibitor MLN4924 triggers protective autophagy in cancer cells.
Inactivation of the MDM2 RING domain enhances p53 transcriptional activity in mice.
Inactivation of the mouse Brca1 gene leads to failure in the morphogenesis of the egg cylinder in early postimplantation development.
Inactivation of the prolyl isomerase Pin1 sensitizes BRCA1-proficient breast cancer to PARP inhibition.
Inactivation of VHL by tumorigenic mutations that disrupt dynamic coupling of the pVHL.hypoxia-inducible transcription factor-1alpha complex.
Inadequate DNA Damage Repair Promotes Mammary Transdifferentiation, Leading to BRCA1 Breast Cancer.
Inbred Strain Characteristics Impact the NKT Cell Repertoire.
Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations.
Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry.
Incidence of BRCA1 somatic mutations and response to neoadjuvant chemotherapy in Chinese women with triple-negative breast cancer.
Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study.
Incidence of contralateral and ipsilateral breast cancers and prognosis in BRCA1/2 pathogenic variant carriers based on the Japanese HBOC Consortium registration.
Incidence of Hypersensitivity Reactions to Carboplatin or Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer With or Without BRCA1 or BRCA2 Mutations.
Incidence of loss of heterozygosity at p53 and BRCA1 loci in serous surface carcinoma.
Incidence of malignant tumours in relatives of BRCA1 and BRCA2 germline mutation carriers.
Incidental Carcinomas in Prophylactic Specimens in BRCA1 and BRCA2 Germ-line Mutation Carriers, With Emphasis on Fallopian Tube Lesions: Report of 6 Cases and Review of the Literature.
Incidental MRI detection of BRCA1-related solitary peritoneal carcinoma during breast screening--A case report.
Incorporating immunohistochemical markers into screening methods for BRCA1-mutated breast cancer.
Incorporating tumor immunohistochemical markers in BRCA1 and BRCA2 carrier prediction.
Incorporating tumour pathology information into breast cancer risk prediction algorithms.
Incorporation of semi-quantitative analysis of splicing alterations for the clinical interpretation of variants in BRCA1 and BRCA2 genes.
Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells.
Increased BRCA1 protein in mammary tumours of rats fed marine omega-3 fatty acids.
Increased cancer risks for relatives of very early-onset breast cancer cases with and without BRCA1 and BRCA2 mutations.
Increased cell survival by inhibition of BRCA1 using an antisense approach in an estrogen responsive ovarian carcinoma cell line.
Increased expression of BRCA1 mRNA predicts favorable response to anthracycline-containing chemotherapy in breast cancers.
Increased Expression of BRCA2 and RAD51 in Lymph Node Metastases of Canine Mammary Adenocarcinomas.
Increased expression of MARCH8, an E3 ubiquitin ligase, is associated with growth of esophageal tumor.
Increased frequency of TP53 mutations in BRCA1 and BRCA2 ovarian tumours.
Increased gene expression variability in BRCA1-associated and basal-like breast tumours.
Increased heterogeneity of chromosome 17 aneuploidy in endometriosis.
Increased ID4 expression, accompanied by mutant p53 accumulation and loss of BRCA1/2 proteins in triple-negative breast cancer, adversely affects survival.
Increased progesterone receptor expression in benign epithelium of BRCA1-related breast cancers.
Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in breast cancer tissue.
Increased rates of chromosome breakage in BRCA1 carriers are normalized by oral selenium supplementation.
Increased risk of male cancer and identification of a potential prostate cancer cluster region in BRCA2.
Increased sensitivity of BRCA defective triple negative breast tumors to plumbagin through induction of DNA Double Strand Breaks (DSB).
Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation.
Independent origin of 185delAG BRCA1 mutation in an Indian family.
Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy.
Individual and Combined Expression of DNA Damage Response Molecules PARP1, ?H2AX, BRCA1, and BRCA2 Predict Shorter Survival of Soft Tissue Sarcoma Patients.
Indole-3-carbinol (I3C) analogues are potent small molecule inhibitors of NEDD4-1 ubiquitin ligase activity that disrupt proliferation of human melanoma cells.
Induced in vivo knockdown of the Brca1 gene in skeletal muscle results in skeletal muscle weakness.
Induced micronucleus frequencies in peripheral lymphocytes as a screening test for carriers of a BRCA1 mutation in breast cancer families.
Inducible degradation of checkpoint kinase 2 links to cisplatin-induced resistance in ovarian cancer cells.
Inducing Synthetic Lethality using PARP Inhibitors.
Induction of apoptosis by the tumor suppressor protein BRCA1.
Induction of c-Cbl contributes to anti-cancer effects of HDAC inhibitor in lung cancer.
Induction of the long noncoding RNA NBR2 from the bidirectional BRCA1 promoter under hypoxic conditions.
Induction of the von Hippel-Lindau tumor suppressor gene by late hypoxia limits HIF-1 expression.
Infantile Epithelioid Sarcoma with Genomic Segmental Amplification of BIRC3/YAP1 as Double Minutes Plus Trisomy 2: A Case Report.
Influence of BRCA1 Germline Mutations in the Somatic Mutational Burden of Triple-Negative Breast Cancer.
Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women.
Influence of chemically modified tetracyclines on proliferation, invasion and migration properties of MDA-MB-468 human breast cancer cells.
Influence of race/ethnicity on genetic counseling and testing for hereditary breast and ovarian cancer.
Influence of Risk Category and Screening Round on the Performance of an MR Imaging and Mammography Screening Program in Carriers of the BRCA Mutation and Other Women at Increased Risk.
Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers.
Influence of tumour suppressor gene (TP53, BRCA1 and BRCA2) polymorphisms on polycystic ovary syndrome in South Indian women.
Information Needs of Mothers Regarding Communicating BRCA1/2 Cancer Genetic Test Results to Their Children.
Informed consent for BRCA1 and BRCA2 testing.
Ingenuity pathway analysis of human facet joint tissues: Insight into facet joint osteoarthritis.
Inheritance of cancer.
Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women.
Inherited BRCA2 mutation associated with high grade breast cancer.
Inherited breast and ovarian cancer.
Inherited breast cancer: an emerging picture.
Inherited genetic susceptibility to breast cancer.
Inherited Mutations in Women With Ovarian Carcinoma.
Inherited predisposition and breast cancer: modifiers of BRCA1/2-associated breast cancer risk.
Inherited predisposition to breast cancer in the Carolina Breast Cancer Study.
Inherited predisposition to cancer: a historical overview.
Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations.
Inhibiting Skp2 E3 Ligase Suppresses Bleomycin-Induced Pulmonary Fibrosis.
Inhibition of AKT suppresses the initiation and progression of BRCA1-associated mammary tumors.
Inhibition of apoptosis via CHIP-mediated proteasomal degradation of TAp73?.
Inhibition of Atrogin-1/MAFbx Expression by Adenovirus-Delivered Small Hairpin RNAs Attenuates Muscle Atrophy in Fasting Mice.
Inhibition of cIAP1 as a strategy for targeting c-MYC-driven oncogenic activity.
Inhibition of CIN85-mediated invasion by a novel SH3 domain binding motif in the lysyl oxidase propeptide.
Inhibition of E2-induced expression of BRCA1 by persistent organochlorines.
Inhibition of Estrogen Signaling Reduces the Incidence of BRCA1-associated Mammary Tumor Formation.
Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors.
Inhibition of IAP's and activation of p53 leads to caspase-dependent apoptosis in gastric cancer cells treated with Scutellarein.
Inhibition of ITCH Suppresses Proliferation and Induces Apoptosis of Lung Cancer Cells.
Inhibition of p53 degradation by Mdm2 acetylation.
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
Inhibition of RIF1 by SCAI Allows BRCA1-Mediated Repair.
Inhibition of Skp2 Sensitizes Chronic Myeloid Leukemia Cells to Imatinib.
Inhibitors of apoptosis (IAPs) regulate intestinal immunity and inflammatory bowel disease (IBD) inflammation.
Inhibitors of SCF-Skp2/Cks1 E3ligase block estrogen-induced growth stimulation and degradation of nuclear p27kip1: therapeutic potential for endometrial cancer.
Insights into BRCA Cancer Predisposition from Integrated Germline and Somatic Analyses in 7632 Cancers.
Insights into Cullin-RING E3 Ubiquitin Ligase Recruitment: Structure of the VHL-EloBC-Cul2 Complex.
Insights into the functions of BRCA1 and BRCA2.
Insights into the Molecular Basis of Human Hereditary Breast Cancer from Studies of the BRCA1 BRCT Domain.
Insights into the targeted elimination of BRCA1-defective cancer stem cells.
Insufficient evidence of endocervical origin in germline BRCA1 and MSH2-associated tumors.
Insulin-like growth factor-1 genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating insulin-like growth factor-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families.
Insulin-like growth factor-I controls BRCA1 gene expression through activation of transcription factor Sp1.
Insurance adjudication favoring prophylactic surgery in hereditary breast-ovarian cancer syndrome.
INT6/EIF3E interacts with ATM and is required for proper execution of the DNA damage response in human cells.
Integrated genomic analyses of ovarian carcinoma.
Integrated genomic characterization of adrenocortical carcinoma.
Integrating PARP inhibitors into the management of breast cancer: where are we?
Integration of BRCA1-mediated miRNA and mRNA profiles reveals microRNA regulation of TRAF2 and NF?B pathway.
Integrative analysis of genomic alterations in triple-negative breast cancer in association with homologous recombination deficiency.
Integrative Bioinformatics and Functional Analyses of GEO, ENCODE, and TCGA Reveal FADD as a Direct Target of the Tumor Suppressor BRCA1.
Integrative data fusion for comprehensive assessment of a novel CHEK2 variant using combined genomics, imaging, and functional-structural assessments via protein informatics.
Integrative Genomic and Transcriptomic Analyses of Tumor Suppressor Genes and Their Role on Tumor Microenvironment and Immunity in Lung Squamous Cell Carcinoma.
Integrative mining of traditional Chinese medicine literature and MEDLINE for functional gene networks.
Integrin beta3 Leu33Pro polymorphism increases BRCA1-associated ovarian cancer risk.
Intensive surveillance with bi-annual dynamic contrast-enhanced magnetic resonance imaging downstages breast cancer in BRCA1 mutation carriers.
Interaction between BRCA1 and human papilloma virus E7: an ontology study.
Interaction between von Hippel-Lindau Protein and Fatty Acid Synthase Modulates Hypoxia Target Gene Expression.
Interaction of p14(ARF) with Brca1 in cancer cell lines and primary breast cancer.
Interactions between BRCT repeats and phosphoproteins: tangled up in two.
Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.
Intercepting early pelvic serous carcinoma by routine pathological examination of the fimbria.
Interferon-inducible TRIM22 contributes to maintenance of HIV-1 proviral latency in T cell lines.
Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers.
Interlaboratory diagnostic validation of conformation-sensitive capillary electrophoresis for mutation scanning.
Interleukin-1 and TRAF6-dependent activation of TAK1 in the absence of TAB2 and TAB3.
International Rates of Breast Reconstruction After Prophylactic Mastectomy in BRCA1 and BRCA2 Mutation Carriers.
International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation.
International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers.
Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis.
Interplay between BRCA1 and GADD45A and Its Potential for Nucleotide Excision Repair in Breast Cancer Pathogenesis.
Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer.
Interplay between Fanconi anemia and homologous recombination pathways in genome integrity.
Interplay between Parkin and p53 Governs a Physiological Homeostasis That Is Disrupted in Parkinson's Disease and Cerebral Cancer.
Interrogation of MDM2 phosphorylation in p53 activation using native chemical ligation: the functional role of Ser17 phosphorylation in MDM2 reexamined.
Interventions to improve psychosocial well-being in female BRCA-mutation carriers following risk-reducing surgery.
Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Intraductal papillary mucinous neoplasm of the pancreas: associated cancers, family history, genetic predisposition?
Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss.
Intrahepatic cholangiocarcinoma development in a patient with a novel BAP1 germline mutation and low exposure to asbestos.
Intratumor heterogeneity of homologous recombination deficiency in primary breast cancer.
Intrinsic ubiquitin E3 ligase activity of histone acetyltransferase Hbo1 for estrogen receptor ?.
Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations.
Intronic alterations in BRCA1 and BRCA2: effect on mRNA splicing fidelity and expression.
Intronic TP53 Germline Sequence Variants Modify the Risk in German Breast/Ovarian Cancer Families.
Invasion patterns of metastatic high-grade serous carcinoma of ovary or fallopian tube associated with BRCA deficiency.
Inverse correlation between Naa10p and Pirh2 expression and the combined prognostic value in oral squamous cell carcinoma patients.
Investigating of variations in BRCA1 gene in Iranian families with breast cancer.
Investigation of the Involvement of Parkin in Parkinson's Disease and Cancer by Monitoring the Changes in SH-SY5Y Cells at the Nuclear Proteome Level.
Involvement and Influence of Healthcare Providers, Family Members, and Other Mutation Carriers in the Cancer Risk Management Decision-Making Process of BRCA1 and BRCA2 Mutation Carriers.
Involvement of a specificity proteins-binding element in regulation of basal and estrogen-induced transcription activity of the BRCA1 gene.
Involvement of the multiple tumor suppressor genes and 12-lipoxygenase in human prostate cancer. Therapeutic implications.
Ionizing radiation or mitomycin-induced micronuclei in lymphocytes of BRCA1 or BRCA2 mutation carriers.
iPSC-Derived Hereditary Breast Cancer Model Reveals the BRCA1-Deleted Tumor Niche as a New Culprit in Disease Progression.
Is BRCA1/BRCA2-related breast carcinogenesis estrogen dependent?
Is hereditary site-specific ovarian cancer a distinct genetic condition?
Is mammographic breast density a breast cancer risk factor in women with BRCA mutations?
Is p53 intronic variant G13964C associated with predisposition to cancer?
Is PARKIN parkinsonism a cancer predisposition syndrome?
Is there a specific magnetic resonance phenotype characteristic of hereditary breast cancer?
Is there more to BARD1 than BRCA1?
Is TP53 dysfunction required for BRCA1-associated carcinogenesis?
Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome?
Is uterine serous papillary carcinoma a BRCA1-related disease? Case report and review of the literature.
Isoform-specific SCF(Fbw7) ubiquitination mediates differential regulation of PGC-1?.
Isogenic normal basal and luminal mammary epithelial isolated by a novel method show a differential response to ionizing radiation.
Isolation, purification and quantification of BRCA1 protein from tumour cells by affinity perfusion chromatography.
Issues in the genetic assessment of predispositions for familial breast and ovarian cancer.
Italian family with two independent mutations: 3358T/A in BRCA1 and 8756delA in BRCA2 genes.
Itch E3 ubiquitin ligase regulates large tumor suppressor 1 tumor-suppressor stability.
ITCH-dependent proteasomal degradation of c-FLIP induced by the anti-HER3 antibody 9F7-F11 promotes DR5/caspase 8-mediated apoptosis of tumor cells.
Japanese Late-Onset Breast Cancer Families: Their Clincopathological Characteristics and Absence of BRCA1 and BRCA2 Germline Mutations.
Jostling for position: optimizing linker location in the design of estrogen receptor-targeting PROTACs.
JP3, an antiangiogenic peptide, inhibits growth and metastasis of gastric cancer through TRIM25/SP1/MMP2 axis.
JunB potentiates function of BRCA1 activation domain 1 (AD1) through a coiled-coil-mediated interaction.
Kaposi's Sarcoma-Associated Herpesvirus Viral Interferon Regulatory Factor 4 Targets MDM2 to Deregulate the p53 Tumor Suppressor Pathway.
Kinetic Detection of E3:PROTAC:Target Ternary Complexes Using NanoBRET Technology in Live Cells.
Klotho gene polymorphisms are associated with healthy aging and longevity: Evidence from a meta-analysis.
Knockdown of COUP-TFII inhibits cell proliferation and induces apoptosis through upregulating BRCA1 in renal cell carcinoma cells.
Knockdown of endogenous RNF4 exacerbates ischaemia-induced cardiomyocyte apoptosis in mice.
Knockdown of TRIM32 inhibits tumor growth and increases the therapeutic sensitivity to temozolomide in glioma in a p53-dependent and -independent manner.
Knocking down of Polo-like kinase 2 inhibits cell proliferation and induced cell apoptosis in human glioma cells.
Knockout mouse models and mammary tumorigenesis.
Knowledge, attitudes, and interest in breast-ovarian cancer gene testing: a survey of a large African-American kindred with a BRCA1 mutation.
KRAS mutation and DNA repair and synthesis genes in non-small-cell lung cancer.
Kras mutation subtypes distinctly affect colorectal cancer cell sensitivity to FL118, a novel inhibitor of survivin, Mcl-1, XIAP, cIAP2 and MdmX.
KRAS, GNAS, and RNF43 mutations in intraductal papillary mucinous neoplasm of the pancreas: a meta-analysis.
KSR1 regulates BRCA1 degradation and inhibits breast cancer growth.
Laboratory determination of hereditary susceptibility to breast and ovarian cancer.
Lack of association between androgen receptor CAG polymorphism and familial breast/ovarian cancer.
Lack of association between cancer history and PARKIN genotype: A family based study in PARKIN/Parkinson's Families.
Lack of genetic and epigenetic changes in meningiomas without NF2 loss.
Lack of HIN-1 methylation in BRCA1-linked and "BRCA1-like" breast tumors.
Lack of RING Finger Domain (RFD) Mutations of the c-Cbl Gene in Oral Squamous Cell Carcinomas in Chennai, India.
Lack of the predominant BRCA1 and BRCA2 mutations in Jewish ovarian carcinoma patients who previously underwent ovulation induction.
Landscape of somatic mutations and clonal evolution in mantle cell lymphoma.
Laparoscopic total fallopian tube removal at the time of bilateral salpingo-oophorectomy in BRCA2 positive women.
Large BRCA1 and BRCA2 genomic rearrangements in Danish high risk breast-ovarian cancer families.
Large BRCA1 and BRCA2 genomic rearrangements in Malaysian high risk breast-ovarian cancer families.
Large BRCA1 and BRCA2 genomic rearrangements in Polish high-risk breast and ovarian cancer families.
Large chromosomal deletions and impaired homologous recombination repairing in HEK293T cells exposed to polychlorinated biphenyl 153.
Large family with both parents affected by distinct BRCA1 mutations: implications for genetic testing.
Large genomic rearrangements of both BRCA2 and BRCA1 are a feature of the inherited breast/ovarian cancer phenotype in selected families.
Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification.
Large-scale Sequencing of Testicular Germ Cell Tumour (TGCT) Cases Excludes Major TGCT Predisposition Gene.
LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC.
Learning about a twist in the road: perspectives of at-risk relatives learning of potential for cancer.
Learning Healthcare System for the Prescription of Genetic Testing in the Gynecological Cancer Risk.
Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells.
Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer.
Lessons learned from BRCA1 and BRCA2.
Levels of DNA Methylation Vary at CpG Sites across the BRCA1 Promoter, and Differ According to Triple Negative and "BRCA-Like" Status, in Both Blood and Tumour DNA.
Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations.
Lifestyle behaviors in women with a BRCA1 or BRCA2 genetic mutation: an exploratory study guided by concepts derived from the Health Belief Model.
Limited significance of family history for presence of BRCA1 gene mutation in Polish breast and ovarian cancer cases.
Linear ubiquitination signals in adaptive immune responses.
Linkage analysis of 26 Canadian breast and breast-ovarian cancer families.
Linkage to markers for the chromosome region 17q12-q21 in 13 Dutch breast cancer kindreds.
Linking distant relatives with BRCA gene mutations: potential for cost savings.
Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment.
Linking uterine serous carcinoma to BRCA1/2-associated cancer syndrome: A meta-analysis and case report.
Links between genome integrity and BRCA1 tumor suppression.
Lipopolysaccharide and Tumor Necrosis Factor Regulate Parkin Expression via Nuclear Factor-Kappa B.
Literature Review of BARD1 as a Cancer Predisposing Gene with a Focus on Breast and Ovarian Cancers.
Lithium Chloride Protects against Sepsis-Induced Skeletal Muscle Atrophy and Cancer Cachexia.
Liver Kinase B1-A Potential Therapeutic Target in Hormone-Sensitive Breast Cancer in Older Women.
lncRNA CISAL Inhibits BRCA1 Transcription by Forming a Tertiary Structure at Its Promoter.
LncRNA NBR2 inhibits epithelial-mesenchymal transition by regulating Notch1 signaling in osteosarcoma cells.
LncRNA NBR2 Inhibits the Malignancy of Thyroid Cancer, Associated With Enhancing the AMPK Signaling.
LncRNA NBR2 inhibits tumorigenesis by regulating autophagy in hepatocellular carcinoma.
Lobular breast cancer: incidence and genetic and non-genetic risk factors.
Lobular carcinoma of the breast in an 85-year-old man.
Localisation of the breast-ovarian cancer susceptibility gene (BRCA1) on 17q12-21 to an interval of < or = 1 cM.
Localization of a novel susceptibility gene for familial ovarian cancer to chromosome 3p22-p25.
Localization of BRCA1 and a splice variant identifies the nuclear localization signal.
Localization of BRCA1 gene expression in adult cynomolgus monkey tissues.
Localization of human BRCA1 and BRCA2 in non-inherited colorectal carcinomas and matched normal mucosas.
Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas.
Localization of potential tumor suppressor loci to a < 2 Mb region on chromosome 17q in human prostate cancer.
Localization of the VHR phosphatase gene and its analysis as a candidate for BRCA1.
Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer.
LOH of chromosome 6q compared with LOH of 17q and 18q in ovarian cancers: relationship to p53 expression and clinicopathological findings.
Long non-coding RNA and microRNAs might act in regulating the expression of BARD1 mRNAs.
Long noncoding RNA lnc-DILC stabilizes PTEN and suppresses clear cell renal cell carcinoma progression.
Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy.
Long-Term BRCA1 Down-Regulation by Small Hairpin RNAs Targeting the 3' Untranslated Region.
Long-term prospective clinical follow-up after BRCA1/2 presymptomatic testing: BRCA2 risks higher than in adjusted retrospective studies.
Long-Term Survival in Locally Advanced KRAS Wild-Type Pancreatic Adenocarcinoma.
Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.
Loss of Bard1, the heterodimeric partner of the Brca1 tumor suppressor, results in early embryonic lethality and chromosomal instability.
Loss of BRCA1 expression and morphological features associated with BRCA1 promoter methylation status in triple-negative breast cancer.
Loss of BRCA1 expression may predict shorter time-to-progression in metastatic breast cancer patients treated with taxanes.
Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention.
Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor-inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice.
Loss of BRCA1 or BRCA2 markedly increases the rate of base substitution mutagenesis and has distinct effects on genomic deletions.
Loss of BRCA1 protein expression as indicator of the BRCAness phenotype is associated with favorable overall survival after complete resection of sporadic ovarian cancer.
Loss of BRCA1 Spontaneously Induces the Tumorigenesis in Lacrimal Gland.
Loss of c-Cbl expression correlates with de-differentiation status and lymphatic metastasis in gastric cancer.
Loss of CHFR in human mammary epithelial cells causes genomic instability by disrupting the mitotic spindle assembly checkpoint.
Loss of cIAP1 in Endothelial Cells Limits Metastatic Extravasation through Tumor-Derived Lymphotoxin Alpha.
Loss of COP1 expression determines poor prognosisin patients with gastric cancer.
Loss of CtIP disturbs homologous recombination repair and sensitizes breast cancer cells to PARP inhibitors.
Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor.
Loss of endogenous RNF43 function enhances proliferation and tumour growth of intestinal and gastric cells.
Loss of expression of FANCD2 protein in sporadic and hereditary breast cancer.
Loss of glucocorticoid receptor activation is a hallmark of BRCA1-mutated breast tissue.
Loss of heterozygosity (LOH) at p53 is correlated with LOH at BRCA1 and BRCA2 in various human malignant tumors.
Loss of heterozygosity at 8p, 9p and 17q in laryngeal cytological specimens.
Loss of heterozygosity at 9p and 17q in human laryngeal tumors.
Loss of Heterozygosity at BRCA1 Locus Is Significantly Associated with Aggressiveness and Poor Prognosis in Breast Cancer.
Loss of heterozygosity at BRCA1/2 loci in hereditary and sporadic ovarian cancers.
Loss of heterozygosity at the BRCA1 locus in Tunisian women with sporadic breast cancer.
Loss of heterozygosity at the BRCA2 locus detected by multiplex ligation-dependent probe amplification is common in prostate cancers from men with a germline BRCA2 mutation.
Loss of heterozygosity in BRCA1 and BRCA2 markers and high-grade malignancy in breast cancer.
Loss of heterozygosity in familial tumors from three BRCA1-linked kindreds.
Loss of heterozygosity in P53, BRCA1, and estrogen receptor genes and correlation to expression of p53 protein in ovarian epithelial tumors of different cell types and biological behavior.
Loss of heterozygosity of BRCA1, BRCA2 and ATM genes in sporadic invasive ductal breast carcinoma.
Loss of heterozygosity of BRCA1, TP53 and TCRD markers analysed in sporadic endometrial cancer.
Loss of heterozygosity of nucleotide excision repair factors in sporadic oral squamous cell carcinoma using microdissected tissue.
Loss of heterozygosity of the BRCA1 and other loci on chromosome 17q in human prostate cancer.
Loss of heterozygosity of the PTH/PTHrP type 1 receptor in oral squamous cell carcinoma.
Loss of heterozygosity of TRIM3 in malignant gliomas.
Loss of heterozygosity on chromosome 17q11-21 in cancers of women who have both breast and ovarian cancer.
Loss of heterozygosity studies in tumors from families with breast-ovarian cancer syndrome.
Loss of INPP4B causes a DNA repair defect through loss of BRCA1, ATM and ATR and can be targeted with PARP inhibitor treatment.
Loss of markers linked to BRCA1 precedes loss at important cell cycle regulatory genes in epithelial ovarian cancer.
Loss of MIEF1/MiD51 confers susceptibility to BAX-mediated cell death and PINK1-PRKN-dependent mitophagy.
Loss of nuclear BRCA1 expression in breast cancers is associated with a highly proliferative tumor phenotype.
Loss of nuclear BRCA1 localization in breast carcinoma is age dependent.
Loss of oncogenic miR-155 in tumor cells promotes tumor growth by enhancing C/EBP-?-mediated MDSC infiltration.
Loss of parkin reduces lung tumor development by blocking p21 degradation.
Loss of RNF43 Function Contributes to Gastric Carcinogenesis by Impairing DNA Damage Response.
Loss of Sirt1 promotes prostatic intraepithelial neoplasia, reduces mitophagy, and delays PARK2 translocation to mitochondria.
Loss of the E3 ubiquitin ligase HACE1 results in enhanced Rac1 signaling contributing to breast cancer progression.
Loss of the inactive X chromosome and replication of the active X in BRCA1-defective and wild-type breast cancer cells.
Loss of the N-terminal methyltransferase NRMT1 increases sensitivity to DNA damage and promotes mammary oncogenesis.
Loss of the novel tumour suppressor and polarity gene Trim62 (Dear1) synergizes with oncogenic Ras in invasive lung cancer.
Loss of the tumor suppressor Hace1 leads to ROS-dependent glutamine addiction.
Loss of the tumour-suppressor genes CHK2 and BRCA1 results in chromosomal instability.
Loss of TRIM62 expression is an independent adverse prognostic factor in acute myeloid leukemia.
Low concentrations of 5-aza-2'-deoxycytidine induce breast cancer stem cell differentiation by triggering tumor suppressor gene expression.
Low concentrations of diindolylmethane, a metabolite of indole-3-carbinol, protect against oxidative stress in a BRCA1-dependent manner.
Low expression of bcl-2 in Brca1-associated breast cancers.
Low Frequency Loss of Heterozygosity in the BRCA1 Region in Japanese Sporadic Breast Cancer.
Low frequency of BRCA1 germline mutations in 45 German breast/ovarian cancer families.
Low frequency of recurrent BRCA1 and BRCA2 mutations in Spain.
Low incidence of BRCA1 mutations among Italian families with breast and ovarian cancer.
Low incidence of BRCA2 mutations in breast carcinoma and other cancers.
Low levels of BRCA1 protein expression predict a worse prognosis in stage I-II colon cancer.
Low prevalence of BRCA1 and BRCA2 mutations in the sporadic breast cancer of Spanish population.
Low prevalence of HER2 positivity amongst BRCA1 and BRCA2 mutation carriers and in primary BRCA screens.
Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes.
Low rates of acceptance of BRCA1 and BRCA2 test results among African American women at increased risk for hereditary breast-ovarian cancer.
Low risk of invasive lobular carcinoma of the breast in carriers of BRCA1 (hereditary breast and ovarian cancer) and TP53 (Li-Fraumeni syndrome) germline mutations.
Low UBE4B expression increases sensitivity of chemoresistant neuroblastoma cells to EGFR and STAT5 inhibition.
Low-grade adenosquamous carcinoma of the breast-A case report with a BRCA1 germline mutation.
Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.
Luring BRCA1 to the scene of the crime.
Lympho-vascular invasion in BRCA related breast cancer compared to sporadic controls.
Lymphoblasts of women with BRCA1 mutations are deficient in cellular repair of 8,5'-Cyclopurine-2'-deoxynucleosides and 8-hydroxy-2'-deoxyguanosine.
Lymphocyte infiltration, expression of interleukin (IL) -1, IL-6 and expression of mutated breast cancer susceptibility gene-1 correlate with malignancy of canine mammary tumours.
Lymphocyte radiosensitivity in BRCA1 and BRCA2 mutation carriers and implications for breast cancer susceptibility.
Lymphocyte telomere length is longer in BRCA1 and BRCA2 mutation carriers but does not affect subsequent cancer risk.
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer.
Making the best of PARP inhibitors in ovarian cancer.
Male breast cancer is not congruent with the female disease.
Mammalian Rad51 protein: a RecA homologue with pleiotropic functions.
Mammalian stanniocalcins and cancer.
Mammary gland development, reproductive history, and breast cancer risk.
Mammary tumor development in dogs is associated with BRCA1 and BRCA2.
Mammary tumor formation in p53- and BRCA1-deficient mice.
Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer.
Mammographic, US, and MR imaging phenotypes of familial breast cancer.
Management of breast cancer risk in BRCA1/2 mutation carriers who are unaffected with cancer.
Management of gynecological tumors associated with BRCA1 and BRCA2 germline mutations. Case report and literature review.
Management options in triple-negative breast cancer.
Management updates for women with a BRCA1 or BRCA2 mutation.
Mapping of a novel ocular and cutaneous malignant melanoma susceptibility locus to chromosome 9q21.32.
Marker segregation information in breast/ovarian cancer genetic counseling: is it still useful? Groupe Génétique et Cancer de la Fédération Nationale des Centres de Lutte Contre le Cancer.
Mass spectrometric and mutational analyses reveal Lys-6-linked polyubiquitin chains catalyzed by BRCA1-BARD1 ubiquitin ligase.
Massively Parallel Functional Analysis of BRCA1 RING Domain Variants.
Maternal Obesity Alters Placental Cell Cycle Regulators in the First Trimester of Human Pregnancy: New Insights for BRCA1.
MCPIP1 Selectively Destabilizes Transcripts Associated with an Antiapoptotic Gene Expression Program in Breast Cancer Cells That Can Elicit Complete Tumor Regression.
MDM2 (murine double minute-2) links inflammation and tubular cell healing during acute kidney injury in mice.
Mdm2 and tumorigenesis: evolving theories and unsolved mysteries.
MDM2 binds and inhibits vitamin D receptor.
MDM2 chaperones the p53 tumor suppressor.
Mdm2 controls CREB-dependent transactivation and initiation of adipocyte differentiation.
MDM2 inhibition: an important step forward in cancer therapy.
MDM2 inhibitor ameliorates cisplatin-induced nephropathy via NF?? signal inhibition.
Mdm2 is a target and mediator of IRP2 in cell growth control.
MDM2 recruitment of lysine methyltransferases regulates p53 transcriptional output.
MDM2 restrains estrogen-mediated AKT activation by promoting TBK1-dependent HPIP degradation.
Mdm2 RING mutation enhances p53 transcriptional activity and p53-p300 interaction.
MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling.
MDM2-C Functions as an E3 Ubiquitin Ligase.
Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity.
MDM2-mediated ubiquitination of NUMB: Identification of a 2nd physiological substrate of MDM2 that employs a Dual-Site docking mechanism.
MdmX inhibits ARF mediated Mdm2 sumoylation.
Mechanism by which TRAF6 Participates in the Immune Regulation of Autoimmune Diseases and Cancer.
Mechanism for survival of homozygous nonsense mutations in the tumor suppressor gene BRCA1.
Mechanism of cytokinesis failure in ovarian cystadenomas with defective BRCA1 and P53 pathways.
Mechanism of hypoxia-specific cytotoxicity of procaspase-3 fused with a VHL-mediated protein destruction motif of HIF-1alpha containing Pro564.
Mechanisms of acquired resistance of BRCA1/2-driven tumors to platinum compounds and PARP inhibitors.
Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma.
Mechanisms of alcohol-associated cancers: introduction and summary of the symposium.
Mechanisms of BRCA1 Tumor Suppression.
Mechanisms of BRCA1-BARD1 nucleosome recognition and ubiquitylation.
Mechanisms of Nuclear Export in Cancer and Resistance to Chemotherapy.
Mechanisms of PARP inhibitor resistance in ovarian cancer.
Mechanisms of PARP inhibitor sensitivity and resistance.
Mechanisms of resistance to therapies targeting BRCA-mutant cancers.
Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer.
Mechanisms promoting escape from mitotic stress-induced tumor cell death.
Mechanistic phenotypes: an aggregative phenotyping strategy to identify disease mechanisms using GWAS data.
Mediation of the malignant biological characteristics of gastric cancer cells by the methylated CpG islands in RNF180 DNA promoter.
Mediator of DNA damage checkpoint protein 1 regulates BRCA1 localization and phosphorylation in DNA damage checkpoint control.
Medullary carcinoma of breast with a novel germline mutation 1123t >g in exon 11 of brca1.
Meiotic Double-Strand Break Processing and Crossover Patterning Are Regulated in a Sex-Specific Manner by BRCA1-BARD1 in Caenorhabditiselegans.
MEKK3 and TAK1 synergize to activate IKK complex in Helicobacter pylori infection.
Merlin's tumor suppression linked to inhibition of the E3 ubiquitin ligase CRL4 (DCAF1).
Mersch J, Jackson MA, Park M, Nebgen D, Peterson SK, Singletary C, Arun BK and Litton JK. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer. 2015;121:269-275.
Messenger RNA expression and methylation of candidate tumor-suppressor genes and risk of ovarian cancer-a case-control analysis.
Meta-analysis of BRCA1 and BRCA2 penetrance.
Meta-Analysis of BRCA1 Polymorphisms and Breast Cancer Susceptibility.
Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.
Metabolomics reveals novel blood plasma biomarkers associated to the BRCA1-mutated phenotype of human breast cancer.
Metaplastic carcinoma of the breast and BRCA1 germline mutation: a case report and review.
Metastatic Triple-negative Breast Cancer.
Metformin inhibits RANKL and sensitizes cancer stem cells to denosumab.
Metformin Pharmacogenomics: A genome-wide association study to identify genetic and epigenetic biomarkers involved in metformin anticancer response using human lymphoblastoid cell lines.
Methyl group metabolism gene polymorphisms as modifier of breast cancer risk in Italian BRCA1/2 carriers.
Methylation analysis of BRCA1, RASSF1, GSTP1 and EPHB2 promoters in prostate biopsies according to different degrees of malignancy.
Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas.
Methylation not a frequent "second hit" in tumors with germline BRCA mutations.
Methylation of BRCA1 promoter region is associated with unfavorable prognosis in women with early-stage breast cancer.
Methylation of Breast Cancer Predisposition Genes in Early-Onset Breast Cancer: Australian Breast Cancer Family Registry.
Methylation of the BRCA1 gene in sporadic breast cancer.
Methylation of the BRCA1 promoter in peripheral blood DNA is associated with triple-negative and medullary breast cancer.
Methylation of the HACE1 Gene is Frequently Detected in Hepatocellular Carcinoma.
Methylation of the tumor suppressor protein, BRCA1, influences its transcriptional cofactor function.
Methylation profile of BRCA1, RASSF1A and ER in Vietnamese women with ovarian cancer.
Methylation Profiles of BRCA1, RASSF1A and GSTP1 in Vietnamese Women with Breast Cancer
Methylation profiles of hereditary and sporadic ovarian cancer.
Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women.
Methylation profiling of twenty promoter-CpG islands of genes which may contribute to hepatocellular carcinogenesis.
Methylation target array for rapid analysis of CpG island hypermethylation in multiple tissue genomes.
Methylation-related mutations in the BRCA1 promoter in peripheral blood cells from cancer-free women.
Methylation-sensitive, single-strand conformation analysis (MS-SSCA): A rapid method to screen for and analyze methylation.
MEX3C promotes osteosarcoma malignant progression through negatively regulating FGF14.
MEX3C regulates lipid metabolism to promote bladder tumorigenesis through JNK pathway.
MGRN1-dependent pigment-type switching requires its ubiquitination activity but not its interaction with TSG101 or NEDD4.
MIB1 upregulates IQGAP1 and promotes pancreatic cancer progression by inducing ST7 degradation.
Mice with a Mutation in the Mdm2 Gene That Interferes with MDM2/Ribosomal Protein Binding Develop a Defect in Erythropoiesis.
Microcephalin is a new novel prognostic indicator in breast cancer associated with BRCA1 inactivation.
Microenvironmental Regulation of BRCA1 Gene Expression by c-Jun and Fra2 in Premalignant Human Ovarian Surface Epithelial Cells.
MicroRNA miR-335 is crucial for the BRCA1 regulatory cascade in breast cancer development.
MicroRNA-155, induced by FOXP3 through transcriptional repression of BRCA1, is associated with tumor initiation in human breast cancer.
MicroRNA-206 is differentially expressed in Brca1-deficient mice and regulates epithelial and stromal cell compartments of the mouse mammary gland.
MicroRNA-424 impairs ubiquitination to activate STAT3 and promote prostate tumor progression.
MicroRNA-based molecular classification of non-BRCA1/2 hereditary breast tumours.
MicroRNAs down-regulate homologous recombination in the G1 phase of cycling cells to maintain genomic stability.
Microsatellite instability of D17S513 on chromosome 17 is associated with progression of breast cancer.
Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition.
Mind Bomb 1 Promotes Pancreatic Cancer Proliferation by Activating ?-Catenin Signaling.
miR-146a and miR-638 in BRCA1-deficient triple negative breast cancer tumors, as potential biomarkers for improved overall survival.
MiR-153 promotes breast cancer cell apoptosis by targeting HECTD3.
miR-185 suppresses tumor proliferation by directly targeting E2F6 and DNMT1 and indirectly upregulating BRCA1 in triple-negative breast cancer.
miR-214 promotes apoptosis and sensitizes breast cancer cells to doxorubicin by targeting the RFWD2-p53 cascade.
MiR-29b-1-5p is altered in BRCA1 mutant tumours and is a biomarker in basal-like breast cancer.
miR-342 regulates BRCA1 expression through modulation of ID4 in breast cancer.
miR-454-3p promotes proliferation and induces apoptosis in human cervical cancer cells by targeting TRIM3.
miR-7-5p overexpression suppresses cell proliferation and promotes apoptosis through inhibiting the ability of DNA damage repair of PARP-1 and BRCA1 in TK6 cells exposed to hydroquinone.
MiR223-3p promotes synthetic lethality in BRCA1-deficient cancers.
miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers.
Mislocalization of the E3 ligase, beta-transducin repeat containing protein 1 ({beta}-TrCP1) in glioblastoma uncouples negative feedback between the PH domain Leucine-rich repeat Protein Phosphatase 1 (PHLPP1) and Akt.
Mismatch repair deficiency in ovarian cancer -- molecular characteristics and clinical implications.
Missense alterations of BRCA1 gene detected in diverse cancer patients.
Missense mutations in disease genes: a Bayesian approach to evaluate causality.
Missense mutations of BRCA1 gene affect the binding with p53 both in vitro and in vivo.
Missense polymorphisms in BRCA1 and BRCA2 and risk of breast and ovarian cancer.
Missense variants of uncertain significance (VUS) altering the phosphorylation patterns of BRCA1 and BRCA2.
Mitigation of cocaine-mediated mitochondrial damage, defective mitophagy and microglial activation by superoxide dismutase mimetics.
Mitochondrial DNA depletion sensitizes cancer cells to PARP inhibitors by translational and post-translational repression of BRCA2.
Mitochondrial localization, ELK-1 transcriptional regulation and growth inhibitory functions of BRCA1, BRCA1a, and BRCA1b proteins.
Mitophagy contributes to alpha-tocopheryl succinate toxicity in GSNOR-deficient hepatocellular carcinoma.
Mitophagy in Carcinogenesis and Tumor progression- A New paradigm with Emerging Importance.
Mitophagy in degenerative joint diseases.
Mitotic accumulation of dimethylated lysine 79 of histone h3 is important for maintaining genome integrity during mitosis in human cells.
Mixed epithelial/mesenchymal metaplastic carcinoma (carcinosarcoma) of the breast in BRCA1 carrier.
MLN4924 and 2DG combined treatment enhances the efficiency of radiotherapy in breast cancer cells.
MLN4924 suppresses the BRCA1 complex and synergizes with PARP inhibition in NSCLC cells.
MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), amplified on chromosome 9, collaborate with p53 deficiency in mouse osteosarcoma progression.
Modeling breast cancer-associated c-Src and EGFR overexpression in human MECs: c-Src and EGFR cooperatively promote aberrant three-dimensional acinar structure and invasive behavior.
Modeling Therapy Resistance in BRCA1/2-Mutant Cancers.
Modelling human regulatory variation in mouse: finding the function in genome-wide association studies and whole-genome sequencing.
Models for predicting BRCA1 and BRCA2 mutations in Han Chinese familial breast and/or ovarian cancer patients.
Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer.
Modes of delivery of genetic testing services and the uptake of cancer risk management strategies in BRCA1 and BRCA2 carriers.
Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1 Interacting Genes.
Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers.
Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis.
Modulation of angiogenic and inflammatory response in glioblastoma by hypoxia.
Modulation of aromatase expression by BRCA1: a possible link to tissue-specific tumor suppression.
Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells.
Modulation of interaction of mutant TP53 and wild type BRCA1 by alkaloids: a computational approach towards targeting protein-protein interaction as a futuristic therapeutic intervention strategy for breast cancer impediment.
Modulation of multidrug resistance in cancer cells by the E3 ubiquitin ligase seven-in-absentia homologue 1.
Molecular Analysis of an Intestinal Neuroendocrine/Non-neuroendocrine Neoplasm (MiNEN) Reveals MLH1 Methylation-driven Microsatellite Instability and a Monoclonal Origin: Diagnostic and Clinical Implications.
Molecular analysis of BRCA1 and BRCA2 genes by next generation sequencing and ultrastructural aspects of breast tumor tissue.
Molecular Analysis of BRCA1 in Human Breast Cancer Cells Under Oxidative Stress.
Molecular analysis of the BRCA1 and BRCA2 genes in 32 breast and/or ovarian cancer Spanish families.
Molecular analysis of the eighteen most frequent mutations in the BRCA1 gene in 63 Chilean breast cancer families.
Molecular analysis of the six most recurrent mutations in the BRCA1 gene in 87 Spanish breast/ovarian cancer families.
Molecular analysis reveals heterogeneity of mouse mammary tumors conditionally mutant for Brca1.
Molecular analysis-based treatment strategies for non-small cell lung cancer.
Molecular and cellular functions of the FANCJ DNA helicase defective in cancer and in Fanconi anemia.
Molecular and cellular response of the most extensively used rodent glioma models to radiation and/or cisplatin.
Molecular and epigenetic profiles of BRCA1-like hormone-receptor-positive breast tumors identified with development and application of a copy-number-based classifier.
Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast/ovarian cancer families.
Molecular and pathological characterization of inherited breast cancer.
Molecular aspects of breast and ovarian cancer.
Molecular aspects of breast cancer resistance to drugs (Review).
Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer.
Molecular Basis for Impaired DNA Damage Response Function Associated with the RAP80 ?E81 Defect.
Molecular basis of gynecological cancer.
Molecular basis of USP7 inhibition by selective small-molecule inhibitors.
Molecular biology and genetics of breast cancer development: a clinical perspective.
Molecular biology in radiation oncology. Radiation oncology perspective of BRCA1 and BRCA2.
Molecular Biomarkers for Early Detection and Prevention of Ovarian Cancer-A Gateway for Good Prognosis: A Narrative Review.
Molecular biosensing system based on intrinsically disordered proteins.
Molecular characteristics and prognostic features of breast cancer in Nigerian compared with UK women.
Molecular characterization and cancer risk associated with BRCA1 and BRCA2 splice site variants identified in multiple-case breast cancer families.
Molecular characterization of breast cancer in young Brazilian women.
Molecular characterization of late stomal recurrence following total laryngectomy.
Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors.
Molecular classification of familial non-BRCA1/BRCA2 breast cancer.
Molecular cloning and characterization of the von Hippel-Lindau-like protein.
Molecular determinants of PAM2 recognition by the MLLE domain of poly(A)-binding protein.
Molecular evidence for putative tumour suppressor genes on chromosome 13q specific to BRCA1 related ovarian and fallopian tube cancer.
Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations.
Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status.
Molecular functions of BRCA1 in the DNA damage response.
Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers.
Molecular genetics and targeted therapy of WNT-related human diseases (Review).
Molecular genetics of breast cancer progression.
Molecular genetics of solid tumours: translating research into clinical practice. What we could do now: breast cancer.
Molecular insights into the OGG1 gene, a cancer risk modifier in BRCA1 and BRCA2 mutations carriers.
Molecular Mechanism Linking BRCA1 Dysfunction to High Grade Serous Epithelial Ovarian Cancers with Peritoneal Permeability and Ascites.
Molecular pathogenesis of breast cancer: impact of miR-99a-5p and miR-99a-3p regulation on oncogenic genes.
Molecular patterns of nuclear and mitochondrial microsatellite alterations in breast tumors.
Molecular Perspective of Nanoparticle Mediated Therapeutic Targeting in Breast Cancer: An Odyssey of Endoplasmic Reticulum Unfolded Protein Response (UPRER) and Beyond.
Molecular phenotypes in triple negative breast cancer from African American patients suggest targets for therapy.
Molecular profile and clinical variables in BRCA1-positive breast cancers. A population-based study.
Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers.
Molecular profiles of BRCA1-associated ovarian cancer treated by platinum-based therapy: Analysis of primary, residual and relapsed tumors.
Molecular profiles of BRCA1-mutated and matched sporadic breast tumours: relation with clinico-pathological features.
Molecular profiles of hereditary epithelial ovarian cancers and their implications for the biology of this disease.
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.
Molecular Profiling of Triple Negative Breast Cancer.
Molecular Role of RNF43 in Canonical and Noncanonical Wnt Signaling.
Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy.
Molecular testing in breast cancer.
Molecular Trajectory of BRCA1 and BRCA2 Mutations.
Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers.
Monitoring regulation of DNA repair activities of cultured cells in-gel using the comet assay.
Monozygotic twins discordant for constitutive BRCA1 promoter methylation, childhood cancer and secondary cancer.
More about: multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations.
More breast cancer genes?
More Modifiers Move on DNA Damage.
Morphologic correlates of molecular alterations in extrauterine Müllerian carcinomas.
Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma.
Morphological predictors of BRCA1 germline mutations in young women with breast cancer.
Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers.
Morphology of breast cancer as a means of triage of patients for BRCA1 genetic testing.
Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study.
Mouse Double Minute 2 Homolog-Mediated Ubiquitination Facilitates Forkhead Box P3 Stability and Positively Modulates Human Regulatory T Cell Function.
Mouse models for BRCA1 associated tumorigenesis: from fundamental insights to preclinical utility.
Mouse models of BRCA1 and their application to breast cancer research.
Mouse models of human familial cancer syndromes.
Moving into the mainstream: healthcare professionals' views of implementing treatment focussed genetic testing in breast cancer care.
Moving towards population-based genetic risk prediction for ovarian cancer.
MRN Complex and Cancer Risk: Old Bottles, New Wine.
mRNA Expression and Clinical Significance of ERCC1, BRCA1, RRM1, TYMS and TUBB3 in Postoperative Patients with Non-Small Cell Lung Cancer.
MSH2 role in BRCA1-driven tumorigenesis: A preliminary study in yeast and in human tumors from BRCA1-VUS carriers.
MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 Trial.
MTA1-mediated transcriptional repression of BRCA1 tumor suppressor gene.
MUC1-C activates EZH2 expression and function in human cancer cells.
MUC1-C activates polycomb repressive complexes and downregulates tumor suppressor genes in human cancer cells.
MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia.
MUC13 protects colorectal cancer cells from death by activating the NF-?B pathway and is a potential therapeutic target.
Mul1 promotes autophagy flux to suppress the development of clear cell renal cell carcinomas.
Mule/Huwe1/Arf-BP1 suppresses Ras-driven tumorigenesis by preventing c-Myc/Miz1-mediated down-regulation of p21 and p15.
Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients.
Multi-step process of human breast carcinogenesis: a role for BRCA1, BECN1, CCND1, PTEN and UVRAG.
Multifaceted control of DNA repair pathways by the hypoxic tumor microenvironment.
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations.
Multifactorial likelihood assessment of BRCA1 and BRCA2 missense variants confirms that BRCA1:c.122A>G(p.His41Arg) is a pathogenic mutation.
Multifocal breast cancers are more prevalent in BRCA2 versus BRCA1 mutation carriers.
Multifunctional transcription factor TFII-I is an activator of BRCA1 function.
Multigene assessment of genetic risk for women for two or more breast cancers.
Multigene methylation in serum of sporadic Chinese female breast cancer patients as a prognostic biomarker.
Multigene panel analysis identified germline mutations of DNA repair genes in breast and ovarian cancer.
Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings.
Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.
Multigene Panel Testing Increases the Number of Loci Associated with Gastric Cancer Predisposition.
Multigene panel testing results in patients with multiple breast cancer primaries.
Multimodal approach to explore the pathogenicity of BARD1, ARG 658 CYS, and ILE 738 VAL mutants.
Multimodal assessment of protein functional deficiency supports pathogenicity of BRCA1 p.V1688del.
Multiple copies of mutant BRCA1 and BRCA2 alleles in breast tumors from germ-line mutation carriers.
Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland.
Multiple gene methylation of nonsmall cell lung cancers evaluated with 3-dimensional microarray.
Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice.
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer.
Multiple intracerebral haemangioblastomas in identical twins with von Hippel-Lindau disease--a clinical and molecular study.
Multiple primary cancers in BRCA 1/2 carriers - A review of literature and our observations.
Multiple roles of BRIT1/MCPH1 in DNA damage response, DNA repair, and cancer suppression.
Multiple target sites of allelic imbalance on chromosome 17 in Barrett's oesophageal cancer.
Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer.
Multiplex mutation screening of the BRCA1 gene in 1000 Japanese breast cancers.
Multiplexed methylation profiles of tumor suppressor genes in bladder cancer.
Multiplexed profiling of candidate genes for CpG island methylation status using a flexible PCR/LDR/Universal Array assay.
Multiplexed Proteomic Approach for Identification of Serum Biomarkers in Hepatocellular Carcinoma Patients with Normal AFP.
Multiplying functions for BRCA1 and BRCA2?. Meeting report, The Breakthrough Breast Cancer Second International Workshop on the function of BRCA1 and BRCA2, Cambridge, UK, 9-10 September 1999.
Multipoint methylation and expression analysis of tumor suppressor genes in human renal cancer cells.
Murine models for familial pancreatic cancer: Histopathology, latency and drug sensitivity among cancers of Palb2, Brca1 and Brca2 mutant mouse strains.
Murine Oviductal High-Grade Serous Carcinomas Mirror the Genomic Alterations, Gene Expression Profiles, and Immune Microenvironment of Their Human Counterparts.
Mutant BRCA1 genes antagonize phenotype of wild-type BRCA1.
Mutated Rnf43 Aggravates Helicobacter Pylori-Induced Gastric Pathology.
Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families.
Mutation analysis in the BRCA2 gene in primary breast cancers.
Mutation analysis of BRCA1 and BRCA2 cancer predisposition genes in radiation hypersensitive cancer patients.
Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population.
Mutation analysis of BRCA1 and BRCA2 in Turkish cancer families: a novel mutation BRCA2 3414del4 found in male breast cancer.
Mutation analysis of BRCA1 gene in African-American patients with breast cancer.
Mutation analysis of BRCA1, TP53, and KRAS2 in ovarian and related pelvic tumors.
Mutation analysis of PALB2 gene in French breast cancer families.
Mutation analysis of the ATR gene in breast and ovarian cancer families.
Mutation analysis of the BRCA1 gene in 23 families with cases of cancer of the breast, ovary, and multiple other sites.
Mutation analysis of the BRCA1 gene in 76 Japanese ovarian cancer patients: four germline mutations, but no evidence of somatic mutation.
Mutation analysis of the BRCA1 gene in ovarian cancers.
Mutation analysis of the THRA1 gene in breast cancer: deletion/fusion of the gene to a novel sequence on 17q in the BT474 cell line.
Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells.
Mutation of the PTEN tumor suppressor gene is not a feature of ovarian cancers.
Mutation screening of BRCA1 using PTT and LOH analysis at 17q21 in breast carcinomas from familial and non-familial cases.
Mutation screening of PALB2 in clinically ascertained families from the Breast Cancer Family Registry.
Mutation screening of the BRCA1 gene in early onset and familial breast/ovarian cancer in Moroccan population.
Mutation screening of the BRCA1 gene in Slovak patients.
Mutation spectrum and prevalence of BRCA1 and BRCA2 genes in patients with familial and early-onset breast/ovarian cancer from Tunisia.
Mutation testing of early-onset breast cancer genes BRCA1 and BRCA2.
Mutational analysis of BRCA1 and BRCA2 and clinicopathologic analysis of ovarian cancer in 82 ovarian cancer families: two common founder mutations of BRCA1 in Japanese population.
Mutational analysis of BRCA1 gene in ovarian and breast-ovarian cancer families in Japan.
Mutational analysis of the BRCA1 tumor suppressor gene in endometrial carcinoma.
Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
Mutational analysis of the LMO4 gene, encoding a BRCA1-interacting protein, in breast carcinomas.
Mutational analysis of TP53 and p21 in familial and sporadic ovarian cancer in Japan.
Mutational analysis of UBR5 gene encoding an E3 ubiquitin ligase in common human cancers.
Mutational Landscape of the Essential Autophagy Gene BECN1 in Human Cancers.
Mutational processes molding the genomes of 21 breast cancers.
Mutational spectrum of p53 mutations in primary breast and ovarian tumors.
Mutations and alternative splicing of the BRCA1 gene in UK breast/ovarian cancer families.
Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing.
Mutations in a gene encoding a midbody protein in binucleated Reed-Sternberg cells of Hodgkin lymphoma.
Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy.
Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer-susceptibility genes?
Mutations in Drosophila myb lead to centrosome amplification and genomic instability.
Mutations in Fbx4 inhibit dimerization of the SCF(Fbx4) ligase and contribute to cyclin D1 overexpression in human cancer.
Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer.
Mutations in the BRCA1 gene in Japanese breast cancer patients.
Mutations in the BRCA1 gene: implications of inter-population differences for predicting the risk of radiation-induced breast cancers.
Mutations in the BRCT domain confer temperature sensitivity to BRCA1 in transcription activation.
Mutations in the RAD54 recombination gene in primary cancers.
Mutations of a novel human RAD54 homologue, RAD54B, in primary cancer.
Mutations of c-Cbl in myeloid malignancies.
Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies.
Mutations of the BRCA1 and BRCA2 genes and the possibilities for predictive testing.
Mutations of the BRCA1 gene in hereditary breast and ovarian cancer in the Czech Republic.
Mutations of the BRCA1 gene in human cancer.
Mutator pathways unleashed by epigenetic silencing in human cancer.
Mutual exclusivity analysis identifies oncogenic network modules.
Mutual regulation between OGT and XIAP to control colon cancer cell growth and invasion.
MYB oncogene amplification in hereditary BRCA1 breast cancer.
MYC amplification in breast cancer: a chromogenic in situ hybridisation study.
MYC and Breast Cancer.
MYC is amplified in BRCA1-associated breast cancers.
MYC overexpression and poor prognosis in sporadic breast cancer with BRCA1 deficiency.
Myc protein is stabilized by suppression of a novel E3 ligase complex in cancer cells.
Myoglobin induces mitochondrial fusion, thereby inhibiting breast cancer cell proliferation.
Myriad Genetics Sues BRCA Diagnostic Rivals.
N-(4-Hydroxyphenyl)retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells.
N6-Isopentenyladenosine promoted HeLa cell apoptosis through inhibitions of AKT and transforming growth factor ?-activated kinase 1 activation.
Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells.
Naturally occurring BRCA2 alternative mRNA splicing events in clinically relevant samples.
NBR2: A former junk gene emerges as a key player in tumor suppression.
NEDD4 E3 ligase: Functions and mechanism in human cancer.
NEDD4 promotes cell growth and motility in hepatocellular carcinoma.
NEDD4 triggers FOXA1 ubiquitination and promotes colon cancer progression under microRNA-340-5p suppression and ATF1 upregulation.
NEDD4: a promising target for cancer therapy.
NEDD8 acts as a 'molecular switch' defining the functional selectivity of VHL.
Negative correlation of ITCH E3 ubiquitin ligase and miRNA-106b dictates metastatic progression in pancreatic cancer.
Negative Regulation of AKT Activation by BRCA1.
Negative regulation of BRCA1 by transforming acidic coiled-coil protein 3 (TACC3).
Negative regulation of the stability and tumor suppressor function of Fbw7 by the Pin1 prolyl isomerase.
Negative Selection on BRCA1 Susceptibility Alleles Sheds Light on the Population Genetics of Late-Onset Diseases and Aging Theory.
Neoadjuvant chemoteraphy in unresectable ovarian cancer with olaparib and weekly carboplatin plus paclitaxel: a phase II, open label multicenter study (NUVOLA trial).
Neoadjuvant Chemotherapy With Anthracycline-Based Regimen for BRCAness Tumors in Triple-Negative Breast Cancer.
Neoadjuvant treatments for triple-negative breast cancer (TNBC).
Neuroblastoma patient outcomes, tumor differentiation, and ERK activation are correlated with expression levels of the ubiquitin ligase UBE4B.
Neutrophil Extracellular Traps Drive Mitochondrial Homeostasis in Tumors to Augment Growth.
New germline BRCA2 gene variant in the Tuvinian Mongol breast cancer patients.
New insight into BIRC3: A novel prognostic indicator and a potential therapeutic target for liver cancer.
New Insights into Protein Hydroxylation and Its Important Role in Human Diseases.
New players in the BRCA1-mediated DNA damage responsive pathway.
New prognostic markers revealed by evaluation of genes correlated with clinical parameters in Wilms tumors.
New sequence variants in BRCA1 and BRCA2 genes detected by high-resolution melting analysis in an elderly healthy female population in Croatia.
Next generation sequencing of BRCA genes in glioblastoma multiform Egyptian patients: a pilot study.
Next Generation Sequencing Reveals High Prevalence of BRCA1 and BRCA2 Variants of Unknown Significance in Early-Onset Breast Cancer in African American Women.
Next-generation sequencing of BRCA1 and BRCA2 genes for rapid detection of germline mutations in hereditary breast/ovarian cancer.
Next-generation sequencing reveals heterogeneous genetic alterations in key signaling pathways of mismatch repair deficient colorectal carcinomas.
Next-generation Sequencing Reveals Recurrent Somatic Mutations in Small Cell Neuroendocrine Carcinoma of the Uterine Cervix.
Next-generation sequencing unravels extensive genetic alteration in recurrent ovarian cancer and unique genetic changes in drug-resistant recurrent ovarian cancer.
NF-?B functions as a molecular link between tumor cells and Th1/Tc1 T cells in the tumor microenvironment to exert radiation-mediated tumor suppression.
NF-?B is a critical mediator of BRCA1-induced chemoresistance.
NFBD1/MDC1, 53BP1 and BRCA1 have both redundant and unique roles in the ATM pathway.
NGS-based BRCA1/2 mutation testing of high-grade serous ovarian cancer tissue: results and conclusions of the first international round robin trial.
Night Shift Work, DNA Methylation and Telomere Length: An Investigation on Hospital Female Nurses.
Niraparib Shrinks BRCA-Mutated Prostate Tumors.
Nitric oxide-donor/PARP-inhibitor combination: A new approach for sensitization to ionizing radiation.
Nitroxoline induces cell apoptosis by inducing MDM2 degradation in small-cell lung cancer.
No association between BRCA1 immunohistochemical expression and tumor grade, stage or overall survival in platinum-treated epithelial ovarian cancer patients.
No Association of Early-Onset Breast or Ovarian Cancer with Early-Onset Cancer in Relatives in BRCA1 or BRCA2 Mutation Families.
No BRCA1 germline mutation in a family with uterine papillary serous carcinoma: a case report.
No evidence for breast cancer susceptibility associated with variants of BRD7, a component of p53 and BRCA1 pathways.
No evidence for deletions of the NBS1 gene in lymphomas.
No evidence for PALB2 methylation in high-grade serous ovarian cancer.
No Evidence of BRCA1/2 genomic rearrangements in high-risk French-Canadian breast/ovarian cancer families.
No Sib Pair Concordance for Breast or Ovarian Cancer in BRCA1 Mutation Carriers.
Non-canonical Activation of the DNA Sensing Adaptor STING by ATM and IFI16 Mediates NF-?B Signaling after Nuclear DNA Damage.
Non-homologous end joining is more important than proton linear energy transfer in dictating cell death.
Non-small cell lung cancer cells with deficiencies in homologous recombination genes are sensitive to PARP inhibitors.
Non-Surgical Cancer Risk Reduction in BRCA1 Mutation Carriers: Disabling the Remote Control.
Noncanonical Role of FBXO6 in Regulating Antiviral Immunity.
Nonhomologous end-joining of ionizing radiation-induced DNA double-stranded breaks in human tumor cells deficient in BRCA1 or BRCA2.
Noninvasive functional imaging of P-glycoprotein-mediated doxorubicin resistance in a mouse model of hereditary breast cancer to predict response, and assign P-gp inhibitor sensitivity.
Nonsense mutation at codon 63 of the BRCA1 gene in Japanese breast cancer patients.
Novel and common BRCA1 mutations in familial breast/ovarian cancer patients from Lithuania.
Novel and recurrent BRCA1/BRCA2 mutations in early onset and familial breast and ovarian cancer detected in the Program of Genetic Counseling in Cancer of Valencian Community (eastern Spain). Relationship of family phenotypes with mutation prevalence.
Novel BRCA1 and BRCA2 genomic rearrangements in Southern Chinese breast/ovarian cancer patients.
Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas.
Novel BRCA1 Large Genomic Rearrangements in Italian Breast/Ovarian Cancer Patients.
Novel BRCA1/2 mutations in Serbian breast and breast-ovarian cancer patients with hereditary predisposition.
Novel consensus DNA-binding sequence for BRCA1 protein complexes.
Novel genomic rearrangements in the BRCA1 gene detected in Greek breast/ovarian cancer patients.
Novel germline BRCA1 and BRCA2 mutations in breast and breast/ovarian cancer families from the Czech Republic.
Novel germline mutations and unclassified variants of BRCA1 and BRCA2 genes in Chinese women with familial breast/ovarian cancer.
Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
Novel germline mutations in the BRCA1 and BRCA2 genes in Indian breast and breast-ovarian cancer families.
Novel high-grade serous epithelial ovarian cancer cell lines that reflect the molecular diversity of both the sporadic and hereditary disease.
Novel indications for BRCA1 screening using individual clinical and morphological features.
Novel Insights Into E3 Ubiquitin Ligase in Cancer Chemoresistance.
Novel mechanism of platinum resistance: Rapid selection of pre-existing BRCA1-proficient tumor cells during neoadjuvant chemotherapy (NACT) for ovarian cancer (OC) in BRCA1 germ-line mutation carriers.
Novel mutations in actionable breast cancer genes by targeted sequencing in an ethnically homogenous cohort.
Novel mutations in the BRCA1 and BRCA2 genes in Iranian women with early-onset breast cancer.
Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions.
Novel roles of Skp2 E3 ligase in cellular senescence, cancer progression, and metastasis.
Novel sequence variants and a high frequency of recurrent polymorphisms in BRCA1 gene in Sri Lankan breast cancer patients and at risk individuals.
Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Novel somatic mutations in the BRCA1 gene in sporadic breast tumors.
Novel splice-switching oligonucleotide promotes BRCA1 aberrant splicing and susceptibility to PARP inhibitor action.
Novel surgical approaches for sampling the ovarian surface epithelium and proximal fluid proteome.
Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition.
Npr2, yeast homolog of the human tumor suppressor NPRL2, is a target of Grr1 required for adaptation to growth on diverse nitrogen sources.
NPR3 protects cardiomyocytes from apoptosis through inhibition of cytosolic BRCA1 and TNF-?.
Nrdp1 expression to predict clinical outcome and efficacy of adjuvant anthracyclines-based chemotherapy in breast cancer: \newline A retrospective study.
Nuclear accumulation of seven in absentia homologue (SIAH)-2 supports motility and proliferation of liver cancer cells.
Nuclear and cytoplasmic expressions of ERbeta1 and ERbeta2 are predictive of response to therapy and alters prognosis in familial breast cancers.
Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase.
Nuclear expression of the ubiquitin ligase seven in absentia homologue (SIAH)-1 induces proliferation and migration of liver cancer cells.
Nuclear HIF1A expression is strongly prognostic in sporadic but not familial male breast cancer.
Nuclear localization and cell cycle-specific expression of CtIP, a protein that associates with the BRCA1 tumor suppressor.
Nuclear location and cell cycle regulation of the BRCA2 protein.
Nuclear Medicine in Prostate Cancer: A New Era for Radiotracers.
Nuclear shuttling and TRAF2-mediated retention in the cytoplasm regulate the subcellular localization of cIAP1 and cIAP2.
Nucleation capacity and presence of centrioles define a distinct category of centrosome abnormalities that induces multipolar mitoses in cancer cells.
Nucleolar localization of BRCA1 protein in human breast cancer.
Nucleolar Stress Induces Ubiquitination-independent Proteasomal Degradation of PICT1 Protein.
Nucleophosmin/B23 is a candidate substrate for the BRCA1-BARD1 ubiquitin ligase.
Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer.
Nutlin-3a induces cytoskeletal rearrangement and inhibits the migration and invasion capacity of p53 wild-type cancer cells.
Nutlin-3a Nanodisks Induce p53 Stabilization and Apoptosis in a Subset of Cultured Glioblastoma Cells.
Nutlin-3a suppresses poly (ADP-ribose) polymerase 1 by mechanisms different from conventional PARP1 suppressors in a human breast cancer cell line.
O6-methylguanine-DNA methyltransferase modulates cisplatin-induced DNA double-strand breaks by targeting the homologous recombination pathway in nasopharyngeal carcinoma.
Occult fallopian tube cancer in a patient with BRCA1 breast cancer.
Occult gynecologic malignancies in BRCA1 and BRCA2 mutation carriers.
Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers.
Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy.
Occult Tubal Carcinoma After Risk-Reducing Salpingo-oophorectomy: A Systematic Review.
Occurrence of both breast and ovarian cancer in a woman is a marker for the BRCA gene mutations: a population-based study from western Sweden.
Oestrogen-mediated phosphorylation and stabilization of BRCA2 protein in breast.
Of mice and (wo)men: genotype-phenotype correlations in BRCA1.
Oh what a tangled web it weaves: BRCA1 and DNA decatenation.
Olaparib , PARP1 inhibitor in ovarian cancer.
Olaparib and rucaparib for the treatment of DNA repair-deficient metastatic castration-resistant prostate cancer.
Olaparib as maintenance therapy and salvage therapy in recurrent ovarian cancer: The early experience in Taiwan.
Olaparib effective in four advanced cancers.
Olaparib for Metastatic Castration-Resistant Prostate Cancer.
Olaparib for the treatment of breast cancer.
Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy.
Olaparib monotherapy as primary treatment in unselected triple negative breast cancer.
Olaparib shows promise in multiple tumor types.
Olaparib: A Novel Therapy for Metastatic Breast Cancer in Patients With a BRCA1/2 Mutation.
Old and new concepts in histopathological characterization of familial breast cancer.
Oligodendroglial deletion of ESCRT-I component TSG101 causes spongiform encephalopathy.
On the use of familial aggregation in population-based case probands for calculating penetrance.
Oncogenic activity of BIRC2 and BIRC3 mutants independent of nuclear factor-?B-activating potential.
Oncogenic BARD1 isoforms expressed in gynecological cancers.
Oncogenic Wnt/?-catenin signalling pathways in the cancer-resistant epididymis have implications for cancer research.
Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53.
Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations.
Online tool to guide decisions for BRCA1/2 mutation carriers.
Opportunistic testing of BRCA1, BRCA2 and mismatch repair genes improves the yield of phenotype driven hereditary cancer gene panels.
Opportunities and hurdles in the treatment of BRCA1-related breast cancer.
Optimal selection for BRCA1 and BRCA2 mutation testing using a combination of 'easy to apply' probability models.
Optimal selection of individuals for BRCA mutation testing: a comparison of available methods.
Optimizing chemotherapy in triple-negative breast cancer: the role of platinum.
Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.
Optimizing the identification of risk-relevant mutations by multigene panel testing in selected hereditary breast/ovarian cancer families.
Organization and running of the first comprehensive hereditary cancer clinic in India.
Origins and molecular pathology of ovarian cancer.
Orthotopic implantation mouse model and cDNA microarray analysis indicates several genes potentially involved in lymph node metastasis of colorectal cancer.
OTUD5 cooperates with TRIM25 in transcriptional regulation and tumor progression via deubiquitination activity.
Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status.
Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers.
Outcome of triple negative breast cancer: comparison of sporadic and BRCA1-associated cancers.
Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations.
Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations.
Outcomes of women at high familial risk for breast cancer: An 8-year single-center experience.
Ovarian and breast cancer risks to women in families with two or more cases of ovarian cancer.
Ovarian cancer associated with inherited mutations in BRCA1 or BRCA2.
Ovarian cancer at young age: the contribution of mismatch-repair defects in a population-based series of epithelial ovarian cancer before age 40.
Ovarian cancer BRCA1 gene therapy: Phase I and II trial differences in immune response and vector stability.
Ovarian cancer BRCA1 mutation detection: Protein truncation test (PTT) outperforms single strand conformation polymorphism analysis (SSCP).
Ovarian cancer death reduction for women at high risk: workload implications for gynaecology services.
Ovarian Cancer Gene Therapy with BRCA1-An Overview.
Ovarian cancer molecular pathology.
Ovarian cancer screening.
Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations.
Ovarian Cancer-associated Mutations Disable Catalytic Activity of CDK12, a Kinase That Promotes Homologous Recombination Repair and Resistance to Cisplatin and Poly(ADP-ribose) Polymerase Inhibitors.
Ovarian cancer: epidemiology, biology, and prognostic factors.
Ovarian carcinoma in situ with germline BRCA1 mutation and loss of heterozygosity at BRCA1 and TP53.
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities.
Ovarian cystadenoma as a characteristic feature of families with hereditary ovarian cancers unassociated with BRCA1 and BRCA2 mutations.
Ovarian surface epithelium: family history and early events in ovarian cancer.
Ovarian tumors associated with multiple endocrine neoplasias and related syndromes (Carney complex, Peutz-Jeghers syndrome, von Hippel-Lindau disease, Cowden's disease).
Over-expression of TRIM37 promotes cell migration and metastasis in hepatocellular carcinoma by activating Wnt/?-catenin signaling.
Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer.
Over-representation of two specific haplotypes among chromosomes harbouring BRCA1 mutations.
Overcoming cancer cell resistance to Smac mimetic induced apoptosis by modulating cIAP-2 expression.
Overexpression of a protein fragment of RNA helicase A causes inhibition of endogenous BRCA1 function and defects in ploidy and cytokinesis in mammary epithelial cells.
Overexpression of Cancer Upregulated Gene 2 (CUG2) Decreases Spry2 Through c-Cbl, Leading to Activation of EGFR and ?-Catenin Signaling.
Overexpression of cellular inhibitor of apoptosis protein 2 is an early event in the progression of pancreatic cancer.
Overexpression of HACE1 in gastric cancer inhibits tumor aggressiveness by impeding cell proliferation and migration.
Overexpression of Raf-1 in basal-like carcinoma of the breast: correlation with clinicopathology and prognosis.
Overexpression of RNF126 Promotes the Development of Colorectal Cancer via Enhancing p53 Ubiquitination and Degradation.
Overexpression of RNF146 in non-small cell lung cancer enhances proliferation and invasion of tumors through the Wnt/?-catenin signaling pathway.
Overexpression of TRIM25 in Lung Cancer Regulates Tumor Cell Progression.
Overview of history and progress in BRCA1 research: the first BRCA1 decade.
Oxidative Stress-Induced Signaling Pathways Implicated in the Pathogenesis of Parkinson's Disease.
Oxygen sensing: recent insights from idiopathic erythrocytosis.
Oxygen sensors and angiogenesis.
P14ARF promotes accumulation of SUMO-1 conjugated (H)Mdm2.
p16 loss rescues functional decline of Brca1-deficient mammary stem cells.
p16INK4a suppresses BRCA1-deficient mammary tumorigenesis.
p27kip1 Expression in non-small cell lung cancer is not an independent prognostic factor.
p53 contains a DNA break-binding motif similar to the functional part of BRCT-related region of Rb.
p53 inactivation is a rare event in familial breast tumors negative for BRCA1 and BRCA2 mutations.
p53 mRNA controls p53 activity by managing Mdm2 functions.
P53 mRNA controls p53 activity by managing Mdm2 functions.
p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours.
p53 suppresses hyper-recombination by modulating BRCA1 function.
p53 Ubiquitination: Mdm2 and beyond.
p53, BRCA1 and breast Cancer chemoresistance.
p53-Dependent BRCA1 Nuclear Export Controls Cellular Susceptibility to DNA Damage.
p53-induced RING-H2 protein, a novel marker for poor survival in hepatocellular carcinoma after hepatic resection.
p97 Promotes a Conserved Mechanism of Helicase Unloading During DNA Crosslink Repair.
PALB2 (partner and localizer of BRCA2).
PALB2 chromatin recruitment restores homologous recombination in BRCA1-deficient cells depleted of 53BP1.
PALB2 connects BRCA1 and BRCA2 in the G2/M checkpoint response.
PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2.
PALB2 is an integral component of the BRCA complex required for homologous recombination repair.
Palb2 synergizes with Trp53 to suppress mammary tumor formation in a model of inherited breast cancer.
PALB2 upregulation is associated with a poor prognosis in pancreatic ductal adenocarcinoma.
PALB2: the hub of a network of tumor suppressors involved in DNA damage responses.
Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs.
Pan-cancer Analysis of NEDD4L and Its Tumor Suppressor Effects in Clear Cell Renal Cell Carcinoma.
Pancreatic adenocarcinoma: epidemiology and genetics.
Pancreatic intraductal tubulopapillary neoplasm is genetically distinct from intraductal papillary mucinous neoplasm and ductal adenocarcinoma.
Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care.
PanGen-Fam: Spanish registry of hereditary pancreatic cancer.
Panobinostat sensitizes cyclin E high, homologous recombination-proficient ovarian cancer to olaparib.
Papers to appear in forthcoming issues
PARG deficiency is neither synthetic lethal with BRCA1 nor PTEN deficiency.
PARK2 orchestrates cyclins to avoid cancer.
Parkin and mitophagy in cancer.
Parkin as a tumor suppressor gene for hepatocellular carcinoma.
Parkin deficiency contributes to pancreatic tumorigenesis by inducing spindle multipolarity and misorientation.
Parkin enhances sensitivity of paclitaxel to NPC by arresting cell cycle.
Parkin enhances the expression of cyclin-dependent kinase 6 and negatively regulates the proliferation of breast cancer cells.
Parkin facilitates proteasome inhibitor-induced apoptosis via suppression of NF-?B activity in hepatocellular carcinoma.
Parkin gene alterations in hepatocellular carcinoma.
Parkin Gene Alterations in Ovarian Carcinoma from Northern Indian Population.
Parkin gene mutations are not common, but its epigenetic inactivation is a frequent event and predicts poor survival in advanced breast cancer patients.
Parkin in cancer: Mitophagy-related/unrelated tasks.
Parkin in Parkinson's Disease and Cancer: a Double-Edged Sword.
Parkin induces apoptotic cell death in TNF-?-treated cervical cancer cells.
Parkin induces G2/M cell cycle arrest in TNF-?-treated HeLa cells.
Parkin Induces Upregulation of 40S Ribosomal Protein SA and Posttranslational Modification of Cytokeratins 8 and 18 in Human Cervical Cancer Cells.
Parkin inhibits BAK and BAX apoptotic function by distinct mechanisms during mitophagy.
Parkin inhibits necroptosis to prevent cancer.
Parkin Is Dispensable for Mitochondrial Function, but Its Ubiquitin Ligase Activity Is Critical for Macroautophagy and Neurotransmitters: Therapeutic Potential beyond Parkinson's Disease.
Parkin modulates expression of HIF-1? and HIF-3? during hypoxia in gliobastoma-derived cell lines in vitro.
Parkin negatively regulates the antiviral signaling pathway by targeting TRAF3 for degradation.
Parkin New Cargos: a New ROS Independent Role for Parkin in Regulating Cell Division.
Parkin on serine: a Parkinson disease gene suppresses serine synthesis in cancer.
Parkin pathway activation mitigates glioma cell proliferation and predicts patient survival.
Parkin protein expression and its impact on survival of patients with advanced colorectal cancer.
Parkin regulates paclitaxel sensitivity in breast cancer via a microtubule-dependent mechanism.
Parkin Regulates the Activity of Pyruvate Kinase M2.
Parkin Somatic Mutations Link Melanoma and Parkinson's Disease.
Parkin targets HIF-1? for ubiquitination and degradation to inhibit breast tumor progression.
Parkin ubiquitinates phosphoglycerate dehydrogenase to suppress serine synthesis and tumor progression.
Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27.
Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect.
Parkin, PINK1 and DJ1 as possible modulators of mTOR pathway in ganglioglioma.
Parkin-Independent Mitophagy Controls Chemotherapeutic Response in Cancer Cells.
Parkin: A targetable linchpin in human malignancies.
Parkinson's disease-associated protein Parkin: an unusual player in cancer.
PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer.
PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells.
PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers.
PARP inhibitor combination therapy.
PARP inhibitor development for systemic cancer targeting.
PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA.
PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?
PARP Inhibitors Display Differential Efficacy in Models of BRCA Mutant High-Grade Serous Ovarian Cancer.
PARP Inhibitors for the Treatment and Prevention of Breast Cancer.
PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond.
PARP inhibitors in the management of breast cancer: current data and future prospects.
PARP Inhibitors in Triple-Negative Breast Cancer Including Those With BRCA Mutations.
PARP inhibitors: an interesting pathway also for Non-Small Cell Lung Cancer?
PARP inhibitors: Synthetic lethality in the clinic.
PARP Inhibitors: The Cornerstone of DNA Repair-Targeted Therapies.
PARP-1 inhibitors: a novel genetically specific agents for cancer therapy.
PARP-1 inhibitors: are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers?
PARP1 Inhibitor Combined With Oxaliplatin Efficiently Suppresses Oxaliplatin Resistance in Gastric Cancer-Derived Organoids via Homologous Recombination and the Base Excision Repair Pathway.
PARP1-driven poly-ADP-ribosylation regulates BRCA1 function in homologous recombination-mediated DNA repair.
PARP3, a new therapeutic target to alter Rictor/mTORC2 signaling and tumor progression in BRCA1-associated cancers.
Patho-biological aspects of basal-like breast cancer.
Pathobiologic characteristics of hereditary breast cancer.
Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection.
Pathogenic Germline Variants in 10,389 Adult Cancers.
Pathogenicity and virulence of Japanese encephalitis virus: Neuroinflammation and neuronal cell damage.
Pathogenicity Evaluation of BRCA1 and BRCA2 Unclassified Variants Identified in Portuguese Breast/Ovarian Cancer Families.
Pathogenicity of the BRCA1 missense variant M1775K is determined by the disruption of the BRCT phosphopeptide-binding pocket: a multi-modal approach.
Pathologic Features and Immunophenotype of Estrogen Receptor-positive Breast Cancers in BRCA1 Mutation Carriers.
Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institution experience.
Pathologic findings in prophylactic oophorectomy specimens in high-risk women.
Pathological characteristics of BRCA-associated breast cancers in Hispanics.
Pathological complete response after cisplatin neoadjuvant therapy is associated with the downregulation of DNA repair genes in BRCA1-associated triple-negative breast cancers.
Pathological complete response after primary chemotherapy in a mother and daughter with hereditary breast carcinoma: two case reports.
Pathological features and BRCA1 mutation screening in premenopausal breast cancer patients.
Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations.
Pathology and heredity of breast cancer in younger women.
Pathology of BRCA1- and BRCA2-associated Breast Cancers: Known and Less Known Connections.
Pathology of Breast Cancer Metastasis and A View of Metastasis to The Brain.
Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.
Pathology of Hereditary Breast and Ovarian Cancer.
Pathology of hereditary breast cancer.
Pathology of ovarian cancers in BRCA1 and BRCA2 carriers.
Pathology of sporadic breast tumors with LOH at the BRCA1 locus: correlation with histopathological features specific to familial BRCA1 tumors and absence of microsatellite instability.
Pathway-specific engineered mouse allograft models functionally recapitulate human serous epithelial ovarian cancer.
Patient satisfaction and cancer-related distress among unselected Jewish women undergoing genetic testing for BRCA1 and BRCA2.
Patients resistant against PSMA-targeting alpha-radiation therapy often harbor mutations in DNA-repair associated genes.
Patients' attitudes about autonomy and confidentiality in genetic testing for breast-ovarian cancer susceptibility.
Patterns and Prevalence of BRCA1 and BRCA2 Germline Mutations Among Patients with Triple-Negative Breast Cancer: Regional Perspectives.
Patterns of allelic loss at the BRCA1 locus in Arabic women with breast cancer.
Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers.
PDGFR? is an essential therapeutic target for BRCA1-deficient mammary tumors.
Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family.
Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
Performance of prediction models for BRCA mutation carriage in three racial/ethnic groups: findings from the Northern California Breast Cancer Family Registry.
Peripheral blood BRCA1 methylation profiling to predict familial ovarian cancer.
Peritoneal cancer arising after total abdominal hysterectomy and bilateral salpingo-oophorectomy for cervical cancer in a patient with right breast cancer and germline mutation of BRCA1 gene: a case report and literature review.
Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.
Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening.
Persistent double strand break accumulation does not precede cell death in an Olaparib-sensitive BRCA-deficient colorectal cancer cell model.
Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer.
Perspective on BRCA1.
Pharmacogenomics and chemical library screens reveal a novel SCF(SKP2) inhibitor that overcomes Bortezomib resistance in multiple myeloma.
Pharmacogenomics and gemcitabine.
Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression.
Pharmacoprevention for hereditary breast and ovarian cancer.
Phase I clinical trial of a peptide vaccine combined with tegafur-uracil plus leucovorin for treatment of advanced or recurrent colorectal cancer.
Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors.
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non-BRCA1/2-Mutant Cancers.
Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.
Phenocopy breast cancer rates in Israeli BRCA1 BRCA2 mutation carrier families: is the risk increased in non-carriers?
Phenol sulfotransferases: hormonal regulation, polymorphism, and age of onset of breast cancer.
Phenotype-directed analysis of genotype in early-onset, familial breast cancers.
Phenotype-genotype correlation in familial breast cancer.
Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers.
Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry.
PHF20L1 as a H3K27me2 reader coordinates with transcriptional repressors to promote breast tumorigenesis.
Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion.
Phosphorylated BRCA1 is predominantly located in the nucleus and mitochondria.
Phosphorylation of Pirh2 by Calmodulin-dependent kinase II impairs its ability to ubiquitinate p53.
Phosphorylation of ribosomal protein S6 confers PARP inhibitor resistance in BRCA1-deficient cancers.
Phosphorylation of Rictor at Thr1135 impairs the Rictor/Cullin-1 complex to ubiquitinate SGK1.
Phosphorylation of serine 1387 in Brca1 is specifically required for the Atm-mediated S-phase checkpoint after ionizing irradiation.
Phosphorylation of SMURF2 by ATM exerts a negative feedback control of DNA damage response.
Phosphorylation-dependent regulation of SPOP by LIMK2 promotes castration-resistant prostate cancer.
Phosphorylation-dependent ubiquitination of cyclin D1 by the SCF(FBX4-alphaB crystallin) complex.
Physical Activity and Breast Cancer: Focusing on High-Risk Subgroups and Putting Recommendations in Context.
Physical mapping, cloning, and identification of genes within a 500-kb region containing BRCA1.
Physicians' experiences with BRCA1/2 testing in community settings.
Phytoestrogen-rich diets modulate expression of Brca1 and Brca2 tumor suppressor genes in mammary glands of female Wistar rats.
PI 3 kinase related kinases-independent proteolysis of BRCA1 regulates Rad51 recruitment during genotoxic stress in human cells.
PIAS? expression in relation to clinicopathological, tumour factors and survival in indigenous black breast cancer women.
PIASx? ligase enhances SUMO1 modification of PTEN protein as a SUMO E3 ligase.
PIBF (progesterone induced blocking factor) is overexpressed in highly proliferating cells and associated with the centrosome.
PIK3CA Mutations and BRCA1 Expression in Breast Cancer: Potential Biomarkers for Chemoresistance.
PINK1/Parkin Influences Cell Cycle by Sequestering TBK1 at Damaged Mitochondria, Inhibiting Mitosis.
Pirh2 E3 Ubiquitin Ligase Monoubiquitinates DNA Polymerase eta to Suppress Translesion DNA Synthesis.
Pirh2 E3 ubiquitin ligase targets DNA polymerase eta for 20S proteasomal degradation.
Pirh2 RING-finger E3 ubiquitin ligase: its role in tumorigenesis and cancer therapy.
Pirh2, an E3 ligase, regulates the AIP4-p73 regulatory pathway by modulating AIP4 expression and ubiquitination.
Pirh2: An E3 ligase with central roles in the regulation of cell cycle, DNA damage response, and differentiation.
PKCzetaII is a target for degradation through the tumour suppressor protein pVHL.
Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer.
PLAGL2 controls the stability of Pirh2, an E3 ubiquitin ligase for p53.
Plasma Metabolome Signature Indicative of BRCA1 Germline Status Independent of Cancer Incidence.
Plasma micronutrients, trace elements, and breast cancer in BRCA1 mutation carriers: an exploratory study.
Plasma mRNA as liquid biopsy predicts chemo-sensitivity in advanced gastric cancer patients.
Plasma mRNA expression levels of BRCA1 and TS as potential predictive biomarkers for chemotherapy in gastric cancer.
Platelet-Activating Factor Acetylhydrolase Expression in BRCA1 Mutant Ovarian Cancer as a Protective Factor and Potential Negative Regulator of the Wnt Signaling Pathway.
Platform comparisons for identification of breast cancers with a BRCA-like copy number profile.
Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence?
Platinum-based neoadjuvant chemotherapy in BRCA1-positive breast cancer: a retrospective cohort analysis and literature review.
Playing Tag with HIF: The VHL Story.
Plk1 interacts with RNF2 and promotes its ubiquitin?dependent degradation.
PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation.
Polo-like Kinase 1 Inhibition as a Therapeutic Approach to Selectively Target BRCA1-Deficient Cancer Cells by Synthetic Lethality Induction.
Poly (ADP-ribose) polymerase inhibitors selectively induce cytotoxicity in TCF3-HLF-positive leukemic cells.
Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.
Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics.
Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic.
Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets.
Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent.
Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective.
Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer.
Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells.
Poly-ADP-ribosyl-polymerase inhibitor resistance mechanisms and their therapeutic implications.
Polycomb complexes associate with enhancers and promote oncogenic transcriptional programs in cancer through multiple mechanisms.
Polycomb repressor complex 1 promotes gene silencing through H2AK119 mono-ubiquitination in acinar-to-ductal metaplasia and pancreatic cancer cells.
Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants.
Polyglutamine repeat length in the AIB1 gene modifies breast cancer susceptibility in BRCA1 carriers.
Polymorphisms in BRCA1, BRCA1-interacting genes and susceptibility of breast cancer in Chinese women.
Polyploid cells rewire DNA damage response networks to overcome replication stress-induced barriers for tumour progression.
Polyubiquitination of apurinic/apyrimidinic endonuclease 1 by Parkin.
Pomalidomide restores immune recognition of primary effusion lymphoma through upregulation of ICAM-1 and B7-2.
Poor response to platinum-based chemotherapy is associated with KRAS mutation and concomitant low expression of BRAC1 and TYMS in NSCLC.
Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancer.
Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study.
Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2.
Positive regulation of the BRCA1 promoter.
Possible causes of chromosome instability: comparison of chromosomal abnormalities in cancer cell lines with mutations in BRCA1, BRCA2, CHK2 and BUB1.
Possible Role of PHD Inhibitors as Hypoxia-Mimicking Agents in the Maintenance of Neural Stem Cells' Self-Renewal Properties.
Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics.
Post translational modification of Parkin.
Post-transcriptional mechanisms contribute to the suppression of the ErbB3 negative regulator protein Nrdp1 in mammary tumors.
Post-transcriptional regulation of BRCA1 through its coding sequence by the miR-15/107 group of miRNAs.
Post-translational modification of Parkin and its research progress in cancer.
Post-translational modification profiling - A novel tool for mapping the protein modification landscape in cancer.
Post-translational Wnt receptor regulation: Is the fog slowly clearing?: The molecular mechanism of RNF43/ZNRF3 ubiquitin ligases is not yet fully elucidated and still controversial.
Posttranscriptional regulation of the breast cancer susceptibility gene BRCA1 by the RNA binding protein HuR.
Potent immunogenicity in BRCA1-mutated patients with high-grade serous ovarian carcinoma.
Potential role of TRIM3 as a novel tumour suppressor in colorectal cancer (CRC) development.
PPAR? is an E3 ligase that induces the degradation of NF?B/p65.
Practical Cancer Genetics and Genomics in Women's Health.
PRAJA is overexpressed in glioblastoma and contributes to neural precursor development.
Pre-counseling education materials for BRCA testing: does tailoring make a difference?
Pre-test prediction models of BRCA1 or BRCA2 mutation in breast/ovarian families attending familial cancer clinics.
Preclinical evaluation of radiation therapy of BRCA1-associated mammary tumors using a mouse model.
Precursors to pelvic serous carcinoma and their clinical implications.
Prediagnosis aspirin use, DNA methylation, and mortality after breast cancer: A population-based study.
Predicted anti-oestrogen resistance in BRCA-associated familial breast cancers.
Predicting Ovarian/Breast Cancer Pathogenic Risks of Human BRCA1 Gene Variants of Unknown Significance.
Predicting the Disease Risk of Protein Mutation Sequences With Pre-training Model.
Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics.
Prediction of BRCA1 germ-line mutation status in patients with breast cancer using histoprognosis grade, MS110, Lys27H3, vimentin, and KI67.
Prediction of BRCA1 germline mutation status in women with ovarian cancer using morphology-based criteria: identification of a BRCA1 ovarian cancer phenotype.
Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype.
Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH.
Prediction of BRCA1/2 mutation status in patients with ovarian cancer from a hospital-based cohort.
Predictive biomarkers in patients with resected non-small cell lung cancer treated with perioperative chemotherapy.
Predictive Factors for BRCA1 and BRCA2 Genetic Testing in an Asian Clinic-Based Population.
Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: A retrospective multicentric study.
Predictive models for customizing chemotherapy in advanced non-small cell lung cancer (NSCLC).
Predictive value of BRCA1 expression on the efficacy of chemotherapy based on anti-microtubule agents: a pooled analysis across different malignancies and agents.
Predictive value of gene methylation for second recurrence following surgical treatment of first bladder recurrence of a primary upper-tract urothelial carcinoma.
Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis.
Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
Predictors of long-term cancer-related distress among female BRCA1 and BRCA2 mutation carriers without a cancer diagnosis: an international analysis.
Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.
Predisposing genes in breast and ovarian cancer: an overview.
Preferences for breast cancer prevention among women with a BRCA1 or BRCA2 mutation.
Preferential allelic expression can lead to reduced expression of BRCA1 in sporadic breast cancers.
Preferential binding of IFI16 protein to cruciform structure and superhelical DNA.
Preimplantation genetic diagnosis (PGD) for heritable neoplasia.
Preimplantation genetic diagnosis for BRCA1 exon 13 duplication mutation using linked polymorphic markers resulting in a live birth.
Preimplantation genetic diagnosis for cancer predisposition syndromes.
Preliminary studies on DNA retardation by MutS applied to the detection of point mutations in clinical samples.
Preparation and Application of a Monoclonal Antibody Against Chicken TRIM62.
Preparing a re-sequencing DNA library of 2 cancer candidate genes using the ligation-by-amplification protocol by two PCR reactions.
Prepubertal estradiol and genistein exposures up-regulate BRCA1 mRNA and reduce mammary tumorigenesis.
Prepubertal octylphenol exposure up-regulate BRCA1 expression, down-regulate ERalpha expression and reduce rat mammary tumorigenesis.
Prepubertal physical activity up-regulates estrogen receptor beta, BRCA1 and p53 mRNA expression in the rat mammary gland.
Presymptomatic breast cancer in Egypt: role of BRCA1 and BRCA2 tumor suppressor genes mutations detection.
Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation.
Presymptomatic testing for BRCA1 and BRCA2: how distressing are the pre-test weeks? Rotterdam/Leiden Genetics Working Group.
Prevalence and characteristics of pancreatic cancer in families with BRCA1 and BRCA2 mutations.
Prevalence and clinical correlations of BRCA1/BRCA2 unclassified variant carriers among unselected primary ovarian cancer cases - preliminary report.
Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer.
Prevalence and clinical significance of pathogenic germline BRCA1/2 mutations in Chinese non-small cell lung cancer patients.
Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer.
Prevalence and founder effect of the BRCA1 p.(Val1833Met) variant in the Greek population, with further evidence for pathogenicity and risk modification.
Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer.
Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group.
Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.
Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer.
Prevalence and Predictors of BRCA1 and BRCA2 Mutations in a Population-Based Study of Breast Cancer in White and Black American Women Ages 35 to 64 Years.
Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers.
Prevalence and Prognostic Role of BRCA1/2 Variants in Unselected Chinese Breast Cancer Patients.
Prevalence and spectrum of AKT1, PIK3CA, PTEN and TP53 somatic mutations in Chinese breast cancer patients.
Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome.
Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer.
Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the Clinical Cancer Genetics Community Research Network.
Prevalence of BRCA1 and BRCA2 genomic rearrangements in a cohort of consecutive Italian breast and/or ovarian cancer families.
Prevalence of BRCA1 and BRCA2 germ line mutations among women with carcinoma of the fallopian tube.
Prevalence of BRCA1 and BRCA2 germline mutations in young breast cancer patients: a population-based study.
Prevalence of BRCA1 and BRCA2 large genomic rearrangements in Tunisian high risk breast/ovarian cancer families: Implications for genetic testing.
Prevalence of BRCA1 and BRCA2 Mutations Among Patients With Ovarian, Primary Peritoneal, and Fallopian Tube Cancer in India: A Multicenter Cross-Sectional Study.
Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer.
Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil.
Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Cuba.
Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patients.
Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from medellín, Colombia.
Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ.
Prevalence of BRCA1 founder mutations in western Poland.
Prevalence of BRCA1 genomic rearrangements in a large cohort of Italian breast and breast/ovarian cancer families without detectable BRCA1 and BRCA2 point mutations.
Prevalence of BRCA1 mutation carriers among U.S. non-Hispanic Whites.
Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study.
Prevalence of BRCA1 Mutations in Familial and Sporadic Greek Ovarian Cancer Cases.
Prevalence of BRCA1/2 mutations in sporadic breast/ovarian cancer patients and identification of a novel de novo BRCA1 mutation in a patient diagnosed with late onset breast and ovarian cancer: implications for genetic testing.
Prevalence of breast cancer predisposition gene mutations in Chinese women and guidelines for genetic testing.
Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1).
Prevalence of five previously reported and recurrent BRCA1 genetic rearrangement mutations in 20,000 patients from hereditary breast/ovarian cancer families.
Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in Hungary.
Prevalence of founder BRCA1 and BRCA2 mutations in unselected French Canadian women with breast cancer.
Prevalence of Hispanic BRCA1 and BRCA2 mutations among hereditary breast and ovarian cancer patients from Brazil reveals differences among Latin American populations.
Prevalence of PALB2 Germline Mutations in Early-onset and Familial Breast/Ovarian Cancer Patients from Pakistan.
Prevalence of pancreaticobiliary cancers in Irish families with pathogenic BRCA1 and BRCA2 variants.
Prevalence of pathogenic variants in DNA damage response and repair genes in patients undergoing cancer risk assessment and reporting a personal history of early-onset renal cancer.
Prevalence of the BRCA1 c.68_69delAG (BIC: 185delAG) mutation in women with breast cancer from north-central Poland and a review of the literature on other regions of the country.
Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families.
Prevalence of TP53 germ line mutations in young Pakistani breast cancer patients.
Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer.
Prevalent somatic BRCA1 mutations shape clinically relevant genomic patterns of nasopharyngeal carcinoma in Southeast Europe.
Preventing breast and ovarian cancers in high-risk BRCA1 and BRCA2 mutation carriers.
Preventing Ovarian Cancer in High-risk Women: One Surgery at a Time.
Preventing ovarian cancer through genetic testing: a population-based study.
Prevention and Screening in Hereditary Breast and Ovarian Cancer.
Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.
Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist.
Prevention of breast cancer: focus on chemoprevention.
Preventive surgery is associated with reduced cancer risk and mortality in women with BRCA1 and BRCA2 mutations.
Primary cancer cell culture: mammary-optimized vs conditional reprogramming.
Primary fallopian tube carcinoma (PFTC) in a BRIP-1 mutation carrier: the first case report.
Primary immunodeficiency with chronic enteropathy and developmental delay in a boy arising from a novel homozygous RIPK1 variant.
Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome.
Primary ovarian dysgerminoma in a patient with a germline BRCA1 mutation.
Primary peritoneal serous papillary carcinoma: a new epidemiologic trend? A matched-case comparison with ovarian serous papillary cancer.
Primary transitional cell carcinoma of the fallopian tube.
PRKN-regulated mitophagy and cellular senescence during COPD pathogenesis.
Probability of BRCA1/2 mutation varies with ovarian histology: results from screening 442 ovarian cancer families.
Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history.
Profiling of the germline mutation BRCA1: p.Ile1845fs in a large cohort of Han Chinese breast cancer.
Progesterone induces BRCA1 mRNA decrease, cell cycle alterations and apoptosis in the MCF7 breast cancer cell line.
Progesterone Receptor A Stability Is Mediated by Glycogen Synthase Kinase-3? in the Brca1-deficient Mammary Gland.
Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives.
Progestin and breast cancer. The missing pieces of a puzzle.
Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and review.
Prognosis of patients with BRCA1-associated ovarian carcinomas depends on TP53 accumulation status in tumor cells.
Prognostic effects of abnormal DNA damage response protein expression in breast cancer.
Prognostic relevance of promoter hypermethylation of multiple genes in breast cancer patients.
Prognostic role of BRCA1 mutation in patients with triple-negative breast cancer.
Prognostic role of HuR in hereditary breast cancer.
Prognostic Significance of Basal-Like Phenotype and Fascin Expression in Node-Negative Invasive Breast Carcinomas.
Prognostic significance of BRCA mutations in ovarian cancer: an updated systematic review with meta-analysis.
Prognostic significance of BRCA1 expression in gastric cancer.
Prognostic significance of BRCA1 expression in Japanese sporadic breast carcinomas.
Prognostic significance of BRCA1 expression in sporadic breast carcinomas.
Prognostic Significance of Fbw7 in Human Melanoma and Its Role in Cell Migration.
Prognostic value of aberrant hypermethylation in pleural effusion of lung adenocarcinoma.
Prognostic value of BRCA1 mutations in familial breast cancer patients affected by a second primary cancer.
Prognostic value of CtIP/RBBP8 expression in breast cancer.
Prognostic value of ERCC1, RRM1, BRCA1 and SETDB1 in early stage of non-small cell lung cancer.
Prognostic Value of the Expression of DNA Repair-Related Biomarkers Mediated by Alcohol in Gastric Cancer Patients.
Progranulin promotes Temozolomide resistance of glioblastoma by orchestrating DNA repair and tumor stemness.
Progress of a Comprehensive Familial Cancer Genetic Counseling Program in the Era of BRCA1 and BRCA2.
Progress toward isolation of a breast cancer susceptibility gene, BRCA1.
Prolactin blocks nuclear translocation of VDR by regulating its interaction with BRCA1 in osteosarcoma cells.
Prolactin inhibits a major tumor-suppressive function of wild type BRCA1.
Prolonged response to treatment based on cell-free DNA analysis and molecular profiling in three patients with metastatic cancer: a case series.
Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature.
Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors.
Promoter Hypermethylation and Expression Changes of BRCA1 Gene in a Cohort of Sporadic Breast Cancer Cases among Pakistani Population.
Promoter hypermethylation and post-transcriptional mechanisms for reduced BRCA1 immunoreactivity in sporadic human breast cancers.
Promoter hypermethylation in male breast cancer: analysis by multiplex ligation-dependent probe amplification.
Promoter hypermethylation of BRCA1 correlates with absence of expression in hereditary breast cancer tumors.
Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer.
Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients.
Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy.
Promoter methylation of BRCA1 is associated with estrogen, progesterone and human epidermal growth factor receptor-negative tumors and the prognosis of breast cancer: A meta-analysis.
Promoter Methylation of BRCA1, DAPK1 and RASSF1A is Associated with Increased Mortality among Indian Women with Breast Cancer
Promoter methylation of RNF180 is associated with H.pylori infection and serves as a marker for gastric cancer and atrophic gastritis.
Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and P53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation carriers.
Promoter Methylation Status of Breast Cancer Susceptibility Gene 1 and 17 Beta Hydroxysteroid Dehydrogenase Type 1 Gene in Sporadic Breast Cancer Patients.
Promoter mutation and reduced expression of BRCA1 in canine mammary tumors.
Promotion of BRCA1-associated triple-negative breast cancer by ovarian hormones.
Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation-related breast cancer.
Prophylactic bilateral salpingo-oophorectomy (PBSO) with or without prophylactic bilateral mastectomy (PBM) or no intervention in BRCA1 mutation carriers: a cost-effectiveness analysis.
Prophylactic mastectomy and inherited predisposition to breast carcinoma.
Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers.
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers.
Prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers: what is going on in a region of northern Italy?
Prophylactic salpingo-oophorectomy in BRCA1 mutation carriers and postoperative incidence of peritoneal and breast cancers.
Prophylactic surgery and other strategies for reducing the risk of familial ovarian cancer.
Prophylactic window therapy with the clinical poly(ADP-ribose) polymerase inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice.
Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer.
Prospective observation of breast/ovarian cancer risk in BRCA1 carriers depending on serum selenium level optimized with diet.
Prospective Study of Breast Cancer Incidence in Women With a BRCA1 or BRCA2 Mutation Under Surveillance With and Without Magnetic Resonance Imaging.
Prospective study of breast cancer risk for mutation negative women from BRCA1 or BRCA2 mutation positive families.
Prospective study of breast MRI in BRCA1 and BRCA2 mutation carriers: effect of mutation status on cancer incidence.
Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype.
Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover.
Protease associated domain of RNF43 is not necessary for the suppression of Wnt/?-catenin signaling in human cells.
Proteasomal degradation of the tumour suppressor FBW7 requires branched ubiquitylation by TRIP12.
Proteasomal regulation of caspase-8 in cancer cell apoptosis.
Proteasomal Regulation of the Hypoxic Response Modulates Aging in C. elegans.
Proteasome-mediated degradation of BRCA1 protein in MCF-7 human breast cancer cells.
Protection from UV-induced skin carcinogenesis by genetic inhibition of the ataxia telangiectasia and Rad3-related (ATR) kinase.
Protective effects of prepubertal genistein exposure on mammary tumorigenesis are dependent on BRCA1 expression.
Protein C receptor is a therapeutic stem cell target in a distinct group of breast cancers.
Protein kinase CK1delta phosphorylates key sites in the acidic domain of murine double-minute clone 2 protein (MDM2) that regulate p53 turnover.
Protein partners of the BRCA1 tumor suppressor.
Protein stability versus function: effects of destabilizing missense mutations on BRCA1 DNA repair activity.
Protein-Protein Interaction Inhibitors of BRCA1 Discovered Using Small Molecule Microarrays.
Proteogenomics analysis unveils a TFG-RET gene fusion and druggable targets in papillary thyroid carcinomas.
Proteome changes in ovarian epithelial cells derived from women with BRCA1 mutations and family histories of cancer.
Proteome-wide analysis reveals substrates of E3 ligase RNF146 targeted for degradation.
Proteomic analysis of a preneoplastic phenotype in ovarian surface epithelial cells derived from prophylactic oophorectomies.
Proteomic analysis of BRCA1-depleted cell line reveals a putative role for replication protein A2 up-regulation in BRCA1 breast tumor development.
Proteomic characterization of pancreatic islet {beta}-cells stimulated with pancreatic carcinoma cell conditioned medium.
Proteomic Profiling of ?-hCG-Induced Spheres in BRCA1 Defective Triple Negative Breast Cancer Cells.
Proteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with diagnostic and prognostic value in human breast cancer.
Proteosomal degradation of NSD2 by BRCA1 promotes leukemia cell differentiation.
Proven non-carriers in BRCA families have an earlier age of onset of breast cancer.
Prp19 Arrests Cell Cycle via Cdc5L in Hepatocellular Carcinoma Cells.
Prp19 facilitates invasion of hepatocellular carcinoma via p38 mitogen-activated protein kinase/twist1 pathway.
Prp19 Is an Independent Prognostic Marker and Promotes Neuroblastoma Metastasis by Regulating the Hippo-YAP Signaling Pathway.
PRP19 upregulation inhibits cell proliferation in lung adenocarcinomas by p21-mediated induction of cell cycle arrest.
Psychological and cancer-specific distress at 18 months post-testing in women with demonstrated BRCA1 mutations for hereditary breast/ovarian cancer.
Psychological Distress, Anxiety, and Depression of Cancer-Affected BRCA1/2 Mutation Carriers: a Systematic Review.
Psychological impact of genetic counselling and testing in women previously diagnosed with breast cancer.
Psychological impact of genetic testing in women from high-risk breast cancer families.
Psychosocial factors and uptake of risk-reducing salpingo-oophorectomy in women at high risk for ovarian cancer.
PTEN mutation, expression and LOH at its locus in ovarian carcinomas. Relation to TP53, K-RAS and BRCA1 mutations.
Purification and characterisation of a soluble N-terminal fragment of the breast cancer susceptibility protein BRCA1.
pVHL Acts as an Adaptor to Promote the Inhibitory Phosphorylation of the NF-kappaB Agonist Card9 by CK2.
pVHL Negatively Regulates Antiviral Signaling by Targeting MAVS for Proteasomal Degradation.
pVHL promotes lysosomal degradation of YAP in lung adenocarcinoma.
Pyrosequencing analysis of BRCA1 methylation level in breast cancer cells.
Pyrosequencing-based DNA methylation profiling of Fanconi anemia/BRCA pathway genes in laryngeal squamous cell carcinoma.
Pyrrolidine Dithiocarbamate Facilitates Arsenic Trioxide Against Pancreatic Cancer via Perturbing Ubiquitin-Proteasome Pathway.
Q356R and S1512I are BRCA1 variants that may be associated with breast cancer in a Cypriot family.
Quantification of BRCA1 protein in sporadic breast carcinoma with or without loss of heterozygosity of the BRCA1 gene.
Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics.
Quantitative analysis of BRCA1 and BRCA2 mRNA expression in sporadic breast carcinomas and its relationship with clinicopathological characteristics.
Quantitative analysis of BRCA1, BRCA2 and Hmsh2 mRNA expression in colorectal Lieberkühnien adenocarcinomas and matched normal mucosa: relationship with cellular proliferation.
Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness.
Quantitative Lys-?-Gly-Gly (diGly) proteomics coupled with inducible RNAi reveals ubiquitin-mediated proteolysis of DNA damage-inducible transcript 4 (DDIT4) by the E3 ligase HUWE1.
Quantitative proteomic identification of the BRCA1 ubiquitination substrates.
Quantity control of the ErbB3 receptor tyrosine kinase at the endoplasmic reticulum.
R1 Regulates Prostate Tumor Growth and Progression By Transcriptional Suppression of the E3 Ligase HUWE1 to Stabilize c-Myc.
Race and cancer genetics: lessons from BRCA1.
RACK1 regulates centriole duplication by controlling localization of BRCA1 to the centrosome in mammary tissue-derived cells.
Rad18 confers hematopoietic progenitor cell DNA damage tolerance independently of the Fanconi Anemia pathway in vivo.
RAD18 contributes to the migration and invasion of human cervical cancer cells via the interleukin?1? pathway.
Rad18 mediates specific mutational signatures and shapes the genomic landscape of carcinogen-induced tumors in vivo.
Rad50 c.687delT does not contribute significantly to familial breast cancer in a French population.
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
RAD51 up-regulation bypasses BRCA1 function and is a common feature of BRCA1-deficient breast tumors.
RAD52 aptamer regulates DNA damage repair and STAT3 in BRCA1/BRCA2?deficient human acute myeloid leukemia.
Rad52 gene mutations in breast/ovarian cancer families and sporadic ovarian carcinoma patients.
RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis.
RANKL/RANK control Brca1 mutation-driven mammary tumors.
RAP80 Acts Independently of BRCA1 in Repair of Topoisomerase II Poison-Induced DNA Damage.
RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites.
Rapid detection of novel BRCA1 rearrangements in high-risk breast-ovarian cancer families using multiplex PCR of short fluorescent fragments.
Rapid detection of regionally clustered germ-line BRCA1 mutations by multiplex heteroduplex analysis. UKCCCR Familial Ovarian Cancer Study Group.
Rapid recruitment of BRCA1 to DNA double-strand breaks is dependent on its association with Ku80.
Rapid screening test of most frequent BRCA1/BRCA2 pathogenic variants in the NGS era.
Rapid selection of BRCA1-proficient tumor cells during neoadjuvant therapy for ovarian cancer in BRCA1 mutation carriers.
Rare BRCA1 haplotypes including 3'UTR SNPs associated with breast cancer risk.
Rare germline large rearrangements in the BRCA1/2 genes and eight candidate genes in 472 patients with breast cancer predisposition.
RASSF6 tumor suppressor regulates apoptosis and cell cycle via MDM2 and p53.
Rates of Jewish ancestral mutations in BRCA1 and BRCA2 in borderline ovarian tumors.
Ratio-Dependent Synergism of a Doxorubicin and Olaparib Combination in 2D and Spheroid Models of Ovarian Cancer.
Rb inactivation accelerates neoplastic growth and substitutes for recurrent amplification of cIAP1, cIAP2 and Yap1 in sporadic mammary carcinoma associated with p53 deficiency.
RBCK1 contributes to chemoresistance and stemness in colorectal cancer (CRC).
RBCK1 negatively regulates tumor necrosis factor- and interleukin-1-triggered NF-kappaB activation by targeting TAB2/3 for degradation.
RBR E3 ubiquitin ligases in tumorigenesis.
RBR-type E3 ubiquitin ligase RNF144A targets PARP1 for ubiquitin-dependent degradation and regulates PARP inhibitor sensitivity in breast cancer cells.
RBX1/ROC1-SCF E3 ubiquitin ligase is required for mouse embryogenesis and cancer cell survival.
Re-engineering a split-GFP reassembly screen to examine RING-domain interactions between BARD1 and BRCA1 mutants observed in cancer patients.
Re: Cancer risks in BRCA1 carriers: time for the next generation of studies.
Re: Catherine H. Marshall, Alexandra O. Sokolova, Andrea L. McNatty, et al. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. Eur Urol 2019;76:452-8.
Re: Increased Cancer Risks for Relatives of Very Early-Onset Breast Cancer Cases With and Without BRCA1 and BRCA2 Mutations.
Re: Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations.
Re: probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history.
Reactivation of p53 by Inhibiting Mdm2 E3 Ligase: A Novel Antitumor Approach.
Real-time detection of BRCA1 gene mutations using a monolithic silicon optocoupler array.
Real-time PCR quantification of full-length and exon 11 spliced BRCA1 transcripts in human breast cancer cell lines.
Real-time PCR-based gene dosage assay for detecting BRCA1 rearrangements in breast-ovarian cancer families.
Real-world health services utilisation and outcomes after BRCA1 and BRCA2 testing in Ontario, Canada: the What Comes Next Cohort Study protocol.
Recent advances in breast cancer biology.
Recent advances in SCF ubiquitin ligase complex: Clinical implications.
Recent developments in ovarian cancer genetics.
Recessive oncogenes: current status.
Reclassification of BRCA1 and BRCA2 variants found in ovarian epithelial, fallopian tube, and primary peritoneal cancers.
Reclassification of BRCA1 and BRCA2 variants of uncertain significance: a multifactorial analysis of multicentre prospective cohort.
Recognition of DNA double strand breaks by the BRCA1 tumor suppressor network.
Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium.
Recruitment of BRCA1 limits MYCN-driven accumulation of stalled RNA polymerase.
Rectal cancer profiling identifies distinct subtypes in India based on age at onset, genetic, epigenetic and clinicopathological characteristics.
Recurrent copy number alterations in BRCA1-mutated ovarian tumors alter biological pathways.
Recurrent genetic alterations and biomarker expression in primary and metastatic squamous cell carcinomas of the vulva.
Recurrent germline mutations in BRCA1 and BRCA2 genes in high risk families in Israel.
Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair.
Recurrent large genomic rearrangements in BRCA1 and BRCA2 in an Irish case series.
Recurrent mutation testing of BRCA1 and BRCA2 in Asian breast cancer patients identify carriers in those with presumed low risk by family history.
Redox biology in normal cells and cancer: Restoring function of the redox/Fyn/c-Cbl pathway in cancer cells offers new approaches to cancer treatment.
Redox regulation in cancer: a double-edged sword with therapeutic potential.
Redox-dependent Brca1 transcriptional regulation by an NADH-sensor CtBP1.
Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia.
Reduced Brca1 protein expression in 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced rat mammary carcinomas.
Reduced BRCA1 transcript levels in freshly isolated blood leukocytes from BRCA1 mutation carriers is mutation specific.
Reduced cell death, invasive and angiogenic features conferred by BRCA1-deficiency in mammary epithelial cells transformed with H-Ras.
Reduced PDZRN4 promotes breast cancer progression and predicts poor prognosis.
Reduction of BRCA1 expression in sporadic ovarian cancer.
Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases.
Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death.
Referencing BRCA in hereditary cancer risk discussions: In search of an anchor in a sea of uncertainty.
Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia.
Refining the role of BRCA1 in combating oxidative stress.
Regional methylation of the 5' end CpG island of BRCA1 is associated with reduced gene expression in human somatic cells.
Regulated necrosis-related molecule mRNA expression in humans and mice and in murine acute tissue injury and systemic autoimmunity leading to progressive organ damage, and progressive fibrosis.
Regulated recruitment of tumor suppressor BRCA1 to the p21 gene by coactivator methylation.
Regulating BRCA1 protein stability by cathepsin S-mediated ubiquitin degradation.
Regulating the balance between necroptosis, apoptosis and inflammation by inhibitors of apoptosis proteins.
Regulating the levels of key factors in cell cycle and DNA repair: new pathways revealed by lamins.
Regulation of APC(Cdh1) E3 ligase activity by the Fbw7/cyclin E signaling axis contributes to the tumor suppressor function of Fbw7.
Regulation of BRCA1 and BRCA2 expression in human breast cancer cells by DNA-damaging agents.
Regulation of BRCA1 by protein degradation.
Regulation of BRCA1 expression and its relationship to sporadic breast cancer.
Regulation of BRCA1 expression by the Rb-E2F pathway.
Regulation of BRCA1 phosphorylation by interaction with protein phosphatase 1alpha.
Regulation of BRCA1 transcription by specific single-stranded DNA binding factors.
Regulation of cancer stem cells by RING finger ubiquitin ligases.
Regulation of centrosomes by the BRCA1-dependent ubiquitin ligase.
Regulation of DNA Damage Response by Estrogen Receptor ?-Mediated Inhibition of Breast Cancer Associated Gene 2.
Regulation of glioma migration and invasion via modification of Rap2a activity by the ubiquitin ligase Nedd4-1.
Regulation of HIF by the von Hippel-Lindau tumour suppressor: implications for cellular oxygen sensing.
Regulation of Krüppel-like factor 8 by the NEDD4 E3 ubiquitin ligase.
Regulation of Oxidative Stress Contributes to BRCA1 Tumor Suppression.
Regulation of p53 level by UBE4B in breast cancer.
Regulation of Parkin expression as the key balance between neural survival and cancer cell death.
Regulation of PCTAIRE1 protein stability by AKT1, LKB1 and BRCA1.
Regulation of progesterone receptor signaling by BRCA1 in mammary cancer.
Regulation of SOX10 stability via ubiquitination-mediated degradation by Fbxw7? modulates melanoma cell migration.
Regulation of the estrogen-inducible gene expression profile by the breast cancer susceptibility gene BRCA1.
Regulation of the insulin-like growth factor-I receptor gene by oncogenes and antioncogenes: implications in human cancer.
Regulation of the p53 response and its relationship to cancer.
Regulation of the p53 tumor suppressor pathway: the problems and promises of studying Mdm2's E3 ligase function.
Regulation of tumor suppressors by nuclear-cytoplasmic shuttling.
Regulators of global genome repair do not respond to DNA damaging therapy but correlate with survival in melanoma.
Regulatory function of praja ring finger ubiquitin ligase 2 mediated by the P2rx3/P2rx7 axis in mouse hippocampal neuronal cells.
Reinforcement of cancer immunotherapy by adoptive transfer of cblb-deficient CD8(+) T cells combined with a DC vaccine.
Reinterpretation of BRCA1 and BRCA2 variants of uncertain significance in patients with hereditary breast/ovarian cancer using the ACMG/AMP 2015 guidelines.
Relationship between loss of heterozygosity of tumor suppressor genes and histologic differentiation in hepatocellular carcinoma.
Relationship between three novel SNPs of BRCA1 and canine mammary tumors.
Relationship of BRCA1 and BRCA2 mutations with cancer burden in the family and tumor incidence.
Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families.
Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women.
Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification.
Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: A national cohort study.
Relevance of DNA methylation in the management of cancer.
Reliability of Tumor Testing Compared to Germline Testing for Detecting BRCA1 and BRCA2 Mutations in Patients with Epithelial Ovarian Cancer.
Removal of BRCA1/CtIP/ZBRK1 repressor complex on ANG1 promoter leads to accelerated mammary tumor growth contributed by prominent vasculature.
Renal cell carcinoma risk in type 2 von Hippel-Lindau disease correlates with defects in pVHL stability and HIF-1alpha interactions.
Repair of chromosomal double-strand breaks by precise ligation in human cells.
Repeated observation of breast tumor subtypes in independent gene expression data sets.
Repetitive demand for radical cancer risk reduction surgery in a young BRCA1 mutation carrier with strong family history of BRCA linked malignancies.
Replicated chromatin curtails 53BP1 recruitment in BRCA1-proficient and BRCA1-deficient cells.
Replication Gaps Underlie BRCA Deficiency and Therapy Response.
Replication Stress Shapes a Protective Chromatin Environment across Fragile Genomic Regions.
Repression of BRCA1 through a feedback loop involving p53.
Repression of the putative tumor suppressor gene Bard1 or expression of Notch4(int-3) oncogene subvert the morphogenetic properties of mammary epithelial cells.
Reproductive history determines Erbb2 locus amplification, WNT signalling and tumour phenotype in a murine breast cancer model.
Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks.
Requirement of heterogeneous nuclear ribonucleoprotein C for BRCA gene expression and homologous recombination.
Residues 240-250 in the C-terminus of the Pirh2 protein complement the function of the RING domain in self-ubiquitination of the Pirh2 protein.
Resources to increase genetics and genomics capacity of oncology nurses.
Response and resistance to the endocrine prevention of breast cancer.
Response to neo-adjuvant chemotherapy in BRCA1 and BRCA2 related stage III breast cancer.
Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers.
Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations.
RESPONSE: more about: multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations
Responsiveness of Brca1 and Trp53 Deficiency-Induced Mammary Preneoplasia to Selective Estrogen Modulators versus an Aromatase Inhibitor in Mus musculus.
Restoration of Replication Fork Stability in BRCA1- and BRCA2-Deficient Cells by Inactivation of SNF2-Family Fork Remodelers.
Restoration of tumor suppression in prostate cancer by targeting the E3 ligase E6AP.
Restriction of Src activity by Cullin-5.
Resveratrol modulates epigenetic regulators of promoter histone methylation and acetylation that restores BRCA1, p53, p21CIP1 in human breast cancer cell lines.
Retention of African American women in cancer genetics research.
Retinoic acid protects human breast cancer cells against etoposide-induced apoptosis by NF-kappaB-dependent but cIAP2-independent mechanisms.
Retrospective reinterpretation and reclassification of BRCA1/2 variants from Chinese population.
Retrospective response analysis of BAP1 expression to predict the clinical activity of systemic cytotoxic chemotherapy in mesothelioma.
Return of Results from Genomic Sequencing: A Policy Discussion of Secondary Findings for Cancer Predisposition.
Reversing effect of ring finger protein 43 inhibition on malignant phenotypes of human hepatocellular carcinoma.
Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer.
Reversion Mutations with Clinical Use of PARP Inhibitors: Many Genes, Many Versions.
Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer.
Reviewing the characteristics of BRCA and PALB2-related cancers in the precision medicine era.
Revisiting the BRCA-pathway through the lens of replication gap suppression: "Gaps determine therapy response in BRCA mutant cancer".
Rho guanosine nucleotide exchange factors are not such bad guys after all in cancer
Ribosomal protein L6 (RPL6) is recruited to DNA damage sites in a poly(ADP-ribose) polymerase-dependent manner and regulates the DNA damage response.
Rictor forms a complex with Cullin-1 to promote SGK1 ubiquitination and destruction.
RING finger E(3) ubiquitin ligases: structure and drug discovery.
Ring Finger Protein 11 acts on ligand-activated EGFR via the direct interaction with the UIM region of ANKRD13 protein family.
Ring finger protein 43 as a new target for cancer immunotherapy.
Ring finger protein 43 associates with gastric cancer progression and attenuates the stemness of gastric cancer stem-like cells via the Wnt-?/catenin signaling pathway.
Ring finger protein 43 expression is associated with genetic alteration status and poor prognosis among patients with intrahepatic cholangiocarcinoma.
RING finger ubiquitin protein ligases: implications for tumorigenesis, metastasis and for molecular targets in cancer.
RING-finger protein 5 promotes hepatocellular carcinoma progression and predicts poor prognosis.
RING1B contributes to Ewing sarcoma development by repressing the NaV1.6 sodium channel and the NF-?B pathway, independently of the fusion oncoprotein.
RING1B recruits EWSR1-FLI1 and cooperates in the remodeling of chromatin necessary for Ewing sarcoma tumorigenesis.
Ring1b-dependent epigenetic remodelling is an essential prerequisite for pancreatic carcinogenesis.
RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis.
Rise of TRIM8: A Molecule of Duality.
Risk algorithms that include pathology adjustment for HER2 amplification need to make further downward adjustments in likelihood scores.
Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation.
Risk modifiers in carriers of BRCA1 mutations.
Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women's Environmental Cancer and Radiation Epidemiology Study.
Risk of breast and ovarian cancer in women with strong family histories.
Risk of Breast Cancer Among Carriers of Pathogenic Variants in Breast Cancer Predisposition Genes Varies by Polygenic Risk Score.
Risk of cancer at sites other than the breast in Swedish families eligible for BRCA1 or BRCA2 mutation testing.
Risk of cancer in BRCA1 and BRCA2 mutation-positive and -negative breast cancer families (Finland).
Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations.
Risk of endometrial carcinoma associated with BRCA mutation.
Risk of Having BRCA1 Mutation in High-Risk Women with Triple-Negative Breast Cancer: A Meta-Analysis.
Risk of Ipsilateral and Contralateral Cancer in BRCA Mutation Carriers with Breast Cancer.
Risk of Second Primary Malignancy in Breast Cancer Survivors: A Nested Population-Based Case-Control Study.
Risk of Serous Endometrial Carcinoma in Women With Pathogenic BRCA1/2 Variant After Risk-Reducing Salpingo-Oophorectomy.
Risk-benefit assessment of the combined oral contraceptive pill in women with a family history of female cancer.
Risk-reducing appendectomy and the elimination of BRCA1-associated intraperitoneal cancer.
Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
Risk-reducing mastectomy.
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.
Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy.
Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2.
Risk-reducing Surgery in Women at Risk for Familial Breast or Ovarian Cancer.
Risk-reducing surgery on the uterine adnexa: timing and type of surgical treatment and pathology report.
Risk-reducing surgery, screening and chemoprevention practices of BRCA1 and BRCA2 mutation carriers: a prospective cohort study.
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
Risks of cancer among members of families in the Gilda Radner Familial Ovarian Cancer Registry.
Risks of cancer due to a single BRCA1 mutation in an extended Utah kindred.
Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
RN181 is a tumour suppressor in gastric cancer by regulation of the ERK/MAPK-cyclin D1/CDK4 pathway.
RN181 regulates the biological behaviors of oral squamous cell carcinoma cells via mediating ERK/MAPK signaling pathway.
RN181 suppressed tumor growth of hepatocellular carcinoma by inhibition of the ERK/MAPK pathway.
RNA analysis of cancer predisposing genes in formalin-fixed paraffin-embedded tissue determines aberrant splicing.
RNA analysis of eight BRCA1 and BRCA2 unclassified variants identified in breast/ovarian cancer families from Spain.
RNA analysis reveals splicing mutations and loss of expression defects in MLH1 and BRCA1.
RNA helicase A interacts with nuclear factor kappaB p65 and functions as a transcriptional coactivator.
RNA-Primed Amplification for Noise-Suppressed Visualization of Single-Cell Splice Variants.
RNF11 is a GGA protein cargo and acts as a molecular adaptor for GGA3 ubiquitination mediated by Itch.
RNF111/Arkadia is regulated by DNA methylation and affects TGF-?/Smad signaling associated invasion in NSCLC cells.
RNF12 promotes p53-dependent cell growth suppression and apoptosis by targeting MDM2 for destruction.
RNF125 is a ubiquitin-protein ligase that promotes p53 degradation.
RNF144A functions as a tumor suppressor in breast cancer through ubiquitin ligase activity-dependent regulation of stability and oncogenic functions of HSPA2.
RNF144A suppresses ovarian cancer stem cell properties and tumor progression through regulation of LIN28B degradation via the ubiquitin-proteasome pathway.
RNF180 Inhibits Proliferation and Promotes Apoptosis of Colorectal Cancer Through Ubiquitination of WISP1.
RNF180 mediates STAT3 activity by regulating the expression of RhoC via the proteasomal pathway in gastric cancer cells.
RNF186 regulates EFNB1 (ephrin B1)-EPHB2-induced autophagy in the colonic epithelial cells for the maintenance of intestinal homeostasis.
RNF2/Ring1b negatively regulates p53 expression in selective cancer cell types to promote tumor development.
RNF20 and histone H2B ubiquitylation exert opposing effects in Basal-Like versus luminal breast cancer.
RNF20 inhibits TFIIS-facilitated transcriptional elongation to suppress pro-oncogenic gene expression.
RNF20 Links Histone H2B Ubiquitylation with Inflammation and Inflammation-Associated Cancer.
RNF20 promotes the polyubiquitination and proteasome-dependent degradation of AP-2? protein.
RNF20 Suppresses Tumorigenesis by Inhibiting SREBP1c-PTTG1 Axis in Kidney Cancer.
RNF20-RNF40: A ubiquitin-driven link between gene expression and the DNA damage response.
RNF208, an estrogen-inducible E3 ligase, targets soluble Vimentin to suppress metastasis in triple-negative breast cancers.
RNF43 and PWWP2B inhibit cancer cell proliferation and are predictive or prognostic biomarker for FDA-approved drugs in patients with advanced gastric cancer.
RNF43 and ZNRF3 are commonly altered in serrated pathway colorectal tumorigenesis.
RNF43 frameshift mutations contribute to tumourigenesis in right-sided colon cancer.
RNF43 germline and somatic mutation in serrated neoplasia pathway and its association with BRAF mutation.
RNF43 Inhibits Cancer Cell Proliferation and Could be a Potential Prognostic Factor for Human Gastric Carcinoma.
RNF43 is a Novel Tumor Suppressor and Prognostic Indicator in Clear Cell Renal Cell Carcinoma.
RNF43 is a tumour suppressor gene mutated in mucinous tumours of the ovary.
RNF43 Is an Early and Specific Mutated Gene in the Serrated Pathway, With Increased Frequency in Traditional Serrated Adenoma and Its Associated Malignancy.
RNF43 is frequently mutated in colorectal and endometrial cancers.
RNF43 is mutated less frequently in Lynch Syndrome compared with sporadic microsatellite unstable colorectal cancers.
RNF43 mutation frequently occurs with GNAS mutation and mucin hypersecretion in intraductal papillary neoplasms of the bile duct.
RNF43 mutation is associated with aggressive tumor biology along with BRAF V600E mutation in right-sided colorectal cancer.
RNF43 Mutations in IPMN Cases: A Potential Prognostic Factor.
RNF43 Pathogenic Germline Variant in a Family with Colorectal Cancer.
RNF43 truncations trap CK1 to drive niche-independent self-renewal in cancer.
Rnf43.
RNF6 facilitates metastasis and radioresistance in hepatocellular carcinoma through ubiquitination of FoxA1.
RNF8 E3 Ubiquitin Ligase Stimulates Ubc13 E2 Conjugating Activity that is Essential for DNA Double-Strand Break Signaling and BRCA1 Tumor Suppressor Recruitment.
RNF8 promotes efficient DSB repair by inhibiting the pro-apoptotic activity of p53 through regulating the function of Tip60.
RNF8 Promotes Epithelial-Mesenchymal Transition in Lung Cancer Cells via Stabilization of Slug.
RNF8 regulates assembly of RAD51 at DNA double-strand breaks in the absence of BRCA1 and 53BP1.
Robust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platforms.
ROC1/RBX1 E3 ubiquitin ligase silencing suppresses tumor cell growth via sequential induction of G2-M arrest, apoptosis, and senescence.
Role for ATM in DNA damage-induced phosphorylation of BRCA1.
Role for the BRCA1 C-terminal repeats (BRCT) protein 53BP1 in maintaining genomic stability.
Role of a BRCT domain in the interaction of DNA ligase III-alpha with the DNA repair protein XRCC1.
Role of Apoptotic Regulators in Human Epithelial Ovarian Cancer.
Role of BRCA gene dysfunction in breast and ovarian cancer predisposition.
Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage.
Role of BRCA1 in brain development.
Role of BRCA1 in controlling mitotic arrest in ovarian cystadenoma cells.
Role of BRCA1 in Neuronal Death in Alzheimer's Disease.
Role of BRCA1 mutation screening in the management of familial ovarian cancer.
Role of BRCA1, HSD17B1 and HSD17B2 methylation in breast cancer tissue.
Role of E3 ubiquitin ligases in lung cancer.
Role of IFI16 in DNA damage and checkpoint.
Role of Pirh2 in mediating the regulation of p53 and c-Myc.
Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1alpha.
Role of RNF20 in cancer development and progression - a comprehensive review.
Role of steroid hormones and growth factors in breast cancer.
Role of the GH-IGF1 system in progression of cancer.
Role of the tumor suppressor gene Brca1 in genetic stability and mammary gland tumor formation.
Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial.
Role of TRAFs in Signaling Pathways Controlling T Follicular Helper Cell Differentiation and T Cell-Dependent Antibody Responses.
Role of TRIM33 in Wnt signaling during mesendoderm differentiation.
Role of tumor suppressor molecules in genomic perturbations and damaged DNA repair involved in the pathogenesis of cancer and neurodegeneration (Review).
Role played by BRCA1 in regulating the cellular response to stress.
Role played by BRCA1 in transcriptional regulation in response to therapy.
Roles of BRCA1 and its interacting proteins.
Roles of BRCA1 in DNA damage repair: a link between development and cancer.
Roles of DNA mutation in the coding region and DNA methylation in the 5' flanking region of BRCA1 in canine mammary tumors.
Roles of E3 ubiquitin ligases in gastric cancer carcinogenesis and their effects on cisplatin resistance.
Rotating night work, lifestyle factors, obesity and promoter methylation in BRCA1 and BRCA2 genes among nurses and midwives.
Routine use of gene panel testing in hereditary breast cancer should be performed with caution.
RPL32 Promotes Lung Cancer Progression by Facilitating p53 Degradation.
RSPO3 antagonism inhibits growth and tumorigenicity in colorectal tumors harboring common Wnt pathway mutations.
RT-qPCR analysis of the tumor antigens TOMM34 and RNF43 in samples extracted from paraffin-embedded specimens of colorectal cancer.
S100A2 is a BRCA1/p63 coregulated tumour suppressor gene with roles in the regulation of mutant p53 stability.
SAG/ROC2/RBX2 E3 ligase promotes UVB-induced skin hyperplasia, but not skin tumors, by simultaneously targeting c-Jun/AP-1 and p27.
Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.
Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma.
SCF E3 Ubiquitin Ligases as Anticancer Targets.
Screen-positive rates and agreement among six family history screening protocols for breast/ovarian cancer in a population-based cohort of 21- to 55-year-old women.
Screening and clinical implications for BRCA1 and BRCA2 mutation carriers.
Screening and prevention of hereditary gynecologic cancers.
Screening and verification of proteins that interact with HSPC238.
Screening for BRCA1 and BRCA2 mutations in Eastern Finnish breast/ovarian cancer families.
Screening for colorectal cancer using the faecal occult blood test, hemoccult.
Screening for genetic risk of breast cancer.
Screening for genomic rearrangements in BRCA1 and BRCA2 genes in Czech high-risk breast/ovarian cancer patients: high proportion of population specific alterations in BRCA1 gene.
Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing.
Screening for microsatellite instability target genes in colorectal cancers.
Screening for mutations in exon 11 of the BRCA1 gene in 70 Italian breast and ovarian cancer patients by protein truncation test.
Screening of 1331 Danish breast and/or ovarian cancer families identified 40 novel BRCA1 and BRCA2 mutations.
Screening of BRCA1 mutation using immunohistochemical staining with C-terminal and N-terminal antibodies in familial ovarian cancers.
Screening of BRCA1/2 deep intronic regions by targeted gene sequencing identifies the first germline BRCA1 variant causing pseudoexon activation in a patient with breast/ovarian cancer.
Screening of BRCA1/2 Mutations Using Direct Sequencing in Indonesian Familial Breast Cancer Cases.
Screening of male breast cancer and of breast-ovarian cancer families for BRCA2 mutations using large bifluorescent amplicons.
Screening of women at high risk for breast cancer.
Screening strategies for ovarian cancer.
Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS).
scribble (scrib) knockdown induces tumorigenesis by modulating Drp1-Parkin mediated mitochondrial dynamics in the wing imaginal tissues of Drosophila.
SCYL1 binding protein 1 promotes the ubiquitin-dependent degradation of Pirh2 and has tumor-suppressive function in the development of hepatocellular carcinoma.
Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance.
Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance.
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor.
Secondary mutations of BRCA1/2 and drug resistance.
Secretome proteomics reveals candidate non-invasive biomarkers of BRCA1 deficiency in breast cancer.
Seeking Balance: Decision Support Needs of Women Without Cancer and a Deleterious BRCA1 or BRCA2 Mutation.
Selected aspects of genetic counselling for BRCA1 mutation carriers.
Selected Aspects of Molecular Diagnostics of Constitutional Alterations in BRCA1 and BRCA2 Genes Associated with Increased Risk of Breast Cancer in the Polish Population.
Selected features of breast and peritoneal cancers diagnosed in BRCA1 carriers after risk-reducing salpingo-oophorectomy.
Selected medical interventions in women with a deleterious BRCA mutation: a population-based study in British Columbia.
Selecting for BRCA1 testing using a combination of homogeneous selection criteria and immunohistochemical characteristics of breast cancers.
Selecting Patients with Ovarian Cancer for Germline BRCA Mutation Testing: Findings from Guidelines and a Systematic Literature Review.
Selective immobilization of DNA and antibody probes on electrode arrays: simultaneous electrochemical detection of DNA and protein on a single platform.
Selective loss of heterozygosity in multiple breast cancers from a carrier of mutations in both BRCA1 and BRCA2.
Selective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells.
Selective removal of the selenocysteine tRNA [Ser]Sec gene (Trsp) in mouse mammary epithelium.
Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer.
Selenium Supplementation Reduced Oxidative DNA Damage in Adnexectomized BRCA1 Mutations Carriers.
Sensitive and selective DNA probe based on "turn-on" photoluminescence of C-dots@RGO.
Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan.
Sensitivity of BRCA1/2 testing in high-risk breast/ovarian/male breast cancer families: little contribution of comprehensive RNA/NGS panel testing.
Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series.
Sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition identifies ubiquitin-specific peptidase 11 (USP11) as a regulator of DNA double-strand break repair.
Sensitization of Carboplatinum- and Taxol-Resistant High-Grade Serous Ovarian Cancer Cells Carrying p53, BRCA1/2 Mutations by Emblica officinalis (Amla) via Multiple Targets.
SEOM clinical guidelines for the treatment of advanced prostate cancer (2020).
Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk.
Sequence determinants in hypoxia-inducible factor-1alpha for hydroxylation by the prolyl hydroxylases PHD1, PHD2, and PHD3.
Sequence Variants of BRCA1 and BRCA2 Genes in Four Iranian Families with Breast and Ovarian Cancer.
Sequence, chromosomal location and expression analysis of the murine homologue of human RAD51L2/RAD51C.
Serine/threonine protein phosphatase type 5 acts upstream of p53 to regulate the induction of p21(WAF1/Cip1) and mediate growth arrest.
Serous cystic neoplasms of the pancreas: clinicopathologic and molecular characteristics.
Serum (circulating) tumor markers for breast cancer.
Setting up a breast cancer family history clinic.
Severe hypoglycemia and finger clubbing in a patient with a BRCA1 mutation in a solitary fibrous tumor: a case report.
Sex ratio distortion in offspring of families with BRCA1 or BRCA2 mutant alleles: an ascertainment bias phenomenon?
Shaping the regulation of the p53 mRNA tumour suppressor: the co-evolution of genetic signatures.
Sharpin prevents skin inflammation by inhibiting TNFR1-induced keratinocyte apoptosis.
Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells.
Short telomeres are frequent in hereditary breast tumors and are associated with high tumor grade.
Should the risk for uterine cancer influence decision making for prophylactic hysterectomy in BRCA1/2 mutated patients- a systematic review and meta-analysis.
Should we screen BRCA1 mutation carriers only with MRI? A multicenter study.
Shuttling imbalance of MLF1 results in p53 instability and increases susceptibility to oncogenic transformation.
Signaling mechanism of tumor cell-induced up-regulation of E3 ubiquitin ligase UBR2.
Signalling pathways in UHRF1-dependent regulation of tumor suppressor genes in cancer.
Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico.
Significant contribution of large BRCA1 gene rearrangements in 120 French breast and ovarian cancer families.
Silencing E3 Ubiqutin ligase ITCH as a potential therapy to enhance chemotherapy efficacy in p53 mutant neuroblastoma cells.
Silencing of unsynapsed meiotic chromosomes in the mouse.
Silencing RBBP6 (Retinoblastoma Binding Protein 6) sensitises breast cancer cells MCF7 to staurosporine and camptothecin-induced cell death.
Silencing UBE4B induces nasopharyngeal carcinoma apoptosis through the activation of caspase3 and p53.
Silibilin-induces apoptosis in breast cancer cells by modulating p53, p21, Bak and Bcl-XL pathways.
Silibinin-induced mitochondria fission leads to mitophagy, which attenuates silibinin-induced apoptosis in MCF-7 and MDA-MB-231 cells.
Simultaneous detection of BRCA mutations and large genomic rearrangements in germline DNA and FFPE tumor samples.
Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making.
Single nucleotide polymorphisms in breast cancer susceptibility gene 1 are associated with susceptibility to lung cancer.
Single nucleotide polymorphisms in clinical genetic testing: the characterization of the clinical significance of genetic variants and their application in clinical research for BRCA1.
Single-Cell RNA Sequencing Reveals the Cellular Origin and Evolution of Breast Cancer in BRCA1 Mutation Carriers.
Single-Cell Transcriptome Analysis Dissects the Replicating Process of Pancreatic Beta Cells in Partial Pancreatectomy Model.
Single-molecule DNA visualization using AT-specific red and non-specific green DNA-binding fluorescent proteins.
Single-nucleotide polymorphisms in the p53 pathway genes modify cancer risk in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent.
SIRT6 Is a Target of Regulation by UBE3A That Contributes to Liver Tumorigenesis in an ANXA2-Dependent Manner.
SIRTing through breast cancer is just a survivin' game.
Skp2 directs Myc-mediated suppression of p27Kip1 yet has modest effects on Myc-driven lymphomagenesis.
Skp2 overexpression increases the expression of MMP-2 and MMP-9 and invasion of lung cancer cells.
Skp2 regulates non-small cell lung cancer cell growth by Meg3 and miR-3163.
Skp2-mediated ubiquitination and mitochondrial localization of Akt drive tumor growth and chemoresistance to cisplatin.
Slug promotes p53 and p21 protein degradation by inducing Mdm2 expression in HCT116 colon cancer cells.
Smac mimetics and TNFalpha: a dangerous liaison?
Smad7 Binds Differently to Individual and Tandem WW3 and WW4 Domains of WWP2 Ubiquitin Ligase Isoforms.
Small mitochondrial Arf (smArf) protein corrects p53-independent developmental defects of Arf tumor suppressor-deficient mice.
Small molecule TSC01682 inhibits osteosarcoma cell growth by specifically disrupting the CUL4B-DDB1 interaction and decreasing the ubiquitination of CRL4B E3 ligase substrates.
Small RING finger proteins RBX1 and RBX2 of SCF E3 ubiquitin ligases: the role in cancer and as cancer targets.
Small RNA sequencing reveals a comprehensive miRNA signature of BRCA1-associated high-grade serous ovarian cancer.
Small-molecule inhibitors identify the RAD52-ssDNA interaction as critical for recovery from replication stress and for survival of BRCA2 deficient cells.
Small-molecule SMAC mimetics as new cancer therapeutics.
SMURF1 amplification promotes invasiveness in pancreatic cancer.
SMURF1, a promoter of tumor cell progression?
SMURF2 prevents detrimental changes to chromatin, protecting human dermal fibroblasts from chromosomal instability and tumorigenesis.
SMURF2-mediated ubiquitin signaling plays an essential role in the regulation of PARP1 PARylating activity, molecular interactions, and functions in mammalian cells.
Society of gynecologic oncologists education committee statement on risk assessment for inherited gynecologic cancer predispositions.
Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions.
Solution structure of the Hdm2 C2H2C4 RING, a domain critical for ubiquitination of p53.
Solution structure, backbone dynamics, and association behavior of the C-terminal BRCT domain from the breast cancer-associated protein BRCA1.
Somatic aberrations of BRCA1 gene are associated with ALDH1, EGFR, and tumor progression in prostate cancer.
Somatic alterations contributing to metastasis of a castration-resistant prostate cancer.
Somatic and germline mutations in the tumor suppressor gene PARK2 impair PINK1/Parkin-mediated mitophagy in lung cancer cells.
Somatic BRCA1 mutations in clinically sporadic breast cancer with medullary histological features.
Somatic BRCA1-associated protein 1 (BAP1) loss is an early and rare event in esophageal adenocarcinoma.
Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition.
Somatic copy number changes in DPYD are associated with lower risk of recurrence in triple-negative breast cancers.
Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus.
Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer.
Somatic mRNA Analysis of BRCA1 Splice Variants Provides a Direct Theranostic Impact on PARP Inhibitors.
Somatic mutations in early onset luminal breast cancer.
Somatic mutations in the BRCA1 gene in Chinese sporadic breast and ovarian cancer.
Somatic mutations in the BRCA1 gene in Chinese women with sporadic breast cancer.
Somatic mutations in the BRCA1 gene in sporadic ovarian tumours.
Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies.
Somatic variants of potential clinical significance in the tumors of BRCA phenocopies.
Some facts and thoughts: p73 as a tumor suppressor gene in the network of tumor suppressors.
Sorafenib targets the mitochondrial electron transport chain complexes and ATP synthase to activate the PINK1-Parkin pathway and modulate cellular drug response.
Sorting Nexin 5 Controls Head and Neck Squamous Cell Carcinoma Progression by Modulating FBW7.
SOX13/TRIM11/YAP axis promotes the proliferation, migration and chemoresistance of anaplastic thyroid cancer.
Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer.
Specialist oncological surgery for removal of the ovaries and fallopian tubes in BRCA1 and BRCA2 pathogenic variant carriers may reduce primary peritoneal cancer risk to very low levels.
Speckle-type POZ protein is negatively associated with malignancies and inhibits cell proliferation and migration in liver cancer.
Speckle-type POZ protein suppresses lipid accumulation and prostate cancer growth by stabilizing fatty acid synthase.
Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer.
Spectrum and Prevalence of Pathogenic Variants in Ovarian Cancer Susceptibility Genes in a Group of 333 Patients.
Spectrum of Germline BRCA1 and BRCA2 Variants Identified in 2351 Ovarian and Breast Cancer Patients Referring to a Reference Cancer Hospital of Rome.
Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
Spectrum of tumors in the families with Hereditary Breast Ovarian Cancer syndrome carrying germline mutations in BRCA1 and 2 genes.
Speed matters: How subtle changes in DNA end resection rate affect repair.
Spinophilin acts as a tumor suppressor by regulating Rb phosphorylation.
Spinophilin loss contributes to tumorigenesis in vivo.
Spinophilin loss correlates with poor patient prognosis in advanced stages of colon carcinoma.
Spinophilin: a new tumor suppressor at 17q21.
Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis.
Splice-site mutation of the p53 gene in a family with hereditary breast-ovarian cancer.
Spliceogenic analysis of BRCA1 c.439T>C (rs794727800) variant by High Resolution Melting Analysis.
Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells.
SPOP E3 Ubiquitin Ligase Adaptor Promotes Cellular Senescence by Degrading the SENP7 deSUMOylase.
SPOP promotes CDCA5 degradation to regulate prostate cancer progression via the AKT pathway.
SPOP regulates prostate epithelial cell proliferation and promotes ubiquitination and turnover of c-MYC oncoprotein.
Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway.
SPSB1 enhances ovarian cancer cell survival by destabilizing p21.
Squamous differentiation in surgically resected malignant pleural mesothelioma with neoadjuvant chemotherapy.
Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells.
Stage of breast cancers found during the surveillance of women with a familial or hereditary risk.
STAT3 and STAT5 Activation in Solid Cancers.
State Institution "National Research Center for Radiation Medicine of the National Academy of Medical Sciences of Ukraine" - research activities and scientific advance in 2014.
State of the Art: Advances in Malignant Pleural Mesothelioma in 2017.
Stathmin expression associates with vascular and immune responses in aggressive breast cancer subgroups.
Stem cell therapy for hereditary breast cancer.
Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes.
Stimulation of lactate receptor (HCAR1) affects cellular DNA repair capacity.
STRAD in Peutz-Jeghers syndrome and sporadic cancers.
Strategies for H-score normalization of preanalytical technical variables with potential utility to immunohistochemical-based biomarker quantitation in therapeutic reponse diagnostics.
Strategies for ovarian cancer prevention.
Strategies for the Use of Poly(adenosine diphosphate ribose) Polymerase (PARP) Inhibitors in Cancer Therapy.
Strong feature sets from small samples.
Strong founder effects in BRCA1 mutation carrier breast cancer patients from Latvia. Mutation in brief no. 258. Online.
Strong preference of BRCA1 protein to topologically constrained non-B DNA structures.
Structural analysis of BRCA1 reveals modification hotspot.
Structural and biochemical characterization of TRAF5 from Notothenia coriiceps and its implications in fish immune cell signaling.
Structural Basis for Bivalent Smac-Mimetics Recognition in the IAP Protein Family.
Structural basis for cell cycle checkpoint control by the BRCA1-CtIP complex.
Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL.
Structural Basis of BRCC36 Function in DNA Repair and Immune Regulation.
Structural basis of DDB1-and-Cullin 4-associated Factor 1 (DCAF1) recognition by merlin/NF2 and its implication in tumorigenesis by CD44-mediated inhibition of merlin suppression of DCAF1 function.
Structural basis of homologous recombination.
Structural basis of phosphopeptide recognition by the BRCT domain of BRCA1.
Structural basis to stabilize the domain motion of BARD1-ARD BRCT by CstF50.
Structural Characterization of the Trimerization of TRAF6 Protein Through Molecular Dynamics Simulations.
Structural consequences of a cancer-causing BRCA1-BRCT missense mutation.
Structural determinants of BRCA1 translational regulation.
Structural evidence for direct interactions between the BRCT domains of human BRCA1 and a phospho-peptide from human ACC1.
Structural requirements for the BARD1 tumor suppressor in chromosomal stability and homology-directed DNA repair.
Structure activity relationship of plumbagin in BRCA1 related cancer cells.
Structure and expression of variant BRCA2a lacking the transactivation domain.
Structure and function of Parkin E3 ubiquitin ligase reveals aspects of RING and HECT ligases.
Structure and mechanism of BRCA1 BRCT domain recognition of phosphorylated BACH1 with implications for cancer.
Structure based virtual screening of natural products to disrupt the structural integrity of TRAF6 C-terminal domain homotrimer.
Structure meets function--centrosomes, genome maintenance and the DNA damage response.
Structure of a BRCA1-BARD1 heterodimeric RING-RING complex.
Structure of a second BRCT domain identified in the nijmegen breakage syndrome protein Nbs1 and its function in an MDC1-dependent localization of Nbs1 to DNA damage sites.
Structure of High-Risk Papillomavirus 31 E6 Oncogenic Protein and Characterization of E6/E6AP/p53 Complex Formation.
Structure of the BRCT repeats of BRCA1 bound to a BACH1 phosphopeptide: implications for signaling.
Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs.
Structure-based assessment of BRCA1 and BRCA2 mutations in a small Spanish population.
Structure-based assessment of missense mutations in human BRCA1: implications for breast and ovarian cancer predisposition.
Structure-based design of covalent siah inhibitors.
Structure-based functional analysis of BRCA1 RING domain variants: Concordance of computational mutagenesis, experimental assay, and clinical data.
Structure-Function Of The Tumor Suppressor BRCA1.
STUB1 suppresseses tumorigenesis and chemoresistance through antagonizing YAP1 signaling.
Studies of ATM Kinase Activity Using Engineered ATM Sensitive to ATP Analogues (ATM-AS).
Studies on selected molecular factors in endometrial cancers.
Study designs in genetic epidemiology.
Study of methylation levels of parkin gene promoter in Parkinson's disease patients.
Study of Selected BRCA1, BRCA2, and PIK3CA Mutations in Benign and Malignant Lesions of Anogenital Mammary-Like Glands.
Studying Therapy Response and Resistance in Mouse Models for BRCA1-Deficient Breast Cancer.
Subcellular dynamics of the VHL tumor suppressor: on the move for HIF degradation.
Subcellular localization and analysis of apparent 180-kDa and 220-kDa proteins of the breast cancer susceptibility gene, BRCA1.
Sublocalization of smallest common regions of deletion on chromosome 17q12-q23 in sporadic primary breast-tumors.
Substantial batch effects in TCGA exome sequences undermine pan-cancer analysis of germline variants.
Substitution of aspartic acid with glutamic acid at position 67 of the BRCA1 RING domain retains ubiquitin ligase activity and zinc(II) binding with a reduced transition temperature.
Substrates of the BRCA1-Dependent Ubiquitin Ligase.
Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor.
Subtypes of familial breast tumours revealed by expression and copy number profiling.
Summaries for patients. The cost-effectiveness of preventive strategies for breast and ovarian cancer for women with BRCA1 or BRCA2 mutations.
SUMO boosts the DNA damage response barrier against cancer.
SUMO-1 modification of Mdm2 prevents its self-ubiquitination and increases Mdm2 ability to ubiquitinate p53.
SUMO1 negatively regulates BRCA1-mediated transcription, via modulation of promoter occupancy.
SUMOylation proteins in breast cancer.
Supplemental screening ultrasound increases cancer detection yield in BRCA1 and BRCA2 mutation carriers.
Suppression of APC/CCdh1 has subtype specific biological effects in acute myeloid leukemia.
Suppression of BRCA1 sensitizes cells to proteasome inhibitors.
Suppression of DNA Polymerase ? Activity Is Synthetically Lethal in BRCA1-Deficient Cells.
Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors.
Suppression of malignant phenotype in a human prostate cancer cell line by fragments of normal chromosomal region 17q.
Suppression of tumorigenicity of breast cancer cells by transfer of human chromosome 17 does not require transferred BRCA1 and p53 genes.
Surmounting cancer drug resistance: New insights from the perspective of N6-methyladenosine RNA modification.
Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status.
Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.
Surveillance of women at increased risk of breast cancer using mammography and clinical breast examination: Further evidence of benefit.
Surveillance of Women with the BRCA1 or BRCA2 Mutation by Using Biannual Automated Breast US, MR Imaging, and Mammography.
Survey of differentially methylated promoters in prostate cancer cell lines.
Survival and recurrence after breast cancer in BRCA1/2 mutation carriers.
Survival and tumor characteristics of German hereditary breast cancer patients.
Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1.
Survival in early-onset BRCA1 breast-cancer patients. Institut Curie Breast Cancer Group.
Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group.
Survival in prospectively ascertained familial breast cancer: analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy.
Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden.
Survival of BRCA1 negative ovarian cancer patients based on family history.
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.
Sustained Complete Response to Cytotoxic Therapy and the PARP Inhibitor Veliparib in Metastatic Castration-Resistant Prostate Cancer - A Case Report.
Switch of FANCL, a key FA-BRCA component, between tumor suppressor and promoter by alternative splicing.
Synaptonemal Complex Protein 3 Transcript Analysis in Breast Cancer.
Synchronous ovarian dysgerminoma and breast carcinoma in a patient with positive immunostain of BRCA1.
Synergistic anticancer action of quercetin and curcumin against triple-negative breast cancer cell lines.
Synergistic apoptotic effects in cancer cells by the combination of CLK and Bcl-2 family inhibitors.
Synergistic Effect of Trabectedin and Olaparib Combination Regimen in Breast Cancer Cell Lines.
Synergistic effects of IAP inhibitor LCL161 and paclitaxel on hepatocellular carcinoma cells.
Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition.
Synergistic Therapeutic Effect of Cisplatin and Phosphatidylinositol 3-Kinase (PI3K) Inhibitors in Cancer Growth and Metastasis of Brca1 Mutant Tumors.
Synthetic lethal targeting of DNA double strand break repair deficient cells by human apurinic/apyrimidinic endonuclease (APE1) inhibitors.
Synthetic lethal targeting of RNF20 through PARP1 silencing and inhibition.
Synthetic lethal therapies for cancer: what's next after PARP inhibitors?
Synthetic lethality between CCNE1 amplification and loss of BRCA1.
Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent.
Synthetic lethality of PARP inhibition in BRCA-network disrupted tumor cells is associated with interferon pathway activation and enhanced by interferon-?
Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations.
Synthetic lethality: the road to novel therapies for breast cancer.
Systematic screening reveals a role for BRCA1 in the response to transcription-associated DNA damage.
Systemic treatment strategies for triple-negative breast cancer.
Systemic VHL gene functions and the VHL disease.
Systems consequences of amplicon formation in human breast cancer.
SYT-SSX1 (Synovial Sarcoma Translocated) regulates PIASy to cause overexpression of NCOA3.
Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations.
TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients.
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
Talking across generations: Family communication about BRCA1 and BRCA2 genetic cancer risk.
Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group.
Tandem duplication of chromosomal segments is common in ovarian and breast cancer genomes.
Targeted capture-based NGS is superior to multiplex PCR-based NGS for hereditary BRCA1 and BRCA2 gene analysis in FFPE tumor samples.
Targeted degradation of proteins by small molecules: a novel tool for functional proteomics.
Targeted disruption of Brca1 in restricted compartments of the mouse mammary epithelia.
Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos.
Targeted next-generation sequencing identifies distinct clinicopathologic and molecular entities of intraductal papillary neoplasms of the bile duct.
Targeted Proteomic Analyses of Histone H4 Acetylation Changes Associated with Homologous-Recombination-Deficient High-Grade Serous Ovarian Carcinomas.
Targeted sequencing to discover germline variants in the BRCA1 and BRCA2 genes in a Russian population and their association with breast cancer risk.
Targeted therapy for cancer using PARP inhibitors.
Targeted Vaccination against Human ?-Lactalbumin for Immunotherapy and Primary Immunoprevention of Triple Negative Breast Cancer.
Targeting anthracyclines in early breast cancer: new candidate predictive biomarkers emerge.
Targeting BRCA1 localization to augment breast tumor sensitivity to poly(ADP-ribose) polymerase inhibition.
Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy.
Targeting cell membrane HDM2: A novel therapeutic approach for acute myeloid leukemia.
Targeting Cul3-scaffold E3 ligase complex via KLHL substrate adaptors for cancer therapy.
Targeting DNA repair in breast cancer: A clinical and translational update.
Targeting Hedgehog Signalling through the Ubiquitylation Process: The Multiple Roles of the HECT-E3 Ligase Itch.
Targeting inhibitor of apoptosis proteins by Smac mimetic elicits cell death in poor prognostic subgroups of chronic lymphocytic leukemia.
Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer.
Targeting inhibitors of apoptosis proteins (IAPs) for new breast cancer therapeutics.
Targeting Nrf2 in healthy and malignant ovarian epithelial cells: Protection versus promotion.
Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.
Targeting on poly(ADP-ribose) polymerase activity with DNA-damaging hybrid lactam-steroid alkylators in wild-type and BRCA1-mutated ovarian cancer cells.
Targeting Replicative Stress and DNA Repair by Combining PARP and Wee1 Kinase Inhibitors Is Synergistic in Triple Negative Breast Cancers with Cyclin E or BRCA1 Alteration.
Targeting RFWD2 as an Effective Strategy to Inhibit Cellular Proliferation and Overcome Drug Resistance to Proteasome Inhibitor in Multiple Myeloma.
Targeting Tankyrase 1 as a therapeutic strategy for BRCA-associated cancer.
Targeting the BRCA1/2 tumor suppressors.
Targeting the DNA Damage Response in Cancer.
Targeting the DNA damage response in oncology: past, present and future perspectives.
Targeting the DNA Double Strand Breaks Repair for Cancer Therapy.
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Targeting the DNA repair defect of BRCA tumours.
Targeting the E3 ubiquitin casitas B-lineage lymphoma decreases osteosarcoma cell growth and survival and reduces tumorigenesis.
Targeting the E3 Ubiquitin Ligase PJA1 Enhances Tumor-Suppressing TGF-? Signaling.
Targeting the Hsp90 C-terminal domain to induce allosteric inhibition and selective client downregulation.
Targeting the lysosome by an aminomethylated Riccardin D triggers DNA damage through cathepsin B-mediated degradation of BRCA1.
Targeting the molecular defect in BRCA-deficient tumors for cancer therapy.
Targeting the NPL4 Adaptor of p97/VCP Segregase by Disulfiram as an Emerging Cancer Vulnerability Evokes Replication Stress and DNA Damage while Silencing the ATR Pathway.
Targeting the nucleotide salvage factor DNPH1 sensitizes BRCA-deficient cells to PARP inhibitors.
Targeting the oncogenic E3 ligase Skp2 in prostate and breast cancer cells with a novel energy restriction-mimetic agent.
Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy.
Targeting the PIAS1 SUMO ligase pathway to control inflammation.
Targeting the von Hippel-Lindau E3 Ubiquitin Ligase Using Small Molecules To Disrupt the VHL/HIF-1? Interaction.
Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON.
TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumors.
TCTP increases stability of hypoxia-inducible factor 1? by interaction with and degradation of the tumour suppressor VHL.
Teaching the basics of repurposing mitochondria-targeted drugs: From Parkinson's disease to cancer and back to Parkinson's disease.
Telephone Genetic Counseling for High-Risk Women Undergoing BRCA1 and BRCA2 Testing: Rationale and Development of a Randomized Controlled Trial.
Telephone genetic counseling for high-risk women undergoing BRCA1 and BRCA2 testing: rationale and development of a randomized controlled trial.
Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer.
Telomere length shows no association with BRCA1 and BRCA2 mutation status.
Ten genes for inherited breast cancer.
Ten novel BRCA1 and BRCA2 mutations in breast and/or ovarian cancer families from northern Germany.
Testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes: a decision analysis.
TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms.
TGF-? activates APC through Cdh1 binding for Cks1 and Skp2 proteasomal destruction stabilizing p27kip1 for normal endometrial growth.
TGF-? promotes PI3K-AKT signaling and prostate cancer cell migration through the TRAF6-mediated ubiquitylation of p85?.
TGF-beta1 inhibits BRCA1 expression through a pathway that requires pRb.
TGF-beta1-induced expression of human Mdm2 correlates with late-stage metastatic breast cancer.
The "portrait" of hereditary breast cancer.
The 185delAG BRCA1 mutation originated before the dispersion of Jews in the diaspora and is not limited to Ashkenazim.
The 2014 society of surgical oncology susan g. Komen for the cure symposium: triple-negative breast cancer.
The 3' untranslated region C > T polymorphism of prohibitin is a breast cancer risk modifier in Polish women carrying a BRCA1 mutation.
The 5' end of the BRCA1 gene lies within a duplicated region of human chromosome 17q21.
The ability of TRIM3 to induce growth arrest depends on RING-dependent E3 ligase activity.
The accumulation of specific amplifications characterizes two different genomic pathways of evolution of familial breast tumors.
The Akt DUBbed InAktive.
The AMPK-Parkin axis negatively regulates necroptosis and tumorigenesis by inhibiting the necrosome.
The anaphase-promoting complex/cyclosome is an E3 ubiquitin ligase for Mdm2.
The Angelina effect: immediate reach, grasp, and impact of going public.
The anti-proliferative effects of 1alpha,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression.
The antiestrogenic effects of black cohosh on BRCA1 and steroid receptors in breast cancer cells.
The antitumorigenic roles of BRCA1-BARD1 in DNA repair and replication.
The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity.
The association between BRCA1 gene polymorphism and cancer risk: a meta-analysis.
The association between smoking and cancer incidence in BRCA1 and BRCA2 mutation carriers.
The association between the methylation frequency of BRCA1/2 gene promoter and occurrence and prognosis of breast carcinoma: A meta-analysis.
The association of a single-nucleotide variant in the microRNA-146a with advanced colorectal cancer prognosis.
The ATM-Chk2 and ATR-Chk1 Pathways in DNA Damage Signaling and Cancer.
The autophagy inhibitor chloroquine targets cancer stem cells in triple negative breast cancer by inducing mitochondrial damage and impairing DNA break repair.
The basal phenotype of BRCA1-related breast cancer: past, present and future.
The basal-like mammary carcinomas induced by Brca1 or Bard1 inactivation implicate the BRCA1/BARD1 heterodimer in tumor suppression.
The basis for somatic gene therapy of cancer.
The Bcl-3 oncoprotein acts as a bridging factor between NF-kappaB/Rel and nuclear co-regulators.
The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
The biological effects and clinical implications of BRCA mutations: where do we go from here?
The BRCA Tumor Suppressor Network in Chromosome Damage Repair by Homologous Recombination.
The BRCA1 3'-UTR: 5711+421T/T_5711+1286T/T Genotype Is a Possible Breast and Ovarian Cancer Risk Factor.
The Brca1 and Brca2 proteins and tumor pathogenesis.
The BRCA1 Breast Cancer Suppressor: Regulation of Transport, Dynamics, and Function at Multiple Subcellular Locations.
The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium.
The BRCA1 c.4096+3A>G Variant Displays Classical Characteristics of Pathogenic BRCA1 Mutations in Hereditary Breast and Ovarian Cancers, But Still Allows Homozygous Viability.
The BRCA1 E3 Ubiquitin Ligase Controls Centrosome Dynamics.
The BRCA1 exon 13 duplication: clinical characteristics of 22 families in Northern Sweden.
The BRCA1 Methylation and PD-L1 Expression in Sporadic Ovarian Cancer.
The BRCA1 RING and BRCT domains cooperate in targeting BRCA1 to ionizing radiation-induced nuclear foci.
The BRCA1 suppressor hypothesis: an explanation for the tissue-specific tumor development in BRCA1 patients.
The BRCA1 syndrome and other inherited breast or breast-ovarian cancers in a Norwegian prospective series.
The BRCA1 Tumor Suppressor Binds to Inositol 1,4,5-Trisphosphate Receptors to Stimulate Apoptotic Calcium Release.
The BRCA1-?11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin.
The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations.
The BRCA1-dependent ubiquitin ligase, gamma-tubulin, and centrosomes.
The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia.
The BRCA1-interacting protein Abraxas is required for genomic stability and tumor suppression.
The BRCA1-RAP80 Complex Regulates DNA Repair Mechanism Utilization by Restricting End Resection.
The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers.
The BRCA1/BARD1 heterodimer assembles polyubiquitin chains through an unconventional linkage involving lysine residue K6 of ubiquitin.
The BRCA1/BARD1 heterodimer, a tumor suppressor complex with ubiquitin E3 ligase activity.
The BRCA1/BARD1-interacting protein OLA1 functions in centrosome regulation.
The BRCA1/BRCA2/Rad51 complex is a prognostic and predictive factor in early breast cancer.
The BRCA2 c.9004G>A (E2003K) variant is likely pathogenic and recurs in breast and/or ovarian cancer families of French Canadian descent.
The BRCA2 is a histone acetyltransferase.
The BRCA2 polymorphic stop codon: stuff or nonsense?
The BRCT Domains of the BRCA1 and BARD1 Tumor Suppressors Differentially Regulate Homology-Directed Repair and Stalled Fork Protection.
The BRCT regions of tumor suppressor BRCA1 and of XRCC1 show DNA end binding activity with a multimerizing feature.
The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin.
The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells.
The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers.
The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype.
The C-terminal (BRCT) domains of BRCA1 interact in vivo with CtIP, a protein implicated in the CtBP pathway of transcriptional repression.
The cancer connection: BRCA1 and BRCA2 tumor suppression in mice and humans.
The cancer genetics and pathology of male breast cancer.
The cancer-predisposing mutation C61G disrupts homodimer formation in the NH2-terminal BRCA1 RING finger domain.
The CD44+/CD24- phenotype is enriched in basal-like breast tumors.
The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K.
The CDK1 inhibitor RO3306 improves the response of BRCA-pro?cient breast cancer cells to PARP inhibition.
The Cell of Origin of BRCA1 Mutation-associated Breast Cancer: A Cautionary Tale of Gene Expression Profiling.
The cellular abundance of the essential transcription termination factor TTF-I regulates ribosome biogenesis and is determined by MDM2 ubiquitinylation.
The central region of BRCA1 binds preferentially to supercoiled DNA.
The CHK2-BRCA1 tumour suppressor pathway ensures chromosomal stability in human somatic cells.
The Clinical and Pathological Profile of BRCA1 Gene Methylated Breast Cancer Women: A Meta-Analysis.
The clinical development of inhibitors of poly(ADP-ribose) polymerase.
The clinical impact of MRI screening for BRCA mutation carriers: the first report in Japan.
The clinical management of BRCA1 and BRCA2 mutation carriers.
The Clinical Significance of Unknown Sequence Variants in BRCA Genes.
The Clinical Utility of Next Generation Sequencing Results in a Community-Based Hereditary Cancer Risk Program.
The clinicopathological and MRI features of patients with BRCA1/2 mutations in familial breast cancer.
The co-regulatory networks of tumor suppressor genes, oncogenes, and miRNAs in colorectal cancer.
The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.
The combination of thymoquinone and paclitaxel shows anti-tumor activity through the interplay with apoptosis network in triple-negative breast cancer.
The complex genetic landscape of familial breast cancer.
The complex relationship between BRCA1 and ERalpha in hereditary breast cancer.
The contribution of breast cancer pathology to statistical models to predict mutation risk in BRCA carriers.
The contribution of germline predisposition gene mutations to clinical subtypes of invasive breast cancer from a clinical genetic testing cohort.
The contribution of inherited factors to the clinicopathological features and behavior of breast cancer.
The correlation of mammographic-and histologic patterns of breast cancers in BRCA1 gene mutation carriers, compared to age-matched sporadic controls.
The CRL3BTBD9 E3 ubiquitin ligase complex targets TNFAIP1 for degradation to suppress cancer cell migration.
The CRM1 nuclear export protein in normal development and disease.
The CUL4B/AKT/?-Catenin Axis Restricts the Accumulation of Myeloid-Derived Suppressor Cells to Prohibit the Establishment of a Tumor-Permissive Microenvironment.
The dark matter of the cancer genome: aberrations in regulatory elements, untranslated regions, splice sites, non-coding RNA and synonymous mutations.
The DeltaNp63 proteins are key allies of BRCA1 in the prevention of basal-like breast cancer.
The deubiquitinase USP10 restores PTEN activity and inhibits non-small cell lung cancer cell proliferation.
The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2.
The disease sites of female genital cancers of BRCA1/2-associated hereditary breast and ovarian cancer: a retrospective study.
The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer.
The DNA resection protein CtIP promotes mammary tumorigenesis.
The double life of MULE in preeclamptic and IUGR placentae.
The downregulation of BAP1 expression by BCR-ABL reduces the stability of BRCA1 in chronic myeloid leukemia.
The Drosophila F-box protein Slimb controls dSmurf protein turnover to regulate the Hippo pathway.
The E3 ligase C-CBL inhibits cancer cell migration by neddylating the proto-oncogene c-Src.
The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells.
The E3 ligase HACE1 is a critical chromosome 6q21 tumor suppressor involved in multiple cancers.
The E3 ligase HUWE1 mediates TGFBR2 ubiquitination and promotes gastric cancer cell proliferation, migration, and invasion.
The E3 ligase PARC mediates the degradation of cytosolic cytochrome c to promote survival in neurons and cancer cells.
The E3 Ligase RING1 Targets p53 for Degradation and Promotes Cancer Cell Proliferation and Survival.
The E3 ligase RNF43 inhibits Wnt signaling downstream of mutated ?-catenin by sequestering TCF4 to the nuclear membrane.
The E3 ligase UBR5 regulates gastric cancer cell growth by destabilizing the tumor suppressor GKN1.
The E3 Ubiquitin Ligase ARIH1 Protects against Genotoxic Stress by Initiating a 4EHP-Mediated mRNA Translation Arrest.
The E3 Ubiquitin Ligase Asb2? in T Helper 2 Cells Negatively Regulates Antitumor Immunity in Colorectal Cancer.
The E3 ubiquitin ligase Cbl-b inhibits tumor growth in multidrug-resistant gastric and breast cancer cells.
The E3 ubiquitin ligase component, Cereblon, is an evolutionarily conserved regulator of Wnt signaling.
The E3 ubiquitin ligase Itch regulates tumor suppressor protein RASSF5/NORE1 stability in an acetylation-dependent manner.
The E3 ubiquitin ligase NEDD4 mediates cell migration signaling of EGFR in lung cancer cells.
The E3 ubiquitin ligase RNF146 promotes colorectal cancer by activating the Wnt/?-catenin pathway via ubiquitination of Axin1.
The E3 Ubiquitin Ligase TRAF6 Intercedes in Starvation-Induced Skeletal Muscle Atrophy through Multiple Mechanisms.
The E3 ubiquitin ligase UBR5 regulates centriolar satellite stability and primary cilia.
The E3 ubiquitin ligase WWP1 sustains the growth of acute myeloid leukaemia.
The E3 ubiquitin-protein ligase MDM2 is a novel interactor of the von Hippel-Lindau tumor suppressor.
The effect of disease-associated HRPT2 mutations on splicing.
The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells.
The effect of marrow stromal cells on TRAF6 expression levels in myeloma cells.
The effect of the histone deacetylase inhibitor M344 on BRCA1 expression in breast and ovarian cancer cells.
The effects of BRCA1 expression on the chemosensitivity of gastric cancer cells to platinum agents.
The effects of BRCA1 missense variants V1804D and M1628T on transcriptional activity.
The effects of nucleoside analogues on promoter methylation of selected tumor suppressor genes in MCF-7 and MDA-MB-231 breast cancer cell lines.
The Eighth AACR American Cancer Society Award lecture on cancer epidemiology and prevention. Genetically tailored preventive strategies: an effective plan for the twenty-first century? American Association for Cancer Research.
The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.
The Emerging Role of PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer.
The Emerging Role of Poly(ADP-Ribose) Polymerase Inhibitors in Cancer Treatment.
The emerging role of SPOP protein in tumorigenesis and cancer therapy.
The emerging, multifaceted role of mitophagy in cancer and cancer therapeutics.
The endonuclease EEPD1 mediates synthetic lethality in RAD52-depleted BRCA1 mutant breast cancer cells.
The epigenetic regulator UHRF1 promotes ubiquitination-mediated degradation of the tumor-suppressor protein promyelocytic leukemia protein.
The epigenetic regulators Bmi1 and Ring1B are differentially regulated in pancreatitis and pancreatic ductal adenocarcinoma.
The ERK signaling target RNF126 regulates anoikis resistance in cancer cells by changing the mitochondrial metabolic flux.
The established and future biomarkers of malignant pleural mesothelioma.
The Evolution, Functions and Applications of the Breast Cancer Genes BRCA1 and BRCA2.
The expanding role of yeast in cancer research and diagnosis: insights into the function of the oncosuppressors p53 and BRCA1/2.
The expression of BRCA1, P53, KAI1, and Nm23 in ovaries of BRCA1 mutation carriers after prophylactic adnexectomy.
The expression of DBC1/CCAR2 is associated with poor prognosis of ovarian carcinoma.
The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer.
The Expression of VHL (Von Hippel-Lindau) After Traumatic Spinal Cord Injury and Its Role in Neuronal Apoptosis.
The F-box protein FBXO44 mediates BRCA1 ubiquitination and degradation.
The Fanconi Anemia Pathway in Cancer.
The Fanconi anemia ubiquitin E3 ligase complex as an anti-cancer target.
The Fbw7/hCDC4 tumor suppressor targets pro-proliferative factor KLF5 for ubiquitination and degradation through multiple phosphodegron motifs.
The Fbx4 tumor suppressor regulates cyclin D1 accumulation and prevents neoplastic transformation.
The FBXW2-MSX2-SOX2 axis regulates stem cell property and drug resistance of cancer cells.
The FBXW7-SHOC2-Raptor Axis Controls the Cross-Talks between the RAS-ERK and mTORC1 Signaling Pathways.
The founder mutations in the BRCA1, BRCA2, and ATM genes in Moroccan Jewish women with breast cancer.
The fragile histidine triad/common chromosome fragile site 3B locus and repair-deficient cancers.
The frequency of cancer predisposition gene mutations in hereditary breast and ovarian cancer patients in Taiwan: From BRCA1/2 to multi-gene panels.
The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators.
The Function of BARD1 in Centrosome Regulation in Cooperation with BRCA1/OLA1/RACK1.
The functional analysis of Cullin 7 E3 ubiquitin ligases in cancer.
The functional BRCA1 rs799917 genetic polymorphism is associated with gastric cancer risk in a Chinese Han population.
The Functional Hallmarks of Cancer Predisposition Genes.
The Functional Landscape of Patient-Derived RNF43 Mutations Predicts Sensitivity to Wnt Inhibition.
The functional role of RNF113A in cervical carcinogenesis.
The functions of breast cancer susceptibility gene 1 (BRCA1) product and its associated proteins.
The future of breast cancer systemic therapy: the next 10 years.
The G1 phase E3 ubiquitin ligase TRUSS that gets deregulated in human cancers is a novel substrate of the S-phase E3 ubiquitin ligase Skp2.
The gene for hereditary breast-ovarian cancer, BRCA1, maps distal to EDH17B2 in chromosome region 17q12-q21.
The Genetic Analyses of French Canadians of Quebec Facilitate the Characterization of New Cancer Predisposing Genes Implicated in Hereditary Breast and/or Ovarian Cancer Syndrome Families.
The genetic basis of breast cancer and its clinical implications.
The genetic components of susceptibility to breast cancer in the rat.
The genetic epidemiology of BRCA1. Breast Cancer Linkage Consortium.
The Genetic Landscape of Malignant Pleural Mesothelioma: Results from Massively Parallel Sequencing.
The genetics of breast cancer susceptibility.
The genetics of breast cancer: risk factors for disease.
THe genetics of familial breast cancer.
The genetics of inherited breast cancer.
The genetics of uterine leiomyomata: what clinicians need to know.
The Genomic Profile of Pregnancy-Associated Breast Cancer: A Systematic Review.
The HECT E3 Ligase E6AP/UBE3A as a Therapeutic Target in Cancer and Neurological Disorders.
The HECTD3 E3 ubiquitin ligase facilitates cancer cell survival by promoting K63-linked polyubiquitination of caspase-8.
The HIF pathway: implications for patterns of gene expression in cancer.
The Hippo tumor pathway promotes TAZ degradation by phosphorylating a phosphodegron and recruiting the SCFbeta-TrCP E3 ligase.
The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study.
The histone and non-histone methyllysine reader activities of the UHRF1 tandem Tudor domain are dispensable for the propagation of aberrant DNA methylation patterning in cancer cells.
The histone H2B-specific ubiquitin ligase RNF20/hBRE1 acts as a putative tumor suppressor through selective regulation of gene expression.
The Histone Variant MacroH2A1 Is a BRCA1 Ubiquitin Ligase Substrate.
The hormone-bound vitamin D receptor enhances the FBW7-dependent turnover of NF-?B subunits.
The HRAS1 minisatellite locus and risk of ovarian cancer.
The human insulin-like growth factor-binding protein 4 gene maps to chromosome region 17q12-q21.1 and is close to the gene for hereditary breast-ovarian cancer.
The ICR639 CPG NGS validation series: A resource to assess analytical sensitivity of cancer predisposition gene testing.
The ICR96 exon CNV validation series: a resource for orthogonal assessment of exon CNV calling in NGS data.
The identification of a novel role for BRCA1 in regulating RNA polymerase I transcription.
The IGF Hormonal Network in Endometrial Cancer: Functions, Regulation, and Targeting Approaches.
The impact of a cascade testing video on recipients' knowledge, cognitive message processing, and affective reactions: A formative evaluation.
The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation.
The important molecular markers on chromosome 17 and their clinical impact in breast cancer.
The incidence of cardiomyopathy in BRCA1 and BRCA2 mutation carriers after anthracycline-based adjuvant chemotherapy.
The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study.
The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib.
The influence of psychological distress on use of genetic testing for cancer risk.
The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss.
The Inhibition and Treatment of Breast Cancer with Poly (ADP-ribose) Polymerase (PARP-1) Inhibitors.
The initiation factor eIF3-f is a major target for atrogin1/MAFbx function in skeletal muscle atrophy.
The interaction between CtIP and BRCA1 is not essential for resection-mediated DNA repair or tumor suppression.
The Interplay among PINK1/PARKIN/Dj-1 Network during Mitochondrial Quality Control in Cancer Biology: Protein Interaction Analysis.
The interplay between BRCA1 and 53BP1 influences death, aging, senescence and cancer.
The joint effect of smoking and AIB1 on breast cancer risk in BRCA1 mutation carriers.
The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers.
The lack of clinical value of peritoneal washing cytology in high risk patients undergoing risk-reducing salpingo-oophorectomy: a retrospective study and review.
The LIM domain protein LMO4 interacts with the cofactor CtIP and the tumor suppressor BRCA1 and inhibits BRCA1 activity.
The Links between Parkinson's Disease and Cancer.
The majority of 22 Dutch high-risk breast cancer families are due to either BRCA1 or BRCA2.
The management of familial breast cancer.
The Mdm2 RING domain C-terminus is required for supramolecular assembly and ubiquitin ligase activity.
The miR-205-5p/BRCA1/RAD17 Axis Promotes Genomic Instability in Head and Neck Squamous Cell Carcinomas.
The molecular basis of cytotoxicity of ?-spinasterol from Ganoderma resinaceum: Induction of apoptosis and overexpression of p53 in breast and ovarian cancer cell lines.
The molecular basis of ovarian cancer.
The molecular basis of radiosensitivity and chemosensitivity in the treatment of breast cancer.
The molecular genetics of breast cancer and targeted therapy.
The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications.
The MSP-RON axis stimulates cancer cell growth in models of triple negative breast cancer.
The MULE/HUWE1 E3 ubiquitin ligase is a tumor suppressor.
The multiple nuclear functions of BRCA1: transcription, ubiquitination and DNA repair.
The nanotube express: Delivering a stapled peptide to the cell surface.
The Neddylation-Cullin 2-RBX1 E3 Ligase Axis Targets Tumor Suppressor RhoB for Degradation in Liver Cancer.
The noncanonical NF-?B pathway.
The nonreceptor tyrosine kinase c-Src attenuates SCF(?-TrCP) E3-ligase activity abrogating Taz proteasomal degradation.
The nonsense-mediated mRNA decay pathway triggers degradation of most BRCA1 mRNAs bearing premature termination codons.
The Norwegian founder mutations in BRCA1: high penetrance confirmed in an incident cancer series and differences observed in the risk of ovarian cancer.
The occurrence of germline BRCA1 and BRCA2 sequence alterations in Slovenian population.
The oncocytic subtype is genetically distinct from other pancreatic intraductal papillary mucinous neoplasm subtypes.
The oncogenic E3 ligase TRIP12 suppresses epithelial-mesenchymal transition (EMT) and mesenchymal traits through ZEB1/2.
The Oncogenic Properties Of The Redox Inflammatory Protein Inducible Nitric Oxide Synthase In ER(-) Breast Cancer.
The Oncormed approach to genetic testing.
The ordering of expression among a few genes can provide simple cancer biomarkers and signal BRCA1 mutations.
The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer.
The p53 response to DNA damage.
The p53 target gene TRIM22 directly or indirectly interacts with the translation initiation factor eIF4E and inhibits the binding of eIF4E to eIF4G.
The p53-Mdm2 network in progenitor cell expansion during mouse postnatal development.
The p73 tumor suppressor is targeted by Pirh2 RING finger E3 ubiquitin ligase for the proteasome-dependent degradation.
The pathology of familial breast cancer: Clinical and genetic counselling implications of breast cancer pathology.
The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2.
The pathology of familial breast cancer: How do the functions of BRCA1 and BRCA2 relate to breast tumour pathology?
The pathology of familial breast cancer: Immunohistochemistry and molecular analysis.
The pathology of familial breast cancer: Morphological aspects.
The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.
The pathology of hereditary breast cancer.
The pathology of inherited breast cancer.
The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer.
The Pink Underside: The Commercialization of Medical Risk Assessment and Decision-Making Tools for Hereditary Breast Cancer Risk.
The Polycomb group protein RING1B is overexpressed in ductal breast carcinoma and is required to sustain FAK steady state levels in breast cancer epithelial cells.
The Polycomb proteins RING1B and EZH2 repress the tumoral pro-inflammatory function in metastasizing primary cutaneous squamous cell carcinoma.
The Potential Contribution of BRCA Mutations to Early Onset and Familial Breast Cancer in Uzbekistan.
The potential for aromatase inhibition in breast cancer prevention.
The potential of exploiting DNA-repair defects for optimizing lung cancer treatment.
The Potential of MLN3651 in Combination with Selumetinib as a Treatment for Merlin-Deficient Meningioma.
The potential role of miRNAs in therapy of breast and ovarian cancers associated with BRCA1 mutation.
The potential role of pharmacogenomic and genomic in the adjuvant treatment of early stage non small cell lung cancer.
The potential role of ubiquitin c-terminal hydrolases in oncogenesis.
The PPAR? agonist efatutazone increases the spectrum of well-differentiated mammary cancer subtypes initiated by loss of full-length BRCA1 in association with TP53 haploinsufficiency.
The preclinical natural history of serous ovarian cancer: defining the target for early detection.
The presence of hereditary BRCA1 gene mutations in women with familial breast or ovarian cancer and the frequency of occurrence of these tumours in their relatives.
The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified.
The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews.
The Prevalence of Founder Mutations Among Individuals from Families with Familial Pancreatic Cancer Syndrome.
The prevalence of occult ovarian cancer in the series of 155 consequently operated high risk asymptomatic patients - Slovenian population based study.
The prevention of hereditary breast and ovarian cancer: a personal view.
The prodigious network of chromosome 17 miRNAs regulating cancer genes that influence the hallmarks of cancer.
The prognostic impact of hormone receptors and c-erbB-2 in pregnancy-associated breast cancer and their correlation with BRCA1 and cell cycle modulators.
The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer.
The Prognostic Relevance of Poly (ADP-Ribose) Polymerase Expression in Ovarian Cancer Tissue of Wild Type and BRCA-Mutation Carrier Patients.
The Prognostic Value of BRCA1 and PARP Expression in Epithelial Ovarian Carcinoma: Immunohistochemical Detection.
The prognostic value of BRCA1 mRNA expression levels following neoadjuvant chemotherapy in breast cancer.
The prognostic value of BRCA1 promoter methylation in early stage triple negative breast cancer.
The RAD51 135 G>C polymorphism modifies breast cancer and ovarian cancer risk in Polish BRCA1 mutation carriers.
The Rbx1 subunit of SCF and VHL E3 ubiquitin ligase activates Rub1 modification of cullins Cdc53 and Cul2.
The RECAP Test Rapidly and Reliably Identifies Homologous Recombination-Deficient Ovarian Carcinomas.
The relationship between coping strategies and anxiety in women from families with familial breast-ovarian cancer in the absence of demonstrated mutations.
The relationship between the roles of BRCA genes in DNA repair and cancer predisposition.
The relationship of REL proto-oncogene to pathobiology and chemoresistance in follicular and transformed follicular lymphoma.
The Retinoblastoma Gene Undergoes Rearrangements in BRCA1-Deficient Basal-like Breast Cancer.
The RING domain of Mdm2 mediates histone ubiquitylation and transcriptional repression.
The RING finger domain E3 ubiquitin ligases BRCA1 and the RNF20/RNF40 complex in global loss of the chromatin mark histone H2B monoubiquitination (H2Bub1) in cell line models and primary high-grade serous ovarian cancer.
The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by the platinum-based anticancer drugs.
The Ripoptosome, a Signaling Platform that Assembles in Response to Genotoxic Stress and Loss of IAPs.
The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.
The RNA-binding protein HuR is a novel target of Pirh2 E3 ubiquitin ligase.
The role and mechanism of action of RNF186 in colorectal cancer through negative regulation of NF-?B.
The role and mechanism of CRL4 E3 ubiquitin ligase in cancer and its potential therapy implications.
The Role of BCA2 in the Endocytic Trafficking of EGFR and Significance as a Prognostic Biomarker in Cancer.
The Role of BRCA Testing in Hereditary Pancreatic and Prostate Cancer Families.
The role of BRCA1 and BRCA2 in prostate cancer.
The role of BRCA1 gene mutations and apoptosis phenomenon in sporadic breast cancer.
The role of BRCA1 in DNA damage response.
The role of BRCA1 in DNA double-strand repair: past and present.
The role of BRCA1 in homologous recombination repair in response to replication stress: significance in tumorigenesis and cancer therapy.
The role of BRCA1 in non-small cell lung cancer.
The role of BRCA1 in the cellular response to chemotherapy.
The role of E3 ubiquitin ligase HECTD3 in cancer and beyond.
The Role of E3, E4 Ubiquitin Ligase (UBE4B) in Human Pathologies.
The Role of Genetic Testing in Patients With Breast Cancer: A Review.
The role of p53 mutation in BRCA1-associated ovarian cancer.
The Role of PALB2 in the DNA Damage Response and Cancer Predisposition.
The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies.
The role of testing for BRCA1 and BRCA2 mutations in cancer prevention.
The role of the BRCA1 tumor suppressor in DNA double-strand break repair.
The role of the breast cancer susceptibility gene 1 (BRCA1) in sporadic epithelial ovarian cancer.
The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability.
The Roles of Cullin-2 E3 Ubiquitin Ligase Complex in Cancer.
The Roles of Ubiquitination Factor E4B (UBE4B) in the Postoperative Prognosis of Patients with Renal Cell Carcinoma and in Renal Tumor Cells Growth and Metastasis.
The Roles of VHL-Dependent Ubiquitination in Signaling and Cancer.
The SCF-type E3 Ubiquitin Ligases as Cancer Targets.
The search for BRCA1.
The shifting landscape of genetic alterations separating endometriosis and ovarian endometrioid carcinoma.
The spectrum and incidence of BRCA1 pathogenic mutations in Slovak breast/ovarian cancer families.
The spectrum of genetic defects in chronic lymphocytic leukemia.
The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 2: extending the scope beyond olaparib and BRCA1/2 mutations.
The stem cell E3-ligase Lin-41 promotes liver cancer progression through inhibition of microRNA-mediated gene silencing.
The Stil protein regulates centrosome integrity and mitosis through suppression of Chfr.
The structure and regulation of the E3 ubiquitin ligase HUWE1 and its biological functions in cancer.
The STUbL RNF4 regulates protein group SUMOylation by targeting the SUMO conjugation machinery.
The TRAF-interacting protein (TRIP) is a regulator of keratinocyte proliferation.
The tripartite motif-containing protein 3 on the proliferation and cytokine secretion of rheumatoid arthritis fibroblast-like synoviocytes.
The tumor suppressive miR-26a regulation of FBXO11 inhibits proliferation, migration and invasion of hepatocellular carcinoma cells.
The tumor suppressor activity induced by adenovirus-mediated BRCA1 overexpression is not restricted to breast cancers.
The tumor suppressor archipelago E3 ligase is required for spermatid differentiation in Drosophila testis.
The tumor suppressor CDC73 interacts with the ring finger proteins RNF20 and RNF40 and is required for the maintenance of histone 2B monoubiquitination.
The tumor suppressor FBW7 and the vitamin D receptor are mutual cofactors in protein turnover and transcriptional regulation.
The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse.
The Tumor Suppressor Hace1 Is a Critical Regulator of TNFR1-Mediated Cell Fate.
The tumour suppressor HACE1 controls cell migration by regulating Rac1 degradation.
The Tumour Suppressor TMEM127 Is a Nedd4-Family E3 Ligase Adaptor Required by Salmonella SteD to Ubiquitinate and Degrade MHC Class II Molecules.
The two human homologues of yeast UFD2 ubiquitination factor, UBE4A and UBE4B, are located in common neuroblastoma deletion regions and are subject to mutations in tumours.
The two major sites of cbl tyrosine phosphorylation in abl-transformed cells select the crkL SH2 domain.
The ubiquitin E3 ligase activity of BRCA1 and its biological functions.
The ubiquitin ligase c-CBL is expressed in undifferentiated marmoset monkey pluripotent stem cells but is not a general stem cell marker.
The ubiquitin ligase CHIP modulates cellular behaviors of gastric cancer cells by regulating TRAF2.
The Ubiquitin Ligase COP1 Promotes Glioma Cell Proliferation by Preferentially Downregulating Tumor Suppressor p53.
The ubiquitin ligase COP1 regulates cell cycle and apoptosis by affecting p53 function in human breast cancer cell lines.
The ubiquitin ligase RNF43 downregulation increases membrane expression of frizzled receptor in pancreatic ductal adenocarcinoma.
The ubiquitin ligase TRIM25 inhibits hepatocellular carcinoma progression by targeting metastasis associated 1 protein.
The ubiquitin ligase TRIM25 targets ERG for degradation in prostate cancer.
The ubiquitin-interacting motif containing protein RAP80 interacts with BRCA1 and functions in DNA damage repair response.
The ubiquitination ligase SMURF2 reduces aerobic glycolysis and colorectal cancer cell proliferation by promoting ChREBP ubiquitination and degradation.
The UBXN1 protein associates with autoubiquitinated forms of the BRCA1 tumor suppressor and inhibits its enzymatic function.
The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings.
The unliganded glucocorticoid receptor positively regulates the tumour suppressor gene BRCA1 through GABP beta.
The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation.
The validation of a simulation model incorporating radiation risk for mammography breast cancer screening in women with a hereditary-increased breast cancer risk.
The Vhl E3 ubiquitin ligase complex regulates melanisation via sima, cnc and the copper import protein Ctr1A.
The VHL protein recruits a novel KRAB-A domain protein to repress HIF-1alpha transcriptional activity.
The VHL Tumor Suppressor: Master Regulator of HIF.
The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer.
The WW domain containing E3 ubiquitin protein ligase 1 upregulates ErbB2 and EGFR through RING finger protein 11.
The yield of full BRCA1/2 genotyping in Israeli high-risk breast/ovarian cancer patients who do not carry the predominant mutations.
The Yin and Yang of YY1 in tumor growth and suppression.
Therapeutic Approaches for Women Predisposed to Breast Cancer.
Therapeutic exploitation of tumor cell defects in homologous recombination.
Therapeutic Impact of Nanoparticle Therapy Targeting Tumor-Associated Macrophages.
Therapeutic opportunities for PLK1 inhibitors: Spotlight on BRCA1-deficiency and triple negative breast cancers.
Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.
Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation.
Therapeutic targeting of BRCA1-mutated breast cancers with agents that activate DNA repair.
Therapy susceptible germline-related BRCA 1-mutation in a case of metastasized mixed adeno-neuroendocrine carcinoma (MANEC) of the small bowel.
Therapy-related myeloid neoplasms in epithelial ovarian cancer patients carrying BRCA1 mutation: Report of two cases.
Thermal and chemical denaturation of the BRCT functional module of human 53BP1.
Thermal denaturation of the BRCT tandem repeat region of human tumour suppressor gene product BRCA1.
Thermal unfolding of human BRCA1 BRCT-domain variants.
Three novel BRCA1 germline mutations (1104delAA, 1276delTT, 3747delGA) detected in breast/ovarian cancer families identified in the south of France.
Three primary malignancies related to BRCA mutation successively occurring in a BRCA1 185delAG mutation carrier.
Three-Dimensional Architecture of the Human BRCA1-A Histone Deubiquitinase Core Complex.
Three-dimensionally specific inhibition of DNA repair-related genes by activated KRAS in colon crypt model.
Thyroid Hormone Receptors Predict Prognosis in BRCA1 Associated Breast Cancer in Opposing Ways.
Time-resolved single-cell analysis of Brca1 associated mammary tumourigenesis reveals aberrant differentiation of luminal progenitors.
Timing of dietary estrogenic exposures and breast cancer risk.
Tissue-specific and age-dependent effects of global Mdm2 loss.
Tissue-specific tumor suppression by BRCA1.
TNF signaling, but not TWEAK triggered cellular Inhibitor of APoptosis protein 1 (cIAP1) degradation, requires cIAP1 RING dimerization and E2 binding.
TNRC9 downregulates BRCA1 expression and promotes breast cancer aggressiveness.
Tobramycin suppresses HUWE1 degradation to control MCL-1 stability during tumour development.
Toenail selenium status and DNA repair capacity among female BRCA1 mutation carriers.
Too much, too soon? Patients and health professionals' views concerning the impact of genetic testing at the time of breast cancer diagnosis in women under the age of 40.
Tools for translational epigenetic studies involving formalin-fixed paraffin-embedded human tissue: applying the Infinium HumanMethyation450 Beadchip assay to large population-based studies.
Topoisomerase IIalpha-positive and BRCA1-negative phenotype: association with favorable response to epirubicin-based regimens for human breast cancers.
TOPORS Functions As A SUMO-1 E3 Ligase for Chromatin-Modifying Proteins.
Toward Greater Precision in Cancer Radiotherapy.
TP53 Binding to BRCA1 and RAD51 in MCF7 and MDA-MB-468 Breast Cancer Cell Lines In vivo and In vitro.
TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution.
TP53 mutations in familial breast cancer: functional aspects.
TP53 mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer.
TP53, BRCA1, and BRCA2 tumor suppressor genes are not commonly mutated in survivors of Hodgkin's disease with second primary neoplasms.
Trabectedin is a promising antitumour agent for synovial sarcoma.
Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach.
Tracking evolution of BRCA1-associated breast cancer.
Tracking of the origin of recurrent mutations of the BRCA1 and BRCA2 genes in the North-East of Italy and improved mutation analysis strategy.
TRADD contributes to tumour suppression by regulating ULF-dependent p19Arf ubiquitylation.
TRAF2 Is a Novel Ubiquitin E3 Ligase for the Na,K-ATPase ?-Subunit That Drives Alveolar Epithelial Dysfunction in Hypercapnia.
TRAF3: a novel tumor suppressor gene in macrophages.
TRAF6 inhibition rescues dexamethasone-induced muscle atrophy.
TRAF6 promotes atypical ubiquitination of mutant DJ-1 and alpha-synuclein and is localized to Lewy bodies in sporadic Parkinson's disease brains.
TRAF6 Regulates the Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Tumor-Bearing Host.
TRAF6 suppresses the apoptosis of hemocytes by activating pellino in Crassostrea hongkongensis.
TRAF6-mediated ubiquitination regulates nuclear translocation of NRIF, the p75 receptor interactor.
TRAIL signals through the ubiquitin ligase MID1 to promote pulmonary fibrosis.
Trans-activation-based risk assessment of BRCA1 BRCT variants with unknown clinical significance.
Transactivation of repair genes by BRCA1.
Transactivation of the estrogen receptor promoter by BRCA1.
Transactivation of the p21 promoter by BRCA1 splice variants in mammary epithelial cells: evidence for both common and distinct activities of wildtype and mutant forms.
Transactivation-dependent and -independent regulation of p73 stability.
Transcription alterations of members of the ubiquitin-proteasome network in prostate carcinoma.
Transcription factor TAFII250 promotes Mdm2-dependent turnover of p53.
Transcription of BRCA1 is dependent on the formation of a specific protein-DNA complex on the minimal BRCA1 Bi-directional promoter.
Transcriptional characteristics of familial non-BRCA1/BRCA2 breast tumors.
Transcriptional down-regulation of Brca1 and E-cadherin by CtBP1 in breast cancer.
Transcriptional Pathways Altered in Response to Vibration in a Model of Hand-Arm Vibration Syndrome.
Transcriptional profiling of breast cancer cells exposed to soy phytoestrogens after BRCA1 knockdown with a whole human genome microarray approach.
Transcriptional regulation of BRCA1 expression by a metabolic switch.
Transcriptional regulation of the base excision repair pathway by BRCA1.
Transcriptional regulation of the insulin-like growth factor-I receptor gene in breast cancer.
Transcriptional Silencing of ALDH2 Confers a Dependency on Fanconi Anemia Proteins in Acute Myeloid Leukemia.
Transfer of malignant trait to BRCA1 deficient human fibroblasts following exposure to serum of cancer patients.
Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models.
Transgenic mouse models of breast cancer.
Translating genomics in cancer care.
Translational advances regarding hereditary breast cancer syndromes.
Translational research on hereditary colon, breast, and ovarian cancers.
Treatment of triple-negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization?
Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer.
TRIAD1 inhibits MDM2-mediated p53 ubiquitination and degradation.
TRIM13 inhibits cell migration and invasion in clear-cell renal cell carcinoma.
TRIM22 can activate the noncanonical NF-?B pathway by affecting IKK?
TRIM22 confers poor prognosis and promotes epithelial-mesenchymal transition through regulation of AKT/GSK3?/?-catenin signaling in non-small cell lung cancer.
TRIM22 inhibits endometrial cancer progression through the NOD2/NF??B signaling pathway and confers a favorable prognosis.
TRIM22 inhibits the proliferation of gastric cancer cells through the Smad2 protein.
TRIM22 inhibits the TRAF6-stimulated NF-?B pathway by targeting TAB2 for degradation.
TRIM22: A Diverse and Dynamic Antiviral Protein.
TRIM23 overexpression is a poor prognostic factor and contributes to carcinogenesis in colorectal cancer.
TRIM25 activates AKT/mTOR by inhibiting PTEN via K63-linked polyubiquitination in non-small cell lung cancer.
TRIM25 blockade by RNA interference inhibited migration and invasion of gastric cancer cells through TGF-? signaling.
TRIM25 contributes to the malignancy of acute myeloid leukemia and is negatively regulated by microRNA-137.
TRIM25 enhances cell growth and cell survival by modulating p53 signals via interaction with G3BP2 in prostate cancer.
TRIM25 promotes the cell survival and growth of hepatocellular carcinoma through targeting Keap1-Nrf2 pathway.
TRIM26 Induces Ferroptosis to Inhibit Hepatic Stellate Cell Activation and Mitigate Liver Fibrosis Through Mediating SLC7A11 Ubiquitination.
TRIM3, a tumor suppressor linked to regulation of p21(Waf1/Cip1).
TRIM32 promotes cell proliferation and invasion by activating ?-catenin signalling in gastric cancer.
TRIM32 Protein Sensitizes Cells to Tumor Necrosis Factor (TNF{alpha})-induced Apoptosis via Its RING Domain-dependent E3 Ligase Activity against X-linked Inhibitor of Apoptosis (XIAP).
TRIM37 orchestrates renal cell carcinoma progression via histone H2A ubiquitination-dependent manner.
TRIM37 prevents formation of centriolar protein assemblies by regulating Centrobin.
TRIM45 functions as a tumor suppressor in the brain via its E3 ligase activity by stabilizing p53 through K63-linked ubiquitination.
TRIM47 promotes malignant progression of renal cell carcinoma by degrading P53 through ubiquitination.
TRIM58 Interacts with Pyruvate Kinase M2 to Inhibit Tumorigenicity in Human Osteosarcoma Cells.
TRIM59 deficiency curtails breast cancer metastasis through SQSTM1-selective autophagic degradation of PDCD10.
TRIM65 negatively regulates p53 through ubiquitination.
TRIM8 interacts with KIF11 and KIFC1 and controls bipolar spindle formation and chromosomal stability.
TRIMming Type I Interferon-Mediated Innate Immune Response in Antiviral and Antitumor Defense.
Tripartite Motif Containing 11 Interacts with DUSP6 to Promote the Growth of Human Osteosarcoma Cells through Regulating ERK1/2 Pathway.
Tripartite motif containing 25 promotes proliferation and invasion of colorectal cancer cells through TGF-? signaling.
Tripartite motif containing 62 is a novel prognostic marker and suppresses tumor metastasis via c-Jun/Slug signaling-mediated epithelial-mesenchymal transition in cervical cancer.
Tripartite motif-containing 3 (TRIM3) inhibits tumor growth and metastasis of liver cancer.
Tripartite motif-containing protein 3 plays a role of tumor inhibitor in cervical cancer.
Tripartite motif-containing protein 37 is overexpressed in human glioma and its downregulation inhibits human glioma cell growth in vitro.
Triple negative breast cancers: clinical and prognostic implications.
Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice.
Triple negative status and BRCA mutations in contralateral breast cancer: a population-based study.
Triple negative tumours: a critical review.
Triple-negative breast cancer and Poly(ADP-ribose) polymerase inhibitors.
Triple-negative breast cancer and PTEN (phosphatase and tensin homologue)loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer.
Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing.
Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies.
Triple-negative breast cancer: are we making headway at least?
Triple-negative breast cancer: disease entity or title of convenience?
Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes.
Triple-negative breast cancer: epidemiological considerations and recommendations.
Triple-negative breast cancer: epidemiology and management options.
Triple-negative breast cancer: therapeutic options.
Triple-Negative Breast Carcinoma.
Triple-Negative versus Non-Triple-Negative Breast Cancers in High-Risk Women: Phenotype Features and Survival from the HIBCRIT-1 MRI-Including Screening Study.
Trp63 is regulated by STAT5 in mammary tissue and subject to differentiation in cancer.
Truncation at conserved terminal regions of BRCA1 protein is associated with highly proliferating hereditary breast cancers.
Tubuline, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy.
Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer.
Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients.
Tumor Cell Recovery from Senescence Induced by Radiation with PARP Inhibition.
Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients.
Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance.
Tumor classification using phylogenetic methods on expression data.
Tumor formation in Brca1 conditional mutant mice.
Tumor formation in mice with conditional inactivation of Brca1 in epithelial tissues.
Tumor markers for breast cancer.
Tumor markers for breast cancer. Current utilities and future prospects.
Tumor Metabolism: MAGE-A Proteins Help TRIM Turn Over AMPK.
Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations.
Tumor necrosis factor receptor- associated factor 6 (TRAF6) regulation of development, function, and homeostasis of the immune system.
Tumor necrosis factor receptor-associated factor 6 (TRAF6) inhibition modulates bone loss and matrix metalloproteinase expression levels in collagen-induced rheumatoid arthritis rat.
Tumor necrosis factor receptor-associated factor 6 contributes to malignant behavior of human cancers through promoting AKT ubiquitination and phosphorylation.
Tumor necrosis factor receptor-associated factor 6 interaction with alpha-synuclein enhances cell death through the Nuclear Factor-kB pathway.
Tumor Necrosis Factor Receptor-Associated Factor 6 Promotes Hepatocarcinogenesis by Interacting With Histone Deacetylase 3 to Enhance c-Myc Gene Expression and Protein Stability.
Tumor necrosis factor receptor-associated factor-6 and ribosomal S6 kinase intracellular pathways link the angiotensin II AT1 receptor to the phosphorylation and activation of the IkappaB kinase complex in vascular smooth muscle cells.
Tumor necrosis factor-alpha-induced lung cell expression of antiapoptotic genes TRAF1 and cIAP2.
Tumor protein expression of the DNA repair gene BRCA1 and lethal prostate cancer.
Tumor suppressor activities of the fbw7 e3 ubiquitin ligase receptor.
Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155.
Tumor suppressor BRCA1 inhibits a breast cancer-associated promoter of the aromatase gene (CYP19) in human adipose stromal cells.
Tumor suppressor BRCA1 is expressed in prostate cancer and controls insulin-like growth factor I receptor (IGF-IR) gene transcription in an androgen receptor-dependent manner.
Tumor suppressor CHK2: regulator of DNA damage response and mediator of chromosomal stability.
Tumor suppressor DCAF15 inhibits epithelial-mesenchymal transition by targeting ZEB1 for proteasomal degradation in hepatocellular carcinoma.
Tumor suppressor genes and breast cancer.
Tumor suppressor genes and their alterations in breast cancer.
Tumor suppressor lnc-CTSLP4 inhibits EMT and metastasis of gastric cancer by attenuating HNRNPAB-dependent Snail transcription.
Tumor suppressor loss in pituitary tumors.
Tumor suppressor miR-145 reverses drug resistance by directly targeting DNA damage-related gene RAD18 in colorectal cancer.
Tumor suppressor p53 is required to modulate BRCA1 expression.
Tumor suppressor SPOP ubiquitinates and degrades EglN2 to compromise growth of prostate cancer cells.
Tumor Testing for Somatic and Germline BRCA1/BRCA2 Variants in Ovarian Cancer Patients in the Context of Strong Founder Effects.
Tumor-associated antigen Prame targets tumor suppressor p14/ARF for degradation as the  receptor protein of CRL2Prame complex.
Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient mammary tumor cells in vivo.
Tumor-protective and tumor-promoting actions of dietary whey proteins in an N-methyl-N-nitrosourea model of rat mammary carcinogenesis.
Tumor-suppressing function of caspase-2 requires catalytic site C320 and site S139 in mice.
Tumoral Expression of BRCA1, Estrogen Receptor Alpha and ID4 Protein in Patients with Sporadic Breast Cancer.
Tumorigenesis and neurodegeneration: two sides of the same coin?
Tumorigenesis as a consequence of genetic instability in Brca1 mutant mice.
Tumorigenesis in mice carrying a truncating Brca1 mutation.
Tumors overexpressing RNF168 show altered DNA repair and responses to genotoxic treatments, genomic instability and resistance to proteotoxic stress.
Tumour biological features of BRCA1-induced breast and ovarian cancer.
Tumour lineage shapes BRCA-mediated phenotypes.
Tumour morphology of early-onset breast cancers predicts breast cancer risk for first-degree relatives: the Australian Breast Cancer Family Registry.
Tumour suppressor genes in chemotherapeutic drug response.
Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors.
Tumour Versus Germline BRCA Testing in Ovarian Cancer: A Single-Site Institution Experience in the United Kingdom.
Tumour-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer.
TUSC4 functions as a tumor suppressor by regulating BRCA1 stability.
TWEAKing death.
Twenty Years of BRCA1 and BRCA2 Molecular Analysis at MMCI - Current Developments for the Classification of Variants.
Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status.
Twenty-three novel BRCA1 and BRCA2 sequence variations identified in a cohort of Swiss breast and ovarian cancer families.
Two decades after BRCA: setting paradigms in personalized cancer care and prevention.
Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy.
Two distinct origins of a common BRCA1 mutation in breast-ovarian cancer families: a genetic study of 15 185delAG-mutation kindreds.
Two founder BRCA2 mutations predispose to breast cancer in young women.
Two identical triplet sisters carrying a germline BRCA1 gene mutation acquire very similar breast cancer somatic mutations at multiple other sites throughout the genome.
Two new CHEK2 germ-line variants detected in breast cancer/sarcoma families negative for BRCA1, BRCA2, and TP53 gene mutations.
Two types of primary mucinous ovarian tumors can be distinguished based on their origin.
Ubc9 mediates nuclear localization and growth suppression of BRCA1 and BRCA1a proteins.
UbcH5A, a member of human E2 ubiquitin-conjugating enzymes, is closely related to SFT, a stimulator of iron transport, and is up-regulated in hereditary hemochromatosis.
UBE3C promotes proliferation and inhibits apoptosis by activating the ?-catenin signaling via degradation of AXIN1 in gastric cancer.
UBE4B levels are correlated with clinical outcomes in neuroblastoma patients and with altered neuroblastoma cell proliferation and sensitivity to epidermal growth factor receptor inhibitors.
UBE4B promotes Hdm2-mediated degradation of the tumor suppressor p53.
UBE4B, a ubiquitin chain assembly factor, is required for MDM2-mediated p53 polyubiquitination and degradation.
Ubiquitin E3 ligase WWP1 as an oncogenic factor in human prostate cancer.
Ubiquitin Ligase Activities of WWP1 Germline Variants K740N and N745S.
Ubiquitin ligase CHIP functions as an oncogene and activates the AKT signaling pathway in prostate cancer.
Ubiquitin ligase Fbw7 restricts the replication of hepatitis C virus by targeting NS5B for ubiquitination and degradation.
Ubiquitin ligase TRIM65 promotes colorectal cancer metastasis by targeting ARHGAP35 for protein degradation.
Ubiquitin pathway and ovarian cancer.
Ubiquitin pathway in VHL cancer syndrome.
Ubiquitin Recognition of BAP1: Understanding its Enzymatic Function.
Ubiquitin systems mark pathogen-containing vacuoles as targets for host defense by guanylate binding proteins.
Ubiquitin- and ubiquitin-like proteins-conjugating enzymes (E2s) in breast cancer.
Ubiquitin-activating enzyme UBA1 is required for cellular response to DNA damage.
Ubiquitin-dependent and -independent functions of OTULIN in cell fate control and beyond.
Ubiquitin-specific protease 7 regulates nucleotide excision repair through deubiquitinating XPC protein and preventing XPC protein from undergoing ultraviolet light-induced and VCP/p97 protein-regulated proteolysis.
Ubiquitination and proteasomal degradation of the BRCA1 tumor suppressor is regulated during cell cycle progression.
Ubiquitination and the ubiquitin - proteasome system in the pathogenesis and treatment of squamous head and neck carcinoma.
Ubiquitination by TOPORS regulates the prostate tumor suppressor NKX3.1.
Ubiquitination of NF-?B p65 by FBXW2 suppresses breast cancer stemness, tumorigenesis, and paclitaxel resistance.
Ubiquitination, Biotech Startups, and the Future of TRIM Family Proteins: A TRIM-Endous Opportunity.
Ubiquitylome profiling of Parkin-null brain reveals dysregulation of calcium homeostasis factors ATP1A2, Hippocalcin and GNA11, reflected by altered firing of noradrenergic neurons.
UBR-box containing protein, UBR5, is over-expressed in human lung adenocarcinoma and is a potential therapeutic target.
UBR5 Contributes to Colorectal Cancer Progression by Destabilizing the Tumor Suppressor ECRG4.
UBTD1 is a mechano-regulator controlling cancer aggressiveness.
Uncertainty in BRCA1 cancer susceptibility testing.
Unclassified variants identified in BRCA1 exon 11: Consequences on splicing.
Uncovering and deciphering the pro-invasive role of HACE1 in melanoma cells.
Uncovering BRCA1-regulated signalling pathways by microarray-based expression profiling.
Uncovering the Translational Regulatory Activity of the Tumor Suppressor BRCA1.
Under-ascertainment of breast cancer susceptibility gene carriers in a cohort of New Zealand female breast cancer patients.
Underestimated survival predictions of the prognostic tools Adjuvant! Online and PREDICT in BRCA1-associated breast cancer patients.
Understanding and treating triple-negative breast cancer.
Understanding germ-line mutations in BRCA1.
Understanding the functions of BRCA1 in the DNA-damage response.
Unexpected cancer-predisposition gene variants in Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome patients without underlying germline PTEN mutations.
Unexpected Findings in a Child with Atypical Hemolytic Uremic Syndrome: An Example of How Genomics Is Changing the Clinical Diagnostic Paradigm.
Unlocking the Mdm2-p53 loop: ubiquitin is the key.
Unravelling modifiers of breast and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: update on genetic modifiers.
Unsolved mystery: the role of BRCA1 in DNA end-joining.
Up-regulation of cullin7 promotes proliferation and migration of pulmonary artery smooth muscle cells in hypoxia-induced pulmonary hypertension.
Update on PARP1 inhibitors in ovarian cancer.
Update Swiss guideline for counselling and testing for predisposition to breast, ovarian, pancreatic and prostate cancer.
Upregulation of IL-6 in CUL4B-deficient myeloid-derived suppressive cells increases the aggressiveness of cancer cells.
Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types.
Uptake and timing of risk-reducing salpingo-oophorectomy among patients with BRCA1 and BRCA2 mutations.
Uptake of BRCA1 rearrangement panel testing: in individuals previously tested for BRCA1/2 mutations.
Uptake of Family-Specific Mutation Genetic Testing Among Relatives of Patients with Ovarian Cancer with BRCA1 or BRCA2 Mutation.
Uptake of hereditary breast/ovarian cancer genetic testing in a French national sample of BRCA1 families. The French Cancer Genetic Network.
Uptake of pre-symptomatic testing for BRCA1 and BRCA2 is age, gender, offspring and time-dependent.
Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers: experience at the National Cancer Center of Korea.
Uptake of testing for germline BRCA mutations in patients with non-mucinous epithelial ovarian cancers in Western Australia: a comparison of different genetic counseling methods.
Urological cancer related to familial syndromes.
Use of association studies to define genetic modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
Use of Gene Expression Profiles of Peripheral Blood Lymphocytes to Distinguish BRCA1 Mutation Carriers in High Risk Breast Cancer Families.
Use of SNP chips to detect rare pathogenic variants: retrospective, population based diagnostic evaluation.
Using BRCA1 to treat cancer.
Using BRET to study chemical compound-induced disruptions of the p53-HDM2 interactions in live cells.
Using core public health functions to promote BRCA best practices among health plans.
Using gene carrier probability to select high risk families for identifying germline mutations in breast cancer susceptibility genes.
Using tumour pathology to identify people at high genetic risk of breast and colorectal cancers.
USP1 Is Required for Replication Fork Protection in BRCA1-Deficient Tumors.
USP11-dependent selective cIAP2 deubiquitylation and stabilization determine sensitivity to Smac mimetics.
USP11: A key regulator of cIAP2 stability and sensitivity to SMAC mimetics.
USP2 is an SKP2 deubiquitylase that stabilizes both SKP2 and its substrates.
Usp28 counteracts Fbw7 in intestinal homeostasis and cancer.
USP4 inhibits p53 through deubiquitinating and stabilizing ARF-BP1.
USP42 protects ZNRF3/RNF43 from R-spondin-dependent clearance and inhibits Wnt signalling.
USP9X destabilizes pVHL and promotes cell proliferation.
USP9X stabilizes BRCA1 and confers resistance to DNA-damaging agents in human cancer cells.
USPSTF Recommendations for BRCA1 and BRCA2 Testing in the Context of a Transformative National Cancer Control Plan.
Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations.
Uterus hyperplasia and increased carcinogen-induced tumorigenesis in mice carrying a targeted mutation of the Chk2 phosphorylation site in Brca1.
Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies.
Utilization of ancillary studies in the cytologic diagnosis of biliary and pancreatic lesions: The papanicolaou society of cytopathology guidelines for pancreatobiliary cytology.
Utilization of ancillary studies in the cytologic diagnosis of biliary and pancreatic lesions: The Papanicolaou Society of Cytopathology Guidelines.
Utilizing fluorescent life time imaging microscopy technology for identify carriers of BRCA2 mutation.
UV-induced proteolysis of RNA polymerase II is mediated by VCP/p97 segregase and timely orchestration by Cockayne syndrome B protein.
UVB-induced cell death signaling is associated with G1-S progression and transcription inhibition in primary human fibroblasts.
Validation of family history of breast cancer and identification of the BRCA1 and other syndromes using a population-based cancer registry.
Validation of SAG/RBX2/ROC2 E3 ubiquitin ligase as an anticancer and radiosensitizing target.
Validation of the BRCA1 antibody MS110 and the utility of BRCA1 as a patient selection biomarker in immunohistochemical analysis of breast and ovarian tumours.
Validation of three BRCA1/2 mutation-carrier probability models Myriad, BRCAPRO and BOADICEA in a population-based series of 183 German families.
Validation of transgenic models of breast cancer: ductal carcinoma in situ (DCIS) and Brca1-mutation-related breast cancer.
Validation study of the LAMBDA model for predicting the BRCA1 or BRCA2 mutation carrier status of North American Ashkenazi Jewish women.
Value of adjuvant chemotherapy and informed microscopic examination for occult gynecologic cancer detected upon risk-reducing salpingo-oophorectomy after chemotherapy for BRCA1/2-associated breast cancer: a case report.
Variation in BRCA1 cancer risks by mutation position.
Variation in rates of uptake of preventive options by Canadian women carrying the BRCA1 or BRCA2 genetic mutation.
Variation in the BRCA2 gene in a child with medulloblastoma and a family history of breast cancer.
VCP, a weak ATPase involved in multiple cellular events, interacts physically with BRCA1 in the nucleus of living cells.
VEGF, HIF-1? expression and MVD as an angiogenic network in familial breast cancer.
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial.
VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment.
Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas.
Viperin interacts with the kinase IRAK1 and the E3 ubiquitin ligase TRAF6, coupling innate immune signaling to antiviral ribonucleotide synthesis.
Viral ubiquitin ligase WSSV222 is required for efficient white spot syndrome virus (WSSV) replication in shrimp.
Vitamin D receptor, Retinoid X receptor and peroxisome proliferator-activated receptor ? are overexpressed in BRCA1 mutated breast cancer and predict prognosis.
Voies de réparation de l'ADN et cancers bronchiques non à petites cellules : perspectives cliniques.
Von Hippel-Lindau gene product directs cytokinesis: a new tumor suppressor function.
von Hippel-Lindau protein binds hyperphosphorylated large subunit of RNA polymerase II through a proline hydroxylation motif and targets it for ubiquitination.
Weighing options for cancer risk reduction in carriers of BRCA1 and BRCA2 mutations.
Western Analysis of Breast Cancer 1 Protein (BRCA1).
What drives breast cancer heterogeneity: oncogenic events or cell of origin?
What is triple-negative breast cancer?
What makes tumors multidrug resistant?
What studies on human longevity tell us about the risk for cancer in the oldest old: data and hypotheses on the genetics and immunology of centenarians.
When the SWI/SNF complex remodels...the cell cycle.
Which Holds the Key to BRCAness: Inability to Repair the Break, Protect the Fork, or Prevent the Gap?
White spot syndrome virus open reading frame 222 encodes a viral E3 ligase and mediates degradation of a host tumor suppressor via ubiquitination.
Whole Exome Sequencing Identifies Candidate Genes Associated with Hereditary Predisposition to Uveal Melanoma.
Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.
Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways.
Whole-exome sequencing of pancreatic neoplasms with acinar differentiation.
Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study.
Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers.
Why choose the treatment with cisplatin for BRCA1 breast cancers patients?
Widespread bimodal intrachromosomal genomic instability in sporadic breast cancers associated with 13q allelic imbalance.
Wild-type APC Is Associated with Poor Survival in Metastatic Microsatellite Stable Colorectal Cancer.
Wild-type genotypes of BRCA1 gene SNPs combined with micro-RNA over-expression in mammary tissue leading to familial breast cancer with an increased risk of distant metastases' occurrence.
Will Chinese ovarian cancer patients benefit from knowing the BRCA2 mutation status?
Wingless and Archipelago, a fly E3 ubiquitin ligase and a homolog of human tumor suppressor FBW7, show an antagonistic relationship in wing development.
Wip1 and ATM in tumor evolution: role for BRCA1.
With the ends in sight: images from the BRCA1 tumor suppressor.
WNT inhibition creates a BRCA-like state in Wnt-addicted cancer.
Wnt-induced proteolytic targeting.
Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer.
Women at high risk of breast cancer: Molecular characteristics, clinical presentation and management.
Women's experiences of undergoing BRCA1 and BRCA2 testing: organisation of the German Hereditary Breast and Ovarian Cancer Consortium Survey and Preliminary Data from Münster.
WRN Loss Induces Switching of Telomerase-Independent Mechanisms of Telomere Elongation.
WSB-1 regulates the metastatic potential of hormone receptor negative breast cancer.
WSB1 promotes tumor metastasis by inducing pVHL degradation.
WW domain-containing E3 ubiquitin protein ligase 1 targets p63 transcription factor for ubiquitin-mediated proteasomal degradation and regulates apoptosis.
WWP1 Gain-of-Function Variants Inactivate PTEN to Raise Cancer Risk.
WWP2 regulates proliferation of gastric cancer cells in a PTEN-dependent manner.
X inactive-specific transcript RNA coating and genetic instability of the X chromosome in BRCA1 breast tumors.
X-linked inhibitor of apoptosis protein (XIAP) regulation of cyclin D1 protein expression and cancer cell anchorage-independent growth via its E3 ligase-mediated protein phosphatase 2A/c-Jun axis.
Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy.
Xp22.2-3 loss of heterozygosity is associated with germline BRCA1 mutation in ovarian cancer.
XY chromosomal bivalent: nucleolar attraction.
Year 1: Experiences of a tertiary cancer centre following implementation of reflex BRCA1 and BRCA2 tumor testing for all high-grade serous ovarian cancers in a universal healthcare system.
Yeast Screens Identify the RNA Polymerase II CTD and SPT5 as Relevant Targets of BRCA1 Interaction.
Yin Yang 1 positively regulates BRCA1 and inhibits mammary cancer formation.
Young age at first pregnancy does protect against early onset breast cancer in BRCA1 and BRCA2 mutation carriers.
Younger birth cohort correlates with higher breast and ovarian cancer risk in European BRCA1 mutation carriers.
ZC3H18 specifically binds and activates the BRCA1 promoter to facilitate homologous recombination in ovarian cancer.
ZNF313 is a novel cell cycle activator with an E3 ligase activity inhibiting cellular senescence by destabilizing p21(WAF1.).
ZNF423: A New Player in Estrogen Receptor-Positive Breast Cancer.
ZNRF3 and RNF43 cooperate to safeguard metabolic liver zonation and hepatocyte proliferation.
ZNRF3 Inhibits the Invasion and Tumorigenesis in Nasopharyngeal Carcinoma Cells by Inactivating the Wnt/?-Catenin Pathway.
ZNRF3 is downregulated in papillary thyroid carcinoma and suppresses the proliferation and invasion of papillary thyroid cancer cells.
[A CASE REPORT OF THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) IN A BREAST CANCER PATIENT].
[A paradox and three egnimas about the role of BRCA1 in breast and ovarian cancers]
[Advance in researches on BRCA1.]
[Analyses of LOH and expression in healthy gland, DCIS and invasive breast cancer gland]
[Analysis of BRCA1/2 and CHEK2 mutations in ovarian cancer and primary multiple tumors involving the ovaries. Patients of Russian population using biochips]
[Analysis of loss of heterozygosity of the tumor suppressor genes p53 and BRCA1 in ovarial carcinomas]
[Analysis of mutations in the BRCA1 gene in patients with cancer of the breast and/or the ovary in Portugal]
[Analysis of polymorphisms in genes of insulin receptor substrate-1 and enzymes involved in estrogen biosynthesis and metabolism among breast cancer patients with BRCA1 mutations]
[Apropos of tests for predisposition for cancers of the breast and ovary related to the BRCA1 gene]
[Are the hereditary forms of BRCA1 and BRCA2 breast cancer sensitive to estrogens?]
[Assessment of applicability of archived cytological lung cancer specimens for molecular genetic analysis].
[Attitudes towards screening and prevention of breast and ovarian cancers with hereditary predisposition. Survey by female gynecologists in the north of France]
[Basal-like carcinoma of the breast--the actual review and clinico-pathological corelations]
[BRCA1 (breast cancer type 1). Tumor suppressor gene]
[BRCA1 and BRCA2 - pathologists starting kit].
[BRCA1 and BRCA2 have reached the clinical medicine. The 10-year old finding of the genetic mutation makes it now possible to prevent breast cancer]
[BRCA1 and BRCA2 mutations in families studied in the Program of Genetic Counselling in Cancer of the Valencian Community (Spain).]
[BRCA1 and BRCA2 mutations in patients with familial breast cancer]
[BRCA1 and BRCA2--breast cancer susceptibility genes]
[BRCA1 and cancer: a new lead]
[BRCA1 and Estrogen Receptor ? Expression Regulation in Breast Cancer Cells].
[BRCA1 associated protein 1 (BAP1) expression in pleural diffuse malignant mesothelioma: A comparative cytological and histological analyses on 50 patients].
[BRCA1 germ line mutations in Chinese early-onset breast cancer patients.]
[BRCA1- and BRCA2- associated breast carcinomas.]
[BRCA1: from the gene identification to the cancer risk estimation]
[Breast cancer in BRCA1/2 mutation carriers].
[Breast cancer susceptibility genes.]
[Case of encapsulated solid papillary carcinoma with triple-negative and basal-like phenotype occurred in pregnant woman with review of the literature].
[Characteristics of selected clinical features in BRCA1 mutation carriers affected with breast cancer undergoing preventive female genital tract surgeries].
[Chinese multicenter randomized trial of customized chemotherapy based on BRCA1 (breast cancer susceptibility gene 1)-RAP80 (receptor-associated protein 80) mRNA expression in advanced non-small cell lung cancer (NSCLC) patients].
[Clinical aspects of familial ovarian cancer - current status and issues in Japan].
[Current clinical issues and recent trends in hereditary breast and ovarian cancer in Japan-genetic testing for HBOC and risk-reducing surgery].
[Detecting Large Germline Rearrangements of BRCA1 by Next Generation Tumor Sequencing].
[Determination of a BRCA1 gene mutation in a family with hereditary breast cancer]
[Diagnostic value of BRCA1 and p16 gene methylation in sporadic breast cancer.]
[DNA damage induces BRCA1 distribution alteration in prostate cancer cell lines]
[Effects of lovastatin on cell cycle distribution in MCF-7 cells transfected with BRCA1]
[Epidemiology and diagnosis of breast cancer].
[Epidemiology and genetics of cancers of the ovary]
[Ethnic aspects of hereditary breast cancer in the region of Siberia].
[Evaluation of cancer risk through genetic analysis?]
[Evaluation of stomatognathic system in BRCA1 gene mutation carriers before and after prophylactic adnexectomy--part II: evaluation of stomatognathic system in BRCA1 gene mutation carriers after prophylactic adnexectomy]
[Familial cancer and oncogenic factors]
[From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
[Gadd45 mediated G2/M cell cycle arrest induced by BRCA1]
[Genes beyond BRCA1 and BRCA2 for hereditary breast cancer.]
[Genes involved in breast cancers]
[Genetic alterations and DNA-based diagnosis in breast cancer]
[Genetic consultation: hereditary cancer risk?].
[Genetic instability on chromosome 17q21 in gastric cancer of Chinese patients]
[Genetic predisposition for breast cancer: BRCA1 and BRCA2 genes].
[Genetic predisposition to breast cancer: a review in April 1998]
[Genetical aspects of surgical treatment in patients with hereditary breast cancer].
[Germ-line epimutations and human cancer]
[Germ-line mutations of the BRCA1 gene in northeastern France]
[Gynecological Care and Prevention of Gynecological Malignancies in BRCA1 and BRCA2 Mutation Carriers].
[Haplotype of the BRCA2 6857delAA mutation in 4 families with breast/ovarian cancer]
[Hemangiosarcoma after breast-conserving therapy of breast cancer: Report of four cases with molecular genetic diagnosis and literature review.]
[Hereditary breast and ovarian cancer - indications for genetic testing, counseling and options for mutation carriers].
[Hereditary breast and ovarian cancers].
[Hereditary breast carcinomas pathologist's perspective].
[Hereditary neoplastic diseases (genetic predisposition and cancer syndromes)]
[Hereditary ovarian cancer]
[Hereditary predisposition for the development of breast and ovarian carcinoma]
[Identification of basal-like carcinomas in clinical practice: "triple zero/BRCA1-like" carcinomas]
[Implications of genetic risk factors in breast cancer: culprit genes and associated malignancies]
[In Process Citation].
[Increased TRIM5 is associated with a poor prognosis and immune infiltration in glioma patients].
[Inherited predisposition to breast cancer: after the BRCA1 and BRCA2 genes, what next?]
[Innovations in the treatment of ovarian cancer. Analysis of the therapeutic development: from platinum to immunotherapy.]
[Is hereditary predisposition to breast cancer linked to BRCA1 a disease of response to genotoxic lesions?]
[Isolation and characterization of a BRCA1-interacting protein]
[Knock-down of Pre-mRNA Splicing Factor Prp19 Causes Chromosome Misalignment and Prometaphase Arrest].
[Malignant phyllode tumor of the breast with features of intraductal carcinoma]
[Management of families at high risk for hereditary breast-ovarian cancers: the endocrinologist's point of view]
[Markers of effectiveness of preoperative taxane-based chemotherapy for locally advanced breast cancer].
[Molecular basis of breast cancer related to BRCA 1 and BRCA2 genes: characteristics and targeting therapy]
[Molecular basis of gynecological oncology--TopBP1 protein and its participation in the transcription process].
[Molecular Diagnosis and Treatment of HBOC Syndrome].
[Molecular study of the BRCA1 and BRCA2 genes in 153 breast cancer families from Castilla and León (Spain): new nine unclassified variants identified]
[Morphologically qnd immunohistochemically based screening criteria for selection of patients with possible mutation of BRCA1 gene in primary ovarian cancer].
[Multiple primary malignancies in BRCA1 mutation carriers--two clinical cases].
[Mutation of breast cancer susceptibility gene in ovarian cancer and its clinical significance]
[Mutational analysis of breast/ovarian cancer hereditary predisposition gene BRCA1 in Tunisian women]
[Mutations in the BRCA1 gene in young Spanish women with breast cancer]
[Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum].
[Overexpression of CHIP in Chronic Myeloid Leukemia K562 Cells Induces Mitotic Abnormality.]
[PALB2, a major susceptibility gene for breast cancer].
[PARP inhibitors: new therapeutic agents in breast and ovarian cancer].
[Pirh2 shRNA mediated by psiRNA-hH1 vector plasmid effectively inhibits the proliferation of lung carcinoma cells: in vitro and in vivo experiments]
[Poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1/2 cancer therapy].
[Possibilities of examination of familial breast cancers and ovarian cancers. Use of molecular-genetic analysis of the BRCA1 gene and the BRCA2 gene]
[Present status and tasks for genetic testing and risk-reducing surgery in patients with hereditary breast and ovarian cancer].
[Progress in the effects of BRAP gene on cardiovascular diseases].
[Prophylactic surgery of mammary and ovarian carcinoma.]
[Relationship between BRCA1 mRNA expression in tumor cells from malignant effusions and chemosensitivity to cisplatin in patients with metastatic malignant effusions].
[Relationship of clinicopathological features and chemotherapeutic outcomes in women with BRCA1 and BRCA2 mutation-negative familial breast cancer].
[Retrospective NGS Study in High-risk Hereditary Cancer Patients at Masaryk Memorial Cancer Institute].
[Review of risk factors for breast cancer--what's new?]
[Risk assessment for familial occurrence of breast cancer]
[Roles of BRCA1 and BRCA2 in DNA repair and tumor suppression]
[Selection and quantitative detection of target genes in oral squamous cell carcinoma]
[Sequence analysis of BRCA1 gene in young breast cancer patients and/or positive family history]
[Should a systematic fertility preservation be proposed to healthy women carrying a BRCA1/2 mutation?].
[Should knowledge of BRCA1 status impact the choice of chemotherapy in metastatic breast cancer: A review].
[Study of BRCA1 and BRCA2 gene mutations in human sporadic breast cancers]
[Testing of mutations in BRCA1 and BRCA2 genes in tumor tissues - possibilities and limitations].
[The importance of genetic factors for development of breast cancer]
[The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada]
[The supply of breast/ovarian cancer genetic susceptibility tests in France]
[Translational research and diagnostics for breast cancer].
[Triple-negative breast cancer: analysis of patients diagnosed and/or treated at the Masaryk Memorial Cancer Institute between 2004 and 2009].
[Tumor risk consultation for predisposed women from high risk cancer families]
Neoplasms, Germ Cell and Embryonal
Down-regulation of RFWD3 inhibits cancer cells proliferation and migration in gastric carcinoma.
Large-scale Sequencing of Testicular Germ Cell Tumour (TGCT) Cases Excludes Major TGCT Predisposition Gene.
Neoplasms, Radiation-Induced
Cancer predisposition, radiosensitivity and the risk of radiation-induced cancers. IV. Prediction of risks in relatives of cancer-predisposed individuals.
Impact of cancer predisposition and radiosensitivity on the population risk of radiation-induced cancers.
Neoplasms, Second Primary
BRCA1 and BRCA2 mutations in breast cancer families with multiple primary cancers.
Evaluation of BRCA1/2 mutational status among German and Austrian women with triple-negative breast cancer.
Hereditary Risk of Breast and Ovarian Carcinoma: The Role of the Oncologist.
Identification of BRCA1 and BRCA2 carriers by allele-specific gene expression (AGE) analysis.
Pathology of BRCA1- and BRCA2-associated Breast Cancers: Known and Less Known Connections.
Prognostic value of BRCA1 mutations in familial breast cancer patients affected by a second primary cancer.
Risk of Having BRCA1 Mutation in High-Risk Women with Triple-Negative Breast Cancer: A Meta-Analysis.
Risk of Second Primary Malignancy in Breast Cancer Survivors: A Nested Population-Based Case-Control Study.
Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
TP53, BRCA1, and BRCA2 tumor suppressor genes are not commonly mutated in survivors of Hodgkin's disease with second primary neoplasms.
Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene.
Neoplastic Cells, Circulating
BRCA1 loss preexisting in small subpopulations of prostate cancer is associated with advanced disease and metastatic spread to lymph nodes and peripheral blood.
Differential Gene Expression of BRCA1,ERBB2 and TP53 biomarkers between Human Breast Tissue and Peripheral Blood Samples of Breast Cancer.
Identification of Somatically Acquired BRCA1/2 Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer.
Neoplastic Syndromes, Hereditary
Analysis and interpretation of RNA splicing alterations in genes involved in genetic disorders.
BRCA1/2 genetic background-based therapeutic tailoring of human ovarian cancer : hope or reality?
Comprehensive analysis of germline mutations in northern Brazil: a panel of 16 genes for hereditary cancer-predisposing syndrome investigation.
Development of a high risk pancreatic screening clinic using 3.0 T MRI.
Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers.
Hereditary cancer syndromes.
Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations.
Intrahepatic cholangiocarcinoma development in a patient with a novel BAP1 germline mutation and low exposure to asbestos.
Next-generation sequencing of BRCA1 and BRCA2 genes for rapid detection of germline mutations in hereditary breast/ovarian cancer.
Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry.
Resources to increase genetics and genomics capacity of oncology nurses.
[Prophylactic surgery of mammary and ovarian carcinoma.]
Nervous System Diseases
A Comprehensive Atlas of E3 Ubiquitin Ligase Mutations in Neurological Disorders.
Deficiency of TRIM32 Impairs Motor Function and Purkinje Cells in Mid-Aged Mice.
Detailed Dissection of UBE3A-Mediated DDI1 Ubiquitination.
Explaining intermediate filament accumulation in giant axonal neuropathy.
Giant axonal neuropathy-associated gigaxonin mutations impair intermediate filament protein degradation.
Involvement and interplay of Parkin, PINK1, and DJ1 in neurodegenerative and neuroinflammatory disorders.
Parkinson's disease-associated parkin colocalizes with Alzheimer's disease and multiple sclerosis brain lesions.
Part I: parkin-associated proteins and Parkinson's disease.
Phosphorylation of CHIP at Ser20 by Cdk5 promotes tAIF-mediated neuronal death.
Primary progressive multiple sclerosis developing in the context of young onset Parkinson's disease.
RNF20 controls astrocytic differentiation through epigenetic regulation of STAT3 in the developing brain.
The Angelman Syndrome protein Ube3A regulates synapse development by ubiquitinating arc.
The HECT E3 Ligase E6AP/UBE3A as a Therapeutic Target in Cancer and Neurological Disorders.
Neuralgia
Dysregulation of p53 and Parkin Induce Mitochondrial Dysfunction and Leads to the Diabetic Neuropathic Pain.
Dysregulation of voltage-gated sodium channels by ubiquitin ligase NEDD4-2 in neuropathic pain.
E3 Ubiquitin Ligase c-cbl Inhibits Microglia Activation After Chronic Constriction Injury.
Increased expression of the Cbl family of E3 ubiquitin ligases decreases Interleukin-2 production in a rat model of peripheral neuropathy.
Neurilemmoma
Axl/Gas6/NF?B signalling in schwannoma pathological proliferation, adhesion and survival.
Neuroblastoma
Differential effects of Parkin and its mutants on protein aggregation, the ubiquitin-proteasome system, and neuronal cell death in human neuroblastoma cells.
Direct effects of Bmi1 on p53 protein stability inactivates oncoprotein stress responses in embryonal cancer precursor cells at tumor initiation.
Disease-associated tau impairs mitophagy by inhibiting Parkin translocation to mitochondria.
DJ-1 is indispensable for the S-nitrosylation of Parkin, which maintains function of mitochondria.
Down-regulation of parkin protein in transient focal cerebral ischemia: A link between stroke and degenerative disease?
E3 Ubiquitin Ligase Nedd4 Promotes Japanese Encephalitis Virus Replication by Suppressing Autophagy in Human Neuroblastoma Cells.
Expression analysis of the gene encoding for the U-box-type ubiquitin ligase UBE4A in human tissues.
Formation of parkin aggregates and enhanced PINK1 accumulation during the pathogenesis of Parkinson's disease.
Gene expression profiles and protein-protein interaction networks in neuroblastoma with MEIS2 depletion.
Induction of parkin expression in the presence of oxidative stress.
K27 ubiquitination of the mitochondrial transport protein Miro is dependent on serine 65 of the Parkin ubiquitin ligase.
Lack of direct role of parkin in the steady-state level and aggregation of alpha-synuclein and the clearance of pre-formed aggregates.
Linking a compound-heterozygous Parkin mutant (Q311R and A371T) to Parkinson's disease by using proteomic and molecular approaches.
Low UBE4B expression increases sensitivity of chemoresistant neuroblastoma cells to EGFR and STAT5 inhibition.
N-myc regulates parkin expression.
Neuroblastoma patient outcomes, tumor differentiation, and ERK activation are correlated with expression levels of the ubiquitin ligase UBE4B.
Parkin attenuates wild-type tau modification in the presence of beta-amyloid and alpha-synuclein.
Parkin increases dopamine uptake by enhancing the cell surface expression of dopamine transporter.
Parkin Interacts with Apoptosis-Inducing Factor and Interferes with Its Translocation to the Nucleus in Neuronal Cells.
Parkin is metabolized by the ubiquitin/proteosome system.
Parkin is not regulated by the unfolded protein response in human neuroblastoma cells.
Parkin is recruited into aggresomes in a stress-specific manner: over-expression of parkin reduces aggresome formation but can be dissociated from parkin's effect on neuronal survival.
Parkin phosphorylation and modulation of its E3 ubiquitin ligase activity.
Parkin promotes intracellular Abeta1-42 clearance.
Parkin protects against tyrosinase-mediated dopamine neurotoxicity by suppressing stress-activated protein kinase pathways.
Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis.
Parkin protects mitochondrial genome integrity and supports mitochondrial DNA repair.
Parkin Selectively Alters the Intrinsic Threshold for Mitochondrial Cytochrome C Release.
Parkin suppresses the expression of monoamine oxidases.
Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation.
Parkin-mediated Ubiquitination Regulates Phospholipase C-gamma1.
Prp19 Is an Independent Prognostic Marker and Promotes Neuroblastoma Metastasis by Regulating the Hippo-YAP Signaling Pathway.
Repeated exposure of cocaine alters mitochondrial dynamics in mouse neuroblastoma Neuro2a.
Restriction of trophic factors and nutrients induces PARKIN expression.
Ret rescues mitochondrial morphology and muscle degeneration of Drosophila Pink1 mutants.
Targeting MDM2 for Neuroblastoma Therapy: In Vitro and In Vivo Anticancer Activity and Mechanism of Action.
Temporal proteomics of NGF-TrkA signaling identifies an inhibitory role for the E3 ligase Cbl-b in neuroblastoma cell differentiation.
The long non-coding RNA GAS5 differentially regulates cell cycle arrest and apoptosis through activation of BRCA1 and p53 in human neuroblastoma.
The two human homologues of yeast UFD2 ubiquitination factor, UBE4A and UBE4B, are located in common neuroblastoma deletion regions and are subject to mutations in tumours.
TRIM32 promotes retinoic acid receptor ?-mediated differentiation in human promyelogenous leukemic cell line HL60.
UBE4B levels are correlated with clinical outcomes in neuroblastoma patients and with altered neuroblastoma cell proliferation and sensitivity to epidermal growth factor receptor inhibitors.
UBE4B, a microRNA-9 target gene, promotes autophagy-mediated Tau degradation.
Ubiquitination of IGF2BP3 by E3 ligase MKRN2 regulates the proliferation and migration of human neuroblastoma SHSY5Y cells.
Ubiquitination of p21 by E3 Ligase TRIM21 Promotes the Proliferation of Human Neuroblastoma Cells.
Neurodegenerative Diseases
A Decade of Boon or Burden: What Has the CHIP Ever Done for Cellular Protein Quality Control Mechanism Implicated in Neurodegeneration and Aging?
Altered Transcriptional Profile of Mitochondrial DNA-Encoded OXPHOS Subunits, Mitochondria Quality Control Genes, and Intracellular ATP Levels in Blood Samples of Patients with Parkinson's Disease.
Ambra1: A Parkin-binding protein involved in mitophagy.
Ataxin-3 deubiquitination is coupled to Parkin ubiquitination via E2 ubiquitin-conjugating enzyme.
Autoregulation of Parkin activity through its ubiquitin-like domain.
Both thapsigargin- and tunicamycin-induced endoplasmic reticulum stress increases expression of Hrd1 in IRE1-dependent fashion.
Brain banking for neurodegenerative diseases.
Clinical and Genetic Characterization of Autosomal Recessive Spinocerebellar Ataxia Type 16 (SCAR16) in Taiwan.
Comparative genomics and protein domain graph analyses link ubiquitination and RNA metabolism.
Cross-functional E3 ligases Parkin and C-terminus Hsp70-interacting protein in neurodegenerative disorders.
Discovery of Therapeutic Deubiquitylase Effector Molecules: Current Perspectives.
Dorfin localizes to the ubiquitylated inclusions in Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and amyotrophic lateral sclerosis.
Drosophila parkin requires PINK1 for mitochondrial translocation and ubiquitinates mitofusin.
Early Dysfunction of Substantia Nigra Dopamine Neurons in the ParkinQ311X Mouse.
Enhancing mitophagy as a therapeutic approach for neurodegenerative diseases.
Eukaryotic translation elongation factor 1 delta inhibits the ubiquitin ligase activity of SIAH-1.
Expression in the mammalian retina of parkin and UCH-L1, two components of the ubiquitin-proteasome system.
Folic Acid Supplementation Ameliorates Oxidative Stress, Metabolic Functions and Developmental Anomalies in a Novel Fly Model of Parkinson's Disease.
Genetics of Lafora progressive myoclonic epilepsy: current perspectives.
Glutathione s-transferase omega 1 activity is sufficient to suppress neurodegeneration in a Drosophila model of Parkinson disease.
Haploinsufficiency of the TDP43 ubiquitin E3 ligase RNF220 leads to ALS-like motor neuron defects in the mouse.
Hyperphosphorylated tau aggregates in the cortex and hippocampus of transgenic mice with mutant human FTDP-17 Tau and lacking the PARK2 gene.
Impact of altered phosphorylation on loss of function of juvenile Parkinsonism-associated genetic variants of the E3 ligase parkin.
Isolated RING2 domain of parkin is sufficient for E2-dependent E3 ligase activity.
Loss of malin, but not laforin, results in compromised autophagic flux and proteasomal dysfunction in cells exposed to heat shock.
Mechanisms of neuronal homeostasis: autophagy in the axon.
Minocycline protects, rescues and prevents knockdown transgenic parkin Drosophila against paraquat/iron toxicity: Implications for autosomic recessive juvenile parkinsonism.
Mitochondria-affecting small molecules ameliorate proteostasis defects associated with neurodegenerative diseases.
Mitochondrial autophagy in neural function, neurodegenerative disease, neuron cell death, and aging.
Mitochondrial Dynamics and Parkinson's Disease: Focus on Parkin.
Mitochondrial dysfunction precedes neurodegeneration in mahogunin (Mgrn1) mutant mice.
Mitophagy in neurodegeneration and aging.
Molecular insights into Parkinson's disease.
Neurodegeneration in mnd2 mutant mice is not prevented by parkin transgene.
Neurodegenerative disease: pink, parkin and the brain.
Overexpression of parkin protects retinal ganglion cells in experimental glaucoma.
p62/SQSTM1 cooperates with Parkin for perinuclear clustering of depolarized mitochondria.
Parkin attenuates wild-type tau modification in the presence of beta-amyloid and alpha-synuclein.
Parkin deficiency delays motor decline and disease manifestation in a mouse model of synucleinopathy.
Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function.
Parkin Levels Decrease in Fibroblasts With Progranulin (PGRN) Pathogenic Variants and in a Cellular Model of PGRN Deficiency.
Parkin mutant in the fly is largely rescued by metal-responsive transcription factor (MTF-1).
Parkin promotes intracellular Abeta1-42 clearance.
Parkin Regulation and Neurodegenerative Disorders.
Parkin reverses TDP-43-induced cell death and failure of amino acid homeostasis.
Parkin Ubiquitinates Drp1 for Proteasome-dependent Degradation: IMPLICATION OF DYSREGULATED MITOCHONDRIAL DYNAMICS IN PARKINSON DISEASE.
Pharmacological antagonism of kainate receptor rescues dysfunction and loss of dopamine neurons in a mouse model of human parkin-induced toxicity.
Quantitative analysis of nasal transcripts reveals potential biomarkers for Parkinson's disease.
Quantitative model of R-loop forming structures reveals a novel level of RNA-DNA interactome complexity.
Regulation of caspase-3 processing by cIAP2 controls the switch between pro-inflammatory activation and cell death in microglia.
Relative high frequency of the c.255delA parkin gene mutation in Spanish patients with autosomal recessive parkinsonism.
Salubrinal, ER stress inhibitor, attenuates kainic acid-induced hippocampal cell death.
Solution Structure of the Ubiquitin-associated (UBA) Domain of Human Autophagy Receptor NBR1 and its Interaction with Ubiquitin and Polyubiquitin.
Somatic and germline mutations in the tumor suppressor gene PARK2 impair PINK1/Parkin-mediated mitophagy in lung cancer cells.
Structural studies of parkin and sacsin: Mitochondrial dynamics in neurodegenerative diseases.
Structure of the human Parkin ligase domain in an autoinhibited state.
Suppression of Parkin enhances nigrostriatal and motor neuron lesion in mice over-expressing human-mutated tau protein.
The Challenge of the Pathogenesis of Parkinson's Disease: Is Autoimmunity the Culprit?
The PINK1-Parkin axis: An Overview.
The Relationship between Parkin and Protein Aggregation in Neurodegenerative Diseases.
The role of synphilin-1 in the pathogenesis of Parkinson's disease.
The role of ubiquitin-protein ligases in neurodegenerative disease.
The synaptic function of parkin.
The ubiquitin-proteasome pathway is necessary for maintenance of the postmitotic status of neurons.
UBE4B: A Promising Regulatory Molecule in Neuronal Death and Survival.
Using proteomics to identify ubiquitin ligase-substrate pairs: how novel methods may unveil therapeutic targets for neurodegenerative diseases.
[Regulation of the protein degradation pathway by the ubiquitin family: its implication in neurodegenerative diseases]
Neuroendocrine Tumors
Homologous Recombination Repair Defect May Predict Treatment Response to Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors.
Neurofibromatoses
Early-Onset Breast Cancer in a Family with Neurofibromatosis Type 1 Associated with a Germline Mutation in BRCA1.
Germline mutations in NF1 and BRCA1 in a family with neurofibromatosis type 1 and early-onset breast cancer.
Giant Intrathoracic Meningocele and Breast Cancer in a Neurofibromatosis Type I Patient.
Preimplantation genetic diagnosis for cancer predisposition syndromes.
Structural basis of DDB1-and-Cullin 4-associated Factor 1 (DCAF1) recognition by merlin/NF2 and its implication in tumorigenesis by CD44-mediated inhibition of merlin suppression of DCAF1 function.
Neurofibromatosis 1
Early-Onset Breast Cancer in a Family with Neurofibromatosis Type 1 Associated with a Germline Mutation in BRCA1.
Germline mutations in NF1 and BRCA1 in a family with neurofibromatosis type 1 and early-onset breast cancer.
Neurofibromatosis 2
Preimplantation genetic diagnosis for cancer predisposition syndromes.
Structural basis of DDB1-and-Cullin 4-associated Factor 1 (DCAF1) recognition by merlin/NF2 and its implication in tumorigenesis by CD44-mediated inhibition of merlin suppression of DCAF1 function.
Neurofibrosarcoma
Clinical and molecular prognostic predictors of malignant peripheral nerve sheath tumor.
Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.
Neuroinflammatory Diseases
A systematic review of molecular approaches that link mitochondrial dysfunction and neuroinflammation in Parkinson's disease.
Genetic Imaging of Neuroinflammation in Parkinson's Disease: Recent Advancements.
Involvement and interplay of Parkin, PINK1, and DJ1 in neurodegenerative and neuroinflammatory disorders.
Loss of Microglial Parkin Inhibits Necroptosis and Contributes to Neuroinflammation.
Neuroinflammation in Parkinson's Disease.
Neurotoxic effects of MPTP on mouse cerebral cortex: Modulation of neuroinflammation as a neuroprotective strategy.
PARKIN modifies peripheral immune response and increases neuroinflammation in active experimental autoimmune encephalomyelitis (EAE).
Phosphoglycerate Mutase 5 Knockdown Alleviates Neuronal Injury After Traumatic Brain Injury Through Drp1-Mediated Mitochondrial Dysfunction.
Potential of PINK1 and PARKIN Proteins as Biomarkers for Active Multiple Sclerosis: A Japanese Cohort Study.
The E3 Ubiquitin Ligase c-Cbl Inhibits Microglia-Mediated CNS Inflammation by Regulating PI3K/Akt/NF-?B Pathway.
The E3 ubiquitin ligase HectD3 attenuates cardiac hypertrophy and inflammation in mice.
TRIM62 knockout protects against cerebral ischemic injury in mice by suppressing NLRP3-regulated neuroinflammation.
USP15 regulates type I interferon response and is required for pathogenesis of neuroinflammation.
Neutropenia
Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom.
BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients.
Nevus
c-CBL regulates melanoma proliferation, migration, invasion and the FAK-SRC-GRB2 nexus.
Caspases and inhibitor of apoptosis proteins in cutaneous and mucosal melanoma: expression profile and clinicopathologic significance.
Prevalence and Preliminary Validation of Screening Criteria to Identify Carriers of Germline BAP1 Mutations.
Nevus, Pigmented
c-CBL regulates melanoma proliferation, migration, invasion and the FAK-SRC-GRB2 nexus.
Newcastle Disease
Molecular characterization, tissue distribution and expression analysis of TRIM25 in Gallus gallus domesticus.
Newcastle Disease Virus V Protein Degrades Mitochondrial Antiviral Signaling Protein To Inhibit Host Type I Interferon Production via E3 Ubiquitin Ligase RNF5.
Viral strategies for triggering and manipulating mitophagy.
Nijmegen Breakage Syndrome
Inactivation of the Nijmegen breakage syndrome gene leads to excess centrosome duplication via the ATR/BRCA1 pathway.
Interactions of the Nijmegen breakage syndrome protein with ATM and BRCA1.
Repair versus Checkpoint Functions of BRCA1 Are Differentially Regulated by Site of Chromatin Binding.
The forkhead-associated domain of NBS1 is essential for nuclear foci formation after irradiation but not essential for hRAD50[middle dot]hMRE11[middle dot]NBS1 complex DNA repair activity.
The Interaction of CtIP and Nbs1 Connects CDK and ATM to Regulate HR-Mediated Double-Strand Break Repair.
Non-alcoholic Fatty Liver Disease
Dual roles of ULK1 (unc-51 like autophagy activating kinase 1) in cytoprotection against lipotoxicity.
Gp78, an E3 ubiquitin ligase acts as a gatekeeper suppressing nonalcoholic steatohepatitis (NASH) and liver cancer.
Hepatocyte SH3RF2 Deficiency Is a Key Aggravator for NAFLD.
Triggering of Parkin Mitochondrial Translocation in Mitophagy: Implications for Liver Diseases.
non-specific serine/threonine protein kinase deficiency
Inhibition of LRRK2 restores parkin-mediated mitophagy and attenuates intervertebral disc degeneration.
Noonan Syndrome
Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype.
Obesity
Alarming Burden of Triple-negative Breast Cancer in India.
BRCA1 and acetyl-CoA carboxylase: the metabolic syndrome of breast cancer.
Breast cancer 1 (BrCa1) may be behind decreased lipogenesis in adipose tissue from obese subjects.
Casitas B-Lineage Lymphoma RING Domain Inhibitors Protect Mice against High-Fat Diet-Induced Obesity and Insulin Resistance.
Casitas b-Lineage Lymphoma-Deficient Mice Are Protected Against High-Fat Diet-Induced Obesity and Insulin Resistance.
Decrease of Cardiac Parkin Protein in Obese Mice.
E3 Ligase FBXW2 Is a New Therapeutic Target in Obesity and Atherosclerosis.
Effects of obesity on breast aromatase expression and systemic metabo-inflammation in women with BRCA1 or BRCA2 mutations.
Enhanced susceptibility of ovaries from obese mice to 7,12-dimethylbenz[a]anthracene-induced DNA damage.
Identification of the inhibitory activity of walnut extract on the E3 ligase Syvn1.
Inactivation of the E3 Ubiquitin Ligase IDOL (Inducible Degrader of the Low-Density Lipoprotein Receptor) Attenuates Diet-Induced Obesity and Metabolic Dysfunction in Mice.
ITCH deficiency protects from diet-induced obesity.
Mex3c mutation reduces adiposity partially through increasing physical activity.
Obesity alters phosphoramide mustard-induced ovarian DNA repair in mice.
Obesity alters the ovarian DNA damage response and apoptotic proteins.
Obesity alters the ovarian proteomic response to zearalenone exposure†.
Requirement of SRC-family tyrosine kinases in fat accumulation.
Rotating night work, lifestyle factors, obesity and promoter methylation in BRCA1 and BRCA2 genes among nurses and midwives.
SCFJFK is functionally linked to obesity and metabolic syndrome.
The E3 ubiquitin ligase parkin is dispensable for metabolic homeostasis in murine pancreatic ? cells and adipocytes.
The mahoganoid mutation (Mgrn1md) improves insulin sensitivity in mice with mutations in the melanocortin signaling pathway independently of effects on adiposity.
The NRF2?PGC?1? pathway activates kynurenine aminotransferase 4 via attenuation of an E3 ubiquitin ligase, synoviolin, in a cecal ligation/perforation?induced septic mouse model.
Ubiquitin ligase Cbl-b and obesity-induced insulin resistance [Review].
What model organisms and interactomics can reveal about the genetics of human obesity.
Obesity, Maternal
Cellular inhibitors of apoptosis (cIAP) 1 and 2 are increased in placenta from obese pregnant women.
Maternal Obesity Alters Placental Cell Cycle Regulators in the First Trimester of Human Pregnancy: New Insights for BRCA1.
Obesity, Morbid
The GID ubiquitin ligase complex is a regulator of AMPK activity and organismal lifespan.
Ocular Motility Disorders
Eye movement disorders are different in Parkin-linked and idiopathic early-onset PD.
Odontogenic Cysts
Expression profile of polycomb group proteins in odontogenic keratocyst and ameloblastoma.
Olfaction Disorders
Olfaction in Parkin heterozygotes and compound heterozygotes: the CORE-PD study.
Olfaction in three genetic and two MPTP-induced Parkinson's disease mouse models.
Oligodendroglioma
Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden.
Glioma tumor grade correlates with parkin depletion in mutant p53-linked tumors and results from loss of function of p53 transcriptional activity.
Simultaneous osteosarcoma and renal cell carcinoma with BRCA1 mutation in a young male adult with prior oligodendroglioma.
Oligospermia
Investigating the relationship between BRCA1 and BRCA2 genes methylation profile and sperm DNA fragmentation in infertile men.
Optic Atrophy
Overexpression of Optic Atrophy Type 1 Protects Retinal Ganglion Cells and Upregulates Parkin Expression in Experimental Glaucoma.
Optic Atrophy, Autosomal Dominant
Curcumin prevents cisplatin-induced renal alterations in mitochondrial bioenergetics and dynamic.
Mitochondrial Dynamics of Proximal Tubular Epithelial Cells in Nephropathic Cystinosis.
Overexpression of Optic Atrophy Type 1 Protects Retinal Ganglion Cells and Upregulates Parkin Expression in Experimental Glaucoma.
Selective packaging of mitochondrial proteins into extracellular vesicles prevents the release of mitochondrial DAMPs.
Oropharyngeal Neoplasms
Cancer risks in women with 2 breast or ovarian cancers: clues to genetic cancer susceptibility.
Osteoarthritis
Mitophagy in degenerative joint diseases.
The E3 ubiquitin ligase Itch limits the progression of post-traumatic osteoarthritis in mice by inhibiting macrophage polarization.
Upregulation of Atrogin-1/FBXO32 is not necessary for cartilage destruction in mouse models of osteoarthritis.
Osteonecrosis
P53 and Parkin co-regulate mitophagy in bone marrow mesenchymal stem cells to promote the repair of early steroid-induced osteonecrosis of the femoral head.
Osteoporosis
Clomipramine causes osteoporosis by promoting osteoclastogenesis via E3 ligase Itch, which is prevented by Zoledronic acid.
Osteoporosis risk and management in BRCA1 and BRCA2 carriers who undergo risk-reducing salpingo-oophorectomy.
Women's health 2019: Osteoporosis, breast cancer, contraception, and hormone therapy.
Osteosarcoma
Activation of TNF-?/NF-?B axis enhances CRL4B
BRCA1-induced apoptosis involves inactivation of ERK1/2 activities.
Cooperation Between BRCA1 and p53 in Repair of Cyclobutane Pyrimidine Dimers.
CRL4B(DCAF11) E3 ligase targets p21 for degradation to control cell cycle progression in human osteosarcoma cells.
Dissociation of mammalian Polycomb-group proteins, Ring1B and Rae28/Ph1, from the chromatin correlates with configuration changes of the chromatin in mitotic and meiotic prophase.
DNA methylation-mediated downregulation of PTPN3 attenuates to boost TGF-? signaling in osteosarcoma cells.
Geranylgeranylacetone promotes human osteosarcoma cell apoptosis by inducing the degradation of PRMT1 through the E3 ubiquitin ligase CHIP.
Germline gene polymorphisms predisposing domestic mammals to carcinogenesis.
LncRNA NBR2 inhibits epithelial-mesenchymal transition by regulating Notch1 signaling in osteosarcoma cells.
MEX3C promotes osteosarcoma malignant progression through negatively regulating FGF14.
MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), amplified on chromosome 9, collaborate with p53 deficiency in mouse osteosarcoma progression.
Polycomb group molecule PHC3 regulates polycomb complex composition and prognosis of osteosarcoma.
Prolactin blocks nuclear translocation of VDR by regulating its interaction with BRCA1 in osteosarcoma cells.
Punicalagin suppresses osteosarcoma growth and metastasis by regulating NF-?B signaling.
RLIM interacts with Smurf2 and promotes TGF-? induced U2OS cell migration.
Rlim, an E3 ubiquitin ligase, influences the stability of Stathmin protein in human osteosarcoma cells.
Simultaneous osteosarcoma and renal cell carcinoma with BRCA1 mutation in a young male adult with prior oligodendroglioma.
Small molecule TSC01682 inhibits osteosarcoma cell growth by specifically disrupting the CUL4B-DDB1 interaction and decreasing the ubiquitination of CRL4B E3 ligase substrates.
Targeting the E3 ubiquitin casitas B-lineage lymphoma decreases osteosarcoma cell growth and survival and reduces tumorigenesis.
The human IFN-inducible p53 target gene TRIM22 colocalizes with the centrosome independently of cell cycle phase.
The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma.
The smac mimetic LCL161 targets established pulmonary osteosarcoma metastases in mice.
YWHAZ Binds to TRIM21 but Is Not Involved in TRIM21-stimulated Osteosarcoma Cell Proliferation.
[Implication of the ubiquitin ligase c-Cbl in bone formation and tumorigenesis].
Ovarian Cysts
Laparoscopic Salpingo-oophorectomy in Conscious Sedation.
Ovarian Neoplasms
"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
"It wasn't just for me": Motivations and implications of genetic testing for women at a low risk of hereditary breast and ovarian cancer syndrome.
"Other" breast cancer susceptibility genes: searching for more holy grail.
"Ring-fencing" BRCA1 tumor suppressor activity.
"Sequencing-grade" screening for BRCA1 variants by oligo-arrays.
19p13.1 is a triple negative-specific breast cancer susceptibility locus.
1H, 13C and 15N backbone resonance assignment of BRCA1 fragment 219-504.
22 genes from chromosome 17q21: cloning, sequencing, and characterization of mutations in breast cancer families and tumors.
53BP1 ablation rescues genomic instability in mice expressing 'RING-less' BRCA1.
53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells.
53BP1 is a positive regulator of the BRCA1 promoter.
6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance.
A 1-kb Alu-mediated germ-line deletion removing BRCA1 exon 17.
A 400 kb novel deletion unit centromeric to the BRCA1 gene in sporadic epithelial ovarian cancer.
A 45-year follow-up of kindred 107 and the search for BRCA2.
A biochemical analysis demonstrates that the BRCA1 intronic variant IVS10-2A--> C is a mutation.
A BRCA1 mutant alters G2-M cell cycle control in human mammary epithelial cells.
A BRCA1 mutation in Native North American families.
A BRCA2 mutation incorrectly mapped in the original BRCA2 reference sequence, is a common West Danish founder mutation disrupting mRNA splicing.
A Case Report of Germline Compound Heterozygous Mutations in the BRCA1 Gene of an Ovarian and Breast Cancer Patient.
A case series of three Sri Lankan families with hereditary breast and ovarian cancer syndrome due to pathogenic germline mutations in the BRCA1 gene
A Clinically Validated Diagnostic Second-Generation Sequencing Assay for Detection of Hereditary BRCA1 and BRCA2 Mutations.
A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening.
A common BRCA1 mutation in Norwegian breast and ovarian cancer families?
A common Greenlandic Inuit BRCA1 RING domain founder mutation.
A common region of deletion on chromosome 17q in both sporadic and familial epithelial ovarian tumors distal to BRCA1.
A common SNP in the uracil-DNA glycosylase gene UNG decreases ovarian cancer risk in BRCA2 mutation carriers.
A Comparative Analysis of Breast and Ovarian Cancer-related Gene Mutations in Canadian and Saudi Arabian Patients with Breast Cancer.
A comparison of ovarian cancer mortality in women with BRCA1 mutations undergoing annual ultrasound screening or preventive oophorectomy.
A competing risks model with binary time varying covariates for estimation of breast cancer risks in BRCA1 families.
A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes.
A computational model for classification of BRCA2 variants using mouse embryonic stem cell-based functional assays.
A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.
A CRISPR-based base-editing screen for the functional assessment of BRCA1 variants.
A critical re-appraisal of BRCA1 methylation studies in ovarian cancer.
A de novo complete BRCA1 gene deletion identified in a Spanish woman with early bilateral breast cancer.
A diagnostic genetic test for the physical mapping of germline rearrangements in the susceptibility breast cancer genes BRCA1 and BRCA2.
A DNA-Damage Selective Role for BRCA1 E3 Ligase in Claspin Ubiquitylation, CHK1 Activation, and DNA Repair.
A Dominantly Inherited 5' UTR Variant Causing Methylation-Associated Silencing of BRCA1 as a Cause of Breast and Ovarian Cancer.
A family pedigree of malignancies associated with BRCA1 pathogenic variants: a reflection of the state of art in China.
A family with three germline mutations in BRCA1 and BRCA2.
A fluorescent multiplex-DGGE screening test for mutations in the BRCA1 gene.
A founder mutation of the BRCA1 gene in Western Sweden associated with a high incidence of breast and ovarian cancer.
A frameshift mutation in BRCA1 leads to hereditary breast and ovarian cancer in one part of a family and to familial pancreatic cancer in another.
A Functional Analysis of the Unclassified Pro2767Ser BRCA2 Variant Reveals Its Potential Pathogenicity that Acts by Hampering DNA Binding and Homology-Mediated DNA Repair.
A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis.
A gene (DLG2) located at 17q12-q21 encodes a new homologue of the Drosophila tumor suppressor dIg-A.
A genome-wide strategy to identify causes and consequences of retrotransposon expression finds activation by BRCA1 in ovarian cancer.
A germline mutation in the BRCA1 3'UTR predicts Stage IV breast cancer.
A guide for functional analysis of BRCA1 variants of uncertain significance.
A haplotype-based case-control study of BRCA1 and sporadic breast cancer risk.
A high frequent BRCA1 founder mutation identified in the Greenlandic population.
A high incidence of BRCA1 mutations in 20 breast-ovarian cancer families.
A high proportion of founder BRCA1 mutations in Polish breast cancer families.
A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families.
A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer.
A High-Throughput Functional Complementation Assay for Classification of BRCA1 Missense Variants.
A highly accurate, low cost test for BRCA1 mutations.
A highly sensitive, fast, and economical technique for mutation analysis in hereditary breast and ovarian cancers.
A Human Head and Neck Squamous Cell Carcinoma Cell Line with Acquired cis-Diamminedichloroplatinum-Resistance Shows Remarkable Upregulation of BRCA1 and Hypersensitivity to Taxane.
A large kindred with 17q-linked breast and ovarian cancer: genetic, phenotypic, and genealogical analysis.
A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families.
A Lowering of Breast and Ovarian Cancer Risk in Women with a BRCA1 Mutation by Selenium Supplementation of Diet.
A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance.
A metastasis of an adenocarcinoma in a BRCA1 mutation carrier, a diagnostic problem not solved by morphology alone.
A missense mutation in the BRCA2 gene in three siblings with ovarian cancer.
A model for estimating ovarian cancer risk: application for preventive oophorectomy.
A mouse model for the molecular characterization of brca1-associated ovarian carcinoma.
A multi-exonic BRCA1 deletion identified in multiple families through single nucleotide polymorphism haplotype pair analysis and gene amplification with widely dispersed primer sets.
A multi-gene panel study in hereditary breast and ovarian cancer in Colombia.
A multi-institutional study on the association between BRCA1/BRCA2 mutational status and triple-negative breast cancer in familial breast cancer patients.
A Multiplex Homology-Directed DNA Repair Assay Reveals the Impact of More Than 1,000 BRCA1 Missense Substitution Variants on Protein Function.
A mutation analysis of the BRCA1 gene in 140 families from southeast France with a history of breast and/or ovarian cancer.
A Nano-Biosensor for the Detection of 185delAG Mutation in BRCA1 Gene, Leading to Breast Cancer.
A naturally occurring allele of BRCA1 coding for a temperature-sensitive mutant protein.
A new bioinformatics tool to help assess the significance of BRCA1 variants.
A new BRCA1 mutation in a Filipino woman with a family history of breast and ovarian cancer.
A new germline mutation in BRCA1 gene in a sicilian family with ovarian cancer.
A new paradigm of genetic testing for hereditary breast/ovarian cancers.
A new pathogenic mutation of the BRCA1 gene in a patient with ovarian cancer: A case report.
A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO.
A new strategy for prophylactic surgery in BRCA women: Combined mastectomy and laparoscopic salpingo-oophorectomy with immediate reconstruction by double DIEP flap.
A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers.
A novel BRCA-1 mutation in Arab kindred from east Jerusalem with breast and ovarian cancer.
A novel BRCA1 mutation in a patient with breast and ovarian cancer: A case report.
A novel BRCA1 mutation in a Spanish patient with ovarian cancer.
A novel BRCA1 mutation in an Indian family with hereditary breast/ovarian cancer.
A novel crosstalk between BRCA1 and sirtuin 1 in ovarian cancer.
A novel deleterious c.2656G>T MSH2 germline mutation in a Pakistani family with a phenotypic overlap of hereditary breast and ovarian cancer and Lynch syndrome.
A novel deletion of BRCA1 gene that eliminates the ATG initiation codon without affecting the promoter region.
A novel domain of BRCA1 interacts with p53 in breast cancer cells.
A novel germline BRCA1 mutation identified in a family with hereditary breast and ovarian cancer syndrome.
A novel method to detect the Mexican founder mutation BRCA1 ex9?12del associated with breast and ovarian cancer using quantitative polymerase chain reaction and TaqMan® probes.
A novel mutation in BRCA1 linked to breast and ovarian cancer and a genotype-phenotype correlation.
A Novel Mutation-BRCA1 Associated Hereditary Haplotype of Intragenic Markers of BRCA1 Gene in a Family with History of Breast Cancer
A Novel Pathogenic BRCA1 Splicing Variant Produces Partial Intron Retention in the Mature Messenger RNA.
A Novel Pathway that Links Caveolin-1 Down-Regulation to BRCA1 Dysfunction in Serous Epithelial Ovarian Cancer Cells.
A Novel Splice Site Mutation in the Noncoding Region of BRCA2: Implications for Fanconi Anemia and Familial Breast Cancer Diagnostics.
A novel tricomplex of BRCA1, Nmi, and c-Myc inhibits c-Myc-induced human telomerase reverse transcriptase gene (hTERT) promoter activity in breast cancer.
A nuclear function for the tumor suppressor BRCA1.
A one-step prescreening for point mutations and large rearrangement in BRCA1 and BRCA2 genes using quantitative polymerase chain reaction and high-resolution melting curve analysis.
A P1-based physical map of the region from D17S776 to D17S78 containing the breast cancer susceptibility gene BRCA1.
A Phase 2, Single Arm Study of Iniparib in Patients With BRCA1 or BRCA2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol.
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.
A physical map and candidate genes in the BRCA1 region on chromosome 17q12-21.
A physical map encompassing GP2B, EPB3, D17S183, D17S78, D17S1183, and D17S1184.
A Pilot Study on Screening of BRCA1 Mutations (185delAG, 1294del40) in Nepalese Breast Cancer Patients.
A Population-Based Analysis of BRCA1/2 Genes and Associated Breast and Ovarian Cancer Risk in Korean Patients: A Multicenter Cohort Study.
A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention.
A population-based assessment of the clustering of breast cancer in families eligible for testing of BRCA1 and BRCA2 mutations.
A population-based study of BRCA1 and BRCA2 mutations in Jewish women with epithelial ovarian cancer.
A potent bivalent Smac mimetic (SM-1200) achieving rapid, complete, and durable tumor regression in mice.
A preliminary validation of a family history assessment form to select women at risk for breast or ovarian cancer for referral to a genetics center.
A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families.
A profile on the FoundationFocus CDxBRCA tests.
A prospective investigation of predictive and modifiable risk factors for breast cancer in unaffected BRCA1 and BRCA2 gene carriers.
A protective role for BRCA2 at stalled replication forks.
A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS).
A review of histopathological subtypes of ovarian cancer in BRCA-related French Canadian cancer families.
A review of the clinical relevance of mismatch-repair deficiency in ovarian cancer.
A risk prediction algorithm for ovarian cancer incorporating BRCA1, BRCA2, common alleles and other familial effects.
A salpingeal carcinoma revealed after prophylactic salpingoophorectomy in an asymptomatic BRCA1 carrier with breast malignancy.
A screening for BRCA1 mutations in breast and breast-ovarian cancer families from the Stockholm region.
A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers.
A somatic mutation in the 5'UTR of BRCA1 gene in sporadic breast cancer causes down-modulation of translation efficiency.
A specific GFP expression assay, penetrance estimate, and histological assessment for a putative splice site mutation in BRCA1.
A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.
A survey of preventive measures among BRCA1 mutation carriers from Poland.
A systematic review and meta-analysis of telephone vs in-person genetic counseling in BRCA1/BRCA2 genetic testing.
A tandem duplication of BRCA1 exons 1-19 through DHX8 exon 2 in four families with hereditary breast and ovarian cancer syndrome.
A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population.
A Turn-On Detection of DNA Sequences by Means of Fluorescence of DNA-Templated Silver Nanoclusters via Unique Interactions of a Hydrated Ionic Liquid.
A UbcH5/ubiquitin noncovalent complex is required for processive BRCA1-directed ubiquitination.
A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers.
Aberrant methylation of breast and ovarian cancer susceptibility gene 1 in chemosensitive human ovarian cancer cells does not involve the phosphatidylinositol 3'-kinase-Akt pathway.
Aberrant subcellular localization of BRCA1 in breast cancer.
Ablation of the Brca1-Palb2 Interaction Phenocopies Fanconi Anemia in Mice.
Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response.
Absence of 185delAG and 6174delT Mutations among Breast Cancer Patients of Eastern India.
Absence of evidence for a familial breast cancer susceptibility gene at chromosome 8p12-p22.
Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families.
Absence of germline BRCA1 mutations in familial pancreatic cancer patients.
Acceptance of, inclination for, and barriers in genetic testing for gene mutations that increase the risk of breast and ovarian cancers among female residents of Warsaw.
Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations.
Accurate classification of BRCA1 variants with saturation genome editing.
Accurate detection and quantification of epigenetic and genetic second hits in BRCA1 and BRCA2-associated hereditary breast and ovarian cancer reveals multiple co-acting second hits.
Acellular fraction of ovarian cancer ascites induce apoptosis by activating JNK and inducing BRCA1, Fas and FasL expression in ovarian cancer cells.
Acetyl-CoA carboxylase alpha is essential to breast cancer cell survival.
Activation of BTAK expression in primary ovarian surface epithelial cells of prophylactic ovaries.
Addressing sexual dysfunction after risk-reducing salpingo-oophorectomy: effects of a brief, psychosexual intervention.
Advances in breast cancer: pathways to personalized medicine.
Advances in the biology of gynecologic cancer.
Advances in the management of epithelial ovarian cancer.
Advances in the understanding of risk factors for ovarian cancer.
Advances in the use of PARP inhibitor therapy for breast cancer.
Advances in the use of PARP inhibitors for BRCA1/2-associated breast cancer: talazoparib.
Advances in using PARP inhibitors to treat cancer.
Age and Geographical Distribution in Families with BRCA1/BRCA2 Mutations in the Slovak Republic.
Age at diagnosis as an indicator of eligibility for BRCA1 DNA testing in familial breast cancer.
Age at diagnosis of cancer in 185delAG BRCA1 mutation carriers of diverse ethnicities: tentative evidence for modifier factors.
Age of ovarian cancer diagnosis among BRIP1, RAD51C, and RAD51D mutation carriers identified through multi-gene panel testing.
Age-dependent penetrance of different germline mutations in the BRCA1 gene.
Age-specific incidence rates for breast cancer in carriers of BRCA1 mutations from Norway.
Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation.
Age-specific risks of incident, contralateral and ipsilateral breast cancer among 1776 Polish BRCA1 mutation carriers.
AKT regulates BRCA1 stability in response to hormone signaling.
ALDH1A1 contributes to PARP inhibitor resistance via enhancing DNA repair in BRCA2-/- ovarian cancer cells.
ALDH1A1 maintains ovarian cancer stem cell-like properties by altered regulation of cell cycle checkpoint and DNA repair network signaling.
Allelic imbalance in BRCA1 and BRCA2 gene expression and familial ovarian cancer.
Allelic loss on chromosome arm 8p: analysis of sporadic epithelial ovarian tumors.
Almost 2% of Spanish breast cancer families are associated to germline pathogenic mutations in the ATM gene.
Alterations in Brca1 expression in mouse ovarian granulosa cells have short-term and long-term consequences on estrogen-responsive organs.
Alterations in oncogenes, tumor suppressor genes, and growth factors associated with epithelial ovarian cancers.
Alterations in the common fragile site gene Parkin in ovarian and other cancers.
Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines.
Altered regulation of BRCA1 exon 11 splicing is associated with breast cancer risk in carriers of BRCA1 pathogenic variants.
Alternative splicing and molecular characterization of splice site variants: BRCA1 c.591C>T as a case study.
Alternative splicing of breast cancer associated gene BRCA1 from breast cancer cell line.
An Alu-mediated 7.1 kb deletion of BRCA1 exons 8 and 9 in breast and ovarian cancer families that results in alternative splicing of exon 10.
An antibody assay predictive of BRCA1 mutations in ovarian tumors and normal tissue.
An evaluation of common breast cancer gene mutations in a population of Ashkenazi Jews.
An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium.
An evaluation of needs of female BRCA1 and BRCA2 carriers undergoing genetic counselling.
An hGCN5/TRRAP histone acetyltransferase complex co-activates BRCA1 transactivation function through histone modification.
An identical novel mutation in BRCA1 and a common haplotype in familial ovarian cancer in non-Ashkenazi Jews.
An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
An inevitable dilemma: prenatal testing for mutations in the BRCA1 breast-ovarian cancer susceptibility gene.
An unaffected individual from a breast/ovarian cancer family with germline mutations in both BRCA1 and BRCA2.
Analysis of 30 putative BRCA1 splicing mutations in hereditary breast and ovarian cancer families identifies exonic splice site mutations that escape in silico prediction.
Analysis of a set of missense, frameshift, and in-frame deletion variants of BRCA1.
Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects.
Analysis of BRCA1 and BRCA2 mutations in an Iranian family with hereditary breast and ovarian cancer syndrome.
Analysis of BRCA1 and RAD51C Promoter Methylation in Italian Families at High-Risk of Breast and Ovarian Cancer.
Analysis of BRCA1 mutations in a Pakistani family with hereditary breast and ovarian cancer syndrome.
Analysis of BRCA1, TP53, and TSG101 germline mutations in German breast and/or ovarian cancer families.
Analysis of BRCA1/2 variants of unknown significance in the prospective Korean Hereditary Breast Cancer study.
Analysis of breast cancer susceptibility genes BRCA1 and BRCA2 in Thai familial and isolated early-onset breast and ovarian cancer.
Analysis of centrosome localization of BRCA1 and its activity in suppressing centrosomal aster formation.
Analysis of clinical characteristics of breast cancer patients with the Japanese founder mutation BRCA1 L63X.
Analysis of Founder Mutations in Rare Tumors Associated With Hereditary Breast/Ovarian Cancer Reveals a Novel Association of BRCA2 Mutations with Ampulla of Vater Carcinomas.
Analysis of large deletions in BRCA1, BRCA2 and PALB2 genes in Finnish breast and ovarian cancer families.
Analysis of PALB2 in a cohort of Italian breast cancer patients: identification of a novel PALB2 truncating mutation.
Analysis of the BRCA1 and BRCA2 genes in sporadic meningiomas.
Androgen receptor CAG repeat length in Jewish Israeli women who are BRCA1/2 mutation carriers: association with breast/ovarian cancer phenotype.
Anthropometric Measures and Risk of Ovarian Cancer Among BRCA1 and BRCA2 Mutation Carriers.
Anticipated uptake and impact of genetic testing in hereditary breast and ovarian cancer families.
Antisense blocking of BRCA1 enhances sensitivity to plumbagin but not tamoxifen in BG-1 ovarian cancer cells.
Antisense RNA to the putative tumor suppressor gene BRCA1 transforms mouse fibroblasts.
Appendectomy and cancer risk in Jewish BRCA1 and BRCA2 mutation carriers.
Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent.
Appraising iniparib, the PARP inhibitor that never was--what must we learn?
Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations.
Are CYP17 genotypes a biomarker for ovarian cancer in patients with cancer history in their family?
Are medullary breast cancers an indication for BRCA1 mutation screening? A mutation analysis of 42 cases of medullary breast cancer.
Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1.
Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families.
Assessment of blind predictions of the clinical significance of BRCA1 and BRCA2 variants.
Assessment of individuals with BRCA1 and BRCA2 large rearrangements in high-risk breast and ovarian cancer families.
Assessment of the functional impact of germline BRCA1/2 variants located in non-coding regions in families with breast and/or ovarian cancer predisposition.
Assessment of the Prognostic Value of Two Common Variants of BRCA1 and BRCA2 Genes in Ovarian Cancer Patients Treated with Cisplatin and Paclitaxel: A Gynecologic Oncology Group Study.
Association between basal-like phenotype and BRCA1/2 germline mutations in Korean breast cancer patients.
Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing.
Association between BRCA1 mutations and ratio of female to male births in offspring of families with breast cancer, ovarian cancer, or both.
Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Association between family history, mutation locations, and prevalence of BRCA1 or 2 mutations in ovarian cancer patients.
Association Between Loss-of-Function Mutations Within the FANCM Gene and Early-Onset Familial Breast Cancer.
Association between nonrandom X-chromosome inactivation and BRCA1 mutation in germline DNA of patients with ovarian cancer.
Association between the cervicovaginal microbiome, BRCA1 mutation status, and risk of ovarian cancer: a case-control study.
Association between vitamin D and ovarian cancer development in BRCA1 mutation carriers.
Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.
Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response.
Association of BRCA1/2 mutations with ovarian cancer prognosis: An updated meta-analysis.
Association of Breast and Ovarian Cancers With Predisposition Genes Identified by Large-Scale Sequencing.
Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3.
Association of death receptor 4 variant (683A>C) with ovarian cancer risk in BRCA1 mutation carriers.
Association of HMGB1, BRCA1 and P62 expression in ovarian cancer and chemotherapy sensitivity.
Association of Risk-Reducing Salpingo-Oophorectomy With Breast Cancer Risk in Women With BRCA1 and BRCA2 Pathogenic Variants.
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
Association of the BRCA1 promoter polymorphism rs11655505 with the risk of familial breast and/or ovarian cancer.
Association of the Variants CASP8 D302H and CASP10 V410I with Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.
Associations between single nucleotide polymorphisms in double-stranded DNA repair pathway genes and familial breast cancer.
Asymmetric real-time PCR detection of BRCA1 5382insC mutation by melting curve analysis in the LightCycler.
ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors.
ATM-Deficient Cancers Provide New Opportunities for Precision Oncology.
Attitudes toward preventive oophorectomy among BRCA1 mutation carriers in Poland.
Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2.
Attitudes, knowledge, risk perceptions and decision-making among women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2 and their spouses.
Autonomy of the epithelial phenotype in human ovarian surface epithelium: changes with neoplastic progression and with a family history of ovarian cancer.
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
Awareness and utilization of BRCA1/2 testing among U.S. primary care physicians.
Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families.
Baseline and post prophylactic tubal-ovarian surgery CA125 levels in BRCA1 and BRCA2 mutation carriers.
BBIT20 inhibits homologous DNA repair with disruption of the BRCA1-BARD1 interaction in breast and ovarian cancer.
BECN1 and BRCA1 Deficiency Sensitizes Ovarian Cancer to Platinum Therapy and Confers Better Prognosis.
Being Young, Female, and BRCA Positive.
Benchmarking of Amplicon-Based Next-Generation Sequencing Panels Combined with Bioinformatics Solutions for Germline BRCA1 and BRCA2 Alteration Detection.
Better life expectancy in women with BRCA2 compared with BRCA1 mutations is attributable to lower frequency and later onset of ovarian cancer.
Beyond BRCA1 and BRCA2 wild-type breast and/or ovarian cancer families: germline mutations in TP53 and PTEN.
Biallelic Deleterious BRCA1 Mutations in a Woman with Early-Onset Ovarian Cancer.
Bias in intervention studies that enroll patients from high-risk clinics.
Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers.
Bile acids upregulate BRCA1 and downregulate estrogen receptor 1 gene expression in ovarian cancer cells.
Binding and recognition in the assembly of an active BRCA1/BARD1 ubiquitin-ligase complex.
Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting.
Biomarkers in the ovary.
BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface.
BRACking news on triple-negative/basal-like breast cancers: how BRCA1 deficiency may result in the development of a selective tumor subtype.
BRC-1 acts in the inter-sister pathway of meiotic double-strand break repair.
BRCA 1 and 2--A Genetic Link to Familial Breast and Ovarian Cancer.
BRCA and Beyond: Comprehensive Image-rich Review of Hereditary Breast and Gynecologic Cancer Syndromes.
BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations.
BRCA genes: BRCA 1 and BRCA 2.
BRCA genes: lessons learned from experimental and clinical cancer.
BRCA Genes: The Role in Genome Stability, Cancer Stemness and Therapy Resistance.
BRCA genetic screening in Middle Eastern and North African: mutational spectrum and founder BRCA1 mutation (c.798_799delTT) in North African.
BRCA Mutation Carriers: Breast and Ovarian Cancer Screening Guidelines and Imaging Considerations.
BRCA mutation frequency and clinical features of ovarian cancer patients: A report from a Chinese study group.
BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
BRCA mutation rate and characteristics of prostate tumor in breast and ovarian cancer families: analysis of 6,591 Italian pedigrees.
BRCA mutation testing for first-degree relatives of women with high-grade serous ovarian cancer.
BRCA mutations and reproduction.
BRCA Share: A Collection of Clinical BRCA Gene Variants.
BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing.
BRCA-associated ovarian cancer: from molecular genetics to risk management.
BRCA1 1675delA and 1135insA account for one third of Norwegian familial breast-ovarian cancer and are associated with later disease onset than less frequent mutations.
BRCA1 185delAG Mutation Enhances Interleukin-1? Expression in Ovarian Surface Epithelial Cells.
BRCA1 185delAG mutation in a non-Ashkenazi Jewish woman with early-onset breast and ovarian cancer.
BRCA1 185delAG truncation protein, BRAt, amplifies caspase-mediated apoptosis in ovarian cells.
BRCA1 4153delA founder mutation in Russian ovarian cancer patients.
BRCA1 5382insC founder mutation has not a significative recurrent presence in Northeastern Romanian cancer patients.
BRCA1 affects lipid synthesis through its interaction with acetyl-CoA carboxylase.
BRCA1 affects the resistance and stemness of SKOV3-derived ovarian cancer stem cells by regulating autophagy.
BRCA1 allele-specific expression in genetic predisposed breast/ovarian cancer.
BRCA1 and BRCA1 Genes and Inherited Breast and/or Ovarian Cancer: Benefits of Genetic Testing.
BRCA1 and BRCA2 and the genetics of breast and ovarian cancer.
BRCA1 and BRCA2 are necessary for the transcription-coupled repair of the oxidative 8-oxoguanine lesion in human cells.
BRCA1 and BRCA2 as ovarian cancer susceptibility genes.
BRCA1 and BRCA2 families and the risk of skin cancer.
BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer.
BRCA1 and BRCA2 gene mutations in hereditary and sporadic ovarian cancer and the clinical implications.
BRCA1 and BRCA2 genes: role in hereditary breast and ovarian cancer in Italy.
BRCA1 and BRCA2 genetic test in high risk patients and families: counselling and management.
BRCA1 and BRCA2 genetic testing for ovarian cancer: is it all good news?
BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models.
BRCA1 and BRCA2 germ-line mutations and oral contraceptives: to use or not to use.
BRCA1 and BRCA2 germline mutation analysis among Indian women from south India: identification of four novel mutations and high-frequency occurrence of 185delAG mutation.
BRCA1 and BRCA2 germline mutation spectrum and frequencies in Belgian breast/ovarian cancer families.
BRCA1 and BRCA2 germline mutational spectrum and evidence for genetic anticipation in Portuguese breast/ovarian cancer families.
BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts.
BRCA1 and BRCA2 germline mutations in Korean ovarian cancer patients.
BRCA1 and BRCA2 germline mutations in lymphoma patients.
BRCA1 and BRCA2 germline testing in Cretan isolates reveals novel and strong founder effects.
BRCA1 and BRCA2 in breast cancer predisposition and recombination control.
BRCA1 and BRCA2 in breast cancer.
BRCA1 and BRCA2 in hereditary breast cancer.
BRCA1 and BRCA2 in Indian breast cancer patients.
BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer.
BRCA1 and BRCA2 mutation analysis in breast-ovarian cancer families from northeastern Poland.
BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer.
BRCA1 and BRCA2 mutation carriers as potential candidates for chemoprevention trials.
BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic.
BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
BRCA1 and BRCA2 mutation predictions using the BRCAPRO and Myriad models in Korean ovarian cancer patients.
BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark.
BRCA1 and BRCA2 mutation status and cancer family history of Danish women affected with multifocal or bilateral breast cancer at a young age.
BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
BRCA1 and BRCA2 mutations among ovarian cancer patients from Colombia.
BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population.
BRCA1 and BRCA2 mutations and the risk for colorectal cancer.
BRCA1 and BRCA2 mutations in a sample of breast and ovarian cancer families from the Colombian pacific.
BRCA1 and BRCA2 mutations in a South American population.
BRCA1 and BRCA2 mutations in an Asian clinic-based population detected using a comprehensive strategy.
BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and ovarian cancer.
BRCA1 and BRCA2 mutations in Belgian families with a history of breast and/or ovarian cancer.
BRCA1 and BRCA2 Mutations in Breast and Ovarian Cancer Syndrome: Reflection on the Creighton University Historical Series of High Risk Families.
BRCA1 and BRCA2 mutations in breast cancer families with multiple primary cancers.
BRCA1 and BRCA2 mutations in Danish families with hereditary breast and/or ovarian cancer.
BRCA1 and BRCA2 mutations in ethnic Lebanese Arab women with high hereditary risk breast cancer.
BRCA1 and BRCA2 mutations in Japanese patients with ovarian, fallopian tube, and primary peritoneal cancer.
BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.
BRCA1 and BRCA2 mutations in ovarian cancer patients from Belarus: update.
BRCA1 and BRCA2 mutations in ovarian cancer patients from China: ethnic-related mutations in BRCA1 associated with an increased risk of ovarian cancer.
BRCA1 and BRCA2 mutations in ovarian cancer.
BRCA1 and BRCA2 mutations in ovarian cancer: Covariation with specific cytogenetic features.
BRCA1 and BRCA2 mutations in Scotland and Northern Ireland.
BRCA1 and BRCA2 Mutations in the Ovarian Cancer Population across Race and Ethnicity: Special Reference to Asia.
BRCA1 and BRCA2 mutations in Turkish familial and non-familial ovarian cancer patients: a high incidence of mutations in non-familial cases.
BRCA1 and BRCA2 mutations in women from Shanghai China.
BRCA1 and BRCA2 mutations in women with familial or early-onset breast/ovarian cancer in the Czech Republic.
BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian.
BRCA1 and BRCA2 point mutations and large rearrangements in breast and ovarian cancer families in Northern Poland.
BRCA1 and BRCA2 protect against oxidative DNA damage converted into double-strand breaks during DNA replication.
BRCA1 and BRCA2 protein expressions in an ovotestis of a 46, XX true hermaphrodite.
BRCA1 and BRCA2 rearrangements in Brazilian individuals with Hereditary Breast and Ovarian Cancer Syndrome.
BRCA1 and BRCA2 sequence variations detected with next-generation sequencing in patients with premature ovarian insufficiency.
BRCA1 and BRCA2 Testing in Medically Underserved Medicare Beneficiaries With Breast or Ovarian Cancer.
BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.
BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double strand break repair.
BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis.
BRCA1 and BRCA2: the genetic testing and the current management options for mutation carriers.
BRCA1 and cell signaling.
Brca1 and differentiation.
BRCA1 and estrogen signaling in breast cancer.
BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents.
BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation.
BRCA1 and implications for response to chemotherapy in ovarian cancer.
BRCA1 and Its Network of Interacting Partners.
BRCA1 and MicroRNAs: Emerging networks and potential therapeutic targets.
BRCA1 and p53 regulate critical prostate cancer pathways.
BRCA1 and PALB2 in a Messy Breakup.
BRCA1 and prostate cancer.
BRCA1 and sex ratio.
BRCA1 as a nicotinamide adenine dinucleotide (NAD)-dependent metabolic switch in ovarian cancer.
BRCA1 as a tumor suppressor linked to the regulation of epigenetic states: keeping oncomiRs under control.
BRCA1 at the crossroad of multiple cellular pathways: approaches for therapeutic interventions.
BRCA1 Attenuates Progesterone Effects on Proliferation and NF?B Activation in Normal Human Mammary Epithelial Cells.
BRCA1 augments transcription by the NF-kappaB transcription factor by binding to the Rel domain of the p65/RelA subunit.
BRCA1 can modulate RNA polymerase II carboxy-terminal domain phosphorylation levels.
BRCA1 can stimulate gene transcription by a unique mechanism.
BRCA1 carries tumor suppressor activity distinct from that of p53 and p21.
BRCA1 Circos: a visualisation resource for functional analysis of missense variants.
BRCA1 contributes to cell cycle arrest and chemoresistance in response to the anticancer agent irofulven.
BRCA1 contributes to transcription-coupled repair of DNA damage through polyubiquitination and degradation of Cockayne syndrome B protein.
BRCA1 DEFICIENCY EXACERBATES ESTROGEN INDUCED DNA DAMAGE AND GENOMIC INSTABILITY.
BRCA1 deficiency in ovarian cancer is associated with alteration in expression of several key regulators of cell motility - A proteomics study.
BRCA1 deficiency increases the sensitivity of ovarian cancer cells to auranofin.
Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities.
BRCA1 deficiency sensitizes breast cancer cells to bromodomain and extra-terminal domain (BET) inhibition.
BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents.
BRCA1 deficient embryonic stem cells display a decreased homologous recombination frequency and an increased frequency of non-homologous recombination that is corrected by expression of a brca1 transgene.
BRCA1 does not paint the inactive X to localize XIST RNA but may contribute to broad changes in cancer that impact XIST and Xi heterochromatin.
BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance.
BRCA1 effects on the cell cycle and the DNA damage response are linked to altered gene expression.
BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer.
BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study.
BRCA1 Expression by Immunohistochemistry and Prognosis in Ovarian Cancer: A Systematic Review and Meta-Analysis.
BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study.
BRCA1 Expression is an Important Biomarker for Chemosensitivity: Suppression of BRCA1 Increases the Apoptosis via Up-regulation of p53 and p21 During Cisplatin Treatment in Ovarian Cancer Cells.
BRCA1 expression is epigenetically repressed in sporadic ovarian cancer cells by overexpression of C-terminal binding protein 2.
BRCA1 facilitates stress-induced apoptosis in breast and ovarian cancer cell lines.
BRCA1 founder mutations compared to ovarian cancer in Belarus.
BRCA1 founder mutations do not contribute to increased risk of gastric cancer in the Polish population.
BRCA1 gene in breast cancer.
BRCA1 gene mutation and loss of heterozygosity on chromosome 17q21 in primary prostate cancer.
BRCA1 Gene Mutation Screening for the Hereditary Breast and/or Ovarian Cancer Syndrome in Breast Cancer Cases: a First High Resolution DNA Melting Analysis in Indonesia.
BRCA1 gene mutations in sporadic ovarian carcinomas: detection by PCR and reverse allele-specific oligonucleotide hybridization.
BRCA1 gene mutations in women with papillary serous carcinoma of the peritoneum.
BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer - a population based study from the Western Sweden Health Care region.
BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD).
BRCA1 gene testing for breast and ovarian cancer in one family.
BRCA1 gene-related hereditary susceptibility to breast and ovarian cancer in Latvia.
BRCA1 gene: function and deficiency.
BRCA1 genetic mutation and its link to ovarian cancer: implications for advanced practice nurses.
BRCA1 genetic testing in 106 breast and ovarian cancer families from southern Italy (Sicily): a mutation analyses.
BRCA1 germline mutational spectrum in Italian families from Tuscany: a high frequency of novel mutations.
BRCA1 germline mutations and polymorphisms in a clinic-based series of ovarian cancer cases: a Gynecologic Oncology Group study.
BRCA1 germline mutations in Chinese patients with hereditary breast and ovarian cancer.
BRCA1 germline mutations in Indian familial breast cancer.
Brca1 heterozygous mice have shortened life span and are prone to ovarian tumorigenesis with haploinsufficiency upon ionizing irradiation.
BRCA1 in breast and ovarian cancer predisposition.
BRCA1 in cancer, cell cycle and genomic stability.
BRCA1 in hormone-responsive cancers.
BRCA1 in special populations.
BRCA1 in the DNA damage response and at telomeres.
BRCA1 interacts with acetyl-CoA carboxylase through its tandem of BRCT domains.
BRCA1 interacts with components of the histone deacetylase complex.
BRCA1 interacts with dominant negative SWI/SNF enzymes without affecting homologous recombination or radiation-induced gene activation of p21 or Mdm2.
BRCA1 is a novel target to improve endothelial dysfunction and retard atherosclerosis.
BRCA1 is a selective co-activator of 14-3-3 sigma gene transcription in mouse embryonic stem cells.
BRCA1 is an essential regulator of heart function and survival following myocardial infarction.
BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer.
BRCA1 is secreted and exhibits properties of a granin.
BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor.
BRCA1 methylation and BRCA1 mutations in ovarian cancer.
BRCA1 methylation: a significant role in tumour development?
BRCA1 modulates ionizing radiation-induced nuclear focus formation by the replication protein A p34 subunit.
BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer.
BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy.
BRCA1 mutation analysis in breast/ovarian cancer families from Greece.
BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.
BRCA1 mutation in breast cancer patients: Analysis of prognostic factors and survival.
BRCA1 Mutation Leads to Deregulated Ubc9 Levels which Triggers Proliferation and Migration of Patient-Derived High Grade Serous Ovarian Cancer and Triple Negative Breast Cancer Cells.
BRCA1 Mutation Status and Follicular Fluid Exposure Alters NF?B Signaling and ISGylation in Human Fallopian Tube Epithelial Cells.
BRCA1 mutation testing for Japanese patients with ovarian cancer in breast cancer screening.
BRCA1 mutations and survival in women with ovarian cancer.
BRCA1 mutations in a population-based sample of young women with breast cancer.
BRCA1 mutations in a population-based study of breast cancer in Stockholm County.
BRCA1 mutations in a selected series of breast/ovarian cancer patients.
BRCA1 mutations in familial ovarian cancer.
BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study.
BRCA1 mutations in primary breast and ovarian carcinomas.
BRCA1 mutations in South African breast and/or ovarian cancer families: evidence of a novel founder mutation in Afrikaner families.
BRCA1 mutations in Taiwanese with epithelial ovarian carcinoma and sporadic primary serous peritoneal carcinoma.
BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer.
BRCA1 mutations in women with familial or early-onset breast cancer and BRCA2 mutations in familial cancer in Estonia.
BRCA1 mutations in women with ovarian cancer.
BRCA1 p.His1673del is a pathogenic mutation associated with a predominant ovarian cancer phenotype.
BRCA1 p.Val1688del is a deleterious mutation that recurs in breast and ovarian cancer families from Northeast Italy.
BRCA1 partially reverses the transforming activity of the ras oncogene.
BRCA1 physically and functionally interacts with ATF1.
BRCA1 physically associates with p53 and stimulates its transcriptional activity.
BRCA1 promoter deletions in young women with breast cancer and a strong family history: a population-based study.
BRCA1 promoter hypermethylation and protein expression in ovarian carcinoma-an Indian study.
BRCA1 promoter methylation and clinical outcomes in ovarian cancer: an individual patient data meta-analysis.
BRCA1 promoter methylation is a marker of better response to platinum-taxane-based therapy in sporadic epithelial ovarian cancer.
BRCA1 promoter methylation predicts adverse ovarian cancer prognosis.
BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study.
BRCA1 protein and nucleolin colocalize in breast carcinoma tissue and cancer cell lines.
BRCA1 proteins are transported to the nucleus in the absence of serum and splice variants BRCA1a, BRCA1b are tyrosine phosphoproteins that associate with E2F, cyclins and cyclin dependent kinases.
BRCA1 proteins regulate growth of ovarian cancer cells by tethering Ubc9.
BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk.
BRCA1 R71K missense mutation contributes to cancer predisposition by increasing alternative transcript levels.
BRCA1 R841W: a strong candidate for a common mutation with moderate phenotype.
BRCA1 regulates follistatin function in ovarian cancer and human ovarian surface epithelial cells.
BRCA1 Regulates g-Tubulin Binding to Centrosomes.
BRCA1 regulates GADD45 through its interactions with the OCT-1 and CAAT motifs.
BRCA1 regulates gene expression for orderly mitotic progression.
BRCA1 regulates HMGA2 levels in the Swan71 trophoblast cell line.
BRCA1 regulates human mammary stem/progenitor cell fate.
BRCA1 regulates IFN-gamma signaling through a mechanism involving the type I IFNs.
Brca1 regulates in vitro differentiation of mammary epithelial cells.
BRCA1 regulates insulin-like growth factor 1 receptor levels in ovarian cancer.
BRCA1 regulates p53-dependent gene expression.
BRCA1 regulation of transcription.
BRCA1 required for transcription-coupled repair of oxidative DNA damage.
BRCA1 screening in patients with a family history of breast or ovarian cancer.
BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing.
BRCA1 suppresses insulin-like growth factor-I receptor promoter activity: potential interaction between BRCA1 and Sp1.
BRCA1 testing in breast and/or ovarian cancer families from northeastern France identifies two common mutations with a founder effect.
BRCA1 transcriptionally regulates genes involved in breast tumorigenesis.
BRCA1 tumor suppressor network: focusing on its tail.
BRCA1 tumour suppression occurs via heterochromatin-mediated silencing.
BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II).
BRCA1 variants in a family study of African-American and Latina women.
BRCA1 wild-type allele modifies risk of ovarian cancer in carriers of BRCA1 germ-line mutations.
BRCA1 Zinc RING Finger Domain Disruption Alters Caspase Response in Ovarian Surface Epithelial Cells.
BRCA1, a 'complex' protein involved in the maintenance of genomic stability.
BRCA1, a gene involved in inherited predisposition to breast and ovarian cancer.
BRCA1, BRCA2 and breast cancer: a concise clinical review.
BRCA1, BRCA2 and CHEK2 (1100 del C) germline mutations in hereditary breast and ovarian cancer families in South India.
BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives.
BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing.
BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway.
BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study.
BRCA1, hormone, and tissue-specific tumor suppression.
BRCA1- and BRCA2-deficient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase II.
BRCA1- and BRCA2-specific in silico tools for variant interpretation in the CAGI 5 ENIGMA challenge.
BRCA1--a good predictive marker of drug sensitivity in breast cancer treatment?
BRCA1-associated and sporadic ovarian carcinomas: outcomes of primary cytoreductive surgery or neoadjuvant chemotherapy.
BRCA1-associated breast and ovarian cancer risks in Poland: no association with commonly studied polymorphisms.
BRCA1-associated complexes: new targets to overcome breast cancer radiation resistance.
BRCA1-associated growth arrest is RB-dependent.
BRCA1-BARD1 associate with the synaptonemal complex and pro-crossover factors and influence RAD-51 dynamics during Caenorhabditis elegans meiosis.
BRCA1-directed, enhanced and aberrant homologous recombination: Mechanism and potential treatment strategies.
BRCA1-hapoinsufficiency: Unraveling the molecular and cellular basis for tissue-specific cancer.
BRCA1-induced apoptosis involves inactivation of ERK1/2 activities.
BRCA1-IRIS Overexpression Promotes Cisplatin Resistance in Ovarian Cancer Cells.
BRCA1-mediated G2/M cell cycle arrest requires ERK1/2 kinase activation.
BRCA1-mediated signaling pathways in ovarian carcinogenesis.
BRCA1-p53 relationship in hereditary breast cancer.
BRCA1-related and sporadic ovarian cancer in the same family: implications for genetic testing.
BRCA1-related breast cancer in Austrian breast and ovarian cancer families: specific BRCA1 mutations and pathological characteristics.
BRCA1/2 gene mutations do not affect the capacity of oocytes from breast cancer candidates for fertility preservation to mature in vitro.
BRCA1/2 mutations in Swiss patients with familial or early-onset breast and ovarian cancer.
BRCA1/2 status and clinicopathologic characteristics of patients with double primary breast and ovarian cancer.
BRCA1/2 testing: complex themes in result interpretation.
BRCA1/BARD1 complex interacts with steroidogenic factor 1--A potential mechanism for regulation of aromatase expression by BRCA1.
BRCA1/BARD1 orthologs required for DNA repair in Caenorhabditis elegans.
BRCA1/BARD1 site-specific ubiquitylation of nucleosomal H2A is directed by BARD1.
BRCA1/BRCA2 founder mutations and cancer risks: impact in the western Danish population.
BRCA1/BRCA2 Pathogenic Variant Breast Cancer: Treatment and Prevention Strategies.
BRCA1: a locus-specific "liaison" in gene expression and genetic integrity.
BRCA1: a movement toward cancer prevention.
BRCA1: a review of structure and putative functions.
BRCA1: exploring the links to transcription.
BRCA1: genetic testing and hereditary breast and ovarian cancer.
BRCA1: mechanisms of inactivation and implications for management of patients.
BRCA1: the enigma of tissue-specific tumor development.
BRCA2 founder mutation in Slovenian breast cancer families.
BRCA2 gene mutations in Greek patients with familial breast cancer.
BRCA2 germline mutations in primary cancer of the fallopian tube.
BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2.
BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers.
BRCA2, but not BRCA1, mutations account for familial ovarian cancer in Iceland: a population-based study.
BRCA2-dependent homologous recombination is required for repair of Arsenite-induced replication lesions in mammalian cells.
BRCAness profile of sporadic ovarian cancer predicts disease recurrence.
BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
BRCT repeats as phosphopeptide-binding modules involved in protein targeting.
Breast and ovarian cancer genetics and prevention.
Breast and ovarian cancer in relatives of cancer patients, with and without BRCA mutations.
Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
Breast and ovarian cancer penetrance of BRCA1/2 mutations among Hong Kong women.
Breast and ovarian cancer predisposition due to de novo BRCA1 and BRCA2 mutations.
Breast and Ovarian Cancer Risk due to Prevalence of BRCA1 and BRCA2 Variants in Pakistani Population: A Pakistani Database Report.
Breast and ovarian cancer risk evaluation in families with a disease-causing mutation in BRCA1/2.
Breast and ovarian cancer risk management in a French cohort of 158 women carrying a BRCA1 or BRCA2 germline mutation: patient choices and outcome.
Breast and ovarian cancer risk perception after prophylactic salpingo-oophorectomy due to an inherited mutation in the BRCA1 or BRCA2 gene.
Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations.
Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies.
Breast and ovarian cancer: the forgotten paternal contribution.
Breast cancer 1 (BRCA1)-deficient embryos develop normally but are more susceptible to ethanol-initiated DNA damage and embryopathies.
Breast cancer and ovarian cancer genetics: an update.
Breast cancer genes: therapeutic strategies.
Breast cancer genetics in African Americans.
Breast cancer in six families from Tolima and Huila: BRCA1 3450del4 mutation
Breast cancer incidence in BRCA mutation carriers with ovarian cancer: A longitudal observational study.
Breast cancer mortality among Ashkenazi Jewish women in São Paulo and Porto Alegre, Brazil.
Breast Cancer Predisposition Genes and Synthetic Lethality.
Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers.
Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations.
Breast cancer risk for noncarriers of family-specific BRCA1 and BRCA2 mutations: findings from the Breast Cancer Family Registry.
Breast cancer risks and risk prediction models.
Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation.
Breast cancer susceptibility variants alter risk in familial ovarian cancer.
Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation.
BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases.
CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer.
CAG repeat length in exon 1 of the androgen receptor gene is related to age of diagnosis but not germ line BRCA1 mutation status in ovarian cancer.
CAG repeat size in Huntingtin alleles is associated with cancer prognosis.
Can chimerism explain breast/ovarian cancers in BRCA non-carriers from BRCA-positive families?
Can the status of the breast and ovarian cancer susceptibility gene 1 product (BRCA1) predict response to taxane-based cancer therapy?
Cancer genetics for the clinician: recommendations on screening for BRCA1 and BRCA2 mutations.
Cancer genetics.
Cancer incidence in a population of Jewish women at risk of ovarian cancer.
Cancer Incidence in BRCA1 mutation carriers.
Cancer Incidence in First- and Second-Degree Relatives of BRCA1 and BRCA2 Mutation Carriers.
Cancer prevalence in 129 breast-ovarian cancer families tested for BRCA1 and BRCA2 mutations.
Cancer Risk Awareness and Concern among Women with a Family History of Breast or Ovarian Cancer.
Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program.
Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: Effects of oral contraceptive use and parental origin of mutation.
Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers.
Cancer risks among BRCA1 and BRCA2 mutation carriers.
Cancer risks for Australian women with a BRCA1 or a BRCA2 mutation.
Cancer risks in first degree relatives of BRCA1 mutation carriers: effects of mutation and proband disease status.
Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13.
Cancer treatment according to BRCA1 and BRCA2 mutations.
Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian.
Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.
Carboplatin and taxol resistance develops more rapidly in functional BRCA1 compared to dysfunctional BRCA1 ovarian cancer cells.
Carcinosarcoma of the ovary in a patient with a germline BRCA2 mutation: evidence for monoclonal origin.
Caretaker Brca1: keeping the genome in the straight and narrow.
Case report: Analysis of BRCA1 and BRCA2 gene mutations in a hereditary ovarian cancer family.
CASP8 D302H polymorphism delays the age of onset of breast cancer in BRCA1 and BRCA2 carriers.
Caspase-dependent BRCA1 cleavage facilitates chemotherapy-induced apoptosis.
Catalysts towards cancer risk management action: A longitudinal study of reproductive-aged women with BRCA1/2 mutations.
Caucasian family with two independent mutations: 2594delC in BRCA1 and 5392delAG in BRCA2 gene.
CDK9 inhibitor CDKI-73 is synergetic lethal with PARP inhibitor olaparib in BRCA1 wide-type ovarian cancer.
cDNA analysis demonstrates that the BRCA2 intronic variant IVS4-12del5 is a deleterious mutation.
Cell cycle regulation of BRCA1 messenger RNA in human breast epithelial cells.
Cell cycle regulation of the BRCA1/acetyl-CoA-carboxylase complex.
Cell cycle-dependent colocalization of BARD1 and BRCA1 proteins in discrete nuclear domains.
Cell cycle-dependent conjugation of endogenous BRCA1 protein with SUMO-2/3.
Cell-nonautonomous induction of ovarian and uterine serous cystadenomas in mice lacking a functional Brca1 in ovarian granulosa cells.
Cellular functions of the BRCA tumour-suppressor proteins.
Central European BRCA2 mutation carriers: birth cohort status correlates with onset of breast cancer.
Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells.
CGH-targeted linkage analysis reveals a possible BRCA1 modifier locus on chromosome 5q.
Challenges and Considerations on Risk-Reducing Surgery in BRCA1/2 Patients with Advanced Breast Cancer.
Challenging the believed proportion of ovarian cancer attributable to BRCA2 versus BRCA1 pathogenic variants.
Changes in health-related behaviours following BRCA 1/2 genetic testing: the case of hormone replacement therapy.
Changes in the expression of plasma proteins associated with thrombosis in BRCA1 mutation carriers.
Changes in the mouse estrus cycle in response to BRCA1 inactivation suggest a potential link between risk factors for familial and sporadic ovarian cancer.
Characterisation of a 161 kb deletion extending from the NBR1 to the BRCA1 genes in a French breast-ovarian cancer family.
Characteristics and spectrum of BRCA1 and BRCA2 mutations in 3,922 Korean patients with breast and ovarian cancer.
Characteristics of BRCA1 mutations in a population-based case series of breast and ovarian cancer.
Characteristics of BRCA1/2 mutations carriers including large genomic rearrangements in high risk breast cancer patients.
Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2.
Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2.
Characteristics of women with ovarian carcinoma who have BRCA1 and BRCA2 mutations not identified by clinical testing.
Characteristics relating to ovarian cancer risk: implications for prevention and detection.
Characterization of 2 novel and 2 recurring BRCA1 germline mutations in breast and/or ovarian carcinoma patients from the area of Naples.
Characterization of a new BRCA1 rearrangement in an Italian woman with hereditary breast and ovarian cancer syndrome.
Characterization of a novel large deletion and single point mutations in the BRCA1 gene in a Greek cohort of families with suspected hereditary breast cancer.
Characterization of a novel trans-activation domain of BRCA1 that functions in concert with the BRCA1 C-terminal (BRCT) domain.
Characterization of BRCA1 and BRCA2 mutations in a large United States sample.
Characterization of BRCA1 and BRCA2 splicing variants: a collaborative report by ENIGMA consortium members.
Characterization of BRCA1 and BRCA2 variants found in a Norwegian breast or ovarian cancer cohort.
Characterization of Brca1 deficient mice.
Characterization of COBRA1 in human breast cancer cell lines using a new polyclonal antibody against COBRA1.
Characterization of common BRCA1 and BRCA2 variants.
Characterization of functional messenger RNA splice variants of BRCA1 expressed in nonmalignant and tumor-derived breast cells.
Characterization of LGALS3 (galectin-3) as a player in DNA damage response.
Characterization of spliceogenic variants located in regions linked to high levels of alternative splicing: BRCA2 c.7976+5G > T as a case study.
Characterization of SWI/SNF protein expression in human breast cancer cell lines and other malignancies.
Characterization of ten novel and 13 recurring BRCA1 and BRCA2 germline mutations in Italian breast and/or ovarian carcinoma patients. Mutations in brief no. 178. Online.
Characterization of the c.190T>C missense mutation in BRCA1 codon 64 (Cys64Arg).
Characterization of three alternative transcripts of the BRCA1 gene in patients with breast cancer and a family history of breast and/or ovarian cancer who tested negative for pathogenic mutations.
Characterization of two novel BRCA1 germ-line mutations involving splice donor sites.
CHEK2 1100 delC mutation in Russian ovarian cancer patients.
Chemopreventive Effects of ROS Targeting in a Murine Model of BRCA1-Deficient Breast Cancer.
Chemosensitivity of BRCA1-Mutated Ovarian Cancer Cells and Established Cytotoxic Agents.
Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?
Childhood Cancer in Families with and without BRCA1 or BRCA2 Mutations Ascertained at a High-Risk Breast Cancer Clinic.
Choice of Management of Southern Chinese BRCA Mutation Carriers.
Chromosome 2q24.2 is lost in sporadic but not in BRCA1-associated ovarian carcinomas.
Circulating cell-free DNA (cfDNA) levels in BRCA1 and BRCA2 mutation carriers: A preliminary study.
Circulating miRNA Profiling in Plasma Samples of Ovarian Cancer Patients.
Circ_0007841 accelerates ovarian cancer development through facilitating MEX3C expression by restraining miR-151-3p activity.
Classification of BRCA1 missense variants of unknown clinical significance.
Classification of IVS1-10T-->C as a polymorphism of BRCA1.
Classification of missense substitutions in the BRCA genes: a database dedicated to Ex-UVs.
Classification of ovarian cancer associated with BRCA1 mutations, immune checkpoints, and tumor microenvironment based on immunogenomic profiling.
Clear cell carcinoma of the fimbria of the fallopian tube in a BRCA1 carrier undergoing prophylactic surgery.
Clinical and genetic evaluation of thirty ovarian cancer families.
Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1.
Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status.
Clinical considerations in the management of individuals at risk for hereditary breast and ovarian cancer.
Clinical features and outcomes of germline mutation BRCA1-linked versus sporadic ovarian cancer patients.
Clinical features of familial ovarian cancer lacking mutations in BRCA1 or BRCA2.
Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1.
Clinical impact of unclassified variants of the BRCA1 and BRCA2 genes.
Clinical implications of using molecular diagnostics for ovarian cancers.
Clinical management of women with genomic BRCA1 and BRCA2 mutations.
Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation.
Clinical Next-Generation Sequencing Pipeline Outperforms a Combined Approach Using Sanger Sequencing and Multiplex Ligation-Dependent Probe Amplification in Targeted Gene Panel Analysis.
Clinical outcome of hereditary breast cancer in the lithuanian population.
Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up.
Clinical significance of large rearrangements in BRCA1 and BRCA2.
Clinical, molecular and geographical features of hereditary breast/ovarian cancer in latvia.
Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance.
Clinicopathologic features of BRCA-linked and sporadic ovarian cancer.
Clinicopathological values of NBS1 and DNA damage response genes in epithelial ovarian cancers.
Cloning and characterization of a new BRCA1 variant: A role for BRCT domains in apoptosis.
Cloning and functional identification of two novel BRCA1 splicing variants.
Co-existence of breast and ovarian cancers in BRCA germ-line mutation carriers.
Color bar coding the BRCA1 gene on combed DNA: a useful strategy for detecting large gene rearrangements.
Colorado family physicians' knowledge of hereditary breast cancer and related practice.
Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.
Combining 53BP1 with BRCA1 as a biomarker to predict the sensitivity of poly(ADP-ribose) polymerase (PARP) inhibitors.
Combining Homologous Recombination and Phosphopeptide-binding Data to Predict the Impact of BRCA1 BRCT Variants on Cancer Risk.
Commentary regarding Schayek et al., entitled "The rate of recurrent BRCA1, BRCA2, and TP53 mutations in the general population, and unselected ovarian cancer cases, in Belo Horizonte, Brazil".
Comments on: Peripheral blood BRCA1 methylation profiling to predict familial ovarian cancer.
Commercial Opportunities and Ethical Pitfalls in Personalized Medicine: A Myriad of Reasons to Revisit the Myriad Genetics Saga.
Common BRCA1 and BRCA2 mutations in breast cancer families: a meta-analysis from systematic review.
Common BRCA1 variants and susceptibility to breast and ovarian cancer in the general population.
Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers.
Common mutations in BRCA1 and BRCA2 do not contribute to early prostate cancer in Jewish men.
Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families.
Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers.
Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
Communication and decision-making about seeking inherited cancer risk information: findings from female survivor-relative focus groups.
Comparative genomic hybridization in inherited and sporadic ovarian tumors in Israel.
Comparative genomic hybridization of microdissected familial ovarian carcinoma: two deleted regions on chromosome 15q not previously identified in sporadic ovarian carcinoma.
Comparison of age at natural menopause in BRCA1/2 mutation carriers with a non-clinic-based sample of women in northern California.
Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations.
Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer.
Comparison of effectiveness of treatment of patients with sporadic and germline BRCA1-related ovarian cancer.
Comparison of prophylactic oophorectomy specimens from carriers and noncarriers of a BRCA1 or BRCA2 gene mutation. United Kingdom Coordinating Committee on Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group.
Comparisons of gene coexpression network modules in breast cancer and ovarian cancer.
Competing risks analysis of correlated failure time data.
Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity.
Complete BRCA mutation screening in breast and ovarian cancer predisposition families from a North-Eastern Romanian population.
Complete mutation screening and haplotype characterization of BRCA1 gene in Tunisian patients with familial breast cancer.
Complex germline rearrangement of BRCA1 associated with breast and ovarian cancer.
Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population.
Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.
Comprehensive analysis of serum tumor markers and BRCA1/2 germline mutations in Chinese ovarian cancer patients.
Comprehensive annotation of splice junctions supports pervasive alternative splicing at the BRCA1 locus: a report from the ENIGMA consortium.
Comprehensive BRCA mutation analysis in the Greek population. Experience from a single clinical diagnostic center.
Comprehensive BRCA1 and BRCA2 mutational profile in Lithuania.
Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.
Comprehensive genomic characterization of breast tumors with BRCA1 and BRCA2 mutations.
Comprehensive profiling of BRCA1 and BRCA2 variants in breast and ovarian cancer in Chinese patients.
Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral.
Conclusions and recommendations from the Helene Harris Memorial Trust Fourth Biennial International Forum on Ovarian Cancer 11-14 May 1993, Toronto, Canada.
Concomitant BRCA1 and BRCA2 gene mutations in an Ashkenazi Jewish woman with primary breast and ovarian cancer.
Conditional knockout of brca1/2 and p53 in mouse ovarian surface epithelium: do they play a role in ovarian carcinogenesis?
Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families.
Conservation of function and primary structure in the BRCA1-associated RING domain (BARD1) protein.
Consideration of hereditary nonpolyposis colorectal cancer in BRCA mutation-negative familial ovarian cancers.
Constant denaturant gel electrophoresis (CDGE) in BRCA1 mutation screening.
Constitutional Mosaic Epimutations - a hidden cause of cancer?
Constitutional mosaicism for a BRCA2 mutation as a cause of early-onset breast cancer.
Constitutive promoter methylation of BRCA1 and RAD51C in patients with familial ovarian cancer and early-onset sporadic breast cancer.
Contralateral recurrence and prognostic factors in familial non-BRCA1/2-associated breast cancer.
Contribution of bioinformatics predictions and functional splicing assays to the interpretation of unclassified variants of the BRCA genes.
Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in Pakistan.
Contribution of BRCA1 and BRCA2 mutations to inherited ovarian cancer.
Contribution of BRCA1 and BRCA2 to familial ovarian cancer: a gynecologic oncology group study.
Contribution of BRCA1 germ-line mutations to breast cancer in Greece: a hospital-based study of 987 unselected breast cancer cases.
Contribution of BRCA1 large genomic rearrangements to early-onset and familial breast/ovarian cancer in Pakistan.
Contribution of BRCA1 mutations to ovarian cancer.
Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population.
Contribution of large genomic BRCA1 alterations to early-onset breast cancer selected for family history and tumour morphology: a report from The Breast Cancer Family Registry.
Contribution of Massive Parallel Sequencing to Diagnosis of Hereditary Ovarian Cancer in the Czech Republic.
Contribution of the BRCA1 and BRCA2 mutations to breast cancer in Tunisia.
Controlled trial of pretest education approaches to enhance informed decision-making for BRCA1 gene testing.
Convenient, nonradioactive, heteroduplex-based methods for identifying recurrent mutations in the BRCA1 and BRCA2 genes.
Cooperation Between BRCA1 and p53 in Repair of Cyclobutane Pyrimidine Dimers.
Coordinated prophylactic surgical management for women with hereditary breast-ovarian cancer syndrome.
Copy number variations are not modifiers of phenotypic expression in a pair of identical twins carrying a BRCA1 mutation.
Correction: BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
Correction: Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers.
Correction: Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers.
Correlation between BRCA1 expression and apoptosis-related biological parameters in sporadic breast carcinomas.
Correlation between BRCA1 expression and clinicopathological factors including brain metastases in patients with non-small-cell lung cancer.
Cost Effectiveness Analysis of Genetic Testing for Breast and Ovarian Cancer Susceptibility Genes: BRCA1 and BRCA2.
Cost-Effectiveness Analysis of Testing for Brca1 and Brca2 Mutations In Women Diagnosed With Ovarian Cancer and Their Female First- And Second Degree Relatives Using A Discrete Event Simulation: A Uk Health Service Perspective.
Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.
Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1 or 2 mutation.
Cost-effectiveness of long-term clinical management of BRCA pathogenic variant carriers.
Cost-effectiveness of risk-reducing surgeries in preventing hereditary breast and ovarian cancer.
Cost-utility analysis of germline BRCA1/2 testing in women with high-grade epithelial ovarian cancer in Spain.
Costs and benefits of diagnosing familial breast cancer.
Could the 185delAG BRCA1 mutation be an ancient Jewish mutation?
Counseling the at risk patient in the BRCA1 and BRCA2 Era.
Cul4 E3 ubiquitin ligase regulates ovarian cancer drug resistance by targeting the antiapoptotic protein BIRC3.
Curcumin induces re?expression of BRCA1 and suppression of ? synuclein by modulating DNA promoter methylation in breast cancer cell lines.
Current condition of genetic medicine for hereditary breast cancer.
Current practices on genetic testing in ovarian cancer.
Current understanding of the epidemiology and clinical implications of BRCA1 and BRCA2 mutations for ovarian cancer.
Cyclin B1 stability is increased by interaction with BRCA1, and its overexpression suppresses the progression of BRCA1-associated mammary tumors.
Cyclin D1 silencing impairs DNA double strand break repair, sensitizes BRCA1 wildtype ovarian cancer cells to olaparib.
Cyclosporine A inhibition of prolactin-dependent up-regulation of BRCA1 protein expression in human breast cell lines.
Cytology material is equivalent to tumor tissue in determining mutations of BRCA 1/2 genes in patients with tubo-ovarian high grade serous carcinoma.
Cytoplasmic mislocalization of BRCA1 caused by cancer-associated mutations in the BRCT domain.
DcR3 binds to ovarian cancer via heparan sulfate proteoglycans and modulates tumor cells response to platinum with corresponding alteration in the expression of BRCA1.
Decapping protein EDC4 regulates DNA repair and phenocopies BRCA1.
Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients.
Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: a more prominent role for oophorectomy.
Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations.
Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression.
Deletion of Exons 1a-2 of BRCA1: A Rather Frequent Pathogenic Abnormality.
Demographic and genetic characteristics of patients with borderline ovarian tumors as compared to early stage invasive ovarian cancer.
Depletion of eIF2.GTP.Met-tRNAi translation initiation complex up-regulates BRCA1 expression in vitro and in vivo.
Description and analysis of genetic variants in French hereditary breast and ovarian cancer families recorded in the UMD-BRCA1/BRCA2 databases.
Description of Genetic Variants in BRCA Genes in Mexican Patients with Ovarian Cancer: A First Step towards Implementing Personalized Medicine.
Design and validation of a next generation sequencing assay for hereditary BRCA1 and BRCA2 mutation testing.
Detailed deletion mapping of chromosome segment 17q12-21 in sporadic breast tumours.
Detection of BRCA1 and BRCA2 gene mutation in Egyptian females with breast cancer and their relatives by PCR-SSCP method.
Detection of BRCA1 and BRCA2 germline mutations in Japanese population using next-generation sequencing.
Detection of BRCA1 gene mutations in families with breast cancer patients and their healthy relatives.
Detection of BRCA1 mutations in women with early-onset ovarian cancer by use of the protein truncation test.
Detection of eight BRCA1 mutations in 10 breast/ovarian cancer families, including 1 family with male breast cancer.
Detection of false positive mutations in BRCA gene by next generation sequencing.
Detection of genomic variations in BRCA1 and BRCA2 genes by long-range PCR and next-generation sequencing.
Detection of Germline Mutation in Hereditary Breast and/or Ovarian Cancers by Next-Generation Sequencing on a Four-Gene Panel.
Detection of heterozygous mutations in BRCA1 using high density oligonucleotide arrays and two-colour fluorescence analysis.
Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing.
Detection of the most frequent mutations in BRCA1 gene on polyacrylamide gels containing Spreadex Polymer NAB.
Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis.
Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2.
Determining joint carrier probabilities of cancer-causing genes using Markov chain Monte Carlo methods.
Development and validation of a variant detection workflow for BRCA1 and BRCA2 genes and its clinical application based on the Ion Torrent technology.
Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.
Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors.
Development of a Novel Autophagy-related Prognostic Signature for Serous Ovarian Cancer.
Development of decision aids for female BRCA1 and BRCA2 mutation carriers in Germany to support preference-sensitive decision-making.
Developmental studies of Brca1 and Brca2 knock-out mice.
Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers.
Diagnostic mRNA splicing assay for variants in BRCA1 and BRCA2 identified two novel pathogenic splicing aberrations.
Diagnostic testing of genetic disorders: limiting the scope of patent claims through disclosure requirements.
Difference in Risk of Breast and Ovarian Cancer According to Putative Functional Domain Regions in Korean BRCA1/2 Mutation Carriers.
Differences in BRCA counseling and testing practices based on ordering provider type.
Differences in Ovarian and Other Cancers Risks by Population and BRCA Mutation Location.
Differences in the frequency and distribution of BRCA1 and BRCA2 mutations in breast/ovarian cancer cases from the Basque country with respect to the Spanish population: implications for genetic counselling.
Different expressivity of BRCA1 and BRCA2: analysis of 179 Italian pedigrees with identified mutation.
Differential effects of HTLV-1 Tax oncoprotein on the different estrogen-induced-ER ?-mediated transcriptional activities.
Differential expression and subcellular localization of murine BRCA1 and BRCA1-delta 11 isoforms in murine and human cell lines.
Differential transcriptional activation by the N-terminal region of BRCA1 splice variants BRCA1a and BRCA1b.
Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer.
Differing effects of breast cancer 1, early onset (BRCA1) and ataxia-telangiectasia mutated (ATM) mutations on cellular responses to ionizing radiation.
Direct detection of mutations in the breast and ovarian cancer susceptibility gene BRCA1 by PCR-mediated site-directed mutagenesis.
Direct to confusion: lessons learned from marketing BRCA testing.
Dissecting PARP inhibitor resistance with functional genomics.
Distinct BRCA1 rearrangements involving the BRCA1 pseudogene suggest the existence of a recombination hot spot.
Distinct gene expression profiles in ovarian cancer linked to Lynch syndrome.
Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer.
DNA array-based method for detection of large rearrangements in the BRCA1 gene.
DNA double strand break repair and its association with inherited predispositions to breast cancer.
DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
DNA Methylation and microRNA patterns are in association with the expression of BRCA1 in ovarian cancer.
DNA polymerase stalling, sister chromatid recombination and the BRCA genes.
DNA Repair and Ovarian Carcinogenesis: Impact on Risk, Prognosis and Therapy Outcome.
DNA repair capacity is impaired in healthy BRCA1 heterozygous mutation carriers.
DNA repair-related functional assays for the classification of BRCA1 and BRCA2 variants: a critical review and needs assessment.
Do Ovarian Cancer Patients with a Family History of Cancer (Suspected BRCA1 or BRCA2 Mutation) Suffer Greater Chemotherapy Toxicity?
Dominant-negative activity of a Brca1 truncation mutant: effects on proliferation, tumorigenicity in vivo, and chemosensitivity in a mouse ovarian cancer cell line.
Double heterozygosity for mutations in BRCA1 and BRCA2 in German breast cancer patients: implications on test strategies and clinical management.
Double heterozygous mutation in the BRCA1 and ATM genes involved in development of primary metachronous tumours: a case report.
Double mutation of APC and BRCA1 in an Italian family.
Down-regulation of BRCA1 and BRCA2 in human ovarian cancer cells exposed to adriamycin and ultraviolet radiation.
Downregulation of the cancer susceptibility protein WRAP53? in epithelial ovarian cancer leads to defective DNA repair and poor clinical outcome.
Driver pattern identification over the gene co-expression of drug response in ovarian cancer by integrating high throughput genomics data.
Drug therapy for hereditary cancers.
Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer.
Dysregulation of x chromosome inactivation in high grade ovarian serous adenocarcinoma.
E3 ligase activity of BRCA1 is not essential for mammalian cell viability or homology-directed repair of double-strand DNA breaks.
Early onset breast cancer in Ashkenazi women carriers of founder BRCA1/2 mutations: beyond 10 years of follow-up.
EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer.
Effect of BRCA1 and XPG Mutations on Treatment Response to Trabectedin and Pegylated Liposomal Doxorubicin in Patients with Advanced Ovarian Cancer - Exploratory Analysis of the Phase 3 OVA-301 Study.
Effect of BRCA1 missense variants on gene reversion in DNA double-strand break repair mutants and cell cycle-arrested cells of Saccharomyces cerevisiae.
Effect of BRCA1 on epidermal growth factor receptor in ovarian cancer.
Effect of misreported family history on Mendelian mutation prediction models.
Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
Effect of the BRCA1-SIRT1-EGFR axis on cisplatin sensitivity in ovarian cancer.
Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers.
Effect of TPA and HTLV-1 Tax on BRCA1 and ERE controlled genes expression.
Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer.
Effectiveness of decision aids for female BRCA1 and BRCA2 mutation carriers: a systematic review.
Effectiveness of risk-reducing salpingo-oophorectomy in preventing ovarian cancer in a high-risk French Canadian population.
Effects of BRCA Germline Mutations on Triple-Negative Breast Cancer Prognosis.
Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.
Effects of coping style and BRCA1 and BRCA2 test results on anxiety among women participating in genetic counseling and testing for breast and ovarian cancer risk.
Effects of Radiation Therapy on Breast Epithelial Cells in BRCA1/2 Mutation Carriers.
Effects on human transcriptome of mutated BRCA1 BRCT domain: a microarray study.
Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials.
Egr-1 regulates the transcription of the BRCA1 gene by etoposide.
Electrophoresis of BRCA1 oncosuppressor.
Elevated level of 8-oxo-7,8-dihydro-2'-deoxyguanosine in leukocytes of BRCA1 mutation carriers compared to healthy controls.
Emerging roles of BRCA1 alternative splicing.
Emerging roles of lamins and DNA damage repair mechanisms in ovarian cancer.
Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study.
Enhanced high density oligonucleotide array-based sequence analysis using modified nucleoside triphosphates.
Enhanced non-homologous end joining contributes toward synthetic lethality of pathological RAD51C mutants with poly (ADP-ribose) polymerase.
Enhancement of BRCA1 gene expression by the peroxisome proliferator-activated receptor gamma in the MCF-7 breast cancer cell line.
Enhancing the sensitivity of ovarian cancer cells to olaparib via microRNA-20b-mediated cyclin D1 targeting.
Epidemiology of breast cancer among BRCA mutation carriers: an overview.
Epidemiology of Patients with Ovarian Cancer with and Without a BRCA1/2 Mutation.
Epidemiology, prevention, and early detection of breast cancer.
Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer.
Epigenetic inactivation of BRCA1 through promoter hypermethylation in ovarian cancer progression.
Epigenetic synthetic lethality approaches in cancer therapy.
Epithelial ovarian cancer. Risk factors, screening and the role of prophylactic oophorectomy.
Epithelial ovarian cancer: prevention, diagnosis, and treatment.
Establishing a control population to screen for the occurrence of nineteen unclassified variants in the BRCA1 gene by denaturing high-performance liquid chromatography.
Establishment and characterization of xenografts and cancer cell cultures derived from BRCA1 -/- epithelial ovarian cancers.
Establishment of three human breast epithelial cell lines derived from carriers of the 999del5 BRCA2 Icelandic founder mutation.
Estimate of the penetrance of BRCA mutation and the COS software for the assessment of BRCA mutation probability.
Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence.
Estimating genetic influence on disease from population-based case-control data: application to cancers of the breast and ovary.
Estimating survival rates after ovarian cancer among women tested for BRCA1 and BRCA2 mutations.
Estrogen controls the survival of BRCA1-deficient cells via a PI3K-NRF2-regulated pathway.
Estrogen upregulation of BRCA1 expression with no effect on localization.
Estrogen-dependent cell signaling and apoptosis in BRCA1-blocked BG1 ovarian cancer cells in response to plumbagin and other chemotherapeutic agents.
Ethical issues related to BRCA gene testing in orthodox Jewish women.
Ethnic differences in cancer risk resulting from genetic variation.
Ethnic-specific BRCA1/2 variation within Asia population: evidence from over 78 000 cancer and 40 000 non-cancer cases of Indian, Chinese, Korean and Japanese populations.
Etiology of familial breast cancer with undetected BRCA1 and BRCA2 mutations: clinical implications.
Evaluating the genetic risk of breast cancer.
Evaluating the NCCN Clinical Criteria for Recommending BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer.
Evaluating the potential of kinase inhibitors to suppress DNA repair and sensitise ovarian cancer cells to PARP inhibitors.
Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities.
Evaluation and management of women with BRCA1/2 mutations.
Evaluation of association methods for analysing modifiers of disease risk in carriers of high-risk mutations.
Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer.
Evaluation of BRCA1 and BRCA2 mutations and risk-prediction models in a typical Asian country (Malaysia) with a relatively low incidence of breast cancer.
Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers.
Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers.
Evaluation of germline BRCA1 and BRCA2 mutations in a multi-ethnic Asian cohort of ovarian cancer patients.
Evaluation of hereditary risk in a mammography population.
Evaluation of mathematical models for breast cancer risk assessment in routine clinical use.
Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers.
Evaluation of RAD51C as cancer susceptibility gene in a large breast-ovarian cancer patient population referred for genetic testing.
Evaluation of Rare Variants in the New Fanconi Anemia Gene ERCC4 (FANCQ) as Familial Breast/Ovarian Cancer Susceptibility Alleles.
Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma.
Evaluation of two different models to predict BRCA1 and BRCA2 mutations in a cohort of Danish hereditary breast and/or ovarian cancer families.
Evaluation of unclassified variants in the breast cancer susceptibility genes BRCA1 and BRCA2 using five methods: results from a population-based study of young breast cancer patients.
Evidence for a transcriptional activation function of BRCA1 C-terminal region.
Evidence for clinical efficacy of mitomycin C in heavily pretreated ovarian cancer patients carrying germ-line BRCA1 mutation.
Evidence of a founder BRCA1 mutation in Scotland.
Evolution of the tumor suppressor BRCA1 locus in primates: implications for cancer predisposition.
Exceptional Response to Olaparib in a Patient With Recurrent Ovarian Cancer and an Entire BRCA1 Germline Gene Deletion.
Exclusion of large deletions and other rearrangements in BRCA1 and BRCA2 in Finnish breast and ovarian cancer families.
Experience of Risk-reducing Salpingo-oophorectomy for a BRCA1 Mutation Carrier and Establishment of a System Performing a Preventive Surgery for Hereditary Breast and Ovarian Cancer Syndrome in Japan: Our Challenges for the Future.
Exploring and comparing adverse events between PARP inhibitors.
Exploring genetic counselors' perceptions of usefulness and intentions to use refined risk models in clinical care based on the Technology Acceptance Model (TAM).
Expression analysis of MIR182 and its associated target genes in advanced ovarian carcinoma.
Expression and clinical implication of Beclin1, HMGB1, p62, survivin, BRCA1 and ERCC1 in epithelial ovarian tumor tissues.
Expression and mutations of BRCA in breast cancer and ovarian cancer: Evidence from bioinformatics analyses.
Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene.
Expression of cancer related BRCA1 missense variants decreases MMS-induced recombination in Saccharomyces cerevisiae without altering its nuclear localization.
Expression of EMSY gene in sporadic ovarian cancer.
Expression of MDR1 in epithelial ovarian cancer and its association with disease progression.
Expression of potential biomarkers associated with homologous recombination repair in patients with ovarian or triple-negative breast cancer.
Ex vivo retrieval and cryopreservation of oocytes from oophorectomized specimens for fertility preservation in a BRCA1 mutation carrier with ovarian cancer.
EZH2 participates in malignant biological behavior of epithelial ovarian cancer through regulating the expression of BRCA1.
Factors associated with decisions about clinical BRCA1/2 testing.
Factors Influencing Clinical Follow-Up for Individuals with a Personal History of Breast and/or Ovarian Cancer and Previous Uninformative BRCA1 and BRCA2 Testing.
Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.
Failure of BRCA1 dysfunction to alter ovarian cancer survival.
Familial breast and ovarian cancers.
Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing.
Familial breast cancer. Approaching the isolation of a susceptibility gene.
Familial breast cancer. BRCA1 down, BRCA2 to go.
Familial Breast Cancer: Clinical Response to Induction Chemotherapy or Radiotherapy Related to BRCA1/2 Mutations Status.
Familial Breast/Ovarian Cancer and BRCA1/2 Genetic Screening: The Role of Immunohistochemistry as an Additional Method in the Selection of Patients.
Familial cancer risks to offspring from mothers with 2 primary breast cancers: leads to cancer syndromes.
Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population.
Familial invasive breast cancers: worse outcome related to BRCA1 mutations.
Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q.
Familial ovarian cancer.
Familial risk and genetic susceptibility for breast cancer.
Familial site-specific ovarian cancer is linked to BRCA1 on 17q12-21.
Family history and BRCA1/BRCA2 status among Japanese ovarian cancer patients and occult cancer in a BRCA1 mutant case.
Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation.
Family history of breast and ovarian cancer and the risk of breast carcinoma in situ.
Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer.
Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations.
Family history predictors of BRCA1/BRCA2 mutation status among Tunisian breast/ovarian cancer families.
FBXO16-mediated hnRNPL ubiquitination and degradation plays a tumor suppressor role in ovarian cancer.
FDA Approval Summary: Rucaparib for the treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer.
Feasibility evaluation of an online tool to guide decisions for BRCA1/2 mutation carriers.
Fertility preservation in BRCA-mutated women: when and how?
Fidelity of DNA double-strand break repair in heterozygous cell lines harbouring BRCA1 missense mutations.
Final report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology, on a fact-finding questionnaire on the status of treatment of hereditary breast and ovarian cancer syndrome in Japan.
Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
First BRCA1 and BRCA2 gene testing implemented in the health care system of Stockholm.
First description of a double heterozygosity for BRCA1 and BRCA2 pathogenic variants in a French metastatic breast cancer patient: A case report.
First recurrent large genomic rearrangement in the BRCA1 gene found in Poland.
FISH analysis of BRCA1 copy number in paraffin-embedded ovarian cancer tissue samples.
Five families living with hereditary breast and ovarian cancer risk.
Five Italian Families with Two Mutations in BRCA Genes.
Five screening-detected breast cancer cases in initially disease-free BRCA1 or BRCA2 mutation carriers.
Founder and Recurrent Mutations in BRCA1 and BRCA2 Genes in Latin American Countries: State of the Art and Literature Review.
Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families.
Founder BRCA1 and BRCA2 mutations in early-onset French Canadian breast cancer cases unselected for family history.
Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families.
Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history.
Founder BRCA1 mutations and two novel germline BRCA2 mutations in breast and/or ovarian cancer families from North-Eastern Poland.
Founder BRCA1/BRCA2/PALB2 pathogenic variants in French-Canadian breast cancer cases and controls.
Founder effect of the BRCA1 5382insC mutation in Brazilian patients with hereditary breast ovary cancer syndrome.
Founder mutations account for the majority of BRCA1-attributable hereditary breast/ovarian cancer cases in a population from Tuscany, Central Italy.
Founder mutations in BRCA1 and BRCA2 genes.
Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer.
Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden.
Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer.
Frequencies of single-nucleotide polymorphisms and mutations in the BRCA1 gene in patients with hereditary breast or ovarian cancer.
Frequency and spectrum of founder and non-founder BRCA1 and BRCA2 mutations in a large series of Russian breast cancer and ovarian cancer patients.
Frequency of BRCA1 and BRCA2 germline mutations in Japanese breast cancer families.
Frequency of BRCA1 and BRCA2 mutations in a clinic-based series of breast and ovarian cancer families.
Frequency of BRCA1 and BRCA2 Mutations in Individuals with Breast and Ovarian Cancer in a Chinese Hakka Population Using Next-Generation Sequencing.
Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer.
Frequency of BRCA1 dysfunction in ovarian cancer.
Frequency of breast cancer attributable to BRCA1 in a population-based series of American women.
Frequency of germline and somatic BRCA1 mutations in ovarian cancer.
Frequency of germline mutations in BRCA1 and BRCA2 in ovarian cancer patients and their effect on treatment outcome.
Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic.
Frequency of Rearrangements Versus Small Indels Mutations in BRCA1 and BRCA2 Genes in Turkish Patients with High Risk Breast and Ovarian Cancer.
Frequency of the ATM IVS10-6T-->G variant in Australian multiple-case breast cancer families.
Frequency of the BRCA1 185delAG mutation among Jewish women with ovarian cancer and matched population controls.
Frequency of three BRCA1 gene founder mutations in breast/ovarian cancer families from the Pomerania-Kujawy region of Poland.
Frequent disease progression and early recurrence in patients with familial ovarian cancer primarily treated with paclitaxel and cis- or carboplatin (preliminary report).
Frequent loss of BRCA1 mRNA and protein expression in sporadic ovarian cancers.
Frequently occurring germ-line mutations of the BRCA1 gene in ovarian cancer families from Russia.
From BRCA1 to RAP1: a widespread BRCT module closely associated with DNA repair.
Function of BRCA1 in the DNA damage response is mediated by ADP-ribosylation.
Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families.
Functional Analysis of Familial Asp67Glu and Thr1051Ser BRCA1 Mutations in Breast/Ovarian Carcinogenesis.
Functional and structural analysis of C-terminal BRCA1 missense variants.
Functional assay for BRCA1: mutagenesis of the COOH-terminal region reveals critical residues for transcription activation.
Functional assessment of intrinsic disorder central domains of BRCA1.
Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation.
Functional characterization of BRCA1 and BRCA2: clues from their interacting proteins.
Functional coding and non-coding variants in human BRCA1 gene and their use in genetic screening.
Functional communication between endogenous BRCA1 and its partner, BARD1, during Xenopus laevis development.
Functional consequences of cyclin D1/BRCA1 interaction in breast cancer cells.
Functional Impact of Sequence Alterations Found in BRCA1 Promoter/5'UTR Region in Breast/Ovarian Cancer Families from Upper Silesia, Poland.
Functional implications of BRCA1 for early detection, prevention, and treatment of breast cancer.
Functional Interaction Between BRCA1 and DNA Repair in Yeast May Uncover a Role of RAD50, RAD51, MRE11A, and MSH6 Somatic Variants in Cancer Development.
Functional isogenic modeling of BRCA1 alleles reveals distinct carrier phenotypes.
Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin.
GEMO, a National Resource to Study Genetic Modifiers of Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Pathogenic Variant Carriers.
Gene expression and prognostic significance in ovarian cancer.
Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers.
Gene expression profiling of hereditary and sporadic ovarian cancers reveals unique BRCA1 and BRCA2 signatures.
Gene Panel Tumor Testing in Ovarian Cancer Patients Significantly Increases the Yield of Clinically Actionable Germline Variants beyond BRCA1/BRCA2.
Gene patents, patenting life and the impact of court rulings on US stem cell patents and research.
Gene therapy for breast and ovarian cancer with BRCA1.
Gene-Specific Genetic Complementation between Brca1 and Cobra1 During Mouse Mammary Gland Development.
Generation and analysis of Brca1 conditional knockout mice.
Generation of induced pluripotent stem cell (iPSC) line from a patient with triple negative breast cancer with hereditary exon 17 deletion of BRCA1 gene.
Genetic alterations in hereditary breast cancer.
Genetic analysis of a breast-ovarian cancer family, with 7 cases of colorectal cancer linked to BRCA1, fails to support a role for BRCA1 in colorectal tumorigenesis.
Genetic analysis of BRCA1 and BRCA2 in breast/ovarian cancer families from Aragon (Spain): two novel truncating mutations and a large genomic deletion in BRCA1.
Genetic and preventive services for hereditary breast and ovarian cancer in the czech republic.
Genetic counseling for families with inherited susceptibility to breast and ovarian cancer.
Genetic counselling and testing for susceptibility to breast, ovarian and colon cancer: where are we today?
Genetic epidemiology of ovarian cancer and prospects for polygenic risk prediction.
Genetic heterogeneity in hereditary breast cancer: role of BRCA1 and BRCA2.
Genetic modifiers of cancer risk for BRCA1 and BRCA2 mutation carriers.
Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy.
Genetic polymorphisms in AURKA, BRCA1, CCNE1 and CDK2 are associated with ovarian cancer susceptibility among Chinese Han women.
Genetic Predisposition to Breast and Ovarian Cancers: How Many and Which Genes to Test?
Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.
Genetic profiles distinguish different types of hereditary ovarian cancer.
Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force.
Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.
Genetic Screens Reveal FEN1 and APEX2 as BRCA2 Synthetic Lethal Targets.
Genetic susceptibility to breast cancer.
Genetic testing and familial implications in breast-ovarian cancer families.
Genetic testing and first presymptomatic diagnosis in Moroccan families at high risk for breast/ovarian cancer.
Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients.
Genetic testing by cancer site: ovary.
Genetic testing by cancer site: stomach.
Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing.
Genetic testing for BRCA1 and BRCA2 in the Province of Ontario.
Genetic testing for breast and ovarian cancer susceptibility: evaluating direct-to-consumer marketing--Atlanta, Denver, Raleigh-Durham, and Seattle, 2003.
Genetic testing for breast cancer predisposition.
Genetic testing for RAD51C mutations: in the clinic and community.
Genetic testing for women previously diagnosed with breast/ovarian cancer: examining the impact of BRCA1 and BRCA2 mutation searching.
Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry.
Genetic testing in Poland and Ukraine: should comprehensive germline testing of BRCA1 and BRCA2 be recommended for women with breast and ovarian cancer?
Genetic testing of breast and ovarian cancer patients: clinical characteristics and hormonal risk modifiers.
Genetic Testing to Guide Risk-Stratified Screens for Breast Cancer.
Genetic Variants in the 3'UTR of BRCA1 and BRCA2 Genes and their Putative Effects on the microRNA Mechanism in Hereditary Breast and Ovarian Cancer.
Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers.
Genetic variation of the brca1 and brca2 genes in macedonian patients.
Genetic Versus Epigenetic BRCA1 Silencing Pathways: Clinical Effects in Primary Ovarian Cancer Patients: A Study of the Tumor Bank Ovarian Cancer Consortium.
Genetics and ovarian carcinoma.
Genetics and the management of women at high risk for breast cancer.
Genistein induces apoptosis in ovarian cancer cells via different molecular pathways depending on Breast Cancer Susceptibility gene-1 (BRCA1) status.
Genome-wide analysis reveals a role for BRCA1 and PALB2 in transcriptional co-activation.
Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk.
Genome-Wide Gene Expression Analyses of BRCA1- and BRCA2-Associated Breast and Ovarian Tumours.
Genome-wide methylation profiles in monozygotic twins with discordance for ovarian carcinoma.
Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.
Genomic rearrangements in the BRCA1 and BRCA2 genes.
Genotype-phenotype correlations among BRCA1 4153delA and 5382insC mutation carriers from Latvia.
Genotype-Phenotype Correlations by Ethnicity and Mutation Location in BRCA Mutation Carriers.
Georgia Primary Care Providers' Knowledge of Hereditary Breast and Ovarian Cancer Syndrome.
Germ line BRCA1 & BRCA2 mutations in Greek breast/ovarian cancer families: 5382insC is the most frequent mutation observed.
Germ line BRCA1 and BRCA2 gene mutations in Turkish breast cancer patients.
Germ line mutations associated with breast cancer susceptibility.
Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer.
Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
Germ-line TP53 mutations in Finnish cancer families exhibiting features of the Li-Fraumeni syndrome and negative for BRCA1 and BRCA2.
German family study on hereditary breast and/or ovarian cancer: germline mutation analysis of the BRCA1 gene.
Germline BRCA1 alterations in a population-based series of ovarian cancer cases.
Germline BRCA1 and BRCA2 Mutations in Ovarian Cancer: Utility of a Histology-Based Referral Strategy.
Germline BRCA1 mutation analysis in Indian breast/ovarian cancer families.
Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer.
Germline BRCA1 mutations in patients from 84 families with breast and/or ovarian cancers in northern France.
Germline BRCA1-2 mutations in non-Ashkenazi families with double primary breast and ovarian cancer.
Germline EMSY sequence alterations in hereditary breast cancer and ovarian cancer families.
Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer.
Germline mutations in Black patients with ovarian, fallopian tube and primary peritoneal carcinomas.
Germline mutations in BRCA1 and BRCA2 genes in ethnically diverse high risk families in Israel.
Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic.
Germline mutations in BRCA1, BRCA2, CHEK2 and TP53 in patients at high-risk for HBOC: characterizing a Northeast Brazilian Population.
Germline mutations in RAD51C and RAD51D and hereditary predisposition to ovarian cancer.
Germline mutations in the BRCA1 gene predisposing to breast and ovarian cancers in Upper Silesia population.
Germline mutations of BRCA1 and BRCA2 in Korean breast and/or ovarian cancer families.
Germline Mutations of BRCA1 and BRCA2 in Korean Ovarian Cancer Patients: Finding Founder Mutations.
Germline mutations of BRCA1 and BRCA2 in Korean sporadic ovarian carcinoma.
Germline mutations of BRCA1 gene exon 11 are not associated with platinum response neither with survival advantage in patients with primary ovarian cancer: understanding the clinical importance of one of the biggest human exons. A study of the Tumor Bank Ovarian Cancer (TOC) Consortium.
Germline mutations of the BRCA1 and BRCA2 genes in a breast and ovarian cancer patient.
Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation.
Germline pathogenic variants identified in women with ovarian tumors.
Germline promoter hypermethylation in BRCA1 and BRCA2 genes is not present in hereditary breast cancer patients.
Germline testing for homologous recombination repair genes-opportunities and challenges.
Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families.
Germline variants in DNA repair genes associated with hereditary breast and ovarian cancer syndrome: analysis of a 21 gene panel in the Brazilian population.
Ginkgo may prevent genetic-associated ovarian cancer risk: multiple biomarkers and anticancer pathways induced by ginkgolide B in BRCA1-mutant ovarian epithelial cells.
Glucocorticoid receptor repression mediated by BRCA1 inactivation in ovarian cancer.
Glucocorticoids inhibit cell death in ovarian cancer and up-regulate caspase inhibitor cIAP2.
Glucose-regulated protein 78 as a novel effector of BRCA1 for inhibiting stress-induced apoptosis.
Granulosa Cell-Specific Brca1 Loss Alone or Combined with Trp53 Haploinsufficiency and Transgenic FSH Expression Fails to Induce Ovarian Tumors.
Gross rearrangements in BRCA1 but not BRCA2 play a notable role in predisposition to breast and ovarian cancer in high-risk families of German origin.
Growth retardation and tumour inhibition by BRCA1.
Growth retardation, DNA repair defects, and lack of spermatogenesis in BRCA1-deficient mice.
Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy.
Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study.
Gynecological-endocrinological aspects in women carriers of BRCA1/2 gene mutations.
Haplotype analysis of BRCA1 gene reveals a new gene rearrangement: characterization of a 19.9 KBP deletion.
Haplotype analysis of BRCA1 intragenic markers in Iranian patients with familial breast and ovarian cancer.
Haplotype analysis of the internationally distributed BRCA1 c.3331_3334delCAAG founder mutation reveals a common ancestral origin in Iberia.
Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study.
Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers.
HDAC inhibitors repress BARD1 isoform expression in acute myeloid leukemia cells via activation of miR-19a and/or b.
Health insurance and discrimination concerns and BRCA1/2 testing in a clinic population.
Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial.
Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome.
Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis.
Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2.
Hereditary breast and ovarian cancer in Asia: genetic epidemiology of BRCA1 and BRCA2.
Hereditary breast and ovarian cancer in Cyprus: identification of a founder BRCA2 mutation.
Hereditary Breast and Ovarian Cancer Syndrome: Moving Beyond BRCA1 and BRCA2.
Hereditary breast and ovarian cancer: assessment of point mutations and copy number variations in Brazilian patients.
Hereditary breast and ovarian cancer: new genes in confined pathways.
Hereditary breast cancer and handling of patients at risk.
Hereditary breast cancer: a review.
Hereditary breast cancer: part I. Diagnosing hereditary breast cancer syndromes.
Hereditary breast cancer: part II. Management of hereditary breast cancer: implications of molecular genetics and pathology.
Hereditary breast cancer; Genetic penetrance and current status with BRCA.
Hereditary breast-ovarian cancer: clinical findings and medical management.
Hereditary Cancer-Associated Mutations in Women Diagnosed with Two Primary Cancers: An Opportunity to Identify Hereditary Cancer Syndromes after the First Cancer Diagnosis.
Hereditary Carcinomas of the Ovary, Fallopian Tube, and Peritoneum.
Hereditary common cancers: molecular and clinical genetics.
Hereditary diffuse gastric cancer and lynch syndromes in a BRCA1/2 negative breast cancer patient.
Hereditary gynaecological malignancies: advances in screening and treatment.
Hereditary non-BRCA gynaecological tumors.
Hereditary Ovarian Cancer and Risk Reduction.
Hereditary ovarian cancer and two-compartment tumor metabolism: epithelial loss of BRCA1 induces hydrogen peroxide production, driving oxidative stress and NF?B activation in the tumor stroma.
Hereditary ovarian cancer in Ashkenazi Jews.
Hereditary ovarian cancer in Poland.
Hereditary ovarian cancer.
Hereditary ovarian cancer: molecular genetics and clinical implications.
Hereditary ovarian cancer: recent molecular insights and their impact on screening strategies.
Hereditary ovarian carcinoma.
Hereditary predisposition to breast cancer.
Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2.
Hereditary Risk of Breast and Ovarian Carcinoma: The Role of the Oncologist.
Hereditary risk of women's cancers.
Hereditary susceptibility to breast cancer: significance of age of onset in family history and contribution of BRCA1 and BRCA2.
High follicular phase luteinizing hormone levels in young healthy BRCA1 mutation carriers: implications for breast and ovarian cancer risk.
High frequency and allele-specific differences of BRCA1 founder mutations in breast cancer and ovarian cancer patients from Belarus.
High frequency of allelic loss at the BRCA1 locus in ovarian cancers: clinicopathologic and molecular associations.
High frequency of BRCA1 185delAG mutation in ovarian cancer in Israel. National Israel Study of Ovarian Cancer.
High frequency of BRCA1 and BRCA2 germline mutations in Ashkenazi Jewish ovarian cancer patients, regardless of family history.
High frequency of BRCA1 and BRCA2 mutations in Ashkenazi Jewish ovarian cancer patients.
High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients.
High frequency of pathogenic non-founder germline mutations in BRCA1 and BRCA2 in families with breast and ovarian cancer in a founder population.
High frequency of recurrent mutations in BRCA1 and BRCA2 genes in Polish families with breast and ovarian cancer.
High grade serous ovarian carcinomas originate in the fallopian tube.
High Incidence of 4153delA BRCA1 Gene Mutations in Lithuanian Breast- and Breast-ovarian Cancer Families.
High incidence of mutations in BRCA1 and BRCA2 genes in ovarian cancer.
High occurrence of BRCA1 intragenic rearrangements in hereditary breast and ovarian cancer syndrome in the Czech Republic.
High penetrances of BRCA1 and BRCA2 mutations confirmed in a prospective series.
High prevalence of BRCA1 stop mutation c.4183C>T in the Tyrolean population: implications for genetic testing.
High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.
High prevalence of two BRCA1 mutations, 4154delA and 5382insC, in Latvia.
High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area.
High throughput fluorescence-based conformation-sensitive gel electrophoresis (F-CSGE) identifies six unique BRCA2 mutations and an overall low incidence of BRCA2 mutations in high-risk BRCA1-negative breast cancer families.
High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors.
Highlight: BRCA1 and BRCA2 proteins in breast cancer.
Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
Histopathology of BRCA1- and BRCA2-associated breast cancer.
Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry.
HMGA2 and high-grade serous ovarian carcinoma.
Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins.
Homologous Recombination Deficiency: Cancer Predispositions and Treatment Implications.
Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study.
Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers.
Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.
Hormone therapy after prophylactic risk-reducing bilateral salpingo-oophorectomy in women who have BRCA gene mutation.
How do real tumors become resistant to cisplatin?
How Far Do We Go With Genetic Evaluation? Gene, Panel, and Tumor Testing.
HP1 regulates the localization of FANCJ at sites of DNA double-strand breaks.
HTLV-1 Tax oncoprotein inhibits the estrogen-induced-ER ?-Mediated BRCA1 expression by interaction with CBP/p300 cofactors.
Human BRCA1 inhibits growth in yeast: potential use in diagnostic testing.
Human disorders of ubiquitination and proteasomal degradation.
Human familial and sporadic breast cancer: analysis of the coding regions of the 17 beta-hydroxysteroid dehydrogenase 2 gene (EDH17B2) using a single-strand conformation polymorphism assay.
Human ovarian cancer of the surface epithelium.
Human VAT-1: a calcium-regulated activation marker of human epithelial cells.
Human, canine and murine BRCA1 genes: sequence comparison among species.
Hypermethylation of the breast cancer-associated gene 1 promoter does not predict cytologic atypia or correlate with surrogate end points of breast cancer risk.
Hypoxia-Activated Alkylating Agents in BRCA1-Mutant Ovarian Serous Carcinoma.
Identification and characterization of missense alterations in the BRCA1 associated RING domain (BARD1) gene in breast and ovarian cancer.
Identification and comprehensive characterization of large genomic rearrangements in the BRCA1 and BRCA2 genes.
Identification and management of inherited cancer susceptibility.
Identification and Management of Women With BRCA Mutations or Hereditary Predisposition for Breast and Ovarian Cancer.
Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.
Identification of a 14 kb deletion involving the promoter region of BRCA1 in a breast cancer family.
Identification of a 3 kb Alu-mediated BRCA1 gene rearrangement in two breast/ovarian cancer families.
Identification of a BRCA1-mRNA splicing complex required for efficient DNA repair and maintenance of genomic stability.
Identification of a common polymorphism in the TopBP1 gene associated with hereditary susceptibility to breast and ovarian cancer.
Identification of a Danish breast/ovarian cancer family double heterozygote for BRCA1 and BRCA2 mutations.
Identification of a founder BRCA2 mutation in Sardinian breast cancer families.
Identification of a functional nuclear export sequence in BRCA1.
Identification of a novel BRCA1 large genomic rearrangement in a Spanish breast/ovarian cancer family.
Identification of a novel BRCA1 nucleotide 4803delCC/c.4684delCC mutation and a nucleotide 249T>A/c.130T>A (p.Cys44Ser) mutation in two Greenlandic Inuit families: implications for genetic screening of Greenlandic Inuit families with high risk for breast and/or ovarian cancer.
Identification of a Novel BRCA1 Pathogenic Mutation in Korean Patients Following Reclassification of BRCA1 and BRCA2 Variants According to the ACMG Standards and Guidelines Using Relevant Ethnic Controls.
Identification of a novel mutations BRCA1*c.80 + 3del4 and BRCA2*c.6589delA in Slovak HBOC families.
Identification of a RING protein that can interact in vivo with the BRCA1 gene product.
Identification of a Splice Variant (c.5074+3A>C) of BRCA1 by RNA Sequencing and TOPO Cloning.
Identification of abrogated pathways in fallopian tube epithelium from BRCA1 mutation carriers.
Identification of BRCA1 and BRCA2 carriers by allele-specific gene expression (AGE) analysis.
Identification of BRCA1-deficient ovarian cancers.
Identification of BRCA2 Cis Double Heterozygous Breast Cancer Cases Using Whole Exome Sequencing: Phenotypic Expression and Impact on Personalized Oncology.
Identification of DBC1 as a transcriptional repressor for BRCA1.
Identification of DNA Repair Pathways that Affect the Survival of Ovarian Cancer Cells Treated with a PARP Inhibitor in a Novel Drug Combination.
Identification of Domains of BRCA1 Critical for the Ubiquitin-Dependent Inhibition of Centrosome Function.
Identification of Eleven Novel BRCA Mutations in Tunisia: Impact on the Clinical Management of BRCA Related Cancers.
Identification of filamin A as a BRCA1-interacting protein required for efficient DNA repair.
Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines.
Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients.
Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach.
Identification of missense and truncating mutations in the BRCA1 gene in sporadic and familial breast and ovarian cancer.
Identification of novel alternatively spliced BRCA1-associated RING domain (BARD1) messenger RNAs in human peripheral blood lymphocytes and in sporadic breast cancer tissues.
Identification of phosphorylation sites on the E3 ubiquitin ligase UBR5/EDD.
Identification of point mutations and large rearrangements in the BRCA1 gene in 667 Turkish unselected ovarian cancer patients.
Identification of residues required for the interaction of BARD1 with BRCA1.
Identification of the deleterious 2080insA BRCA1 mutation in a male renal cell carcinoma patient from a family with multiple cancer diagnoses from Pakistan.
Identification of twenty-nine novel germline unclassified variants of BRCA1 and BRCA2 genes in 1400 Italian individuals.
Identifying and managing hereditary risk of breast and ovarian cancer.
Identifying sequence variants contributing to hereditary breast and ovarian cancer in BRCA1 and BRCA2 negative breast and ovarian cancer patients.
Identifying Women at Risk for Hereditary Breast and Ovarian Cancer Syndrome Utilizing Breast Care Nurse Navigation at Mammography and Imaging Centers.
IGF-1 and BRCA1 signalling pathways in familial cancer.
Immune microenvironment composition in high-grade serous ovarian cancers based on BRCA mutational status.
Immunohistochemical analyses of sporadic and familial (185delAG carriers) ovarian cancer in Israel.
Immunohistochemical classification of non-BRCA1/2 tumors identifies different groups that demonstrate the heterogeneity of BRCAX families.
Immunohistochemical detection of a germline BRCA1 mutation in a breast and ovarian cancer family.
Immunohistochemistry for the detection of BRCA1 and BRCA2 proteins in patients with ovarian cancer: a systematic review.
Immunolocalization of BRCA1 protein in tumor breast tissue: prescreening of BRCA1 mutation in Tunisian patients with hereditary breast cancer?
Impact of a paternal origin of germline BRCA1/2 mutations on the age at breast and ovarian cancer diagnosis in a Southern Swedish cohort.
Impact of amino acid substitutions at secondary structures in the BRCT domains of the tumor suppressor BRCA1: Implications for clinical annotation.
Impact of BRCA mutations on female fertility and offspring sex ratio.
Impact of proactive high-throughput functional assay data on BRCA1 variant interpretation in 3684 patients with breast or ovarian cancer.
Impact of RING and BRCT domain mutations on BRCA1 protein stability, localization and recruitment to DNA damage.
Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity.
Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients.
Implication of BRCA1 gene in breast cancer.
Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer.
Implications of the age range in a population-based BRCA1 testing program with eligibility based on family history of breast and ovarian cancer.
Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer.
Improved survival in BRCA2 carriers with ovarian cancer.
Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations.
In search of the tumour-suppressor functions of BRCA1 and BRCA2.
In silico, in vitro and case-control analyses as an effective combination for analyzing BRCA1 and BRCA2 unclassified variants in a population-based sample.
In-frame deletions of BRCA1 may define critical functional domains.
Inactivating Mutations in GT198 in Familial and Early-Onset Breast and Ovarian Cancers.
Inactivation of BRCA1 and BRCA2 in ovarian cancer.
Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations.
Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry.
Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study.
Incidence of loss of heterozygosity at p53 and BRCA1 loci in serous surface carcinoma.
Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families.
Incidental Carcinomas in Prophylactic Specimens in BRCA1 and BRCA2 Germ-line Mutation Carriers, With Emphasis on Fallopian Tube Lesions: Report of 6 Cases and Review of the Literature.
Incidental serous tubal intraepithelial carcinoma and early invasive serous carcinoma in the nonprophylactic setting: analysis of a case series.
Incorporating medical interventions into carrier probability estimation for genetic counseling.
Incorporating tumour pathology information into breast cancer risk prediction algorithms.
Increased cancer risks for relatives of very early-onset breast cancer cases with and without BRCA1 and BRCA2 mutations.
Increased incidence of brain metastases in BRCA1-related ovarian cancers.
Increased level of chromosomal damage after irradiation of lymphocytes from BRCA1 mutation carriers.
Increased rates of chromosome breakage in BRCA1 carriers are normalized by oral selenium supplementation.
Increased risk for familial ovarian cancer among Jewish women: a population-based case-control study.
Increased sensitivity of BRCA defective triple negative breast tumors to plumbagin through induction of DNA Double Strand Breaks (DSB).
Induced micronucleus frequencies in peripheral lymphocytes as a screening test for carriers of a BRCA1 mutation in breast cancer families.
Induction of apoptosis by the tumor suppressor protein BRCA1.
Induction of ovarian leiomyosarcomas in mice by conditional inactivation of Brca1 and p53.
Inefficacité du dépistage des cancers tubo-ovariens dans les situations de risque héréditaire de cancer de l'ovaire ; l'expérience du Centre Oscar-Lambret.
Influence of estrogen and variations at the BRCA1 promoter region on transcription and translation.
Influence of race/ethnicity on genetic counseling and testing for hereditary breast and ovarian cancer.
Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland.
Informed consent documents for BRCA1 and BRCA2 screening: how large is the readability gap?
Inherited breast and ovarian cancer.
Inherited breast cancer.
Inherited genetic susceptibility to breast cancer.
Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.
Inherited predisposition and breast cancer: modifiers of BRCA1/2-associated breast cancer risk.
Inherited predisposition to breast cancer among African American women.
Inherited susceptibility to breast and ovarian cancer.
Inherited susceptibility to breast cancer.
Inhibition of constitutively activated phosphoinositide 3-kinase/AKT pathway enhances antitumor activity of chemotherapeutic agents in breast cancer susceptibility gene 1-defective breast cancer cells.
Inhibition of human telomerase reverse transcriptase gene expression by BRCA1 in human ovarian cancer cells.
Inhibition of poly(ADP-ribose) polymerase induces synthetic lethality in BRIP1 deficient ovarian epithelial cells.
Inhibitor of apoptosis proteins (IAPs) mediate collagen type XI alpha 1-driven cisplatin resistance in ovarian cancer.
Initiation of translation from a downstream in-frame AUG codon on BRCA1 can generate the novel isoform protein DeltaBRCA1(17aa).
Insulin-like growth factor-I controls BRCA1 gene expression through activation of transcription factor Sp1.
Integrated genomic analyses of ovarian carcinoma.
Integration of functional assay data results provides strong evidence for classification of hundreds of BRCA1 variants of uncertain significance.
Integrin beta3 Leu33Pro polymorphism increases BRCA1-associated ovarian cancer risk.
Interaction of E3 Ubiquitin Ligase MARCH7 with Long Noncoding RNA MALAT1 and Autophagy-Related Protein ATG7 Promotes Autophagy and Invasion in Ovarian Cancer.
Interferon-? signaling is associated with BRCA1 loss-of-function mutations in high grade serous ovarian cancer.
International Szent-Györgyi Prize for Progress in Cancer Research: basic and translational research recognition : Mary-Claire King received the 2016 Prize for her pioneering research that demonstrated the first evidence of genetic predisposition to breast cancer.
International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation.
Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis.
Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations.
Intronic alterations in BRCA1 and BRCA2: effect on mRNA splicing fidelity and expression.
Inverse birth cohort effects in ovarian cancer: Increasing risk in BRCA1/2 mutation carriers and decreasing risk in the general population.
Investigating the effect of 28 BRCA1 and BRCA2 mutations on their related transcribed mRNA.
Investigating the effects of additional truncating variants in DNA-repair genes on breast cancer risk in BRCA1-positive women.
Investigation into the origins of an ancient BRCA1 founder mutation identified among Chinese families in Singapore.
Is hereditary site-specific ovarian cancer a distinct genetic condition?
Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature.
Is there a genetic anticipation in breast and/or ovarian cancer families with the germline c.3481_3491del11 mutation?
Is TP53 dysfunction required for BRCA1-associated carcinogenesis?
Is uterine serous papillary carcinoma a BRCA1-related disease? Case report and review of the literature.
Isolation and characterisation of the NBR2 gene which lies head to head with the human BRCA1 gene.
Isolation of tetranucleotide repeat polymorphisms flanking the BRCA1 gene.
Isolation of the mouse homologue of BRCA1 and genetic mapping to mouse chromosome 11.
Issues of concern in risk assessment, genetic counseling, and genetic testing of younger breast cancer patients in Japan.
It is not all about BRCA: Cullin-Ring ubiquitin Ligases in ovarian cancer.
Keeping it simple: genetics referrals for all invasive serous ovarian cancers.
Key messages for communicating information about BRCA1 and BRCA2 to women with breast or ovarian cancer: Consensus across health professionals and service users.
Kinetic analysis of interaction of BRCA1 tandem breast cancer c-terminal domains with phosphorylated peptides reveals two binding conformations.
Knowledge and opinions regarding BRCA1 and BRCA2 genetic testing among primary care physicians.
Laboratory determination of hereditary susceptibility to breast and ovarian cancer.
Laboratory Verification of a BRCA1 and BRCA2 Massively Parallel Sequencing Assay from Wet Bench to Bioinformatics for Germline DNA Analysis.
Lack of evidence for CDK12 as an ovarian cancer predisposing gene.
Lactate dehydrogenase is correlated with clinical stage and grade and is downregulated by si?SA?B1 in ovarian cancer.
Landscape of BRIP1 molecular lesions in gastrointestinal cancers from published genomic studies.
Laparoscopic Salpingo-oophorectomy in Conscious Sedation.
Laparoscopic total fallopian tube removal at the time of bilateral salpingo-oophorectomy in BRCA2 positive women.
Large BRCA1 and BRCA2 genomic rearrangements in Danish high risk breast-ovarian cancer families.
Large BRCA1 and BRCA2 genomic rearrangements in Polish high-risk breast and ovarian cancer families.
Large BRCA1 gene deletions are found in 3% of German high-risk breast cancer families.
Large genomic deletions inactivate the BRCA2 gene in breast cancer families.
Large genomic rearrangements in BRCA1 and BRCA2 genes in breast and ovarian cancer families in Poland.
Large genomic rearrangements in the familial breast and ovarian cancer gene BRCA1 are associated with an increased frequency of high risk features.
Large genomic rearrangements of both BRCA2 and BRCA1 are a feature of the inherited breast/ovarian cancer phenotype in selected families.
Large Genomic Rearrangements of BRCA1 and BRCA2 among Patients Referred for Genetic Analysis in Galicia (NW Spain): Delimitation and Mechanism of Three Novel BRCA1 Rearrangements.
Large genomic rearrangements of the BRCA1 and BRCA2 genes: review of the literature and report of a novel BRCA1 mutation.
Large-scale meta-analysis of mutations identified in panels of breast/ovarian cancer-related genes - Providing evidence of cancer predisposition genes.
Leveraging DNA repair deficiency in gynecologic oncology.
Limited significance of family history for presence of BRCA1 gene mutation in Polish breast and ovarian cancer cases.
Linkage analysis of 26 Canadian breast and breast-ovarian cancer families.
Linking genotoxicity and cytotoxicity with membrane fluidity: A comparative study in ovarian cancer cell lines following exposure to auranofin.
Linking up and interacting with BRCT domains.
Links between genome integrity and BRCA1 tumor suppression.
Literature Review of BARD1 as a Cancer Predisposing Gene with a Focus on Breast and Ovarian Cancers.
Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy.
Localisation of the breast-ovarian cancer susceptibility gene (BRCA1) on 17q12-21 to an interval of < or = 1 cM.
Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13.
Localization of BRCA1 and a splice variant identifies the nuclear localization signal.
Localization of BRCA1 gene expression in adult cynomolgus monkey tissues.
Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas.
Localization of the VHR phosphatase gene and its analysis as a candidate for BRCA1.
Location of BRCA1 in human breast and ovarian cancer cells.
Log odds of carrying an Ancestral Mutation in BRCA1 or BRCA2 for a Defined personal and family history in an Ashkenazi Jewish woman (LAMBDA).
Long non-coding RNA GEHT1 promoted the proliferation of ovarian cancer cells via modulating the protein stability of HIF1?.
Long-Range PCR and Next-Generation Sequencing of BRCA1 and BRCA2 in Breast Cancer.
Long-term outcomes following a diagnosis of ovarian cancer at the time of preventive oophorectomy among BRCA1 and BRCA2 mutation carriers.
Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2.
Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention.
Loss of BRCA1 protein expression as indicator of the BRCAness phenotype is associated with favorable overall survival after complete resection of sporadic ovarian cancer.
Loss of BRCA1 Spontaneously Induces the Tumorigenesis in Lacrimal Gland.
Loss of BRCA1-A complex function in RAP80 null tumor cells.
Loss of coordinated androgen regulation in nonmalignant ovarian epithelial cells with BRCA1/2 mutations and ovarian cancer cells.
Loss of glucocorticoid receptor activation is a hallmark of BRCA1-mutated breast tissue.
Loss of Heterozygosity at BRCA1 Locus Is Significantly Associated with Aggressiveness and Poor Prognosis in Breast Cancer.
Loss of Heterozygosity in BRCA1 and BRCA2 Genes in Patients with Ovarian Cancer and Probability of Its Use for Clinical Classification of Variations.
Loss of heterozygosity of the BRCA1 and other loci on chromosome 17q in human prostate cancer.
Loss of heterozygosity on chromosome 17q11-21 in cancers of women who have both breast and ovarian cancer.
Loss of heterozygosity studies in tumors from families with breast-ovarian cancer syndrome.
Low frequency of large genomic rearrangements of BRCA1 and BRCA2 in western Denmark.
Low incidence of BRCA1 mutations among Italian families with breast and ovarian cancer.
Low incidence of BRCA2 mutations in breast carcinoma and other cancers.
Low prevalence of BRCA1 exon rearrangements in familial and young sporadic breast cancer patients.
Low Prevalence of the Four Common Colombian Founder Mutations in BRCA1 and BRCA2 in Early-Onset and Familial Afro-Colombian Patients with Breast Cancer.
Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.
Lymphoblasts of women with BRCA1 mutations are deficient in cellular repair of 8,5'-Cyclopurine-2'-deoxynucleosides and 8-hydroxy-2'-deoxyguanosine.
Mainstreaming genetic counseling for BRCA testing into oncology clinics - Indian perspective.
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer.
Making the best of PARP inhibitors in ovarian cancer.
Male BRCA mutation carriers: clinical characteristics and cancer spectrum.
Mammalian stanniocalcins and cancer.
Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer.
Management of Breast Cancer Risk in Women with Ovarian Cancer and Deleterious BRCA1 or BRCA2 Mutations.
Management Options After Prophylactic Surgeries in Women With BRCA Mutations: A Review.
Management updates for women with a BRCA1 or BRCA2 mutation.
Marker segregation information in breast/ovarian cancer genetic counseling: is it still useful? Groupe Génétique et Cancer de la Fédération Nationale des Centres de Lutte Contre le Cancer.
Mass spectrometric and mutational analyses reveal Lys-6-linked polyubiquitin chains catalyzed by BRCA1-BARD1 ubiquitin ligase.
Massive Parallel Sequencing for Diagnostic Genetic Testing of BRCA Genes--a Single Center Experience.
Maternal and paternal lineage double heterozygosity alteration in familial breast cancer: a first case report.
Mechanism for survival of homozygous nonsense mutations in the tumor suppressor gene BRCA1.
Mechanism of tandem duplication formation in BRCA1-mutant cells.
Medium-sized deletion in the BRCA1 gene: Limitations of Sanger sequencing and MLPA analyses.
Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers.
Messenger RNA expression and methylation of candidate tumor-suppressor genes and risk of ovarian cancer-a case-control analysis.
Meta-analysis of BRCA1 and BRCA2 penetrance.
Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.
Metformin inhibits the growth of ovarian cancer cells by promoting the Parkin-induced p53 ubiquitination.
Methylation not a frequent "second hit" in tumors with germline BRCA mutations.
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.
Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics.
Methylation profile of BRCA1, RASSF1A and ER in Vietnamese women with ovarian cancer.
Methylation profiles of hereditary and sporadic ovarian cancer.
Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women.
Methylenetetrahydrofolate reductase polymorphisms modify BRCA1-associated breast and ovarian cancer risks.
Mexican BRCA1 founder mutation: Shortening the gap in genetic assessment for hereditary breast and ovarian cancer patients.
Mice heterozygous for a Brca1 or Brca2 mutation display distinct mammary gland and ovarian phenotypes in response to diethylstilbestrol.
Microarray analysis of differentially expressed genes in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies.
Microelectronic DNA assay for the detection of BRCA1 gene mutations.
Microscopic and Early-Stage Ovarian Cancers in BRCA1/2 Mutation Carriers: Building a Model for Early BRCA-Associated Tumorigenesis.
Minding the gap: the underground functions of BRCA1 and BRCA2 at stalled replication forks.
miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition.
miRNA expression profile changes in the peripheral blood of monozygotic discordant twins for epithelial ovarian carcinoma: potential new biomarkers for early diagnosis and prognosis of ovarian carcinoma.
Mismatch repair deficiency in ovarian cancer -- molecular characteristics and clinical implications.
Missense alterations of BRCA1 gene detected in diverse cancer patients.
Missense mutations (p.H371Y, p.D438Y) in gene CHEK2 are associated with breast cancer risk in women of Balochistan origin.
Missense mutations of BRCA1 gene affect the binding with p53 both in vitro and in vivo.
Missense polymorphisms in BRCA1 and BRCA2 and risk of breast and ovarian cancer.
Mitochondrial localization, ELK-1 transcriptional regulation and growth inhibitory functions of BRCA1, BRCA1a, and BRCA1b proteins.
Model of transcriptional regulation of the BRCA1-NBR2 bi-directional transcriptional unit.
Models for predicting BRCA1 and BRCA2 mutations in Han Chinese familial breast and/or ovarian cancer patients.
Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1 Interacting Genes.
Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers.
Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers.
Modifiers of risk of hereditary breast cancer.
Modifying effect of reproductive risk factors on the age at onset of breast cancer for German BRCA1 mutation carriers.
Modulation of aromatase expression by BRCA1: a possible link to tissue-specific tumor suppression.
Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells.
Molecular analysis of BRCA1 and BRCA2 genes by next generation sequencing and ultrastructural aspects of breast tumor tissue.
Molecular analysis of the BRCA1 and BRCA2 genes in 32 breast and/or ovarian cancer Spanish families.
Molecular analysis of the breast cancer genes BRCA1 and BRCA2 using amplicon-based massive parallel pyrosequencing.
Molecular analysis of the eighteen most frequent mutations in the BRCA1 gene in 63 Chilean breast cancer families.
Molecular analysis of the six most recurrent mutations in the BRCA1 gene in 87 Spanish breast/ovarian cancer families.
Molecular approaches to diagnosis and management of ovarian cancer.
Molecular aspects of breast cancer resistance to drugs (Review).
Molecular biology of breast cancer.
Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors.
Molecular classification of familial non-BRCA1/BRCA2 breast cancer.
Molecular cloning of BRCA1: a gene for early onset familial breast and ovarian cancer.
Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers.
Molecular genetics analysis of hereditary breast and ovarian cancer patients in India.
Molecular genetics of hereditary ovarian cancer.
Molecular insights into the OGG1 gene, a cancer risk modifier in BRCA1 and BRCA2 mutations carriers.
Molecular Mechanism Linking BRCA1 Dysfunction to High Grade Serous Epithelial Ovarian Cancers with Peritoneal Permeability and Ascites.
Molecular modeling of the amino-terminal zinc ring domain of BRCA1.
Molecular pathways involved in response to ionizing radiation of ID-8 mouse ovarian cancer cells expressing exogenous full-length Brca1 or truncated Brca1 mutant.
Molecular profiles of hereditary epithelial ovarian cancers and their implications for the biology of this disease.
Molecular profiling and commercial predication assays in ovarian cancer: still not ready for prime time?
Molecular Trajectory of BRCA1 and BRCA2 Mutations.
Morphology of breast cancer as a means of triage of patients for BRCA1 genetic testing.
Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study.
Mouse Brca1: localization sequence analysis and identification of evolutionarily conserved domains.
Mouse models for BRCA1 associated tumorigenesis: from fundamental insights to preclinical utility.
Mouse Models for Deciphering the Impact of Homologous Recombination on Tumorigenesis.
Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects.
Moving toward personalized medicine: treatment-focused genetic testing of women newly diagnosed with ovarian cancer.
Moving towards population-based genetic risk prediction for ovarian cancer.
MRG15 binds directly to PALB2 and stimulates homology-directed repair of chromosomal breaks.
MRI in the early detection of breast cancer in women with high genetic risk.
MSH2 role in BRCA1-driven tumorigenesis: A preliminary study in yeast and in human tumors from BRCA1-VUS carriers.
Much more than a gene: hereditary breast and ovarian cancer, reproductive choices and family life.
MUL1 E3 ligase regulates the antitumor effects of metformin in chemoresistant ovarian cancer cells via AKT degradation.
Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients.
Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim results.
Multifunctional transcription factor TFII-I is an activator of BRCA1 function.
Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings.
Multiple diseases in carrier probability estimation: accounting for surviving all cancers other than breast and ovary in BRCAPRO.
Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland.
Multiplex ddPCR assay for screening copy number variations in BRCA1 gene.
Murine Brca1: sequence and significance for human missense mutations.
Mutation analysis of BRCA1 and BRCA2 genes in Iranian high risk breast cancer families.
Mutation analysis of BRCA1 and BRCA2 in Turkish cancer families: a novel mutation BRCA2 3414del4 found in male breast cancer.
Mutation analysis of BRCA1 gene in African-American patients with breast cancer.
Mutation analysis of PALB2 in BRCA1 and BRCA2-negative breast and/or ovarian cancer families from Eastern Ontario, Canada.
Mutation analysis of the BRCA1 and BRCA2 genes in the Belgian patient population and identification of a Belgian founder mutation BRCA1 IVS5 + 3A > G.
Mutation analysis of the BRCA1 and BRCA2 genes results in the identification of novel and recurrent mutations in 6/16 flemish families with breast and/or ovarian cancer but not in 12 sporadic patients with early-onset disease. Mutations in brief no. 224. Online.
Mutation analysis of the BRCA1 gene in 76 Japanese ovarian cancer patients: four germline mutations, but no evidence of somatic mutation.
Mutation analysis of the BRCA1 gene in Malaysian breast cancer patients.
Mutation analysis of the BRCA1 gene in ovarian cancers.
Mutation analysis of the THRA1 gene in breast cancer: deletion/fusion of the gene to a novel sequence on 17q in the BT474 cell line.
Mutation of the PTEN tumor suppressor gene is not a feature of ovarian cancers.
Mutation scanning of exon 20 of the BRCA1 gene by high-resolution melting curve analysis.
Mutation screening of BRCA1 using PTT and LOH analysis at 17q21 in breast carcinomas from familial and non-familial cases.
Mutation screening of MIR146A/B and BRCA1/2 3'-UTRs in the GENESIS study.
Mutation screening of RAD51C in high-risk breast and ovarian cancer families.
Mutation screening of the BRCA1 gene in Slovak patients.
Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations.
Mutational analyses of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer.
Mutational analysis of BRCA1 and BRCA2 and clinicopathologic analysis of ovarian cancer in 82 ovarian cancer families: two common founder mutations of BRCA1 in Japanese population.
Mutational analysis of BRCA1 and BRCA2 genes in Chinese ovarian cancer identifies 6 novel germline mutations.
Mutational analysis of BRCA1 and BRCA2 genes in Mexican breast cancer patients.
Mutational analysis of BRCA1 and BRCA2 genes in Peruvian families with hereditary breast and ovarian cancer.
Mutational analysis of BRCA1 and BRCA2 in hereditary breast and ovarian cancer families from Asturias (Northern Spain).
Mutational analysis of BRCA1 gene in ovarian and breast-ovarian cancer families in Japan.
Mutational analysis of the BRCA1 gene in 30 Czech ovarian cancer patients.
Mutational analysis of the estrogen receptor-alpha gene in familial ovarian cancer.
Mutational analysis of TP53 and p21 in familial and sporadic ovarian cancer in Japan.
Mutational Landscape of the Essential Autophagy Gene BECN1 in Human Cancers.
Mutational spectrum in breast cancer associated
Mutational spectrum of p53 mutations in primary breast and ovarian tumors.
Mutations in BRCA1 from fixed, paraffin-embedded tissue can be artifacts of preservation.
Mutations in BRCA1, BRCA2 and other breast and ovarian cancer susceptibility genes in Central and South American populations.
Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer.
Mutations in the BRCA1 gene in Japanese breast cancer patients.
Mutations in the BRCA1-associated RING domain (BARD1) gene in primary breast, ovarian and uterine cancers.
Mutations in the BRCT domain confer temperature sensitivity to BRCA1 in transcription activation.
Mutations of BRCA genes in hereditary breast and ovarian cancer.
MUTATIONS OF GENES BRCA1 AND BRCA2 IN WOMEN WITH OVARIAN CANCER EXPOSED TO FACTORS OF CHORNOBYL NUCLEAR ACCIDENT.
Mutations of the BRCA1 and BRCA2 genes and the possibilities for predictive testing.
Mutations of the BRCA1 gene in hereditary breast and ovarian cancer in the Czech Republic.
Mutations of the BRCA1 gene in human cancer.
Mutations of the BRCA2 gene in ovarian carcinomas.
Mutual exclusivity analysis identifies oncogenic network modules.
Müllerian intra-abdominal carcinomatosis in hereditary breast ovarian cancer syndrome: implications for risk-reducing surgery.
Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells.
Naturally occurring BRCA2 alternative mRNA splicing events in clinically relevant samples.
NBR1 interacts with fasciculation and elongation protein zeta-1 (FEZ1) and calcium and integrin binding protein (CIB) and shows developmentally restricted expression in the neural tube.
Negative Selection on BRCA1 Susceptibility Alleles Sheds Light on the Population Genetics of Late-Onset Diseases and Aging Theory.
Nesprin-2 mediated nuclear trafficking and its clinical implications.
New perspective on maintenance therapies for platinum- sensitive recurrent ovarian cancer in women with germline and somatic mutations in BRCA1 and BRCA2 genes.
New players in the BRCA1-mediated DNA damage responsive pathway.
New recurrent BRCA1/2 mutations in Polish patients with familial breast/ovarian cancer detected by next generation sequencing.
New sequence variants in BRCA1 and BRCA2 genes detected by high-resolution melting analysis in an elderly healthy female population in Croatia.
Next-generation sequencing meets genetic diagnostics: development of a comprehensive workflow for the analysis of BRCA1 and BRCA2 genes.
Next-Generation Sequencing of the BRCA1 and BRCA2 Genes for the Genetic Diagnostics of Hereditary Breast and/or Ovarian Cancer.
NGS-based BRCA1/2 mutation testing of high-grade serous ovarian cancer tissue: results and conclusions of the first international round robin trial.
Nicotinamide adenine dinucleotide (NAD) may affect DNA methyltransferase 1 through regulation of BRCA1 in ovarian cancer.
Nine novel conserved motifs in BRCA1 identified by the chicken orthologue.
No Association of Early-Onset Breast or Ovarian Cancer with Early-Onset Cancer in Relatives in BRCA1 or BRCA2 Mutation Families.
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.
No differences in p53 mutation frequencies between BRCA1-associated and sporadic ovarian cancers.
No Evidence of BRCA1/2 genomic rearrangements in high-risk French-Canadian breast/ovarian cancer families.
No evidence of involvement of germline BACH1 mutations in Finnish breast and ovarian cancer families.
No germline mutations in the histone acetyltransferase gene EP300 in BRCA1 and BRCA2 negative families with breast cancer and gastric, pancreatic, or colorectal cancer.
No Sib Pair Concordance for Breast or Ovarian Cancer in BRCA1 Mutation Carriers.
Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy.
Non-Coding Variants in BRCA1 and BRCA2 Genes: Potential Impact on Breast and Ovarian Cancer Predisposition.
Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations.
Nongenetic screening of ovarian malignancies.
Nonsurgical Prevention Strategies in BRCA1 and BRCA2 Mutation Carriers.
Nordic collaborative study of the BARD1 Cys557Ser allele in 3956 patients with cancer: enrichment in familial BRCA1/BRCA2 mutation-negative breast cancer but not in other malignancies.
Notification of a family history of breast cancer: issues of privacy and confidentiality.
Novel and recurrent BRCA1/BRCA2 mutations in early onset and familial breast and ovarian cancer detected in the Program of Genetic Counseling in Cancer of Valencian Community (eastern Spain). Relationship of family phenotypes with mutation prevalence.
Novel and recurrent BRCA2 mutations in Italian breast/ovarian cancer families widen the ovarian cancer cluster region boundaries to exons 13 and 14.
Novel Associations between BRCA1 Variants C.181 T>G (Rs28897672) and Ovarian Crisk in Saudi Females.
Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
Novel BRCA1 and BRCA2 pathogenic mutations in Slovene hereditary breast and ovarian cancer families.
Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas.
Novel BRCA1 deleterious mutation (c.1918C>T) in familial breast and ovarian cancer syndrome who share a common ancestry.
Novel BRCA1 Large Genomic Rearrangements in Italian Breast/Ovarian Cancer Patients.
Novel BRCA1 mutations and more frequent intron-20 alteration found among 236 women from Western Poland.
Novel BRCA1 splice-site mutation in ovarian cancer patients of Slavic origin.
Novel complex genomic rearrangement of the BRCA1 gene.
Novel genomic rearrangements in the BRCA1 gene detected in Greek breast/ovarian cancer patients.
Novel germline BRCA1 and BRCA2 mutations in Turkish women with breast and/or ovarian cancer and their relatives.
Novel Germline Mutation of BRCA1 Gene in a 56-Year-Old Woman with Breast Cancer, Ovarian Cancer, and Diffuse Large B-Cell Lymphoma.
Novel germline mutations and unclassified variants of BRCA1 and BRCA2 genes in Chinese women with familial breast/ovarian cancer.
Novel germline mutations in the BRCA1 and BRCA2 genes in Indian breast and breast-ovarian cancer families.
Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families.
Novel mechanism of platinum resistance: Rapid selection of pre-existing BRCA1-proficient tumor cells during neoadjuvant chemotherapy (NACT) for ovarian cancer (OC) in BRCA1 germ-line mutation carriers.
Novel mutations in the BRCA1 and BRCA2 genes in Iranian women with early-onset breast cancer.
Novel pleiotropic BRCA2 pathogenic variants in Lebanese families.
Novel somatic mutations in the BRCA1 gene in sporadic breast tumors.
Novel surgical approaches for sampling the ovarian surface epithelium and proximal fluid proteome.
Nrf2, the master redox switch: the Achilles' heel of ovarian cancer?
Occult cancer of the fallopian tube in a BRCA2 germline mutation carrier at prophylactic salpingo-oophorectomy.
Occurrence of a non deleterious gene conversion event in the BRCA1 gene.
Occurrence of both breast and ovarian cancer in a woman is a marker for the BRCA gene mutations: a population-based study from western Sweden.
Of mice and (wo)men: genotype-phenotype correlations in BRCA1.
Of microbes and women: BRCA1, vaginal microbiota, and ovarian cancer.
OLA1 gene sequencing in patients with BRCA1/2 mutation-negative suspected hereditary breast and ovarian cancer.
Olaparib , PARP1 inhibitor in ovarian cancer.
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Olaparib for the treatment of relapsed ovarian cancer with a BRCA1/2 mutation.
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline BRCA mutations: OPINION Phase IIIb study design.
Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort.
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
Olaparib shows promise in multiple tumor types.
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden.
One step direct detection of recurrent mutations in the breast cancer susceptibility gene, BRCA1.
Online tool to guide decisions for BRCA1/2 mutation carriers.
Opportunistic Salpingectomy as an Ovarian Cancer Primary Prevention Strategy.
Opportunities and hurdles in the treatment of BRCA1-related breast cancer.
Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis.
Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations.
Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study.
Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations.
Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis.
Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group.
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
Osmotic and heat stress-dependent regulation of MLK4? and MLK3 by the CHIP E3 ligase in ovarian cancer cells.
Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers.
Ovarian and breast cancer risks to women in families with two or more cases of ovarian cancer.
Ovarian Cancer After Prophylactic Salpingectomy in a Patient With Germline BRCA1 Mutation.
Ovarian Cancer After Prophylactic Salpingectomy in a Patient With Germline BRCA1 Mutation: Correction.
Ovarian cancer among 8005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative for BRCA1 and BRCA2.
Ovarian cancer and genetic susceptibility in relation to the BRCA1 and BRCA2 genes. Occurrence, clinical importance and intervention.
Ovarian cancer associated with inherited mutations in BRCA1 or BRCA2.
Ovarian cancer at young age: the contribution of mismatch-repair defects in a population-based series of epithelial ovarian cancer before age 40.
Ovarian cancer BRCA1 gene therapy: Phase I and II trial differences in immune response and vector stability.
Ovarian cancer BRCA1 mutation detection: Protein truncation test (PTT) outperforms single strand conformation polymorphism analysis (SSCP).
Ovarian Cancer Gene Therapy with BRCA1-An Overview.
Ovarian cancer genome.
Ovarian cancer in BRCA1 and BRCA2 gene mutation carriers: analysis of prognostic factors and survival.
Ovarian cancer patient with germline mutations in both BRCA1 and NBN genes.
Ovarian cancer predisposition beyond BRCA1 and BRCA2 genes.
Ovarian cancer risk assessment in the era of next-generation sequencing.
Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus.
Ovarian cancer risk in Polish BRCA1 mutation carriers is not associated with the prohibitin 3' untranslated region polymorphism.
Ovarian cancer surveillance in the clinical follow up of women with known BRCA1 or BRCA2 pathogenic variants in a large health care system.
Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations.
Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.
Ovarian Cancer-associated Mutations Disable Catalytic Activity of CDK12, a Kinase That Promotes Homologous Recombination Repair and Resistance to Cisplatin and Poly(ADP-ribose) Polymerase Inhibitors.
Ovarian cancer.
Ovarian cancer: epidemiology, biology, and prognostic factors.
Ovarian cancer: in search of better marker systems based on DNA repair defects.
Ovarian carcinoma in situ with germline BRCA1 mutation and loss of heterozygosity at BRCA1 and TP53.
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities.
Ovarian cystadenoma as a characteristic feature of families with hereditary ovarian cancers unassociated with BRCA1 and BRCA2 mutations.
Ovarian endometriosis, a precursor of ovarian cancer: Histological aspects, gene expression and microRNA alterations (Review).
Ovarian remnant syndrome in an aromatase inhibitor-treated patient with BRCA2 mutation following bilateral oophorectomy.
Ovarian tumors associated with multiple endocrine neoplasias and related syndromes (Carney complex, Peutz-Jeghers syndrome, von Hippel-Lindau disease, Cowden's disease).
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
Overestimation of hereditary breast cancer risk.
Overview of history and progress in BRCA1 research: the first BRCA1 decade.
p53 inactivation is a rare event in familial breast tumors negative for BRCA1 and BRCA2 mutations.
Paeonol Pretreatment Attenuates Anoxia-Reoxygenation Induced Injury in Cardiac Myocytes via a BRCA1 Dependent Pathway.
PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2.
PALB2 links BRCA1 and BRCA2 in the DNA-damage response.
Papers to appear in forthcoming issues
Parental origin of mutation and the risk of breast cancer in a prospective study of women with a BRCA1 or BRCA2 mutation.
Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers.
Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation.
Parkin Gene Alterations in Ovarian Carcinoma from Northern Indian Population.
PARP inhibition and synthetic lethality in ovarian cancer.
PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers.
PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?
PARP Inhibitors Display Differential Efficacy in Models of BRCA Mutant High-Grade Serous Ovarian Cancer.
PARP Inhibitors in Clinical Use Induce Genomic Instability in Normal Human Cells.
PARP inhibitors in the management of breast cancer: current data and future prospects.
PARP inhibitors: A new era of targeted therapy.
PARP Theranostic Auger Emitters Are Cytotoxic in BRCA Mutant Ovarian Cancer and Viable Tumors from Ovarian Cancer Patients Enable Ex-Vivo Screening of Tumor Response.
Pathogenic BRCA1 mutations may be necessary but not sufficient for tissue genomic heterogeneity: Deep sequencing data from ovarian cancer patients.
Pathogenicity assessment of variants for breast cancer susceptibility genes based on BRCAness of tumor sample.
Pathogenicity of the BRCA1 missense variant M1775K is determined by the disruption of the BRCT phosphopeptide-binding pocket: a multi-modal approach.
Pathogenicity reclassification of two BRCA1/BRCA2 exonic duplications after identification of genomic breakpoints and tandem orientation.
Pathological splice mutations outside the invariant AG/GT splice sites of BRCA1 exon 5 increase alternative transcript levels in the 5' end of the BRCA1 gene.
Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).
Pathology of Hereditary Breast and Ovarian Cancer.
Pathology of ovarian cancers in BRCA1 and BRCA2 carriers.
Patient reported experiences following laparoscopic prophylactic bilateral salpingo-oophorectomy or salpingectomy in an ambulatory care hospital.
Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testing.
Patterns and duration of primary and recurrent treatment in ovarian cancer patients with germline BRCA mutations.
Pedigree and BRCA gene analysis in breast cancer patients to identify hereditary breast and ovarian cancer syndrome to prevent morbidity and mortality of disease in Indian population.
Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family.
Penetrance of Breast and Ovarian Cancer in Women Who Carry a BRCA1/2 Mutation and Do Not Use Risk-Reducing Salpingo-Oophorectomy: An Updated Meta-Analysis.
Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
Penetrances of BRCA1 1675delA and 1135insA with respect to breast cancer and ovarian cancer.
Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations.
Perceptions of risk and reward in BRCA1 and BRCA2 mutation carriers choosing salpingectomy for ovarian cancer prevention.
Performance of multiplicom's BRCA MASTR Dx kit on the detection of BRCA1 and BRCA2 mutations in fresh frozen ovarian and breast tumor samples.
Performance of prediction models for BRCA mutation carriage in three racial/ethnic groups: findings from the Northern California Breast Cancer Family Registry.
Peripheral blood BRCA1 methylation profiling to predict familial ovarian cancer.
Peripheral blood DNA methylation detected in the BRCA1 or BRCA2 promoter for sporadic ovarian cancer patients and controls.
Peritoneal cancer arising after total abdominal hysterectomy and bilateral salpingo-oophorectomy for cervical cancer in a patient with right breast cancer and germline mutation of BRCA1 gene: a case report and literature review.
Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.
Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening.
PGD for hereditary breast and ovarian cancer: the route to universal tests for BRCA1 and BRCA2 mutation carriers.
Pharmaco(epi)genomics in ovarian cancer.
Pharmacoprevention for hereditary breast and ovarian cancer.
Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors.
Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.
Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.
Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry.
Phosphorylation of serine 1387 in Brca1 is specifically required for the Atm-mediated S-phase checkpoint after ionizing irradiation.
Pitfalls and caveats in BRCA sequencing.
Pitfalls in genetic testing: a case of a SNP in primer-annealing region leading to allele dropout in BRCA1.
Platelet-Activating Factor Acetylhydrolase Expression in BRCA1 Mutant Ovarian Cancer as a Protective Factor and Potential Negative Regulator of the Wnt Signaling Pathway.
Poly (ADP-ribose) polymerase 1 transcriptional regulation: a novel crosstalk between histone modification H3K9ac and ETS1 motif hypomethylation in BRCA1-mutated ovarian cancer.
Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.
Poly-ADP-ribosyl-polymerase inhibitor resistance mechanisms and their therapeutic implications.
Polymorphism in the IL18 gene and epithelial ovarian cancer in non-Hispanic white women.
Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer.
Population based testing of non-mucinous epithelial ovarian cancer in Scotland.
Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
Population screening for hereditary and familial cancer syndromes in Valka district of Latvia.
Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2.
Population-based study of BRCA1/2 mutations: Family history based criteria identify minority of mutation carriers.
Positional analyses of BRCA1-dependent expression in Saccharomyces cerevisiae.
Positive regulation of the BRCA1 promoter.
Potential implications on female fertility and reproductive lifespan in BRCA germline mutation women.
Practical implementation of frailty models in Mendelian risk prediction.
Practice Bulletin No 182: Hereditary Breast and Ovarian Cancer Syndrome.
Practice Bulletin No. 182 Summary: Hereditary Breast and Ovarian Cancer Syndrome.
Pre-counseling education materials for BRCA testing: does tailoring make a difference?
Precious GEMMs: emergence of faithful models for ovarian cancer research.
Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.
Preclinical evaluation of radiation therapy of BRCA1-associated mammary tumors using a mouse model.
Preclinical studies of a new generation retroviral vector for ovarian cancer BRCA1 gene therapy.
Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics.
Prediction of BRCA1 germline mutation status in women with ovarian cancer using morphology-based criteria: identification of a BRCA1 ovarian cancer phenotype.
Prediction of BRCA1/2 mutation status in patients with ovarian cancer from a hospital-based cohort.
Predictive genetic tests: problems and pitfalls.
Predictors of long-term cancer-related distress among female BRCA1 and BRCA2 mutation carriers without a cancer diagnosis: an international analysis.
Preferences for breast cancer prevention among women with a BRCA1 or BRCA2 mutation.
Preimplantation genetic diagnosis for BRCA1 exon 13 duplication mutation using linked polymorphic markers resulting in a live birth.
Preimplantation genetic diagnosis for cancer predisposition syndromes.
Preliminary molecular evidence associating a novel BRCA1 synonymous variant with hereditary ovarian cancer syndrome.
Premature menopause in patients with BRCA1 gene mutation.
Preserving the Self: The Process of Decision Making About Hereditary Breast Cancer and Ovarian Cancer Risk Reduction.
Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation.
Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO.
Prevalence and clinical correlations of BRCA1/BRCA2 unclassified variant carriers among unselected primary ovarian cancer cases - preliminary report.
Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer.
Prevalence and founder effect of the BRCA1 p.(Val1833Met) variant in the Greek population, with further evidence for pathogenicity and risk modification.
Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group.
Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.
Prevalence and Predictors of BRCA1 and BRCA2 Mutations in a Population-Based Study of Breast Cancer in White and Black American Women Ages 35 to 64 Years.
Prevalence and spectrum of BRCA germline variants in mainland Chinese familial breast and ovarian cancer patients.
Prevalence of BRCA mutations among hereditary breast and/or ovarian cancer patients in Arab countries: systematic review and meta-analysis.
Prevalence of BRCA1 and BRCA2 gene mutations in families with medium and high risk of breast and ovarian cancer in Brazil.
Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer.
Prevalence of BRCA1 and BRCA2 genomic rearrangements in a cohort of consecutive Italian breast and/or ovarian cancer families.
Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patients.
Prevalence of BRCA1 and BRCA2 Mutations in Patients with Primary Ovarian Cancer - Does the German Checklist for Detecting the Risk of Hereditary Breast and Ovarian Cancer Adequately Depict the Need for Consultation?
Prevalence of BRCA1 genomic rearrangements in a large cohort of Italian breast and breast/ovarian cancer families without detectable BRCA1 and BRCA2 point mutations.
Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study.
Prevalence of BRCA1 Mutations in Familial and Sporadic Greek Ovarian Cancer Cases.
Prevalence of BRCA1/2 germline mutations in 21?401 families with breast and ovarian cancer.
Prevalence of BRCA1/2 mutations in sporadic breast/ovarian cancer patients and identification of a novel de novo BRCA1 mutation in a patient diagnosed with late onset breast and ovarian cancer: implications for genetic testing.
Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in Hungary.
Prevalence of Hispanic BRCA1 and BRCA2 mutations among hereditary breast and ovarian cancer patients from Brazil reveals differences among Latin American populations.
Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history.
Prevalence of the BLM nonsense mutation, p.Q548X, in ovarian cancer patients from Central and Eastern Europe.
Prevalence of the BRCA1 founder mutation c.5266dup in Brazilian individuals at-risk for the Hereditary Breast and Ovarian Cancer Syndrome.
Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer.
Prevalence of two BRCA1 mutations, 5382insC and 300T?>?G, in ovarian cancer patients from Ukraine.
Prevalence, spectrum, and founder effect of BRCA1 and BRCA2 mutations in epithelial ovarian cancer from the Middle East.
Preventing breast and ovarian cancers in high-risk BRCA1 and BRCA2 mutation carriers.
Preventing ovarian cancer through genetic testing: a population-based study.
Prevention and early detection of ovarian cancer: mission impossible?
Prevention and Screening in Hereditary Breast and Ovarian Cancer.
Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist.
Preventive mastectomy in patients at breast cancer risk due to genetic alterations in the BRCA1 and BRCA2 gene.
Preventive surgery is associated with reduced cancer risk and mortality in women with BRCA1 and BRCA2 mutations.
Primary ovarian dysgerminoma in a patient with a germline BRCA1 mutation.
Primary structure-based function characterization of BRCT domain replicates in BRCA1.
Prioritizing Variants in Complete Hereditary Breast and Ovarian Cancer (HBOC) Genes in Patients Lacking known BRCA Mutations.
Probability of BRCA1/2 mutation varies with ovarian histology: results from screening 442 ovarian cancer families.
Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history.
Probing structure-function relationships in missense variants in the carboxy-terminal region of BRCA1.
Profiling of protein kinases in the neoplastic transformation of human ovarian surface epithelium.
Progesterone induces BRCA1 mRNA decrease, cell cycle alterations and apoptosis in the MCF7 breast cancer cell line.
Progesterone Receptor A Stability Is Mediated by Glycogen Synthase Kinase-3? in the Brca1-deficient Mammary Gland.
Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives.
Prognosis of probability of BRCA1 and BRCA2 mutations carriage in women with compromised family history of breast and/or ovarian cancer.
Progress of a Comprehensive Familial Cancer Genetic Counseling Program in the Era of BRCA1 and BRCA2.
Progress toward isolation of a breast cancer susceptibility gene, BRCA1.
Prolactin inhibits a major tumor-suppressive function of wild type BRCA1.
Prolactin-dependent up-regulation of BRCA1 expression in human breast cancer cell lines.
Proliferation and ovarian hormone signaling are impaired in normal breast tissues from women with BRCA1 mutations: benefit of a progesterone receptor modulator treatment as a breast cancer preventive strategy in women with inherited BRCA1 mutations.
Prolonged response to treatment based on cell-free DNA analysis and molecular profiling in three patients with metastatic cancer: a case series.
Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature.
Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors.
Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer.
Promoter Methylation of the MGRN1 Gene Predicts Prognosis and Response to Chemotherapy of High-Grade Serous Ovarian Cancer Patients.
Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer.
Prophylactic bilateral salpingo-oophorectomy (PBSO) with or without prophylactic bilateral mastectomy (PBM) or no intervention in BRCA1 mutation carriers: a cost-effectiveness analysis.
Prophylactic mastectomy: why and when?
Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers.
Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation.
Prostate cancer susceptibility genes: lessons learned and challenges posed.
Proteasome-mediated degradation of BRCA1 protein in MCF-7 human breast cancer cells.
Protein stability versus function: effects of destabilizing missense mutations on BRCA1 DNA repair activity.
Proteomic analysis of a preneoplastic phenotype in ovarian surface epithelial cells derived from prophylactic oophorectomies.
Psychological distress in women seeking genetic counseling for breast-ovarian cancer risk: the contributions of personality and appraisal.
Psychological responses to BRCA1 mutation testing: preliminary findings.
Psychosocial and ethical issues relating to genetic testing for BRCA1 and BRCA2 breast cancer susceptibility genes.
Public health aspects of breast cancer gene testing in Canada. Part 1: risks and interventions.
Quantifying BRCA1 and BRCA2 mRNA Isoform Expression Levels in Single Cells.
Quantitative Analysis of ?-H2AX and p53 Nuclear Expression Levels in Ovarian and Fallopian Tube Epithelium from Risk-reducing Salpingo-Oophorectomies in BRCA1 and BRCA2 Mutation Carriers.
Quantitative proteomic identification of the BRCA1 ubiquitination substrates.
Rad50 c.687delT does not contribute significantly to familial breast cancer in a French population.
Rad51/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cells.
RAD51C germline mutations found in Spanish site-specific breast cancer and breast-ovarian cancer families.
RAD51C germline mutations in breast and ovarian cancer cases from high-risk families.
RAP80 Acts Independently of BRCA1 in Repair of Topoisomerase II Poison-Induced DNA Damage.
Rapid and cost effective screening of breast and ovarian cancer genes using novel sequence capture method in clinical samples.
Rapid detection of BRCA1 mutations by the protein truncation test.
Rapid detection of carriers with BRCA1 and BRCA2 mutations using high resolution melting analysis.
Rapid detection of copy number variations and point mutations in BRCA1/2 genes using a single workflow by ion semiconductor sequencing pipeline.
Rapid detection of regionally clustered germ-line BRCA1 mutations by multiplex heteroduplex analysis. UKCCCR Familial Ovarian Cancer Study Group.
Rapid evolution of BRCA1 and BRCA2 in humans and other primates.
Rapid recruitment of BRCA1 to DNA double-strand breaks is dependent on its association with Ku80.
Rapid selection of BRCA1-proficient tumor cells during neoadjuvant therapy for ovarian cancer in BRCA1 mutation carriers.
Re: "Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations".
Re: Association between nonrandom X-chromosome inactivation and BRCA1 mutation in germline DNA of patients with ovarian cancer.
Re: Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study.
Reading between the lines: direct-to-consumer advertising of genetic testing in the USA.
Real-world health services utilisation and outcomes after BRCA1 and BRCA2 testing in Ontario, Canada: the What Comes Next Cohort Study protocol.
Reanalysis of BRCA1/2 negative high risk ovarian cancer patients reveals novel germline risk loci and insights into missing heritability.
Reappearance from Obscurity: Mammalian Rad52 in Homologous Recombination.
Recent advances in molecular genetics of breast cancer.
Recent developments in ovarian cancer genetics.
Recent Patents for Homologous Recombination Deficiency Assays Among Women with Ovarian Cancer.
Recent progress in the diagnosis and treatment of ovarian cancer.
Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium.
Recommendations for medical management of hereditary breast and ovarian cancer: the French National Ad Hoc Committee.
Recommendations for Preventive Care for Women with Rare Genetic Cause of Breast and Ovarian Cancer.
Recurrent BRCA1 and BRCA2 germline mutations in ovarian cancer: a founder mutation of BRCA1 identified in the Chinese population.
Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer.
Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients.
Recurrent Mutations in BRCA1, BRCA2, RAD51C, PALB2 and CHEK2 in Polish Patients with Ovarian Cancer.
Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovarian cancer patients in Southern Poland.
Reduced BRCA1 transcript levels in freshly isolated blood leukocytes from BRCA1 mutation carriers is mutation specific.
Reducing the Risk of Gynecologic Cancer in Hereditary Breast Ovarian Cancer Syndrome Mutation Carriers: Moral Dilemmas and the Principle of Double Effect.
Reduction of BRCA1 expression in sporadic ovarian cancer.
Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases.
Refining clinical practice: transforming science research into the art of medicine.
Regulation of angiotensin II type 1 receptor expression in ovarian cancer: a potential role for BRCA1.
Regulation of BRCA1 and BRCA2 expression in human breast cancer cells by DNA-damaging agents.
Regulation of BRCA1 and BRCA2 transcript in response to cisplatin, adriamycin, taxol and ionising radiation is correlated to p53 functional status in ovarian cancer cell lines.
Regulation of BRCA1 by protein degradation.
Regulation of BRCA1 expression by the Rb-E2F pathway.
Regulation of progesterone receptor signaling by BRCA1 in mammary cancer.
Reinterpretation of BRCA1 and BRCA2 variants of uncertain significance in patients with hereditary breast/ovarian cancer using the ACMG/AMP 2015 guidelines.
Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations.
Relationship between MUTYH, OGG1 and BRCA1 mutations and mRNA expression in breast and ovarian cancer predisposition.
Relationship of BRCA1 and BRCA2 mutations with cancer burden in the family and tumor incidence.
Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study.
Reproductive factors and ovarian cancer risk in Jewish BRCA1 and BRCA2 mutation carriers (United States).
Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
Response: Location of BRCA1 in Human Breast and Ovarian Cancer Cells.
RESPONSE: Re: Association Between Nonrandom X-Chromosome Inactivation and BRCA1 Mutation in Germline DNA of Patients With Ovarian Cancer.
Retesting of women who are negative for a BRCA1 and BRCA2 mutation using a 20-gene panel.
Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System.
Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer.
Risk assessment and genetic testing for ovarian cancer.
Risk factors and risk reduction of breast and ovarian cancer.
Risk factors for detecting germline BRCA1 and BRCA2 founder mutations in Ashkenazi Jewish women with breast or ovarian cancer.
Risk factors for lymph node metastasis of ovarian, fallopian tube and primary peritoneal cancer in hereditary breast and ovarian cancer syndrome.
Risk factors for ovarian cancer and early-onset breast cancer in Mongolia.
Risk models for familial ovarian and breast cancer.
Risk modifiers in carriers of BRCA1 mutations.
Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.
Risk of cancer in BRCA1 and BRCA2 mutation-positive and -negative breast cancer families (Finland).
Risk of colorectal cancer associated with BRCA1 and/or BRCA2 mutation carriers: systematic review and meta-analysis.
Risk of contralateral breast cancer associated with common variants in BRCA1 and BRCA2: potential modifying effect of BRCA1/BRCA2 mutation carrier status.
Risk of endometrial carcinoma associated with BRCA mutation.
Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families.
Risk of ovarian cancer in breast-cancer patients with a family history of breast or ovarian cancer: a population-based cohort study.
Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review.
Risk, Prediction and Prevention of Hereditary Breast Cancer - Large-Scale Genomic Studies in Times of Big and Smart Data.
Risk-reducing appendectomy and the elimination of BRCA1-associated intraperitoneal cancer.
Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy.
Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers.
Risk-reducing strategies for women carrying BRCA1/2 mutations with a focus on prophylactic surgery.
Risk-reducing Surgery in Women at Risk for Familial Breast or Ovarian Cancer.
Risk-reducing surgery increases survival in BRCA1/2 mutation carriers unaffected at time of family referral.
Risk-reducing surgery on the uterine adnexa: timing and type of surgical treatment and pathology report.
Risk-reduction surgery in BRCA mutation carriers in a Spanish population: adherence and results.
Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study.
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
Risks of cancer among members of families in the Gilda Radner Familial Ovarian Cancer Registry.
Risks of cancer due to a single BRCA1 mutation in an extended Utah kindred.
Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
RNA profiling reveals familial aggregation of molecular subtypes in non-BRCA1/2 breast cancer families.
RNA-based analysis of BRCA1 and BRCA2 gene alterations.
RNF168 regulates R-loop resolution and genomic stability in BRCA1/2-deficient tumors.
RNF43 mutations are recurrent in Chinese patients with mucinous ovarian carcinoma but absent in other subtypes of ovarian cancer.
Role for ATM in DNA damage-induced phosphorylation of BRCA1.
Role of Apoptotic Regulators in Human Epithelial Ovarian Cancer.
Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage.
Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1.
Role of BRCA1 mutation screening in the management of familial ovarian cancer.
Role of genetic polymorphisms and ovarian cancer susceptibility.
Role of the tumor suppressor gene Brca1 in genetic stability and mammary gland tumor formation.
Role played by BRCA1 in regulating the cellular response to stress.
Role played by BRCA1 in transcriptional regulation in response to therapy.
Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation.
Roles of BRCA1 and its interacting proteins.
Routine germline BRCA1 and BRCA2 testing in ovarian carcinoma patients: analysis of the Scottish real life experience.
Rucaparib Approved for Ovarian Cancer.
Salpingectomy With Delayed Oophorectomy in BRCA1/2 Mutation Carriers: Estimating Ovarian Cancer Risk.
Screening for BRCA1 and BRCA2 mutations in Eastern Finnish breast/ovarian cancer families.
Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer.
Screening for genetic risk of breast cancer.
Screening for genomic rearrangements in BRCA1 and BRCA2 genes in Czech high-risk breast/ovarian cancer patients: high proportion of population specific alterations in BRCA1 gene.
Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing.
Screening for large rearrangements of the BRCA1 gene in German breast or ovarian cancer families using semi-quantitative multiplex PCR method.
Screening for large rearrangements of the BRCA2 gene in Spanish families with breast/ovarian cancer.
Screening for mutations in exon 11 of the BRCA1 gene in 70 Italian breast and ovarian cancer patients by protein truncation test.
Screening for RAD51 and BRCA2 BRC repeat mutations in breast and ovarian cancer families.
Screening for the BRCA1-ins6kbEx13 mutation: potential for misdiagnosis. Mutation in brief #964. Online.
Screening of 1331 Danish breast and/or ovarian cancer families identified 40 novel BRCA1 and BRCA2 mutations.
Screening of BRCA1 mutation using immunohistochemical staining with C-terminal and N-terminal antibodies in familial ovarian cancers.
Screening of BRCA1/2 deep intronic regions by targeted gene sequencing identifies the first germline BRCA1 variant causing pseudoexon activation in a patient with breast/ovarian cancer.
Screening of the BRCA1 gene in Brazilian patients with breast and/or ovarian cancer via high-resolution melting reaction analysis.
Screening semen donors for hereditary diseases. The Fairfax cryobank experience.
Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance.
Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance.
Secondary mutations of BRCA1/2 and drug resistance.
Segregation analysis of epithelial ovarian cancer in Finland.
Segregation analysis of ovarian cancer using diathesis to include other cancers.
Segregation analysis of the BRCA2 c.9227G>T variant in multiple families suggests a pathogenic role in breast and ovarian cancer predisposition.
Selected aspects of genetic counselling for BRCA1 mutation carriers.
Selected Aspects of Molecular Diagnostics of Constitutional Alterations in BRCA1 and BRCA2 Genes Associated with Increased Risk of Breast Cancer in the Polish Population.
Selected medical interventions in women with a deleterious BRCA mutation: a population-based study in British Columbia.
Selecting Patients with Ovarian Cancer for Germline BRCA Mutation Testing: Findings from Guidelines and a Systematic Literature Review.
SEOM clinical guidelines in hereditary breast and ovarian cancer (2019).
SEOM clinical guidelines in Hereditary Breast and ovarian cancer.
Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk.
Sequence analysis of the rat Brca1 homolog and its promoter region.
Sequence kernel association test for survival outcomes in the presence of a non-susceptible fraction.
Sequence Variants of BRCA1 and BRCA2 Genes in Four Iranian Families with Breast and Ovarian Cancer.
Sequential metal binding by the RING finger domain of BRCA1.
Sequential therapeutic targeting of ovarian Cancer harboring dysfunctional BRCA1.
Serous Tubal Intraepithelial Carcinoma in a Japanese Woman with a Deleterious BRCA1 Mutation.
Serum YKL-40 levels in patients with ovarian cancer and women with BRCA1 gene mutation--comparison to CA 125 antigen.
Setting the Threshold for Surgical Prevention in Women at Increased Risk of Ovarian Cancer.
Setting up a breast cancer family history clinic.
Sex ratio distortion in offspring of families with BRCA1 or BRCA2 mutant alleles: an ascertainment bias phenomenon?
Significance of BRCA1 expression in breast and ovarian cancer patients with brain metastasis - A multicentre study.
Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico.
Significant contribution of large BRCA1 gene rearrangements in 120 French breast and ovarian cancer families.
Significant proportion of breast and/or ovarian cancer families of French Canadian descent harbor 1 of 5 BRCA1 and BRCA2 mutations.
Simultaneous detection of BRCA mutations and large genomic rearrangements in germline DNA and FFPE tumor samples.
Single gold-bridged nanoprobes for identification of single point DNA mutations.
Single nucleotide polymorphisms in miRNA binding sites and miRNA genes as breast/ovarian cancer risk modifiers in Jewish high-risk women.
Single-nucleotide polymorphisms in the p53 pathway genes modify cancer risk in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent.
Single-strand conformation polymorphism analysis by capillary and microchip electrophoresis: a fast, simple method for detection of common mutations in BRCA1 and BRCA2.
Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Small RNA sequencing reveals a comprehensive miRNA signature of BRCA1-associated high-grade serous ovarian cancer.
Society of gynecologic oncologists education committee statement on risk assessment for inherited gynecologic cancer predispositions.
Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions.
Solution structure, backbone dynamics, and association behavior of the C-terminal BRCT domain from the breast cancer-associated protein BRCA1.
Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer.
Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.
Somatic mutations in the BRCA1 gene in Chinese sporadic breast and ovarian cancer.
Somatic mutations in the BRCA1 gene in sporadic ovarian tumours.
Somatic variants of potential clinical significance in the tumors of BRCA phenocopies.
Spanish family study on hereditary breast and/or ovarian cancer: analysis of the BRCA1 gene.
Specific changes in the proteomic pattern produced by the BRCA1-Ser1841Asn missense mutation.
Specific H-Ras minisatellite alleles in breast cancer susceptibility.
Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer.
Spectrum and frequencies of BRCA1/2 mutations in Bulgarian high risk breast cancer patients.
Spectrum and prevalence of BRCA1/2 germline mutations in Pakistani breast cancer patients: results from a large comprehensive study.
Spectrum and Prevalence of Pathogenic Variants in Ovarian Cancer Susceptibility Genes in a Group of 333 Patients.
Spectrum of Germline BRCA1 and BRCA2 Variants Identified in 2351 Ovarian and Breast Cancer Patients Referring to a Reference Cancer Hospital of Rome.
Spectrum of mutations in BRCA1 gene in hereditary forms of breast and ovarian cancer in Russian families.
Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
Spectrum of tumors in the families with Hereditary Breast Ovarian Cancer syndrome carrying germline mutations in BRCA1 and 2 genes.
Spliceogenic analysis of BRCA1 c.439T>C (rs794727800) variant by High Resolution Melting Analysis.
Splicing analysis of 14 BRCA1 missense variants classifies nine variants as pathogenic.
Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers.
Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway.
Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells.
Strong preference of BRCA1 protein to topologically constrained non-B DNA structures.
Structural basis to characterise transactivation domain of BRCA1.
Structural determinants of BRCA1 translational regulation.
Structure activity relationship of plumbagin in BRCA1 related cancer cells.
Structure and mechanism of BRCA1 BRCT domain recognition of phosphorylated BACH1 with implications for cancer.
Structure of a BRCA1-BARD1 heterodimeric RING-RING complex.
Structure of an XRCC1 BRCT domain: a new protein-protein interaction module.
Structure-based assessment of BRCA1 and BRCA2 mutations in a small Spanish population.
Structure-based assessment of missense mutations in human BRCA1: implications for breast and ovarian cancer predisposition.
Structure-based functional analysis of BRCA1 RING domain variants: Concordance of computational mutagenesis, experimental assay, and clinical data.
Structure-Function Of The Tumor Suppressor BRCA1.
Study of BRCA1 gene in hereditary breast and ovarian cancer.
Studying Therapy Response and Resistance in Mouse Models for BRCA1-Deficient Breast Cancer.
Substitution of aspartic acid with glutamic acid at position 67 of the BRCA1 RING domain retains ubiquitin ligase activity and zinc(II) binding with a reduced transition temperature.
Summaries for patients. The cost-effectiveness of preventive strategies for breast and ovarian cancer for women with BRCA1 or BRCA2 mutations.
Suppression of BRCA1 sensitizes cells to proteasome inhibitors.
Suppression of DDX39B sensitizes ovarian cancer cells to DNA-damaging chemotherapeutic agents via destabilizing BRCA1 mRNA.
SURF4 maintains stem-like properties via BIRC3 in ovarian cancer cells.
Surgical procedure in patients with ovarian cancer diagnosed at the time of prophylactic oophorectomy. Analysis of two cases, literature review and surgical implications.
Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers.
Survival in epithelial ovarian cancer patients with prior breast cancer.
Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden.
Survival of BRCA1 negative ovarian cancer patients based on family history.
SYK expression level distinguishes control from BRCA1-mutated lymphocytes.
Synchronous Bilateral Tubal Serous Carcinomas in a Patient With Exon 13 Duplication and Loss of Function of BRCA1.
Synchronous ovarian dysgerminoma and breast carcinoma in a patient with positive immunostain of BRCA1.
Synthetic lethality: exploiting the addiction of cancer to DNA repair.
Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies.
Systematic screening reveals a role for BRCA1 in the response to transcription-associated DNA damage.
Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations.
Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers.
Tandem BRCT domains: DNA's Praetorian Guard.
Targeted Proteomic Analyses of Histone H4 Acetylation Changes Associated with Homologous-Recombination-Deficient High-Grade Serous Ovarian Carcinomas.
Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitors.
Targeting DNA repair: the genome as a potential biomarker.
Targeting the DNA repair defect of BRCA tumours.
Targeting the nucleotide salvage factor DNPH1 sensitizes BRCA-deficient cells to PARP inhibitors.
Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents.
Ten novel BRCA1 and BRCA2 mutations in breast and/or ovarian cancer families from northern Germany.
Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status.
Testing for hereditary breast and ovarian cancer in the southeastern United States.
Testing for Hereditary Risk of Ovarian Cancer.
TGFbeta1/Smad3 counteracts BRCA1-dependent repair of DNA damage.
Thai patients who fulfilled NCCN criteria for breast/ovarian cancer genetic assessment demonstrated high prevalence of germline mutations in cancer susceptibility genes: implication to Asian population testing.
The 185delAG BRCA1 mutation originated before the dispersion of Jews in the diaspora and is not limited to Ashkenazim.
The 185delAG mutation (c.68_69delAG) in the BRCA1 gene triggers translation reinitiation at a downstream AUG codon.
The 3' untranslated region C > T polymorphism of prohibitin is a breast cancer risk modifier in Polish women carrying a BRCA1 mutation.
The 3020insC NOD2 gene mutation in patients with ovarian cancer.
The association between smoking and cancer incidence in BRCA1 and BRCA2 mutation carriers.
The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
The basal-like mammary carcinomas induced by Brca1 or Bard1 inactivation implicate the BRCA1/BARD1 heterodimer in tumor suppression.
The biological effects and clinical implications of BRCA mutations: where do we go from here?
The BOADICEA model of genetic susceptibility to breast and ovarian cancer.
The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions.
The BRCA1 3'-UTR: 5711+421T/T_5711+1286T/T Genotype Is a Possible Breast and Ovarian Cancer Risk Factor.
The BRCA1 and BRCA2 breast cancer genes.
The Brca1 and Brca2 proteins and tumor pathogenesis.
The BRCA1 Ashkenazi founder mutations occur on common haplotypes and are not highly correlated with anonymous single nucleotide polymorphisms likely to be used in genome-wide case-control association studies.
The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium.
The BRCA1 c.4096+3A>G Variant Displays Classical Characteristics of Pathogenic BRCA1 Mutations in Hereditary Breast and Ovarian Cancers, But Still Allows Homozygous Viability.
The BRCA1 c.5434C->G (p.Pro1812Ala) variant induces a deleterious exon 23 skipping by affecting exonic splicing regulatory elements.
The BRCA1 c.788G?>?T (NM_007294.4) variant in a high grade serous ovarian cancer (HGSOC) patient: foods for thought.
The BRCA1 Methylation and PD-L1 Expression in Sporadic Ovarian Cancer.
The BRCA1 S1715N mutation segregates with breast and ovarian cancer in an extended family pedigree.
The BRCA1 Ubiquitin ligase function sets a new trend for remodelling in DNA repair.
The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations.
The BRCA1-dependent ubiquitin ligase, gamma-tubulin, and centrosomes.
The BRCA1-interacting protein Abraxas is required for genomic stability and tumor suppression.
The BRCA1/2-directed miRNA signature predicts a good prognosis in ovarian cancer patients with wild-type BRCA1/2.
The BRCA2 c.9004G>A (E2003K) variant is likely pathogenic and recurs in breast and/or ovarian cancer families of French Canadian descent.
The BRCA2 is a histone acetyltransferase.
The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers.
The cancer connection: BRCA1 and BRCA2 tumor suppression in mice and humans.
The cancer-predisposing mutation C61G disrupts homodimer formation in the NH2-terminal BRCA1 RING finger domain.
The carboxyl-terminal of BRCA1 is required for subnuclear assembly of RAD51 after treatment with cisplatin but not ionizing radiation in human breast and ovarian cancer cells.
The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals.
The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%.
The clinical features associated with mutated BRCA1 and 2 genes in ovarian cancer patients.
The clinical management of BRCA1 and BRCA2 mutation carriers.
The Combination of Single-Cell and Next-Generation Sequencing Can Reveal Mosaicism for BRCA2 Mutations and the Fine Molecular Details of Tumorigenesis.
The consequences of risk reducing salpingo-oophorectomy: the case for a coordinated approach to long-term follow up post surgical menopause.
The contribution of BRCA1 and BRCA2 to ovarian cancer.
The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population.
The contribution of founder mutations in BRCA1 to breast and ovarian cancer in Lithuania.
The contribution of founder mutations in BRCA1 to breast cancer in Belarus.
The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes.
The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer.
The counseling and management of young healthy BRCA mutation carriers.
The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes.
The CYP17A1 -34T > C polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers.
The deletion of exons 3-5 of BRCA1 is the first founder rearrangement identified in breast and/or ovarian cancer Spanish families.
The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues.
The DNA damaging revolution.
The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer.
The dynamic landscape of BRCA1 reversion mutations from indel to SNV in a patient with ovarian cancer treated with PARP-inhibitors and immunotherapy.
The effect of BRCA gene testing on family relationships: A thematic analysis of qualitative interviews.
The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells.
The effect of the histone deacetylase inhibitor M344 on BRCA1 expression in breast and ovarian cancer cells.
The effects of BRCA1 expression on the chemosensitivity of gastric cancer cells to platinum agents.
The effects of BRCA1 missense variants V1804D and M1628T on transcriptional activity.
The effects of parity, breastfeeding, and infertility treatment on the risk of hereditary breast and ovarian cancer: a review.
The expression of BRCA1, P53, KAI1, and Nm23 in ovaries of BRCA1 mutation carriers after prophylactic adnexectomy.
The F-box protein FBXO44 mediates BRCA1 ubiquitination and degradation.
The First Nationwide Multicenter Prevalence Study of Germline BRCA1 and BRCA2 Mutations in Chinese Ovarian Cancer Patients.
The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women.
The frequent BRCA1 mutation 1135insA has multiple origins: a haplotype study in different populations.
The Function of BARD1 in Centrosome Regulation in Cooperation with BRCA1/OLA1/RACK1.
The gene for hereditary breast-ovarian cancer, BRCA1, maps distal to EDH17B2 in chromosome region 17q12-q21.
The genesis and evolution of high-grade serous ovarian cancer.
The Genetic Analyses of French Canadians of Quebec Facilitate the Characterization of New Cancer Predisposing Genes Implicated in Hereditary Breast and/or Ovarian Cancer Syndrome Families.
The genetic prediction of risk for gynecologic cancers.
The genetics of breast and ovarian cancer.
THe genetics of familial breast cancer.
The genetics of inherited breast cancer.
The genetics of ovarian cancer: concepts in testing and counseling.
The History of Patenting Genetic Material.
The HRAS1 minisatellite locus and risk of ovarian cancer.
The I1307K APC mutation does not predispose to colorectal cancer in Jewish Ashkenazi breast and breast-ovarian cancer kindreds.
The immunomodulatory effects of pegylated liposomal doxorubicin are amplified in BRCA1- deficient ovarian tumors and can be exploited to improve treatment response in a mouse model.
The impact of a cascade testing video on recipients' knowledge, cognitive message processing, and affective reactions: A formative evaluation.
The impact of a prevention effort on the community.
The Impact of an Expanded Genetic Testing Program and Selective Oophorectomy on the Incidence of Ovarian Cancer in West Pomerania.
The impact of oophorectomy on survival after breast cancer in BRCA1-positive breast cancer patients.
The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study.
The influence of psychological distress on use of genetic testing for cancer risk.
The intronic BRCA1 c.5407-25T>A variant causing partly skipping of exon 23-a likely pathogenic variant with reduced penetrance?
The K898E germline variant in the PP1-binding motif of BRCA1 causes defects in DNA Repair.
The kin-cohort study for estimating penetrance.
The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers.
The lack of clinical value of peritoneal washing cytology in high risk patients undergoing risk-reducing salpingo-oophorectomy: a retrospective study and review.
The Leu33Pro polymorphism in the ITGB3 gene does not modify BRCA1/2-associated breast or ovarian cancer risks: results from a multicenter study among 15,542 BRCA1 and BRCA2 mutation carriers.
The majority of 22 Dutch high-risk breast cancer families are due to either BRCA1 or BRCA2.
The molecular basis of ovarian cancer.
The multiple nuclear functions of BRCA1: transcription, ubiquitination and DNA repair.
The murine homolog of the human breast and ovarian cancer susceptibility gene Brca1 maps to mouse chromosome 11D.
The narrative paradox of the BRCA gene: an ethnographic study in the clinical encounters of ovarian cancer patients.
The Norwegian founder mutations in BRCA1: high penetrance confirmed in an incident cancer series and differences observed in the risk of ovarian cancer.
The novel exon 11 mutation of BRCA1 gene in a high-risk family.
The occurrence of germline BRCA1 and BRCA2 sequence alterations in Slovenian population.
The p53 Arg72Pro and Ins16bp polymorphisms and their haplotypes are not associated with breast cancer risk in BRCA-mutation negative familial cases.
The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer.
The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1(-/-) murine model of ovarian cancer.
The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer.
The potential role of miRNAs in therapy of breast and ovarian cancers associated with BRCA1 mutation.
The preclinical natural history of serous ovarian cancer: defining the target for early detection.
The predictive value of BRCA1 and BRCA2 mutation testing.
The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations.
The presence of hereditary BRCA1 gene mutations in women with familial breast or ovarian cancer and the frequency of occurrence of these tumours in their relatives.
The prevalence of BRCA1 mutations among young women with triple-negative breast cancer.
The prevalence of BRCA1 mutations in Chinese patients with early onset breast cancer and affected relatives.
The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews.
The prevalence of hereditary breast/ovarian cancer risk in patients with a history of breast or ovarian cancer in Japanese subjects.
The preventive effect of breastfeeding against ovarian cancer in BRCA1 and BRCA2 mutation carriers: A systematic review and meta-analysis.
The prognostic value of BRCA1 mRNA expression levels following neoadjuvant chemotherapy in breast cancer.
The pros and cons of genetic testing for breast and ovarian cancer risk.
The psychological impact of breast and ovarian cancer preventive options in BRCA1 and BRCA2 mutation carriers.
The putative oncogene CEP72 inhibits the mitotic function of BRCA1 and induces chromosomal instability.
The RAD51 135 G>C polymorphism modifies breast cancer and ovarian cancer risk in Polish BRCA1 mutation carriers.
The RAD52-S346X variant reduces risk of developing breast cancer in carriers of pathogenic germline BRCA2 mutations.
The rate of recurrent BRCA1, BRCA2, and TP53 mutations in the general population, and unselected ovarian cancer cases, in Belo Horizonte, Brazil.
The responses of research participants and their next of kin to receiving feedback of genetic test results following participation in the Australian Ovarian Cancer Study.
The RING finger domain E3 ubiquitin ligases BRCA1 and the RNF20/RNF40 complex in global loss of the chromatin mark histone H2B monoubiquitination (H2Bub1) in cell line models and primary high-grade serous ovarian cancer.
The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers.
The Role of BRCA Testing in Hereditary Pancreatic and Prostate Cancer Families.
The role of BRCA1 in DNA damage response.
The role of BRCA1 in non-small cell lung cancer.
The role of BRCA1 in the cellular response to chemotherapy.
The role of hereditary nonpolyposis colorectal cancer in the management of familial ovarian cancer.
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing.
The role of p53 mutation in BRCA1-associated ovarian cancer.
The role of the BRCA1 tumor suppressor in DNA double-strand break repair.
The role of the breast cancer susceptibility gene 1 (BRCA1) in sporadic epithelial ovarian cancer.
The search for BRCA1.
The search for the familial breast/ovarian cancer gene.
The second BRCT domain of BRCA1 proteins interacts with p53 and stimulates transcription from the p21WAF1/CIP1 promoter.
The short estrous cycle of mice may influence the effect of BRCA1 mutations.
The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress.
The tumor suppressor activity induced by adenovirus-mediated BRCA1 overexpression is not restricted to breast cancers.
The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse.
The twilight zone between health and sickness: a qualitative exploration with asymptomatic BRCA1 and 2 mutation carriers.
The Tyr978X BRCA1 Mutation in Non-Ashkenazi Jews: Occurrence in High-Risk Families, General Population and Unselected Ovarian Cancer Patients.
The use of ancestral haplotypes in the molecular diagnosis of familial breast cancer.
The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation.
The VEGF_936_C>T 3'UTR polymorphism reduces BRCA1-associated breast cancer risk in Polish women.
The XIST noncoding RNA functions independently of BRCA1 in X inactivation.
Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond.
Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.
THRA1 and D17S183 flank an interval of < 4 cM for the breast-ovarian cancer gene (BRCA1) on chromosome 17q21.
Three novel germline BRCA1 mutations in early-onset breast and ovarian cancer families.
Three per cent of Norwegian ovarian cancers are caused by BRCA1 1675delA or 1135insA.
Three-Dimensional Architecture of the Human BRCA1-A Histone Deubiquitinase Core Complex.
Thyroid Hormones and Vitamin D in Patients with Breast Cancer with Mutations in BRCA1 or BRCA2 Genes.
Time to stop ovarian cancer screening in BRCA1/2 mutation carriers?
TNRC9 downregulates BRCA1 expression and promotes breast cancer aggressiveness.
Too much, too soon? Patients and health professionals' views concerning the impact of genetic testing at the time of breast cancer diagnosis in women under the age of 40.
Towards a New, Endophenotype-Based Strategy for Pathogenicity Prediction in BRCA1 and BRCA2: In Silico Modeling of the Outcome of HDR/SGE Assays for Missense Variants.
Towards classification of BRCA1 missense variants using a biophysical approach.
TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival.
Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach.
Tracking of the origin of recurrent mutations of the BRCA1 and BRCA2 genes in the North-East of Italy and improved mutation analysis strategy.
Tracking the dissemination of a culturally targeted brochure to promote awareness of hereditary breast and ovarian cancer among Black women.
Trans-activation-based risk assessment of BRCA1 BRCT variants with unknown clinical significance.
Transcript identification in the BRCA1 candidate region.
Transcription of BRCA1 is dependent on the formation of a specific protein-DNA complex on the minimal BRCA1 Bi-directional promoter.
Transcriptional autoregulation by BRCA1.
Transcriptome Patterns of BRCA1- and BRCA2- Mutated Breast and Ovarian Cancers.
Translating genomics in cancer care.
Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation.
Treatment with olaparib monotherapy for BRCA2-mutated refractory intrahepatic cholangiocarcinoma: a case report.
Triple-negative breast cancer and PTEN (phosphatase and tensin homologue)loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer.
Truncating BRCA1 mutations are uncommon in a cohort of hereditary prostate cancer families with evidence of linkage to 17q markers.
Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
Tumor BRCA Testing in High Grade Serous Carcinoma: Mutation Rates and Optimal Tissue Requirements.
Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients.
Tumor formation in Brca1 conditional mutant mice.
Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations.
Tumor suppressor genes and their alterations in breast cancer.
Tumorigenesis as a consequence of genetic instability in Brca1 mutant mice.
Tumour biological features of BRCA1-induced breast and ovarian cancer.
Tumour spectrum in non-BRCA hereditary breast cancer families in Sweden.
Tumour Versus Germline BRCA Testing in Ovarian Cancer: A Single-Site Institution Experience in the United Kingdom.
Tumour-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer.
Twenty Years of BRCA1 and BRCA2 Molecular Analysis at MMCI - Current Developments for the Classification of Variants.
Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer families in Southern Germany.
Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer families of Eastern Spain.
Twenty-three novel BRCA1 and BRCA2 sequence variations identified in a cohort of Swiss breast and ovarian cancer families.
Two color hybridization analysis using high density oligonucleotide arrays and energy transfer dyes.
Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy.
Two distinct origins of a common BRCA1 mutation in breast-ovarian cancer families: a genetic study of 15 185delAG-mutation kindreds.
Two novel sequence variants in MSH2 gene in a patient who underwent cancer genetic counseling for a very early-onset epithelial ovarian cancer.
Two novel variants in the 3'UTR of the BRCA1 gene in familial breast and/or ovarian cancer.
Ubc9 mediates nuclear localization and growth suppression of BRCA1 and BRCA1a proteins.
Ubiquitin and breast cancer.
Ubiquitin pathway and ovarian cancer.
Ubiquitination and proteasome-mediated degradation of BRCA1 and BARD1 during steroidogenesis in human ovarian granulosa cells.
UK BRCA mutation testing in patients with ovarian cancer.
Ultrasensitive electrochemical immunoassay for BRCA1 using BMIM·BF?-coated SBA-15 as labels and functionalized graphene as enhancer.
Unclassified Variants of BRCA1 and BRCA2 in Korean Patients With Ovarian Cancer.
Uncovering BRCA1-regulated signalling pathways by microarray-based expression profiling.
Underestimation of Risk of a BRCA1 or BRCA2 Mutation in Women With High-Grade Serous Ovarian Cancer by BRCAPRO: A Multi-Institution Study.
Understanding germ-line mutations in BRCA1.
Understanding the functions of BRCA1 in the DNA-damage response.
Unraveling a difficult diagnosis: the tricks for early recognition of ovarian cancer.
Unraveling the next chapter: sexual development, body image, and sexual functioning in female BRCA carriers.
Unravelling modifiers of breast and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: update on genetic modifiers.
Unsolved mystery: the role of BRCA1 in DNA end-joining.
Unwrapping the implications of BRCA1 and BRCA2 mutations in ovarian cancer.
Update on hereditary breast cancer.
upQMPSF, a Method for the Detection of BRCA1 Exon Copy Number Variants.
Uptake of clinical genetic testing for ovarian cancer in Ontario: a population-based study.
Uptake of Family-Specific Mutation Genetic Testing Among Relatives of Patients with Ovarian Cancer with BRCA1 or BRCA2 Mutation.
Uptake of offer to receive genetic information about BRCA1 and BRCA2 mutations in an Australian population-based study.
Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers.
Usefulness of Canadian Public Health Insurance Administrative Databases to Assess Breast and Ovarian Cancer Screening Imaging Technologies for BRCA1/2 Mutation Carriers.
Using gene carrier probability to select high risk families for identifying germline mutations in breast cancer susceptibility genes.
Validation of a next generation sequencing assay for BRCA1, BRCA2, CHEK2 and PALB2 genetic testing.
Validation of the Manchester scoring system for predicting BRCA1/2 mutations in 9,390 families suspected of having hereditary breast and ovarian cancer.
Validity of models for predicting BRCA1 and BRCA2 mutations.
Variation in BRCA1 cancer risks by mutation position.
Variation in breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene.
VEGFR3 inhibition chemosensitizes ovarian cancer stemlike cells through down-regulation of BRCA1 and BRCA2.
Weight Gain and the Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation Carriers.
What women with ovarian cancer think and know about genetic testing.
When the SWI/SNF complex remodels...the cell cycle.
White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk.
White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk: A Perspective.
Will Chinese ovarian cancer patients benefit from knowing the BRCA2 mutation status?
Women with hereditary breast cancer predispositions should avoid using their smartphones, tablets, and laptops at night.
Women's Decision Making about Risk-Reducing Strategies in the Context of Hereditary Breast and Ovarian Cancer: A Systematic Review.
Women's experiences of undergoing BRCA1 and BRCA2 testing: organisation of the German Hereditary Breast and Ovarian Cancer Consortium Survey and Preliminary Data from Münster.
Xp22.2-3 loss of heterozygosity is associated with germline BRCA1 mutation in ovarian cancer.
Y179C, F486L and N550H are BRCA1 variants that may be associated with breast cancer in a Sicilian family: results of a 5-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study.
Year 1: Experiences of a tertiary cancer centre following implementation of reflex BRCA1 and BRCA2 tumor testing for all high-grade serous ovarian cancers in a universal healthcare system.
Yeast cells reveal the misfolding and the cellular mislocalization of the human BRCA1 protein.
Yeast-based assays for detection and characterization of mutations in BRCA1.
Young premenopausal women with breast cancer, especially estrogen receptor negative, are at significantly increased risk for subsequent ovarian cancer.
Younger birth cohort correlates with higher breast and ovarian cancer risk in European BRCA1 mutation carriers.
ZC3H18 specifically binds and activates the BRCA1 promoter to facilitate homologous recombination in ovarian cancer.
[A Case Report on the Effectiveness of Olaparib in a Patient with Recurrent Breast Cancer with Human Immunodeficiency Virus Infection].
[A new scoring system for the diagnosis of BRCA1/2 associated breast-ovarian cancer predisposition].
[A paradox and three egnimas about the role of BRCA1 in breast and ovarian cancers]
[Analysis of loss of heterozygosity of the tumor suppressor genes p53 and BRCA1 in ovarial carcinomas]
[Analysis of mutation in BRCA1 gene using hybridization with hydrogel microarrays]
[Analysis of mutations in genes BRCA1 and BRCA2 among patients with breast and ovarian cancer in northern Portugal and Galicia]
[Analysis of mutations in the BRCA1 gene in patients with cancer of the breast and/or the ovary in Portugal]
[Association between single nucleotide polymorphism of BARD1 gene and BRCA1 gene mutation in epithelial ovarian cancer].
[BRCA1 and BRCA2 mutations in families studied in the Program of Genetic Counselling in Cancer of the Valencian Community (Spain).]
[BRCA1 and BRCA2 mutations in patients with familial breast cancer]
[BRCA1 and Estrogen Receptor ? Expression Regulation in Breast Cancer Cells].
[Breast and ovarian cancer susceptibility gene product BRCA1]
[Breast cancer genetics. BRCA1 and BRCA2: the main genes for disease predisposition]
[Breast cancer screening for women with a strong familial risk]
[Breast cancer susceptibility gene BRCA1 of hereditary breast cancer/ ovarian cancer syndrome]
[Characteristics of selected features of hereditary ovarian cancer in carriers of constitutional BRCA1 gene mutation]
[Clinical and molecular diagnosis of inherited breast-ovarian cancer]
[Clinical and pathological characteristics and clinical course of patients with breast cancer and BRCA1/BRCA2 mutations]
[Clinical aspects of familial ovarian cancer - current status and issues in Japan].
[Current clinical issues and recent trends in hereditary breast and ovarian cancer in Japan-genetic testing for HBOC and risk-reducing surgery].
[Detecting Large Germline Rearrangements of BRCA1 by Next Generation Tumor Sequencing].
[Diagnostics of breast cancer in high-risk women - our own experience].
[Does ovarian cancer start in the fallopian tubes? Possible implications for preventive adnexal removal].
[Effect of P13K/AKT signal pathway regulation on expression of XIAP and cIAP2 in ovarian cancer cells].
[Effects of lovastatin on cell cycle distribution in MCF-7 cells transfected with BRCA1]
[Evaluation of prognostic factors in gynecological cancer examined by molecular biological study]
[Familial cancer and oncogenic factors]
[Familial ovarian cancer]
[Genetic analysis of Japanese patients with Fanconi anemia: novel findings].
[Genetic counselling in male carriers of BRCA1 and BRCA2 gene mutations].
[Genetic predisposition and ovarian cancer]
[Genetic test and prophylactic treatment in breast cancer families]
[Genetic testing of BRCA1 for familial ovarian cancers]
[Germ-line mutation of BRCA1 in patients with breast and/or ovarian cancer in high risk families in Northern France]
[Germ-line mutations of the BRCA1 gene in northeastern France]
[Germline mutation of BRCA1 gene in Polish families with strong aggregation of breast and/or ovarian cancer based on coding sequence analysis using the SSCP method]
[Hereditary breast and ovarian cancer - indications for genetic testing, counseling and options for mutation carriers].
[Hereditary breast and ovarian cancer: primary and secondary prevention for BRCA1 and BRCA2 mutation carriers]
[Hereditary breast and ovarian cancers].
[Hereditary breast and ovarian cancer].
[Hereditary ovarian cancer. The role of BRCA1 gene dysfunction in response to chemotherapy].
[Hereditary predisposition for the development of breast and ovarian carcinoma]
[Hereditary predispositions to gynaecological cancers]
[Human genes patents: yes or no? Reflections on the ruling of the Supreme Court of the United States].
[Identification and management of hereditary breast-ovarian cancers (2004 update)]
[In cases of familial ovarian cancer, always consider the risk of breast cancer]
[Inactivation of BRCA1, BRCA2 and p53 genes in sporadic ovarian cancer]
[Information spreading about hereditary carriage of a BRCA1/2 mutation and ovarian cancer and rate of consultation of the concerned relatives]
[Inherited breast and ovarian cancers]
[Inserm ad hoc committee: Recommendations for the management of women with a genetic risk for developing cancer of the breast and/or the ovary]
[INSERM-FNCLCC collective expert's report. Recommendations for management of women having a genetic risk of developing breast and/or ovarian cancer. National Federation of Centers of the Fight Against Cancer]
[INSERM-FNCLCC collective expertise. Recommendations for medical management of women with genetic risk of developing breast and/or ovarian cancer]
[Management of hereditary ovarian cancer].
[Modalities for the functionning of a Care Center for women at high risk for breast and ovarian cancers: The French experience of Tenon Hospital]
[Molecular basis of breast cancer related to BRCA 1 and BRCA2 genes: characteristics and targeting therapy]
[Molecular basis of gynecological oncology--TopBP1 protein and its participation in the transcription process].
[Molecular biology of ovarian cancer]
[Molecular Diagnosis and Treatment of HBOC Syndrome].
[Molecular genetics and clinics of hereditary breast cancer]
[Molecular genetics of hereditary breast carcinoma]
[Molecular pathways of autophagy regulation by BRCA1: Implications in cancer].
[Morphologically qnd immunohistochemically based screening criteria for selection of patients with possible mutation of BRCA1 gene in primary ovarian cancer].
[Multiple primary malignancies in BRCA1 mutation carriers--two clinical cases].
[Mutation of breast cancer susceptibility gene in ovarian cancer and its clinical significance]
[No association between MTHFR 677C>T polymorphism and ovarian cancer risk in BRCA1 mutation carriers in Wielkopolska region].
[Oncogenetic consultation for breast cancer]
[Possibilities of examination of familial breast cancers and ovarian cancers. Use of molecular-genetic analysis of the BRCA1 gene and the BRCA2 gene]
[Predictive genetic testing for hereditary breast cancer and hereditary nonpolyposis colorectal cancer]
[Prerequisites for preimplantation genetic diagnosis (PGD in carriers of mutations responsible for hereditary cancers]
[Primary ovarian malignant mixed mesodermal tumor (MMMT) as a second primary tumor in a patient with invasive breast carcinoma--case report].
[Prophylactic surgery of mammary and ovarian carcinoma.]
[Psychological aspects of predictive genetic diagnosis in breast and ovarian carcinoma]
[The coexistence of breast and ovarian cancer in patient with insertion-duplication of 12bp in BRCA1 gene]
[The importance of genetic factors for development of breast cancer]
[The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada]
[The mRNA expression of BRCA1, ERCC1, TUBB3, PRR13 genes and their relationship with clinical chemosensitivity in primary epithelial ovarian cancer].
[The Population Need in Genetic Tests for Predisposition to Breast Cancer].
[The prevalence of BRCA1 mutations among families at high-risk of breast and ovarian cancer in province of Malopolska between 2004-2009]
[The role of BRCA1 and BRCA2 genes in hereditary breast cancer]
[The search for new candidate genes involved in ovarian cancer pathogenesis by exome sequencing].
[Tumor risk consultation for predisposed women from high risk cancer families]
Paget Disease, Extramammary
Study of Selected BRCA1, BRCA2, and PIK3CA Mutations in Benign and Malignant Lesions of Anogenital Mammary-Like Glands.
Pancreatic Cyst
A combination of molecular markers and clinical features improve the classification of pancreatic cysts.
Classification, morphology and molecular pathology of premalignant lesions of the pancreas.
Pancreatic Diseases
The epigenetic regulators Bmi1 and Ring1B are differentially regulated in pancreatitis and pancreatic ductal adenocarcinoma.
Pancreatic Intraductal Neoplasms
KRAS, GNAS, and RNF43 mutations in intraductal papillary mucinous neoplasm of the pancreas: a meta-analysis.
Pancreatic Neoplasms
3F-Box protein 32 degrades ataxia telangiectasia and Rad3-related and regulates DNA damage response induced by gemcitabine in pancreatic cancer.
A frameshift mutation in BRCA1 leads to hereditary breast and ovarian cancer in one part of a family and to familial pancreatic cancer in another.
A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance.
A mutational signature in gastric cancer suggests therapeutic strategies.
A New Strategy to Control and Eradicate "Undruggable" Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology.
A novel somatic BRCA2 point mutation in a metastatic pancreatic cancer patient: a case report.
Absence of germline BRCA1 mutations in familial pancreatic cancer patients.
AGA Clinical Practice Update on Colorectal and Pancreatic Cancer Risk and Screening in BRCA1 and BRCA2 Carriers: Commentary.
AGA Clinical Practice Update on Pancreas Cancer Screening in High-Risk Individuals: Expert Review.
Alternatives to Perpetual Chemotherapy for Metastatic Pancreatic Cancer.
Analysis of Founder Mutations in Rare Tumors Associated With Hereditary Breast/Ovarian Cancer Reveals a Novel Association of BRCA2 Mutations with Ampulla of Vater Carcinomas.
Application of Multilayer Evidence for Annotation of C-Terminal BRCA2 Variants.
Assessing the Significance of BRCA1 and BRCA2 Mutations in Pancreatic Cancer.
Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer.
Beyond BRCA1 and BRCA2: Deleterious Variants in DNA Repair Pathway Genes in Italian Families with Breast/Ovarian and Pancreatic Cancers.
BRCA in Gastrointestinal Cancers: Current Treatments and Future Perspectives.
BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts.
BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts.
BRCA1 and pancreatic cancer: pedigree findings and their causal relationships.
BRCA1 missense polymorphisms are associated with poor prognosis of pancreatic cancer patients in a Chinese population.
BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study.
Cancer Incidence in BRCA1 mutation carriers.
CDK5/FBW7-dependent Ubiquitination and Degradation of EZH2 Inhibits Pancreatic Cancer Cell Migration and Invasion.
CHIP is a novel tumor suppressor in pancreatic cancer through targeting EGFR.
Clinical Characteristics and Prognosis of Gastric Cancer Patients with BRCA 1/2 Germline Mutations: Report of Ten Cases and a Literature Review.
Comparison of Practice Guidelines, BRCAPRO, and Genetic Counselor Estimates to Identify Germline BRCA1 and BRCA2 Mutations in Pancreatic Cancer.
Corrigendum: E3 Ubiquitin Ligase UBR5 Promotes the Metastasis of Pancreatic Cancer via Destabilizing F-Actin Capping Protein CAPZA1.
Cost-Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
Deleterious Germline Mutations Are a Risk Factor for Neoplastic Progression Among High-Risk Individuals Undergoing Pancreatic Surveillance.
Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma.
Delineating the effects BRCA1 and BRCA2 loss of heterozygosity in pancreatic cancer progression.
Different expressivity of BRCA1 and BRCA2: analysis of 179 Italian pedigrees with identified mutation.
Down-regulation of BRCA1 in chronic pancreatitis and sporadic pancreatic adenocarcinoma.
E3 ubiquitin ligase TRIM29 promotes pancreatic cancer growth and progression via stabilizing Yes-associated protein 1.
E3 ubiquitin ligase UBR5 promotes pancreatic cancer growth and aerobic glycolysis by downregulating FBP1 via destabilization of C/EBP?.
E3 Ubiquitin Ligase UBR5 Promotes the Metastasis of Pancreatic Cancer via Destabilizing F-Actin Capping Protein CAPZA1.
Epidemiology of pancreatic cancer: an overview.
Examination of ATM, BRCA1, and BRCA2 promoter methylation in patients with pancreatic cancer.
Familial pancreatic cancer with PALB2 and NBN pathogenic variants: a case report.
Familial pancreatic carcinoma in Jews.
Frequency and Significance of Abnormal Pancreatic Imaging in Patients with BRCA1 and BRCA2 Genetic Mutations.
Genetic characterization of pancreatic cancer patients and prediction of carrier status of germline pathogenic variants in cancer-predisposing genes.
Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial.
Germline BRCA1 mutations predispose to pancreatic adenocarcinoma.
GSK2126458 has the potential to inhibit the proliferation of pancreatic cancer uncovered by bioinformatics analysis and pharmacological experiments.
H2AK119Ub1 and H3K27Me3 in molecular staging for survival prediction of patients with pancreatic ductal adenocarcinoma.
Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib.
Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis.
Hormone therapy after prophylactic risk-reducing bilateral salpingo-oophorectomy in women who have BRCA gene mutation.
Hypoxia induces TWIST-activated epithelial-mesenchymal transition and proliferation of pancreatic cancer cells in vitro and in nude mice.
Identification of a New Class of MDM2 Inhibitor That Inhibits Growth of Orthotopic Pancreatic Tumors in Mice.
Identification of a Ubiquitination-Related Gene Risk Model for Predicting Survival in Patients With Pancreatic Cancer.
Impact of Sixteen Established Pancreatic Cancer Susceptibility Loci in American Jews.
Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma.
Inactivation of the prolyl isomerase Pin1 sensitizes BRCA1-proficient breast cancer to PARP inhibition.
Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline Resectable Pancreatic Cancer.
Inherited pancreatic cancer syndromes.
Inherited predisposition to cancer: a historical overview.
Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations.
Is there any relationship between BRCA1 gene mutation and pancreatic cancer development?
KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer.
Low expression of the E3 ubiquitin ligase CBL confers chemoresistance in human pancreatic cancer and is targeted by epidermal growth factor receptor inhibition.
Lycopene Inhibits Reactive Oxygen Species-Mediated NF-?B Signaling and Induces Apoptosis in Pancreatic Cancer Cells.
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
Maintenance Rucaparib Controls Some Pancreatic Cancers.
MIB1 upregulates IQGAP1 and promotes pancreatic cancer progression by inducing ST7 degradation.
Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy.
MUC1 promotes glycolysis through inhibiting BRCA1 expression in pancreatic cancer.
Multigene Hereditary Cancer Panels Reveal High-Risk Pancreatic Cancer Susceptibility Genes.
Murine models for familial pancreatic cancer: Histopathology, latency and drug sensitivity among cancers of Palb2, Brca1 and Brca2 mutant mouse strains.
Mutations of the BRCA1 and BRCA2 genes and the possibilities for predictive testing.
Nanoformulation of BRD4-Degrading PROTAC: Improving Druggability To Target the 'Undruggable' MYC in Pancreatic Cancer.
NEDD4L downregulates autophagy and cell growth by modulating ULK1 and a glutamine transporter.
Negative correlation of ITCH E3 ubiquitin ligase and miRNA-106b dictates metastatic progression in pancreatic cancer.
Nucleation capacity and presence of centrioles define a distinct category of centrosome abnormalities that induces multipolar mitoses in cancer cells.
Outcome of Pancreatic Cancer Surveillance Among High-Risk Individuals Tested for Germline Mutations in BRCA1 and BRCA2.
Overexpression of cellular inhibitor of apoptosis protein 2 is an early event in the progression of pancreatic cancer.
Parkin deficiency contributes to pancreatic tumorigenesis by inducing spindle multipolarity and misorientation.
PARP-inhibitors in BRCA-associated pancreatic cancer.
Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2.
Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation.
Possible causes of chromosome instability: comparison of chromosomal abnormalities in cancer cell lines with mutations in BRCA1, BRCA2, CHK2 and BUB1.
Predicting the Pathogenic Potential of BRCA1 and BRCA2 Gene Variants Identified in Clinical Genetic Testing.
Predominant Ashkenazi BRCA1/2 mutations in families with pancreatic cancer.
Prevalence and characteristics of pancreatic cancer in families with BRCA1 and BRCA2 mutations.
Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer.
Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer.
Prevention and Screening in Hereditary Breast and Ovarian Cancer.
Rad51/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cells.
Retrospective review of outcomes in patients with DNA-damage repair related pancreatic cancer.
Ring1b-dependent epigenetic remodelling is an essential prerequisite for pancreatic carcinogenesis.
RNF13: a novel RING-type ubiquitin ligase over-expressed in pancreatic cancer.
Role of BRCA1 and BRCA2 mutations in pancreatic cancer.
Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation.
SCF(beta-TrCP1) controls Smad4 protein stability in pancreatic cancer cells.
SHh-Gli1 signaling pathway promotes cell survival by mediating baculoviral IAP repeat-containing 3 (BIRC3) gene in pancreatic cancer cells.
SMURF1 amplification promotes invasiveness in pancreatic cancer.
Snail recruits Ring1B to mediate transcriptional repression and cell migration in pancreatic cancer cells.
Talking Genes in Breast and Pancreatic Malignancies.
Tbx2 is overexpressed and plays an important role in maintaining proliferation and suppression of senescence in melanomas.
Temporal Dynamics of Genomic Alterations in a BRCA1 Germline-Mutated Pancreatic Cancer With Low Genomic Instability Burden but Exceptional Response to Fluorouracil, Oxaliplatin, Leucovorin, and Irinotecan.
The E3 ubiquitin ligase NEDD4 is translationally upregulated and facilitates pancreatic cancer.
The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers.
The Prevalence of Founder Mutations Among Individuals from Families with Familial Pancreatic Cancer Syndrome.
TRAF6 regulates YAP signaling by promoting the ubiquitination and degradation of MST1 in pancreatic cancer.
UVC Radiation Induces Downregulation of EGF Receptor via Phosphorylation at Serine 1046/1047 in Human Pancreatic Cancer Cells.
Pancreatitis
AGA Clinical Practice Update on Pancreas Cancer Screening in High-Risk Individuals: Expert Review.
Familial pancreatic carcinoma in Jews.
The epigenetic regulators Bmi1 and Ring1B are differentially regulated in pancreatitis and pancreatic ductal adenocarcinoma.
The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer.
Pancreatitis, Alcoholic
Down-regulation of BRCA1 in chronic pancreatitis and sporadic pancreatic adenocarcinoma.
Pancreatitis, Chronic
Down-regulation of BRCA1 in chronic pancreatitis and sporadic pancreatic adenocarcinoma.
Pancytopenia
Functional Interaction of BRCA1 and CREBBP in Murine Hematopoiesis.
Papilloma
Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes.
Interaction between BRCA1 and human papilloma virus E7: an ontology study.
Nucleolar localization of BRCA1 protein in human breast cancer.
Rapid DNA mutation identification and fingerprinting using base excision sequence scanning.
Repression of BRCA1 through a feedback loop involving p53.
Restoration of tumor suppression in prostate cancer by targeting the E3 ligase E6AP.
Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells.
Ubiquitin-dependent proteolysis of trihydrophobin 1 (TH1) by the human papilloma virus E6-associated protein (E6-AP).
Paralysis
Aberrant Accumulation of BRCA1 in Alzheimer Disease and Other Tauopathies.
Danhong injection facilitates recovery of post-stroke motion deficit via Parkin-enhanced mitochondrial function.
Does parkin play a role in the peripheral nervous system? A family report.
Parkin polymorphisms in progressive supranuclear palsy.
Progressive supranuclear palsy and tau hyperphosphorylation in a patient with a C212Y parkin mutation.
[A Case Report on the Effectiveness of Olaparib in a Patient with Recurrent Breast Cancer with Human Immunodeficiency Virus Infection].
Paramyxoviridae Infections
Emerging views of mitophagy in immunity and autoimmune diseases.
Viral strategies for triggering and manipulating mitophagy.
Parasitemia
A Plasmodium yoelii HECT-like E3 ubiquitin ligase regulates parasite growth and virulence.
Parkinson Disease
(Patho-)physiological relevance of PINK1-dependent ubiquitin phosphorylation.
14-3-3eta is a novel regulator of parkin ubiquitin ligase.
A Caenorhabditis elegans Parkin mutant with altered solubility couples alpha-synuclein aggregation to proteotoxic stress.
A cancer ubiquitome landscape identifies metabolic reprogramming as target of Parkin tumor suppression.
A Case of Parkinson's Disease with No Lewy Body Pathology due to a Homozygous Exon Deletion in Parkin.
A consanguineous Turkish family with early-onset Parkinson's disease and an exon 4 parkin deletion.
A disease state mutation unfolds the parkin ubiquitin-like domain.
A Drosophila model of mutant human parkin-induced toxicity demonstrates selective loss of dopaminergic neurons and dependence on cellular dopamine.
A family with Parkinson disease, essential tremor, bell palsy, and parkin mutations.
A functional polymorphism in the parkin gene promoter affects the age of onset of Parkinson's disease.
A genetic cluster of early onset Parkinson's disease in a Colombian population.
A LRRK2-Dependent EndophilinA Phosphoswitch Is Critical for Macroautophagy at Presynaptic Terminals.
A meta-analysis of the relationship of the Parkin p.Val380Leu polymorphism to Parkinson's disease.
A multidisciplinary study of patients with early-onset PD with and without parkin mutations.
A multitracer dopaminergic PET study of young-onset parkinsonian patients with and without parkin gene mutations.
A novel modelling mechanism of PAEL receptor and GABARAPL2 interaction involved in Parkinson's disease.
A novel role for kynurenine 3-monooxygenase in mitochondrial dynamics.
A novel role for parkin in trauma-induced central nervous system secondary injury.
A possible role for humoral immunity in the pathogenesis of Parkinson's disease.
A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI(3)K-Akt signalling.
A Sensitive and Quantitative mKeima Assay for Mitophagy via FACS.
A specific subset of E2 ubiquitin-conjugating enzymes regulate Parkin activation and mitophagy differently.
A Splice Intervention Therapy for Autosomal Recessive Juvenile Parkinson's Disease Arising from Parkin Mutations.
A Ubl/ubiquitin switch in the activation of Parkin.
A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease.
Aberrant folding of pathogenic Parkin mutants: aggregation versus degradation.
Aberrant mitochondrial morphology and function associated with impaired mitophagy and DNM1L-MAPK/ERK signaling are found in aged mutant Parkinsonian LRRK2R1441G mice.
Aberrant proteins expressed in skin fibroblasts of Parkinson's disease patients carrying heterozygous variants of glucocerebrosidase and parkin genes.
Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death.
Accumulation of the parkin substrate, FAF1, plays a key role in the dopaminergic neurodegeneration.
Adenosine A2A receptor-mediated control of pilocarpine-induced tremulous jaw movements is Parkinson's disease-associated GPR37 receptor-dependent.
Advances in GBA-associated Parkinson's disease - Pathology, presentation and therapies.
AF-6 is a positive modulator of the PINK1/parkin pathway and is deficient in Parkinson's disease.
AF-6 Protects Against Dopaminergic Dysfunction and Mitochondrial Abnormalities in Drosophila Models of Parkinson's Disease.
Age-associated insolubility of parkin in human midbrain is linked to redox balance and sequestration of reactive dopamine metabolites.
Alpha-synuclein and parkin contribute to the assembly of ubiquitin lysine 63-linked multiubiquitin chains.
alpha-Synuclein and parkin: coming together of pieces in puzzle of Parkinson's disease.
Alterations in the common fragile site gene Parkin in ovarian and other cancers.
Alterations in the E3 ligases Parkin and CHIP result in unique metabolic signaling defects and mitochondrial quality control issues.
Alterations in the solubility and intracellular localization of parkin by several familial Parkinson's disease-linked point mutations.
Altered ?-synuclein, parkin, and synphilin isoform levels in multiple system atrophy brains.
Altered Mitochondrial Respiration and Other Features of Mitochondrial Function in Parkin-Mutant Fibroblasts from Parkinson's Disease Patients.
Alternative mitochondrial quality control mediated by extracellular release.
Alternative splicing generates different parkin protein isoforms: evidences in human, rat, and mouse brain.
Ambra1: A Parkin-binding protein involved in mitophagy.
AMP kinase activation mitigates dopaminergic dysfunction and mitochondrial abnormalities in Drosophila models of Parkinson's disease.
AMPK/ULK1-mediated phosphorylation of Parkin ACT domain mediates an early step in mitophagy.
An autopsy case of PARK2 due to a homozygous exon 2 deletion of parkin and associated with ?-synucleinopathy.
An essential role for UBE2A/HR6A in learning and memory and mGLUR-dependent long-term depression.
Analysis of Dosage Mutation in PARK2 among Korean Patients with Early-Onset or Familial Parkinson's Disease.
Analysis of LRRK2, SNCA, Parkin, PINK1, and DJ-1 in Zambian patients with Parkinson's disease.
Analysis of neural subtypes reveals selective mitochondrial dysfunction in dopaminergic neurons from parkin mutants.
Analysis of PARK genes in a Korean cohort of early-onset Parkinson disease.
Analysis of PArkin Co-Regulated Gene in a Taiwanese-Ethnic Chinese cohort with early-onset Parkinson's disease.
Analysis of the parkin deletion in sporadic and familial Parkinson's disease. Short communication.
Apolipoprotein E (APOE), PARKIN and catechol-O-methyltransferase (COMT) genes and susceptibility to sporadic Parkinson's disease in Finland.
Are parkin patients particularly suited for deep-brain stimulation?
Assessing the prevalence of PINK1 genetic variants in South African patients diagnosed with early- and late-onset Parkinson's disease.
Assessing the relationship between monoallelic PRKN mutations and Parkinson's risk.
Association between early-onset Parkinson's disease and mutations in the parkin gene. French Parkinson's Disease Genetics Study Group.
Association of codon 167 Ser/Asn heterozygosity in the parkin gene with sporadic Parkinson's disease.
Association studies of Parkinson's disease and parkin polymorphisms.
Association study of Parkin gene polymorphisms with idiopathic Parkinson disease.
Astrocytic but not neuronal increased expression and redistribution of parkin during unfolded protein stress.
Ataxin-3 and its e3 partners: implications for machado-joseph disease.
ATF4 protects against neuronal death in cellular Parkinson's disease models by maintaining levels of parkin.
Automated Analysis of Fluorescence Colocalization: Application to Mitophagy.
Autophagy and innate immunity: Insights from invertebrate model organisms.
Autophagy in neurodegeneration: New insights underpinning therapy for neurological diseases.
Autoregulation of Parkin activity through its ubiquitin-like domain.
Autosomal recessive mutations in the development of Parkinson's disease.
Autosomal recessive parkinsonism.
Axonemal localization of Chlamydomonas PACRG, a homologue of the human Parkin-coregulated gene product.
Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant alpha-synuclein.
BAG5 inhibits parkin and enhances dopaminergic neuron degeneration.
Basal mitophagy is widespread in
Bcl-2-associated athanogene 5 (BAG5) regulates Parkin-dependent mitophagy and cell death.
Beyond ubiquitination: the atypical functions of Fbxo7 and other F-box proteins.
Biochemical analysis of Parkinson's disease-causing variants of Parkin, an E3 ubiquitin-protein ligase with monoubiquitylation capacity.
Bioenergetics of neurons inhibit the translocation response of Parkin following rapid mitochondrial depolarization.
BRCA1 degradation in response to mitochondrial damage in breast cancer cells.
Breakpoint mapping of 13 large parkin deletions/duplications reveals an exon 4 deletion and an exon 7 duplication as founder mutations.
Broad activation of the ubiquitin-proteasome system by Parkin is critical for mitophagy.
Bu-Yin-Qian-Zheng Formula Ameliorates MPP+-Induced Mitochondrial Dysfunction in Parkinson's Disease via Parkin.
c-Abl phosphorylates ?-synuclein and regulates its degradation: implication for ?-synuclein clearance and contribution to the pathogenesis of Parkinson's disease.
Carnosic acid protects SH-SY5Y cells against 6-hydroxydopamine-induced cell death through upregulation of parkin pathway.
Case-Control Study of the Parkin Gene in Early-Onset Parkinson Disease.
Caspase-1 and caspase-8 cleave and inactivate cellular parkin.
Caspase-mediated parkin cleavage in apoptotic cell death.
Cell type-specific upregulation of Parkin in response to ER stress.
Cellular parkin mutants are soluble under non-stress conditions.
Central Parkin: The evolving role of Parkin in the heart.
Characterization of a Cul9-Parkin double knockout mouse model for Parkinson's disease.
Characterization of Dopaminergic System in the Striatum of Young Adult Park2
Chemogenomic Profiling of Endogenous PARK2 Expression Using a Genome-Edited Coincidence Reporter.
CHIP is an Essential Determinant of Neuronal Mitochondrial Stress Signaling.
CHIP is associated with Parkin, a gene responsible for familial Parkinson's disease, and enhances its ubiquitin ligase activity.
Chronic overload of SEPT4, a parkin substrate that aggregates in Parkinson's disease, causes behavioral alterations but not neurodegeneration in mice.
Cinnamon treatment upregulates neuroprotective proteins Parkin and DJ-1 and protects dopaminergic neurons in a mouse model of Parkinson's disease.
Cloning and developmental expression of a chick G-protein-coupled receptor SCGPR1.
Cloning and expression analysis of a Parkinson's disease gene, uch-L1, and its promoter in zebrafish.
clueless, a conserved Drosophila gene required for mitochondrial subcellular localization, interacts genetically with parkin.
Co-association of parkin and alpha-synuclein.
Coding polymorphisms in the parkin gene and susceptibility to Parkinson disease.
Combined kinase inhibition modulates parkin inactivation.
Combined Transcriptomic and Proteomic Analysis of Perk Toxicity Pathways.
Common anti-apoptotic roles of parkin and alpha-synuclein in human dopaminergic cells.
Comparative analysis of Parkinson's disease-associated genes in mice reveals altered survival and bioenergetics of Parkin-deficient dopamine neurons.
Comparative genomics and protein domain graph analyses link ubiquitination and RNA metabolism.
Comparative genomics of the RBR family, including the Parkinson's disease-related gene parkin and the genes of the ariadne subfamily.
Compartmentalized Regulation of Parkin-Mediated Mitochondrial Quality Control in the Drosophila Nervous System In Vivo.
Complex I deficiency and dopaminergic neuronal cell loss in parkin-deficient zebrafish (Danio rerio).
Complex interactions in Parkinson's disease: a two-phased approach.
Complex relationship between Parkin mutations and Parkinson disease.
Construction and validation of a Parkinson's disease mutation genotyping array for the Parkin gene.
Convergence of Parkin, PINK1, and ?-Synuclein on Stress-induced Mitochondrial Morphological Remodeling.
Corrigendum to "Transcriptional alterations in skin fibroblasts from Parkinson's disease patients with parkin mutations" [Neurobiol. Aging 65 (2018) 206-216].
Counteracting PINK/Parkin Deficiency in the Activation of Mitophagy: A Potential Therapeutic Intervention for Parkinson's Disease.
Critical role of mitochondrial ubiquitination and the OPTN-ATG9A axis in mitophagy.
Cross-functional E3 ligases Parkin and C-terminus Hsp70-interacting protein in neurodegenerative disorders.
dATF4 regulation of mitochondrial folate-mediated one-carbon metabolism is neuroprotective.
Decreased parkin solubility is associated with impairment of autophagy in the nigrostriatum of sporadic Parkinson's disease.
Defects in Mitochondrial Biogenesis Drive Mitochondrial Alterations in PARKIN-Deficient Human Dopamine Neurons.
Defending the mitochondria: The pathways of mitophagy and mitochondrial-derived vesicles.
Deficiency of parkin and PINK1 impairs age-dependent mitophagy in Drosophila.
Deficiency of parkin suppresses melanoma tumor development and metastasis through inhibition of MFN2 ubiquitination.
Deficiency of Parkinson's disease-related gene Fbxo7 is associated with impaired mitochondrial metabolism by PARP activation.
Defining the ends of Parkin exon 4 deletions in two different families with Parkinson's disease.
Deletions in the Parkin gene and genetic heterogeneity in a Greek family with early onset Parkinson's disease.
Detection of Parkin (PARK2) and DJ1 (PARK7) mutations in early-onset Parkinson disease: Parkin mutation frequency depends on ethnic origin of patients.
Detrimental effects of oxidative losses in parkin activity in a model of sporadic Parkinson's disease are attenuated by restoration of PGC1alpha.
Deubiquitinase USP29 Governs MYBBP1A in the Brains of Parkinson's Disease Patients.
Differential effects of Parkin and its mutants on protein aggregation, the ubiquitin-proteasome system, and neuronal cell death in human neuroblastoma cells.
Differential expression of alpha-synuclein, parkin, and synphilin-1 isoforms in Lewy body disease.
Differential expression of splice variant and wild-type parkin in sporadic Parkinson's disease.
Differentiating symptomatic Parkin mutations carriers from patients with idiopathic Parkinson's disease: contribution of automated segmentation neuroimaging method.
Diminution of eIF4E activity suppresses parkin mutant phenotypes.
Direct binding with histone deacetylase 6 mediates the reversible recruitment of parkin to the centrosome.
Disease-causing mutations in parkin impair mitochondrial ubiquitination, aggregation, and HDAC6-dependent mitophagy.
Distribution of parkin in the adult rat brain.
Distribution, type, and origin of Parkin mutations: review and case studies.
Diversity in the regulation of autophagy and mitophagy: lessons from Parkinson's disease.
DJ-1 (PARK7) mutations are less frequent than Parkin (PARK2) mutations in early-onset Parkinson disease.
DJ-1 mutations in Parkinson's disease.
Does parkin play a role in the peripheral nervous system? A family report.
Dopamine covalently modifies and functionally inactivates parkin.
Dopamine Induces Oscillatory Activities in Human Midbrain Neurons with Parkin Mutations.
Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation.
Down-regulation of parkin protein in transient focal cerebral ischemia: A link between stroke and degenerative disease?
Downregulation of parkin damages antioxidant defenses and enhances proteasome inhibition-induced toxicity in PC12 cells.
Drosophila CHIP protects against mitochondrial dysfunction by acting downstream of Pink1 in parallel with Parkin.
Drosophila melanogaster Parkin ubiquitinates peanut and septin1 as an E3 ubiquitin-protein ligase.
Drosophila overexpressing parkin R275W mutant exhibits dopaminergic neuron degeneration and mitochondrial abnormalities.
Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress.
Drosophila parkin requires PINK1 for mitochondrial translocation and ubiquitinates mitofusin.
Drosophila phosphatidylinositol-4 kinase fwd promotes mitochondrial fission and can suppress Pink1/parkin phenotypes.
Drosophila PINK1 and parkin loss-of-function mutants display a range of non-motor Parkinson's disease phenotypes.
Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin.
Dyrk1A phosphorylates parkin at Ser-131 and negatively regulates its ubiquitin E3 ligase activity.
E3 Ubiquitin Ligases in Neurological Diseases: Focus on Gigaxonin and Autophagy.
Early Dyskinesias in Parkinson's Disease Patients With Parkin Mutation: A Primary Corticostriatal Synaptopathy?
Early Onset Parkinson's Disease in a family of Moroccan origin caused by a p.A217D mutation in PINK1: a case report.
Early-onset Parkinson's disease associated with a new parkin mutation in a Spanish family.
Early-onset Parkinson's disease caused by a novel parkin mutation in a genetic isolate from north-eastern Brazil.
Early-onset Parkinson's disease in a Chinese population: 99mTc-TRODAT-1 SPECT, Parkin gene analysis and clinical study.
Effect of endogenous mutant and wild-type PINK1 on Parkin in fibroblasts from Parkinson disease patients.
Effect of overexpression of wild-type or mutant parkin on the cellular response induced by toxic insults.
Effect of the neurotoxic dose of methamphetamine on gene expression of parkin and Pael-receptors in rat striatum.
Effects of MUL1 and PARKIN on the circadian clock, brain and behaviour in Drosophila Parkinson's disease models.
Elevated TRAF2/6 expression in Parkinson's disease is caused by the loss of Parkin E3 ligase activity.
Emerging Role of Protein-Protein Transnitrosylation in Cell Signaling Pathways.
Endosomal Rab cycles regulate Parkin-mediated mitophagy.
Enhanced parkin levels favor ER-mitochondria crosstalk and guarantee Ca(2+) transfer to sustain cell bioenergetics.
Enrichment of rare variants in E3 ubiquitin ligase genes in Early onset Parkinson's disease.
ER-stress-associated functional link between Parkin and DJ-1 via a transcriptional cascade involving the tumor suppressor p53 and the spliced X-box binding protein XBP-1.
Evaluation of 50 probands with early-onset Parkinson's disease for Parkin mutations.
Evaluation of PARKIN gene variants in West Bengal Parkinson's disease patients.
Event-related potential changes due to early-onset Parkinson's disease in parkin (PARK2) gene mutation carriers and non-carriers.
Evidence that phosphorylated ubiquitin signaling is involved in the etiology of Parkinson's disease.
Exogenous Alpha-Synuclein Evoked Parkin Downregulation Promotes Mitochondrial Dysfunction in Neuronal Cells. Implications for Parkinson's Disease Pathology.
Exon deletions of parkin gene in patients with Parkinson disease.
Exon dosage analysis of parkin gene in Chinese sporadic Parkinson's disease.
Exon dosage variations in Brazilian patients with Parkinson's disease: Analysis of SNCA, PARKIN, PINK1 and DJ-1 genes.
Exonic deletion mutations of the Parkin gene among sporadic patients with Parkinson's disease.
Expression and localization of the Parkin co-regulated gene in mouse CNS suggests a role in ependymal cilia function.
Expression of alpha-synuclein, parkin, and ubiquitin carboxy-terminal hydrolase L1 mRNA in human brain: genes associated with familial Parkinson's disease.
Extended lifespan of Drosophila parkin mutants through sequestration of redox-active metals and enhancement of anti-oxidative pathways.
Extracellular Alpha-Synuclein Oligomers Induce Parkin S-Nitrosylation: Relevance to Sporadic Parkinson's Disease Etiopathology.
Eye movement disorders are different in Parkin-linked and idiopathic early-onset PD.
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase.
Familial Parkinson's disease. Alpha-synuclein and parkin.
Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin.
FBS/BSA media concentration determines CCCP's ability to depolarize mitochondria and activate PINK1-PRKN mitophagy.
Fbxo7 and Pink1 play a reciprocal role in regulating their protein levels.
FBXO7 Y52C polymorphism as a potential protective factor in Parkinson's disease.
Fluorescent Parkin Cell-Based Assay Development for the Screening of Drugs against Parkinson Disease.
Folic Acid Supplementation Ameliorates Oxidative Stress, Metabolic Functions and Developmental Anomalies in a Novel Fly Model of Parkinson's Disease.
Folic acid supplementation rescues anomalies associated with knockdown of parkin in dopaminergic and serotonergic neurons in Drosophila model of Parkinson's disease.
Formation of parkin aggregates and enhanced PINK1 accumulation during the pathogenesis of Parkinson's disease.
Frequency of Heterozygous Parkin (PRKN) Variants and Penetrance of Parkinson's Disease Risk Markers in the Population-Based CHRIS Cohort.
Frequency of heterozygous Parkin mutations in healthy subjects: Need for careful prospective follow-up examination of mutation carriers.
Frequency of parkin mutations in late-onset Parkinson's disease.
Functional alteration of PARL contributes to mitochondrial dysregulation in Parkinson's disease.
Functional association of the parkin gene promoter with idiopathic Parkinson's disease.
Functional Impairment in Miro Degradation and Mitophagy Is a Shared Feature in Familial and Sporadic Parkinson's Disease.
Functional interplay between Parkin and Drp1 in mitochondrial fission and clearance.
Functional parkin promoter polymorphism in Parkinson's disease: new data and meta-analysis.
Functional Pathway Identification With CRISPR/Cas9 Genome-wide Gene Disruption in Human Dopaminergic Neuronal Cells Following Chronic Treatment With Dieldrin.
GDNF-expressing macrophages restore motor functions at a severe late-stage, and produce long-term neuroprotective effects at an early-stage of Parkinson's disease in transgenic Parkin Q311X(A) mice.
Gender differences and estrogen effects in parkin null mice.
Generation of an induced pluripotent stem cell line (CSC-44) from a Parkinson's disease patient carrying a compound heterozygous mutation (c.823C>T and EX6 del) in the PARK2 gene.
Generation of an induced pluripotent stem cell line (EURACi005-A) from a Parkinson's disease patient carrying a homozygous exon 3 deletion in the PRKNgene.
Generation of Naivetropic Induced Pluripotent Stem Cells from Parkinson's Disease Patients for High-Efficiency Genetic Manipulation and Disease Modeling.
Generation of R272Q, S156A and K572R RHOT1/Miro1 point mutations in iPSCs from a healthy individual using FACS-assisted CRISPR/Cas9 genome editing.
Genes influencing Parkinson disease onset: replication of PARK3 and identification of novel loci.
Genetic analysis of Parkin in early onset Parkinson's disease (PD): Novel intron 9 g > a single nucleotide polymorphism and risk of Taiwanese PD.
Genetic and DAT imaging studies of familial parkinsonism in a Taiwanese cohort.
Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update.
Genetic predisposition to leprosy: A major gene reveals novel pathways of immunity to Mycobacterium leprae.
Genetic reduction of the E3 ubiquitin ligase element, SKP1A and environmental manipulation to emulate cardinal features of Parkinson's disease.
Genetic screening for mutations in the Nrdp1 gene in Parkinson disease patients in a Chinese population.
Genetic screening reveals high frequency of PARK2 mutations and reduced Parkin expression conferring risk for Parkinsonism in North West India.
Genetics and Parkinson's disease.
Genetics of Parkinson's disease - a clinical perspective.
Genetics of Parkinson's disease and parkinsonism.
Genetics of Parkinson's disease.
Genome screen to identify susceptibility genes for Parkinson disease in a sample without parkin mutations.
Genome-wide CRISPR screen for PARKIN regulators reveals transcriptional repression as a determinant of mitophagy.
Genome-wide screen for modifiers of Parkinson's disease genes in Drosophila.
Genotype-Phenotype Relations for the Parkinson's Disease Genes Parkin, PINK1, DJ1: MDSGene Systematic Review.
Genotypic and phenotypic characteristics of Dutch patients with early onset Parkinson's disease.
Geographic and ethnic differences in frequencies of two polymorphisms (D/N394 and L/I272) of the parkin gene in sporadic Parkinson's disease.
Ghrelin is neuroprotective in Parkinson's disease: molecular mechanisms of metabolic neuroprotection.
Glutathione s-transferase omega 1 activity is sufficient to suppress neurodegeneration in a Drosophila model of Parkinson disease.
Gonadal hormones and the control of reactive gliosis.
GPR37 associates with the dopamine transporter to modulate dopamine uptake and behavioral responses to dopaminergic drugs.
Guanabenz promotes neuronal survival via enhancement of ATF4 and parkin expression in models of Parkinson disease.
Heparan Sulfate Structure Affects Autophagy, Lifespan, Responses to Oxidative Stress, and Cell Degeneration in Drosophila parkin Mutants.
Heterogeneous phenotype in a family with compound heterozygous parkin gene mutations.
Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease.
Heterozygous mutations in the FGF8, SHH and nodal/transforming growth factor beta pathways do not confer increased dopaminergic neuron vulnerability--a zebrafish study.
Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patients.
Hexokinases link DJ-1 to the PINK1/parkin pathway.
Hidden phenotypes of PINK1/Parkin knockout mice.
High frequency of Parkin exon rearrangements in Mexican-mestizo patients with early-onset Parkinson's disease.
Homozygous deletions in parkin gene in European and North African families with autosomal recessive juvenile parkinsonism. The European Consortium on Genetic Susceptibility in Parkinson's Disease and the French Parkinson's Disease Genetics Study Group.
How could Parkin-mediated ubiquitination of mitofusin promote mitophagy?
How do Parkin mutations result in neurodegeneration?
How to predict the risk of Parkinson disease in relatives of parkin mutation carriers: a complex puzzle of age, penetrance, and number of mutated alleles.
HSPA1A-Independent Suppression of PARK2 C289G Protein Aggregation by Human Small Heat Shock Proteins.
Hydrocortisone-induced parkin prevents dopaminergic cell death via CREB pathway in Parkinson's disease model.
Identification & characterization of leucine-rich repeat kinase 2 & parkin RBR E3 ubiquitin protein ligase variants in patients with Parkinson's disease.
Identification and distribution of Parkin in rat brain.
Identification and functional characterization of a novel R621C mutation in the synphilin-1 gene in Parkinson's disease.
Identification and validation of control cell lines for accurate parkin dosage analysis.
Identification of brain proteins that interact with 2-methylnorharman. An analog of the parkinsonian-inducing toxin, MPP+.
Identification of far upstream element-binding protein-1 as an authentic Parkin substrate.
Imaging of dopaminergic dysfunction with [123I]FP-CIT SPECT in early-onset parkin disease.
Immunocytochemical Monitoring of PINK1/Parkin-Mediated Mitophagy in Cultured Cells.
Immunohistochemical and subcellular localization of Parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients.
Impact of Autosomal Recessive Juvenile Parkinson's Disease Mutations on the Structure and Interactions of the Parkin Ubiquitin-like Domain.
Impact of recent genetic findings in Parkinson's disease.
Impaired in vivo dopamine release in parkin knockout mice.
Impaired transcriptional upregulation of Parkin promoter variant under oxidative stress and proteasomal inhibition: clinical association.
Impairing the mitochondrial fission and fusion balance: a new mechanism of neurodegeneration.
Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures.
In vivo assessment of brain monoamine systems in parkin gene carriers: a PET study.
Inactivation of Pink1 gene in vivo sensitizes dopamine-producing neurons to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and can be rescued by autosomal recessive Parkinson disease genes, Parkin or DJ-1.
Inclusion body formation and neurodegeneration are parkin independent in a mouse model of alpha-synucleinopathy.
Increased glutathione S-transferase activity rescues dopaminergic neuron loss in a Drosophila model of Parkinson's disease.
Induction of macroautophagy by overexpression of the Parkinson's disease-associated GPR37 receptor.
Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study.
Inhibition of dynamin-related protein 1 ameliorates the mitochondrial ultrastructure via PINK1 and Parkin in the mice model of Parkinson's disease.
Inhibition of proteasomal activity causes inclusion formation in neuronal and non-neuronal cells overexpressing Parkin.
Inhibitory PAS domain protein is a substrate of PINK1 and Parkin and mediates cell death in a Parkinson's disease model.
Integrated pathways of parkin control over mitochondrial maintenance - relevance to Parkinson's disease pathogenesis.
Interaction between Parkin and ?-Synuclein in PARK2-Mediated Parkinson's Disease.
Interaction between parkin and mutant glucocerebrosidase variants: a possible link between Parkinson disease and Gaucher disease.
Interaction between RING1 (R1) and the Ubiquitin-like (UBL) Domains Is Critical for the Regulation of Parkin Activity.
Interaction of ?-synuclein and Parkin in iron toxicity on SH-SY5Y cells: implications in the pathogenesis of Parkinson's disease.
Interplay between Parkin and p53 Governs a Physiological Homeostasis That Is Disrupted in Parkinson's Disease and Cerebral Cancer.
Intestinal infection triggers Parkinson's disease-like symptoms in Pink1-/- mice.
Investigation of the Involvement of Parkin in Parkinson's Disease and Cancer by Monitoring the Changes in SH-SY5Y Cells at the Nuclear Proteome Level.
Investigation of the neuroprotective protein parkin - solubility, ligand binding and ubiquitination.
Involvement and interplay of Parkin, PINK1, and DJ1 in neurodegenerative and neuroinflammatory disorders.
iPLA2? knockout mouse, a genetic model for progressive human motor disorders, develops age-related neuropathology.
KF-1 Ubiquitin Ligase: An Anxiety Suppressor.
Lack of association between cancer history and PARKIN genotype: A family based study in PARKIN/Parkinson's Families.
Lack of association between p.Ser167Asn variant of Parkin and Parkinson's disease: a meta-analysis of 15 studies involving 2,280 cases and 2,459 controls.
Lack of direct role of parkin in the steady-state level and aggregation of alpha-synuclein and the clearance of pre-formed aggregates.
Lack of evidence for association of a parkin promoter polymorphism with early-onset Parkinson's disease in a Chinese population.
Lack of evidence for association of Parkin promoter polymorphism (PRKN-258) with increased risk of Parkinson's disease.
Lack of Parkin Anticipates the Phenotype and Affects Mitochondrial Morphology and mtDNA Levels in a Mouse Model of Parkinson's Disease.
Landscape of the PARKIN-dependent ubiquitylome in response to mitochondrial depolarization.
Language Deficits as a Preclinical Window into Parkinson's Disease: Evidence from Asymptomatic Parkin and Dardarin Mutation Carriers.
Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease.
Lessons for Parkinson Disease From the Parkin Genotype.
Leucine-rich repeat kinase interacts with Parkin, DJ-1 and PINK-1 in a Drosophila melanogaster model of Parkinson's disease.
Levodopa-responsive dystonia caused by biallelic PRKN exon inversion invisible to exome sequencing.
Lewy bodies and parkinsonism in families with parkin mutations.
Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers.
Lewy body pathology and typical Parkinson disease in a patient with a heterozygous (R275W) mutation in the Parkin gene (PARK2).
Linkage stratification and mutation analysis at the Parkin locus identifies mutation positive Parkinson's disease families.
Linking a compound-heterozygous Parkin mutant (Q311R and A371T) to Parkinson's disease by using proteomic and molecular approaches.
Linking F-box protein 7 and parkin to neuronal degeneration in Parkinson's disease (PD).
Linking microtubules to Parkinson's disease: the case of parkin.
Lipid profiling of parkin-mutant human skin fibroblasts.
Lipidomic Alterations in the Mitochondria of Aged Parkin Null Mice Relevant to Autophagy.
Long-term overexpression of human wild-type and T240R mutant Parkin in rat substantia nigra induces progressive dopaminergic neurodegeneration.
Loss of Microglial Parkin Inhibits Necroptosis and Contributes to Neuroinflammation.
Loss of Parkin Impairs Mitochondrial Function and Leads to Muscle Atrophy.
Loss of parkin promotes lipid rafts-dependent endocytosis through accumulating caveolin-1: implications for Parkinson's disease.
Loss of Parkin reduces inflammatory arthritis by inhibiting p53 degradation.
Loss of PINK1 impairs stress-induced autophagy and cell survival.
Low frequency of Parkin, Tyrosine Hydroxylase, and GTP Cyclohydrolase I gene mutations in a Danish population of early-onset Parkinson's Disease.
Low Risk of Parkinson's Disease in Quasi-Vegan Cultures May Reflect GCN2-Mediated Upregulation of Parkin.
LRRK2 and parkin immunoreactivity in multiple system atrophy inclusions.
LRRK2 gene in Parkinson disease.
LRRK2 gene in Parkinson disease: mutation analysis and case control association study.
LRRK2 mutations impair depolarization-induced mitophagy through inhibition of mitochondrial accumulation of RAB10.
Lysosomal perturbations in human dopaminergic neurons derived from induced pluripotent stem cells with PARK2 mutation.
Manganese-induced toxicity in normal and human B lymphocyte cell lines containing a homozygous mutation in parkin.
Mapping preclinical compensation in Parkinson's disease: An imaging genomics approach.
Mdm2 enhances ligase activity of parkin and facilitates mitophagy.
Mechanism of parkin activation by phosphorylation.
Mechanisms of mitophagy.
Mechanisms of mitophagy: PINK1, Parkin, USP30 and beyond.
Mechanisms of neuronal homeostasis: autophagy in the axon.
Melatonin rescues zebrafish embryos from the parkinsonian phenotype restoring the parkin/PINK1/DJ-1/MUL1 network.
Meta-analysis of the influence of Parkin p.Asp394Asn variant on the susceptibility of Parkinson's disease.
Metabolomics-based identification of metabolic alterations in PARK2.
Mice expressing mutant parkin exhibit hallmark features of Parkinson's disease.
Mice lacking the PSD-95-interacting E3 ligase, Dorfin/Rnf19a, display reduced adult neurogenesis, enhanced long-term potentiation, and impaired contextual fear conditioning.
Microarray expression analysis reveals genetic pathways implicated in C621 synphilin-1-mediated toxicity.
Microtubule destabilization is shared by genetic and idiopathic Parkinson's disease patient fibroblasts.
Microtubule: a common target for parkin and Parkinson's disease toxins.
Midnolin is a novel regulator of parkin expression and is associated with Parkinson's Disease.
miR-103a-3p regulates mitophagy in Parkinson's disease through Parkin/Ambra1 signaling.
miR-27a and miR-27b regulate autophagic clearance of damaged mitochondria by targeting PTEN-induced putative kinase 1 (PINK1).
Mitochondria and neurodegeneration.
Mitochondria get a Parkin' ticket.
Mitochondrial and autophagic alterations in skin fibroblasts from Parkinson disease patients with Parkin mutations.
Mitochondrial Antigen Presentation: A Vacuolar Path to Autoimmunity in Parkinson's Disease.
Mitochondrial autophagy in neural function, neurodegenerative disease, neuron cell death, and aging.
Mitochondrial contagion induced by Parkin deficiency in Drosophila hearts and its containment by suppressing mitofusin.
Mitochondrial defect and PGC-1? dysfunction in parkin-associated familial Parkinson's disease.
Mitochondrial DNA heteroplasmy rises in substantial nigra of aged PINK1 KO mice.
Mitochondrial Dynamics and Parkinson's Disease: Focus on Parkin.
Mitochondrial dysfunction and mitophagy defect triggered by heterozygous GBA mutations.
Mitochondrial dysfunction and oxidative damage in parkin-deficient mice.
Mitochondrial dysfunction induced by knockdown of mortalin is rescued by Parkin.
Mitochondrial E3 Ubiquitin Ligase Parkin: Relationships with Other Causal Proteins in Familial Parkinson's Disease and Its Substrate-Involved Mouse Experimental Models.
Mitochondrial impairment observed in fibroblasts from South African Parkinson's disease patients with parkin mutations.
Mitochondrial MsrB2 serves as a switch and transducer for mitophagy.
Mitochondrial nanomedicine: Subcellular organelle-specific delivery of molecular medicines.
Mitochondrial quality control in neurodegenerative diseases.
Mitochondrial quality control turns out to be the principal suspect in parkin and PINK1-related autosomal recessive Parkinson's disease.
Mitochondrial Quality Control via the PGC1?-TFEB Signaling Pathway Is Compromised by Parkin Q311X Mutation But Independently Restored by Rapamycin.
Mitochondrial quality control: insights on how Parkinson's disease related genes PINK1, parkin, and Omi/HtrA2 interact to maintain mitochondrial homeostasis.
Mitochondrial Rab GAPs govern autophagosome biogenesis during mitophagy.
Mitofusin-mediated ER stress triggers neurodegeneration in pink1/parkin models of Parkinson's disease.
Mitophagy in degenerative joint diseases.
Mitophagy in neurodegeneration and aging.
Modulation of ARTS and XIAP by Parkin Is Associated with Carnosic Acid Protects SH-SY5Y Cells against 6-Hydroxydopamine-Induced Apoptosis.
Molecular analysis of the parkin gene in South African patients diagnosed with Parkinson's disease.
Molecular chaperone-mediated rescue of mitophagy by a Parkin RING1 domain mutant.
Molecular docking analysis of phytochemicals from ethanolic extract of crescentia cujete with the auto inhibited parkin catalytic domain.
Molecular dynamics simulations of human E3 ubiquitin ligase Parkin.
Molecular findings in familial Parkinson disease in Spain.
Molecular genetic analysis of the alpha-synuclein and the parkin gene in Parkinson's disease in Finland.
Molecular insights into Parkinson's disease.
Molecular pathogenesis of Parkinson's disease: Identification of mutations in the Parkin gene in Indian patients.
Monitoring Mitochondrial Changes by Alteration of the PINK1-Parkin Signaling in Drosophila.
Monitoring PINK1-Parkin Signaling Using Dopaminergic Neurons from iPS Cells.
Mono- and double-mutant mouse models of Parkinson's disease display severe mitochondrial damage.
Motor cortical physiology in patients and asymptomatic carriers of parkin gene mutations.
MPTP and DSP-4 susceptibility of substantia nigra and locus coeruleus catecholaminergic neurons in mice is independent of parkin activity.
MUL1 acts in parallel to the PINK1/parkin pathway in regulating mitofusin and compensates for loss of PINK1/parkin.
Multiple antioxidants in the prevention and treatment of Parkinson's disease.
Multitasking guardian of mitochondrial quality: Parkin function and Parkinson's disease.
Mutant alpha-synuclein-induced degeneration is reduced by parkin in a fly model of Parkinson's disease.
Mutant ataxin-3 promotes the autophagic degradation of parkin.
Mutant Parkin impairs mitochondrial function and morphology in human fibroblasts.
Mutation analysis of parkin and PINK1 genes in early-onset Parkinson's disease in China.
Mutation analysis of the parkin and PINK1 genes in American Caucasian early-onset Parkinson disease families.
Mutation screening and association analysis of the parkin gene in Parkinson's disease patients from South-West China.
Mutational analysis of the PINK1 gene in early-onset parkinsonism in Europe and North Africa.
Mutational Impact on "in-Between-Ring" (IBR) Domain of PARKIN on Protein Stability and Function.
Mutational Screening of PARKIN Identified a 3' UTR Variant (rs62637702) Associated with Parkinson's Disease.
Mutational screening of the parkin gene among South Indians with early onset Parkinson's disease.
Mutations in PINK1 and Parkin Impair Ubiquitination of Mitofusins in Human Fibroblasts.
Mutations in the parkin gene are a minor cause of Parkinson's disease in the South African population.
Myocardial (123)I-metaiodobenzylguanidine scintigraphy in patients with homozygous and heterozygous parkin mutations.
N-acetylcysteine prevents rotenone-induced Parkinson's disease in rat: An investigation into the interaction of parkin and Drp1 proteins.
N-myc regulates parkin expression.
NAC1, A POZ/BTB protein interacts with Parkin and may contribute to Parkinson's disease.
Nature's Parkin experiment: Nix-a novel protective mechanism in Parkinson's disease.
Neddylation positively regulates the ubiquitin E3 ligase activity of parkin.
Neurodegeneration: how does parkin prevent Parkinson's disease?
Neurodegeneration: Impact of S-nitrosylated Parkin, DJ-1 and PINK1 on the pathogenesis of Parkinson's disease.
Neurofilament L gene is not a genetic factor of sporadic and familial Parkinson's disease.
Neuronal Mitophagy: Lessons from a Pathway Linked to Parkinson's Disease.
Neurophysiological evaluation of motor corticospinal pathways by TMS in idiopathic early-onset Parkinson's disease.
Neurophysiological evidence of corticospinal tract abnormality in patients with Parkin mutations.
Neuroproteomics: an insight into ALS.
Neuropsychological Profile of Parkin Mutation Carriers with and without Parkinson Disease: The CORE-PD Study.
Neurotoxicity and behavioral deficits associated with Septin 5 accumulation in dopaminergic neurons.
Nicotine increases lifespan and rescues olfactory and motor deficits in a Drosophila model of Parkinson's disease.
Nigral degeneration and striatal dopaminergic dysfunction in idiopathic and Parkin-linked Parkinson's disease.
Nigral overexpression of alpha-synuclein in the absence of parkin enhances alpha-synuclein phosphorylation but does not modulate dopaminergic neurodegeneration.
Nigrostriatal dysfunction in homozygous and heterozygous parkin gene carriers: An (18)F-dopa PET progression study.
Nitric Oxide Induction of Parkin Translocation in PTEN-Induced Putative Kinase 1 (PINK1) Deficiency: Functional Role of Neuronal Nitric Oxide Synthase During Mitophagy.
Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity.
NLRP3 Inflammasomes in Parkinson's disease and their Regulation by Parkin.
NMR structure of ubiquitin-like domain in PARKIN: gene product of familial Parkinson's disease.
NO parkin in Parkinson's disease.
Non-motor behavioural impairments in parkin-deficient mice.
Non-motor Symptoms in Parkinson's Disease Patients with Parkin Mutations: More Depression and Less Executive Dysfunction.
Nonmotor symptoms in Parkin gene-related parkinsonism.
Novel compound heterozygous of PARKIN causes early-onset Parkinson's disease.
Novel gene (TMEM230) linked to Parkinson's disease.
Novel homozygous p.E64D mutation in DJ1 in early onset Parkinson disease (PARK7).
Novel parkin mutations detected in patients with early-onset Parkinson's disease.
Novel regulation of parkin function through c-Abl-mediated tyrosine phosphorylation: implications for Parkinson's disease.
NP7 protects from cell death induced by oxidative stress in neuronal and glial midbrain cultures from parkin null mice.
Olfaction differentiates parkin disease from early-onset parkinsonism and Parkinson disease.
Olfaction in Parkin carriers in Chinese patients with Parkinson disease.
Olfaction in Parkin heterozygotes and compound heterozygotes: the CORE-PD study.
Olfaction in Parkin single and compound heterozygotes in a cohort of young onset Parkinson's disease patients.
Organelle-specific autophagy in inflammatory diseases: a potential therapeutic target underlying the quality control of multiple organelles.
Overexpression of Buffy enhances the loss of parkin and suppresses the loss of Pink1 phenotypes in Drosophila.
Oxidative stress mechanisms underlying Parkinson's disease-associated neurodegeneration in C. elegans.
p32 regulates mitochondrial morphology and dynamics through parkin.
p62/SQSTM1 cooperates with Parkin for perinuclear clustering of depolarized mitochondria.
Pael-R is accumulated in Lewy bodies of Parkinson's disease.
PARIS farnesylation prevents neurodegeneration in models of Parkinson's disease.
PARIS induced defects in mitochondrial biogenesis drive dopamine neuron loss under conditions of parkin or PINK1 deficiency.
PARK2 Mutation Causes Metabolic Disturbances and Impaired Survival of Human iPSC-Derived Neurons.
Parkin (PARK 2) mutations are rare in Czech patients with early-onset Parkinson's disease.
Parkin absence accelerates microtubule aging in dopaminergic neurons.
Parkin analysis in early onset Parkinson's disease.
Parkin and alpha-synuclein: opponent actions in the pathogenesis of Parkinson's disease.
Parkin and CASK/LIN-2 associate via a PDZ-mediated interaction and are co-localized in lipid rafts and postsynaptic densities in brain.
Parkin and defective ubiquitination in Parkinson's disease.
Parkin and Hsp70 sacked by BAG5.
Parkin and mitochondrial quality control: toward assembling the puzzle.
Parkin and Parkinson disease.
Parkin and Parkinson's disease.
Parkin and Parkinson's disease: differentiated by non-dopaminergic dysfunction?
Parkin and PINK1 functions in oxidative stress and neurodegeneration.
Parkin and PINK1 mutations in early-onset Parkinson's disease: comprehensive screening in publicly available case-control cohorts.
Parkin and PINK1 parkinsonism may represent nigral mitochondrial cytopathies distinct from Lewy body Parkinson's disease.
Parkin and synphilin-1 isoform expression changes in Lewy body diseases.
Parkin and the molecular pathways of Parkinson's disease.
Parkin attenuates manganese-induced dopaminergic cell death.
Parkin attenuates wild-type tau modification in the presence of beta-amyloid and alpha-synuclein.
Parkin cleaves intracellular alpha-synuclein inclusions via the activation of calpain.
Parkin Co-Regulated Gene (PACRG) is regulated by the ubiquitin-proteasomal system and is present in the pathological features of Parkinsonian diseases.
Parkin Co-Regulated Gene is involved in aggresome formation and autophagy in response to proteasomal impairment.
Parkin controls dopamine utilization in human midbrain dopaminergic neurons derived from induced pluripotent stem cells.
Parkin cooperates with GDNF/RET signaling to prevent dopaminergic neuron degeneration.
Parkin counteracts symptoms in a Drosophila model of Parkinson's disease.
Parkin deficiency accentuates chronic alcohol intake-induced tissue injury and autophagy defects in brain, liver and skeletal muscle.
Parkin Deficiency Appears Not to Be Associated with Cardiac Damage in Parkinson's Disease.
Parkin Deficiency Reduces Hippocampal Glutamatergic Neurotransmission by Impairing AMPA Receptor Endocytosis.
Parkin degrades estrogen-related receptors to limit the expression of monoamine oxidases.
Parkin deletions in a family with adult-onset, tremor-dominant parkinsonism: expanding the phenotype.
Parkin depletion delays motor decline dose-dependently without overtly affecting neuropathology in ?-synuclein transgenic mice.
Parkin Disease: A Clinicopathologic Entity?
Parkin disrupts the alpha-synuclein/dopamine transporter interaction: consequences toward dopamine-induced toxicity.
Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations.
Parkin dosage mutations in patients with early-onset sporadic and familial Parkinson's disease in Chinese: an independent pathogenic role.
Parkin expression in muscle from three patients with autosomal recessive Parkinson's disease carrying parkin mutation.
Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function.
Parkin Function in Parkinson Disease.
Parkin function in Parkinson's disease.
Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1.
Parkin gene therapy could treat Parkinson's disease.
Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson's disease.
Parkin gene therapy for alpha-synucleinopathy: A rat model of Parkinson's disease.
Parkin gene variations in late-onset Parkinson's disease: comparison between Norwegian and German cohorts.
Parkin genetics: one model for Parkinson's disease.
Parkin implicated in sporadic Parkinson's disease.
Parkin in Parkinson's Disease and Cancer: a Double-Edged Sword.
Parkin in the regulation of fat uptake and mitochondrial biology: emerging links in the pathophysiology of Parkinson's disease.
PARKIN Inactivation Links Parkinson's Disease to Melanoma.
Parkin inactivation via PARIS (ZNF746) may lead to neurodegeneration in Parkinson's disease.
Parkin increases dopamine uptake by enhancing the cell surface expression of dopamine transporter.
Parkin Induces Upregulation of 40S Ribosomal Protein SA and Posttranslational Modification of Cytokeratins 8 and 18 in Human Cervical Cancer Cells.
Parkin inhibits BAK and BAX apoptotic function by distinct mechanisms during mitophagy.
Parkin interacting substrate zinc finger protein 746 is a pathological mediator in Parkinson's disease.
Parkin interacts with Ambra1 to induce mitophagy.
Parkin Interacts with Apoptosis-Inducing Factor and Interferes with Its Translocation to the Nucleus in Neuronal Cells.
Parkin interacts with LIM Kinase 1 and reduces its cofilin-phosphorylation activity via ubiquitination.
Parkin interacts with the proteasome subunit alpha4.
Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity.
Parkin is activated by PINK1-dependent phosphorylation of ubiquitin at Serine65.
Parkin is an E3 ligase for the ubiquitin-like modifier FAT10, which inhibits Parkin activation and mitophagy.
Parkin is associated with actin filaments in neuronal and nonneural cells.
Parkin Is Dispensable for Mitochondrial Function, but Its Ubiquitin Ligase Activity Is Critical for Macroautophagy and Neurotransmitters: Therapeutic Potential beyond Parkinson's Disease.
Parkin is expressed in vascular endothelial cells.
Parkin is metabolized by the ubiquitin/proteosome system.
Parkin is not regulated by the unfolded protein response in human neuroblastoma cells.
Parkin is protective for substantia nigra dopamine neurons in a tau gene transfer neurodegeneration model.
Parkin is recruited selectively to impaired mitochondria and promotes their autophagy.
Parkin is recruited to the centrosome in response to inhibition of proteasomes.
Parkin is the most common causative gene in a cohort of mainland Chinese patients with sporadic early-onset Parkinson's disease.
Parkin is transcriptionally regulated by ATF4: evidence for an interconnection between mitochondrial stress and ER stress.
Parkin is transcriptionally regulated by the aryl hydrocarbon receptor: Impact on ?-synuclein protein levels.
Parkin is ubiquitinated by Nrdp1 and abrogates Nrdp1-induced oxidative stress.
Parkin Knockout Inhibits Neuronal Development via Regulation of Proteasomal Degradation of p21.
Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies.
Parkin loss leads to PARIS-dependent declines in mitochondrial mass and respiration.
Parkin loss of function contributes to RTP801 elevation and neurodegeneration in Parkinson's disease.
Parkin maintains mitochondrial levels of the protective Parkinson's disease-related enzyme 17-? hydroxysteroid dehydrogenase type 10.
Parkin mediates neuroprotection through activation of IkappaB kinase/nuclear factor-kappaB signaling.
Parkin mediates neuroprotection through activation of Notch1 signaling.
Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation.
Parkin mediates the ubiquitination of VPS35 and modulates retromer-dependent endosomal sorting.
Parkin Modulates Endosomal Organization and Function of the Endo-Lysosomal Pathway.
Parkin modulates expression of HIF-1? and HIF-3? during hypoxia in gliobastoma-derived cell lines in vitro.
Parkin mutant in the fly is largely rescued by metal-responsive transcription factor (MTF-1).
Parkin mutation analysis in clinic patients with early-onset Parkinson's disease (Am J Med Genet 129A: 44-50, 2004).
parkin mutation analysis in clinic patients with early-onset Parkinson's disease.
Parkin mutation and deep brain stimulation outcome.
Parkin mutation associated parkinsonism and cognitive decline, comparison to early onset Parkinson's disease.
Parkin mutation may be associated with serious akinesia in a patient with Parkinson's disease.
Parkin mutations and phenotypic features in Czech patients with early-onset Parkinson's disease.
Parkin mutations and susceptibility alleles in late-onset Parkinson's disease.
Parkin mutations in familial and sporadic Parkinson's disease among Indians.
Parkin occurs in a stable, non-covalent, approximately 110-kDa complex in brain.
Parkin on serine: a Parkinson disease gene suppresses serine synthesis in cancer.
Parkin Overexpression Ameliorates PrP106-126-Induced Neurotoxicity via Enhanced Autophagy in N2a Cells.
Parkin overexpression during aging reduces proteotoxicity, alters mitochondrial dynamics, and extends lifespan.
PARKIN overexpression in human mesenchymal stromal cells from Wharton's jelly suppresses 6-hydroxydopamine-induced apoptosis: Potential therapeutic strategy in Parkinson's disease.
Parkin Plays a Role in Sporadic Parkinson's Disease.
Parkin Pleiotropy: Extremely Atypical Phenotypes in Patients With Compound Heterozygous Mutations.
Parkin polymorphisms and environmental exposure: decrease in age at onset of Parkinson's disease.
Parkin polymorphisms: risk for Parkinson's disease in Indian population.
Parkin potentiates ATP-induced currents due to activation of P2X receptors in PC12 cells.
Parkin promotes proteasomal degradation of p62: implication of selective vulnerability of neuronal cells in the pathogenesis of Parkinson's disease.
Parkin promotes proteasomal degradation of synaptotagmin IV by accelerating polyubiquitination.
Parkin promotes the ubiquitination and degradation of the mitochondrial fusion factor mitofusin 1.
Parkin Protects Against Misfolded SOD1 Toxicity by Promoting Its Aggresome Formation and Autophagic Clearance.
Parkin protects against mitochondrial toxins and beta-amyloid accumulation in skeletal muscle cells.
Parkin protects against neurotoxicity in the 6-hydroxydopamine rat model for Parkinson's disease.
Parkin protects dopaminergic neurons against microtubule-depolymerizing toxins by attenuating microtubule-associated protein kinase activation.
Parkin protects mitochondrial genome integrity and supports mitochondrial DNA repair.
Parkin protein deficiency exacerbates cardiac injury and reduces survival following myocardial infarction.
Parkin recruitment to impaired mitochondria for nonselective ubiquitylation is facilitated by MITOL.
Parkin regulates Eg5 expression by Hsp70 ubiquitination-dependent inactivation of c-Jun NH2-terminal kinase.
Parkin regulates lipopolysaccharide-induced proinflammatory responses in acute lung injury.
Parkin Regulates Mitosis and Genomic Stability through Cdc20/Cdh1.
Parkin regulates NF-?B by mediating site-specific ubiquitination of RIPK1.
Parkin regulates paclitaxel sensitivity in breast cancer via a microtubule-dependent mechanism.
Parkin Regulates the Activity of Pyruvate Kinase M2.
Parkin regulates translesion DNA synthesis in response to UV radiation.
Parkin Regulation and Neurodegenerative Disorders.
Parkin represses 6-hydroxydopamine-induced apoptosis via stabilizing scaffold protein p62 in PC12 cells.
Parkin reverses intracellular beta-amyloid accumulation and its negative effects on proteasome function.
Parkin Selectively Alters the Intrinsic Threshold for Mitochondrial Cytochrome C Release.
Parkin sensitizes toward apoptosis induced by mitochondrial depolarization through promoting degradation of Mcl-1.
Parkin Somatic Mutations Link Melanoma and Parkinson's Disease.
Parkin stabilizes microtubules through strong binding mediated by three independent domains.
Parkin stabilizes PINK1 through direct interaction.
Parkin Structure and Function.
Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila.
Parkin suppresses the expression of monoamine oxidases.
Parkin suppresses wild-type alpha-synuclein-induced toxicity in SHSY-5Y cells.
Parkin targets HIF-1? for ubiquitination and degradation to inhibit breast tumor progression.
Parkin Ubiquitinates Drp1 for Proteasome-dependent Degradation: IMPLICATION OF DYSREGULATED MITOCHONDRIAL DYNAMICS IN PARKINSON DISEASE.
Parkin ubiquitinates phosphoglycerate dehydrogenase to suppress serine synthesis and tumor progression.
Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease.
Parkin uses the UPS to ship off dysfunctional mitochondria.
Parkin variants in North American Parkinson's disease: cases and controls.
Parkin western blotting is useful for identification of patients with Parkin-related Parkinson's disease.
Parkin, an E3 Ubiquitin Ligase, Plays an Essential Role in Mitochondrial Quality Control in Parkinson's Disease.
Parkin, PINK1 and mitochondrial integrity: emerging concepts of mitochondrial dysfunction in Parkinson's disease.
Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation.
PARKIN, PINK1, and DJ1 analysis in early-onset Parkinson's disease in Ireland.
Parkin-associated Parkinson's disease.
PARKIN-coding polymorphisms are not associated with Parkinson's disease in a population from northeastern Mexico.
Parkin-deficient mice are not a robust model of parkinsonism.
Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons.
Parkin-deficient rats are resistant to neurotoxicity of chronic high-dose methamphetamine.
Parkin-dependent and -independent degradation of synaptotagmin-11 in neurons and astrocytes.
Parkin-dependent degradation of the f-box protein fbw7? promotes neuronal survival in response to oxidative stress by stabilizing mcl-1.
Parkin-dependent regulation of the MCU complex component MICU1.
Parkin-induced mitophagy in the pathogenesis of Parkinson disease.
Parkin-mediated K63-linked polyubiquitination targets misfolded DJ-1 to aggresomes via binding to HDAC6.
Parkin-mediated lysine 63-linked polyubiquitination: A link to protein inclusions formation in Parkinson's and other conformational diseases?
Parkin-mediated monoubiquitination of the PDZ protein PICK1 regulates the activity of acid-sensing ion channels.
Parkin-Mediated Protection of Dopaminergic Neurons in a Chronic MPTP-Minipump Mouse Model of Parkinson Disease.
Parkin-mediated responses against infection and wound involve TSPO-VDAC complex in Drosophila.
Parkin-mediated selective mitochondrial autophagy, mitophagy: Parkin purges damaged organelles from the vital mitochondrial network.
Parkin-mediated Ubiquitination Regulates Phospholipase C-gamma1.
Parkin: a multipurpose neuroprotective agent?
Parkin: Much More than a Simple Ubiquitin Ligase.
Parkinson's disease in Ireland: clinical presentation and genetic heterogeneity in patients with parkin mutations.
Parkinson's disease with Lewy bodies associated with a heterozygous PARKIN dosage mutation.
Parkinson's disease-associated parkin colocalizes with Alzheimer's disease and multiple sclerosis brain lesions.
Parkinson's disease-associated protein Parkin: an unusual player in cancer.
Parkinson's disease-associated VPS35 mutant reduces mitochondrial membrane potential and impairs PINK1/Parkin-mediated mitophagy.
Parkinson's disease-linked Parkin mutations impair glutamatergic signaling in hippocampal neurons.
Parkinson's Disease-Related Proteins PINK1 and Parkin Repress Mitochondrial Antigen Presentation.
Parkinson's disease: alpha-synuclein and parkin in protein aggregation and the reversal of unfolded protein stress.
Parkinson's disease: assays for the ubiquitin ligase activity of neural Parkin.
Parkinson's disease: viral vector delivery of parkin generates model results in rats.
Parkinson's genetics--creating exciting new insights.
Parp mutations protect against mitochondrial dysfunction and neurodegeneration in a PARKIN model of Parkinson's disease.
Part I: parkin-associated proteins and Parkinson's disease.
Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss.
Pathogenetic mechanisms of parkin in Parkinson's disease.
Pathogenic mutations inactivate parkin by distinct mechanisms.
Pathologic and therapeutic implications for the cell biology of parkin.
Perturbations in RhoA signalling cause altered migration and impaired neuritogenesis in human iPSC-derived neural cells with PARK2 mutation.
Pharmacological or Genetic Activation of Hsp70 Protects against Loss of Parkin Function.
Phase determination using chromosomal microarray and fluorescence in situ hybridization in a patient with early onset Parkinson disease and two deletions in PRKN.
Phenotype analysis in patients with early onset Parkinson's disease with and without parkin mutations.
Phenotypic characterization of recessive gene knockout rat models of Parkinson's disease.
Phenotypic variability of parkin mutations in single kindred.
Phosphatase and tensin homolog (PTEN)-induced putative kinase 1 (PINK1)-dependent ubiquitination of endogenous Parkin attenuates mitophagy: study in human primary fibroblasts and induced pluripotent stem cell-derived neurons.
Phosphatase and tensin homolog-induced putative kinase 1 and Parkin in diabetic heart: Role of mitophagy.
Phospho-ubiquitin: upending the PINK-Parkin-ubiquitin cascade.
Phosphorylated ubiquitin: a new shade of PINK1 in Parkin activation.
Phosphorylation by PINK1 releases the UBL domain and initializes the conformational opening of the E3 ubiquitin ligase Parkin.
Phosphorylation of Parkin at serine 131 by p38 MAPK promotes mitochondrial dysfunction and neuronal death in mutant A53T ?-synuclein model of Parkinson's disease.
Phosphorylation of Parkin at serine 65 is essential for its activation in vivo.
Phosphorylation of Parkin at Serine65 is essential for activation: elaboration of a Miro1 substrate-based assay of Parkin E3 ligase activity.
Phosphorylation of parkin by Parkinson disease-linked kinase PINK1 activates parkin E3 ligase function and NF-kappaB signaling.
Phosphorylation of Parkin by the cyclin-dependent kinase 5 at the linker region modulates its ubiquitin-ligase activity and aggregation.
Physiological Roles of Ubiquitin Ligases Related to the Endoplasmic Reticulum.
PICK1 inhibits the E3 ubiquitin ligase activity of Parkin and reduces its neuronal protective effect.
PINK1 and Parkin control localized translation of respiratory chain component mRNAs on mitochondria outer membrane.
PINK1 and Parkin flag Miro to direct mitochondrial traffic.
PINK1 and Parkin mitochondrial quality control: a source of regional vulnerability in Parkinson's disease.
PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility.
PINK1 and Parkin – mitochondrial interplay between phosphorylation and ubiquitylation in Parkinson's disease.
PINK1 and Parkin: emerging themes in mitochondrial homeostasis.
PINK1 and Parkin: team players in stress-induced mitophagy.
PINK1 autophosphorylation facilitates Parkin recruitment to mitochondria: new insight in the mechanisms of quality control for mitochondria in young-onset Parkinson's disease.
PINK1 controls mitochondrial localization of Parkin through direct phosphorylation.
PINK1 Primes Parkin-Mediated Ubiquitination of PARIS in Dopaminergic Neuronal Survival.
PINK1, Parkin, and Mitochondrial Quality Control: What can we Learn about Parkinson's Disease Pathobiology?
Pink1, Parkin, DJ-1 and mitochondrial dysfunction in Parkinson's disease.
PINK1-dependent mitophagy is driven by the UPS and can occur independently of LC3 conversion.
PINK1-dependent phosphorylation of PINK1 and Parkin is essential for mitochondrial quality control.
PINK1-dependent recruitment of Parkin to mitochondria in mitophagy.
PINK1-mediated phosphorylation of Parkin boosts Parkin activity in Drosophila.
PINK1-mediated phosphorylation of the Parkin ubiquitin-like domain primes mitochondrial translocation of Parkin and regulates mitophagy.
PINK1-Parkin signaling in Parkinson's disease: Lessons from Drosophila.
PINK1-phosphorylated mitofusin 2 is a Parkin receptor for culling damaged mitochondria.
PINK1/Parkin Mediated Mitophagy, Ca2+ Signalling, and ER-Mitochondria Contacts in Parkinson's Disease.
PINK1/Parkin mitophagy and neurodegeneration-what do we really know in vivo?
PINK1/PARKIN signalling in neurodegeneration and neuroinflammation.
PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1.
Plasma membrane calcium ATPase downregulation in dopaminergic neurons alters cellular physiology and motor behaviour in Drosophila melanogaster.
Pleiotropic effects for Parkin and LRRK2 in leprosy type-1 reactions and Parkinson's disease.
Point mutation in the parkin gene on patients with Parkinson's disease.
Polymorphism in the parkin gene in sporadic Parkinson's disease.
Polymorphisms of the parkin gene in sporadic Parkinson's disease among Chinese in Taiwan.
Polyubiquitination of apurinic/apyrimidinic endonuclease 1 by Parkin.
Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene.
PPEF2 Opposes PINK1-Mediated Mitochondrial Quality Control by Dephosphorylating Ubiquitin.
Predictors of parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease study.
Preliminary studies on parkin gene deletion at exons 1 to 6 in Chinese patients with praecox Parkinson's disease.
Premotor Gray Matter Volume is Associated with Clinical Findings in Idiopathic and Genetically Determined Parkinson's Disease.
Prevalence of homozygous deletions of the parkin gene in a cohort of patients with sporadic and familial Parkinson's disease.
Prevalence of parkin gene mutations and variations in idiopathic Parkinson's disease.
Primary progressive multiple sclerosis developing in the context of young onset Parkinson's disease.
Probes of ubiquitin E3 ligases enable systematic dissection of parkin activation.
Programmed cell death-2 isoform1 is ubiquitinated by parkin and increased in the substantia nigra of patients with autosomal recessive Parkinson's disease.
Progress in familial Parkinson's disease.
Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study.
Progressive supranuclear palsy and tau hyperphosphorylation in a patient with a C212Y parkin mutation.
Proteasomal inhibition reduces parkin mRNA in PC12 and SH-SY5Y cells.
Proteasome and p97 mediate mitophagy and degradation of mitofusins induced by Parkin.
Protective role of Parkin in skeletal muscle contractile and mitochondrial function.
Protein-protein interactions in the mammalian brain.
Proteomic analysis of increased Parkin expression and its interactants provides evidence for a role in modulation of mitochondrial function.
Proteomic analysis of parkin knockout mice: alterations in energy metabolism, protein handling and synaptic function.
Proteomic Profiling of Mitochondrial-Derived Vesicles in Brain Reveals Enrichment of Respiratory Complex Sub-assemblies and Small TIM Chaperones.
Quality of Life in Newly Diagnosed Patients With Parkin-Related Parkinson's Disease.
Quantitative interaction proteomics of neurodegenerative disease proteins.
Quantitative proteomic analysis of Parkin substrates in Drosophila neurons.
rAAV-mediated nigral human parkin over-expression partially ameliorates motor deficits via enhanced dopamine neurotransmission in a rat model of Parkinson's disease.
Rare heterozygous parkin variants in French early-onset Parkinson disease patients and controls.
RBR E3 ubiquitin ligases: new structures, new insights, new questions.
Reactive oxygen species trigger Parkin/PINK1 pathway-dependent mitophagy by inducing mitochondrial recruitment of Parkin.
Recent advances in research on Parkinson disease: synuclein and parkin.
Reduction in endogenous parkin levels renders glial cells sensitive to both caspase-dependent and caspase-independent cell death.
Reduction of protein translation and activation of autophagy protect against PINK1 pathogenesis in Drosophila melanogaster.
Regional and cellular expression of the parkin gene in the rat cerebral cortex.
Regional and cellular localisation of Parkin Co-Regulated Gene in developing and adult mouse brain.
Regulation of DNA repair by parkin.
Regulation of Endoplasmic Reticulum-Mitochondria contacts by Parkin via Mfn2.
Regulation of hippocampal parkin protein by corticosteroids.
Regulation of Iron Homeostasis through Parkin-Mediated Lactoferrin Ubiquitylation.
Regulation of mitochondrial morphology and function by stearoylation of TFR1.
Regulation of parkin and PINK1 by neddylation.
Regulation of Parkin E3 ubiquitin ligase activity.
Relative high frequency of the c.255delA parkin gene mutation in Spanish patients with autosomal recessive parkinsonism.
Relative sensitivity of parkin and other cysteine-containing enzymes to stress-induced solubility alterations.
REM sleep-associated motor behaviors in Parkinson's disease patients with heterozygous Parkin mutations.
Responsiveness to Distracting Stimuli, though Increased in Parkinson's Disease, is Decreased in Asymptomatic PINK1 and Parkin Mutation Carriers.
Restless legs syndrome, rapid eye movement sleep behavior disorder, and hypersomnia in patients with two parkin mutations.
Ret rescues mitochondrial morphology and muscle degeneration of Drosophila Pink1 mutants.
Rhododendrin-Induced RNF146 Expression via Estrogen Receptor ? Activation is Cytoprotective Against 6-OHDA-Induced Oxidative Stress.
Rhomboid-7 and HtrA2/Omi act in a common pathway with the Parkinson's disease factors Pink1 and Parkin.
RING finger ubiquitin-protein isopeptide ligase Nrdp1/FLRF regulates parkin stability and activity.
Risk of Parkinson disease in carriers of parkin mutations: estimation using the kin-cohort method.
ROCK inhibitors upregulate the neuroprotective Parkin-mediated mitophagy pathway.
Role of glucose metabolism and ATP in maintaining PINK1 levels during Parkin-mediated mitochondrial damage responses.
Role of PINK1 Binding to the TOM Complex and Alternate Intracellular Membranes in Recruitment and Activation of the E3 Ligase Parkin.
ROS-dependent regulation of Parkin and DJ-1 localization during oxidative stress in neurons.
S-Nitrosylation of Critical Protein Thiols Mediates Protein Misfolding and Mitochondrial Dysfunction in Neurodegenerative Diseases.
S-Nitrosylation of parkin as a novel regulator of p53-mediated neuronal cell death in sporadic Parkinson's disease.
S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function.
S-nitrosylation of XIAP compromises neuronal survival in Parkinson's disease.
SARM1 and TRAF6 bind to and stabilize PINK1 on depolarized mitochondria.
Second mutation in PARK2 is absent in patients with sporadic Parkinson's disease and heterozygous exonic deletions/duplications in parkin gene.
Selective escape of proteins from the mitochondria during mitophagy.
SEPT5_v2 is a parkin-binding protein.
SH3 domains from a subset of BAR proteins define a Ubl-binding domain and implicate parkin in synaptic ubiquitination.
Short-term temporal memory in idiopathic and Parkin-associated Parkinson's disease.
Siah-1 facilitates ubiquitination and degradation of synphilin-1.
Significance of the parkin gene and protein in understanding Parkinson's disease.
Single-nucleotide polymorphisms in the promoter region of the PARKIN gene and Parkinson's disease.
SLP-2 interacts with Parkin in mitochondria and prevents mitochondrial dysfunction in Parkin-deficient human iPSC-derived neurons and Drosophila.
Small fiber neuropathy and phosphorylated alpha-synuclein in the skin of E46K-SNCA mutation carriers.
Small, N-terminal tags activate Parkin E3 ubiquitin ligase activity by disrupting its autoinhibited conformation.
Somatic and germline mutations in the tumor suppressor gene PARK2 impair PINK1/Parkin-mediated mitophagy in lung cancer cells.
Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies.
Spatiotemporally controlled initiation of Parkin-mediated mitophagy within single cells.
STEP61 is a substrate of the E3 ligase parkin and is upregulated in Parkinson's disease.
Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function.
Stress-induced phospho-ubiquitin formation causes parkin degradation.
Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism.
Structural analysis of the effects of mutations in Ubl domain of Parkin leading to Parkinson's disease.
Structural and Functional Impact of Parkinson Disease-Associated Mutations in the E3 Ubiquitin Ligase Parkin.
Structural findings in the basal ganglia in genetically determined and idiopathic Parkinson's disease.
Structural insights into Parkin substrate lysine targeting from minimal Miro substrates.
Structure and function of Parkin E3 ubiquitin ligase reveals aspects of RING and HECT ligases.
Structure and Function of Parkin, PINK1, and DJ-1, the Three Musketeers of Neuroprotection.
Structure of PINK1 and mechanisms of Parkinson's disease-associated mutations.
Structure of the human Parkin ligase domain in an autoinhibited state.
Structure of the Parkin in-between-ring domain provides insights for E3-ligase dysfunction in autosomal recessive Parkinson's disease.
Study of methylation levels of parkin gene promoter in Parkinson's disease patients.
Substantia nigra hyperechogenicity correlates with clinical status and number of Parkin mutated alleles.
Sulfhydration mediates neuroprotective actions of parkin.
Superoxide dismutating molecules rescue the toxic effects of PINK1 and parkin loss.
Switching on ubiquitylation by phosphorylating a ubiquitous activator.
Synaptotagmin-11 is a critical mediator of parkin-linked neurotoxicity and Parkinson's disease-like pathology.
Synergistic recruitment of UbcH7~Ub and phosphorylated Ubl domain triggers parkin activation.
Synphilin-1 and parkin show overlapping expression patterns in human brain and form aggresomes in response to proteasomal inhibition.
Systematic examination of DNA variants in the parkin gene in patients with Parkinson's disease.
T313M PINK1 mutation in an extended highly consanguineous Saudi family with early-onset Parkinson disease.
Targeted overexpression of the parkin substrate Pael-R in the nigrostriatal system of adult rats to model Parkinson's disease.
Targeting Mitochondrial Dysfunction: Role for PINK1 and Parkin in Mitochondrial Quality Control.
Task matters - challenging the motor system allows distinguishing unaffected Parkin mutation carriers from mutation-free controls.
Teaching the basics of repurposing mitochondria-targeted drugs: From Parkinson's disease to cancer and back to Parkinson's disease.
The accumulation of misfolded proteins in the mitochondrial matrix is sensed by PINK1 to induce PARK2/Parkin-mediated mitophagy of polarized mitochondria.
The aetiology of idiopathic Parkinson's disease.
The AMPK-Parkin axis negatively regulates necroptosis and tumorigenesis by inhibiting the necrosome.
The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease.
The contribution of Parkin, PINK1 and DJ-1 genes to selective neuronal degeneration in Parkinson's disease.
The Copper Metabolism MURR1 Domain Protein 1 (COMMD1) Modulates the Aggregation of Misfolded Protein Species in a Client-Specific Manner.
The deubiquitinase USP15 antagonizes Parkin-mediated mitochondrial ubiquitination and mitophagy.
The E3 Ligase Parkin Maintains Mitochondrial Integrity by Increasing Linear Ubiquitination of NEMO.
The E3 Ubiquitin ligase parkin is recruited to the 26S proteasome via the proteasomal ubiquitin receptor Rpn13.
The E3 ubiquitin ligase seven in absentia homolog 1 may be a potential new therapeutic target for Parkinson's disease.
The effects of oxidative stress on parkin and other E3 ligases.
The endoplasmic reticulum-mitochondria interface is perturbed in PARK2 knockout mice and patients with PARK2 mutations.
The Essential Role of Drp1 and Its Regulation by S-Nitrosylation of Parkin in Dopaminergic Neurodegeneration: Implications for Parkinson's Disease.
The G2019S LRRK2 mutation is rare in Korean patients with Parkinson's disease.
The Impairments of ?-Synuclein and Mechanistic Target of Rapamycin in Rotenone-Induced SH-SY5Y Cells and Mice Model of Parkinson's Disease.
The interplay between parkin and alpha-synuclein; possible implications for the pathogenesis of Parkinson's disease.
The KM-parkin-DB: A Sub-set MutationView Database Specialized for PARK2 (PARKIN) Variants.
The landscape of Parkin variants reveals pathogenic mechanisms and therapeutic targets in Parkinson's disease.
The M458L missense mutation disrupts the catalytic properties of Parkin.
The Machado-Joseph disease-associated mutant form of ataxin-3 regulates parkin ubiquitination and stability.
The many faces of mitophagy.
The mitochondrial deubiquitinase USP30 opposes parkin-mediated mitophagy.
The mitochondrial kinase PINK1: functions beyond mitophagy.
The Mitochondrial Outer Membrane Protein Tom70-Mediator in Protein Traffic, Membrane Contact Sites and Innate Immunity.
The molecular mechanism of mitochondria autophagy in yeast.
The neurological mutant quaking(viable) is Parkin deficient.
The neuropathology of genetic Parkinson's disease.
The parkin gene and its phenotype. Italian PD Genetics Study Group, French PD Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease.
The parkin gene is not a major susceptibility locus for typical late-onset Parkinson's disease.
The parkin gene is not involved in late-onset Parkinson's disease.
The parkin gene S/N167 polymorphism in Australian Parkinson's disease patients and controls.
The parkin protein as a therapeutic target in Parkinson's disease.
The Parkin-Like Human Homolog of Drosophila Ariadne-1 (HHARI) Can Induce Aggresome Formation in Mammalian Cells and Is Immunologically Detectable in Lewy Bodies.
The Parkinson's disease genes pink1 and parkin promote mitochondrial fission and/or inhibit fusion in Drosophila.
The Parkinson's disease-linked proteins Fbxo7 and Parkin interact to mediate mitophagy.
The PINK1 kinase-driven ubiquitin ligase Parkin promotes mitochondrial protein import through the presequence pathway in living cells.
The PINK1 p.I368N mutation affects protein stability and ubiquitin kinase activity.
The PINK1, synphilin-1 and SIAH-1 complex constitutes a novel mitophagy pathway.
The PINK1-Parkin axis: An Overview.
The PINK1-Parkin pathway is involved in the regulation of mitochondrial remodeling process.
The PINK1/Parkin pathway regulates mitochondrial dynamics and function in mammalian hippocampal and dopaminergic neurons.
The PINK1/Parkin pathway: a mitochondrial quality control system?
The PINK1/Parkin-mediated mitophagy is compromised by PD-associated mutations.
The plant triterpenoid celastrol blocks PINK1-dependent mitophagy by disrupting PINK1's association with the mitochondrial protein TOM20.
The proteasomal subunit S6 ATPase is a novel synphilin-1 interacting protein--implications for Parkinson's disease.
The protein interacting with C-kinase (PICK1) interacts with and attenuates parkin-associated endothelial-like (PAEL) receptor-mediated cell death.
The regulatory role of alpha-synuclein and parkin in neuronal cell apoptosis; possible implications for the pathogenesis of Parkinson's disease.
The relation between depression and parkin genotype: The CORE-PD study.
The role of parkin in familial and sporadic Parkinson's disease.
The Role of Parkin in Parkinson's Disease: a stem cell perspective.
The role of parkinson's disease-associated receptor GPR37 in the hippocampus: functional interplay with the adenosinergic system.
The role of PTEN-induced kinase 1 in mitochondrial dysfunction and dynamics.
The role of synphilin-1 in the pathogenesis of Parkinson's disease.
The role of the MAGUK protein CASK in neural development and synaptic function.
The roles of PINK1 and Parkin in Parkinson's disease.
The roles of PINK1, Parkin, and mitochondrial fidelity in Parkinson's disease.
The septin CDCrel-1 is dispensable for normal development and neurotransmitter release.
The sooner, the later - Delayed diagnosis in Parkinson's disease due to Parkin mutations.
The striatal dopaminergic deficit is dependent on the number of mutant alleles in a family with mutations in the parkin gene: evidence for enzymatic parkin function in humans.
The three 'P's of mitophagy: PARKIN, PINK1, and post-translational modifications.
The Transcription Factor Function of Parkin: Breaking the Dogma.
The ubiquitin E3 ligase parkin regulates the proapoptotic function of Bax.
The ubiquitin ligase parkin mediates resistance to intracellular pathogens.
The ubiquitin-conjugating enzymes UBE2N, UBE2L3 and UBE2D2/3 are essential for Parkin-dependent mitophagy.
The ubiquitin-proteasome pathway is necessary for maintenance of the postmitotic status of neurons.
The yeast complex I equivalent NADH dehydrogenase rescues pink1 mutants.
Thioredoxin suppresses Parkin-associated endothelin receptor-like receptor-induced neurotoxicity and extends longevity in Drosophila.
Tissue- and cell-specific mitochondrial defect in Parkin-deficient mice.
Transcription- and phosphorylation-dependent control of a functional interplay between XBP1s and PINK1 governs mitophagy and potentially impacts Parkinson disease pathophysiology.
Transcriptional alterations in skin fibroblasts from Parkinson's disease patients with parkin mutations.
Transcriptional repression of p53 by parkin and impairment by mutations associated with autosomal recessive juvenile Parkinson's disease.
Transgenic overexpression of the alpha-synuclein interacting protein synphilin-1 leads to behavioral and neuropathological alterations in mice.
TRIM3 attenuates apoptosis in Parkinson's disease via activating PI3K/AKT signal pathway.
TRIM9, a novel brain-specific E3 ubiquitin ligase, is repressed in the brain of Parkinson's disease and dementia with Lewy bodies.
Tumorigenesis and neurodegeneration: two sides of the same coin?
Twenty years since the discovery of the parkin gene.
Ubiquitin ligase parkin promotes Mdm2-arrestin interaction but inhibits arrestin ubiquitination.
Ubiquitin phosphorylated at Ser57 hyper-activates parkin.
Ubiquitin-protein ligase parkin and its role in the development of Parkinson's disease.
Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease.
UCP4A protects against mitochondrial dysfunction and degeneration in pink1/parkin models of Parkinson's disease.
Unraveling correlative roles of dopamine transporter (DAT) and Parkin in Parkinson's disease (PD) - A road to discovery?
Update on Parkinson disease.
Upregulation of dopamine D2 receptors in dopaminergic drug-naive patients with Parkin gene mutations.
Upregulation of Parkin Accelerates Osteoblastic Differentiation of Bone Marrow-Derived Mesenchymal Stem Cells and Bone Regeneration by Enhancing Autophagy and ?-Catenin Signaling.
USP33 deubiquitinates PRKN/parkin and antagonizes its role in mitophagy.
USP8 regulates mitophagy by removing K6-linked ubiquitin conjugates from parkin.
Variability in clinical phenotypes of heterozygous and homozygous cases of Parkin-related Parkinson's disease.
VPS13D bridges the ER to mitochondria and peroxisomes via Miro.
XANES Measurements for Studies of Adsorbed Protein Layers at Liquid Interfaces.
Young-onset Parkinson disease with and without parkin gene mutations: a fluorodopa F 18 positron emission tomography study.
ZNF746/PARIS overexpression induces cellular senescence through FoxO1/p21 axis activation in myoblasts.
[A new point mutation on exon 2 of parkin gene in Parkinson's disease]
[A novel point mutation in parkin gene was identified in an early-onset case of Parkinson's disease]
[A Parkin gene (PARK 2) and Parkinson's disease]
[A study on PARKIN gene in three pedigrees with autosomal recessive early-onset Parkinson's disease]
[Analysis of the parkin gene deletion mutations in Chinese patients with Parkinson's disease]
[Association analysis of the parkin gene in patients with sporadic Parkinson's disease from a Han population of Sichuan province]
[Etiology and pathogenesis of Parkinson's disease: from mitochondrial dysfunctions to familial Parkinson's disease]
[Genetic and environmental factors of Parkinson's disease]
[Genetics and environmental factors of Parkinson disease]
[Genotype and phenotype analyses of three families with autosomal recessive juvenile parkinsonism]
[Inactivation of parkin in Parkinson disease]
[Molecular pharmacological studies on the protection mechanism against endoplasmic reticulum stress-induced neurodegenerative disease].
[Neurodegeneration caused by ER stress?--the pathogenetic mechanisms underlying AR-JP]
[New polymorphism (IVS3-20 T-->C) of the parkin gene associated with the early-onset Parkinson's disease in Chinese]
[Parkin protein and molecular mechanism of Parkinson's disease]
[Parkin, alpha-synuclein and other molecular aspects of Parkinson's disease]
[Parkinson's disease: what have we learned from the genes responsible for familial forms?]
[Pathogenesis of Parkinson's disease: a common pathway between alpha-synuclein and parkin and the mechanism of Lewy bodies formation]
[Recent neuropathology of parkinsonian syndromes]
[Regulation of Parkin and Parkinson's disease]
[Regulation of the protein degradation pathway by the ubiquitin family: its implication in neurodegenerative diseases]
[The clinical and genetic characteristics of autosomal recessive juvenile Parkinsonism in a Chinese family]
[Two cases of sporadic juvenile Parkinson's disease caused by homozygous deletion of Parkin gene]
[What can we learn from genes responsible for familial forms of Parkinson's disease?]
{alpha}-Synuclein Aggregates Interfere with Parkin Solubility and Distribution: ROLE IN THE PATHOGENESIS OF PARKINSON DISEASE.
Parkinsonian Disorders
14-3-3eta is a novel regulator of parkin ubiquitin ligase.
A Caenorhabditis elegans Parkin mutant with altered solubility couples alpha-synuclein aggregation to proteotoxic stress.
A clinical and genetic study of early-onset and familial parkinsonism in taiwan: An integrated approach combining gene dosage analysis and next-generation sequencing.
A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia.
A dimeric PINK1-containing complex on depolarized mitochondria stimulates Parkin recruitment.
A double RING-H2 domain in RNF32, a gene expressed during sperm formation.
A homozygous parkin p.G284R mutation in a Chinese family with autosomal recessive juvenile parkinsonism.
A mechanistic review of Parkin activation.
A molecular explanation for the recessive nature of parkin-linked Parkinson's disease.
A multidisciplinary study of patients with early-onset PD with and without parkin mutations.
A new mutation in the parkin gene in a patient with atypical autosomal recessive juvenile parkinsonism.
A novel Cys212Tyr founder mutation in parkin and allelic heterogeneity of juvenile Parkinsonism in a population from North West Colombia.
A novel role for parkin in trauma-induced central nervous system secondary injury.
A Novel Tyrosine Hydroxylase Variant in a Group of Chinese Patients with Dopa-Responsive Dystonia.
A product of the human gene adjacent to parkin is a component of Lewy bodies and suppresses Pael receptor-induced cell death.
A simple cell based assay to measure Parkin activity.
A ubiquitin ligase HRD1 promotes the degradation of Pael receptor, a substrate of Parkin.
A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease.
Aberrant Accumulation of BRCA1 in Alzheimer Disease and Other Tauopathies.
Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death.
Acute and chronic haloperidol treatments increase parkin mRNA levels in the rat brain.
Alterations of the tumor suppressor gene Parkin in non-small cell lung cancer.
An apparently sporadic case with parkin gene mutation in a Korean woman.
An autopsy case of autosomal-recessive juvenile parkinsonism with a homozygous exon 4 deletion in the parkin gene.
An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin.
Analysis of alpha-synuclein, parkin, tau, and UCH-L1 in a Japanese family with autosomal dominant parkinsonism.
Analysis of eighteen deletion breakpoints in the parkin gene.
Are There Common Biochemical and Molecular Mechanisms Controlling Manganism and Parkisonism.
Association of codon 167 Ser/Asn heterozygosity in the parkin gene with sporadic Parkinson's disease.
Autoregulation of Parkin activity through its ubiquitin-like domain.
Autosomal recessive juvenile parkinsonism Cys212Tyr mutation in parkin renders lymphocytes susceptible to dopamine- and iron-mediated apoptosis.
Autosomal recessive parkinsonism linked to parkin gene in a Tunisian family. Clinical, genetic and pathological study.
Autosomal recessive parkinsonism.
Autosomal-dominantly inherited forms of Parkinson's disease.
Autosomal-recessive juvenile parkinsonism in a Jewish Yemenite kindred: mutation of Parkin gene.
Behavioral and neurotransmitter abnormalities in mice deficient for Parkin, DJ-1 and superoxide dismutase.
Benign tremulous parkinsonism of the young-consider Parkin.
Biallelic Parkin (PARK2) mutations can cause a bvFTD phenotype without clinically relevant parkinsonism.
Bilateral subthalamic stimulation in Parkin and PINK1 parkinsonism.
Biochemical analysis of Parkinson's disease-causing variants of Parkin, an E3 ubiquitin-protein ligase with monoubiquitylation capacity.
Brain parenchyma sonography detects preclinical parkinsonism.
Camptocormia, axial dystonia, and parkinsonism: phenotypic heterogeneity of a parkin mutation.
Cardiac (123)I-metaiodobenzylguanidine Scintigraphy in a Patient with Familial Parkinsonism with Parkin Gene Mutation.
Cell type-specific upregulation of Parkin in response to ER stress.
Cell-permeable parkin proteins suppress Parkinson disease-associated phenotypes in cultured cells and animals.
Characterization of parkin in bovine peripheral nerve.
Chronic bilateral subthalamic deep brain stimulation in a patient with homozygous deletion in the parkin gene.
Chronic overload of SEPT4, a parkin substrate that aggregates in Parkinson's disease, causes behavioral alterations but not neurodegeneration in mice.
Clinical and genetic studies on familial parkinsonism: the first report on a parkin gene mutation in a Taiwanese family.
Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations.
Clinical features and [(11)C]-CFT PET analysis of PARK2, PARK6, PARK7-linked autosomal recessive early onset Parkinsonism.
Clinical findings in a large family with a parkin ex3delta40 mutation.
Clinical, 18F-dopa PET, and genetic analysis of an ethnic Chinese kindred with early-onset parkinsonism and parkin gene mutations.
Cloning and distribution of the rat parkin mRNA.
Cloning of rat parkin cDNA and distribution of parkin in rat brain.
Co-association of parkin and alpha-synuclein.
Combined kinase inhibition modulates parkin inactivation.
Common anti-apoptotic roles of parkin and alpha-synuclein in human dopaminergic cells.
Common fragile sites, extremely large genes, neural development and cancer.
Complex relationship between Parkin mutations and Parkinson disease.
Constitutive Activation of PINK1 Protein Leads to Proteasome-mediated and Non-apoptotic Cell Death Independently of Mitochondrial Autophagy.
Crystal structure and molecular dynamics simulation of ubiquitin-like domain of murine parkin.
Deciphering the Molecular Signals of PINK1/Parkin Mitophagy.
Deciphering the role of heterozygous mutations in genes associated with parkinsonism.
Decline of striatal dopamine release in parkin-deficient mice shown by ex vivo autoradiography.
Deletion of the parkin and PACRG gene promoter in early-onset parkinsonism.
Detection of compound heterozygous deletions in the parkin gene of fibroblasts in patients with autosomal recessive hereditary parkinsonism (PARK2).
Developmental changes in the expression of parkin and UbcR7, a parkin-interacting and ubiquitin-conjugating enzyme, in rat brain.
Diagnostic considerations in juvenile parkinsonism.
Differential effects of l-DOPA on monoamine metabolism, cell survival and glutathione production in midbrain neuronal-enriched cultures from parkin knockout and wild-type mice.
Differential expression and tissue distribution of parkin isoforms during mouse development.
Differential expression of the parkin gene in the human brain and peripheral leukocytes.
Differentiating symptomatic Parkin mutations carriers from patients with idiopathic Parkinson's disease: contribution of automated segmentation neuroimaging method.
Disease-causing mutations in parkin impair mitochondrial ubiquitination, aggregation, and HDAC6-dependent mitophagy.
Diverse effects of pathogenic mutations of Parkin that catalyze multiple monoubiquitylation in vitro.
DJ-1 acts in parallel to the PINK1/parkin pathway to control mitochondrial function and autophagy.
DJ-1 is critical for mitochondrial function and rescues PINK1 loss of function.
DJ-1 regulation of mitochondrial function and autophagy through oxidative stress.
DNA damage induces nuclear translocation of parkin.
Does Impairment of the Ubiquitin-Proteasome System or the Autophagy-Lysosome Pathway Predispose Individuals to Neurodegenerative Disorders such as Parkinson's Disease?
Does impairment of the ubiquitin-proteasome system or the autophagy-lysosome pathway predispose individuals to neurodegenerative disorders such as Parkinson's disease?
Dopamine covalently modifies and functionally inactivates parkin.
Dopamine dysregulation syndrome in a patient with early onset Parkinsonism and Parkin gene mutations.
Dopamine-dependent neurodegeneration in rats induced by viral vector-mediated overexpression of the parkin target protein, CDCrel-1.
Down regulation of DJ-1 enhances cell death by oxidative stress, ER stress, and proteasome inhibition.
Down-regulation of LRRK2 in control and DAT transfected HEK cells increases manganese-induced oxidative stress and cell toxicity.
Downregulation of parkin damages antioxidant defenses and enhances proteasome inhibition-induced toxicity in PC12 cells.
Drosophila melanogaster Parkin ubiquitinates peanut and septin1 as an E3 ubiquitin-protein ligase.
Drosophila overexpressing parkin R275W mutant exhibits dopaminergic neuron degeneration and mitochondrial abnormalities.
Dual Function of Phosphoubiquitin in E3 Activation of Parkin.
E3 ubiquitin-protein ligase activity of Parkin is dependent on cooperative interaction of RING finger (TRIAD) elements.
Early Dysfunction of Substantia Nigra Dopamine Neurons in the ParkinQ311X Mouse.
Early-onset Parkinson's disease associated with a new parkin mutation in a Spanish family.
Early-onset Parkinson's disease caused by a novel parkin mutation in a genetic isolate from north-eastern Brazil.
Effect of overexpression of wild-type or mutant parkin on the cellular response induced by toxic insults.
Effect of the neurotoxic dose of methamphetamine on gene expression of parkin and Pael-receptors in rat striatum.
Effect of wild-type or mutant Parkin on oxidative damage, nitric oxide, antioxidant defenses, and the proteasome.
Effects of cinnarizine, a calcium antagonist that produces human parkinsonism, in parkin knock out mice.
Emerging views of mitophagy in immunity and autoimmune diseases.
Enhanced Hyperthermia Induced by MDMA in Parkin Knockout Mice.
Exonic deletion mutations of the Parkin gene among sporadic patients with Parkinson's disease.
Expression profile of parkin isoforms in human gliomas.
Extended lifespan of Drosophila parkin mutants through sequestration of redox-active metals and enhancement of anti-oxidative pathways.
Eye movement disorders are different in Parkin-linked and idiopathic early-onset PD.
Familial Parkinsonism with digenic parkin and PINK1 mutations.
Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin.
Flavin-containing monooxygenase, a new clue of pathological proteins in the rotenone model of parkinsonism.
Folding Underlies Bidirectional Role of GPR37/Pael-R in Parkinson Disease.
Functional association of the parkin gene promoter with idiopathic Parkinson's disease.
Functional modulation of parkin through physical interaction with SUMO-1.
Functional Role of Parkin against Oxidative Stress in Neural Cells.
Gene therapy for Parkinson's disease.
Generation of induced pluripotent stem cell line (ZZUi007-A) from a 52-year-old patient with a novel CHCHD2 gene mutation in Parkinson's disease.
Genes associated with Parkinson syndrome.
Genetic analysis of parkin co-regulated gene (PACRG) in patients with early-onset parkinsonism.
Genetic and genomic studies of Drosophila parkin mutants implicate oxidative stress and innate immune responses in pathogenesis.
Genetic influence on the development of Parkinson's disease.
Genetic screening reveals high frequency of PARK2 mutations and reduced Parkin expression conferring risk for Parkinsonism in North West India.
Genetic zebrafish models of neurodegenerative diseases.
Genetics and epigenetics of Parkinson's disease.
Genetics and iron in the systems biology of Parkinson's disease and some related disorders.
Genetics of movement disorders: an abbreviated overview.
Genetics of Parkinson's disease.
Genomic and Functional Analysis of the E3 Ligase PARK2 in Glioma.
Genotype-phenotype correlates in Taiwanese patients with early-onset recessive parkinsonism.
Genotype-Phenotype Relations for the Atypical Parkinsonism Genes: MDSGene Systematic Review.
Glial dysfunction in parkin null mice: effects of aging.
Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patients.
Homozygous deletion mutation of the parkin gene in patients with atypical parkinsonism.
Homozygous deletions in parkin gene in European and North African families with autosomal recessive juvenile parkinsonism. The European Consortium on Genetic Susceptibility in Parkinson's Disease and the French Parkinson's Disease Genetics Study Group.
Homozygous exon 4 deletion in parkin gene in a Korean family with autosomal recessive early onset parkinsonism.
Homozygous partial genomic triplication of the parkin gene in early-onset parkinsonism.
How do Parkin mutations result in neurodegeneration?
How does parkin ligate ubiquitin to Parkinson's disease?
How much phenotypic variation can be attributed to parkin genotype?
Hyperphosphorylated tau aggregates in the cortex and hippocampus of transgenic mice with mutant human FTDP-17 Tau and lacking the PARK2 gene.
Identification and characterization of a novel endogenous murine parkin mutation.
Identification and characterization of the human parkin gene promoter.
Identification of a novel gene linked to parkin via a bi-directional promoter.
Identification of far upstream element-binding protein-1 as an authentic Parkin substrate.
Imaging of dopaminergic dysfunction with [123I]FP-CIT SPECT in early-onset parkin disease.
Immunodetection of Parkin protein in vertebrate and invertebrate brains: a comparative study using specific antibodies.
Immunohistochemical and subcellular localization of Parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients.
Immunohistochemical localization of a ubiquitin ligase HRD1 in murine brain.
Impact of altered phosphorylation on loss of function of juvenile Parkinsonism-associated genetic variants of the E3 ligase parkin.
Impact of recent genetic findings in Parkinson's disease.
Impaired dopamine release and synaptic plasticity in the striatum of parkin-/- mice.
Impaired in vivo dopamine release in parkin knockout mice.
In vivo assessment of brain monoamine systems in parkin gene carriers: a PET study.
Inactivation of parkin by oxidative stress and C-terminal truncations: a protective role of molecular chaperones.
Increased glutathione S-transferase activity rescues dopaminergic neuron loss in a Drosophila model of Parkinson's disease.
Increased Levels of cAMP by the Calcium-Dependent Activation of Soluble Adenylyl Cyclase in Parkin-Mutant Fibroblasts.
Inhibition of proteasomal activity causes inclusion formation in neuronal and non-neuronal cells overexpressing Parkin.
Involvement of spinal motor neurons in parkin-positive autosomal recessive juvenile parkinsonism.
Is PARKIN parkinsonism a cancer predisposition syndrome?
It's a double knock-out! The quaking mouse is a spontaneous deletion of parkin and parkin co-regulated gene (PACRG).
Juvenile Parkinson disease and the C212Y mutation of parkin.
Juvenile-onset parkinsonism with digenic parkin and PINK1 mutations treated with subthalamic nucleus stimulation at 45 years after disease onset.
Lack of evidence for association of Parkin promoter polymorphism (PRKN-258) with increased risk of Parkinson's disease.
Late onset sporadic Parkinson's disease caused by PINK1 mutations: clinical and functional study.
Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease.
Leucine-rich repeat kinase 2 and alpha-synuclein: intersecting pathways in the pathogenesis of Parkinson's disease?
Lewy bodies and parkinsonism in families with parkin mutations.
Lipopolysaccharide and Tumor Necrosis Factor Regulate Parkin Expression via Nuclear Factor-Kappa B.
Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36.
Loss of locus coeruleus neurons and reduced startle in parkin null mice.
Loss of parkin or PINK1 function increases Drp1-dependent mitochondrial fragmentation.
Loss-of-Function Rodent Models for Parkin and PINK1.
Low doses of paraquat and polyphenols prolong life span and locomotor activity in knock-down parkin Drosophila melanogaster exposed to oxidative stress stimuli: implication in autosomal recessive juvenile Parkinsonism.
Low protein to carbohydrate ratio diet delays onset of Parkinsonism like phenotype in Drosophila melanogaster parkin null mutants.
Marked variation in clinical presentation and age of onset in a family with a heterozygous parkin mutation.
Mechanism of parkin activation by PINK1.
Mechanism of phospho-ubiquitin-induced PARKIN activation.
Mendelian forms of Parkinson's disease.
Metabolomics-based identification of metabolic alterations in PARK2.
Midbrain neuronal cultures from parkin mutant mice are resistant to nitric oxide-induced toxicity.
Minocycline protects, rescues and prevents knockdown transgenic parkin Drosophila against paraquat/iron toxicity: Implications for autosomic recessive juvenile parkinsonism.
Mitochondria and dopamine: new insights into recessive parkinsonism.
Mitochondria-affecting small molecules ameliorate proteostasis defects associated with neurodegenerative diseases.
Mitochondrial Dynamics and Parkinson's Disease: Focus on Parkin.
Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism.
Mitochondrial dysfunction in Parkinson disease: evidence in mutant PARK2 fibroblasts.
Mitochondrial hexokinase HKI is a novel substrate of the Parkin ubiquitin ligase.
Mitochondrial injury: a hot spot for parkinsonism and Parkinson's disease?
Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants.
Mitochondrial pathology in muscle of a patient with a novel parkin mutation.
Mitochondrial Quality Control and Dynamics in Parkinson's Disease.
Mitochondrial quality control mediated by PINK1 and Parkin: links to parkinsonism.
Mitochondrial quality control turns out to be the principal suspect in parkin and PINK1-related autosomal recessive Parkinson's disease.
Modulation of parkin gene expression in noradrenergic neuronal cells.
Molecular cloning, gene expression, and identification of a splicing variant of the mouse parkin gene.
Molecular genetic analysis of a novel Parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: evidence for variable homozygous deletions in the Parkin gene in affected individuals.
Molecular genetics of Parkinson's disease.
Molecular mechanisms underlying PINK1 and Parkin catalyzed ubiquitylation of substrates on damaged mitochondria.
Morphological substrates of mental dysfunction in Lewy body disease: an update.
Morphometric fingerprint of asymptomatic Parkin and PINK1 mutation carriers in the basal ganglia.
Motor cortical physiology in patients and asymptomatic carriers of parkin gene mutations.
Motor reorganization in asymptomatic carriers of a single mutant Parkin allele: a human model for presymptomatic parkinsonism.
Mutation analysis for DJ-1 in sporadic and familial parkinsonism: screening strategy in parkinsonism.
Mutation analysis of Parkin, PINK1 and DJ-1 genes in Chinese patients with sporadic early onset parkinsonism.
Mutation analysis of Parkin, PINK1, DJ-1 and ATP13A2 genes in Chinese patients with autosomal recessive early-onset Parkinsonism.
Mutation analysis of the parkin gene in Russian families with autosomal recessive juvenile parkinsonism.
Mutation of the Parkin gene in a Persian family: clinical progression over a 40-year period.
Mutation screening and association analysis of the parkin gene in Parkinson's disease patients from South-West China.
Mutational Impact on "in-Between-Ring" (IBR) Domain of PARKIN on Protein Stability and Function.
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism.
Myocardial (123)I-metaiodobenzylguanidine scintigraphy in patients with homozygous and heterozygous parkin mutations.
Naturally- and experimentally-designed restorations of the Parkin gene deficit in autosomal recessive juvenile parkinsonism.
Neddylation positively regulates the ubiquitin E3 ligase activity of parkin.
Neurodegeneration in Parkinson's disease: genetics enlightens physiopathology.
Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature.
Neuroprotection of Parkin against apoptosis is independent of inclusion body formation.
New aspects of genetic contributions to Parkinson's disease.
New developments in understanding the etiology of Parkinson's disease and in its treatment.
New mutation (R42P) of the parkin gene in the ubiquitinlike domain associated with parkinsonism.
New parkin mutations and atypical phenotypes in families with autosomal recessive parkinsonism.
New Perception of Mitochondrial Regulatory Pathway in Parkinsonism - Ubiquitin, PINK1, and Parkin.
Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity.
Nonmotor symptoms in Parkin gene-related parkinsonism.
Novel monoclonal antibodies demonstrate biochemical variation of brain parkin with age.
Novel PINK1 mutations in early-onset parkinsonism.
Olfaction and Parkinson's syndromes: its role in differential diagnosis.
Olfaction differentiates parkin disease from early-onset parkinsonism and Parkinson disease.
Origin of the mutations in the parkin gene in Europe: exon rearrangements are independent recurrent events, whereas point mutations may result from Founder effects.
Overexpression of Nrdp1/FLRF sensitizes cells to oxidative stress.
Overexpression of parkin ameliorates dopaminergic neurodegeneration induced by 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
Overexpression of Septin 4, the Drosophila homologue of human CDCrel-1, is toxic for dopaminergic neurons.
p32 regulates mitochondrial morphology and dynamics through parkin.
p62/SQSTM1 is required for Parkin-induced mitochondrial clustering but not mitophagy; VDAC1 is dispensable for both.
Pael receptor is involved in dopamine metabolism in the nigrostriatal system.
Pael receptor, endoplasmic reticulum stress, and Parkinson's disease.
Pael-R transgenic mice crossed with parkin deficient mice displayed progressive and selective catecholaminergic neuronal loss.
PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice.
PARK2 mediates interleukin 6 and monocyte chemoattractant protein 1 production by human macrophages.
PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD study.
PARK6 is a common cause of familial parkinsonism.
PARK6-linked parkinsonism occurs in several European families.
Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36.
Parkin and alpha-synuclein: opponent actions in the pathogenesis of Parkinson's disease.
Parkin and endoplasmic reticulum stress.
Parkin and mitochondrial quality control: toward assembling the puzzle.
Parkin and mitophagy in cancer.
Parkin and PINK1 mutations in early-onset Parkinson's disease: comprehensive screening in publicly available case-control cohorts.
Parkin and PINK1 parkinsonism may represent nigral mitochondrial cytopathies distinct from Lewy body Parkinson's disease.
Parkin and relatives: the RBR family of ubiquitin ligases.
Parkin and the molecular pathways of Parkinson's disease.
PARKIN as a pathogenic gene for autosomal recessive juvenile parkinsonism.
Parkin as a tumor suppressor gene for hepatocellular carcinoma.
Parkin attenuates wild-type tau modification in the presence of beta-amyloid and alpha-synuclein.
Parkin binds the Rpn10 subunit of 26S proteasomes through its ubiquitin-like domain.
Parkin Co-Regulated Gene (PACRG) is regulated by the ubiquitin-proteasomal system and is present in the pathological features of Parkinsonian diseases.
Parkin deficiency accelerates consequences of mitochondrial DNA deletions and Parkinsonism.
Parkin deficiency contributes to pancreatic tumorigenesis by inducing spindle multipolarity and misorientation.
Parkin deficiency delays motor decline and disease manifestation in a mouse model of synucleinopathy.
Parkin deficiency disrupts calcium homeostasis by modulating phospholipase C signalling.
Parkin deficiency increases the resistance of midbrain neurons and glia to mild proteasome inhibition: the role of autophagy and glutathione homeostasis.
Parkin deletions in a family with adult-onset, tremor-dominant parkinsonism: expanding the phenotype.
Parkin disease in a Brazilian kindred: Manifesting heterozygotes and clinical follow-up over 10 years.
Parkin Disease: A Clinicopathologic Entity?
Parkin disease: a phenotypic study of a large case series.
Parkin enhances the expression of cyclin-dependent kinase 6 and negatively regulates the proliferation of breast cancer cells.
Parkin expression in the adult mouse brain.
Parkin expression in the developing mouse.
Parkin expression profile in dopamine d3 receptor knock-out mice brains.
Parkin gene causing benign autosomal recessive juvenile parkinsonism.
Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse.
Parkin gene therapy.
Parkin gene variations and parkinsonism: association does not imply causation.
Parkin immunoreactivity in the brain of human and non-human primates: an immunohistochemical analysis in normal conditions and in Parkinsonian syndromes.
Parkin in Parkinson's Disease and Cancer: a Double-Edged Sword.
Parkin interacts with LIM Kinase 1 and reduces its cofilin-phosphorylation activity via ubiquitination.
Parkin is an E3 ubiquitin-ligase for normal and mutant ataxin-2 and prevents ataxin-2-induced cell death.
Parkin is associated with actin filaments in neuronal and nonneural cells.
Parkin is associated with cellular vesicles.
Parkin is metabolized by the ubiquitin/proteosome system.
Parkin is protective against proteotoxic stress in a transgenic zebrafish model.
Parkin is recruited into aggresomes in a stress-specific manner: over-expression of parkin reduces aggresome formation but can be dissociated from parkin's effect on neuronal survival.
Parkin is transcriptionally regulated by ATF4: evidence for an interconnection between mitochondrial stress and ER stress.
Parkin is transcriptionally regulated by the aryl hydrocarbon receptor: Impact on ?-synuclein protein levels.
Parkin mediates apparent E2-independent monoubiquitination in vitro and contains an intrinsic activity that catalyzes polyubiquitination.
Parkin mediates the degradation-independent ubiquitination of Hsp70.
Parkin modulates gene expression in control and ceramide-treated PC12 cells.
Parkin modulates heteroplasmy of truncated mtDNA in Caenorhabditis elegans.
Parkin mono-ubiquitinates BCL-2 and regulates autophagy.
Parkin Mutation Affects Clock Gene-Dependent Energy Metabolism.
Parkin mutation associated parkinsonism and cognitive decline, comparison to early onset Parkinson's disease.
Parkin mutation dosage and the phenomenon of anticipation: a molecular genetic study of familial parkinsonism.
Parkin mutations and early onset parkinsonism.
Parkin mutations and early-onset parkinsonism in a Taiwanese cohort.
Parkin mutations and susceptibility alleles in late-onset Parkinson's disease.
Parkin mutations are frequent in patients with isolated early-onset parkinsonism.
Parkin mutations are rare in patients with young-onset parkinsonism in a US population.
Parkin negatively regulates JNK pathway in the dopaminergic neurons of Drosophila.
Parkin overexpression selects against a deleterious mtDNA mutation in heteroplasmic cybrid cells.
Parkin pathway activation mitigates glioma cell proliferation and predicts patient survival.
Parkin phosphorylation and modulation of its E3 ubiquitin ligase activity.
Parkin Pleiotropy: Extremely Atypical Phenotypes in Patients With Compound Heterozygous Mutations.
Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death.
Parkin promotes intracellular Abeta1-42 clearance.
Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila.
Parkin regulates kainate receptors by interacting with the GluK2 subunit.
Parkin Regulation and Neurodegenerative Disorders.
Parkin suppresses c-Jun N-terminal kinase-induced cell death via transcriptional regulation in Drosophila.
Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila.
Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity.
Parkin transcript variants in rat and human brain.
Parkin ubiquitinates and promotes the degradation of RanBP2.
Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27.
Parkin, an E3 Ubiquitin Ligase, Plays an Essential Role in Mitochondrial Quality Control in Parkinson's Disease.
Parkin, PINK1 and mitochondrial integrity: emerging concepts of mitochondrial dysfunction in Parkinson's disease.
Parkin-associated Parkinson's disease.
Parkin-catalyzed ubiquitin-ester transfer is triggered by PINK1-dependent phosphorylation.
Parkin-deficient mice are not a robust model of parkinsonism.
Parkin-deficient mice are not more sensitive to 6-hydroxydopamine or methamphetamine neurotoxicity.
Parkin-phosphoubiquitin complex reveals cryptic ubiquitin-binding site required for RBR ligase activity.
Parkin-positive autosomal recessive juvenile Parkinsonism with alpha-synuclein-positive inclusions.
Parkin-proven disease: common founders but divergent phenotypes.
Parkin: a multifaceted ubiquitin ligase.
Parkinson's disease in Ireland: clinical presentation and genetic heterogeneity in patients with parkin mutations.
Parkinson's disease: from monogenic forms to genetic susceptibility factors.
Parkinson's disease: insights from pathways.
Parkinsonism Due to Mutations in PINK1, Parkin, and DJ-1 and Oxidative Stress and Mitochondrial Pathways.
Parkinsonism genes: culprits and clues.
Peripheral neuropathy and parkinsonism: a large clinical and pathogenic spectrum.
Pharmacological antagonism of kainate receptor rescues dysfunction and loss of dopamine neurons in a mouse model of human parkin-induced toxicity.
Phosphorylation of Parkin by the cyclin-dependent kinase 5 at the linker region modulates its ubiquitin-ligase activity and aggregation.
PINK1 enhances insulin-like growth factor-1-dependent Akt signaling and protection against apoptosis.
PINK1 is selectively stabilized on impaired mitochondria to activate Parkin.
PINK1 phosphorylates ubiquitin predominantly in astrocytes.
PINK1 rendered temperature sensitive by disease-associated and engineered mutations.
PINK1, Parkin, and DJ-1 mutations in Italian patients with early-onset parkinsonism.
Polymorphisms of the parkin gene in sporadic Parkinson's disease among Chinese in Taiwan.
Porcine Parkin: molecular cloning of PARK2 cDNA, expression analysis, and identification of a splicing variant.
Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene.
Post translational modification of Parkin.
Post-translational modification of Parkin and its research progress in cancer.
Preserved myocardial [123I]metaiodobenzylguanidine uptake in autosomal recessive juvenile parkinsonism: first case report.
Prevalence of parkin gene mutations and variations in idiopathic Parkinson's disease.
Profiling of Parkin-binding partners using tandem affinity purification.
Programmed cell death and new discoveries in the genetics of parkinsonism.
Progress in the clinical and molecular genetics of familial parkinsonism.
Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study.
Progressive supranuclear palsy and tau hyperphosphorylation in a patient with a C212Y parkin mutation.
Proteasome inhibition promotes parkin-ubc13 interaction and lysine 63-linked ubiquitination.
Proteomic analysis of parkin knockout mice: alterations in energy metabolism, protein handling and synaptic function.
Pseudo-dominant inheritance and exon 2 triplication in a family with parkin gene mutations.
Pseudo-heterozygous rearrangement mutation of parkin.
Quantitative gait analysis in parkin disease: Possible role of dystonia.
Rapid eye movement sleep behavior disorder in parkinsonism with parkin mutations.
Rare heterozygous parkin variants in French early-onset Parkinson disease patients and controls.
Recent advances in research on Parkinson disease: synuclein and parkin.
Reduction in endogenous parkin levels renders glial cells sensitive to both caspase-dependent and caspase-independent cell death.
Relative high frequency of the c.255delA parkin gene mutation in Spanish patients with autosomal recessive parkinsonism.
Relative sensitivity of parkin and other cysteine-containing enzymes to stress-induced solubility alterations.
Rescue of mitochondrial function in parkin-mutant fibroblasts using drug loaded PMPC-PDPA polymersomes and tubular polymersomes.
Restless legs syndrome, rapid eye movement sleep behavior disorder, and hypersomnia in patients with two parkin mutations.
RING finger 1 mutations in Parkin produce altered localization of the protein.
Role of parkin mutations in 111 community-based patients with early-onset parkinsonism.
Rotenone-induced parkinsonism elicits behavioral impairments and differential expression of parkin, heat shock proteins and caspases in the rat.
Screening for DJ-1 mutations in early onset autosomal recessive parkinsonism.
Septin 4, the Drosophila Ortholog of Human CDCrel-1, Accumulates in parkin Mutant Brains and is Functionally Related to the Nedd4 E3 Ubiquitin Ligase.
Significance of the parkin and PINK1 gene in Jordanian families with incidences of young-onset and juvenile parkinsonism.
Significance of the parkin gene and protein in understanding Parkinson's disease.
Site-specific Interaction Mapping of Phosphorylated Ubiquitin to Uncover Parkin Activation.
Stable Isotope Labeling and Label-Free Proteomics of Drosophila parkin Null Mutants.
Steele-Richardson-Olszewski syndrome in a patient with a single C212Y mutation in the parkin protein.
STEP61 is a substrate of the E3 ligase parkin and is upregulated in Parkinson's disease.
Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function.
Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism.
Striatal dopaminergic denervation in early and late onset Parkinson's disease assessed by PET and the tracer [11C]FECIT: preliminary findings in one patient with autosomal recessive parkinsonism (Park2).
Structural Biology: Parkin's Serpentine Shape Revealed in the Year of the Snake.
Structural insights into ubiquitin phosphorylation by PINK1.
Structure of PINK1 in complex with its substrate ubiquitin.
Structure of the C-terminal RING finger from a RING-IBR-RING/TRIAD motif reveals a novel zinc-binding domain distinct from a RING.
Structure of the Parkin in-between-ring domain provides insights for E3-ligase dysfunction in autosomal recessive Parkinson's disease.
Study of methylation levels of parkin gene promoter in Parkinson's disease patients.
Subclinical sensory abnormalities in unaffected PINK1 heterozygotes.
Successful treatment of Juvenile parkinsonism with bilateral subthalamic deep brain stimulation in a 14-year-old patient with parkin gene mutation.
Suppression of Nrdp1 toxicity by Parkin in Drosophila models.
Surprising behavioral and neurochemical enhancements in mice with combined mutations linked to Parkinson's disease.
Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline.
SWATH-MS proteome profiling data comparison of DJ-1, Parkin, and PINK1 knockout rat striatal mitochondria.
Targeted overexpression of the parkin substrate Pael-R in the nigrostriatal system of adult rats to model Parkinson's disease.
Targeting Mitochondrial Dysfunction: Role for PINK1 and Parkin in Mitochondrial Quality Control.
Targeting the cannabinoid CB2 receptor to attenuate the progression of motor deficits in LRRK2-transgenic mice.
The 350-fold compacted Fugu parkin gene is structurally and functionally similar to human Parkin.
The autosomal recessive juvenile Parkinson disease gene product, parkin, interacts with and ubiquitinates synaptotagmin XI.
The C289G and C418R missense mutations cause rapid sequestration of human Parkin into insoluble aggregates.
The cellular protein level of parkin is regulated by its ubiquitin-like domain.
The Drosophila parkin homologue is required for normal mitochondrial dynamics during spermiogenesis.
The endoplasmic reticulum/mitochondria interface: a subcellular platform for the orchestration of the functions of the PINK1-Parkin pathway?
The genomic structure and promoter region of the human parkin gene.
The importance of gene dosage studies: mutational analysis of the parkin gene in early-onset parkinsonism.
The Interplay among PINK1/PARKIN/Dj-1 Network during Mitochondrial Quality Control in Cancer Biology: Protein Interaction Analysis.
The KM-parkin-DB: A Sub-set MutationView Database Specialized for PARK2 (PARKIN) Variants.
The mitochondrial fusion-promoting factor mitofusin is a substrate of the PINK1/parkin pathway.
The nigrostriatal dopaminergic system in familial early onset parkinsonism with parkin mutations.
The p38 subunit of the aminoacyl-tRNA synthetase complex is a Parkin substrate: linking protein biosynthesis and neurodegeneration.
The parkin gene and its phenotype. Italian PD Genetics Study Group, French PD Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease.
The Parkin-Like Human Homolog of Drosophila Ariadne-1 (HHARI) Can Induce Aggresome Formation in Mammalian Cells and Is Immunologically Detectable in Lewy Bodies.
The pathological role of Pael-receptor/GPR37 in AR-JP.
The PINK1/Parkin pathway regulates mitochondrial morphology.
The PINK1/Parkin pathway: a mitochondrial quality control system?
The principal PINK1 and Parkin cellular events triggered in response to dissipation of mitochondrial membrane potential occur in primary neurons.
The regulatory role of alpha-synuclein and parkin in neuronal cell apoptosis; possible implications for the pathogenesis of Parkinson's disease.
The role of ubiquitin-protein ligases in neurodegenerative disease.
The roles of PINK1, Parkin, and mitochondrial fidelity in Parkinson's disease.
The striatal dopaminergic deficit is dependent on the number of mutant alleles in a family with mutations in the parkin gene: evidence for enzymatic parkin function in humans.
The synaptic function of parkin.
The ubiquitin-proteasome pathway is necessary for maintenance of the postmitotic status of neurons.
Three parkin gene mutations in a sibship with autosomal recessive early onset parkinsonism.
To Eat or Not to Eat: Neuronal Metabolism, Mitophagy, and Parkinson's Disease.
Trehalose ameliorates dopaminergic and tau pathology in parkin deleted/tau overexpressing mice through autophagy activation.
Two sides of a coin: Physiological significance and molecular mechanisms for damage-induced mitochondrial localization of PINK1 and Parkin.
Ubiquitin is phosphorylated by PINK1 to activate parkin.
Ubiquitin, proteasome and parkin.
UCH-L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson's disease.
Ultrastructural localization of parkin in the rat brainstem, thalamus and basal ganglia.
Unaltered alpha-synuclein blood levels in juvenile Parkinsonism with a parkin exon 4 deletion.
Uncovering the roles of PINK1 and parkin in mitophagy.
Update on the genetics of Parkinson's disease.
Upregulated Parkin expression protects mitochondrial homeostasis in DJ-1 konckdown cells and cells overexpressing the DJ-1 L166P mutation.
Upregulation of dopamine D2 receptors in dopaminergic drug-naive patients with Parkin gene mutations.
Variability in clinical phenotypes of heterozygous and homozygous cases of Parkin-related Parkinson's disease.
Versatile members of the DNAJ family show Hsp70 dependent anti-aggregation activity on RING1 mutant parkin C289G.
[Discovery of the parkin gene; the gene for young onset autosomal recessive parkinsonism (AR)]
[Exon rearrangement analysis of parkin gene in patients with isolated early-onset parkinsonism using semi-quantitative PCR]
[Future of gene therapy for Parkinson's disease]
[Impairment of the ubiquitin-proteasome system and neurodegeneration]
[Molecular genetics of PINK1]
[Mutation detection of parkin gene by denaturing high performance liquid chromatography]
[Neurodegeneration caused by ER stress?--the pathogenetic mechanisms underlying AR-JP]
[Olfactory dysfunction in Parkinson's disease: its role as a new cardinal sign in early and differential diagnosis]
[Parkin, alpha-synuclein and other molecular aspects of Parkinson's disease]
[Parkinson's disease: what have we learned from the genes responsible for familial forms?]
[Pharmacogenetics focused on special phenotypes].
[Protective effects of HRD1 and 4-phenylbutyric acid against neuronal cell death]
[Revisit to Kii ALS--the innovated concept of ALS-Parkinsonism-dementia complex, clinicopathological features, epidemiology and etiology]
{alpha}-Synuclein Aggregates Interfere with Parkin Solubility and Distribution: ROLE IN THE PATHOGENESIS OF PARKINSON DISEASE.
Pediatric Obesity
BRCA1 and acetyl-CoA carboxylase: the metabolic syndrome of breast cancer.
Periodontitis
Prioritization of Candidate Genes for Periodontitis Using Multiple Computational Tools.
Regulation of Anti-Apoptotic SOD2 and BIRC3 in Periodontal Cells and Tissues.
TRIM16 Promotes Osteogenic Differentiation of Human Periodontal Ligament Stem Cells by Modulating CHIP-Mediated Degradation of RUNX2.
Peripheral Nerve Injuries
Baculoviral inhibitor of apoptosis protein repeat-containing protein 3 delays early Wallerian degeneration after sciatic nerve injury.
Dynamic changes of PIRH2 and p27kip1 expression in injured rat sciatic nerve.
Peripheral Nervous System Diseases
Does parkin play a role in the peripheral nervous system? A family report.
Parkinson's Disease-Associated Kinase PINK1 Regulates Miro Protein Level and Axonal Transport of Mitochondria.
Sensory neuropathy in autosomal recessive juvenile parkinsonism (PARK2).
Peritoneal Neoplasms
Comparative genomic hybridization in inherited and sporadic ovarian tumors in Israel.
Inefficacité du dépistage des cancers tubo-ovariens dans les situations de risque héréditaire de cancer de l'ovaire ; l'expérience du Centre Oscar-Lambret.
Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.
Peritoneal carcinomatosis after risk-reducing surgery in BRCA1/2 mutation carriers.
Peritonitis
BRCA1 gene therapy reduces systemic inflammatory response and multiple organ failure and improves survival in experimental sepsis.
Cellular inhibitors of apoptosis proteins cIAP1 and cIAP2 are required for efficient caspase-1 activation by the inflammasome.
Peroneal Neuropathies
Foot Drop Dystonia Resulting from parkin (PARK2) Mutation.
Persistent Infection
The interferon-stimulated gene TRIM22: A double-edged sword in HIV-1 infection.
TRIM5? and TRIM22 Are Differentially Regulated According to HIV-1 Infection Phase and Compartment.
Peste-des-Petits-Ruminants
Quantitative Proteomics Reveals a Novel Role of the E3 Ubiquitin-Protein Ligase FANCL in the Activation of the Innate Immune Response through Regulation of TBK1 Phosphorylation during Peste des Petits Ruminants Virus Infection.
Pestivirus Infections
TRIM56 Is a Virus- and Interferon-Inducible E3 Ubiquitin Ligase That Restricts Pestivirus Infection.
Peutz-Jeghers Syndrome
AGA Clinical Practice Update on Pancreas Cancer Screening in High-Risk Individuals: Expert Review.
Familial pancreatic carcinoma in Jews.
Genetic testing by cancer site: ovary.
Genetic testing by cancer site: stomach.
Papers to appear in forthcoming issues
Patient and medical barriers preclude uptake of tamoxifen preventative therapy in women with a strong family history.
Susceptibility to breast cancer: hereditary syndromes and low penetrance genes.
Pheochromocytoma
Extracellular Alpha-Synuclein Oligomers Induce Parkin S-Nitrosylation: Relevance to Sporadic Parkinson's Disease Etiopathology.
Phyllodes Tumor
Association of the BRCA1 missense variant R1699W with a malignant phyllodes tumor of the breast.
Early-onset malignant phyllodes breast tumor in a patient with germline pathogenic variants in NF1 and BRCA1 genes.
First description of an acinic cell carcinoma of the breast in a BRCA1 mutation carrier: a case report.
Germline Genetic Mutations in a Multi-center Contemporary Cohort of 550 Phyllodes Tumors: An Opportunity for Expanded Multi-gene Panel Testing.
Pick Disease of the Brain
Aberrant Accumulation of BRCA1 in Alzheimer Disease and Other Tauopathies.
Pituitary Neoplasms
Targeted Inhibition of the E3 Ligase SCFSkp2/Cks1 Has Antitumor Activity in RB1-Deficient Human and Mouse Small-Cell Lung Cancer.
Plague
The Yersinia Type III secretion effector YopM Is an E3 ubiquitin ligase that induced necrotic cell death by targeting NLRP3.
Plant Diseases
The Arabidopsis Botrytis Susceptible1 Interactor Defines a Subclass of RING E3 Ligases that Regulate Pathogen and Stress Responses.
The Chinese wild grapevine (Vitis pseudoreticulata) E3 ubiquitin ligase Erysiphe necator-induced RING finger protein 1 (EIRP1) activates plant defense responses by inducing proteolysis of the VpWRKY11 transcription factor.
Pleural Effusion
A novel Ubc9 -dependent pathway regulates SIRT1- ER-? Axis and BRCA1-associated TNBC lung metastasis.
Cytology material is equivalent to tumor tissue in determining mutations of BRCA 1/2 genes in patients with tubo-ovarian high grade serous carcinoma.
Pneumonia
Blocking of Birc3/TLR4/Myd88 signaling protects carbapenem-resistant klebsiella pneumoniae in a mouse model of infection.
Calmodulin antagonizes a calcium-activated SCF ubiquitin E3 ligase subunit, FBXL2, to regulate surfactant homeostasis.
Dynamic gene expression analysis in a H1N1 influenza virus mouse pneumonia model.
E3 Ligase Subunit Fbxo15 and PINK1 Kinase Regulate Cardiolipin Synthase 1 Stability and Mitochondrial Function in Pneumonia.
Genetic determinants of susceptibility to silver nanoparticle-induced acute lung inflammation in mice.
Itch regulation of innate and adaptive immune responses in mice and humans.
March1 E3 Ubiquitin Ligase Modulates Features of Allergic Asthma in an Ovalbumin-Induced Mouse Model of Lung Inflammation.
The proinflammatory role of HECTD2 in innate immunity and experimental lung injury.
The ubiquitin ligase Cbl-b limits Pseudomonas aeruginosa exotoxin T-mediated virulence.
TRIM65 E3 ligase targets VCAM-1 degradation to limit LPS-induced lung inflammation.
Polycystic Kidney Diseases
Construction of human embryonic cDNA libraries: HD, PKD1 and BRCA1 are transcribed widely during embryogenesis.
Polycystic Kidney, Autosomal Recessive
NEDD4-family E3 ligase dysfunction due to PKHD1/Pkhd1 defects suggests a mechanistic model for ARPKD pathobiology.
Polycystic Ovary Syndrome
Influence of tumour suppressor gene (TP53, BRCA1 and BRCA2) polymorphisms on polycystic ovary syndrome in South Indian women.
Polycythemia
Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia.
Oxygen sensing: recent insights from idiopathic erythrocytosis.
Polycythemia Vera
TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms.
Polyneuropathies
Parkin Pleiotropy: Extremely Atypical Phenotypes in Patients With Compound Heterozygous Mutations.
Porcine Reproductive and Respiratory Syndrome
Autophagy and innate immunity: Insights from invertebrate model organisms.
E3 ligase ASB8 promotes porcine reproductive and respiratory syndrome virus proliferation by stabilizing the viral Nsp1? protein and degrading host IKK? kinase.
Inhibitor of apoptosis (IAP) proteins in regulation of inflammation and innate immunity.
Nuclear localization signal in TRIM22 is essential for inhibition of type 2 porcine reproductive and respiratory syndrome virus replication in MARC-145 cells.
Nucleocapsid protein of porcine reproductive and respiratory syndrome virus antagonizes the antiviral activity of TRIM25 by interfering with TRIM25-mediated RIG-I ubiquitination.
The E3 ubiquitin ligase RNF186 and RNF186 risk variants regulate innate receptor-induced outcomes.
Viral strategies for triggering and manipulating mitophagy.
Pre-Eclampsia
Ceramide-induced BOK promotes mitochondrial fission in preeclampsia.
CLDN1 regulates trophoblast apoptosis and proliferation in preeclampsia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Bioinformatics analysis of gene expression profiles in childhood B-precursor acute lymphoblastic leukemia.
BIRC3 alterations in chronic and B-cell acute lymphocytic leukemia patients.
FBXW7 regulates glucocorticoid response in T-cell acute lymphoblastic leukaemia by targeting the glucocorticoid receptor for degradation.
Response to rotenone is glucose-sensitive in a model of human acute lymphoblastic leukemia: involvement of oxidative stress mechanism, DJ-1, Parkin, and PINK-1 proteins.
Study of methylation levels of parkin gene promoter in Parkinson's disease patients.
The expression and function of E3 ligase SIAH2 in acute T lymphoblastic leukemia.
The notch pathway promotes NF-?B activation through Asb2 in T cell acute lymphoblastic leukemia cells.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Characterization of therapy-related acute leukemia in hereditary breast-ovarian carcinoma patients: role of BRCA1 mutation and topoisomerase II-directed therapy.
Flavone inhibited proliferation of T-ALL by promoting c-Cbl-induced ubiquitinylation and degradation of Notch1.
Frequency of pathogenic/likely pathogenic germline variants in cancer-related genes among children with acute leukemia in Saudi Arabia.
Inhibition of IRAK1/4 sensitizes T cell acute lymphoblastic leukemia to chemotherapies.
Therapeutic targeting of the E3 ubiquitin ligase SKP2 in T-ALL.
Premature Birth
Cellular inhibitors of apoptosis proteins cIAP1 and cIAP2 are increased after labour in foetal membranes and myometrium and are essential for TNF-?-induced expression of pro-labour mediators.
Primary Dysautonomias
Normal cardiovascular reflex testing in patients with parkin disease.
Parkin and PINK1 parkinsonism may represent nigral mitochondrial cytopathies distinct from Lewy body Parkinson's disease.
Primary Myelofibrosis
TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms.
Primary Ovarian Insufficiency
Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks.
Comparison of age at natural menopause in BRCA1/2 mutation carriers with a non-clinic-based sample of women in northern California.
Do BRCA1 and BRCA2 Mutation Carriers Have Earlier Natural Menopause Than Their Noncarrier Relatives? Results From the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer.
Prion Diseases
Absence of Association between Two HECTD2 Polymorphisms and Sporadic Creutzfeldt-Jakob Disease.
HECTD2 is associated with susceptibility to mouse and human prion disease.
Levels of the Mahogunin Ring Finger 1 E3 ubiquitin ligase do not influence prion disease.
MGRN1 mediated ubiquitination of ?-tubulin regulates microtubule dynamics and intracellular transport.
Parkin Overexpression Ameliorates PrP106-126-Induced Neurotoxicity via Enhanced Autophagy in N2a Cells.
Prion topology and toxicity.
Regulation of Mitofusin1 by Mahogunin Ring Finger-1 and the proteasome modulates mitochondrial fusion.
RML prions act through Mahogunin and Attractin-independent pathways.
Ubiquitin-mediated regulation of the E3 ligase GP78 by MGRN1 in trans affects mitochondrial homeostasis.
Progeria
Smurf2 regulates stability and the autophagic-lysosomal turnover of lamin A and its disease-associated form progerin.
Prolactinoma
Giant prolactinoma, germline BRCA1 mutation, and depression: a case report.
Prostatic Neoplasms
5-Aza-2'-deoxycytidine stress response and apoptosis in prostate cancer.
?-Catenin Increases the Stability of EGFR by Decreasing c-Cbl Interaction and Enhances EGFR/Erk1/2 Signaling in Prostate Cancer.
A computational and structural analysis of germline and somatic variants affecting the DDR mechanism, and their impact on human diseases.
A Devastatingly "Minor" Relationship Between Male Breast Cancer and Prostate Cancer.
A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance.
A novel BRCA2 mutation in prostate cancer sensitive to combined radiotherapy and androgen deprivation therapy.
Aberrations of DNA Repair Pathways in Prostate Cancer: Future Implications for Clinical Practice?
Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer.
Absence of truncating BRIP1 mutations in chromosome 17q-linked hereditary prostate cancer families.
Activated Wnt/?-Catenin signaling contributes to E3 ubiquitin ligase EDD-conferred docetaxel resistance in prostate cancer.
AIDIT and IMPACT: building research collaborations in targeted prostate cancer screening.
Akt-mediated phosphorylation of Bmi1 modulates its oncogenic potential, E3 ligase activity, and DNA damage repair activity in mouse prostate cancer.
Allelic loss and microsatellite instability in prostate cancers in Japan.
Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines.
Androgen receptor degradation by the E3 ligase CHIP modulates mitotic arrest in prostate cancer cells.
Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer.
Anti-apoptotic factor Birc3 is up-regulated by ELL2 knockdown and stimulates proliferation in LNCaP cells.
Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing.
Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness.
Association of HO-1 and BRCA1 Is Critical for the Maintenance of Cellular Homeostasis in Prostate Cancer.
Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations.
ATM polymorphisms as risk factors for prostate cancer development.
Aurora B Kinase Promotes CHIP-Dependent Degradation of HIF1? in Prostate Cancer Cells.
Aurora Kinase A Promotes AR Degradation via the E3 Ligase CHIP.
BRCA mutations and risk of prostate cancer in Ashkenazi Jews.
BRCA1 and BRCA2 as molecular targets for phytochemicals indole-3-carbinol and genistein in breast and prostate cancer cells.
BRCA1 and BRCA2 have a limited role in familial prostate cancer.
BRCA1 and BRCA2 mutations among familial breast cancer patients from Costa Rica.
BRCA1 and BRCA2 mutations have no major role in predisposition to prostate cancer in Finland.
BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotype.
BRCA1 and p53 regulate critical prostate cancer pathways.
BRCA1 and prostate cancer.
BRCA1 and VDR gene polymorphisms are associated with prostate cancer risk in Mexican men.
BRCA1 as a potential human prostate tumor suppressor: modulation of proliferation, damage responses and expression of cell regulatory proteins.
BRCA1 gene in breast cancer.
BRCA1 gene mutation and loss of heterozygosity on chromosome 17q21 in primary prostate cancer.
BRCA1 inhibition of estrogen receptor signaling in transfected cells.
BRCA1 interaction with human papillomavirus oncoproteins.
BRCA1 is differentially expressed in human tumor cells.
BRCA1 localization to the telomere and its loss from the telomere in response to DNA damage.
BRCA1 Loss Induces GADD153-Mediated Doxorubicin Resistance in Prostate Cancer.
BRCA1 loss preexisting in small subpopulations of prostate cancer is associated with advanced disease and metastatic spread to lymph nodes and peripheral blood.
BRCA1 mutations and prostate cancer in Poland.
BRCA1 mutations do not increase prostate cancer risk: Results from a meta-analysis including new data.
BRCA1 Versus BRCA2 and PARP Inhibitor Sensitivity in Prostate Cancer: More Different Than Alike?
BRCA1, BRCA2, AR and IGF-I expression in prostate cancer: correlation between RT-qPCR and immunohistochemical detection.
BRCA1-related and sporadic ovarian cancer in the same family: implications for genetic testing.
BRCA2 and Other DDR Genes in Prostate Cancer.
Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores.
Breast cancer in six families from Tolima and Huila: BRCA1 3450del4 mutation
c-Cbl shRNA-expressing adenovirus sensitizes TRAIL-induced apoptosis in prostate cancer DU-145 through increases of DR4/5.
Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications.
Changing face of metastatic prostate cancer: the law of diminishing returns holds true.
Chromosome rearrangement associated inactivation of tumour suppressor genes in prostate cancer.
Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.
Clinical features and management of BRCA1 and BRCA2-associated prostate cancer.
Clinico-pathological significance of the molecular alterations of the SPOP gene in prostate cancer.
Cloning and genomic organization of beclin 1, a candidate tumor suppressor gene on chromosome 17q21.
Coexpression of the mutated BRCA1 mRNA and p53 mRNA and its association in Chinese prostate cancer.
Commentary on "Integrative clinical genomics of advanced prostate cancer". Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM.Cell. 21 May 2015;161(5):1215-1228.
Commentary on "the E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity." Qi J, Tripathi M, Mishra R, Sahgal N, Fazli L, Ettinger S, Placzek WJ, Claps G, Chung LW, Bowtell D, Gleave M, Bhowmick N, Ronai ZA, Signal Transduction Program, Cancer Center, Sanford-Burnham Medical Research Institute, La Jolla, CA, USA.: Cancer Cell 2013;23(6):332-46.
Common mutations in BRCA1 and BRCA2 do not contribute to early prostate cancer in Jewish men.
Common variation in BRCA1 may have a role in progression to lethal prostate cancer after radiation treatment.
Common variation in the BRCA1 gene and prostate cancer risk.
Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer.
Constitutive activation of JAK-STAT3 signaling by BRCA1 in human prostate cancer cells.
Consulting prostate cancer cohort data uncovers transcriptional control: Regulation of the MARCH6 gene.
Coordinate alterations in the expression of BRCA1, BRCA2, p300, and Rad51 in response to genotoxic and other stresses in human prostate cancer cells.
Corrigendum to "Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study" [Eur Urol 2014;66:489-99].
Cyclin D1 antagonizes BRCA1 repression of estrogen receptor alpha activity.
Depletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis.
Designed, synthesized and biological evaluation of proteolysis targeting chimeras (PROTACs) as AR degraders for prostate cancer treatment.
Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants.
Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations.
Disruption of BRCA1 LXCXE motif alters BRCA1 functional activity and regulation of RB family but not RB protein binding.
DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities.
Dynamic Coregulatory Complex Containing BRCA1, E2F1 and CtIP Controls ATM Transcription.
E3 ubiquitin ligase RNF126 promotes cancer cell proliferation by targeting the tumor suppressor p21 for ubiquitin-mediated degradation.
Elevated expression of Ki-67 identifies aggressive prostate cancers but does not distinguish BRCA1 or BRCA2 mutation carriers.
Evidence for a tumor suppressor gene distal to BRCA1 in prostate cancer.
Evidence of independent origin of multiple tumors from patients with prostate cancer.
Expression of androgen receptor coregulators in prostate cancer.
Ezrin ubiquitylation by the E3 ubiquitin ligase, WWP1, and consequent regulation of hepatocyte growth factor receptor activity.
FAM35A/SHLD2/RINN2: A novel determinant of double strand break repair pathway choice and genome stability in cancer.
Family studies and the evidence for genetic susceptibility to prostate cancer.
Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
Functional Link between BRCA1 and BAP1 through Histone H2A, Heterochromatin and DNA Damage Response.
Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array.
Genetic analysis of eight breast-ovarian cancer families with suspected BRCA1 mutations.
Genetic biomarkers to guide poly(ADP-ribose) polymerase inhibitor precision treatment of prostate cancer.
Genome-wide scan for prostate cancer susceptibility genes using families from the University of Michigan prostate cancer genetics project finds evidence for linkage on chromosome 17 near BRCA1.
Germ-line BRCA1 mutations in selected men with prostate cancer.
Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.
Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.
Germline BRCA1 Mutation and Prostate Cancer: Be Careful on Causality.
Germline BRCA1 mutations increase prostate cancer risk.
Germline Mutations in DNA Repair Genes in Patients With Metastatic Castration-resistant Prostate Cancer.
Germline mutations of BRCA1 and BRCA2 genes in Turkish breast, ovarian, and prostate cancer patients.
High Skp2 expression is associated with a mesenchymal phenotype and increased tumorigenic potential of prostate cancer cells.
Histone H2B ubiquitin ligases RNF20 and RNF40 in androgen signaling and prostate cancer cell growth.
Hormone-Dependent Prostate Cancers are Dependent on Rac Signaling for Growth and Survival.
Human PIRH2 enhances androgen receptor signaling through inhibition of histone deacetylase 1 and is overexpressed in prostate cancer.
Identification of
Immunohistochemical expression of BRCA1 and lethal prostate cancer.
Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells.
Increased cancer risks for relatives of very early-onset breast cancer cases with and without BRCA1 and BRCA2 mutations.
Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population.
Increased risk of male cancer and identification of a potential prostate cancer cluster region in BRCA2.
Insights into the targeted elimination of BRCA1-defective cancer stem cells.
Integrative clinical genomics of advanced prostate cancer.
Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation.
Is olaparib cost effective in metastatic castration-resistant prostate cancer patients with at least one favorable gene mutation in BRCA1, BRCA2 or ATM?
Large genomic rearrangement in BRCA1 and BRCA2 and clinical characteristics of men with breast cancer in the United States.
Localization of potential tumor suppressor loci to a < 2 Mb region on chromosome 17q in human prostate cancer.
Long Noncoding RNA Small Nucleolar RNA Host Gene 3 Mediates Prostate Cancer Migration, Invasion, and Epithelial-Mesenchymal Transition by Sponging miR-487a-3p to Regulate TRIM25.
Loss of heterozygosity at the BRCA2 locus detected by multiplex ligation-dependent probe amplification is common in prostate cancers from men with a germline BRCA2 mutation.
Loss of heterozygosity of the BRCA1 and other loci on chromosome 17q in human prostate cancer.
Male BRCA1 and BRCA2 mutation carriers: a pilot study investigating medical characteristics of patients participating in a prostate cancer prevention clinic.
Management of a Prostate Cancer Patient With Inherited Germline BRCA1 and BRCA2 Mutations: A Case Report.
Microelectronic DNA assay for the detection of BRCA1 gene mutations.
MicroRNA-1301 suppresses tumor cell migration and invasion by targeting the p53/UBE4B pathway in multiple human cancer cells.
Missense alterations of BRCA1 gene detected in diverse cancer patients.
Mitochondrial localization, ELK-1 transcriptional regulation and growth inhibitory functions of BRCA1, BRCA1a, and BRCA1b proteins.
Mutant BRCA1 genes antagonize phenotype of wild-type BRCA1.
Mutated SPOP E3 Ligase Promotes 17?HSD4 Protein Degradation to Drive Androgenesis and Prostate Cancer Progression.
Mutations in BRCA1 and BRCA2 and predisposition to prostate cancer.
Mutations in BRCA2 and taxane resistance in prostate cancer.
Mutations of the BRCA1 and BRCA2 genes and the possibilities for predictive testing.
Next-generation sequencing of BRCA1 and BRCA2 genes in Moroccan prostate cancer patients with positive family history.
Niraparib Shrinks BRCA-Mutated Prostate Tumors.
No evidence for a role of BRCA1 or BRCA2 mutations in Ashkenazi Jewish families with hereditary prostate cancer.
NRIP/DCAF6 stabilizes the androgen receptor protein by displacing DDB2 from the CUL4A-DDB1 E3 ligase complex in prostate cancer.
Olaparib and rucaparib for the treatment of DNA repair-deficient metastatic castration-resistant prostate cancer.
Olaparib effective in four advanced cancers.
Olaparib shows promise in multiple tumor types.
Optimizing recruitment to a prostate cancer surveillance program among male BRCA1 mutation carriers: invitation by mail or by telephone.
Overexpression of RAD51 occurs in aggressive prostatic cancer.
Overexpression of the TRIM24 E3 Ubiquitin Ligase is Linked to Genetic Instability and Predicts Unfavorable Prognosis in Prostate Cancer.
p21-Activated kinase 6 (PAK6) inhibits prostate cancer growth via phosphorylation of androgen receptor and tumorigenic E3 ligase murine double minute-2 (Mdm2).
p300 Modulates the BRCA1 inhibition of estrogen receptor activity.
Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity.
PARP Inhibitors in Clinical Use Induce Genomic Instability in Normal Human Cells.
Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial.
Poly(ADP-Ribose) Polymerase Inhibitors in Prostate Cancer: Molecular Mechanisms, and Preclinical and Clinical Data.
Potential excess mortality in BRCA1/2 mutation carriers beyond breast, ovarian, prostate, and pancreatic cancers, and melanoma.
Predicting high risk disease using serum and DNA biomarkers.
Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores.
Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer.
Prevalence and patterns of self-initiated nutritional supplementation in men at high risk of prostate cancer.
Prevalent mutations in prostate cancer.
Prevention and Screening in Hereditary Breast and Ovarian Cancer.
Prognostic value of inhibitors of apoptosis proteins (IAPs) and caspases in prostate cancer: caspase-3 forms and XIAP predict biochemical progression after radical prostatectomy.
Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype.
Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study.
Prostate Cancer Screening in a New Era of Genetics.
Prostate Cancer-associated SPOP mutations enhance cancer cell survival and docetaxel resistance by upregulating Caprin1-dependent stress granule assembly.
Prostate cancer-associated SPOP mutations lead to genomic instability through disruption of the SPOP-HIPK2 axis.
Prostate cancer: germline prediction for a commonly variable malignancy.
Prostate screening uptake in Australian BRCA1 and BRCA2 carriers.
Proteotranscriptomic measurements of E6-Associated Protein (E6AP) targets in DU145 prostate cancer cells.
Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations.
Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics.
Rapid progression of prostate cancer in men with a BRCA2 mutation.
Re: akt-mediated phosphorylation of Bmi1 modulates its oncogenic potential, e3 ligase activity, and DNA damage repair activity in mouse prostate cancer.
Re: Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness.
Re: Catherine H. Marshall, Alexandra O. Sokolova, Andrea L. McNatty, et al. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. Eur Urol 2019;76:452-8.
Re: p21-Activated Kinase 6 (PAK6) Inhibits Prostate Cancer Growth via Phosphorylation of Androgen Receptor and Tumorigenic E3 Ligase Murine Double Minute-2 (Mdm2).
Re: Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study.
Recessive oncogenes: current status.
Redox regulation in cancer: a double-edged sword with therapeutic potential.
Relevance of DNA damage repair in the management of prostate cancer.
Restoration of tumor suppression in prostate cancer by targeting the E3 ligase E6AP.
Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations.
Role of direct interaction in BRCA1 inhibition of estrogen receptor activity.
Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk men.
Role of RNF20 in cancer development and progression - a comprehensive review.
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration.
Selected aspects of inherited susceptibility to prostate cancer and tumours of different site of origin.
SEOM clinical guidelines for the treatment of advanced prostate cancer (2020).
Silencing of PMEPA1 accelerates the growth of prostate cancer cells through AR, NEDD4 and PTEN.
Somatic aberrations of BRCA1 gene are associated with ALDH1, EGFR, and tumor progression in prostate cancer.
Soy phytoestrogens modify DNA methylation of GSTP1, RASSF1A, EPH2 and BRCA1 promoter in prostate cancer cells.
SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG.
SPOP promotes CDCA5 degradation to regulate prostate cancer progression via the AKT pathway.
Structure and expression of variant BRCA2a lacking the transactivation domain.
Suppression of malignant phenotype in a human prostate cancer cell line by fragments of normal chromosomal region 17q.
Survey of differentially methylated promoters in prostate cancer cell lines.
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.
TAGLN Is Downregulated by TRAF6-Mediated Proteasomal Degradation in Prostate Cancer Cells.
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study.
Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study.
Targeting ADT-Induced Activation of the E3 Ubiquitin Ligase Siah2 to Delay the Occurrence of Castration-Resistant Prostate Cancer.
Targeting PARP in Prostate Cancer: Novelty, Pitfalls, and Promise.
TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer.
TGF-? signaling regulates SPOP expression and promotes prostate cancer cell stemness.
The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation.
The anti-proliferative effects of 1alpha,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression.
The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis.
The BIRC6 gene as a novel target for therapy of prostate cancer: dual targeting of inhibitors of apoptosis.
The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer.
The emerging role of PARP inhibitors in prostate cancer.
The ErbB family and androgen receptor signaling are targets of Celecoxib in prostate cancer.
The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators.
The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib.
The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer.
The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel.
The resounding effect of DNA repair deficiency in prostate cancer.
The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.
The Role of BRCA Testing in Hereditary Pancreatic and Prostate Cancer Families.
The role of BRCA1 and BRCA2 in prostate cancer.
The SPOP-ITCH Signaling Axis Protects Against Prostate Cancer Metastasis.
The ubiquitin ligase TRIM25 targets ERG for degradation in prostate cancer.
The ubiquitin ligase UBE4A inhibits prostate cancer progression by targeting interleukin-like EMT inducer (ILEI).
Therapeutic opportunities for PLK1 inhibitors: Spotlight on BRCA1-deficiency and triple negative breast cancers.
Thiazolidinediones modulate the expression of beta-catenin and other cell-cycle regulatory proteins by targeting the F-box proteins of Skp1-Cul1-F-box protein E3 ubiquitin ligase independently of peroxisome proliferator-activated receptor gamma.
TRAF4-mediated ubiquitination of NGF receptor TrkA regulates prostate cancer metastasis.
TRIM25 enhances cell growth and cell survival by modulating p53 signals via interaction with G3BP2 in prostate cancer.
TRIM28 protects TRIM24 from SPOP-mediated degradation and promotes prostate cancer progression.
TRIM68 regulates ligand-dependent transcription of androgen receptor in prostate cancer cells.
Truncating BRCA1 mutations are uncommon in a cohort of hereditary prostate cancer families with evidence of linkage to 17q markers.
Tumor protein expression of the DNA repair gene BRCA1 and lethal prostate cancer.
Tumor suppressor BRCA1 is expressed in prostate cancer and controls insulin-like growth factor I receptor (IGF-IR) gene transcription in an androgen receptor-dependent manner.
Tumor suppressor SPOP ubiquitinates and degrades EglN2 to compromise growth of prostate cancer cells.
Ubiquitin E3 ligase WWP1 as an oncogenic factor in human prostate cancer.
Ubiquitin-specific protease 14 promotes prostate cancer progression through deubiquitinating the transcriptional factor ATF2.
Ubiquitylation of epsilon-COP by PIRH2 and regulation of the secretion of PSA.
Urological cancer related to familial syndromes.
Zinc sensitizes prostate cancer cells to sorafenib and regulates the expression of Livin.
[Current clinical issues and recent trends in hereditary breast and ovarian cancer in Japan-genetic testing for HBOC and risk-reducing surgery].
[DNA damage induces BRCA1 distribution alteration in prostate cancer cell lines]
[Hereditary Breast and Ovarian Cancer Syndrome].
[Recent advances on molecular pathology of prostate carcinoma]
protein acetyllysine n-acetyltransferase deficiency
SIRT3 deficiency exacerbates p53/Parkin?mediated mitophagy inhibition and promotes mitochondrial dysfunction: Implication for aged hearts.
Protein Deficiency
Parkin protein deficiency exacerbates cardiac injury and reduces survival following myocardial infarction.
protein-serine/threonine phosphatase deficiency
Phosphoglycerate Mutase 5 Knockdown Alleviates Neuronal Injury After Traumatic Brain Injury Through Drp1-Mediated Mitochondrial Dysfunction.
Pruritus
Regulation of T cell differentiation and allergic responses by the E3 ubiquitin ligase itch.
Pseudohypoaldosteronism
Decrease of WNK4 ubiquitination by disease-causing mutations of KLHL3 through different molecular mechanisms.
Involvement of selective autophagy mediated by p62/SQSTM1 in KLHL3-dependent WNK4 degradation.
Kelch-Like Protein 2 Mediates Angiotensin II-With No Lysine 3 Signaling in the Regulation of Vascular Tonus.
Pseudomyxoma Peritonei
Molecular and clinicopathological features of appendiceal mucinous neoplasms.
Psoriasis
E3 Ligase Trim21 Ubiquitylates and Stabilizes Keratin 17 to Induce STAT3 Activation in Psoriasis.
Targeting TRAF6 E3 ligase activity with a small-molecule inhibitor combats autoimmunity.
Trim21 promotes inflammation in keratinocytes of psoriatic patients.
Puberty, Precocious
Papers to appear in forthcoming issues
Pulmonary Arterial Hypertension
Inhibition of Siah2 ubiquitin ligase ameliorates monocrotaline-induced pulmonary arterial remodeling through inactivation of YAP.
Pulmonary Disease, Chronic Obstructive
CUL1-Mediated Organelle Fission Pathway Inhibits the Development of Chronic Obstructive Pulmonary Disease.
Impaired mitophagy leads to cigarette smoke stress-induced cellular senescence: implications for chronic obstructive pulmonary disease.
Is mitochondrial dysfunction a driving mechanism linking COPD to nonsmall cell lung carcinoma?
MicroRNA miR-24-3p reduces DNA damage responses, apoptosis, and susceptibility to chronic obstructive pulmonary disease.
Molecular signalling towards mitochondrial breakdown is enhanced in skeletal muscle of patients with chronic obstructive pulmonary disease (COPD).
Multiple-level validation identifies PARK2 in the development of lung cancer and chronic obstructive pulmonary disease.
Organelle-specific autophagy in inflammatory diseases: a potential therapeutic target underlying the quality control of multiple organelles.
PRKN-regulated mitophagy and cellular senescence during COPD pathogenesis.
TRAIL signals through the ubiquitin ligase MID1 to promote pulmonary fibrosis.
Pulmonary Fibrosis
Cyclosporine attenuates Paraquat-induced mitophagy and pulmonary fibrosis.
Inhibiting Skp2 E3 Ligase Suppresses Bleomycin-Induced Pulmonary Fibrosis.
Molecular Pathogenesis of Pulmonary Fibrosis, with Focus on Pathways Related to TGF-? and the Ubiquitin-Proteasome Pathway.
Multi?layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/??catenin signaling activation (Review).
Rectal Neoplasms
BRCA1-related malignancies in a family presenting with von Recklinghausen's disease.
Rectal Prolapse
Gut Microbiota Contributes to Spontaneous Colitis in E3 Ligase Itch-Deficient Mice.
Reflex, Abnormal
Parkin deletions in a family with adult-onset, tremor-dominant parkinsonism: expanding the phenotype.
Parkin is the most common causative gene in a cohort of mainland Chinese patients with sporadic early-onset Parkinson's disease.
REM Sleep Behavior Disorder
Rapid eye movement sleep behavior disorder in parkinsonism with parkin mutations.
Restless legs syndrome, rapid eye movement sleep behavior disorder, and hypersomnia in patients with two parkin mutations.
Renal Insufficiency
eIF3-f function in skeletal muscles: to stand at the crossroads of atrophy and hypertrophy.
Renal Insufficiency, Chronic
Genome-wide gene expression array identifies novel genes related to disease severity and excessive daytime sleepiness in patients with obstructive sleep apnea.
Reoviridae Infections
The E3 Ubiquitin Ligase Siah-1 Suppresses Avian Reovirus Infection by Targeting p10 for Degradation.
Reperfusion Injury
c-Cbl inhibition: A novel therapeutic approach for attenuating myocardial ischemia and reperfusion injury.
Clearance of damaged mitochondria via mitophagy is important to the protective effect of ischemic preconditioning in kidneys.
Ginaton improves neurological function in ischemic stroke rats via inducing autophagy and maintaining mitochondrial homeostasis.
Into the heart: The emerging role of the ubiquitin-proteasome system.
Respiratory Distress Syndrome
Close Relationship between cIAP2 and Human ARDS Induced by Severe H7N9 Infection.
Respiratory Insufficiency
TRAF2 Is a Novel Ubiquitin E3 Ligase for the Na,K-ATPase ?-Subunit That Drives Alveolar Epithelial Dysfunction in Hypercapnia.
Restless Legs Syndrome
Co-occurrence of restless legs syndrome and Parkin mutations in two families.
Parkin gene modifies the effect of RLS4 on the age at onset of restless legs syndrome (RLS).
Restless legs syndrome, rapid eye movement sleep behavior disorder, and hypersomnia in patients with two parkin mutations.
Retinal Degeneration
A Mouse Model of Retinal Recovery From Photo-Oxidative/Photo-Inflammatory Injury: Nrf2, SOD1, DJ-1, and Parkin Are Not Essential to Recovery.
Mice With a Combined Deficiency of Superoxide Dismutase 1 (Sod1), DJ-1 (Park7), and Parkin (Prkn) Develop Spontaneous Retinal Degeneration With Aging.
Mutant alpha-synuclein-induced degeneration is reduced by parkin in a fly model of Parkinson's disease.
PINK1 and Parkin cooperatively protect neurons against constitutively active TRP channel-induced retinal degeneration in Drosophila.
Retinal Neovascularization
A role for protein ubiquitination in VEGFR-2 signalling and angiogenesis.
c-Cbl inhibits angiogenesis and tumor growth by suppressing activation of PLC?1.
Retinitis Pigmentosa
Diverse mechanisms of autophagy dysregulation and their therapeutic implications: does the shoe fit?
Retinoblastoma
A Novel Retinoblastoma Protein (RB) E3 Ubiquitin Ligase (NRBE3) Promotes RB Degradation and Is Transcriptionally Regulated by E2F1 Transcription Factor.
Allelic loss of the BRCA1 and BRCA2 genes and other regions on 17q and 13q in breast cancer among women from Taiwan (area of low incidence but early onset).
Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins.
BRCA1 effects on the cell cycle and the DNA damage response are linked to altered gene expression.
BRCA1 overexpression sensitizes cancer cells to lovastatin via regulation of cyclin D1-CDK4-p21WAF1/CIP1 pathway: analyses using a breast cancer cell line and tumoral xenograft model.
BRCA1-Mediated Ubiquitination Inhibits Topoisomerase IIalpha Activity in Response to Oxidative Stress.
CDC-25.2, a C. elegans ortholog of cdc25, is essential for the progression of intestinal divisions.
Cyclin D1 antagonizes BRCA1 repression of estrogen receptor alpha activity.
Differential regulation of cardiomyocyte survival and hypertrophy by MDM2, an E3 ubiquitin ligase.
Disruption of BRCA1 LXCXE motif alters BRCA1 functional activity and regulation of RB family but not RB protein binding.
Epstein-Barr virus nuclear antigen 3C augments Mdm2-mediated p53 ubiquitination and degradation by deubiquitinating Mdm2.
Expression and function of retinoblastoma binding protein 6 (RBBP6) in human lung cancer.
Hereditary common cancers: molecular and clinical genetics.
Histological groups of human postpubertal testicular germ cell tumours harbour different genetic alterations.
Human CtIP: A 'double agent' in DNA repair and tumorigenesis.
Identification and management of inherited cancer susceptibility.
MicroRNA-154-5p regulates the HPV16 E7-pRb pathway in Cervical Carcinogenesis by targeting CUL2.
Nuclear tumor suppressors in space and time.
On the dynamics of breast tumor development in women carrying germline BRCA1 and BRCA2 mutations.
Preimplantation genetic diagnosis (PGD) for heritable neoplasia.
Prognostic value of CtIP/RBBP8 expression in breast cancer.
Retinoblastoma protein and anaphase-promoting complex physically interact and functionally cooperate during cell-cycle exit.
Retinoblastoma susceptibility protein, Rb, possesses multiple BRCT-Ws, BRCA1 carboxyl-terminus-related W regions with DNA break-binding activity.
The crystal structure of gankyrin, an oncoprotein found in complexes with cyclin-dependent kinase 4, a 19 S proteasomal ATPase regulator, and the tumor suppressors Rb and p53.
The E2F1/Rb and p53/MDM2 pathways in DNA repair and apoptosis: understanding the crosstalk to develop novel strategies for prostate cancer radiotherapy.
[Mechanisms of high-risk human papillomavirus-induced cervical carcinogenesis]
Retroviridae Infections
A rare null allele potentially encoding a dominant-negative TRIM5alpha protein in Baka pygmies.
A retrovirus restriction factor TRIM5alpha is transcriptionally regulated by interferons.
A TRIM5alpha exon 2 polymorphism is associated with protection from HIV-1 infection in the Pumwani sex worker cohort.
Adaptive evolution of primate TRIM5alpha, a gene restricting HIV-1 infection.
Anti-retroviral activity of TRIM5 alpha.
Comparative requirements for the restriction of retrovirus infection by TRIM5alpha and TRIMCyp.
Nonhuman TRIM5 Variants Enhance Recognition of HIV-1-Infected Cells by CD8+ T Cells.
Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha.
Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor.
TRIM5 Acts as More Than a Retroviral Restriction Factor.
TRIM5 structure, HIV-1 capsid recognition, and innate immune signaling.
[Advances of TRIM5alpha on retrovirus infection restriction]
Rift Valley Fever
Protein Kinase R Degradation Is Essential for Rift Valley Fever Virus Infection and Is Regulated by SKP1-CUL1-F-box (SCF)FBXW11-NSs E3 Ligase.
TRIM69 inhibits Vesicular Stomatitis Indiana Virus (VSIV).
ring-type e3 ubiquitin transferase deficiency
53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers.
A dual role of BRCA1 in two distinct homologous recombination mediated repair in response to replication arrest.
A mammary-specific, long-range deletion on mouse chromosome 11 accelerates Brca1-associated mammary tumorigenesis.
A mouse model of basal-like breast carcinoma with metaplastic elements.
A porcine model system of BRCA1 driven breast cancer.
A portable BRCA1-HAC (human artificial chromosome) module for analysis of BRCA1 tumor suppressor function.
A role for BRCA1 in uterine leiomyosarcoma.
A selective requirement for 53BP1 in the biological response to genomic instability induced by Brca1 deficiency.
Absence of full-length Brca1 sensitizes mice to oxidative stress and carcinogen-induced tumorigenesis in the esophagus and forestomach.
Absence of the full-length breast cancer-associated gene-1 leads to increased expression of insulin-like growth factor signaling axis members.
Activation of estrogen signaling pathways collaborates with loss of Brca1 to promote development of ERalpha-negative and ERalpha-positive mammary preneoplasia and cancer.
Akt1 inhibits homologous recombination in Brca1-deficient cells by blocking the Chk1-Rad51 pathway.
Akt2 ablation prolongs life span and improves myocardial contractile function with adaptive cardiac remodeling: role of Sirt1-mediated autophagy regulation.
Altered Hippocampal Synaptic Physiology in Aged Parkin-Deficient Mice.
Alternative splicing generates different parkin protein isoforms: evidences in human, rat, and mouse brain.
Applying the RatWalker System for Gait Analysis in a Genetic Rat Model of Parkinson's Disease.
ATM-Chk2-p53 activation prevents tumorigenesis at an expense of organ homeostasis upon Brca1 deficiency.
BECN1 and BRCA1 Deficiency Sensitizes Ovarian Cancer to Platinum Therapy and Confers Better Prognosis.
Biallelic variants in BRCA1 gene cause a recognisable phenotype within chromosomal instability syndromes reframed as BRCA1 deficiency.
Bioactive food components prevent carcinogenic stress via Nrf2 activation in BRCA1 deficient breast epithelial cells.
BRACking news on triple-negative/basal-like breast cancers: how BRCA1 deficiency may result in the development of a selective tumor subtype.
BRCA1 affects global DNA methylation through regulation of DNMT1.
BRCA1 and BRCA2 tumor suppressors in neural crest cells are essential for craniofacial bone development.
BRCA1 and implications for response to chemotherapy in ovarian cancer.
BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells.
BRCA1 contributes to cell cycle arrest and chemoresistance in response to the anticancer agent irofulven.
BRCA1 controls the cell division axis and governs ploidy and phenotype in human mammary cells.
BRCA1 deficiency and synthetic lethality in leukemias; not only gene mutation matters.
Brca1 deficiency causes bone marrow failure and spontaneous hematologic malignancies in mice.
BRCA1 DEFICIENCY EXACERBATES ESTROGEN INDUCED DNA DAMAGE AND GENOMIC INSTABILITY.
BRCA1 Deficiency Impairs Mitophagy and Promotes Inflammasome Activation and Mammary Tumor Metastasis.
BRCA1 deficiency in ovarian cancer is associated with alteration in expression of several key regulators of cell motility - A proteomics study.
BRCA1 deficiency in skin epidermis leads to selective loss of hair follicle stem cells and their progeny.
BRCA1 deficiency increases the sensitivity of ovarian cancer cells to auranofin.
BRCA1 deficiency induces protective autophagy to mitigate stress and provides a mechanism for BRCA1 haploinsufficiency in tumorigenesis.
BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation.
Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities.
BRCA1 deficiency sensitizes breast cancer cells to bromodomain and extra-terminal domain (BET) inhibition.
BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents.
BRCA1 deficient Mouse Models to Study Pathogenesis and Therapy of Triple Negative Breast Cancer.
BRCA1 Expression by Immunohistochemistry and Prognosis in Ovarian Cancer: A Systematic Review and Meta-Analysis.
BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells.
BRCA1 Haploinsufficiency Is Masked by RNF168-Mediated Chromatin Ubiquitylation.
BRCA1 induces antioxidant gene expression and resistance to oxidative stress.
BRCA1 is a negative modulator of the PRC2 complex.
BRCA1 is required for meiotic spindle assembly and spindle assembly checkpoint activation in mouse oocytes.
BRCA1 loss activates cathepsin L-mediated degradation of 53BP1 in breast cancer cells.
BRCA1 Mutation: A Predictive Marker for Radiation Therapy?
BRCA1 participates in DNA decatenation.
BRCA1 positively regulates FOXO3 expression by restricting FOXO3 gene methylation and epigenetic silencing through targeting EZH2 in breast cancer.
BRCA1 represses DNA replication initiation through antagonizing estrogen signaling and maintains genome stability in parallel with WEE1-MCM2 signaling during pregnancy.
BRCA1 role in the mitigation of radiotoxicity and chromosomal instability through repair of clustered DNA lesions.
BRCA1 tumour suppression occurs via heterochromatin-mediated silencing.
BRCA1, a potential predictive biomarker in the treatment of breast cancer.
BRCA1-associated R-loop affects transcription and differentiation in breast luminal epithelial cells.
BRCA1-associated structural variations are a consequence of polymerase theta-mediated end-joining.
BRCA1-Dependent Translational Regulation in Breast Cancer Cells.
BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution.
Brcal required for T cell lineage development but not TCR loci rearrangement.
Breast cancer 1 (BRCA1)-deficient embryos develop normally but are more susceptible to ethanol-initiated DNA damage and embryopathies.
c-Cbl deficiency leads to diminished lymphocyte development and functions in an age-dependent manner.
Cellular inhibitor of apoptosis proteins prevent clearance of hepatitis B virus.
Characterization of a Cul9-Parkin double knockout mouse model for Parkinson's disease.
Class I histone deacetylase inhibition is synthetic lethal with BRCA1 deficiency in breast cancer cells.
Clinicopathological and molecular characteristics of Ku 70/80 expression in Nigerian breast cancer and its potential therapeutic implications.
Clinicopathological and molecular significance of Sumolyation marker (ubiquitin conjugating enzyme 9 (UBC9)) expression in breast cancer of black women.
Collaboration of Brca1 and Chk2 in tumorigenesis.
Complex I deficiency and dopaminergic neuronal cell loss in parkin-deficient zebrafish (Danio rerio).
Compromised Fanconi anemia response due to BRCA1 deficiency in cisplatin-sensitive head and neck cancer cell lines.
Conditional inactivation of Brca1, p53 and Rb in mouse ovaries results in the development of leiomyosarcomas.
Considerations regarding the etiology and future treatment of autosomal recessive versus idiopathic Parkinson disease.
Cytoskeletal Alterations and Biomechanical Properties of parkin-Mutant Human Primary Fibroblasts.
Decapping protein EDC4 regulates DNA repair and phenocopies BRCA1.
Decline of striatal dopamine release in parkin-deficient mice shown by ex vivo autoradiography.
Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase.
Deficiency of parkin and PINK1 impairs age-dependent mitophagy in Drosophila.
Deficiency of parkin suppresses melanoma tumor development and metastasis through inhibition of MFN2 ubiquitination.
Development of a Bioluminescent BRCA1-Deficient Xenograft Model of Disseminated, High-Grade Serous Ovarian Cancer.
Downregulation of stromal BRCA1 drives breast cancer tumor growth via upregulation of HIF-1?, autophagy and ketone body production.
DSB repair pathway choice is regulated by recruitment of 53BP1 through cell cycle-dependent regulation of Sp1.
Dysregulation of the BRCA1/long non-coding RNA NEAT1 signaling axis contributes to breast tumorigenesis.
Dysregulation of the centrosome induced by BRCA1 deficiency contributes to tissue-specific carcinogenesis.
E2F3b over-expression in ovarian carcinomas and in BRCA1 Haploinsufficient fallopian tube epithelium.
E3 ligase c-Cbl regulates intestinal inflammation through suppressing fungi-induced noncanonical NF-?B activation.
E3 ligase TRIM25 ubiquitinates RIP3 to inhibit TNF induced cell necrosis.
Ectopic RNF168 expression promotes break-induced replication-like DNA synthesis at stalled replication forks.
Elevated level of 8-oxo-7,8-dihydro-2'-deoxyguanosine in leukocytes of BRCA1 mutation carriers compared to healthy controls.
Elevated TRAF2/6 expression in Parkinson's disease is caused by the loss of Parkin E3 ligase activity.
Elucidating the novel BRCA1 function as a non-genomic metabolic restraint in ER-positive breast cancer cell lines.
Extended lifespan of Drosophila parkin mutants through sequestration of redox-active metals and enhancement of anti-oxidative pathways.
FOXA1 repression is associated with loss of BRCA1 and increased promoter methylation and chromatin silencing in breast cancer.
Functional Interaction of BRCA1 and CREBBP in Murine Hematopoiesis.
Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors.
Glial dysfunction in parkin null mice: effects of aging.
Haploinsufficiency of Parp1 accelerates Brca1-associated centrosome amplification, telomere shortening, genetic instability, apoptosis, and embryonic lethality.
High frequency of allelic loss at the BRCA1 locus in ovarian cancers: clinicopathologic and molecular associations.
High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Human ITCH E3 ubiquitin ligase deficiency causes syndromic multisystem autoimmune disease.
Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer.
Identification of BRCA1 Deficiency Using Multi-Analyte Estimation of BRCA1 and Its Repressors in FFPE Tumor Samples from Patients with Triple Negative Breast Cancer.
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors.
Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors.
Impaired in vivo dopamine release in parkin knockout mice.
Inactivation of c-Cbl or Cbl-b differentially affects signaling from the high affinity IgE receptor.
Inactivation of parkin by promoter methylation correlated with lymph node metastasis and genomic instability in nasopharyngeal carcinoma.
Increased vulnerability of parkin knock down PC12 cells to hydrogen peroxide toxicity: the role of salsolinol and NM-salsolinol.
Influence of BRCA1 Germline Mutations in the Somatic Mutational Burden of Triple-Negative Breast Cancer.
Invasion patterns of metastatic high-grade serous carcinoma of ovary or fallopian tube associated with BRCA deficiency.
ITCH deficiency protects from diet-induced obesity.
Loss of parkin promotes lipid rafts-dependent endocytosis through accumulating caveolin-1: implications for Parkinson's disease.
Lysosomal perturbations in human dopaminergic neurons derived from induced pluripotent stem cells with PARK2 mutation.
Mex3c regulates insulin-like growth factor 1 (IGF1) expression and promotes postnatal growth.
Mitochondrial contagion induced by Parkin deficiency in Drosophila hearts and its containment by suppressing mitofusin.
Mitochondrial function and morphology are impaired in parkin-mutant fibroblasts.
Modulation of aromatase expression by BRCA1: a possible link to tissue-specific tumor suppression.
Molecular analysis reveals heterogeneity of mouse mammary tumors conditionally mutant for Brca1.
Molecular characteristics and prognostic features of breast cancer in Nigerian compared with UK women.
Molecular phenotypes in triple negative breast cancer from African American patients suggest targets for therapy.
Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells.
MYC overexpression and poor prognosis in sporadic breast cancer with BRCA1 deficiency.
Negative feedback loop of BRCA1-BARD1 ubiquitin ligase on estrogen receptor alpha stability and activity antagonized by cancer-associated isoform of BARD1.
Negative Regulation of AKT Activation by BRCA1.
NOTCH1 activation compensates BRCA1 deficiency and promotes triple-negative breast cancer formation.
Opportunities and hurdles in the treatment of BRCA1-related breast cancer.
Ovarian cancer genome.
p53 suppresses hyper-recombination by modulating BRCA1 function.
Pancreatic Ductal Organoids React Kras Dependent to the Removal of Tumor Suppressive Roadblocks.
Parkin absence accelerates microtubule aging in dopaminergic neurons.
Parkin as a tumor suppressor gene for hepatocellular carcinoma.
Parkin deficiency accelerates consequences of mitochondrial DNA deletions and Parkinsonism.
Parkin deficiency accentuates chronic alcohol intake-induced tissue injury and autophagy defects in brain, liver and skeletal muscle.
Parkin Deficiency Appears Not to Be Associated with Cardiac Damage in Parkinson's Disease.
Parkin deficiency contributes to pancreatic tumorigenesis by inducing spindle multipolarity and misorientation.
Parkin deficiency delays motor decline and disease manifestation in a mouse model of synucleinopathy.
Parkin deficiency disrupts calcium homeostasis by modulating phospholipase C signalling.
Parkin deficiency elevates hepatic ischemia/reperfusion injury accompanying decreased mitochondrial autophagy, increased apoptosis, impaired DNA damage repair and altered cell cycle distribution.
Parkin deficiency exacerbate ethanol-induced dopaminergic neurodegeneration by P38 pathway dependent inhibition of autophagy and mitochondrial function.
Parkin deficiency increases the resistance of midbrain neurons and glia to mild proteasome inhibition: the role of autophagy and glutathione homeostasis.
Parkin deficiency increases vulnerability to inflammation-related nigral degeneration.
Parkin deficiency modulates NLRP3 inflammasome activation by attenuating an A20-dependent negative feedback loop.
Parkin deficiency perturbs striatal circuit dynamics.
Parkin deficiency prevents chronic ethanol-induced hepatic lipid accumulation through ?-catenin accumulation.
Parkin Deficiency Reduces Hippocampal Glutamatergic Neurotransmission by Impairing AMPA Receptor Endocytosis.
Parkin deficiency results in accumulation of abnormal mitochondria in aging myocytes.
Parkin depletion delays motor decline dose-dependently without overtly affecting neuropathology in ?-synuclein transgenic mice.
Parkin Impairs Antiviral Immunity by Suppressing the Mitochondrial Reactive Oxygen Species-Nlrp3 Axis and Antiviral Inflammation.
Parkin interacts with Klokin1 for mitochondrial import and maintenance of membrane potential.
Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity.
Parkin is protective against proteotoxic stress in a transgenic zebrafish model.
Parkin promotes proteasomal degradation of p62: implication of selective vulnerability of neuronal cells in the pathogenesis of Parkinson's disease.
Parkin Regulates Mitosis and Genomic Stability through Cdc20/Cdh1.
Parkin regulates translesion DNA synthesis in response to UV radiation.
Parkin Selectively Alters the Intrinsic Threshold for Mitochondrial Cytochrome C Release.
Parkin ubiquitinates phosphoglycerate dehydrogenase to suppress serine synthesis and tumor progression.
Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect.
Parkin-associated Parkinson's disease.
Parkin-independent mitophagy requires Drp1 and maintains the integrity of mammalian heart and brain.
PDGFR? is an essential therapeutic target for BRCA1-deficient mammary tumors.
Perturbations in RhoA signalling cause altered migration and impaired neuritogenesis in human iPSC-derived neural cells with PARK2 mutation.
PIAS? expression in relation to clinicopathological, tumour factors and survival in indigenous black breast cancer women.
PINK1/Parkin-Mediated Mitophagy Plays a Protective Role in the Bone Impairment Caused by Aluminum Exposure.
Polo-like Kinase 1 Inhibition as a Therapeutic Approach to Selectively Target BRCA1-Deficient Cancer Cells by Synthetic Lethality Induction.
Polydatin protects SH-SY5Y in models of Parkinson's disease by promoting Atg5-mediated but parkin-independent autophagy.
Polyglucosan body myopathy caused by defective ubiquitin ligase RBCK1.
PP2A and E3 ubiquitin ligase deficiencies: Seminal biological drivers in endometrial cancer.
Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH.
Premature senescence is a major response to DNA cross-linking agents in BRCA1-defective cells: implication for tailored treatments of BRCA1 mutation carriers.
Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers.
Proteomic analysis of BRCA1-depleted cell line reveals a putative role for replication protein A2 up-regulation in BRCA1 breast tumor development.
Proteomic characterisation of polyglucosan bodies in skeletal muscle in RBCK1 deficiency.
Repression of c-Cbl leads to enhanced G-CSF Jak-STAT signaling without increased cell proliferation.
Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer.
RNF111-facilitated neddylation potentiates cGAS-mediated antiviral innate immune response.
RNF20 controls astrocytic differentiation through epigenetic regulation of STAT3 in the developing brain.
Rnf20 deficiency in adipocyte impairs adipose tissue development and thermogenesis.
Role played by BRCA1 in transcriptional regulation in response to therapy.
Secretome proteomics reveals candidate non-invasive biomarkers of BRCA1 deficiency in breast cancer.
Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer.
Selenium Supplementation Reduced Oxidative DNA Damage in Adnexectomized BRCA1 Mutations Carriers.
Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells.
Studying Therapy Response and Resistance in Mouse Models for BRCA1-Deficient Breast Cancer.
Synaptotagmin-11 is a critical mediator of parkin-linked neurotoxicity and Parkinson's disease-like pathology.
Synthetic lethality between BRCA1 deficiency and poly(ADP-ribose) polymerase inhibition is modulated by processing of endogenous oxidative DNA damage.
Targeting UBE4A Revives Viperin Protein in Epithelium to Enhance Host Antiviral Defense.
The AMPK-Parkin axis negatively regulates necroptosis and tumorigenesis by inhibiting the necrosome.
The correlations between BRCA1 defect and environmental factors in the risk of breast cancer.
The E3 ligase c-Cbl regulates dendritic cell activation.
The E3 ubiquitin ligase parkin is dispensable for metabolic homeostasis in murine pancreatic ? cells and adipocytes.
The homologous recombination component EEPD1 is required for genome stability in response to developmental stress of vertebrate embryogenesis.
The PPAR? agonist efatutazone increases the spectrum of well-differentiated mammary cancer subtypes initiated by loss of full-length BRCA1 in association with TP53 haploinsufficiency.
The role of BRCA1 in homologous recombination repair in response to replication stress: significance in tumorigenesis and cancer therapy.
Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation.
Transcriptional profiling of breast cancer cells exposed to soy phytoestrogens after BRCA1 knockdown with a whole human genome microarray approach.
TRAP1 rescues PINK1 loss-of-function phenotypes.
TRIM25 inhibits infectious bursal disease virus replication by targeting VP3 for ubiquitination and degradation.
Tumor susceptibility gene 101 regulates predisposition to apoptosis via ESCRT machinery accessory proteins.
Uncovering the Translational Regulatory Activity of the Tumor Suppressor BRCA1.
Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies.
VCP Is Essential for Mitochondrial Quality Control by PINK1/Parkin and this Function Is Impaired by VCP Mutations.
Western Analysis of Breast Cancer 1 Protein (BRCA1).
RNA Virus Infections
Negative regulation of the innate antiviral immune response by TRIM62 from orange spotted grouper.
The E3 ubiquitin ligase Triad3A negatively regulates the RIG-I/MAVS signaling pathway by targeting TRAF3 for degradation.
TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity.
Rubella
Polymorphisms in the vitamin A receptor and innate immunity genes influence the antibody response to rubella vaccination.
Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfected patients.
Rubella vaccine-induced cellular immunity: evidence of associations with polymorphisms in the Toll-like, vitamin A and D receptors, and innate immune response genes.
Salivary Gland Neoplasms
Are pathogenic BRCA1 mutations associated with parotid mucoepidermoid carcinoma? A case report.
Sarcoma
A novel TP53 germline mutation in a family with a history of multiple malignancies: case report and review of the literature.
BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients.
ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma.
Familial cancer risks to offspring from mothers with 2 primary breast cancers: leads to cancer syndromes.
Familial sarcoma: challenging pedigrees.
Genetic predisposition to radiation induced sarcoma: possible role for BRCA and p53 mutations.
Germline mutations of TP53 and BRCA2 genes in breast cancer/sarcoma families.
Identification of prognostic alternative splicing events in sarcoma.
Individual and Combined Expression of DNA Damage Response Molecules PARP1, ?H2AX, BRCA1, and BRCA2 Predict Shorter Survival of Soft Tissue Sarcoma Patients.
Infantile Epithelioid Sarcoma with Genomic Segmental Amplification of BIRC3/YAP1 as Double Minutes Plus Trisomy 2: A Case Report.
Inheritance of cancer.
Loss of TRIM62 expression is an independent adverse prognostic factor in acute myeloid leukemia.
Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: A retrospective multicentric study.
Prospective assessment of the predictive value of the BRCA1 gene status in sarcoma patients treated with trabectedin: an updated analysis of the EORTC 62091 trial.
Protein SUMOylation, an emerging pathway in amyotrophic lateral sclerosis.
Ring finger protein 149 is an E3 ubiquitin ligase active on wild-type v-Raf murine sarcoma viral oncogene homolog B1 (BRAF).
Two new CHEK2 germ-line variants detected in breast cancer/sarcoma families negative for BRCA1, BRCA2, and TP53 gene mutations.
Uterine cancer in Jewish Israeli BRCA1/2 mutation carriers.
Sarcoma, Avian
CBP/p300 interact with and function as transcriptional coactivators of BRCA1.
Tsg101 can replace Nedd4 function in ASV Gag release but not membrane targeting.
Sarcoma, Ewing
Author Correction: EWS-FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma.
EWS-FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma.
Interaction of the EWS NH2 terminus with BARD1 links the Ewing's sarcoma gene to a common tumor suppressor pathway.
RING1B contributes to Ewing sarcoma development by repressing the NaV1.6 sodium channel and the NF-?B pathway, independently of the fusion oncoprotein.
RING1B recruits EWSR1-FLI1 and cooperates in the remodeling of chromatin necessary for Ewing sarcoma tumorigenesis.
SPOP and OTUD7A Control EWS-FLI1 Protein Stability to Govern Ewing Sarcoma Growth.
TRIM3 Negatively Regulates Autophagy Through Promoting Degradation of Beclin1 in Ewing Sarcoma Cells.
TRIM8 modulates the EWS/FLI oncoprotein to promote survival in Ewing sarcoma.
Sarcoma, Kaposi
c-MIR, a human E3 ubiquitin ligase, is a functional homolog of herpesvirus proteins MIR1 and MIR2 and has similar activity.
Interaction With 14-3-3 Correlates With Inactivation of the RIG-I Signalosome by Herpesvirus Ubiquitin Deconjugases.
Sarcopenia
Parkin overexpression protects from ageing-related loss of muscle mass and strength.
Parkin sarcopenia in its tracks by improving mitochondrial health.
Parkin the progression of sarcopenia.
Scleroderma, Systemic
E3 ubiquitin ligase: A potential regulator in fibrosis and systemic sclerosis.
Scrapie
Enhanced Mitophagy Activity in Prion-Infected Cultured Cells and Prion-Infected Experimental Mice via a Pink1/Parkin-Dependent Mitophagy Pathway.
RML prions act through Mahogunin and Attractin-independent pathways.
Seizures
An E3 ubiquitin ligase, Really Interesting New Gene (RING) Finger 41, is a candidate gene for anxiety-like behavior and beta-carboline-induced seizures.
Seminoma
Histological groups of human postpubertal testicular germ cell tumours harbour different genetic alterations.
Sepsis
AMPK activates Parkin independent autophagy and improves post sepsis immune defense against secondary bacterial lung infections.
BRCA1 gene therapy reduces systemic inflammatory response and multiple organ failure and improves survival in experimental sepsis.
Effect of Deletion of cIAP2 on Intestinal Microcirculation in Mouse Endotoxemia and Poly-bacterial Sepsis.
Inhibition of Atrogin-1/MAFbx Expression by Adenovirus-Delivered Small Hairpin RNAs Attenuates Muscle Atrophy in Fasting Mice.
lncRNA MALAT1 Accelerates Skeletal Muscle Cell Apoptosis and Inflammatory Response in Sepsis by Decreasing BRCA1 Expression by Recruiting EZH2.
LPS impairs phospholipid synthesis by triggering beta-transducin repeat-containing protein (beta-TrCP)-mediated polyubiquitination and degradation of the surfactant enzyme acyl-CoA:lysophosphatidylcholine acyltransferase I (LPCAT1).
Melatonin alleviates sepsis-induced heart injury through activating the Nrf2 pathway and inhibiting the NLRP3 inflammasome.
Parkin Overexpression Attenuates Sepsis-Induced Muscle Wasting.
Prognostic Significance of the Fission1/Parkin Ratio for Sepsis: A Prospective Cohort Study.
Rational cyclization-based minimization of entropy penalty upon the binding of Nrf2-derived linear peptides to Keap1: A new strategy to improve therapeutic peptide activity against sepsis.
The initiation factor eIF3-f is a major target for atrogin1/MAFbx function in skeletal muscle atrophy.
TRIM22-Mediated Apoptosis is Associated with Bak Oligomerization in Monocytes.
Sertoli Cell Tumor
Comparative genomic hybridization in inherited and sporadic ovarian tumors in Israel.
Papers to appear in forthcoming issues
Shock, Septic
Bioinformatics Analysis for Multiple Gene Expression Profiles in Sepsis.
Effect of norepinephrine challenge on cardiovascular determinants assessed using a mathematical model in septic shock: a physiological study.
Peli1 facilitates TRIF-dependent Toll-like receptor signaling and proinflammatory cytokine production.
Serum Mitochondrial Quality Control Related Biomarker Levels are Associated with Organ Dysfunction in Septic Patients.
The ubiquitin ligase ZNRF1 promotes caveolin-1 ubiquitination and degradation to modulate inflammation.
Sigmoid Neoplasms
A diagnostic dilemma following risk-reducing surgery for BRCA1 mutation - a case report of primary papillary serous carcinoma presenting as sigmoid cancer.
Situs Inversus
Mice with mutations in Mahogunin ring finger-1 (Mgrn1) exhibit abnormal patterning of the left-right axis.
Sjogren's Syndrome
Anti-Ro52 autoantibodies from patients with Sjogren's syndrome inhibit the E3 ligase activity of Ro52 by blocking the E3:E2 interface.
Skin Diseases
c-CBL E3 Ubiquitin Ligase Expression Increases Across the Spectrum of Benign and Malignant T-Cell Skin Diseases.
Skin Neoplasms
BRCA1 and BRCA2 families and the risk of skin cancer.
Parkin regulates translesion DNA synthesis in response to UV radiation.
Sleep Initiation and Maintenance Disorders
Restless legs syndrome, rapid eye movement sleep behavior disorder, and hypersomnia in patients with two parkin mutations.
Sleep Wake Disorders
Clinical, neuropathological and genotypic variability in SNCA A53T familial Parkinson's disease. Variability in familial Parkinson's disease.
Small Cell Lung Carcinoma
A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts.
CUL4 E3 ligase regulates the proliferation and apoptosis of lung squamous cell carcinoma and small cell lung carcinoma.
Predictive Value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOP?-IIA, TOPOIIB and C-MYC Genes in Patients with Small Cell Lung Cancer (SCLC) Who Received First Line Therapy with Cisplatin and Etoposide.
Smallpox
The poxvirus p28 virulence factor is an E3 ubiquitin ligase.
Solitary Fibrous Tumors
Severe hypoglycemia and finger clubbing in a patient with a BRCA1 mutation in a solitary fibrous tumor: a case report.
Spinal Cord Injuries
Rapamycin Enhances Mitophagy and Attenuates Apoptosis After Spinal Ischemia-Reperfusion Injury.
Spinal Dysraphism
Health related quality of life in patients with spina bifida: a prospective assessment before and after lower urinary tract reconstruction.
The Impact of BRCA1 on Spina Bifida Meningomyelocele Lesions.
Spinocerebellar Ataxias
Clustering of Parkinson disease: shared cause or coincidence?
Diverse mechanisms of autophagy dysregulation and their therapeutic implications: does the shoe fit?
Most mutations that cause spinocerebellar ataxia autosomal recessive type 16 (SCAR16) destabilize the protein quality-control E3 ligase CHIP.
Quantitative interaction proteomics of neurodegenerative disease proteins.
Spinocerebellar ataxia type 48: last but not least.
Spondylitis, Ankylosing
SMAD-specific E3 ubiquitin ligase 2 promotes angiogenesis by facilitating PTX3 degradation in MSCs from patients with ankylosing spondylitis.
Squamous Cell Carcinoma of Head and Neck
A Human Head and Neck Squamous Cell Carcinoma Cell Line with Acquired cis-Diamminedichloroplatinum-Resistance Shows Remarkable Upregulation of BRCA1 and Hypersensitivity to Taxane.
Assessing the spectrum of germline variation in Fanconi anemia genes among patients with head and neck carcinoma before age 50.
BRCA1 and ?H2AX as independent prognostic markers in oral squamous cell carcinoma.
Butyrate response factor 1 enhances cisplatin sensitivity in human head and neck squamous cell carcinoma cell lines.
Cytoplasmic HuR expression correlates with cIAP2 expression and clinicopathologic factors in oral squamous cell carcinoma cells.
Detection of PIK3CA Gene Mutation in Head and Neck Squamous Cell Carcinoma Using Droplet Digital PCR and RT-qPCR.
Downregulation of Fanconi anemia genes in sporadic head and neck squamous cell carcinoma.
Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma.
Gain of function mutant p53 proteins cooperate with E2F4 to transcriptionally downregulate RAD17 and BRCA1 gene expression.
High expression of Pirh2, an E3 ligase for p27, is associated with low expression of p27 and poor prognosis in head and neck cancers.
Human Homolog of Drosophila Ariadne (HHARI) is a marker of cellular proliferation associated with nuclear bodies.
Inverse correlation between Naa10p and Pirh2 expression and the combined prognostic value in oral squamous cell carcinoma patients.
Lack of RING Finger Domain (RFD) Mutations of the c-Cbl Gene in Oral Squamous Cell Carcinomas in Chennai, India.
NF?B mediates cisplatin resistance through histone modifications in head and neck squamous cell carcinoma (HNSCC).
Overexpression of cIAP2 contributes to 5-FU resistance and a poor prognosis in oral squamous cell carcinoma.
Redox-dependent Brca1 transcriptional regulation by an NADH-sensor CtBP1.
RN181 regulates the biological behaviors of oral squamous cell carcinoma cells via mediating ERK/MAPK signaling pathway.
Smad4 loss in mice causes spontaneous head and neck cancer with increased genomic instability and inflammation.
The E3 ubiquitin ligase SIAH2 is a prosurvival factor overexpressed in oral cancer.
The Expression and Effection of MicroRNA-499a in High-Tobacco Exposed Head and Neck Squamous Cell Carcinoma: A Bioinformatic Analysis.
The miR-205-5p/BRCA1/RAD17 Axis Promotes Genomic Instability in Head and Neck Squamous Cell Carcinomas.
Variation in cisplatinum sensitivity is not associated with Fanconi Anemia/BRCA pathway inactivation in head and neck squamous cell carcinoma cell lines.
Starvation
A proposed role for selective autophagy in regulating auxin-dependent lateral root development under phosphate starvation in Arabidopsis.
A selective transmembrane recognition mechanism by a membrane-anchored ubiquitin ligase adaptor.
Arabidopsis ubiquitin-specific proteases UBP12 and UBP13 shape ORE1 levels during leaf senescence induced by nitrogen deficiency.
BRCA1 deficiency induces protective autophagy to mitigate stress and provides a mechanism for BRCA1 haploinsufficiency in tumorigenesis.
BRCA1 proteins are transported to the nucleus in the absence of serum and splice variants BRCA1a, BRCA1b are tyrosine phosphoproteins that associate with E2F, cyclins and cyclin dependent kinases.
Changes in cIAP2, survivin and BimEL expression characterize the switch from autophagy to apoptosis in prolonged starvation.
Dhh1 regulates the G1/S-checkpoint following DNA damage or BRCA1 expression in yeast.
Dysregulation of Parkin-mediated mitophagy in thyroid Hürthle cell tumors.
Epigenetic and transcriptional regulation of autophagy.
Expression of Pirh2, a p27(Kip1) ubiquitin ligase, in hepatocellular carcinoma: correlation with p27(Kip1) and cell proliferation.
Global identification of genes related to nutrient deficiency in intervertebral disc cells in an experimental nutrient deprivation model.
Hepatitis B Virus X protein elevates Parkin-mediated mitophagy through Lon Peptidase in starvation.
IKK-dependent, NF-?B-independent control of autophagic gene expression.
Inhibition of constitutively activated phosphoinositide 3-kinase/AKT pathway enhances antitumor activity of chemotherapeutic agents in breast cancer susceptibility gene 1-defective breast cancer cells.
Low protein to carbohydrate ratio diet delays onset of Parkinsonism like phenotype in Drosophila melanogaster parkin null mutants.
Mex3c mutation affects lactation through impairing milk ejection in female mice.
Modulating mitophagy in mitochondrial disease.
Molecular cloning and characterization of OsUPS, a U-box containing E3 ligase gene that respond to phosphate starvation in rice (Oryza sativa).
Overexpression of GbWRKY1 positively regulates the Pi starvation response by alteration of auxin sensitivity in Arabidopsis.
Parkin Regulates the Activity of Pyruvate Kinase M2.
PEX2 is the E3 ubiquitin ligase required for pexophagy during starvation.
Promotion of S-phase entry and cell growth under serum starvation by SAG/ROC2/Rbx2/Hrt2, an E3 ubiquitin ligase component: association with inhibition of p27 accumulation.
Quantitative RT-PCR Gene Evaluation and RNA Interference in the Brown Marmorated Stink Bug.
Regulation of autophagy by cytoplasmic p53.
Restriction of trophic factors and nutrients induces PARKIN expression.
SAG/ROC2/Rbx2/Hrt2, a component of SCF E3 ubiquitin ligase: genomic structure, a splicing variant, and two family pseudogenes.
Suitable reference genes for RT-qPCR analysis in Dichelops melacanthus (Hemiptera: Pentatomidae).
Sumoylation, a post-translational regulatory process in plants.
The F-box E3 ubiquitin ligase BAF1 mediates the degradation of the brassinosteroid-activated transcription factor BES1 through selective autophagy in Arabidopsis.
The function of LPR1 is controlled by an element in the promoter and is independent of SUMO E3 Ligase SIZ1 in response to low pi stress in Arabidopsis thaliana.
The GST-BHMT assay reveals a distinct mechanism underlying proteasome inhibition-induced macroautophagy in mammalian cells.
The HECT E3 ubiquitin ligase NEDD4 interacts with and ubiquitylates SQSTM1 for inclusion body autophagy.
The RNA degradation pathway regulates the function of GAS5 a non-coding RNA in mammalian cells.
Thiazolidinediones Mimic Glucose Starvation in Facilitating Sp1 Degradation Through the Upregulation of {beta}-TRCP.
Tumors overexpressing RNF168 show altered DNA repair and responses to genotoxic treatments, genomic instability and resistance to proteotoxic stress.
Up-Regulation of Glioma-Associated Oncogene Homolog 1 Expression by Serum Starvation Promotes Cell Survival in ER-Positive Breast Cancer Cells.
Status Epilepticus
Transcriptional Response of Polycomb Group Genes to Status Epilepticus in Mice is Modified by Prior Exposure to Epileptic Preconditioning.
Stomach Neoplasms
A case of familial breast cancer with double heterozygosity for BRCA1 and BRCA2 genes.
A possible role of cIAP2 in Helicobacter pylori-associated gastric cancer.
A three-gene signature as potential predictive biomarker for irinotecan sensitivity in gastric cancer.
ASPP2 suppresses invasion and TGF-?1-induced epithelial-mesenchymal transition by inhibiting Smad7 degradation mediated by E3 ubiquitin ligase ITCH in gastric cancer.
BRCA1 and BRCA2 mutations among familial breast cancer patients from Costa Rica.
BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin.
BRCA1 founder mutations do not contribute to increased risk of gastric cancer in the Polish population.
c-FLIP is a target of the E3 ligase deltex1 in gastric cancer.
Characterization of the gene structure, functional significance, and clinical application of RNF180, a novel gene in gastric cancer.
circRNA RNF111 regulates the growth, migration and invasion of gastric cancer cells by binding to miR?27b?3p.
Clinical and experimental role of ring finger protein 180 on lymph node metastasis and survival in gastric cancer.
Clinical significance of BRCA1 and BRCA2 mRNA and protein expression in patients with sporadic gastric cancer.
Clinical significance of UGT1A1 polymorphism and expression of ERCC1, BRCA1, TYMS, RRM1, TUBB3, STMN1 and TOP2A in gastric cancer.
Co-occurrence of germline BRCA1 and CDH1 pathogenic variants.
Decreased expression of TRIM3 gene predicts a poor prognosis in gastric cancer.
Detection of aberrant promoter methylation of RNF180, DAPK1 and SFRP2 in plasma DNA of patients with gastric cancer.
Differing effects of adjuvant chemotherapy according to BRCA1 nuclear expression in gastric cancer.
DNA damage regulates ARID1A stability via SCF ubiquitin ligase in gastric cancer cells.
DNA methylation profile in diffuse type gastric cancer: evidence for hypermethylation of the BRCA1 promoter region in early-onset gastric carcinogenesis.
DNMT3A-mediated silence in ADAMTS9 expression is restored by RNF180 to inhibit viability and motility in gastric cancer cells.
DR5-Cbl-b/c-Cbl-TRAF2 complex inhibits TRAIL-induced apoptosis by promoting TRAF2-mediated polyubiquitination of caspase-8 in gastric cancer cells.
ECD promotes gastric cancer metastasis by blocking E3 ligase ZFP91-mediated hnRNP F ubiquitination and degradation.
Elevated TRIM23 expression predicts poor prognosis in Chinese gastric cancer.
ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel.
Evaluating the clinical feasibility: The direct bisulfite genomic sequencing for examination of methylated status of E3 ubiquitin ligase RNF180 DNA promoter to predict the survival of gastric cancer.
Evidence for predictive role of BRCA1 and bTUBIII in gastric cancer.
Exosomal TRIM3 is a novel marker and therapy target for gastric cancer.
Expression of TRF1, TRF2, TIN2, TERT, KU70, and BRCA1 proteins is associated with telomere shortening and may contribute to multistage carcinogenesis of gastric cancer.
FOXO3a-dependent Parkin regulates the development of gastric cancer by targeting ATP-binding cassette transporter E1.
Frequent microsatellite instability and loss of heterozygosity in the region including BRCA1 (17q21) in young patients with gastric cancer.
Gastric Cancer in BRCA1 Germline Mutation Carriers: Results of Endoscopic Screening and Molecular Analysis of Tumor Tissues.
Genetic instability of BRCA1 gene at locus D17S855 is related to clinicopathological behaviors of gastric cancer from Chinese population.
Genetic testing and prevention of hereditary cancer at the MMCI--over 10 years of experience.
Genetic testing by cancer site: stomach.
Germline E-cadherin mutations in familial lobular breast cancer.
Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers.
Germline Mutations in PALB2, BRCA1, and RAD51C, Which Regulate DNA Recombination Repair, in Patients With Gastric Cancer.
H. pylori infection confers resistance to apoptosis via Brd4-dependent BIRC3 eRNA synthesis.
Helicobacter pylori Eradication Downregulates Cellular Inhibitor of Apoptosis Protein 2 in Gastric Carcinogenesis.
Identification and Validation of SNP-Containing Genes With Prognostic Value in Gastric Cancer via Integrated Bioinformatics Analysis.
Identification of High-Frequency Methylation Sites in RNF180 Promoter Region Affecting Expression and Their Relationship with Prognosis of Gastric Cancer.
Interferon-? sensitizes human gastric cancer cells to TRAIL-induced apoptosis via activation of the c-CBL-dependent MAPK/ERK pathway.
JWA down-regulates HER2 expression via c-Cbl and induces lapatinib resistance in human gastric cancer cells.
Knockdown of RNF6 inhibits gastric cancer cell growth by suppressing STAT3 signaling.
Loss of c-Cbl expression correlates with de-differentiation status and lymphatic metastasis in gastric cancer.
Mediation of the malignant biological characteristics of gastric cancer cells by the methylated CpG islands in RNF180 DNA promoter.
Met Kinase-dependent Loss of the E3 Ligase Cbl in Gastric Cancer.
Methylation of CpG sites in RNF180 DNA promoter prediction poor survival of gastric cancer.
mRNA Expression of BRCA1, PIAS1, and PIAS4 and Survival After Second-line Docetaxel in Advanced Gastric Cancer.
Neddylation inhibitor MLN4924 suppresses growth and migration of human gastric cancer cells.
Overexpression of E3 ubiquitin ligase tripartite motif 32 correlates with a poor prognosis in patients with gastric cancer.
Plasma mRNA as liquid biopsy predicts chemo-sensitivity in advanced gastric cancer patients.
Plasma mRNA expression levels of BRCA1 and TS as potential predictive biomarkers for chemotherapy in gastric cancer.
Prevalence and clinical significance of pathogenic germline BRCA1/2 mutations in Chinese non-small cell lung cancer patients.
Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.
Prognostic significance of BRCA1 expression in gastric cancer.
Promoter methylation of cancer-related genes in gastric carcinoma.
Promoter methylation of RNF180 is associated with H.pylori infection and serves as a marker for gastric cancer and atrophic gastritis.
RBBP8/CtIP suppresses P21 expression by interacting with CtBP and BRCA1 in gastric cancer.
RING finger protein 38 induces gastric cancer cell growth by decreasing the stability of the protein tyrosine phosphatase SHP-1.
Ring finger protein 43 associates with gastric cancer progression and attenuates the stemness of gastric cancer stem-like cells via the Wnt-?/catenin signaling pathway.
RN181 is a tumour suppressor in gastric cancer by regulation of the ERK/MAPK-cyclin D1/CDK4 pathway.
RNF180 mediates STAT3 activity by regulating the expression of RhoC via the proteasomal pathway in gastric cancer cells.
RNF43 and PWWP2B inhibit cancer cell proliferation and are predictive or prognostic biomarker for FDA-approved drugs in patients with advanced gastric cancer.
RNF43 Inhibits Cancer Cell Proliferation and Could be a Potential Prognostic Factor for Human Gastric Carcinoma.
RNF43: A Biomarker With Potential Ramifications for Therapeutic Intervention in Gastric Cancer.
STUB1 suppresseses tumorigenesis and chemoresistance through antagonizing YAP1 signaling.
Successful personalized chemotherapy for metastatic gastric cancer based on quantitative BRCA1 mRNA expression level: A case report.
Susceptibility to breast cancer: hereditary syndromes and low penetrance genes.
Testin and filamin-C downregulation by acetylated Siah2 increases invasiveness of Helicobacter pylori-infected gastric cancer cells.
The E3 ligase HUWE1 mediates TGFBR2 ubiquitination and promotes gastric cancer cell proliferation, migration, and invasion.
The E3 ligase UBR5 regulates gastric cancer cell growth by destabilizing the tumor suppressor GKN1.
The E3 ubiquitin ligase NEDD4 mediates cell migration signaling of EGFR in lung cancer cells.
The effects of BRCA1 expression on the chemosensitivity of gastric cancer cells to platinum agents.
The functional BRCA1 rs799917 genetic polymorphism is associated with gastric cancer risk in a Chinese Han population.
The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers.
The Role of PRAJA and ELF in TGF-beta Signaling and Gastric Cancer.
The SUMO E3 ligase CBX4 is identified as a poor prognostic marker of gastric cancer through multipronged OMIC analyses.
Tissue microRNAs as predictive markers for gastric cancer patients undergoing palliative chemotherapy.
TRIM22 inhibits the proliferation of gastric cancer cells through the Smad2 protein.
TRIM25 blockade by RNA interference inhibited migration and invasion of gastric cancer cells through TGF-? signaling.
[Epigenetics in the pathogenesis and early detection of gastric cancer].
[Genetic instability on chromosome 17q21 in gastric cancer of Chinese patients]
Stroke
Activation of TGR5 protects blood brain barrier via the BRCA1/Sirt1 pathway after middle cerebral artery occlusion in rats.
Danhong injection facilitates recovery of post-stroke motion deficit via Parkin-enhanced mitochondrial function.
Down-regulation of parkin protein in transient focal cerebral ischemia: A link between stroke and degenerative disease?
Ischemic stroke induces cardiac dysfunction and alters transcriptome profile in mice.
Molecular mechanisms of signaling via the docosanoid neuroprotectin D1 for cellular homeostasis and neuroprotection.
TRIM62 knockout protects against cerebral ischemic injury in mice by suppressing NLRP3-regulated neuroinflammation.
Supranuclear Palsy, Progressive
Aberrant Accumulation of BRCA1 in Alzheimer Disease and Other Tauopathies.
Parkin polymorphisms in progressive supranuclear palsy.
Progressive supranuclear palsy and tau hyperphosphorylation in a patient with a C212Y parkin mutation.
Steele-Richardson-Olszewski syndrome in a patient with a single C212Y mutation in the parkin protein.
Syndactyly
Mutations in the HECT domain of NEDD4L lead to AKT-mTOR pathway deregulation and cause periventricular nodular heterotopia.
Synovitis
cIAP2 expression and clinical significance in pigmented villonodular synovitis.
Synovitis, Pigmented Villonodular
cIAP2 expression and clinical significance in pigmented villonodular synovitis.
Synucleinopathies
Are PARKIN patients ideal candidates for dopaminergic cell replacement therapies?
Gene therapy for Parkinson's disease.
Inclusion body formation and neurodegeneration are parkin independent in a mouse model of alpha-synucleinopathy.
Novel monoclonal antibodies demonstrate biochemical variation of brain parkin with age.
Parkin and defective ubiquitination in Parkinson's disease.
Parkin deficiency delays motor decline and disease manifestation in a mouse model of synucleinopathy.
Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson's disease.
Parkin gene therapy for alpha-synucleinopathy: A rat model of Parkinson's disease.
Parkin gene therapy.
The interplay between parkin and alpha-synuclein; possible implications for the pathogenesis of Parkinson's disease.
Ubiquitin specific protease-13 independently regulates parkin ubiquitination and alpha-synuclein clearance in alpha-synucleinopathies.
Tauopathies
Aberrant Accumulation of BRCA1 in Alzheimer Disease and Other Tauopathies.
Colocalization of BRCA1 with Tau Aggregates in Human Tauopathies.
Hyperphosphorylated tau aggregates in the cortex and hippocampus of transgenic mice with mutant human FTDP-17 Tau and lacking the PARK2 gene.
Morphological substrates of mental dysfunction in Lewy body disease: an update.
Suppression of Parkin enhances nigrostriatal and motor neuron lesion in mice over-expressing human-mutated tau protein.
Trehalose ameliorates dopaminergic and tau pathology in parkin deleted/tau overexpressing mice through autophagy activation.
Tay-Sachs Disease
Mendelian diseases among Roman Jews: implications for the origins of disease alleles.
Screening semen donors for hereditary diseases. The Fairfax cryobank experience.
TDP-43 Proteinopathies
Distinct multilevel misregulations of Parkin and PINK1 revealed in cell and animal models of TDP-43 proteinopathy.
Parkin Levels Decrease in Fibroblasts With Progranulin (PGRN) Pathogenic Variants and in a Cellular Model of PGRN Deficiency.
Telangiectasia, Hereditary Hemorrhagic
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Telangiectasis
ATR, BRCA1 and gammaH2AX localize to unsynapsed chromosomes at the pachytene stage in human oocytes.
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Dynamic Coregulatory Complex Containing BRCA1, E2F1 and CtIP Controls ATM Transcription.
Effect of DNA damage on a BRCA1 complex.
Gallic acid induces DNA damage and inhibits DNA repair-associated protein expression in human oral cancer SCC-4 cells.
Hsa-miR-520d-5p promotes survival in human dermal fibroblasts exposed to a lethal dose of UV irradiation.
Human Rif1, ortholog of a yeast telomeric protein, is regulated by ATM and 53BP1 and functions in the S-phase checkpoint.
The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes.
Teratocarcinoma
Expression of c-cbl proto-oncogene is modulated during differentiation but not during induction of proliferation.
Teratoma
Analysis of Induced Pluripotent Stem Cells from a BRCA1 Mutant Family.
Coexistence of the BRCA1 and KRAS mutations in a patient with salivary gland carcinoma arising in mediastinal mature teratoma.
Thrombasthenia
Prenatal diagnosis of Glanzmann thrombasthenia using the polymorphic markers BRCA1 and THRA1 on chromosome 17.
Thrombocythemia, Essential
TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms.
Thrombosis
Changes in the expression of plasma proteins associated with thrombosis in BRCA1 mutation carriers.
cIAP2 via NF-?B signalling affects cell proliferation and invasion in hepatocellular carcinoma.
Loss of c-Cbl expression correlates with de-differentiation status and lymphatic metastasis in gastric cancer.
Thymoma
Anti-Apoptotic Signature in Thymic Squamous Cell Carcinomas - Functional Relevance of Anti-Apoptotic BIRC3 Expression in the Thymic Carcinoma Cell Line 1889c.
Deficient tyrosine phosphorylation of c-Cbl and associated proteins in phorbol ester-resistant EL4 mouse thymoma cells.
Thyroid Cancer, Papillary
BRCA2 3'-UTR Polymorphism rs15869 Alters Susceptibility to Papillary Thyroid Carcinoma via Binding hsa-mir-1178-3p.
MARCH6 promotes Papillary Thyroid Cancer development by destabilizing DHX9.
Thyroid Neoplasms
Are pathogenic BRCA1 mutations associated with parotid mucoepidermoid carcinoma? A case report.
Association of BRCA1 functional single nucleotide polymorphisms with risk of differentiated thyroid carcinoma.
Cancer Incidence in First- and Second-Degree Relatives of BRCA1 and BRCA2 Mutation Carriers.
Hereditary common cancers: molecular and clinical genetics.
MARCH6 promotes Papillary Thyroid Cancer development by destabilizing DHX9.
Poly r(C) binding protein (PCBP) 1 expression is regulated by the E3 ligase UBE4A in thyroid carcinoma.
State Institution "National Research Center for Radiation Medicine of the National Academy of Medical Sciences of Ukraine" - research activities and scientific advance in 2013.
Tics
System-level analysis of neuroblastoma tumor-initiating cells implicates AURKB as a novel drug target for neuroblastoma.
Tongue Neoplasms
BRCA1 expression in leukoplakia and carcinoma of the tongue.
E3 Ubiquitin ligase RNF126 regulates the progression of tongue cancer.
E3 ubiquitin ligase, RNF139, inhibits the progression of tongue cancer.
Emodin, aloe-emodin and rhein induced DNA damage and inhibited DNA repair gene expression in SCC-4 human tongue cancer cells.
The E3 ubiquitin ligase RNF135 regulates the tumorigenesis activity of tongue cancer SCC25 cells.
Tremor
A Novel Mutation of PARK-2 Gene in a Patient with Early-onset Parkinson's Disease.
Clinical findings in a large family with a parkin ex3delta40 mutation.
Detection of compound heterozygous deletions in the parkin gene of fibroblasts in patients with autosomal recessive hereditary parkinsonism (PARK2).
New parkin mutations and atypical phenotypes in families with autosomal recessive parkinsonism.
Parkin Disease: A Clinicopathologic Entity?
Parkin Pleiotropy: Extremely Atypical Phenotypes in Patients With Compound Heterozygous Mutations.
Preliminary studies on parkin gene deletion at exons 1 to 6 in Chinese patients with praecox Parkinson's disease.
Pseudo-orthostatic and resting leg tremor in a large Spanish family with homozygous truncating parkin mutation.
[Analysis of the parkin gene deletion mutations in Chinese patients with Parkinson's disease]
Triple Negative Breast Neoplasms
"An addendum to breast cancer": the triple negative experience.
A BRCA1 deficient, NF?B driven immune signal predicts good outcome in triple negative breast cancer.
A functional BRCA1 coding sequence genetic variant contributes to prognosis of triple-negative breast cancer, especially after radiotherapy.
A germline mutation in the BRCA1 3'UTR predicts Stage IV breast cancer.
A major response to carboplatin in a metastatic triple-negative breast cancer patient with somatic mutation of BRCA1 and RAD51B: When chemotherapy meets precision medicine.
A novel BRCA1 germline mutation promotes triple-negative breast cancer cells progression and enhances sensitivity to DNA damage agents.
A novel de novo BRCA1 mutation in a Chinese woman with early onset breast cancer.
A Paternally Inherited BRCA1 Mutation Associated with an Unusual Aggressive Clinical Phenotype.
A Provocative Molecular Link between Mammographic Density and BRCA1-loss associated TNBC.
Analysis of clinical characteristics of breast cancer patients with the Japanese founder mutation BRCA1 L63X.
Androgen Receptor, EGFR, and BRCA1 as Biomarkers in Triple-Negative Breast Cancer: A Meta-Analysis.
ANKLE1 N6 -Methyladenosine-related variant is associated with colorectal cancer risk by maintaining the genomic stability.
Antibody-drug conjugates in triple negative breast cancer.
Association of BRCA1 germline mutations in young onset triple-negative breast cancer (TNBC).
Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
Association of Genetic Testing Results with Mortality Among Women with Breast Cancer or Ovarian Cancer.
Basal Cytokeratin and Epidermal Growth Factor Receptor Expression Are Not Predictive of BRCA1 Mutation Status in Women With Triple-negative Breast Cancers.
BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy.
Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
Biologic, demographic, and social factors affecting triple negative breast cancer outcomes.
BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile.
BRCA1 and BRCA2 mutations in ethnic Lebanese Arab women with high hereditary risk breast cancer.
BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation.
BRCA1 deficient Mouse Models to Study Pathogenesis and Therapy of Triple Negative Breast Cancer.
BRCA1 loss activates cathepsin L-mediated degradation of 53BP1 in breast cancer cells.
BRCA1 Mutation Leads to Deregulated Ubc9 Levels which Triggers Proliferation and Migration of Patient-Derived High Grade Serous Ovarian Cancer and Triple Negative Breast Cancer Cells.
BRCA1 polymorphisms and breast cancer epidemiology in the Western New York exposures and breast cancer (WEB) study.
BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer.
BRCA1 promoter methylation in peripheral blood is associated with the risk of triple-negative breast cancer.
BRCA1 promoter methylation is a marker of better response to anthracycline-based therapy in sporadic TNBC.
BRCA1 regulation of epidermal growth factor receptor (EGFR) expression in human breast cancer cells involves microRNA-146a and is critical for its tumor suppressor function.
BRCA1 subcellular localization regulated by PI3K signaling pathway in triple-negative breast cancer MDA-MB-231 cells and hormone-sensitive T47D cells.
BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years.
BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer.
BRCA1-associated triple-negative breast cancer and potential treatment for ruthenium-based compounds.
BRCA2 mutations and triple-negative breast cancer.
BRCAness is beneficial for indicating triple negative breast cancer patients resistant to taxane.
Breast cancer associated pathogenic variants among women 61?years and older with triple negative breast cancer.
Canonical Wnt signaling regulates Slug activity and links epithelial-mesenchymal transition with epigenetic Breast Cancer 1, Early Onset (BRCA1) repression.
Cellular responses of BRCA1-defective and triple-negative breast cancer cells and in vitro BRCA1 interactions induced by metallo-intercalator ruthenium(II) complexes containing chloro-substituted phenylazopyridine.
Characteristics of BRCA1/2 mutations carriers including large genomic rearrangements in high risk breast cancer patients.
Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women.
Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.
Clinical correlates of 'BRCAness' in triple-negative breast cancer of patients receiving adjuvant chemotherapy.
Clinical implications for BRCA gene mutation in breast cancer.
Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers.
Clinicopathological and Molecular Study of Triple-Negative Breast Cancer in Algerian Patients.
Clinicopathological Features of BRCA1/2 Mutation-Positive Breast Cancer.
Coexistent Loss of the Expressions of BRCA1 and p53 Predicts Poor Prognosis in Triple-Negative Breast Cancer.
Collective evidence supports neutrality of BRCA1 V1687I, a novel sequence variant in the conserved THV motif of the first BRCT repeat.
Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers.
Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia.
CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer.
CRISPR/Cas9-mediated mutagenesis to validate the synergy between PARP1 inhibition and chemotherapy in BRCA1-mutated breast cancer cells.
DCAF13 promotes triple-negative breast cancer metastasis by mediating DTX3 mRNA degradation.
Decreased miR-206 expression in BRCA1 wild-type triple-negative breast cancer cells after concomitant treatment with gemcitabine and a Poly(ADP-ribose) polymerase-1 inhibitor.
Design and synthesis of some barbituric and 1,3-dimethylbarbituric acid derivatives: A non-classical scaffold for potential PARP1 inhibitors.
Detection of novel germline mutations in six breast cancer predisposition genes by targeted next-generation sequencing.
Differential Claudin 3 and EGFR Expression Predicts BRCA1 Mutation in Triple-Negative Breast Cancer.
Differential immunomodulatory effect of PARP inhibition in BRCA1 deficient and competent tumor cells.
Diverse mechanisms of autophagy dysregulation and their therapeutic implications: does the shoe fit?
DNA repair genes implicated in triple negative familial non-BRCA1/2 breast cancer predisposition.
Dual PARP and RAD51 Inhibitory Drug Conjugates Show Synergistic and Selective Effects on Breast Cancer Cells.
E3 ubiquitin ligase CHIP attenuates cellular proliferation and invasion abilities in triple-negative breast cancer cells.
E3 Ubiquitin Ligase UBR5 Drives the Growth and Metastasis of Triple-Negative Breast Cancer.
Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.
Effect of AR antagonist combined with PARP1 inhibitor on sporadic triple-negative breast cancer bearing AR expression and methylation-mediated BRCA1 dysfunction.
Effectiveness of Neoadjuvant Therapy with Platinum-Based Agents for Patients with BRCA1 and BRCA2 Germline Mutations - A Retrospective Analysis of Breast Cancer Patients Treated at MMCI Brno.
Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers.
EGFR, BRCA1, BRCA2 and TP53 genetic profile in Moroccan triple negative breast cancer cases.
Epigenetic Activation of BRCA1 by Genistein In Vivo and Triple Negative Breast Cancer Cells Linked to Antagonism toward Aryl Hydrocarbon Receptor.
Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer.
Establishment of chemosensitivity tests in triple-negative and BRCA-mutated breast cancer patient-derived xenograft models.
Evaluation of BRCA1 mutations in an unselected patient population with triple-negative breast cancer.
Evaluation of Complete Pathological Regression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients with BRCA1 Founder Mutation Aided Bayesian A/B Testing Approach.
Evaluation of tolerability and efficacy of incorporating carboplatin in neoadjuvant anthracycline and taxane based therapy in a BRCA1 enriched triple-negative breast cancer cohort.
Expression of potential biomarkers associated with homologous recombination repair in patients with ovarian or triple-negative breast cancer.
FAM35A/SHLD2/RINN2: A novel determinant of double strand break repair pathway choice and genome stability in cancer.
Family history of breast cancer in first-degree relatives and triple-negative breast cancer risk.
Frequency of triple-negative breast cancer in BRCA1 mutation carriers: comparison between common Ashkenazi Jewish and other mutations.
Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers.
Gene Sequencing for Pathogenic Variants Among Adults With Breast and Ovarian Cancer in the Caribbean.
Generation of induced pluripotent stem cell (iPSC) line from a patient with triple negative breast cancer with hereditary exon 17 deletion of BRCA1 gene.
Genetic evaluation of BRCA1 associated a complex genes with triple-negative breast cancer susceptibility in chinese women.
Genetics of triple-negative breast cancer: Implications for patient care.
Genistein Inhibits Proliferation of BRCA1 Mutated Breast Cancer Cells: The GPR30-Akt Axis as a Potential Target.
Germline mutations of multiple breast cancer-related genes are differentially associated with triple-negative breast cancers and prognostic factors.
High Levels of Nucleolar Spindle-Associated Protein and Reduced Levels of BRCA1 Expression Predict Poor Prognosis in Triple-Negative Breast Cancer.
High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients.
High prevalence of BRCA1 founder mutations in Greek breast/ovarian families.
Hypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer.
Hypoxia-induced protein CAIX is associated with somatic loss of BRCA1 protein and pathway activity in triple negative breast cancer.
Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer.
Identification of BRCA1 Deficiency Using Multi-Analyte Estimation of BRCA1 and Its Repressors in FFPE Tumor Samples from Patients with Triple Negative Breast Cancer.
Identification of Eleven Novel BRCA Mutations in Tunisia: Impact on the Clinical Management of BRCA Related Cancers.
Identification of miR-10b, miR-26a, miR-146a and miR-153 as potential triple-negative breast cancer biomarkers.
Identification of recurrent BRCA1 mutation and its clinical relevance in Chinese Triple-negative breast cancer cohort.
Identification of Recurrent Variants in BRCA1 and BRCA2 across Multiple Cancers in the Chinese Population.
Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance.
Inactivation of the prolyl isomerase Pin1 sensitizes BRCA1-proficient breast cancer to PARP inhibition.
Incidence of BRCA1 somatic mutations and response to neoadjuvant chemotherapy in Chinese women with triple-negative breast cancer.
Increased ID4 expression, accompanied by mutant p53 accumulation and loss of BRCA1/2 proteins in triple-negative breast cancer, adversely affects survival.
Influence of BRCA1 Germline Mutations in the Somatic Mutational Burden of Triple-Negative Breast Cancer.
Inherited Breast Cancer in Nigerian Women.
Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.
Inherited predisposition to breast cancer in the Carolina Breast Cancer Study.
ITCH nuclear translocation and H1.2 polyubiquitination negatively regulate the DNA damage response.
Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers.
Liquiritigenin decreases tumorigenesis by inhibiting DNMT activity and increasing BRCA1 transcriptional activity in triple-negative breast cancer.
LncRNA HCP5 promotes triple negative breast cancer progression as a ceRNA to regulate BIRC3 by sponging miR-219a-5p.
Loss of BRCA1 expression and morphological features associated with BRCA1 promoter methylation status in triple-negative breast cancer.
Loss of glucocorticoid receptor activation is a hallmark of BRCA1-mutated breast tissue.
Low incidence of methylation of the promoter region of the FANCF gene in Japanese primary breast cancer.
LSD1 Overexpression Is Associated with Poor Prognosis in Basal-Like Breast Cancer, and Sensitivity to PARP Inhibition.
Metaplastic carcinoma of the breast and BRCA1 germline mutation: a case report and review.
Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events.
Mexican BRCA1 founder mutation: Shortening the gap in genetic assessment for hereditary breast and ovarian cancer patients.
MicroRNA deregulation in triple negative breast cancer reveals a role of miR-498 in regulating BRCA1 expression.
miR-10b, miR-26a, miR-146a And miR-153 Expression in Triple Negative Vs Non Triple Negative Breast Cancer: Potential Biomarkers.
miR-146a and miR-638 in BRCA1-deficient triple negative breast cancer tumors, as potential biomarkers for improved overall survival.
miR-185 suppresses tumor proliferation by directly targeting E2F6 and DNMT1 and indirectly upregulating BRCA1 in triple-negative breast cancer.
miR-342 overexpression results in a synthetic lethal phenotype in BRCA1-mutant HCC1937 breast cancer cells.
miR-522 regulates cell proliferation, migration, invasion capacities and acts as a potential biomarker to predict prognosis in triple-negative breast cancer.
miR-638 mediated regulation of BRCA1 affects DNA repair and sensitivity to UV and cisplatin in triple-negative breast cancer.
Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells.
Modulation of the BRCA1 protein and induction of apoptosis in triple negative breast cancer cell lines by the polyphenolic compound curcumin.
Molecular alterations in triple-negative breast cancer-the road to new treatment strategies.
Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
Mutation analysis of BRCA1, BRCA2, PALB2 and BRD7 in a hospital-based series of German patients with triple-negative breast cancer.
Nano-delivery of RAD6/Translesion Synthesis Inhibitor SMI#9 for Triple-negative Breast Cancer Therapy.
Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers.
Neoadjuvant Chemotherapy With Anthracycline-Based Regimen for BRCAness Tumors in Triple-Negative Breast Cancer.
Next Generation Sequencing Reveals High Prevalence of BRCA1 and BRCA2 Variants of Unknown Significance in Early-Onset Breast Cancer in African American Women.
NOTCH1 activation compensates BRCA1 deficiency and promotes triple-negative breast cancer formation.
Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition.
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
Optimal surgical management for high-risk populations.
Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations.
Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs.
PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer.
PARP inhibitor olaparib has a potential to increase the effectiveness of electrochemotherapy in BRCA1 mutated breast cancer in mice.
PARP Inhibitors for the Treatment and Prevention of Breast Cancer.
Patterns and Prevalence of BRCA1 and BRCA2 Germline Mutations Among Patients with Triple-Negative Breast Cancer: Regional Perspectives.
Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers.
PIAS? expression in relation to clinicopathological, tumour factors and survival in indigenous black breast cancer women.
Predictive Factors for BRCA1 and BRCA2 Genetic Testing in an Asian Clinic-Based Population.
Prevalence and characterization of BRCA1 and BRCA2 germline mutations in Chinese women with familial breast cancer.
Prevalence and clinical outcomes of germline mutations in BRCA1/2 and PALB2 genes in 2769 unselected breast cancer patients in China.
Prevalence and oncologic outcomes of BRCA 1/2 mutations in unselected triple-negative breast cancer patients in Korea.
Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer.
Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer.
Prevalence of BRCA1 and BRCA2 gene mutations in Chinese patients with high-risk breast cancer.
Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer.
Prevalence of BRCA1 and BRCA2 mutations in Japanese patients with triple-negative breast cancer: A single institute retrospective study.
Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer.
Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study.
Prevalence of BRCA1 mutations and responses to neoadjuvant chemotherapy among BRCA1 carriers and non-carriers with triple-negative breast cancer.
Prevalence of BRCA1/2 large genomic rearrangements in Chinese women with sporadic triple-negative or familial breast cancer.
Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history.
Primary resistance to docetaxel-based chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations.
Prognostic role of BRCA1 mutation in patients with triple-negative breast cancer.
Promoter hypermethylation of p16, BRCA1 and RASSF1A genes in triple-negative breast cancer patients from Serbia.
Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy.
Proteomic Profiling of ?-hCG-Induced Spheres in BRCA1 Defective Triple Negative Breast Cancer Cells.
RAD6B is a major mediator of triple negative breast cancer cisplatin resistance: Regulation of translesion synthesis/Fanconi anemia crosstalk and BRCA1 independence.
Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib.
Resistomycin attenuates triple-negative breast cancer progression by inhibiting E3 ligase Pellino-1 and inducing SNAIL/SLUG degradation.
Risk of Having BRCA1 Mutation in High-Risk Women with Triple-Negative Breast Cancer: A Meta-Analysis.
Risk of Late-Onset Breast Cancer in Genetically Predisposed Women.
RNF208, an estrogen-inducible E3 ligase, targets soluble Vimentin to suppress metastasis in triple-negative breast cancers.
SAHA and EGCG Promote Apoptosis in Triple-negative Breast Cancer Cells, Possibly Through the Modulation of cIAP2.
Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor activity of olaparib in triple negative breast cancer regardless of BRCA1 mutation status.
Synergistic anticancer action of quercetin and curcumin against triple-negative breast cancer cell lines.
Synthetically Lethal BMN 673 (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 Mutant Triple Negative Breast Cancer.
Talazoparib Loaded Solid Lipid Nanoparticles: Preparation, Characterization and Evaluation the Therapeutic Efficacy In Vitro.
Targeted Next-generation Sequencing for Reliable Detection of Genetic Status in Breast Cancer.
Targeting DNA damage and repair by curcumin.
Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON.
The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer.
The miR-106b-25 cluster mediates breast tumor initiation through activation of NOTCH1 via direct repression of NEDD4L.
The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells.
The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer.
The prevalence of BRCA1 mutations among young women with triple-negative breast cancer.
The prognostic value of BRCA1 promoter methylation in early stage triple negative breast cancer.
The Role of Genetic Testing in Patients With Breast Cancer: A Review.
Therapy response testing of breast cancer in a 3D high-throughput perfused microfluidic platform.
Time-resolved single-cell analysis of Brca1 associated mammary tumourigenesis reveals aberrant differentiation of luminal progenitors.
Tools for translational epigenetic studies involving formalin-fixed paraffin-embedded human tissue: applying the Infinium HumanMethyation450 Beadchip assay to large population-based studies.
Treatment of triple-negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization?
Triple Negative Breast Cancer in BRCA1 Mutation Carriers With a Complete Radiologic Response to Neoadjuvant Paclitaxel: A Case Report.
Triple negative breast cancer: microRNA expression profile and novel discriminators according to BRCA1 status.
Triple-negative breast cancer and PTEN (phosphatase and tensin homologue)loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer.
Triple-negative breast cancer in African-American women: disparities versus biology.
Triple-negative breast cancer: therapeutic options.
Tumor-associated inflammation as a potential prognostic tool in BRCA1/2-associated breast cancer.
Value of adjuvant chemotherapy and informed microscopic examination for occult gynecologic cancer detected upon risk-reducing salpingo-oophorectomy after chemotherapy for BRCA1/2-associated breast cancer: a case report.
What is triple-negative breast cancer?
Whole exome sequencing of breast cancer (TNBC) cases from India: association of MSH6 and BRIP1 variants with TNBC risk and oxidative DNA damage.
[Breast Cancer in Young Women - Correlation of Clinical Histomorphological, and Molecular-genetic Features of Breast Carcinoma in Women Younger than 35 Years of Age].
[Effects of Olaparib, a PARP-1 Inhibitor, on Triple Negative Breast Cancer Cells with a BRCA1 Mutation].
[Relationship of clinicopathological features and chemotherapeutic outcomes in women with BRCA1 and BRCA2 mutation-negative familial breast cancer].
Tuberculosis
In vitro ubiquitination of Mycobacterium tuberculosis by E3 ubiquitin ligase, MKRN1.
MicroRNA-325-3p Facilitates Immune Escape of Mycobacterium tuberculosis through Targeting LNX1 via NEK6 Accumulation to Promote Anti-Apoptotic STAT3 Signaling.
Modulation of Roquin Function in Myeloid Cells Reduces Mycobacterium tuberculosis-Induced Inflammation.
TRIM14 Is a Key Regulator of the Type I IFN Response during Mycobacterium tuberculosis Infection.
TRIM22 regulates macrophage autophagy and enhances Mycobacterium tuberculosis clearance by targeting the nuclear factor-multiplicity ?B/beclin 1 pathway.
TRIM25 upregulation by Mycobacterium tuberculosis infection promotes intracellular survival of M.tb in RAW264.7 cells.
Tuberculosis, Pulmonary
TRIM25 upregulation by Mycobacterium tuberculosis infection promotes intracellular survival of M.tb in RAW264.7 cells.
Tuberous Sclerosis
Apparent preferential loss of heterozygosity at TSC2 over TSC1 chromosomal region in tuberous sclerosis hamartomas.
Involvement of C/EBP?-related signaling pathway in methamphetamine-induced neuronal autophagy and apoptosis.
The GID ubiquitin ligase complex is a regulator of AMPK activity and organismal lifespan.
Tubular Sweat Gland Adenomas
Study of Selected BRCA1, BRCA2, and PIK3CA Mutations in Benign and Malignant Lesions of Anogenital Mammary-Like Glands.
Unilateral Breast Neoplasms
Accuracy of the BRCAPRO model among women with bilateral breast cancer.
Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing.
BRCA1 and BRCA2 mutations in breast cancer patients from Saudi Arabia.
Breast Cancer Surgery Trend Changes Since the Introduction of BRCA1/2 Mutation Screening: A Retrospective Cohort Analysis of 158 Mutation Carriers Treated at a Single Institution.
Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2.
Contralateral Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
Contribution of BRCA1 germline mutation in patients with sporadic breast cancer.
Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
Effects of Radiation Therapy on Breast Epithelial Cells in BRCA1/2 Mutation Carriers.
Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations.
Mutations of the BRCA1 and BRCA2 genes in patients with bilateral breast cancer.
Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.
Predictors of uptake of contralateral prophylactic mastectomy in women with nonhereditary breast cancer.
Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update.
The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study.
Trends in contralateral prophylactic mastectomy rate according to clinicopathologic and socioeconomic status.
Variation of breast cancer risk among BRCA1/2 carriers.
Women's preferences for contralateral prophylactic mastectomy: An investigation using protection motivation theory.
Urinary Bladder Neoplasms
BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer.
ciRs-6 upregulates March1 to suppress bladder cancer growth by sponging miR-653.
E3 ligase cIAP2 mediates downregulation of MRE11 and radiosensitization in response to HDAC inhibition in bladder cancer.
E3 ubiquitin ligase RNF126 affects bladder cancer progression through regulation of PTEN stability.
Expression of the IAP protein family acts cooperatively to predict prognosis in human bladder cancer patients.
FAVL impairment of the Fanconi anemia pathway promotes the development of human bladder cancer.
Implications of targeted next-generation sequencing for bladder cancer: report of four cases.
Loss of heterozygosity studies in tumors from families with breast-ovarian cancer syndrome.
Multiplexed methylation profiles of tumor suppressor genes in bladder cancer.
Nuclear cIAP1 overexpression is a tumor stage- and grade-independent predictor of poor prognosis in human bladder cancer patients.
Pancancer survival analysis of cancer hallmark genes.
Somatic FGFR3 Mutations Distinguish a Subgroup of Muscle-Invasive Bladder Cancers with Response to Neoadjuvant Chemotherapy.
Upregulated WDR5 promotes proliferation, self-renewal and chemoresistance in bladder cancer via mediating H3K4 trimethylation.
XPC deficiency leads to centrosome amplification by inhibiting BRCA1 expression upon cisplatin-mediated DNA damage in human bladder cancer.
Urologic Neoplasms
Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry.
Usher Syndromes
The E3 ligase Ubr3 regulates Usher syndrome and MYH9 disorder proteins in the auditory organs of Drosophila and mammals.
Uterine Cervical Neoplasms
Activation of p53 in cervical cancer cells by human papillomavirus E6 RNA interference is transient, but can be sustained by inhibiting endogenous nuclear export-dependent p53 antagonists.
Allelic loss of 6q25-27, the PARKIN tumor suppressor gene locus, in cervical carcinoma.
BRCA1 interaction with human papillomavirus oncoproteins.
Case report: Analysis of BRCA1 and BRCA2 gene mutations in a hereditary ovarian cancer family.
Complete pathological response to olaparib and bevacizumab in advanced cervical cancer following chemoradiation in a BRCA1 mutation carrier: a case report.
E3 ubiquitin ligase isolated by differential display regulates cervical cancer growth in vitro and in vivo via microRNA-143.
Evaluation of Fanconi anaemia genes FANCA, FANCC and FANCL in cervical cancer susceptibility.
Expression of HPV-induced DNA Damage Repair Factors Correlates With CIN Progression.
Expression profile of BRCA1 and BRCA2 genes in premenopausal Mexican women with breast cancer: clinical and immunohistochemical correlates.
Identification of Recurrent Variants in BRCA1 and BRCA2 across Multiple Cancers in the Chinese Population.
miR-454-3p promotes proliferation and induces apoptosis in human cervical cancer cells by targeting TRIM3.
Mitomycin C modulates DNA-double strand break repair genes in cervical carcinoma cells.
Next Generation Cancer Protection: The Bivalent HPV Vaccine for Females.
Nucleolar and spindle associated protein 1 promotes metastasis of cervical carcinoma cells by activating Wnt/?-catenin signaling.
p300 Modulates the BRCA1 inhibition of estrogen receptor activity.
Pancancer survival analysis of cancer hallmark genes.
Parkin induces apoptotic cell death in TNF-?-treated cervical cancer cells.
Parkin Induces Upregulation of 40S Ribosomal Protein SA and Posttranslational Modification of Cytokeratins 8 and 18 in Human Cervical Cancer Cells.
Peritoneal cancer arising after total abdominal hysterectomy and bilateral salpingo-oophorectomy for cervical cancer in a patient with right breast cancer and germline mutation of BRCA1 gene: a case report and literature review.
Phosphorylation of I?B? at serine 32 by T-lymphokine-activated killer cell-originated protein kinase is essential for chemoresistance against doxorubicin in cervical cancer cells.
Polymorphisms in HPV E6/E7 protein interacted genes and risk of cervical cancer in Chinese women: a case-control analysis.
Proteomics Analysis of Andrographolide-Induced Apoptosis via the Regulation of Tumor Suppressor p53 Proteolysis in Cervical Cancer-Derived Human Papillomavirus 16-Positive Cell Lines.
Tripartite motif-containing protein 3 plays a role of tumor inhibitor in cervical cancer.
Uterine Neoplasms
Hereditary gynaecological malignancies: advances in screening and treatment.
Hereditary non-BRCA gynaecological tumors.
Mortality reduction and cost-effectiveness of performing hysterectomy at the time of risk-reducing salpingo-oophorectomy for prophylaxis against serous/serous-like uterine cancers in BRCA1 mutation carriers.
Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers.
Should the risk for uterine cancer influence decision making for prophylactic hysterectomy in BRCA1/2 mutated patients- a systematic review and meta-analysis.
Uterine cancer in Jewish Israeli BRCA1/2 mutation carriers.
Vaccinia
BRCA1 Regulates IFI16 Mediated Nuclear Innate Sensing of Herpes Viral DNA and Subsequent Induction of the Innate Inflammasome and Interferon-? Responses.
Vaccinia Virus BBK E3 Ligase Adaptor A55 Targets Importin-Dependent NF-?B Activation and Inhibits CD8+ T-Cell Memory.
Vaccinia virus protein A49 activates Wnt signalling by targetting the E3 ligase ?-TrCP.
Vascular Calcification
Nedd4 Deficiency in Vascular Smooth Muscle Promotes Vascular Calcification by Stabilizing pSmad1.
Vascular System Injuries
Suppression of c-Cbl tyrosine phosphorylation inhibits neointimal formation in balloon-injured rat arteries.
Vesicular Stomatitis
A specific region of 37 amino acid residues in the SPRY (B30.2) domain of African green monkey TRIM5alpha determines species-specific restriction of simian immunodeficiency virus SIVmac infection.
Autophagy and innate immunity: Insights from invertebrate model organisms.
The RING domain of TRIM69 promotes higher-order assembly.
TRIM69 inhibits Vesicular Stomatitis Indiana Virus (VSIV).
Ubiquitination and degradation of NF90 by Tim-3 inhibits antiviral innate immunity.
Vesicular Stomatitis Virus Transcription Is Inhibited by TRIM69 in the Interferon-Induced Antiviral State.
Viremia
Short-term Treatment With Interferon Alfa Diminishes Expression of HIV-1 and Reduces CD4+ T-Cell Activation in Patients Coinfected With HIV and Hepatitis C Virus and Receiving Antiretroviral Therapy.
Susceptibility to Repeated, Low-Dose, Rectal SHIVSF162P3 Challenge Is Independent of TRIM5 Genotype in Rhesus Macaques.
TRIM5 alpha Drives SIVsmm Evolution in Rhesus Macaques.
Virus Diseases
A SPOPL/Cullin-3 ubiquitin ligase complex regulates endocytic trafficking by targeting EPS15 at endosomes.
Alpha interferon enhances TRIM5alpha-mediated antiviral activities in human and rhesus monkey cells.
Autoubiquitination of TRIM26 links TBK1 to NEMO in RLR-mediated innate antiviral immune response.
Biochemical and biophysical characterization of a chimeric TRIM21-TRIM5alpha protein.
Cellular inhibitor of apoptosis protein cIAP2 protects against pulmonary tissue necrosis during influenza virus infection to promote host survival.
Characterization of TRIM5alpha trimerization and its contribution to human immunodeficiency virus capsid binding.
Comparative transcriptome analysis reveals key epigenetic targets in SARS-CoV-2 infection.
Control of virus-specific CD8+ T-cell exhaustion and immune-mediated pathology by E3 ubiquitin ligase Cbl-b during chronic viral infection.
Cyclophilin A-regulated ubiquitination is critical for RIG-I-mediated antiviral immune responses.
Discovery of Small-Molecule Inhibitors Targeting the E3 Ubiquitin Ligase Activity of the Herpes Simplex Virus 1 ICP0 Protein Using an In Vitro High-Throughput Screening Assay.
E1B-55K-Mediated Regulation of RNF4 SUMO-Targeted Ubiquitin Ligase Promotes Human Adenovirus Gene Expression.
E3 ligase FBXW7 is critical for RIG-I stabilization during antiviral responses.
E3 Ubiquitin Ligase NEDD4 Promotes Influenza Virus Infection by Decreasing Levels of the Antiviral Protein IFITM3.
E3 Ubiquitin Ligase RNF114 Inhibits Innate Immune Response to Red-Spotted Grouper Nervous Necrosis Virus Infection in Sea Perch by Targeting MAVS and TRAF3 to Mediate Their Degradation.
Effects of human TRIM5alpha polymorphisms on antiretroviral function and susceptibility to human immunodeficiency virus infection.
Evaluation of TRIM5 and TRIM22 polymorphisms on treatment responses in Iranian patients with chronic hepatitis C virus infection.
Gene profiling involved in immature CD4+ T lymphocyte responsible for systemic lupus erythematosus.
Genome-wide gene expression pattern underlying differential host response to high or low pathogenic H5N1 avian influenza virus in ducks.
Glioma tumor grade correlates with parkin depletion in mutant p53-linked tumors and results from loss of function of p53 transcriptional activity.
HERC5 and the ISGylation Pathway: Critical Modulators of the Antiviral Immune Response.
Herpes simplex virus type 1 immediate-early protein ICP0 and is isolated RING finger domain act as ubiquitin E3 ligases in vitro.
Histone H2B-IFI16 Recognition of Nuclear Herpesviral Genome Induces Cytoplasmic Interferon-? Responses.
Host Intrinsic and Innate Intracellular Immunity During Herpes Simplex Virus Type 1 (HSV-1) Infection.
Identification of Glial Activation Markers by Comparison of Transcriptome Changes between Astrocytes and Microglia following Innate Immune Stimulation.
Identification of TRIM23 as a cofactor involved in the regulation of NF-kappaB by human cytomegalovirus.
Influenza A Virus Infection Induces Muscle Wasting via IL-6 Regulation of the E3 Ubiquitin Ligase Atrogin-1.
Innate immunity to RNA virus is regulated by temporal and reversible sumoylation of RIG-I and MDA5.
Interaction of c-Cbl with myosin IIA regulates Bleb associated macropinocytosis of Kaposi's sarcoma-associated herpesvirus.
Interferon-? Stimulation Elicited by the Influenza Virus Is Regulated by the Histone Methylase Dot1L through the RIG-I-TRIM25 Signaling Axis.
Intracellular antibody receptor TRIM21 prevents fatal viral infection.
iRhom2 is essential for innate immunity to RNA virus by antagonizing ER- and mitochondria-associated degradation of VISA.
ISG12a Restricts Hepatitis C Virus Infection through the Ubiquitination-Dependent Degradation Pathway.
LncRNA Malat1 inhibition of TDP43 cleavage suppresses IRF3-initiated antiviral innate immunity.
Negative feedback regulation of cellular antiviral signaling by RBCK1-mediated degradation of IRF3.
Negative regulation of NEMO signaling by the ubiquitin E3 ligase MARCH2.
Negative regulation of RIG-I-mediated antiviral signaling by TRK-fused gene (TFG) protein.
Noncanonical Role of FBXO6 in Regulating Antiviral Immunity.
Nuclear redistribution of BRCA1 during viral infection.
OsRFPH2-10, a RING-H2 Finger E3 Ubiquitin Ligase, Is Involved in Rice Antiviral Defense in the Early Stages of Rice dwarf virus Infection.
Overexpression of feline tripartite motif-containing 25 interferes with the late stage of feline leukemia virus replication.
Positive regulatory role of c-Src-mediated TRIM25 tyrosine phosphorylation on RIG-I ubiquitination and RIG-I-mediated antiviral signaling pathway.
Proteasome inhibition reveals that a functional preintegration complex intermediate can be generated during restriction by diverse TRIM5 proteins.
Protein Kinase R Degradation Is Essential for Rift Valley Fever Virus Infection and Is Regulated by SKP1-CUL1-F-box (SCF)FBXW11-NSs E3 Ligase.
Quantitative Proteomics Reveals a Novel Role of the E3 Ubiquitin-Protein Ligase FANCL in the Activation of the Innate Immune Response through Regulation of TBK1 Phosphorylation during Peste des Petits Ruminants Virus Infection.
Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfected patients.
Restriction of feline retroviruses: lessons from cat APOBEC3 cytidine deaminases and TRIM5alpha proteins.
RING domain is essential for the antiviral activity of TRIM25 from orange spotted grouper.
Selective autophagy controls the stability of TBK1 via NEDD4 to balance host defense.
SS-A/Ro52 promotes apoptosis by regulating Bcl-2 production.
SUMOylation of DDX39A Alters Binding and Export of Antiviral Transcripts to Control Innate Immunity.
The E3 ligase VHL promotes follicular helper T cell differentiation via glycolytic-epigenetic control.
The E3 ubiquitin ligase Itch is required for the differentiation of follicular helper T cells.
The E3 ubiquitin ligase NEDD4 enhances killing of membrane-perturbing intracellular bacteria by promoting autophagy.
The E3 Ubiquitin Ligase SIAH1 Targets MyD88 for Proteasomal Degradation During Dengue Virus Infection.
The long noncoding RNA Lnczc3h7a promotes a TRIM25-mediated RIG-I antiviral innate immune response.
The ORF3 protein of porcine circovirus type 2 interacts with porcine ubiquitin E3 ligase Pirh2 and facilitates p53 expression in viral infection.
The poly-proline tail of SIVmac Vpx provides gain of function for resistance to a cryptic proteasome-dependent degradation pathway.
The RING domain of TRIM69 promotes higher-order assembly.
The role of E1B55K in E4orf6/E1B55K E3 ligase complexes formed by different human adenovirus serotypes.
The Ubiquitin E3 Ligase Parkin Inhibits Innate Antiviral Immunity Through K48-Linked Polyubiquitination of RIG-I and MDA5.
Transcriptomic profiling and genomic mutational analysis of Human coronavirus (HCoV)-229E -infected human cells.
TRIM proteins: another class of viral victims.
TRIM22 E3 ubiquitin ligase activity is required to mediate antiviral activity against encephalomyocarditis virus.
TRIM22 Inhibits Influenza A Virus Infection by Targeting the Viral Nucleoprotein for Degradation.
Trim23 promotes WSSV replication though negative regulation of antimicrobial peptides expression in Macrobrachium nipponense.
TRIM25 Binds RNA to Modulate Cellular Anti-viral Defense.
TRIM5alpha Modulates Immunodeficiency Virus Control in Rhesus Monkeys.
TRIM62 From Chicken as a Negative Regulator of Reticuloendotheliosis Virus Replication.
TRIMming Type I Interferon-Mediated Innate Immune Response in Antiviral and Antitumor Defense.
Virus-triggered ubiquitination of TRAF3/6 by cIAP1/2 is essential for induction of interferon-beta (IFN-beta) and cellular antiviral response.
[Hierarchical clustering analysis to detect associations between clinical and pathological features of gastric tumors and hypermethylation of suppressor genes.]
von Hippel-Lindau Disease
Identification and management of inherited cancer susceptibility.
Kinetic Detection of E3:PROTAC:Target Ternary Complexes Using NanoBRET Technology in Live Cells.
Preimplantation genetic diagnosis (PGD) for heritable neoplasia.
Waldenstrom Macroglobulinemia
Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas.
Werner Syndrome
Application of DNA Machineries for the Barcode Patterned Detection of Genes or Proteins.
Collaboration of Werner syndrome protein and BRCA1 in cellular responses to DNA interstrand cross-links.
Mutator pathways unleashed by epigenetic silencing in human cancer.
The G2-phase decatenation checkpoint is defective in Werner syndrome cells.
Williams Syndrome
Williams-Beuren syndrome TRIM50 encodes an E3 ubiquitin ligase.
Wilms Tumor
Development of Breast Cancer in a 21-Year-Old Childhood Wilms' Tumor Survivor With a BRCA1 2634delC Mutation.
Identification and management of inherited cancer susceptibility.
Immunohistochemical Loss of BRCA1 Protein in Uterine Serous Carcinoma.
Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor.
WTAP and BIRC3 are involved in the posttranscriptional mechanisms that impact on the expression and activity of the human lactonase PON2.
Wiskott-Aldrich Syndrome
The SH3 domain of Bruton's tyrosine kinase displays altered ligand binding properties when auto-phosphorylated in vitro.
Wolfram Syndrome
The E3 ligase Smurf1 regulates Wolfram syndrome protein stability at the endoplasmic reticulum.
Xeroderma Pigmentosum
BRCA1 transcriptionally regulates damaged DNA binding protein (DDB2) in the DNA repair response following UV-irradiation.
Monoubiquitinated H2A destabilizes photolesion-containing nucleosomes with the concomitant release of the UV-damaged DNA-binding protein E3 ligase.
The CUL4A ubiquitin ligase is a potential therapeutic target in skin cancer and other malignancies.
The xeroderma pigmentosum group E gene product DDB2 activates nucleotide excision repair by regulating the level of p21Waf1/Cip1.
Zika Virus Infection
Zika virus increases mind bomb 1 levels, causing degradation of pericentriolar material 1 (PCM1) and dispersion of PCM1-containing granules from the centrosome.